PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fenteany, G; Schreiber, SL				Fenteany, G; Schreiber, SL			Lactacystin, proteasome function, and cell fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; ENDOGENOUS INHIBITOR; NEUROBLASTOMA-CELLS; NEURITE OUTGROWTH; BETA-LACTONE; DEGRADATION; PROTEIN; UBIQUITIN; NEURITOGENESIS; TRANSFORMATION		Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute	Fenteany, G (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	fenteany@slsiris.harvard.edu; sls@slsiris.harvard.edu	Fenteany, Gabriel/F-4944-2018	Fenteany, Gabriel/0000-0001-7407-2195; Fenteany, Gabriel/0000-0003-0335-4587				Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Fenteany G, 1996, CHEM BIOL, V3, P905, DOI 10.1016/S1074-5521(96)90179-9; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gonzalez J, 1996, J EXP MED, V184, P1909, DOI 10.1084/jem.184.5.1909; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KATAGIRI M, 1995, J ANTIBIOT, V48, P344, DOI 10.7164/antibiotics.48.344; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; MITSUI K, 1991, J NEUROCHEM, V57, P556, DOI 10.1111/j.1471-4159.1991.tb03786.x; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; TANAKA H, 1995, BIOCHEM BIOPH RES CO, V216, P291, DOI 10.1006/bbrc.1995.2623; TSUBUKI S, 1994, FEBS LETT, V344, P229, DOI 10.1016/0014-5793(94)00388-2; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; TSUJI S, 1988, J NEUROCHEM, V50, P414, DOI 10.1111/j.1471-4159.1988.tb02928.x; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5	34	366	395	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8545	8548		10.1074/jbc.273.15.8545	http://dx.doi.org/10.1074/jbc.273.15.8545			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535824	hybrid			2022-12-27	WOS:000072990800001
J	Frasch, SC; Nick, JA; Fadok, VA; Bratton, DL; Worthen, GS; Henson, PM				Frasch, SC; Nick, JA; Fadok, VA; Bratton, DL; Worthen, GS; Henson, PM			p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROGRAMMED CELL-DEATH; FAS-MEDIATED APOPTOSIS; GAMMA-RADIATION; JNK ACTIVATION; MAP KINASES; T-CELLS; INHIBITION; INFLAMMATION; PHAGOCYTOSIS	Human neutrophils undergo apoptosis spontaneously when cultured in vitro; however, the signal transduction pathways involved remain largely unknown, In some cell types, c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase (MAPK) have been implicated in the pathways leading to stress-induced apoptosis, In this study, we bean to define two pathways leading to apoptosis in the neutrophil induced either by stress stimuli (UV, hyperosmolarity, sphingosine) or by anti-Fas antibody or overnight culture in vitro (spontaneous apoptosis), Apoptosis induced by stress stimuli activated p38 MAPK, and apoptosis was inhibited by the specific p38 MAPK inhibitor, 6-(4-Fluorophenyl)-2.3-dihydro-5-(4-puridinyl)imidazo(2,1-beta)thiazole dihydrochloride, Furthermore, differentiation of HL-60 cells toward the neutrophil phenotype resulted in a loss in c-Jun NH2-terminal kinase activation with concomitant acquisition of formylmethionylleucylphenylalanine-stimulatable and stress-inducible p38 MAPK activity as well as apoptosis blockade by the p38 MAPK inhibitor, In contrast, anti-Fas-induced or spontaneous apoptosis occurred independent of p38 MAPK activation and was not blocked by the inhibitor, Both pathways appear to utilize member(s) of the caspase family, since pretreatment with either Val-Ala-Asp-fluoromethyl ketone or Asp-Glu-Val Asp-fluoromethyl ketone inhibited apoptosis induced by each of the stimuli, We propose the presence of at least two pathways leading to apoptosis in human neutrophils, a stress-activated pathway that is dependent on p38 MAPK activation and an anti-FAS/spontaneous pathway that is p38 MAPK-independent.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Frasch, SC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA.	fraschc@njc.org			NIGMS NIH HHS [GM48211] Funding Source: Medline; PHITPO CDC HHS [HK50319] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048211] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHITPO CDC HHS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BRACH MA, 1992, BLOOD, V80, P2920; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLOTTA F, 1992, BLOOD, V80, P2012; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Cox G, 1996, AM J PHYSIOL-LUNG C, V271, pL566, DOI 10.1152/ajplung.1996.271.4.L566; COX G, 1995, AM J RESP CELL MOL, V12, P232, DOI 10.1165/ajrcmb.12.2.7865221; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERRERO D, 1983, BLOOD, V61, P171; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; HASLETT C, 1985, AM J PATHOL, V119, P101; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LILES WC, 1995, J IMMUNOL, V155, P3289; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NEWMAN SL, 1982, J EXP MED, V156, P430, DOI 10.1084/jem.156.2.430; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SANDBORG RR, 1988, LAB INVEST, V59, P300; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SAVILL JS, 1989, J CLIN INVEST, V84, P1518, DOI 10.1172/JCI114328; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; STEINBACH KH, 1979, BLUT, V39, P27, DOI 10.1007/BF01008072; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Suchard SJ, 1997, J IMMUNOL, V158, P4961; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Sweeney JF, 1997, J LEUKOCYTE BIOL, V62, P517, DOI 10.1002/jlb.62.4.517; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	61	261	271	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8389	8397		10.1074/jbc.273.14.8389	http://dx.doi.org/10.1074/jbc.273.14.8389			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525949	hybrid			2022-12-27	WOS:000072876300083
J	Kalafatis, M				Kalafatis, M			Identification and partial characterization of factor Va heavy chain kinase from human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; COAGULATION FACTOR-V; DEPENDENT ENZYME COMPLEXES; BOVINE FACTOR-V; CELLULAR-REGULATION; SYNTHETIC PEPTIDES; HUMAN-FIBRINOGEN; CASEIN KINASE-2; COMPLETE CDNA; PHOSPHORYLATION	Factor Va, the essential cofactor for prothrombinase, is phosphorylated on the acidic COOH terminus of the heavy chain of the cofactor, at Ser(692), by a platelet membrane-associated casein kinase II (CKII), Consistent with this observation, phosphorylation of the factor Va heavy chain by the platelet kinase was inhibited by heparin, The membrane-associated platelet CKII kinase was partially purified using heparin-agarose, phosphocellulose, and ion exchange chromatography, CKII antigen was monitored using a polyclonal antibody to the alpha-subunit, and kinase activity in the various fractions was confirmed using human factor Va as a substrate, Immunoblotting experiments using polyclonal antibodies raised against synthetic peptides mimicking a portion of the deduced amino acid sequence of the alpha-, alpha'-, and beta-subunits of human CKII demonstrated the coexistence of both alpha- and alpha'-subunits in platelets and suggested that the platelet CKII kinase may exist in part as an alpha alpha' beta(2) complex, It is also possible that there are two distinct populations of CKII in platelets, one that is alpha alpha/beta beta and one that is alpha'alpha'/beta beta. In the presence of the purified platelet-derived CKII, human factor Va incorporates between 0.8 and 1.3 mol of phosphate/mol of factor Va depending on the concentration of the beta-subunit in the kinase preparation, A peptide mimicking the sequence 687-705 of the human factor V molecule incorporates radioactivity in the presence of purified CKII and inhibits factor Va heavy chain phosphorylation by the platelet CKII, In contrast, a peptide with an alanine instead of a serine at position 692 neither incorporates phosphate nor inhibits factor Va phosphorylation by the platelet CKII, Human factor Va is inactivated by activated protein C following three cleavages of the heavy chain at Arg(506), Arg(306), and Arg(679). Cleavage at Arg(506) is necessary for efficient exposure of the inactivating cleavage site at Arg(306). The phosphorylated cofactor has increased susceptibility to inactivation by activated protein C, since phosphorylated factor Va was found to be inactivated approximately 3-fold faster than its native counterpart, Acceleration of the inactivation process of the phosphorylated cofactor occurs because of acceleration of the rate of cleavage at Arg(506). These data suggest a critical role for factor Va phosphorylation on the surface of platelets in regulating cofactor activity.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University of Vermont	Kalafatis, M (corresponding author), Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA.	m.kalafatis@csuohio.edu						BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; CAMIRE RM, 1995, J BIOL CHEM, V270, P20794, DOI 10.1074/jbc.270.35.20794; CATCHER CH, 1990, CIRCULATION, V82, P131; CHIANG TM, 1985, ARCH BIOCHEM BIOPHYS, V243, P530, DOI 10.1016/0003-9861(85)90530-2; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GALABRU J, 1983, BIOCHEM BIOPH RES CO, V113, P370, DOI 10.1016/0006-291X(83)91736-9; GIRARD TJ, 1990, BIOCHEM J, V270, P621, DOI 10.1042/bj2700621; GUASCH MD, 1986, BIOCHEM J, V234, P523, DOI 10.1042/bj2340523; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HELDIN P, 1987, ARCH BIOCHEM BIOPHYS, V257, P269, DOI 10.1016/0003-9861(87)90566-2; HORTIN GL, 1990, BLOOD, V76, P946; HOYT CH, 1994, BLOOD, V83, P3517; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kalafatis M, 1996, BLOOD, V87, P4695, DOI 10.1182/blood.V87.11.4695.bloodjournal87114695; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1993, BLOOD, V81, P704; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kalafatis M, 1996, CIRCULATION, V94, P1270; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRUST B, 1983, BIOCHEM BIOPH RES CO, V117, P350, DOI 10.1016/0006-291X(83)91583-8; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1990, BLOOD, V76, P1; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOVOTNY WF, 1988, BLOOD, V72, P2020; PAPANIKOLAOU P, 1982, FEBS LETT, V143, P199, DOI 10.1016/0014-5793(82)80098-7; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAND MD, 1994, BLOOD, V83, P2180; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; STEINER M, 1975, ARCH BIOCHEM BIOPHYS, V171, P245, DOI 10.1016/0003-9861(75)90029-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1979, J BIOL CHEM, V254, P354	56	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8459	8466		10.1074/jbc.273.14.8459	http://dx.doi.org/10.1074/jbc.273.14.8459			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525959	hybrid			2022-12-27	WOS:000072876300093
J	Zhang, HJ; Sheng, XR; Niu, WD; Pan, XM; Zhou, JM				Zhang, HJ; Sheng, XR; Niu, WD; Pan, XM; Zhou, JM			Evidence for at least two native forms of rabbit muscle adenylate kinase in equilibrium in aqueous solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; STAPHYLOCOCCAL NUCLEASE; ESCHERICHIA-COLI; DOMAIN CLOSURE; PROLINE ISOMERISM; 2 CONFORMATIONS; CALBINDIN D9K; INDUCED-FIT; RESOLUTION; COMPLEXES	The time course of 8-anilino-1-naphthalenesulfonic acid (ANS) binding to adenylate kinase (AK) is a biphasic process. The burst phase ends in the dead-time of the stopped-flow apparatus (about 15 ms), whereas the slow phase completes in about 10 min, A Job's plot tests of the binding stoichiometry demonstrates that there is one ANS binding site on AK, but only about 70% of the enzyme can rapidly bind with ANS, indicating that the conformation of native AK molecules is not homogeneous. Further kinetic analysis shows that the effects of ANS and substrates concentration on the burst and slow phase fluorescence building agree well with the multiple native forms mechanism, One form (denoted N-1) binds with ANS, whereas the other (denoted N-2) does not, ANS binding to N-1 results in a burst phase fluorescence increase, followed by the interconversion of N-2 to N-1, to give the slow phase ANS binding. Under urea denaturation conditions, N-2 is easily perturbed by urea and unfolds completely at low denaturant concentrations, whereas N-1 is relatively resistant to denaturation and unfolds at higher denaturant concentrations, The existence of multiple native forms in solution may shed some light on the interpretation of the enzyme catalytic mechanism.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Pan, XM (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	xmpan@sun5.ibp.ac.cn						ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; ARATA Y, 1973, ANN NY ACAD SCI, V222, P230, DOI 10.1111/j.1749-6632.1973.tb15265.x; BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; Bilderback T, 1996, BIOCHEMISTRY-US, V35, P6100, DOI 10.1021/bi951833i; Cantor CR, 1980, BIOPHYSICAL CHEM 3, P1135; CHAZIN WJ, 1989, P NATL ACAD SCI USA, V86, P2195, DOI 10.1073/pnas.86.7.2195; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DREUSICKE D, 1988, J MOL BIOL, V203, P1021, DOI 10.1016/0022-2836(88)90126-X; EVANS PA, 1987, NATURE, V329, P266, DOI 10.1038/329266a0; EVANS PA, 1989, BIOCHEMISTRY-US, V28, P362, DOI 10.1021/bi00427a050; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; HAMADA M, 1992, STUDY ENZYMES, V2, P403; KALBITZER HR, 1982, EUR J BIOCHEM, V126, P531, DOI 10.1111/j.1432-1033.1982.tb06813.x; Kumar TKS, 1996, BBA-PROTEIN STRUCT M, V1294, P103, DOI 10.1016/0167-4838(96)00023-4; MARKLEY JL, 1970, P NATL ACAD SCI USA, V65, P645, DOI 10.1073/pnas.65.3.645; MCDONALD GG, 1975, J BIOL CHEM, V250, P6947; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NODA L, 1973, ENZYMES, V8, P273; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; ROSCH P, 1989, BIOCHEMISTRY-US, V28, P4318; RUSSELL PJ, 1990, J BIOL CHEM, V265, P11804; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; Schlauderer GJ, 1996, J MOL BIOL, V256, P223, DOI 10.1006/jmbi.1996.0080; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Sheng XR, 1997, FEBS LETT, V413, P429, DOI 10.1016/S0014-5793(97)00951-4; Sinev MA, 1996, BIOCHEMISTRY-US, V35, P6425, DOI 10.1021/bi952687j; SVENSSON LA, 1992, J MOL BIOL, V223, P601, DOI 10.1016/0022-2836(92)90976-Q; TANIUCHI H, 1966, J BIOL CHEM, V241, P4366; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6808; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; VETTER IR, 1990, BIOCHEMISTRY-US, V29, P7459, DOI 10.1021/bi00484a015; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; ZHANG YL, 1993, BIOCHIM BIOPHYS ACTA, V1164, P61, DOI 10.1016/0167-4838(93)90112-5; Zhang YL, 1996, BBA-PROTEIN STRUCT M, V1295, P239, DOI 10.1016/0167-4838(96)00044-1	34	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7448	7456		10.1074/jbc.273.13.7448	http://dx.doi.org/10.1074/jbc.273.13.7448			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516443	hybrid			2022-12-27	WOS:000072738500039
J	Parvathenani, LK; Buescher, ES; Chacon-Cruz, E; Beebe, SJ				Parvathenani, LK; Buescher, ES; Chacon-Cruz, E; Beebe, SJ			Type I cAMP-dependent protein kinase delays apoptosis in human neutrophils at a site upstream of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROGRAMMED CELL-DEATH; RESPIRATORY BURST; BINDING-SITES; ANNEXIN-V; INHIBITION; ANALOGS; ACTIVATION; SURVIVAL; PROLONGATION	Current data suggest that apoptosis controls neutrophil numbers in tissues. We analyzed roles for and the sites of action for the cAMP-dependent protein kinases (cAPKs) in apoptosis induced in human neutrophils by in vitro storage, cycloheximide (CIM) exposure, and anti-Fas exposure. Treatment with 8-chlorophenylthio-cAMP (8-CPT-cAMP) prolonged the time required for 50% of the cells to exhibit apoptotic morphology (t(50)) from 16.3 to 41.8 h (in vitro culture), from 2.4 to 7.8 h (CHX), and from 4.8 to 6.5 h (anti-Pas). CHX +/- 8-CPT-cAMP did not significantly alter resting intracellular calcium levels and H-89, a selective inhibitor of cAPK, had no effect on apoptosis in the absence of the analogue. In contrast, site-selective cAMP analogues that specifically activated the type I cAPK, but not type II cAPK, synergistically attenuated apoptosis. Exposure to 8-CPT-cAMP delayed, in parallel, the activity of caspase-3 (CPP-32 beta), whereas mitogen-activated protein kinase kinase (MAPKK) inhibitor, PD98059, had no effect on CHX-induced apoptosis +/- 8-CPT-cAMP. Together these results indicate that type I cAPK activation is necessary and sufficient to mediate cAMP-induced delay in human neutrophil apoptosis induced by several mechanisms and suggest that one of the major sites of cAPK action is upstream of caspase-3 (CPP-32 beta) activation.	Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Ctr Pediat Res, Norfolk, VA 23510 USA	Eastern Virginia Medical School	Beebe, SJ (corresponding author), Ctr Pediat Res, 855 W Brambleton Ave, Norfolk, VA 23510 USA.	sbeebe@chkd.com		Chacon-Cruz, Enrique/0000-0003-2466-4920				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; AOSHIBA K, 1995, ANTIMICROB AGENTS CH, V39, P872, DOI 10.1128/AAC.39.4.872; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BEEBE SJ, 1984, J BIOL CHEM, V259, P3539; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; BEEBE SJ, 1986, ENZYMES, V17, P43; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BRACH MA, 1992, BLOOD, V80, P2920; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLOTTA F, 1992, BLOOD, V80, P2012; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRENCK RW, 1989, PEDIATR RES, V26, P43, DOI 10.1203/00006450-198907000-00014; HARVATH L, 1991, J IMMUNOL, V146, P224; HOMBURG CHE, 1995, BLOOD, V85, P532; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; WONG K, 1981, CAN J PHYSIOL PHARM, V59, P915, DOI 10.1139/y81-141; ZHIVOTOVSKY B, 1994, INT ARCH ALLERGY IMM, V105, P333, DOI 10.1159/000236778	40	114	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6736	6743		10.1074/jbc.273.12.6736	http://dx.doi.org/10.1074/jbc.273.12.6736			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506973	hybrid, Green Published			2022-12-27	WOS:000072775900023
J	Pierpaoli, EV; Sandmeier, E; Schonfeld, HJ; Christen, P				Pierpaoli, EV; Sandmeier, E; Schonfeld, HJ; Christen, P			Control of the DnaK chaperone cycle by substoichiometric concentrations of the co-chaperones DnaJ and GrpE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; ATP HYDROLYSIS; BINDING; SYSTEM; TRANSLOCATION; SIGMA(32); KINETICS; RELEASE	The polypeptide binding and release cycle of the molecular chaperone DnaK (Hsp70) of Escherichia coli is regulated by the two co-chaperones DnaJ and GrpE, Here, we show that the DnaJ-triggered conversion of DnaK.ATP (T state) to DnaK.ADP.P-i (R state), as monitored by intrinsic protein fluorescence, is monophasic and occurs simultaneously with ATP hydrolysis. This is in contrast with the T-->R conversion in the absence of DnaJ which is biphasic, the first phase occurring simultaneously with the hydrolysis of ATP (Theyssen, H,, Schuster, H,-P,, Packschies, L,, Bukau, B,, and Reinstein, J, (1996) J, Mol. Biol, 263, 657-670), Apparently, DnaJ not only stimulates ATP hydrolysis but also couples it with conformational changes of DnaK. In the absence of GrpE, DnaJ forms a tight ternary complex with peptide DnaK.ADP.P-i (K-d = 0.14 mu M). However, by monitoring complex formation between DnaK (1 mu M) and a fluorophore-labeled peptide in the presence of ATP (1 mM), DnaJ (1 mu M), and varying concentrations of the ADP/ATP exchange factor GrpE (0.1-3 mu M), substoichiometric concentrations of GrpE were found to shift the equilibrium from the slowly binding and releasing, high-affinity R state of DnaK completely to the fast binding and releasing, low-affinity T state and thus to prevent the formation of a long lived ternary DnaJ substrate.DnaK.ADP.P-i complex. Under lit vivo conditions with an estimated chaperone ratio of DnaK;DnaJ:GrpE = 10:1:3, both DnaJ and GrpE appear to control the chaperone cycle by transient interactions with DnaK.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; F Hoffmann La Roche & Co Ltd, Pharmaceut Res Infect Dis, CH-4070 Basel, Switzerland	University of Zurich; Roche Holding	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							Banecki B, 1996, J BIOL CHEM, V271, P6137, DOI 10.1074/jbc.271.11.6137; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; Kudlicki W, 1996, J BIOL CHEM, V271, P31160, DOI 10.1074/jbc.271.49.31160; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P7545, DOI 10.1093/nar/16.15.7545; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHONFELD HJ, 1997, PROTEIN FOLDING CATA, V290, P269; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	33	72	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6643	6649		10.1074/jbc.273.12.6643	http://dx.doi.org/10.1074/jbc.273.12.6643			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506960	hybrid			2022-12-27	WOS:000072775900010
J	Rosin, O; Koch, C; Schmitt, I; Semmes, OJ; Jeang, KT; Grassmann, R				Rosin, O; Koch, C; Schmitt, I; Semmes, OJ; Jeang, KT; Grassmann, R			A human T-cell leukemia virus Tax variant incapable of activating NF-KB retains its immortalizing potential for primary T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I TAX; HERPESVIRUS-SAIMIRI; KAPPA-B; RESPONSE ELEMENT; RAT FIBROBLASTS; BINDING-PROTEIN; TRANSFORMATION; GENE; PATHWAY; TRANSCRIPTION	The human T-cell leukemia virus type 1 (HTLV-1) transactivator (Tax) has been shown to interfere with regulated cellular proliferation. Many studies have focused on the ability of Tax to transform rodent fibroblasts; however, none has defined the molecular requirements for Tax transformation of human lymphoid cells, We show here that tax induces permanent growth of human primary T-lymphocytes by using a transformation/immortalization defective rhadinovirus vector, The cells phenotypically resemble HTLV-immortalized lymphocytes and contain episomally persisting recombinant rhadinoviral sequences, which stably express functional Tax protein. As Tax can activate major cellular signal transducing pathways including NF-kappa B and cAMP-responsive element binding protein (CREB), we asked for the relevance of these routes in the immortalization of human lymphocytes. By using Tax mutants that either activate exclusively CREB/activating transcription factor or are defective in activating this signaling pathway, we delineated that Tax can induce immortalization of primary human T-lymphocytes through a mechanism independent of NF-kappa B activation.	Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany; NIAID, Mol Virol Sect, NIH, Bethesda, MD 20892 USA	University of Erlangen Nuremberg; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Grassmann, R (corresponding author), Univ Erlangen Nurnberg, Inst Klin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	grassmann@viro.med.uni-erlangen.de	Jeang, Kuan-Teh/A-2424-2008; Semmes, Oliver/GQA-5179-2022					AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; ALT M, 1993, ONCOGENE, V8, P1421; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DESROSIERS RC, 1986, J VIROL, V57, P701, DOI 10.1128/JVI.57.2.701-705.1986; Fickenscher H, 1996, J VIROL, V70, P6012, DOI 10.1128/JVI.70.9.6012-6019.1996; GESSAIN A, 1985, LANCET, V2, P407; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; GRONE M, 1994, VIROLOGY, V204, P144, DOI 10.1006/viro.1994.1518; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; INATSUKI A, 1989, J IMMUNOL, V143, P1327; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KOGA Y, 1989, J IMMUNOL, V142, P4493; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MOCH H, 1992, J VIROL, V66, P7346, DOI 10.1128/JVI.66.12.7346-7354.1992; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; NERENBERG MI, 1990, CURR TOP MICROBIOL, V160, P121; OSAME M, 1986, LANCET, V2, P104; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; PLAETINCK G, 1990, J IMMUNOL, V145, P3340; PLATZER C, 1994, TRANSPLANTATION, V58, P264, DOI 10.1097/00007890-199407270-00025; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	42	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6698	6703		10.1074/jbc.273.12.6698	http://dx.doi.org/10.1074/jbc.273.12.6698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506967	hybrid			2022-12-27	WOS:000072775900017
J	Arnould, T; Kim, E; Tsiokas, L; Jochimsen, F; Gruning, W; Chang, JD; Walz, G				Arnould, T; Kim, E; Tsiokas, L; Jochimsen, F; Gruning, W; Chang, JD; Walz, G			The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JNK/SAPK SIGNALING PATHWAY; SYSTEM EFFECTOR FUNCTION; RECEPTOR ZETA-CHAIN; T-CELL; DIFFERENTIAL ACTIVATION; EPITHELIAL-CELLS; DOMAINS; EXPRESSION; PROLIFERATION; TRANSDUCTION	Autosomal dominant polycystic kidney disease (ADPKD) is a common hereditary disorder that accounts far 8-10% of end stage renal disease, PKD1, one of two recently isolated ADPKD gene products, has been implicated in cell-cell and cell-matrix interactions, However, the signaling pathway of PKD1 remains undefined, We found that the C-terminal 226 amino acids of PKD1 transactivate an AP-1. promoter construct in human embryonic kidney cells (293T). PKD1-induced transcription is specific for AP-1; promoter constructs containing cAMP response element-binding protein, c-Fos, c-Myc, or NF kappa B-binding sites are unaffected by PKD1. In vitro kinase assays revealed that PKD1 triggers the activation of c-Jun N-terminal kinase (JNK), but not of mitogen-activated protein kinases p38 or p44, Dominant-negative Rac-1 and Cdc42 mutations abrogated PKD1-mediated JNK and AP-1 activation, suggesting a critical role for small GTP-binding proteins in PKD1-mediated signaling. Several protein kinase C (PRC) inhibitors decreased PKD1-mediated AP-1 activation, Conversely, expression of the C-terminal domain of PKD1 increased PRC activity in 293T cells, A dominant-negative PKC alpha, but not a dominant-negative PKC beta or delta, abrogated PKD1-mediated AP-1 activation, These findings indicate that small GTP-binding proteins and PKC alpha mediate PKD1-induced JNK/AP-1 activation, together comprising a signaling cascade that may regulate renal tubulogenesis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Cardiol Div, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Mol & Dev Neurosci, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Walz, G (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, 330 Brookline Ave, Boston, MA 02215 USA.	gwalz@bidmc.harvard.edu		Tsiokas, Leonidas/0000-0002-3659-1813	NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH001147] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-01147] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; AMERONGEN HM, 1989, J CELL BIOL, V109, P2129, DOI 10.1083/jcb.109.5.2129; BELL RM, 1991, J BIOL CHEM, V266, P4661; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CADWALLADER K, 1997, BIOCHEM J, V321, P765; CALVET JP, 1995, KIDNEY INT, V47, P715, DOI 10.1038/ki.1995.89; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY BD, 1989, J BIOL CHEM, V264, P8389; Crespo P, 1996, ONCOGENE, V13, P455; Davis AF, 1997, J CELL BIOCHEM, V65, P308, DOI 10.1002/(SICI)1097-4644(19970601)65:3<308::AID-JCB2>3.0.CO;2-W; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; DU J, 1995, AM J PHYSIOL-CELL PH, V269, pC487, DOI 10.1152/ajpcell.1995.269.2.C487; Faller DV, 1997, VIROLOGY, V227, P331, DOI 10.1006/viro.1996.8345; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; GATTONE VH, 1991, SEMIN NEPHROL, V11, P617; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Grantham JJ, 1996, AM J KIDNEY DIS, V28, P788, DOI 10.1016/S0272-6386(96)90378-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATA A, 1993, J BIOL CHEM, V268, P9122; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HERRERA GA, 1991, KIDNEY INT, V40, P509, DOI 10.1038/ki.1991.239; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O., 1996, Journal of the American Society of Nephrology, V7, P1599; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIM E, 1997, J AM SOC NEPHROL, V8, P375; KIM K, 1997, J AM SOC NEPHROL, V8, P375; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Lanoix J, 1996, ONCOGENE, V13, P1153; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1462; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NORMAN J, 1995, KIDNEY INT, V47, P727, DOI 10.1038/ki.1995.105; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; QIAN F, 1997, J AM SOC NEPHROL, V8, P380; RANKIN CA, 1992, J CELL PHYSIOL, V152, P578, DOI 10.1002/jcp.1041520318; ROMEO C, 1992, COLD SPRING HARB SYM, V57, P117, DOI 10.1101/SQB.1992.057.01.015; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; TANJI M, 1994, J NEUROCHEM, V63, P1908; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; Wilson P D, 1992, Adv Nephrol Necker Hosp, V21, P125; WILSON PD, 1995, KIDNEY INT, V47, P724, DOI 10.1038/ki.1995.101; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; Wilson PD, 1997, AM J PHYSIOL-RENAL, V272, pF434, DOI 10.1152/ajprenal.1997.272.4.F434; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	65	146	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6013	6018		10.1074/jbc.273.11.6013	http://dx.doi.org/10.1074/jbc.273.11.6013			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497315	hybrid			2022-12-27	WOS:000072488500007
J	Garner, B; Witting, PK; Waldeck, AR; Christison, JK; Raftery, M; Stocker, P				Garner, B; Witting, PK; Waldeck, AR; Christison, JK; Raftery, M; Stocker, P			Oxidation of high density lipoproteins - I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MEDIATED PEROXIDATION; CHOLESTEROL; PLASMA; LDL; RAT; HYDROPEROXIDES; PROTEINS; CELLS	The lipids of high density lipoproteins (HDL) are initially oxidized in preference to those in low density lipoprotein when human plasma is exposed to aqueous peroxyl radicals, In this work we report on the relative susceptibility of HDL protein and lipid to oxidation and on the role HDL's alpha-tocopherol (alpha-TOH) plays in modulating protein oxidation, Exposure of isolated HDL to either low fluxes of aqueous peroxyl radicals, Cu2+ ions, or soybean lipoxygenase resulted in the oxidation of apoAI and apoAII during the earliest stages of the reaction, i,e. after consumption of ubiquinol-10 and in the presence of alpha-TOH. Hydro(pero)xides of cholesteryl esters and phospholipids initially accumulated together with specific oxidized forms of apoAI and apoAII, separated by high pressure liquid chromatography. The specific oxidized forms of apoAI were 16 and 32 mass units heavier than those of the native apolipoproteins and contained 1 and 2 methionine sulfoxide residues per protein, respectively, The third methionine residue in apoAI, as well as Trp residues, remained unoxidized during the earliest stages of HDL oxidation examined, Exposure of isolated apoAI to peroxyl radicals, Cu2+, or soybean lipoxygenase resulted in nonspecific (for peroxyl radicals) or no discernible protein oxidation (Cu2+ and soybean lipoxygenase), This indicated that the formation of the specific oxidized forms of apoAI observed with native HDL was not the result of direct reaction of these oxidants with the apolipoprotein, In vitro and in vivo enrichment of HDL with alpha-TOH resulted in a dose-dependent increase in the extent of peroxyl radical induced formation of HDL cholesteryl ester hydroperoxides (r = 0.96) and cholesteryl ester hydroxides (r = 0.92), as well as the loss of apoAI (r = 0.96) and apoAII (T = 0.94), alpha-TOH enrichment also enhanced HDL lipid and protein oxidation induced by Cu2+ Or soybean lipoxygenase, These results indicate that the earliest stages of HDL oxidation are accompanied by the oxidation of specific methionine residues in apoAI and apoAII and that in the absence of co antioxidants, alpha-TOH can promote this process.	Heart Res Inst, Biochem Grp, Sydney, NSW 2050, Australia; Heart Res Inst, Immunol Grp, Sydney, NSW 2050, Australia	University of Sydney; Heart Research Institute; University of Sydney; Heart Research Institute	Stocker, P (corresponding author), Heart Res Inst, Biochem Grp, 145 Missenden Rd, Sydney, NSW 2050, Australia.	r.stocker@hri.edu.au	Mudd, Julie/ABD-6794-2021; Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020	Mudd, Julie/0000-0002-7499-0241; Witting, Paul/0000-0003-2237-7004				AITKEN A, 1989, PROTEIN SEQUENCING P, P43; Anantharamaiah GM, 1996, METHOD ENZYMOL, V263, P267; ANANTHARAMAIAH GM, 1988, J LIPID RES, V29, P309; Bielicki JK, 1996, J LIPID RES, V37, P1012; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; Christison J, 1996, BIOCHEM J, V314, P739, DOI 10.1042/bj3140739; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; CHUNG H, 1982, J BIOL CHEM, V257, P2961; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; GEBICKI S, 1993, BIOCHEM J, V289, P743, DOI 10.1042/bj2890743; HUGHES TA, 1988, J LIPID RES, V29, P363; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; LUX SE, 1972, J BIOL CHEM, V247, P7519; MARCEL YL, 1989, J BIOL CHEM, V264, P19942; MAZIERE JC, 1993, ATHEROSCLEROSIS, V104, P213, DOI 10.1016/0021-9150(93)90192-W; MOHR D, 1994, ARTERIOSCLER THROMB, V14, P1186, DOI 10.1161/01.ATV.14.7.1186; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; NEUZIL J, 1995, J PEDIATR-US, V126, P785, DOI 10.1016/S0022-3476(95)70412-4; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; NEUZIL J, 1993, BIOCHEM J, V293, P601; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; REYFTMANN JP, 1990, BIOCHIM BIOPHYS ACTA, V1042, P159, DOI 10.1016/0005-2760(90)90002-F; RYE KA, 1994, J BIOL CHEM, V269, P10298; SATTLER W, 1995, FREE RADICAL BIO MED, V18, P421, DOI 10.1016/0891-5849(94)00170-O; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SEGREST JP, 1992, J LIPID RES, V33, P141; SENAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1046, P81, DOI 10.1016/0005-2760(90)90097-H; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Upston JM, 1996, J LIPID RES, V37, P2650; VONECKARDSTEIN A, 1991, J LIPID RES, V32, P1465	38	159	173	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6080	6087		10.1074/jbc.273.11.6080	http://dx.doi.org/10.1074/jbc.273.11.6080			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497325	hybrid			2022-12-27	WOS:000072488500017
J	Jain, MK; Layne, MD; Watanabe, M; Chin, MT; Feinberg, MW; Sibinga, NES; Hsieh, CM; Yet, SF; Stemple, DL; Lee, ME				Jain, MK; Layne, MD; Watanabe, M; Chin, MT; Feinberg, MW; Sibinga, NES; Hsieh, CM; Yet, SF; Stemple, DL; Lee, ME			In vitro system for differentiating pluripotent neural crest cells into smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR-BETA; TRANSGENIC MICE; GENE; PROMOTER; EXPRESSION; MYOGENESIS; PHENOTYPES; PROTEINS; CYCLIN	The change in vascular smooth muscle cells (SMC) from a differentiated to a dedifferentiated state is the critical phenotypic response that promotes occlusive arteriosclerotic disease, Despite its importance, research into molecular mechanisms regulating smooth muscle differentiation has been hindered by the lack of an in vitro cell differentiation system, me identified culture conditions that promote efficient differentiation of Monc-1 pluripotent neural crest cells into SMC. Exclusive Monc-1 to SMC differentiation was indicated by cellular morphology and time-dependent induction of the SMC markers smooth muscle alpha-actin, smooth muscle myosin heavy chain, calponin, SM22 alpha, and APEG-1. The activity of the SM22 alpha promoter was low in Monc-1 cells. Differentiation of these cells into SMC caused a 20-30-fold increase in the activity of the wild-type SM22 alpha promoter and that of a hybrid promoter containing three copies of the CArG element. By gel mobility shift analysis, we identified new DNA-protein complexes in nuclear extracts prepared from differentiated Monc-1 cells. One of the new complexes contained serum response factor. This Monc-1 to SMC model should facilitate the identification of nodal regulators of smooth muscle development and differentiation.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Natl Inst Med Res, Div Dev Biol, London NW7 1AA, England	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; MRC National Institute for Medical Research	Lee, ME (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.	lee@cvlab.harvard.edu	Sibinga, Nicholas/GOJ-8544-2022; Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010; Pillay, Nischalan/F-9536-2012	Sibinga, Nicholas/0000-0003-4838-910X; Feinberg, Mark/0000-0001-9523-3859; Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870	NHLBI NIH HHS [HL03274, HL03745] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; GROSCHELSTEWART U, 1976, HISTOCHEMISTRY, V46, P229, DOI 10.1007/BF02462786; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012-1606(74)90291-7; LEE ME, 1990, J BIOL CHEM, V265, P10446; Lenkei Z, 1996, J COMP NEUROL, V373, P322, DOI 10.1002/(SICI)1096-9861(19960923)373:3<322::AID-CNE2>3.0.CO;2-4; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Moessler H, 1996, DEVELOPMENT, V122, P2415; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OWENS GK, 1995, PHYSIOL REV, V75, P487; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	34	52	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					5993	5996		10.1074/jbc.273.11.5993	http://dx.doi.org/10.1074/jbc.273.11.5993			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497310	hybrid			2022-12-27	WOS:000072488500002
J	Otter, I; Conus, S; Ravn, U; Rager, M; Olivier, R; Monney, L; Fabbro, D; Borner, C				Otter, I; Conus, S; Ravn, U; Rager, M; Olivier, R; Monney, L; Fabbro, D; Borner, C			The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DEATH; INHIBITION; SEQUENCE; HOMOLOG; FAMILY; DOMAIN	The oncogene product Bcl-2 protects cells from apoptosis whereas its homolog Bax functions to kill cells. Several binding partners of Bcl-2 and Bax have been isolated, but none of them has yet provided clues as to exactly how Bcl-2 and Bax work. According to one view, Bcl-2 and Bax interact with survival and death effector molecules, respectively, and neutralize each other through heterodimerization. Alternatively, Bcl-2 requires Bax for death protection, and additional proteins bind to the heterodimer to regulate its activity. Here we used a co-immunoprecipitation strategy to distinguish between these two possibilities. We show that the Bcl-2-Bax heterodimer is maintained, and no other protein associates stably in detectable amounts with Bcl-2, Bax, or the heterodimer in anti-Bcl-2 and anti-Bax immunoprecipitates from normal cells and cells exposed to apoptotic stimuli. Analysis of cells expressing various levels of Bcl-2 and Bax, however, revealed that the degree of protection against apoptosis does not correlate with the number of Bcl-2-Bax heterodimers but the amount of Bcl-2 that is free of Bax. In addition, the survival activity of Bcl-2 is unaffected when Bax expression is ablated by an antisense strategy. Our findings suggest that the Bcl-2-Bax heterodimer is a negative regulator of death protection, and that Bcl-2 requires neither Bax nor major, stable interactions with other cellular proteins to exert its survival function. We therefore propose that Bcl-2 acts as an enzyme (capturing substrates in a transient way), as a homodi- or multimer, or through the interaction with non-proteaceous targets (lipids, ions).	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Novartis Ltd, Dept Oncol, CH-4002 Basel, Switzerland	University of Fribourg; Novartis	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.							ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7294; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DSaEipper C, 1996, CANCER RES, V56, P3879; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Gibson L, 1996, ONCOGENE, V13, P665; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; OLIVER B, 1997, BIOCHEM J, V234, P75; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Thomas A, 1996, ONCOGENE, V12, P1055; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN XM, 1994, NATURE, V356, P768; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	30	74	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6110	6120		10.1074/jbc.273.11.6110	http://dx.doi.org/10.1074/jbc.273.11.6110			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497329	hybrid			2022-12-27	WOS:000072488500021
J	Torgersen, D; Mullin, NP; Drickamer, K				Torgersen, D; Mullin, NP; Drickamer, K			Mechanism of ligand binding to E- and P-selectin analyzed using selectin/mannose-binding protein chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING; CARBOHYDRATE-RECOGNITION; ANIMAL LECTINS; TYROSINE SULFATION; AMINO-TERMINUS; CELL-ADHESION; MUTAGENESIS; SPECIFICITY; DOMAIN; PSGL-1	The mechanism of oligosaccharide binding to the selectin cell adhesion molecules has been analyzed by transferring regions of the carbohydrate-recognition domains of E- and P-selectin into corresponding sites in the homologous rat serum mannose-binding protein. Insertion of two basic regions and an adjacent glutamic acid residue leads to efficient binding of HL-60 cells and sialyl-Lewis(x)-conjugated serum albumin. Substitution of glycine for a histidine residue known to stabilize mannose in the binding site of wild type mannose-binding protein results in dramatic loss of affinity for mannose without decreasing binding to sialyl-Lewis(x). The accumulated effect of these changes is to alter the ligand binding selectivity of the domain so that it resembles E- or P-selectin more closely than it resembles the parental mannose-binding domain. Affinity labeling using sialyl-Lewis(x) in which the sialic acid has been mildly oxidized has been used to verify this switch in specificity and to show that the sialic acid-containing portion of the ligand interacts near the sequence Lys-Lys-Lys corresponding to residues 111-113 of E-selectin. The binding of sialyl-Lewis(x)-serum albumin is inhibited dramatically at physiological and higher salt concentrations, consistent with a significant electrostatic component to the binding interaction, The binding characteristics of these gain-of-function chimeras suggest that they contain many of the selectin residues responsible for selective ligand binding.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Drickamer, K (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	kd@glycob.ox.ac.uk		Mullin, Nicholas/0000-0003-4802-440X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; Blanck O, 1996, J BIOL CHEM, V271, P7289, DOI 10.1074/jbc.271.13.7289; Bornstein P, 1977, Methods Enzymol, V47, P132; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1989, BIOCHEM SOC T, V17, P13, DOI 10.1042/bst0170013; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HOLLENBAUGH D, 1995, BIOCHEMISTRY-US, V34, P5678, DOI 10.1021/bi00016a044; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; Imberty A, 1997, CURR OPIN STRUC BIOL, V7, P617, DOI 10.1016/S0959-440X(97)80069-3; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1991, J BIOL CHEM, V266, P13828; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Puri KD, 1996, J BIOL CHEM, V271, P5404, DOI 10.1074/jbc.271.10.5404; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; VANLENTEN L, 1972, METHODS ENZYMOLOGY B, V28, P209; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313, DOI 10.1016/S0065-2776(08)60645-8	36	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6254	6261		10.1074/jbc.273.11.6254	http://dx.doi.org/10.1074/jbc.273.11.6254			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497351	hybrid			2022-12-27	WOS:000072488500043
J	McKie, AE; Edlind, T; Walker, J; Mottram, JC; Coombs, GH				McKie, AE; Edlind, T; Walker, J; Mottram, JC; Coombs, GH			The primitive protozoon Trichomonas vaginalis contains two methionine gamma-lyase genes that encode members of the gamma-family of pyridoxal 5 '-phosphate-dependent enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CLONING; IDENTIFICATION; HYDROGENOSOME; PURIFICATION; PROTEIN; OVALIS	Methionine gamma-lyase, the enzyme that catalyzes the breakdown of methionine by an alpha,gamma-elimination reaction and is a member of the gamma-family of pyridoxal 5 '-phosphate-dependent enzymes, is present in high activity in the primitive protozoan parasite Trichomonas vaginalis but is absent from mammals. Two genes, mgl1 and mgl2, encoding methionine gamma-lyase, have now been isolated from T. vaginalis. They are both single copy, encode predicted proteins (MGL1 and MGL2) of 43 kDa, have 69% sequence identity with each other, and show a high degree of sequence identity to methionine gamma-lyase from Pseudomonas putida (44%) and other related pyridoxal 5 '-phosphate-dependent enzymes such as human cystathionine gamma-lyase (42%) and Escherichia coli cystathionine beta-lyase (30%), mgl1 and mgl2 have been expressed in E. coli as a fusion with a six-histidine tag and the recombinant proteins (rMGL1 and rMGL2) purified by metal-chelate affinity chromatography, rMGL1 and rMGL2 were found to have high activity toward methionine (10.4 and 0.67 mu mol/min/mg of protein, respectively), homocysteine (370 and 128 mu mol/min/mg of protein), cysteine (6.02 and 1.06 mu mol/min/mg of protein), and O-acetylserine (3.74 and 1.51 mu mol/min/mg of protein), but to be inactive toward cystathionine. Site-directed mutagenesis of an active site cysteine (C113G for MGL1 and C116G for MGL2) reduced the activity of the recombinant enzymes toward both methionine and homocysteine by approximately 80% (rMGL1) and 90% (rMGL2). In contrast, the activity of mutated rMGL2 toward cysteine and O-acetylserine was increased (to 214 and 142%, respectively), whereas that of mutated rMGL1 was reduced to 39 and 49%, respectively. These findings demonstrate the importance of this cysteine residue in the alpha,beta-elimination and alpha,gamma-elimination reactions catalyzed by trichomonad methionine gamma-lyase.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Wellcome Unit Mol Parasitol, Anderson Coll, Glasgow G11 6NU, Lanark, Scotland; Allegheny Univ Hlth Sci, Dept Immunol & Microbiol, Philadelphia, PA 19129 USA	University of Glasgow; University of Glasgow; Drexel University	Coombs, GH (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.coombs@bio.gla.ac.uk		Mottram, Jeremy/0000-0001-5574-3766; Britten, Amanda/0000-0003-2431-7849	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Bradley PJ, 1997, EMBO J, V16, P3484, DOI 10.1093/emboj/16.12.3484; Bui ETN, 1996, MOL BIOCHEM PARASIT, V76, P305, DOI 10.1016/0166-6851(96)02567-4; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; Clausen T, 1997, BIOL CHEM, V378, P321; Clausen T, 1996, J MOL BIOL, V262, P202, DOI 10.1006/jmbi.1996.0508; Coombs GH, 1997, PARASITOLOGY, V114, pS61, DOI 10.1017/S003118209700111X; COOMBS GH, 1995, BIOCH M OL BIOL PARA, P407; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; Czok R, 1974, METHOD ENZYMAT AN, V3, P1446; DUCHANGE N, 1983, J BIOL CHEM, V258, P4868; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; ESAKI N, 1987, METHOD ENZYMOL, V143, P459; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; GIOVANELLI J, 1987, METHOD ENZYMOL, V143, P443; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; GUNDERSON J, 1995, J EUKARYOT MICROBIOL, V42, P411, DOI 10.1111/j.1550-7408.1995.tb01604.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Hausler T, 1997, EUR J CELL BIOL, V73, P240; Hori H, 1996, CANCER RES, V56, P2116; HORNER DS, 1997, P R SOC LOND B, V263, P1053; INOUE H, 1995, J BIOCHEM-TOKYO, V117, P1120, DOI 10.1093/oxfordjournals.jbchem.a124816; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; Lockwood B.C., 1991, P113; LOCKWOOD BC, 1991, BIOCHEM J, V279, P675, DOI 10.1042/bj2790675; LU Y, 1992, BIOCHEM BIOPH RES CO, V189, P749, DOI 10.1016/0006-291X(92)92265-Y; MALLINSON DJ, 1994, MICROBIOL-UK, V140, P2725, DOI 10.1099/00221287-140-10-2725; MOTTRAM JC, 1993, J BIOL CHEM, V268, P21044; Muller M, 1998, SYST ASSOC SPEC VOL, V56, P109; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; NAKAYAMA T, 1988, AGR BIOL CHEM TOKYO, V52, P177; NAKAYAMA T, 1988, BIOCHEMISTRY-US, V27, P1587, DOI 10.1021/bi00405a029; ONO BI, 1992, J BACTERIOL, V174, P3339, DOI 10.1128/jb.174.10.3339-3347.1992; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; SODA K, 1968, ANAL BIOCHEM, V25, P228, DOI 10.1016/0003-2697(68)90095-X; SODA K, 1987, METHOD ENZYMOL, V143, P452; TANAKA H, 1977, BIOCHEMISTRY-US, V16, P100, DOI 10.1021/bi00620a016; TANAKA H, 1976, FEBS LETT, V66, P307, DOI 10.1016/0014-5793(76)80528-5; THONG KW, 1985, IRCS MED SCI-BIOCHEM, V13, P493; THONG KW, 1987, MOL BIOCHEM PARASIT, V23, P223, DOI 10.1016/0166-6851(87)90029-6; THONG KW, 1987, EXP PARASITOL, V63, P143, DOI 10.1016/0014-4894(87)90155-X	41	61	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5549	5556		10.1074/jbc.273.10.5549	http://dx.doi.org/10.1074/jbc.273.10.5549			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488680	hybrid			2022-12-27	WOS:000072345000023
J	Pan, GH; O'Rourke, K; Dixit, VM				Pan, GH; O'Rourke, K; Dixit, VM			Caspase-9, Bcl-X-L, and Apaf-1 form a ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; APOPTOSIS; HOMOLOG; DOMAIN; BAX	Genetic analysis of apoptosis in the nematode Caenorhabditis elegans has revealed the cell death machine to be composed of three core interacting components. CED-4 (equivalent to mammalian Apaf-1) is a nucleotide binding molecule that complexes with the zymogen form of the death protease CED-3, leading to its autoactivation and cell death, CED-9 blocks death by complexing with CED-4 and attenuating its ability to promote CED-3 activation, An equivalent ternary complex was found to be present in mammalian cells involving Apaf-1, the mammalian death protease caspase-9, and Bcl-X-L, an anti-apoptotic member of the Bcl-2 family, Consistent with a central role for caspase-9, a dominant negative form effectively inhibited cell death initiated by a wide variety of inducers.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Dixit, VM (corresponding author), Genentech Inc, 1 DNA Way,M-S-40, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIEHS NIH HHS [ES08111] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	31	448	473	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5841	5845		10.1074/jbc.273.10.5841	http://dx.doi.org/10.1074/jbc.273.10.5841			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488720	hybrid			2022-12-27	WOS:000072345000063
J	Romero, F; Germani, A; Puvion, E; Camonis, J; Varin-Blank, N; Gisselbrecht, S; Fischer, S				Romero, F; Germani, A; Puvion, E; Camonis, J; Varin-Blank, N; Gisselbrecht, S; Fischer, S			Vav binding to heterogeneous nuclear ribonucleoprotein (hnRNP) C - Evidence for Vav-hnRNP interactions in an RNA-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE PRODUCT; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; T-CELL; INTRANUCLEAR DISTRIBUTION; PERICHROMATIN FIBRILS; SITU HYBRIDIZATION; SIGNALING PATHWAY; PREMESSENGER RNA; SH3 DOMAIN	The vav proto-oncogene is exclusively expressed in hematopoietic cells and encodes a 95-kDa protein that contains multiple structural domains, Vav is involved in the expansion of T and B cells, in antigen-mediated proliferative responses, and in the induction of intrathymic T cell maturation. It becomes rapidly and transiently tyrosine-phosphorylated upon triggering of a large number of surface receptors and catalyzes GDP/GTP exchange on Rac-1, We now provide evidence for the specific interaction of Vav with heterogeneous nuclear ribonucleoprotein (hnRNP) C. Vav and hnRNP C interact both in vivo and in vitro mediated through the carboxyl Src homology 3 domain of Vav and the proline-rich motif located in the nuclear retention sequence of hnRNP C. More importantly, Vav-hnRNP C complexes are present in living hematopoietic cells and both proteins localize in the nuclei, mainly on perichromatic fibrils but also on clusters of interchromatin granules. The Vav-hnRNP C interaction is regulated by poly(U) RNA although a basal association is still detected in the absence of RNA. Furthermore, RNA homopolymers differentially alter the binding affinity of Vav to hnRNP C and hnRNP K, We propose that Vav-hnRNP interactions may be established in an RNA-dependent manner.	Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France; CNRS, UPR 9044, Lab Biol & Ultrastruct Noyau, F-94801 Villejuif, France; INSERM, U248, Inst Curie, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Romero, F (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	romero@iegm.cochin.inserm.fr	Romero, Francisco/K-2101-2014; Varin-Blank, Nadine/G-4396-2013	Romero, Francisco/0000-0002-9588-6881; VARIN-BLANK, Nadine/0000-0003-2769-018X				ALAI M, 1992, J BIOL CHEM, V267, P18021; BACHELLERIE JP, 1975, EUR J BIOCHEM, V58, P327, DOI 10.1111/j.1432-1033.1975.tb02379.x; BERNHARD W, 1969, J ULTRA MOL STRUCT R, V27, P250, DOI 10.1016/S0022-5320(69)80016-X; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FAKAN S, 1976, EXP CELL RES, V99, P155, DOI 10.1016/0014-4827(76)90690-X; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; NASH RE, 1975, J ULTRA MOL STRUCT R, V53, P395, DOI 10.1016/S0022-5320(75)80040-2; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PUVION E, 1978, EXP CELL RES, V115, P79, DOI 10.1016/0014-4827(78)90404-4; PUVION E, 1984, J ULTRA MOL STRUCT R, V87, P180, DOI 10.1016/S0022-5320(84)80077-5; REEVES WH, 1994, MANUAL BIOL MARKERS, P1; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Romero F, 1996, MOL CELL BIOL, V16, P37; ROTH J, 1989, METHOD CELL BIOL, V31, P513; SACERES JF, 1994, SCIENCE, V265, P1706; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuebel KE, 1996, ONCOGENE, V13, P363; Sherman F., 1986, METHODS YEAST GENETI; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; VISA N, 1993, EUR J CELL BIOL, V60, P308; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; [No title captured]	57	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5923	5931		10.1074/jbc.273.10.5923	http://dx.doi.org/10.1074/jbc.273.10.5923			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488731	hybrid			2022-12-27	WOS:000072345000074
J	Sarov-Blat, L; Livneh, Z				Sarov-Blat, L; Livneh, Z			The mutagenesis protein MucB interactions with single strand DNA binding protein and induces a major conformational change in its complex with single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DEFICIENT; POLYMERASE-III HOLOENZYME; SOS-REGULATED PROTEINS; RECA-PROTEIN; ULTRAVIOLET-LIGHT; UV MUTAGENESIS; DEOXYRIBONUCLEIC-ACID; APURINIC SITES; REPLICATION; UMUD	The MucA and MucB proteins are plasmid-encoded homologues of the Escherichia coli UmuD and UmuC proteins, respectively. These proteins are required for SOS mutagenesis, although their mechanism of action is unknown. By using the yeast two-hybrid system we have discovered that MucB interacts with SSB, the single strand DNA binding protein (SSB) of E. coli. To examine the interaction at the protein level, the MucA, MucA', and MucB proteins were overproduced, purified in denatured state, and refolded. Purified MucA and MucA' each formed homodimers, whereas MucB was a monomer under native conditions. RecA promoted the cleavage of MucA to MucA', and MucB was found to bind single-stranded DNA (ssDNA), similarly to the properties of the homologous UmuD and UmuC proteins. Purified MucB caused a shift in the migration of SSB in a sucrose density gradient, consistent with an interaction between these proteins, Addition of MucB to SSB-coated ssDNA caused increased electrophoretic mobility of the nucleoprotein complex and increased staining al the DNA by ethidium bromide, Analysis of radiolabeled SSB in the complexes revealed that only a marginal release of SSB occurred upon addition of MucB, These results suggest that MucB induces a major conformational change in the SSB.ssDNA complex but does not promote massive release of SSB from the DNA. The interaction with SSB might he related to the role of MucB in SOS-regulated mutagenesis.	Weizmann Inst Sci, Fac Biochem, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Livneh, Z (corresponding author), Weizmann Inst Sci, Fac Biochem, Dept Biol Chem, IL-76100 Rehovot, Israel.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; Bruck I, 1996, J BIOL CHEM, V271, P10767, DOI 10.1074/jbc.271.18.10767; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRISTENSEN JR, 1988, J MOL BIOL, V203, P635, DOI 10.1016/0022-2836(88)90198-2; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; COHENFIX O, 1994, J BIOL CHEM, V269, P4953; ELLEDGE SJ, 1983, J MOL BIOL, V164, P175, DOI 10.1016/0022-2836(83)90074-8; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; FREITAG N, 1989, P NATL ACAD SCI USA, V86, P8363, DOI 10.1073/pnas.86.21.8363; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HAUSER J, 1992, J BACTERIOL, V174, P6844, DOI 10.1128/JB.174.21.6844-6851.1992; HEVRONI D, 1988, P NATL ACAD SCI USA, V85, P5046, DOI 10.1073/pnas.85.14.5046; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jonczyk P, 1996, J BACTERIOL, V178, P2580, DOI 10.1128/jb.178.9.2580-2585.1996; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kornberg A., 1991, DNA REPLICATION; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KUNKEL TA, 1981, NATURE, V291, P349, DOI 10.1038/291349a0; LIEBERMAN HB, 1981, MOL GEN GENET, V183, P348, DOI 10.1007/BF00270639; LIEBERMAN HB, 1983, MOL GEN GENET, V190, P92, DOI 10.1007/BF00330329; LIVNEH Z, 1986, J BIOL CHEM, V261, P9526; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LIVNEH Z, 1986, P NATL ACAD SCI USA, V83, P4599, DOI 10.1073/pnas.83.13.4599; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARSH L, 1987, J BACTERIOL, V169, P1818, DOI 10.1128/jb.169.5.1818-1823.1987; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; Miller J.H., 1972, EXPT MOL GENETICS; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; PazElizur T, 1997, J BIOL CHEM, V272, P28906, DOI 10.1074/jbc.272.46.28906; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; PERRY KL, 1985, P NATL ACAD SCI USA, V82, P4331, DOI 10.1073/pnas.82.13.4331; PERRY KL, 1982, NATURE, V300, P278, DOI 10.1038/300278a0; PETIT MA, 1994, J BIOL CHEM, V269, P23824; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SHIBA T, 1990, MOL GEN GENET, V224, P169, DOI 10.1007/BF00271549; SHINAGAWA H, 1983, GENE, V23, P167; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; STRAUSS BS, 1985, CANCER SURV, V4, P493; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Szekeres ES, 1996, J BACTERIOL, V178, P2559, DOI 10.1128/jb.178.9.2559-2563.1996; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TESSMAN I, 1985, P NATL ACAD SCI USA, V82, P6614, DOI 10.1073/pnas.82.19.6614; Tomer G, 1996, P NATL ACAD SCI USA, V93, P1376, DOI 10.1073/pnas.93.4.1376; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WOODGATE R, 1994, J BACTERIOL, V176, P5011, DOI 10.1128/jb.176.16.5011-5021.1994; Woodgate R, 1996, CANCER SURV, V28, P117; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301	60	29	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5520	5527		10.1074/jbc.273.10.5520	http://dx.doi.org/10.1074/jbc.273.10.5520			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488676	hybrid			2022-12-27	WOS:000072345000019
J	Scharer, OD; Nash, HM; Jiricny, J; Laval, J; Verdine, GL				Scharer, OD; Nash, HM; Jiricny, J; Laval, J; Verdine, GL			Specific binding of a designed pyrrolidine abasic site analog to multiple DNA glycosylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; EXCISION-REPAIR PATHWAY; SUBSTRATE-SPECIFICITY; DAMAGED DNA; CATALYTIC MECHANISM; ENDONUCLEASE-III; STRUCTURAL BASIS; ALKYLATED DNA; HELA-CELLS; 3-METHYLADENINE	In the base excision DNA repair pathway, DNA glycosylases recognize damaged bases in DNA and catalyze their excision through hydrolysis of the N-glycosidic bond. Attempts to understand the structural basis for DNA damage recognition by DNA glycosylases have been hampered by the short-lived association of these enzymes with their DNA substrate. To overcome this problem, we have employed an approach involving the design and synthesis of inhibitors that form stable complexes with DNA glycosylases, which can then be studied biochemically and structurally. We have previously reported that double-stranded DNA containing a pyrrolidine abasic site analog (PYR) forms an extremely stable complex with the DNA glycosylase AlkA and potently inhibits the reaction catalyzed by the enzyme (Scharer, O. D., Ortholand, J.-Y., Ganesan, A., Ezaz-Nikpay, R., and Verdine, G. L. (1995) J. Am. Chem. Sec. 117, 6623-6624). Here we investigate the interaction of this inhibitor with a variety of additional DNA glycosylases. With the exception of uracil DNA glycosylase all the glycosylases tested bind specifically to PYR containing oligonucleotides. By comparing the interaction of DNA glycosylases with PYR and the structurally related tetrahydrofuran abasic site analog, we assess the importance of the positively charged ammonium group of the pyrrolidine in binding to the active site of these enzymes. Such a general inhibitor of DNA glycosyases provides a valuable tool to study stable complexes of these enzymes bound to substrate-like molecules.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Inst Med Radiobiol, CH-8029 Zurich, Switzerland; Inst Gustave Roussy, Grp Reparat ADN, URA 147 CNRS, PRII, F-94805 Villejuif, France	Harvard University; UNICANCER; Gustave Roussy	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	verdine@chemistry.harvard.edu	Scharer, Orlando/B-8908-2008; Schärer, Orlando D./AAF-8613-2021	Scharer, Orlando/0000-0003-2425-2715; 				BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; Bulychev NV, 1996, BIOCHEMISTRY-US, V35, P13147, DOI 10.1021/bi960694h; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Deng L, 1997, J AM CHEM SOC, V119, P7865, DOI 10.1021/ja970828u; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LATHAM KA, 1994, DNA DAMAGE, P181; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lu AL, 1996, J BIOL CHEM, V271, P24138, DOI 10.1074/jbc.271.39.24138; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; MATIJASEVIC Z, 1992, P NATL ACAD SCI USA, V89, P9331, DOI 10.1073/pnas.89.19.9331; MATIJASEVIC Z, 1993, P NATL ACAD SCI USA, V90, P11855, DOI 10.1073/pnas.90.24.11855; Mattes WB, 1996, CARCINOGENESIS, V17, P643, DOI 10.1093/carcin/17.4.643; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; McCullough AK, 1996, J BIOL CHEM, V271, P32147, DOI 10.1074/jbc.271.50.32147; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; NASH HM, 1996, CURR BIOL, V6, P868; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Porello SL, 1996, J AM CHEM SOC, V118, P10684, DOI 10.1021/ja9602206; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SCHARER OD, 1995, J AM CHEM SOC, V117, P10781, DOI 10.1021/ja00148a036; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; SCHARER OD, 1996, THESIS HARVARD U CAM; SCHRAMM VL, 1994, J BIOL CHEM, V269, P18259; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Sitaram A, 1997, MOL CELL BIOL, V17, P564, DOI 10.1128/MCB.17.2.564; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	57	91	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8592	8597		10.1074/jbc.273.15.8592	http://dx.doi.org/10.1074/jbc.273.15.8592			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535832	hybrid, Green Published			2022-12-27	WOS:000072990800009
J	Santos-Ocana, C; Cordoba, F; Crane, FL; Clarke, CF; Navas, P				Santos-Ocana, C; Cordoba, F; Crane, FL; Clarke, CF; Navas, P			Coenzyme Q(6) and iron reduction are responsible for the extracellular ascorbate stabilization at the plasma membrane of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUINONE BIOSYNTHESIS; ELECTRON-TRANSPORT; MOLECULAR CHARACTERIZATION; FERRIC REDUCTASE; STRUCTURAL GENE; REDOX SYSTEM; CELL-LINE; YEAST; PROTEIN; GROWTH	Yeast plasma membrane contains an electron transport system that maintains ascorbate in its reduced form in the apoplast, Reduction of ascorbate free radical by this system is comprised of two activities, one of them dependent on coenzyme Q(6) (CoQ(6)), Strains with defects in CoQ(6) synthesis exhibit decreased capacity for ascorbate stabilization compared with wild type or with atp2 or cor1 respiratory-deficient mutant strains, Both CoQ(6) content in plasma membranes and ascorbate stabilization were increased during log phase growth, The addition of exogenous CoQ(6) to whole cells resulted in its incorporation in the plasma membrane, produced levels of CoQ(6) in the coq3 mutant strain that were 2-fold higher than in the wild type, and increased ascorbate stabilization activity in both strains, although it was higher in the coq3 mutant than in wild type, Other antioxidants, such as benzoquinone or alpha-tocopherol, did not change ascorbate stabilization. The CoQ(6)-independent reduction of ascorbate free radical was not due to copper uptake, pH changes or to the presence of CoQ(6) biosynthetic intermediates, but decreased to undetectable levels when coq3 mutant strains were cultured in media supplemented with ferric iron, Plasma membrane CoQ(6) levels were unchanged by either the presence or absence of iron in wild type, atp2, or cor1 strains, Ascorbate stabilization appears to be a function of the yeast plasma membrane, which is partially based on an electron transfer chain in which CoQ(6) is the central electron carrier, whereas the remainder is independent of CoQ(6) and other antioxidants but is dependent on the iron-regulated ferric reductase complex.	Univ Cordoba, Fac Ciencias, Dept Biol Celular, E-14004 Cordoba, Spain; Univ Huelva, Dept Ciencias Agroforestales, Huelva 21819, Spain; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Universidad de Cordoba; Universidad de Huelva; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California Los Angeles	Navas, P (corresponding author), Univ Cordoba, Fac Ciencias, Dept Biol Celular, Ave San Alberto Magno S-N, E-14004 Cordoba, Spain.	bc1nallp@lucano.uco.es	NAVAS, PLACIDO/R-5943-2019; CORDOBA, FRANCISCO/I-1687-2015; Ocaña, Carlos Santos/E-8115-2011	NAVAS, PLACIDO/0000-0002-4115-7966; CORDOBA, FRANCISCO/0000-0002-2009-7992; Ocaña, Carlos Santos/0000-0002-2379-796X	NIGMS NIH HHS [GM-45952] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCAIN FJ, 1990, CANCER RES, V50, P5887; ALCAIN FJ, 1991, BIOCHIM BIOPHYS ACTA, V1073, P380, DOI 10.1016/0304-4165(91)90146-8; ASARD H, 1987, PLANT SCI, V53, P109, DOI 10.1016/0168-9452(87)90120-8; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; BEYER RE, 1994, J BIOENERG BIOMEMBR, V26, P349, DOI 10.1007/BF00762775; Buettner GR, 1996, HDB ANTIOXIDANTS, P91; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; CordobaPedregosa MD, 1996, PLANT PHYSIOL, V112, P1119, DOI 10.1104/pp.112.3.1119; CRANE FL, 1982, J BIOENERG BIOMEMBR, V14, P191, DOI 10.1007/BF00745020; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; EIDE D, 1992, J BIOL CHEM, V267, P20774; GomezDiaz C, 1997, BIOCHEM BIOPH RES CO, V234, P79, DOI 10.1006/bbrc.1997.6582; GOMEZDIAZ C, 1997, J BIOENERG BIOMEMBR, V29, P253; GONZALEZQUEVEDO M, 1991, CANCER J - FRANCE, V4, P262; GONZALEZREYES JA, 1994, PLANT SCI, V100, P23, DOI 10.1016/0168-9452(94)90130-9; Kaiser C., 1994, METHODS YEAST GENETI; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; KANEKO T, 1994, FREE RADICAL BIO MED, V16, P405, DOI 10.1016/0891-5849(94)90043-4; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; LARM JA, 1994, J BIOL CHEM, V269, P30097; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MARTINUS RD, 1993, BIOCHEM MOL BIOL INT, V31, P997; MENENDEZ A, 1995, ANAL BIOCHEM, V230, P308, DOI 10.1006/abio.1995.1479; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; NAVARRO F, 1995, BIOCHEM BIOPH RES CO, V212, P138, DOI 10.1006/bbrc.1995.1947; NICHOLAS DJD, 1957, METHOD ENZYMOL, V3, P1035, DOI 10.1016/S0076-6879(57)03494-1; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; RAMIREZ JM, 1984, PLANT SCI LETT, V34, P103, DOI 10.1016/0304-4211(84)90132-9; SANTIAGO LA, 1993, ARCH BIOCHEM BIOPHYS, V306, P16, DOI 10.1006/abbi.1993.1474; SantosOcana C, 1995, J BIOENERG BIOMEMBR, V27, P597, DOI 10.1007/BF02111657; STAHL JD, 1995, ARCH BIOCHEM BIOPHYS, V322, P221, DOI 10.1006/abbi.1995.1455; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	42	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8099	8105		10.1074/jbc.273.14.8099	http://dx.doi.org/10.1074/jbc.273.14.8099			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525912	hybrid, Green Published			2022-12-27	WOS:000072876300046
J	Vassias, I; Hazan, U; Michel, Y; Sawa, C; Handa, H; Gouya, L; Morinet, F				Vassias, I; Hazan, U; Michel, Y; Sawa, C; Handa, H; Gouya, L; Morinet, F			Regulation of human B19 parvovirus promoter expression by hGABP (E4TF1) transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; P6 PROMOTER; CELL-LINE; NONSTRUCTURAL PROTEIN; MAMMALIAN-CELLS; MINUTE VIRUS; ETS FAMILY; ACTIVATION; BINDING; INVITRO	The genetic expression of human B19 parvovirus is only dependent on one promoter in vivo and in vitro. This is the P6 promoter, which is located on the left side of the genome and is a single-stranded DNA molecule. This led us to investigate the regulation of the P6 promoter and the possible resulting variability of the nucleotide sequence. After analysis of the promoter region of 17 B19 strains, only 1.5% variability was found. More exciting was the finding of mutations that were clustered around the TATA box and defined a highly conserved region (nucleotides 113-210) in the proximal part of the P6 promoter. HeLa and UT7/Epo cell extracts were found to protect this region, which contained a core motif for Ets family proteins, with YY1 and Sp1 binding sites on either side, Gel mobility shift assays performed with nuclear proteins from HeLa and UT7/Epo cells identified DNA-binding proteins specific for these sites. By supershift analysis, we demonstrated the binding of the hGABP (also named E4TF1) protein to the Ets binding site and the fixation of Sp1 and YY1 proteins on their respective motifs. In Drosophila SL2 cells, hGABP alpha and -beta stimulated P6 promoter activity, and hGABP alpha/hGABP beta and Sp1 exerted synergistic stimulation of this activity, an effect diminished by YY1.	Hop St Louis, Microbiol Serv, Unite Virol, F-75475 Paris 10, France; Hop St Louis, Microbiol Serv, CNRS, UPR 9051, F-75475 Paris, France; Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 226, Japan	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Tokyo Institute of Technology	Morinet, F (corresponding author), Hop St Louis, Microbiol Serv, Unite Virol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.			Gouya, Laurent/0000-0002-1326-7025				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERNS KI, 1994, ARCH VIROL         S, V10, P166; BLUNDELL MC, 1987, VIROLOGY, V157, P534, DOI 10.1016/0042-6822(87)90296-0; BLUNDELL MC, 1989, J VIROL, V63, P4814, DOI 10.1128/JVI.63.11.4814-4823.1989; BROWN KE, 1994, CRIT REV ONCOL HEMAT, V16, P1, DOI 10.1016/1040-8428(94)90040-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COTMORE SF, 1986, J VIROL, V60, P548, DOI 10.1128/JVI.60.2.548-557.1986; DEISS V, 1990, VIROLOGY, V175, P247, DOI 10.1016/0042-6822(90)90205-6; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DOERIG C, 1990, J VIROL, V64, P387, DOI 10.1128/JVI.64.1.387-396.1990; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fuks F, 1996, J VIROL, V70, P1331, DOI 10.1128/JVI.70.3.1331-1339.1996; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Klug J, 1996, MOL CELL BIOL, V16, P6398; KOMATSU N, 1991, CANCER RES, V51, P341; LERUEZ M, 1994, J GEN VIROL, V75, P1475, DOI 10.1099/0022-1317-75-6-1475; LeruezVille M, 1997, J GEN VIROL, V78, P215, DOI 10.1099/0022-1317-78-1-215; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; LIU JM, 1991, VIROLOGY, V185, P39, DOI 10.1016/0042-6822(91)90751-V; LUO WX, 1993, VIROLOGY, V195, P448, DOI 10.1006/viro.1993.1395; Moffatt S, 1996, J VIROL, V70, P8485, DOI 10.1128/JVI.70.12.8485-8491.1996; MOMOEDA M, 1994, J VIROL, V68, P7159, DOI 10.1128/JVI.68.11.7159-7168.1994; MORTIMER PP, 1983, NATURE, V302, P426, DOI 10.1038/302426a0; OZAWA K, 1986, SCIENCE, V233, P883, DOI 10.1126/science.3738514; OZAWA K, 1987, J VIROL, V61, P2395, DOI 10.1128/JVI.61.8.2395-2406.1987; Pallier C, 1997, J VIROL, V71, P9482, DOI 10.1128/JVI.71.12.9482-9489.1997; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIMOMURA S, 1992, BLOOD, V79, P18; SOL N, 1993, J GEN VIROL, V74, P2011, DOI 10.1099/0022-1317-74-9-2011; SRIVASTAVA A, 1990, BLOOD, V76, P1997; TAKAHASHI T, 1990, BLOOD, V75, P603; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Wang XS, 1995, P NATL ACAD SCI USA, V92, P12416, DOI 10.1073/pnas.92.26.12416; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840	49	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8287	8293		10.1074/jbc.273.14.8287	http://dx.doi.org/10.1074/jbc.273.14.8287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525935	hybrid			2022-12-27	WOS:000072876300069
J	Yao, H; York, RD; Misra-Press, A; Carr, DW; Stork, PJS				Yao, H; York, RD; Misra-Press, A; Carr, DW; Stork, PJS			The cyclic adenosine monophosphate-dependent protein kinase (PKA) is required for the sustained activation of mitogen-activated kinases and gene expression by nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; COMPLEX FACTOR ELK-1; NEURITE OUTGROWTH; RESPONSIVE ELEMENT; SIGNALING PATHWAY; RAPIDLY ACTIVATE; FACTOR RECEPTORS; DOWN-REGULATION; MAP KINASES; CAMP	Induction of neuronal differentiation of the rat pheochromocytoma cell line, PC12 cells, by nerve growth factor (NGF) requires activation of the mitogen-activated protein (MAP) kinase or extracellular signal-regulated kinase (ERK). cAMP-dependent protein kinase (protein kinase A (PKA)) also call induce differentiation of these cells. Like NGF, the ability of PKA. to differentiate PC12 cells is associated with a sustained activation of ERKs, Here we show that maximal sustained activation of ERK1 by NGF requires PKA, Inhibitors of PKA partially blocked activation of ERK1 by NGF but had no effect on activation of ERK1 by EGF. Inhibition of PRA also reduced the ability of NGF and cAMP, but not EGF, to activate the transcription factor Elk-1, reduced the induction of both immediate early and late genes after NGF treatment, and blocked the nuclear translocation of ERK1 induced by NGF. We propose that PKA is an important contributor to the activation of ERK1 by NGF and is required for maximal induction of gene expression by NGF.	Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Grad Program Neurosci, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Endocrinol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University	Carr, DW (corresponding author), Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	stork@ohsu.edu						BALBI D, 1994, MOL BRAIN RES, V23, P310, DOI 10.1016/0169-328X(94)90240-2; BERG KA, 1995, J NEUROCHEM, V64, P220; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; BUDAY L, 1995, ONCOGENE, V11, P1327; Canossa M, 1996, EMBO J, V15, P3369, DOI 10.1002/j.1460-2075.1996.tb00702.x; CARR DW, 1993, J BIOL CHEM, V268, P20729; Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DAY RN, 1989, J BIOL CHEM, V264, P431; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FILLMORE HL, 1992, J NEUROSCI RES, V31, P662, DOI 10.1002/jnr.490310410; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1156; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mark MD, 1997, J BIOL CHEM, V272, P17238, DOI 10.1074/jbc.272.27.17238; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILLBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NORDSTROM LA, 1995, MOL CELL NEUROSCI, V6, P56, DOI 10.1006/mcne.1995.1006; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; PATTEN SMV, 1992, MOL ENDOCRINOL, V6, P2114; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RACE HM, 1985, J NEUROCHEM, V44, P1588, DOI 10.1111/j.1471-4159.1985.tb08799.x; RICHTERLANDSBERG C, 1986, J CELL BIOL, V102, P821, DOI 10.1083/jcb.102.3.821; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; Vijayaraghavan S, 1997, BIOL REPROD, V57, P1517, DOI 10.1095/biolreprod57.6.1517; VOLONTE C, 1993, J NEUROCHEM, V61, P664; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; VOLONTE C, 1995, J NEUROSCI RES, V40, P108, DOI 10.1002/jnr.490400112; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	74	122	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8240	8247		10.1074/jbc.273.14.8240	http://dx.doi.org/10.1074/jbc.273.14.8240			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525930	hybrid			2022-12-27	WOS:000072876300064
J	Dandoy-Dron, F; Guillo, F; Benboudjema, L; Deslys, JP; Lasmezas, C; Dormont, D; Tovey, MG; Dron, M				Dandoy-Dron, F; Guillo, F; Benboudjema, L; Deslys, JP; Lasmezas, C; Dormont, D; Tovey, MG; Dron, M			Gene expression in scrapie - Cloning a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRION PROTEIN-FRAGMENT; RAT CATHEPSIN-S; ALZHEIMERS-DISEASE; TISSUE DISTRIBUTION; DIFFERENTIAL DISPLAY; MESSENGER-RNA; BRAIN; MOUSE; CELLS; ASTROCYTES	To define genes associated with or responsible for the neurodegenerative changes observed in transmissible spongiform encephalopathies, we analyzed gene expression in scrapie-infected mouse brain using "mRNA differential display." The RNA transcripts of eight genes were increased 3-8-fold in the brains of scrapie-infected animals, Five of these genes have not previously been reported to exhibit increased expression in this disease: cathepsin S, the C1q B-chain of complement, apolipoprotein D, and two previously unidentified genes denominated scrapie-responsive gene (ScRG)-1 and ScRG-2, which are preferentially expressed in brain tissue, Increased expression of the three remaining genes, beta 2 microglobulin, F4/80, and metallothionein II, has previously been reported to occur in experimental scrapie, Kinetic analysis revealed a concomitant increase in the levels of ScRG-1, cathepsin S, the C1q B-chain of complement, and beta 2 microglobulin mRNA as well as glial fibrillary acidic protein and F4/80 transcripts, markers of astrocytosis and microglial activation, respectively, In contrast, the level of ScRG-2, apolipoprotein D, and metallothionein II mRNA was only increased at the terminal stage of the disease. ScRG-1 mRNA was found to be preferentially expressed in glial cells and to code for a short protein of 47 amino acids with a strong hydrophobic N-terminal region.	IFC1, CNRS, UPR 9045, Lab Oncol Virale, F-94801 Villejuif, France; CEA, Lab Neurovirol, F-92265 Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); CEA	Dron, M (corresponding author), IFC1, CNRS, UPR 9045, Lab Oncol Virale, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.	mdron@infobiogen.fr	DRON, Michel/M-7093-2017	Tovey, Michael/0000-0002-3058-0494				Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; CAMPBELL IL, 1994, J VIROL, V68, P2383, DOI 10.1128/JVI.68.4.2383-2387.1994; Castelnau PA, 1997, NEUROSCI LETT, V234, P15, DOI 10.1016/S0304-3940(97)00670-8; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Chesebro B, 1997, NAT MED, V3, P491, DOI 10.1038/nm0597-491; Chiesa R, 1996, EUR J NEUROSCI, V8, P589, DOI 10.1111/j.1460-9568.1996.tb01244.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DIEDRICH JF, 1993, MICROB PATHOGENESIS, V15, P1, DOI 10.1006/mpat.1993.1051; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; DUGUID J, 1993, P NATL ACAD SCI USA, V90, P114, DOI 10.1073/pnas.90.1.114; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Haga S, 1996, NEUROSCI LETT, V216, P191, DOI 10.1016/S0304-3940(96)13040-8; Hope J, 1996, NEURODEGENERATION, V5, P1, DOI 10.1006/neur.1996.0001; KENWARD N, 1994, J NEUROCHEM, V62, P1870; KOROTZER AR, 1995, EXP NEUROL, V134, P214, DOI 10.1006/exnr.1995.1051; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; LAZARINI F, 1992, J GEN VIROL, V73, P1645, DOI 10.1099/0022-1317-73-7-1645; LAZARINI F, 1994, J COMP PATHOL, V111, P87, DOI 10.1016/S0021-9975(05)80114-8; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEMERE CA, 1995, AM J PATHOL, V146, P848; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LIBERSKI PP, 1993, NEURODEGENERATION, V2, P215; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; MONIARI L, 1994, P NATL ACAD SCI USA, V91, P2839; OESH B, 1985, CELL, V40, P735; Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; Petanceska S, 1996, J BIOL CHEM, V271, P4403; PETANCESKA S, 1994, NEUROSCIENCE, V59, P729, DOI 10.1016/0306-4522(94)90190-2; Petry F, 1996, IMMUNOGENETICS, V43, P370, DOI 10.1007/BF02199805; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; QIAN F, 1989, CANCER RES, V49, P4870; Scott MR, 1997, J VIROL, V71, P9032, DOI 10.1128/JVI.71.12.9032-9044.1997; SEGUIN D, 1995, MOL BRAIN RES, V30, P242, DOI 10.1016/0169-328X(95)00008-G; SHI GP, 1994, J BIOL CHEM, V269, P11530; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Williams A, 1997, EXP NEUROL, V144, P433, DOI 10.1006/exnr.1997.6424; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X; Williams A, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P167	48	130	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7691	7697		10.1074/jbc.273.13.7691	http://dx.doi.org/10.1074/jbc.273.13.7691			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516475	hybrid			2022-12-27	WOS:000072738500071
J	De Cesaris, P; Starace, D; Riccioli, A; Padula, F; Filippini, A; Ziparo, E				De Cesaris, P; Starace, D; Riccioli, A; Padula, F; Filippini, A; Ziparo, E			Tumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; CULTURED SERTOLI CELLS; STIMULATORY FACTOR-II; INFLAMMATORY CYTOKINES; PROTEIN-KINASES; MAMMALIAN-CELLS; GROWTH-FACTOR; BETA-CASEIN; HEAT-SHOCK; ACTIVATION	Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic cytokine that elicits a large number of biological effects. However, the intracellular signaling mechanisms that are responsible for the TNF-alpha effects remain largely unknown. We have previously demonstrated that cultured mouse Sertoli cells, after TNF-alpha treatment, increase the surface expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and interleukin-6 (IL-6) production (Riccioli, A., Filippini, A., De Cesaris, P., Barbacci, E., Stefanini, M., Starace, G., and Ziparo, E. (1995) Proc. Natl. Acad Sci. U.S.A. 92, 5808-5812). Here, we show that, in cultured Sertoli cells, TNF-alpha activates the mitogen-activated protein kinase pathway (p38, c-Jun N-terminal protein kinase/stress-activated protein kinase, and the p42/p44 mitogen-activated protein kinases) as revealed by an increased phosphorylation of p38, activating transcription factor-2, c-Jun, and Elk-1. Furthermore, our data indicate that the biological effects induced by TNF-alpha in Sertoli cells (enhancement of ICAM-1, VCAM-1, and IL-6 expression) depend on the activation of different signaling pathways. SB203580, a highly specific p38 inhibitor, does not affect ICAM-1 and VCAM-1 expression, but strongly inhibits IL-6 production. Moreover, interferon-gamma, which up-regulates adhesion molecule expression and reduces IL-6 production, does not induce phosphorylation of p38. Our data strongly support the hypothesis that, in response to TNF-alpha, activation of p38 leads to IL-6 production, whereas ICAM-1 and VCAM-1 expression could be induced by activation of the c-Jun N-terminal protein kinase/stress activated protein kinase pathway.	Univ Rome La Sapienza, Dept Histol & Med Embryol, Ist Pasteur, Fdn Cenci Bolognetti, I-00161 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; University of L'Aquila	Ziparo, E (corresponding author), Univ Rome La Sapienza, Dept Histol & Med Embryol, Ist Pasteur, Fdn Cenci Bolognetti, Via A Scarpa 16, I-00161 Rome, Italy.	ziparo@axrma.uniroma1.it		Ziparo, Elio/0000-0002-8776-3515				Baker SJ, 1996, ONCOGENE, V12, P1; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DE SK, 1993, ENDOCRINOLOGY, V133, P389, DOI 10.1210/en.133.1.389; DECESARIS P, 1992, BIOCHEM BIOPH RES CO, V186, P1639; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINARELLO CA, 1991, CURR OPIN IMMUNOL, V3, P941, DOI 10.1016/S0952-7915(05)80018-4; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FILIPPINI A, 1989, GAMETE RES, V23, P367, DOI 10.1002/mrd.1120230402; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Galdieri M, 1981, J ANDROL, V5, P249; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; GUY GR, 1991, J BIOL CHEM, V266, P14343; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HIRANO T, 1987, P NATL ACAD SCI USA, V84, P228, DOI 10.1073/pnas.84.1.228; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAUER P, 1989, FEBS LETT, V258, P269; KOHNO S, 1983, J REPROD IMMUNOL, V5, P339, DOI 10.1016/0165-0378(83)90243-7; KOHNO S, 1983, J IMMUNOL, V130, P2675; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANSDORP PM, 1986, CURR TOP MICROBIOL, V132, P105; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN A, 1990, ENDOCRINOLOGY, V127, P651, DOI 10.1210/endo-127-2-651; MAUDUIT C, 1993, ENDOCRINOLOGY, V133, P69, DOI 10.1210/en.133.1.69; Mauduit C, 1996, BIOCHEM BIOPH RES CO, V224, P631, DOI 10.1006/bbrc.1996.1077; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PALOMBI F, 1988, BIOL REPROD, V39, P1101, DOI 10.1095/biolreprod39.5.1101; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stefanini M., 1985, P59; STEFANINI M, 1992, SEX ORIGIN EVOLUTION, P299; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TIISALA S, 1994, BIOCHEM BIOPH RES CO, V203, P443, DOI 10.1006/bbrc.1994.2202; TUNG KSK, 1993, CELL MOL BIOL TESTIS, P474; TUNG KSK, 1980, IMMUNOLOGICAL ASPECT, P33; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; YULE TD, 1993, ENDOCRINOLOGY, V133, P1098, DOI 10.1210/en.133.3.1098	54	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7566	7571		10.1074/jbc.273.13.7566	http://dx.doi.org/10.1074/jbc.273.13.7566			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516459	hybrid			2022-12-27	WOS:000072738500055
J	Li, DZ; Gallup, M; Fan, N; Szymkowski, DE; Basbaum, CB				Li, DZ; Gallup, M; Fan, N; Szymkowski, DE; Basbaum, CB			Cloning of the amino-terminal and 5 '-flanking region of the human MUC5AC mucin gene and transcriptional up-regulation by bacterial exoproducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INTESTINAL MUCIN; CDNA; EXPRESSION; SEQUENCE; AIRWAY; RICH; LOCALIZATION; CELLS	To obtain gene regulatory sequence for the mucin gene MUC5AC, we have isolated the MUC5AC amino terminus cDNA and 5'-flanking region. This was possible through the use of rapid amplification of cDNA ends-polymerase chain reaction (RACE-PCR) in which the 5' sequence of the human gastric mucin cDNA HGM-1 (1) was used to design the first MUC5AC-specific primer. Primers for subsequent rounds of RACE were designed from the 5'-ends of amplified RACE products. After five rounds of RACE-PCR, we could no longer generate upstream extensions of the cDNA and hypothesized that we had reached the 5'-end. Primer extension and RNase protection analysis confirmed this. Combined nucleotide sequence for the RACE-PCR products was 3.3 kb with an open reading frame encoding 1100 amino acids. A putative translation start site was found at nucleotide +48. This was followed by a 45 nucleotide putative signal sequence. This amino-terminal sequence contains no tandem repeats but is >60% similar to the amino terminal nucleotide sequence of MUC2. The positions of cysteine residues in this MUC2-similar region are almost 100% conserved between the two genes. Northern analysis showed expression of cognate RNA in the stomach and airway but not muscle and esophagus. This pattern was the same as that obtained using previously reported 3'-MUC5AC sequences. We have cloned approximately 4 kb of genomic DNA upstream of the transcription start site and have sequenced 1366 nucleotides containing a TATA box, a CACCC box, and putative binding sites for KF kappa B and Sp 1. Within 4 kb of the transcription start site are elements mediating transcriptional up-regulation in response to bacterial exoproducts.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Roche Biosci, Palo Alto, CA 94304 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Roche Holding	Basbaum, CB (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	cbas@itsa.ucsf.edu		Szymkowski, David/0000-0002-8934-7902	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43762, HL 24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GENDLER S, 1996, PEDIATR PULM, V13, P290; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUYONNETDUPERAT V, 1995, BIOCH J, V211; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; JACKOWSKI JT, 1991, AM J PHYSIOL, V260, pL61, DOI 10.1152/ajplung.1991.260.2.L61; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; MASSION PP, 1994, J CLIN INVEST, V93, P26, DOI 10.1172/JCI116954; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; OHMORI H, 1994, J BIOL CHEM, V269, P17833; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; SHANKAR V, 1994, BIOCHEM J, V300, P295, DOI 10.1042/bj3000295; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398	27	151	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6812	6820		10.1074/jbc.273.12.6812	http://dx.doi.org/10.1074/jbc.273.12.6812			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506983	hybrid			2022-12-27	WOS:000072775900033
J	Norris, JD; Fan, DJ; Stallcup, MR; McDonnell, DP				Norris, JD; Fan, DJ; Stallcup, MR; McDonnell, DP			Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; HUMAN PROGESTERONE-RECEPTOR; MIXED AGONIST ACTIVITY; NUCLEAR RECEPTORS; RESPONSIVE ELEMENT; RETINOIC ACID; TRANSACTIVATION DOMAIN; STEROID-RECEPTORS; PROMOTER-CONTEXT	The human estrogen receptor (ER) contains two major activation functions (AFs) responsible for its transcriptional activity. One of these, activation function 2 (AF-2), located within the hormone-binding domain (HBD), has been shown to mediate the ligand-dependent transcriptional activity of ER as well as other members of the nuclear receptor superfamily. Recently, proteins interacting with the HBD of several nuclear receptors have been cloned. One of these proteins, glucocorticoid receptor interacting protein (GRIP-1), has been shown to interact with ER and was originally hypothesized to mediate its transcriptional activity through AF-2. However, we find in this study that the transcriptional activity of ER, containing mutations in the AF-2 core sequence, can be enhanced by coexpression of the coactivator GRIP-I, suggesting that this protein may not rely solely on the AF-2 domain for interaction. We propose, therefore, that the HBD of ER either contains multiple binding sites that are necessary for association with GRIP-I or, alternatively, that this coactivator contacts the receptor in an undetermined region within the HBD. Importantly, these studies demonstrate also that mutations or deletion of AF-2 alter the ligand pharmacology of the receptor such that ER loses the ability to discriminate between agonists and antagonists. Interestingly, on these mutant receptors GRIP-I still functions as a coactivator independent of the nature of the bound ligand. It is likely, therefore, that the C-terminal AF-2 domain may function as a molecular switch allowing the wild-type receptor to discriminate between agonists and antagonists as well as providing a surface with which associated proteins can interact.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Dept Mol Biol, Los Angeles, CA 90033 USA; Unic Coll Galway, Dept Biochem, Galway, Ireland	Duke University; University of Southern California; University of Southern California; University of Southern California; Ollscoil na Gaillimhe-University of Galway	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	mcdon016@acpub.duke.edu		Norris, John/0000-0001-6553-8053	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048807, R01DK048807] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48807] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; BOUGET W, 1995, NATURE, V375, P377; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Elgort MG, 1996, MOL ENDOCRINOL, V10, P477, DOI 10.1210/me.10.5.477; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; INCE BA, 1994, MOL ENDOCRINOL, V8, P1397, DOI 10.1210/me.8.10.1397; JACKSONTA, 1997, MOL ENDOCRINOL, V11, P693; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner BL, 1996, P NATL ACAD SCI USA, V93, P8739, DOI 10.1073/pnas.93.16.8739; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	62	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6679	6688		10.1074/jbc.273.12.6679	http://dx.doi.org/10.1074/jbc.273.12.6679			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506965	Green Published, hybrid			2022-12-27	WOS:000072775900015
J	Perez-Vilar, J; Hill, RL				Perez-Vilar, J; Hill, RL			The carboxyl-terminal 90 residues of porcine submaxillary mucin are sufficient for forming disulfide-bonded dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORRIE DISEASE; VONWILLEBRAND-FACTOR; CANDIDATE GENE; DIMERIZATION; MUTATIONS	COS-7 cells transfected with expression vectors encoding 90 and 154 amino acid residues, respectively, from the carboxyl terminus of the disulfide-rich domain (240 residues) of porcine submaxillary mucin were shown to form disulfide-bonded dimers, Cells with expression vectors that encoded the disulfide-rich domain lacking the last 90 and 150 carboxyl-terminal residues, respectively, from the carboxyl terminus of the disulfide-rich domain were unable to secrete truncated domains, These results indicate that the information required to form disulfide-bonded dimers resides in only 90 residues, including 11 half-cystines, Site specific mutagenesis was employed to change, one at a time, each codon for the 11 half-cystines to serine, Eight of the 11 mutants formed disulfide-bonded dimers indistinguishable from those produced by unmutated vector, although 6 of the 8 mutants also produced aggregates thought to be misfolded protein with scrambled disulfide bonds, Two additional mutant vectors encoding serine instead of half-cystine at residues 13244 and 13246 in submaxillary mucin expressed both monomers and dimers of the disulfide-rich domain but no aggregates, The final mutant vector, C13223S, expressed protein aggregates that were poorly secreted from transfected cells, A mutant vector with two codon changes, C13244A/C13246A, expressed both monomers and dimers, just like the single mutants at these half-cystines, These results suggest that three half-cystine residues (Cys(13223), Cys(13244), and Cys(13246)) may be involved in forming interchain disulfide bonds in mucin dimers, Two of these half-cystines, Cys(13244) and Cys(13246), are in the highly conserved sequence (CLCC)-L-13244-C-13246 in the disulfide rich domain of several other human mucins and in prepro-von Willebrand factor and norrin, a protein that in mutant forms gives rise to Norrie disease, Support for the involvement of these half-cystines in formation of disulfide-bonded dimers of these molecules is also provided by known mutations in prepro-von Willebrand factor and norrin.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hill, RL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	hill@biochem.duke.edu			PHS HHS [25766] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hebert DN, 1995, COLD SPRING HARB SYM, V60, P405, DOI 10.1101/SQB.1995.060.01.045; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MEINDL A, 1992, NAT GENET, V2, P139, DOI 10.1038/ng1092-139; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; Schneppenheim R, 1996, P NATL ACAD SCI USA, V93, P3581, DOI 10.1073/pnas.93.8.3581; SCHUBACK DE, 1995, HUM MUTAT, V5, P285, DOI 10.1002/humu.1380050403; STRASBERG P, 1995, HUM MOL GENET, V4, P2179, DOI 10.1093/hmg/4.11.2179; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195	24	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6982	6988		10.1074/jbc.273.12.6982	http://dx.doi.org/10.1074/jbc.273.12.6982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507005	hybrid			2022-12-27	WOS:000072775900055
J	Zhao, J; Zhou, QS; Wiedmer, T; Sims, PJ				Zhao, J; Zhou, QS; Wiedmer, T; Sims, PJ			Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSBILAYER MOVEMENT; EXPOSURE; ERYTHROCYTES; LYMPHOCYTES; RECOGNITION; MECHANISMS; MEMBRANES	We recently identified a 35-kDa erythrocyte membrane protein, phospholipid scramblase, that promotes Ca2+-dependent transbilayer movement of phosphatidylserine (PS) and other phospholipids (PL) in reconstituted proteoliposomes (Zhou, Q., Zhao, J., Stout, J. G., Luhm, R. A, Wiedmer, T., and Sims, P. J, (1997) J. Biol. Chen 272, 18240-18244). To determine whether this same protein is responsible for the rapid movement of PS from inner-to-outer plasma membrane leaflets in other cells exposed to elevated cytosolic calcium concentration ([Ca2+](c)), we analyzed how induced movement of PS to the cell surface related to expression of PL scramblase. Exposure to Ca2+ ionophore A28187 resulted in rapid PS exposure in those cell lines constitutively high in PL scramblase (HEL, Epstein-Barr virus-transformed B-lymphocytes, and Jurkat), whereas this response was markedly attenuated in cells expressing low amounts of this protein (Raji, HL60, and Dami). To confirm this apparent correlation between PL scramblase expression and PS egress at elevated [Ca2+](c), Raji cells were transfected with PL scramblase cDNA in pEGFP-C2, and stable transformants expressing various amounts of GFP-PL scramblase fusion protein were obtained. Clones expressing GFP-PL scramblase showed distinctly plasma membrane-localized fluorescence. When compared either with untransfected Raji cells or with transformants expressing GFP alone, clones expressing GFP-PL scramblase fusion protein showed increased exposure of PS at the cell surface in response to elevated [Ca2+](c), accompanied by increased expression of membrane catalytic function for the prothrombinase enzyme complex, These data indicate that transfection with PL scramblase cDNA promotes movement of PS to cell surfaces and suggest that this protein normally mediates redistribution of plasma membrane phospholipids in activated, injured, or apoptotic cells.	Blood Res Inst, Blood Ctr SE Wisconsin, Milwaukee, WI 53201 USA	Versiti Blood Center of Wisconsin	Sims, PJ (corresponding author), Blood Res Inst, Blood Ctr SE Wisconsin, POB 2178, Milwaukee, WI 53201 USA.				NHLBI NIH HHS [HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; CHANG CP, 1993, J BIOL CHEM, V268, P7171; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FADOK VA, 1992, J IMMUNOL, V148, P2207; Frey T, 1997, CYTOMETRY, V28, P253, DOI 10.1002/(SICI)1097-0320(19970701)28:3<253::AID-CYTO10>3.0.CO;2-O; KOJIMA H, 1994, J CLIN INVEST, V94, P2237, DOI 10.1172/JCI117586; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WANG RH, 1993, J CLIN INVEST, V92, P1326, DOI 10.1172/JCI116706; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	17	157	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6603	6606		10.1074/jbc.273.12.6603	http://dx.doi.org/10.1074/jbc.273.12.6603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506954	hybrid			2022-12-27	WOS:000072775900004
J	Henkel, JR; Weisz, OA				Henkel, JR; Weisz, OA			Influenza virus M2 protein slows traffic along the secretory pathway - pH perturbation of acidified compartments affects early Golgi transport steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL ACTIVITY; RECOMBINANT VACCINIA VIRUS; ADP-RIBOSYLATION FACTOR; M(2) PROTEIN; A VIRUS; DEPENDENT FORMATION; HEMAGGLUTININ; INFECTION; APPARATUS; INHIBITOR	M2, an acid-activated ion channel, is an influenza A virus membrane protein required for efficient nucleocapsid release after viral fusion with the endosomal membrane. Recombinant M2 slows protein traffic through the Golgi complex (Sakaguchi, T., Leser, G. P)., and Lamb, R. A. (1996) J. Cell Biol, 133, 733-47). Despite its critical role in viral infection, little is known about the subcellular distribution of M2 or its fate following delivery to the plasma membrane (PM). We measured the kinetics of M2 transport in HeLa cells, and found that active M2 reached the PM considerably more slowly than inactive M2. In addition, M2 delayed intra-Golgi transport and cell surface delivery of influenza hemagglutinin (HA). We hypothesized that the effects of M2 on transport through non-acidified compartments are due to inefficient retrieval from the trans-Golgi of machinery required for intra-Golgi transport. In support of this, acutely activated M2 had no effect on intra-Golgi transport of HA, but still slowed HA delivery to the PM. Thus, M2 has an indirect effect on early transport steps, but a direct effect on late steps in PM delivery. These findings may help explain the conflicting and unexplained effects on protein traffic observed with other perturbants of intraorganelle pH such as weak bases and inhibitors of V-type ATPases.	Univ Pittsburgh, Div Renal Electrolyte, Lab Epithelial Cell Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Div Renal Electrolyte, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15213 USA.	weisz@med1.dept-med.pitt.edu						Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CIAMPOR F, 1992, VIROLOGY, V188, P14, DOI 10.1016/0042-6822(92)90730-D; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COSSON P, 1989, J CELL BIOL, V108, P377, DOI 10.1083/jcb.108.2.377; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; HAY AJ, 1979, J GEN VIROL, V42, P189, DOI 10.1099/0022-1317-42-1-189; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LAMB RA, 1981, VIROLOGY, V112, P729, DOI 10.1016/0042-6822(81)90317-2; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MUROI M, 1993, CELL STRUCT FUNCT, V18, P139, DOI 10.1247/csf.18.139; OHUCHI M, 1994, J VIROL, V68, P920, DOI 10.1128/JVI.68.2.920-926.1994; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; WEISZ OA, 1994, METHOD CELL BIOL, V43, P137; YILLA M, 1993, J BIOL CHEM, V268, P19092; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	28	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6518	6524		10.1074/jbc.273.11.6518	http://dx.doi.org/10.1074/jbc.273.11.6518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497387	hybrid			2022-12-27	WOS:000072488500079
J	Aoyama, T; Peters, JM; Iritani, N; Nakajima, T; Furihata, K; Hashimoto, T; Gonzalez, FJ				Aoyama, T; Peters, JM; Iritani, N; Nakajima, T; Furihata, K; Hashimoto, T; Gonzalez, FJ			Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPAR alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ACYL-COENZYME-A; BETA-OXIDATION ENZYMES; LONG-CHAIN; MOLECULAR-CLONING; GENE-EXPRESSION; 3-HYDROXYACYL-COA DEHYDROGENASE; TRANSCRIPTIONAL REGULATION; NUCLEOTIDE-SEQUENCE; OMEGA-HYDROXYLASE	Peroxisome proliferative-activated receptor alpha (PPAR alpha) is a member of the steroid/nuclear receptor superfamily and mediates the biological and toxicological effects of peroxisome proliferators. To determine the physiological role of PPAR alpha in fatty acid metabolism, levels of peroxisomal and mitochondrial fatty acid metabolizing enzymes were determined in the PPAR alpha null mouse, Constitutive liver beta-oxidation of the long chain fatty acid, palmitic acid, was lower in the PPAR alpha null mice as compared with wild type mice, indicating defective mitochondrial fatty acid catabolism. In contrast, constitutive oxidation of the very long chain fatty acid, lignoceric acid, was not different between wild type and PPAR alpha null mice, suggesting that constitutive expression of enzymes involved in peroxisomal beta-oxidation is independent of PPAR alpha. Indeed, the PPAR alpha null mice had normal levels of the peroxisomal acyl-CoA oxidase, bifunctional protein (hydratase + 3-hydroxyacyl-CoA dehydrogenase), and thiolase but lower constitutive expression of the D-type bifunctional protein (hydratase + 3-hydroxyacyl-CoA dehydrogenase), Several mitochondrial fatty acid metabolizing enzymes including very long chain acyl-CoA dehydrogenase, long chain acyl-CoA dehydrogenase, short chain-specific 3-ketoacyl-CoA thiolase, and long chain acyl-CoA synthetase are also expressed at lower levels in the untreated PPAR alpha null mice, whereas other fatty acid metabolizing enzymes were not different between the untreated null mice and wild type mice. A lower constitutive expression of mRNAs encoding these enzymes was also found, suggesting that the effect was due to altered gene expression. In wild type mice, both peroxisomal and mitochondrial enzymes were induced by the peroxisome proliferator Wy-14,643; induction was not observed in the PPAR alpha null animals, These data indicate that PPAR alpha modulates constitutive expression of genes encoding several mitochondrial fatty acid-catabolizing enzymes in addition to mediating inducible mitochondrial and peroxisomal fatty acid beta-oxidation, thus establishing a role for the receptor in fatty acid homeostasis.	Shinshu Univ, Sch Med, Dept Biochem, Asahi Ku, Nagano 390, Japan; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Tezukayama Gakuin Coll, Osaka 590, Japan; Shinshu Univ, Sch Med, Dept Hyg & Med Genet, Nagano 390, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Nagano 390, Japan	Shinshu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shinshu University; Shinshu University	Aoyama, T (corresponding author), Shinshu Univ, Sch Med, Dept Biochem, Asahi Ku, Nagano 390, Japan.	toshifu@gipac.shinshu-u.ac.jp	Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998				AMAYA Y, 1986, EUR J BIOCHEM, V156, P9, DOI 10.1111/j.1432-1033.1986.tb09541.x; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; AUWERX J, 1996, ATHEROSCLEROSIS, V124, P29; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FUKAO T, 1989, J BIOCHEM-TOKYO, V106, P197, DOI 10.1093/oxfordjournals.jbchem.a122832; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; FURUTA S, 1980, J BIOCHEM, V88, P1059, DOI 10.1093/oxfordjournals.jbchem.a133057; GEARING KL, 1994, J NUTR, V124, pS1284, DOI 10.1093/jn/124.suppl_8.1284S; GINSBERG HN, 1987, AM J MED, V83, P66, DOI 10.1016/0002-9343(87)90873-4; GLOCK GE, 1953, BIOCHEM J, V55, P400, DOI 10.1042/bj0550400; Goldfischer S L, 1988, Prog Clin Biol Res, V282, P117; GREEN S, 1992, TOXICOL LETT, V64-5, P131, DOI 10.1016/0378-4274(92)90182-J; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; GUSTAFSSON JA, 1994, PROG CLIN BIOL RES, V387, P21; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; Hsu R.Y., 1969, METHODS ENZYMOL, V14, P33; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; IZAI K, 1992, J BIOL CHEM, V267, P1027; Jiang LL, 1996, J BIOCHEM, V120, P633; KATSURADA A, 1987, EUR J BIOCHEM, V168, P487, DOI 10.1111/j.1432-1033.1987.tb13443.x; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; Lake BG, 1995, TOXICOL LETT, V82-3, P673, DOI 10.1016/0378-4274(95)03513-3; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; MIYAZAWA S, 1983, J BIOCHEM, V94, P529, DOI 10.1093/oxfordjournals.jbchem.a134384; MIYAZAWA S, 1981, EUR J BIOCHEM, V117, P425, DOI 10.1111/j.1432-1033.1981.tb06356.x; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NAKANISHI S, 1970, EUR J BIOCHEM, V16, P161, DOI 10.1111/j.1432-1033.1970.tb01068.x; OCHOA S, 1955, METHOD ENZYMOL, V1, P739, DOI 10.1016/0076-6879(55)01129-4; OSUMI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P372, DOI 10.1016/0003-9861(80)90189-7; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; PALMER CNA, 1988, IN PRESS MOL PHARM; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; PETERS JM, 1997, CARCINOGENESIS, V18, P2023; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Saladin R, 1996, EUR J BIOCHEM, V239, P451, DOI 10.1111/j.1432-1033.1996.0451u.x; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SHINDO Y, 1978, J BIOCHEM, V84, P1177, DOI 10.1093/oxfordjournals.jbchem.a132234; SHINDO Y, 1978, BIOCHEM PHARMACOL, V27, P2683; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Staels B, 1996, ISRAEL J MED SCI, V32, P490; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; Takeda Y., 1969, METHOD ENZYMOL, V13, P153, DOI [DOI 10.1016/0076-6879(69)13032-3, 10.1016/0076-6879(69)13032-3]; Tugwood JD, 1996, ANN NY ACAD SCI, V804, P252, DOI 10.1111/j.1749-6632.1996.tb18620.x; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WARD JM, 1998, IN PRESS TOXICOL PAT; Willson TM, 1996, ANN NY ACAD SCI, V804, P276, DOI 10.1111/j.1749-6632.1996.tb18622.x; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhang ZF, 1997, BBA-GENE STRUCT EXPR, V1350, P53, DOI 10.1016/S0167-4781(96)00141-8	63	717	742	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5678	5684		10.1074/jbc.273.10.5678	http://dx.doi.org/10.1074/jbc.273.10.5678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488698	hybrid			2022-12-27	WOS:000072345000041
J	Frodyma, ME; Downs, D				Frodyma, ME; Downs, D			ApbA, the ketopantoate reductase enzyme of Salmonella typhimurium is required for the synthesis of thiamine via the alternative pyrimidine biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID REDUCTASES; PANTOTHENATE; PURIFICATION; LACTONE	The apbA gene of Salmonella typhimurium was shown to encode ketopantoic acid reductase. ApbA was purified from crude cell-free extracts to greater than 95% homogeneity after two chromatographic steps. N-terminal amino acid sequencing (first 15 amino acids) and Western blot analysis confirmed the isolated protein was ApbA. The functional protein was a monomer with a molecular mass of 31.1 kDa. Optimal reaction conditions for the reduction of ketopantoic acid were established at a pH of 6.25, and a temperature of 42 degrees C. The preferred electron source was NADPH, and the apparent K-m constants of the enzyme for NADPH and ketopantoic acid were determined to be 0.776 +/- 0.09 mM and 0.742 +/- 0.01 mM, respectively. The homogeneous enzyme had a specific activity of 64.3.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Downs, D (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DOWNS DM, 1991, J BACTERIOL, V173, P6597, DOI 10.1128/jb.173.20.6597-6604.1991; DOWNS DM, 1992, J BACTERIOL, V174, P1515, DOI 10.1128/jb.174.5.1515-1521.1992; DOWNS DM, 1994, J BACTERIOL, V176, P4858, DOI 10.1128/jb.176.16.4858-4864.1994; HAWLOW E, 1988, ANTIBODIES LAB MANUA; KING HL, 1974, J BIOL CHEM, V249, P4689; KING HL, 1972, J BIOL CHEM, V247, P4096; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPTON SH, 1949, J AM CHEM SOC, V71, P2364, DOI 10.1021/ja01175a032; PRIMERANO DA, 1982, J BACTERIOL, V150, P1202, DOI 10.1128/JB.150.3.1202-1211.1982; PRIMERANO DA, 1983, J BACTERIOL, V153, P259, DOI 10.1128/JB.153.1.259-269.1983; SHIMIZU S, 1988, J BIOL CHEM, V263, P12077; STOLZ A, 1991, J BIOL CHEM, V266, P15253; TABOR S, 1990, CURRENT PROTOCOLS MO	13	24	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5572	5576		10.1074/jbc.273.10.5572	http://dx.doi.org/10.1074/jbc.273.10.5572			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488683	hybrid			2022-12-27	WOS:000072345000026
J	Hovland, AR; Powell, RL; Takimoto, GS; Tung, L; Horwitz, KB				Hovland, AR; Powell, RL; Takimoto, GS; Tung, L; Horwitz, KB			An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; HUMAN-BREAST-CANCER; LIGAND-BINDING DOMAIN; ACTIVATION DOMAINS; STEROID-RECEPTORS; CRYSTAL-STRUCTURE; NUCLEAR-BINDING; CHICK OVIDUCT; DNA-BINDING; REGION	The B-isoform of human progesterone receptors (PR) contains three activation functions (AF3, AF1, and AF2), two of which (AF1 and AF2) are shared with the A-isoform. AF3 is in the B-upstream segment (BUS), the far N-terminal 164 amino acids of B-receptors; AF1 is in the 392-amino acid N-terminal region common to both receptors; and AF2 is in the C-terminal hormone binding domain, B receptors are usually stronger transactivators than A-receptors due to transcriptional synergism between AF3 and one of the two downstream AFs, We now show that the N terminus of PR common to both isoforms contains an inhibitory function (IF) located in a 292-amino acid segment lying upstream of AF1. IF represses the activity of A-receptors but is not inhibitory in the context of B-receptors due to constraints imparted by BUS. As a result, IF inhibits AF1 or AF2 but not AF3, regardless of the position of IF relative to BUS. IF is functionally independent and strongly represses transcription when it is fused upstream of estrogen receptors. These data demonstrate the existence of a novel, transferable inhibitory function, mapping to the PR N terminus, which begins to assign specific roles to this large undefined region.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Horwitz, KB (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.			Horwitz, Kathryn/0000-0001-7402-6455	NATIONAL CANCER INSTITUTE [R37CA026869, R01CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER; NCI NIH HHS [CA-26869] Funding Source: Medline; NIDDK NIH HHS [DK-48238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOYDLEINEN P, 1984, J BIOL CHEM, V259, P2411; BOYDLEINEN PA, 1982, ENDOCRINOLOGY, V111, P30, DOI 10.1210/endo-111-1-30; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; FRIEDL EM, 1995, EUR J BIOCHEM, V234, P308, DOI 10.1111/j.1432-1033.1995.308_c.x; GRAHAM JD, 1995, CANCER RES, V55, P5063; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATO J, 1993, J STEROID BIOCHEM, V47, P173, DOI 10.1016/0960-0760(93)90072-5; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRETT NL, 1988, BIOCHEM BIOPH RES CO, V157, P278, DOI 10.1016/S0006-291X(88)80044-5; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Miller MM, 1997, J CLIN ENDOCR METAB, V82, P2956, DOI 10.1210/jc.82.9.2956; MOHAMED MK, 1994, J STEROID BIOCHEM, V51, P241, DOI 10.1016/0960-0760(94)90036-1; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SCHRADER WT, 1972, J BIOL CHEM, V247, P51; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; SPELSBERG TC, 1980, ENDOCRINOLOGY, V107, P1234, DOI 10.1210/endo-107-4-1234; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEI LL, 1990, MOL ENDOCRINOL, V4, P1833, DOI 10.1210/mend-4-12-1833; WIEHLE RD, 1995, 77 ANN M END SOC WAS, P224	46	115	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5455	5460		10.1074/jbc.273.10.5455	http://dx.doi.org/10.1074/jbc.273.10.5455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488667	hybrid			2022-12-27	WOS:000072345000010
J	Nishida, CR; de Montellano, PRO				Nishida, CR; de Montellano, PRO			Electron transfer and catalytic activity of nitric oxide synthases - Chimeric constructs of the neuronal, inducible, and endothelial isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME IRON REDUCTION; ESCHERICHIA-COLI; BINDING DOMAINS; L-ARGININE; CALMODULIN; EXPRESSION; ENZYME; TETRAHYDROBIOPTERIN; IDENTIFICATION; PURIFICATION	The nitric oxide synthases (NOS) are single polypeptides that encode a heme domain, a calmodulin binding motif, and a flavoprotein domain with sequence similarity to P450 reductase. Despite this basic structural similarity, the three major NOS isoforms differ significantly in their rates of . NO synthesis, cytochrome c reduction, and NADPH utilization and in the Ca2+ dependence of these rates. To assign the origin of these differences to specific protein domains, we constructed chimeras in which the reductase domains of endothelial and inducible NOS, respectively, were replaced by the reductase domain of neuronal NOS. The results with the chimeric proteins confirm the modular organization of the NOS polypeptide chain and demonstrate that (a) similar residues establish the necessary contacts between the reductase and heme domains in the three NOS isoforms, (b) the maximal rate of . NO synthesis is determined by the maximum intrinsic ability of the reductase domain to deliver electrons to the heme domain, (c) the Ca2+ independence of inducible NOS requires interactions of calmodulin with both the calmodulin binding motif and the flavoprotein domain, and (d) the effects of tetrahydrobiopterin and L-arginine arm electron transfer rates are mediated exclusively by heme domain interactions.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Fossetta JD, 1996, FEBS LETT, V379, P135, DOI 10.1016/0014-5793(95)01496-9; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; *GEN COMP GROUP, 1994, WINS PACK VERS 8 0; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GREBER NC, 1997, ARCH BIOCHEM BIOPHYS, V343, P249; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; Huhmer AFR, 1997, CHEM RES TOXICOL, V10, P618, DOI 10.1021/tx960188t; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1992, J BIOL CHEM, V267, P11374; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; LIU JW, 1994, J BIOL CHEM, V269, P11691; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Picciotto M R, 1996, Adv Pharmacol, V36, P251, DOI 10.1016/S1054-3589(08)60585-2; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; Rafferty S, 1996, BIOCHEM BIOPH RES CO, V220, P1002, DOI 10.1006/bbrc.1996.0522; RHYNER JA, 1992, BIOCHEMISTRY-US, V31, P12826, DOI 10.1021/bi00166a017; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SESSA WC, 1992, J BIOL CHEM, V267, P15274; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	48	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5566	5571		10.1074/jbc.273.10.5566	http://dx.doi.org/10.1074/jbc.273.10.5566			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488682	hybrid			2022-12-27	WOS:000072345000025
J	Turner, RJ; Bonner, ER; Grabner, GK; Switzer, RL				Turner, RJ; Bonner, ER; Grabner, GK; Switzer, RL			Purification and characterization of Bacillus subtilis PyrR, a bifunctional pyr mRNA-binding attenuation protein/uracil phosphoribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE BIOSYNTHETIC OPERON; URACIL PHOSPHORIBOSYLTRANSFERASE; TRANSCRIPTIONAL ATTENUATION; PHOSPHOTRANSFERASE SYSTEM; ESCHERICHIA-COLI; GENE-CLUSTER; RNA; IDENTIFICATION; EXPRESSION; MECHANISM	Bacillus subtilis PyrR Has been shown to mediate transcriptional attenuation at three separate sites within the pyrimidine nucleotide biosynthetic (pyr) operon, Molecular genetic evidence suggests that regulation is achieved by PyrR binding to pyr mRNA, PyrR is also a uracil phosphoribosyltransferase (UPRTase), Recombinant PyrR was expressed in Escherichia coli, purified to homogeneity, physically and chemically characterized, and examined with respect to both of these activities. Mass spectroscopic characterization of PyrR demonstrated a monomeric mass of 20,263 Da. Cel filtration chromatography showed the native mass of PyrR to be dependent on protein concentration and suggested a rapid equilibrium between dimeric and hexameric forms, The UPRTase activity of PyrR has a pH optimum of 8.2, The K-m value for uracil is very pH-dependent; the K-m for uracil, at pH 7.7 is 990 +/- 114 mu M, which is much. higher than far most UPRTases and may account for the low physiological activity of PyrR as a UPRTase, Using an electrophoretic mobility shift assay, PyrR was shown to bind pyr RNA that includes sequences from its predicted binding site in the second attenuator region, Binding of PyrR to pyr RNA was specific and UMP-dependent with apparent K-d values of 10 and 220 nM in the presence and absence of UMP, respectively. The concentration of UMP required for half-maximal stimulation of binding of PyrR. to RNA was 6 mu M, The results support a model for the regulation of pyr transcription whereby termination is governed by the UMP-dependent binding of PyrR to pyr RNA and provide purified and characterized PyrR for detailed biochemical studies of RNA binding and transcriptional attenuation.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Switzer, RL (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	rswitzer@uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047112] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07283, GM47112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1993, J CELL BIOCHEM, V51, P83, DOI 10.1002/jcb.240510115; Andersen PS, 1996, J BACTERIOL, V178, P5005, DOI 10.1128/jb.178.16.5005-5012.1996; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; Batey RT, 1996, J MOL BIOL, V261, P536, DOI 10.1006/jmbi.1996.0481; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; Elagoz A, 1996, GENE, V182, P37, DOI 10.1016/S0378-1119(96)00461-1; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GHIM SY, 1994, J BACTERIOL, V176, P3698, DOI 10.1128/JB.176.12.3698-3707.1994; Ghim SY, 1996, J BACTERIOL, V178, P2351, DOI 10.1128/jb.178.8.2351-2355.1996; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; Henkin TM, 1996, ANNU REV GENET, V30, P35, DOI 10.1146/annurev.genet.30.1.35; Jensen HK, 1997, PROTEIN EXPRES PURIF, V10, P356, DOI 10.1006/prep.1997.0755; Jensen KF, 1996, EUR J BIOCHEM, V240, P637, DOI 10.1111/j.1432-1033.1996.0637h.x; Kahler AE, 1996, J BACTERIOL, V178, P5013, DOI 10.1128/jb.178.16.5013-5016.1996; Kaneko T, 1996, DNA Res, V3, P109; LERNER CG, 1987, J BACTERIOL, V169, P2202, DOI 10.1128/jb.169.5.2202-2206.1987; LI XT, 1995, J BACTERIOL, V177, P6866, DOI 10.1128/jb.177.23.6866-6873.1995; Lu Y, 1996, J BACTERIOL, V178, P7206, DOI 10.1128/jb.178.24.7206-7211.1996; LU Y, 1995, J BACTERIOL, V177, P1315, DOI 10.1128/jb.177.5.1315-1325.1995; Lu Y, 1996, P NATL ACAD SCI USA, V93, P14462, DOI 10.1073/pnas.93.25.14462; Maniatis T., 1982, MOL CLONING; Manival X, 1997, EMBO J, V16, P5019, DOI 10.1093/emboj/16.16.5019; MARTINUSSEN J, 1995, J BACTERIOL, V177, P271, DOI 10.1128/jb.177.1.271-274.1995; Miller JH., 1972, EXPT MOL GENETICS, P353; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NORRANDER J, GENE AMST, V26, P101; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RASMUSSEN UB, 1986, BIOCHIM BIOPHYS ACTA, V881, P268, DOI 10.1016/0304-4165(86)90013-9; TURNER RJ, 1994, J BACTERIOL, V176, P3708, DOI 10.1128/JB.176.12.3708-3722.1994; VandeCasteele M, 1997, J BACTERIOL, V179, P3470, DOI 10.1128/jb.179.11.3470-3481.1997; vanTilbeurgh H, 1997, EMBO J, V16, P5030, DOI 10.1093/emboj/16.16.5030	36	30	32	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5932	5938		10.1074/jbc.273.10.5932	http://dx.doi.org/10.1074/jbc.273.10.5932			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488732	hybrid			2022-12-27	WOS:000072345000075
J	Enrique-Tarancon, G; Marti, L; Morin, N; Lizcano, JM; Unzeta, M; Sevilla, L; Camps, M; Palacin, M; Testar, X; Carpene, C; Zorzano, A				Enrique-Tarancon, G; Marti, L; Morin, N; Lizcano, JM; Unzeta, M; Sevilla, L; Camps, M; Palacin, M; Testar, X; Carpene, C; Zorzano, A			Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; INSULIN-STIMULATED TRANSLOCATION; VASCULAR SMOOTH-MUSCLE; HYDROGEN-PEROXIDE; 3T3-L1 ADIPOCYTES; MONOAMINE-OXIDASE; BINDING-SITES; FAT-CELLS; GLUT4-ENRICHED VESICLES; H-3 IDAZOXAN	The previous characterization of an abundant population of non-adrenergic imidazoline-I-2 binding sites in adipocytes and the recent demonstration of the interplay between these binding sites and amine oxidases led us to analyze the amine oxidase activity in membranes from isolated rat adipocytes. Adipocyte membranes had substantial levels of semicarbazide-sensitive amine oxidase (SSAO), SSAO activity and immunoreactive SSAO protein were maximal in plasma membranes, and they were also detectable in intracellular membranes, Vesicle immunoisolation analysis indicated that GLUT4-containing vesicles from rat adipocytes contain substantial levels of SSAO activity and immunoreactive SSAO protein, Immunotitration of intracellular GLUT4 vesicles indicated that GLUT4 and SSAO colocalize in an endosomal compartment in rat adipocytes, SSAO activity was also found in GLUT4 vesicles from 3T3-L1 adipocytes and rat skeletal muscle. Benzylamine, a substrate of SSAO activity, caused a marked stimulation of glucose transport in isolated rat adipocytes in the presence of very low vanadate concentrations that by themselves were ineffective in exerting insulin-like effects. This synergistic effect of benzylamine and vanadate on glucose transport was totally abolished in the presence of semicarbazide, a specific inhibitor of SSAO. Subcellular membrane fractionation revealed that the combination of benzylamine and vanadate caused a recruitment of GLUT4 to the plasma membrane of adipose cells, The stimulatory effects of benzylamine and vanadate on glucose transport were blocked by catalase, suggesting that hydrogen peroxide production coupled to SSAO activity plays a crucial regulatory role, Based on these results we propose that SSAO activity might contribute through hydrogen peroxide production to the in vivo regulation of GLUT4 trafficking in adipose cells.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Toulouse 3, CHU Rangueil, Inst Louis Bugnard, INSERM,U317, F-31403 Toulouse 4, France; Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Barcelona 08290, Spain	University of Barcelona; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Autonomous University of Barcelona; University of Barcelona	Zorzano, A (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avinguda Diagonal 645, E-08028 Barcelona, Spain.	azorzano@porthos.bio.ub.es	Camps, Marta/F-6557-2016; Palacín, Manuel/G-9786-2015; Carpéné, Christian/S-3279-2019; Lizcano, Jose M/E-6080-2010; Zorzano, Antonio/R-5479-2018; lizcano, jose m/AAK-3577-2020	Camps, Marta/0000-0001-5392-1792; Lizcano, Jose M/0000-0002-3154-5383; lizcano, jose m/0000-0002-3154-5383; Palacin, Manuel/0000-0002-8670-293X; UNZETA, Mercedes/0000-0002-7113-3383				ALEDO JC, 1995, BIOCHEM BIOPH RES CO, V215, P321, DOI 10.1006/bbrc.1995.2469; BARRAND MA, 1982, BIOCHEM PHARMACOL, V31, P2177, DOI 10.1016/0006-2952(82)90511-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALLINGHAM BA, 1991, BIOCHEM SOC T, V19, P228, DOI 10.1042/bst0190228; CARPENE C, 1993, BIOCHEM J, V296, P99, DOI 10.1042/bj2960099; CARPENE C, 1995, J PHARMACOL EXP THER, V272, P681; CARPENE C, 1990, BIOCHEM PHARMACOL, V40, P437, DOI 10.1016/0006-2952(90)90541-R; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Cormont M, 1996, MOL CELL BIOL, V16, P6879; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CZECH MP, 1974, J BIOL CHEM, V249, P5421; DEARRIBA AF, 1991, BIOCHEM PHARMACOL, V42, P2355, DOI 10.1016/0006-2952(91)90241-V; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; FISCHER Y, 1993, BIOCHIM BIOPHYS ACTA, V1153, P97, DOI 10.1016/0005-2736(93)90280-D; FOWLER CJ, 1981, BIOCHEM PHARMACOL, V30, P3329, DOI 10.1016/0006-2952(81)90607-9; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GUMA A, 1992, FEBS LETT, V310, P51, DOI 10.1016/0014-5793(92)81144-B; Hajduch E, 1997, BIOCHEM J, V321, P233, DOI 10.1042/bj3210233; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; JAMES DE, 1987, J BIOL CHEM, V262, P11817; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kandror KV, 1996, SEMIN CELL DEV BIOL, V7, P269, DOI 10.1006/scdb.1996.0035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1990, MOL PHARMACOL, V37, P876; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LEWINSOHN R, 1981, J PHARM PHARMACOL, V33, P569, DOI 10.1111/j.2042-7158.1981.tb13868.x; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Lizcano JM, 1996, BIOCHEM PHARMACOL, V52, P187, DOI 10.1016/0006-2952(96)00132-3; LIZCANO JM, 1994, J NEURAL TRANSM-SUPP, P415; LYLES GA, 1985, J PHARM PHARMACOL, V37, P637, DOI 10.1111/j.2042-7158.1985.tb05100.x; LYLES GA, 1987, PHARM TOXICOL S1, V60, P33; MACKINNON AC, 1989, BRIT J PHARMACOL, V98, P1143, DOI 10.1111/j.1476-5381.1989.tb12658.x; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; MAY JM, 1979, J BIOL CHEM, V254, P2214; Mora S, 1997, BIOCHEM J, V324, P455, DOI 10.1042/bj3240455; Morris NJ, 1997, J BIOL CHEM, V272, P9388; MU D, 1994, J BIOL CHEM, V269, P9926; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Munoz P, 1996, J BIOL CHEM, V271, P8133, DOI 10.1074/jbc.271.14.8133; MUNOZ P, 1995, BIOCHEM J, V307, P273, DOI 10.1042/bj3070273; NORQVIST A, 1989, BIOGENIC AMINES, V6, P65; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Ozaita A, 1997, BRIT J PHARMACOL, V121, P901, DOI 10.1038/sj.bjp.0701214; Parini A, 1996, TRENDS PHARMACOL SCI, V17, P13, DOI 10.1016/0165-6147(96)81564-1; RAIMONDI L, 1991, BIOCHEM PHARMACOL, V41, P469, DOI 10.1016/0006-2952(91)90549-K; SEREGI A, 1983, J NEUROCHEM, V40, P407, DOI 10.1111/j.1471-4159.1983.tb11297.x; Sevilla L, 1997, ENDOCRINOLOGY, V138, P3006, DOI 10.1210/en.138.7.3006; Sherman LA, 1996, ENDOCRINOLOGY, V137, P266, DOI 10.1210/en.137.1.266; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SORENSEN SS, 1980, BIOCHIM BIOPHYS ACTA, V602, P433, DOI 10.1016/0005-2736(80)90322-3; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; TESSON F, 1995, J BIOL CHEM, V270, P9856, DOI 10.1074/jbc.270.17.9856; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; YU PH, 1993, DIABETES, V42, P594, DOI 10.2337/diabetes.42.4.594; YU PH, 1986, NEUROMETHODS, V5, P235; Zhang XP, 1996, GENE, V179, P279, DOI 10.1016/S0378-1119(96)00387-3; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	63	143	152	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8025	8032		10.1074/jbc.273.14.8025	http://dx.doi.org/10.1074/jbc.273.14.8025			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525902	hybrid			2022-12-27	WOS:000072876300036
J	Washington, MT; Patel, SS				Washington, MT; Patel, SS			Increased DNA unwinding efficiency of bacteriophage T7 DNA helicase mutant protein 4A '/E348K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI RECBCD ENZYME; ESCHERICHIA-COLI; ATP HYDROLYSIS; RNA-POLYMERASE; CLONED GENES; PRIMASE; BINDING; EXPRESSION; SUBUNITS	Bacteriophage T7 4A' protein is a DNA helicase that unwinds DNA in a reaction coupled to dTTP hydrolysis. To understand better its mechanism of DNA unwinding, we characterized a set of 4A' mutant proteins (Washington, M. T., Rosenberg, A. H., Griffin, K., Studier, F. W., and Patel, S. S. (1996) J. Biol. Chem. 271, 26825-26834). We showed here, using single turnover DNA unwinding assays, that the 4A'/E348K mutant protein had the unusual property of unwinding DNA (with a 5-6 fold slower rate) despite a significant defect in its dTTPase activity (a 25-30-fold slower rate). comparing the DNA unwinding rates to the dTTPase rates, we estimated the DNA unwinding efficiencies of both wild-type (about 1 base pair unwound per dTTP hydrolysis) and mutant (4 to 6 base pairs unwound per dTTP hydrolysis). Thus the mutant had a 4-6 fold improvement in its DNA unwinding efficiency over that of the wild-type. We believe that this mutant undergoes less slippage (uncoupled dTTP hydrolysis) than the wild-type. We speculate that nature has selected for a high rate of DNA unwinding rather than a high efficiency of DNA unwinding. Thus even though the mutant is more efficient at DNA unwinding, the wild-type probably was selected because it unwinds DNA faster.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	Ohio State University	Patel, SS (corresponding author), Ohio State Univ, Dept Biochem, 484 W 12Th Ave, Columbus, OH 43210 USA.	Patel.85@osu.edu		Washington, Todd/0000-0001-8680-2992	NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; ARAI N, 1981, J BIOL CHEM, V256, P5294; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KORANGY F, 1994, BIOCHEMISTRY-US, V33, P9552, DOI 10.1021/bi00198a022; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MILLER H, 1987, METHOD ENZYMOL, V152, P145; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7993, DOI 10.1021/bi963180r; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	31	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7880	7887		10.1074/jbc.273.14.7880	http://dx.doi.org/10.1074/jbc.273.14.7880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525882	hybrid			2022-12-27	WOS:000072876300016
J	Ganesan, AK; Frank, DW; Misra, RP; Schmidt, G; Barbieri, JT				Ganesan, AK; Frank, DW; Misra, RP; Schmidt, G; Barbieri, JT			Pseudomonas aeruginosa exoenzyme S ADP-ribosylates Ras at multiple sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; INFECTIONS; RIBOSYLTRANSFERASE; FAMILY	Pseudomonas aeruginosa exoenzyme S (ExoS) ADP-ribosylated Ras to a stoichiometry of similar to 2 molecules of ADP-ribose incorporated per molecule of Ras, which suggested that ExoS could ADP-ribosylate Ras at more than one arginine residue, SDS-polyacrylamide gel electrophoresis analysis showed that ADP-ribosylated Ras possessed a slower mobility than non-ADP-ribosylated Ras, Analysis of the ADP-ribosylation of in vitro transcribed/translated Ras by ExoS identified two electrophoretically shifted forms of Ras, which was consistent with the ADP-ribosylation of Ras at two distinct arginine residues, Analysis of ADP-ribosylated in vitro transcribed/translated Ras mutants possessing individual Arg-to-Ala substitutions showed that Arg-41 was the preferred site of ADP-ribosylation and that the second ADP-ribosylation event occurred at a slower rate than the ADP-ribosylation at Arg-41, but did not occur at a specific arginine residue. Analysis of bacterially expressed wild-type Ras Delta CAAX and Ras Delta CAAXR41K supported the conclusion that Arg-41 was the preferred site of ADP-ribosylation. Arg-41 is located adjacent to the switch 1 region of Ras, which is involved in effector interactions. Introduction of ExoS into eukaryotic cells inhibited Ras-mediated eukaryotic signal transduction since infection of PC-12 cells with an ExoS-producing strain of P. aeruginosa inhibited nerve growth factor-stimulated neurite formation, This is the first demonstration that ExoS disrupts a Ras-mediated signal transduction pathway.	Med Coll Wisconsin, Dept Microbiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Freiburg, Inst Pharmacol & Toxicol, D-79104 Freiburg, Germany	Medical College of Wisconsin; Medical College of Wisconsin; University of Freiburg	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol, 8701 Watertown Plk Rd, Milwaukee, WI 53226 USA.	toxin@mcw.edi			NIAID NIH HHS [R01-AI-30162, R01-AI-31665, K04-AI001087] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001087, R01AI030162, R01AI031665] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; BODEY GP, 1983, REV INFECT DIS, V5, P279; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1992, CURR TOP MICROBIOL, V175, P133; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FrithzLindsten E, 1997, MOL MICROBIOL, V25, P1125, DOI 10.1046/j.1365-2958.1997.5411905.x; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, BIOCHEMISTRY-US, V34, P326, DOI 10.1021/bi00001a040; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KNIGHT DA, 1995, INFECT IMMUN, V63, P3182, DOI 10.1128/IAI.63.8.3182-3186.1995; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; KRUEGER KM, 1995, CLIN MICROBIOL REV, V8, P34, DOI 10.1128/CMR.8.1.34; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCGUFFIE EM, 1997, GEN M AM SOC MICR MA, P56; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Nicas T I, 1985, Antibiot Chemother (1971), V36, P40; NICAS TI, 1985, J INFECT DIS, V152, P716, DOI 10.1093/infdis/152.4.716; NICAS TI, 1985, EUR J CLIN MICROBIOL, V4, P175, DOI 10.1007/BF02013593; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SHIROUZU M, 1994, ONCOGENE, V9, P2153; Szeberenyi J., 1996, Neurobiology (Budapest), V4, P1; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x	26	98	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7332	7337		10.1074/jbc.273.13.7332	http://dx.doi.org/10.1074/jbc.273.13.7332			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516428	hybrid			2022-12-27	WOS:000072738500024
J	Goryshin, IY; Reznikoff, WS				Goryshin, IY; Reznikoff, WS			Tn5 in vitro transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MULTIMERIZATION; IDENTIFICATION; PURIFICATION; COMPLEX; PROTEIN; TERMINI; SITE; IS50; DNAA	This communication reports the development of an efficient in vitro transposition system for Tn5. A key component of this system was the use of hyperactive mutant transposase. The inactivity of wild type transposase is likely to be related to the low frequency of in vivo transposition. The in vitro experiments demonstrate the following: the only required macromolecules for most of the steps in Tn5 transposition are the transposase, the specific 19-bp Tn5 end sequences, and target DNA; transposase may not be able to self-dissociate from product DNAs; Tn5 transposes by a conservative "cut and paste" mechanism; and Tn5 release from the donor backbone involves precise cleavage of both 3' and 5' strands at the ends of the specific end sequences.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.				NIGMS NIH HHS [GM50692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BERG CM, 1989, MOBILE DNA, P879; Berg DE, 1989, MOBILE DNA; BERG DE, 1989, MOBILE DNA, P185; BIECK D, 1980, P NATL ACAD SCI USA, V77, P6047; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; DELACRUZ NB, 1993, J BACTERIOL, V175, P6932, DOI 10.1128/jb.175.21.6932-6938.1993; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; Gary PA, 1996, J MOL BIOL, V257, P301; GORYSHIN IY, 1994, P NATL ACAD SCI USA, V91, P10834, DOI 10.1073/pnas.91.23.10834; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; JILK RA, 1993, J BACTERIOL, V175, P1264, DOI 10.1128/JB.175.5.1264-1271.1993; JOHNSON RC, 1982, CELL, V30, P873, DOI 10.1016/0092-8674(82)90292-6; JOHNSON RC, 1983, NATURE, V204, P280; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PHADNIS SH, 1989, P NATL ACAD SCI USA, V86, P5908, DOI 10.1073/pnas.86.15.5908; REZNIKOFF WS, 1993, ANNU REV MICROBIOL, V47, P945, DOI 10.1146/annurev.mi.47.100193.004501; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAKAWA C, 1983, P NATL ACAD SCI-BIOL, V80, P7293, DOI 10.1073/pnas.80.23.7293; SAVELIEV SV, 1995, GENE DEV, V9, P248, DOI 10.1101/gad.9.2.248; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WEINREICH MD, 1994, J MOL BIOL, V241, P166, DOI 10.1006/jmbi.1994.1486; WEINREICH MD, 1994, GENE DEV, V8, P2363, DOI 10.1101/gad.8.19.2363; WEINREICH MD, 1994, J BACTERIOL, V176, P5494, DOI 10.1128/JB.176.17.5494-5504.1994; WIEGAND TW, 1992, J BACTERIOL, V174, P1229, DOI 10.1128/jb.174.4.1229-1239.1992; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; YIN JCP, 1987, J BACTERIOL, V169, P4637, DOI 10.1128/jb.169.10.4637-4645.1987; Zhou M, 1997, J MOL BIOL, V271, P362, DOI 10.1006/jmbi.1997.1188; [No title captured]	36	262	346	6	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7367	7374		10.1074/jbc.273.13.7367	http://dx.doi.org/10.1074/jbc.273.13.7367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516433	hybrid			2022-12-27	WOS:000072738500029
J	Ho, YS; Gargano, M; Cao, J; Bronson, RT; Heimler, I; Hutz, RJ				Ho, YS; Gargano, M; Cao, J; Bronson, RT; Heimler, I; Hutz, RJ			Reduced fertility in female mice lacking copper-zinc superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; NEONATAL LETHALITY; RADICAL PRODUCTION; LUNG MITOCHONDRIA; DEFICIENT MICE; RAT LUNGS; CELLS; PARAQUAT; OXYGEN; HYPEROXIA	Copper-zinc superoxide dismutase (CuZn-SOD) is believed to play a major role in the first line of antioxidant defense by catalyzing the dismutation of superoxide anion radicals to form hydrogen peroxide and molecular oxygen. Recent studies have shown that missense mutations in this gene contribute, evidently through a gain-of-function mechanism, to about 20% of familial amyotrophic lateral sclerosis. To define further the physiologic role of this enzyme, a model of mice deficient in this enzyme was generated using gene targeting technology. Mice lacking this enzyme were apparently healthy and displayed no increased sensitivity to hyperoxia, However, they exhibited a pronounced susceptibility to paraquat toxicity. Most surprisingly, female homozygous knock out mice showed a markedly reduced fertility compared with that of wild-type and heterozygous knock-out mice, Further studies revealed that although these mice ovulated and conceived normally, they exhibited a marked increase in embryonic lethality. These data, for the first time, suggest a role of oxygen free radicals in causing abnormality of female reproduction in mammals.	Wayne State Univ, Inst Chem Toxicol, Detroit, MI 48201 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Univ Wisconsin, Dept Biol Sci, Milwaukee, WI 53211 USA	Wayne State University; Wayne State University; Tufts University; University of Wisconsin System; University of Wisconsin Milwaukee	Ho, YS (corresponding author), Wayne State Univ, Inst Chem Toxicol, 2727 2nd Ave, Detroit, MI 48201 USA.	aa2359@wayne.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639, R15ES006807] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56421] Funding Source: Medline; NIEHS NIH HHS [P30 ES06639, ES06807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; BarPeled O, 1996, P NATL ACAD SCI USA, V93, P8530, DOI 10.1073/pnas.93.16.8530; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BENEDETTO MT, 1991, GENE, V99, P191, DOI 10.1016/0378-1119(91)90126-V; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Crapo J D, 1978, Methods Enzymol, V53, P382; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DANCIGER E, 1986, P NATL ACAD SCI USA, V83, P3619, DOI 10.1073/pnas.83.11.3619; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; FISHER CL, 1991, FREE RADICAL RES COM, V12-3, P287, DOI 10.3109/10715769109145797; Forman H.J., 1982, OXYGEN LIVING PROCES, P235; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FREEMAN BA, 1982, LAB INVEST, V47, P412; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KRALL J, 1988, J BIOL CHEM, V263, P1910; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RUGH R, 1990, MOUSE ITS REPROD DEV, P24; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	40	262	274	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7765	7769		10.1074/jbc.273.13.7765	http://dx.doi.org/10.1074/jbc.273.13.7765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516486	hybrid			2022-12-27	WOS:000072738500082
J	Kikkawa, S; Yoshida, N; Nakagawa, M; Iwasa, T; Tsuda, M				Kikkawa, S; Yoshida, N; Nakagawa, M; Iwasa, T; Tsuda, M			A novel rhodopsin kinase in octopus photoreceptor possesses a pleckstrin homology domain and is activated by G protein beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; MUSCARINIC ACETYLCHOLINE-RECEPTORS; LIGHT-DEPENDENT PHOSPHORYLATION; BINDING; FAMILY; PURIFICATION; EXPRESSION; CLONING; MEMBER; ISOPRENYLATION	G protein-coupled receptor kinases (GRKs) play an important role in stimulus-dependent receptor phosphorylation and desensitization of the receptors, Mammalian rhodopsin kinase (RH) and beta-adrenergic receptor kinase (beta ARK) are the most studied members among known GRKs, In this work, we purified RK from octopus photoreceptors for the first time from invertebrate tissues, The molecular mass of the purified enzyme was 80 kDa as estimated by SDS-polyacrylamide gel electrophoresis, and this was 17 kDa larger than that of the vertebrate enzymes, Unlike vertebrate RK, octopus RK (ORK) was directly activated by beta gamma-subunits of a photoreceptor G protein, We examined the effects of various known activators and inhibitors of GRKs on the activity of the purified ORK and found that their effects were different from those on either bovine RK or beta ARK, To analyze the primary structure of the enzyme, we cloned the cDNA encoding ORK from an octopus retinal cDNA library, The deduced amino acid sequence of the cDNA was highly homologous to beta ARK over the entire molecule, including a pleckstrin homology domain located in the C-terminal region, and homology to RK was significantly lower, Furthermore, Western blot analysis of various octopus tissues with an antibody against the purified ORK showed that ORK is expressed solely in the retina, which confirmed the identity of the enzyme as rhodopsin kinase, Thus, ORIC appears to represent a unique subgroup in the GRK family, which is distinguished from vertebrate RK.	Himeji Inst Technol, Dept Life Sci, Harima Sci Garden City, Hyogo 6781279, Japan	University of Hyogo	Tsuda, M (corresponding author), Himeji Inst Technol, Dept Life Sci, Harima Sci Garden City, Hyogo 6781279, Japan.	mtsuda@sci.himeji-tech.ac.jp						Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ANANT JS, 1992, BIOCHEM BIOPH RES CO, V183, P468, DOI 10.1016/0006-291X(92)90505-F; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA T, 1994, J NEUROCHEM, V63, P400; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; Kikkawa S, 1996, BIOCHEMISTRY-US, V35, P15857, DOI 10.1021/bi961360v; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOUTALOS Y, 1989, BIOCHEMISTRY-US, V28, P2732, DOI 10.1021/bi00432a055; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUDA M, 1992, PHOTOCHEM PHOTOBIOL, V56, P1167, DOI 10.1111/j.1751-1097.1992.tb09741.x; TSUDA M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P204, DOI 10.1016/0167-4889(90)90077-Q; TSUDA M, 1987, PHOTOCHEM PHOTOBIOL, V45, P915, DOI 10.1111/j.1751-1097.1987.tb07903.x; TSUDA M, 1986, FEBS LETT, V198, P5, DOI 10.1016/0014-5793(86)81173-5; TSUDA M, 1982, JINBUN SHIZEN KAGAKU, V23, P37; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	40	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7441	7447		10.1074/jbc.273.13.7441	http://dx.doi.org/10.1074/jbc.273.13.7441			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516442	hybrid			2022-12-27	WOS:000072738500038
J	Richter-Cook, NJ; Dever, TE; HEnsold, JO; Merrick, WC				Richter-Cook, NJ; Dever, TE; HEnsold, JO; Merrick, WC			Purification and characterization of a new eukaryotic protein translation factor - Eukaryotic initiation factor 4H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP MUTATION; RABBIT RETICULOCYTES; RNA HELICASE; YEAST; SUPPRESSOR; BINDING; SEQUENCE; ENCODES; HOMOLOG	A new protein with translational activity has been identified on the basis of its ability to stimulate translation in an in vitro globin synthesis assay deficient in eukaryotic initiation factor (eIF) 4B and eIF4F, This protein has been purified to greater than 80% homogeneity from rabbit reticulocyte lysate and has been given the name eIF4H. eIF4H was shown to stimulate the in vitro activities of eIF4B and eIF4F in globin synthesis, as well as the in vitro RNA-dependent ATPase activities of eIF4A, eIF4B, and eIF4F, Three tryptic fragments of eIF4H yielded amino acid sequences that were 100% identical to a human sequence found in the GeneBank(TM) that codes for a previously uncharacterized protein (HUMORFU_1). The calculated molecular weight of the protein encoded by this sequence, its predicted cyanogen bromide fragmentation, and calculated isoelectric point are all consistent with those determined experimentally for eIF4H. Also, the presence of an RNA recognition motif within HUMORFU_1 suggests that eIF4H may interact with mRNA. We conclude that this newly characterized protein, eIF4H, functions to stimulate the initiation of protein synthesis at the level of mRNA utilization, and is encoded by the gene for HUMORFU_1.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Vet Affairs Med Ctr & Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	wcm2@po.cwru.edu	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43414, DK 07319] Funding Source: Medline; NIGMS NIH HHS [GM 26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1987, THESIS CASE W RESERV; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BLUM H, 1987, ELECTROPHORESIS, V8, P2897; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; CARVALHO JF, 1984, ARCH BIOCHEM BIOPHYS, V234, P591, DOI 10.1016/0003-9861(84)90309-6; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DEVER TE, 1990, THESIS CASE W RESERV; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FREIFELDER D, 1982, PHYSICAL BIOCH, P242; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JOSHI B, 1994, J BIOL CHEM, V269, P2048; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1990, BIOCHIM BIOPHYS ACTA, V1050, P235, DOI 10.1016/0167-4781(90)90173-Y; Merrick WC., 1996, TRANSLATION CONTROL, P31; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Nomura N, 1994, DNA Res, V1, P47, DOI 10.1093/dnares/1.1.47; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; RAYCHAUDHURI P, 1984, J BIOL CHEM, V259, P1930; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schmidt S, 1997, NUCLEIC ACIDS RES, V25, P3433, DOI 10.1093/nar/25.17.3433; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; VALENZUELA DM, 1982, J BIOL CHEM, V257, P7712; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	35	97	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7579	7587		10.1074/jbc.273.13.7579	http://dx.doi.org/10.1074/jbc.273.13.7579			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516461	hybrid			2022-12-27	WOS:000072738500057
J	Romero, F; Ramos-Morales, F; Dominguez, A; Rios, RM; Schweighoffer, F; Tocque, B; Pinto-Toro, JA; Fischer, S; Tortolero, M				Romero, F; Ramos-Morales, F; Dominguez, A; Rios, RM; Schweighoffer, F; Tocque, B; Pinto-Toro, JA; Fischer, S; Tortolero, M			Grb2 and its apoptotic isoform Grb3-3 associate with heterogeneous nuclear ribonucleoprotein C, and these interactions are modulated by poly(U) RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; PROTOONCOGENE PRODUCT; SIGNALING PATHWAY; BINDING PROTEINS; SRC; COMPLEXES; RAS; PARTICLES; RECONSTITUTION; ADAPTER	Grb2 is an adaptor molecule comprising one Src homology (SH) 2 and two SH3 domains. This protein has a natural isoform named Grb3-3 with a deletion within the SH2 domain. Numerous evidence points to a functional connection between SH2- and SH3-containing proteins and molecules implicated in RNA. biogenesis. In this context, we have examined the binding of Grb2 and Grb3-3 to heterogeneous nuclear ribonucleoprotein (hnRNP) C. By the use of an in vivo genetic approach and through in vitro experiments, we furnish evidence that both Grb2 and Grb3-3 interact with hnRNP C proteins. Subcellular fractionation studies clearly show that Grb2 is partially localized in the nucleus. In addition, coimmunoprecipitation experiments demonstrate that Grb2 hnRNP C complexes exist in intact hematopoietic cells. The carboxyl-terminal SH3 domains of Grb2 and Grb3-3 are primarily responsible for the association with hnRNP C. However, although the proline-rich motif of hnRNP C is involved in the interaction with Grb2, it is not in the binding to Grb3-3. Furthermore, poly(U) RNA inhibits the association of Grb2 with hnRNP C, whereas it enhances the interaction between Grb3-3 and hnRNP C. These findings suggest that the Grb2/Grb3-3-hnRNP C interactions might fulfill different biological functions.	Hop Cochin, Inst Cochin Genet Mol, INSERM, U363, F-75014 Paris, France; Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Sevilla, Spain; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry, France; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Sevilla, Spain	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Sevilla; Sanofi-Aventis; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Romero, F (corresponding author), Hop Cochin, Inst Cochin Genet Mol, INSERM, U363, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	romero@icgm.cochin.inserm.fr	Ramos-Morales, Francisco/C-5734-2008; Tortolero, Maria/K-5744-2014; Romero, Francisco/K-2101-2014; rios, rosa m/G-5742-2015; Pintor-Toro, Jose/L-4737-2014	Ramos-Morales, Francisco/0000-0002-1151-4547; Tortolero, Maria/0000-0003-1797-9940; Romero, Francisco/0000-0002-9588-6881; rios, rosa m/0000-0001-5778-6946; Pintor-Toro, Jose/0000-0002-9060-5243				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FELLER SM, 1995, ONCOGENE, V10, P1465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; PULLMAN JM, 1983, J CELL BIOL, V97, P99, DOI 10.1083/jcb.97.1.99; RamosMorales F, 1997, BIOCHEM BIOPH RES CO, V237, P735, DOI 10.1006/bbrc.1997.7221; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; REY I, 1995, CELL DEATH DIFFER, V2, P105; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENKEL J, 1988, EUR J BIOCHEM, V171, P565, DOI 10.1111/j.1432-1033.1988.tb13825.x; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sherman F., 1986, METHODS YEAST GENETI; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JO, 1983, J MOL BIOL, V171, P439, DOI 10.1016/0022-2836(83)90039-6; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WILK HE, 1983, BIOCHEMISTRY-US, V22, P4592, DOI 10.1021/bi00288a038; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	49	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7776	7781		10.1074/jbc.273.13.7776	http://dx.doi.org/10.1074/jbc.273.13.7776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516488	hybrid			2022-12-27	WOS:000072738500084
J	Udovichenko, IP; Newton, AC; Williams, DS				Udovichenko, IP; Newton, AC; Williams, DS			Regulation of the phosphorylation state of rhodopsin by dopamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADRENERGIC-RECEPTOR KINASE; ROD OUTER SEGMENTS; LOCALIZATION; RETINA; PHOSPHATASE; VERTEBRATE; VISION; BOVINE; DEPHOSPHORYLATION	G protein-coupled receptors (GPCRs) are regulated by kinases and phosphatases that control their phosphorylation state. Here, the possibility that the state of GPCR phosphorylation could be affected by paracrine input was explored. We show that dopamine increased the rate of dephosphorylation of rhodopsin, the light receptor, in intact frog retinas. Further, we found that rod outer segments from dopamine-treated retinas contained increased rhodopsin phosphatase activity, indicating that this effect of dopamine on rhodopsin was mediated by stimulation of rhodopsin phosphatase. Dopamine is a ubiquitous neuromodulator and, in the retina, is released from the inner cell layers. Thus, our results identify a pathway for feedback regulation of rhodopsin from the inner retina and illustrate the involvement of dopamine in paracrine regulation of the sensitivity of a GPCR.	Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Williams, DS (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Mail Code 0983,9500 Gilman Dr, La Jolla, CA 92093 USA.	dswilliams@ucsd.edu			NEI NIH HHS [EY08820, EY07042] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; Besharse J.C., 1988, PROGR RETINAL RES, V7, P21; BoeszeBattaglia K, 1997, BIOCHEMISTRY-US, V36, P6835, DOI 10.1021/bi9627370; BRANN MR, 1986, NEUROSCI LETT, V69, P221, DOI 10.1016/0304-3940(86)90483-0; Burnside B., 1983, PROG RETIN RES, V2, P67, DOI [10.1016/0278-4327(83)90004-4, DOI 10.1016/0278-4327(83)90004-4]; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; DEARRY A, 1991, CELL MOL NEUROBIOL, V11, P437, DOI 10.1007/BF00734808; DJAMGOZ MBA, 1992, NEUROCHEM INT, V20, P139, DOI 10.1016/0197-0186(92)90166-O; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; Greene NM, 1997, J BIOL CHEM, V272, P10341; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HILLMAN DW, 1995, J NEUROCHEM, V64, P1326; Hosey MM, 1996, PROG BRAIN RES, V109, P169; IUVONE PM, 1978, SCIENCE, V202, P901, DOI 10.1126/science.30997; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1976, BIOCHIM BIOPHYS ACTA, V428, P13, DOI 10.1016/0304-4165(76)90103-3; Kutuzov MA, 1996, EUR J BIOCHEM, V238, P613, DOI 10.1111/j.1432-1033.1996.0613w.x; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; MANGOLD HK, 1969, THIN LAYER CHROMATOG, P792; MURESAN Z, 1993, J COMP NEUROL, V331, P149, DOI 10.1002/cne.903310202; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OGAWA N, 1995, ACTA MED OKAYAMA, V49, P1; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; REME C, 1984, BRAIN RES, V298, P99, DOI 10.1016/0006-8993(84)91150-8; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; SIBLEY DR, 1993, INT REV NEUROBIOL, V35, P391, DOI 10.1016/S0074-7742(08)60573-5; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; Stoffel RH, 1997, J MEMBRANE BIOL, V157, P1, DOI 10.1007/s002329900210; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TRAN VT, 1992, INVEST OPHTH VIS SCI, V33, P1620; Udovichenko IP, 1997, J BIOL CHEM, V272, P7952, DOI 10.1074/jbc.272.12.7952; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687; WAGNER HJ, 1993, J COMP NEUROL, V331, P469, DOI 10.1002/cne.903310404; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; WIRZJUSTICE A, 1984, NEUROSCI LETT, V45, P21, DOI 10.1016/0304-3940(84)90323-9; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	44	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7181	7184		10.1074/jbc.273.13.7181	http://dx.doi.org/10.1074/jbc.273.13.7181			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516406	hybrid			2022-12-27	WOS:000072738500002
J	Yurewicz, EC; Sacco, AG; Gupta, SK; Xu, NX; Gage, DA				Yurewicz, EC; Sacco, AG; Gupta, SK; Xu, NX; Gage, DA			Hetero-oligomerization-dependent binding of pig oocyte zona pellucida glycoproteins ZPB and ZPC to boar sperm membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; MOUSE SPERM; EGG-BINDING; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; ALPHA-GLYCOPROTEIN; ACROSOME REACTION; TREFOIL MOTIF; PROTEIN; FERTILIZATION	The zona pellucida surrounding the pig oocyte contains two M-r 55,000 glycoproteins, pZPB and pZPC, which are orthologues of mouse zona proteins ZP1 and ZP3, respectively, We previously reported that isolated boar sperm membrane vesicles possess high affinity binding sites for partially purified pZPB, but not pZPC. Interestingly, co-incubation experiments also implicated pZPB-pZPC complexes as potential ligands. We now report that when depleted of a minor pZPC contaminant by size exclusion chromatography, pZPB lacks independent binding activity. In solid phase binding assays employing immobilized boar sperm membranes, pZPB failed to compete with biotin-(pZPB+pZPC) probe, and biotin-labeled pZPB yielded negligible binding. However, when co-incubated with pZPC prior to the binding assays, pZPB acted as a potent competitor, and biotin-labeled pZPB exhibited high affinity, saturable binding. Binding activity was attributed to pZPB-pZPC heterocomplexes, which were detected in co-incubation mixtures by size exclusion chromatography and Western blot analysis. In the pig, therefore, sperm membranes possess a zona-binding protein with high affinity sites for pZPB-pZPC heterocomplexes, but not free glycoprotein subunits. Consequently, associative interactions between zona molecules can contribute toward both the assembly of the zona matrix and generation of ligands important for sperm-zona interactions.	Wayne State Univ, Dept Obstet Gynecol, Detroit, MI 48201 USA; Natl Inst Immunol, Gamete Antigen Lab, New Delhi 110067, India; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Wayne State University; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Michigan State University	Yurewicz, EC (corresponding author), Wayne State Univ, Dept Obstet Gynecol, 275 E Hancock, Detroit, MI 48201 USA.	e.yurewicz@wayne.edu	Gupta, Satish/B-9934-2009	Gupta, Satish/0000-0003-3717-0436	NCRR NIH HHS [RR00480] Funding Source: Medline; NICHD NIH HHS [HD23163] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Afzalpurkar A, 1997, AM J REPROD IMMUNOL, V38, P26; BABA T, 1989, J BIOL CHEM, V264, P11920; BEEBE SJ, 1992, DEV BIOL, V151, P48, DOI 10.1016/0012-1606(92)90212-Y; BERGER T, 1989, BIOL REPROD, V40, P525, DOI 10.1095/biolreprod40.3.525; BERGER T, 1989, J REPROD FERTIL, V86, P559, DOI 10.1530/jrf.0.0860559; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; BORK P, 1993, PROTEIN SCI, V2, P669; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BURKS DJ, 1995, SCIENCE, V269, P83, DOI 10.1126/science.7541556; Cosowsky L, 1997, J BIOL CHEM, V272, P3309, DOI 10.1074/jbc.272.6.3309; DE A, 1994, P NATL ACAD SCI USA, V91, P1084, DOI 10.1073/pnas.91.3.1084; DOSTALOVA Z, 1995, EUR J BIOCHEM, V230, P329, DOI 10.1111/j.1432-1033.1995.tb20567.x; DUNBAR BS, 1985, BIOL REPROD, V32, P619, DOI 10.1095/biolreprod32.3.619; DUNBAR BS, 1987, J REPROD FERTIL, V81, P363, DOI 10.1530/jrf.0.0810363; EPIFANO O, 1995, J BIOL CHEM, V270, P27254, DOI 10.1074/jbc.270.45.27254; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; GUPTA SK, 1995, MOL REPROD DEV, V42, P220, DOI 10.1002/mrd.1080420211; GUPTA SK, 1993, AM J REPROD IMMUNOL, V30, P95, DOI 10.1111/j.1600-0897.1993.tb00608.x; HALL LLH, 1995, J SOC GYNECOL INVEST, V2, P552, DOI 10.1016/1071-5576(94)00063-7; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HARRIS JD, 1994, DNA SEQUENCE, V4, P361, DOI 10.3109/10425179409010186; HEDRICK JL, 1986, ANAL BIOCHEM, V157, P63, DOI 10.1016/0003-2697(86)90196-X; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; JONES R, 1991, DEVELOPMENT, V111, P1155; KILLICK R, 1995, J CELL BIOL, V129, P535, DOI 10.1083/jcb.129.2.535; KINLOCH RA, 1988, P NATL ACAD SCI USA, V85, P6409, DOI 10.1073/pnas.85.17.6409; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LIANG LF, 1990, MOL CELL BIOL, V10, P1507, DOI 10.1128/MCB.10.4.1507; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NOGUCHI S, 1992, EUR J BIOCHEM, V204, P1089, DOI 10.1111/j.1432-1033.1992.tb16733.x; Prasad SV, 1996, MOL REPROD DEV, V43, P519, DOI 10.1002/(SICI)1098-2795(199604)43:4&lt;519::AID-MRD15&gt;3.0.CO;2-U; SACCO AG, 1989, BIOL REPROD, V41, P523, DOI 10.1095/biolreprod41.3.523; SANZ L, 1992, EUR J BIOCHEM, V205, P645, DOI 10.1111/j.1432-1033.1992.tb16822.x; SCHWOEBEL E, 1991, J BIOL CHEM, V266, P7214; SHUR BD, 1988, J BIOL CHEM, V263, P17706; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; TAYA T, 1995, BIOCHEM BIOPH RES CO, V207, P790, DOI 10.1006/bbrc.1995.1256; Thaler CD, 1996, J BIOL CHEM, V271, P23289, DOI 10.1074/jbc.271.38.23289; Tulsiani DRP, 1997, BIOL REPROD, V57, P487, DOI 10.1095/biolreprod57.3.487; URCH UA, 1985, J EXP ZOOL, V233, P479, DOI 10.1002/jez.1402330317; YAMASAKI N, 1995, MOL REPROD DEV, V40, P48, DOI 10.1002/mrd.1080400107; YONEZAWA N, 1995, EUR J BIOCHEM, V233, P35, DOI 10.1111/j.1432-1033.1995.035_1.x; YUREWICZ EC, 1987, J BIOL CHEM, V262, P564; YUREWICZ EC, 1991, MOL REPROD DEV, V30, P126, DOI 10.1002/mrd.1080300209; YUREWICZ EC, 1993, MOL REPROD DEV, V36, P382, DOI 10.1002/mrd.1080360315; YUREWICZ EC, 1993, BIOCHIM BIOPHYS ACTA, V1174, P211, DOI 10.1016/0167-4781(93)90119-X; YUREWICZ EC, 1983, BIOL REPROD, V29, P511, DOI 10.1095/biolreprod29.2.511; YUREWICZ EC, 1993, J REPROD FERTIL, V98, P147; Zhu XL, 1997, P NATL ACAD SCI USA, V94, P4704, DOI 10.1073/pnas.94.9.4704	51	133	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7488	7494		10.1074/jbc.273.13.7488	http://dx.doi.org/10.1074/jbc.273.13.7488			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516448	hybrid			2022-12-27	WOS:000072738500044
J	Diochot, S; Schweitz, H; Beress, L; Lazdunski, M				Diochot, S; Schweitz, H; Beress, L; Lazdunski, M			Sea anemone peptides with a specific blocking activity against the fast inactivating potassium channel Kv3.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR MAGNETIC-RESONANCE; POLYPEPTIDE ANTHOPLEURIN-B; RESISTANT NA+ CHANNELS; MOTOR-NERVE TERMINALS; PROTEIN BDS-I; K+-CHANNELS; RAT-BRAIN; SECONDARY STRUCTURE; SODIUM-CHANNEL	Sea anemone venom is known to contain toxins that are active on voltage-sensitive Na+ channels, as well as on delayed rectifier K+ channels belonging to the Kv1 family. This report describes the properties of a new set of peptides from Anemonia sulcata that act as blockers of a specific member of the Kv3 potassium channel family. These toxins, blood depressing substance (BDS)-I and BDS-II, are 43 amino acids long and differ at only two positions. They share no sequence homologies with other K+ channel toxins from sea anemones, such as AsKS, AsKC, ShK, or BgK. In COS-transfected cells, the Kv3.4 current was inhibited in a reversible manner by BDS-I, with an IC50 value of 47 nM. This inhibition is specific because BDS-I failed to block other K+ channels in the Kv1, Kv2, Kv3, and Kv4 subfamilies. Inward rectifier K+ channels are also insensitive to BDS-I. BDS-I and BDS-II share the same binding site on brain synaptic membranes, with K-0.5 values of 12 and 19 nM, respectively. We observed that BDS-I and BDS-II have some sequence homologies with other sea anemone Na+ channels toxins, such as AsI, AsII, and AxI. However, they had a weak effect on tetrodotoxin-sensitive Na+ channels in neuroblastoma cells and no effect on Na+ channels in cardiac and skeletal muscle cells. BDS-I and BDS-II are the first specific blockers identified so far for the rapidly inactivating Kv3.4 channel.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Kiel Klinikum, Abt Toxikol, D-2300 Kiel, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Kiel; Schleswig Holstein University Hospital	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.		Diochot, Sylvie/ABG-5495-2020					AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J; AWAN KA, 1991, NEUROSCIENCE, V40, P29, DOI 10.1016/0306-4522(91)90172-K; BERESS L, 1985, Patent No. 3324689; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; CATTERALL WA, 1980, J SUPRAMOL STR CELL, V14, P295, DOI 10.1002/jss.400140304; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; DREYER F, 1987, J PHYSIOL-LONDON, V386, P455, DOI 10.1113/jphysiol.1987.sp016544; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2178, DOI 10.1021/bi00431a032; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2188, DOI 10.1021/bi00431a033; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HARVEY AL, 1996, BIOCH ASPECTS MARINE, P121; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; HUGUES M, 1982, P NATL ACAD SCI-BIOL, V79, P1308, DOI 10.1073/pnas.79.4.1308; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Khera PK, 1996, BIOCHEMISTRY-US, V35, P3503, DOI 10.1021/bi9528457; LLEWELLYN LE, 1991, BIOCHEM INT, V24, P937; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LORET EP, 1994, J BIOL CHEM, V269, P16785; MABBUTT BC, 1990, EUR J BIOCHEM, V187, P555, DOI 10.1111/j.1432-1033.1990.tb15337.x; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MOCKZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95; MOURRE C, 1984, EUR J PHARMACOL, V100, P135, DOI 10.1016/0014-2999(84)90329-7; MOURRE C, 1988, BRAIN RES, V446, P106, DOI 10.1016/0006-8993(88)91300-5; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; PENNINGTON MW, 1995, INT J PEPT PROT RES, V46, P354; PERNEY T M, 1991, Current Opinion in Cell Biology, V3, P663, DOI 10.1016/0955-0674(91)90039-2; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; PONGS O, 1992, PHYSIOL REV, V72, pS69; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; RENAUD JF, 1986, EUR J PHARMACOL, V120, P161, DOI 10.1016/0014-2999(86)90536-4; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; ROWAN EG, 1988, BRIT J PHARMACOL, V94, P839, DOI 10.1111/j.1476-5381.1988.tb11595.x; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; SCHEFFLER JJ, 1982, BIOCHEM BIOPH RES CO, V107, P272, DOI 10.1016/0006-291X(82)91700-4; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCHWEITZ H, 1990, TOXICON, V28, P847, DOI 10.1016/S0041-0101(09)80007-X; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SCHWEITZ H, 1989, FEBS LETT, V250, P519, DOI 10.1016/0014-5793(89)80788-4; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; TANAKA M, 1977, BIOCHEMISTRY-US, V16, P204, DOI 10.1021/bi00621a007; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; VINCENT JP, 1980, P NATL ACAD SCI-BIOL, V77, P1646, DOI 10.1073/pnas.77.3.1646; WIDMER H, 1988, EUR J BIOCHEM, V171, P177, DOI 10.1111/j.1432-1033.1988.tb13774.x; WUNDERER G, 1976, EUR J BIOCHEM, V68, P193, DOI 10.1111/j.1432-1033.1976.tb10778.x; WUNDERER G, 1978, EUR J BIOCHEM, V89, P11, DOI 10.1111/j.1432-1033.1978.tb20890.x	61	159	190	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6744	6749		10.1074/jbc.273.12.6744	http://dx.doi.org/10.1074/jbc.273.12.6744			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506974	hybrid			2022-12-27	WOS:000072775900024
J	Nelson, KL; Rogers, JA; Bowman, TL; Jove, R; Smithgall, TE				Nelson, KL; Rogers, JA; Bowman, TL; Jove, R; Smithgall, TE			Activation of STAT3 by the c-Fes protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; PROTOONCOGENE PRODUCT; CYTOKINE RECEPTORS; SIGNAL TRANSDUCERS; GROWTH ARREST; ABL ONCOGENE; CELL-LINES; DIFFERENTIATION	STATs (signal transducers and activators of transcription) are transcription factors that contain SH2 domains and are activated by tyrosine phosphorylation, often in response to cytokine stimulation. Recent evidence indicates that the transforming tyrosine kinases encoded by the v-Src, v-Abl, and v-Fps oncogenes can induce STAT activation, suggesting that their normal cellular homologs may contribute to STAT activation under physiological conditions, In this report, we provide direct evidence that c-Fes, the normal human homolog of v-Fps, potently activates STAT3, Transient transfection of human 293T cells with STAT3 and Fes resulted in strong stimulation of STAT3 DNA binding activity. In contrast, only modest activation of STATE by Fes was observed in this system, indicative of possible selectivity, To determine whether Fes induced STAT3 activation is dependent upon endogenous mammalian kinases, co-expression studies were also performed in Sf-9 insect cells, Fes also induced a dramatic increase in STAT3 DNA binding activity in this system, whereas no activation of STAT5 was observed. As a positive control, both STAT3 and STATE were shown to be activated by the Bcr-Abl tyrosine kinase in Sf-9 cells, Fes induced strong tyrosine phosphorylation of STETS in both expression systems, consistent with the gel-shift results, Fes and STAT3 have been independently linked to myeloid differentiation. Results presented here suggest that these proteins may cooperate to promote differentiation signaling in response to hematopoietic cytokines.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Nebraska System; University of Nebraska Medical Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Smithgall, TE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42nd St, Omaha, NE 68198 USA.	tsmithga@unmc.edu	Rogers, John/L-2798-2016		NATIONAL CANCER INSTITUTE [R01CA058667, P30CA036727] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727, CA58667] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nelson KL, 1996, J BIOL CHEM, V271, P18061, DOI 10.1074/jbc.271.30.18061; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shuai K, 1996, ONCOGENE, V13, P247; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Woldman I, 1997, J IMMUNOL, V159, P877; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YU G, 1989, J BIOL CHEM, V264, P10276	37	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7072	7077		10.1074/jbc.273.12.7072	http://dx.doi.org/10.1074/jbc.273.12.7072			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507017	hybrid			2022-12-27	WOS:000072775900067
J	Avramoglu, RK; Nimpf, J; McLeod, RS; Ko, KWS; Wang, YW; FitzGerald, D; Yao, ZM				Avramoglu, RK; Nimpf, J; McLeod, RS; Ko, KWS; Wang, YW; FitzGerald, D; Yao, ZM			Functional expression of the chicken low density lipoprotein receptor-related protein in a mutant Chinese hamster ovary cell line restores toxicity of Pseudomonas exotoxin A and degradation of alpha(2)-macroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; INSULIN-RECEPTOR; MICE LACKING; BINDING; AERUGINOSA; SECRETION; LRP; CHYLOMICRONS	The low density lipoprotein receptor-related protein (LRP) is responsible for the clearance of several physiological ligands including a complex of proteinase and alpha(2)-macroglobulin (alpha(2)M) and for the entrance of Pseudomonas exotoxin A (PEA) into cells, We have prepared expression plasmids for the full-length chicken LRP (designated LRP100) and two intermediates encoding 25 and 67% of the receptor (designated LRP25 and LRP67, respectively) using overlapping: cDNA fragments, LRP25 and LRP67 encode the N-terminal 22 and 64%, respectively, of LRP100 plus the transmembrane and intracellular domains, Transient transfection of these plasmids into COS-7 cells yielded recombinant proteins of expected molecular mass and immunoreactivity, However, LRP100 was incompletely processed into alpha- (515-kDa) and beta- (85-kDa) chains and was poorly transported from the endoplasmic reticulum to the Golgi compartment. Stable transformants of LRP100, LRP67, and LRP25 were generated in a mutant Chinese hamster ovary cell line that lacked expression of endogenous LRP and was resistant to PEA. All forms of recombinant LRP proteins were transported from the endoplasmic reticulum to the Golgi apparatus in Chinese hamster ovary cells as shown by their sensitivity to endoglycosidase H and resistance to neuraminidase. Cell surface iodination and subcellular fractionation studies indicated that all three LRP variants were expressed on the plasma membrane, Furthermore, expression of the three LRP variants restored, to various degrees, sensitivity to PEA and the ability to degrade methylamine-activated alpha(2)M (alpha(2)M*). These data suggest that deletion of large internal portions of LRP, including the processing site, does not prevent transport of LRP to the plasma membrane, nor does it abolish the interaction of LRP with alpha(2)M* or PEA. This LRP expression system may allow for the characterization of domains within LRP responsible for its multifunctionality.	Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Inst Heart, Dept Biochem, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4E9, Canada; Univ Vienna, Vienna, Austria; Bioctr, Dept Mol Genet, Vienna, Austria; NCI, Mol Biol Lab, Div Canc Biol Diag & Ctr, NIH, Bethesda, MD 20892 USA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Vienna; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4E9, Canada.		McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569; Nimpf, Johannes/0000-0002-9273-3492				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; ESSER V, 1988, J BIOL CHEM, V263, P13282; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; JI ZS, 1994, J BIOL CHEM, V269, P2764; KAKEHI T, 1988, J CLIN INVEST, V81, P2020, DOI 10.1172/JCI113553; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Krapp A, 1996, J LIPID RES, V37, P926; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NIMPF J, 1994, J BIOL CHEM, V269, P212; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; OGATA M, 1990, J BIOL CHEM, V265, P20678; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SNELL K, 1978, INFECT IMMUN, V19, P839, DOI 10.1128/IAI.19.3.839-845.1978; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WICK MJ, 1990, ANNU REV MICROBIOL, V44, P335, DOI 10.1146/annurev.mi.44.100190.002003; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	39	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6057	6065		10.1074/jbc.273.11.6057	http://dx.doi.org/10.1074/jbc.273.11.6057			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497322	hybrid			2022-12-27	WOS:000072488500014
J	Koshkin, V; Dunford, HB				Koshkin, V; Dunford, HB			Reaction of prostaglandin endoperoxide synthase with cis,cis-eicosa-11,14-dienoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; H SYNTHASE; PEROXIDASE REACTION; SOYBEAN LIPOXYGENASE; ARACHIDONIC-ACID; COMPOUND-I; CYCLOOXYGENASE; KINETICS; HYDROPEROXIDES; STOICHIOMETRY	The pre-steady-state phase of the oxygenase reaction of prostaglandin endoperoxide synthase with cis,cis-eicosa-11,14-dienoic acid has been studied using stopped flow techniques, Because some intermediate forms of prostaglandin endoperoxide synthase are spectrally indistinguishable, the enzyme and substrate transformations were monitored in parallel to simplify the interpretation of the kinetics, Over a wide range of conditions, the formation of the enzyme intermediate II, the form of compound I containing the tyrosyl radical, precedes substrate oxidation, This result supports the occurrence of a unimolecular conversion of compound I into intermediate II. Furthermore, the rate of intermediate II formation was stimulated by increased concentration of dienoic acid, perhaps because of increased occupation of the fatty acid binding site, The importance of the unimolecular formation of intermediate II was confirmed by simulated kinetics of the oxygenase reaction. These results provide evidence that intermediate II is the primary oxidant in the reaction of prostaglandin synthase with the dienoic acid, as it is with arachidonic acid.	Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Alberta	Dunford, HB (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.							Bakovic M, 1996, PROSTAG LEUKOTR ESS, V54, P341, DOI 10.1016/S0952-3278(96)90048-4; BAKOVIC M, 1994, BIOCHEMISTRY-US, V33, P6475, DOI 10.1021/bi00187a013; Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; Bakovic M, 1995, PROSTAG LEUKOTR ESS, V53, P423, DOI 10.1016/0952-3278(95)90107-8; BAKOVIC M, 1995, BIOPHYS CHEM, V54, P237, DOI 10.1016/0301-4622(94)00135-7; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HSUANYU Y, 1991, ANAL BIOCHEM, V198, P174, DOI 10.1016/0003-2697(91)90524-W; HSUANYU YC, 1990, BIOCHEM CELL BIOL, V68, P965, DOI 10.1139/o90-142; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; RUF HH, 1993, BIOCHEM SOC T, V21, P739, DOI 10.1042/bst0210739; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Tsai AL, 1997, BIOCHEMISTRY-US, V36, P13085, DOI 10.1021/bi970397s; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034	28	8	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6046	6049		10.1074/jbc.273.11.6046	http://dx.doi.org/10.1074/jbc.273.11.6046			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497320	hybrid			2022-12-27	WOS:000072488500012
J	Tsuda, H; Takebayashi, K; Nakanishi, S; Kageyama, R				Tsuda, H; Takebayashi, K; Nakanishi, S; Kageyama, R			Structure and promoter analysis of Math3 gene, a mouse homolog of Drosophila proneural gene atonal - Neural-specific expression by dual promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX FACTOR; DEVELOPING NERVOUS-SYSTEM; CELL-DIFFERENTIATION; MAMMALIAN HAIRY; BHLH PROTEIN; RAT-BRAIN; NEURONS; RETINA; NEUROGENESIS; ENHANCER	ath3, a vertebrate basic helix-loop-helix gene homologous to Drosophila proneural gene atonal, can directly convert non-neural cells into neurons with the anterior features, In the mouse, ath3 expression initially occurs widely in the developing nervous system and then gradually becomes restricted to the neural retina. Here, we characterized the genomic organization and promoter activity of mouse ath3 (Math3). Math3 gene consists of two exons separated by an 8-kilobase intron, and the whole protein-coding region is located in the second exon. Transcription starts at two sites, which are 75 nucleotides apart from each other, and there is no typical TATA bog in the upstream region of either start site. Transient transfection analysis showed that the 5'-region of Math3 can direct efficient expression in neuroblastoma cells but not in glioma or fibroblast cells. Deletion studies revealed that the proximal 193-base pair region, which contains the downstream transcription initiation site but not the upstream site, is essential for the Math3 promoter activity and can direct efficient expression in neuroblastoma cells. In contrast, retrovirus-mediated promoter analysis demonstrated that a region further upstream is additionally necessary for retinal expression. These results indicate that Math3 promoter contains two essential regulatory regions, the proximal 193-base pair region, which confers efficient neural-specific expression, and a region further upstream, required for retinal expression.	Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 606, Japan	Kyoto University	Kageyama, R (corresponding author), Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Yoshida, Kyoto 606, Japan.							AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Bao ZZ, 1997, J NEUROSCI, V17, P1425; BARTHOLOMA A, 1994, MECH DEVELOP, V48, P217, DOI 10.1016/0925-4773(94)90061-2; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; CAFFE AR, 1989, CURR EYE RES, V8, P1083, DOI 10.3109/02713688908997401; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHAPMAN DB, 1963, MOUSE NEWS LETT, V28, P32; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; Gradwohl G, 1996, DEV BIOL, V180, P227, DOI 10.1006/dbio.1996.0297; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; IKENAKA K, 1992, NEW BIOL, V4, P53; Isaka F, 1996, GENOMICS, V37, P400, DOI 10.1006/geno.1996.0577; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KAGEYAMA R, 1995, CRIT REV NEUROBIOL, V9, P177; Kawakami H, 1996, BIOCHEM BIOPH RES CO, V221, P199, DOI 10.1006/bbrc.1996.0569; Kume H, 1996, BIOCHEM BIOPH RES CO, V219, P526, DOI 10.1006/bbrc.1996.0267; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SHIMIZU C, 1995, EUR J BIOCHEM, V229, P239, DOI 10.1111/j.1432-1033.1995.0239l.x; SPARROW JR, 1990, DEV BRAIN RES, V51, P69, DOI 10.1016/0165-3806(90)90259-2; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; Takebayashi K, 1997, EMBO J, V16, P384, DOI 10.1093/emboj/16.2.384; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Yasunami M, 1996, BIOCHEM BIOPH RES CO, V220, P754, DOI 10.1006/bbrc.1996.0476	41	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6327	6333		10.1074/jbc.273.11.6327	http://dx.doi.org/10.1074/jbc.273.11.6327			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497361	hybrid, Green Submitted			2022-12-27	WOS:000072488500053
J	Yang, JH; Briggs, WH; Libby, P; Lee, RT				Yang, JH; Briggs, WH; Libby, P; Lee, RT			Small mechanical strains selectively suppress matrix metalloproteinase-1 expression by human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGENASE GENE-EXPRESSION; SIGNALING CASCADE; ACTIVATION; STROMELYSIN; FIBRONECTIN; GROWTH; INTEGRINS; JUN; MECHANOTRANSDUCTION; ATHEROSCLEROSIS	Mechanical forces and biochemical stimuli may interact to regulate cellular responses, In this study, we tested the hypothesis that very small mechanical strains interact with growth factors in the regulation of matrix metalloproteinase (MMP)-1. Human vascular smooth muscle cells (VSMCs) were cultured on a precoated silicone membrane in a device that imposes a highly uniform biaxial strain, VSMCs cultured on fibronectin were treated with cyclic 1-Hz strains of 0, 1, or 4%, and MMPs were assayed by Western analysis or gelatin zymography. Small strains did not induce MMP-1 in VSMCs, but strain was a potent inhibitor of platelet-derived growth factor (PDGF)- or tumor necrosis factor-alpha-induced synthesis of MMP-1. In contrast, MMP-2 and TIMP-2 levels were not changed by PDGF and/or mechanical strain. VSMCs strained on the 120-kDa chymotryptic fragment of fibronectin or RGD peptides suppressed PDGF-induced expression of MMP-1, indicating that this effect is not mediated by the heparin-binding domain or connecting segment-1 of fibronectin. Northern analysis of ets-1, a transcriptional activator of MMP-1 expression, showed that strain down-regulated ets-1 expression, whereas c-fos expression was augmented. Thus, small deformations can selectively suppress MMP-1 synthesis by VSMCs, demonstrating the exquisite sensitivity of the cell to mechanical stimuli.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Lee, RT (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.	RTLEE@BICS.BWH.HARVARD.EDU	Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054759, P01HL048743, R29HL054759] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54759, HL-48743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Buttice G, 1996, ONCOGENE, V13, P2297; Calara F, 1996, ARTERIOSCL THROM VAS, V16, P187, DOI 10.1161/01.ATV.16.2.187; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GIMBRONE MA, 1975, LAB INVEST, V33, P16; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAUGEN PK, 1990, J CELL BIOL, V111, P2733, DOI 10.1083/jcb.111.6.2733; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAMES TW, 1993, J CELL PHYSL, V157, P427; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; KOLPAKOV V, 1995, CIRC RES, V77, P823, DOI 10.1161/01.RES.77.4.823; KUMORO I, 1996, FASEB J, V10, P631; Lee RT, 1996, ARTERIOSCL THROM VAS, V16, P1070, DOI 10.1161/01.ATV.16.8.1070; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LEUNG DYM, 1976, SCIENCE, V191, P475; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; OSOL G, 1995, J VASC RES, V32, P275, DOI 10.1159/000159102; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERB Z, 1986, J CELL BIOL, V102, P697, DOI 10.1083/jcb.102.3.697; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YANAGI H, 1991, ATHEROSCLEROSIS, V91, P207, DOI 10.1016/0021-9150(91)90168-3	43	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6550	6555		10.1074/jbc.273.11.6550	http://dx.doi.org/10.1074/jbc.273.11.6550			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497391	hybrid			2022-12-27	WOS:000072488500083
J	Zapun, A; Darby, NJ; Tessier, DC; Michalak, M; Bergeron, JJM; Thomas, DY				Zapun, A; Darby, NJ; Tessier, DC; Michalak, M; Bergeron, JJM; Thomas, DY			Enhanced catalysis of ribonuclease B folding by the interaction of calnexin or calreticulin with ERp57	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM; CHAPERONE ACTIVITY; GLYCOPROTEINS; EXPRESSION; ASSOCIATION; CLONING	The endoplasmic reticulum is the site of folding, disulfide bond formation, and N-glycosylation of secretory proteins. Correctly folded proteins are exported from the endoplasmic reticulum, whereas incorrectly folded proteins are retained by a quality control system. The type I membrane-protein calnexin and its soluble homologue calreticulin are constituents of this system that recognize monoglucosylated N-linked glycans that are present on unfolded glycoproteins. Although several components of the quality control apparatus are well characterized, it is not known whether and how they interact with enzymes that catalyze protein folding. The endoplasmic reticulum protein ERp57 is homologous to protein-disulfide isomerase and can be cross-linked to the same monoglucosylated glycoproteins that bind to calnexin and calreticulin, The present study demonstrates that the disulfide isomerase activity of ERp57 on the refolding of monoglucosylated ribonuclease B is much greater when this glycoprotein is associated with calnexin or calreticulin. This result is in contrast to protein-disulfide isomerase, whose activity on monoglucosylated ribonuclease B is decreased in the presence of these lectins. No direct binding of monoglucosylated ribonuclease B or monoglucosylated glycans to ERp57 could be detected, but we show that ERp57 interacts directly with calnexin.	Natl Res Council Canada, Biotechnol Res Inst, Genet Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada	National Research Council Canada; McGill University; European Molecular Biology Laboratory (EMBL); University of Alberta; McGill University	Zapun, A (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Zapun, Andre/0000-0001-8953-4399; Thomas, David/0000-0002-8854-762X				Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1992, PROTEIN EXPRES PURIF, V3, P322, DOI 10.1016/1046-5928(92)90008-K; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOSE S, 1994, BIOCHEM J, V300, P865, DOI 10.1042/bj3000865; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; CAI H, 1994, J BIOL CHEM, V269, P24550; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Desilva MG, 1996, DNA CELL BIOL, V15, P9, DOI 10.1089/dna.1996.15.9; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GRAFL R, 1987, J BIOL CHEM, V262, P10624; HAYANO T, 1995, FEBS LETT, V372, P210, DOI 10.1016/0014-5793(95)00996-M; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; RUPP K, 1994, J BIOL CHEM, V269, P2501; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	31	295	300	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6009	6012		10.1074/jbc.273.11.6009	http://dx.doi.org/10.1074/jbc.273.11.6009			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497314	hybrid			2022-12-27	WOS:000072488500006
J	Arispe, N; Ma, JJ; Jacobson, KA; Pollard, HB				Arispe, N; Ma, JJ; Jacobson, KA; Pollard, HB			Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNEL; ADENOSINE RECEPTORS; IDENTIFICATION; DELTA-F508; GENE; MUTATION; EFFLUX; CELLS; DOMAIN	8-Cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX) are xanthine adenosine antagonists which activate chloride efflux from cells expressing either wild-type or mutant (Delta F508) cystic fibrosis transmembrane conductance regulator (CFTR). These drugs are active in extremely low concentrations, suggesting their possible therapeutic uses in treating cystic fibrosis. However, knowledge of the mechanism of action of these compounds is lacking. We report here that the same low concentrations of both CPX and DAX which activate chloride currents from cells also generate a profound activation of CFTR channels incorporated into planar lipid bilayers. The process of activation involves a pronounced increase in the total conductive time of the incorporated CFTR channels. The mechanism involves an increase in the frequency and duration of channel opening events. Thus, activation by these drugs of chloride efflux in cells very likely involves direct interaction of the drugs with the CFTR protein. We anticipate that this new information will contribute fundamentally to the rational development of these and related compounds for cystic fibrosis therapy.	Uniformed Serv Univ Hlth Sci, Inst Mol Med, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; NIDDK, Bioorgan Chem Sect, Chem Lab, NIH, Bethesda, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Arispe, N (corresponding author), Uniformed Serv Univ Hlth Sci, Inst Mol Med, Bethesda, MD 20814 USA.		Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031127-01, Z99 DK999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BARNOY S, 1996, PEDIAT PULMONOLOGY, V13, P213; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CASAVOLA V, 1995, AM J PHYSIOL-CELL PH, V269, pC226, DOI 10.1152/ajpcell.1995.269.1.C226; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Cohen BE, 1997, BIOCHEMISTRY-US, V36, P6455, DOI 10.1021/bi970150v; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EIDELMAN O, 1992, P NATL ACAD SCI USA, V89, P5562, DOI 10.1073/pnas.89.12.5562; GRIS DB, 1997, BIOCHEMISTRY-US, V34, P7739; GUAYBRODER C, 1995, BIOCHEMISTRY-US, V34, P9079, DOI 10.1021/bi00028a017; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JACOBSON KA, 1995, BIOCHEMISTRY-US, V34, P9088, DOI 10.1021/bi00028a018; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Ko YH, 1997, BIOCHEMISTRY-US, V36, P5053, DOI 10.1021/bi9630265; LEE G, 1995, PEDIATR PULM, V12, P185; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHWEIBERT E, 1992, PEDIAT PULM S, V8, P257; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; VENGLARIK CJ, 1994, J GEN PHYSIOL, V104, P123, DOI 10.1085/jgp.104.1.123; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; XIE JX, 1995, J BIOL CHEM, V270, P28084; Xie JX, 1996, BIOPHYS J, V71, P3148, DOI 10.1016/S0006-3495(96)79508-5	39	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5727	5734		10.1074/jbc.273.10.5727	http://dx.doi.org/10.1074/jbc.273.10.5727			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488705	hybrid			2022-12-27	WOS:000072345000048
J	Borza, DB; Morgan, WT				Borza, DB; Morgan, WT			Histidine-proline-rich glycoprotein as a plasma pH sensor - Modulation of its interaction with glycosaminoglycans by pH and metals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC POLY-ELECTROLYTES; FIBROBLAST GROWTH-FACTOR; HEPARIN BINDING; RESPIRATORY BURST; SERUM; ANTITHROMBIN; LEUKOCYTES; PLASMINOGEN; FIBRINOGEN; THROMBOSIS	The middle domain of plasma histidine-proline-rich glycoprotein (HPRG) contains unusual tandem pentapeptide repeats (consensus G(H/P)(H/P)PH) and binds heparin and transition metals, Unlike other proteins that interact with heparin via lysine or arginine residues, HPRG relies exclusively on histidine residues for this interaction, To assess the consequences of this unusual requirement, we have studied the interaction between human plasma HPRG and immobilized glycosaminoglycans (GAGs) using resonant mirror biosensor techniques, HPRG binding to immobilized heparin was strikingly pH-sensitive, producing a titration curve with a midpoint at pH 6.8, There was little binding of HPRG to heparin at physiological pH in the absence of metals, but the interaction was promoted by nanomolar concentrations of free zinc and copper, and its pH dependence was shifted toward alkaline pH by zinc. The affinity of HPRG for various GAGs measured in a competition assay decreased in the following order: heparin > dermatan sulfate > heparan sulfate > chondroitin sulfate A, Binding of HPRG to immobilized dermatan sulfate had a midpoint at pH 6.5, was less influenced by zinc, and exhibited cooperativity, Importantly, plasminogen interacted specifically with GAG-bound HPRG, We propose that HPRG is a physiological pH sensor, interacting with negatively charged GAGs on cell surfaces only when it acquires a net positive charge by protonation and/or metal binding, This provides a mechanism to regulate the function of HPRG (the local pH) and rationalizes the role of its unique, conserved histidine-proline-rich domain, Thus, under conditions of local acidosis (e.g. ischemia or hypoxia), HPRG can co-immobilize plasminogen at the cell surface as well as compete for heparin with other proteins such as antithrombin.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Morgan, WT (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X				Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; Borza DB, 1996, BIOCHEMISTRY-US, V35, P1925, DOI 10.1021/bi952061t; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BURCH MK, 1987, BIOCHEMISTRY-US, V26, P7477, DOI 10.1021/bi00397a042; CASTAMAN G, 1993, THROMB RES, V69, P297, DOI 10.1016/0049-3848(93)90027-L; CASTELLIN OFI, 1981, METHOD ENZYMOL, V90, P365; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CHANG NS, 1992, IMMUNOLOGY, V77, P532; FALKON L, 1992, THROMB RES, V66, P265, DOI 10.1016/0049-3848(92)90197-I; GIBBS D, 1989, INFLAMMATION, V13, P465, DOI 10.1007/BF00914929; GINSBURG I, 1982, ADV EXP MED BIOL, V155, P151; GINSBURG I, 1989, FREE RADICAL RES COM, V8, P11, DOI 10.3109/10715768909087968; GINSBURG I, 1987, INFLAMMATION, V11, P253, DOI 10.1007/BF00915832; GINSBURG I, 1987, INFLAMMATION, V11, P489, DOI 10.1007/BF00915991; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; Hall DR, 1997, ANAL BIOCHEM, V244, P152, DOI 10.1006/abio.1996.9867; Hanakam F, 1996, BIOCHEMISTRY-US, V35, P11036, DOI 10.1021/bi960789j; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; Ichikura T, 1992, Nihon Rinsho, V50, P2237; JESPERSEN J, 1984, THROMB HAEMOSTASIS, V51, P99; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Kluszynski BA, 1997, J BIOL CHEM, V272, P13541, DOI 10.1074/jbc.272.21.13541; KOIDE T, 1987, FEBS LETT, V216, P17, DOI 10.1016/0014-5793(87)80748-2; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; Lamanna JC, 1996, ADV EXP MED BIOL, V388, P283; LAMBWHARTON RJ, 1993, CELL IMMUNOL, V152, P544, DOI 10.1006/cimm.1993.1311; LERCH PG, 1988, BRIT J HAEMATOL, V70, P219, DOI 10.1111/j.1365-2141.1988.tb02467.x; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; LIJNEN HR, 1983, THROMB HAEMOSTASIS, V50, P560; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MAGNESON GR, 1987, J BIOL CHEM, V262, P11140; Miles E W, 1977, Methods Enzymol, V47, P431; MORGAN WT, 1978, BIOCHIM BIOPHYS ACTA, V535, P319, DOI 10.1016/0005-2795(78)90098-3; MORGAN WT, 1978, P SOC EXP BIOL MED, V158, P647; MORGAN WT, 1981, BIOCHEMISTRY-US, V20, P1054, DOI 10.1021/bi00508a002; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; Olsen HM, 1996, IMMUNOLOGY, V88, P198, DOI 10.1111/j.1365-2567.1996.tb00005.x; PERIN DD, 1983, BUFFERS PH METAL ION, P94; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; PUNNIAMOORTHY A, 1987, J ORAL PATHOL MED, V16, P36, DOI 10.1111/j.1600-0714.1987.tb00674.x; SAIGO K, 1989, J BIOL CHEM, V264, P8249; Schuck P, 1996, ANAL BIOCHEM, V240, P262, DOI 10.1006/abio.1996.0356; SHIMADA K, 1989, BLOOD, V73, P191; WIGGINS RC, 1977, P NATL ACAD SCI USA, V74, P4636, DOI 10.1073/pnas.74.10.4636; ZAMMIT A, 1995, BLOOD, V85, P720, DOI 10.1182/blood.V85.3.720.bloodjournal853720; ZAMNIT A, 1993, THROMB HAEMOSTASIS, V70, P951	48	94	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5493	5499		10.1074/jbc.273.10.5493	http://dx.doi.org/10.1074/jbc.273.10.5493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488672	hybrid			2022-12-27	WOS:000072345000015
J	Gao-Sheridan, HS; Pershad, HR; Armstrong, FA; Burgess, BK				Gao-Sheridan, HS; Pershad, HR; Armstrong, FA; Burgess, BK			Discovery of a novel ferredoxin from Azotobacter vinelandii containing two [4Fe-4S] clusters with widely differing and very negative reduction potentials	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; MAGNETIC CIRCULAR-DICHROISM; AMINO-ACID-SEQUENCE; RHODOBACTER-CAPSULATUS; CHROMATIUM-VINOSUM; NITROGEN-FIXATION; MOLECULAR-CLONING; 2<4FE-4S> FERREDOXIN; ELECTRON-TRANSFER; FDXN GENE	Ferredoxins that contain 2[4Fe-4S](2+/+) clusters can be divided into two classes. The "clostridial-type" ferredoxins have two Cys-Xaa-Xaa-Cys-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Cys-Pro motifs. The "chromatium-type" ferredoxins have one motif of that type and one more unusual Cys-Xaa-Xaa-Cys-Xaa(7-9)-Cys-Xaa-Xaa-Xaa-Cys-Pro motif. Here we report the purification of a novel ferredoxin (FdIII) from Azotobacter vinelandii which brings to 12 the number of small [Fe-S] proteins that have now been reported from this organism. NH2-terminal sequencing of the first 56 amino acid residues shows that FdIII is a chromatium-type ferredoxin with 77% identity and 88% similarity to Chromatium vinosum ferredoxin. Studies of the purified protein by matrix-assisted laser desorption ionization-time of flight mass spectroscopy, iron analysis, absorption, circular dichroism, and electron paramagnetic resonance spectroscopies show that FdIII contains 2[4Fe-4S](2+/+) clusters in a 9,220-Da polypeptide. All 2[4Fe-4S](2+/+) ferredoxins that have been studied to date, including C. vinosum ferredoxin, are reported to have extremely similar or identical reduction potentials for the two clusters. In contrast, electrochemical characterization of FdIII clearly establishes that the two [4Fe-4S](2+/+) clusters have very different and highly negative reduction potentials of -486 mV and -644 mV versus the standard hydrogen electrode.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Oxford, Inorgan Chem Lab, Oxford OX1 3QR, England	University of California System; University of California Irvine; University of Oxford	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 Bio Sci 2, Irvine, CA 92697 USA.	bburgess@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45209] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1976, J BIOL CHEM, V251, P3801; Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; ARMSTRONG FA, 1993, METHOD ENZYMOL, V227, P479, DOI 10.1016/0076-6879(93)27020-H; Armstrong FA, 1997, CHEM SOC REV, V26, P169, DOI 10.1039/cs9972600169; BACHES G, 1991, J BIOL CHEM, V113, P2055; BACHOFEN R, 1966, BIOCHIM BIOPHYS ACTA, V120, P259, DOI 10.1016/0926-6585(66)90345-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BERTINI I, 1993, J AM CHEM SOC, V115, P12020, DOI 10.1021/ja00078a046; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; DUFF JLC, 1996, J A CHEM SOC, V118, P8603; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HALLENBECK PC, 1982, BIOCHIM BIOPHYS ACTA, V681, P168, DOI 10.1016/0005-2728(82)90020-2; HUBER JG, 1995, BIOCHEMISTRY-US, V34, P194, DOI 10.1021/bi00001a024; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; IISMAA SE, 1989, MOL MICROBIOL, V3, P1753, DOI 10.1111/j.1365-2958.1989.tb00161.x; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KE B, 1974, ARCH BIOCHEM BIOPHYS, V162, P301, DOI 10.1016/0003-9861(74)90129-5; KLIPP W, 1989, MOL GEN GENET, V216, P293, DOI 10.1007/BF00334368; LESLIE DL, 1993, FEMS MICROBIOL LETT, V111, P331, DOI 10.1111/j.1574-6968.1993.tb06407.x; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MINAMI Y, 1984, J BIOCHEM-TOKYO, V96, P585, DOI 10.1093/oxfordjournals.jbchem.a134873; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MORTENSEN LE, 1993, ANNU REV MICROBIOL, V17, P115; MOSHIRI F, 1994, MOL MICROBIOL, V14, P101, DOI 10.1111/j.1365-2958.1994.tb01270.x; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; Moulis JM, 1996, BBA-GENE STRUCT EXPR, V1308, P12, DOI 10.1016/0167-4781(96)00082-6; NAUD I, 1994, EUR J BIOCHEM, V222, P933, DOI 10.1111/j.1432-1033.1994.tb18942.x; NICHOLSON RS, 1964, ANAL CHEM, V36, P706, DOI 10.1021/ac60210a007; ORMEJOHNSON WH, 1973, IRON SULFUR PROTEINS, V2, P195; PETROULEAS V, 1989, BIOCHEMISTRY-US, V28, P8980, DOI 10.1021/bi00449a004; RAINA R, 1993, MOL GEN GENET, V236, P459, DOI 10.1007/BF00277149; RAINA R, 1988, MOL GEN GENET, V214, P121, DOI 10.1007/BF00340189; Reyntjens B, 1997, J BIOL INORG CHEM, V2, P595, DOI 10.1007/s007750050174; RIEDEL KU, 1995, EUR J BIOCHEM, V231, P742, DOI 10.1111/j.1432-1033.1995.0742d.x; SCHATT E, 1989, J BACTERIOL, V171, P6218, DOI 10.1128/jb.171.11.6218-6226.1989; Scherings G, 1977, Eur J Biochem, V77, P21; SHEN BH, 1993, J BIOL CHEM, V268, P25928; SHETHNA YI, 1968, BIOCHEM BIOPH RES CO, V31, P862, DOI 10.1016/0006-291X(68)90531-7; SMITH ET, 1990, J BIOL CHEM, V265, P14371; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; Stiefel EI, 1994, BIOINORG CHEM, P365; STOMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633, DOI 10.1021/bi00657a024; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; TANAKA M, 1975, BIOCHEMISTRY-US, V14, P1938, DOI 10.1021/bi00680a021; TANAKA M, 1974, BIOCHEMISTRY-US, V13, P2953, DOI 10.1021/bi00711a026; THOMSON AJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P423, DOI 10.1016/0005-2728(81)90047-5; TOLLIN G, 1993, BIOPHYS CHEM, V48, P259, DOI 10.1016/0301-4622(93)85014-9; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; VONSTERNBERG R, 1993, BIOCHIM BIOPHYS ACTA, V1144, P435, DOI 10.1016/0005-2728(93)90131-X; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WIENTJENS R, 1993, THESIS AGR U WAGENIN, P48; Yannone SM, 1997, J BIOL CHEM, V272, P14454, DOI 10.1074/jbc.272.22.14454	58	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5514	5519		10.1074/jbc.273.10.5514	http://dx.doi.org/10.1074/jbc.273.10.5514			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488675	hybrid			2022-12-27	WOS:000072345000018
J	Jian, B; de la Llera-Moya, M; Ji, Y; Wang, N; Phillips, MC; Swaney, JB; Tall, AR; Rothblat, GH				Jian, B; de la Llera-Moya, M; Ji, Y; Wang, N; Phillips, MC; Swaney, JB; Tall, AR; Rothblat, GH			Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CORONARY-ARTERY DISEASE; SR-BI; CULTURED FIBROBLASTS; KINETIC POOLS; CELLS; MECHANISM; MEMBRANE; MACROPHAGES	We recently reported that the rate of efflux of cholesterol from cells to high density lipoprotein (HDL) was related to the expression level of scavenger receptor class B type I (SR-BI). Moreover, the expression of this receptor in atheromatous arteries raises the possibility that SR-BI mediates cholesterol efflux in the arterial wall (Ji, Y., Jian, B., Wang, N., Sun, Y., de la Llera Moya, IM., Phillips, M. C., Rothblat, G. H., Swaney, J. B., and Tall, A. R. (1997) J. Biol. Chem. 272, 20982-20985). In this paper we describe studies that suggest that the presence of phospholipid on acceptor particles plays an important role in modulating interaction with the SR-BI. Specifically, enrichment of serum with phospholipid resulted in marked stimulation of cholesterol efflux from cells that had higher levels of SR-BI expression, like Fu5AH or Y1-BS1 cells, and little or no stimulation in cells with low SR-BI levels, such as Y-1 cells. Stimulation of efflux by phospholipid enrichment was also a function of SR-BI levels in Chinese hamster ovary cells transfected with the SR-BI gene. Efflux to protein-free vesicles prepared with 1-palmitoyl-2-oleoylphosphatidylcholine also correlated with SR-BI levels, suggesting that phospholipid, as well as protein, influences the interaction that results in cholesterol efflux. By contrast, cholesterol efflux from a non-cell donor showed no stimulation consequent to phospholipid enrichment of the serum acceptor. These results may help to explain observations in the literature that document an increased risk of atherosclerosis in patients with depressed levels of HDL phospholipid even in the face of normal HDL cholesterol levels.	Allegheny Univ Hlth Sci, Dept Biochem, Philadelphia, PA 19129 USA; Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Drexel University; Columbia University	Rothblat, GH (corresponding author), Allegheny Univ Hlth Sci, Dept Biochem, 2900 Queen Lane, Philadelphia, PA 19129 USA.		Tall, Alan/AAT-8528-2021; Eckhardt, Erik/G-1567-2010	Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, R37HL022682, R01HL022682, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633, HL54591, HL22682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; BAGDADE JD, 1995, ATHEROSCLEROSIS, V117, P209, DOI 10.1016/0021-9150(95)05573-F; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BOVET P, 1989, ATHEROSCLEROSIS, V80, P41, DOI 10.1016/0021-9150(89)90066-X; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CAVALLERO E, 1995, ARTERIOSCL THROM VAS, V15, P2130, DOI 10.1161/01.ATV.15.12.2130; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; DUCHENE D, 1997, 5 INT S CYCL MARCH 2; FEDOROFF S, 1962, J NATL CANCER I, V29, P331; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1991, CURR OPIN LIPIDOL, V2, P376; Fournier N, 1996, J LIPID RES, V37, P1704; Fournier N, 1997, ARTERIOSCL THROM VAS, V17, P2685, DOI 10.1161/01.ATV.17.11.2685; FRANCONE OL, 1990, J LIPID RES, V31, P2195; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; HARA H, 1991, J BIOL CHEM, V266, P3080; Hatch F T, 1968, Adv Lipid Res, V6, P1; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1997, J LIPID RES, V38, P734; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUKSIS A, 1982, ARTERIOSCLEROSIS, V2, P296, DOI 10.1161/01.ATV.2.4.296; KUNZ F, 1994, ARTERIOSCLER THROMB, V14, P1146, DOI 10.1161/01.ATV.14.7.1146; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MOYA MD, 1994, ARTERIOSCLER THROMB, V14, P1056; NICHOLS AV, 1978, LIPIDS, V13, P943, DOI 10.1007/BF02533854; ORAM JF, 1987, J BIOL CHEM, V262, P2405; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Oram JF, 1996, J LIPID RES, V37, P2473; ORAM JF, 1981, J BIOL CHEM, V256, P8348; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; TALL AR, 1978, BIOCHEMISTRY-US, V17, P322, DOI 10.1021/bi00595a020; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Xu SZ, 1997, J LIPID RES, V38, P1289; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	55	253	260	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5599	5606		10.1074/jbc.273.10.5599	http://dx.doi.org/10.1074/jbc.273.10.5599			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488688	hybrid			2022-12-27	WOS:000072345000031
J	Kraus, RL; Sinnegger, MJ; Glossmann, H; Hering, S; Striessnig, J				Kraus, RL; Sinnegger, MJ; Glossmann, H; Hering, S; Striessnig, J			Familial hemiplegic migraine mutations change alpha(1A) Ca2+ channel kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; AUXILIARY SUBUNITS; MESSENGER-RNAS; ION CHANNELS; BETA-SUBUNIT; PATHOPHYSIOLOGY; INACTIVATION; EXPRESSION	Missense mutations in the pore-forming human alpha(1A) subunit of neuronal P/Q-type Ca2+ channels are associated with familial hemiplegic migraine (FHM). The pathophysiological consequences of these mutations are unknown. We have introduced the four single mutations reported for the human alpha(1A) subunit into the conserved rabbit alpha(1A) (R192Q, T666M, V714A, and I1819L) and investigated possible changes in channel function after functional expression of mutant subunits in Xenopus laevis oocytes. Changes in channel gating were observed for mutants T666M, V714A, and I1819L but not for R192Q, Ba2+ current (I-Ba) inactivation was slightly faster in mutants T666M and V714A than in wild type. The time course of recovery from channel inactivation was slower than in wild type in T666M and accelerated in V714A and I1819L. As a consequence, accumulation of channel inactivation during a train of 1-Hz pulses was more pronounced for mutant T666M and less pronounced for V714A and I1819A. Our data demonstrate that three of the four FHM mutations, located at the putative channel pore, alter inactivation gating and provide a pathophysiological basis for the postulated neuronal instability in patients with FHM.	Inst Biochem Pharmacol, A-6020 Innsbruck, Austria		Hering, S (corresponding author), Inst Biochem Pharmacol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.		Glossmann, Hartmut/AAL-9790-2020; Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120; Brauns, Martina/0000-0002-0547-2731; glossmann, hartmut h./0000-0002-7392-3266				Bayliss DA, 1997, J NEUROPHYSIOL, V77, P1362, DOI 10.1152/jn.1997.77.3.1362; BOURINET E, 1996, P NATL ACAD SCI USA, V431, P470; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; Durell SR, 1996, NEUROPHARMACOLOGY, V35, P761, DOI 10.1016/0028-3908(96)00097-4; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FARKKILA M, 1994, ANN MED, V26, P7, DOI 10.3109/07853899409147320; Flippen C, 1997, CURR OPIN NEUROL, V10, P226, DOI 10.1097/00019052-199706000-00010; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; Hayward LJ, 1997, BIOPHYS J, V72, P1204, DOI 10.1016/S0006-3495(97)78768-X; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hille B., 1991, IONIC CHANNELS EXCIT; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MAY A, 1995, HUM GENET, V96, P604, DOI 10.1007/BF00197420; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Pedarzani P, 1996, EUR J NEUROSCI, V8, P2098, DOI 10.1111/j.1460-9568.1996.tb00731.x; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Schoenen J, 1997, CURR OPIN NEUROL, V10, P237, DOI 10.1097/00019052-199706000-00012; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TFELTHANSEN P, 1994, PHARMACOL TOXICOL, V75, P72, DOI 10.1111/j.1600-0773.1994.tb02003.x; Wang SY, 1997, BIOPHYS J, V72, P1633, DOI 10.1016/S0006-3495(97)78809-X; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WITTKA R, 1991, FEBS LETT, V286, P193, DOI 10.1016/0014-5793(91)80972-6; ZAGAMI AS, 1994, CURR OPIN NEUROL, V7, P272, DOI 10.1097/00019052-199406000-00016; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; ZUHLKE RD, 1994, RECEPTOR CHANNEL, V2, P237	38	160	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5586	5590		10.1074/jbc.273.10.5586	http://dx.doi.org/10.1074/jbc.273.10.5586			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488686	hybrid			2022-12-27	WOS:000072345000029
J	Platanias, LC; Domanski, P; Nadeau, OW; Yi, TL; Uddin, S; Fish, E; Neel, BG; Colamonici, OR				Platanias, LC; Domanski, P; Nadeau, OW; Yi, TL; Uddin, S; Fish, E; Neel, BG; Colamonici, OR			Identification of a domain in the beta subunit of the type I interferon (IFN) receptor that exhibits a negative regulatory effect in the growth inhibitory action of type I IFNs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; PROTEIN-TYROSINE PHOSPHATASES; ALPHA RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN CHROMOSOME-21; GENE; PHOSPHORYLATION; KINASE; ASSOCIATION; EXPRESSION	Expression of human alpha and long form of the beta (beta(L)) subunits of type I interferon receptor (IFN-R) in mouse cells is sufficient to activate the Jak-Stat pathway and to elicit an antiviral state in response to human IFN alpha 2 and IFN beta. We demonstrate herein, however, that these cells respond to the antiproliferative effects of murine IFN alpha beta but not human type I IFNs. These results suggest that an unknown species-specific component is required for the antiproliferative effect of human type I IFNs. The absence of this component can be complemented by expressing the human beta(L) chain truncated at amino acid 346, Thus, the distal region of beta(L) appears to function as a negative regulator of the growth inhibitory effects of type I IFNs. Further studies looking for possible targets of the beta(L), regulatory domain demonstrated that this region associates with a tyrosine phosphatase. These results suggest that a protein associated with the negative regulatory domain of beta(L), likely a tyrosine phosphatase, plays a role in regulating the growth inhibitory effects of human type I IFNs.	Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; Univ Illinois, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Affairs Hosp, Chicago, IL 60607 USA; Cleveland Clin Fdn, Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Beth Israel Hosp, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation; University of Toronto; Harvard University; Beth Israel Deaconess Medical Center	Colamonici, OR (corresponding author), Univ Tennessee, Dept Pathol, 899 Madison Ave M-576, Memphis, TN 38163 USA.	OColamonici@utmem1.utmem.edu		Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R29CA073381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NCI NIH HHS [CA73381] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Adachi M, 1996, CELL, V85, P15; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; EPSTEIN CJ, 1982, BIOCHEM BIOPH RES CO, V107, P1060, DOI 10.1016/0006-291X(82)90629-5; GHISLAIN J, 1995, J BIOL CHEM, V270, P21785, DOI 10.1074/jbc.270.37.21785; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; HERTZOG PJ, 1994, J BIOL CHEM, V269, P14088; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; RAZ R, 1995, SOMAT CELL MOLEC GEN, V21, P139, DOI 10.1007/BF02255789; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; REVEL M, 1976, NATURE, V260, P139, DOI 10.1038/260139a0; SCHINDLER S, 1995, ANNU REV BIOCHEM, V64, P621; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAN YH, 1976, NATURE, V260, P141, DOI 10.1038/260141a0; TAN YH, 1974, SCIENCE, V186, P61, DOI 10.1126/science.186.4158.61; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Yan H, 1996, MOL CELL BIOL, V16, P2074; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	49	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5577	5581		10.1074/jbc.273.10.5577	http://dx.doi.org/10.1074/jbc.273.10.5577			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488684	hybrid			2022-12-27	WOS:000072345000027
J	Serizawa, H				Serizawa, H			Cyclin-dependent kinase inhibitor p16(INK4A) inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; LARGE SUBUNIT; HOLOENZYME; PROTEIN; COMPLEX; CANCER; DOMAIN; MO15; FORM; CTD	The cell cycle is regulated by various protein kinases, including cyclin-dependent kinases (CDKs), D-type CDKs, CDK4, and CDK6, phosphorylate retinoblastoma protein and are believed to regulate through the G(1) phase of the cell cycle, CDK inhibitor p16(INK4A) has been characterized as binding CDK4 and CDK6 and as inhibiting phosphorylation of retinoblastoma protein by these CDKs, Thus p16(INK4A) is implicated in regulating the cell cycle at the G(1) phase, The largest subunit of RNA polymerase II (pol II) contains an essential C-terminal domain (CTD). General transcription factor TFIIH, which contains CDK7, phosphorylates the CTD in vitro, The CTD phosphorylation is shown to be involved in transcriptional regulation in vivo and in vitro, Phosphorylation of RNA pol II CTD by TFIIH is thought to play an important role in transcriptional regulation. Here we report that p16(INK4A) associates with RNA pol II CTD and TFIIH. p16(INK4A) inhibited the CTD phosphorylation by TFIIH. These findings suggest that p16(INK4A) may regulate transcription via CTD phosphorylation in the cell cycle.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Serizawa, H (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.							Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1994, J BIOL CHEM, V269, P20750; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5427	5430		10.1074/jbc.273.10.5427	http://dx.doi.org/10.1074/jbc.273.10.5427			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488660	hybrid			2022-12-27	WOS:000072345000003
J	Wojcikiewicz, RJH; Luo, SG				Wojcikiewicz, RJH; Luo, SG			Phosphorylation of inositol 1,4,5-trisphosphate receptors by cAMP-dependent protein kinase - Type I, II and III receptors are differentially susceptible to phosphorylation and are phosphorylated in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE RECEPTOR; NEUROBLASTOMA-CELLS; ADENYLYL CYCLASES; LIGAND-BINDING; CA2+ FLUX; EXPRESSION; SH-SY5Y; CALCIUM; TISSUES; LOCALIZATION	The ability of cAMP-dependent protein kinase (PKA) to phosphorylate type I, II, and III inositol 1,4,5-trisphosphate (InsP(3)) receptors was examined, The receptors either were immunopurified from cell lines and then phosphorylated with purified PMA or were phosphorylated in intact cells after activating intracellular cAMP formation, The former studies showed that the type I receptor was a good substrate for PKA (0.65 mol P-i incorporated/mol receptor), whereas type II and III receptors were phosphorylated relatively weakly. The latter studies showed that despite these differences, each of the receptors was phosphorylated in intact cells in response to forskolin or activation of neurohormone receptors. Detailed examination of SH-SY5Y neuroblastoma cells, which express greater than or equal to 99% type I receptor, revealed that minor increases in cAMP concentration were sufficient to cause maximal phosphorylation. Thus, VIP and pituitary adenylyl cyclase activating peptide (acting through G(s)-coupled pituitary adenylyl cyclase activating peptide-I receptors) were potent stimuli of type I receptor phosphorylation, send remarkably, even slight increases in cAMP concentration induced by carbachol (acting through G(q)-coupled muscarinic receptors) or other Ca2+ mobilizing agents were sufficient to cause phosphorylation. Finally, PKA enhanced InsP(3)-induced Ca2+ mobilization in a range of permeabilized cell types, irrespective of whether the type I, II, or III receptor was predominant. In summary, these data show that all InsP(3) receptors are phosphorylated by PKA, albeit with marked differences in stoichiometry. The ability of both G(s)- and G(q)-coupled cell surface; receptors to effect InsP(3) receptor phosphorylation by PHA. suggests that this process is widespread in mammalian cells and provides multiple routes by which the cAMP signaling pathway can influence Ca2+ mobilization.	SUNY Hlth Sci Ctr, Coll Med, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Wojcikiewicz, RJH (corresponding author), SUNY Hlth Sci Ctr, Coll Med, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	WOJCIKIR@VAX.CS.HSCSYR.EDU			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049194, R01DK049194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON M, 1992, REGUL PEPTIDES, V40, P41, DOI 10.1016/0167-0115(92)90082-6; BAUMGOLD J, 1988, BIOCHEM BIOPH RES CO, V154, P1137, DOI 10.1016/0006-291X(88)90259-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; HARMAR T, 1994, TRENDS PHARMACOL SCI, V15, P97, DOI 10.1016/0165-6147(94)90042-6; HIRST RA, 1995, BIOCHEM PHARMACOL, V49, P1633, DOI 10.1016/0006-2952(95)00075-B; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; SCHRAMM CM, 1995, AM J PHYSIOL-LUNG C, V269, pL715, DOI 10.1152/ajplung.1995.269.5.L715; Sharma K, 1997, J BIOL CHEM, V272, P14617, DOI 10.1074/jbc.272.23.14617; SIMEONE DM, 1995, REGUL PEPTIDES, V55, P197, DOI 10.1016/0167-0115(94)00107-9; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; VAUGHAN PFT, 1995, GEN PHARMACOL-VASC S, V26, P1191, DOI 10.1016/0306-3623(94)00312-B; Vertongen P, 1996, J CELL PHYSIOL, V167, P36, DOI 10.1002/(SICI)1097-4652(199604)167:1<36::AID-JCP4>3.0.CO;2-D; WALL SJ, 1991, MOL PHARMACOL, V40, P783; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WASCHEK JA, 1989, FEBS LETT, V250, P611, DOI 10.1016/0014-5793(89)80806-3; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; WOJCIKIEWICZ RJH, 1988, IN PRESS MOL PHARM; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591	45	140	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5670	5677		10.1074/jbc.273.10.5670	http://dx.doi.org/10.1074/jbc.273.10.5670			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488697	hybrid			2022-12-27	WOS:000072345000040
J	Mascaro, C; Acosta, E; Ortiz, JA; Marrero, PF; Hegardt, FG; Haro, D				Mascaro, C; Acosta, E; Ortiz, JA; Marrero, PF; Hegardt, FG; Haro, D			Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FATTY-ACIDS; EXPRESSION; HEART; INDUCTION; ENZYME; LIGAND; LIVER; GAMMA	The expression of several genes involved in intra-and extracellular lipid metabolism, notably those involved in peroxisomal and mitochondrial beta-oxidation, is mediated by ligand-activated receptors, collectively referred to as peroxisome proliferator-activated receptors (PPARs). To gain more insight into the control of expression of carnitine palmitoyltransferase (CPT) genes, which are regulated by fatty-acids, we have examined the transcriptional regulation of the human MCPT I gene. We have cloned by polymerase chain reaction the 5'-flanking region of this gene and demonstrated its transcriptional activity by transfection experiments with the CAT gene as a reporter. We have also shown that this is a target gene for the action of PPARs, and we have localized a PPAR responsive element upstream of the first exon. These results show that PPAR regulates the entry of fatty acids into the mitochondria, which is a crucial step in their metabolism, especially in tissues Like heart, skeletal muscle and brown adipose tissue in which fatty acids are a major source of energy.	Univ Barcelona, Fac Farm, Unit Bioquim, Sch Pharm, E-08028 Barcelona, Spain	University of Barcelona	Haro, D (corresponding author), Univ Barcelona, Fac Farm, Unit Bioquim, Sch Pharm, Avda Diagonal 643, E-08028 Barcelona, Spain.		Ortiz Salcedo, José Antonio/HHN-7691-2022; Haro, Diego/I-4623-2015; Marrero, Pedro F/I-1919-2015	Ortiz Salcedo, José Antonio/0000-0003-0505-3032; Haro, Diego/0000-0001-9147-0486; 				ASINS G, 1994, BIOCHEM PHARMACOL, V47, P1373, DOI 10.1016/0006-2952(94)90336-0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HARRIS MI, 1989, DIABETES CARE, V12, P464, DOI 10.2337/diacare.12.7.464; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Park KS, 1997, DIABETES, V46, P1230, DOI 10.2337/diabetes.46.7.1230; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; WEIS BC, 1994, J BIOL CHEM, V269, P18712; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3	25	259	267	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8560	8563		10.1074/jbc.273.15.8560	http://dx.doi.org/10.1074/jbc.273.15.8560			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535828	hybrid			2022-12-27	WOS:000072990800005
J	Ichida, M; Endo, H; Ikeda, U; Matsuda, C; Ueno, E; Shimada, K; Kagawa, Y				Ichida, M; Endo, H; Ikeda, U; Matsuda, C; Ueno, E; Shimada, K; Kagawa, Y			MyoD is indispensable for muscle-specific alternative splicing in mouse mitochondrial ATP synthase gamma-subunit pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; MESSENGER-RNA; GENE-EXPRESSION; TRANSCRIPTION FACTORS; MYOGENIN GENE; DNA-BINDING; FACTOR-BETA; SKELETAL MYOGENESIS; CELL-ADHESION; SINGLE GENE	Muscle-specific alternative RNA splicing is an essential step during myogenesis. In this paper, we report that a muscle-specific transcription factor, MyoD, plays a central role in the induction of muscle-specific alternative splicing during myogenesis. Recently, we reported that muscle and nonmuscle isoforms of the mitochondrial ATP synthase gamma-subunit (F-1 gamma) were generated by alternative splicing and that acidic stimulation promoted this muscle-specific alternative splicing (Endo, H., Matsuda, C., and Kagawa, Y. (1994) J. Biol. Chem. 269, 12488-12493), In this report, mouse myoblasts are shown to express the muscle-specific isoform of F-1 gamma after induction with low-serum medium (differentiation medium) or acidic medium, although myotube formation tvas not detected after acidic induction, RNA blot analysis revealed that the expression levels of both MEF2 and myogenin were increased by low-serum induction, but not by acidic induction, High expression of MyoD mRNA was observed after both types of induction, Overexpression of exogenous MyoD in fibroblasts showed that MyoD was necessary for muscle-specific alternative splicing in both types of induction, Exogenous Id, a negative regulator of MyoD, blocked muscle-specific alternative splicing of F-1 gamma pre-mRNA by both types of induction. In addition, MyoD induced several muscle-specific alternative splicings, including structural protein pre-mRNAs such as beta-tropomyosin and neural-cell adhesion molecule and transcriptional protein pre-mRNAs such as MEF2A and MEF2D. Our analysis of the two induction systems shows a common MyoD-dependent mechanism of muscle-specific alternative splicing in several genes, independent of MEF2 and myogenin.	Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 32904, Japan; Jichi Med Sch, Dept Cardiol, Minami Kawachi, Tochigi 32904, Japan	Jichi Medical University; Jichi Medical University	Endo, H (corresponding author), Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 32904, Japan.							BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; ENDO H, 1994, J BIOL CHEM, V269, P12488; FORRYSCHAUDIES S, 1991, J BIOL CHEM, V266, P13821; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HAMSHERE M, 1991, NUCLEIC ACIDS RES, V19, P4709, DOI 10.1093/nar/19.17.4709; HARADA Y, 1995, J BIOCHEM-TOKYO, V118, P780, DOI 10.1093/oxfordjournals.jbchem.a124980; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; HEINO J, 1990, J BIOL CHEM, V265, P10181; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIBRI D, 1989, J BIOL CHEM, V264, P2935; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; Maniatis T., 1982, MOL CLONING LAB MANU; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SAITOH O, 1990, J BIOL CHEM, V265, P19381; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WANG YC, 1992, J BIOL CHEM, V267, P2728; WANG YC, 1992, J BIOL CHEM, V267, P12004; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZIMMERLE CT, 1988, BIOCHEMISTRY-US, V27, P7766, DOI 10.1021/bi00420a027	52	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8492	8501		10.1074/jbc.273.14.8492	http://dx.doi.org/10.1074/jbc.273.14.8492			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525963	hybrid			2022-12-27	WOS:000072876300097
J	Sobolev, AS; Rosenkranz, AA; Smirnova, OA; Nikitin, VA; Neugodova, GL; Naroditsky, BS; Shilov, IN; Shatski, IN; Ernst, LK				Sobolev, AS; Rosenkranz, AA; Smirnova, OA; Nikitin, VA; Neugodova, GL; Naroditsky, BS; Shilov, IN; Shatski, IN; Ernst, LK			Receptor-mediated transfection of murine and ovine mammary glands in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYLYSINE DNA COMPLEXES; GENE-TRANSFER; MAMMALIAN-CELLS; IN-VIVO; PARTIAL-HEPATECTOMY; AIRWAY EPITHELIUM; INVIVO; DELIVERY; EXPRESSION; THERAPY	Transfection of HC-11 murine epithelial mammary cells as well as murine and sheep mammary glands were carried out using insulin-containing constructs that deliver DNA by receptor-mediated endocytosis to receptor-expressing cells. In vivo transfection of mammary gland tissue with the luciferase gene was carried out by introducing the DNA constructs into the mammary ducts of both mice and sheep. The successful transfection of ewe mammary glands was demonstrated by the detection of luciferase activity was demonstrated by the detection of luciferase activity in mammary gland biopsy material up to a month after a single administration of the construct. To test whether products of expression of transfected genes could be secreted into the milk in this system, the N-terminal secretory signal sequences of bovine beta-lactoglobulin or the entire coding sequence of human alpha-lactalbumin were fused to the N terminus of the luciferases, both murine and sheep milk could be shown to contain luciferase activity, whereas mice, which had been transfected with the nonmodified luciferase gene, did not secrete any activity in the milk. This approach demonstrates for the first time the possibility of gene transfer in vivo into mammary gland epithelial cells using constructs delivering DNA via receptor-mediated endocytosis.	Moscow MV Lomonosov State Univ, Fac Biol, Dept Biophys, Moscow 119889, Russia; Russian Inst Agr Biotechnol, Lab Genet Engn & Mol Diagnost Microorganisms, Moscow 127550, Russia; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119899, Russia	Lomonosov Moscow State University; All-Russia Research Institute of Agricultural Biotechnology; Lomonosov Moscow State University	Sobolev, AS (corresponding author), Moscow MV Lomonosov State Univ, Fac Biol, Dept Biophys, Moscow 119889, Russia.	asobol@1.biophys.bio.msu.ru	Shatsky, Ivan N/A-5331-2012; Rosenkranz, Andrey A/J-3514-2015; Sobolev, Alexander S./P-6302-2015; Naroditsky, Boris S/F-9135-2012	Rosenkranz, Andrey A/0000-0001-9941-6118; Sobolev, Alexander S./0000-0001-8315-7764; Naroditsky, Boris/0000-0001-5522-8238				AKHLYNINA TV, 1995, CANCER RES, V55, P1014; Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; ALI M, 1994, GENE THER, V1, P367; BOMMINENI VR, 1994, J BIOL CHEM, V269, P25200; BUSCHLE M, 1995, HUM GENE THER, V6, P753, DOI 10.1089/hum.1995.6.6-753; CHARDONN.Y, 1970, VIROLOGY, V40, P462, DOI 10.1016/0042-6822(70)90189-3; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; CLARK AJ, 1987, TRENDS BIOTECHNOL, V5, P20, DOI 10.1016/0167-7799(87)90076-X; Cooper MJ, 1996, SEMIN ONCOL, V23, P172; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; COTTEN M, 1995, CURR TOP MICROBIOL, V199, P283; Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; DRUTSA VL, 1991, BIOORG KHIM+, V17, P1487; Felgner PL, 1995, ANN NY ACAD SCI, V772, P126, DOI 10.1111/j.1749-6632.1995.tb44738.x; Fender P, 1997, NAT BIOTECHNOL, V15, P52, DOI 10.1038/nbt0197-52; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; FERKOL T, 1993, FASEB J, V7, P1081, DOI 10.1096/fasebj.7.11.8370479; FOWLER PA, 1991, J DAIRY RES, V58, P151, DOI 10.1017/S0022029900029691; GAO L, 1993, HUM GENE THER, V4, P17, DOI 10.1089/hum.1993.4.1-17; GUY J, 1995, MOL BIOTECHNOL, V3, P237, DOI 10.1007/BF02789334; JUNG G, 1981, BIOCHEM BIOPH RES CO, V101, P599, DOI 10.1016/0006-291X(81)91301-2; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; Perales JC, 1997, J BIOL CHEM, V272, P7398, DOI 10.1074/jbc.272.11.7398; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; PLANK C, 1994, J BIOL CHEM, V269, P12918; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; PRATT WK, 1978, DIGITAL IMAGE PROCES, P492; ROSENKRANZ AA, 1992, EXP CELL RES, V199, P323, DOI 10.1016/0014-4827(92)90441-A; Rosenkranz AA, 1997, BIOCHEM BIOPH RES CO, V236, P750, DOI 10.1006/bbrc.1997.7040; ROZENKRANTS AA, 1990, DOKL AKAD NAUK SSSR+, V312, P493; SIMPSON WJ, 1991, J BIOLUM CHEMILUM, V6, P97, DOI 10.1002/bio.1170060207; SOBOLEV AS, 1994, Patent No. 2025487; SOBOLEV AS, 1988, INT C MED BIOCH OCT; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338; YOM HC, 1993, AM J CLIN NUTR, V58, P299, DOI 10.1093/ajcn/58.2.299S	48	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7928	7933		10.1074/jbc.273.14.7928	http://dx.doi.org/10.1074/jbc.273.14.7928			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525889	hybrid			2022-12-27	WOS:000072876300023
J	Schmidt, M; Voss, M; Thiel, M; Bauer, B; Grannass, A; Tapp, E; Cool, RH; de Gunzburg, J; von Eichel-Streiber, C; Jakobs, KH				Schmidt, M; Voss, M; Thiel, M; Bauer, B; Grannass, A; Tapp, E; Cool, RH; de Gunzburg, J; von Eichel-Streiber, C; Jakobs, KH			Specific inhibition of phorbol ester-stimulated phospholipase D by Clostridium sordellii lethal toxin and Clostridium difficile toxin B-1470 in HEK-293 cells - Restoration by Ral GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; PROTEIN-KINASE-C; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; D ACTIVATION; HL-60 CELLS; SIGNAL-TRANSDUCTION; RHO-PROTEINS; MEMBRANE; RECEPTOR	Activation of m3 muscarinic acetylcholine receptor (mAChR), stably expressed in human embryonic kidney (HEK)-293 cells, leads to phospholipase D (PtD) stimulation, a process apparently involving Rho GTPases, as shown by studies with Clostridium botulinum C3 exoenzyme and Clostridium difficile toxin B (TcdB). Direct activation of protein kinase C (PHC) by phorbol esters, such as phorbol 12-myristate 13-acetate (PMA), also induces PLD stimulation, which is additive to the mAChR action and which is only poorly sensitive to inactivation of Rho proteins by TcdB. To study whether Ras-like GTPases are involved in PLD regulation, we studied the effects of the TcdB variant TcdB-1470 and Clostridium sordellii lethal toxin (Test), known to inactivate Rac and some members of the Bus protein family, on PLD activities. TcdB-1470 and Test did not affect basal PLD activity and PLD stimulation by mAChR or direct G; protein activation. In contrast, PMA-induced PtD stimulation was inhibited by TcdB-1470 and Test in a time- and concentration-dependent manner, without alteration in immunologically detectable PKC isozyme levels. In membranes of HEK-293 cells pretreated with TcdB-1470 or Test, basal and stable GTP analog-stimulated PLD activities measured with exogenous phosphatidylcholine, in the presence or absence of phosphatidylinositol 4,5-bisphosphate, were not altered, In contrast, pretreatment with TcdB-1470 and Test, but not TcdB, strongly reduced PMA-stimuIated PLD activity. The addition of recombinant Rad, serving as glucosylation substrate for TcdB, Test, and TcdB-1470, did not restore PtD stimulation by PMA. Furthermore, PMA-stimulated PLD activity, suppressed by prior treatment with TcdB-1470 or Test, was not rescued by the addition of recombinant Ras (RasG12V) or Rap proteins, acting as glucosylation substrates for Test only (Das) or TcdB-1470 and Test (Rap). In contrast, the addition of recombinant Ral proteins (RalA and RalB), glucosylation substrates for TscL and TcdB-1470, but not for TcdB, to membranes of TcdB-1470- or TcsL-treated cells fully restored PtD stimulation by PMA. without altering the strict MgATP dependence of PMA-induced PLD stimulation. RalA-mediated restoration of PMA-stimulated PLD activity in membranes of Test-treated cells was not enhanced by coaddition of RasG12V. In conclusion, the data presented indicate that TcdB-1470 and Test selectively interfere with phorbol ester stimulation of PLD and suggest an essential role of Ral proteins in PKC signaling to PLD in HEK-293 cells.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany; Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany; INSERM, U248, F-75231 Paris 05, France; Univ Mainz, Inst Med Mikrobiol & Hyg, D-55101 Mainz, Germany	University of Duisburg Essen; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); Johannes Gutenberg University of Mainz	Jakobs, KH (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Schmidt, Martina/C-5339-2018	Schmidt, Martina/0000-0003-3075-0630; Cool, Robbert/0000-0002-9845-2202				AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BERANGER F, 1991, ONCOGENE, V6, P1835; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; delPeso L, 1997, BIOCHEM J, V322, P519; delPeso L, 1996, J CELL BIOCHEM, V61, P599, DOI 10.1002/(SICI)1097-4644(19960616)61:4<599::AID-JCB14>3.0.CO;2-B; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Hofmann F, 1996, BIOCHEM BIOPH RES CO, V227, P77, DOI 10.1006/bbrc.1996.1470; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Ohguchi K, 1996, INFECT IMMUN, V64, P4433, DOI 10.1128/IAI.64.11.4433-4437.1996; Ojio K, 1996, BIOCHEM BIOPH RES CO, V224, P591, DOI 10.1006/bbrc.1996.1069; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VONEICHELSTREIBER C, 1995, MOL MICROBIOL, V17, P313, DOI 10.1111/j.1365-2958.1995.mmi_17020313.x; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Yokozeki T, 1996, J NEUROCHEM, V66, P1234; Yoshimura S, 1996, BIOCHEM BIOPH RES CO, V225, P494, DOI 10.1006/bbrc.1996.1201; Yoshimura S, 1997, J NEUROCHEM, V69, P713	65	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7413	7422		10.1074/jbc.273.13.7413	http://dx.doi.org/10.1074/jbc.273.13.7413			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516439	hybrid, Green Published			2022-12-27	WOS:000072738500035
J	Bell, AW; Jiang, JG; Chen, QY; Liu, YH; Zarnegar, R				Bell, AW; Jiang, JG; Chen, QY; Liu, YH; Zarnegar, R			The upstream regulatory regions of the hepatocyte growth factor gene promoter are essential for its expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; MET PROTOONCOGENE PRODUCT; FACTOR SCATTER FACTOR; FACTOR MESSENGER-RNA; C-MET; TYROSINE KINASE; MOLECULAR-CLONING; HEPATOPOIETIN-A; FACTOR RECEPTOR; FACTOR HGF	To understand the molecular mechanisms of hepatocyte growth factor (HGF) gene transcription in vivo, we report the generation and characterization of transgenic mice harboring various lengths of the mouse HGF promoter linked to the chloramphenicol acetyltransferase reporter gene. Analysis of different tissues of the transgenic mouse lines having the 2.7-kilobase (kb) promoter construct revealed a pattern of reporter gene expression in embryonic and adult tissues that paralleled that of endogenous HGF gene expression. A similar expression pattern was observed in the 0.7-kb transgenic lines. However, in contrast to in vitro data, no promoter activity was detected in four independent transgenic lines harboring the 0.1-kb construct. Akin to the activity of the endogenous HGF gene, which is induced in the liver, lung, and spleen in response to 70% partial hepatectomy, the reporter gene driven by the 2.7-kb promoter construct was strongly induced, whereas that driven by the 0.7-kb promoter construct was modestly induced in these organs after partial hepatectomy. Together, these data suggest that the region between -0.1 and -0.7 kb of the HGF gene promoter is essential to drive its expression in vivo and that additional upstream sequences located between -0.7 and -2.7 kb are also necessary for its maximum inducibility in response to cues that stimulate tissue growth and regeneration.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Rm S419,Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.		Bell, Aaron/GSN-2294-2022; Jiang, Jie-Gen/K-3845-2019	Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES-06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON KP, 1993, MOL BIOL CELL, V4, P1077, DOI 10.1091/mbc.4.10.1077; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HOGAN B, 1986, MANIPULATING MOUSE E, P174; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P146; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; LI S, 1994, J BIOL CHEM, V269, P14235; LIU YH, 1993, BIOCHIM BIOPHYS ACTA, V1216, P299, DOI 10.1016/0167-4781(93)90159-B; LIU YH, 1994, J BIOL CHEM, V269, P4152; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LIU YH, 1994, GENE, V144, P179, DOI 10.1016/0378-1119(94)90376-X; LIU YH, 1994, MOL CELL ENDOCRINOL, V104, P173, DOI 10.1016/0303-7207(94)90120-1; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1992, J BIOL CHEM, V267, P24917; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V188, P235; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; RONG S, 1993, CANCER RES, V53, P5355; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAMURA M, 1993, J BIOL CHEM, V268, P8140; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	52	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6900	6908		10.1074/jbc.273.12.6900	http://dx.doi.org/10.1074/jbc.273.12.6900			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506994	hybrid			2022-12-27	WOS:000072775900044
J	Yu, JM; Wessling-Resnick, M				Yu, JM; Wessling-Resnick, M			Influence of copper depletion on iron uptake mediated by SFT, a stimulator of Fe transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN-BOUND IRON; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; FERRIREDUCTASE ACTIVITY; ENDOCYTIC VESICLES; FERRIC REDUCTASE; K562 CELLS; OXIDASE; PROTEIN; MECHANISMS	We recently identified a novel factor involved in cellular iron assimilation called SFT or Stimulator of Fe Transport (Gutierrez, J. A., Yu, J., Rivera, S., and Wessling-Resnick, M. (1997) J. Cell Biol. 149, 895-905). When stably expressed in HeLa cells, SFT was found to stimulate the uptake of both transferrin-and nontransferrin-bound Fe (iron), Assimilation of nontransferrin-bound Fe by HeLa cells stably expressing SFT was time- and temperature-dependent; both the rate and extent of uptake was enhanced relative to the activity of control nontransfected cells, Although the apparent K-m for Fe uptake was unaffected by expression of SFT (5.6 versus 5.1 mu M measured for control), the V-max of transport was increased from 7.0 to 14.7 pmol/min/mg protein, Transport mediated by SFT was inhibitable by diethylenetriaminepentaacetic acid and ferrozine, Fe3+- and Fe2+-specific chelators, Because cellular copper status is known to influence Fe assimilation, we investigated the effects of Cu (copper) depletion on SFT function, After 4 days of culture in Cu-deficient media, HeLa cell Cu,Zn superoxide dismutase activity was reduced by more than 60%, Both control cells and cells stably expressing SFT displayed reduced Fe uptake as well; levels of transferrin-mediated import fell by similar to 80%, whereas levels of nontransferrin-bound Fe uptake were similar to 50% that of Cu-replete cells, The failure of SFT expression to stimulate Fe uptake above basal levels in Cu-depleted cells suggests a critical role for Cu in SFT function, A current model for both transferrin-and nontransferrin-bound Pe uptake involves the function of a ferrireductase that acts to reduce Fe3+ to Fe2+, with subsequent transport of the divalent cation across the membrane bilayer, SFT expression did not enhance levels of HeLa cell surface reductase activity; however, Cu depletion was found to reduce endogenous activity by 60%, suggesting impaired ferrireductase function may account for the influence of Cu depletion on SPT-mediated Fe uptake, To test this hypothesis, the ability of SFT to directly mediate Fe2+ import was examined, Although expression of SMT enhanced Fe2+ uptake by HeLa cells, Cu depletion did not significantly reduce this activity, Thus, we conclude that a ferrireductase activity is required for SFT function in Fe3+ transport and that Cu depletion reduces cellular iron assimilation by affecting this activity.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Yu, JM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 666 Huntington Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052371] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BARISANI D, 1995, AM J PHYSIOL-GASTR L, V269, pG570, DOI 10.1152/ajpgi.1995.269.4.G570; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN WY, 1980, ANN CLIN LAB SCI, V10, P338; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; Devidas S, 1997, CURR OPIN CELL BIOL, V9, P547, DOI 10.1016/S0955-0674(97)80032-4; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; EDWARDS JA, 1972, P SOC EXP BIOL MED, V141, P81; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; GARRICK MD, 1993, J BIOL CHEM, V268, P14867; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; Gutierrez JA, 1996, CRIT REV EUKAR GENE, V6, P1; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; INMAN RS, 1993, J BIOL CHEM, V268, P8521; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; MORGAN EH, 1981, BIOCHIM BIOPHYS ACTA, V642, P119, DOI 10.1016/0005-2736(81)90143-7; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OWEN CA, 1973, AM J PHYSIOL, V224, P514; PERCIVAL SS, 1992, P SOC EXP BIOL MED, V200, P522, DOI 10.3181/00379727-200-43465; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; RIEDEL HD, 1995, BIOCHEM J, V309, P745, DOI 10.1042/bj3090745; SCHWEINZER E, 1992, EUR J BIOCHEM, V206, P807, DOI 10.1111/j.1432-1033.1992.tb16988.x; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TEICHMANN R, 1990, J CLIN INVEST, V86, P2145, DOI 10.1172/JCI114953; Tong KK, 1996, BRIT J NUTR, V75, P97, DOI 10.1079/BJN19960113; VANDENBERG GJ, 1992, BIOL TRACE ELEM RES, V35, P77, DOI 10.1007/BF02786240; WATKINS JA, 1992, BIOCHEMISTRY-US, V31, P5820, DOI 10.1021/bi00140a018; Winzerling JJ, 1997, ANNU REV NUTR, V17, P501, DOI 10.1146/annurev.nutr.17.1.501; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	43	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6909	6915		10.1074/jbc.273.12.6909	http://dx.doi.org/10.1074/jbc.273.12.6909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506995	hybrid			2022-12-27	WOS:000072775900045
J	Zapata, JM; Takahashi, R; Salvesen, GS; Reed, JC				Zapata, JM; Takahashi, R; Salvesen, GS; Reed, JC			Granzyme release and caspase activation in activated human T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; APOPTOTIC CELL-DEATH; PROTEOLYTIC ACTIVATION; CYTOTOXIC-CELLS; PROTEIN-KINASE; PROTEASES; ICE; LOCALIZATION; CLEAVAGE; FAMILY	Recently it has been reported that caspase-3 activation occurs in stimulated T-lymphocytes without associated apoptosis (Miossec, C., Dutilleul, V., Fassy, F., and Diu-Hercend, A. (1997) J. Biol. Chem. 272, 13459-13462). To explore this phenomenon, human peripheral blood lymphocytes (PBLs) were stimulated with mitogenic lectins or anti-CD3 antibody, and the proteolytic processing of different caspases and caspase substrates was analyzed by immunoblotting. Proteolytic processing of caspases-3 and -7 and the caspase substrates poly(ADP-ribose) polymerase, GDP dissociation inhibitor, and PKC delta was observed when PBLs were activated in vitro, and lysates were prepared using RIPA buffer which contains 1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS. In contrast, when a lysis buffer containing 2% SDS was used, the caspases remained in their zymogen pro-forms, and no proteolytic processing of caspase substrates was detected. Moreover, in experiments using intact cells and a cell-permeable fluorigenic caspase substrate, no caspase activity was observed in activated T-cells, whereas it was clearly detected when PBLs were treated with the apoptosis inducing anticancer drug etoposide. Since the granzyme B is a direct activator of caspase-3 and its expression is induced following T-cell activation, we tested the effects of anti-GraB, an engineered serpin that specifically inhibits GraB. When the activated T-lymphocytes were lysed in RIPA buffer containing anti-GraB, no proteolytic processing or activation of caspase-3 was observed, strongly suggesting that release of GraB or similar proteases from their storage sites in cytotoxic granules during the lysis procedure is responsible for caspase activation. These findings demonstrate that T-cells do not process caspases upon activation and caution about the method of cell lysis used when studying granzyme-expressing cells.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Zapata, Juan M/J-6304-2014	Zapata, Juan M/0000-0002-0110-0009	NATIONAL CANCER INSTITUTE [R01CA072994] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051399] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72994] Funding Source: Medline; NHLBI NIH HHS [HL-51399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Bras A, 1997, J IMMUNOL, V159, P3168; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; CLEMENT MV, 1994, TRANSPLANTATION, V57, P322, DOI 10.1097/00007890-199402150-00002; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Duriez PJ, 1997, BBA-GEN SUBJECTS, V1334, P65, DOI 10.1016/S0304-4165(96)00077-3; EBNET K, 1991, INT IMMUNOL, V3, P9, DOI 10.1093/intimm/3.1.9; EBNET K, 1995, J EXP MED, V181, P755, DOI 10.1084/jem.181.2.755; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; GARCIASANZ JA, 1990, J IMMUNOL, V145, P3111; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HADDAD P, 1993, EUR J IMMUNOL, V23, P625, DOI 10.1002/eji.1830230307; HAMEED A, 1991, AM J PATHOL, V138, P1069; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1996, ANAL BIOCHEM, V236, P221, DOI 10.1006/abio.1996.0160; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMMER JA, 1995, CLIN EXP IMMUNOL, V100, P164; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Pham C T, 1997, Semin Immunol, V9, P127, DOI 10.1006/smim.1997.0060; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; TAK PP, 1994, ARTHRITIS RHEUM, V37, P1735, DOI 10.1002/art.1780371205; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tan XQ, 1997, J BIOL CHEM, V272, P9613; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	57	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6916	6920		10.1074/jbc.273.12.6916	http://dx.doi.org/10.1074/jbc.273.12.6916			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506996	Green Published, hybrid			2022-12-27	WOS:000072775900046
J	Li, S; Ku, CY; Farmer, AK; Cong, YS; Chen, CF; Lee, WH				Li, S; Ku, CY; Farmer, AK; Cong, YS; Chen, CF; Lee, WH			Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SV40 T-ANTIGEN; RETINOBLASTOMA PROTEIN; IMPORT SUBSTRATE; LOCATION SIGNAL; PORE COMPLEXES; DNA-BINDING; C-TERMINUS; TRANSPORT; GENE	Active transport of proteins into the nucleus is mediated by interaction between the classical nuclear localization signals (NLSs) of the targeted proteins and the NLS receptor (importin) complex. This nuclear transport system is highly regulated and conserved in eukaryotes and is essential for cell survival. Using a fragment of BRCA1 containing the two NLS motifs as a bait for yeast two-hybrid screening, we have isolated four clones, one of which is importin alpha. Here we characterize one of the other clones identified, BRAP2, which is a novel gene and expressed as a 2-kilobase mRNA in human mammary epithelial cells and some but not all tissues of mice. The isolated full-length cDNA encodes a novel protein containing 600 amino acid residues with pI 6.04. Characteristic motifs of C2H2 zinc fingers and leucine heptad repeats are present in the middle and C-terminal regions of the protein, respectively, BRAP2 also shares significant homology with a hypothetical protein from yeast Saccharomyces cerevisiae, especially in the zinc finger region. Antibodies prepared against the C-terminal region of BRAP2 fused to glutathione S-transferase specifically recognize a cellular protein with a molecular size of 68 kDa, consistent with the size of the in vitro translated protein. Cellular BRAP2 is mainly cytoplasmic and binds to the NLS motifs of BRCA1 with similar specificity to that of importin alpha in both two-hybrid assays in yeast and glutathione S-transferase pull-down assays in vitro. Other motifs such as the SV40 large T antigen NLS motif and the bipartite NLS motif found in mitosin are also recognized by BRAP2. Similarly, the yeast homolog of BRAP2 also binds to these NLS motifs in vitro. These results imply that BRAP2 may function as a cytoplasmic retention protein and play a role in regulating transport of nuclear proteins.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), 15355 Lambda Dr, San Antonio, TX 78245 USA.	leew@uthscsa.edu	LI, SHANG/HII-4989-2022	Chen, Chi-Fen/0000-0002-6391-821X; LI, SHANG/0000-0002-6226-3362	NCI NIH HHS [P50-CA58183, P01-CA30195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, P01CA030195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen CF, 1996, MOL CELL BIOL, V16, P4691; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CHEN Y, 1996, SCIENCE, V270, P789; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UAUSUBEL FM, 1995, CURRENT PROTOCOLS MO; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0; ZHU XL, 1995, J BIOL CHEM, V270, P19545, DOI 10.1074/jbc.270.33.19545	45	103	108	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6183	6189		10.1074/jbc.273.11.6183	http://dx.doi.org/10.1074/jbc.273.11.6183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497340	hybrid			2022-12-27	WOS:000072488500032
J	Meriin, AB; Gabai, VL; Yaglom, J; Shifrin, VI; Sherman, MY				Meriin, AB; Gabai, VL; Yaglom, J; Shifrin, VI; Sherman, MY			Proteasome inhibitors activate stress kinases and induce Hsp72 - Diverse effects on apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEINS; CELL-DEATH; JNK ACTIVATION; U937 CELLS; PHOSPHORYLATION; RESISTANCE; SIGNAL	Inhibition of the major cytosolic protease, proteasome, has been reported to induce programmed cell death in several cell lines, while with other lines, similar inhibition blocked apoptosis triggered by a variety of harmful treatments. To elucidate the mechanism of pro- and antiapoptotic action of proteasome inhibitors, their effects on U937 lymphoid and 293 kidney human tumor cells were tested, Treatment with peptidyl aldehyde MG132 and other proteasome inhibitors led to a steady increase in activity of c-Jun N-terminal kinase, JNK1, which is known to initiate the apoptotic program in response to certain stresses. Dose dependence of MG132-induced JNK activation was parallel with that of apoptosis. Furthermore, inhibition of the JNK signaling pathway strongly suppressed MG132-induced apoptosis. These data indicate that JNK is critical for the cell death caused by proteasome inhibitors. An antiapoptotic action of proteasome inhibitors could be revealed by a short incubation of cells with MG132 followed by its withdrawal. Under these conditions, the major heat shock protein Hsp72 accumulated in cells and caused suppression of JNK activation in response to certain stresses. Accordingly, pretreatment with MG132 reduced JNK-dependent apoptosis caused by heat shock or ethanol, but it was unable to block JNK-independent apoptosis induced by TNF alpha. Therefore, proteasome inhibitors activate JNK, which initiates an apoptotic program, and simultaneously they induce Hsp72, which suppresses JNK-dependent apoptosis. A balance between these two effects might define the fate of cells exposed to the inhibitors.	Boston Biomed Res Inst, Boston, MA 02114 USA; Inst Influenza, St Petersburg 197022, Russia; Med Radiol Res Ctr, Obninsk 249020, Russia; Dana Farber Canc Inst, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Dana-Farber Cancer Institute	Sherman, MY (corresponding author), Boston Biomed Res Inst, Boston, MA 02114 USA.	sherman@bbri.harvard.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Yaglom, Julia/0000-0002-8723-3506; Meriin, Anatoli/0000-0003-0087-814X				Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BUSH KT, 1997, J BIOL CHEM, V272, P906; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Feige U., 1996, STRESS INDUCIBLE CEL; Fujita E, 1996, BIOCHEM BIOPH RES CO, V224, P74, DOI 10.1006/bbrc.1996.0986; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Kabakov A. E., 1997, HEAT SHOCK PROTEINS; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Ridley SH, 1997, J IMMUNOL, V158, P3165; ROMAC JMJ, 1994, MOL CELL BIOL, V14, P4662, DOI 10.1128/MCB.14.7.4662; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHERMAN MYS, 1996, STRESS INDUCIBLE CEL, P57; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Tanimoto Y, 1997, J BIOCHEM-TOKYO, V121, P542; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; XIA Z, 1995, SCIENCE, V136, P1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	37	274	278	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6373	6379		10.1074/jbc.273.11.6373	http://dx.doi.org/10.1074/jbc.273.11.6373			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497367	hybrid			2022-12-27	WOS:000072488500059
J	Higgs, HN; Han, MH; Johnson, GE; Glomset, JA				Higgs, HN; Han, MH; Johnson, GE; Glomset, JA			Cloning of a phosphatidic acid-preferring phospholipase A(1) from bovine testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HUMAN LIPOPROTEIN-LIPASE; COILED COILS; SEQUENCE; DIACYLGLYCEROL; PURIFICATION; NEUTROPHILS; ACTIVATION; EXPRESSION; ENZYME	We report the molecular cloning and expression of a phosphatidic acid-preferring phospholipase A(1) from bovine testis, The open reading frame encoded am 875-amino acid protein with a calculated molecular mass of 97,576 daltons and a pI of 5.61. The sequence included a region similar to a lipase consensus sequence containing the putative active site serine and also included a potential, coiled-coil-forming region. Expression of the open reading frame in COS1 cells resulted in a 28-44-fold increase in phosphatidic acid phospholipase A(1) activity over that of control cells, Mutation of the putative active site serine (amino acid 540) demonstrated that it was essential far this increase in enzyme activity. Northern blot analysis revealed at. least five different messages with the highest overall message levels in mature testis, but detectable message in all tissues examined. Two possible alternately spliced regions in the spent reading frame also were identified. Finally, a search of the data base identified six related proteins: a potential counterpart of the phospholipase A(1) in Caenorhabditis elegans, two putative lipases in yeast, and three proteins separately encoded by the drosophila retinal degeneration B gene and its mouse and human homologues.	Univ Washington, Howard Hughes Med Inst, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Glomset, JA (corresponding author), Univ Washington, Howard Hughes Med Inst, Dept Med, Box 357370, Seattle, WA 98195 USA.			Higgs, Henry/0000-0002-2917-9644	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; Aikawa Y, 1997, BIOCHEM BIOPH RES CO, V236, P559, DOI 10.1006/bbrc.1997.7009; AUSUBEL FM, 1992, CURRENT PROTOCOL S14, V14; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BOCCKINO SB, 1996, HANDB LIP R, V8, P75; BODMER MW, 1987, BIOCHIM BIOPHYS ACTA, V909, P237, DOI 10.1016/0167-4781(87)90083-2; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Harlow E., 1988, ANTIBODIES LAB MANUA; HENIKOFF S, 1995, GENE-COMBIS, V163, pGC17, DOI 10.1016/0378-1119(95)00486-P; HIDE WA, 1992, J LIPID RES, V33, P167; Higgs HN, 1996, J BIOL CHEM, V271, P10874, DOI 10.1074/jbc.271.18.10874; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; Hodgkin MN, 1996, BIOCHEM SOC T, V24, P991, DOI 10.1042/bst0240991; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; Kanoh H, 1996, J LIPID MEDIAT CELL, V14, P245, DOI 10.1016/0929-7855(96)00532-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P7; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Rubboli Francesca, 1997, Genes and Function, V1, P205; Sato T, 1997, J BIOL CHEM, V272, P2192; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VIHTELIC TS, 1991, GENETICS, V127, P761; Wang AJ, 1997, J BIOL CHEM, V272, P22030, DOI 10.1074/jbc.272.35.22030; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	41	77	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5468	5477		10.1074/jbc.273.10.5468	http://dx.doi.org/10.1074/jbc.273.10.5468			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488669	hybrid			2022-12-27	WOS:000072345000012
J	Lu, Z; Cyr, DM				Lu, Z; Cyr, DM			The conserved carboxyl terminus and zinc finger-like domain of the co-chaperone Ydj1 assist Hsp70 in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNAJ MOLECULAR CHAPERONE; ESCHERICHIA-COLI; ATPASE ACTIVITY; ENDOPLASMIC-RETICULUM; SECONDARY STRUCTURE; SUBSTRATE-BINDING; REACTION CYCLE; HOMOLOG; YEAST; TRANSLOCATION	Ydj1 is a member of the Hsp40 (DnaJ-related) chaperone family that facilitates cellular protein folding by regulating Hsp70 ATPase activity and binding unfolded polypeptides, Ydj1 contains four conserved subdomains that appear to represent functional units. To define the action of these regions, protease-resistant Ydj1 fragments and Ydj1 mutants were analyzed for activities exhibited by the unmodified protein, The Ydj1, mutant proteins analyzed were unable to support growth of yeast at elevated temperatures and mere found to have alterations in the J-domain (Ydj1 H34Q), zinc finger-like region (Ydj1 C159T), and conserved carboxyl terminus (Ydj1 G315D), Fragment Ydj1 (1-90) contains the J-domain and a small portion of the G/F-rich region and could regulate Hsp70 ATPase activity but could not suppress the aggregation of the model protein rhodanese, Ydj1 H34Q could not regulate the ATPase activity of Hsp70 but could bind unfolded polypeptides, The J-domain functions independently and was sufficient to regulate Hsp70 ATPase activity, Fragment Ydj1 (179-384) could suppress rhodanese aggregation but was unable to regulate Hsp70. Ydj1 (179-384) contains the conserved carboxyl terminus of DnaJ but is missing the J-domain, G/F-rich region, and a major portion of the zinc finger-like region. Ydj1 G315D exhibited severe defects in its ability to suppress rhodanese aggregation and form complexes with unfolded luciferase. The conserved carboxyl terminus of Ydj1 appeared to participate in the binding of unfolded polypeptides. Pdj1 C159T could form stable complexes with unfolded proteins and suppress protein aggregation but was inefficient at refolding denatured luciferase, The zinc finger-like region of Ydj1 appeared to function in conjunction with the conserved carboxyl terminus to fold proteins, However, Ydj1 does not require an intact zinc finger-like region to bind unfolded polypeptides. These data suggest that the combined functions of the J-domain, zinc finger-like region, and the conserved carboxyl terminus are required for Pdj1 to cooperate with Hsp70 and facilitate protein folding in the cell.	Univ Alabama, Med Ctr, Sch Med, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cyr, DM (corresponding author), Univ Alabama, Med Ctr, Sch Med, Dept Cell Biol, 1918 Univ Blvd, Birmingham, AL 35294 USA.			Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056981] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM56981, R01 GM056981] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; Cyr DM, 1997, J BIOENERG BIOMEMBR, V29, P29, DOI 10.1023/A:1022455621111; CYR DM, 1997, GUIDEBOOK MOL CHAPER, P89; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lee DH, 1996, MOL CELL BIOL, V16, P4773; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SHERMAN MY, 1992, EMBO J, V11, P71; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025	47	146	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5970	5978		10.1074/jbc.273.10.5970	http://dx.doi.org/10.1074/jbc.273.10.5970			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488737	hybrid			2022-12-27	WOS:000072345000080
J	So, OY; Scarafia, LE; Mak, AY; Callan, OH; Swinney, DC				So, OY; Scarafia, LE; Mak, AY; Callan, OH; Swinney, DC			Dynamics of prostaglandin H synthases - Studies with prostaglandin H synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE ACTIVE-SITE; SELECTIVE-INHIBITION; G/H SYNTHASE-1; BINDING; ACID; RAT; STOICHIOMETRY; BIOSYNTHESIS; ARGININE-120	Prostaglandin H synthases (PGHSs) catalyze the conversion of arachidonic acid to prostaglandins. In this report, we describe the effect of a PGHS2 Y355F mutation on the dynamics of PGHS2 catalysis and inhibition, Tyr(355) is part of a hydrogen-bonding network located at the entrance to the cyclooxygenase active site, The Y355F mutant exhibited allosteric activation kinetics in the presence of arachidonic acid that was defined by a curved Eadie-Scatchard plot and a Hill coefficient of 1.36 +/- 0.05, Arachidonic acid induced allosteric activation has not been directly observed with wild type PGHS2. The mutation also decreased the observed time-dependent inhibition by indomethacin, flurbiprofen, RS-57067, and SC-57666, Detailed kinetic analysis showed that the Y355F mutation decreased the transition state energy associated with slow-binding inhibition (EI double dagger) relative to the energy associated with catalysis (ES double dagger) by 1.33, 0.67, and 1.06 kcal/mol, respectively, for indomethacin, flurbiprofen, and RS-57067, These observations show Tyr(355) to be involved in the molecular mechanism of time-dependent inhibition, We interpret these results to indicate that slow binding inhibitors and the Y355F mutant slow the rate and unmask intrinsic, dynamic events associated with product formation, We hypothesize that the dynamic events are the equilibrium between relaxed and tightened organizations of the hydrogen-bonding network at the entrance to the cyclooxygenase active site, It is these rearrangements that control the rate of substrate binding and ultimately the rate of prostaglandin formation.	Roche Biosci, Inflammatory Dis Unit, Palo Alto, CA 94304 USA	Roche Holding	Swinney, DC (corresponding author), Roche Biosci, Inflammatory Dis Unit, S3-1,3401 Hillview Ave, Palo Alto, CA 94304 USA.							BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; Callan OH, 1996, J BIOL CHEM, V271, P3548; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; FLOWER R, 1972, NATURE-NEW BIOL, V238, P104, DOI 10.1038/newbio238104a0; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; KURUMBAIL RG, 1996, NATURE, V384, P544; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REITZ DB, 1994, J MED CHEM, V37, P3878, DOI 10.1021/jm00049a005; RICH DH, 1989, COMPUTER AIDED DRUG, P185; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SLOANE DL, 1995, GENE, V161, P243, DOI 10.1016/0378-1119(95)00211-N; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Swinney DC, 1997, J BIOL CHEM, V272, P12393, DOI 10.1074/jbc.272.19.12393; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Wong E, 1997, J BIOL CHEM, V272, P9280; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	32	80	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5801	5807		10.1074/jbc.273.10.5801	http://dx.doi.org/10.1074/jbc.273.10.5801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488715	hybrid			2022-12-27	WOS:000072345000058
J	Schaeper, U; Subramanian, T; Lim, L; Boyd, JM; Chinnadurai, G				Schaeper, U; Subramanian, T; Lim, L; Boyd, JM; Chinnadurai, G			Interaction between a cellular protein that binds to the C-terminal region of adenovirus E1A (CtBP) and a novel cellular protein is disrupted by E1A through a conserved PLDLS motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY EPITHELIAL-CELLS; RAT EMBRYO CELLS; RETINOBLASTOMA PROTEIN; 2ND EXON; TRANSFORMATION; GENE; TUMORIGENESIS; INHIBITION; MODULATION; METASTASIS	Adenovirus E1A proteins immortalize primary animal cells and cooperate with several other oncogenes in oncogenic transformation. These activities are primarily determined by the N-terminal half (exon 1) of Elk Although the C-terminal half (exon 2) is also essential for some of these activities, it is dispensable for cooperative transformation with the activated T24 ras oncogene. Exon 2 negatively modulates in vitro cooperative transformation with T24 ras as well as the tumorigenic and metastatic potentials of transformed cells. A short C-terminal sequence of ELA governs the oncogenesis-restraining activity of exon 2. This region of E1A binds with a cellular phosphoprotein, CtBP, through a 5-amino acid motif, PLDLS, conserved among the E1A proteins of human adenoviruses. To understand the mechanism by which interaction between E1A and CtBP results in tumorigenesis-restraining activity, we searched for cellular proteins that complex with CtBP. Here, we report the cloning and characterization of a 125-kDa protein, CtIP, that binds with CtBP through the PLDLS moth, E1A exon 2 peptides that contain the PLDLS moth disrupt the CtBP-CtIP complex. Our results suggest that the tumorigenesis-restraining activity of E1A exon 2 may be related to the disruption of the CtBP-CtIP complex through the PLDLS moth.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NCI NIH HHS [CA-33616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FATTAEY A, 1993, PHILOS T ROY SOC B, V340, P333, DOI 10.1098/rstb.1993.0075; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; LINDER S, 1992, ONCOGENE, V7, P439; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1994, CURR OPIN GENE DEV, V4, P13; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; REEVES WH, 1989, J BIOL CHEM, V264, P5047; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10667; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; STEEG PS, 1988, CANCER RES, V48, P6550; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	20	152	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8549	8552		10.1074/jbc.273.15.8549	http://dx.doi.org/10.1074/jbc.273.15.8549			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535825	hybrid			2022-12-27	WOS:000072990800002
J	Majima, HJ; Oberley, TD; Furukawa, K; Mattson, MP; Yen, HC; Szweda, LI; St Clair, DK				Majima, HJ; Oberley, TD; Furukawa, K; Mattson, MP; Yen, HC; Szweda, LI; St Clair, DK			Prevention of mitochondrial injury by manganese superoxide dismutase reveals a primary mechanism for alkaline-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CULTURED-MAMMALIAN-CELLS; RESPIRATORY ALKALOSIS; OXYGEN-CONSUMPTION; ESCHERICHIA-COLI; INTRACELLULAR PH; TRANSGENIC MICE; FREE-RADICALS; TOXICITY; RESISTANCE	Alkalosis is a clinical complication resulting from various pathological and physiological conditions, Although it is well established that reducing the cellular proton concentration is lethal, the mechanism leading to cell death is unknown. Mitochondrial respiration generates a proton gradient and superoxide radicals, suggesting a possible link between oxidative stress, mitochondrial integrity, and alkaline-induced cell death. Manganese superoxide dismutase removes superoxide radicals in mitochondria, and thus protects mitochondria from oxidative injury. Cells cultured under alkaline conditions were found to exhibit elevated levels of mitochondrial membrane potential, reactive oxygen species, and calcium which was accompanied by mitochondrial damage, DNA fragmentation, and cell death. Overexpression of manganese superoxide dismutase reduced the levels of intracellular reactive oxygen species and calcium, restored mitochondrial transmembrane potential, and prevented cell death. The results suggest that mitochondria are the primary target for alkaline-induced cell death and that free radical generation is an important and early event conveying cell death signals under alkaline conditions.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Wisconsin, Sch Med, Vet Adm Hosp, Lab Med Serv, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Vet Adm Hosp, Dept Pathol, Madison, WI 53705 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	University of Kentucky; University of Kentucky; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 342 Hlth Sci Res Bldg, Lexington, KY 40536 USA.	dstcl00@pop.uky.edu	Mattson, Mark P/F-6038-2012; Majima, Hideyuki J./K-3778-2019		NATIONAL CANCER INSTITUTE [R01CA049797, R29CA049797, R01CA059835] Funding Source: NIH RePORTER; NCI NIH HHS [CA49797, CA59835] Funding Source: Medline; NHLBI NIH HHS [HL03544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALKJAER C, 1988, J PHYSIOL-LONDON, V402, P391, DOI 10.1113/jphysiol.1988.sp017211; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BOLWELL GP, 1995, FREE RADICAL RES, V23, P517, DOI 10.3109/10715769509065273; CAIN SM, 1970, J APPL PHYSIOL, V28, P4, DOI 10.1152/jappl.1970.28.1.4; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GIULIVI C, 1995, ARCH BIOCHEM BIOPHYS, V316, P909, DOI 10.1006/abbi.1995.1122; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; HALLIWELL B, 1989, FREE RADICAL BIO MED, V2, P543; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KARETZKY MS, 1970, J APPL PHYSIOL, V28, P8, DOI 10.1152/jappl.1970.28.1.8; KHAMBATTA HJ, 1973, ANESTHESIOLOGY, V38, P53, DOI 10.1097/00000542-197301000-00014; KRALL J, 1988, J BIOL CHEM, V263, P1910; Kruman I, 1997, J NEUROSCI, V17, P5089; KUHL OK, 1994, STAT PRINCIPLES RES, P686; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MAJIMA H, 1992, INT J RADIAT ONCOL, V22, P1019, DOI 10.1016/0360-3016(92)90802-O; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; OBERLEY LW, 1982, SUPEROXIDE DISMUTASE; PETTEPHER CC, 1991, J BIOL CHEM, V266, P3113; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROSE BD, 1994, CLIN PHYSL ACID BASE, P550; SAFFORD SE, 1994, CANCER RES, V54, P4261; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; SLATER RM, 1992, J CLIN ANESTH, V4, P462, DOI 10.1016/0952-8180(92)90219-Q; SPITZ DR, 1990, BIOCHEM J, V267, P453, DOI 10.1042/bj2670453; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WANG ZH, 1990, CYTOMETRY, V11, P617, DOI 10.1002/cyto.990110509; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	55	125	127	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8217	8224		10.1074/jbc.273.14.8217	http://dx.doi.org/10.1074/jbc.273.14.8217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525927	hybrid			2022-12-27	WOS:000072876300061
J	Zhao, RB; Assaraf, YG; Goldman, ID				Zhao, RB; Assaraf, YG; Goldman, ID			A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; L1210 LEUKEMIA; DIHYDROFOLATE-REDUCTASE; ACQUIRED-RESISTANCE; TRANSPORT-DEFICIENT; MEDIATED TRANSPORT; KINETIC-PROPERTIES; BINDING-PROTEINS; LINE; SENSITIVITY	With 5-formyltetrahydrofolate (5-CHO-THF) as the folate source a methotrexate (MTX) transport-deficient murine leukemia cell line, L1210-Gla, was isolated after chemical mutagenesis and MTX selection. This cell line was 10-fold resistant to MTX in comparison to parental L1210 cells, yet the EC50 for 5-CHO-THF was increased by a factor of only 2. The initial uptake of MTX, at a concentration of 1 mu M, was decreased by a factor of 40, whereas influx of B-CHO-THF dropped by a factor of only 8. This difference in initial uptake rates was attributed solely to changes in influx V-max without a significant change in K-m. Whereas the RFC1 mRNA level in L1210-Gla cells was indistinguishable from that of parental L1210 cells, a serine to asparagine substitution was identified at amino acid 46 within the first predicted transmembrane domain. This was a result of a homozygous mutation of G --> A in the genome. Transfection of the mutated RFC1 cDNA into MTX(r)A cells, which lack functional endogenous carrier, resulted in a clonal derivative MTX(r)A-S46N. The increase in influx of 5-CHO-THF and 5-CH3THF was 5 and 13 times greater than that for MTX in the transfectant, consistent with the influx ratio in the L1210-Gla line. The functional expression of the mutated RFC1 reduced the growth requirement for 5-CHO-THF by a factor of 30, compared with only a 3-fold decrease in the MTX IC50. This represents the first reported RFC1 mutation that confers resistance to MTX due to sl markedly impaired influx with relative conservation of reduced folate transport. The kinetic changes are consistent with a substrate-dependent alteration in carrier mobility that favors reduced folates over MTX. These changes may account for the development of MTX resistance due to impaired drug transport in vivo, allowing tumor cells to meet their folate requirement with 5-CH3THF, the predominant blood folate.	Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Goldman, ID (corresponding author), Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Chanin 2,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA-39807] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165; COWAN KH, 1984, J BIOL CHEM, V259, P793; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1994, J BIOL CHEM, V269, P17; DUE AD, 1995, BIOCHEM BIOPH RES CO, V208, P590, DOI 10.1006/bbrc.1995.1379; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1971, BIOCHIM BIOPHYS ACTA, V233, P624, DOI 10.1016/0005-2736(71)90162-3; GOLDMAN ID, 1986, MEMBRANE TRANSPORT A, P283; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; Gorlick R, 1996, NEW ENGL J MED, V335, P1041, DOI 10.1056/NEJM199610033351408; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kumar CK, 1997, J BIOL CHEM, V272, P6226, DOI 10.1074/jbc.272.10.6226; MATHERLY LH, 1995, BLOOD, V85, P500; MOSCOW JA, 1995, CANCER RES, V55, P3790; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; SARAVOLAC EG, 1997, FACILITATIVE GLUCOSE, P39; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Seatter MJ, 1997, BIOCHEMISTRY-US, V36, P6401, DOI 10.1021/bi970261u; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P4732; SIROTNAK FM, 1986, MEMBRANE TRANSPORT A, P241; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; TRIPPETT T, 1992, BLOOD, V80, P1158; Tse A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P162; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2984; Wong S. C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P162; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; YANG CH, 1983, J MEMBRANE BIOL, V75, P11, DOI 10.1007/BF01870795; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	43	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7873	7879		10.1074/jbc.273.14.7873	http://dx.doi.org/10.1074/jbc.273.14.7873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525881	hybrid			2022-12-27	WOS:000072876300015
J	Desai, UR; Petitou, M; Bjork, I; Olson, ST				Desai, UR; Petitou, M; Bjork, I; Olson, ST			Mechanism of heparin activation of antithrombin - Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; ANTI-THROMBIN-III; CONFORMATIONAL CHANGE; PROTEINASE REACTIONS; BINDING SEQUENCE; FACTOR-XA; ACCELERATION; SITE; FLUORESCENCE; ENHANCEMENT	To determine the role of individual saccharide residues of a specific heparin pentasaccharide, denoted DEFGH, in the allosteric activation of the serpin, antithrombin, we studied the effect of deleting pentasaccharide residues on this activation, Binding, spectroscopic, and kinetic analyses demonstrated that deletion of reducing-end residues G and H or nonreducing-end residue D produced variable losses in pentasaccharide binding energy of similar to 15-75% but did not affect the oligosaccharide's ability to conformationally activate the serpin or to enhance the rate at which the serpin inhibited factor Xa, Rapid kinetic studies revealed that elimination of the reducing end disaccharide marginally affected binding to the native low-heparin-affinity conformational state of antithrombin but greatly affected the conversion of the serpin to the activated high-heparin-affinity state, although the activated conformation was still favored. In contrast, removal of the nonreducing-end residue D drastically affected the initial low-heparin-affinity interaction so as to favor an alternative activation pathway wherein the oligosaccharide shifted a preexisiting equilibrium between native and activated serpin conformations in favor of the activated state. These results demonstrate that the nonreducing-end residues of the pentasaccharide function both to recognize the native low-heparin-affinity conformation of antithrombin and to induce and stabilize the activated high-heparin-affinity conformation. Residues at the reducing end, however, poorly recognize the native conformation and instead function primarily to bind and stabilize the activated antithrombin conformation, Together, these findings establish an important role of the heparin pentasaccharide sequence in preferential binding and stabilization of the activated conformational state of the serpin.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Sanofi Rech, Ligne Hemobiol, F-31036 Toulouse, France; Swedish Univ Agr Sci, Dept Vet Med Chem, S-75123 Uppsala, Sweden	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Sanofi-Aventis; Sanofi France; Swedish University of Agricultural Sciences	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Room 530E Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.		Desai, Umesh/D-3741-2013	Desai, Umesh/0000-0002-1976-6597	NHLBI NIH HHS [HL 39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039888, R29HL039888, R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BAE JH, 1994, BIOCHEM J, V301, P121, DOI 10.1042/bj3010121; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Carrell R, 1997, THROMB HAEMOSTASIS, V78, P516; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHOAY J, 1989, ANN NY ACAD SCI, V556, P61; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOAY J, 1981, ANN NY ACAD SCI, V370, P640; FAN BQ, 1994, FEBS LETT, V354, P84, DOI 10.1016/0014-5793(94)01083-8; FERSHT A, 1985, ENZYME STRUCTURE MEC, P139; FERSHT AR, 1974, BIOCHEMISTRY-US, V13, P1416, DOI 10.1021/bi00704a016; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GROOTENHUIS PDJ, 1995, NAT STRUCT BIOL, V2, P736, DOI 10.1038/nsb0995-736; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MASCOTTI DP, 1995, BIOCHEMISTRY-US, V34, P2908, DOI 10.1021/bi00009a022; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; Petitou M, 1997, GLYCOBIOLOGY, V7, P323, DOI 10.1093/glycob/7.3.323-e; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; PETITOU M, 1992, PROGR CHEM ORGANIC N, P143; RAGAZZI M, 1990, CARBOHYD RES, V195, P169, DOI 10.1016/0008-6215(90)84165-Q; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; VANBOECKEL CAA, 1988, TETRAHEDRON LETT, V29, P803, DOI 10.1016/S0040-4039(00)80214-2	45	149	153	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7478	7487		10.1074/jbc.273.13.7478	http://dx.doi.org/10.1074/jbc.273.13.7478			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516447	hybrid, Green Submitted			2022-12-27	WOS:000072738500043
J	Porter, DJT				Porter, DJT			Inhibition of the hepatitis C virus helicase-associated ATPase activity by the combination of ADP, NaF, MgCl2, and poly(rU) - Two ADP binding sites on the enzyme-nucleic acid complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; COLI REP HELICASE; TIGHT-BINDING; BERYLLIUM FLUORIDE; KINETIC MECHANISM; CALCIUM ATPASE; MAGNESIUM; DNA; ANALOGS; TRIPHOSPHATASE	Hepatitis C virus (HCV) helicase has an intrinsic ATPase activity and a nucleic acid (poly(rU))-stimulated ATPase activity, The poly(rU)-stimulated ATPase activity was inhibited by F- in a time-dependent manner during ATP hydrolysis, Inhibition was the result of trapping an enzyme bound ADP-poly(rU) ternary complex generated during the catalytic cycle and was not the result of generating enzyme-free ADP that subsequently inhibited the enzyme, However, catalysis was not required for efficient inhibition by F-. The stimulated and the intrinsic ATPase activities were also inhibited by treatment of the enzyme with F-, ADP, and poly(rU), The inhibited enzyme slowly recovered (t(1/2) = 23 min) ATPase activity after a 2000-fold dilution into assay buffer, The onset of inhibition by 500 mu M ADP and 15 mM F- in the absence of nucleic acid was very slow (t(1/2) > 40 min), However, the sequence of addition of poly(rU) to a diluted solution of ADP/NaF-treated enzyme had a pro found effect on the extent of inhibition, If the ADP/NaF-treated enzyme was diluted into an assay that lacked poly(rU) and the assay was subsequently initiated with poly(rU), the treated enzyme was not inhibited, Alternatively, if the treated enzyme was diluted into an assay containing poly(rU), the enzyme was inhibited, ATP protected the enzyme from inhibition by ADP/NaF. The stoichiometry between ADP and enzyme monomer in the inhibited enzyme complex was 2, as determined from titration of the ATPase activity ([ADP]/[E] = 2.2) and from the number of radiolabeled ADP bound to the inhibited enzyme ([ADP]/[E] = 1.7) in the presence of excess NaF, MgCl2, and poly(rU), The Hill coefficient for titration of ATPase activity with F- (n = 2.8) or MgCl2 (n = 2.1) in the presence of excess ADP and poly(rU) suggested that multiple F- and Mg2+ were involved in forming the inhibited enzyme complex, The stoichiometry between (dU)(18), a defined oligomeric nucleic acid substituting for poly(rU), and enzyme monomer in the inhibited enzyme complex was estimated to be 1 ([(dU)(18)/[E] = 1.2) from titration of the ATPase activity in the presence of excess ADP, MgCl2, and NaF.	Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Porter, DJT (corresponding author), Glaxo Wellcome Inc, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.							ANTONNY B, 1992, J BIOL CHEM, V267, P6710; ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; Berdis AJ, 1997, BIOCHEMISTRY-US, V36, P2733, DOI 10.1021/bi962139l; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; BOYER PD, 1962, ENZYMES, V6, P95; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COLL RJ, 1992, J BIOL CHEM, V267, P21584; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; MOORE KJM, 1995, BIOPHYS J, V68, pS180; MURPHY AJ, 1992, J BIOL CHEM, V267, P16995; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Stole E, 1997, BIOCHEMISTRY-US, V36, P3483, DOI 10.1021/bi962881l; SUBRAMANYA HS, 1966, NATURE, V85, P379; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	28	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7390	7396		10.1074/jbc.273.13.7390	http://dx.doi.org/10.1074/jbc.273.13.7390			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516436	hybrid			2022-12-27	WOS:000072738500032
J	Proost, P; De Meester, I; Schols, D; Struyf, S; Lambeir, AM; Wuyts, A; Opdenakker, G; De Clercq, E; Scharpe, S; Van Damme, J				Proost, P; De Meester, I; Schols, D; Struyf, S; Lambeir, AM; Wuyts, A; Opdenakker, G; De Clercq, E; Scharpe, S; Van Damme, J			Amino-terminal truncation of chemokines by CD26/dipeptidylpeptidase IV - Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; T-CELL ACTIVATION; NH2-TERMINAL RESIDUES; BETA-THROMBOGLOBULIN; CD26; HIV; IDENTIFICATION; INTERLEUKIN-8; RECEPTORS; INVITRO	Chemokines are key players in inflammation and infection. Natural forms of the C-X-C chemokine granulocyte chemotactic protein-2 (GCP-2) and the C-C chemokine regulated on activation normal T cell expressed and secreted (RANTES), which miss two NH2-terminal residues, including a Pro in the penultimate position, have been isolated from leukocytes or tumor cells. In chemotaxis and intracellular calcium mobilization assays, the truncation caused a reduction in the specific activity of RANTES but not of GCP-2. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) could induce this observed NH2-terminal truncation of GCP-2 and RANTES but not that of the monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. No significant difference in neutrophil activation was detected between intact and CD26/DPP IV-truncated GCP-2. In contrast to intact natural RANTES(1-68), which still chemoattracts monocytes at 10 ng/ml, CD26/DPP IV-truncated RANTES(3-68) was inactive at 300 ng/ml and behaved as a natural chemotaxis inhibitor. Compared with intact RANTES, only a 10-fold higher concentration of RANTES(3-68) induced a significant Ca2+ response. Furthermore, RANTES(3-68) inhibited infection of mononuclear cells by an M-tropic HIV-1 strain 5-fold more efficiently than intact RANTES. Thus, proteolytic processing of RANTES by CD26/DPP IV may constitute an important regulatory mechanism during anti-inflammatory and antiviral responses.	Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Expt Chemotherapy, B-3000 Louvain, Belgium; Univ Instelling Antwerp, Dept Clin Biochem, B-2610 Antwerp, Belgium	KU Leuven; KU Leuven; University of Antwerp	Proost, P (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.	Paul.Proost@rega.kuleuven.ac.be	Struyf, Sofie/U-2455-2017; Opdenakker, Ghislain/V-8562-2019; Proost, Paul/V-3052-2017; Schols, Dominique/S-9057-2017; Schols, Dominique/AAC-1309-2021; Opdenakker, Ghislain/Q-3130-2017; De Meester, Ingrid/A-6881-2017; Lambeir, Anne-Marie/B-2477-2017	Struyf, Sofie/0000-0003-4558-0769; Opdenakker, Ghislain/0000-0003-1714-2294; Proost, Paul/0000-0002-0133-5545; Schols, Dominique/0000-0003-3256-5850; Schols, Dominique/0000-0003-3256-5850; Opdenakker, Ghislain/0000-0003-1714-2294; De Meester, Ingrid/0000-0002-3421-0124; Lambeir, Anne-Marie/0000-0001-9386-3777; De Clercq, Erik/0000-0002-2985-8890				ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOFFMANN T, 1993, FEBS LETT, V336, P61, DOI 10.1016/0014-5793(93)81609-4; Korom S, 1997, TRANSPLANTATION, V63, P1495, DOI 10.1097/00007890-199705270-00021; KUBOTA T, 1992, CLIN EXP IMMUNOL, V89, P192; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Noso N, 1996, J IMMUNOL, V156, P1946; ORAVECZ T, 1995, NAT MED, V1, P919, DOI 10.1038/nm0995-919; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; PROOST P, 1995, CYTOKINE, V7, P97, DOI 10.1006/cyto.1995.1013; PROOST P, 1993, J IMMUNOL, V150, P1000; Proost Paul, 1996, Methods (Orlando), V10, P82, DOI 10.1006/meth.1996.0082; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; TAUB DD, 1996, CYTOKINE GROWTH F R, V7, P335; VANDAMME J, 1990, EUR J IMMUNOL, V20, P2113, DOI 10.1002/eji.1830200933; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; WALZ A, 1989, BIOCHEM BIOPH RES CO, V159, P969, DOI 10.1016/0006-291X(89)92203-1; WU BL, 1997, J EXP MED, V185, P1681; Wuyts A, 1997, BIOCHEMISTRY-US, V36, P2716, DOI 10.1021/bi961999z	37	237	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7222	7227		10.1074/jbc.273.13.7222	http://dx.doi.org/10.1074/jbc.273.13.7222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516414	hybrid			2022-12-27	WOS:000072738500010
J	Shirouzu, M; Morinaka, K; Koyama, S; Hu, CD; Hori-Tamura, N; Okada, T; Kariya, K; Kataoka, T; Kikuchi, A; Yokoyama, S				Shirouzu, M; Morinaka, K; Koyama, S; Hu, CD; Hori-Tamura, N; Okada, T; Kariya, K; Kataoka, T; Kikuchi, A; Yokoyama, S			Interactions of the amino acid residue at position 31 of the c-Ha-Ras protein with Raf-1 and RalGDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; SIGNAL-TRANSDUCTION; EFFECTOR REGION; R-RAS; IDENTIFICATION; BINDING; KINASE; GENE; TRANSFORMATION; DOWNSTREAM	The Ras and Rap1A proteins can bind to the Raf and RalGDS families. Ras and Rap1A have Glu and Lys, respectively, at position 31. In the present study, we analyzed the effects of mutating the Glu at position 31 of the c-Ha-Ras protein to Asp, Ala, Arg, and Lys on the interactions with Raf-1 and RalGDS. The Ras-binding domain (RBD) of Raf-1 binds the E31R and E31K Ras mutants less tightly than the wild-type, E31A, and E81D Ras proteins; the introduction of the positively charged Lys or Arg residue at position 31 specifically impairs the binding of Ras with the Raf-1 RBD. On the other hand, the ability of the oncogenic Ras(G12V) protein to activate Raf-1 in HEK293 cells was only partially reduced by the E31R mutation but was drastically impaired by the E31K mutation. Correspondingly, Ras(G12V)(E31K) as well as Rap1A, but not Ras(G12V)(E31R), exhibited abnormally tight binding with the cysteine-rich domain of Raf-1. On the other hand, the E31A, E31R, and E31K mutations, but not the E31D mutation, enhanced the RalGDS RBD-binding activity of Ras, indicating that the negative charge at position 31 of Ras is particularly unfavorable to the interaction with the RalGDS RBD. Ras(G12V)(E31K), Ras(G12V)(E31A), and Rap1A stimulate the RalGDS action more efficiently than the wild-type Ras in the liposome reconstitution assay. All of these results clearly show that the sharp contrast between the characteristics of Ras and Rap1A, with respect to the interactions with Raf-1 and RalGDS, depends on their residues at position 31.	RIKEN, Inst Phys & Chem Res, Cellular Signaling Lab, Wako, Saitama 35101, Japan; Hiroshima Univ, Sch Med, Dept Biochem 1, Minami Ku, Hiroshima 734, Japan; Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 650, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 113, Japan	RIKEN; Hiroshima University; Kobe University; University of Tokyo	Yokoyama, S (corresponding author), RIKEN, Inst Phys & Chem Res, Cellular Signaling Lab, Hirosawa 2-1, Wako, Saitama 35101, Japan.	yokoyama@postman.riken.go.jp	Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; GOTOH Y, 1994, ONCOGENE, V9, P1891; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MIURA K, 1986, JPN J CANCER RES, V77, P45; Murai H, 1997, J BIOL CHEM, V272, P10483; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PIZON V, 1988, ONCOGENE, V3, P201; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SHIROUZU M, 1992, ONCOGENE, V7, P475; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Summers MD, 1987, MANUAL METHODS BACUL; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wolthuis RMF, 1996, ONCOGENE, V13, P353	42	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7737	7742		10.1074/jbc.273.13.7737	http://dx.doi.org/10.1074/jbc.273.13.7737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516482	hybrid			2022-12-27	WOS:000072738500078
J	Bergmann, M; Hart, L; Lindsay, M; Barnes, PJ; Newton, R				Bergmann, M; Hart, L; Lindsay, M; Barnes, PJ; Newton, R			I kappa B alpha degradation and nuclear factor-kappa B DNA binding are insufficient for interleukin-1 beta and tumor necrosis factor-alpha-induced kappa B-dependent transcription - Requirement for an additional activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PROMOTER; GENE; UBIQUITINATION; TRANSLOCATION; MECHANISM; INDUCTION; INHIBITOR; FAMILY; CELLS	Two closely related I kappa B alpha kinases as well as the upstream kinase, NIK, which integrates interleukin-1 beta (IL-1 beta)- and tumor necrosis factor (TNF)-alpha-dependent activation of the transcription factor NF-kappa B have recently been described. However, in this emerging pathway the role of previously identified components of cytokine-induced NF-kappa B activation, namely phosphatidylcholine-specific phospholipase C and protein kinase C, remains unclear, We now show that, in A549 human alveolar epithelial cells, the activation of a stably transfected NF-kappa B dependent reporter gene by TNF-alpha and IL-1 beta is completely blocked by the phosphatidylcholine-specific phospholipase C inhibitor D609 and the protein kinase C inhibitor RO31-8220. However, IL-1 beta-induced I kappa B alpha degradation as well as NF-kappa B nuclear translocation and DNA binding, as determined by Western blot and electro-mobility shift assay, respectively, are not affected by these inhibitors, A similar effect, although less pronounced, is observed with the p38 mitogen-activated protein kinase inhibitor SE 203580. On the basis of these data we propose the existence of a second signaling pathway induced by IL-1 beta and TNF-alpha that is activated in parallel to the cascade leading to I kappa B alpha degradation and is specifically required for NF-kappa B-dependent transcriptional competency.	Imperial Coll, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Newton, R (corresponding author), Imperial Coll, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.	robert.newton@ic.ac.uk	Newton, Robert/C-6814-2012	Newton, Robert/0000-0002-4919-8498; Barnes, Peter/0000-0002-5122-4018				Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HOHASHI N, 1995, INT IMMUNOL, V7, P1851, DOI 10.1093/intimm/7.11.1851; ISRAEL N, 1992, J IMMUNOL, V149, P3386; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Kuo ML, 1997, MOL PHARMACOL, V52, P535, DOI 10.1124/mol.52.3.535; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MECO MTD, 1994, EMBO J, V13, P2842; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Newton R, 1996, LIFE SCI, V60, P67, DOI 10.1016/S0024-3205(96)00590-5; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	38	167	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6607	6610		10.1074/jbc.273.12.6607	http://dx.doi.org/10.1074/jbc.273.12.6607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506955	hybrid			2022-12-27	WOS:000072775900005
J	Min, DS; Park, SK; Exton, JH				Min, DS; Park, SK; Exton, JH			Characterization of a rat brain phospholipase D isozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; PROTEIN-KINASE-C; GTPASE-ACTIVATING PROTEIN; CELL-FREE SYSTEM; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; HUMAN NEUTROPHILS; HL-60 CELLS; ACID PHOSPHOLIPIDS; PLASMA-MEMBRANE; BINDING	We have recently cloned a cDNA encoding a phospholipase D (PLD) from rat brain and named it rPLD1, It shows 90% amino acid identity with the human PLD isoform hPLD1b, We have expressed rPLD1 as a histidine-tagged fusion protein in insect (Sf9) cells using the expression vector pBlueBacHis and purified the recombinant protein to homogeneity by Ni2+-agarose affinity chromatography. Phosphatidylinositol 4,5-P-2 and phosphatidylinositol 3,4,5-P-3 activated the PLD equipotently, but other acidic phospholipids were ineffective. The activity of rPLD1 was dependent on both Mg2+ and Ca2+, It was specific for phosphatidylcholine and showed a broad dependence on pH with optimum activity at pH 6.5-7.5. The enzyme was inhibited by oleate and activated by the small G proteins ARF3 and RhoA in the presence of guanosine 5'-3-O-(thio)triphosphate. Protein kinase C (PKC)-alpha and -beta II, but not PKC-gamma, -delta, -epsilon, or -zeta, activated rPLD1 in a manner that was stimulated by phorbol ester but did not require ATP, Neither synergistic interactions between ARF3 and RhoA nor between these G proteins and PKC-alpha or -beta II were observed, Recombinant PKC-alpha and -beta II phosphorylated purified rPLD1 to high stoichiometry in vitro, and the phosphorylated PLD exhibited a mobility shift upon electrophoresis, Phosphorylation of the PLD by PKC was correlated with inhibition of its catalytic activity. rPLD1 bound to concanavalin A-Sepharose beads, and its electrophoretic mobility was altered by treatment with endoglycosidase F. The amount of PLD bound to the beads was decreased in a concentration-dependent manner when tunicamycin was added to the Sf9 expression system, Tunicamycin also decreased membrane localization of rPLD1, These results suggest that rPLD1 is a glycosylated protein and that it is negatively regulated by phosphorylation by PKC in vitro.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47448] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4942; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; TERUI T, 1994, J BIOL CHEM, V269, P28130; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WANG XM, 1994, J BIOL CHEM, V269, P20312; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	48	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7044	7051		10.1074/jbc.273.12.7044	http://dx.doi.org/10.1074/jbc.273.12.7044			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507013	hybrid			2022-12-27	WOS:000072775900063
J	Nauseef, WM; McCormick, SJ; Goedken, M				Nauseef, WM; McCormick, SJ; Goedken, M			Coordinated participation of calreticulin and calnexin in the biosynthesis of myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL-LINE; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; CATALYTIC ACTIVITY; MISSENSE MUTATION; HEME; BINDING; PROTEIN; DEFICIENCY; MEMBRANE	Myeloperoxidase (MPO) is a neutrophil lysosomal hemeprotein essential for optimal oxygen-dependent microbicidal activity, We have demonstrated previously that calreticulin, a luminal endoplasmic reticulum protein, functions as a molecular chaperone during myeloperoxidase biosynthesis, associating reversibly with the heme-fi ee precursor apopro-MPO, Because the membrane-bound endoplasmic reticulum protein calnexin is structurally and functionally related to calreticulin, we assessed the role of calnexin in myeloperoxidase biosynthesis. Like calreticulin, calnexin coprecipitated exclusively with glycosylated MPO precursors and with apopro-MPO but, in contrast to calreticulin, also with the enzymatically active, heme-containing precursor pro-MPO, To determine if calnexin participated in heme insertion into MPO, we compared the kinetics of chaperone association with MPO precursors using stable transfectants expressing cDNA encoding wild type MPO or mutated forms that do not acquire heme, Transfectants expressing mutant cDNA had prolonged association of MPO-related precursors with calreticulin and especially with calnexin, These studies demonstrate that I) both calreticulin and calnexin associated with glycosylated apopro-MPO; 2) only calnexin associated selectively with the enzymatically active, heme-containing precursor pro-MPO; and 3) mutants unable to incorporate heme had prolonged association with calnexin, These findings represent the first evidence of a specialized role for calnexin in facilitating protein maturation in the endoplasmic reticulum of myeloid cells.	Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Nauseef, WM (corresponding author), Univ Iowa, Dept Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Nauseef, William/0000-0003-4032-757X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053592] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-53592] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BLRD VA		ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BHUVA M, 1994, AM J MED, V97, P169, DOI 10.1016/0002-9343(94)90027-2; CAPPS GG, 1994, J BIOL CHEM, V269, P18051; CASTANEDA VL, 1992, EXP HEMATOL, V20, P916; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Denning GM, 1997, BLOOD, V90, P372; DePillis GD, 1997, J BIOL CHEM, V272, P8857; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FLORIS R, 1995, J AM CHEM SOC, V117, P3907, DOI 10.1021/ja00119a003; Gullberg U, 1997, EUR J HAEMATOL, V58, P137; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HORI H, 1994, J BIOL CHEM, V269, P8388; IKEDASAITO M, 1985, FEBS LETT, V184, P52, DOI 10.1016/0014-5793(85)80651-7; JACQUET A, 1992, FEBS LETT, V302, P189, DOI 10.1016/0014-5793(92)80437-L; JACQUET A, 1994, BIOCHEM BIOPH RES CO, V202, P73, DOI 10.1006/bbrc.1994.1895; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; LE AQ, 1994, J BIOL CHEM, V269, P7514; Meldolesi J, 1996, CELL CALCIUM, V20, P83, DOI 10.1016/S0143-4160(96)90053-6; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NAUSEEF WM, 1994, J BIOL CHEM, V269, P1212; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SONO M, 1991, P NATL ACAD SCI USA, V88, P11148, DOI 10.1073/pnas.88.24.11148; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; TUCKER KA, 1987, BLOOD, V70, P372; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	54	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7107	7111		10.1074/jbc.273.12.7107	http://dx.doi.org/10.1074/jbc.273.12.7107			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507022	hybrid			2022-12-27	WOS:000072775900072
J	Shamsi, FA; Partal, A; Sady, C; Glomb, MA; Nagaraj, RH				Shamsi, FA; Partal, A; Sady, C; Glomb, MA; Nagaraj, RH			Immunological evidence for methylglyoxal-derived modifications in vivo - Determination of antigenic epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; ADVANCED GLYCATION ENDPRODUCTS; MAILLARD REACTION-PRODUCTS; MONOCYTIC THP-1 CELLS; HUMAN SERUM ALBUMINS; DIABETIC COMPLICATIONS; ALDOSE REDUCTASE; GLYOXALASE SYSTEM; CROSS-LINKING; HUMAN LENS	The Maillard reaction, a non-enzymatic reaction of ketones and aldehydes with amino groups of proteins, contributes to the aging of proteins and to complications associated with diabetes, Methylglyoxal (MG) is a 2-oxoaldehyde derived from glycolytic intermediates and produced during the Maillard reaction, We reported previously the formation of a lysine-lysine protein crosslinking structure (imidazolysine) and a fluorescent arginine modification (argpyrimidine) from the Maillard reaction of MG, Here we show that rabbit antibodies to MG modified ribonuclease A identify proteins modified by the Maillard reaction of glucose, fructose, ribose, glyceraldehyde, glyoxal, ascorbate, and ascorbate oxidation products (dehydroascorbate, 2,3-diketogulonate, L-xylosone, and L-threose) in addition to those modified by MG;, The antibody recognized imidazolysine and argpyrimidine and a glyoxal-derived lysine-lysine cross-link, It did not react with N epsilon-carboxymethyllysine. Incubations with amino acids revealed strongest reactivity with N alpha-t-butoxycarbonylarginine and MG, and we identified argpyrimidine as one of the epitopes from this incubation mixture. Serum proteins from human diabetics reacted more strongly with the antibody than those from normal individuals, and the levels correlated with glycemic control, Collagen from human corneas contained MG-derived modifications, with those from older subjects containing higher levels of modified proteins than those from younger ones, An immunoaffinity-purified antibody showed higher reactivity with old corneas than with younger ones and localized the antigens primarily within the stromal region of the cornea, These results confirm reported MG-derived modifications in tissue proteins and show that dicarbonyl mediated protein modification occurs during Maillard reactions in vivo.	Case Western Reserve Univ, Dept Ophthalmol, Ctr Vis Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Tech Univ Berlin, Inst Food Chem, D-13355 Berlin, Germany	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Technical University of Berlin	Nagaraj, RH (corresponding author), Case Western Reserve Univ, Dept Ophthalmol, Ctr Vis Res, Wearn Bldg,Rm 637, Cleveland, OH 44106 USA.	nhr@po.cwru.edu			NATIONAL EYE INSTITUTE [R29EY009912, P30EY011373, R01EY009912] Funding Source: NIH RePORTER; NEI NIH HHS [EY 09912, P-30 EY11373] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abordo EA, 1996, IMMUNOL LETT, V53, P7, DOI 10.1016/0165-2478(96)02601-6; Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; ARAKI N, 1992, J BIOL CHEM, V267, P10211; BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; BEISSWENGER PJ, 1997, INVEST OPHTHALMOL  S, V38, P765; BRENNAN M, 1989, J BIOL CHEM, V264, P20947; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HAIK GM, 1994, EXP EYE RES, V59, P497, DOI 10.1006/exer.1994.1135; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1959, DOI 10.1080/00021369.1986.10867691; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; Keyhani A, 1996, J AGR FOOD CHEM, V44, P2511, DOI 10.1021/jf960067z; Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474; KRYMKIEWICZ N, 1973, FEBS LETT, V29, P51, DOI 10.1016/0014-5793(73)80013-4; KUME S, 1995, AM J PATHOL, V147, P654; LO TWC, 1994, J BIOL CHEM, V269, P32299; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MADSON MA, 1981, CARBOHYD RES, V94, P183, DOI 10.1016/S0008-6215(00)80716-8; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MALIK NS, 1992, BIOCHIM BIOPHYS ACTA, V1138, P222, DOI 10.1016/0925-4439(92)90041-K; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; Meng J, 1996, DIABETES, V45, P1037, DOI 10.2337/diabetes.45.8.1037; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MOORE S, 1954, J BIOL CHEM, V211, P907; MOUNIER VM, 1992, DIABETES, V41, P36; Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; Niwa T, 1997, J CLIN INVEST, V99, P1272, DOI 10.1172/JCI119285; OTSUKA M, 1985, AMINOCARBONYL REACTI, P1; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; Perrin DD, 1988, PURIFICATION LAB CHE; Ratliff DM, 1996, J CLIN ENDOCR METAB, V81, P488, DOI 10.1210/jc.81.2.488; RICHARD S, 1991, DIABETES, V40, P1049, DOI 10.2337/diabetes.40.8.1049; SADY C, 1995, BIOCHEM BIOPH RES CO, V214, P793, DOI 10.1006/bbrc.1995.2356; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SATO K, 1994, J BIOCHEM-TOKYO, V116, P711, DOI 10.1093/oxfordjournals.jbchem.a124585; Schmidt AM, 1996, DIABETES, V45, pS77, DOI 10.2337/diab.45.3.S77; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485; SHINOHARA M, 1996, DIABETES S, V45, P126; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STOLWIJK TR, 1992, INVEST OPHTH VIS SCI, V33, P92; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; Uchida K, 1997, FEBS LETT, V410, P313, DOI 10.1016/S0014-5793(97)00610-8; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; VLASSARA H, 1994, LAB INVEST, V70, P138; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; Westwood ME, 1996, IMMUNOL LETT, V50, P17, DOI 10.1016/0165-2478(96)02496-0; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; Westwood ME, 1997, BBA-MOL CELL RES, V1356, P84, DOI 10.1016/S0167-4889(96)00154-1; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185	64	95	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6928	6936		10.1074/jbc.273.12.6928	http://dx.doi.org/10.1074/jbc.273.12.6928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506998	hybrid			2022-12-27	WOS:000072775900048
J	Tsuji, T; Duh, FM; Latif, F; Popescu, NC; Zimonjic, DB; McBride, J; Matsuo, K; Ohyama, H; Todd, R; Nagata, E; Terakado, N; Sasaki, A; Matsumura, T; Lerman, MI; Wong, DTW				Tsuji, T; Duh, FM; Latif, F; Popescu, NC; Zimonjic, DB; McBride, J; Matsuo, K; Ohyama, H; Todd, R; Nagata, E; Terakado, N; Sasaki, A; Matsumura, T; Lerman, MI; Wong, DTW			Cloning, mapping, expression, function, and mutation analyses of the human ortholog of the hamster putative tumor suppressor gene doc-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; RETINOIC ACID; LOCALIZATION; EOSINOPHILS; KERATIN-19; RECEPTORS; CANCER; ALPHA	doc-1 is a putative tumor suppressor gene isolated and identified from the hamster oral cancer model, Here, we report the molecular cloning and the functional characterization of the human ortholog of the hamster doc-l gene, Human doc-l cDNA is 1.6 kilobase pairs in length and encodes for a 115-amino acid polypeptide (12.4 kDa, pi 9.53). Sequence analysis showed 98% identity between human and hamster doc-l protein sequences. DOC-1 is expressed in all normal human tissues examined. In oral keratinocytes, expression of DOC-1 is restricted to normal oral keratinocytes, By immunostaining of normal human mucosa, DOC-1 is detected in both the cytoplasm and nuclei of basal oral keratinocytes; while in suprabasilar cells, it is primarily found in the nuclei, Human oral cancers in vivo did not exhibit immunostaining for DOC-1, Like murine DOC-1, human DOC-1 associates with DNA polymerase alpha/primase and mediates the phosphorylation of the large p180 catalytic subunit, suggesting it may be a potential regulator of DNA replication in the S phase of the cell cycle, Using a human doc-l cosmid as a probe, human doc-l is mapped to chromosome 12q24. We identified four exons in the entire human doc-l gene and determined the intron-exon boundaries. By polymerase chain reaction and direct sequencing, we examined premalignant oral lesion and oral cancer cell lines and found no intragenic mutations.	Harvard Univ, Sch Dent Med, Div Oral Pathol, Lab Mol Pathol, Boston, MA 02115 USA; SAIC, Intramural Res Support Program, Frederick, MD USA; NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Div Basic Sci, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Okayama Univ, Sch Dent, Dept Oral & Maxillofacial Surg 2, Okayama 700, Japan	Harvard University; Harvard School of Dental Medicine; Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Okayama University	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Div Oral Pathol, Lab Mol Pathol, 188 Longwood Ave, Boston, MA 02115 USA.		Zimonjic, Drazen/AAX-7513-2020; Todd, Robert/GWM-4486-2022		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467, R29DE011983, R01DE008680] Funding Source: NIH RePORTER; NIDCR NIH HHS [1 R29 DE11983-01, 1 PO1 DE12467, 2 RO1 DE08680-08] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		DAVIS LG, 1986, BASIC METHODS MOL BI, P130; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; GIMENEZCONTI IB, 1993, J CELL BIOCHEM, P83; GORDON HM, 1992, J IMMUNOL, V148, P4021; HATAKEYAMA S, 1997, BIOL PROTEOLYSIS, P48; HU L, 1991, CANCER RES, V51, P3972; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; LERMAN MI, 1991, HUM GENET, V86, P567; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; Schon M, 1996, J INVEST DERMATOL, V107, P428, DOI 10.1111/1523-1747.ep12363411; Shklar G, 1984, ORAL CANCER, P41; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SILVERMAN S, 1988, CANCER, V62, P1796, DOI 10.1002/1097-0142(19881015)62:1+<1796::AID-CNCR2820621319>3.0.CO;2-E; SLAGA TJ, 1992, NATL CANCER I MONOGR, V13, P55; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; VandeVen W, 1996, CYTOGENET CELL GENET, V73, P25; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; WONG DTW, 1991, BLOOD, V78, P2702; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; Zani VJ, 1996, BLOOD, V87, P3124, DOI 10.1182/blood.V87.8.3124.bloodjournal8783124; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	26	55	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6704	6709		10.1074/jbc.273.12.6704	http://dx.doi.org/10.1074/jbc.273.12.6704			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506968	hybrid			2022-12-27	WOS:000072775900018
J	Wong, JT; Tran, K; Pierce, GN; Chan, AC; O, K; Choy, PC				Wong, JT; Tran, K; Pierce, GN; Chan, AC; O, K; Choy, PC			Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LOW-DENSITY-LIPOPROTEIN; CYTOSOLIC PHOSPHOLIPASE A(2); NITRIC-OXIDE SYNTHASE; TIGHT-BINDING INHIBITORS; ALPHA-1-ACID GLYCOPROTEIN; DEPENDENT ACTIVATION; CALCIUM TRANSIENTS; ADENYLYL-CYCLASE; HUMAN-MONOCYTES	Lysophosphatidylcholine (lyse-PC) is a product of phosphatidylcholine hydrolysis by phospholipase A(2) (PLA(2)) and is present in cell membranes, oxidized lipoproteins, and atherosclerotic tissues. It has the ability to alter endothelial functions and is regarded as a causal agent in atherogenesis. In this study, the modulation of arachidonate release by lyse-PC in human umbilical vein endothelial cells was examined. Incubation of endothelial cells with lyse-PC resulted in an enhanced release of arachidonate in a time-and concentration dependent manner. Maximum arachidonate release was observed at 10 min of incubation with 50 mu M lyse-PC. Lyse-PC species containing palmitoyl (C-16:0) or stearoyl (C-18:0) groups elicited the enhancement of arachidonate release, while other lysolipids such as lysophosphatidylethanolamine, lysophosphatidylserine, lysophosphatidylinositol, or lysophosphatidate were relatively ineffective. Lyse-PC-induced arachidonate release was decreased by treatment of cells with PLA(2) inhibitors such as para-bromophenacyl bromide and arachidonoyl trifluoromethyl ketone. Furthermore, arachidonate release was attenuated in cells grown in the presence of antisense oligodeoxynucleotides that specifically bind cytosolic PLA(2) mRNA. Treatment of cells with lyse-PC resulted in a translocation of PLA(2) activity from the cytosolic to the membrane fractions of cells. Lyse-PC induced a rapid influx of Ca2+ from the medium into the cells, with a simultaneous enhancement of protein kinase C (PKC) activity in the membrane fractions. The lyse-PC-induced arachidonate release was attenuated when cells were preincubated with specific inhibitors of PKC (staurosporine and Ro31-8220) or a specific inhibitor of mitogen-activated protein kinase/extracellular regulated kinase kinase (PD098059). Taken together, the results of this study show that lyse-PC caused the elevation of cellular Ca2+ and the activation of PKC, which stimulated cytosolic PLA(2) in an indirect manner and resulted in an enhanced release of arachidonate.	Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada	University of Manitoba; University of Manitoba; University of Ottawa	Choy, PC (corresponding author), Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, 770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.			O, Karmin/0000-0002-2163-9458; Pierce, Grant/0000-0001-7674-0142				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BENT ED, 1995, BBA-LIPID LIPID MET, V1254, P349, DOI 10.1016/0005-2760(94)00201-9; CHAN AC, 1990, LIPIDS, V25, P17, DOI 10.1007/BF02562422; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHEN L, 1997, J LIPID RES, V38, P192; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CHRISTIANSEN K, 1983, BIOCHIM BIOPHYS ACTA, V735, P225, DOI 10.1016/0005-2736(83)90297-3; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DAGHER SM, 1975, EUR J BIOCHEM, V55, P185, DOI 10.1111/j.1432-1033.1975.tb02150.x; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DUDEK R, 1995, PHARMACOLOGY, V50, P257, DOI 10.1159/000139290; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ehringer WD, 1996, J CELL PHYSIOL, V167, P562, DOI 10.1002/(SICI)1097-4652(199606)167:3<562::AID-JCP20>3.3.CO;2-K; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; FINK KL, 1984, CIRC RES, V55, P585, DOI 10.1161/01.RES.55.5.585; HIRATA K, 1995, CIRC RES, V76, P958, DOI 10.1161/01.RES.76.6.958; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; KINNAIRD AAA, 1988, LIPIDS, V23, P32, DOI 10.1007/BF02535301; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P1123, DOI 10.1093/oxfordjournals.jbchem.a131168; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU K, 1993, J BIOL CHEM, V268, P4145; LIU SY, 1994, CARDIOVASC RES, V28, P1476, DOI 10.1093/cvr/28.10.1476; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; MENDZ GL, 1990, BIOCHEMISTRY-US, V29, P2304, DOI 10.1021/bi00461a014; MILLER MR, 1979, EXP CELL RES, V120, P421, DOI 10.1016/0014-4827(79)90404-X; MONCADA S, 1978, PHARMACOL REV, V30, P293; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MUROHARA T, 1994, AM J PHYSIOL-HEART C, V267, pH2441, DOI 10.1152/ajpheart.1994.267.6.H2441; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NITISEWOJO P, 1976, EUR J BIOCHEM, V67, P87, DOI 10.1111/j.1432-1033.1976.tb10636.x; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; OCHI H, 1995, CIRC RES, V77, P530, DOI 10.1161/01.RES.77.3.530; OISHI K, 1988, J BIOL CHEM, V263, P6865; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; PHILLIPS GB, 1957, P NATL ACAD SCI USA, V43, P566, DOI 10.1073/pnas.43.7.566; PORTMAN OW, 1969, J LIPID RES, V10, P158; QIU ZH, 1994, J BIOL CHEM, V269, P19480; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RABINI RA, 1994, DIABETES, V43, P915, DOI 10.2337/diabetes.43.7.915; RESNICK RJ, 1994, J BIOL CHEM, V269, P32336; RODRIGUEZ F, 1987, J MED, V18, P153; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUABNYI GM, 1993, J CARDIOVASC PHAR S4, V22, pS1; SAITO T, 1988, P NATL ACAD SCI USA, V85, P8246, DOI 10.1073/pnas.85.21.8246; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SASAKI Y, 1993, FEBS LETT, V320, P47, DOI 10.1016/0014-5793(93)81655-J; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SU Z, 1995, CARDIOSCIENCE, V6, P31; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tran K, 1996, BIOCHEM J, V319, P385, DOI 10.1042/bj3190385; VADAS P, 1986, LAB INVEST, V55, P391; VEERING BT, 1990, BRIT J CLIN PHARMACO, V29, P201, DOI 10.1111/j.1365-2125.1990.tb03620.x; VIANI A, 1992, INT J CLIN PHARM TH, V30, P128; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; YANG HL, 1994, THROMB HAEMOSTASIS, V71, P325; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006; Zhu Y, 1997, BBA-LIPID LIPID MET, V1345, P93, DOI 10.1016/S0005-2760(96)00169-5	82	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6830	6836		10.1074/jbc.273.12.6830	http://dx.doi.org/10.1074/jbc.273.12.6830			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506985	hybrid			2022-12-27	WOS:000072775900035
J	Han, ZQ; Wax, MB; Patil, RV				Han, ZQ; Wax, MB; Patil, RV			Regulation of aquaporin-4 water channels by phorbol ester-dependent protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; XENOPUS-OOCYTES; PERMEABILITY; EXPRESSION; MEMBRANE; GLYCEROL; TISSUES; CDNA; FAMILY; KINASE	The molecular mechanisms for regulating water balance in many tissues are unknown, Like the kidney, the eye contains multiple water channel proteins (aquaporins) that transport water through membranes, including two (AQP1 and AQP4) in the ciliary body, the site of aqueous humor production. However, because humans with defective AQP1 are phenotypically normal and because the ocular application of phorbol esters reduce intraocular pressure, we postulated that the water channel activity of AQP4 may be regulated by these agents. We now report that protein kinase C activators, phorbol 12,13-dibutyrate, and phorbol 14-myristate 13-acetate strongly stimulate the phosphorylation of AQP4 and inhibit its activity in a dose-dependent manner. Phorbol 12,13-dibutyrate (10 mu M) and phorbol 12-myristate 13-acetate (10 nM) reduced the rate of AQP4-expressing oocyte swelling by 87 and 92%, respectively. Further, phorbol 12,13-dibutyrate significantly increased the amount of phosphorylated AQP4. These results demonstrate that protein kinase C can regulate the activity of AQP4 through a mechanism involving protein phosphorylation. Moreover, they suggest important potential roles for AQP4 in several clinical disorders involving rapid water transport such as glaucoma, brain edema, and swelling of premature infant lungs.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Patil, RV (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid, St Louis, MO 63110 USA.	patil@am.seer.wustl.edu			NATIONAL EYE INSTITUTE [P30EY002687, R55EY010423, R29EY010423] Funding Source: NIH RePORTER; NEI NIH HHS [EY06810, EY02687, EY10423] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abrami L, 1996, PFLUG ARCH EUR J PHY, V431, P408, DOI 10.1007/BF02207279; Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BROWN D, 1995, HISTOCHEM CELL BIOL, V104, P1, DOI 10.1007/BF01464780; CALAMITA G, 1995, J BIOL CHEM, V270, P29063, DOI 10.1074/jbc.270.49.29063; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; Koyama Y, 1997, J BIOL CHEM, V272, P30329, DOI 10.1074/jbc.272.48.30329; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Lee MD, 1997, MEDICINE, V76, P141, DOI 10.1097/00005792-199705000-00001; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; Ma TH, 1997, GENOMICS, V43, P387, DOI 10.1006/geno.1997.4836; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; MITTAG TW, 1987, INVEST OPHTH VIS SCI, V28, P2057; Moriarty T M, 1988, Brain Res, V464, P201; Patil RV, 1997, BIOCHEM BIOPH RES CO, V238, P392, DOI 10.1006/bbrc.1997.7310; Patil RV, 1997, SCIENCE, V275, P1492; PATIL RV, 1994, BIOCHEM BIOPH RES CO, V204, P861, DOI 10.1006/bbrc.1994.2539; Patil RV, 1997, EXP EYE RES, V64, P203, DOI 10.1006/exer.1996.0196; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Umenishi F, 1996, AM J RESP CELL MOL, V15, P673, DOI 10.1165/ajrcmb.15.5.8918374; VANLIEBURG AF, 1995, PEDIATR NEPHROL, V9, P228, DOI 10.1007/BF00860757; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216	38	119	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6001	6004		10.1074/jbc.273.11.6001	http://dx.doi.org/10.1074/jbc.273.11.6001			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497312	hybrid			2022-12-27	WOS:000072488500004
J	Pfaff, M; Liu, SC; Erle, DJ; Ginsberg, MH				Pfaff, M; Liu, SC; Erle, DJ; Ginsberg, MH			Integrin beta cytoplasmic domains differentially cytoskeletal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL COILED-COILS; FIBRONECTIN RECEPTOR; SYNTHETIC MODEL; CELL-ADHESION; SUBUNIT; ALPHA; LOCALIZATION; EXPRESSION; BINDING; TALIN	Integrin cytoplasmic domains connect these receptors to the cytoskeleton, Furthermore, integrin-cytoskeletal interactions involve ligand binding (occupancy) to the integrin extracellular domain and clustering of the integrin, To construct mimics of the cytoplasmic face of an occupied and clustered integrin, we fused the cytoplasmic domains of integrin beta subunits to an N terminal sequence containing four heptad repeat sequences. The heptad repeats form coiled coil dimers in which the cytoplasmic domains are parallel dimerized and held in an appropriate vertical stagger. In these mimics we found 1) that both conformation and protein binding properties are altered by insertion of Gly spacers C-terminal to the heptad repeat sequences; 2) that the cytoskeletal proteins talin and filamin are among the polypeptides that bind to the integrin beta 1A tail, Filamin, but not talin binding, is enhanced by the insertion of Gly spacers; 3) binding of both cytoskeletal proteins to beta 1A is direct and specific, since it occurs with purified talin and filamin and is inhibited in a point mutant (beta 1A(Y788A)) or in splice variants (beta 1B, beta 1C) known to disrupt cytoskeletal associations of beta 1 integrins; 4) that the muscle-specific splice variant, beta 1D, binds talin more tightly than beta 1A and is therefore predicted to form more stable cytoskeletal associations; and 5) that the beta 7 cyto plasmic domain binds filamin better than beta 1A, The structural specificity of these associations suggests that these mimics offer a useful approach for the analysis of the interactions and structure of the integrin cytoplasmic face.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Francisco	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA.	ginsberg@scripps.edu		Erle, David/0000-0002-2171-0648				ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BELKIN AM, 1986, FEBS LETT, V200, P32, DOI 10.1016/0014-5793(86)80505-1; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hemler M.E, 1994, INTEGRINS BIOL PROBL, P1; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SALOMON D, 1992, J CELL SCI, V102, P7; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TAPLEY P, 1989, ONCOGENE, V4, P325; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; VANDERFLIER A, 1995, FEBS LETT, V369, P340, DOI 10.1016/0014-5793(95)00814-P; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZHIDKOVA NI, 1995, BIOCHEM BIOPH RES CO, V214, P279, DOI 10.1006/bbrc.1995.2285; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	44	240	244	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6104	6109		10.1074/jbc.273.11.6104	http://dx.doi.org/10.1074/jbc.273.11.6104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497328	hybrid			2022-12-27	WOS:000072488500020
J	Shen, Y; Schneider, G; Cloutier, JF; Veillette, A; Schaller, MD				Shen, Y; Schneider, G; Cloutier, JF; Veillette, A; Schaller, MD			Direct association of protein-tyrosine phosphatase PTP-PEST with paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; SIGNAL-TRANSDUCTION PATHWAYS; V-SRC; EXTRACELLULAR-MATRIX; BINDING PROTEIN; PHOSPHORYLATION; P130(CAS); PP125(FAK); DOMAIN	Tyrosine phosphorylation of focal adhesion-associated proteins may be involved in the regulation of the cytoskeleton and in the control of signals for growth and survival, The focal adhesion kinase (FAK) functions in regulating tyrosine phosphorylation of several of these proteins, including paxillin, tensin, and p130(cas). Proetin-tyrosine phosphatases, the counterparts of protein-tyrosine kinases, also presumably regulate phosphorylation of these proteins, We have tested the hypothesis that FAK intimately associates with a protein-tyrosine phosphatase, Protein-tyrosine phosphatase activity associated with the recombinant C-terminal domain of FAK in vitro and could be coimmunoprecipitated with both FAK and paxillin from lysates of chicken embryo cells, However, the interaction with FAK appeared to be indirect and mediated via paxillin, The protein-tyrosine phosphatase was subsequently identified as protein tyrosine phosphatase-PEST, a nonreceptor protein-tyrosine phosphatase. The C-terminal noncatalytic domain of protein-tyrosine phosphatase-PEST directly bound to paxillin in vitro, The association of both a protein-tyrosine kinase and a protein-tyrosine phosphatase with paxillin suggests that paxillin may play a critical role in the regulation of the phosphotyrosine content of proteins in focal adhesions.	Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Dent, Dept Prosthodont, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; McGill University	Schaller, MD (corresponding author), Univ N Carolina, Sch Med, Dept Cell Biol & Anat, 534 Taylor Hall,CB 7090, Chapel Hill, NC 27599 USA.	crispy4@med.unc.edu	Cloutier, Jean-François/K-2003-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053666] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53666] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; CHUN JS, 1993, MOL BIOL CELL, V4, P271; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Cornelis G R, 1994, Curr Top Microbiol Immunol, V192, P243; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HABIB T, 1994, J BIOL CHEM, V269, P25243; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PATCH LA, 1995, J CELL SCI, V108, P1371; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; VUORI K, 1993, J BIOL CHEM, V268, P21459; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENG ZG, 1993, J BIOL CHEM, V268, P14956; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YANG Q, 1993, J BIOL CHEM, V268, P6622	65	144	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6474	6481		10.1074/jbc.273.11.6474	http://dx.doi.org/10.1074/jbc.273.11.6474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497381	Green Published, hybrid			2022-12-27	WOS:000072488500073
J	Zerbe-Burkhardt, K; Ratnatilleke, A; Philippon, N; Birch, A; Leiser, A; Vrijbloed, JW; Hess, D; Hunziker, P; Robinson, JA				Zerbe-Burkhardt, K; Ratnatilleke, A; Philippon, N; Birch, A; Leiser, A; Vrijbloed, JW; Hess, D; Hunziker, P; Robinson, JA			Cloning, sequencing, expression, and insertional inactivation of the gene for the large subunit of the coenzyme B-12-dependent isobutyryl-CoA mutase from Streptomyces cinnamonensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALINE DEHYDROGENASE; A MUTASE; B-12; IDENTIFICATION; REARRANGEMENT; PURIFICATION; POLYMERASE; HISTIDINE; SYNTHASE; PROTEINS	Purification of the coenzyme B-12-dependent isobutaryl-CoA mutase (ICM) from Streptomyces cinnamonensis gave a protein of similar to 65 kDa by SDS-polyacrylamide gel electrophoresis, whose gene icmA was cloned using se quences derived from tryptic peptide fragments, The gene encodes a protein of 566 residues (62,487 Da), with 43-44% sequence identity to the large subunit of methylmalonyl-CoA mutase (MCM) from S. cinnamonensis and Propionibacterium shermanii. Targeted disruption of the icmA gene yielded an S. cinnamonensis mutant devoid of ICM activity, The IcmA protein is similar to 160 residues shorter than the large subunit of the bacterial MCMs, corresponding to a loss of the entire C terminal coenzyme B-12 binding domain. The sequence of the (beta/ alpha)(8)-barrel comprising residues A1-A400 in P. shermanii MCM is highly conserved in IcmA. The protein was produced in Streptomyces lividans and Escherichia coli with an N-terminal His(6) tag (His(6)-IcmA), but after purification His(6)-IcmA showed no ICM activity. In the presence of coenzyme B-12, protein from S. lividans and S. cinnamonensis of similar to 17 kDa by SDS-polyacrylamide gel electrophoresis could be selectively eluted with His(6)-IcmA from a Ni2+ affinity column, After purification, this small subunit showed no ICM activity but gave active enzyme when recombined with coenzyme B-12 and IcmA or His(6)-IcmA.	Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Robinson, JA (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	robinson@oci.unizh.ch						AGARWAL RK, 1993, NUCLEIC ACIDS RES, V21, P5283, DOI 10.1093/nar/21.22.5283; ALLEN RH, 1972, J BIOL CHEM, V247, P7695; ARROWSMITH TJ, 1992, MOL GEN GENET, V234, P254, DOI 10.1007/BF00283846; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BIRCH A, 1993, J BACTERIOL, V175, P3511, DOI 10.1128/jb.175.11.3511-3519.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; Hopwood D.A., 1985, GENETIC MANIPULATION; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; LEDLEY FD, 1988, P NATL ACAD SCI USA, V85, P3518, DOI 10.1073/pnas.85.10.3518; Leiser A, 1996, GENE, V177, P217, DOI 10.1016/0378-1119(96)00305-8; Ludwig ML, 1996, STRUCTURE, V4, P505, DOI 10.1016/S0969-2126(96)00056-1; LYDIATE DJ, 1989, J GEN MICROBIOL, V135, P941; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARSH EN, 1989, BIOCHEM J, V260, P345, DOI 10.1042/bj2600345; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MOORE BS, 1995, J AM CHEM SOC, V117, P11285, DOI 10.1021/ja00150a028; MUTH G, 1989, MOL GEN GENET, V219, P341, DOI 10.1007/BF00259605; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; PADMAKUMAR R, 1995, J AM CHEM SOC, V117, P7033, DOI 10.1021/ja00131a039; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PRIESTLEY ND, 1989, BIOCHEM J, V261, P853, DOI 10.1042/bj2610853; RETEY J, 1982, STEREOSPECIFICITY OR, V13, P185; Retey J., 1982, B12, VII, P357; REYNOLDS KA, 1988, J CHEM SOC PERK T 1, P3195, DOI 10.1039/p19880003195; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARK WM, 1968, ANTIMICROB AGENTS CH, V1967, P353; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUPPERICH E, 1990, EUR J BIOCHEM, V193, P105, DOI 10.1111/j.1432-1033.1990.tb19310.x; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; WILKEMEYER MF, 1990, BIOCHEM J, V271, P449, DOI 10.1042/bj2710449; YAMADA R, 1972, J BIOL CHEM, V247, P6266; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	27	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6508	6517		10.1074/jbc.273.11.6508	http://dx.doi.org/10.1074/jbc.273.11.6508			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497386	hybrid			2022-12-27	WOS:000072488500078
J	Zhon, LW; Arner, ESJ; Ljung, J; Aslund, F; Holmgren, A				Zhon, LW; Arner, ESJ; Ljung, J; Aslund, F; Holmgren, A			Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; RIBONUCLEOTIDE REDUCTASE; PLASMODIUM-FALCIPARUM; PURIFICATION; GENE; SELENOPROTEIN; INHIBITION; MECHANISM; DISULFIDE; SEQUENCES	We have determined the sequence of 23 peptides from bovine thioredoxin reductase covering 364 amino acid residues, The result was used to identify a rat cDNA clone (2.19 kilobase pairs), which contained an open reading frame of 1496 base pairs encoding a protein with 498 residues, The bovine and rat thioredoxin reductase sequences revealed a close homology to glutathione reductase including the conserved active site sequence (Cys-Val-Asn-Val-Gly-Cys). This also confirmed the identity of a previously published putative human thioredoxin reductase cDNA clone, Moreover, one peptide of the bovine enzyme contained a selenocysteine residue in the motif Gly-Cys-SeCys-Gly (where SeCys represents selenocysteine), This motif was conserved at the carboxyl terminus of the rat and human enzymes, provided that TGA in the sequence GGC TGC TGA GGT TAA, being identical in both cDNA clones, is translated as selenocysteine and that TAA confers termination of translation, The 3'-untranslated region of both cDNA clones contained a selenocysteine insertion sequence that may form potential stem loop structures typical of eukaryotic selenocysteine insertion sequence elements required for the decoding of UGA as selenocysteine. Carboxypeptidase Y treatment of bovine thioredoxin reductase after reduction by NADPH released selenocysteine from the enzyme with a concomitant loss of enzyme activity measured as reduction of thioredoxin or 5,5'-dithiobis(2-nitrobenzoic acid). This showed that the carboxyl-terminal motif was essential for the catalytic activity of the enzyme.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.		Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114				ABRAMOWITZ N, 1967, BIOCHEM BIOPH RES CO, V29, P862, DOI 10.1016/0006-291X(67)90299-9; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BECKER K, 1997, FLAVINS FLAVOPROTEIN; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BJORKMAN L, 1993, J TRACE ELEM ELECT H, V7, P157; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; Dai SD, 1996, J MOL BIOL, V264, P1044, DOI 10.1006/jmbi.1996.0695; Farber PM, 1996, EUR J BIOCHEM, V239, P655, DOI 10.1111/j.1432-1033.1996.0655u.x; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1997, OXIDATIVE STRESS CAN, P229; Koishi R, 1997, J BIOL CHEM, V272, P2570; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; Liu SY, 1997, P NATL ACAD SCI USA, V94, P6138, DOI 10.1073/pnas.94.12.6138; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1613, DOI 10.1016/0006-2952(92)90220-D; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1621; MILLER SM, 1989, BIOCHEMISTRY-US, V28, P1194, DOI 10.1021/bi00429a037; MirandaVizuete A, 1997, BIOCHEM J, V325, P287, DOI 10.1042/bj3250287; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; SCHALLREUTER KU, 1990, BIOCHIM BIOPHYS ACTA, V1054, P14, DOI 10.1016/0167-4889(90)90199-N; SCHALLREUTER KU, 1989, BIOCHEM BIOPH RES CO, V160, P573, DOI 10.1016/0006-291X(89)92471-6; SHEN QC, 1993, J BIOL CHEM, V268, P11463; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Walczak R, 1996, RNA, V2, P367; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YODOI J, 1991, ADV CANCER RES, V57, P381	50	223	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8581	8591		10.1074/jbc.273.15.8581	http://dx.doi.org/10.1074/jbc.273.15.8581			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535831	hybrid			2022-12-27	WOS:000072990800008
J	Burcelin, R; Mrejen, C; Decaux, JF; De Mouzon, SH; Girard, J; Charron, MJ				Burcelin, R; Mrejen, C; Decaux, JF; De Mouzon, SH; Girard, J; Charron, MJ			In vivo and in vitro regulation of hepatic glucagon receptor mRNA concentration by glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE CYCLASE SYSTEM; ISOLATED RAT HEPATOCYTES; DIABETIC RATS; GENE-EXPRESSION; MESSENGER-RNA; FUNCTIONAL EXPRESSION; GLUCOKINASE ACTIVITY; SIGNAL-TRANSDUCTION; LIVER GLUCOKINASE; PRIMARY CULTURE	We have recently cloned the murine glucagon receptor (GR) gene and shown that it is expressed mainly in liver, In this organ, the glucagon-GR system is involved in the control of glucose metabolism as it initiates a cascade of events leading to release of glucose into the blood stream, which is a main feature in several physiological and pathological conditions, To better define the metabolic regulators of Gn expression in liver we analyzed GR mRNA concentration in physiological conditions associating various glucose metabolic pathways in vivo and in vitro in the rat and in the mouse, First, we report that the concentration of the GR mRNA progressively increased from the first day of life to the adult stage. This effect was abolished when newborn rodents were fasted, Second, under conditions where intrahepatic glucose metabolism was active such as during fasting, diabetes, and hyperglycemic clamp, the concentration of GR mRNA increased independent of the origin of the pathway that generated the glucose flux. These effects were blunted when hyperglycemia was corrected by phlorizin treatment of diabetic rats or not sustained during euglycemic clamp, In accordance with these observations, we demonstrated that the glycolytic substrates glucose, mannose, and fructose, as well as the gluconeognic substrates glycerol and dihydroxyacetone, increased the concentration of GR mRNA in primary cultures of hepatocytes from fed rats, Glucagon blunted the effect of glucose without being dominant, The stimulatory effect of those substrates was not mimicked by the nonmetabolizable carbohydrate L-glucose or the glucokinase inhibitor glucosamine or when hepatocytes were isolated from starved rats, In addition, inhibitors of gluconeogenesis and lipolysis could decrease the concentration of GR mRNA from hepatocytes of starved rats, Combined, these data strongly suggest that glucose flux in the glycolytic and gluconeogenic pathways at the level of triose intermediates could control expression of GR mRNA and participate in controlling its own metabolism.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; CNRS, Ctr Rech Endocrinol Mol & Dev, F-92190 Meudon, France	Yeshiva University; Albert Einstein College of Medicine; Centre National de la Recherche Scientifique (CNRS)	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		burcelin, remy/M-6013-2014	DECAUX, Jean-Francois/0000-0003-0014-4197	NIDDK NIH HHS [DK47425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN N, 1995, J BIOL CHEM, V270, P15853, DOI 10.1074/jbc.270.26.15853; ADKINSMARSHALL BA, 1990, DIABETES, V39, P87, DOI 10.2337/diabetes.39.1.87; AGIUS L, 1993, BIOCHEM J, V289, P255, DOI 10.1042/bj2890255; BIRNBAUMER L, 1972, J BIOL CHEM, V247, P2038; Boden G, 1996, OBSTET GYN CLIN N AM, V23, P1, DOI 10.1016/S0889-8545(05)70241-2; BOILEAU P, 1995, J CLIN INVEST, V96, P309, DOI 10.1172/JCI118036; BRICHARD SM, 1993, DIABETOLOGIA, V36, P292, DOI 10.1007/BF00400230; BURCELIN R, 1995, GENE, V164, P305, DOI 10.1016/0378-1119(95)00472-I; Burcelin R, 1996, DIABETES METAB, V22, P373; BURCELIN R, 1992, BIOCHEM J, V288, P675, DOI 10.1042/bj2880675; BURCELIN R, 1993, AM J PHYSIOL, V265, pE392, DOI 10.1152/ajpendo.1993.265.3.E392; CHAN YL, 1984, J BIOL CHEM, V259, P224; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; CHERRINGTON AD, 1991, JPEN-PARENTER ENTER, V15, pS71, DOI 10.1177/014860719101500371S; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1986, BIOL NEONATE, V50, P331, DOI 10.1159/000242617; Ferraz M, 1997, RES COMMUN MOL PATH, V95, P147; GEHNRICH SC, 1988, J BIOL CHEM, V263, P11755; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GIRARD J, 1990, BIOL NEONATE, V1, P3; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; HEATH DF, 1977, BIOCHEM J, V162, P653, DOI 10.1042/bj1620653; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KOFOD H, 1988, INT J PEPT PROT RES, V32, P436; Lane RH, 1996, PEDIATR RES, V39, P390, DOI 10.1203/00006450-199603000-00003; LEPINE AJ, 1993, BRIT J NUTR, V70, P81, DOI 10.1079/BJN19930106; LIN MC, 1975, J BIOL CHEM, V250, P4246; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MYERS SR, 1991, METABOLISM, V40, P66, DOI 10.1016/0026-0495(91)90194-2; PILKIS SJ, 1976, J BIOL CHEM, V251, P7841; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; RAMOS P, 1995, AM J PHYSIOL-ENDOC M, V269, pE858, DOI 10.1152/ajpendo.1995.269.5.E858; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; RENDELL M, 1975, J BIOL CHEM, V250, P4253; RODBELL M, 1978, NATL CANC I MONOGR, V48, P271; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SALOMON Y, 1975, J BIOL CHEM, V250, P4239; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SHAMBAUGH GE, 1985, FED PROC, V44, P2347; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SOCHOR M, 1988, BIOCHEM INT, V16, P15; TANIGAWA K, 1989, ENDOCRINOL JAPON, V36, P195; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Unger R H, 1982, Compr Ther, V8, P53; UNGER RH, 1985, DIABETOLOGIA, V28, P574, DOI 10.1007/BF00281991; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1991, FASEB J, V5, P326, DOI 10.1096/fasebj.5.3.2001793; VOLZ A, 1995, FEBS LETT, V373, P23, DOI 10.1016/0014-5793(95)01006-Z; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; YOUNUS MJ, 1994, BBA-BIOMEMBRANES, V1190, P444, DOI 10.1016/0005-2736(94)90106-6	61	31	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8088	8093		10.1074/jbc.273.14.8088	http://dx.doi.org/10.1074/jbc.273.14.8088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525910	hybrid			2022-12-27	WOS:000072876300044
J	Edberg, JC; Moon, JJ; Chang, DJ; Kimberly, RP				Edberg, JC; Moon, JJ; Chang, DJ; Kimberly, RP			Differential regulation of human neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16)-induced Ca2+ transients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; IMMUNE-COMPLEX ACTIVATION; MONOCYTIC THP-1 CELLS; TYROSINE PHOSPHORYLATION; RESPIRATORY BURST; IMMUNOGLOBULIN-G; INOSITOL 1,4,5-TRISPHOSPHATE; PHOSPHOLIPASE-C; CROSS-LINKING; A2 RECEPTORS	Human neutrophils express two structurally distinct receptors for the Fc region of IgG, Fc gamma IIa and Fc gamma RIIIb, Although earlier studies have suggested that the functional properties of these receptors are similar, mounting evidence suggests that these receptors are capable of inducing distinct functional responses, Accordingly, we have examined the regulation of intracellular Ca2+ transients induced by each of these receptors alone (homotypic receptor cross-linking) and together (heterotypic receptor cross-linking), The glycosylphosphatidylinositol-anchored Fc gamma RIIIb induces a rise in [Ca2+] after homotypic cross-linking that is independent of ligand-mediated engagement of the transmembrane Fc gamma RIIa, Both receptors were sensitive to the protein-tyrosine kinase inhibitor methyl 2,5-dihydroxycinnamate, but Fc gamma RIIa-induced signaling was uniquely sensitive to the protein-tyrosine kinase inhibitor genistein, Fc gamma RIIa but not Fc gamma RIIIb engages a cAMP-sensitive and inositol 1,4,5-trisphosphate-dependent pathway(s) that results in the Ca2+-transient, When these receptors are cross-linked into heterotypic clusters, a synergistic rise in [Ca2+] is observed that is accompanied by synergistic increases in the phospholipase C gamma-breakdown products inositol 1,4,5-trisphosphate and diglyceride. These data provide a mechanism for the functional differences between these two receptors and suggest the possibility that they can be differentially modulated.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Edberg, JC (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 1900 Univ Blvd, Birmingham, AL 35294 USA.			Kimberly, Robert/0000-0002-5330-3086	NIAMS NIH HHS [R01-AR33062, P60-AR38320, R01-AR42476] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042476, R01AR033062] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Choi OH, 1996, NATURE, V380, P634; CRONSTEIN BN, 1988, BIOCHEM J, V252, P709, DOI 10.1042/bj2520709; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DELLABIANCA V, 1993, BIOCHEM BIOPH RES CO, V196, P1233, DOI 10.1006/bbrc.1993.2384; EDBERG JC, 1989, J IMMUNOL, V143, P1642; Edberg JC, 1997, EXP CLIN IMMUNOGENET, V14, P183; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; EDBERG JC, 1994, J IMMUNOL, V152, P5826; EDBERG JC, 1992, J IMMUNOL METHODS, V148, P179, DOI 10.1016/0022-1759(92)90171-O; FALLMAN M, 1989, J CLIN INVEST, V84, P886, DOI 10.1172/JCI114249; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; GERWINS P, 1993, ANAL BIOCHEM, V210, P45, DOI 10.1006/abio.1993.1148; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; Guse AH, 1997, ADV EXP MED BIOL, V419, P431; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; Indik Z K, 1995, Semin Immunol, V7, P45, DOI 10.1016/1044-5323(95)90007-1; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KITSIS EA, 1991, J RHEUMATOL, V18, P1461; KOBAYASHI K, 1995, J BIOCHEM, V117, P1156, DOI 10.1093/oxfordjournals.jbchem.a124838; Kocher M, 1997, J IMMUNOL, V159, P3940; Law CL, 1996, MOL CELL BIOL, V16, P1305; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; LIANG L, 1995, BIOCHEM J, V306, P489, DOI 10.1042/bj3060489; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MACINTYRE EA, 1988, J IMMUNOL, V141, P4333; Maxfield FR, 1997, ADV EXP MED BIOL, V419, P355; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PARREN PWHI, 1992, J CLIN INVEST, V90, P1537, DOI 10.1172/JCI116022; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Rapuano BE, 1997, PROSTAGLANDINS, V53, P163, DOI 10.1016/S0090-6980(97)00011-7; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; ROSALES C, 1992, J BIOL CHEM, V267, P5265; SALMON JE, 1995, J CLIN INVEST, V95, P2877, DOI 10.1172/JCI117994; SALMON JE, 1991, J IMMUNOL, V146, P997; SALMON JE, 1992, J CLIN INVEST, V89, P1274, DOI 10.1172/JCI115712; SALMON JE, 1990, J IMMUNOL, V145, P2235; SHEN ZH, 1994, J IMMUNOL, V152, P3017; Todd RF, 1997, J LAB CLIN MED, V129, P492, DOI 10.1016/S0022-2143(97)90003-2; TRONCHERE H, 1995, J BIOL CHEM, V270, P13138, DOI 10.1074/jbc.270.22.13138; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; Vu CQ, 1997, ADV EXP MED BIOL, V419, P381; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Wainstein E., 1996, Arthritis and Rheumatism, V39, pS210; Watson F, 1997, J BIOL CHEM, V272, P17944, DOI 10.1074/jbc.272.29.17944; XUE W, 1994, J IMMUNOL, V152, P4630; ZALAVARY S, 1994, BBA-MOL CELL RES, V1222, P249, DOI 10.1016/0167-4889(94)90176-7; Zhang W, 1996, J IMMUNOL, V156, P2599; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZHOU MJ, 1993, J IMMUNOL, V150, P3030	62	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8071	8079		10.1074/jbc.273.14.8071	http://dx.doi.org/10.1074/jbc.273.14.8071			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525908	hybrid			2022-12-27	WOS:000072876300042
J	Matzaris, M; O'Malley, CJ; Badger, A; Speed, CJ; Bird, PI; Mitchell, CA				Matzaris, M; O'Malley, CJ; Badger, A; Speed, CJ; Bird, PI; Mitchell, CA			Distinct membrane and cytosolic forms of inositol polyphosphate 5-phosphatase II - Efficient membrane localization requires two discrete domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE 5-PHOSPHATASE; HUMAN-PLATELETS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; POLYPHOSPHATE-5-PHOSPHATASE; EXPRESSION; IDENTIFICATION; CLONING; TRISPHOSPHATE; SUBSTRATE; BINDING	The 75-kDa inositol polyphosphate 5-phosphatase (5-phosphatase II) hydrolyzes various signaling molecules including the following: inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, phosphatidylinositol 4,5-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate. Although studied extensively, a demonstratably full-length cDNA encoding 5-phosphatase II has yet to be isolated. In this study we used a human partial 2.3-kilobase pair (kb) cDNA to screen mouse brain and kidney cDNA libraries, resulting in the isolation of a 3.7-kb cDNA (M5), which by multiple criteria represents a full-length cDNA encoding a 115-kDa 5-phosphatase II. We also isolated a smaller cDNA (M22) with a unique N terminus that encodes a 104-kDa polypeptide. Analysis of these cDNAs suggests a further 87-kDa isoform may arise from differential splicing resulting in translation at methionine 234 in M5. RNA analysis of tissues demonstrates expression of two mRNA species of approximately 4.0 or 3.0 kb, respectively. Probes unique to the 5' end of M5 or M22 hybridized to the 4.0- or 3.0-kb transcripts, respectively. RNA analysis using probes derived from sequence 3' to the potential splice site in M5 and M22 hybridized to both transcripts. Expression of the recombinant 115-kDa protein, or a smaller protein lacking the N terminus transiently in COS-7 cells, showed localization of enzyme activity to the membrane. Removal of the C-terminal CAAX motif resulted in a significant translocation of the protein lacking the cytosol. Western blot analysis of membrane and cytosolic fractions of multiple mouse tissues confirmed the 115-ka 5-phosphatase II was located in the membrane, whereas the 104- and 87-kDa isoforms were prominent in the cytosol. Collectively these studies demonstrates the widespread expression of at least three isoforms of allows differential distribution of the 5-phosphatase II activity between the membrane and cytosol of the cell and thereby may regulate enzyme access to phsophoinositide-derived signaling molecules.	Monash Univ, Box Hill Hosp, Dept Med, Melbourne, Vic 3128, Australia	Box Hill Hospital; Monash University	Mitchell, CA (corresponding author), Monash Univ, Box Hill Hosp, Dept Med, Nelson Rd, Melbourne, Vic 3128, Australia.	christina.mitchell@med.monash.edu.au		O'Malley, Cindy/0000-0003-1779-5105; Mitchell, Christina A/0000-0001-9372-3192; Bird, Phillip/0000-0002-6695-606X				ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Communi D, 1996, J BIOL CHEM, V271, P11676, DOI 10.1074/jbc.271.20.11676; Communi D, 1996, BIOCHEM J, V320, P181, DOI 10.1042/bj3200181; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lin T, 1997, AM J HUM GENET, V60, P1384, DOI 10.1086/515471; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MADISON EL, 1992, GENE, V121, P179, DOI 10.1016/0378-1119(92)90179-S; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Sambrook J., 2002, MOL CLONING LAB MANU; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; SPEED CJ, 1995, EUR J BIOCHEM, V234, P216, DOI 10.1111/j.1432-1033.1995.216_c.x; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; Woscholski R, 1997, J BIOL CHEM, V272, P9625; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	39	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8256	8267		10.1074/jbc.273.14.8256	http://dx.doi.org/10.1074/jbc.273.14.8256			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525932	hybrid			2022-12-27	WOS:000072876300066
J	Pipe, SW; Morris, JA; Shah, J; Kaufman, RJ				Pipe, SW; Morris, JA; Shah, J; Kaufman, RJ			Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-VIII; GLUCOSE-REGULATED PROTEINS; CHAIN BINDING-PROTEIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; MOLECULAR CHAPERONE; GLYCOPROTEIN GLUCOSYLTRANSFERASE; B-DOMAIN; FUNCTIONAL-CHARACTERIZATION	Factor VIII (FVIII) and factor V (FV) are homologous coagulation cofactors sharing a similar domain organization (A1-A2-B-A3-C1-C2) and are both extensively glycosylated within their B-domains, In mammalian cell expression systems, compared with FV, the FVIII primary translation product is inefficiently transported out of the endoplasmic reticulum, Here we show that FVIII is degraded within the cell by a lactacystin-inhibitable pathway, implicating the cytosolic 20 S proteasome machinery, Protein chaperones calnexin (CNX) and calreticulin (CRT) preferentially interact with glycoproteins containing monoglucosylated N-linked oligosaccharides and are proposed to traffic proteins through degradative and/or secretory pathways, Utilizing co-immunoprecipitation assays, intracellular FVIII was detected in association with CNX maximally within 30 min to 1 h following synthesis, whereas FV could not be detected in association with CNX, In contrast, both FVIII and FV displayed interaction with CRT during transit through the secretory pathway, B-domain deleted FVIII significantly reduced the CNX and CRT interaction, indicating the B-domain may represent a primary CNX and CRT interaction site, In the presence of inhibitors of glucose trimming, the interactions of FVIII with CNX, and of FVIII and FV with CRT, were significantly reduced whereas the secretion of FVIII, and not FV, was inhibited, In addition, transfection in a glucosidase I-deficient Chinese hamster ovary cell line (Lec23) demonstrated that both degradation and secretion of FVIII were inhibited, with little effect on the secretion of FV, These results support that CNX and CRT binding, mediated at least in part by the B-domain of FVIII, is required for efficient FVIII degradation and secretion, In contrast, FV does not require CNX interaction for efficient secretion, The results suggest a unique requirement for carbohydrate processing and molecular chaperone interactions that may limit the productive secretion of FVIII.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Pediat, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu	Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173, P01HL057345, R01HL053777] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53777, HL52173, P01HL57345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BIHOREAU N, 1991, BIOCHEM J, V277, P23, DOI 10.1042/bj2770023; BONTEMPO FA, 1987, BLOOD, V69, P1721; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CHIU HC, 1985, J CLIN INVEST, V75, P339, DOI 10.1172/JCI111706; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; Fallaux FJ, 1996, MOL CELL BIOL, V16, P4264; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HELLSTERN P, 1986, THROMB HAEMOSTASIS, V56, P353; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAIZFULLER B, 1995, EUR J BIOCHEM, V231, P344; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KELLY DA, 1984, BRIT J HAEMATOL, V56, P535, DOI 10.1111/j.1365-2141.1984.tb02178.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LOO TW, 1994, J BIOL CHEM, V269, P28683; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MEULIEN P, 1988, PROTEIN ENG, V2, P301, DOI 10.1093/protein/2.4.301; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; PIND S, 1994, J BIOL CHEM, V269, P12784; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1993, BLOOD, V81, P2925; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RAY MK, 1991, J BIOL CHEM, V266, P22818; SARVER N, 1987, DNA-J MOLEC CELL BIO, V6, P553, DOI 10.1089/dna.1987.6.553; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Swaroop M, 1997, J BIOL CHEM, V272, P24121, DOI 10.1074/jbc.272.39.24121; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TROMBETTA S E, 1991, Glycobiology, V1, P155, DOI 10.1093/glycob/1.2.155; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILSON DB, 1984, J CLIN INVEST, V73, P654, DOI 10.1172/JCI111256; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; Yao ZM, 1997, J LIPID RES, V38, P1937; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; ZATLOUKAL K, 1994, P NATL ACAD SCI USA, V91, P5148, DOI 10.1073/pnas.91.11.5148; ZELECHOWSKA MG, 1985, NATURE, V317, P729, DOI 10.1038/317729a0	82	127	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8537	8544		10.1074/jbc.273.14.8537	http://dx.doi.org/10.1074/jbc.273.14.8537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525969	hybrid			2022-12-27	WOS:000072876300103
J	Presta, M; Belleri, M; Vecchi, A; Hesselgesser, J; Mantovani, A; Horuk, R				Presta, M; Belleri, M; Vecchi, A; Hesselgesser, J; Mantovani, A; Horuk, R			Noncompetitive, chemokine-mediated inhibition of basic fibroblast growth factor-induced endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLASMINOGEN-ACTIVATOR PRODUCTION; HEPARAN-SULFATE PROTEOGLYCANS; FACTOR RECEPTOR; MITOGENIC ACTIVITY; PLATELET FACTOR-4; SIGNALING PATHWAY; DNA-SYNTHESIS; ANGIOGENESIS; BINDING	The proinflammatory and chemoattractant chemokine interleukin-8 (IL-8) inhibits cell proliferation induced by basic fibroblast growth factor (bFGF) in mouse endothelial cells isolated from subcutaneous sponge implant (sponge-induced mouse endothelial cells) and in bovine aortic endothelial GM 7373 cells, The mechanism of action of IL-8 was investigated in GM 7373 cells, IL-8 did not prevent the binding of bFGF to its tyrosine kinase FGF receptors (FGFRs) nor to cell surface heparan sulfate proteoglycans (HSPGs), A transient interaction of IL-8 with the cell before the addition of the growth factor was sufficient to prevent bFGF activity, The inhibitory activity of IL-8 was abolished by protein kinase C (PKC) inhibitors and was mimicked by the PKC activator 12-O-tetradecanoylphorbol-13-acetate. Accordingly, both IL-8 and 12-O-tetradecanoylphorbol-13-acetate caused a similar to 60% decrease of the binding capacity of GM 7373 cells due to the down-regulation of FGFRs. Several C-X-C and C-C chemokines exerted an inhibi tory action on bFGF activity similar to IL-8, Soluble heparin, 6-O-desulfated heparin, N-desulfated heparin, and heparan sulfate but not a O-desulfated heparin, chondroitin-4-sulfate, hyaluronic acid, and K5 polysaccharide abrogated IL-8 inhibitory activity consistently with the presence of low affinity, high capacity HSPG-like chemokine-binding sites on GM 7373 cells, Finally, neovascularization induced by bFGF in murine subcutaneous sponge implants was reduced significantly by IL-8, In conclusion, IL-8 inhibits the mitogenic activity exerted by bFGF on cultured endothelial cells by a PKC-dependent, noncompetitive mechanism of action that causes FGFR down-regulation. This activity is shared by several chemokines and requires endothelial cell surface HSPGs. The endothelial cell line utilized in the present study may help to elucidate the complex interplay among chemokines, HSPGs, growth factors, and receptors in endothelial cells.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA	University of Brescia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.	presta@med.unibs.it	Presta, Marco/B-4345-2010; Mantovani, Alberto/HCI-7449-2022	Mantovani, Alberto/0000-0001-5578-236X; PRESTA, Marco/0000-0002-4398-8376				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLTRINI D, 1994, BIOCHEM J, V303, P583, DOI 10.1042/bj3030583; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GRISPAN JB, 1983, J CELL PHYSL, V114, P328; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; HOSHI H, 1988, FASEB J, V2, P2797, DOI 10.1096/fasebj.2.12.2457532; HU DE, 1994, INFLAMMATION, V18, P45, DOI 10.1007/BF01534597; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KIMATA H, 1995, BIOCHEM BIOPH RES CO, V207, P1044, DOI 10.1006/bbrc.1995.1290; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1995, SCIENCE, V21, P447; LINDAHL U, 1991, THROMB HAEMOSTASIS, V66, P44; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; MAHER PA, 1993, J BIOL CHEM, V268, P4244; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; MCCARTHY SA, 1991, TRENDS PHARMACOL SCI, V12, P462, DOI 10.1016/0165-6147(91)90637-8; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Norrby K, 1996, CELL PROLIFERAT, V29, P315, DOI 10.1111/j.1365-2184.1996.tb01583.x; PASSANITI A, 1992, LAB INVEST, V67, P519; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; STRIETER RM, 1992, AM J PATHOL, V141, P1279; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZETTER BR, 1988, ENDOTHELIAL CELLS, V2, P63	62	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7911	7919		10.1074/jbc.273.14.7911	http://dx.doi.org/10.1074/jbc.273.14.7911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525887	hybrid			2022-12-27	WOS:000072876300021
J	Dittmar, KD; Banach, M; Galigniana, MD; Pratt, WB				Dittmar, KD; Banach, M; Galigniana, MD; Pratt, WB			The role of DnaJ-like proteins in glucocorticoid receptor center dot hsp90 heterocomplex assembly by the reconstituted hsp90 center dot p60 center dot hsp70 foldosome complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; STEROID-RECEPTOR; FUNCTIONAL HETEROCOMPLEX; RETICULOCYTE LYSATE; MOLECULAR CHAPERONES; ATPASE ACTIVITY; HSP90; HSP70	The glucocorticoid receptor (GR) is recovered from hormone-free cells in a heterocomplex with the molecular chaperone hsp90, which is required to produce the proper folding state for steroid binding. GR.hsp90 heterocomplexes are formed by a multiprotein system that appears to exist in all eukaryotic cells, Recently, we have reconstituted a receptor.hsp90 heterocomplex assembly system with purified rabbit hsp90 and hsp70 and bacterially expressed human p23 and p60. We have shown that hsp90, p60, and hsp70 form an hsp90.p60.hsp70 complex that converts the GR from a non-steroid binding to a steroid binding form (Dittmar, K. D., and Pratt, W. B. (1997) J. Biol. Chem. 272, 13047-13054). The resulting GR.hsp90 heterocomplex rapidly disassembles unless p23 is present to bind to the ATP-dependent conformation of hsp90 and stabilize its association with the receptor (Dittmar, K. D., Demady, D., R., Stancato, L. F., Krishna, P., and Pratt, W. B. (1997) J. Biol. Chem. 272, 21213-21220). In the current work, we show that the purified rabbit hsp70 utilized in prior studies is contaminated with a small amount of the rabbit DnaJ homolog hsp40. Elimination of the hsp40 from the purified GR.hsp90 assembly system reduces assembly activity, and the activity is restored by addition of the purified yeast DnaJ homolog YDJ-1. hsp40 is a component of the hsp90.p60.hsp70 foldosome complex isolated from reticulocyte lysate with antibody against p60. Under conditions that promote binding of p23 to hsp90 (elevated temperature, ATP, Nonidet P-40, molybdate), a five-membered (p23.hsp90.p60.hsp70.hsp40) complex of chaperone proteins is formed in reticulocyte lysate or from purified proteins. The hsp40-free, purified assembly system has a modest level of assembly activity that is maximally potentiated by YDJ-1 when it is present at about one-twentieth the concentration of hsp70. Although hsp40 is not in the final GR.hsp90 heterocomplex isolated from L cell cytosol, it is in the GR.hsp90 heterocomplex assembled in reticulocyte lysate. We conclude that hsp40 is a component of the multiprotein hsp90-based chaperone system where it potentiates GR.hsp90 heterocomplex assembly.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.			GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R01DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXIS MN, 1992, EUR J BIOCHEM, V204, P75, DOI 10.1111/j.1432-1033.1992.tb16607.x; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Picard Didier, 1998, P1; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; REXIN M, 1991, J BIOL CHEM, V266, P24601; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	53	135	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7358	7366		10.1074/jbc.273.13.7358	http://dx.doi.org/10.1074/jbc.273.13.7358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516432	hybrid			2022-12-27	WOS:000072738500028
J	Hirai, S; Noda, K; Moriguchi, T; Nishida, E; Yamashita, A; Deyama, T; Fukuyama, K; Ohno, S				Hirai, S; Noda, K; Moriguchi, T; Nishida, E; Yamashita, A; Deyama, T; Fukuyama, K; Ohno, S			Differential activation of two JNK activators, MKK7 and SEK1, by MKN28-derived nonreceptor serine/threonine kinase mixed lineage kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; C-JUN; SIGNAL-TRANSDUCTION; STRESS; PATHWAY; FAMILY; PHOSPHORYLATES; IDENTIFICATION; MEMBER; MEKK	MKN28-derived nonreceptor type of serine/threonine kinase/mixed lineage kinase 2 (MST/MLK2) directly phosphorylates and activates SEK1/MKK4/JNKK1/SKK1 in vitro, thereby acting as a mitogen-activated protein (MAP) kinase kinase kinase in the JNK/SAPK pathway (Hirai, S.-i., Katoh, M., Terada, M., Kyriakis, J. M., Zon, L. I., Rana, A., Avruch, J., and Ohno, S. (1997) J. Biol. Chem. 272, 15167-15173). The in vitro reconstitution system for the kinase cascade allowed us now to identify JNK/SAPK activators involved in the MST/MLK2-dependent activation of JNK/SAPK in, vivo. We show that at least two distinct MST/MLK2-dependent JNK/SAPK activators are present in the fractionated COS-1 cell lysate, and that they appear to be SEK1/MKK4/JNNK1/SKK1 and MKK7/JNKK2/SKK4 by Western blot analysis. Notably, a ma jority of the MST/MLK2-dependent JNK/SAPK-activating activity is found in MKK7-containing fractions, whereas the MEKK1-dependent activity is comparably distributed in SEK1- and MKK7-containing fractions. Moreover, MST/MLK2 activates recombinant MKK7 more effectively than recombinant SEK1, whereas MEKK1 activates both to a similar extent. In addition, the deletion analysis on MST/MLK2 showed that the kinase domain is responsible for the determination of substrate specificity. These results provide a molecular aspect to the differential regulation of the two JNK activators by a variety of cellular stimuli.	Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 60601, Japan	Yokohama City University; Kyoto University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 236, Japan.	sh3312@med.yokohama-cu.ac.jp	Ohno, Shigeo/B-1768-2010; Moriguchi, Tetsuo/D-7061-2012	Ohno, Shigeo/0000-0002-1294-5269; Moriguchi, Tetsuo/0000-0002-9598-4991				DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NISHINA H, 1997, SCIENCE, V385, P350; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	28	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7406	7412		10.1074/jbc.273.13.7406	http://dx.doi.org/10.1074/jbc.273.13.7406			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516438	hybrid			2022-12-27	WOS:000072738500034
J	Hoshijima, M; Sah, VP; Wang, YB; Chien, KR; Brown, JH				Hoshijima, M; Sah, VP; Wang, YB; Chien, KR; Brown, JH			The low molecular weight GTPase rho regulates myofibril formation and organization in neonatal rat ventricular myocytes - Involvement of Rho kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; SERINE-THREONINE KINASE; CONTRACTILE ACTIVITY; TRANSCRIPTIONAL ACTIVATION; DEPENDENT PATHWAYS; CELL HYPERTROPHY; GENE-EXPRESSION; PUTATIVE TARGET; SMOOTH-MUSCLE; LIGHT-CHAIN	The assembly of contractile proteins into organized sarcomeric units is one of the most distinctive features of cardiac myocyte hypertrophy. In a well characterized in vitro model system using cultured neonatal rat ventricular myocytes, a subset of G protein-coupled receptor agonists has been shown to induce actin-myosin filament organization. Pretreatment of myocytes with C3 exoenzyme ADP-ribosylated Rho and inhibited the characteristic alpha(1)-adrenergic receptor agonist-induced myofibrillar organization, suggesting involvement of the Rho GTPase in cardiac myofibrillogenesis. We used adenoviral mediated gene transfer to examine the effects of activated Rho and inhibitory mutants of one of its effecters, Rho kinase, in myocytes. Rho immunoreactivity was increased in the particulate fraction of myocytes infected with a recombinant adenovirus expressing constitutively activated Rho. Rho-infected cells demonstrated a striking increase in the assembly and organization of sarcomeric units and in the expression of the atrial natriuretic factor protein. These Rho-induced responses were markedly inhibited by co-infection with adenoviruses expressing putative dominant negative forms of Rho kinase. A parallel pathway involving Ras-induced myofibrillar organization and atrial natriuretic factor expression was only minimally affected. alpha(1)-Adrenergic receptor agonist-induced myofibrillogenesis was inhibited by some but not all of the Rho kinase mutants. Our data demonstrate that activated Rho has profound effects on myofibrillar organization in cardiac myocytes and suggest that Rho kinase mediates Rho-induced hypertrophic responses.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Grad Program Biomed Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu		Wang, Yibin/0000-0003-0852-0767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL028143, R37HL028143] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; Gong MC, 1997, MOL BIOL CELL, V8, P279, DOI 10.1091/mbc.8.2.279; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOSHIJIMA M, 1995, CIRCULATION, V92, P2724; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Liu XL, 1997, METABOLISM, V46, P71, DOI 10.1016/S0026-0495(97)90171-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; Nishio H, 1997, BIOCHEM BIOPH RES CO, V236, P570, DOI 10.1006/bbrc.1997.7005; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; QI M, 1994, AM J PHYSIOL, V267, pC520, DOI 10.1152/ajpcell.1994.267.2.C520; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SAMAREL AM, 1991, AM J PHYSIOL, V261, pH1067, DOI 10.1152/ajpheart.1991.261.4.H1067; SHARP WW, 1993, CIRC RES, V73, P172, DOI 10.1161/01.RES.73.1.172; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; THORBURN A, 1993, J BIOL CHEM, V268, P2244; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; Ueyama T, 1997, CIRC RES, V81, P672; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wang SM, 1997, J CELL BIOCHEM, V66, P43; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	50	169	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7725	7730		10.1074/jbc.273.13.7725	http://dx.doi.org/10.1074/jbc.273.13.7725			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516480	hybrid			2022-12-27	WOS:000072738500076
J	McMillan, DR; Xiao, XZ; Shao, L; Graves, K; Benjamin, IJ				McMillan, DR; Xiao, XZ; Shao, L; Graves, K; Benjamin, IJ			Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; PROTEIN-SYNTHESIS; TRANSGENIC MICE; BREAST-CANCER; C-MYC; CELL; STRESS; YEAST; ACTIVATION; GENE	Heat shock transcription factor 1 (HSF1) is a member of the vertebrate HSF family that regulates stress-inducible synthesis of heat shock proteins (HSPs). Although the synthesis of the constitutively expressed and inducible members of the heat shock family of stress proteins correlates with increased cellular protection, their relative contributions in acquired cellular resistance or "thermotolerance" in mammalian cells is presently unknown. We report here that constitutive expression of multiple HSPs in cultured embryonic cells was unaffected by disruption of the murine HSF1 gene. In contrast, thermotolerance was not attainable in hsf1((-/-)) cells, and this response was required for protection against heat-induced apoptosis. We conclude that 1) constitutive and inducibly expressed HSPs exhibit distinct physiological functions for cellular maintenance and adaptation, respectively, and 2) other mammalian HSFs or distinct evolutionarily conserved stress response pathways do not compensate for HSF1 in the physiological response to heat shock.	Univ Texas, SW Med Ctr, Dept Internal Med, Mol Cardiol Res Labs, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Mol Cardiol Res Labs, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Benjamin, IJ (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Mol Cardiol Res Labs, Dallas, TX 75235 USA.	benjamin@ryburn.swmed.edu	xiao, xiang/GWU-6035-2022					AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CIOCCA DR, 1992, CANCER RES, V52, P3648; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MEZGER V, 1994, DEV BIOL, V165, P627, DOI 10.1006/dbio.1994.1281; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SMITH BJ, 1991, P NATL ACAD SCI USA, V88, P11091, DOI 10.1073/pnas.88.24.11091; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRASSER A, 1995, CELL GROWTH DIFFER, V6, P799; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	44	415	438	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7523	7528		10.1074/jbc.273.13.7523	http://dx.doi.org/10.1074/jbc.273.13.7523			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516453	hybrid			2022-12-27	WOS:000072738500049
J	Miyazawa, K; Mori, A; Yamamoto, K; Okudaira, H				Miyazawa, K; Mori, A; Yamamoto, K; Okudaira, H			Transcriptional roles of CCAAT/enhancer binding protein-beta, nuclear factor-kappa B, and C-promoter binding factor 1 in interleukin (IL)-1 beta-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STIMULATORY FACTOR-II; T-CELL; REGULATORY ELEMENTS; SYNOVIAL-FLUID; ARTHRITIS; GENE; ACTIVATION; INDUCTION; SEQUENCE	The involvement of interleukin (IL)-6 in the pathogenesis of rheumatoid arthritis (RA) has been recently demonstrated. IL-1 beta stimulated rheumatoid fibroblast-like synoviocytes (FLSs) to produce IL-6 in a concentration-and time-dependent manner. In the present study we investigated how the IL-6 promoter is transcriptionally regulated in rheumatoid FLSs in response to a physiologically relevant mediator of inflammation, IL-1 beta. Deletion analysis showed that the IL-6 promoter is regulated by two positive elements (located at -159 to -142 base pairs (bp) and -77 to -59 bp). Electrophoretic mobility shift assays revealed that CCAAT/enhancer binding protein-beta (C/EBP beta) binding to nucleotides -159 to -142 bp was constitutively present. The probe corresponding to nucleotides -77 to -59 bp gave three positive bands. The two slower migrating bands were induced by IL-1 beta and comprised an nuclear factor (NF)-kappa B p50/p65 heterodimer and a p65/p65 homodimer. The faster migrating band was constitutively expressed and identified as Epstein-Barr virus C-promoter binding factor 1, CBF1. Site-specific mutagenesis analysis demonstrated that the NF-kappa B and CBF1 binding elements regulated inducible activity of the IL-6 promoter in response to IL-1 beta stimulation, whereas the C/EBP beta binding element mainly regulated basal activity. We also provide the first evidence that CBF1 functions as a positive regulator of human IL-6 gene transcription.	Univ Tokyo, Fac Med, Dept Med & Phys Therapy, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Miyazawa, K (corresponding author), Kissei Pharmaceut Co Ltd, 4365-1 Kashiwabara, Nagano 3998304, Japan.		Yamamoto, Kazuhiko/N-5096-2015					AKIRA S, 1993, ADV IMMUNOL, V56, P1; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZIK M, 1992, J RHEUMATOL, V19, P63; BUCHAN G, 1988, CLIN EXP IMMUNOL, V71, P295; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; LEEUWEN MA, 1995, ANN RHEUM DIS, V54, P33; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Marok R, 1996, ARTHRITIS RHEUM, V39, P583, DOI 10.1002/art.1780390407; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; MORI N, 1994, BLOOD, V84, P2904; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; Ridley SH, 1997, J IMMUNOL, V158, P3165; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHMITZ R, 1991, EMBO J, V10, P3805; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SENGUPTA TK, 1995, J EXP MED, V181, P1015, DOI 10.1084/jem.181.3.1015; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YOSHIZAKI K, 1996, JPN SOC IMMUNOL, V26, P115; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	50	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7620	7627		10.1074/jbc.273.13.7620	http://dx.doi.org/10.1074/jbc.273.13.7620			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516466	hybrid			2022-12-27	WOS:000072738500062
J	Patterton, HG; Landel, CC; Landsman, D; Peterson, CL; Simpson, RT				Patterton, HG; Landel, CC; Landsman, D; Peterson, CL; Simpson, RT			The biochemical and phenotypic characterization of Hho1p, the putative linker histone H1 of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; NUCLEOSOME CORE PARTICLE; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; H-1 HISTONES; CHROMATIN CONDENSATION; CAENORHABDITIS-ELEGANS; NUCLEOTIDE-SEQUENCE; HO GENE	There is currently no published report on the isolation and definitive identification of histone H1 in Saccharomyces cerevisiae. It was, however, recently shown that the yeast HHO1 gene codes for a predicted protein homologous to H1 of higher eukaryotes (Landsman, D. (1996) Trends Biochem. Sci. 21, 287-288; Ushinsky, S. C., Bussey, H., Ahmed, A. A., Wang, Y., Friesen, J., Williams, B. A., and Storms, R. K. (1997) Yeast 13, 151-161), although there is no biochemical evidence that shows that Hho1p is, indeed, yeast histone H1, We showed that purified recombinant Hho1p (rHho1p) has electrophoretic and chromatographic properties similar to linker histones. The protein forms a stable ternary complex with a reconstituted core di-nucleosome in vitro at molar rHho1p:core ratios up to 1. Reconstitution of rHho1p with H1-stripped chromatin confers a kinetic pause at similar to 168 base pairs in the micrococcal nuclease digestion pattern of the chromatin, These results strongly suggest that Hho1p is a bona fide linker histone, We deleted the HHO1 gene and showed that the strain is viable and has no growth or mating defects. Hho1p is not required for telomeric silencing, basal transcriptional repression, or efficient sporulation. Unlike core histone mutations, a hho1 Delta strain does not exhibit a Sin or Spt phenotype. The absence of Hho1p does not lead to a change in the nucleosome repeat length of bulk chromatin nor to differences in the in vivo micrococcal nuclease cleavage sites in individual genes as detected by primer extension mapping.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Labs 308, University Pk, PA 16802 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Patterton, HG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Labs 308, University Pk, PA 16802 USA.	hgp1@psu.edu	Landsman, David/GZK-5496-2022; Landsman, David/C-5923-2009	Landsman, David/0000-0002-9819-6675; Patterton, Hugh-George/0000-0003-2550-0493	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054096] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054096, 1 RO1 GM52399, 1 RO1 GM54096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Bedoyan JK, 1996, J BIOL CHEM, V271, P18485, DOI 10.1074/jbc.271.31.18485; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRIAND G, 1980, FEBS LETT, V112, P147, DOI 10.1016/0014-5793(80)80167-0; BROWN DT, 1993, J BIOL CHEM, V268, P713; Bussey H, 1997, NATURE, V387, P103, DOI 10.1038/387s103; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; COLE RD, 1984, ANAL BIOCHEM, V136, P24, DOI 10.1016/0003-2697(84)90303-8; COLE RD, 1989, METHOD ENZYMOL, V170, P524; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; COLES LS, 1987, J BIOL CHEM, V262, P9656; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; EICK S, 1989, EUR J CELL BIOL, V49, P110; GANTT JS, 1987, EUR J BIOCHEM, V166, P119, DOI 10.1111/j.1432-1033.1987.tb13490.x; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANNON R, 1984, J MOL BIOL, V180, P131, DOI 10.1016/0022-2836(84)90434-0; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; KENT NA, 1993, NUCLEIC ACIDS RES, V21, P4653, DOI 10.1093/nar/21.19.4653; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KNOWLES JA, 1986, NUCLEIC ACIDS RES, V14, P8121, DOI 10.1093/nar/14.20.8121; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; Landsman D, 1996, TRENDS BIOCHEM SCI, V21, P287, DOI 10.1016/S0968-0004(96)30030-3; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LENNOX RW, 1984, DEV BIOL, V103, P80, DOI 10.1016/0012-1606(84)90009-5; LEVY S, 1982, J BIOL CHEM, V257, P9438; LINDER C, 1994, MOL CELL BIOL, V14, P2822, DOI 10.1128/MCB.14.4.2822; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MATSUO Y, 1989, NUCLEIC ACIDS RES, V17, P225, DOI 10.1093/nar/17.1.225; MEZQUITA J, 1985, J MOL EVOL, V21, P209, DOI 10.1007/BF02102355; MILOSHEV G, 1994, J GEN APPL MICROBIOL, V40, P359, DOI 10.2323/jgam.40.359; MIRZABEKOV AD, 1978, P NATL ACAD SCI USA, V75, P4184, DOI 10.1073/pnas.75.9.4184; MURPHY TJ, 1986, NUCLEIC ACIDS RES, V14, P5563, DOI 10.1093/nar/14.13.5563; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PATTERTON HG, 1993, J MOL BIOL, V229, P637, DOI 10.1006/jmbi.1993.1069; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RATTNER JB, 1982, J CELL BIOL, V93, P217, DOI 10.1083/jcb.93.1.217; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROCHE J, 1985, NATURE, V314, P197, DOI 10.1038/314197a0; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; Rose MD., 1990, METHODS YEAST GENETI; ROTH SY, 1988, J CELL BIOL, V107, P2473, DOI 10.1083/jcb.107.6.2473; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SANICOLA M, 1990, J MOL BIOL, V212, P259, DOI 10.1016/0022-2836(90)90123-4; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; SREBREVA L, 1987, EUR J BIOCHEM, V165, P449, DOI 10.1111/j.1432-1033.1987.tb11459.x; STEDMAN E, 1951, PHILOS T ROY SOC B, V235, P565, DOI 10.1098/rstb.1951.0008; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Ushinsky SC, 1997, YEAST, V13, P151, DOI 10.1002/(SICI)1097-0061(199702)13:2<151::AID-YEA94>3.0.CO;2-5; VANFLETEREN JR, 1988, BIOCHEM J, V255, P647; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; WAN JS, 1995, P NATL ACAD SCI USA, V92, P5664, DOI 10.1073/pnas.92.12.5664; WILEY EA, 1995, GENETICS, V139, P67; WINSTON F, 1987, GENETICS, V115, P649; WINSTON F, 1984, GENETICS, V107, P179; ZHU JG, 1992, MOL CELL BIOL, V12, P4733, DOI 10.1128/MCB.12.10.4733	87	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7268	7276		10.1074/jbc.273.13.7268	http://dx.doi.org/10.1074/jbc.273.13.7268			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516420	hybrid			2022-12-27	WOS:000072738500016
J	Seibold, A; January, BG; Friedman, J; Hipkin, RW; Clark, RB				Seibold, A; January, BG; Friedman, J; Hipkin, RW; Clark, RB			Desensitization of beta(2)-adrenergic receptors with mutations of the proposed G protein-coupled receptor kinase phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; HETEROLOGOUS DESENSITIZATION; ADENYLYL CYCLASE; LYMPHOMA-CELLS; IDENTIFICATION; RHODOPSIN; SEQUESTRATION; PATHWAYS	Tentative identification of the G protein-coupled receptor kinase 2 and 5 (GRK2 and GRK5) sites of phosphorylation of the beta(2)-adrenergic receptor (beta AR) was recently reported based on in vitro phosphorylation of recombinant receptor (Fredericks, Z, L,, Pitcher, J, A, and Lefkowitz, R, J, (1996) J, Biol Chem. 271, 13796-13803), Phosphorylated residues identified for GRK2 were threonine 384 and serines 396, 401, and 407, GRK5 phosphorylated these four residues as well as threonine 393 and serine 411, To determine if mutation of these sites altered desensitization, we have constructed beta ARs in which the threonines and serines of the putative GRK2 and GRK5 sites were substituted with alanines, These constructs were further modified to eliminate the cAMP-dependent protein kinase (PKA) consensus sites, Mutants beta ARs were transfected into HEH 293 cells, and standard kinetic parameters were measured following 10 mu M epinephrine treatment of cells, The mutant and wild type (WT) receptors were all desensitized 89-94% after 5 min of 10 mu M epinephrine stimulation and 96-98% after a 30-min pretreatment. There were no significant changes observed for any of the mutant beta ARs relative to the WT in the extent of 10 mu M epinephrine-induced internalization (77-82% after 30 min), Epinephrine treatment for 1 min induced a rapid increase in the phosphorylation of the GRK5 and PKA(-) mutant beta ARs as well as the WT, We conclude that sites other than the GRK2 and GRK5 sites identified by in vitro phosphorylation are involved in mediating the major effects of the in vivo GRK-dependent desensitization of the beta AR.	Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77225 USA	University of Texas System	Clark, RB (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, POB 20708, Houston, TX 77225 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31208] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; BAROVSKY K, 1980, J CYCLIC NUCL PROT, V6, P297; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GREEN DA, 1981, J CYCLIC NUCL PROT, V7, P161; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HOYER D, 1984, MOL PHARMACOL, V25, P209; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SLOWIEJKO DM, 1994, J NEUROCHEM, V62, P1795; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YUAN NY, 1994, J BIOL CHEM, V269, P23032	25	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7637	7642		10.1074/jbc.273.13.7637	http://dx.doi.org/10.1074/jbc.273.13.7637			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516468	hybrid			2022-12-27	WOS:000072738500064
J	He, WM; Rose, DW; Olefsky, JM; Gustafson, TA				He, WM; Rose, DW; Olefsky, JM; Gustafson, TA			Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the Pleckstrin homology and SH2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; MITOGENIC SIGNAL-TRANSDUCTION; TYROSINE KINASE DOMAIN; PHOSPHATIDYLINOSITOL 3'-KINASE; GLUCOSE-TRANSPORT; NPEY MOTIF; SUBSTRATE-1; PROTEIN; CELLS; ACTIVATION	The Grb10 protein appears to be an adapter protein of unknown function that has been implicated in insulin receptor (IR) signaling, The interaction of this protein with the IR has been shown to be mediated in part by the Src homology 2 (SH2) domain of Grb10, Here we demonstrate the existence of a second novel domain within Grb10 that interacts with the TR and insulin-like growth factor receptor in a kinase-dependent manner, This do main was localized to a region of approximately 50 amino acids, and we term it the BPS domain to denote its location between the PH and SH2 domains, The BPS domain does not bear any obvious resemblance to other known protein interaction domains but is highly conserved among the Grb10-related proteins Grb7 and Grb14, We show that the BPS domain interaction is dependent upon receptor tyrosine kinase activity, Furthermore, interaction of the BPS domain requires the kinase domain of the IR, since mutation of the paired tyrosine residues (Y1150F/Y1151F) within the HC. activation loop dramatically reduced the interaction, Last, our data suggest that the presence of two distinct protein interaction domains may help to determine the specificity by which Grb10 interacts with different receptors, Specifically, the IR, which appears to interact most strongly with Grb10, interacts well with both the SH2 and BPS domains, Conversely, the insulin-like growth factor receptor and EGFR, which interact less avidly with Grb10, interact well only with the BPS domain or the SH2 domain, respectively. In summary, our findings demonstrate the existence of a previously unidentified tyrosine kinase activity-dependent binding domain located between the Pleckstrin homology and SH2 domains of Grb10.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Mol & Cellular Biol, Baltimore, MD 21201 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego	Gustafson, TA (corresponding author), Metabolex Inc, 3876 Bay Ctr Pl, Hayward, CA 94545 USA.		Roszak, Joanna/F-4003-2010		NIDDK NIH HHS [DK50602, DK44093, DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093, R01DK050602, R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, GUIDE YEAST GENETICS; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Miller J.H., 1972, EXPT MOL GENETICS; Morrione A, 1996, CANCER RES, V56, P3165; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1610; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1988, J BIOL CHEM, V263, P2969; XIAO S, 1994, J BIOL CHEM, V269, P21244; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	50	122	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6860	6867		10.1074/jbc.273.12.6860	http://dx.doi.org/10.1074/jbc.273.12.6860			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506989	hybrid			2022-12-27	WOS:000072775900039
J	Shetzline, MA; Premont, RT; Walker, JKL; Vigna, SR; Caron, MG				Shetzline, MA; Premont, RT; Walker, JKL; Vigna, SR; Caron, MG			A role for receptor kinases in the regulation of Class II G protein-coupled receptors - Phosphorylation and desensitization of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTOR; IDENTIFICATION; BETA-ARK1; BINDING; SIGNAL; FAMILY	The secretin receptor is a member of a structurally distinct class of G protein-coupled receptors designated as Class II. The molecular mechanisms of secretin receptor signal termination are unknown. Using transiently transfected HEK 293 cells expressing the secretin receptor, we investigated its mechanisms of desensitization. Binding of [I-125]-secretin to plasma membranes of receptor-expressing cells was specific, with K-d of 2 nM. Secretin evoked an increase in cellular cAMP with an EC50 of 0.4 nM. The response was maximal by 20 min and desensitized rapidly and completely. Immunoprecipitation of a functional, N-terminal epitope-tagged secretin receptor was used to demonstrate agonist-dependent receptor phosphorylation, with an EC50 of 14 nM. Pretreatment with protein kinase A or C inhibitors failed to alter secretin-stimulated cAMP accumulation. G protein coupled receptor kinases (GRKs) are known to be involved in the desensitization of Class I G protein-coupled receptors; therefore, the effect of cotransfection of GRKs on secretin-stimulated cAMP signaling and phosphorylation was evaluated. GRKs 2 and 5 were the most potent at augmenting desensitization, causing a 40% reduction in the maximal cAMP response to secretin. GRK 5 also caused a shift in the EC50 to the right (p < 0.05), GRK 4 and GRK 6 did not alter dose-dependent signaling, and GRK 3 was intermediate in effect, Receptor phosphorylation correlated with desensitization for each GRK studied, whereas second messenger dependent kinase phosphorylation appeared to be less important in secretin receptor signal termination, We demonstrate agonist-dependent secretin receptor phosphorylation coincident with profound receptor desensitization of the signaling function in HEK 293 cells, suggesting a role for receptor phosphorylation in this paradigm. Although GRK activity appears important in secretin receptor desensitization in HEK 293 cells, protein kinases A and C appear to play only a minor role. These results demonstrate that the GRK-arrestin system regulates Class II G protein-coupled receptors.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol,Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Cardiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol,Div Gastroenterol, Box 3287, Durham, NC 27710 USA.			Premont, Richard/0000-0002-8053-5026	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07568] Funding Source: Medline; NINDS NIH HHS [NS19576] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; FAROUK M, 1992, GASTROENTEROLOGY, V102, P963, DOI 10.1016/0016-5085(92)90183-Y; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; KONG GH, 1994, J BIOL CHEM, V269, P13084; LEITER AB, 1994, GUT PEPTIDES BIOCH P, P147; LeSage G, 1996, GASTROENTEROLOGY, V111, P1633, DOI 10.1016/S0016-5085(96)70027-6; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OZCELEBI F, 1995, MOL PHARMACOL, V48, P818; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Tiberi M, 1996, J BIOL CHEM, V271, P3771	27	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6756	6762		10.1074/jbc.273.12.6756	http://dx.doi.org/10.1074/jbc.273.12.6756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506976	hybrid			2022-12-27	WOS:000072775900026
J	Gri, G; Savio, D; Trinchieri, G; Ma, XJ				Gri, G; Savio, D; Trinchieri, G; Ma, XJ			Synergistic regulation of the human interleukin-12 p40 promoter by NF kappa B and Ets transcription factors in Epstein-Barr virus-transformed B cells and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT MEMBRANE PROTEIN-1; IMMUNOREGULATORY FUNCTIONS; GENE-EXPRESSION; FAMILY PROTEINS; ACTIVATION; IFN; CYTOKINE; IRF-1; ELEMENTS; IL-12	Monocytes/macrophages produce interleukin-12 (IL-12) in response to pathogenic stimulation, whereas most Epstein-Barr virus-transformed (EBV+) B cells constitutively secrete IL-12. The molecular mechanism regulating the constitutive IL-12 gene expression in EBV+ B cells has not been addressed. In this study, using the EBV+ B cell line RPMI-8866, we localized to the human IL-12 p40 promoter two essential cia elements, the NF kappa B site and the Ets site. The NF kappa B site was shown to interact with members of the NF kappa B family: p50 and c-Rel. The Ets site constitutively bound a multi-component Ets-2-containing complex. While the NF kappa B and Ets sites appear equally critical for inducible p40 promoter activity in macrophage cell lines, NF kappa B plays a more dominant role in the constitutive p40 promoter activity in EBV+ B cells. Transient expression of Ets-2 and c-Rel in B, T, and monocytic cell lines synergistically activated the IL-12 p40 promoter, apparently overcoming the requirement for cell type- or stimulant-specific transcription factors. These data provide new evidence that full activation of the human IL-12 p40 promoter may result primarily from the interplay between NF kappa B and Ets family members.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Trinchieri, G (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	trinchieri@wista.wistar.upenn.edu		GRI, Giorgia/0000-0002-2826-0459	NCI NIH HHS [CA10815, CA32898, CA20833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA020833, R01CA020833, P30CA010815, R01CA032898] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Benjamin D, 1996, J IMMUNOL, V156, P1626; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; COUTELIER JP, 1995, J VIROL, V69, P1955, DOI 10.1128/JVI.69.3.1955-1958.1995; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HUEN DS, 1995, ONCOGENE, V10, P549; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P192; Kang KF, 1996, J IMMUNOL, V156, P1402; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Kuprash DV, 1996, J IMMUNOL, V156, P2465; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; SCHWALLER J, 1995, BLOOD, V85, P2182, DOI 10.1182/blood.V85.8.2182.bloodjournal8582182; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	46	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6431	6438		10.1074/jbc.273.11.6431	http://dx.doi.org/10.1074/jbc.273.11.6431			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497375	hybrid			2022-12-27	WOS:000072488500067
J	Ichiba, M; Nakajima, K; Yamanaka, Y; Kiuchi, N; Hirano, T				Ichiba, M; Nakajima, K; Yamanaka, Y; Kiuchi, N; Hirano, T			Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CRE-LIKE SITE; TRANSCRIPTION FACTOR; DNA-BINDING; SIGNAL TRANSDUCERS; INTERFERON-ALPHA; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; LEPTIN RECEPTOR; JUNB PROMOTER	STAT3 (signal transducer and activator of transcription (3) under bar) is a key transcription factor mediating the signals for a variety of cytokines, including interleukin-6 (IL-6), The Stat3 gene itself is activated by IL-6 signals, We show that the region of the signal-transducing subunit, gp130, essential for STAT3 activation, is also required for activation of the Stat3 gene. To elucidate the mechanisms activating the Stat3 gene, we identified an IL-6 response element (IL-6RE) in the Stat3 gene promoter containing both a low affinity STAT3-binding element and a cAMP-responsive element (CRE), Electrophoretic mobility shift assays showed that IL-6 induced a slowly migrating complex on the IL-6RE containing a STAT3 homodimer and an unidentified CRE-binding protein, With the combination of transient transfection assays using mutant Stat3 promoter-reporter constructs and electrophoretic mobility shift assays, we found that the formation of a slowly migrating complex was required for full activation of the Stat3 gene. Thus, STAT3 activates the Stat3 gene in cooperation with an unidentified CRE-binding protein, This regulatory mechanism is similar to that of the junB gene, which is activated by IL-6 through the junB IL-6RE, which contains a low affinity STAT3-binding site and a CRE-like site.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Mol Oncol, Suita, Osaka 565, Japan	Osaka University	Hirano, T (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Mol Oncol, 2-2 Yamadaoka, Suita, Osaka 565, Japan.		Hirano, Toshio/C-8194-2009	Yamanaka, Yojiro/0000-0003-1483-8691				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JAMISON SR, 1995, P NATL ACAD SCI USA, V92, P4215; Kojima H, 1996, ONCOGENE, V12, P547; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shi W, 1996, INT IMMUNOL, V8, P1205, DOI 10.1093/intimm/8.8.1205; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	42	143	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6132	6138		10.1074/jbc.273.11.6132	http://dx.doi.org/10.1074/jbc.273.11.6132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497331	hybrid			2022-12-27	WOS:000072488500023
J	Kong, DC; Richardson, CC				Kong, DC; Richardson, CC			Role of the acidic carboxyl-terminal domain of the single-stranded DNA-binding protein of bacteriophage T7 in specific protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-DESTABILIZING PROTEIN; GENE 32 PROTEIN; POLYMERASE-III HOLOENZYME; HELICASE ASSEMBLY PROTEIN; ESCHERICHIA-COLI; UNWINDING PROTEIN; T4 GENE-32; DEOXYRIBONUCLEIC-ACID; LIMITED PROTEOLYSIS; REPLICATION COMPLEX	The gene 2.5 single-stranded DNA (ssDNA) binding protein of bacteriophage T7 is essential for T7 DNA replication and recombination, Earlier studies have shown that the COOH-terminal 21 amino acids of the gene 2.5 protein are essential for specific protein-protein interaction with T7 DNA polymerase and T7 DNA helicase/ primase, A truncated gene 2.5 protein, in which the acidic COOH-terminal 21 amino acid residues are deleted no longer supports T7 growth, forms dimers, or interacts with either T7 DNA polymerase or T7 helicase/primase in vitro. The single-stranded DNA-binding protein encoded by Escherichia coli (SSB protein) and phage T4 (gene 32 protein) also have acidic COOH-terminal domains, but neither protein can substitute for T7 gene 2.5 protein in vivo. To determine if the specificity for the protein-protein interaction involving gene 2.5 protein resides in its COOH terminus, we replaced the COOH-terminal region of the gene 2.5 protein with the COOH-terminal region from either E. coli SSB protein or T4 gene 32 protein, Both of the two chimeric proteins can substitute for T7 gene 2.5 protein to support the growth of phage T7, The two chimeric proteins, like gene 2.5 protein, form dimers and interact with T7 DNA polymerase and helicase/primase to stimulate their activities, In contrast, chimeric proteins in which the COOH terminus of T7 gene 2.5 protein replaced the COOH terminus of E. coli SSB protein or T4 gene 32 protein cannot support the growth of phage T7, We conclude that an acidic COOH terminus of the gene 2.5 protein is essential for protein-protein interaction, but it alone cannot account for the specificity of the interaction.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	ccr@bcmp.med.harvard.edu			NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1986, VIROLOGY, V149, P208, DOI 10.1016/0042-6822(86)90122-4; BARRY J, 1994, J BIOL CHEM, V269, P33049; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; DOHERTY DH, 1982, MOL GEN GENET, V188, P77, DOI 10.1007/BF00332998; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Ellis EL, 1939, J GEN PHYSIOL, V22, P365, DOI 10.1085/jgp.22.3.365; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HOSODA J, 1980, ICN UCLA S MOL CELL, V19, P505; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KONG D, 1993, J BACTERIOL, V176, P5904; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1997, P NATL ACAD SCI USA, V94, P2987, DOI 10.1073/pnas.94.7.2987; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; LOW RL, 1982, J BIOL CHEM, V257, P6242; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOISE H, 1976, NATURE, V259, P455, DOI 10.1038/259455a0; MOLINEUX IJ, 1974, P NATL ACAD SCI USA, V71, P3858, DOI 10.1073/pnas.71.10.3858; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PRASAD BVV, 1987, J MOL BIOL, V193, P579; QUINONES A, 1987, J BASIC MICROB, V27, P263, DOI 10.1002/jobm.3620270508; QUIRK S, 1991, J BACTERIOL, V173, P6665, DOI 10.1128/jb.173.21.6665-6669.1991; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SIGAL N, 1972, P NATL ACAD SCI USA, V69, P3537, DOI 10.1073/pnas.69.12.3537; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STENT GS, 1963, MOL BIOL BACTERIAL V, P74; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; TESSMAN ES, 1982, J BACTERIOL, V152, P572; TSUGITA A, 1978, J MOL BIOL, V122, P255, DOI 10.1016/0022-2836(78)90041-4; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WILLIAMS KR, 1980, P NATL ACAD SCI-BIOL, V77, P4614, DOI 10.1073/pnas.77.8.4614; WILLIAMS KR, 1981, J BIOL CHEM, V256, P1754; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	56	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6556	6564		10.1074/jbc.273.11.6556	http://dx.doi.org/10.1074/jbc.273.11.6556			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497392	hybrid, Green Published			2022-12-27	WOS:000072488500084
J	Stefansson, S; Muhammad, S; Cheng, XF; Battey, FD; Strickland, DK; Lawrence, DA				Stefansson, S; Muhammad, S; Cheng, XF; Battey, FD; Strickland, DK; Lawrence, DA			Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; UROKINASE RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; ESCHERICHIA-COLI; ALPHA(2)-MACROGLOBULIN RECEPTOR; MEDIATES ENDOCYTOSIS; TYPE-1 COMPLEX; VITRONECTIN; DEGRADATION; CELLS	Much of the controversy surrounding the binding of plasminogen activator inhibitor-1 (PAI-1) to the low density lipoprotein receptor-related protein (LRP) may be due to the labile structure of PAI-1 and the distinct conformations that it can adopt, To examine this possibility and to test the hypothesis that PAI-1 contains a specific high affinity binding site for LRP, a sensitive and quantitative assay for PAI-1 binding to LRP was developed, This assay utilizes a unique PAI-1 mutant that was constructed with a hexapeptide tag at the NH2 terminus, which is recognized by the protein kinase, heart muscle kinase and can be specifically labeled with P-32. Our results show that only P-32-PAI-1 in complex with a proteinase binds LRP with high affinity and is efficiently endocytosed by cells, indicating that a high affinity site for LRP is generated on PAI-1 only when in complex with a proteinase. In addition, PAI-1 in complex with different proteinases is shown to cross-compete for LRP binding, demonstrating that the binding site is independent of the proteinase and therefore must reside on the PAI-1 portion of the complex. Finally, mutagenesis of PAI-1 results in loss of LRP binding, confirming that the high affinity binding site is located on PAI-1 and suggesting that the LRP binding site lays within a region of PAI-1 previously shown to contain the heparin binding domain.	Amer Red Cross, Jerome H Holland Lab, Dept Biochem, Rockville, MD 20855 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	American Red Cross; American Red Cross	Lawrence, DA (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	Laurencd@hlnt.redcross.org		Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055747, R01HL055374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55747, HL55374] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOCK PE, 1983, J BIOL CHEM, V258, P5079; CONESE M, 1994, J BIOL CHEM, V269, P17886; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; GRIMSLEY PG, 1995, THROMB RES, V79, P353, DOI 10.1016/0049-3848(95)00123-9; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; Horn I. R., 1996, Fibrinolysis, V10, P21; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; LAWRENCE DA, 1986, BIOCHEMISTRY-US, V25, P6351, DOI 10.1021/bi00369a001; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LAWRENCE DA, 1995, MOL BASIS THROMBOSIS, P517; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STRANDBERG L, 1991, J BIOL CHEM, V266, P13852; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Ukraincik K, 1981, Methods Enzymol, V74 Pt C, P497; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719	57	112	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6358	6366		10.1074/jbc.273.11.6358	http://dx.doi.org/10.1074/jbc.273.11.6358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497365	hybrid			2022-12-27	WOS:000072488500057
J	Battistoni, A; Folcarelli, S; Cervoni, L; Polizio, F; Desideri, A; Giartosio, A; Rotilio, G				Battistoni, A; Folcarelli, S; Cervoni, L; Polizio, F; Desideri, A; Giartosio, A; Rotilio, G			Role of the dimeric structure in Cu,Zn superoxide dismutase - pH-dependent, reversible denaturation of the monomeric enzyme from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; FREE CYSTEINES; COPPER; THERMOSTABILITY; STABILITY; RESIDUES; SITE	To investigate the structural/functional role of the dimeric structure in Cu,Zn superoxide dismutases, we have studied the stability to a variety of agents of the Escherichia coli enzyme, the only monomeric variant of this class so far isolated, Differential scanning calorimetry of the native enzyme showed the presence of two well defined peaks identified as the metal free and holoprotein, Unlike dimeric Cu,Zn superoxide dismutases, the unfolding of the monomeric enzyme was found to be highly reversible, a behavior that may be explained by the absence of free cysteines and the highly polar nature of its molecular surface. The melting temperature of the E. coli enzyme was found to be pH-dependent with the holoenzyme transition centered at 66 degrees C at pH 7.8 and at 79.3 degrees C at pH 6.0, The active-site metals, which were easily displaced from the active site by EDTA, were found to enhance the thermal stability of the monomeric apoprotein but to a lower extent than in the dimeric enzymes from eukaryotic sources, Apo-superoxide dismutase from E. coli was shown to be nearly as stable as the bovine apoenzyme, whose hole form is much more stable and less sensitive to pH variations. The remarkable pH susceptibility of the E. coli enzyme structure was paralleled by the slow decrease in activity of the enzyme incubated at alkaline pH and by modification of the EPR spectrum at lower pH values than in the case of dimeric enzymes, Unlike eukaryotic Cu,Zn superoxide dismutases, the active-site structure of the E. coli enzyme was shown to be reversibly perturbed by urea, These observations suggest that the conformational stability of Cu,Zn superoxide dismutases is largely due to the intrinsic stability of the beta-barrel fold rather than to the dimeric structure and that pH sensitivity and weak metal binding of the E. coli enzyme are due to higher flexibility and accessibility to the solvent of its active-site region.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy	University of Rome Tor Vergata; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Rotilio, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.		Battistoni, Andrea/A-4778-2016	Battistoni, Andrea/0000-0003-4085-7917; desideri, alessandro/0000-0003-1541-4217				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ABERNETHY JL, 1974, J BIOL CHEM, V249, P7339; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Battistoni A, 1996, BIOCHEM J, V320, P713, DOI 10.1042/bj3200713; BATTISTONI A, 1995, FEBS LETT, V374, P199, DOI 10.1016/0014-5793(95)01106-O; Battistoni A, 1996, PROTEIN SCI, V5, P2125, DOI 10.1002/pro.5560051020; Benov L, 1997, ARCH BIOCHEM BIOPHYS, V340, P305, DOI 10.1006/abbi.1997.9940; Benov LT, 1996, FREE RADICAL BIO MED, V21, P117, DOI 10.1016/0891-5849(95)02217-1; BENOV LT, 1994, J BIOL CHEM, V269, P25310; BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; DESIDERI A, 1992, J MOL BIOL, V223, P337, DOI 10.1016/0022-2836(92)90734-2; DIPATTI MCB, 1994, INT CONGR SER, V1058, P129; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Foti D, 1997, BIOCHEMISTRY-US, V36, P7109, DOI 10.1021/bi963020f; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; Imlay KRC, 1996, J BACTERIOL, V178, P2564, DOI 10.1128/jb.178.9.2564-2571.1996; KROLL JS, 1995, MICROBIOL-UK, V141, P2271, DOI 10.1099/13500872-141-9-2271; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; LEPOCK JR, 1985, ARCH BIOCHEM BIOPHYS, V241, P243, DOI 10.1016/0003-9861(85)90380-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P5055, DOI 10.1021/bi00590a005; MARKLUND S, 1974, European Journal of Biochemistry, V47, P469, DOI 10.1111/j.1432-1033.1974.tb03714.x; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCREE DE, 1990, J BIOL CHEM, V265, P14234; ONEILL P, 1988, BIOCHEM J, V251, P41, DOI 10.1042/bj2510041; PERRY LJ, 1987, PROTEIN ENG, V1, P101, DOI 10.1093/protein/1.2.101; Polticelli F, 1996, PROTEIN SCI, V5, P248; RIGO A, 1978, BIOCHEMISTRY-US, V175, P534; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; ROTILIO G, 1971, BIOCHEMISTRY-US, V10, P616, DOI 10.1021/bi00780a011	33	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5655	5661		10.1074/jbc.273.10.5655	http://dx.doi.org/10.1074/jbc.273.10.5655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488695	hybrid			2022-12-27	WOS:000072345000038
J	Iida, J; Meijne, AML; Oegema, TR; Yednock, TA; Kovach, NL; Furcht, LT; McCarthy, JB				Iida, J; Meijne, AML; Oegema, TR; Yednock, TA; Kovach, NL; Furcht, LT; McCarthy, JB			A role of chondroitin sulfate glycosaminoglycan binding site in alpha(4)beta(1) integrin-mediated melanoma cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; ALPHA-4-BETA-1 INTEGRIN; VASCULAR ENDOTHELIUM; EXTRACELLULAR-MATRIX; PROTEOGLYCAN ANTIGEN; PLASMA FIBRONECTIN; SYNTHETIC PEPTIDE; L-SELECTIN; PROTEIN; RECEPTOR	We have previously reported that alpha(4) beta(1) (but not alpha(5) beta(1)) integrin-mediated melanoma cell adhesion is inhibited by removal of cell surface chondroitin sulfate glycosaminoglycan (CSGAG), suggesting that melanoma chondroitin sulfate proteoglycan plays a role in modulating the adhesive function of alpha(4) beta(1) integrin, In the current study, we demonstrated that alpha(4) beta(1) integrin binds to CSGAG, We have identified a peptide from within a, integrin termed SG1 (KKEKDIMKKTI) that binds to cell surface melanoma chondroitin sulfate proteoglycan, indicating that SG1 represents a CSGAG binding site within the alpha(4) integrin subunit, Soluble SG1 inhibits alpha(4) beta(1) integrin-mediated human melanoma cell adhesion to CS1. Polyclonal antibody generated against the peptide inhibits melanoma cell adhesion to CS1, and the inhibition is reversed by Mn2+ and an activating monoclonal antibody anti-beta(1) (8A2). Additionally, pretreatment of cells with anti-SG1 IgG inhibits the expression of the monoclonal antibody 15/7 epitope in the presence of soluble CS1 peptide, suggesting that anti-SG1 IgG prevents ligand binding by alpha(4) beta(1) integrin, These results demon strate that alpha(4) beta(1) integrin interacts directly with CSGAG through SG1 site, and that this site can affect the ligand binding properties of the integrin.	Univ Minnesota, Ctr Hlth, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Orthoped Surg & Biochem, Minneapolis, MN 55455 USA; Athena Neurosci Inc, S San Francisco, CA 94080 USA; Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA; Univ Minnesota, Inst Biomed Engn, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities	Iida, J (corresponding author), Univ Minnesota, Ctr Hlth, Dept Lab Med & Pathol, Box 609,420 Delaware St SE, Minneapolis, MN 55455 USA.				NATIONAL CANCER INSTITUTE [R01CA021463, R37CA021463] Funding Source: NIH RePORTER; NCI NIH HHS [CA21463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1993, SEMIN CANCER BIOL, V4, P215; ALTEVOGT P, 1995, J EXP MED, V182, P345, DOI 10.1084/jem.182.2.345; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BUMOL TF, 1982, P NATL ACAD SCI-BIOL, V79, P1245, DOI 10.1073/pnas.79.4.1245; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHAN BMC, 1991, J IMMUNOL, V147, P398; CHATTOPADHYAY P, 1992, P NATL ACAD SCI USA, V89, P2684, DOI 10.1073/pnas.89.7.2684; COHEN IR, 1994, CANCER RES, V54, P5771; Crottet P, 1996, GLYCOBIOLOGY, V6, P191, DOI 10.1093/glycob/6.2.191; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; FIDLER IJ, 1986, CANCER METAST REV, V5, P29, DOI 10.1007/BF00049529; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GARAFOLO A, 1995, CANCER RES, V55, P414; HARPER JR, 1983, J NATL CANCER I, V71, P259; HARPER JR, 1984, J IMMUNOL, V132, P2096; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HYNES RO, 1992, CELL, V69, P443; IIDA J, 1995, CANCER RES, V55, P2177; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; IIDA J, 1994, TRENDS GLYCOSCI GLYC, V6, P1; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; PIAN F, 1995, CELL, V77, P335; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; RICE GE, 1988, AM J PATHOL, V133, P204; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; Skubitz APN, 1996, AM J PATHOL, V148, P1445; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERFAILLIE CM, 1994, BLOOD, V84, P1802; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277; YAMAGATA M, 1993, J CELL SCI, V106, P55; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219	56	81	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5955	5962		10.1074/jbc.273.10.5955	http://dx.doi.org/10.1074/jbc.273.10.5955			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488735	hybrid			2022-12-27	WOS:000072345000078
J	Kelly-Hershkovitz, E; Weizman, R; Spanier, I; Leschiner, S; Lahav, M; Weisinger, G; Gavish, M				Kelly-Hershkovitz, E; Weizman, R; Spanier, I; Leschiner, S; Lahav, M; Weisinger, G; Gavish, M			Effects of peripheral-type benzodiazepine receptor antisense knockout on MA-10 Leydig cell proliferation and steroidogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIAZEPAM-BINDING INHIBITOR; ANTIPROLIFERATIVE ACTION; STEROID-BIOSYNTHESIS; <H-3>RO 5-4864; TUMOR-CELLS; TISSUES; SITES; GENE; DIETHYLPYROCARBONATE; PK-11195	The peripheral-type benzodiazepine receptor (PBR) is not only widely expressed throughout the body, but it is also genetically conserved. from bacteria to humans, Many functions have been attributed to it, but its primary role remains a puzzle. In the current study, we stably transfected cultures of MA-10 Leydig cells with either control or 18-kDa PBR antisense knockout plasmids, The antisense knockout vector was driven by the human enkephalin promoter, which contains two cAMP response elements, such that cAMP treatment of transfected cells could superinduce 18-kDa PBR antisense RNA transcription and, hence, down-regulate endogenous 18-kDa PBR mRNA levels. Control and knockout MA-10 cell lines were then compared at the level of receptor binding, thymidine incorporation, and steroid biosynthesis. Eighteen-kilodalton PBR knockout reduced the maximal binding capacity of tritium-labeled PBR ligands, and the affinity of receptors to the ligands remained unaltered. Additionally, 24-h accumulation of progesterone was lower in the knockout cells, Exposure of the two cell types to 8-bromo-cAMP resulted in a robust increase in steroid production. However, a complex pattern of steroid accumulation was observed, in which further progestin metabolism was indicated, The later decline in accumulated progesterone as well as the synthesis of androstenedione were different in the two cell types. At the level of cell proliferation, reduction of 18-kDa PBR mRNA showed no effect, Thus, we conclude that the 18-kDa PBR may have a more important role in steroidogenesis than in proliferation in this Leydig cell line.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Endocrinol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Clin Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Tel Aviv Community Mental Hlth Ctr, IL-97197 Tel Aviv, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Gavish, M (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, POB 9649, IL-31096 Haifa, Israel.	mgavish@tx.technion.ac.il						ANHOLT RRH, 1986, TRENDS PHARMACOL SCI, V7, P506, DOI 10.1016/0165-6147(86)90438-4; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; AWAD M, 1988, LIFE SCI, V43, P167, DOI 10.1016/0024-3205(88)90294-9; AWAD M, 1987, J NEUROCHEM, V49, P1407, DOI 10.1111/j.1471-4159.1987.tb01007.x; BARKEY RJ, 1994, P SOC EXP BIOL MED, V206, P243; BAUMINGER S, 1974, J STEROID BIOCHEM, V5, P739, DOI 10.1016/0022-4731(74)90061-2; BEAUMONT K, 1988, BIOCHEM PHARMACOL, V37, P1009, DOI 10.1016/0006-2952(88)90502-3; BENAVIDES J, 1984, LIFE SCI, V35, P1249, DOI 10.1016/0024-3205(84)90095-X; BOUJRAD N, 1993, P NATL ACAD SCI USA, V90, P5728, DOI 10.1073/pnas.90.12.5728; CAMINS A, 1995, EUR J PHARMACOL, V272, P289, DOI 10.1016/0014-2999(94)00652-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444; GAVISH M, 1992, MOL CELL ENDOCRINOL, V88, P1, DOI 10.1016/0303-7207(92)90003-O; GAVISH M, 1995, J STEROID BIOCHEM, V53, P57, DOI 10.1016/0960-0760(95)00040-7; GAVISH M, 1993, PERIPHERAL BENZODIAZ, P209; GORMAN AMC, 1989, J NEUROCHEM, V53, P849, DOI 10.1111/j.1471-4159.1989.tb11782.x; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; KREUGER KE, 1990, J BIOL CHEM, V265, P15015; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; KRUEGER KE, 1992, ANNU REV PHARMACOL, V32, P211, DOI 10.1146/annurev.pa.32.040192.001235; LARCHER JC, 1989, EUR J PHARMACOL, V161, P197, DOI 10.1016/0014-2999(89)90843-1; LIN D, 1993, GENOMICS, V18, P643, DOI 10.1016/S0888-7543(05)80367-2; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; ODBER J, 1994, NEUROREPORT, V5, P1093, DOI 10.1097/00001756-199405000-00018; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RUFF MR, 1985, SCIENCE, V229, P1281, DOI 10.1126/science.2994216; Sambrook J., 2002, MOL CLONING LAB MANU; SKOWRONSKI R, 1987, EUR J PHARMACOL, V143, P305, DOI 10.1016/0014-2999(87)90454-7; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; VERMA A, 1989, ANNU REV PHARMACOL, V29, P307; VERMA A, 1987, P NATL ACAD SCI USA, V84, P2256, DOI 10.1073/pnas.84.8.2256; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P753, DOI 10.1073/pnas.81.3.753; WEISINGER G, 1995, BIOCHEM BIOPH RES CO, V214, P530, DOI 10.1006/bbrc.1995.2319	37	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5478	5483		10.1074/jbc.273.10.5478	http://dx.doi.org/10.1074/jbc.273.10.5478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488670	hybrid			2022-12-27	WOS:000072345000013
J	Kragten, E; Lalande, I; Zimmermann, K; Roggo, S; Schindler, P; Muller, D; van Oostrum, J; Waldmeier, P; Furst, P				Kragten, E; Lalande, I; Zimmermann, K; Roggo, S; Schindler, P; Muller, D; van Oostrum, J; Waldmeier, P; Furst, P			Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL DNA GLYCOSYLASE; AGE-INDUCED APOPTOSIS; NORMAL HUMAN-CELLS; PARKINSONS-DISEASE; POLYACRYLAMIDE GELS; CEREBELLAR NEURONS; DYING NEURONS; PC12 CELLS; DEPRENYL; SELEGILINE	R-(-)-Deprenyl (Selesline) represents one of the drugs currently used for the treatment of Parkinson's disease. This compound was shown to protect neurons or glias from programmed cell death in a variety of models, The mechanism of action of neuroprotection as well as inhibition of apoptosis remains elusive, CGP 3466 is a structurally related analog of R-(-)-deprenyl that exhibits virtually no monoamine oxidase type B inhibiting activity but is neuroprotective in the picomolar concentration range, We showed specific binding of CGP 3466 to glyceraldehyde-3-phosphate dehydrogenase by affinity binding, by affinity labeling, and by means of BIAcore(R) technology. Apoptosis assays based on the human neuroblastoma cell line PAJU established the importance of this interaction for mediating drug-induced inhibition of programmed cell death.	Novartis Pharma Res, Core Technol Area, CH-4002 Basel, Switzerland; Novartis Pharma Res, CH-4002 Basel, Switzerland	Novartis; Novartis	Furst, P (corresponding author), Novartis Pharma Res, Core Technol Area, K-681-344, CH-4002 Basel, Switzerland.	peter.furst@pharma.novartis.com						AGID Y, 1995, B ACAD NAT MED PARIS, V179, P1193; AGID Y, 1995, B ACAD NATL MED, V79, P1203; ARCARI P, 1989, BIOCHEM GENET, V27, P439, DOI 10.1007/BF02399673; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; Calne DB, 1995, BMJ-BRIT MED J, V311, P1583, DOI 10.1136/bmj.311.7020.1583; CONWAY A, 1968, BIOCHEMISTRY-US, V7, P4011, DOI 10.1021/bi00851a031; COOL BL, 1989, CANCER RES, V49, P3029; DEVIJLDER JJ, 1968, BIOCHIM BIOPHYS ACTA, V167, P23, DOI 10.1016/0005-2744(68)90274-X; DOUZHENKOVA IV, 1988, BIOCHIM BIOPHYS ACTA, V957, P60, DOI 10.1016/0167-4838(88)90157-4; Galler Robert Michael, 1996, Journal of the American Osteopathic Association, V96, P228; Gelowitz D. L., 1994, Society for Neuroscience Abstracts, V20, P246; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; HEINONEN EH, 1994, CLIN PHARMACOL THER, V56, P742, DOI 10.1038/clpt.1994.204; Ishitani R, 1996, J PHARMACOL EXP THER, V278, P447; Ishitani R, 1996, P NATL ACAD SCI USA, V93, P9937, DOI 10.1073/pnas.93.18.9937; Ishitani R, 1996, J NEUROCHEM, V66, P928; Iwasaki Y, 1996, NEUROL RES, V18, P168; Koutsilieri E, 1996, EUR J PHARMACOL, V306, P181, DOI 10.1016/0014-2999(96)00184-7; KWAN SW, 1995, ARCH BIOCHEM BIOPHYS, V316, P385, DOI 10.1006/abbi.1995.1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSUR NR, 1993, NUCLEIC ACIDS RES, V21, P993, DOI 10.1093/nar/21.4.993; MEYERSIEGLER K, 1992, CARCINOGENESIS, V13, P2127, DOI 10.1093/carcin/13.11.2127; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MICHEL PP, 1994, EUR J NEUROSCI, V6, P577, DOI 10.1111/j.1460-9568.1994.tb00302.x; Mochizuki H, 1997, J NEURAL TRANSM-SUPP, P125; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; Mytilineou C, 1997, J NEUROCHEM, V68, P33; MYTILINEOU C, 1985, J NEUROCHEM, V45, P1951, DOI 10.1111/j.1471-4159.1985.tb10556.x; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; OLANOW CW, 1996, NEUROLOGY, V47, P210; Paterson IA, 1997, NEUROSCI BIOBEHAV R, V21, P181, DOI 10.1016/S0149-7634(96)00008-5; Piccoli F, 1995, J NEURAL TRANSM-SUPP, P187; PIECHACZYK M, 1984, NATURE, V312, P469, DOI 10.1038/312469a0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROY E, 1993, NEUROREPORT, V4, P1183; SALO PT, 1992, J NEUROSCI RES, V31, P394, DOI 10.1002/jnr.490310223; Sambrook J., 2002, MOL CLONING LAB MANU; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1996, LIFE SCI, V58, P2271, DOI 10.1016/0024-3205(96)00123-3; Stern G, 1996, ADV NEUROL, V69, P101; TATTON WG, 1995, ADV EXP MED BIOL, V363, P15; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; TATTON WG, 1991, J NEUROSCI RES, V30, P666, DOI 10.1002/jnr.490300410; TATTON WG, 1994, J NEUROCHEM, V63, P1572; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	50	182	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5821	5828		10.1074/jbc.273.10.5821	http://dx.doi.org/10.1074/jbc.273.10.5821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488718	hybrid			2022-12-27	WOS:000072345000061
J	Sakai, J; Nohturfft, A; Goldstein, JL; Brown, MS				Sakai, J; Nohturfft, A; Goldstein, JL; Brown, MS			Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein - Evidence from in vivo competition studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE; DEGRADATION; MUTAGENESIS; SEQUENCE; DOMAIN	Sterol regulatory element-binding proteins (SREBPs) are membrane-bound transcription factors that promote lipid synthesis in animal cells. They are embedded in the membranes of the endoplasmic reticulum (ER) in a helical hairpin orientation and are released from the ER by a two-step proteolytic process. Proteolysis begins when the SREBPs are cleaved at Site-1, which is located at a leucine residue in the middle of the hydrophobic loop in the lumen of the ER, Sterols suppress Site-1. cleavage, apparently by interacting with a polytopic membrane protein designated SREBP cleavage-activating protein (SCAP), SREBPs and SCAP are joined together in ER membranes through interaction of their cytoplasmic COOH-terminal domains. Here we use an in vivo competition assay in transfected cells to show that the SREBP SCAP complex is essential for Site-1 cleavage, Overexpression of the truncated COOH-terminal domains of either SREBP-2 or SCAP disrupted the complex between full-length SREBP-2 and SCAP as measured by co-immunoprecipitation. This resulted in a complete inhibition of Site-1 cleavage that was restored by concomitant overexpression of full-length SCAP, The transfected COOH-terminal domains also inhibited the transcription of a reporter gene driven by an SRE-containing promoter, and this, too, was restored by overexpression of full-length SCAP, We interpret these data to indicate that the SREBP SCAP complex directs the Site-1 protease to its target in the lumenal domain of SREBP and that disruption of this complex inactivates the Site-1 cleavage reaction.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sakai, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.			Nohturfft, Axel/0000-0001-9484-3209; Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN KS, 1993, J BIOL CHEM, V268, P18726; AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P481, DOI 10.1007/BF02255839; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; NUA X, 1996, CELL, V87, P415; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; TOMATSU S, 1989, GENE, V80, P353	22	188	197	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5785	5793		10.1074/jbc.273.10.5785	http://dx.doi.org/10.1074/jbc.273.10.5785			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488713	hybrid			2022-12-27	WOS:000072345000056
J	An, SZ; Bleu, T; Hallmark, OG; Goetzl, EJ				An, SZ; Bleu, T; Hallmark, OG; Goetzl, EJ			Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; CELLS; ACTIVATION; MESSENGER; ENCODES; CLONING	The recent identification of the Vzg-1/Edg2 protein as a functional G protein coupled receptor for lysophosphatidic acid (LPA) has allowed a sequence based search for new ones that may encode novel subtypes of LPA receptors. A human cDNA encoding a G protein-coupled receptor, designated Edg4, was identified by searching the GenBank(TM) for homologs of the human Ed2 LPA receptor. The Edg4 protein is 46% identical and 72% similar in amino acid sequence to human Edg2. When overexpressed in Jurkat T cells, the Edg4 protein mediated LPA-induced activation of a serum response element reporter gene with LPR concentration dependence (EC50 of 10 nM) and specificity, This LPA-induced reporter gene activation could be partially inhibited by pretreatment with petussis toxin or C3 exoenzyme, suggesting requirements for both a G(i) protein and Rho GTPase. Overexpression of Edg4 in Jurkat cells also led to increases in specific binding sites for [H-3]LPA. Northern blots revealed that two edg4 mRNA transcripts of 1.8 and 8 kilobases are distributed very differently from edg2 nRNAs in adult human tissues and several cancer cell lines. The existence and distinctive tissue expression of structurally different subtypes of LPA receptors may provide one basis for tissue-specific functions and permit independent regulation of each subtype of LPA receptor.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	An, SZ (corresponding author), Univ Calif San Francisco, Dept Med, 533 Parnassus,Box 0711, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HLA T, 1990, J BIOL CHEM, V265, P9308; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Liliom K, 1996, MOL PHARMACOL, V50, P616; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 2002, MOL CLONING LAB MANU; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569	21	473	508	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7906	7910		10.1074/jbc.273.14.7906	http://dx.doi.org/10.1074/jbc.273.14.7906			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525886	hybrid			2022-12-27	WOS:000072876300020
J	Bauer, MKA; Vogt, M; Los, M; Siegel, J; Wessellborg, S; Schulze-Osthoff, K				Bauer, MKA; Vogt, M; Los, M; Siegel, J; Wessellborg, S; Schulze-Osthoff, K			Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; FAS-MEDIATED APOPTOSIS; OXIDATIVE STRESS; IMMUNE-SYSTEM; HIV-1 TAT; T-CELLS; INVOLVEMENT; CYTOTOXICITY	Activation-induced cell death of T lymphocytes requires the inducible expression of CD95 (APO-1/Fas) ligand, which triggers apoptosis in CD95-bearing target cells by an autocrine or paracrine mechanism. Although execution of the CD95 death pathway is largely independent of reactive oxygen intermediates, activation-induced cell death is blocked by a variety of antioxidants. In the present study, we investigated the involvement of redox processes in the regulation of CD95 ligand (CD95L) expression in Jurkat T cells. We show that various antioxidants potently inhibited the transcriptional activation of CD95L following T cell receptor litigation or stimulation of cells with phorbol ester and ionomycin. Conversely, a prooxidant such as hydrogen peroxide alone was able to increase CD95L expression. As detected by Western blot and cytotoxicity assays, functional expression of CD95L protein was likewise diminished by antioxidants. Inhibition of CD95L expression was associated with a decreased DNA binding activity of nuclear factor (NF)-kappa B, an important redox-controlled transcription factor. Moreover, inhibition of NF-kappa B activity by a transdominant I kappa B mutant attenuated CD95L expression. Our data suggest that, although reactive oxygen intermediates do not act as mediators in the execution phase of CD95-mediated apoptosis, they are involved in the transcriptional regulation of CD95L expression.	Univ Tubingen, Med Clin, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Freiburg, Dept Virol, Freiburg, Germany	Eberhard Karls University of Tubingen; University of Freiburg	Schulze-Osthoff, K (corresponding author), Univ Tubingen, Med Clin, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X; Los, Marek/0000-0001-9518-1411				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cui HL, 1997, P NATL ACAD SCI USA, V94, P7515, DOI 10.1073/pnas.94.14.7515; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KONSTANTINOV AA, 1987, BIOCHIM BIOPHYS ACTA, V894, P1, DOI 10.1016/0005-2728(87)90206-4; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAI JH, 1995, MOL CELL BIOL, V15, P4260; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAGATA S, 1996, NAT MED, V2, P130; Oshimi Y, 1996, J IMMUNOL, V157, P2909; Oyaizu N, 1997, J IMMUNOL, V158, P2456; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Williams MS, 1996, J IMMUNOL, V157, P2395; ZANZAMI N, 1995, J EXP MED, V182, P367	67	160	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8048	8055		10.1074/jbc.273.14.8048	http://dx.doi.org/10.1074/jbc.273.14.8048			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525905	Green Published, hybrid			2022-12-27	WOS:000072876300039
J	Chou, DKH; Tobet, SA; Jungalwala, FB				Chou, DKH; Tobet, SA; Jungalwala, FB			Restoration of synthesis of sulfoglucuronylglycolipids in cerebellar granule neurons promotes dedifferentiation and neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURKINJE-CELL ABNORMALITY; NERVOUS-SYSTEM; DEVELOPMENTAL EXPRESSION; L2/HNK-1 CARBOHYDRATE; HNK-1-REACTIVE ANTIGENS; HNK-1 ANTIBODY; ADHESION MOLECULES; MURINE MUTANTS; GLYCOLIPIDS; NEOLACTOGLYCOLIPIDS	Sulfoglucuronyl carbohydrate (SGC) linked to the terminal moiety of neolacto-oligosaccharides is expressed in several glycoproteins of the immunoglobulin superfamily involved in neural cell-cell recognition as well as in two sulfoglucuronylglycolipids (SGGLs) of the nervous system. SGGLs and SGC-containing glycoproteins are temporally and spatially regulated during development of the nervous system, In the cerebellum, the expression of SGC, particularly that of SGGLs, is biphasic, Several studies have suggested that the initial rise and decline in the levels of SGGLs and SGC-containing proteins correlated with the migration of granule neurons from the external granule cell layer to the internal granule cell layer and their subsequent maturation, whereas the later rise and continued expression of SGGLs in the adult was associated with their localization in the Purkinje neurons and their dendrites in the molecular layer. Here it is shown by immunocytochemical methods that the expression of SGC declined progressively in granule neurons isolated from cerebella of increasing age, The decline in the expression of SGC in granule neurons was also shown with time in culture. These results correlated with the previously shown declining activity of the regulatory enzyme lactosylceramide N-acetylglucosaminyltransferase (GlcNAc-Tr) with age in vivo and in isolated granule neurons in culture, GlcNAc-Tr synthesizes a key precursor, lactotriosylceramide, involved in the biosynthesis of SGGL-1. The downregulated synthesis of SGGLs in the mature granule neurons was shown by immunocytochemical and biochemical methods to be restored when a precursor, glucuronylneolactotetraosylceramide (GGL-1), which is beyond the GlcNAc-Tr step, was exogenously provided to these cells, The biological effect of such restoration of the synthesis of SGGLs in the mature granule neurons leads to cell aggregation and enhanced proliferation of neurites, amounting to dedifferentiation.	Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dept Biomed Sci, Waltham, MA 02254 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Jungalwala, FB (corresponding author), Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dept Biomed Sci, 200 Trapelo Rd, Waltham, MA 02254 USA.			Tobet, Stuart/0000-0002-1615-7331	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD004147] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 04147, P01-HD05505] Funding Source: Medline; NINDS NIH HHS [R01-NS24405] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1997, RELATION ITS EVOLUTI, P324; BRONNERFRASER M, 1987, DEV BIOL, V123, P321, DOI 10.1016/0012-1606(87)90390-3; Chou DKH, 1996, J BIOL CHEM, V271, P28868, DOI 10.1074/jbc.271.46.28868; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; CHOU DKH, 1994, J NEUROCHEM, V62, P307; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; DASTON MM, 1991, J CELL BIOL, V112, P1229, DOI 10.1083/jcb.112.6.1229; HALL H, 1995, GLYCOBIOLOGY, V5, P435, DOI 10.1093/glycob/5.4.435; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HOLLEY JA, 1987, DEV NEUROSCI-BASEL, V9, P105, DOI 10.1159/000111613; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V150, P342, DOI 10.1016/0006-291X(88)90526-8; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KROG L, 1992, APMIS, V100, P53; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; Nair SM, 1997, J NEUROCHEM, V68, P1286; NAIR SM, 1993, J COMP NEUROL, V332, P282, DOI 10.1002/cne.903320303; Nair SM, 1997, J NEUROCHEM, V69, pS26; NAIR SM, 1998, IN PRESS NEUROSCIENC; PRASADARAO N, 1990, J HISTOCHEM CYTOCHEM, V38, P1193, DOI 10.1177/38.8.1694876; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; Schachner M, 1995, PROG BRAIN RES, V105, P183; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; VALNES K, 1985, J HISTOCHEM CYTOCHEM, V33, P755, DOI 10.1177/33.8.3926864	33	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8508	8515		10.1074/jbc.273.14.8508	http://dx.doi.org/10.1074/jbc.273.14.8508			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525965	hybrid			2022-12-27	WOS:000072876300099
J	Fitzmaurice, AM; Kolattukudy, PE				Fitzmaurice, AM; Kolattukudy, PE			An acyl-CoA synthase (acoas) gene adjacent to the mycocerosic acid synthase (mas) locus is necessary for mycocerosyl lipid synthesis in Mycobacterium tuberculosis var. bovis BCG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; PHTHIOCEROL DIESTER; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ALLELIC EXCHANGE; SYNTHETASE; BIOSYNTHESIS; PURIFICATION; MYCOSIDES; CLUSTER	An open reading frame, ORF3, first identified adjacent to the mycocerosic acid synthase gene in Mycobacterium bovis BCG encodes a protein with acyl-CoA synthase (ACoAS) activity. Genes homologous to acoas are found adjacent to other multifunctional polyketide synthase genes in the mycobacterial genome. To test whether these gene products are necessary to esterify the fatty acids generated by the adjacent polyketide synthase gene products, the acoas gene was disrupted in M. bovis BCG using a suicide vector containing the acoas gene with an internal deletion and the hygromycin-resistant gene as selection marker. Allelic exchange at the acoas locus was confirmed by Southern hybridization and polymerase chain reaction amplification of both nanking regions expected hom homologous recombination, Immunoblot analysis indicated that the 65-kDa ACoAS protein product was absent in the mutant. Chromatographic analysis of lipids derived from [1-C-14]propionate showed that the mutant did not produce mycocerosyl lipids, although it produced normal levels of mycocerosic acid synthase. These results suggest that ACoAS is involved in the synthesis of mycocerosyl Lipids of the mycobacterial cell wall.	Ohio State Univ, Dept Biochem, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kolattukudy, PE (corresponding author), Ohio State Univ, Dept Biochem, Neurobiotechnol Ctr, 206 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	Kolattukudy.2@osu.edu	kolattukudy, pappachan e/A-1350-2012		NIAID NIH HHS [AI35272] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035272] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Balasubramanian V, 1996, J BACTERIOL, V178, P273, DOI 10.1128/jb.178.1.273-279.1996; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; COLLINS FM, 1991, REV INFECT DIS, V13, P940; DAFFE M, 1989, BIOCHIM BIOPHYS ACTA, V1002, P333, DOI 10.1016/0005-2760(89)90347-0; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DECRECYLAGARD V, 1998, IN PRESS COMPREHENSI; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; Fernandes ND, 1998, J BIOL CHEM, V273, P2823, DOI 10.1074/jbc.273.5.2823; Fitzmaurice AM, 1997, J BACTERIOL, V179, P2608, DOI 10.1128/jb.179.8.2608-2615.1997; FOLCH J, 1957, J BIOL CHEM, V226, P497; GREENWAY DLA, 1983, J BIOL CHEM, V258, P3034; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; HORI K, 1989, J BIOCHEM-TOKYO, V106, P639, DOI 10.1093/oxfordjournals.jbchem.a122909; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MATHUR M, 1992, J BIOL CHEM, V267, P19388; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; RAIBAUD A, 1991, J BACTERIOL, V173, P4454, DOI 10.1128/JB.173.14.4454-4463.1991; RAINWATER DL, 1985, J BIOL CHEM, V260, P616; REYRAT JM, 1995, P NATL ACAD SCI USA, V92, P8768, DOI 10.1073/pnas.92.19.8768; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; YOUNG DB, 1993, J BACTERIOL, V175, P1, DOI 10.1128/JB.175.1.1-6.1993	30	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8033	8039		10.1074/jbc.273.14.8033	http://dx.doi.org/10.1074/jbc.273.14.8033			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525903	hybrid			2022-12-27	WOS:000072876300037
J	Kemball-Cook, G; Johnson, DJD; Takamiya, O; Banner, DW; McVey, JH; Tuddenham, EGD				Kemball-Cook, G; Johnson, DJD; Takamiya, O; Banner, DW; McVey, JH; Tuddenham, EGD			Coagulation factor VII Gln(100)-> Arg - Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; GAMMA-CARBOXYLATION; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; HEMOPHILIA-B; FACTOR-XA; SITE; RESIDUES; COMPLEX; IDENTIFICATION	We have used recombinant mammalian expression and purification of the factor VII (FVII) variant Gln(100) --> Arg (Q100RFVII) to study FVII deficiency in subjects with this mutation. Q100RFVII was secreted poorly in comparison with wild-type FVII (WTFVII) in a stable mammalian expression system, and purified variant protein was found to have undetectable clotting activity. Following activation by immobilized factor Xa, Q100RFVIIa had amidolytic activity similar to WTFVIIa in the absence of soluble tissue factor (sTF); however, unlike WTFVIIa no typical increase in activity was seen after addition of sTF. In a factor X activation assay using relipidated transmembrane truncated tissue factor (residues 1-243), Q100RFVIIa showed less than 5% of the ability of WTFVIIa to activate factor X. We performed direct binding analysis of WT and Q100RFVII/FVIIa to immobilized sTF using surface plasmon resonance, and severely reduced binding of both non-activated and activated Q100RFVII to sTF was seen, indicating a pronounced defect in tissue factor (TF) interaction with this variant. In the sTF-FVIIa crystal structure the candidate residue Gln(100) is not in contact with TF but is at the epidermal growth factor 2-protease domain interface, We suggest that the mutation results in a global fold change severely reducing tissue factor interaction; mutation of FVII residues not directly involved in the interaction with TF may still result in variant FVII unable to take part in the initiation of coagulation.	Hammersmith Hosp, Imperial Coll, Sch Med, MRC,Clin Sci Ctr,Haemostasis Res Grp, London W12 0NN, England; Shinshu Univ, Sch Allied Med Sci, Matsumoto, Nagano 390, Japan; Hoffmann La Roche Ag, Div Pharma, CH-4002 Basel, Switzerland	Imperial College London; Shinshu University; Roche Holding	Kemball-Cook, G (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, MRC,Clin Sci Ctr,Haemostasis Res Grp, Du Cane Rd, London W12 0NN, England.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909; McVey, John/0000-0002-7416-533X	MRC [MC_U120074259] Funding Source: UKRI; Medical Research Council [MC_U120074259] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHTON AW, 1995, FEBS LETT, V374, P141, DOI 10.1016/0014-5793(95)01093-T; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bhardwaj D, 1996, J BIOL CHEM, V271, P30685, DOI 10.1074/jbc.271.48.30685; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; CHAING S, 1994, BLOOD, V83, P3524; Clarke BJ, 1996, BRIT J HAEMATOL, V93, P445, DOI 10.1046/j.1365-2141.1996.5141054.x; Cooper DN, 1997, THROMB HAEMOSTASIS, V78, P151; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Edgington TS, 1997, THROMB HAEMOSTASIS, V78, P401; FAIR DS, 1983, BLOOD, V62, P784; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KAZAMA Y, 1992, BLOOD COAGUL FIBRIN, V3, P697, DOI 10.1097/00001721-199212000-00001; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KEMBALLCOOK G, 1994, GENE, V139, P275, DOI 10.1016/0378-1119(94)90769-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUPPUSWAMY MN, 1993, THROMB HAEMOSTASIS, V69, P1293; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Leonard BJN, 1998, BLOOD, V91, P142, DOI 10.1182/blood.V91.1.142.142_142_148; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; MORTON TA, 1998, IN PRESS METHODS ENZ; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OBRIEN DP, 1993, BIOCHEM J, V292, P7, DOI 10.1042/bj2920007; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Persson E, 1996, HAEMOSTASIS, V26, P31; Persson E, 1996, FEBS LETT, V385, P241, DOI 10.1016/0014-5793(96)00400-0; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1995, BIOCHEMISTRY-US, V34, P6310, DOI 10.1021/bi00019a008; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; RUF W, 1991, BIOCHEM J, V278, P729, DOI 10.1042/bj2780729; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; Sridhara S, 1996, AM J HEMATOL, V53, P66; TAKAMIYA O, 1993, HUM MOL GENET, V2, P1355, DOI 10.1093/hmg/2.9.1355; TARTARY M, 1993, BRIT J HAEMATOL, V84, P662, DOI 10.1111/j.1365-2141.1993.tb03143.x; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011	41	23	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8516	8521		10.1074/jbc.273.14.8516	http://dx.doi.org/10.1074/jbc.273.14.8516			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525966	hybrid			2022-12-27	WOS:000072876300100
J	Qiu, ZH; Gijon, MA; de Carvalho, MS; Spencer, DM; Leslie, CC				Qiu, ZH; Gijon, MA; de Carvalho, MS; Spencer, DM; Leslie, CC			The role of calcium and phosphorylation of cytosolic phospholipase A(2) in regulating arachidonic acid release in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; PROTEIN-KINASE-C; EXTRACELLULAR CALCIUM; HUMAN-NEUTROPHILS; NUCLEAR-ENVELOPE; PLASMA-MEMBRANE; ACTIVATION; CELLS; MOBILIZATION; TRANSLOCATION	Arachidonic acid release is induced in macrophages with diverse agonists including calcium ionophores, phorbol myristate acetate (PMA), okadaic acid, and the phagocytic particle, zymosan, and correlates with activation of cytosolic phospholipase A(2) (cPLA(2)). The role of calcium and phosphorylation of cPLA(2) in regulating arachidonic acid release was investigated, Zymosan induced a rapid and transient increase in [Ca2+](i). This in itself is not sufficient to induce arachidonic acid release since ATP and platelet activating factor (PAF), agonists that induce transient calcium mobilization in macrophages, induced little arachidonic acid release, Unlike zymosan, which is a strong activator of mitogen-activated protein kinase (MAPK), ATP and PAF were weak MAPK activators and induced only a partial and transient increase in cPLA(2) phosphorylation (gel shift). However, ATP or PAF together with colony stimulating factor-1 (CSF-1) synergistically stimulated arachidonic acid release, CSF-1 is a strong MAPK activator that induces a rapid and complete cPLA(2) gel shift but not calcium mobilization or arachidonic acid release, Arachidonic acid release was more rapid in response to CSF-1 plus ATP or PAF than zymosan and correlated with the time course of the cPLA(2) gel shift. Although low concentrations of ionomycin induced a lower magnitude of calcium mobilization than ATP, the response was more sustained resulting in arachidonic acid release, A23187 and ionomycin induced weak MAPK activation, and a partial and transient cPLA(2) gel shift. The MAPK kinase inhibitor, PD 98059 suppressed A23187-induced MAPK activation and cPLA(2) gel shift but had little effect on arachidonic acid release. These results indicate that in macrophages a transient increase in [Ca2+](i) and sustained phosphorylation of cPLA(2) can act together to promote arachidonic acid release but neither alone is sufficient. A sustained increase in calcium is sufficient for inducing arachidonic acid release. However, PMA and okadaic acid induce arachidonic acid release without increasing [Ca2+](i), although resting levels of calcium are required, suggesting alternative mechanisms of regulation.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org			NHLBI NIH HHS [HL34303, P01 HL034303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSOTORRE SR, 1993, J BIOL CHEM, V268, P18640; AMBS P, 1995, BIOCHEM J, V311, P189, DOI 10.1042/bj3110189; BALSINDE J, 1992, BIOCHIM BIOPHYS ACTA, V1136, P75, DOI 10.1016/0167-4889(92)90087-R; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHOW SC, 1993, BIOCHIM BIOPHYS ACTA, V1179, P81, DOI 10.1016/0167-4889(93)90074-Y; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; EMILSSON A, 1986, BIOCHIM BIOPHYS ACTA, V876, P533, DOI 10.1016/0005-2760(86)90041-X; FERNANDEZ B, 1991, BIOCHEM BIOPH RES CO, V180, P1036, DOI 10.1016/S0006-291X(05)81170-2; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Ishimoto T, 1996, J BIOCHEM-TOKYO, V120, P1247; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PICELLO E, 1990, J BIOL CHEM, V265, P5635; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RANDRIAMAMPITA C, 1989, FEBS LETT, V249, P199, DOI 10.1016/0014-5793(89)80624-6; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SierraHonigmann R, 1996, LAB INVEST, V74, P684; XU XX, 1994, J BIOL CHEM, V269, P31693	32	178	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8203	8211		10.1074/jbc.273.14.8203	http://dx.doi.org/10.1074/jbc.273.14.8203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525925	hybrid			2022-12-27	WOS:000072876300059
J	Takahashi, R; Deveraux, Q; Tamm, I; Welsh, K; Assa-Munt, N; Salvesen, GS; Reed, JC				Takahashi, R; Deveraux, Q; Tamm, I; Welsh, K; Assa-Munt, N; Salvesen, GS; Reed, JC			A single BIR domain of XIAP sufficient for inhibiting caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS PROTEINS; CELL-DEATH; GENES; IAP; HOMOLOGS; FAMILY	The inhibitor of apoptosis proteins (IAPs) constitute an evolutionarily conserved family of homologous proteins that suppress apoptosis induced by multiple stimuli. Some IAP family proteins, including XIAP, cIAP-1, and cIAP-2, can bind and directly inhibit selected caspases, a group of intracellular cell death proteases. These caspase-inhibiting IAP family proteins all contain three tandem BIR domains followed by a RING zinc finger domain. To determine the structural basis for caspase inhibition by XIAP, we analyzed the effects of various fragments of this IAP family protein on caspase activity in vitro and on apoptosis suppression in intact cells. The RING domain of XIAP failed to inhibit the activity of recombinant caspases-3 or -7, whereas a fragment of XIAP encompassing the three tandem BIR domains potently inhibited these caspases in vitro and blocked Fas (CD95)-induced apoptosis when expressed in cells. Further dissection of the XIAP protein demonstrated that only the second of the three BIR domains (BIR2) was capable of binding and inhibiting these caspases. The apparent inhibition constants (K-i) for BIR2-mediated inhibition of caspases-3 and -7 were 2-5 nM, indicating that this single BIR domain possesses potent anti caspase activity, Expression of the BIR2 do main in cells also partially suppressed Fas-induced apoptosis and blocked cytochrome c-induced processing of caspase-9 in cytosolic extracts, whereas BIR1 and BIR3 did not. These findings identify BIR2 as the minimal caspase-inhibitory domain of XIAP and indicate that a single BIR domain can be sufficient for binding and inhibiting caspases.	Burnham Inst, Program Apoptosis & Cell Death Regulat, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Regulat, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-institute.org			NCI NIH HHS [CA-69381, CA-72994, CA-30199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381, P30CA030199, R01CA072994] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DEVERAUX QL, 1998, IN PRESS EMBO J; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; HARVEY AJ, 1998, IN PRESS CELL DEATH; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	24	503	545	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7787	7790		10.1074/jbc.273.14.7787	http://dx.doi.org/10.1074/jbc.273.14.7787			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525868	hybrid			2022-12-27	WOS:000072876300002
J	Pagliuca, A; Cannada-Bartoli, P; Lania, L				Pagliuca, A; Cannada-Bartoli, P; Lania, L			A role for Sp and helix-loop-helix transcription factors in the regulation of the human Id4 gene promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTUALLY EXCLUSIVE EXPRESSION; DNA-BINDING PROTEINS; NEGATIVE REGULATOR; G(1) PROGRESSION; MAMMALIAN-CELLS; B-CELLS; DIFFERENTIATION; ACTIVATION; ENHANCER; MOTIF	Id family helix-loop helix (HLH) proteins are involved in the regulation of proliferation and differentiation of several cell types. To identify cis and trans-acting factors that regulate Id4 gene expression, we have analyzed the promoter regulatory sequences of the human Id4 gene in transient transfections and gel mobility shift assays. We have identified two functional elements, both located downstream from the TATA motif, that control Id4 promoter activity. One element contains a consensus E-box, and we demonstrated that the protein complex binding to the E-box contains the bHLH-zip upstream stimulatory factor (USF) transcription factor. Enforced expression of USF1 leads to E-box-mediated stimulation of promoter activity. The E-box also mediated stimulatory effects of several bHLH transcription factors, and co expression of Id4 blocked the stimulatory effect mediated by the bHLH factors. A second element is a GA motif, located downstream from the transcriptional start sites, mutation of which resulted in a 20-fold increase in transcriptional activity. Gel-shift analysis and transfections into Drosophila Schneider SL2 cells showed that the repressor element is recognized by both Sp1 and Sp3 factors. These data suggest that Id4 transcription control is highly complex, involving both negative and positive regulatory elements, including a novel inhibitory function exerted by Sp1 and Sp3 transcription factors.	Univ Naples Federico II, Dept Genet Mol & Gen Biol, I-80134 Naples, Italy	University of Naples Federico II	Lania, L (corresponding author), Univ Naples Federico II, Dept Genet Mol & Gen Biol, Via Mezzocannone 8, I-80134 Naples, Italy.	lania@biol.dgbm.unina.it	pagliuca, alfredo/J-3107-2012; Pagliuca, Alfredo/AAI-3689-2020	pagliuca, alfredo/0000-0002-8703-2077; 				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DEED RW, 1993, ONCOGENE, V8, P599; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARA E, 1994, J BIOL CHEM, V269, P2139; HOFMANN A, 1997, P NATL ACAD SCI USA, V94, P8928; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KURABAYASHI M, 1994, J BIOL CHEM, V269, P31162; LANFRANCONE L, 1992, GENOMICS, V12, P720, DOI 10.1016/0888-7543(92)90301-8; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; MAJELLO B, 1995, ONCOGENE, V10, P1841; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN K, 1995, FEBS LETT, V374, P279, DOI 10.1016/0014-5793(95)01128-2; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; RIECHMANN V, 1995, CELL GROWTH DIFFER, V6, P837; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAISANIT S, 1995, MOL CELL BIOL, V15, P1513; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHOJI W, 1994, J BIOL CHEM, V269, P5078; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Tournay O, 1996, MOL CELL BIOL, V16, P2418; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILSON R, 1995, MECH DEVELOP, V49, P211, DOI 10.1016/0925-4773(94)00319-I; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	54	34	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7668	7674		10.1074/jbc.273.13.7668	http://dx.doi.org/10.1074/jbc.273.13.7668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516472	hybrid			2022-12-27	WOS:000072738500068
J	Takashima, S; Yoshida, Y; Kanematsu, T; Kojima, N; Tsuji, S				Takashima, S; Yoshida, Y; Kanematsu, T; Kojima, N; Tsuji, S			Genomic structure and promoter activity of the mouse polysialic acid synthase (mST8Sia IV/PST) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; DEVELOPMENTALLY-REGULATED MEMBER; HUMAN POLYSIALYLTRANSFERASE; EMBRYONIC BRAIN; NERVOUS-SYSTEM; EXPRESSION; CLONING; STX; ALPHA-2,8-SIALYLTRANSFERASE; FAMILY	The mouse gene encoding ST8Sia IV/PST, one of two polysialic acid synthases, was isolated and characterized, The mST8Sia IV/PST gene was found to comprise over 60 kilobases and to be composed of five exons, Primer extension analysis revealed that transcription started from 333 nucleotides upstream of the translational initiation site, Transfection with nested deletion mutants of the 5'-flanking region fused to the luciferase reporter gene revealed that the promoter activity of the -107/+145 region was correlated with the gene expression of mST8Sia IV/PST in embryonal carcinoma P19 and neuroblastoma F11 cells, This proximal promoter region lacks an apparent TATA box but has putative binding sites for transcription factors Sp1 and NF-Y (CCAAT binding protein) at nucleotide positions -66/ -57 and -47/-37, respectively, Individual deletions and mutations of the inverted Sp1 binding site or inverted NF-Y binding site caused significant reduction of the promoter activity, indicating that each binding site was involved in essential transcription control, Mobility shift assaying also revealed that Sp1 and NF-Y in a nuclear extract of P19 cells bind to the promoter region of the mST8Sia IV/PST gene, Deletion of the region from -60 to -40, which contains parts of both the Sp1 and NF-Y binding sites, completely abolished the promoter activity, suggesting that both Sp1 and NF-Y are synergetically involved in transcription regulation of the mST8Sia IV/PST gene in P19 and F11 cells, Although the overall structures of the two polysialic acid synthase genes (ST8Sia II/STX and IV/PST) are very similar, there is no extensive sequence homology between the 5'-flanking regions of the ST8Sia II/STX and IV/PST genes, suggesting that these two genes are expressed under different regulatory systems.	Inst Phys & Chem Res, Dept Mol Glycobiol, Frontier Res Program, Wako, Saitama 35101, Japan	RIKEN	Tsuji, S (corresponding author), Inst Phys & Chem Res, Dept Mol Glycobiol, Frontier Res Program, Wako, Saitama 35101, Japan.	stsuji@postman.riken.go.jp	Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219				CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; HUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1996, J BIOL CHEM, V271, P22058, DOI 10.1074/jbc.271.36.22058; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAKAMATSU K, 1994, CANCER RES, V54, P2598; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Twyman RM, 1995, J NEUROGENET, V10, P67, DOI 10.3109/01677069509083457; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; Yoshida Y, 1996, GLYCOBIOLOGY, V6, P573, DOI 10.1093/glycob/6.6.573; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7675	7683		10.1074/jbc.273.13.7675	http://dx.doi.org/10.1074/jbc.273.13.7675			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516473	hybrid			2022-12-27	WOS:000072738500069
J	Aleryani, S; Milo, E; Rose, Y; Kostka, P				Aleryani, S; Milo, E; Rose, Y; Kostka, P			Superoxide-mediated decomposition of biological S-nitrosothiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GLUTATHIONE-PEROXIDASE; RADICALS; CELLS	Incubation of S-nitrosocysteine or S-nitrosoglutathione (5-100 mu M) in the presence of a generator of superoxide (xanthine/xanthine oxidase) resulted in a time-dependent decomposition of S-nitrosothiols and accumulation of nitrite/nitrate in reaction mixtures, Quantitatively, the amounts of nitrite/nitrate represented >90% of nitrosonium equivalent of S-nitrosothiols degraded during the incubation, The reaction rates were unaffected by the presence catalase (1 unit/ml). Kinetic analysis showed that the degradation of S-nitrosothiols in the presence of superoxide proceeded at second order rate constants of 76,900 M-1 s(-1) (S-nitrosocysteine) and 12,800 M-1 s(-1) (S-nitrosoglutathione), respectively, with a stoichiometric ratio of 1 mol of S-nitrosothiol per 2 mol of superoxide, The findings provide the evidence for the involvement of superoxide in the metabolism of S-nitrosothiols. Furthermore, substantially slower reaction rates of superoxide with S-nitrosothiols relative to the reaction rate with NO are consistent with the contention that the transient formation of S-nitrosothiols in biological systems may protect NO from its rapid destruction by superoxide, thus enabling these compounds to serve as carriers or buffers of NO.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland State University	Kostka, P (corresponding author), Cleveland State Univ, Dept Chem, 2399 Euclid Ave, Cleveland, OH 44115 USA.							ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; ASKEW SC, 1995, J CHEM SOC PERK T 2, P741, DOI 10.1039/p29950000741; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BIELSKI BHJ, 1980, J PHYS CHEM-US, V84, P830, DOI 10.1021/j100445a006; BIELSKI BHJ, 1978, PHOTOCHEM PHOTOBIOL, V28, P645, DOI 10.1111/j.1751-1097.1978.tb06986.x; BOLTZ DF, 1974, COLORIMETRIC DETERMI, P197; BORS W, 1985, HDB METHODS OXYGEN R, P181; Fridovich I., 1985, HDB METHODS OXYGEN R, P51; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hou YC, 1996, BIOCHEM BIOPH RES CO, V228, P88, DOI 10.1006/bbrc.1996.1620; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; Naseem KM, 1996, BIOCHEM J, V318, P759, DOI 10.1042/bj3180759; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; Park JKJ, 1997, ANAL BIOCHEM, V249, P61, DOI 10.1006/abio.1997.2159; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; TAKABE T, 1980, BIOCHEMISTRY-US, V19, P3985, DOI 10.1021/bi00558a015	27	74	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6041	6045		10.1074/jbc.273.11.6041	http://dx.doi.org/10.1074/jbc.273.11.6041			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497319	hybrid			2022-12-27	WOS:000072488500011
J	Hopf, C; Hoch, W				Hopf, C; Hoch, W			Dimerization of the muscle-specific kinase induces tyrosine phosphorylation of acetylcholine receptors and their aggregation on the surface of myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NEUROMUSCULAR-JUNCTION; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; ALPHA-DYSTROGLYCAN; SKELETAL-MUSCLE; HEPARAN-SULFATE; BETA-SUBUNIT; AGRIN; EXPRESSION	During development of the neuromuscular junction, neuronal splice variants of agrin initiate the aggregation of acetylcholine receptors on the myotube surface. The muscle-specific kinase is thought to be part of an agrin receptor complex, although the recombinant protein does not bind agrin with high affinity. To specify its function, we induced phosphorylation and activation of this kinase in the absence of agrin by incubating myotubes with antibodies directed against its N-terminal sequence, Antibody-induced dimerization of the muscle-specific kinase but not treatment with Fab fragments was sufficient to trigger two key events of early postsynaptic development: acetylcholine receptors accumulated into aggregates, and their P-subunits became phosphorylated on tyrosine residues. Heparin partially inhibited receptor aggregation induced by both agrin and anti-muscle-specific kinase antibodies, In contrast, it did not affect kinase or acetylcholine receptor phosphorylation. These data indicate that agrin induces postsynaptic differentiation by dimerizing the muscle-specific kinase, They also suggest that activation of the kinase domain can account for only part of agrin's effects. Dimerization of this molecule appears to activate an additional signal, mast likely by organizing a scaffold for other postsynaptic proteins.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Hoch, W (corresponding author), Max Planck Inst Entwicklungsbiol, Biochem Abt, Spemannstr 35, D-72076 Tubingen, Germany.	werner.hoch@tuebingen.mpg.de	Hopf, Carsten/A-3275-2015	Hopf, Carsten/0000-0003-0802-6451				APEL ED, 1997, NEURON, V18, P1; Besser J, 1996, MECH DEVELOP, V59, P41, DOI 10.1016/0925-4773(96)00573-4; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CifuentesDiaz C, 1996, EUR J NEUROSCI, V8, P1666, DOI 10.1111/j.1460-9568.1996.tb01310.x; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FENDLY BM, 1990, CANCER RES, V50, P1550; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FROEHNER SC, 1981, P NATL ACAD SCI-BIOL, V78, P5230, DOI 10.1073/pnas.78.8.5230; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P144; GANJU P, 1995, ONCOGENE, V11, P281; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1997, P NATL ACAD SCI USA, V94, P8848, DOI 10.1073/pnas.94.16.8848; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HALL ZW, 1993, NEURON S, V10, P99; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HIRANO Y, 1989, J NEUROSCI, V9, P1555; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hopf C, 1996, J BIOL CHEM, V271, P5231; Hopf C, 1997, EUR J NEUROSCI, V9, P1170, DOI 10.1111/j.1460-9568.1997.tb01471.x; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; LIN PH, 1991, METHOD ENZYMOL, V198, P251; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; STONE DM, 1995, J NEUROSCI, V15, P6767; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Wallace B, 1997, NAT BIOTECHNOL, V15, P721, DOI 10.1038/nbt0897-721; WALLACE BG, 1990, J NEUROSCI, V10, P3576; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITE MF, 1988, J BIOL CHEM, V263, P2969; Xie MH, 1997, NAT BIOTECHNOL, V15, P768, DOI 10.1038/nbt0897-768	49	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6467	6473		10.1074/jbc.273.11.6467	http://dx.doi.org/10.1074/jbc.273.11.6467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497380	hybrid			2022-12-27	WOS:000072488500072
J	Toure, A; Dorseuil, O; Morin, L; Timmons, P; Jegou, B; Reibel, L; Gacon, G				Toure, A; Dorseuil, O; Morin, L; Timmons, P; Jegou, B; Reibel, L; Gacon, G			MgcRacGAP, a new human GTPase-activating protein for Rac and Cdc42 similar to Drosophila rotundRacGAP gene product, is expressed in male germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; N-CHIMAERIN; KINASE-C; RHO; DOMAIN; SPECIFICITIES; P21RAC; TARGET; FAMILY; REGION	In a search for new partners of the activated form of Pac GTPase, we have isolated through a two-hybrid cloning procedure a human cDNA encoding a new GTPase-activating protein (GAP) for Rho family GTPases, A specific mRNA of 3.2 kilobases was detected in low abundance in many cell types and found highly expressed in testis. A protein of the predicted size 58 kDa, which we call MgcRacGAP, was detected in human testis as well. as in germ cell. tumor extracts by immunoblotting with antibodies specific to recombinant protein, In vitro, the GAP domain of MgcRacGAP strongly stimulates Rad and Cdc42 GTPase activity but is almost inactive on RhoA N-terminal to its GAP domain, MgcRacGAP contains a cysteine-rich zinc finger-like motif characteristic of the Chimaerin family of RhoGAPs, The closest homolog of MgcRacGAP is RotundRacGAP, a product of the Drosophila refund locus, In situ hybridization experiments in human testis demonstrate a specific expression of mgcRacGAP mRNA in spermatocytes similar to that of retundRacGAP in Drosophila testis, Therefore, protein sequence similarity and analogous developmental and tissue specificities of gene expression support the hypothesis that RotundRacGAP and MgcRacGAP have equivalent functions in insect and mammalian germ cells, Since refundRacGAP deletion leads to male sterility in the fruit fly, the mgcRacGAP gene may prove likewise to play a key role in mammalian male fertility.	Inst Cochin Genet Mol, INSERM, U257, F-75014 Paris, France; Univ Rennes 1, INSERM, U435, F-35042 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Gacon, G (corresponding author), Inst Cochin Genet Mol, INSERM, U257, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Jégou, Bernard/I-4742-2015; TOURE, Aminata/B-3236-2018	TOURE, Aminata/0000-0001-5629-849X; JEGOU, Bernard/0000-0003-0623-3609				AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; AGNEL M, 1989, GENE DEV, V3, P85, DOI 10.1101/gad.3.1.85; AHMED S, 1994, J BIOL CHEM, V269, P17642; AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AHMED S, 1995, METHOD ENZYMOL, V256, P114; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; Hoemann CD, 1996, GENE, V168, P135, DOI 10.1016/0378-1119(95)00747-4; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KAISER C, 1989, METHODS YEAST GENETI; KERRIDGE S, 1988, ROUX ARCH DEV BIOL, V197, P19, DOI 10.1007/BF00376037; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILKINSON DG, 1990, POST IMPLANTATION MA, P55; XU XM, 1994, J BIOL CHEM, V269, P23569	32	126	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6019	6023		10.1074/jbc.273.11.6019	http://dx.doi.org/10.1074/jbc.273.11.6019			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497316	hybrid			2022-12-27	WOS:000072488500008
J	Dytrych, L; Sherman, DL; Gillespie, CS; Brophy, PJ				Dytrych, L; Sherman, DL; Gillespie, CS; Brophy, PJ			Two PDZ domain proteins encoded by the murine periaxin gene are the result of alternative intron retention and are differentially targeted in Schwann cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PRE-MESSENGER-RNA; SEPTATE JUNCTIONS; BINDING DOMAIN; CYCLIC-AMP; SEQUENCE; HOMOLOG; MYELIN; ORGANIZATION; RECOGNITION	Periaxin was first described as a 147-kDa protein that was suggested to have a potential role in the initiation of myelin deposition in peripheral nerves based upon its abundance, cell type specificity, pattern of developmental expression, and localization (Gillespie, C. S., Sherman, D. L., Blair, G. E., and Brophy. P. J. (1994) Neuron 12, 497-508), Here we show that the murine periaxin gene spans 20.6 kilobases and encodes two mRNAs of 4.6 and 5.2 kilobases that encode two periaxin isoforms, L-periaxin and S-periaxin of 147 and 16 kDa respectively. The larger mRNA is produced by a retained intron mechanism that introduces a stop codon and results in a truncated protein with an intron-encoded C terminus of 21 amino acids. Both proteins possess a PDZ domain at the N terminus; nevertheless, they are targeted differently in Schwann cells, Like other proteins that contain PDZ domains, L-periaxin is localized to the plasma membrane of myelinating Schwann cells: in contrast, S-periaxin is expressed diffusely in the cytoplasm, This suggests that proteins that contain this protein-binding module may also participate in protein-protein interactions at sites other than the cell cortex.	Univ Edinburgh, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland	University of Edinburgh	Brophy, PJ (corresponding author), Univ Edinburgh, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTIERI DC, 1994, BIOCHEMISTRY-US, V33, P13848, DOI 10.1021/bi00250a039; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Blanchard AD, 1996, J NEUROSCI RES, V46, P630, DOI 10.1002/(SICI)1097-4547(19961201)46:5<630::AID-JNR11>3.0.CO;2-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DIRKSEN WP, 1995, J BIOL CHEM, V270, P5346, DOI 10.1074/jbc.270.10.5346; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GILLESPIE CS, 1994, NEURON, V12, P497, DOI 10.1016/0896-6273(94)90208-9; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JESAITIS LA, 1994, J CELL BIOL, V124, P946; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LEMKE G, 1988, DEVELOPMENT, V102, P499; LI XB, 1994, J NEUROCHEM, V63, P28; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Maniatis T., 1989, MOL CLONING LAB MANU; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; PODUSLO JF, 1995, J NEUROCHEM, V65, P149; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scherer SS, 1995, DEVELOPMENT, V121, P4265; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	38	69	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5794	5800		10.1074/jbc.273.10.5794	http://dx.doi.org/10.1074/jbc.273.10.5794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488714	hybrid			2022-12-27	WOS:000072345000057
J	Feng, Y; Chung, D; Garrard, L; McEnroe, G; Lim, D; Scardina, J; McFadden, K; Guzzetta, A; Lam, A; Abraham, J; Liu, D; Endemann, G				Feng, Y; Chung, D; Garrard, L; McEnroe, G; Lim, D; Scardina, J; McFadden, K; Guzzetta, A; Lam, A; Abraham, J; Liu, D; Endemann, G			Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; INTEGRIN MAC-1; I-DOMAIN; NEUTROPHIL ADHESION; CELL-ADHESION; ICAM-1 CD54; A-DOMAIN; CD11B/CD18; RECEPTOR; SEQUENCE	Peptides or small molecules that can block the interaction of the integrin Mac-1 with its receptor, intercellular adhesion molecule-1 (ICAM-1), have not previously been developed, We studied this interaction by measuring the adherence of ICAM-1-expressing Chinese hamster ovary (CHO) cells to immobilized, purified Mac-1. Nucleotide sequence information was obtained for the complementarity determining regions (CDRs) of three antibodies (44aacb, MY904, and 118.1) shown to block Mac-1-mediated cell adherence, Peptides were synthe sized based on the predicted amino acid sequences of the CDRs and tested for the ability to block cell adhesion to Mac-1. Peptides derived from CDR1 of 44aacb, CDR2 of 118.1, and CDRs 1 and 3 of MY904 heavy chains were found to possess blocking activity at 10-100 rho M. This may indicate that one or two CDRs contribute disproportionately to the antibody binding affinity. The binding of ligands to Mac-1 has been shown to require a region of the a-chain known as the I- or A-domain. We have recombinantly produced Mac-1 I-domain, and show that it is also capable of supporting the adherence of ICAM-1-expressing CHO cells. The adherence of ICAM-1-CHO cells to the I-domain is inhibited by 44aacb and 118.1 and by the CDR peptides from 44aacb and 118.1. By using phage display of peptide libraries based on the 118.1 CDR peptide with five residues randomized, we were able to identify a novel peptide inhibitor of Mac-1 with substitutions at all five positions. These peptides provide lead structures for development of Mac-1 antagonists.	Scios Inc, Sunnyvale, CA 94086 USA	Scios	Endemann, G (corresponding author), Scios Inc, 820 W Maude Ave, Sunnyvale, CA 94086 USA.							ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; DANA N, 1986, J IMMUNOL, V137, P3259; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Endemann G, 1996, J PHARMACOL EXP THER, V276, P5; GARRARD LJ, 1991, BIO-TECHNOL, V9, P1373, DOI 10.1038/nbt1291-1373; HARLAN JM, 1992, ADHESION ITS ROLE IN; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LI R, 1993, J BIOL CHEM, V268, P17513; Madden K, 1997, INFLAMM RES, V46, P216, DOI 10.1007/s000110050176; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; ROSS L, 1992, J BIOL CHEM, V267, P8537; ROZDZINSKI E, 1995, J CLIN INVEST, V95, P1078, DOI 10.1172/JCI117754; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; Satoh T, 1997, J BIOL CHEM, V272, P12175, DOI 10.1074/jbc.272.18.12175; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TAUB R, 1989, J BIOL CHEM, V264, P259; TAUB R, 1992, J BIOL CHEM, V267, P5977; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WILLIAMS WV, 1991, J BIOL CHEM, V266, P9241; WONG SC, 1993, TECHNIQUES PROTEIN C, V4, P371; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	31	27	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5625	5630		10.1074/jbc.273.10.5625	http://dx.doi.org/10.1074/jbc.273.10.5625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488691	hybrid			2022-12-27	WOS:000072345000034
J	Hiromura, M; Yano, M; Mori, H; Inoue, M; Kido, H				Hiromura, M; Yano, M; Mori, H; Inoue, M; Kido, H			Intrinsic ADP-ATP exchange activity is a novel function of the molecular chaperone, Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOATING ATPASE; PEPTIDE-BINDING; PROTEIN; HYDROLYSIS; KINASE; DISSOCIATION; DNAK; BIP	Hsp70 is a multifunctional molecular chaperone whose interactions with protein substrates are regulated by ATP hydrolysis and ADP-ATP exchange. We show here that, in addition to ATPase activity, purified Hsp70 free from nucleoside-diphosphate (NDP) kinase exhibits intrinsic ADP-ATP exchange activity. The rate constants for ATP hydrolysis and ATP synthesis were in a similar range at the optimum pH of 7.5-8.5 in the presence of 5 mM ATP and 0.5 mM ADP. Hsp70 exhibited a considerably strict preference for ATP as a phosphate donor, and a biased substrate specificity, unlike NDP kinase; ADP, UDP, CDP > dTDP, dCDP > GDP, dGDP. During the reaction, Hsp70 formed an acid-labile autophosphorylated intermediate, and nucleoside diphosphate-dependent dephosphorylation of the latter then occurred. These properties of Hsp70 are not identical but similar to those of NDP kinase, but are not similar to those of adenylate kinase and ATP synthase.	Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 770, Japan	Tokushima University	Kido, H (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 770, Japan.							AGARWAL RP, 1978, METHOD ENZYMOL, V52, P375; Biondi RM, 1996, ANAL BIOCHEM, V242, P165, DOI 10.1006/abio.1996.0449; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; DEVILLEBONNE D, 1996, BIOCHEMISTRY-US, V35, P14648; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GAO BC, 1993, J BIOL CHEM, V268, P8507; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; INGRAHAM JL, 1978, METHOD ENZYMOL, V52, P371; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PRASAD K, 1993, J BIOL CHEM, V268, P23758; RASSOW J, 1995, TRENDS CELL BIOL, V5, P107; ROISIN MP, 1978, BIOCHIM BIOPHYS ACTA, V526, P418, DOI 10.1016/0005-2744(78)90133-X; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9402; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHIKATA H, 1989, BIOCHEM INT, V18, P943; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229	30	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5435	5438		10.1074/jbc.273.10.5435	http://dx.doi.org/10.1074/jbc.273.10.5435			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488662	hybrid			2022-12-27	WOS:000072345000005
J	Wendt, H; Thomas, RM; Ellenberger, T				Wendt, H; Thomas, RM; Ellenberger, T			DNA-mediated folding and assembly of MyoD-E47 heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; TRANSCRIPTIONAL ACTIVATION; INHIBITORY DOMAIN; CRYSTAL-STRUCTURE; ENHANCER-BINDING; B/HLH/Z DOMAIN; ACHAETE-SCUTE; RECOGNITION; DROSOPHILA; DAUGHTERLESS	Basic region helix-loop-helix (bHLH) transcription factors regulate key steps in early development by binding to regulatory DNA sites as heterodimers consisting of a tissue-specific factor and a widely expressed factor. We have examined the folding, dimerization, and DNA binding properties of the muscle-specific bHLH protein MyoD and its partner E47, to understand why these proteins preferentially associate in heterodimeric complexes with DNA. In the absence of DNA, the E47 bHLH domain forms a very stable homodimer, whereas MyoD is unfolded and monomeric. Fluorescence quenching experiments show that MyoD does not dimerize with E47 under dilute conditions in the absence of DNA. Residues in and around the loop of the E47 bHLH domain contribute to its markedly greater stability. An altered MyoD bHLH substituted with the loop segment from E47 folds in the absence of DNA, and it readily dimerizes with E47. In the presence of a specific DNA binding site, MyoD and E47 both form homodimeric complexes with DNA that have similar dissociation constants, despite the very different stabilities of these protein dimers off DNA. A 1:1 mixture of these bHLH domains forms almost exclusively heterodimeric complexes on DNA. Assembly of these bHLH-DNA complexes is apparently governed by the strength of each subunit's interaction with the DNA and not by the strength of protein-protein interactions at the dimer interface. These findings suggest that preferential association of MyoD with E47 in DNA complexes results from more favorable DNA contacts made by one or both subunits of the heterodimer in comparison with either homodimeric complex.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; ETH Zurich, Inst Polymere, CH-8092 Zurich, Switzerland	Harvard University; Harvard Medical School; Swiss Federal Institutes of Technology Domain; ETH Zurich	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.							ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Maleki SJ, 1997, BIOCHEMISTRY-US, V36, P6762, DOI 10.1021/bi970262m; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MEIERHANS D, 1995, BIOCHEMISTRY-US, V34, P11026, DOI 10.1021/bi00035a008; Metallo SJ, 1997, NAT STRUCT BIOL, V4, P115, DOI 10.1038/nsb0297-115; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Pace C N, 1986, Methods Enzymol, V131, P266; PARK C, 1996, J AM CHEM SOC, V118, P6287; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; SAMBROOK J., 1989, MOL CLONING LAB MANU, pB23; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Segel IH, 1975, ENZYME KINETICS BEHA; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENDT H, 1994, J AM CHEM SOC, V116, P6973, DOI 10.1021/ja00094a077; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185	50	47	52	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5735	5743		10.1074/jbc.273.10.5735	http://dx.doi.org/10.1074/jbc.273.10.5735			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488706	hybrid			2022-12-27	WOS:000072345000049
J	Tsuruga, M; Matsuoka, A; Hachimori, A; Sugawara, Y; Shikama, K				Tsuruga, M; Matsuoka, A; Hachimori, A; Sugawara, Y; Shikama, K			The molecular mechanism of autoxidation for human oxyhemoglobin - Tilting of the distal histidine causes nonequivalent oxidation in the beta chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEMINATE RECOMBINATION; NUCLEOPHILIC DISPLACEMENT; HUMAN-HEMOGLOBIN; OXYMYOGLOBIN; DISSOCIATION; SUPEROXIDE; MYOGLOBIN; ASSOCIATION; GENERATION; ANIONS	Human oxyhemoglobin showed a biphasic autoxidation curve containing two rate constants, i.e. k(f) for the fast autoxidation due to the alpha chains, and k(s) for the slow autoxidation of the beta chains, respectively. Consequently, the autoxidation of the HbO(2) tetramer produces two different curves from the pH dependence of k(f) and k(s). The analysis of these curves revealed that the beta chain of the HbO(2) tetramer does not exhibit any proton-catalyzed autoxidation, unlike the alpha chain, where a proton-catalyzed process involving the distal histidine residue can play a dominant role in the autoxidation rate. When the alpha and beta chains were separated from the HbO(2) tetramer, however, each chain was oxidized much more rapidly than in the tetrameric parent. Moreover, the separated beta chain was recovered completely to strong acid catalysis in its autoxidation rate. These new findings lead us to conclude that the formation of the alpha(1) beta(1) contact produces in the beta chain a conformational constraint whereby the distal histidine at position 63 is tilted away slightly from the bound dioxygen, preventing the proton-catalyzed displacement of O-2(.) by a solvent water molecule. The beta chains have thus acquired a delayed autoxidation in the HbO(2) tetramer.	Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan	Tohoku University	Shikama, K (corresponding author), Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan.							BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; EDELSTEI.SJ, 1970, J BIOL CHEM, V245, P4372; GERACI G, 1969, J BIOL CHEM, V244, P4664; GOTOH T, 1976, J BIOCHEM-TOKYO, V80, P397, DOI 10.1093/oxfordjournals.jbchem.a131289; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; ICHIKAWA T, 1997, THESIS TOHOKU U SEND; LEVY A, 1990, BIOCHEMISTRY-US, V29, P9311, DOI 10.1021/bi00492a002; MANSOURI A, 1973, BIOCHEMISTRY-US, V12, P4946, DOI 10.1021/bi00748a020; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; Perutz M. F., 1990, MECH COOPERATIVITY; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; RIFKIND JM, 1994, METHOD ENZYMOL, V231, P449; ROSEMEYER MA, 1967, J MOL BIOL, V25, P253, DOI 10.1016/0022-2836(67)90141-6; SATOH Y, 1981, J BIOL CHEM, V256, P272; SHAANAN B, 1982, NATURE, V296, P683, DOI 10.1038/296683a0; SHIKAMA K, 1986, BIOCHEMISTRY-US, V25, P3898, DOI 10.1021/bi00361a024; SHIKAMA K, 1994, BIOL REV, V69, P233, DOI 10.1111/j.1469-185X.1994.tb01507.x; SHIKAMA K, 1988, COORDIN CHEM REV, V83, P73, DOI 10.1016/0010-8545(88)80019-5; SHIKAMA K, 1978, EUR J BIOCHEM, V91, P407, DOI 10.1111/j.1432-1033.1978.tb12693.x; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SUGAWARA Y, 1995, BIOPHYS J, V69, P583, DOI 10.1016/S0006-3495(95)79932-5; SUGAWARA Y, 1980, EUR J BIOCHEM, V110, P241, DOI 10.1111/j.1432-1033.1980.tb04861.x; SUGAWARN Y, 1993, JPN J PHYSL, V43, P31; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; Tsuruga M, 1997, BBA-PROTEIN STRUCT M, V1337, P96, DOI 10.1016/S0167-4838(96)00156-2; TSURUGA M, 1997, THESIS TOHOKU U SEND; TURCI SM, 1985, J CHROMATOGR, V343, P168, DOI 10.1016/S0378-4347(00)84581-8; TYUMA I, 1966, BIOCHEMISTRY-US, V5, P2957, DOI 10.1021/bi00873a027; VALDES R, 1977, J BIOL CHEM, V252, P74; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, BIOCHEM BIOPH RES CO, V57, P1104, DOI 10.1016/0006-291X(74)90810-9; WEVER R, 1973, BIOCHIM BIOPHYS ACTA, V302, P475, DOI 10.1016/0005-2744(73)90180-0; WILLIAMS RC, 1973, ANAL BIOCHEM, V54, P137, DOI 10.1016/0003-2697(73)90256-X; ZHANG L, 1991, J BIOL CHEM, V266, P24698	39	104	104	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8607	8615		10.1074/jbc.273.15.8607	http://dx.doi.org/10.1074/jbc.273.15.8607			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535834	hybrid			2022-12-27	WOS:000072990800011
J	Benoist, P; Mas, JA; Marco, R; Cervera, M				Benoist, P; Mas, JA; Marco, R; Cervera, M			Differential muscle-type expression of the Drosophila troponin T gene - A 3-base pair microexon is involved in visceral and hypodermic muscle specification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRETCH-ACTIVATED MUSCLES; SKELETAL-MUSCLE; THIN FILAMENT; FLIGHT-MUSCLE; CAENORHABDITIS-ELEGANS; MYOFIBRILLAR PROTEIN; CONSENSUS SEQUENCES; TROPOMYOSIN; MELANOGASTER; PARAMYOSIN	The complete genomic organization of the Drosophila troponin T (TnT) gene shows many interesting features, including the presence of a microexon of only 3 nucleotides conserved among Drosophilidae, It is the smallest bona fide exon so far described, placing a new lower limit on the nucleotide number required for correct splicing, Four muscle-type specific transcripts are generated by developmentally regulated alternative splicing, Exons 3, 4, and 5 are absent in the transcript present in jump and flight muscles. A total of 11 exons are present in the adult hypodermic muscles transcript, whereas the microexon is absent in the larval hypodermic musculature, The two isoforms differ in a lysine residue, Post-translational regulation of the flight muscles/tergal depressor of the trochanter-specific isoform is involved in flight and/or jump function. The interaction domains of TnT in the tropomyosin-troponin complex are strongly conserved in the known vertebrate and invertebrate TnT sequences, whereas the terminal regions show an important variability, The COOH-terminal region shows important phylogenetic variations, whereas the NH2-terminal domain is associated with specific muscle types in a particular organism, a finding that discloses a selective value for these domains in the functionality of distinct muscles in different organisms.	Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Cervera, M (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim, Arzobispo Morcillo 4, E-28029 Madrid, Spain.	mcervera@mvax.fmed.uam.es						ANDERSON PAW, 1991, CIRC RES, V69, P73; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q; BECKER KD, 1992, J CELL BIOL, V116, P669, DOI 10.1083/jcb.116.3.669; BERGAMINI CM, 1995, BIOCHEM BIOPH RES CO, V206, P201, DOI 10.1006/bbrc.1995.1028; BERNSTEIN SI, 1986, MOL CELL BIOL, V6, P2511, DOI 10.1128/MCB.6.7.2511; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; BJELLQVIST B, 1994, ELECTROPHORESIS, V15, P529, DOI 10.1002/elps.1150150171; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; Carlo T, 1996, RNA, V2, P342; COLLIER VL, 1990, GENE DEV, V4, P885, DOI 10.1101/gad.4.6.885; COOPER TA, 1985, J BIOL CHEM, V260, P1140; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P6999; DOMINGO A, 1998, IN PRESS J MUSCLE RE; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; EPSTEIN HF, 1985, J CELL BIOL, V100, P904, DOI 10.1083/jcb.100.3.904; EPSTEIN HF, 1988, J CELL BIOL, V106, P1985, DOI 10.1083/jcb.106.6.1985; EPSTEIN HF, 1992, DEV BIOL, V154, P231, DOI 10.1016/0012-1606(92)90064-N; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FYRBERG E, 1990, TRENDS GENET, V6, P126, DOI 10.1016/0168-9525(90)90127-R; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GREMKE L, 1993, DEV BIOL, V159, P513, DOI 10.1006/dbio.1993.1260; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; Inoue A, 1996, J BIOCHEM-TOKYO, V120, P834; ISHII Y, 1991, J BIOL CHEM, V266, P6894; Jha PK, 1996, BIOCHEMISTRY-US, V35, P16573, DOI 10.1021/bi9622433; JIN JP, 1994, FEBS LETT, V341, P135, DOI 10.1016/0014-5793(94)80256-4; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; Maroto M, 1996, J CELL BIOL, V134, P81, DOI 10.1083/jcb.134.1.81; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Moore M., 1993, RNA WORLD, P303; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; OHTSUKI I, 1982, ADV BIOPHYS, V15, P93, DOI 10.1016/0065-227X(82)90006-5; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PEARLSTONE JR, 1977, J BIOL CHEM, V252, P983; PECKHAM M, 1990, J MUSCLE RES CELL M, V11, P203, DOI 10.1007/BF01843574; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; PRINGLE JWS, 1978, PROC R SOC SER B-BIO, V201, P107, DOI 10.1098/rspb.1978.0035; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RUEGG JC, 1992, CALCIUM MUSCLE CONTR; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPARROW JC, 1995, NATURE, V373, P592; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; TREGEAR RT, 1977, INSECT FLIGHT MUSCLE; TRIEZENBERG SJ, 1993, CURRENT PROTOCOLS MO; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; VIGOREAUX JO, 1994, J MUSCLE RES CELL M, V15, P607, DOI 10.1007/BF00121068; VIGOREAUX JO, 1993, J CELL BIOL, V121, P587, DOI 10.1083/jcb.121.3.587; VINOS J, 1991, J MOL BIOL, V220, P687, DOI 10.1016/0022-2836(91)90110-R; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x	64	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7538	7546		10.1074/jbc.273.13.7538	http://dx.doi.org/10.1074/jbc.273.13.7538			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516455	hybrid			2022-12-27	WOS:000072738500051
J	Clerk, A; Fuller, SJ; Michael, A; Sugden, PH				Clerk, A; Fuller, SJ; Michael, A; Sugden, PH			Stimulation of "Stress-regulated" mitogen-activated protein kinases (stress-activated protein kinases c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; P38 MAP KINASE; HYDROGEN-PEROXIDE; CARDIAC MYOCYTES; SIGNAL-TRANSDUCTION; PROTOONCOGENE EXPRESSION; DIFFERENTIAL ACTIVATION; VENTRICULAR MYOCYTES; MYOCARDIAL-ISCHEMIA; RADICAL GENERATION	"Stress regulated" mitogen-activated protein kinases (SR-MAPKs) comprise the stress activated protein kinases (SAPKs)/c-Jun N-terminal kinases (JNKs) and the p38-MAPKs. In the perfused heart, ischemia/reperfusion activates SR-MAPKs. Although the agent(s) directly responsible is unclear, reactive oxygen species are generated during ischemia/reperfusion. We have assessed the ability of oxidative stress (as exemplified by H2O2) to activate SR-MAPKs in the perfused heart and compared it with the effect of ischemia/reperfusion. H2O2 activated both SAPKs/JNKs and p38-MAPK. Maximal activation by H2O2 in both cases was observed at 0.5 mM. Whereas activation of p38-MAPK by H2O2 was comparable to that of ischemia and ischemia/reperfusion, activation of the SAPKs/JNKs was less than that of ischemia/reperfusion. As with ischemia/reperfusion, there was minimal activation of the ERK MAPK subfamily by H2O2. MAPK-activated protein kinase 2 (MAPKAPK2), a downstream substrate of p38-MAPKs, was activated by H2O2 to a similar extent as with ischemia or ischemia/reperfusion. In all instances, activation of MAPKAPK2 in perfused hearts was inhibited by SB203580, an inhibitor of p38-MAPKs. Perfusion of hearts at high aortic pressure (20 kilopascals) also activated the SR-MAPKs and MAPKAPK2. Free radical trapping agents (dimethyl sulfoxide and N-t-butyl-alpha-phenyl nitrone) inhibited the activation of SR-MAPKs and MAPKAPK2 by ischemia/reperfusion. These data are consistent with a role for reactive oxygen species in the activation of SR-MAPKs during ischemia/reperfusion.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst Div, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, London W6 8RF, England	Imperial College London; Imperial College London	Sugden, PH (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst Div, Royal Brompton Campus,Dovehouse St, London SW3 6LY, England.	p.sugden@ic.ac.uk		Clerk, Angela/0000-0002-5658-0708				BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BAKER JE, 1994, FREE RADICAL RES, V20, P145, DOI 10.3109/10715769409147512; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOGOYEVITCH MA, 1996, CIRC RES, V79, P161; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRADAMANTE S, 1992, J MOL CELL CARDIOL, V24, P375, DOI 10.1016/0022-2828(92)93192-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BYLER RM, 1994, AM J PHYSIOL, V266, pH121, DOI 10.1152/ajpheart.1994.266.1.H121; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; CLERK A, 1994, J BIOL CHEM, V269, P32848; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; FERRARI R, 1993, EUR HEART J, V14, P25; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN JH, 1993, J BIOL CHEM, V268, P25009; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JANERO DR, 1991, J CELL PHYSIOL, V149, P347, DOI 10.1002/jcp.1041490302; Jennings R B, 1995, Monogr Pathol, V37, P47; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; KRAMER JH, 1987, FREE RADICAL BIO MED, V3, P153, DOI 10.1016/S0891-5849(87)80011-4; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIP GYH, 1994, BRIT MED BULL, V50, P299, DOI 10.1093/oxfordjournals.bmb.a072893; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SLEZAK J, 1995, AM J PATHOL, V147, P772; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAKEMURA G, 1993, FREE RADICAL BIO MED, V15, P13, DOI 10.1016/0891-5849(93)90121-A; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Ushiroda S, 1997, JPN HEART J, V38, P91; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	74	277	291	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7228	7234		10.1074/jbc.273.13.7228	http://dx.doi.org/10.1074/jbc.273.13.7228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516415	hybrid			2022-12-27	WOS:000072738500011
J	Lamande, SR; Sigalas, E; Pan, TC; Chu, ML; Dziadek, M; Timpl, R; Bateman, JR				Lamande, SR; Sigalas, E; Pan, TC; Chu, ML; Dziadek, M; Timpl, R; Bateman, JR			The role of the alpha 3(VI) chain in collagen VI assembly - Expression of an alpha 3(VI) chain lacking N-terminal modules N10-N7 restores collagen VI assembly, secretion, and matrix deposition in an alpha 3(VI)-deficient cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERINATAL OSTEOGENESIS IMPERFECTA; EXTRACELLULAR-MATRIX; MESSENGER-RNA; RECOMBINANT EXPRESSION; PROTEIN VARIANTS; MOSAIC STRUCTURE; GENE; FIBROBLASTS; DOMAIN; DEGRADATION	Collagen VI is a microfibrillar protein found in the extracellular matrix of virtually all connective tissues, Three genetically distinct subunits, the alpha 1(VI), alpha 2(VI), and alpha 3(VI) chains, associate intracellularly to form triple-helical monomers, which then assemble into disulfide-bonded dimers and tetramers before secretion, Although sequence considerations suggest that collagen VI monomers composed of all three chains are the most stable isoform, the precise chain composition of collagen VI remains controversial and alternative assemblies containing only alpha 1(VI) and alpha 2(VI) chains have also been proposed, To address this question directly and study the role of the alpha 3(VI) chain in assembly, we have characterized collagen VI biosynthesis and in vitro matrix formation by a human osteosarcoma cell line (SaOS-2) that is deficient in alpha 3(VI) production, Northern analysis showed an abundance of alpha 1(VI) and alpha 2(VI) mRNAs, but no detectable alpha 3(VI) mRNA was apparent in SaOS-2 cells, By day 30 of culture, however, small amounts of alpha 3(VI) mRNA were detected, although the level of expression was still much less than alpha 1(VI) and alpha 2(VI), Collagen VI protein was not detected in SaOS-2 medium or cell layer samples until day 30 of culture, demonstrating that despite the abundant synthesis of alpha 1(VI) and alpha 2(VI), no stable collagen VI protein was produced without expression of alpha 3(VI). The alpha 1(VI) and alpha 2(VI) chains produced in the absence of alpha 3(VI) were non-helical and were largely retained intracellularly and degraded, The critical role of the alpha 3(VI) chain in collagen VI assembly was directly demonstrated after stable transfection of SaOS-2 cells with an alpha 3(VI) cDNA expression construct that lacked 4 of the 10 N-terminal type A subdomains, The transfected alpha 3(VI) N6-C5 chains associated with endogenous alpha 1(VI) and alpha 2(VI) and formed collagen VI dimers and tetramers, which were secreted and deposited into an extensive network in the extracellular matrix, These data demonstrated that alpha 3(VI) is essential for the formation of stable collagen VI molecules and subdomains N10-N7 are not required for molecular assembly.	Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia; Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3052, Australia; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Royal Children's Hospital Melbourne; University of Melbourne; Jefferson University; Jefferson University; University of Melbourne; Max Planck Society	Bateman, JR (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.	bateman@cryptic.rch.unimelb.edu.au		Bateman, John/0000-0001-8542-0730; Lamande, Shireen/0000-0003-2938-2711	NIAMS NIH HHS [AR38912] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038912] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BONALDO P, 1989, J BIOL CHEM, V264, P20235; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRANDSABERI B, 1994, ANN ANAT, V176, P539, DOI 10.1016/S0940-9602(11)80391-2; BRANDSABERI B, 1994, CELL TISSUE RES, V277, P465, DOI 10.1007/s004410050174; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; COLOMBATTI A, 1991, BLOOD, V77, P2305; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; Dziadek M, 1996, EXP CELL RES, V226, P302, DOI 10.1006/excr.1996.0231; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; HATAMOCHI A, 1989, J BIOL CHEM, V264, P3494; HECKMANN M, 1992, FEBS LETT, V310, P79, DOI 10.1016/0014-5793(92)81151-B; HECKMANN M, 1989, EUR J BIOCHEM, V182, P719, DOI 10.1111/j.1432-1033.1989.tb14884.x; JANDER R, 1983, EUR J BIOCHEM, V133, P39, DOI 10.1111/j.1432-1033.1983.tb07427.x; Katagiri K, 1996, J DERMATOL SCI, V13, P37, DOI 10.1016/0923-1811(95)00492-0; Kielty Cay M., 1993, P103; KIELTY CM, 1990, BIOCHEM J, V272, P787, DOI 10.1042/bj2720787; KIELTY CM, 1993, BIOCHEM BIOPH RES CO, V191, P1230, DOI 10.1006/bbrc.1993.1349; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LAMANDE SR, 1993, MATRIX, V13, P323, DOI 10.1016/S0934-8832(11)80028-4; MAYER U, 1994, EUR J BIOCHEM, V225, P573, DOI 10.1111/j.1432-1033.1994.00573.x; MCQUILLAN DJ, 1995, BONE, V16, P415; Myint E, 1996, CORNEA, V15, P490; OLSEN DR, 1989, J CLIN INVEST, V83, P791, DOI 10.1172/JCI113959; RIPLEY CR, 1993, J BIOL CHEM, V268, P3677; RODAN SB, 1987, CANCER RES, V47, P4961; SAITTA B, 1990, J BIOL CHEM, V265, P6473; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SCHREIER T, 1987, FEBS LETT, V213, P319, DOI 10.1016/0014-5793(87)81514-4; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; STOKES DG, 1991, J BIOL CHEM, V266, P8626; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493; WAKE SA, 1985, BIOCHEM J, V228, P425, DOI 10.1042/bj2280425; WU JJ, 1987, BIOCHEM J, V248, P373, DOI 10.1042/bj2480373; ZANUSSI S, 1992, J BIOL CHEM, V267, P24082	55	55	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7423	7430		10.1074/jbc.273.13.7423	http://dx.doi.org/10.1074/jbc.273.13.7423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516440	hybrid			2022-12-27	WOS:000072738500036
J	Radjendirane, V; Joseph, P; Lee, YH; Kimura, S; Klein-Szanto, AJP; Gonzalez, FJ; Jaiswal, AK				Radjendirane, V; Joseph, P; Lee, YH; Kimura, S; Klein-Szanto, AJP; Gonzalez, FJ; Jaiswal, AK			Disruption of the DT diaphorase (NQ01) gene in mice leads to increased menadione toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H-MENADIONE OXIDOREDUCTASE; METABOLIZING-ENZYMES; CDNA SEQUENCE; CANCER; DIOXIN; ANTIOXIDANT; EXPRESSION; CHEMOTHERAPY; POLYMORPHISM; MUTAGENICITY	NAD(P)H:quinone oxidoreductase 1 (NQO1) is a flavoenzyme that catalyzes two-electron reductive metabolism and detoxification of quinones and their derivatives leading to protection of cells against redox cycling and oxidative stress. To examine the in vivo role of NQO1, a NQO1-null mouse was produced using targeted gene disruption. Mice lacking NQO1 gene expression showed no detectable phenotype and were indistinguishable from wild-type mice. However, NQO1-null mice exhibited increased toxicity when administered menadione compared with wild-type mice. These results establish a role for NQO1 in protection against quinone toxicity. The NQO1-null mice are a model for NQO1 deficiency in humans and can be used to determine the role of this enzyme in sensitivity to toxicity and carcinogenesis.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu	Klein-Szanto, A./E-6218-2010		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007943] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES07943] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEFLORA S, 1985, CANCER RES, V45, P3188; EICKELMANN P, 1994, BIOL CHEM H-S, V375, P439, DOI 10.1515/bchm3.1994.375.7.439; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; JOSEPH P, 1994, ONCOL RES, V6, P525; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335; KOLESAR JM, 1995, J NATL CANCER I, V87, P1022, DOI 10.1093/jnci/87.13.1022-a; KUEHL BL, 1995, BRIT J CANCER, V72, P555, DOI 10.1038/bjc.1995.373; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LIND C, 1985, ARCH BIOCHEM BIOPHYS, V240, P226, DOI 10.1016/0003-9861(85)90027-X; MARTIN LF, 1987, CANCER LETT, V36, P341, DOI 10.1016/0304-3835(87)90028-0; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; Radjendirane Venugopal, 1997, P441; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003; Rothman N, 1997, CANCER RES, V57, P2839; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SAL GD, 1989, BIOTECHNIQUES, V7, P514; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Tampo Y, 1996, ARCH BIOCHEM BIOPHYS, V334, P163, DOI 10.1006/abbi.1996.0442; TRAVER RD, 1992, CANCER RES, V52, P797; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VASILIOU V, 1994, PHARMACOGENETICS, V4, P341, DOI 10.1097/00008571-199412000-00007; WATTENBERG LW, 1992, CANCER RES, V52, pS2085; WATTENBERG LW, 1985, CANCER RES, V45, P1; WORKMAN P, 1994, ONCOL RES, V6, P461; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669	41	214	220	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7382	7389		10.1074/jbc.273.13.7382	http://dx.doi.org/10.1074/jbc.273.13.7382			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516435	hybrid			2022-12-27	WOS:000072738500031
J	Bazzoni, G; Ma, L; Blue, ML; Hemler, ME				Bazzoni, G; Ma, L; Blue, ML; Hemler, ME			Divalent cations and ligands induce conformational changes that are highly divergent among beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; ALPHA(5)BETA(1) INTEGRINS; FIBRONECTIN RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; DEPENDENT EPITOPE; REGULATORY REGION; COLLAGEN RECEPTOR; BINDING FUNCTION	Here we show striking differences in conformational regulation among beta(1) integrins. Upon manganese stimulation, a beta(1) epitope defined by monoclonal antibody (mAb) 9EG7 was induced strongly (on alpha(4) beta(1)), moderately (on alpha(5) beta(1)), weakly (on alpha(2) beta(1)), or was scarcely detectable (on alpha(6) beta(1) and alpha(3) beta(1)). Comparable results were seen for the beta(1) epitope defined by mAb 15/7. Likewise, soluble ligands caused strong (alpha(4) beta(1)), moderate (alpha(5) beta(1)), weak (alpha(2) beta(1), alpha(6) beta(1)), Or minimal (alpha(3) beta(1)) induction of the 9EG7 epitope. Exchange or deletion of alpha chain cytoplasmic tails did not alter Mn2+-induced 9EG7 epitope levels. Upon removal of calcium by EGTA or EDTA, the hierarchy of 9EG7 epitope induction was similar (alpha(5) beta(1) > alpha(2) beta(1) > alpha(6) beta(1) > alpha(3) beta(1)), except that EGTA reduced rather than induced 9EG7 expression on alpha(4) beta(1). Thus in contrast to other beta(1) integrins, calcium uniquely supports constitutive expression of the 9EG7 epitope on alpha(4) beta(1). Likewise, calcium supported vascular cell adhesion molecule-stimulated 9EG7 appearance on alpha(4) beta(1), whereas calcium inhibited ligand-induced 9EG7 epitope on other integrins. Constitutive expression of 9EG7 on alpha(4) beta(1) was eliminated by a D698E mutation in alpha(4), suggesting that Asp-698 may play a key role in maintaining atypical alpha(4) beta(1) response to calcium. In conclusion, our results (i) demonstrate that mAb such as 9EG7 and 15/7 have limited diagnostic utility as reporters of ligand or Mn2+ occupancy for beta(1) integrins, (ii) indicate pronounced differences in conformational flexibilities (alpha(4) beta(1) > alpha(5) beta(1) > alpha(2) beta(1) > alpha(6) beta(1) > alpha(3) beta(1)), (iii) allow us to hypothesize that beta(1) integrins may differ markedly in conformation-dependent inside-out signaling, and (iv) have uncovered an atypical alpha(4) beta(1) response to calcium that requires alpha(4) Asp-698.	Harvard Univ, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA; Bayer Res Ctr, W Haven, CT 06516 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Bayer AG	Hemler, ME (corresponding author), Harvard Univ, Dana Farber Canc Inst, Sch Med, Rm M-413,44 Binney St, Boston, MA 02115 USA.	Martin_Hemler@DFCI.HARVARD.EDU	Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472	NCI NIH HHS [CA42368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ARROYO AG, 1995, EUR J IMMUNOL, V25, P1720, DOI 10.1002/eji.1830250635; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P445; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Driessens MHE, 1995, CELL ADHES COMMUN, V3, P327, DOI 10.3109/15419069509081017; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DU XP, 1993, J BIOL CHEM, V268, P23087; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1983, J IMMUNOL, V131, P334; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1995, BLOOD, V85, P159, DOI 10.1182/blood.V85.1.159.bloodjournal851159; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MA L, 1995, J BIOL CHEM, V270, P18401, DOI 10.1074/jbc.270.31.18401; Mannion BA, 1996, J IMMUNOL, V157, P2039; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; PICKER LJ, 1993, EUR J IMMUNOL, V23, P2751, DOI 10.1002/eji.1830231105; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; PUJADES C, 1997, MOL BIOL CELL, V8, P2635; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; SHIMIZU Y, 1993, J IMMUNOL, V151, P4106; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	73	84	86	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6670	6678		10.1074/jbc.273.12.6670	http://dx.doi.org/10.1074/jbc.273.12.6670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506964	hybrid			2022-12-27	WOS:000072775900014
J	Doyle, DD; Goings, GE; Upshaw-Earley, J; Page, E; Ranscht, B; Palfrey, HC				Doyle, DD; Goings, GE; Upshaw-Earley, J; Page, E; Ranscht, B; Palfrey, HC			T-cadherin is a major glycophosphoinositol-anchored protein associated with noncaveolar detergent-insoluble domains of the cardiac sarcolemma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; CELL-SURFACE; ADP-RIBOSYLTRANSFERASE; SKELETAL-MUSCLE; N-CADHERIN; MOLECULAR CHARACTERIZATION; PLASMALEMMAL-CAVEOLAE; CROSS-LINKING; LOCALIZATION; EXPRESSION	Sucrose-density flotation analysis of Triton-insoluble membrane domains isolated from highly purified sheep ventricular sarcolemma revealed the presence of two major 120- and 100-kDa proteins, Both species migrated in two-dimensional isoelectric focussing/SDS gels with an apparent pI of similar to 4.3, suggesting that they might be related. Microsequence analysis of peptides derived from the 100-kDa protein yielded amino acid sequences with high homology to T-cadherin, a truncated cadherin lacking a cytoplasmic domain, The similarity was confirmed using antibodies to chicken T-cadherin that reacted with both proteins on immunoblots, T-cadherin was released from the detergent-insoluble sarcolemmal fraction by phospholipase C treatment indicating that it is linked to the membrane by a glycophosphoinositol anchor, T-cadherin could be ADP-ribosylated by a transferase that was also present in the caveolin-enriched Triton-insoluble fraction, T-cadherin-containing membrane fragments cofractionated on sucrose gradients with caveolin-3, a marker protein for myocyte caveolae. However, immunopurified caveolin-3-containing membranes contained no associated T-cadherin. Immunocytochemical analysis of cultured rat atrial myocytes revealed that T-cadherin and caveolin have related but nonoverlapping staining patterns. These results suggest that T-cadherin is a major glycophosphoinositol-linked protein in cardiac myocytes and that it may be located in plasma membrane "rafts" distinct from but possibly adjacent to caveolae.	Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Burnham Res Inst, La Jolla, CA USA	University of Chicago; University of Chicago; Sanford Burnham Prebys Medical Discovery Institute	Palfrey, HC (corresponding author), Univ Chicago, Dept Pharmacol & Physiol Sci, 947 E 58th St, Chicago, IL 60637 USA.	hpalfrey@midway.uchicago.edu			NHLBI NIH HHS [HL-54302, HL-10503] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054302, R01HL010503, R37HL010503] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CIFUENTESDIAZ C, 1994, DEVELOPMENT, V120, P1; Doyle DD, 1997, CIRC RES, V81, P86, DOI 10.1161/01.RES.81.1.86; DOYLE DD, 1986, J BIOL CHEM, V261, P6556; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FRA AM, 1994, J BIOL CHEM, V269, P30745; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GONCHAROVA EJ, 1992, DEVELOPMENT, V114, P173; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; KLEBL BM, 1994, FEBS LETT, V342, P66, DOI 10.1016/0014-5793(94)80586-5; Koller E, 1996, J BIOL CHEM, V271, P30061, DOI 10.1074/jbc.271.47.30061; KORDYLEWSKI L, 1993, CIRC RES, V73, P135, DOI 10.1161/01.RES.73.1.135; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; LEVIN KR, 1980, CIRC RES, V46, P244, DOI 10.1161/01.RES.46.2.244; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; Okazaki I J, 1996, Adv Pharmacol, V35, P247, DOI 10.1016/S1054-3589(08)60277-X; PAGE E, 1994, CIRC RES, V75, P949, DOI 10.1161/01.RES.75.5.949; PALADE GE, 1953, J APPL PHYS, V24, P1424; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; SACRISTAN MP, 1993, J NEUROSCI RES, V34, P664, DOI 10.1002/jnr.490340610; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	44	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6937	6943		10.1074/jbc.273.12.6937	http://dx.doi.org/10.1074/jbc.273.12.6937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506999	hybrid			2022-12-27	WOS:000072775900049
J	Susskind, M; Brade, L; Brade, H; Holst, O				Susskind, M; Brade, L; Brade, H; Holst, O			Identification of a novel heptoglycan of alpha 1 -> 2-linked D-glycero-D-manno-heptopyranose - Chemical and antigenic structure of lipopolysaccharides from Klebsiella pneumoniae ssp. Pneumoniae rough strain R20 (O1(-): K20(-))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CORE REGION; MONOCLONAL-ANTIBODIES; SHIGELLA-SONNEI; FATTY-ACIDS; INNER-CORE; LIPID-A; SALMONELLA; NMR; OLIGOSACCHARIDE	In a preliminary investigation (Susskind, M., Muller-Loennies, S., Nimmich, W., Brade, H., and Hoist, O. (1995) Carbohydr. Res. 269, C1-C7), we identified after deacylation of lipopolysaccharides (LPS) from Klebsiella pneumoniae ssp. pneumoniae rough strain R20 (O1(-):K20(-)) as a major fraction the oligosaccharide, [GRAPHICS] where Kdo was 3-deoxy-D-manno-oct-2-ulopyranosonic acid and Hepp was manno-heptopyranose. The presence of the threo-hex-4-enuronopyranosyl residue indicated a substituent at O-4 of the second GalA residue linked to O-3 of the second L,D-Hep residue, which had been eliminated by treatment with hot alkali. We now report the complete structure of lipopolysaccharide, which was elucidated by additional characterization of isolated core oligosaccharides and analysis of the lipid A. The substituent at O-4 of the second GalpA is D-GlcpN, which in a fraction of the LPS is substituted at O-6 by three or four residues of D-glycero-D-manno-heptopyranose (D,D-Hepp). The complete carbohydrate backbone of the LPS is as follows, [GRAPHICS] (L-glycero-D-manno-heptopyranose; L,D-Hepp), where all hexoses possess the D-configuration. Sugars marked with an asterisk are present in nonstoichiometric amounts. The structure is unique with regard to the presence of an alpha 1-->2-linked D-glycero-D-manno-heptoglycan (oligosaccharide), which has not been described to date, and does not contain phosphate substituents in the core region. Fatty acid analysis of lipid A identified (R)-3-hydroxytetradecanoic acid as sole amide-linked fatty acid and (R)-3-hydroxytetradecanoic acid, tetradecanoic acid, small amounts of 2-hydroxytetradecanoic acid, hexadecanoic acid, and traces of dodecanoic acid as ester-linked fatty acids, substituting the carbohydrate backbone D-GlcpN4P beta 1-->6D-GlcpN alpha 1P. The nonreducing GlcN carries four fatty acids, present as two 3-O-tetradecanoyltetradecanoic acid residues, one of which is amide-linked and the other ester-linked to O-3'. The reducing GlcN is substituted in a nature fraction of lipid A by two residues of (R)-3-hydroxytetradecanoic acid, one in amide and the other in ester linkage at O-3. Two minor fractions of lipid A were identified; in one, the amide-linked (R)-3-hydroxytetradecanoic acid at the reducing GlcN is esterified with hexadecanoic acid, resulting in 3-O-hexadecanoyltetradecanoic acid, and in the second, one of the 3-O-tetradecanoyltetradecanoic acid residues at the nonreducing GlcN is replaced by 3-O-dodecanoyltetradecanoic acid. Thus, the complete structure of LPS is as shown in Fig. 1. After immunization of BALB/c mice, two monoclonal antibodies were obtained that were shown to be specific for the core of LPS from IL pneumoniae ssp. pneumoniae, since they did not react with LPS or whole-cell lysates of a variety of other Gram-negative species. Both monoclonal antibodies could be inhibited by LPS but not by isolated oligosaccharides and are thus considered to recognize a conformational epitope in the core region.	Res Ctr Borstel, Div Med & Biochem Microbiol, Ctr Med & Biosci, D-23845 Borstel, Germany	Forschungszentrum Borstel	Holst, O (corresponding author), Res Ctr Borstel, Div Med & Biochem Microbiol, Ctr Med & Biosci, Parkallee 22, D-23845 Borstel, Germany.							Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; ASPINALL GO, 1997, IR J MED SCI S3, V166, P5; ASPINALL GO, 1996, 18 INT CARB S MIL IT; BAX A, 1981, J MAGN RESON, V42, P501, DOI 10.1016/0022-2364(81)90272-9; Brade L, 1996, J ENDOTOXIN RES, V3, P39, DOI 10.1177/096805199600300105; Brade L, 1997, INFECT IMMUN, V65, P3961, DOI 10.1128/IAI.65.9.3961-3965.1997; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DIPADOVA FE, 1993, INFECT IMMUN, V61, P3863, DOI 10.1128/IAI.61.9.3863-3872.1993; DIPADOVA FE, 1995, NOVEL THERAPEUTIC ST, P13; FU YC, 1992, INFECT IMMUN, V60, P1314, DOI 10.1128/IAI.60.4.1314-1321.1992; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; HOLST O, 1998, IN PRESS ENDOTOXIN S; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KJAER M, 1994, METHODS ENZYMOL, V239, P288; KOCSIS B, 1984, J BIOL CHEM, V259, P1858; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; LEHMANN V, 1973, EUR J BIOCHEM, V32, P268, DOI 10.1111/j.1432-1033.1973.tb02607.x; LINDNER B, 1990, ANAL MICROBIOLOGY ME, P149; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MONTEIRO MA, 1997, IR J MED SCI S3, V166, P32; MONTGOMERIE JZ, 1979, REV INFECT DIS, V1, P736; MULLERLOENNIES S, 1994, EUR J BIOCHEM, V224, P751, DOI 10.1111/j.1432-1033.1994.t01-1-00751.x; MULLERLOENNIES S, 1997, 9 EUR CARB S UTR NET; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RADZIEJEWSKALEBRECHT J, 1986, EOS-RIV IMMUNOL, V6, P167; RADZIEJEWSKALEBRECHT J, 1994, EUR J BIOCHEM, V221, P343, DOI 10.1111/j.1432-1033.1994.tb18746.x; RADZIEJEWSKALEBRECHT J, 1989, EUR J BIOCHEM, V183, P573, DOI 10.1111/j.1432-1033.1989.tb21086.x; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RIETSCHEL ET, 1976, EUR J BIOCHEM, V64, P423, DOI 10.1111/j.1432-1033.1976.tb10318.x; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; Rozalski A, 1997, MOL MICROBIOL, V23, P569, DOI 10.1046/j.1365-2958.1997.d01-1877.x; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; Severn WB, 1996, J BACTERIOL, V178, P1731, DOI 10.1128/jb.178.6.1731-1741.1996; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SHASHKOV AS, 1995, 8 EUR CARB S SEV SPA; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUSSKIND M, 1995, CARBOHYD RES, V269, pC1, DOI 10.1016/0008-6215(95)00002-B; SWIERZKO A, 1994, J ENDOTOXIN RES, V1, P38; TACKEN A, 1986, CARBOHYD RES, V149, P279, DOI 10.1016/S0008-6215(00)90051-X; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vinogradov EV, 1996, EUR J BIOCHEM, V239, P602, DOI 10.1111/j.1432-1033.1996.0602u.x; Williams P., 1990, Reviews in Medical Microbiology, V1, P196; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3	50	82	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7006	7017		10.1074/jbc.273.12.7006	http://dx.doi.org/10.1074/jbc.273.12.7006			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507008	hybrid			2022-12-27	WOS:000072775900058
J	Brunner, NA; Brinkmann, H; Siebers, B; Hensel, R				Brunner, NA; Brinkmann, H; Siebers, B; Hensel, R			NAD(+)-dependent glyceraldehyde-3-phosphate dehydrogenase from Thermoproteus tenax - The first identified archaeal, member of the aldehyde dehydrogenase superfamily is a glycolytic enzyme with unusual regulatory properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIUM METHANOTHERMUS-FERVIDUS; 3-PHOSPHOGLYCERATE KINASES; PHYLOGENETIC TREES; PROTEIN SEQUENCES; GENE; DNA; EXPRESSION; RNA; ELECTROPHORESIS; PURIFICATION	The hyperthermophilic archaeum Thermoproteus tenax possesses two glyceraldehyde-3-phosphate dehydrogenases differing in cosubstrate specificity and phosphate dependence of the catalyzed reaction, NAD(+)- dependent glyceraldehyde-3-phosphate dehydrogenase catalyzes the phosphate-independent irreversible oxidation of D-glyceraldehyde 3-phosphate to 8-phosphoglycerate, The coding gene was cloned, sequenced, and expressed in Escherichia coli, Sequence comparisons showed no similarity to phosphorylating glyceraldehyde-3-phosphate dehydrogenases but revealed a relationship to aldehyde dehydrogenases, with the highest similarity to the subgroup of nonphosphorylating glyceraldehyde-3-phosphate dehydrogenases. The activity of the enzyme is affected by a series of metabolites, All effecters tested influence the affinity of the enzyme for its cosubstrate NAD(+), Whereas NADP(H), NADH, and ATP reduce the affinity for the cosubstrate, AMP, ADP, glucose 1-phosphate, and fructose 6-phosphate increase the affinity for NAD(+), Additionally, most of the effecters investigated induce cooperativity of NAD(+) binding. The irreversible catabolic oxidation of glyceraldehyde 3-phosphate, the control of the enzyme by energy charge of the cell, and the regulation by intermediates of glycolysis and glucan degradation identify the NAD(+)-dependent glyceraldehyde-3-phosphate dehydrogenase as an integral constituent of glycolysis in T, tenax. Its regulatory properties substitute for those lacking in the reversible nonregulated pyrophosphate-dependent phosphofructokinase in this variant of the Embden-Meyerhof-Parnas pathway.	Univ Essen Gesamthsch, Dept Microbiol, Fachbereich 9, D-45117 Essen, Germany; Univ Paris 11, Dept Cell Biol, F-91405 Orsay, France	University of Duisburg Essen; UDICE-French Research Universities; Universite Paris Saclay	Hensel, R (corresponding author), Univ Essen Gesamthsch, Dept Microbiol, Fachbereich 9, Univ Str 5, D-45117 Essen, Germany.	bmb000@sp2.power.uni-essen.de		Siebers, Bettina/0000-0002-9905-541X				ALTEKAR W, 1992, ARCH MICROBIOL, V158, P356, DOI 10.1007/BF00245365; ARNON DI, 1954, NATURE, V173, P1132, DOI 10.1038/1731132a0; BEDINO S, 1992, INT J BIOCHEM, V24, P1697, DOI 10.1016/0020-711X(92)90115-H; BOYD DA, 1995, J BACTERIOL, V177, P2622, DOI 10.1128/jb.177.10.2622-2627.1995; Brinkmann H, 1996, PLANT MOL BIOL, V30, P65, DOI 10.1007/BF00017803; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CERFF R, 1995, TRACING BIOL EVOLUTI; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CROW VL, 1979, J BIOL CHEM, V254, P1134; DANSON MJ, 1992, BIOCHEM SOC SYMP, V58, P7; FABRY S, 1987, EUR J BIOCHEM, V165, P147, DOI 10.1111/j.1432-1033.1987.tb11205.x; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FONTANA A, 1986, PRACTICAL PROTEIN CH, P83; Freiberg C, 1996, GENOME RES, V6, P590, DOI 10.1101/gr.6.7.590; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HABENICHT A, 1994, J MOL BIOL, V237, P165, DOI 10.1006/jmbi.1994.1217; HENSEL R, 1989, CAN J MICROBIOL, V35, P81, DOI 10.1139/m89-012; HENSEL R, 1987, EUR J BIOCHEM, V170, P325, DOI 10.1111/j.1432-1033.1987.tb13703.x; HESS D, 1995, EUR J BIOCHEM, V233, P227, DOI 10.1111/j.1432-1033.1995.227_1.x; HIDAKA T, 1995, GENE, V158, P149, DOI 10.1016/0378-1119(95)00101-B; Higgins D G, 1994, Methods Mol Biol, V25, P307; IGLESIAS AA, 1988, ARCH BIOCHEM BIOPHYS, V260, P830, DOI 10.1016/0003-9861(88)90514-0; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JUNGBLUT P, 1990, ELECTROPHORESIS, V11, P581, DOI 10.1002/elps.1150110709; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KEELING PJ, 1996, P NATL ACAD SCI USA, V94, P1270; KELLY GJ, 1973, PLANT PHYSIOL, V52, P111, DOI 10.1104/pp.52.2.111; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; Kimura M., 1983, NEUTRAL THEORY MOL E; KONIG H, 1982, ARCH MICROBIOL, V132, P297, DOI 10.1007/BF00413378; LEINFELDER W, 1985, SYST APPL MICROBIOL, V6, P164, DOI 10.1016/S0723-2020(85)80050-3; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; MATEOS MI, 1992, PLANT SCI, V84, P163, DOI 10.1016/0168-9452(92)90130-E; MEAKIN SA, 1991, J MICROBIOL METH, V14, P119, DOI 10.1016/0167-7012(91)90041-N; POPOV KM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P69, DOI 10.1016/0167-4838(92)90236-7; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Siebers B, 1997, ARCH MICROBIOL, V168, P120, DOI 10.1007/s002030050477; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; WEIL CF, 1988, J BACTERIOL, V170, P4718, DOI 10.1128/jb.170.10.4718-4726.1988; WIEMANN S, 1995, BIOTECHNIQUES, V18, P688; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	49	111	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6149	6156		10.1074/jbc.273.11.6149	http://dx.doi.org/10.1074/jbc.273.11.6149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497334	hybrid			2022-12-27	WOS:000072488500026
J	Mackintosh, JA; Veal, DA; Beattie, AJ; Gooley, AA				Mackintosh, JA; Veal, DA; Beattie, AJ; Gooley, AA			Isolation from an ant Myrmecia gulosa of two inducible O-glycosylated proline-rich antibacterial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL DIARRHEA VIRUS; ANTIMICROBIAL PEPTIDE; ANTIBIOTICS; DROSOPHILA; IMMUNITY; SPECTRUM; INSECT; MODE	Reported here is the isolation and characterization of two antibacterial peptides synthesized in an ant Myrmecia gulosa in response to bacterial challenge. The peptides were purified by reversed-phase high performance liquid chromatography and characterized by peptide sequencing and mass spectrometry. Both peptides were formed from 16 amino acids, were rich in proline (similar to 30%), and had N-acetylgalactosamine O-linked to a conserved threonine. The activity of a synthetic non-glycosylated isoform was markedly reduced demonstrating that glycosylation was necessary for maximum activity. The peptides were active only against growing Escherichia coli. They were inactive against stationary cells, Grampositive bacteria, the yeast Candida albicans, two species of mammalian cells, and bovine pestivirus.	Macquarie Univ, Sch Biol Sci, Sydney, NSW 2109, Australia; Macquarie Univ, Ctr Analyt Biotechnol, Sydney, NSW 2109, Australia	Macquarie University; Macquarie University	Mackintosh, JA (corresponding author), Macquarie Univ, Sch Biol Sci, Sydney, NSW 2109, Australia.	jmackint@ma.bio.mq.edu.au						BOMAN HG, 1974, ANN NY ACAD SCI, V235, P569, DOI 10.1111/j.1749-6632.1974.tb43291.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; Borneman J, 1996, APPL ENVIRON MICROB, V62, P1935, DOI 10.1128/AEM.62.6.1935-1943.1996; Bulet P, 1996, EUR J BIOCHEM, V238, P64, DOI 10.1111/j.1432-1033.1996.0064q.x; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1994, J BIOL CHEM, V269, P26107; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; Chernysh S, 1996, J INSECT PHYSIOL, V42, P81, DOI 10.1016/0022-1910(95)00085-2; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; Ebert Dieter, 1996, Trends in Ecology and Evolution, V11, P79, DOI 10.1016/0169-5347(96)81047-0; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Gooley AA, 1997, NATURE, V385, P557, DOI 10.1038/385557a0; HARA S, 1995, BIOCHEM J, V310, P651, DOI 10.1042/bj3100651; Hetru Charles, 1994, P43; HULTMARK D, 1980, EUR J BIOCHEM, V106, P7, DOI 10.1111/j.1432-1033.1980.tb05991.x; HYERA JMK, 1987, J VET MED B, V34, P227, DOI 10.1111/j.1439-0450.1987.tb00392.x; KIRKLAND PD, 1991, VET REC, V128, P587, DOI 10.1136/vr.128.25.587; MACKINTOSH JA, 1995, CAN J MICROBIOL, V41, P136, DOI 10.1139/m95-018; Oren Z, 1996, EUR J BIOCHEM, V237, P303, DOI 10.1111/j.1432-1033.1996.0303n.x; Ou KL, 1996, J CHROMATOGR A, V723, P219, DOI 10.1016/0021-9673(95)00879-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rees JA, 1997, INSECT BIOCHEM MOLEC, V27, P413, DOI 10.1016/S0965-1748(97)00013-1; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SCHMID-HEMPEL P, 1997, INFECT POLYMORPHISM, P43; SHANNON AD, 1991, J VIROL METHODS, V34, P1, DOI 10.1016/0166-0934(91)90116-H; Yan JX, 1996, J CHROMATOGR A, V736, P291, DOI 10.1016/0021-9673(95)01285-0	30	84	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6139	6143		10.1074/jbc.273.11.6139	http://dx.doi.org/10.1074/jbc.273.11.6139			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497332	hybrid			2022-12-27	WOS:000072488500024
J	Turko, IV; Francis, SH; Corbin, JD				Turko, IV; Francis, SH; Corbin, JD			Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CAMP PHOSPHODIESTERASE; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; PROTEIN; IDENTIFICATION; COMPLEX; SITE; MUTAGENESIS; ACTIVATION	The known mammalian 3':5'-cyclic nucleotide phosphodiesterases (PDEs) contain a conserved region located toward the carboxyl terminus, which constitutes a catalytic domain, To identify amino acids that are important for catalysis, we introduced substitutions at 23 conserved residues within the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (cGBPDE; PDES). Wild-type and mutant proteins were compared with respect to K-m for cGMP, k(cat) and IC50 for zaprinast, The most dramatic decrease in k(cat) was seen with H643A and D754A mutants with the decrease in free energy of binding (Delta Delta G(T)) being about 4.5 kcal/mol for each, which is within the range predicted for loss of a hydrogen bond involving a charged residue, His(643)?S and Asp(754) conserved in all known PDEs and are sarong candidates to be directly involved in catalysis, Substitutions of His(603), His(607), His(647), Glu(672), Asp(714) also produced marked changes in k(cat) and these residues are likely to be important for efficient catalysis, The Y602A and E775A mutants exhibited the most dramatic increases in K-m for cGAMP, with calculated Delta Delta G(T) of 2.9 and 2.8 kcaj/mol, respectively, that these two residues are important for cGMP binding in the catalytic site, Zaprinast is a potent competitive inhibitor of cGB-PDE, but the key residues for its binding differ significantly from those that bind cGMP.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Corbin, JD (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BELTMAN J, 1995, MOL PHARMACOL, V47, P330; Boldt YR, 1997, BIOCHEMISTRY-US, V36, P2147, DOI 10.1021/bi962362i; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; Cheung PP, 1996, BLOOD, V88, P1321, DOI 10.1182/blood.V88.4.1321.bloodjournal8841321; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; GIDHJAIN M, 1994, J BIOL CHEM, V269, P27732; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Ishikawa K, 1996, BIOCHEMISTRY-US, V35, P8329, DOI 10.1021/bi960493d; Jacobitz S, 1996, MOL PHARMACOL, V50, P891; Jacobitz S, 1997, MOL PHARMACOL, V51, P999, DOI 10.1124/mol.51.6.999; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; OMBURO GA, 1995, ARCH BIOCHEM BIOPHYS, V323, P1, DOI 10.1006/abbi.1995.0001; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SRIVASTAVA D, 1995, BIOCHEM J, V308, P653, DOI 10.1042/bj3080653; STRELKOV SV, 1995, J MOL BIOL, V249, P665, DOI 10.1006/jmbi.1995.0327; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; TUCKER MM, 1981, J BIOL CHEM, V256, P9051; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P1219, DOI 10.1073/pnas.84.5.1219; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	35	62	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6460	6466		10.1074/jbc.273.11.6460	http://dx.doi.org/10.1074/jbc.273.11.6460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497379	hybrid			2022-12-27	WOS:000072488500071
J	Worthylake, DR; Prakash, S; Prakash, L; Hill, CP				Worthylake, DR; Prakash, S; Prakash, L; Hill, CP			Crystal structure of the Saccharomyces cerevisiae ubiquitin-conjugating enzyme Rad6 at 2.6 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR GENES; N-END RULE; PROTEIN-DEGRADATION; YEAST RAD6; SEQUENCE; PATHWAY; MUTAGENESIS; PROTEASOME; MUTATIONS; TERMINUS	The Saccharomyces cerevisiae ubiquitin-conjugating enzyme (UBC) Rad6 is required for several functions, including the repair of UV damaged DNA, damage-induced mutagenesis, sporulation, and the degradation of cellular proteins that possess destabilizing N-terminal residues. Rad6 mediates its role in N-end rule-dependent protein degradation via interaction with the ubiquitin-protein ligase Ubr1 and in DNA repair via interactions with the DNA binding protein Rad18. We report here the crystal structure of Rad6 refined at 2.6 Angstrom resolution to an R factor of 21.3%. The protein adopts an alpha/beta fold that is very similar to other UBC structures. An apparent difference at the functionally important first helix, however, has prompted a reassessment of previously reported structures. The active site cysteine lies in a cleft formed by a coil region that includes the 3(10) helix and a loop that is in different conformations for the three molecules in the asymmetric unit. Residues important for Rad6 interaction with Ubr1 and Rad18 are on the opposite side of the structure from the active site, indicating that this part of the UBC surface participates in protein-protein interactions that define Rad6 substrate specificity.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Medical Branch Galveston	Hill, CP (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.	chris@msscc.med.utah.edu	Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050163, R01GM019261] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-T32-GM08573, GM50163, GM19261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG JD, 1994, MUTAT RES-DNA REPAIR, V315, P281, DOI 10.1016/0921-8777(94)90039-6; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG XL, 1992, GENETICS, V130, P285; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; MADURA K, 1993, J BIOL CHEM, V268, P12046; MCDONOUGH M, 1995, J BACTERIOL, V177, P580, DOI 10.1128/jb.177.3.580-585.1995; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RABOY B, 1994, EUR J BIOCHEM, V221, P247, DOI 10.1111/j.1432-1033.1994.tb18735.x; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250	42	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6271	6276		10.1074/jbc.273.11.6271	http://dx.doi.org/10.1074/jbc.273.11.6271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497353	hybrid			2022-12-27	WOS:000072488500045
J	Firestein, R; Feuerstein, N				Firestein, R; Feuerstein, N			Association of activating transcription factor 2 (ATF2) with the ubiquitin-conjugating enzyme hUBC9 - Implications of the ubiquitin/proteasome pathway in regulation of ATF2 in T class	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; BINDING PROTEIN CREB; DNA-BINDING; SIGNAL-TRANSDUCTION; PROTEASOME PATHWAY; DECAMER MOTIF; C-JUN; ANTIGEN RECEPTOR; LYMPHOCYTES-B; HUMAN HOMOLOG	Activating transcription factor 2 (ATF2) is regulated by phosphorylation via the Jun N-terminal kinase, and its binding activity is markedly induced at]late stages of T and B lymphocyte activation (Feuerstein, M,, Firestein, R., Aiyer, M., Xiao, H., Murasko, D,, and Cristofalo, V, (1996) J. Immunol. 156, 4582-4593), To identify proteins that interact specifically with ATF2 in lymphocytes, the yeast two-hybrid interaction system was employed using ATF2 cDNA as a "bait." In two separate screenings, a clone was identified that revealed st novel sequence with homology to several members of the ubiquitin-conjugating enzyme family, An identical sequence was recently reported as the human homolog of the yeast UBC9, hUBC9. Northern blot analysis revealed a 1.3-kilobase RNA transcript, which showed differential levels of expression in various human tissues and a moderate induction after a 48-h stimulation of peripheral blood T lymphocytes, An antibody that was generated against the bacterially expressed glutathione S-transferase-hUBC9 detected a similar to 19-kDa protein, which localizes predominantly in the nuclei of T cells, Further quantitative assays using the yeast two-hybrid system confirmed a high and specific level of interaction of hUBC9 with ATF2 and lack of interaction with lamin or control vectors, Two other cyclic AMP-responsive element-binding transcription factors, CREB and ATF1, also showed significant levels of interaction with hUBC9. However, this interaction was severalfold lower as compared with ATF2, Far Western, blot analysis confirmed the specific binding of ATF2 and hUBC9 also in vitro, Evidence is presented that indicates a physiological significance for the interaction of hUBC9 with ATF2. (a) We show that ATF2 is ubiquitinated in vivo and in vitro, and (b) ATF2 ubiquitination irt vitro is facilitated by addition of purified hUBC9, (c) ATF2 is shown to undergo a proteolytic process, which is rapidly regulated upon T cell activation concomitant with induction of ATF2 phosphorylation, (d) a proteasome inhibitor delays the down-regulation of ATF2 phophorylation after T cell activation, Taken collectively, these results implicate a role for hUBC9 and the ubiquitin/proteasome pathway in regulation of ATF2 in T cells.	Univ Penn, Div Rheumatol, Dept Med, Philadelphia, PA 19104 USA; Allegheny Univ Hlth Sci, Ctr Gerontol, Philadelphia, PA 19104 USA	University of Pennsylvania; Drexel University	Feuerstein, N (corresponding author), Univ Penn, Div Rheumatol, Dept Med, 909 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040620] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40620] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ALKHODAIRY F, 1995, J CELL SCI, V108, P475; ANDERSON SJ, 1989, MOL CELL BIOL, V9, P4835, DOI 10.1128/MCB.9.11.4835; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BENBROOK DM, 1990, ONCOGENE, V5, P295; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; CHEN Z, 1995, GENE DEV, V91, P1586; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Dam H., 1995, EMBO J, V14, P1798; DOLMETSCH DE, 1997, NATURE, V386, P855; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; Feuerstein N, 1996, J IMMUNOL, V156, P4582; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P4746; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GAO MH, 1993, J IMMUNOL, V150, P4376; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEE MR, 1992, J IMMUNOL, V148, P1906; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsai EY, 1996, MOL CELL BIOL, V16, P459; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WHILHEM D, 1995, IMMUNOBIOLOGY, V193, P143; WOLLBERG P, 1994, J BIOL CHEM, V269, P19719; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	57	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5892	5902		10.1074/jbc.273.10.5892	http://dx.doi.org/10.1074/jbc.273.10.5892			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488727	hybrid			2022-12-27	WOS:000072345000070
J	Francesconi, A; Duvoisin, RM				Francesconi, A; Duvoisin, RM			Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-COUPLED RECEPTORS; MOLECULAR CHARACTERIZATION; CA2+-SENSING RECEPTOR; AGONIST SELECTIVITY; XENOPUS OOCYTES; PHOSPHOLIPASE-C; EXPRESSION; DOMAIN; MUTAGENESIS	On the basis of sequence homology and structural similarities, metabotropic glutamate receptors (mGluRs), extracellular Ca2+-sensing receptor, gamma-aminobutyric acid type B receptor, and pheromone receptors are enlisted in a distinct family within the larger G protein-coupled receptor superfamily, When expressed in heterologous systems, group I mGluRs can activate dual signal transduction pathways, phosphoinositides turnover and cAMP production. To investigate the structural basis of these coupling properties, we introduced single amino acid substitutions within the second and third intracellular loops (i2 and i3) of mGluR1 alpha. Wildtype and mutant receptors were expressed in human embryonic kidney 293 cells and analyzed for their capacity to stimulate both signaling cascades. Each domain appeared to be critical for the coupling to phospholipase C and adenylyl cyclase. Within i2, Thr(695), Lys(697), and Ser(702) were found to be selectively involved in the interaction with G class alpha subunit(s), whereas mutation of Pro(698) and the deletion Cys(694)-Thr(695) affected only G(s) coupling. Furthermore, the mutation K690A profoundly altered mGluR1 alpha signaling properties and imparted to the receptor the ability to couple to the inhibitory cAMP pathway. Within i3, we uncovered two residues, Arg(775) and Phe(781), that are crucial for coupling to both pathways, since their substitution leads to receptor inactivation.	Cornell Univ Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10021 USA	Cornell University	Francesconi, A (corresponding author), Cornell Univ Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, POB 233,1300 York Ave, New York, NY 10021 USA.	afrance@med.cornell.edu			NATIONAL EYE INSTITUTE [R01EY009534] Funding Source: NIH RePORTER; NEI NIH HHS [EY09534] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE T, 1992, J BIOL CHEM, V267, P13361; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1983, BIOCHEM J, V212, P472; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASABONA G, 1992, J NEUROCHEM, V59, P1161, DOI 10.1111/j.1471-4159.1992.tb08360.x; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Flavin HJ, 1996, PROG BRAIN RES, V108, P263, DOI 10.1016/S0079-6123(08)62545-5; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HARLOW E, 1988, ANTIBODIES LAB MANUA, P495; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; JOLY C, 1995, J NEUROSCI, V15, P3970; KASAHARA J, 1994, FEBS LETT, V355, P41, DOI 10.1016/0014-5793(94)01170-2; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; LAW SF, 1993, J BIOL CHEM, V268, P10721; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nasman J, 1997, J BIOL CHEM, V272, P9703; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Prezeau L, 1996, MOL PHARMACOL, V49, P422; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REID SNM, 1995, J COMP NEUROL, V355, P470, DOI 10.1002/cne.903550311; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Saugstad JA, 1996, J NEUROSCI, V16, P5979; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SAVARESE TM, 1992, BIOCHEM J, V283, P1; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TAUSSIG R, 1992, J BIOL CHEM, V268, P9	53	142	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5615	5624		10.1074/jbc.273.10.5615	http://dx.doi.org/10.1074/jbc.273.10.5615			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488690	hybrid			2022-12-27	WOS:000072345000033
J	Gelderloos, JA; Rosenkranz, S; Bazenet, C; Kazlauskas, A				Gelderloos, JA; Rosenkranz, S; Bazenet, C; Kazlauskas, A			A role for Src in signal relay by the platelet-derived growth factor alpha receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA; PDGF RECEPTOR; PHOSPHATIDYLINOSITOL-3 KINASE; DNA-SYNTHESIS; FAMILY; PHOSPHORYLATION; BINDING; TRANSDUCTION; ACTIVATION	Previous studies have shown that Src is required for platelet-derived growth factor (PDGF)-dependent cell cycle progression in fibroblasts. Since fibroblasts usually express both PDGF receptors (PDGFBs), these findings suggested that Src Tvas mandatory for signal relay by both the alpha and beta PDGFRs. In this study, we have focused on the role of Src in signal relay by the alpha PDGFR. In response to stimulation with PDGF-AA, which selectively engages the alpha PDGFR, Src family members (Src) associated with the alpha PDGFR and Src kinase were activated, A mutant receptor, in which tyrosines 572 and 574 were replaced with phenylalanine (F72/74), failed to efficiently associate with Src or activate Src. The wild type (WT) and F72/74 receptors induced the expression of c-myc and c-fos to comparable levels. Furthermore, an equivalent extent of PDGF-dependent soft agar growth was observed in cells expressing the WT of the F72/74 alpha PDGFR. Comparing the ability of these two receptors to initiate tyrosine phosphorylation of signaling molecules indicated that both receptors mediated phosphorylation of the receptor itself, phospholipase C gamma 1, and SHP-2 to similar levels. In contrast, the F72/74 receptor triggered phosphorylation of Shc to 1 and 20% of the WT levels for the 55- and 46-kDa Shc isoforms, respectively, These findings indicate that after exposure of cells to PDGF-AA, Src stably associates with the alpha PDGFR, and Src activity-is increased. Furthermore, Src is required for the PDGF-dependent phosphorylation of signaling molecules such as She. Finally, activation of Src during the G(0)/G(1) transition does not appear to be required for latter cell. cycle events such as induction of c-myc or cell proliferation.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Gelderloos, JA (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	kazlauskas@vision.eri.harvard.edu						ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DeMali KA, 1997, J BIOL CHEM, V272, P9011; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HALLER H, 1994, ANN NY ACAD SCI, V733, P313, DOI 10.1111/j.1749-6632.1994.tb17281.x; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HOOSHMANDRAD R, 1998, IN PRESS J CELL SCI; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; YEO EJ, 1994, J BIOL CHEM, V269, P27823; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	42	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5908	5915		10.1074/jbc.273.10.5908	http://dx.doi.org/10.1074/jbc.273.10.5908			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488729	hybrid			2022-12-27	WOS:000072345000072
J	Kleijn, M; Welsh, GI; Scheper, GC; Voorma, HO; Proud, CG; Thomas, AAM				Kleijn, M; Welsh, GI; Scheper, GC; Voorma, HO; Proud, CG; Thomas, AAM			Nerve and epidermal growth factor induce protein synthesis and eIF2B activation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3; CAP-BINDING-PROTEIN; RAT SKELETAL-MUSCLE; POLYPEPTIDE-CHAIN INITIATION; TRANSLATION INITIATION; PHAS-I; MESSENGER-RNA; RABBIT RETICULOCYTES	The regulation of protein synthesis and of eukaryotic initiation factor eIF2B was studied in PC12 cells. An increase in protein synthesis was observed after nerve growth factor (NGF) and epidermal growth a factor (EGF) treatment of PC12 cells, and this increase coincided with activation of eIF2B. Growth factor addition in the presence of the phosphatidylinositol-3'-OH kinase inhibitor wortmannin showed that both NGF- and EGF-induced protein synthesis and eIF2B activation were phosphatidylinasitol-3'-OH kinase dependent. The EGF-induced stimulation of protein synthesis and activation of eIF2B was dependent upon FK506-binding protein-rapamycin-associated protein, as shown with the immunosuppressant rapamycin, whereas NGF induction was partially dependent upon FK506-bindinag protein-rapamycin-associated protein. The activities of two kinases that act on eIF2B, glycogen synthase kinase-3 and casein kinase II, were measured to assess their potential roles in the activation of eIF2B in PC12 cells. inactivation of glycogen synthase kinase-3 was seen in response to both NGF and EGF and this coincided with activation of eIF2B. However, inactivation of glycogen synthase kinase-3 was not rapamycin sensitive, in contrast to the activation of eIF2B. This indicates the involvement of another protein kinase or regulatory mechanism in the eIF2B activation. Both growth factors activated casein kinase II. However, the time course of its activation and its insensitivity to wortmannin and rapamycin suggest that casein kinase II does not play a major regulatory role in eIF2B activation under these conditions.	Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	Utrecht University; University of Kent	Thomas, AAM (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	A.A.M.Thomas@biol.ruu.nl	Scheper, Gert C/D-7001-2014	Welsh, Gavin Iain/0000-0002-2148-6658; Proud, Christopher/0000-0003-0704-6442				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GIERMAN TM, 1992, VIROLOGY, V188, P934, DOI 10.1016/0042-6822(92)90557-6; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GROSS M, 1989, J BIOL CHEM, V264, P21879; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; JEFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; Kleijn M, 1996, VIROLOGY, V217, P486, DOI 10.1006/viro.1996.0143; Kleijn M, 1995, J CELL BIOCHEM, V59, P443, DOI 10.1002/jcb.240590405; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEHTA HB, 1983, J BIOL CHEM, V258, P3438; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNIERLE BS, 1992, VIROLOGY, V188, P981; Singh LP, 1996, BIOCHEMISTRY-US, V35, P3206, DOI 10.1021/bi9522099; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410	67	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5536	5541		10.1074/jbc.273.10.5536	http://dx.doi.org/10.1074/jbc.273.10.5536			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488678	hybrid			2022-12-27	WOS:000072345000021
J	Rafty, LA; Khachigian, LM				Rafty, LA; Khachigian, LM			Zinc finger transcription factors mediate high constitutive platelet-derived growth factor-B expression in smooth muscle cells derived from aortae of newborn rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; VASCULAR ENDOTHELIAL-CELLS; FACTOR-LIKE MOLECULES; GENE-EXPRESSION; ARTERIAL INJURY; MESSENGER-RNA; SYNERGISTIC ACTIVATION; OSTEOSARCOMA CELLS; RECEPTOR GENE; FACTOR-I	Platelet-derived growth factor (PDGF) B-chain gene is differentially expressed in smooth muscle cells (SMCs) derived from the rat aortic wall. SMCs cultured from two week-old rats (pups) express high levels of PDGF-B mRNA, whereas cells isolated from three month-old rats (adults) express low levels of PDGF-B. Nuclear run-off experiments indicate that increased PDGF-B gene expression in pups is mediated, at least in part, at the transcriptional level. We used electrophoretic mobility shift assays and Western blot analysis to demonstrate that levels of Sp1 and Sp3, two zinc finger transcription factors which mediate basal expression of the PDGF-B gene, are elevated in pup nuclei compared with adult nuclei. The immediate-early transcription factor, Egr-1, which footprints the PDGF-B promoter, is also constitutively expressed in these cells. Transient transfection and binding studies show that these factors interact with a region in the proximal PDGF-B promoter key for basal expression in pup cells. Mutation of this proximal element in transfected pup cells attenuates reporter gene expression to levels observed in adult cells. Conversely, overexpression of Sp1 in adult cells augments PDGF-B expression in cultured newborn rat SMCs may therefore require high constitutive expression of a number of zinc finger transcription factors and their specific interactions with the proximal PDGF-B promoter.	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.	L.Khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				BARVE SS, 1994, J IMMUNOL, V152, P1171; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; ELDER GA, 1992, NUCLEIC ACIDS RES, V20, P6281, DOI 10.1093/nar/20.23.6281; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GERRITY RG, 1975, LAB INVEST, V32, P585; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; IKEDA K, 1993, GENE, V136, P341; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LINDNER V, 1995, CIRC RES, V76, P951, DOI 10.1161/01.RES.76.6.951; MADORE SJ, 1995, VIROLOGY, V206, P1150, DOI 10.1006/viro.1995.1041; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MALAYANKAR UM, 1996, FASEB J, V10, pA1134; MALYANKAR UM, 1996, J VASC RES, V33, P62; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MINOWA T, 1994, J BIOL CHEM, V269, P11656; Muller S, 1996, ONCOGENE, V13, P1955; NGO VM, 1995, MOL CELL ENDOCRINOL, V108, P95, DOI 10.1016/0303-7207(94)03462-3; POMPILI VJ, 1995, ARTERIOSCL THROM VAS, V15, P2254, DOI 10.1161/01.ATV.15.12.2254; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; Scarpati EM, 1996, J BIOL CHEM, V271, P3025, DOI 10.1074/jbc.271.6.3025; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; VANNECK JW, 1994, AM J PATHOL, V143, P269; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311	44	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5758	5764		10.1074/jbc.273.10.5758	http://dx.doi.org/10.1074/jbc.273.10.5758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488709	hybrid			2022-12-27	WOS:000072345000052
J	Nguyen, HHT; Elliott, SJ; Yip, JHK; Chan, SI				Nguyen, HHT; Elliott, SJ; Yip, JHK; Chan, SI			The particulate methane monooxygenase from methylococcus capsulatus (Bath) is a novel copper-containing three-subunit enzyme - Isolation and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; NITROSOSPIRA SP NPAV; X-RAY-ABSORPTION; HYDROXYLASE COMPONENT; AMMONIA MONOOXYGENASE; MONO-OXYGENASE; NITROSOMONAS-EUROPAEA; DIIRON CENTER; OXIDATION; GENE	The particulate methane monooxygenase (pMMO) is known to be very difficult to study mainly due to its unusual activity instability in vitro, By cultivating Methylococcus capsulatus (Bath) under methane stress conditions and high copper levels in the growth medium, membranes highly enriched in the pMMO with exceptionally stable activity can be isolated from these cells. Purified and active pMMO can be subsequently obtained from these membrane preparations using protocols in which an excess of reductants and anaerobic conditions were maintained during membrane solubilization by dodecyl beta-D-maltoside and purification by chromatography. The pMMO was found to be the major constituent in these membranes, constituting 60-80% of total membrane proteins. The dominant species of the pMMO was found to consist of three subunits, alpha, beta and gamma, with an apparent molecular mass of 45, 26, and 23 kDa, respectively. A second species of the PMMO, a proteolytically processed version of the enzyme, was found to be composed of three subunits, alpha', beta, and gamma, with an apparent molecular mass of 35, 26, and 23 kDa, respectively. The alpha and alpha' subunits from these two forms of the pMMO contain identical N-terminal sequences. The gamma subunit, however, exhibits variation in its N-terminal sequence. The pMMO is a copper-containing protein only and shows a requirement for Cu(I) ions, Approximately 12-15 Cu ions per 94-kDa monomeric unit were observed. The pMMO is sensitive to dioxygen tension. On the basis of dioxygen sensitivity, three kinetically distinct forms of the enzyme can be distinguished. A slow but air-stable form, which is converted into a "pulsed" state upon direct exposure to atmospheric oxygen pressure, is considered as type I pMMO, This form was the subject of our pMMO isolation effort. Other forms (types II and III) are deactivated to various extents upon exposure to atmospheric dioxygen pressure. Under inactivating conditions, these unstable forms release protons to the buffer (approximate-to 10 H+/94-kDa monomeric unit) and eventually become completely inactive.	CALTECH, Arthur Amos Noyes Lab Chem Phys 127 72, Pasadena, CA 91125 USA	California Institute of Technology	Chan, SI (corresponding author), CALTECH, Arthur Amos Noyes Lab Chem Phys 127 72, Pasadena, CA 91125 USA.	chans@cco.caltech.edu		Yip, John/0000-0002-0955-4873; Elliott, Sean/0000-0003-0096-9551	NIGMS NIH HHS [GM 22432] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022432, R37GM022432] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKENT'EVA N P, 1988, Biokhimiya, V53, P91; ANTHONY C, 1982, BIOCH METHYLOTROPHS, P296; BEDARD C, 1989, MICROBIOL REV, V53, P68; BERGMANN DJ, 1994, BIOCHEM BIOPH RES CO, V204, P759, DOI 10.1006/bbrc.1994.2524; Chan S.I., 1993, BIOINORGANIC CHEM CO, P184; Chan Sunney I., 1993, P93; CORNISH A, 1985, BIOTECHNOL LETT, V5, P319; CRABTREE RH, 1995, CHEM REV, V95, P987, DOI 10.1021/cr00036a005; Dalton H, 1984, MICROBIAL GROWTH C C, P1; DeRose VJ, 1996, J AM CHEM SOC, V118, P121, DOI 10.1021/ja951108v; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DEWITT JG, 1995, INORG CHEM, V34, P2505, DOI 10.1021/ic00114a007; DISPIRITO AA, 1994, ARCH MICROBIOL, V161, P258, DOI 10.1007/s002030050051; DRUMMOND D, 1989, EUR J BIOCHEM, V1982, P667; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GERSHONI JM, 1982, ANAL BIOCHEM, V124, P396, DOI 10.1016/0003-2697(82)90056-2; GREEN J, 1985, J BIOL CHEM, V260, P5795; GREEN J, 1988, J BIOL CHEM, V263, P17561; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HOLMES AJ, 1995, FEMS MICROBIOL LETT, V132, P203, DOI 10.1016/0378-1097(95)00311-R; KLOTZ MG, 1995, GENE, V163, P159, DOI 10.1016/0378-1119(95)00392-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SK, 1993, J BIOL CHEM, V268, P21569; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU KE, 1993, J AM CHEM SOC, V115, P939, DOI 10.1021/ja00056a018; LIU Y, 1995, J BIOL CHEM, V270, P24662, DOI 10.1074/jbc.270.42.24662; LUND J, 1985, EUR J BIOCHEM, V147, P291, DOI 10.1111/j.1432-1033.1985.tb08749.x; MCTAVISH H, 1993, J BACTERIOL, V175, P2436, DOI 10.1128/JB.175.8.2436-2444.1993; Moir JWB, 1996, FEBS LETT, V387, P71, DOI 10.1016/0014-5793(96)00463-2; NAKAJIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P736, DOI 10.1271/bbb.56.736; Nguyen HHAT, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P150; NGUYEN HHT, 1994, J BIOL CHEM, V269, P14995; Nguyen HHT, 1996, J AM CHEM SOC, V118, P12766, DOI 10.1021/ja961778g; Norton JM, 1996, FEMS MICROBIOL LETT, V139, P181, DOI 10.1111/j.1574-6968.1996.tb08200.x; PATEL RN, 1982, APPL ENVIRON MICROB, V44, P1130, DOI 10.1128/AEM.44.5.1130-1137.1982; PAULSEN KE, 1994, BIOCHEMISTRY-US, V33, P713, DOI 10.1021/bi00169a013; PILKINGTON SJ, 1990, METHOD ENZYMOL, V188, P181; PRIESTLEY ND, 1992, J AM CHEM SOC, V114, P7561, DOI 10.1021/ja00045a037; PRINCE RC, 1988, BIOCHIM BIOPHYS ACTA, V952, P220, DOI 10.1016/0167-4838(88)90119-7; PRIOR SD, 1985, J GEN MICROBIOL, V131, P155; PULVER S, 1993, J AM CHEM SOC, V115, P12409, DOI 10.1021/ja00079a024; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; ROTHAWE JH, 1995, FEMS MICROBIOL, V133, P131; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT D, 1981, J GEN MICROBIOL, V125, P63; SEMRAU JD, 1995, J INORG BIOCHEM, V58, P235, DOI 10.1016/0162-0134(94)00056-G; SEMRAU JD, 1995, J BACTERIOL, V177, P3071, DOI 10.1128/jb.177.11.3071-3079.1995; SHIEMKE AK, 1995, ARCH BIOCHEM BIOPHYS, V321, P421, DOI 10.1006/abbi.1995.1413; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STAINTHORPE AC, 1990, FEMS MICROBIOL LETT, V70, P103; STANLEY SH, 1983, BIOTECHNOL LETT, V5, P487, DOI 10.1007/BF00132233; TONGE GM, 1977, BIOCHEM J, V161, P333, DOI 10.1042/bj1610333; Whittenbury R., 1981, PROKARYOTES, P894, DOI DOI 10.1007/978-3-662-13187-9_71; Wilkinson B, 1996, J AM CHEM SOC, V118, P921, DOI 10.1021/ja953407q; Zahn JA, 1996, J BACTERIOL, V178, P1018, DOI 10.1128/jb.178.4.1018-1029.1996	59	174	189	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7957	7966		10.1074/jbc.273.14.7957	http://dx.doi.org/10.1074/jbc.273.14.7957			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525893	Green Submitted, hybrid			2022-12-27	WOS:000072876300027
J	Wang, LW; Zhu, YQ; Sharma, K				Wang, LW; Zhu, YQ; Sharma, K			Transforming growth factor-beta 1 stimulates protein kinase A in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; CAMP-RESPONSIVE ELEMENT; FACTOR-BETA; EXTRACELLULAR-MATRIX; TGF-BETA; GENE-TRANSCRIPTION; FIBRONECTIN GENE; HIGH GLUCOSE; PHOSPHORYLATION; EXPRESSION	We recently demonstrated that transforming growth factor-beta (TGF-beta) stimulates phosphorylation of the type I inositol 1,4,5-trisphosphate receptor (Sharma, K., Wang, L., Zhu, Y., Bokkala, S., and Joseph, S. (1997) J. Biol. Chem. 272, 14617-14623), possibly via protein kinase A (PKA) activation in murine mesangial cells. In the present study, we evaluated whether TGF-beta stimulates PKA activation. Utilizing a specific PKA kinase assay, me found that TGF-beta increases PRA activity by 3-fold within 15 min of TGF-beta treatment, and the enhanced kinase activity was completely reversed by the inhibitory peptide for PKA (PKI; 1 mu M). In mesangial cells transfected with a PKI expression vector, enhanced PKA activity could not be demonstrated with TGF-beta 1 treatment, TGF-beta 1 was also found to stimulate translocation of the alpha-catalytic subunit of PKA to the nucleus by Western analysis of nuclear protein as well as by confocal microscopy. TGF-beta 1-mediated phosphorylation of cAMP response element-binding protein was completely reversed by H-89 (3 mu M), a specific inhibitor of PKA. Stimulation of fibronectin mRNA by TGF-beta 1 was also attenuated in cells overexpressing PKI. We thus conclude that TGF-beta stimulates the PKA signaling pathway in mesangial cells and that PKA activation contributes to TGF-beta stimulation of cAMP response element-binding protein phosphorylation and fibronectin expression.	Thomas Jefferson Univ, Sch Med, Dept Med, Div Nephrol, Philadelphia, PA 19107 USA	Jefferson University	Sharma, K (corresponding author), Thomas Jefferson Univ, Sch Med, Dept Med, Div Nephrol, Suite 353,JAH 1020 Locust St, Philadelphia, PA 19107 USA.	sharma1@jeflin.tju.edu			NIDDK NIH HHS [KO8 DK02308] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002308] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BARLAT I, 1995, ONCOGENE, V11, P1309; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAY RN, 1989, J BIOL CHEM, V264, P431; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; FONTENAY M, 1992, J CELL PHYSIOL, V152, P507, DOI 10.1002/jcp.1041520310; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; Kreisberg JI, 1996, KIDNEY INT, V50, P805, DOI 10.1038/ki.1996.379; KREISBERG JI, 1994, KIDNEY INT, V46, P1019, DOI 10.1038/ki.1994.362; LUTZ MP, 1994, ANAL BIOCHEM, V220, P268, DOI 10.1006/abio.1994.1337; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Potchinsky MB, 1997, EXP CELL RES, V231, P96, DOI 10.1006/excr.1996.3422; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARMA K, 1994, AM J PHYSIOL-RENAL, V267, pF1094, DOI 10.1152/ajprenal.1994.267.6.F1094; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; SHARMA K, 1994, AM J PHYSIOL, V266, pF829, DOI 10.1152/ajprenal.1994.266.6.F829; Sharma K, 1997, J BIOL CHEM, V272, P14617, DOI 10.1074/jbc.272.23.14617; WOLF G, 1992, AM J PATHOL, V140, P95; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9	29	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8522	8527		10.1074/jbc.273.14.8522	http://dx.doi.org/10.1074/jbc.273.14.8522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525967	hybrid			2022-12-27	WOS:000072876300101
J	Holthoff, HP; Baack, M; Richter, A; Ritzi, M; Knippers, R				Holthoff, HP; Baack, M; Richter, A; Ritzi, M; Knippers, R			Human protein MCM6 on HeLa cell chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; YEAST MCM3; HOMOLOG; P1; NUCLEOSOMES; COMPLEXES; COMPONENT; BINDING; FAMILY	Minichromosome maintenance (Mcm) proteins perform essential functions regulating the replication of chromatin, Human cells, like other eukaryotic cells, express at least six Mcm proteins conserved in the central region, We have earlier described the primary structures of five human Mcm proteins, but the primary structure of the sixth human Mcm protein, MCM6, was identified only recently, We now use antibodies, specific for the MCM6 protein, to assess its intranuclear distribution, We find that a fraction of MCM6 protein occurs in the nucleosol, forming multiprotein complexes with other Mcm proteins, More importantly, we use for the first time micrococcal nuclease as a tool to investigate the association of MCM6 protein with chromatin, After short digestion times, a considerable fraction of the MCM6 protein is released from chromatin as a multiprotein complex that includes other Mcm proteins as well, In addition, fractions of MCM3 and MCM6 proteins are released by nuclease digestion as monomeric proteins indicating that at least these two Mcm proteins may also occur as single molecules on chromatin, The data also suggest that the chromatin regions with bound Mcm proteins are more vulnerable to nuclease attack than bulk chromatin and may therefore differ in the arrangement of nucleosomes.	Univ Constance, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Knippers, R (corresponding author), Univ Constance, Dept Biol, D-78457 Constance, Germany.	rolf.knippers@uni-konstanz.de						ADAM SA, 1992, METHOD ENZYMOL, V219, P97; BURKHART R, 1995, EUR J BIOCHEM, V228, P41; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Fujita M, 1997, J BIOL CHEM, V272, P10928; HANCOCK R, 1974, J MOL BIOL, V86, P649, DOI 10.1016/0022-2836(74)90187-9; HARLOW E, 1988, ANTIBODIES LAB HDB; Holthoff HP, 1996, GENOMICS, V37, P131, DOI 10.1006/geno.1996.0530; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; OHYASHIKI JH, 1988, CANCER GENET CYTOGEN, V34, P159, DOI 10.1016/0165-4608(88)90255-5; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; SCHLAEGER EJ, 1982, BIOCHEMISTRY-US, V21, P3167, DOI 10.1021/bi00256a021; SCHULTE D, 1995, J CELL SCI, V108, P1381; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; van Holde K.E., 1988, CHROMATIN; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	36	21	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7320	7325		10.1074/jbc.273.13.7320	http://dx.doi.org/10.1074/jbc.273.13.7320			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516426	hybrid			2022-12-27	WOS:000072738500022
J	Wu, GF; Fan, RS; Li, WH; Srinivas, V; Brattain, MG				Wu, GF; Fan, RS; Li, WH; Srinivas, V; Brattain, MG			Regulation of transforming growth factor-beta type II receptor expression in human breast cancer MCF-7 cells by vitamin D-3 and its analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; TGF-BETA; MICROSATELLITE INSTABILITY; CELLULAR RECEPTOR; GENE-EXPRESSION; RETINOIC ACID; INHIBITION; BINDING; LINES; COMPLEX	In view of the tumor suppressor role of the transforming growth factor-beta (TGF beta) type II receptor (RII), the identification and characterization of agents that can induce the expression of this receptor are of potential importance to the development of chemoprevention approaches as well as treatment of cancer. To date, the identification of exogenous agents that control RII expression has been rare. We demonstrated that proliferation of MCF-7 early passage cells (MCF-7 E), which express RII and are sensitive to TGF beta growth inhibition activity, was significantly inhibited by vitamin D-3 and its analogue EB1089. In contrast, proliferation of MCF-7 late passage cells (MCF-7 L), which have lost cell surface RII and are resistant to TGF beta, was not affected by these two compounds. TGF beta-neutralizing antibody was able to block the inhibitory effect on MCF-7 E cells by these compounds, indicating that treatment induced autocrine-negative TGF beta activity. An RNase protection assay showed approximately a 3-fold induction of the RII mRNA, while a receptor cross linking assay revealed a 3-4-fold induction of the RII protein. In contrast, there was no change in either RII mRNA or protein in the MCF-7 L cells.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Dartmouth Coll, Sch Med, Dept Pharmacol, Hanover, NH 03755 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	University of Texas System; University of Texas Health San Antonio; Dartmouth College	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA.				NCI NIH HHS [CA38173, CA72001, CA50457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050457, R37CA038173, R01CA072001, R01CA038173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEHASHIMOTO J, 1993, CANCER RES, V53, P2534; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BERGER U, 1987, CANCER RES, V47, P6793; BOYAN BD, 1994, J BIOL CHEM, V269, P28374; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHET C, 1988, J BIOL CHEM, V263, P5707; COHEN PS, 1995, CANCER RES, V55, P2380; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P693, DOI 10.1016/0006-2952(92)90405-8; DANIELPOUR D, 1995, J CELL PHYSL, V166, P31; EISMAN JA, 1981, CANCER RES, V41, P5121; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JENG MH, 1993, MOL CELL ENDOCRINOL, V97, P115, DOI 10.1016/0303-7207(93)90217-8; JORDAN VC, 1989, RESISTANCE ANTINEOPL, P403; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KHAN N, 1994, CARCINOGENESIS, V15, P2645, DOI 10.1093/carcin/15.11.2645; KIM HJ, 1992, J CELL PHYSIOL, V151, P579, DOI 10.1002/jcp.1041510318; KOLI K, 1995, CANCER RES, V55, P1540; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; MYEROFF LL, 1995, CANCER RES, V55, P5545; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PASQUALINI JR, 1988, J STEROID BIOCHEM, V31, P613, DOI 10.1016/0022-4731(88)90013-1; RIZZINO A, 1988, CANCER RES, V48, P4266; ROBERTS AB, 1992, CANCER SURV, V14, P205; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROSS TK, 1993, P NATL ACAD SCI USA, V90, P9257, DOI 10.1073/pnas.90.20.9257; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SKOWRONSKI RJ, 1995, ENDOCRINOLOGY, V136, P20, DOI 10.1210/en.136.1.20; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; TURLEY JM, 1995, CELL GROWTH DIFFER, V6, P655; WAKEFIELD L, 1990, J CELL SCI, P139; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	56	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7749	7756		10.1074/jbc.273.13.7749	http://dx.doi.org/10.1074/jbc.273.13.7749			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516484	hybrid			2022-12-27	WOS:000072738500080
J	Annunen, P; Autio-Harmainen, E; Kivirikko, KI				Annunen, P; Autio-Harmainen, E; Kivirikko, KI			The novel type II prolyl 4-hydroxylase is the main enzyme form in chondrocytes and capillary endothelial cells, whereas the type I enzyme predominates in most cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; COLLAGEN; CLONING	Procollagen-proline dioxygenase (EC 1.14.11.2), an alpha(2) beta(2) tetramer in vertebrates, plays a central role in the synthesis of all collagens. Recently an isoform of the alpha subunit, the alpha(II) subunit, was characterized in man and mouse and found to form a tetramer with the same beta subunit as the previously known alpha(I) subunit, We report here that the (alpha(I))(2) beta(2) type I tetramer is the main enzyme form in most cell types and tissues and that its contribution to total prolyl 4-hydroxylase activity in cultured cells increases in confluence. Surprisingly, however, the (alpha(II))(2) beta(2) type II enzyme was found to represent at least about 70% of the total prolyl 4-hydroxylase activity in cultured mouse chondrocytes and about 80% in mouse cartilage, the corresponding percentage in mouse bone being about 45% and that in many other mouse tissues about 10% or less. Immunofluorescence studies on samples from a fetal human foot confirmed these data and additionally indicated that the type II enzyme represents the main or only enzyme form in capillary endothelial cells. Thus the type II, prolyl 4-hydroxylase is likely to play a major role in the development of cartilages and cartilaginous bones and also of capillaries.	Univ Oulu, Dept Med Biochem, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90220 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu	Kivirikko, KI (corresponding author), Univ Oulu, Dept Med Biochem, Kajaanintie 52A, FIN-90220 Oulu, Finland.							Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; BENYA PD, 1986, ARTICULAR CARTILAGE, P219; HAGG PM, 1997, AM J PATHOL, V138, P413; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; MYLLYLA R, 1983, EUR J BIOCHEM, V134, P7, DOI 10.1111/j.1432-1033.1983.tb07523.x; MYLLYLA R, 1981, BIOCHEM J, V196, P683, DOI 10.1042/bj1960683	11	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					5989	5992		10.1074/jbc.273.11.5989	http://dx.doi.org/10.1074/jbc.273.11.5989			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497309	hybrid			2022-12-27	WOS:000072488500001
J	delCardayre, SB; Stock, KP; Newton, GL; Fahey, RC; Davies, JE				delCardayre, SB; Stock, KP; Newton, GL; Fahey, RC; Davies, JE			Coenzyme A disulfide reductase, the primary low molecular weight disulfide reductase from Staphylococcus aureus - Purification and characterization of the native enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOTHIONE REDUCTASE; TRYPANOSOMA-CONGOLENSE; CRITHIDIA-FASCICULATA; GLUTATHIONE-REDUCTASE; SELECTIVE INHIBITORS; THIOLS; EVOLUTION; MECHANISM; PROTEIN	The human pathogen Staphylococcus aureus does not utilize the glutathione thiol/disulfide redox system employed by eukaryotes and many bacteria. Instead, this organism produces CoA as its major low molecular weight thiol. We report the identification and purification of the disulfide reductase component of this thiol/disulfide redox system. Coenzyme A disulfide reductase (CoADR) catalyzes the specific reduction of CoA disulfide by NADPH. CoADR has a pH optimum of 7.5-8.0 and is a dimer of identical subunits of M-r 49,000 each. The visible absorbance spectrum is indicative of a flavoprotein with a lambda(max) = 452 nm. The liberated flavin from thermally denatured enzyme was identified as flavin adenine dinucleotide. Steady-state kinetic analysis revealed that CoADR catalyzes the reduction of CoA disulfide by NADPH at pH 7.8 with a K-m for NADPH of 2 mu M and for CoA disulfide of 11 mu M. In addition to CoA disulfide CoADR reduces 4,4'-diphosphopantethine but has no measurable ability to reduce oxidized glutathione, cystine, pantethine, or H2O2. CoADR demonstrates a sequential kinetic mechanism and employs a single active site cysteine residue that forms a stable mixed disulfide with CoA during catalysis. These data suggest that S. aureus employs a thiol/disulfide redox system based on CoA/CoA-disulfide and CoADR, an unorthodox new member of the pyridine nucleotide-disulfide reductase superfamily.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA	University of British Columbia; University of California System; University of California San Diego	delCardayre, SB (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.	stephen_delcardayre@maxygen.com						Ausubel FM, 1988, MOL REPROD DEV; BENSON TJ, 1992, BIOCHEM J, V286, P9, DOI 10.1042/bj2860009; CARLSSON J, 1979, APPL ENVIRON MICROB, V37, P383, DOI 10.1128/AEM.37.3.383-390.1979; CENAS N, 1994, BIOCHEM BIOPH RES CO, V204, P224, DOI 10.1006/bbrc.1994.2448; CHAN C, 1995, BIOCH SOC T S, V23, P511; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Cleland W W, 1979, Methods Enzymol, V63, P103; delCardayre SB, 1998, J BIOL CHEM, V273, P5752, DOI 10.1074/jbc.273.10.5752; DOLPHIN D, 1988, GLUTATHIONE CHEM B A, V3; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FAHEY RC, 1977, PROTEIN CROSSLINKI A, P1; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FAIRLAMB AH, 1989, PARASITOLOGY, V99, pS93, DOI 10.1017/S003118200008344X; FENTON SS, 1986, ANAL BIOCHEM, V154, P34, DOI 10.1016/0003-2697(86)90492-6; FREIFELDER D, 1976, PHYSICAL BIOCH, P242; GREEN CJ, 1994, ASM NEWS, V44, P231; LANTWIN CB, 1994, PROTEINS, V18, P161, DOI 10.1002/prot.340180208; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NEWTON GL, 1993, J BACTERIOL, V175, P2734, DOI 10.1128/JB.175.9.2734-2742.1993; NEWTON GL, 1989, GLUTATHIONE METABOLI, P69; PAI EF, 1983, J BIOL CHEM, V258, P1752; PONASIK JA, 1995, BIOCHEM J, V311, P371, DOI 10.1042/bj3110371; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SHAMES SL, 1988, BIOCHEMISTRY-US, V27, P5014, DOI 10.1021/bi00414a010; SPIES HSC, 1994, EUR J BIOCHEM, V224, P204; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; SUNDQUIST AR, 1989, J BIOL CHEM, V264, P719; SUNDQUIST AR, 1989, J MOL EVOL, V29, P429, DOI 10.1007/BF02602913; SWARTZ MN, 1994, P NATL ACAD SCI USA, V91, P2420, DOI 10.1073/pnas.91.7.2420; SWERDLOW RD, 1983, J BACTERIOL, V153, P475, DOI 10.1128/JB.153.1.475-484.1983; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016	35	88	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5744	5751		10.1074/jbc.273.10.5744	http://dx.doi.org/10.1074/jbc.273.10.5744			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488707	hybrid			2022-12-27	WOS:000072345000050
J	Lin, MF; Meng, TC; Rao, PS; Chang, CS; Schonthal, AH; Lin, FF				Lin, MF; Meng, TC; Rao, PS; Chang, CS; Schonthal, AH; Lin, FF			Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CARCINOMA-CELLS; BREAST-CANCER; GENE-EXPRESSION; GLUCOCORTICOID RECEPTORS; TYROSINE PHOSPHORYLATION; INDEPENDENT GROWTH; HORMONAL-THERAPY; MESSENGER-RNA; WILD-TYPE	Androgen plays a critical role in regulating the growth and differentiation of normal prostate epithelia, as well as the initial growth of prostate cancer cells, Nevertheless, prostate carcinomas eventually become androgen-unresponsive, and the cancer is refractory to hormonal therapy, To gain insight into the mechanism involved in this hormone-refractory phenomenon, we have examined the potential role of the androgen receptor (AR) in that process, We have investigated the expression of AR and two prostate-specific androgen-responsive antigens, prostatic acid phosphatase (PAcP) and prostate-specific antigen (PSA), for the functional activity of AR in LNCaP and PC-3 human prostate carcinoma cells, Our results are as follows. (i) Clone 33 LNCaP cells express AR, PAcP, and PSA, and cell growth is stimulated by 5 alpha-dihydrotestosterone (DHT). Stimulation of cell growth correlates with decreased cellular PAcP activity. (ii) In clone 81 LNCaP cells, the expression of PAcP decreases with a concurrent decrease in the degree of androgen stimulation of cell growth, whereas the expression of PSA mRNA level is up-regulated by DHT, as in clone 33 cells. Conversely, in PAcP cDNA-transfected clone 81 cells, an additional expression of cellular PAcP correlates with an increased stimulation by androgen, higher than the corresponding control cells, (iii) PC-3 cells express a low level of functional AR with no detectable PAcP or PSA, and the growth of PC-3 cells is not affected by DHT treatment, Nevertheless, in two PAcP cDNA-transfected PC-3 sublines, the expression of exogenous cellular PAcP correlates with androgen stimulation, This androgen stimulation of cell growth concurs with an increased tyrosine phosphorylation of a phosphoprotein of 185 kDa, In summary, the data indicate that the expression of AR alone is not sufficient for androgen stimulation of cell growth, Furthermore, in AR-expressing prostate cancer cells, the expression of cellular PAcP correlates with androgen stimulation of cell proliferation.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Dept Urol Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Res Inst, Omaha, NE 68198 USA; Univ Wisconsin, Dept Med, Madison, WI 53792 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Southern California	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42Nd St, Omaha, NE 68198 USA.		Schonthal, Axel/ABH-3846-2020; Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021; Schonthal, Axel/0000-0003-0662-5653	NATIONAL CANCER INSTITUTE [R29CA052112, R01CA072274, R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NCI NIH HHS [CA55639, CA72274, CA52112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; APARICIO LF, 1992, CELL GROWTH DIFFER, V3, P363; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; BERGER FG, 1989, ANNU REV PHYSIOL, V51, P51, DOI 10.1146/annurev.ph.51.030189.000411; BROWN T, 1993, CURRENT PROTOCOLS MO; BUTLER TM, 1990, CANCER RES, V50, P6323; BUZZI M, 1992, CANCER RES, V52, P4027; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; COHEN P, 1991, METHOD ENZYMOL, V201, P389; CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103; DARBRE PD, 1987, CELL, V51, P521, DOI 10.1016/0092-8674(87)90121-8; DEWINTER JAR, 1990, J PATHOL, V160, P329, DOI 10.1002/path.1711600409; DIAMOND DA, 1984, J UROLOGY, V132, P821, DOI 10.1016/S0022-5347(17)49881-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANK DA, 1988, CANCER RES, V48, P52; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GRAYHACK JT, 1987, CANCER, V60, P589, DOI 10.1002/1097-0142(19870801)60:3+<589::AID-CNCR2820601526>3.0.CO;2-R; GRUPPUSO PA, 1991, J BIOL CHEM, V266, P3444; Gyorkey F, 1973, METHOD CANCER RES, V10, P279; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; ISAACS JT, 1982, CANCER RES, V42, P2353; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KAIGHN ME, 1979, INVEST UROL, V17, P16; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1986, MOL CELL BIOL, V6, P4753, DOI 10.1128/MCB.6.12.4753; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; Mohler JL, 1996, CLIN CANCER RES, V2, P889; MONCHARMONT B, 1991, CANCER RES, V51, P3843; MORENO JG, 1992, CANCER RES, V52, P6110; MOWSZOWICZ I, 1993, MOL ENDOCRINOL, V7, P861, DOI 10.1210/me.7.7.861; NAWATA H, 1981, J BIOL CHEM, V256, P6895; OSTANIN K, 1994, J BIOL CHEM, V269, P8971; QUARMBY VE, 1990, CANCER RES, V50, P735; SAKAI H, 1991, PROSTATE, V19, P265, DOI 10.1002/pros.2990190307; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SCOTT WW, 1980, CANCER-AM CANCER SOC, V45, P1929, DOI 10.1002/cncr.1980.45.s7.1929; SEDLACEK SM, 1984, STEROIDS, V44, P467, DOI 10.1016/S0039-128X(84)80029-X; SINHA AA, 1988, PROSTATE, V13, P1, DOI 10.1002/pros.2990130102; SLUYSER M, 1981, CANCER LETT, V13, P71, DOI 10.1016/0304-3835(81)90088-4; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; SUZUKI H, 1994, PROSTATE, V25, P310, DOI 10.1002/pros.2990250605; TENNISWOOD M, 1986, PROSTATE, V9, P375, DOI 10.1002/pros.2990090407; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; WESTPHAL HM, 1984, EMBO J, V3, P1493, DOI 10.1002/j.1460-2075.1984.tb02001.x; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; YOUNG CYF, 1991, CANCER RES, V51, P3748; YUAN SX, 1993, CANCER RES, V53, P1304	57	123	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5939	5947		10.1074/jbc.273.10.5939	http://dx.doi.org/10.1074/jbc.273.10.5939			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488733	hybrid			2022-12-27	WOS:000072345000076
J	Urfer, R; Tsoulfas, P; O'Connell, L; Hongo, JA; Zhao, W; Presta, LG				Urfer, R; Tsoulfas, P; O'Connell, L; Hongo, JA; Zhao, W; Presta, LG			High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the trk receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; TYROSINE PROTEIN-KINASE; LEUCINE-RICH MOTIF; CRYSTAL-STRUCTURE; PROTOONCOGENE PRODUCT; ANGSTROM RESOLUTION; TISSUE DISTRIBUTION; BIOLOGICAL-ACTIVITY; HUMAN CD4; BRAIN	Neurotrophic factors are important for survival and maintenance of neurons during developmental and adult stages of the vertebrate nervous system. The neurotrophins mediate their signal into the cell by specific interaction with tyrosine kinase receptors of the Trk family, The extracellular immunoglobulin-like domain of the Trk receptors adjacent to the membrane has previously been shown to be the dominant element for specific neurotrophin binding. Using computer graphics models of the human TrkA and TrkC immunoglobulinlike domains as a guide, the residues involved in binding to their respective neurotrophins were mapped by mutational analysis. TrkC primarily utilizes loop EF, between beta-strands E and F, for binding. In contrast, TrkA utilizes the EF loop as well as additional residues, the latter being prime candidates for determining the specificity of TrkA versus TrkC, When selected TrkC and TrkA mutants with reduced binding were expressed on NIH3T3 cells, neurotrophin-induced autophosphorylation was strongly reduced or absent.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33135 USA; Univ Miami, Sch Med, Miami Project, Miami, FL 33135 USA	Roche Holding; Genentech; University of Miami; University of Miami	Urfer, R (corresponding author), Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.		Tsoulfas, Pantelis/GNH-1922-2022	Tsoulfas, Pantelis/0000-0003-1974-6366				BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; Fisher KL, 1997, MOL BIOL CELL, V8, P501, DOI 10.1091/mbc.8.3.501; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; HONGO JAS, 1995, HYBRIDOMA, V14, P253, DOI 10.1089/hyb.1995.14.253; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; ILAG LL, 1994, J BIOL CHEM, V269, P19941; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; KAHLE P, 1992, J BIOL CHEM, V267, P22707; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; PFUHL M, 1995, STRUCTURE, V3, P391, DOI 10.1016/S0969-2126(01)00170-8; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PRESTA L, 1994, J BIOL CHEM, V269, P26368; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; Ryden M, 1996, J BIOL CHEM, V271, P5623, DOI 10.1074/jbc.271.10.5623; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SHIH A, 1994, J BIOL CHEM, V269, P27679; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TANNAHILL L, 1995, EUR J NEUROSCI, V7, P1424, DOI 10.1111/j.1460-9568.1995.tb01136.x; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urfer R, 1997, BIOCHEMISTRY-US, V36, P4775, DOI 10.1021/bi962877+; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Viney JL, 1996, J IMMUNOL, V157, P2488; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	64	61	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5829	5840		10.1074/jbc.273.10.5829	http://dx.doi.org/10.1074/jbc.273.10.5829			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488719	hybrid			2022-12-27	WOS:000072345000062
J	Hassett, RF; Romeo, AM; Kosman, DJ				Hassett, RF; Romeo, AM; Kosman, DJ			Regulation of high affinity iron uptake in the yeast Saccharomyces cerevisiae - Role of dioxygen and Fe(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL CONTROL; TRANSPORT PROTEIN; FERRIC REDUCTASE; GENE-EXPRESSION; FET3 GENE; COPPER; ENCODES; OXYGEN	High affinity iron uptake in Saccharomyces cerevisiae requires a metal reductase, a multicopper ferroxidase, and an iron permease. Fet3, the apparent ferroxidase, is proposed to facilitate iron uptake by catalyzing the oxidation of reductase-generated Fe(II) to Fe(III) by O-2; in this model, Fe(III) is the substrate for the iron permease, encoded by FTR1 (Kaplan, J., and O'Halloran, T. V. (1996) Science 271, 1510-1512). We show here that dioxygen also plays an essential role in the expression of these iron uptake activities. Cells grown anaerobically exhibited no Fe(III) reductase or high affinity iron uptake activity, even if assayed for these activities under air. Northern blot analysis showed that the amount of those mRNAs encoding proteins associated with this uptake was repressed in anaerobic cultures but was rapidly induced by exposure of the culture to dioxygen. The anaerobic repression was reduced in cells expressing an iron-independent form of the trans activator, Aft1, a protein that regulates the expression of these proteins. Thus, the effect of oxygenation on this expression appeared due at least in part to the state or distribution of iron in the cells. In support of this hypothesis, the membrane-permeant Fe(II) chelator, 2,2'-bipyridyl, in contrast to the impermeant chelator bathophenanthroline disulfonate, caused a strong and rapid induction of these transcripts under anaerobic conditions. An increase in the steady-state levels of iron-regulated transcripts upon oxygenation or 2,2'-bipyridyl addition occurred within 5 min, indicating that a relatively small, labile intracellular pool of Fe(II) regulates the expression of these activities, The strength of the anaerobic repression was dependent on the low affinity, Fe(II)specific iron transporter, encoded by FET4, suggesting that this Fe(II) pool was linked in part to iron brought into the cell via Fet4 protein. The data suggest a model in which dioxygen directly or indirectly modulates the Fe(III)/Fe(II) ratio in an iron pool linked to Aft1 protein while bipyridyl increases this ratio by chelating Fe(II). These results indicate that dioxygen both modulates the sensitivity to iron-dependent transcriptional regulation and acts as substrate for Fet3 in the ferroxidase reaction catalyzed by this ceruloplasmin homologue.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kosman, DJ (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@acsu.buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adcock LM, 1996, METAB BRAIN DIS, V11, P359, DOI 10.1007/BF02029496; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; CHIAO JJC, 1994, J LAB CLIN MED, V124, P432; COY M, 1994, BIOMETALS, V7, P292; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DESLVA D, 1997, J BIOL CHEM, V272, P14208; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; Goldstein S, 1990, Int Rev Exp Pathol, V31, P133; HASSAN HM, 1994, FEMS MICROBIOL REV, V14, P315, DOI 10.1111/j.1574-6976.1994.tb00105.x; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HILL HAO, 1983, BIOL ASPECTS METALS, P15; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; OSAKI S, 1966, J BIOL CHEM, V241, P2746; POLLACK S, 1992, AM J HEMATOL, V39, P113, DOI 10.1002/ajh.2830390208; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; UNDEN G, 1991, ANTON LEEUW INT J G, V59, P65, DOI 10.1007/BF00445650; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhao GC, 1997, AM J RESP CELL MOL, V16, P293, DOI 10.1165/ajrcmb.16.3.9070614; ZITOMER RS, 1992, MICROBIOL REV, V56, P1; Zitomer RS, 1997, METHODS, V11, P279, DOI 10.1006/meth.1996.0422; [No title captured]	37	67	68	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7628	7636		10.1074/jbc.273.13.7628	http://dx.doi.org/10.1074/jbc.273.13.7628			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516467	hybrid			2022-12-27	WOS:000072738500063
J	Lee, CH; Chang, SC; Chen, CJ; Chang, MF				Lee, CH; Chang, SC; Chen, CJ; Chang, MF			The nucleolin binding activity of hepatitis delta antigen is associated with nucleolus targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS LARGE ANTIGEN; B VIRUS; RNA-BINDING; FUNCTIONAL DOMAINS; HBSAG-CARRIERS; LEUCINE ZIPPER; SELF-CLEAVAGE; REPLICATION; LOCALIZATION; PROTEIN	Hepatitis delta antigens (HDAgs) are important for the replication and assembly of hepatitis delta virus (HDV), To understand the association between HDAgs and cellular proteins and the mechanism of viral multiplication, we have studied the interaction between HDAgs and nucleolin, a major nucleolar phosphoprotein, The interaction between HDAgs and nucleolin was first demonstrated by immunofluorescence staining studies, HDAgs and endogenous nucleolin were colocalized in the nucleoli of cultured cells transfected with plasmids encoding the small and large HDAg, Coimmunoprecipitation results indicated that the NH2-terminal domain of HDAg was essential for its binding to nucleolin, In vitro ligand binding assays revealed two nucleolin binding sites, NBS1 and NBS2, Each spanned amino acid residues 35-50 and 51-65, respectively, with a conserved core sequence H(K/R)XK. HDV replication was modulated by exogenous human nucleolin, In addition, a small HDAg mutant S-d65/75, which possesses both NBS1 and NBS2, was capable of transactivating HDV replication, whereas the small HDAg mutant S-d50/75, which retained NBS1 but not NBS2, was unable to support the replication of HDV, Thus, the nucleolin binding activity of HDAg is critical for its nucleolar targeting and is involved in the modulation of HDV replication.	Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Microbiol, Taipei, Taiwan	National Taiwan University; National Taiwan University	Chang, MF (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem, No 1 Jen-Ai Rd,1st Sect, Taipei, Taiwan.	mfchang@ha.mc.ntu.edu.tw	Lee, Chia-Huei/B-1063-2010	CHANG, MING-FU/0000-0001-7062-3578; Lee, Chia-Huei/0000-0002-8847-3288				ARICO S, 1985, LANCET, V2, P356; Bichko VV, 1996, J VIROL, V70, P8064, DOI 10.1128/JVI.70.11.8064-8070.1996; BONINO F, 1986, J VIROL, V58, P945, DOI 10.1128/JVI.58.3.945-950.1986; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRANCH AD, 1991, P NATL ACAD SCI USA, V88, P10163, DOI 10.1073/pnas.88.22.10163; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; CASEY JL, 1992, P NATL ACAD SCI USA, V89, P7149, DOI 10.1073/pnas.89.15.7149; CHANG FL, 1991, P NATL ACAD SCI USA, V88, P8490, DOI 10.1073/pnas.88.19.8490; CHANG MF, 1988, J VIROL, V62, P2403, DOI 10.1128/JVI.62.7.2403-2410.1988; CHANG MF, 1994, J VIROL, V68, P646, DOI 10.1128/JVI.68.2.646-653.1994; CHANG MF, 1995, J VIROL, V69, P2508, DOI 10.1128/JVI.69.4.2508-2514.1995; CHANG MF, 1993, J VIROL, V67, P2529, DOI 10.1128/JVI.67.5.2529-2536.1993; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHEN CM, 1991, J BIOL CHEM, V266, P7754; CHEN PJ, 1992, J VIROL, V66, P2853, DOI 10.1128/JVI.66.5.2853-2859.1992; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GOVINDARAJAN S, 1984, GASTROENTEROLOGY, V86, P1416; JACOBSON IM, 1985, HEPATOLOGY, V5, P188, DOI 10.1002/hep.1840050205; KOJIMA T, 1989, J MED VIROL, V28, P183, DOI 10.1002/jmv.1890280314; KOS A, 1986, NATURE, V323, P558, DOI 10.1038/323558a0; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LAZINSKI DW, 1994, J VIROL, V68, P2879, DOI 10.1128/JVI.68.5.2879-2888.1994; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; MACNAUGHTON TB, 1993, J VIROL, V67, P2228, DOI 10.1128/JVI.67.4.2228-2234.1993; MACNAUGHTON TB, 1991, VIROLOGY, V184, P387, DOI 10.1016/0042-6822(91)90855-6; MACNAUGHTON TB, 1990, VIROLOGY, V177, P692, DOI 10.1016/0042-6822(90)90535-Y; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; NEGRO F, 1991, J HEPATOL, V13, pS125, DOI 10.1016/0168-8278(91)90043-B; PACCHIONI D, 1992, HUM PATHOL, V23, P557, DOI 10.1016/0046-8177(92)90133-N; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PONZETTO A, 1984, P NATL ACAD SCI-BIOL, V81, P2208, DOI 10.1073/pnas.81.7.2208; PONZETTO A, 1988, HEPATOLOGY, V8, P1655, DOI 10.1002/hep.1840080631; RIZZETTO M, 1980, J INFECT DIS, V141, P590, DOI 10.1093/infdis/141.5.590; RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sarria L, 1992, Enferm Infecc Microbiol Clin, V10, P470; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; WANG HW, 1994, J VIROL, V68, P6363, DOI 10.1128/JVI.68.10.6363-6371.1994; WANG JG, 1993, J VIROL, V67, P446, DOI 10.1128/JVI.67.1.446-454.1993; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WEINER AJ, 1988, J VIROL, V62, P594, DOI 10.1128/JVI.62.2.594-599.1988; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; XIA YP, 1992, J VIROL, V66, P6641, DOI 10.1128/JVI.66.11.6641-6648.1992; XIA YP, 1990, VIROLOGY, V178, P331, DOI 10.1016/0042-6822(90)90415-N; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068	61	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7650	7656		10.1074/jbc.273.13.7650	http://dx.doi.org/10.1074/jbc.273.13.7650			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516470	hybrid			2022-12-27	WOS:000072738500066
J	Warder, SE; Prorok, M; Chen, ZG; Li, LP; Zhu, Y; Pedersen, LG; Ni, F; Castellino, FJ				Warder, SE; Prorok, M; Chen, ZG; Li, LP; Zhu, Y; Pedersen, LG; Ni, F; Castellino, FJ			The roles of individual gamma-carboxyglutamate residues in the solution structure and cation-dependent properties of conantokin-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; CONTAINING PEPTIDES; SECONDARY STRUCTURE; CALCIUM; ACID; ANTAGONIST; CHANNELS; BINDING; VENOMS	The solution structure of the Ca2+-loaded conantokin-T (con-T), a gamma-carboxyglutamate (Gla)-containing al-residue peptide (NH2-G(1)E gamma gamma Y(5)QKML gamma(10)NLR gamma A(15)EVKKN(20)A-CONH2, gamma = = Gla), has been elucidated by use of distance geometry calculations with experimental distances derived from two-dimensional H-1 NMR spectroscopy. An end-to-end cc-helix was the dominant conformation in solution, similar to that of apo-con-T, except that reorientation of several side chains occurred in the Ca2+-coordinated complex. The most notable examples of this were those of Gla(10) and Gla(14), which were more optimally positioned for complexation with Ca2+. In addition to the stabilization offered to the alpha-helix by Ca2+ binding, hydrophobic clustering of the side chains of Tyr(5), Met(8), Leu(9), and Leu(12), and ionic interactions between Lys(7) and Gla(3)/Gla(10) and between Arg(13) and Gla(14), along with hydrogen bonding between Gln(6) and Gla(10), were among the side chain interactions Likely playing a significant role in maintenance of the alpha-helical conformation. Docking of Ca2+ in the con-T structure was accomplished using genetic algorithm-molecular dynamics simulation approaches. The results showed that one Ca2+ ion is most likely coordinated by four side chain oxygen atoms, two each from Gla(10) and Gla(14). Another bound Ca2+ ion has as its donor sites three oxygen atoms, two from Gla(3) and one from Gln(6). To examine the functional roles of the individual Gla residues, a series of variant peptides have been synthesized with Ala substituted for each Gla residue, and several properties of the resulting variants have been examined. The data obtained demonstrated the importance of Gla(10) and Gla(14) in stabilizing binding of the highest affinity Ca2+ site and in governing the conformational change induced by Ca2+. The critical nature of Gla(3) and Gla(4) in inhibition of the spermine-induced potentiation of the binding of MK-801 to open ion channels of the N-methyl-D-aspartate receptor was established, as well as the role of Gla(4) in stabilizing the apo-con-T alpha-helical conformation.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal Joint Ctr Struct Biol, Biomol NMR Lab, Montreal, PQ H4P 2R2, Canada; NIEHS, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of Notre Dame; National Research Council Canada; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu	Ni, Feng/AAN-6388-2020; Pedersen, Lee G/E-3405-2013; Li, Leping/F-6497-2019	Pedersen, Lee G/0000-0003-1262-9861; Li, Leping/0000-0003-4208-0259	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19982, HL-06530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS ME, 1993, BIOCHEMISTRY-US, V32, P12566, DOI 10.1021/bi00210a003; ARGOS P, 1978, FEBS LETT, V93, P19, DOI 10.1016/0014-5793(78)80795-9; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clapes P, 1996, TETRAHEDRON LETT, V37, P417, DOI 10.1016/0040-4039(95)02175-2; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; HAACK JA, 1990, J BIOL CHEM, V265, P6025; LEVY GC, 1992, P 33 EXP NMR C, P152; Li LP, 1997, BIOCHEMISTRY-US, V36, P2132, DOI 10.1021/bi962250r; Lin CH, 1997, FEBS LETT, V407, P243, DOI 10.1016/S0014-5793(97)00354-2; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; MYERS RA, 1990, J TOXICOL-TOXIN REV, V9, P179, DOI 10.3109/15569549009033113; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PEARLMAN DA, 1995, AMBER; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; SKOLNICK P, 1994, PHARM TOXICOLOGY BAS, P155; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhou LM, 1996, J NEUROCHEM, V66, P620; ZHU Y, 1992, TECHNICAL REPORT DEP	29	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7512	7522		10.1074/jbc.273.13.7512	http://dx.doi.org/10.1074/jbc.273.13.7512			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516452	hybrid			2022-12-27	WOS:000072738500048
J	Innamorati, G; Sadeghi, H; Birnbaumer, M				Innamorati, G; Sadeghi, H; Birnbaumer, M			Transient phosphorylation of the V1a vasopressin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; PROTEIN-KINASE-C; CELLS; RAT; DNA; DESENSITIZATION; EXPRESSION; LIGAND	The V1a arginine vasopressin receptor (V1aR) expressed in HEK 293 cells was phosphorylated after binding to arginine vasopressin (AVP). The phosphate was incorporated very rapidly into the protein but remained attached for a very short time despite the continuous presence of hormone. The extent of phosphorylation depended upon the concentration of AVP suggesting the involvement of G-protein-coupled receptor kinases. Protein kinase C (PKC) contributed to V1aR phosphorylation as demonstrated by the fact that inhibition of the kinase decreased the amount of phosphate incorporated into the receptor. However, PKC activity was not responsible for the transient nature of V1aR phosphorylation. The hormone-free receptor could be phosphorylated by phorbol ester-activated PKC. Although the phosphorylation was transient, the phosphate groups incorporated remained on the receptor protein longer than those incorporated after AVP treatment. PRC phosphorylation of unoccupied V1aR was not sufficient to promote sequestration. Vasopressin also promoted sequestration of about 80% of the surface receptor, but measurements of the rate of accumulation of inositol phosphates in the sustained presence of the ligand did not reveal a significant desensitization of coupling to phospholipase C activity. The addition of a V1aR antagonist inhibited the sustained accumulation of inositol phosphates establishing that the sustained stimulation of PLC was mediated by receptors located on the cell surface. The transient character of V1aR phosphorylation seemed intrinsic to the receptor protein rather than a consequence of signaling within the cell, and receptor sequestration appeared to be responsible for the desensitization observed in HEK 293 cells.	Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Birnbaumer, M (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Anesthesiol, Los Angeles, CA 90095 USA.		Innamorati, Giulio/AAR-6314-2020; Innamorati, Giulio/GVU-1941-2022; Mir-mohammad Sadeghi, Hamid/A-8741-2016	Innamorati, Giulio/0000-0003-0123-8777; Mir-mohammad Sadeghi, Hamid/0000-0002-4834-4502	NIDDK NIH HHS [DK 41-244] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041244] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ancellin N, 1997, FEBS LETT, V413, P323, DOI 10.1016/S0014-5793(97)00914-9; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BIRNBAUMER M, 1994, MOL ENDOCRINOL, V8, P886, DOI 10.1210/me.8.7.886; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BRINER VA, 1992, P NATL ACAD SCI USA, V89, P2854, DOI 10.1073/pnas.89.7.2854; Diviani D, 1996, J BIOL CHEM, V271, P5049; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1996, BIOCHEM J, V314, P710; JARD S, 1988, KIDNEY INT S, V26, P38; JARD S, 1986, CARDIOVASC PHARM S, V8, P12; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; Krueger KM, 1997, J BIOL CHEM, V272, P5; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Ozcelebi F, 1996, J BIOL CHEM, V271, P3750; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THIBONNIER M, 1993, AM J PHYSIOL, V265, pE906, DOI 10.1152/ajpendo.1993.265.6.E906; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; ZHU X, 1994, MOL PHARMACOL, V46, P460	28	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7155	7161		10.1074/jbc.273.12.7155	http://dx.doi.org/10.1074/jbc.273.12.7155			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507030	hybrid			2022-12-27	WOS:000072775900080
J	Ryu, KS; Lee, HY; Kim, SP; Beauchamp, J; Tung, CS; Isaacs, NW; Ji, IH; Ji, TH				Ryu, KS; Lee, HY; Kim, SP; Beauchamp, J; Tung, CS; Isaacs, NW; Ji, IH; Ji, TH			Modulation of high affinity hormone binding - Human choriogonadotropin binding to the exodomain of the receptor is influenced by exoloop 2 of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; TRANSMEMBRANE DOMAIN; ACTIVATION; RESIDUES; LYS(583); LOOP	The lutropin/choriogonadotropin receptor is a seven-transmembrane receptor and consists of two major domains of similar size, an extracellular exodomain and a membrane-associated endodomain which includes 3 exoloops. The uniquely large exodomain is responsible for high affinity hormone binding whereas receptor activation occurs at the endodomain. However, little is known about the relationship between the exodomain and endodomain. It was reported that hormone binding to the exodomain was improved when the endodomain was truncated. This result suggests that hormone binding to the exodomain was influenced by the endodomain. To test this hypothesis, amino acids of exoloop 2 were examined by Ala substitutions. The binding affinity was enhanced by some Ala substitutions but attenuated by others. These results indicate that exoloop 2 influences the hormone binding to the exodomain. Particularly, the high affinity hormone binding at the exodomain is constrained by a group of amino acids, Ser(484), ASn(485), Lys(488), Ser(490), and Ser(499). Computer modeling suggests these residues may be positioned on one side of exoloop 2. It also influences the affinity for cAMP induction and the maximal cAMP production in distinct ways, in addition to its influence on the hormone binding affinity. The distinct ways of influencing these functions are sometimes in conflict and compromised to attain the maximal affinity for cAMP induction. As a result, the exodomain attains the maximal affinity for hormone binding when the endodomain is truncated and cAMP induction is disengaged.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA	University of Wyoming; University of Glasgow; United States Department of Energy (DOE); Los Alamos National Laboratory	Ji, TH (corresponding author), Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.	Ji@uwyo.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Couture L, 1996, EUR J BIOCHEM, V241, P627, DOI 10.1111/j.1432-1033.1996.00627.x; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Hong SH, 1997, J BIOL CHEM, V272, P4166, DOI 10.1074/jbc.272.7.4166; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; Tung CS, 1997, BIOPHYS J, V72, P876, DOI 10.1016/S0006-3495(97)78722-8; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722	22	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6285	6291		10.1074/jbc.273.11.6285	http://dx.doi.org/10.1074/jbc.273.11.6285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497355	hybrid			2022-12-27	WOS:000072488500047
J	Sudo, T; Hidaka, H				Sudo, T; Hidaka, H			Regulation of calcyclin (S100A6) binding by alternative splicing in the N-terminal regulatory domain of annexin XI isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING; NUCLEAR-LOCALIZATION; MOLECULAR-CLONING; MEMBRANE-FUSION; RABBIT CAP-50; PROTEIN; CALCIUM; CELLS; SITE; P11	Annexin XI is a Ca2+/phospholipid-binding protein that interacts with a member of S100 protein family, calcyclin (S100A6), in a Ca2+-dependent manner. There are two isoforms of annexin XI, annexin XI-A and -B, generated by alternative splicing in the N-terminal regulatory domain. To determine the role of the alternative splicing region in the calcyclin-binding, we identified and characterized its calcyclin binding site. Experiments with glutathione S-transferase fusion proteins with N-terminal sites of annexin XI-A showed the calcyclin binding site to be in residues Gln(49)-Thr(62) of rabbit annexin XI-A, which contains part of the splicing region. A synthesized peptide corresponding to Tyr(43)-Thr(62) Of annexin XI-A inhibited the interaction of annexin XI with calcyclin in liposome co-pelleting assay. The calcyclin binding site possesses a hydrophobic residue cluster conserved among S100 binding sites of annexin I and II. Recombinant annexin XI isoforms were expressed in Sf9 cells using a baculovirus expression system. In contrast to annexin XI-A, it was found that annexin XI-B protein could not bind to calcyclin by the liposome co-pelleting assay. In Sf9 cells coexpressing calcyclin with annexin XI isoforms, the calcyclin binding was observed only for annexin XI-A isoform. These results indicate that the calcyclin binding ability of annexin XI is an annexin XI-A isoform-specific character, suggesting that annexin XI isoforms might play distinct roles in cells through each alternative splicing regions.	Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 466, Japan	Nagoya University	Hidaka, H (corresponding author), Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 466, Japan.							BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BIANCHI R, 1992, FEBS LETT, V296, P158, DOI 10.1016/0014-5793(92)80369-R; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; Jost M, 1997, J CELL SCI, V110, P221; KUBE E, 1992, J BIOL CHEM, V267, P14175; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; MAMIYA N, 1994, BIOCHEM BIOPH RES CO, V202, P403, DOI 10.1006/bbrc.1994.1942; MINAMI H, 1992, FEBS LETT, V305, P217, DOI 10.1016/0014-5793(92)80671-3; MISAKI Y, 1994, J BIOL CHEM, V269, P4240; MIZUTANI A, 1993, J BIOL CHEM, V268, P15517; MIZUTANI A, 1995, ARCH BIOCHEM BIOPHYS, V318, P157, DOI 10.1006/abbi.1995.1216; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; NAKA M, 1994, BBA-MOL CELL RES, V1223, P348, DOI 10.1016/0167-4889(94)90094-9; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; SHELDON A, 1995, ANNEXINS MOL STRUCTU, P133; Sudo T, 1996, BIOCHEM BIOPH RES CO, V223, P706, DOI 10.1006/bbrc.1996.0967; TOKUMITSU H, 1992, BIOCHEM BIOPH RES CO, V186, P1227, DOI 10.1016/S0006-291X(05)81537-2; TOKUMITSU H, 1993, ARCH BIOCHEM BIOPHYS, V303, P302, DOI 10.1006/abbi.1993.1287; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V288, P202, DOI 10.1016/0003-9861(91)90184-K; TOWLE CA, 1992, J BIOL CHEM, V267, P5416; TOWLE CA, 1992, BIOCHIM BIOPHYS ACTA, V1131, P223, DOI 10.1016/0167-4781(92)90084-D; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405	43	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6351	6357		10.1074/jbc.273.11.6351	http://dx.doi.org/10.1074/jbc.273.11.6351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497364	hybrid			2022-12-27	WOS:000072488500056
J	Schwandner, R; Wiegmann, K; Bernardo, K; Kreder, D; Kronke, M				Schwandner, R; Wiegmann, K; Bernardo, K; Kreder, D; Kronke, M			TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; CELL-DEATH; CYTOPLASMIC DOMAIN; CD95 FAS/APO-1; NEUTRAL SPHINGOMYELINASE; INDUCED APOPTOSIS; PHOSPHOLIPASE-C; FACTOR-ALPHA; CERAMIDE	Sphingomyelinase (SMase) activation and ceramide generation have emerged as an important signaling pathway transducing diverse biological effects of cytokine receptors like p55 tumor necrosis factor (TNF) receptor or Fas, Here we describe the TNF-dependent activation of acid SMase (A-SMase) through the p55 TNF receptor-associated proteins TRADD and FADD, Overexpression of TRADD and FADD in 293 cells did not change basal activity of A-SMase but enhanced TNF-induced stimulation of A-SMase. Other TNF R55-associated proteins like TRAF2 and RIP, which were reported to mediate TNF R55-mediated activation of nuclear factor kappa B, did mot affect activation of A-SMase. Caspase inhibitors markedly reduced A-SMase activity, suggesting the involvement of an ICE-like protease in TRADD/ FADD-mediated activation of A-SMase. Overexpression of caspase-8/a (FLICE/MACH) or caspase-10/b (FLICE2) did not change A-SMase activity, suggesting that TRADD/FADD-mediated activation of A-SMase involves a yet to be defined caspase-like protease distinct from caspase-8/a or -10/b.	Univ Kiel, Inst Immunol, D-24105 Kiel, Germany	University of Kiel	Kronke, M (corresponding author), Univ Kiel, Inst Immunol, Brunswiker Str 4, D-24105 Kiel, Germany.							Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; ADAM D, 1995, J BIOL CHEM, V270, P17482; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; AUSUBEL FM, 1994, CURENT PROTOCOLS MOL; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; KOLESNICK RN, 1998, IN PRESS ANN REV PHY, V60; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; ROGNIER CH, 1997, CELL, V90, P373; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	43	138	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5916	5922		10.1074/jbc.273.10.5916	http://dx.doi.org/10.1074/jbc.273.10.5916			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488730	hybrid			2022-12-27	WOS:000072345000073
J	Wu, Y; Spencer, SD; Lasky, LA				Wu, Y; Spencer, SD; Lasky, LA			Tyrosine phosphorylation regulates the SH3-mediated binding of the Wiskott-Aldrich syndrome protein to PSTPIP, a cytoskeletal-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; ACTIN POLYMERIZATION; IDENTIFICATION; MUTATIONS; KINASE; GENE; SPECIFICITY; WASP	Wiskott-Aldrich syndrome is an X-linked hematopoietic disease that manifests itself in platelet deficiency and a compromised immune system. Analysis of hematopoietic cells from affected individuals reveals that mutations in the Wiskott-Aldrich syndrome protein (WASP) result in structural and functional abnormalities in the cell cortex, consistent with the suggestion that WASP is involved with regulation of the actin-rich cortical cytoskeleton. Here we report that WASP interacts with a recently described cytoskeletal-associated protein, PSTPIP, a molecule that is related to the Schizosaccharomyces pombe cleavage furrow regulatory protein, CDC15p. This association is mediated by an interaction between the PSTPIP SH3 domain and two polyproline-rich regions in WASP. Co-expression of PSTPIP with WASP in vivo results in a loss of WASP-induced actin bundling activity and co-localization of the two proteins, which requires the PSTPIP SH3 domain. Analysis of tyrosine phosphorylation of PSTPIP reveals that two sites are modified in response to v-Src co-transfection or pervanadate incubation. One of these tyrosines is found in the SH3 domain poly-proline recognition site, and mutation of this tyrosine to aspartate or glutamate to mimic this phosphorylation state results in a loss of WASP binding in vitro and a dissolution of co-localization in vivo. In addition, PSTPIP that is tyrosine phosphorylated in the SH3 domain interacts poorly with WASP in vitro. These data suggest that the PSTPIP and WASP interaction is regulated by tyrosine phosphorylation of the PSTPIP SH3 domain, and this binding event may control aspects of the actin cytoskeleton.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Lasky, LA (corresponding author), Genentech Inc, Dept Mol Oncol, 460 Pt San Bruno Blvd, San Francisco, CA 94080 USA.	lal@gene.com						Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cory GOC, 1996, J IMMUNOL, V157, P3791; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dowbenko D, 1998, J BIOL CHEM, V273, P989, DOI 10.1074/jbc.273.2.989; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; Featherstone C, 1997, SCIENCE, V275, P27, DOI 10.1126/science.275.5296.27; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; Kinnon C, 1997, BIOCHEM SOC T, V25, P648, DOI 10.1042/bst0250648; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Miki H, 1997, CELL GROWTH DIFFER, V8, P195; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; OCHS HD, 1980, BLOOD, V55, P243; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; SIMON H, 1995, J CLIN INVEST, V90, P159; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	31	108	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5765	5770		10.1074/jbc.273.10.5765	http://dx.doi.org/10.1074/jbc.273.10.5765			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488710	hybrid			2022-12-27	WOS:000072345000053
J	Antonsson, B; Kassel, DB; Di Paolo, G; Lutjens, R; Riederer, BM; Grenningloh, G				Antonsson, B; Kassel, DB; Di Paolo, G; Lutjens, R; Riederer, BM; Grenningloh, G			Identification of in vitro phosphorylation sites in the growth cone protein SCG10 - Effect of phosphorylation site mutants on microtubule-destabilizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CDC2-LIKE KINASE; DIFFERENTIAL DISTRIBUTION; MASS-SPECTROMETRY; COMPLEX-MIXTURES; CEREBRAL-CORTEX; CORPUS-CALLOSUM; TAU-PROTEINS; RAT-BRAIN; IN-VITRO; STATHMIN	SCG10 is a neuron-specific, membrane-associated protein that is highly concentrated in growth cones of developing neurons. Previous studies have suggested that it is a regulator of microtubule dynamics and that it may influence microtubule polymerization in growth cones. Here, we demonstrate that in vivo, SCG10 exists in both phosphorylated and unphosphorylated forms. By two-dimensional gel electrophoresis, two phosphoisoforms were detected in neonatal rat brain, Using in vitro phosphorylated recombinant protein, four phosphorylation sites were identified in the SCG10 sequence, Ser-50 and Ser-97 were the target sites for protein kinase A, Ser-62 and Ser-73 for mitogen-activated protein kinase and Ser-73 for cyclin-dependent kinase. We also show that overexpression of SCG10 induces a disruption of the microtubule network, in COS-7 cells, By expressing different phosphorylation site mutants, we have dissected the roles of the individual phosphorylation sites in regulating its microtubule-destabilizing activity. We show that nonphosphorylatable mutants have increased activity, whereas mutants in which phosphorylation is mimicked by serine-to-aspartate substitutions have decreased activity, These data suggest that the microtubule-destabilizing activity of SCG10 is regulated by phosphorylation, and that SCG10 may link signal transduction of growth or guidance cues involving serine/threonine protein kinases to alterations of microtubule dynamics in the growth cone.	Univ Lausanne, IBCM, CH-1005 Lausanne, Switzerland; Glaxo Wellcome Res & Dev SA, Geneva Biomed Res Inst, CH-1228 Plan Les Ouates, Switzerland; Glaxo Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; University of Lausanne; GlaxoSmithKline; GlaxoSmithKline	Grenningloh, G (corresponding author), Univ Lausanne, IBCM, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.							Antonsson B, 1997, PROTEIN EXPRES PURIF, V9, P295, DOI 10.1006/prep.1996.0679; Antonsson B, 1997, PROTEIN EXPRES PURIF, V9, P363, DOI 10.1006/prep.1996.0710; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Challacombe JF, 1997, J NEUROSCI, V17, P3085; Di Paolo G, 1997, J NEUROSCI RES, V50, P1000, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8; DING JM, 1994, RAPID COMMUN MASS SP, V8, P94, DOI 10.1002/rcm.1290080118; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; HIMI T, 1994, NEUROSCIENCE, V60, P907, DOI 10.1016/0306-4522(94)90271-2; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; LETOURNEAU PC, 1984, J CELL BIOL, V98, P1355, DOI 10.1083/jcb.98.4.1355; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LIM SS, 1989, J CELL BIOL, V109, P253, DOI 10.1083/jcb.109.1.253; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MCNEILL TH, 1992, PROGR PARKINSON RES, V2, P299; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; Pigino G, 1997, J CELL SCI, V110, P257; RIEDERER BM, 1990, DEV BRAIN RES, V56, P235, DOI 10.1016/0165-3806(90)90088-G; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; RIEDERER BM, 1991, EUR J NEUROSCI, V3, P1134, DOI 10.1111/j.1460-9568.1991.tb00048.x; RIEDERER BM, 1994, BRAIN RES BULL, V33, P155, DOI 10.1016/0361-9230(94)90245-3; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Sugiura Y, 1995, DEV BRAIN RES, V90, P73, DOI 10.1016/0165-3806(96)83488-2; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; TANAKA E, 1995, J CELL BIOL, V115, P381; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; Williamson T, 1996, P NATL ACAD SCI USA, V93, P15221, DOI 10.1073/pnas.93.26.15221	38	80	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8439	8446		10.1074/jbc.273.14.8439	http://dx.doi.org/10.1074/jbc.273.14.8439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525956	hybrid			2022-12-27	WOS:000072876300090
J	Ishimi, Y; Komamura, Y; You, ZY; Kimura, H				Ishimi, Y; Komamura, Y; You, ZY; Kimura, H			Biochemical function of mouse minichromosome maintenance 2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; REPLICATION LICENSING SYSTEM; HUMAN NUCLEAR-PROTEIN; DNA-REPLICATION; CELL-CYCLE; MCM-PROTEINS; S-PHASE; HISTONE H3; YEAST; FAMILY	Minichromosome maintenance (MCM) proteins play an essential role in eukaryotic DNA replication and bind to chromatin before the initiation of DNA replication. We reported that MCM protein complexes consisting of MCM2, -4, -6, and -7 bind strongly to a histone Sepharose column (Ishimi, Y., Ichinose, S., Omori, A., Sate, K., and Kimura, H. (1996) J. Biol. Chem. 271, 24115-24122). Here, we have analyzed this interaction at the molecular level, We found that among six mouse MCM proteins, only MCM2 binds to histone; amino acid residues 63-153 are responsible for this binding. The region required for nuclear localization of MCM2 was mapped near this histone-binding domain. Far-Western blotting analysis of truncated forms of H3 histone indicated that amino acid residues 26-67 of H3 histone are required for binding to MCM2. We have also shown that mouse MCM2 can inhibit the DNA helicase activity of the human MCM4, -6, and -7 protein complex. These results suggest that MCM2 plays a different role in the initiation of DNA replication than the other MCM proteins.	Mitsubishi Kasei Inst Life Sci, Tokyo 194, Japan; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Ishimi, Y (corresponding author), Mitsubishi Kasei Inst Life Sci, 11 Minamiooya, Tokyo 194, Japan.	yukio@libra.Is.m-kagaku.co.jp	Kimura, Hiroshi/B-9524-2015	Kimura, Hiroshi/0000-0003-0854-083X				Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fujita M, 1997, J BIOL CHEM, V272, P10928; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HEREFORD LM, 1981, CELL, V24, P367, DOI 10.1016/0092-8674(81)90326-3; Holthoff HP, 1996, GENOMICS, V37, P131, DOI 10.1006/geno.1996.0530; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jallepalli PV, 1997, CURR OPIN CELL BIOL, V9, P358, DOI 10.1016/S0955-0674(97)80008-7; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Krude T, 1996, J CELL SCI, V109, P309; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; LUGAR K, 1997, NATURE, V389, P251; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; Stemmer C, 1997, J MOL BIOL, V273, P52, DOI 10.1006/jmbi.1997.1270; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Takizawa N, 1995, GENE, V167, P343, DOI 10.1016/0378-1119(95)00713-X; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; YONG MR, 1997, MOL BIOL CELL, V8, P1587; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	47	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8369	8375		10.1074/jbc.273.14.8369	http://dx.doi.org/10.1074/jbc.273.14.8369			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525946	hybrid			2022-12-27	WOS:000072876300080
J	Minami, K; Wick, MJ; Stern-Bach, Y; Dildy-Mayfield, JE; Brozowski, SJ; Gonzales, EL; Trudell, JR; Harris, RA				Minami, K; Wick, MJ; Stern-Bach, Y; Dildy-Mayfield, JE; Brozowski, SJ; Gonzales, EL; Trudell, JR; Harris, RA			Sites of volatile anesthetic action on kainate (glutamate receptor 6) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL-ANESTHESIA; ION CHANNELS; SUBUNIT; EXPRESSION; PROTEIN; AMPA; RAT; DETERMINANTS; HIPPOCAMPUS; CURRENTS	Molecular mechanisms of anesthetic action on neurotransmitter receptors are poorly understood. The major excitatory neurotransmitter in the central nervous system is glutamate, and recent studies found that volatile anesthetics inhibit the function of the alpha-amino-3-hydroxyisoxazolepropionic acid subtype of glutamate receptors (e.g. glutamate receptor 3 (GluR3)), but enhance kainate (GluR6) receptor function, We used this dissimilar pharmacology to identify sites of anesthetic action on the kainate GluR6 receptor by constructing chimeric GluR3/GluR6 receptors, Results with chimeric receptors implicated a transmembrane region (TM4) of GluR6 in the action of halothane. Site directed mutagenesis subsequently showed that a specific amino acid, glycine 819 in TM4, is important for enhancement of receptor function by halothane (0.2-2 mM). Mutations of Gly-819 also markedly decreased the response to isoflurane (0.2-2 mM), enflurane (0.2-2 mM), and 1-chloro-1,2,2-trifluorocyclobutane (0.2-2 mM). The nonanesthetics 1,2-dichlorohexafluorocyclobutane and 2,3-dichlorooctafluorobutane had no effect on the functions of either wild-type GluR6 or receptors mutated at Gly-819. Ethanol and pentobarbital inhibited the function of both wild-type and mutant receptors. These results suggest that a specific amino acid, Gly-819, is critical for the action of volatile anesthetics, but not of ethanol or pentobarbital, on the GluR6 receptor.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Vet Adm Med Ctr, Denver, CO 80220 USA; Hebrew Univ Jerusalem, Hadassah Dent Sch, Div Anat, IL-91120 Jerusalem, Israel; Stanford Univ, Dept Anesthesia, Stanford, CA 94305 USA; Stanford Univ, Program Mol & Genet Med, Stanford, CA 94305 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Hebrew University of Jerusalem; Stanford University; Stanford University	Harris, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave,POB C236, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA006399] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 06399] Funding Source: Medline; NIGMS NIH HHS [GM 47818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL SG, 1986, BRIT J PHARMACOL, V87, P345, DOI 10.1111/j.1476-5381.1986.tb10823.x; BAHN S, 1994, J NEUROSCI, V14, P5525; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Cunha RA, 1997, EUR J PHARMACOL, V323, P167, DOI 10.1016/S0014-2999(97)00043-5; DANIELL LC, 1991, PHARMACOL BIOCHEM BE, V40, P767, DOI 10.1016/0091-3057(91)90083-E; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; DildyMayfield JE, 1996, BRIT J PHARMACOL, V118, P378, DOI 10.1111/j.1476-5381.1996.tb15413.x; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Hartenstein B, 1996, EMBO J, V15, P1275, DOI 10.1002/j.1460-2075.1996.tb00469.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; KURODA Y, 1993, ANESTH ANALG, V77, P795; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANTZ J, 1992, ANESTHESIOLOGY, V76, P844, DOI 10.1097/00000542-199205000-00023; MCFARLANE C, 1992, ANESTHESIOLOGY, V77, P1165, DOI 10.1097/00000542-199212000-00018; MIHIC SJ, 1994, MOL PHARMACOL, V46, P851; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Rubinsztein DC, 1997, P NATL ACAD SCI USA, V94, P3872, DOI 10.1073/pnas.94.8.3872; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SAWADA S, 1985, EXP BRAIN RES, V59, P226; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; YAMAKURA T, 1995, FEBS LETT, V374, P412, DOI 10.1016/0014-5793(95)01163-9; [No title captured]	35	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8248	8255		10.1074/jbc.273.14.8248	http://dx.doi.org/10.1074/jbc.273.14.8248			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525931	hybrid			2022-12-27	WOS:000072876300065
J	Nguyen, DHD; Hussaini, IM; Gonias, SL				Nguyen, DHD; Hussaini, IM; Gonias, SL			Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; SINGLE-CHAIN UROKINASE; VITRONECTIN; SURFACE; TYROSINE; ADHESION; COMPLEX; LINES; PROUROKINASE; INVASIVENESS	Binding of urokinase-type plasminogen activator (uPA) to its receptor, uPAR, regulates cellular adhesion, migration, and tumor cell invasion, Some of these activities may reflect the ability of uPAR to initiate signal transduction even though this receptor is linked to the plasma membrane only by a glycosylphosphatidylinositol anchor, In this study, we demonstrated that single-chain uPA activates extracellular signal-regulated kinase 1 (ERK1) and ERK2 in MCF-7 breast cancer cells. Phosphorylation of ERK1 and ERK2 was increased 1 min after adding uPA and returned to baseline levels by 5 min, The amino-terminal fragment (ATF) of uPA, which binds to uPAR but lacks proteinase activity, also activated ERK1 and ERK2. Responses to uPA and ATF were eliminated when the cells were pretreated with PD098059, an inhibitor of mitogen-activated protein kinase kinase, uPA and ATF promoted the migration of MCF-9 cells across serum-coated Transwell membranes in vitro, Migration was increased 2.1 +/- 0.4-fold when uPA was added to the top chamber, 4.8 +/- 0.8-fold when uPA was added to the bottom chamber, and 7.7 +/- 1.0-fold when uPA was added to both chambers, MCF-7 cells that were pulse-exposed to uPA for 30 min, and then washed to remove unbound ligand, demonstrated increased motility even though migration was allowed to occur for 24 h, PD098059 completely neutralized the effects of uPA on MCF-7 cellular-motility, irrespective of whether the uPA was present for the entire. motility assay or administered by pulse-exposure, These results demonstrate a novel, receptor-dependent signaling activity which is required for uPA-stimulated breast cancer cell migration.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Box 214, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA-53462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BERKENPAS MB, 1991, P NATL ACAD SCI USA, V88, P7768, DOI 10.1073/pnas.88.17.7768; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Costantini V, 1996, CANCER-AM CANCER SOC, V77, P1079, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1079::AID-CNCR12>3.0.CO;2-Z; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; DEMUNK GAW, 1990, FIBRINOLYSIS, V4, P1, DOI 10.1016/S0268-9499(05)80034-7; DUFFY MJ, 1990, CANCER RES, V50, P6827; DUGGAN C, 1995, INT J CANCER, V61, P597, DOI 10.1002/ijc.2910610502; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KORTY PE, 1991, J IMMUNOL, V146, P4092; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; Mirshahi SS, 1997, FEBS LETT, V411, P322, DOI 10.1016/S0014-5793(97)00683-2; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; OGRADY P, 1985, CANCER RES, V45, P6216; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SCHMITT M, 1991, BIOMED BIOCHIM ACTA, V50, P731; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SUMIYOSHI K, 1991, THROMB RES, V63, P59, DOI 10.1016/0049-3848(91)90270-7; SUMIYOSHI K, 1992, INT J CANCER, V50, P345, DOI 10.1002/ijc.2910500303; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Wang JY, 1997, EUR J BIOCHEM, V247, P256, DOI 10.1111/j.1432-1033.1997.00256.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Yeh E T, 1994, Semin Immunol, V6, P73, DOI 10.1006/smim.1994.1011	42	194	202	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8502	8507		10.1074/jbc.273.14.8502	http://dx.doi.org/10.1074/jbc.273.14.8502			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525964	hybrid			2022-12-27	WOS:000072876300098
J	Ni, HY; Li, AL; Simonsen, N; Wilkins, JA				Ni, HY; Li, AL; Simonsen, N; Wilkins, JA			Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta(1) integrin chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; CELL-ADHESION; PHORBOL ESTER; POLYMORPHONUCLEAR LEUKOCYTES; GLYCOPROTEIN IIB/IIIA; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; DIVALENT-CATIONS; BINDING-SITE; EPITOPE	Integrins can be expressed in at least three functional states (i.e. latent, active, and ligand-occupied), However, the molecular bases for the transitions between these states are unknown, In the present study, changes in the accessibility of several beta(1) epitopes (e.g. N29, B44, and B3B11) were used to probe activation-related conformational changes, Dithiothreitol or Mn2+ activation of integrin mediated adhesion in the human B cell line, IM9, resulted in a marked increase in the exposure of the B44 epitope, while N29 expression levels were most sensitive to dithiothreitol treatment, These results contrasted with the epitope expression patterns of spontaneously adherent K562 cells, where N29 was almost fully accessible and B44 was low, Addition of a soluble ligand resulted in a marked increase in B44 levels, suggesting that this antibody detected a ligand-induced binding site, The N29 epitope was mapped to a cysteine-rich region near the NH2 terminus of the integrin chain, thus defining a novel regulatory site. These studies indicate that the activation of integrin function by different stimuli may involve related but nonidentical conformations, Both Mn2+ and dithiothreitol appear to induce localized conformational changes that mimic a ligand-occupied receptor, This differs from the "physiologically" activated integrins on K562 cells that display a marked increase in overall epitope accessibility without exposure of the ligand-induced binding site epitopes, The increased exposure of the N29 site on K562 cells may indicate a role for this region in the regulation of integrin function.	Univ Manitoba, RDU Res Lab, Winnipeg, MB R3A 1M4, Canada; Univ Manitoba, Dept Med, Winnipeg, MB R3A 1M4, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3A 1M4, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3A 1M4, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba	Wilkins, JA (corresponding author), Univ Manitoba, RDU Res Lab, RR014 800 Sherbrook St, Winnipeg, MB R3A 1M4, Canada.			Ni, Heyu/0000-0002-7621-2945				BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; BROWN DL, 1989, J CLIN INVEST, V84, P366, DOI 10.1172/JCI114166; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CALVETE JJ, 1994, BIOCHEM J, V298, P1; CHAN BMC, 1991, J IMMUNOL, V147, P398; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIS GE, 1993, J IMMUNOL, V151, P7138; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Faull RJ, 1996, J BIOL CHEM, V271, P25099, DOI 10.1074/jbc.271.41.25099; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAO JX, 1995, CELL IMMUNOL, V163, P178, DOI 10.1006/cimm.1995.1114; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HAAZENBERGER D, 1997, J IMMUNOL, V158, P76; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOUNS WC, 1994, BLOOD, V84, P1108; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MARGUERIE GA, 1981, BIOCHEMISTRY-US, V20, P1074, DOI 10.1021/bi00508a005; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; NI H, 1997, IN PRESS CELL ADHES; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; STUPACK DG, 1994, CELL IMMUNOL, V155, P237, DOI 10.1006/cimm.1994.1116; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; Wilkins JA, 1996, J BIOL CHEM, V271, P3046, DOI 10.1074/jbc.271.6.3046; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	44	95	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7981	7987		10.1074/jbc.273.14.7981	http://dx.doi.org/10.1074/jbc.273.14.7981			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525896	hybrid			2022-12-27	WOS:000072876300030
J	Prinz, WA; Boyd, DH; Ehrmann, M; Beckwith, J				Prinz, WA; Boyd, DH; Ehrmann, M; Beckwith, J			The protein translocation apparatus contributes to determining the topology of an integral membrane protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; DISULFIDE BOND FORMATION; MALTOSE-BINDING PROTEIN; AMINO-ACID RESIDUES; CYTOPLASMIC MEMBRANE; SECRETORY PROTEINS; EXPORT; PEPTIDE; ORIENTATION; INSERTION	The assembly of integral membrane proteins is determined by features of these proteins and the protein translocation apparatus, We used alkaline phosphatase fusions to the membrane protein MalF to investigate the role of the protein translocation machinery in the arrangement of proteins in the cytoplasmic membrane of Escherichia coli. In particular, we studied the effects of prlA mutations on membrane protein topology, These mutations lie in the secY gene, which encodes a core component of the protein translocation apparatus, We find that the topology of some of the fusion proteins is changed and, in one case, is completely inverted in prlA mutants, We discuss the mechanism of prlA-mediated export and the role of the protein translocation apparatus in contributing to membrane protein topology.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Konstanz, Fak Biol, D-78434 Konstanz, Germany	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Konstanz	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	jbeckwit@warren.med.harvard.edu	Ehrmann, Michael/A-7307-2012	Ehrmann, Michael/0000-0002-1927-260X	NIGMS NIH HHS [GM38922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038922, R01GM038922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BOST B, 1997, J BACTERIOL, V272, P4087; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; KIMBROUGH TG, 1994, J BACTERIOL, V119, P736; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LEE JI, 1992, J BIOL CHEM, V267, P20758; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; POGLIANO KJ, 1993, GENETICS, V133, P763; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; UHLAND K, 1994, J BACTERIOL, V176, P4565, DOI 10.1128/JB.176.15.4565-4571.1994; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; YAMANE K, 1988, J BIOL CHEM, V263, P19690	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8419	8424		10.1074/jbc.273.14.8419	http://dx.doi.org/10.1074/jbc.273.14.8419			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525953	hybrid			2022-12-27	WOS:000072876300087
J	Thompson, PD; Jurutka, PW; Haussler, CA; Whitfield, CK; Haussler, MR				Thompson, PD; Jurutka, PW; Haussler, CA; Whitfield, CK; Haussler, MR			Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced by 1,25-dihydroxyvitamin D-3 and inhibited by 9-cis-retinoic acid - Evidence for allosteric receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RESPONSIVE ELEMENT; OSTEOCALCIN GENE; TRANSCRIPTIONAL ACTIVATION; 24-HYDROXYLASE GENE; AUXILIARY FACTOR; DIRECT REPEAT; EXPRESSION; HORMONE; IDENTIFICATION; PATHWAYS	Gel mobility shift analysis was utilized to investigate the molecular function of 1 alpha,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) and 9-cis-retinoic acid (9-cis-RA) ligands in the binding of the vitamin D receptor (VDR) and retinoid X receptor (RXR) to mouse osteopontin and rat osteocalcin vitamin D-response elements (VDREs). At physiological ionic strength and reduced concentrations of expressed proteins, efficient binding to either VDRE occurs as a VDR.RXR heterodimer, not as a VDR homodimer. 1,25-(OH)(2)D-3 dramatically enhances heterodimer-VDRE interaction, whereas somewhat higher concentrations of 9-cis-RA inhibit this association, perhaps related to the role of this retinoid in facilitating RXR homodimer formation. Interestingly, if VDR is occupied by 1,25-(OH)(2)D-3 prior to complexing with RXR, the resulting heterodimer is relatively resistant to dissociation and diversion to other pathways by 9-cis-RA. Therefore, a proposed molecular action of 1,25-(OH)(2)D-3 is to generate an allosteric switch in VDR to a form that not only binds to the VDRE with high affinity and specificity as a heterodimer with RXR, but also interacts with the RXR partner to conformationally restrict the action of its cognate ligand.	Univ Arizona, Coll Med, Dept Biochem, Tucson, AZ 85724 USA	University of Arizona	Haussler, MR (corresponding author), Univ Arizona, Coll Med, Dept Biochem, Tucson, AZ 85724 USA.	hausler@u.arizona.edu		Jurutka, Peter/0000-0002-4950-9161; Haussler, Mark/0000-0002-7097-1801; Haussler, Carol/0000-0001-8360-3066	NIAMS NIH HHS [AR-15781] Funding Source: Medline; NIDDK NIH HHS [DK-33351] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR015781, R01AR015781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033351, R01DK033351] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREEN EC, 1994, P NATL ACAD SCI USA, V91, P12902, DOI 10.1073/pnas.91.26.12902; CAO X, 1993, J BIOL CHEM, V268, P27371; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FREEDMAN LP, 1994, MOL ENDOCRINOL, V8, P265, DOI 10.1210/me.8.3.265; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; Haussler MR, 1997, J ENDOCRINOL, V154, pS57; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HSIEH JC, 1995, J STEROID BIOCHEM, V53, P583, DOI 10.1016/0960-0760(95)00112-D; KATO S, 1995, MOL CELL BIOL, V15, P5858; KimmelJehan C, 1997, ARCH BIOCHEM BIOPHYS, V341, P75, DOI 10.1006/abbi.1997.9952; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANOLAGAS SC, 1994, SEMIN NEPHROL, V14, P129; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; NISHIKAWA J, 1994, NUCLEIC ACIDS RES, V22, P2902, DOI 10.1093/nar/22.15.2902; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OZONO K, 1990, J BIOL CHEM, V265, P21881; PIKE JW, 1982, P NATL ACAD SCI-BIOL, V79, P7719, DOI 10.1073/pnas.79.24.7719; REICHEL H, 1990, PROG CLIN BIOL RES, V332, P81; ROSS TK, 1993, P NATL ACAD SCI USA, V90, P9257, DOI 10.1073/pnas.90.20.9257; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SONE T, 1991, J BIOL CHEM, V266, P23296; Summers MD, 1987, MANUAL METHODS BACUL; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	42	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8483	8491		10.1074/jbc.273.14.8483	http://dx.doi.org/10.1074/jbc.273.14.8483			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525962	hybrid			2022-12-27	WOS:000072876300096
J	Klostermann, A; Lohrum, M; Adams, RH; Puschel, AW				Klostermann, A; Lohrum, M; Adams, RH; Puschel, AW			The chemorepulsive activity of the axonal guidance signal semaphorin D requires dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAPSIN-1 MESSENGER-RNA; RECEPTOR TYROSINE KINASES; SPINAL-CORD; EXPRESSION; GROWTH; FAMILY; PROTEIN; DOMAINS; MEMBER	The axonal guidance signal semaphorin D is a member of a large family of proteins characterized by the presence of a highly conserved semaphorin domain of about 500 amino acids. The vertebrate semaphorins can be divided into four different classes that contain both secreted and membrane-bound proteins. Here we show that class III (SemD) and class IV semaphorins (SemB) form homodimers linked by intermolecular disulfide bridges. In addition to the 95-kDa form of SemD (SemD(95k)), proteolytic processing of SemD creates a 65-kDa isoform (SemD(65k)) that lacks the 33-kDa carboxyl-terminal domain. Although SemD(95k) formed dimers, the removal of the carboxyl-terminal domain resulted in the dissociation of SemD homodimers to monomeric SemD(65k). Mutation of cysteine 723, one of four conserved cysteine residues in the 33-kDa fragment, revealed its requirement both for the dimerization of SemD and its chemorepulsive activity. We suggest that dimerization is a general feature of semaphorins which depends on class-specific sequences and is important for their function.	Max Planck Inst Hirnforsch, Neurochem Abt, D-60528 Frankfurt, Germany	Max Planck Society	Puschel, AW (corresponding author), Max Planck Inst Hirnforsch, Neurochem Abt, Deutschordenstr 46, D-60528 Frankfurt, Germany.	pueschel@mpih-frankfurt.mpg.de	Adams, Ralf H/AAE-9274-2019					Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BOUGERET C, 1992, J IMMUNOL, V148, P318; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Furuyama T, 1996, J BIOL CHEM, V271, P33376, DOI 10.1074/jbc.271.52.33376; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Luo Yuling, 1994, Current Opinion in Neurobiology, V4, P648, DOI 10.1016/0959-4388(94)90005-1; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; NICOLA MA, 1992, NEUROSCI LETT, V138, P173, DOI 10.1016/0304-3940(92)90499-W; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; Puschel AW, 1996, EUR J NEUROSCI, V8, P1317, DOI 10.1111/j.1460-9568.1996.tb01593.x; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; RAPER JA, 1990, NEURON, V2, P12; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Zhou L, 1997, MOL CELL NEUROSCI, V9, P26, DOI 10.1006/mcne.1997.0607	28	92	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7326	7331		10.1074/jbc.273.13.7326	http://dx.doi.org/10.1074/jbc.273.13.7326			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516427	hybrid			2022-12-27	WOS:000072738500023
J	Rahmoune, H; Chen, HL; Gallagher, JT; Rudland, PS; Fernig, DG				Rahmoune, H; Chen, HL; Gallagher, JT; Rudland, PS; Fernig, DG			Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF - Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; FACTOR FAMILY; DNA-SYNTHESIS; HUMAN-BREAST; GLAND; DIFFERENTIATION; EXPRESSION; CULTURE; IDENTIFICATION; PROLIFERATION	We have determined the relationship between the binding sites for acidic fibroblast growth factor (aFGF) and basic FGF (bFGF) in heparan sulfate (HS) prepared from a panel of mammary cell lines and the ability of the HS to activate aFGF and bFGF in DNA synthesis assays. The k(a) of the HS for aFGF fell into three groups, whereas the k(d) (0.0015-0.016 s(-1)) and the K-d (0.4-8.6 mu M) formed a continuum. bFGF possessed a high affinity binding site (K-d 22-30 nM) with a fast k(a) (320,000-550,000 M-1 s(-1)), termed "fast/high," and a lower affinity site (K-d 47-320 nM) with a slower k(a) (35,000-150,000 M-1 s(-1)), termed "slow/low." Most of the species of HS possessed the latter binding site, which was able to activate bFGF in HS-deficient fibroblasts. However, the HS from the culture medium of the mammary fibroblasts and the myoepithelial-like cells possessed both a fast/high and a slow/low binding site and could not activate bFGF, although it could potentiate the growth-stimulatory activity of aFGF. Treatment of the HS possessing two binding sites for bFGF with heparitinase 1 released oligosaccharides that were able to restore the activity of bFGF in HS-deficient fibroblasts.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Christie Hosp, Canc Res Campaign, Dept Med Oncol, Manchester M20 9BX, Lancs, England	University of Liverpool; Christie NHS Foundation Trust; Christie Hospital	Fernig, DG (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	dgfernig@liv.ac.uk	Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Chen, Hai-Lan/0000-0002-5766-0531				ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; BARRACLOUGH R, 1990, J CELL PHYSIOL, V144, P333, DOI 10.1002/jcp.1041440220; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Chen HL, 1996, BIOSCIENCE REP, V16, P249, DOI 10.1007/BF01207339; CHEN HL, 1996, BIOCHEM SOC T, V24, P358; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; COLTRINI D, 1994, BIOCHEM J, V303, P583, DOI 10.1042/bj3030583; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FERNIG DG, 1993, INT J CANCER, V54, P629, DOI 10.1002/ijc.2910540418; FERNIG DG, 1992, GROWTH FACTORS, V5, P27; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; IOZZO RV, 1988, CANCER METAST REV, V7, P39, DOI 10.1007/BF00048277; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; JOSHI K, 1986, LAB INVEST, V54, P52; JOSHI K, 1986, AM J PATHOL, V124, P199; KE YQ, 1993, J CELL SCI, V106, P135; KE YQ, 1990, BIOCHEM BIOPH RES CO, V171, P963, DOI 10.1016/0006-291X(90)90778-L; KE YQ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P307, DOI 10.1016/0167-4781(92)90029-Y; KINSELLA L, 1998, IN PRESS GLYCOCONJUG, V14; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MALI M, 1994, J BIOL CHEM, V269, P27795; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; Rahmoune H, 1997, BIOCHEM SOC T, V25, P1299; Rahmoune H, 1996, BIOCHEM SOC T, V24, pS355, DOI 10.1042/bst024355s; RAHMOUNE H, 1991, AM J RESP CELL MOL, V4, P156, DOI 10.1165/ajrcmb/4.2.156; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUDLAND PS, 1984, J CELL PHYSIOL, V120, P364, DOI 10.1002/jcp.1041200315; RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385; RUDLAND PS, 1993, J HISTOCHEM CYTOCHEM, V41, P887, DOI 10.1177/41.6.7686196; RUDLAND PS, 1996, STEM CELLS CANC, P147; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TAKEUCHI J, 1976, CANCER RES, V36, P2133; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WALKER A, 1994, J BIOL CHEM, V269, P931; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	49	114	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7303	7310		10.1074/jbc.273.13.7303	http://dx.doi.org/10.1074/jbc.273.13.7303			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516424	hybrid			2022-12-27	WOS:000072738500020
J	Stone, SJ; Cui, Z; Vance, JE				Stone, SJ; Cui, Z; Vance, JE			Cloning and expression of mouse liver phosphatidylserine synthase-1 cDNA - Overexpression in rat hepatoma cells inhibits the CDP-ethanolamine pathway for phosphatidylethanolamine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; MEMBRANE LIPID-SYNTHESIS; PHOSPHATIDYLCHOLINE SYNTHESIS; ESCHERICHIA-COLI; PHOSPHOETHANOLAMINE CYTIDYLYLTRANSFERASE; HEPATOCYTES; PROTEIN; MITOCHONDRIA; GENE; PHOSPHOLIPIDS	In eukaryotic cells, phosphatidylserine (PtdSer) is synthesized by two distinct synthases on the endoplasmic reticulum by a base-exchange reaction in which the polar head-group of an existing phospholipid is replaced with serine. We report the cloning and expression of a cDNA for mouse liver PtdSer synthase-1, The deduced protein sequence is >90% identical to that of PtdSer synthase-1 from Chinese hamster ovary cells and a sequence from a human myeloblast cell Line, PtdSer synthase-1 cDNA was stably expressed in M.9.1.1 cells which are mutant Chinese hamster ovary cells defective in PtdSer synthase-1 activity, are ethanolamine auxotrophs, and have a reduced content of PtdSer and phosphatidylethanolamine (PtdEtn), The growth defect of M.9.1.1 cells was eliminated, and a normal phospholipid composition was restored in the absence of exogenous ethanolamine, implying that the cloned cDNA encoded PtdSer synthase, Mouse liver PtdSer synthase-1 was also expressed in McArdle 7777 rat hepatoma cells, In addition to a 3-fold higher in vitro serine-exchange activity, these cells also exhibited enhanced choline- and ethanolamine-exchange activities and incorporated more [H-3]serine into PtdSer than did control cells. However, the levels of PtdSer and PtdEtn in cells overexpressing PtdSer synthase-1 activity were not increased, Excess PtdSer produced by the transfected cells was rapidly decarboxylated to PtdEtn and the degradation of PtdSer, and/or PtdEtn derived from PtdSer, was increased, Moreover, the CDP-ethanolamine pathway for PtdEtn biosynthesis was inhibited, These data suggest that (i) cellular levels of PtdSer and PtdEtn are tightly controlled, and (ii) the metabolism of PtdSer and PtdEtn is coordinately regulated to maintain phospholipid homeostasis.	Univ Alberta, Lipid & Lipoprot Res Grp, Heritage Med Res Ctr 315, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Lipid & Lipoprot Res Grp, Heritage Med Res Ctr 315, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca						Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; BAGY JR, 1995, NAT STRUCT BIOL, V2, P114, DOI 10.1038/nsb0295-114; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DENNIS EA, 1972, J LIPID RES, V13, P263; FADOK VA, 1992, J IMMUNOL, V148, P2207; HUBSCHER G, 1959, BIOCHIM BIOPHYS ACTA, V36, P518, DOI 10.1016/0006-3002(59)90194-5; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KANOSUEOKA T, 1979, P NATL ACAD SCI USA, V76, P5741, DOI 10.1073/pnas.76.11.5741; KANOSUEOKA T, 1983, J CELL PHYSIOL, V117, P109, DOI 10.1002/jcp.1041170115; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; MACALA LJ, 1983, J LIPID RES, V24, P1243; MENON AK, 1992, J BIOL CHEM, V267, P15277; MILLER MA, 1986, J BIOL CHEM, V261, P9753; MURAKAMI H, 1982, P NATL ACAD SCI-BIOL, V79, P1158, DOI 10.1073/pnas.79.4.1158; Nakashima A, 1997, J BIOL CHEM, V272, P9567; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTA A, 1981, J BIOL CHEM, V256, P2219; OKADA M, 1994, J BACTERIOL, V176, P7456, DOI 10.1128/JB.176.24.7456-7461.1994; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; RAETZ CRH, 1977, P NATL ACAD SCI USA, V74, P1412, DOI 10.1073/pnas.74.4.1412; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; SAMBORSKI RW, 1993, BIOCHIM BIOPHYS ACTA, V1167, P15, DOI 10.1016/0005-2760(93)90211-Q; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sasaki H, 1997, P NATL ACAD SCI USA, V94, P7320, DOI 10.1073/pnas.94.14.7320; SCHNEIDER W, 1986, ANAL BIOCHEM, V14, P121; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SUNDLER R, 1973, BIOCHIM BIOPHYS ACTA, V306, P218, DOI 10.1016/0005-2760(73)90227-0; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIJBURG LBM, 1987, BIOCHIM BIOPHYS ACTA, V922, P184, DOI 10.1016/0005-2760(87)90153-6; TIJBURG LBM, 1989, BIOCHEM J, V257, P645, DOI 10.1042/bj2570645; TIJBURG LBM, 1992, METHOD ENZYMOL, V209, P258; TIJBURG LBM, 1987, BIOCHIM BIOPHYS ACTA, V919, P49, DOI 10.1016/0005-2760(87)90216-5; TIJBURG LBM, 1989, BIOCHEM BIOPH RES CO, V160, P1275, DOI 10.1016/S0006-291X(89)80141-X; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANHELLEMOND JJ, 1994, J BIOL CHEM, V269, P15415; VERMEULEN PS, 1993, J BIOL CHEM, V268, P7458; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YEUNG SKF, 1976, LIPIDS, V11, P498, DOI 10.1007/BF02532893; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102; ZHOU X, 1992, J LIPID RES, V33, P1233	60	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7293	7302		10.1074/jbc.273.13.7293	http://dx.doi.org/10.1074/jbc.273.13.7293			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516423	hybrid			2022-12-27	WOS:000072738500019
J	True, HL; Celander, DW				True, HL; Celander, DW			Protein components contribute to active site architecture for eukaryotic ribonuclease P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-P; ESCHERICHIA-COLI; RIBONUCLEOPROTEINS; IDENTIFICATION; EXPRESSION; SUBSTRATE; SUBUNIT; MOIETY; ENZYME; CELLS	In eukaryotes, ribonuclease P (RNase P) requires both RNA and protein components for catalytic activity. The eukaryotic RNase P RNA, unlike its bacterial counterparts, does not possess intrinsic catalytic activity in the absence of holoenzyme protein components. We have used a sensitive photoreactive cross-linking assay to explore the substrate-binding environment for different eukaryotic RNase P holoenzymes. Protein components from the Tetrahymena thermophila and human RNase P holoenzymes form specific products in photoreactions containing [4-thio]-uridine-labeled pre-tRNA(Gln). The HeLa RNase P RNA in neither the presence nor the absence of holoenzyme protein components formed cross-link products to the pre-tRNA(Gln) probe. Parallel photo-cross-linking experiments with the Escherichia coli RNase P holoenzyme revealed that only the bacterial RNase P RNA forms specific substrate photoadducts. A protein-rich active site for the eukaryotic RNase P represents one unique feature that distinguishes holoenzyme organization between bacteria and eukaryotes.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Chem & Life Sci Lab B103, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Celander, DW (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	dcelande@uiuc.edu	True, Heather/D-2979-2012		NIGMS NIH HHS [GM47854] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAER MF, 1990, METHOD ENZYMOL, V181, P569; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; Chen JL, 1997, RNA, V3, P557; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; ELDER PS, 1997, P NATL ACAD SCI USA, V94, P1101; Fouts DE, 1997, BIOCHEMISTRY-US, V36, P13256, DOI 10.1021/bi971551d; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HANNA MM, 1989, METHOD ENZYMOL, V180, P383; LACY MJ, 1986, J IMMUNOL METHODS, V87, P169, DOI 10.1016/0022-1759(86)90527-2; Lygerou Z, 1996, EMBO J, V15, P5936, DOI 10.1002/j.1460-2075.1996.tb00980.x; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; NICHOLS M, 1988, P NATL ACAD SCI USA, V85, P1379, DOI 10.1073/pnas.85.5.1379; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RIVERALEON R, 1995, J BACTERIOL, V177, P2564, DOI 10.1128/jb.177.9.2564-2566.1995; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEITZ JA, 1989, METHOD ENZYMOL, V180, P468; True HL, 1996, J BIOL CHEM, V271, P16559, DOI 10.1074/jbc.271.28.16559; ZIMMERLY S, 1993, EUR J BIOCHEM, V217, P501, DOI 10.1111/j.1432-1033.1993.tb18270.x	24	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7193	7196		10.1074/jbc.273.13.7193	http://dx.doi.org/10.1074/jbc.273.13.7193			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516409	hybrid			2022-12-27	WOS:000072738500005
J	Champeil, P; Menguy, T; Soulie, S; Juul, B; de Gracia, AG; Rusconi, F; Falson, P; Denoroy, L; Henao, F; le Maire, M; Moller, JV				Champeil, P; Menguy, T; Soulie, S; Juul, B; de Gracia, AG; Rusconi, F; Falson, P; Denoroy, L; Henao, F; le Maire, M; Moller, JV			Characterization of a protease-resistant domain of the cytosolic portion of sarcoplasmic reticulum Ca2+-ATPase - Nucleotide- and metal-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING; ADENOSINE 5'-TRIPHOSPHATE; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE; LANTHANIDE IONS; CATALYTIC SITE; FLUORESCEIN ISOTHIOCYANATE; CA-2+-TRANSPORTING ATPASE; TRYPTOPHAN RESIDUES; CIRCULAR-DICHROISM	Treatment of rabbit sarcoplasmic reticulum Ca2+-ATPase with a variety of proteases, including elastase, proteinase K, and endoproteinases Asp-N and Glu-C, results in accumulation of soluble fragments starting close to the ATPase phosphorylation site Asp(351) and ending in the Lys(605)-Arg(615) region, well before the conserved sequences generally described as constituting the "hinge" region of this P-type ATPase (residues 670-760). These fragments, designated as p29/30, presumably originate from a relatively compact domain of the cytoplasmic head of the ATPase. They retain two structural characteristics of intact Ca2+-ATPase as follows: high sensitivity of peptidic bond Arg(505)-Ala(506) to trypsin cleavage, and high reactivity of lysine residue Lys(515) toward the fluorescent label fluorescein 5'-isothiocyanate. Regarding functional properties, these fragments retain the ability to bind nucleotides, although with reduced affinity compared with intact Ca2+-ATPase. The fragments also bind Nd3+ ions, leaving open the possibility that these fragments could contain the metal-binding site(s) responsible for the inhibitory effect of lanthanide ions on ATPase activity, The p29/30 soluble domain, like similar proteolytic fragments that can be obtained from other P-type ATPases, may be useful for obtaining three-dimensional structural information an the cytosolic portion of these ATPases, with or without bound nucleotides. From our findings we infer that a real hinge region with conformational flexibility is located at the C-terminal boundary of p29/30 (rather than in the conserved region of residues 670-760); we also propose that the ATP-binding cleft is mainly located within the p29/30 domain, with the phosphorylation site strategically located at the N-terminal border of this domain.	CEA Saclay, URA 2096 CNRS, F-91191 Gif Sur Yvette, France; CEA Saclay, Sect Biophys Prot & Membranes, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France; Lab Neurobiol & Diversite Cellulaire, CNRS URA 2054, F-75231 Paris, France; Ecole Super Phys & Chim Ind, F-75231 Paris 05, France; CNRS, Serv Cent Anal, F-69390 Vernaison, France; Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol, Badajoz 06080, Spain; Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Centre National de la Recherche Scientifique (CNRS); Universidad de Extremadura; Aarhus University	Champeil, P (corresponding author), CEA Saclay, URA 2096 CNRS, F-91191 Gif Sur Yvette, France.		Henao, Fernando/F-6694-2016	Henao, Fernando/0000-0003-1117-8544; Falson, Pierre/0000-0002-9760-4577; Rusconi, Filippo Matteo/0000-0003-1822-0397				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; DUX L, 1985, J BIOL CHEM, V260, P1730; Farley RA, 1997, BIOCHEMISTRY-US, V36, P941, DOI 10.1021/bi962153y; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; GIRARDET JL, 1993, EUR J BIOCHEM, V217, P225, DOI 10.1111/j.1432-1033.1993.tb18237.x; GREEN NM, 1989, NATURE, V339, P424, DOI 10.1038/339424a0; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; HENAO F, 1992, J BIOL CHEM, V267, P10302; HIGHSMITH S, 1984, BIOCHEM BIOPH RES CO, V124, P183, DOI 10.1016/0006-291X(84)90934-3; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P1049, DOI 10.1021/bi00353a015; IMAMURA Y, 1991, J BIOCHEM-TOKYO, V110, P214, DOI 10.1093/oxfordjournals.jbchem.a123559; IVKOVA MN, 1992, BIOCHIM BIOPHYS ACTA, V1118, P231, DOI 10.1016/0167-4838(92)90280-Q; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; KARAS M, 1990, ANAL CHIM ACTA, V241, P175, DOI 10.1016/S0003-2670(00)83645-4; Kasho VN, 1997, BIOCHEMISTRY-US, V36, P8045, DOI 10.1021/bi970472z; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LEE AG, 1996, BIOMEMBR, V5, P1; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; leMaire M, 1996, ACS SYM SER, V635, P36; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MATA AM, 1989, FEBS LETT, V253, P273, DOI 10.1016/0014-5793(89)80974-3; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; Norby JG, 1997, J GEN PHYSIOL, V109, P555, DOI 10.1085/jgp.109.5.555; OGURUSU T, 1991, BIOCHEMISTRY-US, V30, P9966, DOI 10.1021/bi00105a022; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1982, J BIOL CHEM, V257, P6120; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rusconi F, 1997, BIOCHEMISTRY-US, V36, P11021, DOI 10.1021/bi970752e; SACCOMANI G, 1987, BIOCHIM BIOPHYS ACTA, V912, P63, DOI 10.1016/0167-4838(87)90248-2; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P4157; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; SPROWL CD, 1989, BIOPHYS J, V55, P16; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; SWILLENS S, 1995, TRENDS PHARMACOL SCI, V16, P151, DOI 10.1016/S0165-6147(00)89007-0; TAI MM, 1989, BIOCHEMISTRY-US, V28, P3183, DOI 10.1021/bi00434a011; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TRAN CM, 1994, J BIOL CHEM, V269, P6558; VANUEM TJF, 1991, BIOCHEM J, V280, P243, DOI 10.1042/bj2800243; VILSEN B, 1991, J BIOL CHEM, V266, P16157; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; WATANABE T, 1982, J BIOL CHEM, V257, P1510; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; Yonekura K, 1997, BIOPHYS J, V72, P997, DOI 10.1016/S0006-3495(97)78752-6	65	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6619	6631		10.1074/jbc.273.12.6619	http://dx.doi.org/10.1074/jbc.273.12.6619			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506958	hybrid			2022-12-27	WOS:000072775900008
J	Gagnon, AW; Kallal, L; Benovic, JL				Gagnon, AW; Kallal, L; Benovic, JL			Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; PROTEIN-COUPLED RECEPTOR; PLASMA-MEMBRANE; MESSENGER-RNA; ARRESTIN; SEQUESTRATION; RESENSITIZATION; INTERNALIZATION; DYNAMIN	Previous studies have demonstrated that non-visual arrestins function as adaptors in clathrin-mediated endocytosis to promote agonist-induced internalization of the beta(2)-adrenergic receptor (beta(2)AR), Here, we characterized the effects of arrestins and other modulators of clathrin-mediated endocytosis on down-regulation of the beta(2)AR, In COS-1 and HeLa cells, non-visual arrestins promote agonist-induced internalization and down-regulation of the beta(2)AR, whereas dynamin-K44A, a dominant negative mutant of dynamin that inhibits clathrin-mediated endocytosis, attenuates beta(2)AR internalization and down-regulation. In HEK293 cells, dynamin-K44A profoundly inhibits agonist-induced internalization and down-regulation of the beta(2)AR, suggesting that receptor internalization is critical for down-regulation in these cells, Moreover, a dominant-negative mutant of beta-arrestin, beta-arrestin-(319-418), also inhibits both agonist-induced receptor internalization and down-regulation. Immunofluorescence microscopy analysis reveals that the beta(2)AR is trafficked to lysosomes in HEK293 cells, where presumably degradation of the receptor occurs, These studies demonstrate that down-regulation of the beta(2)AR is in part due to trafficking of the beta(2)AR via the clathrin-coated pit endosomal pathway to lysosomes.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM044944, R01GM047417] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM47417, GM44944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FERGUSON SG, 1996, SCIENCE, V217, P363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEIN L, 1994, J BIOL CHEM, V269, P27719; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Penn RB, 1998, HANDBK PHYS, V1, P125; Petrou C, 1997, J BIOL CHEM, V272, P2326; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	37	186	190	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6976	6981		10.1074/jbc.273.12.6976	http://dx.doi.org/10.1074/jbc.273.12.6976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507004	hybrid			2022-12-27	WOS:000072775900054
J	Gao, J; Li, ZL; Paulin, D				Gao, J; Li, ZL; Paulin, D			A novel site, Mt, in the human desmin enhancer is necessary for maximal expression in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C GENE; UPSTREAM REGULATORY REGION; CREATINE-KINASE ENHANCER; HELIX-LOOP-HELIX; LIGHT-CHAIN GENE; M-CAT ELEMENTS; BINDING-FACTOR; TRANSCRIPTION FACTORS; I GENE; TRANSGENIC MICE	Previous investigations have shown that expression of the muscle-specific intermediate filament desmin gene in skeletal muscle is controlled in part by a 5' muscle-specific enhancer, This enhancer activity can be divided into myoblast-specific and myotube-specific activation domains. The myotube-specific region contains a MyoD and MEF2 sites, whereas the myoblast-specific region contains Sp1, Krox, and Mb sites. In the present study, we designed mutations in the conserved portion of the myotube-specific region; transfection analysis of these mutations showed that a novel site located between the MyoD and MEF2 sites, named Mt (GGTATTT), is required for full transcriptional activity of the desmin enhancer in skeletal muscle. Although gel mobility shift assays demonstrate that myotube, myoblast, fibroblast, and HeLa nuclear extracts contain a nuclear factor that binds specifically to Mt, four copies of the Mt site function as the native enhancer only in myotubes. Functional synergism among the MyoD, MEF2, and Mt sites in myotubes has been demonstrated. These results show that the novel Mt site cooperates with MyoD and MEF2 to give maximal expression of the desmin gene.	Inst Pasteur, SCME, F-75015 Paris 15, France; Univ Paris 07, Lab Biol Mol Differentiat Cellulaire, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Li, ZL (corresponding author), Inst Pasteur, SCME, 25 Rue Dr Roux, F-75015 Paris 15, France.		Li, Zhenlin/E-3937-2016	LI, Zhenlin/0000-0002-3706-4505				ALLEN RE, 1991, J CELL PHYSIOL, V149, P525, DOI 10.1002/jcp.1041490323; ANDRES V, 1995, J BIOL CHEM, V270, P23246, DOI 10.1074/jbc.270.40.23246; BABAI F, 1990, DIFFERENTIATION, V44, P132, DOI 10.1111/j.1432-0436.1990.tb00546.x; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BIBEN C, 1994, MOL CELL BIOL, V14, P3504, DOI 10.1128/MCB.14.5.3504; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; CORIN SJ, 1994, J BIOL CHEM, V269, P10651; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEHESH K, 1992, EMBO J, V11, P4131, DOI 10.1002/j.1460-2075.1992.tb05506.x; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; FabreSuver C, 1996, J BIOL CHEM, V271, P4646, DOI 10.1074/jbc.271.9.4646; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FEO S, 1995, MOL CELL BIOL, V15, P5991; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; HALLAUER PL, 1993, DEVELOPMENT, V119, P691; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; IANELLO RC, 1991, J BIOL CHEM, V266, P3309; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LI Z, 1993, DEVELOPMENT, V117, P947; LI ZL, 1989, GENE, V78, P243; LI ZL, 1993, J BIOL CHEM, V268, P10403; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; LI ZL, 1991, J BIOL CHEM, V266, P6562; LILIENBAUM A, 1988, CELL MOL BIOL, V34, P663; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MOBUN TJ, 1991, EMBO J, V10, P933; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1990, J BIOL CHEM, V265, P15970; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SAVETTI A, 1993, MOL CELL BIOL, V13, P89; SCHREIER T, 1990, J BIOL CHEM, V265, P21247; SEIDEL U, 1989, J BIOL CHEM, V264, P16109; SHIRAKATA M, 1988, MOL CELL BIOL, V8, P2581, DOI 10.1128/MCB.8.6.2581; SORTORELLI V, 1997, MOL CELL BIOL, V17, P1010; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; TSUJINO S, 1989, J BIOL CHEM, V264, P15334; VANDEKLUNDERT FAJM, 1994, J BIOL CHEM, V269, P220; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	70	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6402	6409		10.1074/jbc.273.11.6402	http://dx.doi.org/10.1074/jbc.273.11.6402			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497371	hybrid			2022-12-27	WOS:000072488500063
J	Kang, SW; Chae, HZ; Seo, MS; Kim, KH; Baines, IC; Rhee, SG				Kang, SW; Chae, HZ; Seo, MS; Kim, KH; Baines, IC; Rhee, SG			Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; NF-KAPPA-B; ALKYL HYDROPEROXIDE REDUCTASE; MOUSE OSTEOBLASTIC CELLS; ATP-DEPENDENT PROTEASE; GLUTATHIONE-PEROXIDASE; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION	Mammalian tissues express three immunologically distinct peroxiredoxin (Prx) proteins (Prx I, II, and III), which are the products of distinct genes. With the use of recombinant proteins Prx I, II, and III, all have now been shown to possess peroxidase activity and to rely on Trx as a source of reducing equivalents for the reduction of H2O2. Prx I and II are cytosolic proteins, whereas Prx III is localized in mitochondria. Transient overexpression of Prx I or II in cultured cells showed that they were able to eliminate the intracellular H2O2 generated in response to growth factors. Moreover, the activation of nuclear factor kappa B (NF kappa B) induced by extracellularly added H2O2 or tumor necrosis factor-alpha was blocked by overproduction of Prx II. These results suggest that, together with glutathione peroxidase and catalase, Prx enzymes Likely play an important role in eliminating peroxides generated during metabolism. In addition, Prx I and II might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentration of H2O2.	NHLBI, Lab Cell Signalling, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signalling, NIH, Bldg 3,Rm 122, Bethesda, MD 20892 USA.							ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ASAYAMA K, 1994, HISTOCHEMISTRY, V102, P213, DOI 10.1007/BF00268898; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHU FF, 1993, J BIOL CHEM, V268, P2571; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; ISHII T, 1995, BIOCHEM BIOPH RES CO, V216, P970, DOI 10.1006/bbrc.1995.2715; ISHII T, 1993, J BIOL CHEM, V268, P18633; IWAHARA S, 1995, BIOCHEMISTRY-US, V34, P13398, DOI 10.1021/bi00041a017; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; JIN DY, 1997, NUCLEIC ACIDS RES, V25, P378; KAWAI S, 1994, J BIOCHEM-TOKYO, V115, P641, DOI 10.1093/oxfordjournals.jbchem.a124388; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LIM YS, 1993, BIOCHEM BIOPH RES CO, V107, P279; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; RHEE SG, 1994, MOL CELLS, V4, P137; SAURI H, 1995, BIOCHEM BIOPH RES CO, V208, P964, DOI 10.1006/bbrc.1995.1428; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TONISSEN KF, 1989, NUCLEIC ACIDS RES, V17, P3973, DOI 10.1093/nar/17.10.3973; TSUJI K, 1995, BIOCHEM J, V307, P377, DOI 10.1042/bj3070377; WATABE S, 1995, BIOCHEM BIOPH RES CO, V213, P1010, DOI 10.1006/bbrc.1995.2229; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; YAMAMOTO T, 1989, GENE, V80, P337; YIM MB, 1994, J BIOL CHEM, V269, P1621; YORK JD, 1994, J BIOL CHEM, V269, P19992	46	602	629	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6297	6302		10.1074/jbc.273.11.6297	http://dx.doi.org/10.1074/jbc.273.11.6297			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497357	hybrid			2022-12-27	WOS:000072488500049
J	Pan, CJ; Lei, KJ; Annabi, B; Hemrika, W; Chou, JY				Pan, CJ; Lei, KJ; Annabi, B; Hemrika, W; Chou, JY			Transmembrane topology of glucose-6-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; ENDOPLASMIC-RETICULUM; ENZYME-DEFICIENT; RAT-LIVER; GENE; MUTATIONS; 1A	Deficiency of microsomal glucose-6-phosphatase (G6Pase), the key enzyme in glucose homeostasis, causes glycogen storage disease type 1a, an autosomal recessive disorder. Characterization of the transmembrane topology of G6Pase should facilitate the identification of amino acid residues contributing to the active site and broaden our understanding of the effects of mutations that cause glycogen storage disease type 1a, Using N- and C-terminal tagged G6Pase, we show that in intact microsomes, the N terminus is resistant to protease digestion, whereas the C terminus is sensitive to such treatment. Our results demonstrate that G6Pase possesses an odd number of transmembrane helices, with its N and C termini facing the endoplasmic reticulum lumen and the cytoplasm, respectively. During catalysis, a phosphoryl enzyme intermediate is formed, and the phosphoryl acceptor in G6Pase is a His residue, Sequence alignment suggests that mammalian G6Pases, lipid phosphatases, acid phosphatases, and a vanadium-containing chloroperoxidase (whose tertiary structure is known) share a conserved phosphatase motif, Active-site alignment of the vanadium-containing chloroperoxidase and G6Pases predicts that Arg-83, His-119, and His-176 in G6Pase contribute to the active site and that His-176 is the residue that covalently binds the phosphoryl moiety during catalysis, This alignment also predicts that Arg-83, His-119, and His-176 reside on the same side of the endoplasmic reticulum membrane, which is supported by the recently predicted nine-transmembrane helical model for G6Pase. We have previously shown that Arg-83 is involved in positioning the phosphate during catalysis and that His-119 is essential for G6Pase activity. Here we demonstrate that substitution of His-176 with structurally similar or dissimilar amino acids inactivates the enzyme, suggesting that His-176 could be the phosphoryl acceptor in G6Pase during catalysis.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Univ Amsterdam, EC Slater Inst Biochem Res, NL-1018 TV Amsterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Amsterdam	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.							Ausubel FM, 1992, CURRENT PROTOCOLS MO; Chen Y-T, 1995, METABOLIC MOL BASES, P935; ChevalierPorst F, 1996, J MED GENET, V33, P358, DOI 10.1136/jmg.33.5.358; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; FELDMAN F, 1972, BIOCHIM BIOPHYS ACTA, V268, P698, DOI 10.1016/0005-2744(72)90274-4; Hemrika W, 1997, FEBS LETT, V409, P317, DOI 10.1016/S0014-5793(97)00530-9; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; HERS H. G., 1964, ADVAN METAB DISORDERS, V1, P1; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KAJIHARA S, 1995, AM J HUM GENET, V57, P549; Lee WJ, 1996, CLIN GENET, V50, P206; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; LEI KJ, 1995, AM J HUM GENET, V57, P766; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; MOSES SW, 1990, J PEDIATR GASTR NUTR, V11, P155, DOI 10.1097/00005176-199008000-00004; NILSSON O, 1975, FEBS LETT, V58, P190, DOI 10.1016/0014-5793(75)80256-0; NILSSON OS, 1978, EUR J BIOCHEM, V82, P627, DOI 10.1111/j.1432-1033.1978.tb12059.x; NORDLIE RC, 1966, J BIOL CHEM, V241, P3136; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; PARVARI R, 1995, J INHERIT METAB DIS, V18, P21, DOI 10.1007/BF00711368; Parvari R, 1997, EUR J HUM GENET, V5, P191, DOI 10.1159/000484762; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; Smyth DG., 1967, METHOD ENZYMOL, V11, P214; SPETH M, 1992, BIOCHEM BIOPH RES CO, V183, P590, DOI 10.1016/0006-291X(92)90523-N; Stukey J, 1997, PROTEIN SCI, V6, P469; WADDELL ID, 1991, BIOCHEM J, V275, P133, DOI 10.1042/bj2750133; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287	33	136	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6144	6148		10.1074/jbc.273.11.6144	http://dx.doi.org/10.1074/jbc.273.11.6144			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497333	hybrid			2022-12-27	WOS:000072488500025
J	Servidei, T; Aoki, Y; Lewis, SE; Symes, A; Fink, JS; Reeves, SA				Servidei, T; Aoki, Y; Lewis, SE; Symes, A; Fink, JS; Reeves, SA			Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; CULTURED SYMPATHETIC NEURONS; NEUROBLASTOMA CELL-LINE; GENE-EXPRESSION; PROTEIN-KINASE; GROWTH-FACTORS; CYCLIC-AMP; JAK-STAT; ACTIVATION	The src homology 2 (SH2) domain-containing protein-tyrosine phosphatase SHP-2 has been implicated as an important positive regulator of several mitogenic signaling pathways. SHP-2 has more recently been shown to be tyrosine phosphorylated and recruited to the gp130 component of the ciliary neurotrophic factor (CNTF) receptor complex upon stimulation with CNTF. CNTF does not, however, have a proliferative effect on responsive cells, but rather enhances the survival and differentiation of sympathetic, motor, and sensory neurons, In this study, expression of an interfering mutant of SHP-2 in the neuroblastoma cell line NBFL increased CNTF induction of a vasoactive intestinal peptide (VIP) reporter gene, and in cultures of sympathetic neurons, it resulted in an up-regulation of endogenous VIP and substance P (SP) gene expression. Members of the CNTF family of cytokines transmit their signal by activating signaling pathways involving both STAT and Fos-Jun transcription factors. In CNTF-stimulated NBFL cells that constitutively express the SHP-2 interfering mutant, there was increased and prolonged formation of STAT/DNA complexes, but decreased AP-1 binding activity, that mirrored a down-regulation of c-fos expression both at the mRNA and protein level. Taken together, these data indicate that SHP-2 has dual and opposing roles in a signaling cascade triggered by the same ligand, as illustrated by its ability to differentially regulate the levels of activity of both STAT and AP-1 transcription factors.	Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02129 USA; Massachusetts Gen Hosp, Program Neurosci, Boston, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Uniformed Services University of the Health Sciences - USA	Reeves, SA (corresponding author), Massachusetts Gen Hosp, Neurosurg Serv, 149 13th St, Boston, MA 02129 USA.	reeves@helix.mgh.harvard.edu	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Servidei, Tiziana/0000-0003-0529-7686	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027514] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS27514-08] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CARTER MS, 1990, J NEUROSCI, V10, P2203; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FANN MJ, 1993, J NEUROCHEM, V61, P1349, DOI 10.1111/j.1471-4159.1993.tb13628.x; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FISH TM, 1987, MOL CELL BIOL, V7, P3490; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; GELLER AI, 1988, SCIENCE, V241, P1149; GILMAN MZ, 1986, MOL CELL BIOL, V6, P1050; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hawrot E, 1979, Methods Enzymol, V58, P574; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOTZBAUER PT, 1994, NEURON, V12, P763, DOI 10.1016/0896-6273(94)90329-8; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LAWRANCE G, 1995, J NEUROCHEM, V64, P1483; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Manthorpe M, 1993, NEUROTROPHIC FACTORS, P443; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SENDTNER M, 1994, J NEUROBIOL, V25, P1436, DOI 10.1002/neu.480251110; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; WOLINSKY E, 1983, J NEUROSCI, V3, P1495; WOLINSKY EJ, 1985, J NEUROSCI, V5, P1497; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YIN TG, 1994, J BIOL CHEM, V269, P3731; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZHANG Z, 1995, SCIENCE, V267, P1990; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	72	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6233	6241		10.1074/jbc.273.11.6233	http://dx.doi.org/10.1074/jbc.273.11.6233			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497348	hybrid			2022-12-27	WOS:000072488500040
J	DiBello, PR; Garrison, TR; Apanovitch, DM; Hoffman, G; Shuey, DJ; Mason, K; Cockett, MI; Dohlman, HG				DiBello, PR; Garrison, TR; Apanovitch, DM; Hoffman, G; Shuey, DJ; Mason, K; Cockett, MI; Dohlman, HG			Selective uncoupling of RGS action by a single point mutation in the G protein alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; YEAST SACCHAROMYCES-CEREVISIAE; GTPASE-ACTIVATING PROTEINS; CRYSTAL-STRUCTURE; FAMILY; TRANSDUCIN; HYDROLYSIS; MYRISTOYLATION; LOCALIZATION; G(I-ALPHA-1)	Heterotrimeric G proteins function as molecular relays, shuttling between cell surface receptors and intracellular effecters that propagate a signal, G protein signaling is governed by the rates of GTP binding (catalyzed by the receptor) and GTP hydrolysis. RGS proteins (regulators of G protein signaling) were identified as potent negative regulators of G protein signaling pathways in simple eukaryotes and are now known to act as GTPase-activating proteins (GAPs) for G; protein alpha-subunits in vitro, It is not known, however, if G alpha GAP activity is responsible far the regulatory action of RGS proteins in vivo. We describe here a G alpha mutant in yeast (gpa1(sst)) that phenotypically mimics the loss of its cognate RGS protein (SST2), The gpa1(sst) mutant is resistant to an activated allele of SST2 in vivo and is unresponsive to RGS GAP activity in vivo. The analogous mutation in a mammalian G(q) alpha is also resistant to RGS action in transfected cells. These mutants demonstrate that RGS proteins act through G alpha and that RGS-GAP activity is responsible for their desensitizing activity in cells. The G alpha(sst) mutant will be useful for uncoupling RGS-mediated regulation from other modes of signal regulation in whole cells and animals.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Wyeth Ayerst Res, Dept Cent Nervous Syst Disorders, Princeton, NJ 08543 USA; Wyeth Ayerst Res, Dept Biol Struct, Princeton, NJ 08543 USA	Yale University; Pfizer; Pfizer	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Dohlman, Henrik/0000-0003-2443-0729	NCI NIH HHS [T 32CA 09085] Funding Source: Medline; NIGMS NIH HHS [R01 GM055316, GM 55316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055316, R29GM055316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Iyengar R, 1997, SCIENCE, V275, P42, DOI 10.1126/science.275.5296.42; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SHUEY DJ, 1998, IN PRESS J NEUROCHEM; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P21; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1997, J BIOL CHEM, V272, P8853; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	38	100	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5780	5784		10.1074/jbc.273.10.5780	http://dx.doi.org/10.1074/jbc.273.10.5780			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488712	hybrid			2022-12-27	WOS:000072345000055
J	Park, SH; Pastuszak, I; Drake, R; Elbein, AD				Park, SH; Pastuszak, I; Drake, R; Elbein, AD			Purification to apparent homogeneity and properties of pig kidney L-fucose kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								L-Fucokinase was purified to apparent homogeneity from pig kidney cytosol. The molecular mass of the enzyme on a gel filtration column was 440 kDa, whereas on SDS gels a single protein band of 110 kDa was observed. This 110-kDa protein was labeled in a concentration-dependent manner by azido-[P-32]ATP, and labeling was inhibited by cold ATP, The 110-kDa protein was subjected to endo-Lys-C digestion, and several peptides were sequenced, These showed very little similarity to other known protein sequences. The enzyme phosphorylated L-fucose using ATP to form beta-L-fucose-1-P. Of many sugars tested, the only other sugar phosphorylated by the purified enzyme was D-arabinose, at about 10% the rate of L-fucose. Many of the properties of the enzyme were determined and are described in this paper, This enzyme is part of a salvage pathway for reutilization of L-fucose and is also a valuable biochemical tool to prepare activated L-fucose derivatives for fucosylation reactions.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Elbein, AD (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17783] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEKESI JG, 1967, J BIOL CHEM, V242, P3873; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COFFEY JW, 1964, J BIOL CHEM, V239, P4011; FOSTER DW, 1961, BIOCHIM BIOPHYS ACTA, V54, P376, DOI 10.1016/0006-3002(61)90386-9; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; GINSBURG V, 1960, J BIOL CHEM, V235, P2196; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HEATH EC, 1958, J BIOL CHEM, V230, P511; ISHIHARA H, 1968, J BIOL CHEM, V243, P1103; ISHIHARA H, 1968, J BIOL CHEM, V243, P1110; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Watkins W M, 1980, Adv Hum Genet, V10, P1; WILKINSON JF, 1959, NATURE, V180, P995; YURCHENCO PD, 1975, BIOCHEMISTRY-US, V14, P3107, DOI 10.1021/bi00685a011	16	56	61	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5685	5691		10.1074/jbc.273.10.5685	http://dx.doi.org/10.1074/jbc.273.10.5685			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488699	hybrid			2022-12-27	WOS:000072345000042
J	Rethinaswamy, A; Birnbaum, MJ; Glover, CVC				Rethinaswamy, A; Birnbaum, MJ; Glover, CVC			Temperature-sensitive mutations of the CKA1 gene reveal a role for casein kinase II in maintenance of cell polarity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS SUPERFAMILY GENES; RHO-TYPE GTPASES; PROTEIN-KINASE; BUD FORMATION; BETA-SUBUNIT; REGULATORY SUBUNITS; ALPHA-SUBUNIT; BUDDING YEAST; MORPHOGENESIS; CYCLE	Casein kinase II (CKII) of Saccharomyces cerevisiae contains two distinct catalytic subunits, gamma and alpha', that are encoded by the CKA1 and -2 genes, respectively. We have constructed conditional alleles of the CKA1 gene. In contrast to cka1 cka2(ts) strains, which exhibit a defect in both G(1) and G(2)/M cell cycle progression, cha1(ts) cha2 strains continue to divide for three cell cycles after a shift to restrictive temperature and then arrest as a mixture of budded and unbudded cells with a spherical morphology, Arrested cells exhibit continued growth, a nonpolarized actin cytoskeleton, delocalized chitin deposition, and a significant fraction of multinucleate cell bodies, confirming the presence of a cell polarity defect in cha1(ts) strains, The presence of budded as well as unbudded cells in the arrested population suggests that CKII is required for maintenance rather than establishment of cell polarity, although a role in both processes is also possible. The terminal phenotype of cha1(ts) strains bears a strong resemblance to that of orb5 strains of Schizosaccharomyces pombe, which carry a temperature-sensitive CKII catalytic subunit mutation, but the underlying mechanism appears to be different in the two cases, These results establish a requirement for CKII in cell polarity in S. cerevisiae and provide the first evidence for functional specialization of CKA1 and -2.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Glover, CVC (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	glover@bscr.uga.edu			NIGMS NIH HHS [GM33237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Bender L, 1996, J CELL BIOL, V133, P879, DOI 10.1083/jcb.133.4.879; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRETSCHER A, 1994, J CELL BIOL, V126, P821, DOI 10.1083/jcb.126.4.821; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CHESTER N, 1995, J BIOL CHEM, V270, P7501, DOI 10.1074/jbc.270.13.7501; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; GLOVER CVC, 1994, CELL MOL BIOL RES, V40, P481; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Imai J, 1996, GENETICS, V142, P359; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; LIPKE PN, 1984, J BACTERIOL, V159, P797, DOI 10.1128/JB.159.2.797-799.1984; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; Matsui Y, 1996, J CELL BIOL, V133, P865, DOI 10.1083/jcb.133.4.865; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Mondesert G, 1996, J CELL BIOL, V132, P137, DOI 10.1083/jcb.132.1.137; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; REED JC, 1994, J BIOL CHEM, V269, P18192; ROSA MD, 1990, METHODS YEAST GENETI; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; Sarno S, 1996, J BIOL CHEM, V271, P10595, DOI 10.1074/jbc.271.18.10595; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4	48	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5869	5877		10.1074/jbc.273.10.5869	http://dx.doi.org/10.1074/jbc.273.10.5869			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488724	hybrid			2022-12-27	WOS:000072345000067
J	Flattery-O'Brien, JA; Dawes, IW				Flattery-O'Brien, JA; Dawes, IW			Hydrogen peroxide causes RAD9-dependent cell cycle arrest in G(2) in Saccharomyces cerevisiae whereas menadione causes G(1) arrest independent of RAD function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; OXIDATIVE STRESS; TRANSCRIPTIONAL INDUCTION; YEAST; GENE; GLUTATHIONE; CHECKPOINT; RESPONSES; YAP1; PROTEINS	This study shows differences at the level of cell cycle arrest between the response of yeast cells to hydrogen peroxide and superoxide stress. These include both cell cycle phases at which arrest occurs and the involvement of the RADS checkpoint gene. Wild-type and rads cells were treated with hydrogen peroxide or the superoxide-generating agent menadione, rad9 mutants were up to 100-fold more sensitive to hydrogen peroxide but not affected in their resistance to menadione, Hydrogen peroxide caused G(2)-phase arrest, whereas menadione treated cells arrested in G(1) . G(2) arrest, induced by methyl 2-benzimidazil carbamate, increased cellular resistance to hydrogen peroxide but not to menadione. G(1) arrest mediated by alpha-factor caused an increase in survival of wild-type cells treated with menadione but not with hydrogen peroxide. A cdc28 mutant arrested in G(1) was significantly more sensitive to hydrogen peroxide than other cde mutants arrested in later phases, including G(2). rad9 cells have normal stationary phase resistance to hydrogen peroxide, the ability to adapt to it, glutathione content and induction of genes via the stress responsive element. Although rad9-dependent G(2) arrest is important, other rad9-dependent factors may be involved in the resistance of cells to hydrogen peroxide since arrest in G(2) did not make rad9 cells fully resistant.	Univ New S Wales, Sch Biochem & Mol Genet, Cooperat Res Ctr Food Ind Innovat, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Dawes, IW (corresponding author), Univ New S Wales, Sch Biochem & Mol Genet, Cooperat Res Ctr Food Ind Innovat, Sydney, NSW 2052, Australia.							Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P829; FLATTERYOBRIEN J, 1993, J GEN MICROBIOL, V139, P501, DOI 10.1099/00221287-139-3-501; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GALIAZZO F, 1993, FEBS LETT, V315, P197, DOI 10.1016/0014-5793(93)81162-S; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOFFMANN ME, 1984, BIOCHIM BIOPHYS ACTA, V781, P234, DOI 10.1016/0167-4781(84)90088-5; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Kiser GL, 1996, MOL BIOL CELL, V7, P703, DOI 10.1091/mbc.7.5.703; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Lapshina EA, 1995, BIOCHEM MOL BIOL INT, V37, P903; Lee JW, 1996, J BIOL CHEM, V271, P24885, DOI 10.1074/jbc.271.40.24885; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MORRISON H, 1984, BIOCHEM PHARMACOL, V33, P1763, DOI 10.1016/0006-2952(84)90347-2; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Nunes E, 1996, RADIAT ENVIRON BIOPH, V35, P55, DOI 10.1007/BF01211243; Paulovich AG, 1997, GENETICS, V145, P45; POOT M, 1993, DNA FREE RADICALS, P221; REED SI, 1980, GENETICS, V95, P561; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SAKURAI A, 1984, FEBS LETT, V166, P339, DOI 10.1016/0014-5793(84)80108-8; SCHENBER.A, 1972, MOL GEN GENET, V115, P243, DOI 10.1007/BF00268888; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1993, GENETICS, V134, P63; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WOOD JS, 1982, J CELL BIOL, V94, P718, DOI 10.1083/jcb.94.3.718	42	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8564	8571		10.1074/jbc.273.15.8564	http://dx.doi.org/10.1074/jbc.273.15.8564			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535829	hybrid			2022-12-27	WOS:000072990800006
J	Bischof, LJ; Kagawa, N; Moskow, JJ; Takahashi, Y; Iwamatsu, A; Buchberg, AM; Waterman, MR				Bischof, LJ; Kagawa, N; Moskow, JJ; Takahashi, Y; Iwamatsu, A; Buchberg, AM; Waterman, MR			Members of the Meis1 and Pbx homeodomain protein families cooperatively bind a cAMP-responsive sequence (CRS1) from bovine CYP17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROTOONCOGENE PBX1; DNA-BINDING; HOX PROTEINS; TRANSCRIPTIONAL REGULATION; HOMEOBOX GENES; PRE-B; EXTRADENTICLE; MOTIF; SPECIFICITY; COMPLEX	The mammalian Pbx homeodomain proteins provide specificity and increased DNA binding affinity to other homeodomain proteins, A cAMP-responsive sequence (CRS1) from bovine CYP17 has previously been shown to be a binding site for Pbx1, A member of a second mammalian homeodomain family, Meis1, is now also demon strated to be a CRS1-binding protein upon purification using CRS1 affinity chromatography, CRS1 binding complexes from Y1 adrenal cell nuclear extract contain both Pbx1 and Meis1, This is the first transcriptional regulatory element reported as a binding site for members of the Meis1 homeodomain family. Pbx1 and Meis1 bind cooperatively to CRS1, whereas neither protein can bind this element alone. Mutagenesis of the CRS1 element indicates a binding site for Meis1 adjacent to the Pbx site, All previously identified Pbx binding partners have Pbx interacting motifs that contain a tryptophan residue amino-terminal to the homeodomain that is required for cooperative binding to DNA with Pbx. Members of the Meis1 family contain one tryptophan residue amino-terminal to the homeodomain, but site-directed mutagenesis indicates that this residue is not required for cooperative CRS1 binding with Pbx, Thus, the Pbx-Meis1 interaction is unique among Pbx complexes. Meis1 also cooperatively binds CRS1 with the Pbx homologs extradenticle from Drosophila melanogaster and ceh-20 from Caenorhabditis elegans, indicating that this interaction is evolutionarily conserved, Thus, CYP17 CRS1 is a transcriptional regulatory element containing both Pbx and Meis1 binding sites, which permit these two homeodomain proteins to bind and potentially regulate cAMP-dependent transcription through this sequence.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 221, Japan	Vanderbilt University; Jefferson University; Kirin Brewery Company Limited	Bischof, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.			Buchberg, Arthur/0000-0002-0543-5631	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28350] Funding Source: Medline; NIEHS NIH HHS [ES00267-31] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Burglin Thomas R., 1994, P25; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chen HM, 1997, GENOMICS, V41, P193, DOI 10.1006/geno.1997.4632; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; GEHRING WJ, 1992, TRENDS BIOCHEM SCI, V17, P277, DOI 10.1016/0968-0004(92)90434-B; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; LUND J, 1990, J BIOL CHEM, V265, P3304; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Ogo A, 1997, ARCH BIOCHEM BIOPHYS, V338, P193, DOI 10.1006/abbi.1996.9838; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327	49	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7941	7948		10.1074/jbc.273.14.7941	http://dx.doi.org/10.1074/jbc.273.14.7941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525891	hybrid			2022-12-27	WOS:000072876300025
J	Coscoy, S; Lingueglia, E; Lazdunski, M; Barbry, P				Coscoy, S; Lingueglia, E; Lazdunski, M; Barbry, P			The Phe-Met-Arg-Phe-amide-activated sodium channel is a tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; CAENORHABDITIS-ELEGANS; HOMOLOGOUS SUBUNITS; ION CHANNELS; NEURODEGENERATION; EXPRESSION; PROTEINS; CLONING; RESIDUES; BINDING	The Helix aspersa Phe-Met-Arg-Phe-amide (FMRF-amide)-gated sodium channel is formed by homomultimerization of several FMRFamide-activated Na+ channel (FaNaCh) proteins. FaNaCh is homologous to the subunits that compose the amiloride-sensitive epithelial sodium channel, to Caenorhabditis elegans degenerins, and to acid-sensing ionic channels, FaNaCh properties were analyzed in stably transfected human embryonic kidney cells (HEK-293), The channel was functional with an EC50 for FMRFamide of 1 mu M and an IC50 (25 degrees C) for amiloride of 6.5 mu M as assessed by Na-22(+) uptake measurements. The channel activity was associated with the presence of a protein at the cell surface with an apparent molecular mass of 82 kDa. The 82-kDa form was derived from an incompletely glycosylated form of 74 kDa found in the endoplasmic reticulum, Formation of covalent bonds between subunits of the same complex were observed either after formation of intersubunit disulfide bonds following cell homogenization and solubilization with Triton X-100 or after use of bifunctional cross-linkers. This resulted in the formation of covalent multimers that contained up to four subunits, Hydrodynamic properties of the solubilized FaNaCh complex also indicated a maximal stoichiometry of four subunits per complex. It is likely that epithelial Na+ channels, acid-sensing ionic channels, degenerins, and the other proteins belonging to the same ion channel superfamily also associate within tetrameric complexes.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Barbry, P (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	pbarbry@itsa.ucsf.edu	Barbry, Pascal/O-5021-2016; LINGUEGLIA, Eric/F-5509-2013	Barbry, Pascal/0000-0001-9632-6483; LINGUEGLIA, Eric/0000-0003-3902-3405; Coscoy, Sylvie/0000-0003-3963-3609				Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CLARKE S, 1975, J BIOL CHEM, V250, P5459; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DAVIS A, 1984, MOL CHEM CHARACTERIZ, V3, P161; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; GREEN KA, 1994, PFLUG ARCH EUR J PHY, V428, P232, DOI 10.1007/BF00724502; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	34	89	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8317	8322		10.1074/jbc.273.14.8317	http://dx.doi.org/10.1074/jbc.273.14.8317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525939	hybrid			2022-12-27	WOS:000072876300073
J	Fluiter, K; van der Westhuijzen, DR; van Berkel, TJC				Fluiter, K; van der Westhuijzen, DR; van Berkel, TJC			In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPROTEIN-A-I; SR-BI; ACID SYNTHESIS; HEPATOCYTES; PROTEINS; INVIVO; EXPRESSION; TISSUES; INVITRO; CLONING	High density lipoprotein cholesteryl esters (HDL-CE) are selectively taken up by liver parenchymal cells without parallel apolipoprotein uptake. This selective uptake route forms an important step in the so-called reverse cholesterol transport. Scavenger receptor BI (SR-BI) is the only known HDL receptor which can mediate selective uptake of HDL-CE. In the present study we investigated its regulation in liver cells. The down-regulation of SR-BI expression in liver by 17 alpha-ethinyl estradiol (EE) treatment was found by immunoblotting to be the con sequence of down-regulation of SR-BI in parenchymal cells, while SR-BI expression in Kupffer cells was up-regulated. The selective uptake of HDL-CE in vivo by parenchymal and Kupffer cells was measured by labeling of HDL with [H-3]CE and analysis of the cellular uptake at 10 min after injection. After EE treatment, uptake of [H-3]CE-labeled HDL by parenchymal cells decreased by 85%, while Kupffer cells showed a 4-fold increase in selective uptake of [H-3]CE labeled HDL was 3-4-fold lower, indicating that the in vivo observations are also reflected in vitro. A 2-week high-cholesterol diet leads to lowering of SR-BI expression in parenchymal cells, while the expression in Kupffer cells is increased. Like EE treatment, the selective uptake of [H-3]CE-labeled HDL by the two hepatic cell types in vivo correlated with the changes in expression of SR-BI. Our results thus demonstrate that within the liver, the regulation of SR-BI expression by EE treatment or a high-cholesterol diet, correlates with changes in the selective uptake of HDL-CE, supporting a function of SR-BI to mediate the selective uptake of HDL-CE in the liver parenchymal cells. The contrasting regulatory effect on parenchymal cells and Kupffer cells might indicate a different function of SR-BI in the latter cell type.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA	Leiden University; Leiden University - Excl LUMC; University of Kentucky	van Berkel, TJC (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Sylvius Labs, POB 9503, NL-2300 RA Leiden, Netherlands.		Fluiter, Kees/H-2828-2015; Van Berkel, Theo/ABD-7677-2021	Fluiter, Kees/0000-0003-0898-7260; 				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DERIJKE YB, 1994, J BIOL CHEM, V269, P824; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; HARKES L, 1983, FEBS LETT, V154, P75, DOI 10.1016/0014-5793(83)80878-3; HIDAKA H, 1992, BIOCHEM J, V284, P161, DOI 10.1042/bj2840161; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKINNON AM, 1987, J LIPID RES, V28, P847; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANBERKEL TJC, 1982, BIOCHEM J, V208, P493, DOI 10.1042/bj2080493; VELDHUIS HD, 1982, ENDOCRINOLOGY, V110, P2044, DOI 10.1210/endo-110-6-2044; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WEISGRABER KH, 1980, J LIPID RES, V21, P316; Xu SZ, 1997, J LIPID RES, V38, P1289	37	131	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8434	8438		10.1074/jbc.273.14.8434	http://dx.doi.org/10.1074/jbc.273.14.8434			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525955	hybrid, Green Published			2022-12-27	WOS:000072876300089
J	Whiteman, P; Downing, AK; Smallridge, R; Winship, PR; Handford, PA				Whiteman, P; Downing, AK; Smallridge, R; Winship, PR; Handford, PA			A Gly -> Ser change causes defective folding in vitro of calcium-binding epidermal growth factor-like domains from factor IX and fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; HEMOPHILIA-B; MARFAN-SYNDROME; POINT MUTATIONS; GENE; IDENTIFICATION; ORGANIZATION; MICROFIBRILS; DISORDERS; COMPONENT	The calcium-binding epidermal growth factor-like (cbEGF) domain is a common motif found in extracellular proteins. A mutation that changes a highly conserved Gly residue to Ser in this domain has been identified both in the factor IX (FIX) and fibrillin-1 genes, where it is associated with relatively mild variants of hemophilia B and Marfan syndrome, respectively. We have investigated the structural consequences in vitro of this amino acid change when introduced into single cbEGF domains from human FIX (G60S) and human fibrillin-1 (G1127S), and a covalently linked pair of cbEGF domains from fibrillin-1. High pressure liquid chromatography analysis, mass spectrometry, and H-1 NMR analysis demonstrate that wild-type cbEGF domains purified in the reduced form and refolded in vitro adopt the native fold, In contrast, the Gly --> Ser change causes defective folding of FIX and fibrillin-1 cbEGF domains. However, in the case of the factor IX mutant domain, a Ca2+-dependent change in conformation, identified by NMR in a proportion of the refolded material, suggests that some material refolds to a native-like structure. This is consistent with enzyme-linked immunosorbent assay analysis of FIX G60S from a hemophilia B patient Oxford d2, which demonstrates that the mutant protein is partially recognized by a monoclonal antibody specific for this region of FIX. NMR analysis of a covalently linked pair of fibrillin cbEGF domains demonstrates that the C-terminal domain adopts the native epidermal growth factor fold, despite the fact that the adjacent mutant domain is misfolded. The implications of these results for disease pathogenesis are discussed.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England	University of Oxford; University of Oxford; University of Sheffield	Whiteman, P (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Collod-Beroud G, 1997, NUCLEIC ACIDS RES, V25, P147, DOI 10.1093/nar/25.1.147; DENTON PH, 1988, BLOOD, V72, P1407; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FRANCKE U, 1995, AM J HUM GENET, V56, P1287; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, PROTEIN ENG, V4, P319, DOI 10.1093/protein/4.3.319; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; JAENICKE R, 1989, PROTEIN STRUCTURE PR, P208; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KETTERLING RP, 1991, GENOMICS, V10, P1093, DOI 10.1016/0888-7543(91)90207-U; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; YOSHIOKA A, 1985, BRIT J HAEMATOL, V59, P265, DOI 10.1111/j.1365-2141.1985.tb02993.x	27	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7807	7813		10.1074/jbc.273.14.7807	http://dx.doi.org/10.1074/jbc.273.14.7807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525872	hybrid			2022-12-27	WOS:000072876300006
J	Wood, SM; Wiesener, MS; Yeates, KM; Okada, N; Pugh, CW; Maxwell, PH; Ratcliffe, PJ				Wood, SM; Wiesener, MS; Yeates, KM; Okada, N; Pugh, CW; Maxwell, PH; Ratcliffe, PJ			Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1 alpha) - Characterization of HIF-1 alpha-dependent and -independent hypoxia-inducible GENE expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN 3' ENHANCER; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAINS; HEME OXYGENASE; PROTEIN; RECEPTOR; INTERFERON; DEFICIENT; IDENTIFICATION; STABILIZATION	Hypoxia-inducible expression has been demonstrated for many groups of mammalian genes, and studies of transcriptional control have revealed the existence of hypoxia-responsive elements (HREs) in the cis-acting sequences of several of these genes, These sequences generally contain one or more binding sites for a heterodimeric DNA binding complex termed hypoxia-inducible factor-1 (HIF-1), To analyze this response further, Chinese hamster ovary cells were stably transfected with plasmids bearing HREs linked 60 genes encoding imnmunoselectable cell surface markers, and clones that showed reduced or absent hypoxia-inducible marker expression were selected from a mutagenized culture of cells. Analysis of these cells revealed several closes with transacting defects in HRE activation, and in one the defect was identified as a failure to express the ru-subunit of HIF-1, Comparison of hypoxia-inducible gene expression in wild type, HIF-1 alpha-defective, and HIF-1 alpha-complemented cells revealed tyro types of response, For some genes (e.g. glucose transporter-1), hypoxia-inducible expression was critically dependent on HIF-1 alpha, whereas for other genes (e.g. heme oxygenase-1) hypoxia-inducible expression appeared largely independent of the expression of HIF-1 alpha. These experiments show the utility of mutagenesis and selection of mutant cells in the analysis of mammalian transcriptional responses to hypoxia and demonstrate the operation of HIF-1 alpha-dependent and HIF-1 alpha-independent pathways of hypoxia-inducible gene expression in Chinese hamster ovary cells.	John Radcliffe Hosp, Inst Mol Med, Erythropoietin Grp, Oxford OX3 9DS, England	University of Oxford	Ratcliffe, PJ (corresponding author), John Radcliffe Hosp, Inst Mol Med, Erythropoietin Grp, Room 420, Oxford OX3 9DS, England.		Maxwell, Patrick H/C-5557-2008	Maxwell, Patrick H/0000-0002-0338-2679; Pugh, Chris/0000-0002-5170-1662; Ratcliffe, Peter/0000-0002-2853-806X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM NG, 1991, J CELL BIOCHEM, V47, P43, DOI 10.1002/jcb.240470106; BULLA GA, 1992, SOMAT CELL MOLEC GEN, V18, P361, DOI 10.1007/BF01235759; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; DAVIES RL, 1982, CELL, V31, P521, DOI 10.1016/0092-8674(82)90308-7; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; FERGUSON LR, 1990, MUTAGENESIS, V5, P529, DOI 10.1093/mutage/5.6.529; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FUSCOE JC, 1979, CANCER RES, V39, P4875; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; ONEILL JP, 1979, BANBURY REPORT, V2, P55; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Pugh CW, 1997, J BIOL CHEM, V272, P11205; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	39	163	168	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8360	8368		10.1074/jbc.273.14.8360	http://dx.doi.org/10.1074/jbc.273.14.8360			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525945	hybrid			2022-12-27	WOS:000072876300079
J	Gomez, C; Perez, DG; Lopez-Bayghen, E; Orozco, E				Gomez, C; Perez, DG; Lopez-Bayghen, E; Orozco, E			Transcriptional analysis of the EhPgp1 promoter of Entamoeba histolytica multidrug-resistant mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORAMPHENICOL ACETYLTRANSFERASE GENE; P-GLYCOPROTEIN HOMOLOGS; DICTYOSTELIUM-DISCOIDEUM; TRANSIENT EXPRESSION; MESSENGER-RNAS; BINDING FACTOR; HMG BOX; SEQUENCE; EMETINE; CELLS	We present here the cloning and characterization of the EhPgp1 multidrug resistance gene promoter isolated from the Entamoeba histolytica drug resistant mutant clone C2. The EhPgp1 promoter lacks the typical TATA box and the transcriptional initiation sequences described for other E. histolytica promoters. The major transcription initiation site of the EhPgp1 gene was located at the ATG start codon. The EhPgp1 core promoter located within the first 244 base pairs showed a higher chloramphenicol acetyltransferase expression in the transfected trophozoites of clone C2 than in those of the sensitive clone A. Gel shift assays revealed three specific DNA-protein complexes (Ia, IIa, and IIIc) using nuclear extracts from clone C2, whereas three main complexes (If, IIf, and IIg) were limited to clone A, Competition assays suggested the presence of C/EBP-like and OCT-like proteins in complexes Ia and IIa, respectively, probably involved in the expression of the EhPgp1 gene, whereas complex IIIc was competed by GATA-1, C/EBP, OCT, and HOX oligonucleotides. Thus, differential DNA-protein complexes may be formed by transcriptional factors involved in the regulation of the EhPgp1 gene expression.	Inst Politecn Nacl, CINVESTAV, Ctr Invest & Estudios Avanzados, Dept Patol Expt, Mexico City 07300, DF, Mexico; Inst Politecn Nacl, CINVESTAV, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Mexico City 07300, DF, Mexico; Ctr Invest Ciencia Aplicada & Tecnol Avanzada, Mexico City, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Orozco, E (corresponding author), Inst Politecn Nacl, CINVESTAV, Ctr Invest & Estudios Avanzados, Dept Patol Expt, AP 14-740, Mexico City 07300, DF, Mexico.	eorazco@gwpat.pat.cinvestav.mx	Lopez-Bayghen, Esther/A-8006-2008	Lopez-Bayghen, Esther/0000-0002-2849-7587				AYALA P, 1990, EXP PARASITOL, V71, P169, DOI 10.1016/0014-4894(90)90019-9; Biagi F, 1981, Antibiot Chemother (1971), V30, P20; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; BURCHARD GD, 1988, EXP PARASITOL, V66, P231, DOI 10.1016/0014-4894(88)90095-1; BUSS H, 1995, MOL BIOCHEM PARASIT, V72, P1, DOI 10.1016/0166-6851(95)00060-E; CEDENO JR, 1983, J INFECT DIS, V148, P1090, DOI 10.1093/infdis/148.6.1090; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COWMAN AF, 1991, PARASITOL TODAY, V7, P70, DOI 10.1016/0169-4758(91)90197-V; DESCOTEAUX S, 1995, GENE, V164, P179, DOI 10.1016/0378-1119(95)00533-C; DESCOTEAUX S, 1992, MOL BIOCHEM PARASIT, V54, P200; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DONAHUE TF, 1983, CELL, V32, P89, DOI 10.1016/0092-8674(83)90499-3; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENTNER N, 1962, J PROTOZOOL, V9, P466, DOI 10.1111/j.1550-7408.1962.tb02655.x; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FOSNAUGH KL, 1993, DEV BIOL, V157, P38, DOI 10.1006/dbio.1993.1110; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Ghosh SK, 1996, MOL BIOCHEM PARASIT, V82, P257, DOI 10.1016/0166-6851(96)02733-8; Gilchrist CA, 1995, MOL BIOCHEM PARASIT, V74, P1, DOI 10.1016/0166-6851(95)02474-3; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; Higgins CF, 1993, CURR OPIN CELL BIOL, V5, P684, DOI 10.1016/0955-0674(93)90140-L; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAVELLE D, 1991, P NATL ACAD SCI USA, V88, P7318, DOI 10.1073/pnas.88.16.7318; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; Maniatis T., 1982, MOL CLONING; MCPHERSON CE, 1993, J MOL BIOL, V232, P386, DOI 10.1006/jmbi.1993.1398; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKEL R, 1994, P NATL ACAD SCI USA, V91, P7095, DOI 10.1073/pnas.91.15.7095; NORRIS SM, 1990, AMEBIASIS HUMAN INFE, P734; OROZCO E, 1985, MOL BIOCHEM PARASIT, V15, P49, DOI 10.1016/0166-6851(85)90028-3; OROZCO E, 1995, PARASITOL TODAY, V11, P473, DOI 10.1016/0169-4758(95)80067-0; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; Perez DG, 1998, J BIOL CHEM, V273, P7285, DOI 10.1074/jbc.273.13.7285; POOLE SJ, 1984, J MOL BIOL, V172, P203, DOI 10.1016/S0022-2836(84)80038-8; Purdy JE, 1996, MOL BIOCHEM PARASIT, V78, P91, DOI 10.1016/S0166-6851(96)02614-X; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SAMUELSON J, 1990, MOL BIOCHEM PARASIT, V38, P281, DOI 10.1016/0166-6851(90)90031-G; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SMIT JJM, 1995, BBA-GENE STRUCT EXPR, V1261, P44, DOI 10.1016/0167-4781(94)00214-N; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; *WHO, 1985, B WORLD HEALTH ORGAN, V63, P417; YU LJ, 1995, CELL GROWTH DIFFER, V6, P1505	58	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7277	7284		10.1074/jbc.273.13.7277	http://dx.doi.org/10.1074/jbc.273.13.7277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516421	hybrid			2022-12-27	WOS:000072738500017
J	Kew, Y; Olsen, LR; Japour, AJ; Prasad, VR				Kew, Y; Olsen, LR; Japour, AJ; Prasad, VR			Insertions into the beta 3-beta 4 hairpin loop of HIV-1 reverse transcriptase reveal a role for fingers subdomain in processive polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; DNA-SYNTHESIS; H ACTIVITIES; RETROVIRUS; MECHANISMS; PROTEIN; SUBSTITUTIONS; PURIFICATION	Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) displays a characteristic poor processivity during DNA polymerization. Structural elements of RT that determine processivity are poorly understood. The three-dimensional structure of HTV-1 RT, which assumes a hand-like structure, shows that the fingers, palm, and thumb subdomains form the template-binding cleft and may be involved in determining the degree of processivity. To assess the influence of fingers subdomain of HIV-1 RT in polymerase processivity, two insertions were engineered in the beta 3-beta 4 hairpin of HIV-1(NL4-3) RT. The recombinant mutant RTs, named FE20 and FE103, displayed wild type or near wild type levels of RNA-dependent DNA polymerase activity on all templates tested and wild type or near wild type-like sensitivities to dideoxy-NTPs. When polymerase activities were measured under conditions that allow a single cycle of DNA polymerization, both of the mutants displayed 25-30% greater processivity than wild type enzyme. Homology modeling the three-dimensional structures of wild type HIV-1(NL4-3), RT and its finger insertion mutants revealed that the extended loop between the beta 3 and beta 4 strands protrudes into the cleft, reducing the distance between the fingers and thumb subdomains to similar to 12 Angstrom. Analysis of the models for the mutants suggests an extensive interaction between the protein and template-primer, which may reduce the degree of superstructure in the template-primer, Our data suggest that the beta 3-beta 4 hairpin of fingers subdomain is an important determinant of processive polymerization by HIV-1 RT.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Beth Israel Hosp, Boston, MA 02215 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center	Prasad, VR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	prasad@aecom.yu.edu	Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030861, R21AI030861, R01AI030861] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30861] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; Bui M, 1996, J VIROL, V70, P8391, DOI 10.1128/JVI.70.12.8391-8401.1996; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEW Y, 1994, J BIOL CHEM, V269, P15331; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LEGRICE SFJ, 1993, REVERSE TRANSCRIPTAS, P163; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; STEITZ TA, 1993, COLD SPRING HARB SYM, V58, P495, DOI 10.1101/SQB.1993.058.01.056; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; Yang GZ, 1996, J ACQ IMMUN DEF SYND, V11, P326, DOI 10.1097/00042560-199604010-00002	41	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7529	7537		10.1074/jbc.273.13.7529	http://dx.doi.org/10.1074/jbc.273.13.7529			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516454	hybrid			2022-12-27	WOS:000072738500050
J	Yamane, Y; Tohno-oka, R; Yamada, S; Furuya, S; Shiokawa, K; Hirabayashi, Y; Sugino, H; Sugahara, K				Yamane, Y; Tohno-oka, R; Yamada, S; Furuya, S; Shiokawa, K; Hirabayashi, Y; Sugino, H; Sugahara, K			Molecular characterization of Xenopus embryo heparan sulfate - Differential structural requirements for the specific binding to basic fibroblast growth factor and follistatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVIN-BINDING; MESODERM INDUCTION; MAST-CELLS; PROTEOGLYCANS; EXPRESSION; PROTEIN; LAEVIS; AFFINITY; GENE; OLIGOSACCHARIDES	Enzymatic elimination of heparan sulfate (HS) causes abnormal mesodermal and neural formation in Xenopus embryos, and HS plays an indispensable role in establishing the embryogenesis and tissue morphogenesis during early Xenopus development (Furuya, S., Sera, M., Tohno-oka, R., Sugahara, K., Shiokawa, K. and Hirabayashi, Y. (1995) Dev. Growth Differ. 37, 337-346). In this study, HS was purified from Xenopus embryos to investigate its disaccharide composition and binding ability to basic fibroblast growth factor (bFGF) and follistatin (FS), the latter being provided in two isoforms with core sequences of 315 and 288 amino acids (designated FS-315 and FS-288) originating from alternative mRNA splicing. Disaccharide composition analysis of the purified Xenopus HS showed the preponderance of a disulfated disaccharide unit with uronic acid 2-O-sulfate and glucosamine S-N-sulfate, which has been implicated in the interactions with bFGF. Specific binding of the HS to bFGF and FS-288, the COOH-terminal truncated form, was observed in the filter binding assay, whereas HS did not bind to FS-315, indicating that the acidic Glu-rich domain of FS-315 precluded the binding. The binding of the HS to bFGF or FS-288 was markedly inhibited by heparin (HP) and various HS preparations, but not by chondroitin sulfate, supporting the binding specificity of HS. The binding specificity was further investigated using FS-288 and bovine intestinal [H-3]HS. Competitive inhibition assays of the HS binding to FS-288 using size-defined HP oligosaccharides revealed that the minimum size required for significant inhibition was a dodecasaccharide, which is larger than the pentasaccharide required for bFGF binding. The binding affinity of FS to HS increased in the presence of activin, a growth/differentiation factor, which could be inactivated by direct binding to FS. These results, taken together, indicate that the structural requirement for binding of HS to bFGF and FS is different. HS may undergo dynamic changes in its structure during early Xenopus embryogenesis in response to the temporal and spatial expression of various growth/differentiation factors.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan; RIKEN, Inst Phys & Chem Res, Frontier Res Program, Lab Cellular Glycobiol, Wako, Saitama 35101, Japan; Univ Tokyo, Fac Sci, Inst Zool, Mol Embryol Lab, Tokyo 113, Japan; Univ Tokushima, Inst Enzyme Res, Tokushima 770, Japan	Kobe Pharmaceutical University; RIKEN; University of Tokyo; Tokushima University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan.	k-sugar@kobepharma-u.ac.jp		Furuya, Shigeki/0000-0001-9020-3597				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRICKMAN MC, 1994, DEV BIOL, V164, P484, DOI 10.1006/dbio.1994.1218; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; EKKER SC, 1995, DEVELOPMENT, V121, P2337; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FINDLAY JK, 1993, BIOL REPROD, V48, P15, DOI 10.1095/biolreprod48.1.15; FURUYA S, 1995, DEV GROWTH DIFFER, V37, P337; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; ITOH K, 1994, DEVELOPMENT, V120, P2703; IWANE M, 1987, BIOCHEM BIOPH RES CO, V146, P470, DOI 10.1016/0006-291X(87)90553-5; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KIM JJ, 1982, J BIOL CHEM, V257, P1670; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; KINOSHITA A, 1997, 19 JAP CARB S AUG 5, P106; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOGA C, 1995, ROUX ARCH DEV BIOL, V204, P172, DOI 10.1007/BF00241269; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MCGREW LL, 1992, DEVELOPMENT, V115, P463; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; NAKAMURA H, 1995, MECH DEVELOP, V49, P123, DOI 10.1016/0925-4773(94)00309-B; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SEKIGUCHI K, 1995, J BIOCHEM-TOKYO, V118, P94, DOI 10.1093/oxfordjournals.jbchem.a124898; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SONG JW, 1994, MECH DEVELOP, V48, P141, DOI 10.1016/0925-4773(94)90055-8; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGINO K, 1993, J BIOL CHEM, V268, P15579; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; UEOKA C, 1997, 4 BIA S JAP NOV 6 7, P62; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WOODRUFF TK, 1995, ANNU REV PHYSIOL, V57, P219; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	57	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7375	7381		10.1074/jbc.273.13.7375	http://dx.doi.org/10.1074/jbc.273.13.7375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516434	hybrid			2022-12-27	WOS:000072738500030
J	Itzhaki, H; Naveh, L; Lindahl, M; Cook, M; Adam, Z				Itzhaki, H; Naveh, L; Lindahl, M; Cook, M; Adam, Z			Identification and characterization of DegP, a serine protease associated with the luminal side of the thylakoid membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL PROCESSING PROTEASE; OXYGEN-EVOLVING COMPLEX; ESCHERICHIA-COLI SURVIVAL; D1 PRECURSOR PROTEIN; II REACTION-CENTER; PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; SCENEDESMUS-OBLIQUUS; PARTIAL-PURIFICATION; MOLECULAR-CLONING	The proteases involved in proteolytic degradation in the thylakoid lumen are largely unknown. Western analysis with an antibody against the Escherichia coli periplasmic serine protease DegP suggested that pea chloroplasts contain a homologue of this protease. This homologue was peripherally bound to the luminal side of the thylakoid membrane and could only be removed by a combination of high salt and non-ionic detergent. Its level increased almost a-fold in pea seedlings exposed to elevated temperature for 4 h, suggesting this protease's role in the chloroplast's heat response. Isolated thylakoid membranes containing the chloroplastic homologue of DegP degraded beta-casein, an in vitro substrate of the bacterial protease. This activity was partially inhibited by a serine protease inhibitor, suggesting that at least part of the casein-degrading activity in the thylakoid membrane is attributable to DegP. The existence of chloroplastic DegP was further supported by isolating a full-length Arabidopsis cDNA (designated AtDegP) encoding a protein that is 37% identical and 60% similar to the E. coli protease. The amino terminus of the deduced amino acid sequence contained a bipartite transit peptide, typical of proteins targeted to the thylakoid lumen, and the mature portion of the protein contained the highly conserved serine protease catalytic triad His-Asp-Ser. The possible physiological roles of chloroplastic DegP protease are discussed.	Hebrew Univ Jerusalem, Fac Agr, Dept Agr Bot, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem	Adam, Z (corresponding author), Hebrew Univ Jerusalem, Fac Agr, Dept Agr Bot, IL-76100 Rehovot, Israel.	zach@agri.huji.ac.il	Lindahl, Marika/H-2259-2017	Lindahl, Marika/0000-0003-1627-0809				ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; Adam Z, 1996, PLANT MOL BIOL, V32, P773, DOI 10.1007/BF00020476; Andersson B, 1997, PHYSIOL PLANTARUM, V100, P780, DOI 10.1034/j.1399-3054.1997.1000405.x; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; DINER BA, 1988, J BIOL CHEM, V263, P8972; FUJITA S, 1995, PLANT CELL PHYSIOL, V36, P1169; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; Hershkovits G, 1997, MOL GEN GENET, V254, P345, DOI 10.1007/s004380050425; Inagaki N, 1996, PLANT MOL BIOL, V30, P39, DOI 10.1007/BF00017801; INAGAKI N, 1989, FEBS LETT, V246, P218, DOI 10.1016/0014-5793(89)80286-8; JAMES HE, 1989, J BIOL CHEM, V264, P19573; Jentsch S, 1996, SCIENCE, V271, P955, DOI 10.1126/science.271.5251.955; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; Ostersetzer O, 1997, PLANT CELL, V9, P957, DOI 10.1105/tpc.9.6.957; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Roffey RA, 1996, PLANT PHYSIOL, V111, P1329, DOI 10.1104/pp.111.4.1329; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SkorkoGlonek J, 1997, J BIOL CHEM, V272, P8974; SKORKOGLONEK J, 1995, GENE, V163, P47, DOI 10.1016/0378-1119(95)00406-V; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140	29	108	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7094	7098		10.1074/jbc.273.12.7094	http://dx.doi.org/10.1074/jbc.273.12.7094			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507020	hybrid			2022-12-27	WOS:000072775900070
J	Ouwendijk, J; Peters, WJM; van de Vorstenbosch, RA; Ginsel, LA; Naim, HY; Fransen, JAM				Ouwendijk, J; Peters, WJM; van de Vorstenbosch, RA; Ginsel, LA; Naim, HY; Fransen, JAM			Routing and processing of lactase-phlorizin hydrolase in transfected Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PHLORHIZIN HYDROLASE; SUCRASE-ISOMALTASE; PRO-REGION; EXPRESSION; MEMBRANE; TRANSPORT; BIOSYNTHESIS; IDENTIFICATION; PROTEIN	Human lactase-phlorizin hydrolase (LPH) is a digestive enzyme that is expressed in the small intestinal brush-border membrane, After terminal glycosylation in the Golgi apparatus, the 230-kDa pro-LPH is cleaved into the 160-kDa brush-border LPH beta and the 100-kDa profragment (LPH alpha). Since LPH beta is not transport-competent when it is expressed separately from LPH alpha in COS-1 cells, it was suggested that LPH alpha functions as an intramolecular chaperone, What happens to LPH alpha after cleavage is still unclear, To analyze and localize LPH alpha in polarized epithelial cells, wild type and tagged LPH were stably expressed in Caco-2 cells, In tagged LPH, a vesicular stomatitis virus epitope tag was inserted into the LPH alpha region, Wild type and tagged proteins were processed at similar rates, and both cleaved LPH beta forms were expressed at the apical cell surface, Pro-LPH was recognized by antibodies against LPH, a profragment epitope and the vesicular stomatitis virus tag, LPH alpha alone, however, could not be recovered by these antibodies, Our data suggest that LPH alpha is degraded immediately after cleavage.	Univ Nijmegen, Dept Cell Biol & Histol, NL-6500 HB Nijmegen, Netherlands; Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	Radboud University Nijmegen; University of Veterinary Medicine Hannover, Foundation	Ouwendijk, J (corresponding author), Univ Nijmegen, Dept Cell Biol & Histol, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Fransen, Jack/E-8924-2010; Peters, W.H.M./L-4572-2015	Fransen, Jack/0000-0002-0571-7639; 				CHANTRET I, 1994, J CELL SCI, V107, P213; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; FRANSEN JAM, 1985, EUR J CELL BIOL, V38, P6; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRUNBERG J, 1992, FEBS LETT, V314, P224, DOI 10.1016/0014-5793(92)81476-3; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; JACOB R, 1994, J BIOL CHEM, V269, P2712; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; NAIM HY, 1995, BIOL CHEM H-S, V376, P255; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1994, J BIOL CHEM, V269, P26933; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; Thorens B, 1995, DIABETES METAB, V21, P311; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Vachon PH, 1996, J CELL PHYSIOL, V166, P198, DOI 10.1002/(SICI)1097-4652(199601)166:1<198::AID-JCP21>3.0.CO;2-A; WACKER H, 1992, J BIOL CHEM, V267, P18744; Wuthrich M, 1996, ARCH BIOCHEM BIOPHYS, V336, P27, DOI 10.1006/abbi.1996.0528	26	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6650	6655		10.1074/jbc.273.12.6650	http://dx.doi.org/10.1074/jbc.273.12.6650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506961	hybrid, Green Published			2022-12-27	WOS:000072775900011
J	Sommer, A; Bousset, K; Kremmer, E; Austen, M; Luscher, B				Sommer, A; Bousset, K; Kremmer, E; Austen, M; Luscher, B			Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROTEIN; CASEIN KINASE-II; LOOP-HELIX PROTEIN; IN-VIVO; E-BOX; CELL-DIFFERENTIATION; EPIDERMAL DIFFERENTIATION; DEPENDENT TRANSFORMATION; ACTIVATES TRANSCRIPTION; PHOSPHORYLATION SITES	In the past, eukaryotic cell derived complexes of the Myc/Max/Mad network of transcriptional regulators have largely been refractory to DNA binding studies. We have developed electrophoretic mobility shift assay conditions to measure specific DNA binding of Myc/max/Mad network complexes using a COS7 cell-based overexpression system. With the established protocol, we have measured on-and off-rates of c-Myc/Max, Max/Max, and Mad1/Max complexes and determined relative affinities. All three complexes appeared to bind with comparable affinity to a Myc E-box sequence. Furthermore, our data derived from competition experiments suggested that the Mad3/Max and Mad4/Max complexes also possess comparable DNA binding affinities. The conditions established for COS7 cell-overexpressed proteins were then used to identify c-Myc/Max, Max/Max, and Mnt/Max complexes in HL-60 cells. However, no Mad1/Max could be detected, despite the induction of Mad1 expression during differentiation. Whereas the DNA binding activity of c-Myc/Max complexes was down-regulated, Max/Max binding increased, and Mnt/Max binding remained unchanged. In addition, we have also tested for upstream stimulatory factor (USF) binding and observed that, in agreement with published data, USF comprises a major Myc E-box-binding factor that is more abundant than any of the Myc/Max/Mad network complexes. Similar to the Mnt/Max complex, the binding activity of USF remained constant during HL-60 differentiation. Our findings establish conditions for the analysis of DNA binding of Myc/Max/Mad complexes and indicate posttranslational regulation of the Max/Max complex.	Med Hsch Hannover, Inst Mol Biol, D-30623 Hannover, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Immunol, D-81377 Munich, Germany	Hannover Medical School; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Luscher, B (corresponding author), Med Hsch Hannover, Inst Mol Biol, Carl Neuberg Str 1, D-30623 Hannover, Germany.		Sommer, Anette/T-7674-2019; Luscher, Bernhard/A-7330-2011	Sommer, Anette/0000-0002-1576-3110; Luscher, Bernhard/0000-0002-9622-8709				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEGLEY CG, 1987, INT J CANCER, V39, P99, DOI 10.1002/ijc.2910390118; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; BOUSSET K, UNPUB; BROWNLIE P, 1997, CURR BIOL, V5, P509; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CEGLAREK JA, 1989, ELECTROPHORESIS, V10, P360, DOI 10.1002/elps.1150100514; CERNI C, 1995, ONCOGENE, V11, P587; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; COLLINS SJ, 1987, BLOOD, V70, P1233; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; LARSSON LG, 1994, ONCOGENE, V9, P1247; Larsson LG, 1997, CURR TOP MICROBIOL, V224, P191; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTSCHER B, 1997, TRANSCRIPTION FACTOR, P235; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nozaki N, 1997, J BIOCHEM-TOKYO, V121, P550; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; Peters MA, 1997, MOL CELL BIOL, V17, P1037, DOI 10.1128/MCB.17.3.1037; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A., UNPUB; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Walhout AJM, 1997, NUCLEIC ACIDS RES, V25, P1493, DOI 10.1093/nar/25.8.1493; WATERS CM, 1991, ONCOGENE, V6, P797; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	94	103	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6632	6642		10.1074/jbc.273.12.6632	http://dx.doi.org/10.1074/jbc.273.12.6632			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506959	hybrid			2022-12-27	WOS:000072775900009
J	Huh, CG; Aldrich, J; Mottahedeh, J; Kwon, HC; Johnson, C; Marsh, R				Huh, CG; Aldrich, J; Mottahedeh, J; Kwon, HC; Johnson, C; Marsh, R			Cloning and characterization of Physarum polycephalum tectonins - Homologues of limulus lectin L-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX; PROTEINS; RICIN	Previous investigators have reported the presence of two dominant proteins, tectonin I (25 kDa) and tectonin II (39 kDa), in nuclei and nuclear matrix from plasmodia of Physarum polycephalum. We demonstrate, by a modification of the nuclear isolation protocol and by protease sensitivity, that the tectonins are not nuclear proteins but rather are located on the exterior surface of the plasma membrane. We report the sequences of cDNAs of tectonins I and II, which encode 217 and 353 amino acids, respectively. Tectonin I is homologous to the C-terminal two-thirds of tectonin II. Both proteins contain six tandem repeats that are each 33-37 amino acids in length and define a new consensus sequence. Homologous repeats are found in L-6, a bacterial lipopolysaccharide-binding lectin from horseshoe crab hemocytes. The repetitive sequences of the tectonins and L-6 are reminiscent of the WD repeats of the beta-subunit of G proteins, suggesting that they form beta-propeller domains. Tectonin II has an additional N-terminal domain that includes a 47-residue sequence highly similar to the galactoside-binding sequence of the B-chain of ricin. The tectonins may be lectins that function as part of a transmembrane signaling complex during phagocytosis.	Univ Texas, Cell & Mol Biol Program, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Marsh, R (corresponding author), Univ Texas, Cell & Mol Biol Program, Richardson, TX 75083 USA.	rmarsh@utdallas.edu						Adler A J, 1973, Methods Enzymol, V27, P675; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMERO SA, 1988, J BIOL CHEM, V263, P10734; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Daniel J. W., 1964, METHOD CELL PHYSIOL, P9; DEE J, 1960, NATURE, V185, P780, DOI 10.1038/185780a0; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DENOVANWRIGHT EM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P25, DOI 10.1016/0167-4781(91)90148-F; EBERHARTER A, 1993, EUR J BIOCHEM, V212, P573, DOI 10.1111/j.1432-1033.1993.tb17695.x; FARR DR, 1972, CARBOHYD RES, V24, P207, DOI 10.1016/S0008-6215(00)82282-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Hacker U, 1997, J CELL SCI, V110, P105; KOWALSKALOTH B, 1986, MOL BIOL REP, V11, P219, DOI 10.1007/BF00419600; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KYSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203; LEHAR SM, 1994, PROTEIN ENG, V7, P1261, DOI 10.1093/protein/7.10.1261; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MITCHELSON KR, 1979, J CELL SCI, V39, P247; MOHBERG J, 1971, EXP CELL RES, V66, P305, DOI 10.1016/0014-4827(71)90682-3; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEGGION E, 1971, MACROMOLECULES, V4, P725, DOI 10.1021/ma60024a011; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8	27	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6565	6574		10.1074/jbc.273.11.6565	http://dx.doi.org/10.1074/jbc.273.11.6565			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497393	hybrid			2022-12-27	WOS:000072488500085
J	Nguyen, TD; Chen, P; Huang, WD; Chen, H; Johnson, D; Polansky, JR				Nguyen, TD; Chen, P; Huang, WD; Chen, H; Johnson, D; Polansky, JR			Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN-ANGLE GLAUCOMA; MOLECULAR-CLONING; MESSENGER-RNAS; SEQUENCE; PROMOTER; IDENTIFICATION; PROTEINS; LINKAGE; SIGNAL	Expression of the trabecular meshwork inducible glucocorticoid response (TIGR) gene progressively increases from barely detectable levels to greater than 2% of total cellular mRNA over 10 days exposure of trabecular meshwork (TM) cells to dexamethasone. Cycloheximide blocked most of the TIGR mRNA induction, suggesting a requirement for ongoing protein synthesis. The genomic structure of TIGR (similar to 20 kilobases) consists of 3 exons, and a 5-kilobase promoter region that contains 13 predicted hormone response elements, including several glucocorticoid regulatory elements, and other potentially important regulatory motifs. TIGR cDNA encodes an olfactomedin-related glycoprotein of 504 amino acids with motifs for N- and O-linked glycosylation, glycosaminoglycan initiation, hyaluronic acid binding, and leucine zippers. Recombinant TIGR (rTIGR) showed oligomerization and specific binding to TM cells. Anti-rTIGR antibody detected multiple translational/post-translational forms of TIGR produced by the cells (including secreted 66 kDa/55 kDa glycoproteins/proteins in the media and 55 kDa cellular proteins), whereas Northern blot showed a single mRNA species. The findings suggest potential mechanisms by which TIGR could obstruct the aqueous humor fluid flow and participate in the pathogenesis of glaucoma.	Univ Calif San Francisco, Sch Med, Dept Ophthalmol, Cellular Pharmacol Labs, San Francisco, CA 94143 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	University of California System; University of California San Francisco; Mayo Clinic	Nguyen, TD (corresponding author), Univ Calif San Francisco, Sch Med, Dept Ophthalmol, Cellular Pharmacol Labs, San Francisco, CA 94143 USA.	thai@cgl.ucsf.edu			NATIONAL EYE INSTITUTE [R01EY002477, R01EY008905] Funding Source: NIH RePORTER; NEI NIH HHS [EY08905, EY02477, EY07065] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; ACOTT TS, 1992, PHARM GLAUCOMA, P125; ARMALY MF, 1963, ARCH OPHTHALMOL-CHIC, V70, P492, DOI 10.1001/archopht.1963.00960050494011; BAUSE E, 1979, EUR J BIOCHEM, V101, P531, DOI 10.1111/j.1432-1033.1979.tb19748.x; BAXTER JD, 1979, GLUCOCORTICOID HORMO, P1; BECKER B, 1964, AM J OPHTHALMOL, V57, P543, DOI 10.1016/0002-9394(64)92500-0; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; BOORSTEIN WR, 1997, METHOD ENZYMOL, V180, P347; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BREZIN AP, 1997, INVEST OPHTHALMOL VI, V38; Bulens F, 1997, J BIOL CHEM, V272, P663; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CUMMINGS MP, 1994, MOL BIOL EVOL, V11, P1; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DONEHOWER LA, 1989, NUCLEIC ACIDS RES, V17, P699, DOI 10.1093/nar/17.2.699; Fauss D, 1993, BASIC ASPECTS GLAUCO, VIII, P319; GATTI RA, 1984, BIOTECHNIQUES    MAY, P148; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KARAVANICH C, 1997, IN PRESS MOL BIOL EV; KARIN M, 1982, NUCLEIC ACIDS RES, V10, P3165, DOI 10.1093/nar/10.10.3165; KOLKER AE, 1983, BECKERSCHAFFERS DIAG, P21; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; Lerner LE, 1997, INVEST OPHTH VIS SCI, V38, P1222; MEYER A, 1994, CR ACAD SCI III-VIE, V317, P565; Michels-Rautenstrauss KG, 1998, HUM GENET, V102, P103, DOI 10.1007/s004390050661; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NGUYEN TD, 1993, BASIC ASPECTS GLAUCO, V3, P331; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; OTOOLE P, 1992, P NATL ACAD SCI USA, V89, P8661, DOI 10.1073/pnas.89.18.8661; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; POLANSKY JR, 1979, INVEST OPHTH VIS SCI, V18, P1043; Polansky JR, 1991, GLAUCOMA UPDATE 4, P20; RAYMOND V, 1997, INVEST OPHTHALMOL VI, V38; RICHARDS JE, 1994, AM J HUM GENET, V54, P62; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47; SNYDER DA, 1991, BIOCHEMISTRY-US, V30, P9143, DOI 10.1021/bi00102a004; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; *WASHU MERCK EST, 1995, H10467 WASHU MERCK E; WENGER RH, 1993, J BIOL CHEM, V268, P23345; YAGANISHITA M, 1992, J BIOL CHEM, V267, P9451; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655	52	317	340	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6341	6350		10.1074/jbc.273.11.6341	http://dx.doi.org/10.1074/jbc.273.11.6341			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497363	hybrid			2022-12-27	WOS:000072488500055
J	Prangishvili, D; Klenk, HP; Jakobs, G; Schmiechen, A; Hanselmann, C; Holz, I; Zillig, W				Prangishvili, D; Klenk, HP; Jakobs, G; Schmiechen, A; Hanselmann, C; Holz, I; Zillig, W			Biochemical and phylogenetic characterization of the dUTPase from the archaeal virus SIRV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; DEOXYURIDINE TRIPHOSPHATASE; PROTEIN P-30; GENE; IDENTIFICATION; PURIFICATION; GAG; DNA	The derived amino acid sequence from a 474-base pair open reading frame in the genome of the Sulfolobus islandicus rod-shaped virus SIRV shows striking similarity to bacterial dCTP deaminases and to dUTPases from eukaryotes, bacteria, Poxviridae, and Retroviridae, The putative gene was expressed in Escherichia coli, and dUTPase activity of the recombinant enzyme was demonstrated by hydrolysis of dUTP to dUMP. Deamination of dCTP by the enzyme was not detected, Phylogenetic analysis based on amino acid sequences of the characterized enzyme and its homologues showed that the dUTPase-encoding dut genes and the dCTP deaminase encoding dcd genes constitute a paralogous gene family, This report is the first identification and functional characterization of an archaeal dUTPase and the first phylogeny derived for the dcd-dut gene family.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Prangishvili, D (corresponding author), Max Planck Inst Biochem, Am Klopferspitz 18A, D-82152 Martinsried, Germany.	Prangish@biochem.mpg.de	Jacobs, Gunnar/A-4969-2009					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRESSON OS, 1993, VIROLOGY, V193, P89, DOI 10.1006/viro.1993.1106; BECK CF, 1975, J BIOL CHEM, V250, P609; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BROYLES SS, 1993, VIROLOGY, V195, P863, DOI 10.1006/viro.1993.1446; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; DAVISON AJ, 1992, VIROLOGY, V186, P9, DOI 10.1016/0042-6822(92)90056-U; DOIGNON F, 1993, YEAST, V9, P1131, DOI 10.1002/yea.320091014; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FISCHER FB, 1886, VIROLOGY, V148, P190; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; HAIN J, 1992, NUCLEIC ACIDS RES, V20, P5423, DOI 10.1093/nar/20.20.5423; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KOPPE B, 1994, J VIROL, V68, P2313; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LUNDBERG LG, 1983, EMBO J, V2, P967, DOI 10.1002/j.1460-2075.1983.tb01529.x; MASSUNG RF, 1993, VIROLOGY, V197, P511, DOI 10.1006/viro.1993.1625; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MERCER AA, 1989, VIROLOGY, V172, P665, DOI 10.1016/0042-6822(89)90212-2; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; MUKSHELISHVILI G, 1990, BIOCHEMISTRY-US, V55, P517; Nyce GW, 1996, J BACTERIOL, V178, P914, DOI 10.1128/jb.178.3.914-916.1996; ODONOVAN GA, 1978, DNA SYNTHESIS, P209; OUZOUNIS C, 1995, NUCLEIC ACIDS RES, V23, P565, DOI 10.1093/nar/23.4.565; PRESTON VG, 1984, VIROLOGY, V138, P58, DOI 10.1016/0042-6822(84)90147-8; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; QUERAT G, 1990, VIROLOGY, V175, P434, DOI 10.1016/0042-6822(90)90428-T; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P2445, DOI 10.1093/nar/16.6.2445; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; SLABAUGH MB, 1989, P NATL ACAD SCI USA, V86, P4132; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; WANG LH, 1992, J BACTERIOL, V174, P5647, DOI 10.1128/JB.174.17.5647-5653.1992; YORK DF, 1992, J VIROL, V66, P4930, DOI 10.1128/JVI.66.8.4930-4939.1992; ZILLIG W, 1994, SYST APPL MICROBIOL, V16, P609	44	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6024	6029		10.1074/jbc.273.11.6024	http://dx.doi.org/10.1074/jbc.273.11.6024			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497317	hybrid			2022-12-27	WOS:000072488500009
J	Gachhui, R; Abu-Soud, HM; Ghosha, DK; Presta, A; Blazing, MA; Mayer, B; George, SE; Stuehr, DJ				Gachhui, R; Abu-Soud, HM; Ghosha, DK; Presta, A; Blazing, MA; Mayer, B; George, SE; Stuehr, DJ			Neuronal nitric-oxide synthase interaction with calmodulin-troponin C chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; L-ARGININE; ENZYME ACTIVATION; CALCIUM-BINDING; EXPRESSION; DOMAIN; CELLS	Calmodulin (CaM) binding activates neuronal nitric-oxide synthase (nNOS) catalytic functions and also upregulates electron transfer into its flavin and heme centers, Here, we utilized seven tight binding CaM-troponin C chimeras, which variably activate nNOS NO synthesis to examine the relationship between CaM domain structure, activation of catalytic functions, and control of internal electron transfer at two points within nNOS, Chimeras that were singly substituted with troponin C domains 4, 3, 2, or 1 were increasingly unable to activate NO synthesis, but all caused some activation of cytochrome c reduction compared with CaM-free nNOS, The magnitude by which each chimera activated NO synthesis was approximately proportional to the rate of heme iron reduction supported by each chimera, which varied from 0% to similar to 80% compared with native CaM and remained coupled to NO synthesis in all cases, In contrast, chimera activation of cytochrome c reduction was not always associated with accelerated reduction of nNOS flavins, and certain chimeras activated cytochrome c reduction without triggering heme iron reduction, We conclude: 1) CaM effects on electron transfer at two points within nNOS can be functionally separated. 2) CaM controls NO synthesis by governing heme iron reduction, but enhances reductase activity by two mechanisms, only one of which is associated with an increased rate of flavin reduction.	Cleveland Clin Fdn, Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	Cleveland Clinic Foundation; Duke University; Duke University; University of Graz	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@cesmtp.ccf.org	Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48862] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; FORSTERMANN U, 1995, BIOCHEM PHARMACOL, V50, P1321, DOI 10.1016/0006-2952(95)00181-6; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; George SE, 1996, BIOCHEMISTRY-US, V35, P8307, DOI 10.1021/bi960495y; GREBER NC, 1997, J BIOL CHEM, V272, P6285; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLATT P, 1993, J BIOL CHEM, V268, P14781; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Stuehr D J, 1995, Adv Pharmacol, V34, P207; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117	24	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5451	5454		10.1074/jbc.273.10.5451	http://dx.doi.org/10.1074/jbc.273.10.5451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488666	hybrid			2022-12-27	WOS:000072345000009
J	Wang, YB; Su, B; Sah, VP; Brown, JH; Han, JH; Chien, KR				Wang, YB; Su, B; Sah, VP; Brown, JH; Han, JH; Chien, KR			Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-jun NH2-terminal kinase in ventricular muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; STIMULATION; GROWTH	Activation of stress-activated protein kinases, including the p38 and the c-Jun NH2-terminal kinases (JNK), have been associated with the onset of cardiac hypertrophy and cell death in response to hemodynamic overload and ischemia/reperfusion injury. Upon infection of cultured neonatal rat cardiac myocytes with recombinant adenoviral vectors expressing a wild type and a constitutively active mutant of MKK7 (or JNKK2), JNK was specifically activated without affecting other mitogen-activated protein kinases, including extracellular signal-regulated protein kinases and p38. Specific activation of the JNK pathway in cardiac myocytes induced characteristic features of hypertrophy, including an increase in cell size, elevated expression of atrial natriuretic factor, and induction of sarcomere organization. In contrast, co-activation of both JNK (by MKK7) and p38 (by MKK3 or MKK6) in cardiomyocytes led to an induction of cytopathic responses and suppression of hypertrophic responses. These data provide the first direct evidence that activation of JNK alone is sufficient to induce characteristic features of cardiac hypertrophy, thereby supporting an active role for the JNK pathway in the development of cardiac hypertrophy, The cytopathic response, as a result of co activation of both JNK and p38, may contribute to the loss of contractile function and viability of cardiomyocytes following hemodynamic overload and cardiac ischemia/reperfusion injury.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Immunol, Houston, TX 77030 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; UTMD Anderson Cancer Center; Scripps Research Institute	Chien, KR (corresponding author), Univ Calif San Diego, Dept Med, Mail Box 0613-C,9500 Gilman Dr, La Jolla, CA 92093 USA.	kchien@ucsd.edu	Han, J/G-4671-2010	Wang, Yibin/0000-0003-0852-0767	NHLBI NIH HHS [HL28143] Funding Source: Medline; NIAID NIH HHS [AI41637] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barunwald E, 1996, HEART DIS TXB CARDIO, P1626; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Christensen G, 1997, AM J PHYSIOL-HEART C, V272, pH2513, DOI 10.1152/ajpheart.1997.272.6.H2513; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEMBO G, 1995, ANN NY ACAD SCI, V752, P115, DOI 10.1111/j.1749-6632.1995.tb17414.x; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	21	253	259	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5423	5426		10.1074/jbc.273.10.5423	http://dx.doi.org/10.1074/jbc.273.10.5423			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488659	hybrid			2022-12-27	WOS:000072345000002
J	Wei, JY; Shaw, LM; Mercurio, AM				Wei, JY; Shaw, LM; Mercurio, AM			Regulation of mitogen-activated protein kinase activation by the cytoplasmic domain of the alpha(6) integrin subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; S6 KINASE; PATHWAY; CELL; LAMININ; RAS; ADHESION; VARIANTS	We examined the possibility that the alpha(6A) and alpha(6B) cytoplasmic domain variants of the alpha(6) beta(1) integrin differentially activate p42 and p44 mitogen-activated protein (MAP) kinases, P388D1 macrophages that express equivalent surface levels of either the alpha(6A)beta(1) or alpha(6B)beta(1) integrin were used to examine this issue. Adhesion to laminin-1 mediated by the alpha(6A)beta(1) integrin triggered activation of a substantial fraction of total p42 and p44 MAP kinases as assessed using a mobility shift assay, immunoblot analysis with a phosphospecific MAP kinase antibody, and an immune complex kinase assay, In contrast, ligation of the alpha(6B)beta(1) integrin did not trigger significant MAP kinase activation, These data were confirmed by antibody clustering of the alpha(6) beta(1) integrins, Both the alpha(6A)beta(1) and alpha(6B)beta(1) integrins were capable of activating the p70 ribosomal S6 kinase and this activation, unlike MAP kinase activation, is dependent on phosphoinositide 3-OH kinase, Activation of MAP kinase by alpha(6) beta(1) requires both Pas and protein kinase C activity, A functional correlate for differential activation of MAP kinase was provided by the findings that the alpha(6A)beta(1) transfectants migrated significantly better on laminin than the alpha(6B)beta(1) transfectants and this migration was dependent on MAP kinase activity based on the use of the MAP kinase kinase (MEK1) inhibitor PD98059, Our findings demonstrate that the alpha(6) beta(1) integrin can activate MAP kinase, that this activation is regulated by the cytoplasmic domain of the alpha(6) subunit, and that it relates to alpha(6) beta(1)-mediated migration.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,GI Div, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mercurio, AM (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,GI Div, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.	amercuri@bidmc.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039264] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39264] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Domanico SZ, 1997, MOL BIOL CELL, V8, P2253, DOI 10.1091/mbc.8.11.2253; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; SHAW LM, 1995, J BIOL CHEM, V270, P23648, DOI 10.1074/jbc.270.40.23648; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WARY KK, 1996, CELL, V87, P1; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	30	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5903	5907		10.1074/jbc.273.10.5903	http://dx.doi.org/10.1074/jbc.273.10.5903			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488728	hybrid			2022-12-27	WOS:000072345000071
J	Oehlen, LJWM; Cross, FR				Oehlen, LJWM; Cross, FR			The role of Cdc42 in signal transduction and mating of the budding yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RESPONSE PATHWAY; PLASMA-MEMBRANE; PROTEIN CDC42P; GTPASE CDC42; CDC24; ESTABLISHMENT; MORPHOGENESIS; ACTIVATION; POLARITY	The small G-protein Cdc42 functions in many eukaryotic signal transduction pathways. In the budding yeast Saccharomyces cerevisiae, cells with defective Cdc42 fail to induce mating-specific genes in response to mating factor and to adopt the proper morphology for conjugation. Here we show that the failure of mating factor-induced transcription is largely the indirect result of arrest at a specific cell cycle position and/or the accumulation of high levels of the Cln1/2-Cdc28 kinase, a known repressor of mating factor signal transduction. Cdc42 defective cells with restored transcriptional induction have a partially restored mating ability but are still defective in the morphological response to mating factor. These results show that Cdc42 is not required for transduction of the mating factor signal per se but that it is essential for proper mating factor-induced morphogenesis.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Oehlen, LJWM (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049716] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49716] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; HARTWELL LH, 1973, GENETICS, V74, P267; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	30	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8556	8559		10.1074/jbc.273.15.8556	http://dx.doi.org/10.1074/jbc.273.15.8556			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535827	hybrid			2022-12-27	WOS:000072990800004
J	Desclozeaux, M; Poulat, F; Barbara, PD; Capony, JP; Turowski, P; Jay, P; Mejean, C; Moniot, B; Boizet, B; Berta, P				Desclozeaux, M; Poulat, F; Barbara, PD; Capony, JP; Turowski, P; Jay, P; Mejean, C; Moniot, B; Boizet, B; Berta, P			Phosphorylation of an N-terminal motif enhances DNA-bindng activity of the human SRY protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SEX DETERMINATION; TESTIS-DETERMINING FACTOR; DETERMINING GENE SRY; HMG BOX; TRANSCRIPTIONAL ACTIVITY; BINDING PROPERTIES; TRANSFECTED CELLS; C-JUN; KINASE; SEQUENCE	Of the several strategies that eukaryotes have evolved to modulate transcription factor activity, phosphorylation is regarded as one of the major mechanisms in signal-dependent transcriptional control, To conclusively demonstrate that the human sex-determining gene SRY is affected by such a post-translational control mechanism, we have analyzed its phosphorylation status in living cells. in the present study, we show that the cyclic AMP-dependent protein kinase (PKA) phosphorylates the human SRY protein in vitro as well as in vivo on serine residues located in the N-terminal part of the protein, This phosphorylation event was shown to positively regulate SRY DNA-binding activity and to enhance the ability of SRY to inhibit a basal promoter activity located downstream of an SRY DNA-binding site concatamer. Together these results strongly support the hypothesis that human SRY is a natural substrate for PKA in vivo and that this phosphorylation significantly modulates its major activity, DNA-binding, thereby possibly altering its biological function.	Ctr Rech Biochim Macromol, CNRS, ERS 155, F-34033 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Berta, P (corresponding author), Ctr Rech Biochim Macromol, CNRS, ERS 155, 1919 Route Mende,BP 5051, F-34033 Montpellier, France.	berta@vega.crbm.cnrs-mop.fr	Jay, Philippe/ABD-9223-2020; Jay, Philippe/I-7116-2016; de Santa Barbara, Pascal/N-6426-2015; POULAT, FRANCIS/AAV-2170-2020; de Santa Barbara, Pascal/AAO-5969-2021	Jay, Philippe/0000-0003-0156-5700; Jay, Philippe/0000-0003-0156-5700; de Santa Barbara, Pascal/0000-0001-9040-2481; POULAT, FRANCIS/0000-0003-2070-1296; de Santa Barbara, Pascal/0000-0001-9040-2481				BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CLEPET C, 1993, HUM MOL GENET, V2, P2007, DOI 10.1093/hmg/2.12.2007; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Greenfield A, 1996, CURR TOP DEV BIOL, V34, P1, DOI 10.1016/S0070-2153(08)60707-3; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Harley VR, 1996, FEBS LETT, V391, P24, DOI 10.1016/0014-5793(96)00694-1; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Koopman P, 1995, REPROD FERT DEVELOP, V7, P713, DOI 10.1071/RD9950713; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; POULAT F, 1994, HUM MUTAT, V3, P200, DOI 10.1002/humu.1380030305; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Vilain Eric, 1992, Methods in Molecular and Cellular Biology, V3, P128; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	44	70	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7988	7995		10.1074/jbc.273.14.7988	http://dx.doi.org/10.1074/jbc.273.14.7988			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525897	hybrid			2022-12-27	WOS:000072876300031
J	Doran, KS; Konieczny, I; Helinski, DR				Doran, KS; Konieczny, I; Helinski, DR			Replication origin of the broad host range plasmid RK2 - Positioning of various motifs is critical for initiation of replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; GRAM-NEGATIVE BACTERIA; OPEN-COMPLEX-FORMATION; DNAC GENE-PRODUCT; NUCLEOTIDE-SEQUENCE; PROTEIN BINDS; MAINTENANCE; REGIONS; INVITRO; TRFA	The 393-base pair minimal origin, oriV, of plasmid RK2 contains three iterated motifs essential for initiation of replication: consensus sequences for binding the bacterial DnaA protein, DnaA boxes, which have recently been shown to bind the DnaA protein; 17-base pair direct repeats, iterons, which bind the plasmid encoded replication protein, TrfA; and A + T-rich repeated sequences, 13-mers, which serve as the initial site of helix destabilization. To investigate how the organization of the RK2 origin contributes to the mechanism of replication initiation, mutations were introduced into the minimal origin which altered the sequence and/or spacing of each particular region relative to the rest of the origin, These altered origins were analyzed for replication activity in vivo and in vitro, for localized strand opening and for DnaB helicase mediated unwinding, Mutations in the region between the iterons and the 13-mers which altered the helical phase or the intrinsic DNA curvature prevented strand opening of the origin and consequently abolished replication activity, Insertions of more or less than one helical turn between the DnaA boxes and the iterons also inactivated the replication origin, In these mutants, however, strand opening appeared normal but the levels of DnaB helicase activity were substantially reduced. These results demonstrate that correct helical phasing and intrinsic DNA curvature are critical for the formation of an open complex and that the DnaA boxes must be on the correct side of the helix to load DnaB helicase.	Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA; Univ Gdansk, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of California System; University of California San Diego; Fahrenheit Universities; University of Gdansk	Helinski, DR (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA.			Konieczny, Igor/0000-0002-1588-5601	NIAID NIH HHS [AI-07194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ARAI K, 1981, J BIOL CHEM, V256, P5247; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BIEK DP, 1989, J BACTERIOL, V171, P2066, DOI 10.1128/jb.171.4.2066-2074.1989; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CEREGHINO JL, 1992, THESIS BIOL, P156; COOPER TG, 1977, TOOLS BIOCH, P194; COWAN P, 1982, PLASMID, V8, P164, DOI 10.1016/0147-619X(82)90054-3; CROSS MA, 1986, PLASMID, V15, P132, DOI 10.1016/0147-619X(86)90049-1; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HSU J, 1994, MOL MICROBIOL, V11, P903, DOI 10.1111/j.1365-2958.1994.tb00369.x; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MEYER RJ, 1977, BIOCHIM BIOPHYS ACTA, V478, P109, DOI 10.1016/0005-2787(77)90249-0; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; MUKHOPADHYAY G, 1993, J MOL BIOL, V231, P19, DOI 10.1006/jmbi.1993.1253; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; PEREZMARTIN J, 1988, NUCLEIC ACIDS RES, V16, P9113, DOI 10.1093/nar/16.19.9113; PERRI S, 1991, J BIOL CHEM, V266, P12536; PERRI S, 1993, J BIOL CHEM, V268, P3662; RYDER K, 1986, CELL, V44, P719, DOI 10.1016/0092-8674(86)90838-X; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SCHMIDHAUSER TJ, 1985, J BACTERIOL, V164, P446, DOI 10.1128/JB.164.1.446-455.1985; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; WOELKER B, 1993, NUCLEIC ACIDS RES, V21, P5025, DOI 10.1093/nar/21.22.5025; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZHAN K, 1987, SCIENCE, V236, P416	56	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8447	8453		10.1074/jbc.273.14.8447	http://dx.doi.org/10.1074/jbc.273.14.8447			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525957	hybrid			2022-12-27	WOS:000072876300091
J	Hildebrand, EL; Grossman, L				Hildebrand, EL; Grossman, L			Introduction of a tryptophan reporter group into the ATP binding motif of the Escherichia coli UvrB protein for the study of nucleotide binding and conformational dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; SITE-SPECIFIC MUTAGENESIS; EXCISION-REPAIR; UVRABC ENDONUCLEASE; PREINCISION COMPLEX; (A)BC EXCINUCLEASE; ENZYMATIC-PROPERTIES; MICROCOCCUS-LUTEUS; DAMAGED DNA; GENE	The DNA-dependent ATPase activity of UvrB is required to support preincision steps in nucleotide excision repair in Escherichia coli. This activity is, however, cryptic. Elicited in nucleotide excision repair by association with the UvrA protein, it may also be unmasked by a specific proteolysis eliminating the C-terminal domain of UvrB (generating UvrB*). We introduced fluorescent reporter groups (tryptophan replacing Phe(47) or Asn(51)) into the ATP binding motif of UvrB, without significant alteration of behavior, to study both nucleotide binding and those conformational changes expected to be essential to function. The inserted tryptophans occupy moderately hydrophobic, although potentially heterogeneous, environments as evidenced by fluorescence emission and time-resolved decay characteristics, yet are accessible to the diffusible quencher acrylamide. Activation, via specific proteolysis, is accompanied by conformational change at the ATP binding site, with multiple changes in emission spectra and a greater shielding of the tryptophans from diffusible quencher. Titration of tryptophan fluorescence with ATP has revealed that, although catalytically incompetent, UvrB can bind ATP and bind with an affinity equal to that of the active UvrB* form (K-d of similar to 1 mM). The Atp binding site of UvrB is therefore functional and accessible, suggesting that conformational change either brings amino acid residues into proper alignment for catalysis and/or enables response to effector DNA.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Grossman, L (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, 615 N Wolfe St, Baltimore, MD 21205 USA.	lg@welchlink.welch.jhu.edu			NIGMS NIH HHS [GM-22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022846, R01GM022846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BACKENDORF C, 1986, NUCLEIC ACIDS RES, V14, P2877, DOI 10.1093/nar/14.7.2877; Badea M G, 1979, Methods Enzymol, V61, P378; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; BLACK CG, 1995, J BACTERIOL, V177, P1952, DOI 10.1128/jb.177.8.1952-1958.1995; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MP, 1994, J BIOL CHEM, V269, P12600; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P9651, DOI 10.1093/nar/16.20.9651; CHEN R F, 1967, Analytical Letters, V1, P35; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GAYDA RC, 1978, J BACTERIOL, V136, P369, DOI 10.1128/JB.136.1.369-380.1978; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GRINVALD A, 1976, BIOCHIM BIOPHYS ACTA, V427, P663, DOI 10.1016/0005-2795(76)90210-5; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HILDEBRAND EL, 1994, ANN NY ACAD SCI, V726, P317, DOI 10.1111/j.1749-6632.1994.tb52838.x; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; Nakagawa N, 1997, J BIOL CHEM, V272, P22703, DOI 10.1074/jbc.272.36.22703; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; RICE KG, 1991, BIOCHEMISTRY-US, V30, P6646, DOI 10.1021/bi00241a003; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4361, DOI 10.1021/bi00518a020; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SHIOTA S, 1988, MOL GEN GENET, V213, P21, DOI 10.1007/BF00333393; SICARD N, 1992, J BACTERIOL, V174, P2412, DOI 10.1128/JB.174.7.2412-2415.1992; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1994, BIOCHEMISTRY-US, V33, P9881, DOI 10.1021/bi00199a009; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wong CY, 1997, PROTEIN SCI, V6, P689; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	62	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7818	7827		10.1074/jbc.273.14.7818	http://dx.doi.org/10.1074/jbc.273.14.7818			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525874	hybrid			2022-12-27	WOS:000072876300008
J	Roudier, N; Verbavatz, JM; Maurel, C; Ripoche, P; Tacnet, F				Roudier, N; Verbavatz, JM; Maurel, C; Ripoche, P; Tacnet, F			Evidence for the presence of aquaporin-3 in human red blood cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; WATER CHANNEL; GLYCEROL FACILITATOR; SOLUTE PERMEABILITY; ESCHERICHIA-COLI; XENOPUS-OOCYTES; UREA TRANSPORT; MIP FAMILY; MEMBRANE; EXPRESSION	A facilitated diffusion for glycerol is present in human erythrocytes. Glycerol transporters identified to date belong to the Major Intrinsic Protein (MIP) family of integral membrane proteins, and one of them, aquaporin-3 (AQP3), has been characterized in mammals. Us ing an antibody raised against a peptide corresponding to the rat AQP3 carboxyl terminus, we examined the presence of AQP3 in normal and Colton-null (aquaporin-1 (AQP1)-deficient) human erythrocytes. Three immunoreactive bands were detected on immunoblots of both normal and Colton-null red cells, very similar to the bands revealed in rat kidney, a material in which AQP3 has been extensively studied. By immunofluorescence, anti-AQP3 antibodies stained the plasma membranes of both normal and Colton-null erythrocytes. Glycerol transport was measured on intact erythrocytes by stopped-flow light scattering and on one-step pink ghosts by a rapid filtration technique. Glycerol permeability values, similar in both cell types, suggest that AQP1 does not represent the major path for glycerol movement across red blood cell membranes. Further more, pharmacological studies showed that Colton-null red cells remain sensitive to water and glycerol flux inhibitors, supporting the idea that another proteinaceous path, probably AQP3, mediates most of the glycerol movements across red cell membranes and represents part of the residual water transport activity found in AQP1-deficient red cells.	CEA Saclay, Dept Biol Cellulaire & Mol, Serv Biol Cellulaire, F-91191 Gif Sur Yvette, France; CNRS, Inst Sci Vegetales, F-91198 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Tacnet, F (corresponding author), CEA Saclay, Dept Biol Cellulaire & Mol, Serv Biol Cellulaire, F-91191 Gif Sur Yvette, France.		TACNET, Frédérique/B-3074-2009	Verbavatz, Jean-Marc/0000-0002-4654-1174				ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; CARLSEN A, 1976, ACTA PHYSIOL SCAND, V97, P501, DOI 10.1111/j.1748-1716.1976.tb10290.x; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DIX JA, 1985, BIOCHIM BIOPHYS ACTA, V821, P243, DOI 10.1016/0005-2736(85)90093-8; DU JY, 1994, BBA-BIOMEMBRANES, V1194, P1, DOI 10.1016/0005-2736(94)90196-1; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; ISHIHASHI K, 1997, J AM SOC NEPHROL, V8, P18; JACOBS MH, 1950, J EXP ZOOL, V113, P277, DOI 10.1002/jez.1401130203; JAY AWL, 1975, BIOPHYS J, V15, P205, DOI 10.1016/S0006-3495(75)85812-7; JENNINGS ML, 1976, J GEN PHYSIOL, V67, P381, DOI 10.1085/jgp.67.4.381; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIZE V, 1995, FEBS LETT, V373, P269, DOI 10.1016/0014-5793(95)01060-R; LEVITT DG, 1983, J GEN PHYSIOL, V81, P239, DOI 10.1085/jgp.81.2.239; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MA TH, 1994, J BIOL CHEM, V269, P21845; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; MARTIAL S, 1991, ANAL BIOCHEM, V197, P296, DOI 10.1016/0003-2697(91)90395-A; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MAZUR P, 1974, J MEMBRANE BIOL, V15, P107, DOI 10.1007/BF01870084; MEYER MM, 1986, AM J PHYSIOL, V251, pC549, DOI 10.1152/ajpcell.1986.251.4.C549; OJCIUS DM, 1988, BIOCHIM BIOPHYS ACTA, V944, P19, DOI 10.1016/0005-2736(88)90312-4; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; TOON MR, 1987, J MEMBRANE BIOL, V99, P157, DOI 10.1007/BF01995696; Toon MR, 1996, J MEMBRANE BIOL, V153, P137, DOI 10.1007/s002329900117; VomDahl S, 1997, AM J PHYSIOL-GASTR L, V272, pG563, DOI 10.1152/ajpgi.1997.272.3.G563	36	110	113	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8407	8412		10.1074/jbc.273.14.8407	http://dx.doi.org/10.1074/jbc.273.14.8407			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525951	hybrid			2022-12-27	WOS:000072876300085
J	Joneson, T; Fulton, JA; Volle, DJ; Chaika, OV; Bar-Sagi, D; Lewis, RE				Joneson, T; Fulton, JA; Volle, DJ; Chaika, OV; Bar-Sagi, D; Lewis, RE			Kinase suppressor of Ras inhibits the activation of extracellular ligand-regulated (ERK) mitogen-activated protein (MAP) kinase by growth factors, activated Ras, and Ras effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; NEURONAL DIFFERENTIATION; PC12 CELLS; C-ELEGANS; RECEPTOR; MEMBRANE; RAF-1; TRANSFORMATION; COMPLEXES	Kinase suppressor of Ras (KSR) is a loss-of-function allele that suppresses the rough eye phenotype of activated Ras in Drosophila and the multivulval phenotype of activated Ras in Caenorhabditis elegans. Genetic and biochemical studies suggest that KSR is a positive regulator of Ras signaling that functions between Ras and, Raf or in a pathway parallel to Raf. We examined the effect of mammalian KSR expression on the activation of extracellular ligand-regulated (ERR) mitogen-activated protein (MAP) kinase in fibroblasts, Ectopic expression of HSR inhibited the activation of ERK MAP kinase by insulin, phorbol ester, or activated alleles of Ras, Raf, and mitogen and extracellular-regulated kinase, Expression of deletion mutants of HSR demonstrated that the KSR kinase domain was necessary and sufficient for the inhibitory effect of KSR on ERR MAP kinase activity, KSR inhibited cell transformation by activated Ras(Val-12) but had no effect on the ability of Ras(Val-12) to induce membrane ruffling, These data indicate that KSR is a potent modulator of a signaling pathway essential to normal and oncogenic cell growth and development.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lewis, RE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.	rlewis@unmc.edu	Lewis, Robert E./H-3404-2019	Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [P30CA036727, R37CA055360, R01CA055360, R56CA055360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052809] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727, CA55360] Funding Source: Medline; NIDDK NIH HHS [DK52809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENOUEL A, 1997, 13 ANN M ONC, V13, P22; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAO GN, 1994, J BIOL CHEM, V269, P32586; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X	33	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7743	7748		10.1074/jbc.273.13.7743	http://dx.doi.org/10.1074/jbc.273.13.7743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516483	hybrid			2022-12-27	WOS:000072738500079
J	Nakamoto, RK; Verjovski-Almeida, S; Allen, KE; Ambesi, A; Rao, R; Slayman, CW				Nakamoto, RK; Verjovski-Almeida, S; Allen, KE; Ambesi, A; Rao, R; Slayman, CW			Substitutions of aspartate 378 in the phosphorylation domain of the yeast PMA1 H+-ATPase disrupt protein folding and biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASES; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-TRANSPORT; TRANSLOCATING ATPASE; DIRECTED MUTAGENESIS; INTERMEDIATE; GENE	There is strong evidence that Asp-378 of the yeast PMA1 ATPase plays an essential role in ATP hydrolysis by forming a covalent beta-aspartyl phosphate reaction intermediate, In this study, Asp-378 was replaced by Asn, Ser, and Glu, and the mutant ATPases were expressed in a temperature-sensitive secretion-deficient strain (sec6-4) that allowed their properties to be examined, Although all three mutant proteins were produced at nearly normal levels and remained stable for at least 2 h at 37 degrees C, they failed to travel to the vesicles that serve as immediate precursors of the plasma membrane; instead, they became arrested at an earlier step of the secretory pathway, A closer look at the mutant proteins revealed that they were firmly inserted into the bilayer and were not released by washing with high salt, urea, or sodium carbonate (pH 11), treatments commonly used to strip nonintegral proteins from membranes, However, all three mutant ATPases were extremely sensitive to digestion by trypsin, pointing to a marked abnormality in protein folding, Furthermore, in contrast to the wildtype enzyme, the mutant ATPases could not be protected against trypsinolysis by ligands such as MgATP, MgADP, or inorganic orthovanadate. Thus, Asp-378 functions in an unexpectedly complex way during the acquisition of a mature structure by the yeast PMA1 ATPase.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Slayman, CW (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.		Verjovski-Almeida, Sergio/E-4082-2012	Verjovski-Almeida, Sergio/0000-0002-6356-2401	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; AMORY A, 1982, J BIOL CHEM, V257, P4723; AMORY A, 1980, J BIOL CHEM, V255, P9353; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CHANG A, 1993, P NATL ACAD SCI USA, V90, P5808, DOI 10.1073/pnas.90.12.5808; CHANG A, 1995, J CELL BIOL, V128, P6815; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; DAME JB, 1981, J BIOL CHEM, V256, P724; DAME JB, 1980, BIOCHEMISTRY-US, V19, P2931, DOI 10.1021/bi00554a018; DEGANI C, 1974, ANN NY ACAD SCI, V242, P77, DOI 10.1111/j.1749-6632.1974.tb19080.x; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FAHN S, 1968, J BIOL CHEM, V243, P1993; FOURY F, 1981, EUR J BIOCHEM, V119, P395, DOI 10.1111/j.1432-1033.1981.tb05621.x; GEITZ RD, 1988, GENE, V74, P527; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MALPARTIDA F, 1981, EUR J BIOCHEM, V116, P413, DOI 10.1111/j.1432-1033.1981.tb05350.x; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; NA S, 1995, J BIOL CHEM, V270; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pedersen PA, 1996, BIOCHEMISTRY-US, V35, P16085, DOI 10.1021/bi961614c; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Portillo F, 1997, FEBS LETT, V402, P136, DOI 10.1016/S0014-5793(96)01515-3; POST RL, 1973, J BIOL CHEM, V248, P6993; POST RL, 1965, J BIOL CHEM, V240, P1437; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; RAO R, 1996, MYCOTA, V3, P29; Reis EMR, 1996, BIOSCIENCE REP, V16, P107, DOI 10.1007/BF01206200; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; Sorin A, 1997, J BIOL CHEM, V272, P9895; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; SUPPLY P, 1995, MOL CELL BIOL, V15, P5389; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; WALDERHAUG MO, 1985, J BIOL CHEM, V260, P3852; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163	52	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7338	7344		10.1074/jbc.273.13.7338	http://dx.doi.org/10.1074/jbc.273.13.7338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516429	Green Published, hybrid			2022-12-27	WOS:000072738500025
J	Tang, HK; Singh, S; Saunders, GF				Tang, HK; Singh, S; Saunders, GF			Dissection of the transactivation function of the transcription factor encoded by the eye developmental gene PAX6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; BINDING-PROTEINS; PAIRED DOMAIN; EYELESS GENE; DNA-BINDING; BSAP PAX-5; ANIRIDIA; ACTIVATION; MUTATIONS; SEQUENCE	PAX6 is a transcription activator that regulates eye development in animals ranging from Drosophila to human, The C terminal region of PAX6 is proline/serine/threonine-rich (PST) and functions as a potent transactivation domain when attached to a heterologous DNA-binding domain of the yeast transcription factor, GAL4. The PST region comprises 152 amino acids encoded by four exons. The transactivation function of the PST region has not been defined and characterized in detail by in vitro mutagenesis. We dissected the PST domain in two independent systems, a heterologous system using a GAL4 DNA-binding site and the native system of PAX6. Our data consistently showed that in both systems all four constituent exons of the PST domain are responsible for the transactivation function. The four exon fragments act synergistically to stimulate transcription, although none of them can function individually as an independent transactivation domain. Combinations of two or more exon fragments can reconstitute substantial transactivation activity when fused to the DNA-binding domain of GAL4, but they surprisingly do not produce much activity in the context of native PAX6, although the mutant PAX6 proteins are stable and their DNA-binding function remains unaffected. Our data suggest that these mutants may antagonize the wildtype PAX6 activity by competing for target DNA-binding sites. We conclude that the PAX6 protein contains an unusually large transactivation domain that is evolutionarily conserved to a high degree and that its full transactivation activity relies on the synergistic action of the four exon fragments.	Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.	sa08301@odin.mdacc.tmc.edu			NCI NIH HHS [CA16672] Funding Source: Medline; NEI NIH HHS [EY09675, EY10608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009675, P30EY010608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; DAVIS A, 1993, HUM MOL GENET, V2, P2093, DOI 10.1093/hmg/2.12.2093; DONATELLA L, 1993, GENE DEV, V7, P1341; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Glaser T., 1995, MOL GENETICS OCULAR, P51; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HANSON IM, 1993, HUM MOL GENET, V2, P915; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hirsch N, 1997, J NEUROBIOL, V32, P45, DOI 10.1002/(SICI)1097-4695(199701)32:1<45::AID-NEU5>3.3.CO;2-V; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; Loosli F, 1996, P NATL ACAD SCI USA, V93, P2658, DOI 10.1073/pnas.93.7.2658; LYONS LA, 1992, GENOMICS, V13, P925, DOI 10.1016/0888-7543(92)90002-A; MARTHA A, 1994, AM J HUM GENET, V54, P801; MARTHA AD, 1994, HUM MUTAT, V3, P297, DOI 10.1002/humu.1380030319; MARTIN P, 1992, ONCOGENE, V7, P1721; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NELSON LB, 1984, SURV OPHTHALMOL, V28, P621, DOI 10.1016/0039-6257(84)90184-X; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAW MW, 1960, AM J HUM GENET, V12, P389; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; TANG K, 1994, J CELL BIOCHEM, P203; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TON CCT, 1992, GENOMICS, V13, P251, DOI 10.1016/0888-7543(92)90239-O; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Xu ZP, 1997, J BIOL CHEM, V272, P3430, DOI 10.1074/jbc.272.6.3430; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0	55	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7210	7221		10.1074/jbc.273.13.7210	http://dx.doi.org/10.1074/jbc.273.13.7210			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516413	hybrid			2022-12-27	WOS:000072738500009
J	Wells, GB; Dickson, RC; Lester, RL				Wells, GB; Dickson, RC; Lester, RL			Heat-induced elevation of ceramide in Saccharomyces cerevisiae via de novo synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; PHOSPHOLIPASE-C GENE; MUTANT STRAINS; SPHINGOLIPIDS; INOSITOL; STRESS; PLC1; PHOSPHATIDYLINOSITOL; GROWTH	Sphingolipid-related metabolites have been implicated as potential signaling molecules in many studies with mammalian cells as well as in some studies with yeast, Our previous work showed that sphingolipid-deficient strains of Saccharomyces cerevisiae are unable to resist a heat shock, indicating that sphingolipids are necessary for surviving heat stress, Recent evidence suggests that one role for the sphingolipid intermediate ceramide may be to act as a second messenger to signal accumulation of the thermoprotectant trehalose, We examine here the mechanism for generating the severalfold increase in ceramide observed during heat shock, As judged by compositional analysis and mass spectrometry, the major ceramides produced during heat shock are similar to those found in complex sphingolipids, a mixture of N-hydroxyhexacosanoyl C-18 and C-20 phytosphingosines. Since the most studied mechanism for ceramide generation in animal cells is via a phospholipase C-type sphingomyelin hydrolysis, we examined S. cerevisiae for an analogous enzyme, Using [H-3]phytosphingosine and [H-3]inositol-labeled yeast sphingolipids, a novel membrane-associated phospholipase C-type activity that generated ceramide from inositol-P-ceramide, mannosylinositol-P-ceramide, and mannose(inositol-P)(2)-ceramide was demonstrated, The sphingolipid head groups were concomitantly liberated with the expected stoichiometry, However, other data demonstrate that the ceramide generated during heat shock is not likely to be derived by breakdown of complex sphingolipids, For example, the water-soluble fraction of heat-shocked cells showed no increase in any of the sphingolipid head groups, which is inconsistent with complex sphingolipid hydrolysis. Rather, we find that de novo ceramide synthesis involving ceramide synthase appears to be responsible for heat-induced ceramide elevation, In support of this hypothesis, we find that the potent ceramide synthase inhibitor, australifungin, completely inhibits both the heat-induced increase in incorporation of [H-3]sphinganine into ceramide as well as the heat-induced increase in ceramide as measured by mass, Thus, heat-induced ceramide most likely arises by temperature activation of the enzymes that generate ceramide precursors, activation of ceramide synthase itself, or both.	Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Lester, RL (corresponding author), Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA.	rlester@pop.uky.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Ella KM, 1997, ARCH BIOCHEM BIOPHYS, V340, P101, DOI 10.1006/abbi.1997.9897; FEWSTER ME, 1969, J CHROMATOGR, V43, P120, DOI 10.1016/S0021-9673(00)99173-8; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1993, ADV LIPID RES, V25, P27; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LESTER RL, 1993, ADV LIPID RES, V26, P253; LESTER RL, 1993, J BIOL CHEM, V268, P845; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Oda T., 1958, CHEM PHARM BULL, V6, P682; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; SIKORSKI RS, 1989, GENETICS, V122, P19; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996; WELLS GB, 1996, ANN M AM SOC BIOCH M; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644	37	108	109	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7235	7243		10.1074/jbc.273.13.7235	http://dx.doi.org/10.1074/jbc.273.13.7235			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516416	hybrid			2022-12-27	WOS:000072738500012
J	Natochin, M; McEntaffer, RL; Artemyev, NO				Natochin, M; McEntaffer, RL; Artemyev, NO			Mutational analysis of the Asn residue essential for RGS protein binding to G-proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ROD OUTER SEGMENTS; CGMP PHOSPHODIESTERASE; CRYSTAL-STRUCTURE; ALPHA-SUBUNITS; TRANSDUCIN; MECHANISM; DOMAIN; FAMILY; CHROMATOGRAPHY	Members of the RGS family serve as GTPase-activating proteins (GAPs) for heterotrimeric G-proteins and negatively regulate signaling via G-protein-coupled receptors, The recently resolved crystal structure of RGS4 bound to G(i) alpha(1) suggests two potential mechanisms for the GAP activity of RGS proteins as follows: stabilization of the G(i) alpha(1) switch regions by RGS4 and the catalytic action of RGS4 residue Asn(128), To elucidate a role of the Asn residue for RGS GAP function, we have investigated effects of the synthetic peptide corresponding to the Ga binding domain of human retinal RGS (hRGSr) containing the key Asn at position 131, and we have carried out mutational analysis of Asn(131), Synthetic peptide hRGSr-(123-140) retained its ability to bind the AlF4--complexed transducin alpha-subunit, G(t) alpha.AlF4-, but failed to elicit stimulation of Gt alpha GTPase activity, Wild-type hRGSr stimulated G(t) alpha GTPase activity by similar to 10-fold with an EC50 value of 100 nM. Mutant hRGSr proteins with substitutions of Asn(131) by Ser and Gin had a significantly reduced affinity for G(t) alpha but were capable of substantial stimulation of G(t) alpha GTPase activity, 80 and 60% of V-max, respectively, Mutants hRGSr-Leu(131), hRGSr-Ala(131), and hRGSr-Asp(131) were able to accelerate G(t) alpha GTPase activity only at very high concentrations (>10 mu m which appears to correlate with a further decrease of their affinity for transducin, Two mutants, hRGSr-His(131) and hRGSr-Delta(131), had no detectable binding to transducin, Mutational analysis of Asn(131) suggests that the stabilization of the G-protein switch regions rather than catalytic action of the Asn residue is a key component for the RGS GAP action.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, 5-660 Bowen SciBldg, Iowa City, IA 52242 USA.	Nikolai-Artemyev@UIOWA.EDU		Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1997, J BIOL CHEM, V272, P8853; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	34	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6731	6735		10.1074/jbc.273.12.6731	http://dx.doi.org/10.1074/jbc.273.12.6731			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506972	hybrid			2022-12-27	WOS:000072775900022
J	Privitera, S; Prody, CA; Callahan, JW; Hinek, A				Privitera, S; Prody, CA; Callahan, JW; Hinek, A			The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; CHONDROITIN SULFATE; DUCTUS-ARTERIOSUS; ELASTIN RECEPTOR; TROPOELASTIN; MECHANISM; PRECURSOR; PEPTIDES	Our previous studies showed immunological and functional similarities, as well as partial sequence homology, between the enzymatically inactive alternatively spliced variant of human beta-galactosidase (S-gal) and the 67-kDa elastin/laminin-binding protein (EBP) from sheep. To define the genetic origin of the EBP further, a full-length human S-gal cDNA clone was constructed and subjected to in vitro transcription/translation. The cDNA was also transfected into COS-1 cells and into the EBP-deficient smooth muscle cells (SMC) from sheep ductus arteriosus (DA). In vitro translation yielded an unglycosylated form of the S-gal protein, which immunoreacted with anti-beta-galactosidase antibodies and bound to elastin and laminin affinity columns. S-gal cDNA transfections into COS-1 and DA SMC increased expression of a 67-kDa protein that immunolocalized intracellularly and to the cell surface and, when extracted from the cells, bound to elastin. The S-gal-transfected cells displayed increased adherence to elastin-covered dishes, consistent with the cell surface distribution of the newly produced S-gal-encoded protein. Transfection of DA SMC additionally corrected their impaired elastic fiber assembly. These results conclusively identify the 67-kDa splice variant of beta-galactosidase as EBP.	Hosp Sick Children, Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Neurosci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Hinek, A (corresponding author), Hosp Sick Children, Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Hinek, Aleksander/V-8790-2019					ABELDA SM, 1993, LAB INVEST, V68, P4; BOUDREAU N, 1991, LAB INVEST, V64, P187; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; FULOP T, 1989, CELL CALCIUM METABOL; GROSSO LE, 1993, BIOCHEMISTRY-US, V32, P13369, DOI 10.1021/bi00211a052; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HINEK A, 1994, CELL ADHES COMMUN, V2, P185, DOI 10.3109/15419069409004436; HINEK A, 1992, EXP CELL RES, V203, P344, DOI 10.1016/0014-4827(92)90008-V; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HINEK A, 1993, J CLIN INVEST, V91, P1198, DOI 10.1172/JCI116280; Hinek A, 1996, BIOL CHEM, V377, P471; Hinek A, 1996, EXP CELL RES, V225, P122, DOI 10.1006/excr.1996.0163; HINEK A, 1995, EXP CELL RES, V220, P1; JACOB MP, 1987, P NATL ACAD SCI USA, V84, P995, DOI 10.1073/pnas.84.4.995; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MECHAM RP, 1988, BIOCHEM BIOPH RES CO, V151, P822, DOI 10.1016/S0006-291X(88)80355-3; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; MOLOSSI S, 1995, J CELL PHYSIOL, V163, P19, DOI 10.1002/jcp.1041630104; MORREAU H, 1989, J BIOL CHEM, V264, P20655; OkamuraOho Y, 1996, BIOCHEM J, V313, P787, DOI 10.1042/bj3130787; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; ROBERT L, 1994, J JPN ATHEROSCLER SO, V21, P613; Sambrook J., 2002, MOL CLONING LAB MANU; SUZUKI Y, 1995, METABOLIC BASIS INHE, V2; UAUSBEL FM, 1996, CURRENT PROTOCOLS S, V36; VARGA Z, 1989, FEBS LETT, V258, P5, DOI 10.1016/0014-5793(89)81602-3; YAMAMOTO Y, 1990, DNA CELL BIOL, V9, P119, DOI 10.1089/dna.1990.9.119; ZHANG SQ, 1994, BIOCHEM J, V304, P281, DOI 10.1042/bj3040281	33	146	155	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6319	6326		10.1074/jbc.273.11.6319	http://dx.doi.org/10.1074/jbc.273.11.6319			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497360	hybrid			2022-12-27	WOS:000072488500052
J	Valhmu, WB; Palmer, GD; Dobson, J; Fischer, SG; Ratcliffe, A				Valhmu, WB; Palmer, GD; Dobson, J; Fischer, SG; Ratcliffe, A			Regulatory activities of the 5 '- and 8 '-untranslated regions and promoter of the human aggrecan gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LARGE AGGREGATING PROTEOGLYCAN; IRON-RESPONSIVE ELEMENTS; CORE PROTEIN; ARTICULAR-CARTILAGE; GROWTH-FACTOR; MESSENGER-RNA; LINK PROTEIN; EXPERIMENTAL OSTEOARTHRITIS; 3'-UNTRANSLATED REGIONS	Identification and characterization of the regulatory elements of the human aggrecan gene are necessary first steps in addressing the molecular mechanisms through which the gene is regulated. Using luciferase reporter constructs driven by the human aggrecan pro-meter or the cytomegalovirus promoter, the 5'- and 3'-untranslated regions of the human aggrecan gene were found to regulate gene expression transcriptionally in a promoter- and/or cell type-specific manner. Independent of cell type, the 5'-untranslated region was inhibitory with respect to the cytomegalovirus promoter, but it was stimulatory to the human aggrecan promoter. The 5'-untranslated region inhibited the cytomegalovirus promoter by approximately 60% in both chondrocytes and NIH 3T3 cells, but it stimulated the activity of the human aggrecan promoter about 8-fold in chondrocytes and 40-fold in NIH 3T3 cells, In contrast, the 3'-untranslated region inhibited the activities of the human aggrecan promoter by 40-70% in both cell types, but it stimulated the cytomegalovirus promoter activities by 50-60% in NIH 3T3 cells and inhibited its activity by 70% in chondrocytes. The differential effects of the untranslated regions on the two types of promoters may be a reflection of differences in regulation of TATA-less promoters, such as the human aggrecan promoter, and TATA-containing promoters, such as the cytomegalovirus promoter.	Columbia Univ, Dept Orthopaed Surg, Orthopaed Res Lab, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Valhmu, WB (corresponding author), Columbia Presbyterian Med Ctr, Orthopaed Res Lab, Room BB-1412,630 W 168th St, New York, NY 10032 USA.			Valhmu, Wilmot/0000-0003-1580-8910	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043597, R01AR042003, R01AR043597] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43597, AR42003] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bachrach NM, 1995, J BIOMECH, V28, P1561, DOI 10.1016/0021-9290(95)00103-4; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; Domowicz M, 1996, INT J DEV NEUROSCI, V14, P191, DOI 10.1016/0736-5748(96)00007-X; DOMOWICZ M, 1995, DEV BIOL, V171, P655, DOI 10.1006/dbio.1995.1312; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; FULOP C, 1993, J BIOL CHEM, V268, P17377; GRAY ML, 1989, BIOCHIM BIOPHYS ACTA, V991, P415, DOI 10.1016/0304-4165(89)90067-6; Guilak F, 1994, Osteoarthritis Cartilage, V2, P91, DOI 10.1016/S1063-4584(05)80059-7; HALL AC, 1991, J ORTHOPAED RES, V9, P1, DOI 10.1002/jor.1100090102; HAN J, 1991, J IMMUNOL, V146, P1843; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HARDINGHAM TE, 1994, EUR J CLIN CHEM CLIN, V32, P249; HARVEY AK, 1993, BIOCHEM J, V292, P129, DOI 10.1042/bj2920129; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HYDER SM, 1992, J BIOL CHEM, V267, P18047; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; JUUL SE, 1995, AM J RESP CELL MOL, V13, P629, DOI 10.1165/ajrcmb.13.6.7576700; Kim YJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P331, DOI 10.1006/abbi.1996.0181; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LECAM A, 1995, EUR J BIOCHEM, V231, P620; Li H, 1995, J MOL EVOL, V41, P878; LI H, 1993, J BIOL CHEM, V268, P23504; MATYAS JR, 1995, ARTHRITIS RHEUM, V38, P420, DOI 10.1002/art.1780380320; MORGELIN M, 1988, BIOCHEM J, V253, P175; NASO MF, 1994, J BIOL CHEM, V269, P32999; PALMOSKI MJ, 1984, ARTHRITIS RHEUM, V27, P675, DOI 10.1002/art.1780270611; PALMOSKI MJ, 1980, ARTHRITIS RHEUM, V23, P83, DOI 10.1002/art.1780230114; PARKKINEN JJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P458, DOI 10.1006/abbi.1993.1062; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Pettway Z, 1996, EXP CELL RES, V225, P195, DOI 10.1006/excr.1996.0170; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ratcliffe Anthony, 1996, Am J Ther, V3, P129, DOI 10.1097/00045391-199602000-00006; Rauch U, 1997, GENOMICS, V44, P15, DOI 10.1006/geno.1997.4853; RAUCH U, 1995, GENOMICS, V28, P405, DOI 10.1006/geno.1995.1168; RE P, 1995, ANAL BIOCHEM, V225, P356, DOI 10.1006/abio.1995.1169; REED DJ, 1994, J IMMUNOL, V152, P5330; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SANDY JD, 1984, ARTHRITIS RHEUM, V27, P388, DOI 10.1002/art.1780270405; Schwartz NB, 1996, PERSPECT DEV NEUROBI, V3, P291; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; TANAKA T, 1988, J BIOL CHEM, V263, P15831; TZEN CY, 1994, EXP CELL RES, V211, P12, DOI 10.1006/excr.1994.1052; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154	57	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6196	6202		10.1074/jbc.273.11.6196	http://dx.doi.org/10.1074/jbc.273.11.6196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497342	hybrid			2022-12-27	WOS:000072488500034
J	Wilson, GF; Wang, Z; Chouinard, SW; Griffith, LC; Ganetzky, B				Wilson, GF; Wang, Z; Chouinard, SW; Griffith, LC; Ganetzky, B			Interaction of the K channel beta subunit, Hyperkinetic, with eag family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; ALPHA-SUBUNITS; DROSOPHILA; INACTIVATION; TRANSMISSION; HERG	Assembly of K channel alpha subunits of the Sharer (Sh) family occurs in a subfamily specific manner. It has been suggested that subfamily specificity also applies in the association of beta subunits with Sh channels (Rhodes, & J., Keilbaugh, S. A. Barrezueta, N. X. Lopez, K. L., and Trimmer, J, S, (1995) J. Neurosci. 15, 5360-5371; Sewing, S., Roeper, J. and Pongs, O. (1996) Neuron 16, 455-463; Yu, W., Xu, J., and Li, M. (1996) Neuron 16, 441-453). Here we show that the Drosophila beta subunit homologue hyperkinetic (Elk) associates with members of the ether a go-go (eag), as well as Sh, families. Anti-BAG antibody coprecipitates EAG and HK indicating a physical association between proteins. Heterologously expressed Hk dramatically increases the amplitudes of eag currents and also affects gating and modulation by progesterone. Through their ability to interact with a range of alpha subunits, the beta subunits of voltage-gated K channels are likely to have a much broader impact on the signaling properties of neurons and muscle fibers than previously suggested.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	University of Wisconsin System; University of Wisconsin Madison; Brandeis University	Wilson, GF (corresponding author), Univ Wisconsin, Genet Lab, 445 Henry Mall, Madison, WI 53706 USA.			Wang, Zheng/0000-0001-7678-0072; Griffith, Leslie/0000-0003-3164-9876	NIGMS NIH HHS [R01 GM054408] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CURRAN ME, 1995, CELL, V80, P1; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KAPLAN WD, 1979, PSYCHOL SURVEY, V2, P90; KOSTELLOW AB, 1993, MOL CELL ENDOCRINOL, V92, P33, DOI 10.1016/0303-7207(93)90072-R; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Moore DD, 1995, GLOB MOB SURV; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; SANGUINETTI MC, 1995, CELL, V81, P1; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; STERN M, 1989, J NEUROGENET, V5, P215, DOI 10.3109/01677068909066209; Titus SA, 1997, J NEUROSCI, V17, P875; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang JW, 1996, BIOPHYS J, V71, P3167, DOI 10.1016/S0006-3495(96)79510-3; Wang XJ, 1997, J NEUROSCI, V17, P882; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P34; WILSON GF, 1997, 27 ANN SOC NEUR M NE; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	29	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6389	6394		10.1074/jbc.273.11.6389	http://dx.doi.org/10.1074/jbc.273.11.6389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497369	hybrid			2022-12-27	WOS:000072488500061
J	Shearwin, KE; Brumby, AM; Egan, JB				Shearwin, KE; Brumby, AM; Egan, JB			The Tum protein of coliphage 186 is an antirepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; C1 REPRESSOR; TEMPERATE COLIPHAGE-186; PROPHAGE INDUCTION; ESCHERICHIA-COLI; DNA-BINDING; LYSOGENY; LEXA; MAINTENANCE; CLEAVAGE	The tum gene of coliphage 186, encoded on a LexA controlled operon, is essential for UV induction of a 186 prophage. Primer extension analysis is used to confirm that Tnm is the sole phage function required for prophage induction and that it acts against the maintenance repressor, GI, to relieve repression of the lytic promoters, P-R and p(B), and thereby bring about lytic development. In vitro experiments with purified proteins demonstrate that Tum prevents CH binding to its operator sites. Tum does not compete with CI for binding sites on DNA, and unlike RecA mediated induction of lambda prophage, the action of Tum on CI is reversible, Mechanisms by which Tum may act against CI are discussed.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	University of Adelaide	Egan, JB (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.		Shearwin, Keith/AAS-1247-2021	Shearwin, Keith/0000-0002-7736-2742				Brumby AM, 1996, VIROLOGY, V219, P105, DOI 10.1006/viro.1996.0227; BRUMBY AM, 1994, THESIS U ADELAIDE; DIBBENS JA, 1992, MOL MICROBIOL, V6, P2643, DOI 10.1111/j.1365-2958.1992.tb01441.x; Dodd IB, 1996, J BIOL CHEM, V271, P11532, DOI 10.1074/jbc.271.19.11532; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; EGAN JB, 1994, ENCY VIROLOGY, P1003; GALLAGHER SR, 1993, CURRENT PROTOCOLS MO; HEINZEL T, 1990, J BIOL CHEM, V265, P17928; HEINZEL T, 1992, J BIOL CHEM, V267, P4183; HOCKING SM, 1982, J VIROL, V44, P1056, DOI 10.1128/JVI.44.3.1056-1067.1982; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; LAMONT I, 1989, P NATL ACAD SCI USA, V86, P5492, DOI 10.1073/pnas.86.14.5492; LAMONT I, 1993, J BACTERIOL, V175, P5286, DOI 10.1128/JB.175.16.5286-5288.1993; LEWIS LK, 1994, J MOL BIOL, V241, P507, DOI 10.1006/jmbi.1994.1528; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; Liu T, 1997, J VIROL, V71, P4502, DOI 10.1128/JVI.71.6.4502-4508.1997; MOLIN S, 1979, J BACTERIOL, V138, P70, DOI 10.1128/JB.138.1.70-79.1979; Neufing PJ, 1996, MOL MICROBIOL, V21, P751, DOI 10.1046/j.1365-2958.1996.351394.x; REDDY KJ, 1989, CURRENT PROTOCOLS MO; Reed MR, 1997, MOL MICROBIOL, V23, P669, DOI 10.1046/j.1365-2958.1997.2521620.x; RIEDEL HD, 1993, FEBS LETT, V334, P165, DOI 10.1016/0014-5793(93)81705-5; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER RT, 1982, J BIOL CHEM, V257, P4458; Shearwin KE, 1996, J BIOL CHEM, V271, P11525, DOI 10.1074/jbc.271.19.11525; STRZELECKA TE, 1995, BIOCHEMISTRY-US, V34, P2946, DOI 10.1021/bi00009a026; SUSSKIND MM, 1983, LAMBDA, V2, P347; WALKER GC, 1987, ESCHERICHIA COLI SAL, V2; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WOODS WH, 1974, J VIROL, V14, P1349, DOI 10.1128/JVI.14.6.1349-1356.1974; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	33	61	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5708	5715		10.1074/jbc.273.10.5708	http://dx.doi.org/10.1074/jbc.273.10.5708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488703	hybrid			2022-12-27	WOS:000072345000046
J	Hegde, R; Srinivasula, SM; Ahmad, M; Fernandes-Alnemri, T; Alnemri, ES				Hegde, R; Srinivasula, SM; Ahmad, M; Fernandes-Alnemri, T; Alnemri, ES			Blk, a BHS-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; APOPTOSIS; SURVIVAL; DISTINCT; SEQUENCE; DOMAIN; FAMILY	We identified and cloned a novel murine member of the pro-apoptotic Bcl-2 family, This protein, designated Blk, is structurally and functionally related to human Bik and localized to the mitochondrial membrane. Blk contains a conserved BH3 domain and can interact with the anti-apoptotic proteins Bcl-2 and Bcl-xL. Ectopic expression of Blk in mammalian cells induces apoptosis, which can be inhibited by mutations in the BH3 domain and by overexpression of Bcl-2 or Bcl-xL but not by CrmA. The apoptotic activity of Blk is also inhibited by a dominant negative caspase-9, suggesting that Blk induces apoptosis through activation of the cytochrome c-Apaf-1-caspase-9 pathway.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg 904,233 S 10th St, Philadelphia, PA 19107 USA.	E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010		NIA NIH HHS [AG14357, AG13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014357, R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOYD JM, 1995, ONCOGENE, V11, P1921; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Han J, 1996, MOL CELL BIOL, V16, P5857; Hawkins C J, 1997, Semin Immunol, V9, P25, DOI 10.1006/smim.1996.0052; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Orth R, 1997, J BIOL CHEM, V272, P8841; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	23	82	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7783	7786		10.1074/jbc.273.14.7783	http://dx.doi.org/10.1074/jbc.273.14.7783			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525867	hybrid			2022-12-27	WOS:000072876300001
J	Rojo, EE; Guiard, B; Neupert, W; Stuart, RA				Rojo, EE; Guiard, B; Neupert, W; Stuart, RA			Sorting of D-lactate dehydrogenase to the inner membrane of mitochondria - Analysis of topogenic signal and energetic requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEMBRANE SPACE; MATRIX ATP; CYTOCHROME B(2); IMPORT PATHWAY; SUBUNIT VA; PROTEINS; TRANSLOCATION; PRESEQUENCE; MECHANISM; PRECURSOR	D-Lactate dehydrogenase (D-LD) is located in the inner membrane of mitochondria. It spans the membrane once in an N-in-C-out orientation with the bulk of the protein residing as a folded domain in the intermembrane space. D-LD is synthesized as a precursor with an N-terminal cleavable presequence and is imported into the mitochondria in a Delta psi-dependent, but mt-Hsp70-independent manner. Upon import in vitro D-LD folds in the intermembrane space to attain a conformation indistinguishable from endogenous D-LD. Sorting of D-LD to the inner membrane is directed by a composite topogenic signal consisting of the hydrophobic transmembrane segment and a cluster of charged amino acids C-terminal to it. We propose a model for the mode of operation of the sorting signal of D-LD. This model also accounts for the driving force of translocation across the outer membrane, in the apparent absence of mt-Hsp70-dependent assisted import and involves the folding of the D-LD in the intermembrane space.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Univ Paris 06, Ctr Genet Mol, CNRS, F-91190 Gif Sur Yvette, France	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Stuart, RA (corresponding author), Univ Munich, Inst Physiol Chem, Geethestr 33, D-80336 Munich, Germany.							Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CYR DM, 1993, J BIOL CHEM, V268, P23751; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; Gruhler A, 1997, J BIOL CHEM, V272, P17410, DOI 10.1074/jbc.272.28.17410; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODI T, 1993, MOL GEN GENET, V238, P315, DOI 10.1007/BF00291989; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Sambrook J., 2002, MOL CLONING LAB MANU; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Towbin H., 1979, P NATL ACAD SCI USA, V79, P267; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x	23	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8040	8047		10.1074/jbc.273.14.8040	http://dx.doi.org/10.1074/jbc.273.14.8040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525904	hybrid			2022-12-27	WOS:000072876300038
J	Wang, Y; Spellman, MW				Wang, Y; Spellman, MW			Purification and characterization of a GDP-fucose : polypeptide fucosyltransferase from Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED FUCOSE; GROWTH-FACTOR DOMAIN; HUMAN FACTOR-IX; PLASMINOGEN-ACTIVATOR; GLYCOSYLATION; OLIGOSACCHARIDES; IDENTIFICATION; SERINE-61	A GDP-fucose:polypeptide fucosyltransferase was purified 5000-fold to homogeneity from Chinese hamster ovary cell extracts in the absence of detergent. The purification procedure included two affinity chromatographic steps using the acceptor substrate, a recombinant factor VII EGF-1 domain, and the donor substrate analog, GDP-hexanolamine, as ligands. The purified enzyme migrates as a single band of 44,000 daltons on SDS-polyacrylamide gel electrophoresis and is itself a glycoprotein with more than one high mannose type oligosaccharide chain with a total molecular weight of 4000. The K-m values for factor VII EGF-1 domain and GDP-fucose are 15 and 6 mu M, respectively. The V-max is 2.5 mu mol.min(-1).mg(-1). The presence of 50 nM Mn2+ increased the enzyme activity 17-fold, but Mn2+ was not absolutely required, since the enzyme exhibited some activity even in the presence of EDTA. The acceptor substrate specificity was studied using site-directed mutagenesis of human factor IX EGF domain. Only one of several differently folded species could serve as acceptor substrate, although they all had the same molecular weight as determined by liquid chromatography on-line with mass spectrometry. This indicates that the enzyme requires proper folding of the epidermal growth factor domain for its activity.	Genentech Inc, Dept Pharmacokinet & Metab, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Spellman, MW (corresponding author), Genentech Inc, Dept Pharmacokinet & Metab, S San Francisco, CA 94080 USA.	mws@gene.com						BJOERN S, 1991, J BIOL CHEM, V266, P11051; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; Gohlke M, 1996, J BIOL CHEM, V271, P7381, DOI 10.1074/jbc.271.13.7381; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837	21	93	103	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8112	8118		10.1074/jbc.273.14.8112	http://dx.doi.org/10.1074/jbc.273.14.8112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525914	hybrid			2022-12-27	WOS:000072876300048
J	Ali, S; Ali, S				Ali, S; Ali, S			Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; MAMMARY-GLAND FACTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; INTRACELLULAR DOMAIN; GENE FAMILY; KINASE JAK2; BETA CHAIN; CELL-LINE	The SH2 domain containing signal transducers and activators of transcription (Stat proteins) are effector molecules downstream of cytokine receptors. Ligand/receptor engagement triggers Stat proteins tyrosine phosphorylation, dimerization, and translocation to the nucleus where they regulate gene transcription. Stat5, originally identified as a mammary gland growth factor, is an essential mediator of prolactin (PRL)-induced milk protein gene activation. Prolactin receptor (PRLR) is a member of the cytokine/growth hormone/PRL receptor superfamily. The mechanism through which PRLR modulates Stat5 tyrosine phosphorylation, nuclear translocation, and DNA binding was analyzed in HC11 cells, a mammary epithelial cell line, and 293-LA. cells, a human kidney cell line stably overexpressing Jak2 kinase. We have found that in HC11 cells, Stat5 is specifically activated by PRL treatment, demonstrating that Stat5 is a physiological substrate downstream of PRLR. Furthermore, using different forms natural forms of the PRLR as well as receptor tyrosine to phenylalanine mutant forms, we determined that tyrosine phosphorylation of Stat5 is independent of PRLR phosphotyrosines. We established, however, that the C-terminal tyrosine of the PRLR Nb2 form, Tyr(382), plays an essential positive role in PRLR-dependent Stat5 nuclear translocation and subsequently DNA binding. All together, our data propose a new model for activation of Stat5 through the PRLR, suggesting that Stat5 tyrosine phosphorylation and nuclear translocation are two separately regulated events.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med, Div Hematol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Ali, S (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, H5-81,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	sali@RVHMED.Lan.McGill.ca						ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BALL RK, 1988, MOL ENDOCRINOL, V2, P133, DOI 10.1210/mend-2-2-133; BAZAN F, 1989, BIOCHEM BIOPH RES CO, V164, P798; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; de Vlaming V.L., 1979, P561; DOPPLER W, 1994, REV PHYSIOL BIOCH P, V124, P93, DOI 10.1007/BFb0031032; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hansen JA, 1997, J MOL ENDOCRINOL, V18, P213, DOI 10.1677/jme.0.0180213; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; MIURA O, 1994, J BIOL CHEM, V269, P614; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; REN HY, 1994, J BIOL CHEM, V269, P19633; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG X, MOL ENDOCRINOL, V10, P1249; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	53	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7709	7716		10.1074/jbc.273.13.7709	http://dx.doi.org/10.1074/jbc.273.13.7709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516478	hybrid			2022-12-27	WOS:000072738500074
J	Pietromonaco, SF; Simons, PC; Altman, A; Elias, L				Pietromonaco, SF; Simons, PC; Altman, A; Elias, L			Protein kinase C-theta phosphorylation of moesin in the actin-binding sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BIOCHEMICAL-CHARACTERIZATION; MEMBRANE ASSOCIATION; HEMATOPOIETIC-CELLS; LEUKEMIC-CELLS; PKC-THETA; F-ACTIN; EZRIN; FAMILY; MEMBER	Moesin, a member of the ezrin-radixin-moesin (ERM) family of membrane/cytoskeletal linkage proteins, is known to be threonine-phosphorylated at Thr(558) in activated platelets within its conserved putative actin-binding domain, The pathway leading to this phosphorylation step and its control have not been previously elucidated, We have detected and characterized reactions leading to moesin phosphorylation in human leukocyte extracts, In vitro phosphorylation of endogenous moesin, which was identified by peptide microsequencing, was dependent on phosphatidylglycerol (PG) or to a lesser extent, phosphatidylinositol (PI), but not phosphatidylserine (PS) and diacylglycerol (DAG), Analysis of charge shifts, phosphoamino acid analysis, and stoichiometry was consistent with a single phosphorylation site, By using mass spectroscopy and direct microsequencing of CNBr fragments of phospho-moesin, the phosphorylation site was identified as KYKT*LRQIR (where * indicates the phosphorylation site) (Thr(558)), which is conserved in the ERM family, Recombinant moesin demonstrated similar in vitro phospholipid-dependent phosphorylation compared with the endogenous protein, The phosphorylation site sequence of moesin displays a high degree of conservation with the pseudosubstrate sequences of the protein kinase C (PKC) family, We identified the kinase activity as PKC-theta on the basis of immunodepletion of the moesin kinase activity and copurification of PKC-theta with the enzymic activity, We further demonstrate that PKC-theta displays a preference for PG vesicles over PI or PS/DAG, with minimal activation by DAG, as well as specificity for moesin compared with myelin basic protein, histone H1, or other cellular proteins, Expression of a human His(6)-tagged PKC-theta in Jurkat cells and purification by Ni2+ chelate chromatography yield an active enzyme that phosphorylates moesin, PG vesicle binding experiments with expressed PKC-theta and moesin demonstrate that both bind to vesicles independently of one another, Thus, PKC-theta is identified as a major kinase within cells with specificity for moesin and with activation under non-classical PKC conditions, It appears likely that this activity corresponds to a specific intracellular pathway controlling the function of moesin as well as other ERM proteins.	Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; La Jolla Inst Allergy & Immunol, Div Cell Biol, La Jolla, CA 92121 USA	University of New Mexico; University of New Mexico; La Jolla Institute for Immunology	Elias, L (corresponding author), Univ New Mexico, Ctr Canc, 900 Camino de Salud NE, Albuquerque, NM 87131 USA.	lelias@cobra.unm.edu			NATIONAL CANCER INSTITUTE [R01CA042520, R01CA035299] Funding Source: NIH RePORTER; NCI NIH HHS [CA35299, CA42520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRUNS KA, 1988, BLOOD, V72, P234; CELIS JE, 1992, ELECTROPHORESIS, V13, P893, DOI 10.1002/elps.11501301198; CHANG JD, 1993, J BIOL CHEM, V268, P14208; COOPER JA, 1991, METHOD ENZYMOL, V201, P251; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; ELIAS L, 1985, J BIOL CHEM, V260, P7023; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ERDEL M, 1995, GENOMICS, V25, P595, DOI 10.1016/0888-7543(95)80068-W; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FURTHMAYR H, 1992, KIDNEY INT, V41, P665, DOI 10.1038/ki.1992.102; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLEMM DJ, 1987, J BIOL CHEM, V262, P7580; KLEMM DJ, 1988, EXP HEMATOL, V16, P855; KORANT BD, 1974, ANAL BIOCHEM, V59, P75, DOI 10.1016/0003-2697(74)90011-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; Meller N, 1996, MOL CELL BIOL, V16, P5782; MISCHAK H, 1993, FEBS LETT, V326, P51, DOI 10.1016/0014-5793(93)81759-S; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGITA K, 1991, METHOD ENZYMOL, V200, P228; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seki K, 1996, ARCH BIOCHEM BIOPHYS, V326, P193, DOI 10.1006/abbi.1996.0065; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; SIMONS PC, 1993, BLOOD, V82, P3343; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; STDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TOKER A, 1994, J BIOL CHEM, V269, P32358; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; WILGENBUS KK, 1993, GENOMICS, V16, P199, DOI 10.1006/geno.1993.1159; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641	62	178	199	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7594	7603		10.1074/jbc.273.13.7594	http://dx.doi.org/10.1074/jbc.273.13.7594			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516463	hybrid			2022-12-27	WOS:000072738500059
J	Standaert, M; Bandyopadhyay, G; Galloway, L; Ono, Y; Mukai, H; Farese, R				Standaert, M; Bandyopadhyay, G; Galloway, L; Ono, Y; Mukai, H; Farese, R			Comparative effects of CTP gamma S and insulin on the activation of Rho, phosphatidylinositol 3-kinase, and protein kinase N in rat adipocytes - Relationship to glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-CELLS; TRANSLOCATION; 3,4,5-TRISPHOSPHATE; INHIBITION; WORTMANNIN; BINDING; FAMILY; GLUT4	Electroporation of rat adipocytes with guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) elicited sizable insulinlike increases in glucose transport and GLUT4 translocation. Like insulin, GTP gamma S activated membrane phosphatidylinositol (PI) 3-kinase in rat adipocytes, but, unlike insulin, this activation was blocked by Clostridium botulinum C3 transferase, suggesting a requirement for the small G-protein, RhoA. Also suggesting that Rho may operate upstream of PI 3-kinase during GTP gamma S action, the stable overexpression of Rho in 3T3/L1 adipocytes provoked increases in membrane PI 3-kinase activity. As with insulin treatment, GTP gamma S stimulation of glucose transport in rat adipocytes was blocked by C3 transferase, wortmannin, LY294002, and RO 31-8220; accordingly, the activation of glucose transport by GTP gamma S, as well as insulin, appeared to require Rho, PI S-kinase, and another downstream kinase, e.g. protein kinase C-zeta (PKC-zeta) and/or protein kinase N (PKN). Whereas insulin activated both PKN and PKC-zeta, GTP gamma S activated PKN but not PKC-zeta. In transfection studies in 3T3/L1 cells, stable expression of wild-type Rho and PKN activated glucose transport, and dominant-negative forms of Rho and PKN inhibited insulin stimulated glucose transport. In transfection studies in rat adipocytes, transient expression of wild-type and constitutive Rho and wildtype PI(N provoked increases in the translocation of hemagglutinin (HA)-tagged GLUT4 to the plasma membrane; in contrast, transient expression of dominant-negative forms of Rho and PKN inhibited the effects of both insulin and GTP gamma S on HA-GLUT4 translocation. Our findings suggest that (a) GTP gamma S and insulin activate Rho, PI S-kinase, and PKN, albeit by different mechanisms; (b) each of these signaling substances appears to be required for, and may contribute to, increases in glucose transport; and (c) PKC-zeta may contribute to increases in glucose transport during insulin, but not GTP gamma S, action.	James A Haley Vet Hosp, Res Serv VAR 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem Mol Biol, Tampa, FL 33612 USA; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Kobe University	Farese, R (corresponding author), James A Haley Vet Hosp, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.			Mukai, Hideyuki/0000-0002-0167-8695	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BANDYOPADHYAY B, 1997, J BIOL CHEM, V272, P2551; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CORMONT M, 1993, J BIOL CHEM, V268, P19491; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; IZAWA T, 1993, RES COMMUN CHEM PATH, V82, P307; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Standaert ML, 1996, FEBS LETT, V388, P26, DOI 10.1016/0014-5793(96)00492-9; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	24	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7470	7477		10.1074/jbc.273.13.7470	http://dx.doi.org/10.1074/jbc.273.13.7470			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516446	hybrid			2022-12-27	WOS:000072738500042
J	Tintut, Y; Parhami, F; Bostrom, K; Jackson, SM; Demer, LL				Tintut, Y; Parhami, F; Bostrom, K; Jackson, SM; Demer, LL			cAMP stimulates osteoblast-like differentiation of calcifying vascular cells - Potential signaling pathway for vascular calcification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; SMOOTH-MUSCLE; CYCLIC-AMP; ADENOSINE-MONOPHOSPHATE; ENDOTHELIAL-CELLS; GLA PROTEIN; OSTEOPONTIN; EXPRESSION; GROWTH; PROLIFERATION	The role of the cAMP signaling pathway in vascular calcification was investigated using calcifying vascular cells (CVC) derived from primary aortic medial cell cultures. We previously showed that CVC have fibroblastic morphology and express several osteoblastic differentiation markers. After confluency, they aggregate into cellular condensations, which later mature into nodules where mineralization is localized. Here, we investigated the effects of cAMP on CVC differentiation because it plays a role in both osteoblastic differentiation and vascular disease. Dibutyryl-cAMP or forskolin treatment of CVC for 3 days induced osteoblast-like "cuboidal" morphology, inhibited proliferation, and enhanced alkaline phosphatase activity, all early markers of osteoblastic differentiation. Isobutylmethylxanthine and cholera toxin had the same effects. Treatment of CVC with pertussis toxin, however, did not induce the morphological change or increase alkaline phosphatase activity, although it inhibited CVC proliferation to a similar extent. cAMP also increased type I procollagen production and gene expression of matrix gamma-carboxyglutamic acid protein, recently shown to play a role in in vivo vascular calcification. cAMP inhibited the expression of osteopontin but did not affect the expression of osteocalcin and core binding factor, Prolonged cAMP treatment enhanced matrix calcium-mineral incorporation but inhibited the condensations resulting in diffuse mineralization throughout the monolayer of cells. Treatment of CVC with a protein kinase A-specific inhibitor, KT5720, inhibited alkaline phosphatase activity and mineralization during spontaneous CVC differentiation. These results suggest that the cAMP pathway promotes in vitro vascular calcification by enhancing osteoblast like differentiation of CVC.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol,Ctr Hlth Sci 47 123, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tintut, Y (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol,Ctr Hlth Sci 47 123, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NHLBI NIH HHS [HL30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUBIN JE, 1995, BONE, V17, P77; AUGUSTYN JM, 1975, SCIENCE, V187, P449, DOI 10.1126/science.163039; BARONE LM, 1991, J CELL BIOCHEM, V46, P351, DOI 10.1002/jcb.240460410; Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; Dennis JE, 1996, CONNECT TISSUE RES, V35, P93, DOI 10.3109/03008209609029179; Dubey RK, 1996, HYPERTENSION, V28, P765, DOI 10.1161/01.HYP.28.5.765; DUNLOP LLT, 1995, INT J DEV BIOL, V39, P357; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; GALLE J, 1992, ARTERIOSCLER THROMB, V12, P180, DOI 10.1161/01.ATV.12.2.180; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; HALL BK, 1992, ANAT EMBRYOL, V186, P107; HOEG JM, 1994, ARTERIOSCLER THROMB, V14, P1066, DOI 10.1161/01.ATV.14.7.1066; HONYE J, 1992, CIRCULATION, V85, P1012, DOI 10.1161/01.CIR.85.3.1012; KIEFER MC, 1990, NUCLEIC ACIDS RES, V18, P1909, DOI 10.1093/nar/18.7.1909; Kruger MC, 1997, PROG LIPID RES, V36, P131, DOI 10.1016/S0163-7827(97)00007-6; Langner RO, 1996, RES COMMUN MOL PATH, V94, P193; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317; McKee MD, 1996, ANAT RECORD, V245, P394, DOI 10.1002/(SICI)1097-0185(199606)245:2<394::AID-AR19>3.0.CO;2-K; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P611, DOI 10.1097/00005344-199504000-00015; NEFUSSI JR, 1989, BONE, V10, P345, DOI 10.1016/8756-3282(89)90131-2; NODA M, 1990, ENDOCRINOLOGY, V127, P185, DOI 10.1210/endo-127-1-185; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PARHAMI F, 1997, J ARTERIOSCLER THROM, V17, P680; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; POVINELLI CM, 1992, BIOCHIM BIOPHYS ACTA, V1115, P243, DOI 10.1016/0304-4165(92)90061-X; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; REDDI AH, 1993, J BONE MINER RES, V8, P499; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; Robey PG, 1996, CONNECT TISSUE RES, V35, P131, DOI 10.3109/03008209609029183; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; SIDDHANTI SR, 1994, J CELL BIOCHEM, V55, P310, DOI 10.1002/jcb.240550307; Silkensen JR, 1995, J CLIN INVEST, V96, P2646, DOI 10.1172/JCI118330; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; VICKER MG, 1994, J CELL SCI, V107, P659; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZHANG LM, 1994, ENDOCRINOLOGY, V134, P1297, DOI 10.1210/en.134.3.1297	44	152	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7547	7553		10.1074/jbc.273.13.7547	http://dx.doi.org/10.1074/jbc.273.13.7547			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516456	hybrid			2022-12-27	WOS:000072738500052
J	Baron, V; Calleja, V; Ferrari, P; Alengrin, F; Van Obberghen, E				Baron, V; Calleja, V; Ferrari, P; Alengrin, F; Van Obberghen, E			p125(Fak) focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; SIGNAL-TRANSDUCTION; LYSOPHOSPHATIDIC ACID; DOMAIN AUTOPHOSPHORYLATION; MAP-KINASE; CROSS-TALK; PHOSPHORYLATION; PROTEIN; PAXILLIN; DEPHOSPHORYLATION	The focal adhesion kinase p125(Fak) is a widely expressed cytosolic tyrosine kinase, which is involved in integrin signaling and in signal transduction of a number of growth factors. In contrast to tyrosine kinase receptors such as the platelet-derived growth factor and the hepatocyte growth factor receptors, which induce p125(Fak) phosphorylation, insulin has been shown to pro mote its dephosphorylation. In this study, we compared p125(Fak) phosphorylation in insulin-stimulated cells maintained in suspension or in an adhesion state. We found that, in nonattached cells, insulin promotes p125(Fak) phosphorylation, whereas dephosphorylation occurred in attached cells, This was observed in Rat-1 fibroblasts overexpressing the insulin receptor, as well as in Hep G2 hepatocytes and in 3T3-L1 adipocytes expressing more natural levels of insulin receptors. Insulin-induced p125(Fak) phosphorylation correlated with an increase in paxillin phosphorylation, indicating that p125(Fak) kinase activity may be stimulated by insulin. Mixing of purified insulin or insulin-like growth factor-I (IGF-I) receptors with p125(Fak) resulted in an increase in p125(Fak) phosphorylation. Using a kinase-deficient p125(Fak) mutant, we found that this protein is a direct substrate of the insulin and IGF-I receptor tyrosine kinases. This view is supported by two additional findings. (i) A peptide corresponding to p125(Fak) sequence comprising amino acids 568-582, which contains tyrosines 576 and 577 of the kinase domain regulatory loop, is phosphorylated by the insulin receptor; and (ii) p125(Fak) phosphorylation by the insulin receptor is prevented by addition of this peptide, Finally, we observed that p125(Fak) phosphorylation by the receptor results in its activation. Our results show that the nature of the crosstalk between the insulin/IGF-I receptors and p125(Fak) is dependent on the cell architecture, and hence the interaction of the insulin/IGF-I signaling system with the integrin system will vary accordingly.	Fac Med Nice, INSERM, U145, F-06107 Nice 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Baron, V (corresponding author), Fac Med Nice, INSERM, U145, Ave Valombrose, F-06107 Nice 02, France.							BARON V, 1995, EUR J BIOCHEM, V229, P27, DOI 10.1111/j.1432-1033.1995.tb20433.x; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KMIECIK TE, 1987, CELL, V49, P69; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MITRA G, 1991, ONCOGENE, V6, P2237; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RANKIN S, 1994, J BIOL CHEM, V269, P704; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUEFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TARTARE S, 1994, J BIOL CHEM, V269, P11449; Tobe K, 1996, MOL CELL BIOL, V16, P4765; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	62	94	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7162	7168		10.1074/jbc.273.12.7162	http://dx.doi.org/10.1074/jbc.273.12.7162			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507031	hybrid			2022-12-27	WOS:000072775900081
J	Fridell, YWC; Villa, J; Attar, EC; Liu, ET				Fridell, YWC; Villa, J; Attar, EC; Liu, ET			GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; GROWTH-FACTOR; PROTEIN-S; CELLS; MIGRATION; SKY; PRODUCT; CLONING; LIGAND	Atherosclerosis and arterial restenosis are disease processes involving the accumulation of vascular smooth muscle cells following vascular injury. Key events leading to these processes are migration and proliferation of these cells. Here, we demonstrate that GAS6, encoded by the growth arrest-specific gene 6, induces a directed migration (chemotaxis) of both rat and human primary vascular smooth muscle cells while showing only marginal mitogenic potential in human vascular smooth muscle cells. GAS6 stimulation induces Axl autophosphorylation in human vascular smooth muscle cells, indicating that specific GAS6-Axl interactions may be associated with GAS6-directed chemotaxis, To test this hypothesis, vascular smooth muscle cells overexpressing Axl were generated by gene transfer and assessed for their ability to migrate along a GAS6 gradient. These Axl overexpressors exhibited 2-5-fold increased sensitivity to GAS6-induced chemotaxis, Furthermore, vascular smooth muscle cells expressing the kinase dead mutant of Axl or exposure to the soluble Axl extracellular domain showed attenuated GAS6-induced migration, Taken together, these results suggest that GAS6 is a novel chemoattractant that induces Axl-mediated migration of vascular smooth muscle cells, The separation of mitogenesis from migration provided by this study may enhance the molecular dissection of cell migration in vascular damage.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Liu, ET (corresponding author), NCI, Div Clin Sci, Sect Mol Signalling & Oncogenesis, NIH, 10-6C206 10 Ctr Dr,MSC 1585, Bethesda, MD 20892 USA.		Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [R01CA049240] Funding Source: NIH RePORTER; NCI NIH HHS [CA49240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; LAI C, 1994, ONCOGENE, V9, P2567; Li RH, 1996, J NEUROSCI, V16, P2012; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; Nakano T, 1996, FEBS LETT, V387, P75, DOI 10.1016/0014-5793(96)00394-8; Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOCHEM, V117, P1267, DOI 10.1093/oxfordjournals.jbchem.a124854; OHASHI K, 1994, ONCOGENE, V9, P699; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Ross R, 1996, NAT MED, V2, P527, DOI 10.1038/nm0596-527; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	29	154	174	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7123	7126		10.1074/jbc.273.12.7123	http://dx.doi.org/10.1074/jbc.273.12.7123			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507025	hybrid, Green Published			2022-12-27	WOS:000072775900075
J	Leopoldt, D; Hanck, T; Exner, T; Maier, U; Wetzker, R; Nurnberg, B				Leopoldt, D; Hanck, T; Exner, T; Maier, U; Wetzker, R; Nurnberg, B			G beta gamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH DOMAINS; BINDING; KINASE; PURIFICATION; ACTIVATION; PROTEINS; BRAIN	Class I phosphoinositide 3-kinases (PI3Ks) regulate important cellular processes such as mitogenesis, apoptosis, and cytoskeletal functions. They include PI3K alpha, -beta, and -delta isoforms coupled to receptor tyrosine kinases and a PI3K gamma isoform activated by receptor-stimulated G proteins. This study examines the direct interaction of purified recombinant PI3K gamma catalytic subunit (p110 gamma) and G beta gamma complexes. When phosphatidylinositol was used as a substrate, G beta gamma stimulated p110 gamma lipid kinase activity more than 60-fold (EC50, similar to 20 nM). Stimulation was inhibited by G alpha(o)-GDP or wortmannin in a concentration-dependent fashion. Stoichiometric binding of a monoclonal antibody to the putative pleckstrin homology domain of p110 gamma did not affect G beta gamma-mediated enzymatic stimulation, whereas incubation of G beta gamma with a synthetic peptide resembling a predicted G beta gamma effector domain of type 2 adenylyl cyclase selectively inhibited activation of p110 gamma. G beta gamma complexes bound to N- as well as C-terminal deletion mutants of p110 gamma. Correspondingly, these enzymatically inactive N- and C-terminal mutants inhibited G beta gamma-mediated activation of wild type p110 gamma. Our data suggest that (i) p110 gamma directly interacts with G beta gamma, (ii) the pleckstrin homology domain is not the only region important for G beta gamma-mediated activation of the lipid kinase, and (iii) G beta gamma binds to at least two contact sites of p110 gamma, one of which is close to or within the catalytic core of the enzyme.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Dahlem, Germany; Univ Jena, Max Planck Arbeitsgrp Mol Zellbiol, D-6900 Jena, Germany	Free University of Berlin; Friedrich Schiller University of Jena; Max Planck Society	Nurnberg, B (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Dahlem, Germany.		Wetzker, Reinhard/AAD-8713-2019	Nurnberg, Bernd/0000-0002-5995-6555				CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; DHAND R, 1994, EMBO J, V13, P4261; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; NURNBERG B, 1994, BIOCHEM J, V300, P387; Nurnberg B, 1997, BACTERIAL TOXINS TOO, P47; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Srinivasan N, 1996, BIOCHEM BIOPH RES CO, V220, P697, DOI 10.1006/bbrc.1996.0467; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	45	182	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7024	7029		10.1074/jbc.273.12.7024	http://dx.doi.org/10.1074/jbc.273.12.7024			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507010	hybrid			2022-12-27	WOS:000072775900060
J	Lo, YYC; Luo, L; McCulloch, CAG; Cruz, TF				Lo, YYC; Luo, L; McCulloch, CAG; Cruz, TF			Requirements of focal adhesions and calcium fluxes for interleukin-1-induced ERK kinase activation and c-fos expression in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; COLLAGENASE PRODUCTION; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; PHOSPHORYLATION; CHONDROCYTES; INDUCTION; CELLS; IDENTIFICATION	Interleukin-1 (IL-1) is an important inflammatory mediator and plays a central role in the destruction of connective tissue matrices in diseases such as arthritis and periodontitis, It is well established that IL-1 activation of the mitogen-activated protein (MAP) kinase pathway and induction of c-fos expression is a required step in the induction of matrix metalloproteinase expression involved in tissue degradation, Previous studies in our laboratory showed that IL-l-induced calcium flux is dependent on focal adhesion formation, suggesting a matrix-dependent restriction system for IL-1 signaling, Therefore, in the present study, we examined the consequences of this restriction on IL-l-mediated activation of the MAP kinase family and on c-fos expression, Treatment of human gingival fibroblasts with IL-1 activated extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK), and p38 kinase activity and induced c-fos expression in a dose-and time-dependent fashion, Plating cells on poly-L-lysine prevented focal adhesion formation, eliminated IL-l-induced calcium influx, abolished ERR stimulation, and blocked c-fos expression, Cells in suspension and hence with no suitable substratum for focal adhesion formation also showed no ERK activation or enhanced c-fos expression in response to IL-1, In contrast, eliminating focal adhesion formation or calcium depletion in cells plated on fibronectin had no effect on IL-1 stimulation of JNK and p38 kinases, demonstrating that their activation was mediated through pathways independent of focal adhesions and calcium, Calcium depletion abolished IL-1-induced calcium uptake, ERK activation, and c-fos expression, The focal adhesion dependence of IL-1-induced ERK activation and c-fos expression could be circumvented in cells plated on poly-L-lysine by simultaneous incubation with IL-l and the calcium ionophore ionomycin, In transfection studies, IL-l stimulation of serum responsive element (SRE) transcriptional activity was dependent on the presence of extracellular calcium, This is consistent with a requirement for calcium in the activation of ERKs and their involvement in the induction of c-fos expression through the SRE site on the 5' promoter of the c-fos gene, Our results demonstrate that in cells attached to substrates by focal adhesion, IL-l-mediated calcium flux is required for ERI( activation and c-fos expression but not for JNK or p38 activation, We conclude that cellular interactions with the extracellular matrix play an important role in restricting ERK and c-fos-dependent processes.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Fac Dent, MRC, Periodontal Physiol Grp, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Cruz, TF (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.							ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Ausubel FM, 1991, CURRENT PROTOCOLS MO; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CRUZ TF, 1990, BIOCHEM J, V269, P717, DOI 10.1042/bj2690717; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DOWER SK, 1990, J INVEST DERMATOL, V94, pS68, DOI 10.1111/1523-1747.ep12875154; DOWER SK, 1992, CHEM IMMUNOL, V51, P33; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; GABBIANI G, 1983, P NATL ACAD SCI-BIOL, V80, P2361, DOI 10.1073/pnas.80.8.2361; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Luo L, 1997, BIOCHEM J, V324, P653, DOI 10.1042/bj3240653; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; NG SB, 1994, J BIOL CHEM, V269, P19021; PELLETIER JP, 1993, RHEUM DIS CLIN N AM, V19, P545; POSTLETHWAITE AE, 1983, J EXP MED, V157, P801, DOI 10.1084/jem.157.2.801; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; TATAKIS DN, 1993, J PERIODONTOL, V64, P416; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531	42	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7059	7065		10.1074/jbc.273.12.7059	http://dx.doi.org/10.1074/jbc.273.12.7059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507015	hybrid			2022-12-27	WOS:000072775900065
J	Marie-Claire, C; Roques, BP; Beaumont, A				Marie-Claire, C; Roques, BP; Beaumont, A			Intramolecular processing of prothermolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA ELASTASE; SITE-DIRECTED MUTAGENESIS; NEUTRAL PROTEASE; ACTIVE-SITE; BACILLUS-SUBTILIS; PRO-SEQUENCE; DENATURED SUBTILISIN; CATALYTIC ACTIVITY; ESCHERICHIA-COLI; THERMOLYSIN	Thermolysin, an extracellular zinc endopeptidase from Bacillus thermoproteolyticus, is synthesized as a pre-proenzyme and the prosequence has been shown to assist the refolding of the denatured enzyme in vitro and to inhibit enzyme activity (O'Donohue, M. J., and Beaumont, A. (1996) J. Biol. Chem. 271, 26477-26481), To determine whether prosequence cleavage from the mature enzyme is autocatalytic and if so, whether it is an intermolecular or intramolecular process, N-terminal histidine-tagged prothermolysin was expressed in Escherichia coli, Although partial processing to mature enzyme occurred, most of the proenzyme was recovered intact from inclusion bodies, This was then solubilized in guanidinium hydrochloride, immobilized on a cobalt-containing resin, and after dialysis against renaturation buffer, was quantitatively transformed to mature enzyme, However, when a mutation was introduced into the mature sequence to inactivate thermolysin, the proenzyme was not processed either in vivo or in vitro. In addition, mutated prothermolysin was not processed by exogenous thermolysin under a variety of experimental conditions, The results demonstrate that thermolysin maturation can proceed via an autocatalytic intramolecular pathway.	UER Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, F-75270 Paris 06, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Beaumont, A (corresponding author), UER Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, 4 Ave Observ, F-75270 Paris 06, France.		Marie-Claire, Cynthia/L-4582-2017; MARIE-CLAIRE, Cynthia/AAX-6752-2021	Marie-Claire, Cynthia/0000-0002-2282-134X; MARIE-CLAIRE, Cynthia/0000-0002-2282-134X				BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BEAUMONT A, 1995, J BIOL CHEM, V270, P16803, DOI 10.1074/jbc.270.28.16803; BEAUMONT A, 1997, CELL SURFACE PEPTIDA, P59; BENCHETRIT T, 1987, BIOCHEM BIOPH RES CO, V147, P1034, DOI 10.1016/S0006-291X(87)80174-2; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; CHANG SC, 1994, J BIOL CHEM, V269, P3584; CORBETT A, 1988, BIOCH CELL BIOL, V64, P953; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EIJSINK VGH, 1995, NAT STRUCT BIOL, V2, P374, DOI 10.1038/nsb0595-374; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu ZX, 1996, J BIOL CHEM, V271, P3375; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KAWAMOTO S, 1993, INFECT IMMUN, V61, P1400, DOI 10.1128/IAI.61.4.1400-1405.1993; KESSLER E, 1994, J BIOL CHEM, V269, P22726; Kojima S, 1997, FEBS LETT, V411, P128, DOI 10.1016/S0014-5793(97)00678-9; Li YY, 1996, J MOL BIOL, V262, P591, DOI 10.1006/jmbi.1996.0537; Litster SA, 1996, ACTA CRYSTALLOGR D, V52, P543; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MCIVER K, 1991, J BACTERIOL, V173, P7781, DOI 10.1128/jb.173.24.7781-7789.1991; ODonohue MJ, 1996, J BIOL CHEM, V271, P26477, DOI 10.1074/jbc.271.43.26477; ODONOHUE MJ, 1994, BIOCHEM J, V300, P599, DOI 10.1042/bj3000599; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; RAWLINGS N, 1995, METHOD ENZYMOL, V290, P205; ROCHE RS, 1978, CRC CR REV BIOCH MOL, V5, P1; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Sambrook F., 1989, MOL CLONING LAB MANU; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; TAKAGI M, 1989, J FERMENT BIOENG, V67, P71, DOI 10.1016/0922-338X(89)90182-7; TAYLOR M, 1995, PROTEIN ENG, V15, P59; TOMA S, 1989, PROTEIN ENG, V2, P359, DOI 10.1093/protein/2.5.359; Volkov A, 1996, J MOL BIOL, V262, P595, DOI 10.1006/jmbi.1996.0538; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; WEI L, 1991, J BIOL CHEM, V266, P9002; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WETMORE DR, 1994, MOL MICROBIOL, V12, P747, DOI 10.1111/j.1365-2958.1994.tb01062.x; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	42	40	43	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5697	5701		10.1074/jbc.273.10.5697	http://dx.doi.org/10.1074/jbc.273.10.5697			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488701	hybrid			2022-12-27	WOS:000072345000044
J	Chen, YQ; Su, M; Walia, RR; Hao, Q; Covington, JW; Vaughan, DE				Chen, YQ; Su, M; Walia, RR; Hao, Q; Covington, JW; Vaughan, DE			Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; INSULIN-RESISTANCE; RISK FACTOR; C-FOS; TYPE-1; TRANSCRIPTION; ATHEROSCLEROSIS	This study was designed to characterize the direct effects of hyperglycemia on plasminogen activator inhibitor-1 (PAI-1) expression in cultured vascular smooth muscle cells, Glucose induced dose- and time-dependent increases of PAI-1 mRNA expression in rat aortic smooth muscle (RASM) cells in vitro, Using a series of luciferase reporter gene constructs containing PAI-1 5'-flanking sequence (from -6.4 kilobase to -42 base pairs (bp)) transfected into RASM, we found that glucose (25 mM) consistently induced a 4-fold increase in luciferase activity, with the response localized to sequence between -85 and -42 bp. Mutagenesis of two putative Sp1-binding sites located in the region of interest essentially obliterated the glucose-response. Electrophoretic mobility shift assays with radiolabeled oligonucleotides containing the two putative Sp1-binding sites from PAI-1 promoter and nuclear extracts from RASM cells revealed that glucose treatment markedly changed the mobility pattern of the major protein-DNA complexes. Supershift assay showed that transcription factor Sp1 was present in the complexes under control and hyperglycemic conditions. These results suggest that glucose regulates PAI-1 gene expression in RASM cells through an effect on two adjacent Sp1 sites located between -85 and -42 bp of the PAI-1 5'-flanking region and that the release of a transcriptional repressor from the Sp1 complexes may explain the activation of the PAI-1 gene under high glucose conditions in RASM cells.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville Vet Affairs Med Ctr,Cardiovasc Div, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Vaughan, DE (corresponding author), Vanderbilt Univ, Med Ctr, Div Cardiol, Rm 352B MRB 2, Nashville, TN 37232 USA.			Chen, Yan Q/0000-0001-9311-6077	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050878, R01HL051387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51387, HL50878] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; Chen YQ, 1996, HYPERTENSION, V27, P1224, DOI 10.1161/01.HYP.27.6.1224; CHOMIKI N, 1994, THROMB HAEMOSTASIS, V72, P44; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; GATLIN J, 1995, BIOTECHNIQUES, V19, P559; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; GRAINGER DJ, 1994, BIOCHEM J, V299, P227, DOI 10.1042/bj2990227; JUHANVAGUE I, 1989, THROMB HAEMOSTASIS, V61, P370; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KERINS DM, 1995, J CLIN INVEST, V96, P2515, DOI 10.1172/JCI118312; KNUDSEN H, 1994, EUR J BIOCHEM, V220, P63, DOI 10.1111/j.1432-1033.1994.tb18599.x; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; MAIELLO M, 1992, DIABETES, V41, P1009, DOI 10.2337/diabetes.41.8.1009; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; NORDT TK, 1994, CIRCULATION, V89, P321, DOI 10.1161/01.CIR.89.1.321; NORDT TK, 1993, ARTERIOSCLER THROMB, V13, P1822, DOI 10.1161/01.ATV.13.12.1822; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SCHWARTZ CJ, 1992, DIABETES CARE, V15, P1156, DOI 10.2337/diacare.15.9.1156; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VANLOON BJP, 1993, METABOLISM, V42, P945, DOI 10.1016/0026-0495(93)90005-9; Xiao Q, 1997, P NATL ACAD SCI USA, V94, P10335, DOI 10.1073/pnas.94.19.10335	36	158	163	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8225	8231		10.1074/jbc.273.14.8225	http://dx.doi.org/10.1074/jbc.273.14.8225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525928	hybrid			2022-12-27	WOS:000072876300062
J	Hayashi, H; De Bellis, L; Yamaguchi, K; Kato, A; Hayashi, M; Nishimura, M				Hayashi, H; De Bellis, L; Yamaguchi, K; Kato, A; Hayashi, M; Nishimura, M			Molecular characterization of a glyoxysomal long chain acyl-CoA oxidase that is synthesized as a precursor of higher molecular mass in pumpkin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL PRESEQUENCE; NORTHERN BLOT ANALYSIS; CITRATE SYNTHASE; RAT-LIVER; COTYLEDONS; PURIFICATION; PEROXISOMES; IDENTIFICATION; MICROBODIES; TRANSITION	A cDNA clone for pumpkin acyl-CoA oxidase (EC 1.3.3.6; ACOX) was isolated from a lambda gt11 cDNA library constructed from poly(A)(+) RNA extracted from etiolated cotyledons, The inserted cDNA clone contains 2313 nucleotides and encodes a polypeptide of 690 amino acids, Analysis of the amino-terminal sequence of the protein indicates that the pumpkin acyl-CoA oxidase protein is synthesized as a larger precursor containing a cleavable amino-terminal presequence of 45 amino acids. This presequence shows high similarity to the typical peroxisomal targeting signal (PTS2). Western blot analysis following cell fractionation in a sucrose gradient revealed that ACOX is localized in glyoxysomes, A partial purification of ACOX from etiolated pumpkin cotyledons indicated that the ACOX cDNA codes for a long chain acyl-CoA oxidase, The amount of ACOX increased and reached to the maximum activity by day 5 of germination but decreased about 4-fold on the following days during the subsequent microbody transition from glyoxysomes to leaf peroxisomes. By contrast, the amount of mRNA was already high at day 1 of germination, increased by about 30% at day 3, and faded com pletely by day 7. These data indicated that the expression pattern of ACOX was very similar to that of the glyoxysomal enzyme 3-ketoacyl-CoA thiolase, another marker enzyme of the beta-oxidation spiral, during germination and suggested that the expression of each enzyme of P-oxidation is coordinately regulated.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 444, Japan; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 444, Japan; Dipartimento Biol Piante Agr, Sez Fisiol Vegetale, I-56124 Pisa, Italy	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Nishimura, M (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 444, Japan.	mikosome@nibb.ac.jp	De Bellis, Luigi/I-2950-2019	De Bellis, Luigi/0000-0002-6047-3526; Nishimura, Mikio/0000-0001-7960-9721; Yamaguchi, Katsushi/0000-0001-6871-7882				Aebi H., 1974, METHODS ENZYMATIC AN, Vsecond, P673, DOI [DOI 10.1016/B978-0-12-091302-2.50032-3, 10.1016/B978-0-12-091302-2.50032-3]; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BEEVERS H, 1979, ANNU REV PLANT PHYS, V30, P159, DOI 10.1146/annurev.pp.30.060179.001111; Do YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P295, DOI 10.1006/abbi.1997.0212; DUBOURDIEU M, 1977, J BIOL CHEM, V252, P1453; GERHARDT B, 1987, METHOD ENZYMOL, V148, P516; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Hodges T K, 1974, Methods Enzymol, V32, P392; Hooks MA, 1996, BIOCHEM J, V320, P607, DOI 10.1042/bj3200607; HUANG AHC, 1983, PLANT PEROXISOME; KATO A, 1995, PLANT MOL BIOL, V27, P377, DOI 10.1007/BF00020191; Kato A, 1998, PLANT CELL PHYSIOL, V39, P186, DOI 10.1093/oxfordjournals.pcp.a029356; Kato A, 1996, PLANT MOL BIOL, V31, P843, DOI 10.1007/BF00019471; Kato A, 1996, PLANT CELL, V8, P1601, DOI 10.1105/tpc.8.9.1601; KINDL H, 1987, BIOCH PLANTS, V9, P31; KIRSCH T, 1986, J BIOL CHEM, V261, P8570; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORI H, 1991, EUR J BIOCHEM, V197, P331, DOI 10.1111/j.1432-1033.1991.tb15915.x; MORI H, 1989, FEBS LETT, V244, P163, DOI 10.1016/0014-5793(89)81184-6; NISHIMURA M, 1986, PLANT PHYSIOL, V81, P313, DOI 10.1104/pp.81.1.313; OSUMI T, 1978, BIOCHEM BIOPH RES CO, V83, P479, DOI 10.1016/0006-291X(78)91015-X; PREISIGMULLER R, 1993, PLANT MOL BIOL, V22, P59, DOI 10.1007/BF00038995; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; Subramani S, 1996, J BIOL CHEM, V271, P32483, DOI 10.1074/jbc.271.51.32483; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V8, P4321; TITUS DE, 1985, J CELL BIOL, V101, P1288, DOI 10.1083/jcb.101.4.1288; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUGEKI R, 1993, PLANT CELL PHYSIOL, V34, P51; VANVELDHOVEN PP, 1994, EUR J BIOCHEM, V222, P795; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065	32	50	53	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8301	8307		10.1074/jbc.273.14.8301	http://dx.doi.org/10.1074/jbc.273.14.8301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525937	hybrid			2022-12-27	WOS:000072876300071
J	Boesen-de Cock, JGR; Tepper, AD; de Vries, E; van Blitterswijk, WJ; Borst, J				Boesen-de Cock, JGR; Tepper, AD; de Vries, E; van Blitterswijk, WJ; Borst, J			CD95 (Fas/APO-1) induces ceramide formation and apoptosis in the absence of a functional acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; TNF-RECEPTOR; CELL-DEATH; NEUTRAL SPHINGOMYELINASE; SIGNALING COMPLEX; PHOSPHOLIPASE-C; DEFICIENT MICE; FAS; PATHWAY; DOMAIN	CD95 is a potent inducer of apoptosis. It activates the caspase cascade, but also induces ceramide (Cer) production, reportedly involving acid sphingomyelinase (aSMase) activity. A role for Cer as a second messenger for apoptosis induction was proposed, based on the finding that synthetic Cer analogues can induce cell death. We have tested whether aSMase is required for 1) apo ptosis induction and 2) Cer production by CD95. For this purpose, we have used cultured Niemann-Pick disease (NPD) lymphoid cells with a defined mutation (R600H) in the aSMase protein. Despite their inherited deficiency of aSMase, we found that these cells readily undergo apoptosis upon CD95 stimulation. After retrovirus-mediated gene transfer of the aSMase cDNA, the transduced (i.e. "corrected") NPD cells showed neither increased levels of apoptosis nor altered kinetics of caspase-8 and caspase-3 activation and apoptosis induction as compared with empty vector-transduced cells. The slow sustained elevation of Cer levels in response to CD95, which we have previously documented for Jurkat T cells (Tepper, A. D., Boesen-de Cock, J. G. R., de Vries, E., Borst, J., and van Blitterswijk, W. J. (1997) J. Biol. Chem. 272, 24308-24312), was similarly found in NPD cells. Moreover, the kinetics of Cer formation remained unaffected after aSMase transduction. These results indicate that this Cer does not result from aSMase activity. We conclude that aSMase is not required for and does not facilitate CD95-mediated apoptosis and that it is not responsible for the late Cer response.	Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Dept Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jborst@nki.nl		Borst, Jannie/0000-0002-8043-5009				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HEEMSKERK MHM, 1997, J EXP MED, V186, P1; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUCHMAN EH, 1994, METABOLIC MOL BASES, P2601; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	42	96	98	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7560	7565		10.1074/jbc.273.13.7560	http://dx.doi.org/10.1074/jbc.273.13.7560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516458	hybrid			2022-12-27	WOS:000072738500054
J	Hanson, ES; Leibold, EA				Hanson, ES; Leibold, EA			Regulation of iron regulatory protein 1 during hypoxia and hypoxia/reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; NITRIC-OXIDE; RNA-BINDING; OXIDATIVE STRESS; ESCHERICHIA-COLI; ERYTHROPOIETIN GENE; RESPONSIVE ELEMENTS; ACONITASE ACTIVITY; EXPRESSION; SUPEROXIDE	Given the important relationship between O-2 and iron (Fenton chemistry) a study was undertaken to characterize the effects of hypoxia, as well as subsequent reoxygenation, on the iron-regulatory proteins 1 and 2 (IRP1 and IRP2) in a rat hepatoma cell line. IRP1 and IRP2 are cytosolic RNA-binding proteins that bind RNA stem-loops located in the 5'- or 3'-untranslated regions of specific mRNAs encoding proteins that are involved in iron homeostasis. In cells exposed to hypoxia, IRP1 RNA binding was decreased similar to 2.8-fold after a 6-h exposure to 3% O-2. Hypoxic inactivation of IRP1 was abolished when cells were pretreated with the iron chelator desferrioxamine, indicating a role for iron in inactivation. IRP1 inactivation was reversible since re-exposure of hypoxically-treated cells to 21% O-2 increased RNA binding activity similar to 7-fold after 21 h with an increase in activity seen as early as 1-h post-reoxygenation. IRP1 protein levels were unaffected during hypoxia as well as during reoxygenation. Whereas the protein synthesis inhibitor cycloheximide did not block IRP1 inactivation during hypoxia, it completely blocked IRP1 reactivation during subsequent reoxygenation. Reactivation of IRP1 during reoxygenation was also partially blocked by the phosphatase inhibitor okadaic acid. Finally, reactivated IRP1 was found to be resistant to inactivation by exogenous iron known to down-regulate its activity during normoxia. These data demonstrate that IRP1 RNA binding activity is post-translationally regulated during hypoxia and hypoxia/reoxygenation. Regulation of IRP1 by changing oxygen tension may provide a novel mechanism for post-transcriptionally regulating gene expression under these stresses.	Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Leibold, EA (corresponding author), Univ Utah, Eccles Program Human Mol Biol & Genet, 15 N 2030 E,Bldg 533,Rm 2100, Salt Lake City, UT 84112 USA.	betty.leibold@genetics.utah.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07115] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUST SD, 1985, ADV FREE RADICAL BIO, V1, P1; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; FANTINI GA, 1993, AM J PHYSIOL, V264, pH1953, DOI 10.1152/ajpheart.1993.264.6.H1953; FLINT DH, 1993, J BIOL CHEM, V268, P25547; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; KAZUHIRO I, 1995, EMBO J, V14, P5350; KENEDY MC, 1997, J BIOL CHEM, V272, P20340; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; PALMER C, 1994, STROKE, V25, P1039, DOI 10.1161/01.STR.25.5.1039; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; PATT A, 1990, J PEDIATR SURG, V25, P224, DOI 10.1016/0022-3468(90)90407-Z; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; PHILLIPS JD, 1996, BLOOD, V50, P1; QI Y, 1995, J NEUROCHEM, V64, P2458; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Seko Y, 1996, CIRC RES, V78, P82, DOI 10.1161/01.RES.78.1.82; THORBURN J, 1994, J BIOL CHEM, V269, P30580; WANG GL, 1993, BLOOD, V82, P3610; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; YU Y, 1992, J BIOL CHEM, V267, P19005	48	107	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7588	7593		10.1074/jbc.273.13.7588	http://dx.doi.org/10.1074/jbc.273.13.7588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516462	hybrid			2022-12-27	WOS:000072738500058
J	Monfardini, C; Ramamoorthy, M; Rosenbaum, H; Fang, Q; Godillot, PA; Canziani, G; Chaiken, IM; Williams, WV				Monfardini, C; Ramamoorthy, M; Rosenbaum, H; Fang, Q; Godillot, PA; Canziani, G; Chaiken, IM; Williams, WV			Construction and binding kinetics of a soluble granulocyte-macrophage colony-stimulating factor receptor alpha-chain-Fc fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTOR; HIGH-AFFINITY BINDING; HUMAN GM-CSF; MOLECULAR-CLONING; BIOLOGIC ACTIVITY; BETA-CHAIN; EXPRESSION; IDENTIFICATION; LINE; ANTIBODIES	Granulocyte-macrophage colony-stimulating factor (GM-CSF) activity is mediated by a cellular receptor (GM-CSFR) that is comprised of an alpha-chain (GM-CSFR alpha), which specifically binds GM-CSF, and a beta-chain (beta(c)), shared with the interleukin-3 and interleukin-5 receptors, GM-CSFR alpha exists in both a transmembrane (tmGM-CSFR alpha) and a soluble form (sGM-CSFR alpha). We designed an sGM-CSFR alpha-Fc fusion protein to study GM-CSF interactions with the GM-CSFR alpha. The construct was pre pared by fusing the coding region of the sGM-CSFR alpha with the CH2-CH3 regions of murine IgG2a, Purified sGM-CSFR alpha-Fc ran as a monomer of 60 kDa on reducing SDS-polyacrylamide gel electrophoresis but formed a trimer of 160-200 kDa under nonreducing conditions. The sGM-CSFR alpha-Fc bound specifically to GM-CSF as demonstrated by standard and competitive immunoassays, as well as by radioligand assay with I-125-GM-CSF, The sGM-CSFR alpha-Fc also inhibited GM-CSF-dependent cell growth and therein is a functional antagonist. Kinetics of sGM-CSFR alpha-Fc binding to GM-CSF were evaluated using an IAsys biosensor (Affinity Sensors, Paramus, NJ) with two assay systems, In the first, the sGM-CSFR alpha-Fc was bound to immobilized staphylococcal protein A on the biosensor surface, and binding kinetics of GM-CSF in solution were determined, This revealed a rapid K-off of 2.43 x 10(-2)/s, A second set of experiments was performed with GM-CSF immobilized to the sensor surface and the sGM-CSFR alpha-Fc in solution, The dissociation rate constant (k(off)) for the sGM-CSFR alpha-Fc trimer from GM-CSF was 1.57 x 10(-3)/s, attributable to the higher avidity of binding in this assay, These data indicate rapid dissociation of GM-CSF from the sGM-CSFR alpha-Fc and suggest that in vivo, sGM-CSFR alpha may need to be present in the local environment of a responsive cell to exert its antagonist activity.	Univ Penn, Sch Med, Stellar Chance Labs 913, Dept Med,Div Rheumatol, Philadelphia, PA 19104 USA	University of Pennsylvania	Williams, WV (corresponding author), Univ Penn, Sch Med, Stellar Chance Labs 913, Dept Med,Div Rheumatol, 422 Curie Blvd, Philadelphia, PA 19104 USA.	rheum@sunspark.med.upenn.edu		Williams, William/0000-0003-3611-9284	NIAID NIH HHS [AI/GM 40462, R01 AI/GM 36502] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040462] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; Ausubel FM, 1988, MOL REPROD DEV; BROWN CB, 1990, J IMMUNOL, V144, P2184; BURSTIN SJ, 1982, VIROLOGY, V117, P146, DOI 10.1016/0042-6822(82)90514-1; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CHIBA S, 1990, LEUKEMIA, V4, P29; COLIGAN JE, 1990, CURRENT PROTOCOLS IM; DIPERSIO JF, 1991, J BIOL CHEM, V266, P279; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MONFARDINI C, 1995, J BIOL CHEM, V270, P6628, DOI 10.1074/jbc.270.12.6628; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; PARK LS, 1986, J BIOL CHEM, V261, P4177; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAKI K, 1992, BIOCHEM BIOPH RES CO, V183, P252, DOI 10.1016/0006-291X(92)91636-5; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; Williams W V, 1992, PCR Methods Appl, V2, P86; WILLIAMS WV, 1992, J CLIN INVEST, V90, P326, DOI 10.1172/JCI115866; WILLIAMS WV, 1994, ARTHRITIS RHEUM, V37, P1468, DOI 10.1002/art.1780371010; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x	31	15	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7657	7667		10.1074/jbc.273.13.7657	http://dx.doi.org/10.1074/jbc.273.13.7657			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516471	hybrid			2022-12-27	WOS:000072738500067
J	Joukov, V; Kumar, V; Sorsa, T; Arighi, E; Weich, H; Saksela, O; Alitalo, K				Joukov, V; Kumar, V; Sorsa, T; Arighi, E; Weich, H; Saksela, O; Alitalo, K			A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCHAIN DISULFIDE BONDS; TYROSINE KINASES; CELLS; FLT4; ANGIOGENESIS; KDR; IDENTIFICATION; LIGAND; GENE; PDGF	The vascular endothelial growth factor (VEGF) and the VEGF-C promote growth of blood vessels and lymphatic vessels, respectively, VEGF activates the endothelial VEGF receptors (VEGFR) 1 and 2, and VEGF-C activates VEGFR-3 and VEGFR-2. Both VEGF and VEGF-C are also potent vascular permeability factors. Here we have analyzed the receptor binding and activating properties of several cysteine mutants of VEGF-C including those (Cys(156) and Cys(165)), which in other platelet-derived growth factor/VEGF family members mediate interchain disulfide bonding, Surprisingly, we found that the recombinant mature VEGF-C in which Cys(156) was replaced by a Ser residue is a selective agonist of VEGFR-3. This mutant, designated Delta N Delta C156S, binds and activates VEGFR-3 but neither binds VEGFR-2 nor activates its autophosphorylation or downstream signaling to the ERK/MAPK pathway. Unlike VEGF-C, Delta N Delta C156S neither induces vascular permeability in vivo nor stimulates migration of bovine capillary endothelial cells in culture. These data point out the critical role of VEGFR-2-mediated signal transduction for the vascular permeability activity of VEGF-C and strongly suggest that the redundant biological effects of VEGF and VEGF-C depend on binding and activation of VEGFR-2. The Delta N Delta C156S mutant may provide a valuable tool for the analysis of VEGF-C effects mediated selectively via VEGFR-3. The ability of Delta N Delta C156S to form homodimers also emphasizes differences in the structural requirements for VEGF and VEGF-C dimerization.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki 00014, Finland; Univ Helsinki, Haartman Inst, Dept Virol, Helsinki 00014, Finland; GBF, Dept Gene Express, D-38124 Braunschweig, Germany	University of Helsinki; University of Helsinki; Helmholtz Association; Helmholtz-Center for Infection Research	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, PL 21,Haartmaninkatu 3, Helsinki 00014, Finland.		Joukov, Vladimir/K-3525-2019; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1993, GROWTH FACTORS, V8, P245, DOI 10.3109/08977199308991570; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MAGLIONA D, 1996, P NATL ACAD SCI USA, V93, P2576; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PARK JE, 1994, J BIOL CHEM, V269, P25646; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wilting J, 1996, DEV BIOL, V176, P76, DOI 10.1006/dbio.1996.9993	28	188	211	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6599	6602		10.1074/jbc.273.12.6599	http://dx.doi.org/10.1074/jbc.273.12.6599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506953	hybrid			2022-12-27	WOS:000072775900003
J	Widmann, C; Gibson, S; Johnson, GL				Widmann, C; Gibson, S; Johnson, GL			Caspase-dependent cleavage of signaling proteins during apoptosis - A turn-off mechanism for anti-apoptotic signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GAMMA-RADIATION; KINASE; CELLS; RAS; RECEPTOR; MICE	Caspases are activated during apoptosis and cleave specific proteins, resulting in the irreversible commitment to cell death. The signal transduction proteins MEKK1, p21-activated kinase 2, and focal adhesion kinase are caspase substrates that contribute to the cell death response when cleaved. Thirty additional signaling proteins were screened for their ability to be cleaved during apoptosis. Twenty-two of these proteins were not affected in Jurkat cells stimulated to undergo apoptosis by Fas ligation, exposure to ultraviolet-C or incubation with etoposide. Ras GTPase-activating protein was found to be a caspase substrate whose cleavage followed the same time course as that for activation of caspase activity and the cleavage of MEKK1 and focal adhesion kinase. Four additional proteins, Cbl, Cbl-b, Raf-1, and Akt-1, were cleaved later in the apoptotic response. These signaling proteins were similarly cleaved in U937 cells undergoing apoptosis, Cleavage of the proteins was blocked by caspase inhibitors in Jurkat cells or in U937 cells expressing Bclx(L), demonstrating that the cleavage was dependent on caspase activation. Cleavage of Raf-1 and Akt correlated with the loss of extracellular signal-regulated kinase and Akt activities in apoptotic cells. Neither c-Jun N-terminal kinase nor p38 mitogen-activated protein kinase was cleaved in cells undergoing apoptosis, and the activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways was not compromised in apoptotic cells. These results indicate that caspase-dependent cleavage of specific proteins induces the turn off of survival pathways, such as the extracellular signal-regulated kinase and phosphatidylinositol-3 kinase/Akt pathways, that could otherwise interfere with the apoptotic response.	Natl Jewish Med & Res Ctr, Div Basic Sci, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Gibson, Spencer/0000-0003-0119-732X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AUGUST A, 1995, TISSUE ANTIGENS, V46, P155, DOI 10.1111/j.1399-0039.1995.tb03114.x; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; JARPE MB, 1998, IN PRESS ONCOGENE; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; WIDMANN C, 1998, IN PRESS MOL CELL BI; WIDMANN C, 1997, ONCOGENE, V15; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	35	386	390	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7141	7147		10.1074/jbc.273.12.7141	http://dx.doi.org/10.1074/jbc.273.12.7141			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507028	hybrid			2022-12-27	WOS:000072775900078
J	Brand, C; Cherradi, N; Defaye, G; Chinn, A; Chambaz, EM; Feige, JJ; Bailly, S				Brand, C; Cherradi, N; Defaye, G; Chinn, A; Chambaz, EM; Feige, JJ; Bailly, S			Transforming growth factor beta(1) decreases cholesterol supply to mitochondria via repression of steroidogenic acute regulatory protein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENOCORTICAL-CELLS; DIFFERENTIATED FUNCTIONS; ADRENAL-GLAND; TGF-BETA; FACTOR-BETA-1; STAR; INVITRO; GROWTH-FACTOR-BETA-1; CYTOCHROME-P-450; BIOSYNTHESIS	Transforming growth factor-beta s (TGF-beta s) constitute a family of dimeric proteins that affect growth and differentiation of many cell types, TGF-beta(1) has also been proposed to be an autocrine regulator of adrenocortical steroidogenesis, acting mainly by decreasing the expression of cytochrome P450c17. Here, we demonstrate that TGF-beta(1) has a second target in bovine adrenocortical cells, namely the steroidogenic acute regulatory protein (StAR). Indeed, supplying cells with steroid precursors revealed that TGF-beta(1) inhibited two steps in the steroid synthesis pathway, one prior to pregnenolone production and another corresponding to P450c17. More specifically, TGF-beta(1) inhibited pregnenolone production but neither the conversion of 25-hydroxycholesterol to pregnenolone nor P450scc activity. Thus, TGF-beta(1) must decrease the cholesterol supply to P450scc. We therefore examined the effect of TGF-beta(1) on the expression of StAR, a mitochondrial protein implicated in intramitochondrial cholesterol transport, TGF-beta(1) decreased the steady state level of StAR mRNA in a time- and concentration-dependent manner. This inhibition occurs at the level of StAR transcription and depends on RNA and protein synthesis. It is likely that the TGF-beta(1)-induced decrease of StAR expression that we report here may be expanded to other steroidogenic cells in which a decrease of cholesterol accessibility to P450scc by TGF-beta(1) has been hypothesized.	CEA Grenoble, BRCE, DBMS, INSERM,U244, F-38054 Grenoble, France; Univ Hosp Geneva, Fac Med, Dept Internal Med, Div Endocrinol & Diabetol, CH-1211 Geneva 14, Switzerland	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Geneva	Bailly, S (corresponding author), CEA Grenoble, BRCE, DBMS, INSERM,U244, 17 Rue Martyrs, F-38054 Grenoble, France.		bailly, sabine/G-3540-2013; Cherradi, Nadia/K-9695-2016; Feige, Jean-Jacques/M-8905-2017	bailly, sabine/0000-0003-1043-7030; Cherradi, Nadia/0000-0002-4292-774X; Feige, Jean-Jacques/0000-0002-1354-7692				Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; AVALLET O, 1987, BIOCHEM BIOPH RES CO, V146, P575, DOI 10.1016/0006-291X(87)90567-5; BENAHMED M, 1989, MOL CELL ENDOCRINOL, V67, P155, DOI 10.1016/0303-7207(89)90205-0; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; COCHET C, 1988, J BIOL CHEM, V263, P5707; DUPERRAY A, 1980, J STEROID BIOCHEM, V13, P1359, DOI 10.1016/0022-4731(80)90098-9; ENGELHARDT H, 1992, MOL CELL ENDOCRINOL, V85, P117, DOI 10.1016/0303-7207(92)90131-O; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FEIGE JJ, 1986, BIOCHEM BIOPH RES CO, V139, P693, DOI 10.1016/S0006-291X(86)80046-8; FEIGE JJ, 1991, ENDOCR RES, V17, P267, DOI 10.1080/07435809109027201; FEIGE JJ, 1987, J BIOL CHEM, V262, P13491; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; GUPTA P, 1993, ENDOCRINOLOGY, V132, P1184, DOI 10.1210/en.132.3.1184; HARTUNG S, 1995, BIOCHEM BIOPH RES CO, V215, P646, DOI 10.1006/bbrc.1995.2513; HOTTA M, 1986, P NATL ACAD SCI USA, V83, P7795, DOI 10.1073/pnas.83.20.7795; HOTTA M, 1987, ENDOCRINOLOGY, V121, P150, DOI 10.1210/endo-121-1-150; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JUENGEL JL, 1995, ENDOCRINOLOGY, V136, P5423, DOI 10.1210/en.136.12.5423; KERAMIDAS M, 1991, ENDOCRINOLOGY, V129, P517, DOI 10.1210/endo-129-1-517; Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LEBRETHON MC, 1994, J CLIN ENDOCR METAB, V79, P1033, DOI 10.1210/jc.79.4.1033; LeRoy C, 1996, J BIOL CHEM, V271, P11027, DOI 10.1074/jbc.271.18.11027; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MCNAMARA BC, 1990, MOL CELL ENDOCRINOL, V73, P123, DOI 10.1016/0303-7207(90)90125-R; NaamanReperant E, 1996, ENDOCRINOLOGY, V137, P886, DOI 10.1210/en.137.3.886; PARKER KL, 1997, ENDOCR REV, V18, P261; PERRIN A, 1991, ENDOCRINOLOGY, V128, P357, DOI 10.1210/endo-128-1-357; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Pilon N, 1997, ENDOCRINOLOGY, V138, P1085, DOI 10.1210/en.138.3.1085; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; RAINEY WE, 1990, ENDOCRINOLOGY, V127, P1910, DOI 10.1210/endo-127-4-1910; RAINEY WE, 1988, MOL CELL ENDOCRINOL, V60, P189, DOI 10.1016/0303-7207(88)90178-5; RAINEY WE, 1991, ENDOCR RES, V17, P281, DOI 10.1080/07435809109027202; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; Stocco DM, 1996, BIOCHEM PHARMACOL, V51, P197, DOI 10.1016/0006-2952(95)02093-4; Stocco DM, 1997, STEROIDS, V62, P29, DOI 10.1016/S0039-128X(96)00155-9; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TAKESHITA A, 1995, J IMMUNOL, V155, P419; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; van Zoelen E J, 1990, Prog Growth Factor Res, V2, P131, DOI 10.1016/0955-2235(90)90001-Z; Waterman MR, 1997, FASEB J, V11, P419, DOI 10.1096/fasebj.11.6.9194522	48	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6410	6416		10.1074/jbc.273.11.6410	http://dx.doi.org/10.1074/jbc.273.11.6410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497372	hybrid			2022-12-27	WOS:000072488500064
J	Cichy, SB; Uddin, S; Danilkovich, A; Guo, SD; Klippel, A; Unterman, TG				Cichy, SB; Uddin, S; Danilkovich, A; Guo, SD; Klippel, A; Unterman, TG			Protein kinase B/Akt mediates effects of insulin on hepatic insulin-like growth factor-binding protein-1 gene expression through a conserved insulin response sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	79th Annual Meeting of the Endocrine-Society	JUN 10-14, 1997	MINNEAPOLIS, MN	Endocrine Soc			PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; PHOSPHATIDYLINOSITOL 3-KINASE; MULTIHORMONAL REGULATION; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; SER/THR KINASE; DOMINANT ROLE; PEPCK GENE; C-AKT; TRANSCRIPTION	Insulin regulates the expression of multiple hepatic genes through a conserved insulin response sequence (IRS) (CAAAAC/TAA) by an as yet undetermined mechanism, Protein kinase B/Akt (PKB/Akt), a member of the PKA/PKC serine/threonine kinase family, functions downstream from phosphatidylinositol 3'-kinase (PI3K) in mediating effects of insulin on glucose transport and glycogen synthesis, We asked whether PKB/Akt mediates sequence-specific effects of insulin on hepatic gene expression using the model of the insulin-like growth factor binding protein-1 (IGFBP-1) promoter. Insulin lowers IGFBP-1 mRNA levels, inhibits IGFBP-1 promoter activity, and activates PKB/Akt in HepG2 hepatoma cells through a PI3K-dependent, rapamycin insensitive mechanism, Constitutively active PI3K and PKB/ Akt are each sufficient to mediate effects of insulin on the IGFBP-1 promoter in a nonadditive fashion, Dominant negative K179 PKB/Akt disrupts the ability of insulin and PI3K to activate PKB/Akt and to inhibit pro- meter activity, The IGFBP-1 promoter contains two IRSs each of which is sufficient to mediate sequence-specific effects of insulin, PI3K, and PKB/Akt on promoter activity, Highly related IRSs from the phosphoenolpyruvate carboxykinase and apolipoprotein CIII genes also are effective in this setting, These results indicate that PKB/Akt functions downstream from PI3R in mediating sequence-specific effects of insulin on the expression of IGFBP-1 and perhaps multiple hepatic genes through a conserved IRS.	Vet Affairs Chicago Area Hlth Care Syst, W Side Div, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Chiron Corp, Emeryville, CA 94608 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Novartis	Unterman, TG (corresponding author), Vet Affairs Chicago Area Hlth Care Syst, W Side Div, Rm 5A122A Res MP 151,820 S Damen Ave, Chicago, IL 60612 USA.	unterman@uic.edu	Danilkovich, Alexey/E-4014-2010	Danilkovich, Alexey/0000-0002-4650-9860; Uddin, Shahab/0000-0003-1886-6710	NIDDK NIH HHS [DK41430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041430, R01DK041430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Band CJ, 1997, J BIOL CHEM, V272, P138; BANG P, 1994, J CLIN ENDOCR METAB, V78, P960, DOI 10.1210/jc.78.4.960; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BELLACOSA A, 1993, ONCOGENE, V8, P745; BREWER MT, 1998, BIOCHEM BIOPH RES CO, V152, P1289; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OOI GT, 1993, J BIOL CHEM, V268, P16664; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Powell David R., 1995, Progress in Growth Factor Research, V6, P93, DOI 10.1016/0955-2235(95)00034-8; POWELL DR, 1991, J BIOL CHEM, V266, P18868; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QUINN PG, 1994, J BIOL CHEM, V269, P14375; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SEGER R, 1994, J BIOL CHEM, V269, P25699; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Unterman T., 1995, Progress in Growth Factor Research, V6, P119, DOI 10.1016/0955-2235(95)00020-8; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	51	150	153	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6482	6487		10.1074/jbc.273.11.6482	http://dx.doi.org/10.1074/jbc.273.11.6482			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	ZB597	9497382	hybrid			2022-12-27	WOS:000072488500074
J	Recksiek, R; Selmer, T; Dierks, T; Schmidt, B; von Figura, K				Recksiek, R; Selmer, T; Dierks, T; Schmidt, B; von Figura, K			Sulfatases, trapping of the sulfated enzyme intermediate by substituting the active site formylglycine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; ARYLSULFATASE-A; EXPRESSION; MECHANISM; CONSERVATION; MUTATIONS; PROTEIN; CLONING	Sulfatases contain an active site formylglycine residue that is generated by post-translational modification, Crystal structures of two lysosomal sulfatases revealed significant similarity Do the catalytic site of alkaline phosphatase containing a serine at the position of formylglycine, To elucidate the catalytic mechanism of sulfate ester hydrolysis, the formylglycine of arylsulfatases A and B was substituted by serine, These mutants upon incubation with substrate were covalently sulfated at the introduced serine, This sulfated enzyme intermediate was stable at pH 5, At alkaline pH it was slowly hydrolyzed. These characteristics are analogous to that of alkaline phosphatase which forms a phosphoserine intermediate that is stable at pH 5, but is hydrolyzed at alkaline pH, In wild-type sulfatases the hydroxyl needed for formation of the sulfated enzyme intermediate is provided by the aldehyde hydrate of the formylglycine, The second, non-esterified hydroxyl of the aldehyde hydrate is essential for rapid desulfation of the enzyme at acidic pH, which most likely occurs by elimination, The lack of this second hydroxyl in the serine mutants explains the trapping of the sulfated enzyme intermediate, Thus, in acting as a geminal diol the formylglycine residue allows for efficient ester hydrolysis in an acidic milieu.	Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen	von Figura, K (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, Gosslerstr 12D, D-37073 Gottingen, Germany.		Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BROOKS DA, 1995, BIOCHEM J, V307, P457, DOI 10.1042/bj3070457; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; GETTINS P, 1985, J BIOL CHEM, V260, P2875; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; HOPWOOD JJ, 1986, BIOCHEM J, V234, P507, DOI 10.1042/bj2340507; JERFY A, 1973, BIOCHIM BIOPHYS ACTA, V293, P178, DOI 10.1016/0005-2744(73)90389-6; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GD, 1975, ARCH BIOCHEM BIOPHYS, V166, P280, DOI 10.1016/0003-9861(75)90389-6; LUKATELA G, 1998, IN PRESS BIOCHEMISTR; MEHL E, 1968, BIOCHIM BIOPHYS ACTA, V151, P619, DOI 10.1016/0005-2744(68)90008-9; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; PARTRIDGE SM, 1949, NATURE, V164, P433; PETERS C, 1990, J BIOL CHEM, V265, P3374; PROSSER CI, 1980, BIOCHIM BIOPHYS ACTA, V613, P130, DOI 10.1016/0005-2744(80)90199-0; Reid T.W., 1971, ENZYMES, V4, P373; ROY AB, 1953, BIOCHEM J, V55, P653, DOI 10.1042/bj0550653; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SEILER H, 1964, HELV CHIM ACTA, V47, P264, DOI 10.1002/hlca.19640470134; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; SOMMERLADE HJ, 1994, J BIOL CHEM, V269, P20977; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; STEIN C, 1989, J BIOL CHEM, V264, P1252	29	67	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6096	6103		10.1074/jbc.273.11.6096	http://dx.doi.org/10.1074/jbc.273.11.6096			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497327	hybrid			2022-12-27	WOS:000072488500019
J	Rodionov, DG; Bakke, O				Rodionov, DG; Bakke, O			Medium chains of adaptor complexes AP-1 and AP-2 recognize leucine-based sorting signals from the invariant chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC TAIL; COATED VESICLES; IN-VITRO; PROTEINS; BINDING; MOTIF	Interactions between tyrosine-and leucine-based sorting signals in the cytoplasmic tails of transmembrane proteins and adaptor complexes AP-1 and AP-2 are believed to be the first step in the formation of clathrin-coated vesicles that deliver these proteins to their destination. Medium chains of AP-1 and AP-2 have been reported to interact with tyrosine-based sorting signals in a number of in vitro assays. In the present study we found that recombinant medium chains could interact with leucine-based sorting signals from the cytoplasmic tail of the invariant chain. Medium chains may therefore be responsible for the proper recognition of both tyrosine and leucine sorting signals by AP-1 and AP-2 complexes.	Univ Oslo, Dept Biol, Div Mol Cell Biol, N-0316 Oslo, Norway	University of Oslo	Bakke, O (corresponding author), Univ Oslo, Dept Biol, Div Mol Cell Biol, POB 1055,Blindern, N-0316 Oslo, Norway.	obakke@bio.uio.no		Bakke, Oddmund/0000-0003-4843-7626				Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BREMNES B, 1994, J CELL SCI, V107, P2021; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PIETERS J, 1993, J CELL SCI, V106, P831; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801	24	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6005	6008		10.1074/jbc.273.11.6005	http://dx.doi.org/10.1074/jbc.273.11.6005			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497313	hybrid			2022-12-27	WOS:000072488500005
J	Twigg, SM; Baxter, RC				Twigg, SM; Baxter, RC			Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEIN; TRANSFORMED HUMAN FIBROBLASTS; FACTOR-I; HUMAN-SERUM; BIOLOGICAL-FLUIDS; RADIOIMMUNOASSAY; IDENTIFICATION; PURIFICATION; SECRETION; CELLS	Up to 90% of circulating insulin-like growth factors (IGF-I and IGF-II) are carried in heterotrimeric complexes with a binding protein (IGFBP) and a liver-derived glycoprotein known as the acid-labile subunit, IGFBP-3 is considered unique among the six well characterized IGFBPs in its ability to complex with the acid labile subunit, However, a basic carboxyl-terminal domain of IGFBP-3, known to be involved in its interaction with the acid-labile subunit, is shared by IGFBP-5, suggesting the possibility of ternary complexes containing IGFBP-5. We now demonstrate using three independent methods that human IGFBP-5, when occupied by IGF I or IGF-II, forms ternary complexes of approximately 130 kDa with the acid-labile subunit, IGFBP-3 competes with approximately twice the potency of IGFBP-5 for the formation of such complexes, No other IGFBP complexes with the acid-labile subunit itself or competes with IGFBP-5 for complex formation, ks observed for IGFBP-3, ternary complexes containing IGFBP-5 form preferentially in the presence of IGF-I, even though IGFBP-5 has a preferential affinity for IGF-II over IGF-I, By size fractionation chromatography, serum IGFBP-5 co-elutes predominantly with ternary complexes, The demonstration of IGFBP-5-containing ternary complexes indicates an unrecognized form of IGF transport in the circulation and an additional mechanism for regulating IGF bioavailability.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Baxter, RC (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ARAI T, 1994, J BIOL CHEM, V269, P20388; BANG P, 1994, J CLIN ENDOCR METAB, V78, P1119, DOI 10.1210/jc.78.5.1119; BARRECA A, 1995, J CLIN ENDOCR METAB, V80, P1318, DOI 10.1210/jc.80.4.1318; BAXTER RC, 1988, J CLIN ENDOCR METAB, V67, P265, DOI 10.1210/jcem-67-2-265; BAXTER RC, 1995, METABOLISM, V44, P12, DOI 10.1016/0026-0495(95)90215-5; BAXTER RC, 1992, J ENDOCRINOL, V134, P133, DOI 10.1677/joe.0.1340133; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P423, DOI 10.1210/jcem-65-3-423; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHIN E, 1994, ENDOCRINOLOGY, V134, P2398; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1991, J CLIN ENDOCR METAB, V73, P727, DOI 10.1210/jcem-73-4-727; CONOVER CA, 1991, J CLIN INVEST, V88, P1354, DOI 10.1172/JCI115441; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; DAUGHADAY WH, 1989, P NATL ACAD SCI USA, V86, P6778, DOI 10.1073/pnas.86.17.6778; DROP SLS, 1992, GROWTH REGULAT, V2, P69; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; FURLANETTO RW, 1980, J CLIN ENDOCR METAB, V51, P12, DOI 10.1210/jcem-51-1-12; GOLDSTEIN S, 1993, J CELL PHYSIOL, V156, P294, DOI 10.1002/jcp.1041560211; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HINTZ RL, 1980, GROWTH HORMONE OTHER, P133; Honda Y, 1996, J CLIN ENDOCR METAB, V81, P1389, DOI 10.1210/jcem.81.4.8636339; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1996, ENDOCR REV, V16, P3; Khosravi MJ, 1997, J CLIN ENDOCR METAB, V82, P3944, DOI 10.1210/jc.82.12.3944; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KOU K, 1994, GENOMICS, V21, P653, DOI 10.1006/geno.1994.1329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1995, ENDOCRINOLOGY, V136, P4982, DOI 10.1210/en.136.11.4982; Lee CY, 1997, ENDOCRINOLOGY, V138, P1649, DOI 10.1210/en.138.4.1649; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LEWITT MS, 1994, ENDOCRINOLOGY, V134, P2404, DOI 10.1210/en.134.6.2404; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; Mohan S, 1996, J CLIN ENDOCR METAB, V81, P3817, DOI 10.1210/jc.81.11.3817; MOHAN S, 1995, J CLIN ENDOCR METAB, V80, P2638, DOI 10.1210/jc.80.9.2638; NICOLAS V, 1995, CALCIFIED TISSUE INT, V57, P206, DOI 10.1007/BF00310260; Ono T, 1996, J CLIN ENDOCR METAB, V81, P2111, DOI 10.1210/jc.81.6.2111; POWELL DR, 1993, PEDIATR RES, V33, P136, DOI 10.1203/00006450-199302000-00011; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Schmid C, 1996, AM J PHYSIOL-ENDOC M, V271, pE1029, DOI 10.1152/ajpendo.1996.271.6.E1029; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SUIKKARI AM, 1991, J CLIN ENDOCR METAB, V73, P1377, DOI 10.1210/jcem-73-6-1377; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; XU S, 1995, J CLIN ENDOCR METAB, V80, P2940, DOI 10.1210/jc.80.10.2940; ZAPF J, 1995, EUR J ENDOCRINOL, V132, P645, DOI 10.1530/eje.0.1320645	61	147	160	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6074	6079		10.1074/jbc.273.11.6074	http://dx.doi.org/10.1074/jbc.273.11.6074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497324	hybrid			2022-12-27	WOS:000072488500016
J	Uittenbogaard, A; Ying, YS; Smart, EJ				Uittenbogaard, A; Ying, YS; Smart, EJ			Characterization of a cytosolic heat-shock protein caveolin chaperone complex - Involvement in cholesterol trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CAVEOLAE; TRANS-GOLGI-NETWORK; ENDOPLASMIC-RETICULUM; EPITHELIAL-CELLS; ANCHORED PROTEINS; SMOOTH-MUSCLE; MA104 CELLS; RECEPTOR; LOCALIZATION; SURFACE	Caveolin is a 22-kDa protein that appears to play a critical role in regulating the cholesterol concentration of caveolae, Even though caveolin is thought to be a membrane protein, several reports suggest that this peculiar protein can traffic independently of membrane vesicles, We now present evidence that a cytosolic pool of caveolin is part of a heat-shock protein-immunophilin chaperone complex consisting of caveolin, heat-shock protein 56, cyclophilin 40, cyclophilin A, and cholesterol. Treatment of MH 3T3 cells with 1 mu m cyclosporin A or 100 nM rapamycin disrupted the putative transport complex and prevented rapid (10-20 min) transport of cholesterol to caveolae, The lymphoid cell line, L1210-JF, does not express caveolin, does not form an immunophilin-caveolin complex, and does not transport newly synthesized cholesterol to caveolae, Transfection of caveolin cDNA into L1210-JF cells allowed the assembly of a transport complex identical to that found in NIH 3T3 cells, In addition, newly synthesized cholesterol in transfected cells was rapidly (10-20 min) and specifically transported to caveolae, These data strongly suggest that a caveolin-chaperone complex is a mechanism by which newly synthesized cholesterol is transported from the endoplasmic reticulum through the cytoplasm to caveolae.	Univ Kentucky, Dept Physiol, Sch Med, Lexington, KY 40536 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Kentucky; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Smart, EJ (corresponding author), Univ Kentucky, Dept Physiol, Sch Med, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.	ejsmart@pop.uky.edu			NHLBI NIH HHS [R29HL58475-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ENGSTROEM L, 1961, BIOCHIM BIOPHYS ACTA, V52, P36, DOI 10.1016/0006-3002(61)90901-5; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GRAHAM JM, 1993, BIOMEMBRANE PROTOCOL, V19, P1; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KITTEL A, 1994, CELL BIOL INT, V18, P875, DOI 10.1006/cbir.1994.1124; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISCUM L, 1992, J LIPID RES, V33, P1239; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PAGE E, 1994, CIRC RES, V75, P949, DOI 10.1161/01.RES.75.5.949; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Smart EJ, 1995, COLD SPRING HARB SYM, V60, P243, DOI 10.1101/SQB.1995.060.01.028; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; URBANI L, 1990, J BIOL CHEM, V265, P1919; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	59	279	289	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6525	6532		10.1074/jbc.273.11.6525	http://dx.doi.org/10.1074/jbc.273.11.6525			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497388	hybrid			2022-12-27	WOS:000072488500080
J	Zhang, S; Pohnert, G; Kongsaeree, P; Wilson, DB; Clardy, J; Ganem, B				Zhang, S; Pohnert, G; Kongsaeree, P; Wilson, DB; Clardy, J; Ganem, B			Chorismate mutase-prephenate dehydratase from Escherichia coli - Study of catalytic and regulatory domains using genetically engineered proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; PHEA-GENE; PHENYLALANINE; PURIFICATION; CONFORMATION; QUANTITIES; MECHANISM; TYROSINE; BINDING; NACL	The bifunctional P-protein, which plays a central role in Escherichia coli phenylalanine biosynthesis, contains two catalytic domains (chorismate mutase and prephenate dehydratase activities) as well as one R-domain (for feedback inhibition by phenylalanine). Six genes coding for P-protein domains or subdomains were constructed and successfully expressed. Proteins containing residues 1-285 and residues 1-300 retained full mutase and dehydratase activity, but exhibited no feedback inhibition. Proteins containing residues 101-386 and residues 101-300 retained full dehydratase activity, but lacked mutase activity. Fluorescence emission spectra and binding assays indicated that residues 286-386 were crucial for phenylalanine binding. The mutase (residues 1-109), dehydratase (residues 101-285), and regulatory (residues 286-386) activities were thus shown to reside in discrete domains of the P-protein. Both the mutase domain and the native P-protein formed dimers. Deletion of the mutase domain diminished phenylalanine binding to the regulatory site as well as prephenate binding to the dehydratase domain, both through cooperative effects. Besides eliminating feedback inhibition, removal of the R-domain decreased the affinity of chorismate mutase for chorismate.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University; Cornell University	Ganem, B (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Pohnert, Georg/D-3721-2013	Pohnert, Georg/0000-0003-2351-6336	NATIONAL CANCER INSTITUTE [R01CA024487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024054] Funding Source: NIH RePORTER; NCI NIH HHS [CA 24487] Funding Source: Medline; NIGMS NIH HHS [GM 24054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1988, EUR J BIOCHEM, V116, P69; BACKMAN KC, 1988, Patent No. 4753883; BALDWIN GS, 1983, BIOCHIM BIOPHYS ACTA, V742, P374, DOI 10.1016/0167-4838(83)90324-2; BALDWIN GS, 1981, ARCH BIOCHEM BIOPHYS, V211, P76, DOI 10.1016/0003-9861(81)90431-8; BALDWIN GS, 1981, ARCH BIOCHEM BIOPHYS, V211, P66, DOI 10.1016/0003-9861(81)90430-6; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DOPHEIDE TA, 1972, J BIOL CHEM, V247, P4447; DUGGLEBY RG, 1978, BIOCHEMISTRY-US, V17, P1548, DOI 10.1021/bi00601a030; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; FRIEDRICH B, 1976, J BACTERIOL, V126, P712, DOI 10.1128/JB.126.2.712-722.1976; GETHING MJ, 1978, EUR J BIOCHEM, V86, P165, DOI 10.1111/j.1432-1033.1978.tb12296.x; GETHING MJ, 1978, EUR J BIOCHEM, V86, P159, DOI 10.1111/j.1432-1033.1978.tb12295.x; GETHING MJH, 1977, EUR J BIOCHEM, V78, P103, DOI 10.1111/j.1432-1033.1977.tb11718.x; GETHING MJH, 1976, EUR J BIOCHEM, V71, P327, DOI 10.1111/j.1432-1033.1976.tb11119.x; GETHING MJH, 1976, EUR J BIOCHEM, V71, P317, DOI 10.1111/j.1432-1033.1976.tb11118.x; GETHING MJH, 1977, EUR J BIOCHEM, V78, P111, DOI 10.1111/j.1432-1033.1977.tb11719.x; HALL EAH, 1991, BIOSENSORS; Haslam E., 1993, SHIKIMIC ACID METABO; HUDSON GS, 1984, J MOL BIOL, V180, P1023, DOI 10.1016/0022-2836(84)90269-9; LEE AY, 1995, CHEM BIOL, V2, P195, DOI 10.1016/1074-5521(95)90269-4; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NELMS J, 1992, APPL ENVIRON MICROB, V58, P2592, DOI 10.1128/AEM.58.8.2592-2598.1992; PATEL N, 1977, J BIOL CHEM, V252, P5839; PERUTZ MF, 1990, MECHANISMS COOPERATI; PITTARD AJ, 1987, ESCHERICHIA COLI SAL, P368; ROMERO RM, 1995, PHYTOCHEMISTRY, V40, P1015, DOI 10.1016/0031-9422(95)00408-Y; Segel IH, 1976, BIOCH CALCULATIONS; SHIMAN R, 1994, J BIOL CHEM, V269, P24647; STEWART J, 1991, TETRAHEDRON, V47, P2573, DOI 10.1016/S0040-4020(01)81790-7; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; XIA TH, 1992, APPL ENVIRON MICROB, V58, P2792, DOI 10.1128/AEM.58.9.2792-2798.1992; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5; ZURAWSKI G, 1978, P NATL ACAD SCI USA, V75, P4271, DOI 10.1073/pnas.75.9.4271	36	76	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6248	6253		10.1074/jbc.273.11.6248	http://dx.doi.org/10.1074/jbc.273.11.6248			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497350	hybrid			2022-12-27	WOS:000072488500042
J	Pearson, GD; Merrill, GF				Pearson, GD; Merrill, GF			Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; HUMAN P53; TRANSCRIPTION FACTOR; YEAST; MUTATION; SUPPRESSION; ACTIVATION; GROWTH	The prevalence of p53 gene mutations in many human tumors implies that p53 protein plays an important role in preventing cancers. Central among the activities ascribed to p53 is its ability to stimulate transcription of other genes that inhibit cells from entering S phase with damaged DNA. Human p53 can be studied in yeast where genetic tools can be used to identify proteins that affect its ability to stimulate transcription. Although p53 strongly stimulated reporter gene expression in wild type yeast, it only weakly stimulated reporter gene expression in Delta trr1 yeast that lacked the gene encoding thioredoxin reductase. Furthermore, ectoptic expression of TRR1 in Delta trr1 yeast restored p53-dependent reporter gene activity to high levels. Immunoblot assays established that the Delta trr1 mutation affected the activity and not the level of p53 protein, The results suggest that p53 can form disulfides and that these disulfides must be reduced in order for the protein to function as a transcription factor.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Merrill, GF (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; KOERTE A, 1995, J BIOL CHEM, V270, P22556, DOI 10.1074/jbc.270.38.22556; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SIKORSKI RS, 1989, GENETICS, V122, P19; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6	26	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5431	5434		10.1074/jbc.273.10.5431	http://dx.doi.org/10.1074/jbc.273.10.5431			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488661				2022-12-27	WOS:000072345000004
J	Bokoch, GM; Reilly, AM; Daniels, RH; King, CC; Olivera, A; Spiegel, S; Knaus, UG				Bokoch, GM; Reilly, AM; Daniels, RH; King, CC; Olivera, A; Spiegel, S; Knaus, UG			A GTPase-independent mechanism of p21-activated kinase activation - Regulation by sphingosine and other biologically active lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; PROTEIN-KINASE; HUMAN-NEUTROPHILS; ADAPTER PROTEIN; PHOSPHORYLATION; MYOSIN; FAMILY; CDC42; PAK1; AUTOPHOSPHORYLATION	p21-activated kinases (PAKs) are serine/threonine kinases that have been identified as targets for the small GTPases Rac and Cdc42. PAKs have been implicated in cytoskeletal regulation, stimulation of mitogen-activated protein kinase cascades, and in control of the phagocyte NADPH oxidase. Membrane targeting of PAK1 induced increased kinase activity in a GTPase-independent manner, suggesting that other mechanisms for PAK regulation exist. We observed concentration- and time-dependent activation of PAK1 by sphingosine and several related long chain sphingoid bases but not by ceramides or a variety of other lipids, Although phospholipids were generally ineffective, phosphatidic acid and phosphatidylinositol also had stimulatory effects on PAK1, Lipid stimulation induced a similar level of PAK1 activity as did stimulation by GTPases, and the patterns of PAK1 autophosphorylation determined after partial tryptic digestion and two-dimensional peptide analysis were similar with each class of activator. Lipid stimulation of PAK1 activity was dependent upon intact PAK kinase activity, as indicated by studies with a kinase-dead PAK1 mutant, Treatment of COS-7 cells expressing wild type PAK1 with sphingosine, fumonisin B, or sphingomyelinase, all of which are able to elevate the levels of free sphingosine, induced increased activity of PAK1 as determined using a p47(phox) peptide substrate, Studies using PAK1 mutants suggest that lipids act at a site overlapping or identical to the GTPase-binding domain on PAK. The inactive sphingosine derivative N,N-dimethylsphingosine was an effective inhibitor of PAK1 activation in response to either sphingosine or Cdc42, Our results demonstrate a novel GTPase-independent mechanism of PAK activation and, additionally, suggest that PAK(s) may be important mediators of the biological effects of sphingolipids.	Scripps Res Inst, Dept Immunol IMM14, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Scripps Research Institute; Scripps Research Institute; Georgetown University	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol IMM14, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R01GM039434, R37GM043880, R01GM044428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39434, GM43880, GM44428] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Ding JB, 1996, J BIOL CHEM, V271, P24869, DOI 10.1074/jbc.271.40.24869; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; HANNUN YA, 1996, SCIENCE, V274, P855; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KULESZALIPKA D, 1993, J BIOL CHEM, V268, P17995; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Masaracchia R, 1996, FASEB J, V10, P1538; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; TUAZON PT, 1984, J BIOL CHEM, V259, P541; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WILSON E, 1988, J BIOL CHEM, V263, P9304; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	36	167	169	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8137	8144		10.1074/jbc.273.14.8137	http://dx.doi.org/10.1074/jbc.273.14.8137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525917	hybrid			2022-12-27	WOS:000072876300051
J	Leong, P; MacLennan, DH				Leong, P; MacLennan, DH			A 37-amino acid sequence in the skeletal muscle ryanodine receptor interacts with the cytoplasmic loop between domains II and III in the skeletal muscle dihydropyridine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; JUNCTIONS; REGIONS	Interactions between the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor or RyR1) and the loop linking domains II and III (II-III loop) of the skeletal muscle L-type Ca2+ channel (dihydropyridine receptor or DHPR) are critical for excitation-contraction coupling in skeletal muscle. The DHPR II-III loop was fused to glutathione S-transferase-or His-peptide and used as a protein affinity column for S-35-labeled in vitro translated fragments from the N-terminal three-fourths of RyR1. RyR1 residues Leu(922)-Asp(1112) bound specifically to the DHPR II-III loop column, but the corresponding fragment from the cardiac ryanodine receptor (RS RS) did not. The use of chimeras between RyR1 and RyR2 localized the interaction to 37 amino acids, Arg(1076)-Asp(1112), in RyR1. The RyR1 922-1112 fragment did not bind to the cardiac DHPR II-III loop but did bind to the skeletal muscle Na+ channel II-III loop. The skeletal DHPR II-III loop double mutant K677E/K682E lost most of its capacity to interact with RyR1, suggesting that two positively charged residues are important in the interaction between RyR and DHPR.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.							Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Kozak M, 1979, Methods Enzymol, V60, P360; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; Meissner G, 1995, BIOSCIENCE REP, V15, P399, DOI 10.1007/BF01788371; Monnier N, 1997, AM J HUM GENET, V60, P1316, DOI 10.1086/515454; Murray BE, 1997, BIOCHEM J, V324, P689, DOI 10.1042/bj3240689; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; OTSU K, 1990, J BIOL CHEM, V265, P13472; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7791	7794		10.1074/jbc.273.14.7791	http://dx.doi.org/10.1074/jbc.273.14.7791			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525869	hybrid			2022-12-27	WOS:000072876300003
J	Loyet, KM; Kowalchyk, JA; Chaudhary, A; Chen, J; Prestwich, GD; Martin, TFJ				Loyet, KM; Kowalchyk, JA; Chaudhary, A; Chen, J; Prestwich, GD; Martin, TFJ			Specific binding of phosphatidylinositol 4,5-bisphosphate to calcium-dependent activator protein for secretion (CAPS), a potential phosphoinositide effector protein for regulated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHOLIPASE-C; HIGH-AFFINITY; CA2+-ACTIVATED SECRETION; ACIDIC PHOSPHOLIPIDS; IMMOBILIZED NEOMYCIN; ALPHA-SNAP; PH DOMAIN; FUSION; KINASE	The calcium-dependent activator protein for secretion (CAPS) is a novel neural/endocrine-specific cytosolic and peripheral membrane protein required for the Ca2+-regulated exocytosis of secretory vesicles, CAPS acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2). In the present studies, CAPS is shown to bind liposomes that contain acidic phospholipids and binding was markedly enhanced by inclusion of PtdIns(4,5)P-2 but not other phosphoinositides in the absence of Ca2+. PtdIns(4,5)P-2, but not other phosphoinositides including PtdIns(3,4)P-2 and PtdIns(3,4,5)P-3, altered the susceptibility of CAPS to proteolysis by trypsin and proteinase K, suggesting that phosphoinositide binding promoted a conformational change, Photoaffinity labeling studies with a photoactivatable benzoylcinnimidyl acyl chain derivative of PtdIns(4,5)P-2 confirmed the phosphoinositide-binding properties of CAPS and suggested a hydrophobic aspect of the interaction, CAPS, as one of very few characterized proteins with a binding specificity for 4-,5-phosphorylated inositides over 3-phosphorylated inositides, may function in regulated exocytosis as an effector of PtdIns(4,5)P-2.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah	Loyet, KM (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.							Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Calakos N, 1996, PHYSIOL REV, V76, P1; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Chen J, 1996, J ORG CHEM, V61, P6305, DOI 10.1021/jo960895r; CHERNOMORDIK LV, 1995, CURR OPIN STRUC BIOL, V5, P541, DOI 10.1016/0959-440X(95)80041-7; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOA W, 1997, J BIOL CHEM, V272, P6393; HUSEBYE ES, 1990, BIOCHIM BIOPHYS ACTA, V1042, P330, DOI 10.1016/0005-2760(90)90161-P; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Martin TFJ, 1997, BIOCHEM SOC T, V25, P1137, DOI 10.1042/bst0251137; Martin TFJ, 1997, J BIOL CHEM, V272, P14447, DOI 10.1074/jbc.272.22.14447; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mochida S, 1997, NEUROSCIENCE, V77, P937; MOHAMED MA, 1989, ANAL BIOCHEM, V177, P287, DOI 10.1016/0003-2697(89)90053-5; PALMER FBSC, 1981, J LIPID RES, V22, P1296; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHACHT J, 1978, J LIPID RES, V19, P1063; Schacht J, 1981, Methods Enzymol, V72, P626; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; YU FX, 1992, J BIOL CHEM, V267, P14616; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	56	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8337	8343		10.1074/jbc.273.14.8337	http://dx.doi.org/10.1074/jbc.273.14.8337			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525942	hybrid			2022-12-27	WOS:000072876300076
J	Mazza, C; Breton, R; Housset, D; Fontecilla-Camps, JC				Mazza, C; Breton, R; Housset, D; Fontecilla-Camps, JC			Unusual charge stabilization of NADP(+) in 17 beta-hydroxysteroid dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ESTRADIOL 17-BETA-DEHYDROGENASE; X-RAY-DIFFRACTION; DROSOPHILA ALCOHOL-DEHYDROGENASE; COLI DIHYDROFOLATE-REDUCTASE; SITE-DIRECTED MUTAGENESIS; HUMAN-BREAST TUMORS; ESCHERICHIA-COLI; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURES; ACTIVE-SITE	Type 1 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD1), a member of the short chain dehydrogenase reductase (SDR) family, is responsible for the synthesis of 17 beta-estradiol, the biologically active estrogen involved in the genesis and development of human breast cancers. Here, we report the crystal structures of the H221L 17 beta-HSD1 mutant complexed to NADP(+) and estradiol and the H221L mutant/NAD(+) and a H221Q mutant/estradiol complexes. These structures provide a complete picture of the NADP(+)-enzyme interactions involving the flexible 191-199 loop (well ordered in the H221L mutant) and suggest that the hydrophobic residues Phe(192)-Met(193) could facilitate hydride transfer. 17 beta-HSD1 appears to be unique among the members of the SDR protein family in that one of the two basic residues involved in the charge compensation of the 2'-phosphate does not belong to the Rossmann-fold motif. The remarkable stabilization of the NADP(+) 2'-phosphate by the enzyme also clearly establishes its preference for this cofactor relative to NAD(+). Analysis of the catalytic properties of, and estradiol binding to, the two mutants suggests that the His(221)-steroid O-3 hydrogen bond plays an important role in substrate specificity.	CNRS, CEA, Inst Biol Struct JP Ebel, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Housset, D (corresponding author), CNRS, CEA, Inst Biol Struct JP Ebel, Cristallog & Cristallogenese Prot Lab, 41 Ave Martyrs, F-38027 Grenoble, France.	housset@lccp.ibs.fr; juan@lccp.ibs.fr		HOUSSET, Dominique/0000-0003-1732-0193				ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2; ALBALAT R, 1992, FEBS LETT, V308, P235; AREZKI A, 1996, NAT STRUCT BIOL, V3, P665; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BAKER ME, 1990, FASEB J, V4, P222, DOI 10.1096/fasebj.4.2.2153594; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BONNEY RC, 1983, CLIN ENDOCRINOL, V19, P727, DOI 10.1111/j.1365-2265.1983.tb00051.x; BRETON R, 1994, J STEROID BIOCHEM, V50, P275, DOI 10.1016/0960-0760(94)90132-5; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; BRUNGER AT, 1990, XPLOR MANUAL VER 3 1; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; CHIN CC, 1982, BIOCHEMISTRY-US, V21, P3322, DOI 10.1021/bi00257a012; ENSOR CM, 1991, BIOCHEM BIOPH RES CO, V176, P840, DOI 10.1016/S0006-291X(05)80262-1; FISHMAN J, 1977, J STEROID BIOCHEM, V8, P893, DOI 10.1016/0022-4731(77)90100-5; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Hubbard SJ, 1993, NACCESS COMPUTER PRO; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROZOWSKI Z, 1994, J STEROID BIOCHEM, V51, P125, DOI 10.1016/0960-0760(94)90084-1; KROZOWSKI Z, 1992, MOL CELL ENDOCRINOL, V84, pC25, DOI 10.1016/0303-7207(92)90064-D; LANGER LJ, 1958, J BIOL CHEM, V233, P583; LI LY, 1992, BIOCHEMISTRY-US, V31, P7826, DOI 10.1021/bi00149a012; LIN SX, 1992, J BIOL CHEM, V267, P16182; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOY JP, 1994, NUCL INSTRUM METH A, V348, P641, DOI 10.1016/0168-9002(94)90815-X; MURDOCK GL, 1983, J BIOL CHEM, V258, P1460; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; PURANEN TJ, 1994, BIOCHEM J, V304, P289, DOI 10.1042/bj3040289; REED MJ, 1983, CANCER RES, V43, P3940; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; *SERC DAR LAB, 1979, COLL COMP PROJ 4 SUI; SU Y, 1993, J BIOL CHEM, V268, P26836; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; VERMEULEN A, 1986, EUR J CANCER CLIN ON, V22, P515, DOI 10.1016/0277-5379(86)90121-5; ZHU DW, 1993, J MOL BIOL, V234, P242, DOI 10.1006/jmbi.1993.1578	52	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8145	8152		10.1074/jbc.273.14.8145	http://dx.doi.org/10.1074/jbc.273.14.8145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525918	hybrid			2022-12-27	WOS:000072876300052
J	Mortillaro, MJ; Berezney, R				Mortillaro, MJ; Berezney, R			Matrin CYP, an SR-rich cyclophilin that associates with the nuclear matrix and splicing factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; RNA-POLYMERASE-II; PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORINE-A; MESSENGER-RNA; CHAPERONE ACTIVITIES; SIGNAL TRANSDUCTION; HOMOLOGOUS DOMAIN; SECRETORY PATHWAY; CONSERVED FAMILY	We report the identification and cloning of a nuclear matrix protein termed matrin cyclophilin or matrin CYP. The derived sequence of matrin cyp encodes a protein of 752 amino acids with a predicted mass of 88 kDa. A 172-residue stretch at the amino terminus shows high identity with the ubiquitous family of cyclophilins. Clustered throughout the carboxyl half of the protein are a series of serine-arginine (SR) repeats that are a characteristic feature of many RNA splicing factors. Antibodies raised against matrin CYP recognize a 106-kDa antigen that is detected in isolated nuclei and quantitatively subfractionates in the nuclear matrix. Laser scanning confocal microscopy localizes most of the anti-matrin CYP-specific antigen within the nucleus in a pattern of large bright speckles that co-localize with splicing factors and diffuse nucleoplasmic staining. A strikingly similar pattern of staining is observed in cells extracted for in situ nuclear matrices. A fusion protein containing the cyclophilin domain of matrin CYP exhibits cyclosporin A (CsA)-sensitive, peptidylprolyl cis trans-isomerase activity that is characteristic of native cyclophilins. Although total rat liver nuclei contains predominantly CsA-resistant PPIase activity, the corresponding activity in the nuclear matrix is largely CsA-sensitive.	SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Berezney, R (corresponding author), SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA.	Berezney@acsu.buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023922] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23922] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BASLER J, 1981, BIOCHEMISTRY-US, V20, P6921, DOI 10.1021/bi00527a027; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BEREZNEY R, 1995, INT REV CYTOL A, V162, P2; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BLENCOWE BJ, 1995, RNA, V1, P852; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; CARONI P, 1991, J BIOL CHEM, V266, P10739; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DREYFUSS G, 1990, EUKARYOTIC NUCLEUS S, P503; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; FU XD, 1995, RNA, V1, P663; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Giardina SL, 1996, BLOOD, V87, P2269, DOI 10.1182/blood.V87.6.2269.bloodjournal8762269; GODAY A, 1994, PLANT CELL, V6, P351, DOI 10.1105/tpc.6.3.351; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HEITMAN J, 1992, NEW BIOL, V4, P448; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LIPPUNER V, 1994, J BIOL CHEM, V269, P7863; Lu KP, 1996, NATURE, V380, P544; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; MEIR UT, 1992, CELL, V70, P127; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; Papavassiliou Athanasios G., 1992, Methods in Molecular and Cellular Biology, V3, P149; PATTURAJAN M, 1998, IN PRESS MOL CELL BI; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REUTER R, 1985, EXP CELL RES, V159, P63, DOI 10.1016/S0014-4827(85)80038-0; RINFRET A, 1994, BIOCHEMISTRY-US, V33, P1668, DOI 10.1021/bi00173a008; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5453; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONG CS, 1985, J IMMUNOL, V135, P3354; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1984, BIOL CELL, V51, P109, DOI 10.1111/j.1768-322X.1984.tb00289.x; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; SPIK G, 1991, J BIOL CHEM, V266, P10735; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TANNER S, 1997, J BIOL CHEM, V378, P565; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; VERHEIJEN R, 1986, J CELL SCI, V80, P103; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	94	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8183	8192		10.1074/jbc.273.14.8183	http://dx.doi.org/10.1074/jbc.273.14.8183			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525923	hybrid			2022-12-27	WOS:000072876300057
J	Umata, T; Mekada, E				Umata, T; Mekada, E			Diphtheria toxin translocation across endosome membranes - A novel cell permeabilization assay reveals new diphtheria toxin fragments in endocytic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; VERO CELLS; LOW PH; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; A-FRAGMENT; EFFICIENT DELIVERY; ADP-RIBOSYLATION; ESCHERICHIA-COLI; EUKARYOTIC CELLS	By using cells overexpressing diphtheria toxin (DT) receptor and a novel method of permeabilizing the plasma membrane with a bacterial pore-forming toxin, specific translocation of fragment A to the cytosol was observed, whereas full-size DT and other minor species of DT-derived fragments were left in intracellular vesicles, The translocation competence of DT proteins with mutations in the transmembrane domain is consistent with their cytotoxicities. The charge-reversal mutants E349K and D352K do not translocate their fragment A to the cytosol, whereas D352N is partially competent. ADP-ribosyltransferase activity of fragment A is not required for translocation. Novel fragments of DT with apparent molecular masses of 28 and 35 kDa were detected in endocytic vesicles, The 28-kDa fragment consists of fragment A and an N-terminal piece of fragment B, whereas the 35-kDa fragment contains part of fragment B and may be complementary to the 28-kDa fragment. Time course studies show that the 28-kDa fragment appears in endocytic vesicles prior to translocation of fragment A to the cytosol, raising the possibility that the 28-kDa fragment is an intermediate in translocation. We present a model for translocation of fragment A that incorporates the observations made using the novel permeabilization method.	Kurume Univ, Inst Life Sci, Div Cell Biol, Fukuoka 839, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Cellular & Dev Biol Div, Fukuoka 839, Japan	Kurume University; Kurume University	Mekada, E (corresponding author), Kurume Univ, Inst Life Sci, Div Cell Biol, Fukuoka 839, Japan.			Mekada, Eisuke/0000-0001-8858-4781				BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; COLLIER RJ, 1994, HDB NATURAL TOXINS, V8, P81; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DORLAND RB, 1979, J BIOL CHEM, V254, P1337; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ERIKSEN S, 1994, EMBO J, V13, P4433, DOI 10.1002/j.1460-2075.1994.tb06765.x; FISHER MH, 1981, P SOC EXP BIOL MED, V168, P233; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; GILL DM, 1980, J INFECT DIS, V141, P64, DOI 10.1093/infdis/141.1.64; GILL DM, 1971, J BIOL CHEM, V246, P1492; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HONJO T, 1968, J BIOL CHEM, V243, P3553; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; JIANG GS, 1989, J BIOL CHEM, V264, P17170; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1980, J BIOL CHEM, V255, P2247; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MADSHUS IH, 1994, J BIOL CHEM, V269, P17723; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MEKADA E, 1979, EXP CELL RES, V123, P137, DOI 10.1016/0014-4827(79)90430-0; MEKADA E, 1981, J BIOL CHEM, V256, P1225; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1989, J BIOL CHEM, V264, P11367; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OBRIG TG, 1985, BIOCHEM BIOPH RES CO, V130, P879, DOI 10.1016/0006-291X(85)90498-X; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPINI E, 1993, J BIOL CHEM, V268, P1567; REISBIG R, 1981, J BIOL CHEM, V256, P8739; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STENMARK H, 1988, J BIOL CHEM, V263, P13449; THELESTAM M, 1980, INFECT IMMUN, V29, P863; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; UCHIDA T, 1972, SCIENCE, V175, P901, DOI 10.1126/science.175.4024.901; UCHIDA T, 1978, J BIOL CHEM, V253, P6307; UMATA T, 1990, J BIOL CHEM, V265, P21940; VANDERSPEK JC, 1993, J BIOL CHEM, V268, P12077; VANDERSPEK JC, 1994, PROTEIN ENG, V7, P985, DOI 10.1093/protein/7.8.985; WEDEL N, 1983, EXP CELL RES, V148, P413, DOI 10.1016/0014-4827(83)90163-5	64	25	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8351	8359		10.1074/jbc.273.14.8351	http://dx.doi.org/10.1074/jbc.273.14.8351			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525944	hybrid			2022-12-27	WOS:000072876300078
J	Zocchi, E; Daga, A; Usai, C; Franco, L; Guida, L; Bruzzone, S; Costa, A; Marchetti, C; De Flora, A				Zocchi, E; Daga, A; Usai, C; Franco, L; Guida, L; Bruzzone, S; Costa, A; Marchetti, C; De Flora, A			Expression of CD38 increases intracellular calcium concentration and reduces doubling time in HeLa and 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRANSMEMBRANE GLYCOPROTEIN CD38; TYROSINE PHOSPHORYLATION; HUMAN ERYTHROCYTES; ANTIGEN CD38; B-CELLS; SURFACE; NUCLEOTIDES; ACTIVATION; HYDROLYSIS	CD38 is a bifunctional ectoenzyme, predominantly expressed on hematopoietic cells during differentiation, that catalyzes the synthesis (cyclase) and the degradation (hydrolase) of cyclic ADP-ribose (cADPR), a powerful calcium mobilizer from intracellular stores, Due to the well established role of calcium levels in the regulation of apoptosis, proliferation, and differentiation, the CD38/cADPR system seems to be a likely candidate involved in the control of these fundamental processes. The ectocellular localization of the cyclase activity, however, contrasts with the intracellular site of action of cADPR. Here we demonstrate that ectocellular expression of human CD38 in CD38(-) HeLa and 3T3 cells results in intracellular CD38 substrate (NAI(+) + NADH) consumption and product (cADPR) accumulation. Furthermore, a causal relationship is established between presence of intracellular cADPR, partial depletion of thapsigargin-sensitive calcium stores, increase in basal free cytoplasmic calcium concentration, and decrease of cell doubling time. The significant shortening of the S phase in CD38(+) HeLa cells, as compared with controls, demonstrates an effect of intracellular cADPR on the mammalian cell cycle.	Univ Genoa, Inst Biochem, I-16132 Genoa, Italy; Adv Biotechnol Ctr, I-16132 Genoa, Italy; Natl Res Council, Inst Cybernet & Biophys, I-16149 Genoa, Italy; Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan	Zocchi, E (corresponding author), Univ Genoa, Inst Biochem, Viale Benedetto XV 1, I-16132 Genoa, Italy.	ezocchi@unige.it	Bruzzone, Santina/A-4264-2015; Marchetti, Carla/L-3093-2013; Daga, Antonio/Z-2417-2019; Daga, Antonio/C-3041-2008	Bruzzone, Santina/0000-0003-2034-3716; Marchetti, Carla/0000-0001-9219-1825; Daga, Antonio/0000-0001-5845-8530; Usai, Cesare/0000-0001-8863-7759				BEGG AC, 1985, CYTOMETRY, V6, P620, DOI 10.1002/cyto.990060618; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; Berridge MJ, 1997, AM J NEPHROL, V17, P1, DOI 10.1159/000169064; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; DEFLORA A, 1985, BLOOD, V66, P294; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; FRANCO L, 1994, BIOCHEM BIOPH RES CO, V202, P1710, DOI 10.1006/bbrc.1994.2132; GERSHENGORN MC, 1981, J BIOL CHEM, V256, P2445; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KIRKHAM PA, 1994, IMMUNOLOGY, V83, P513; Kontani K, 1996, J BIOL CHEM, V271, P1534; Lahouratate P, 1997, AM J PHYSIOL-HEART C, V273, pH1082, DOI 10.1152/ajpheart.1997.273.3.H1082; LEE HC, 1994, CELL SIGNAL, V6, P591, DOI 10.1016/0898-6568(94)90042-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; MIZUGUCHI M, 1995, BRAIN RES, V697, P235, DOI 10.1016/0006-8993(95)00885-T; OLUGBENGA A, 1996, AM J PHYSIOL, V270, pF469; Paillasson S, 1997, EXP CELL RES, V231, P226, DOI 10.1006/excr.1996.3464; Silvennoinen O, 1996, J IMMUNOL, V156, P100; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TOHGO A, 1994, J BIOL CHEM, V269, P28555; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; ZOCCHI E, 1993, BIOCHEM J, V295, P121, DOI 10.1042/bj2950121; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1990, BIOCHEM BIOPH RES CO, V173, P179, DOI 10.1016/S0006-291X(05)81038-1; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	39	112	113	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8017	8024		10.1074/jbc.273.14.8017	http://dx.doi.org/10.1074/jbc.273.14.8017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525901	hybrid			2022-12-27	WOS:000072876300035
J	Barklis, E; McDermott, J; Wilkens, S; Fuller, S; Thompson, D				Barklis, E; McDermott, J; Wilkens, S; Fuller, S; Thompson, D			Organization of HIV-1 capsid proteins on a lipid monolayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MATRIX PROTEIN; ANTIGEN	In an in vitro system that mimics the assembly of immature human immunodeficiency virus (HIV) particles, ordered arrays of HIV-1 capsid (CA) proteins encoded by the viral gag gene have been obtained by incubation of histidine-tagged capsid proteins (His-HIVCA) beneath lipid monolayers containing the nickel-chelating lipid, 1,2-di-O-hexadecyl-sn-glycero-3-(1'-2 "-hydroxy-3'-N-(5-amino-1-carboxypentyl)iminodiacetic acid)propyl ether. The membrane-bound His-HIVCA proteins formed small crystalline arrays of primitive (p1) unit cells with dimensions of a = 74.2 Angstrom, b = 126.2 Angstrom, gamma = 89.3 degrees. The image-analyzed two-dimensional projection of His-HIVCA assemblies shows a cage-like lattice, consisting of hexamer and trimer units, surrounding protein-free cage holes. The hexamer-coordinated cage holes of 26.3-Angstrom diameter are spaced at 74.2-Angstrom intervals: these distances, and the hexamer-trimer arrangement, are consistent with previous, lower resolution studies on immature HIV-1 virus particles produced in vivo. Additionally, HIV-1 matrix protein trimer unit structures align to the His-HIVCA trimer units such that residues previously shown to interact with the HIV-1 gp120/gp41 envelope protein complex are oriented toward the hexamer cage holes. Our results form a bridge between results from conventional methods for the analysis of HIV particle structure.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Microbiol, Portland, OR 97201 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; European Mol Biol Lab, Struct Biol Programme, D-69012 Heidelberg, Germany; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Oregon Health & Science University; Oregon Health & Science University; University of Oregon; European Molecular Biology Laboratory (EMBL); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Barklis, E (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	barklis@ohsu.edu		McDermott, Jason/0000-0003-2961-2572	NCI NIH HHS [2R01 CA47088] Funding Source: Medline; NIGMS NIH HHS [5R01 GM52914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barklis E, 1997, EMBO J, V16, P1199, DOI 10.1093/emboj/16.6.1199; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Faecke Michael, 1993, Journal of Virology, V67, P4972; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Hardt S, 1996, J STRUCT BIOL, V116, P68, DOI 10.1006/jsbi.1996.0012; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; McDermott J, 1996, J VIROL, V70, P5106, DOI 10.1128/JVI.70.8.5106-5114.1996; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; MORRELET N, 1992, EMBO J, V11, P3059; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; WANG C, 1993, J VIROL, V67, P5550	22	58	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7177	7180		10.1074/jbc.273.13.7177	http://dx.doi.org/10.1074/jbc.273.13.7177			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516405	hybrid			2022-12-27	WOS:000072738500001
J	Pollard, H; Remy, JS; Loussouarn, G; Demolombe, S; Behr, JP; Escande, D				Pollard, H; Remy, JS; Loussouarn, G; Demolombe, S; Behr, JP; Escande, D			Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; PLASMID DNA; MECHANISM; CULTURE; VECTORS	The beta-galactosidase reporter gene, either free or complexed with various cationic vectors, was microinjected into mammalian cells. Cationic lipids but not polyethylenimine or polylysine prevent transgene expression when complexes are injected in the nucleus. Polyethylenimine and to a lesser extent polylysine, but not cationic lipids, enhance transgene expression when complexes are injected into the cytoplasm, This latter effect was independent of the polymer vector/cDNA ionic charge ratio, suggesting that nucleic acid compaction rather than surface charge was critical for efficient nuclear trafficking. Cell division was not required for nuclear entry. Finally, comparative transfection and microinjection experiments with various cell lines confirm that barriers to gene transfer vary with cell type. We conclude that polymers but not cationic lipids promote gene delivery from the cytoplasm to the nucleus and that transgene expression in the nucleus is prevented by complexation with cationic lipids but not with cationic polymers.	Hop Hotel Dieu, Lab Physiopathol & Pharmacol Cellulaires & Mol, INSERM, CJF 96 01, F-44093 Nantes, France; Fac Pharm, Lab Chim Genet, CNRS, URA 1386, Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Centre National de la Recherche Scientifique (CNRS)	Escande, D (corresponding author), Hop Hotel Dieu, Lab Physiopathol & Pharmacol Cellulaires & Mol, INSERM, CJF 96 01, F-44093 Nantes, France.	denis.escande@sante.univ-nantes.fr	Loussouarn, Gildas/ABH-6043-2020; Remy, Jean-Serge/A-9821-2011; Loussouarn, Gildas/D-3590-2015	Loussouarn, Gildas/0000-0001-8007-5931; Remy, Jean-Serge/0000-0002-3935-0433; Loussouarn, Gildas/0000-0001-8007-5931				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BEHR JP, 1993, ACCOUNTS CHEM RES, V26, P274, DOI 10.1021/ar00029a008; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boussif O, 1996, GENE THER, V3, P1074; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Gao X, 1995, GENE THER, V2, P710; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GOLDMAN C, 1997, NAT BIOTECHNOL, V15, P1; LabatMoleur F, 1996, GENE THER, V3, P1010; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LIM K, 1989, BIOTECHNIQUES, V7, P576; MINASCHEK G, 1989, EXP CELL RES, V183, P434, DOI 10.1016/0014-4827(89)90402-3; MOHAMMADPANAH R, 1998, IN PRESS AM J PHYSL; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; Sola B, 1997, J NEUROSCI METH, V71, P183, DOI 10.1016/S0165-0270(96)00141-0; Vigneron JP, 1996, P NATL ACAD SCI USA, V93, P9682, DOI 10.1073/pnas.93.18.9682; Wilke M, 1996, GENE THER, V3, P1133; WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3	25	591	631	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7507	7511		10.1074/jbc.273.13.7507	http://dx.doi.org/10.1074/jbc.273.13.7507			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516451	Green Published, hybrid			2022-12-27	WOS:000072738500047
J	Tran, K; Boren, J; Macri, J; Wang, YW; McLeod, R; Avramoglu, RK; Adeli, K; Yao, ZM				Tran, K; Boren, J; Macri, J; Wang, YW; McLeod, R; Avramoglu, RK; Adeli, K; Yao, ZM			Functional analysis of disulfide linkages clustered within the amino terminus of human apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; LIPID RECRUITMENT; SECRETION; EXPRESSION; CELLS; DEGRADATION; POLYMORPHISM	We tested the involvement of N-terminal six disulfide bonds (Cys-1 through Cys-12) of human apolipoprotein (apo) B in the assembly and secretion of lipoproteins using two C-terminal truncated apoB variants, namely B50 and B18, In transfected rat hepatoma McA-RH7777 cells, B50 could assemble very low density lipoproteins (VLDL), and B18 was secreted as high density lipoproteins, When all 12 cysteine residues were substituted with alanines in B50, the mutant protein (B50C1-12) lost its ability to assemble lipid and was degraded intracellularly, However, mutation had no effect on B50C1-12 translation or translocation across the microsomal membrane, Post-translational degradation of B50C1-12 was partially inhibited by the proteasome inhibitor MG132. To determine which cysteines were critical in VLDL assembly and secretion, we prepared three additional mutant B50s, each containing four selected Cys-to-Ala substitutions in tandem (i.e. Cys-1 to Cys-4, Cys-5 to Cys-8, and Cys-9 to Cys-12), Expression of these mutants showed that disruption of disulfide bond formation within Cys-8 to Cys-8 diminished apoB secretion, whereas within Cys-1 to Cys-4 or Cys-9 to Cys-12 had lesser or no effect, In another two mutants in which only one disulfide bond (i.e. between Cys-5 and Cys-6 or between Cys-7 and Cys-8) was eliminated, only secretion of B50 with mutations at Cys-7 and Cys-8 was decreased, Thus, the disulfide bond involving Cys-7 and Cys-8 is most important for VLDL assembly and secretion, In addition, assembly and secretion of VLDL containing endogenous B100 or B48 were impaired in cells transfected with B50s containing Cys-7 and Cys-8 mutation, The Cys-to-Ala substitution abolished recognition of B50 by MB19, a conformational antibody with an epitope at the N terminus of human apoB, The Cys-to-Ala substitution also attenuated secretion of B18, but the effect of the mutation on B18 secretion was less evident than on B50.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Inst Heart, Dept Biochem, Ottawa, ON K1Y 4E9, Canada; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Windsor	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4E9, Canada.	zyao@heartinst.on.ca	; McLeod, Roger/F-8014-2015	Adeli, Khosrow/0000-0002-5839-5709; McLeod, Roger/0000-0002-6740-5569				Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; CHAN L, 1992, J BIOL CHEM, V267, P25621; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Ingram MF, 1997, J BIOL CHEM, V272, P10279; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MILNE R, 1989, J BIOL CHEM, V264, P19754; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PEASE RJ, 1990, J BIOL CHEM, V265, P553; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Wang L, 1997, J BIOL CHEM, V272, P27644, DOI 10.1074/jbc.272.44.27644; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yao ZM, 1997, J LIPID RES, V38, P1937; YAO ZM, 1992, J BIOL CHEM, V267, P1175; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; YOUNG SG, 1989, J LIPID RES, V30, P443; YOUNG SG, 1986, P NATL ACAD SCI USA, V83, P1101, DOI 10.1073/pnas.83.4.1101	40	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7244	7251		10.1074/jbc.273.13.7244	http://dx.doi.org/10.1074/jbc.273.13.7244			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516417	hybrid			2022-12-27	WOS:000072738500013
J	Nakamura, T; Muraoka, S; Sanokawa, R; Mori, N				Nakamura, T; Muraoka, S; Sanokawa, R; Mori, N			N-Shc and Sck, two neuronally expressed Shc adapter homologs - Their differential regional expression in the brain and roles in neurotrophin and Src signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MAP KINASE ACTIVATION; TYROSINE KINASES; BINDING DOMAINS; RAT-BRAIN; C-DELTA; PROTEIN; TRANSDUCTION; PATHWAY; TRK	The Shc adapter protein is ubiquitously expressed and has been implicated in phosphotyrosine signalings following a variety of extracellular stimulation, e.g. growth factor stimulation, Ca2+ elevation, and G-protein coupled receptor stimulation. In neuronal cells such as PC12, Shc was demonstrated to be involved in vitro in Ras-dependent mitogen-activated protein kinase activation following nerve growth factor stimulation and Ca2+ entry. However, Shc mRNA was hardly detectable in the brain, and therefore, Shc is unlikely to participate in phosphotyrosine signaling in the central nervous system. Two recently isolated Shc homologs, N-Shc and Sck, have been shown to be expressed in the brain and are expected to function as neuronal adapters instead of She. In this study, the neuronal distribution and function of these novel Shc members were investigated. In human and rat central nervous systems, the expression profiles of N-Shc and Sck mRNAs considerably overlapped, although some distinct localization between them was observed: in the adult rat brain, the level of N-Shc mRNA was the highest in the thalamus, whereas that of Sck mRNA was the highest in the hippocampus. In the peripheral nervous system, transcripts of Shc and Sck, but not of N-Shc, were detected. Immunoprecipitation experiments demonstrated functional differences between N-Shc and Sck: (i) N-Shc was a higher affinity adapter molecule than Sck in nerve growth factor and brain-derived neurotrophic factor signaling; and (ii) N-Shc, but not Sck, was efficiently phosphorylated by activated Src tyrosine kinase, whereas Sck, but not N-Shc, formed a complex with pp135, a protein highly phosphorylated by v-Src. These results suggest that neurally expressed N-Shc and Sck may have distinct roles in neuronal signaling in the brain.	Sumitomo Elect Ind Ltd, Biomed Res & Dev Dept, Sakae Ku, Yokohama, Kanagawa 244, Japan; Sci & Technol Corp Japan, PRESTO, Inheritance & Variat Grp, Kyoto 61902, Japan; Natl Inst Longev Sci, Dept Mol Genet Res, Aichi 474, Japan; Sci & Technol Corp Japan, CREST, Program Protecting Brain, Aichi 474, Japan	Sumitomo Electric Industries; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Nakamura, T (corresponding author), Sumitomo Elect Ind Ltd, Biomed Res & Dev Dept, Sakae Ku, Yokohama, Kanagawa 244, Japan.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HEFTI F, 1992, NEUROTROPHIC FACTORS, P25; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Heumann Rolf, 1994, Current Opinion in Neurobiology, V4, P668, DOI 10.1016/0959-4388(94)90008-6; HIMI T, 1994, NEUROSCIENCE, V60, P907, DOI 10.1016/0306-4522(94)90271-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI WQ, 1994, J BIOL CHEM, V269, P2349; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miettinen S, 1996, J NEUROSCI, V16, P6236; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Miki H, 1997, CELL GROWTH DIFFER, V8, P195; Nakamura T, 1996, ONCOGENE, V13, P1111; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U	49	78	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6960	6967		10.1074/jbc.273.12.6960	http://dx.doi.org/10.1074/jbc.273.12.6960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507002	hybrid			2022-12-27	WOS:000072775900052
J	Van Lint, J; Ni, YP; Valius, M; Merlevede, W; Vandenheede, JR				Van Lint, J; Ni, YP; Valius, M; Merlevede, W; Vandenheede, JR			Platelet-derived growth factor stimulates protein kinase D through the activation of phospholipase C gamma and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ADRENERGIC-RECEPTOR KINASE; SMOOTH-MUSCLE CELLS; SWISS 3T3; PHOSPHATIDYLINOSITOL 3-KINASE; PHORBOL ESTERS; BETA-SUBUNIT; D PKD; DOMAIN; PHOSPHORYLATION	Platelet-derived growth factor (PDGF) stimulates protein kinase D (PKD) in a time-and dose-dependent manner. We have used a series of PDGF receptor mutants that display a selective impairment of the binding of SH2-containing proteins (GTPase-activating protein, SHP-2, phospholipase C gamma (PLC gamma), or phosphatidylinositol S'-kinase (PI3K)) to show that Tyr-1021, the PLC gamma-binding site, is essential for PKD stimulation by PDGF in A431 cells. We next investigated whether any one of these four binding sites could mediate PI(D activation in the absence of the other three sites. F5, a receptor mutant that lacks all four binding sites for GTPase-activating protein, PLC gamma, PI3K, and SHP-2, fails to activate PKD. A panel of single add-back mutants was used to investigate if any one of these four sites could restore signaling to PKD. Of the four sites, only the PLC gamma(+) single add-back receptor restored PDGF-mediated activation of PKD, and only this add-back receptor produced diacylglycerol (DAG) in a PDGF-dependent manner. 1,2-Dioctanoyl-sn-glycerol, a membrane permeant DAG analog, was found to be sufficient for activation of PKD. Taken together, these data indicate that PLC gamma activation is not only necessary, but also sufficient to mediate PDGF-induced PKD activation. Although the presence of a pleckstrin homology domain makes PKD a potential PI3K target, PKD was not stimulated by selective PI3K activation, and wortmannin, an inhibitor of PI3K, did not inhibit PDGF signaling to PKD. The activation of PKD by DAG or by the wild-type and PLC gamma(+) add-back PDGF receptors was inhibited by GF109203X, suggesting a role for protein kinase C in the stimulation of PKD by PDGF. PDGF induced a time-dependent phosphorylation of PKD that closely correlated with activation. The PDGF-induced activation and phosphorylation of PKD were reversed by in vitro incubation of PKD with protein phosphatase 1 or 2A, indicating that PDGF signaling to PKD involves the Ser/Thr phosphorylation of PKD. Taken together, these results conclusively show that PDGF activates PKD through a pathway that involves activation of PLC gamma and, subsequently, protein kinase C.	Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	Universite Catholique Louvain	Van Lint, J (corresponding author), Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr, B-3000 Louvain, Belgium.		Valius, Mindaugas/F-2734-2012; Van Lint, Johan/P-9073-2019; Valius, Mindaugas/N-1220-2019	Valius, Mindaugas/0000-0001-8478-8517; Van Lint, Johan/0000-0002-0275-571X				ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; AXELROD J, 1995, TRENDS NEUROSCI, V18, P64; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHOUDHURY GG, 1993, AM J PHYSIOL, V265, pF634, DOI 10.1152/ajprenal.1993.265.5.F634; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HERGET T, 1994, EUR J BIOCHEM, V225, P539, DOI 10.1111/j.1432-1033.1994.00539.x; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; MA YH, 1994, J BIOL CHEM, V269, P30734; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301; YEO EJ, 1994, J BIOL CHEM, V269, P27823; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	45	65	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7038	7043		10.1074/jbc.273.12.7038	http://dx.doi.org/10.1074/jbc.273.12.7038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507012	hybrid			2022-12-27	WOS:000072775900062
J	Lee, GW; Melchior, F; Matunis, MJ; Mahajan, R; Tian, QS; Anderson, P				Lee, GW; Melchior, F; Matunis, MJ; Mahajan, R; Tian, QS; Anderson, P			Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin-conjugating enzyme homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; IDENTIFICATION; RAN/TC4; TRANSPORT; INTERACTS; IMPORT; SYSTEM; P53	Covalent modification of the Ran GTPase-activating protein RanGAP1 with the ubiquitin-related protein SUMO-1 promotes its association with Nup358, a component of the cytoplasmic fibrils emanating from the nuclear pore complex (1, 2), In Xenopus egg extracts, Nup358 can be found in a complex with Ubc9 (3), a structural homologue of the E2-type ubiquitin-conjugating enzymes (UBCs). Here we show that a subset of the human homologue of Ubc9 (HsUbc9) colocalizes with RanGAP1 at the nuclear envelope, HsUbc9 forms thiolester conjugates with recombinant SUMO-1, but not with recombinant ubiquitin, indicating that it is functionally distinct from EB-type UBCs, Finally, HsUbc9 is required for the modification of RanGAP1 by SUMO-1. These results suggest that HsUbc9 is a component of a novel enzymatic cascade that modifies RanGAP1, and possibly other substrates, with SUMO-1.	Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Scripps Research Institute; Howard Hughes Medical Institute; Rockefeller University	Lee, GW (corresponding author), Brigham & Womens Hosp, Div Rheumatol, Smith Bldg 608,75 Francis St, Boston, MA 02115 USA.	glee@rics.bwh.harvard.edu	Melchior, Frauke/E-2014-2014	Melchior, Frauke/0000-0001-9546-8797; Matunis, Michael/0000-0002-9350-6611				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Boddy MN, 1996, ONCOGENE, V13, P971; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jiang WD, 1996, MOL GEN GENET, V251, P153; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MAHAJAN R, 1998, IN PRESS J CEL BIOL; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MATUNIS MJ, 1998, IN PRESS J CELL BIOL; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Okura T, 1996, J IMMUNOL, V157, P4277; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Wright DA, 1996, J BIOL CHEM, V271, P31037, DOI 10.1074/jbc.271.49.31037; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	30	121	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6503	6507		10.1074/jbc.273.11.6503	http://dx.doi.org/10.1074/jbc.273.11.6503			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497385	hybrid			2022-12-27	WOS:000072488500077
J	Kalman, K; Nguyen, A; Tseng-Crank, J; Dukes, ID; Chandy, G; Hustad, CM; Copeland, NG; Jenkins, NA; Mohrenweiser, H; Brandriff, B; Cahalan, M; Gutman, GA; Chandy, KG				Kalman, K; Nguyen, A; Tseng-Crank, J; Dukes, ID; Chandy, G; Hustad, CM; Copeland, NG; Jenkins, NA; Mohrenweiser, H; Brandriff, B; Cahalan, M; Gutman, GA; Chandy, KG			Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; GENETIC-LINKAGE MAP; K+ CHANNELS; FUNCTIONAL EXPRESSION; NUCLEOTIDE-SEQUENCE; LEPTIN RECEPTOR; DROSOPHILA; ENCODES; FAMILY; MUSCLE	We report the isolation of a novel mouse voltage-gated Shaker-related K+ channel gene, Kv1.7 (Kcna7/KCNA7). Unlike other known Kv1 family genes that have intronless coding regions, the protein-coding region of Ku1.7 is interrupted by a 1,9-kilobase pair intron, The Kv1.7 gene and the related Kv3.3 (Kcnc3/KCNC3) gene map to mouse chromosome 7 and human chromosome 19q13.3, a region that has been suggested to contain a diabetic susceptibility locus, The mouse Kv1,7 channel is voltage-dependent and rapidly inactivating, exhibits cumulative inactivation, and has a single channel conductance of 21 pS, It is potently blocked by noxiustoxin and stichodactylatoxin, and is insensitive to tetraethylammonium, kaliotoxin, and charybdotoxin. Northern blot analysis reveals similar to 3-kilobase pair Kv1.7 transcripts in mouse heart and skeletal muscle, In situ hybridization demonstrates the presence of Kv1.7 in mouse pancreatic islet cells. Kv1.7 was also isolated from mouse brain and hamster insulinoma cells by polymerase chain reaction.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Glaxo Wellcome Res Inst, Res Triangle Pk, NC 27709 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Mammalian Genet Lab, Frederick, MD 21702 USA; Univ Calif Lawrence Livermore Natl Lab, Ctr Human Genome, Livermore, CA 94550 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Rm 291,Joan Irvine Simth Hall, Irvine, CA 92697 USA.	gchandy@uci.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R37NS014609, R56NS014609] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24783] Funding Source: Medline; NIGMS NIH HHS [GMOD54872] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BETSHOLTZ C, 1990, FEBS LETT, V263, P121, DOI 10.1016/0014-5793(90)80719-Y; BRANDRIFF BF, 1992, GENOMICS, V12, P778; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; ELBEIN SC, 1994, DIABETES, V43, P1061, DOI 10.2337/diabetes.43.8.1061; Estivill X, 1996, NAT GENET, V12, P348, DOI 10.1038/ng0496-348; GHANSHANI S, 1992, GENOMICS, V12, P190, DOI 10.1016/0888-7543(92)90365-Y; GINTANT GA, 1992, HEART CARDIOVASCULAR, P1122; Green EL, 1981, GENETICS PROBABILITY, P77; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GROOP LC, 1993, NEW ENGL J MED, V328, P10, DOI 10.1056/NEJM199301073280102; HILLE B, 1993, IONIC CHANNELS EXCIT; IKEDA SR, 1992, PFLUG ARCH EUR J PHY, V422, P201, DOI 10.1007/BF00370422; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MCCLOSKEY M, 1990, J GEN PHYSIOL, V95, P208; NGUYEN QA, 1996, MOL PHARMACOL, V50, P1672; PERMUTT MA, 1989, P NATL ACAD SCI USA, V86, P8688, DOI 10.1073/pnas.86.22.8688; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; REDER RF, 1981, CIRC RES, V48, P658, DOI 10.1161/01.RES.48.5.658; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; SAUNDERS AM, 1990, GENOMICS, V8, P525, DOI 10.1016/0888-7543(90)90040-2; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; SMITH PA, 1990, J GEN PHYSIOL, V95, P1041, DOI 10.1085/jgp.95.6.1041; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153	37	62	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5851	5857		10.1074/jbc.273.10.5851	http://dx.doi.org/10.1074/jbc.273.10.5851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488722	hybrid			2022-12-27	WOS:000072345000065
J	Kawamata, S; Hori, T; Imura, A; Takaori-Kondo, A; Uchiyama, T				Kawamata, S; Hori, T; Imura, A; Takaori-Kondo, A; Uchiyama, T			Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF)2- and TRAF5-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CYTOPLASMIC DOMAIN; T-CELLS; MOLECULAR-CLONING; INDUCED APOPTOSIS; CONTAINS 2; PROTEIN; FAMILY; INTERACTS; ANTIGEN	We investigated the intracellular signaling of OX40, a member of the tumor necrosis factor receptor family. Activation of NF-kappa B in OX40-transfected HSB-2 cells was detected by electrophoretic mobility shift assay within 30 min after the binding of the Ligand gp34. In vitro binding experiments showed that tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF2, TRAF3, and TRAF5 but not TRAF4 associated with glutathione S-transferase-OX40 fusion protein, The cotransfection experiments using human embryo kidney cell derived HEK 293T cells showed that TRAF2, TRAF3, and TRAF5 associated with OX40 in vivo. Studies with OX40 deletion mutants demonstrated that the cytoplasmic portion consisting of amino acid sequence 256-263 (GGSFRTPI) was required for the association with TRAFs and NF-kappa activation. The introduction of the dominant negative mutants of TR4F2 and TRAF5 into HSB-2-OX40 cells suppressed NF-kappa B activation in a dose-dependent manner. In addition, the introduction of TRAF3 together with the dominant negative mutants of TRAF2 or TRAF5 further reduced NF-kappa B activation. These results indicate that the NF-kappa B activation resulting from OX40 stimulation is mediated by both TRAF2 and TRAF5, and is likely to be negatively modulated by TRAF3.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 606, Japan	Kyoto University	Uchiyama, T (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, 53 Shogoin-kawaracho, Kyoto 606, Japan.							AIZAWA S, 1997, J BIOL CHEM, V272, P20442; Baker SJ, 1996, ONCOGENE, V12, P1; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; CALDERHEAD DM, 1993, J IMMUNOL, V151, P5261; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; FORCE WR, 1994, J BIOL CHEM, V269, P8863; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; GODFREY WR, 1994, J EXP MED, V180, P757, DOI 10.1084/jem.180.2.757; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; Imura A, 1997, BLOOD, V89, P2951, DOI 10.1182/blood.V89.8.2951; LATZA U, 1994, EUR J IMMUNOL, V24, P677, DOI 10.1002/eji.1830240329; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; Matsumura Y, 1997, ARCH DERMATOL RES, V289, P653, DOI 10.1007/s004030050255; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Sun SC, 1996, MOL CELL BIOL, V16, P1058; TANAKA Y, 1985, INT J CANCER, V36, P549, DOI 10.1002/ijc.2910360506; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weinberg AD, 1996, NAT MED, V2, P183, DOI 10.1038/nm0296-183	50	150	160	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5808	5814		10.1074/jbc.273.10.5808	http://dx.doi.org/10.1074/jbc.273.10.5808			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488716	hybrid			2022-12-27	WOS:000072345000059
J	Young, P; Deveraux, Q; Beal, RE; Pickart, CM; Rechsteiner, M				Young, P; Deveraux, Q; Beal, RE; Pickart, CM; Rechsteiner, M			Characterization of two polyubiquitin binding sites in the 26 S protease subunit 5a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; MULTIUBIQUITIN-CHAIN; PHENOTYPIC SELECTION; PROTEOLYTIC COMPLEX; CELL-CYCLE; UBIQUITIN; COMPONENT; PURIFICATION; DEGRADATION; MUTANT	Ubiquitylated proteins are degraded by the 26 S protease, an enzyme complex that contains 30 or more unique subunits, One of these proteins, subunit 5a (S5a), has been shown to bind ubiquitin-lysozyme conjugates and free polyubiquitin chains, Using deletional analysis, we have identified in the carboxyl-terminal half of human S5a, two independent polyubiquitin binding sites whose sequences are highly conserved among higher eukaryotic S5a homologs, The sites are approximately 30-amino acids long and are separated by 50 intervening residues, When expressed as small fragments or when present in full-length S5a molecules, the sites differ at least 10-fold in their apparent affinity for polyubiquitin chains, Each binding site contains 5 hydrophobic residues that form an alternating pattern of large and small side chains, e.g. Leu-Ala-Leu-Ala-Leu, and this pattern is essential for binding ubiquitin chains, Based on the importance of the alternating hydrophobic residues in the binding sites and previous studies showing that a hydrophobic patch on the surface of ubiquitin is essential for proteolytic targeting, we propose a model for molecular recognition of polyubiquitin chains by S5a.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Johns Hopkins Univ Hosp, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Utah System of Higher Education; University of Utah; Johns Hopkins University; Johns Hopkins Medicine	Young, P (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.				NIDDK NIH HHS [DK46984] Funding Source: Medline; NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P5492, DOI 10.1073/pnas.74.12.5492; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1986, J BIOL CHEM, V261, P2391; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Myers JK, 1997, P NATL ACAD SCI USA, V94, P2833, DOI 10.1073/pnas.94.7.2833; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PICKART CM, 1994, J BIOL CHEM, V269, P7115; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856	44	252	259	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5461	5467		10.1074/jbc.273.10.5461	http://dx.doi.org/10.1074/jbc.273.10.5461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488668	hybrid			2022-12-27	WOS:000072345000011
J	Zhou, ZM; Peng, SB; Crider, BP; Slaughter, C; Xie, XS; Stone, DK				Zhou, ZM; Peng, SB; Crider, BP; Slaughter, C; Xie, XS; Stone, DK			Molecular characterization of the 50- and 57-kDa subunits of the bovine vacuolar proton pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; TRANSLOCATING COMPLEX; ATPASE SUBUNIT; IN-VITRO; RECONSTITUTION; PROTEIN; POLYPEPTIDE; MEMBRANES; SEQUENCE	The vacuolar type proton-translocating ATPase of clathrin-coated vesicles is composed of two large domains: an extramembranous catalytic sector and a transmembranous proton channel. In addition, two polypeptides of 50 and 57 kDa have been found to copurify with the pump, These proteins, termed SFD (sub-fifty-eight-kDa dimer) activate ATPase activity of the enzyme and couple ATPase activity to proton flow (Xie, X.-S., Chem B.P., Ma, Y.-M., and Stone, D. K. (1994) J. Biol. Chem, 269, 28509-25818). It has also been reported that the clathrin-coated vesicle proton pump contains AP50, a 50-kDa component of the AP-2 complex responsible for the assembly of clathrin-coated pits, and that AP50 is essential for function of the proton pump (Liu, Q., Feng, Y., and Forgac, M. (1994) J. Biol. Chem. 269, 31592-31597), We demonstrate through the use of anti-AP50 antibody, identical to that of the latter study, that hydroxylapatite chromatography removes AP50 from impure proton pump preparations and that purified proton pump, devoid of AP50, is fully functional. To determine the true molecular identity of SFD, both the 50- and 57-kDa polpeptides were directly sequenced. A polymerase chain reaction-based strategy was used to screen a bovine brain cDNA library, yielding independent full-length clones (SFD-4A and SFD-21); these were identical in their open reading frames and encoded a protein with a predicted mass of 54,187 Da. The SFD-21 clone was then used in a reverse transcription-polymerase chain reaction-based strategy to isolate a related, but distinct, transcript present in bovine brain mRNA. The nucleotide and predicted amino acid sequences of this isolate are identical to SFD-21 except, that the isolate contains a 54-base pair insert in the open reading frame, resulting in a protein with a predicted mass of 55,933 Da. Both clones had 16% identity to VMA13 of Saccharomyces cerevisiae. No sequence homology between the SFD clones and AP50 was detectable. Anti-peptide antibodies were generated against an epitope common to the two proteins and to the unique 18-amimao acid insert of the larger protein. The former reacted with both components of native SFD, whereas the latter reacted only with the 57-kDa component. We term the 57- and 50-kDa polypeptides SFD alpha and SFD beta, respectively.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Mol Transport, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stone, DK (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Mol Transport, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1988, J CELL BIOL, V106, P529; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FUCHS R, 1994, P NATL ACAD SCI USA, V91, P4811, DOI 10.1073/pnas.91.11.4811; GRAF R, 1994, J BIOL CHEM, V269, P3767; HO MN, 1993, J BIOL CHEM, V268, P18286; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU Q, 1994, J BIOL CHEM, V269, P31592; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MEYERS M, 1993, J BIOL CHEM, V268, P9184; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STONE DK, 1988, KIDNEY INT, V3, P403; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859	26	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5878	5884		10.1074/jbc.273.10.5878	http://dx.doi.org/10.1074/jbc.273.10.5878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488725	hybrid			2022-12-27	WOS:000072345000068
J	Bogenhagen, DF; Pinz, KG				Bogenhagen, DF; Pinz, KG			The action of DNA ligase at abasic sites in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASES; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; CATALYTIC MECHANISM; ESCHERICHIA-COLI; IMINO INTERMEDIATE; POLYMERASE-BETA; FPG PROTEIN; EXCISION; REPAIR; GLYCOSYLASES	Apurinic/apyrimidinic (AP) sites occur frequently in DNA as a result of spontaneous base loss or following removal of a damaged base by a DNA glycosylase. The action of many AP endonuclease enzymes at abasic sites in DNA leaves a 5'-deoxyribose phosphate (dRP) residue that must be removed during the base excision repair process. This 5'-dRP group may be removed by AP lyase enzymes that employ a beta-elimination mechanism. This beta-elimination reaction typically involves a transient Schiff base intermediate that can react with sodium borohydride to trap the DNA-enzyme complex. With the use of this assay as well as direct 5'-dRP group release assays, we show that T4 DNA ligase, a representative ATP-dependent DNA ligase, contains AP lyase activity. the AP lyase activity of T4 DNA ligase is inhibited in the presence of ATP, suggesting that the adenylated lysine residue is part of the active site for both the ligase and lyase activities. A model is proposed whereby the AP lyase activity of DNA ligase may contribute to the repair of abasic sites in DNA.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bogenhagen, DF (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.				PHS HHS [P01-04068] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; BRICTEUXGREGOIRE S, 1989, NUCLEIC ACIDS RES, V17, P6269, DOI 10.1093/nar/17.15.6269; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GOFFIN C, 1987, NUCLEIC ACIDS RES, V15, P8755, DOI 10.1093/nar/15.21.8755; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PINZ KG, 1998, IN PRESS MOL CELL BI, V18; Sambrook J., 2002, MOL CLONING LAB MANU; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400	22	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7888	7893		10.1074/jbc.273.14.7888	http://dx.doi.org/10.1074/jbc.273.14.7888			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525883	hybrid			2022-12-27	WOS:000072876300017
J	Alexander, DS; Sipley, JD; Quigley, JP				Alexander, DS; Sipley, JD; Quigley, JP			Autoactivation of avian urokinase-type plasminogen activator (uPA) - A novel mode of initiation of the uPA/plasmin cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; HUMAN SARCOMA-CELLS; INTRINSIC ACTIVITY; HAGEMAN-FACTOR; DEPENDENT AUTOACTIVATION; ENZYMATIC-ACTIVITY; BLOOD-COAGULATION; PRO-UROKINASE; 1ST COMPONENT; FACTOR-VII	In contrast to mammalian urokinase-type plasminogen activator (uPA), which is produced and maintained in zymogen form, avian uPA is found in the active two-chain form in cultures of normal and transformed chicken cells in the absence of plasmin, the putative natural activator of pro-uPA, Recombinant chicken uPA (ch-uPA(wt)) synthesized in two distinct expression systems also presents in the active two-chain form. In addition, conversion to the active uPA in both natural and recombinant expression systems could be prevented by uPA-specific inhibitors including a monoclonal antibody that uniquely inhibits the catalytic activity of ch-uPA, Most significantly, an active site mutant of avian uPA (ch-uPA(S353A)) that lacks catalytic activity is produced and maintained in single-chain form, Furthermore, the single-chain ch-uPA(S353A) mutant can be converted to the two-chain form by purified active chu-PA(wt). These results strongly indicate an autocatalytic mechanism of activation of ch-uPA. Autoactivation appears to be an intrinsic property of ch-uPA and may be the initiating molecular event in uPA-mediated proteolytic cascades.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Quigley, JP (corresponding author), SUNY Stony Brook, Dept Pathol, BHS T9-168, Stony Brook, NY 11794 USA.	jquigley@path.som.sunysb.edu			NCI NIH HHS [CA76039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BERKENPAS MB, 1991, P NATL ACAD SCI USA, V88, P7768, DOI 10.1073/pnas.88.17.7768; BIANCHINO AC, 1988, J IMMUNOL, V141, P3930; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; DODDS AW, 1978, BIOCHEM J, V175, P383, DOI 10.1042/bj1750383; DUNN JT, 1982, J BIOL CHEM, V257, P1779; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1989, J BIOL CHEM, V264, P2185; FLEURY V, 1993, J BIOL CHEM, V268, P18554; GOLDFARB RH, 1980, BIOCHEMISTRY-US, V19, P5463, DOI 10.1021/bi00565a001; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; LESLIE ND, 1990, J BIOL CHEM, V265, P1339; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIU JN, 1995, J BIOL CHEM, V270, P8408, DOI 10.1074/jbc.270.15.8408; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; QUIGLEY JP, 1990, CELL DIFFER DEV, V32, P263, DOI 10.1016/0922-3371(90)90039-Y; Sipley JD, 1997, P NATL ACAD SCI USA, V94, P2933, DOI 10.1073/pnas.94.7.2933; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; SULLIVAN LM, 1986, CELL, V45, P905, DOI 10.1016/0092-8674(86)90565-9; TANS G, 1983, J BIOL CHEM, V258, P8215; TILLY JL, 1990, ENDOCRINOLOGY, V126, P2079, DOI 10.1210/endo-126-4-2079; Tischkau SA, 1996, BIOL REPROD, V55, P75, DOI 10.1095/biolreprod55.1.75; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; VALINSKY JE, 1981, CELL, V25, P471, DOI 10.1016/0092-8674(81)90065-9; WIGGINS RC, 1979, J EXP MED, V150, P1122, DOI 10.1084/jem.150.5.1122	35	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7457	7461		10.1074/jbc.273.13.7457	http://dx.doi.org/10.1074/jbc.273.13.7457			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516444	hybrid			2022-12-27	WOS:000072738500040
J	Ono, F; Nakagawa, T; Saito, S; Owada, Y; Sakagami, H; Goto, K; Suzuki, M; Matsuno, S; Kondo, H				Ono, F; Nakagawa, T; Saito, S; Owada, Y; Sakagami, H; Goto, K; Suzuki, M; Matsuno, S; Kondo, H			A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-PROTEIN; GROWTH-FACTOR; DIACYLGLYCEROL KINASE; RAT-LIVER; C2 DOMAIN; GENE; CLONING; PHOSPHORYLATION; INDUCTION	We report herein the cloning and characterization of a novel class II phosphoinositide 3-kinase, termed PI3K-II gamma, from the cDNA library of regenerating rat liver. This cDNA encodes a protein of 1505 amino acids with a calculated molecular mass of 170,972 Da. The amino acid sequence of PI3K-II gamma is highly similar to those of class II PI 3-kinases, including murine Cpk-m/p170 and human HsC2-PI3K. It contains a C2 domain at the C terminus but no recognizable protein motifs at its N terminus. PI3K-II gamma displays a restricted substrate specificity for PtdIns and PtdIns 4-P, but not for PtdIns 4,5-P-2. By epitope tag immunocytochemistry, the immunoreactivity for PI3K-II gamma is localized in the juxtanuclear Golgi region at high levels and also in the plasma and nuclear membranes at low levels. By Northern blot analysis and in situ hybridization histochemistry, PI3K-II gamma mRNA expression is confined to the liver throughout the development with much higher expression in adult liver than in fetal liver. In addition, its expression increases during liver regeneration after partial hepatectomy with maximal expression after the growth period, suggesting that PI3K-II gamma may function mainly in highly differentiated hepatic cells.	Tohoku Univ, Sch Med, Dept Histol, Aoba Ku, Sendai, Miyagi 98077, Japan; Tohoku Univ, Sch Med, Dept Surg 1, Aoba Ku, Sendai, Miyagi 98077, Japan; Yamagata Univ, Sch Med, Dept Anat, Yamagata 99023, Japan	Tohoku University; Tohoku University; Yamagata University	Kondo, H (corresponding author), Tohoku Univ, Sch Med, Dept Histol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 98077, Japan.	hkondo@mail.cc.tohoku.ac.jp	Unno, Michiaki/AAX-5246-2020	Unno, Michiaki/0000-0002-2145-6416; Owada, Yuji/0000-0002-5109-0531				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLDSWORTHY SM, 1993, CELL PROLIFERAT, V26, P511, DOI 10.1111/j.1365-2184.1993.tb00029.x; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Ho LKF, 1997, BIOCHEM BIOPH RES CO, V235, P130, DOI 10.1006/bbrc.1997.6747; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Ito Y, 1996, MOL BRAIN RES, V37, P329; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P2; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TANABE Y, 1988, MOL CELL BIOL, V8, P466; VANHAESEBROECK B, 1997, P NATL ACAD SCI USA, V94, P430; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184	37	57	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7731	7736		10.1074/jbc.273.13.7731	http://dx.doi.org/10.1074/jbc.273.13.7731			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516481	hybrid			2022-12-27	WOS:000072738500077
J	Poggi, A; Rubartelli, A; Zocchi, MR				Poggi, A; Rubartelli, A; Zocchi, MR			Involvement of dihydropyridine-sensitive calcium channels in human dendritic cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 TAT PROTEIN; GROWTH-FACTOR; T-CELLS; RECEPTORS; APOPTOSIS; CYTOKINE; BINDING; TYPE-1; PROLIFERATION	The entry of extracellular calcium in leukocytes mediates several cellular processes; however, unlike in excitable tissues, the underlying molecular mechanisms are poorly defined, In this paper we provide phenotypical and biochemical evidence that peripheral blood-derived human dendritic cells express dihydropyridine-sensitive calcium channels. Exposure to the dihydropyridine drug nifedipine, which binds L-type calcium channels blocking calcium influx, prevents two dendritic cell functions that are dependent on extracellular calcium entry: apoptotic body engulfment and interleukin-12 production induced by cross-linking of the surface lectin NKRP1A. It is known that exogenous human immunodeficiency virus, type 1 Tat affects several Ca2+-dependent immune cell responses. Here we demonstrate that Tat inhibits apoptotic body engulfment and interleukin-12 production by blocking extracellular calcium influx. This inhibition is prevented by the calcium channel agonist dihydropyridine derivative Bay K 8644, suggesting the involvement of L-type calcium channels. This hypothesis is further supported by the observation that Tat and dihydropyridine drugs compete for binding to dendritic cells. Taken together, these findings indicate that exogenous Tat exerts its inhibitory effects on dendritic cells by blocking dihydropyridine-sensitive L-type calcium channels.	Ist Nazl Ric Canc, Clin Pathol Lab, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Immunopathol Lab, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Adv Biotechnol Ctr, I-16132 Genoa, Italy; San Raffaele Sci Inst, Lab Tumor Immunol, I-20132 Milan, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Zocchi, MR (corresponding author), Ist Nazl Ric Canc, Clin Pathol Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	annarub@hp380.ist.unige.it	Poggi, Alessandro/K-6664-2016; Rubartelli, Anna/AAA-1259-2021	Poggi, Alessandro/0000-0002-1860-430X; Zocchi, Maria Raffaella/0000-0002-0022-8385				AKCHA AAS, 1996, J BIOL CHEM, V271, P7297; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BERGER W, 1994, BIOCHEMISTRY-US, V33, P11875, DOI 10.1021/bi00205a025; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRAKE DA, 1993, J CELL BIOL, V121, P461; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Lamont AG, 1996, IMMUNOL TODAY, V17, P214, DOI 10.1016/0167-5699(96)30011-X; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Morgavi P, 1997, J BIOL CHEM, V272, P11256, DOI 10.1074/jbc.272.17.11256; Poggi A, 1997, EUR J IMMUNOL, V27, P2965, DOI 10.1002/eji.1830271132; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; ZAULI G, 1993, CANCER RES, V53, P4481; Zocchi MR, 1997, AIDS, V11, P1227, DOI 10.1097/00002030-199710000-00005	36	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7205	7209		10.1074/jbc.273.13.7205	http://dx.doi.org/10.1074/jbc.273.13.7205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516412	hybrid			2022-12-27	WOS:000072738500008
J	Shainskaya, A; Nesaty, V; Karlish, SJD				Shainskaya, A; Nesaty, V; Karlish, SJD			Interactions between fragments of trypsinized Na,K-ATPase detected by thermal inactivation of Rb+ occlusion and dissociation of the M5/M6 fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION OCCLUSION; NA/K-ATPASE; TRYPTIC FRAGMENTS; ALPHA-SUBUNIT; BETA-SUBUNIT; DOMAIN; NA+,K+-ATPASE; BINDING; SITES; IONS	This work provides evidence for interactions between fragments of "19-kDa membranes," a trypsinized preparation of Na,K-ATPase that retains cation occlusion and ouabain binding. Previously, we reported rapid thermal inactivation of Rb+ occlusion at 37 degrees C (Or, E., David, P., Shainskaya, A., Tal, D. M., and Karlish, S. J. D. (1993) J. Biol, Chem. 268, 16929-16937). We describe here the detailed kinetics of thermal inactivation. In the range 25-35 degrees C, a two-step model (N <-> U --> I, where N is the native species, U is the reversibly unfolded intermediate, and I is the irreversibly denatured form) fits the data. Reversibility of inactivation has been observed at 25 degrees C, consistent with the model. At 37 degrees C and higher temperatures, the data can be fitted to the simple mechanism N --> I, i.e. U is not significant as an intermediate. Occluded cations (Na+, Rb+, K+, Tl+, NH4+, and Cs+) and ouabain protect strongly against thermal inactivation. Ca2+, Ba2+, and La3+ ions do not protect. Proteolysis experiments provide independent evidence that disorganization can occur in stages, first in transmembrane segments and then in extra-membrane segments of the fragments. Analysis of selective dissociation of the M5/M6 fragment at 37 degrees C (Lutsenko, S., and Kaplan, J. H. (1995) Proc. Natl. Acad Sci. U.S.A. 92, 7936-7940), using a specific antibody, showed that inactivation of Rb+ occlusion precedes dissociation of the fragment, and only similar to 50% of the fragment is released when occlusion is fully inactivated. In the presence of Ca2+ ions, occlusion is inactivated, but the M5/M6 fragment is not released. The experiments demonstrate that occlusion is inactivated by disruption of interactions between fragments of 19-kDa membranes, and only then does the M5/M6 fragment dissociate. Interactions between the M5/M6 and M7/M10 fragments seem to be essential for maintenance of Rb+ occlusion.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	BCKARLIS@WEIZMAN.WEIZMANN.AC.IL						BAMBERG K, 1994, J BIOL CHEM, V269, P16909; Bevington P. R, 1969, DATA REDUCTION ERROR; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DAVID P, 1991, J BIOL CHEM, V266, P14896; FISHER TH, 1983, BIOCHEM J, V211, P771; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GROSSMAN Z, 1990, EXP PARASITOL, V70, P62, DOI 10.1016/0014-4894(90)90086-R; HOVING S, 1995, J BIOL CHEM, V270, P29788; HUANG R, 1981, PHYSICAL CHEM APPL B, P348; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu LQ, 1997, J BIOL CHEM, V272, P14380, DOI 10.1074/jbc.272.22.14380; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; OR E, 1993, J BIOL CHEM, V268, P16929; Ptitsyn Oleg B., 1992, P243; RICE WJ, 1996, BIOPHYS J, V66, pA121; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWAPPACH B, 1994, J BIOL CHEM, V269, P21620; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7311	7319		10.1074/jbc.273.13.7311	http://dx.doi.org/10.1074/jbc.273.13.7311			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516425	hybrid			2022-12-27	WOS:000072738500021
J	Ojcius, DM; Degani, H; Mispelter, J; Dautry-Varsat, A				Ojcius, DM; Degani, H; Mispelter, J; Dautry-Varsat, A			Enhancement of ATP levels and glucose metabolism during an infection by Chlamydia - NMR studies of living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SKELETAL-MUSCLE; HELA-CELLS; TRACHOMATIS; TRANSPORTERS; PSITTACI; SPECTROSCOPY; GLYCOLYSIS; INCLUSION; CULTURE	The Chlamydia species are obligate intracellular bacteria that proliferate only within the infected cell. Since the extracellular bacteria are metabolically inert and there are no cell free systems for characterizing Chlamydia metabolism, we studied metabolic changes related to ATP synthesis and glycolysis in HeLa cells infected with Chlamydia psittaci during the course of the a-day infection cycle using noninvasive P-31 and C-13 NMR methods. We find that the infection stimulates ATP synthesis in the infected cell, with a peak of ATP levels occurring midway through the infection cycle, when most of the metabolically active bacteria are proliferating. The infection also stimulates synthesis of glutamate with a similar time course as for ATP. The stimulation is apparently due to an enhancement in glucose consumption by the infected cell, which also results in an increased rate of lactate production and glutamate synthesis as well as higher glycogen accumulation during the infection. Concurrently, infection leads to an increase in the expression of the glucose transporter, GLUT-1, on HeLa cells, which may account for the enhanced glucose consumption. The chlamydiae are thus able to stimulate glucose transport in the host cell sufficiently to compensate for the extra energy load on the cell represented by the infection.	Inst Pasteur, CNRS 1960, Unite Biol Interact Cellulaires, F-75724 Paris 15, France; Inst Curie, INSERM U350, Orsay, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ojcius, DM (corresponding author), Inst Pasteur, CNRS 1960, Unite Biol Interact Cellulaires, 25 Rue Dr Roux, F-75724 Paris 15, France.							BATTEIGER BE, 1987, INFECT IMMUN, V55, P1767, DOI 10.1128/IAI.55.8.1767-1773.1987; Bavoil PM, 1996, B I PASTEUR, V94, P5, DOI 10.1016/0020-2452(96)85299-7; BECKER Y, 1978, MICROBIOL REV, V42, P274, DOI 10.1128/MMBR.42.2.274-306.1978; BISSELL MJ, 1976, J CELL PHYSIOL, V89, P701, DOI 10.1002/jcp.1040890430; Degani H., 1994, NMR PHYSL BIOMEDICIN, P329; Dominguez JH, 1996, J CLIN INVEST, V98, P395, DOI 10.1172/JCI118805; EVANS FE, 1977, P NATL ACAD SCI USA, V74, P4909, DOI 10.1073/pnas.74.11.4909; GALLIS JL, 1991, NMR BIOMED, V4, P279, DOI 10.1002/nbm.1940040606; GILL SDA, 1970, CAN J MICROBIOL, V16, P997, DOI 10.1139/m70-169; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HATCH TP, 1982, J BACTERIOL, V150, P662, DOI 10.1128/JB.150.2.662-670.1982; HEINZEN RA, 1996, INFECT IMMUN, V64, P769; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; Jackson LA, 1996, CURR OPIN INFECT DIS, V9, P89, DOI 10.1097/00001432-199604000-00009; JAMES DE, 1993, J CELL SCI, V104, P607; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MAVROV I I, 1991, Mikrobiologicheskii Zhurnal (Kiev), V53, P95; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; MOULDER JW, 1970, J BACTERIOL, V104, P1189, DOI 10.1128/JB.104.3.1189-1196.1970; NAVON G, 1978, P NATL ACAD SCI USA, V75, P891, DOI 10.1073/pnas.75.2.891; NEEMAN M, 1988, MAGNET RESON MED, V7, P236, DOI 10.1002/mrm.1910070212; NEEMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P255, DOI 10.1016/0167-4889(90)90219-4; Ojcius DM, 1996, RES IMMUNOL, V147, P175, DOI 10.1016/0923-2494(96)83169-5; PAAVONEN J, 1989, HUM REPROD, V4, P111, DOI 10.1093/oxfordjournals.humrep.a136855; PERARA E, 1990, INFECT IMMUN, V58, P3816, DOI 10.1128/IAI.58.11.3816-3818.1990; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Raulston JE, 1997, INFECT IMMUN, V65, P4539, DOI 10.1128/IAI.65.11.4539-4547.1997; REN JM, 1993, J BIOL CHEM, V268, P16113; ROCKEY DD, 1995, MOL MICROBIOL, V15, P617, DOI 10.1111/j.1365-2958.1995.tb02371.x; SCHACHTER J, 1994, METHOD ENZYMOL, V236, P377; Schramm N, 1996, INFECT IMMUN, V64, P1208, DOI 10.1128/IAI.64.4.1208-1214.1996; SHEDD SF, 1993, NMR BIOMED, V6, P254, DOI 10.1002/nbm.1940060405; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; Tyagi RK, 1996, MAGN RESON MED, V35, P194, DOI 10.1002/mrm.1910350210; WEISS E, 1969, J BACTERIOL, V97, P719, DOI 10.1128/JB.97.2.719-724.1969; WINKLER HH, 1990, ANNU REV MICROBIOL, V44, P131, DOI 10.1146/annurev.mi.44.100190.001023	37	76	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7052	7058		10.1074/jbc.273.12.7052	http://dx.doi.org/10.1074/jbc.273.12.7052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507014	hybrid, Green Submitted			2022-12-27	WOS:000072775900064
J	Ross, IL; Yue, X; Ostrowski, MC; Hume, DA				Ross, IL; Yue, X; Ostrowski, MC; Hume, DA			Interaction between PU.1 and another Ets family transcription factor promotes macrophage-specific basal transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PLASMINOGEN-ACTIVATOR GENE; C-FMS PROTOONCOGENE; FACTOR-RECEPTOR; NUCLEAR FACTOR; CELL-LINES; EXPRESSION; ENHANCER; DOMAINS; SPI-1	Numerous macrophage-restricted promoters lack TATA boxes or other conventional initiation motifs but contain high affinity binding sites (PU boxes) for the macrophage-restricted Ets family transcription factor PU.1, In RAW264 murine macrophages, multimerized PU boxes were not active as enhancers when placed upstream of a minimal promoter. To model their role in basal promoters, we inserted PU boxes into a promoterless luciferase reporter plasmid, Two sites, regardless of orientation, were necessary and sufficient to direct reporter gene expression in transient transfections of the RAW264 macrophage-like cell line, This activity was absent in transfected 3T3 fibroblasts but could be induced by PU.1 coexpression. Both the model promoter and the macrophage-specific mouse and human c-fms promoters were activated in RAW264 cells by other Ets family transcription factors, Ets-2 and Elf-1. In fibroblasts, the effects of PU.1 and Ets-a were multiplicative, whereas overexpression of PU.1 in RAW264 cells reduced activation of c-fms or model promoters by the other Ets factors, The PU.1 and Ets-a binding sites of the mouse c-fms promoter have been located by DNase footprinting. A conserved Ets-like motif at the transcription site, CAG-GAAC, that bound only weakly to PU.1, was identified as an additional critical basal c-fms promoter element, Comparison of studies on the model promoter, c-fms and other myeloid promoters provides evidence for a conserved mechanism that involves three separate and functionally distinct Ets-like motifs.	Univ Queensland, Dept Microbiol, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University of Queensland; University of Queensland; University of Queensland; University System of Ohio; Ohio State University	Hume, DA (corresponding author), Univ Queensland, Dept Microbiol, Brisbane, Qld 4072, Australia.	D.Hume@cmcb.uq.edu.au	Ross, Ian/A-8622-2011; Hume, David A/C-7695-2013; Ostrowski, Michael/H-3108-2011	Ross, Ian/0000-0002-2389-4292; Hume, David/0000-0002-2615-1478; Ostrowski, Michael/0000-0003-2948-6297				Aperlo C, 1996, MOL CELL BIOL, V16, P6851; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHEN HM, 1995, ONCOGENE, V11, P1549; Davis JN, 1996, GENE, V171, P265, DOI 10.1016/0378-1119(96)00013-3; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; FAVOT P, 1995, ONCOGENE, V11, P1371; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Helftenbein G, 1996, ONCOGENE, V12, P931; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HUME DA, 1995, BRIT J HAEMATOL, V90, P939, DOI 10.1111/j.1365-2141.1995.tb05220.x; JIN DI, 1995, MOL CELL BIOL, V15, P693; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; KISTLER B, 1995, ONCOGENE, V11, P1095; KLEMSZ M, 1990, CELL, V61, P1165; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; KONDANPANI Y, 1996, NATURE, V380, P456; Lodie TA, 1997, J IMMUNOL, V158, P1848; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Miyazaki Y, 1996, ONCOGENE, V13, P1721; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; ROSS IL, 1994, ONCOGENE, V9, P121; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; SWEET MJ, 1997, IN PRESS J INFLAMMAT; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yang BS, 1996, MOL CELL BIOL, V16, P538; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	47	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6662	6669		10.1074/jbc.273.12.6662	http://dx.doi.org/10.1074/jbc.273.12.6662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506963	hybrid			2022-12-27	WOS:000072775900013
J	Xiao, GS; Chen, W; Kulmacz, RJ				Xiao, GS; Chen, W; Kulmacz, RJ			Comparison of structural stabilities of prostaglandin H synthase-1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHEEP VESICULAR GLAND; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TIME-DEPENDENT INHIBITION; ENDOPEROXIDE SYNTHETASE; HUMAN CYCLOOXYGENASE-2; GLUTATHIONE TRANSFERASE; SELECTIVE-INHIBITION; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; G/H SYNTHASE-1	There are two known isoforms of prostaglandin H synthase (PGHS), a key enzyme in the conversion of arachidonic acid to bioactive prostanoids, The "constitutive" isoform, PGHS-1, is thought to have housekeeping functions, and the "inducible" isoform, PGHS-2, has been implicated in cellular responses to cytokines. The two isoforms have high sequence conservation in the cyclooxygenase active site and quite similar crystallographic structures, but differ markedly in their interactions with many cyclooxygenase substrates and inhibitors. We have evaluated the stability of the overall folding, and of the active sites of ovine PGHS-1 and human PGHS-2 using denaturation with guanidinium hydrochloride (GdmHCl), Changes in hydrodynamic and cross-linking properties indicated a dimer --> monomer transition for both isoforms between 0.5 and 2 M GdmHCl; the monomers unfolded at higher GdmHCl levels. Changes in overall secondary and tertiary structure, measured by tryptophan fluorescence and circular dichroism, occurred in two phases for each isoform, with the transition between the phases at 0.2-0.5 M GdmHCl. Disruption of active site functions (cyclooxygenase, peroxidase, and cyclooxygenase inhibitor binding activities) began at GdmHCl levels below 0.2 M, The structural and functional changes were completely reversible up to about 2 M GdmHCl, they were more pronounced at lower protein levels, and they required lower GdmHCl levels for PGHS-2 than for PGHS-1, The results are consistent with a four-state denaturation process for both isoforms: native dimers --> inactive dimers --> compact monomers --> unfolded monomers, The first two steps are reversible for both isoforms; PGHS-2 undergoes the first and last steps more readily than PGHS-1. Thus, the structural stability of PGHS-2, both in the active site regions and in the subunits overall, is distinctly less than that of PGHS-1, These differences in structural stability may contribute to the isoforms' active site ligand selectivity.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.				NIGMS NIH HHS [GM 52170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Callan OH, 1996, J BIOL CHEM, V271, P3548; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; CHENG XD, 1993, BIOCHEMISTRY-US, V32, P8130, DOI 10.1021/bi00083a011; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Guo QP, 1997, ARCH BIOCHEM BIOPHYS, V344, P150, DOI 10.1006/abbi.1997.0192; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERSKOVITS TT, 1968, BIOCHEMISTRY-US, V7, P2523, DOI 10.1021/bi00847a012; Herskovits TT, 1967, METHOD ENZYMOL, V11, P748; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LACKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P347; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai ZH, 1997, BIOCHEMISTRY-US, V36, P10230, DOI 10.1021/bi963195p; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Nozaki Y, 1972, Methods Enzymol, V26, P43; OHKI S, 1979, J BIOL CHEM, V254, P829; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; Pace C N, 1986, Methods Enzymol, V131, P266; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P11; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1981, J BIOL CHEM, V256, P18; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; SACCHETTA P, 1993, EUR J BIOCHEM, V215, P741, DOI 10.1111/j.1432-1033.1993.tb18087.x; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; TSOU CL, 1993, SCIENCE, V262, P380, DOI 10.1126/science.8211158; UENO R, 1982, J BIOL CHEM, V257, P5584; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8; WHITE MF, 1993, BIOCHEM J, V291, P479, DOI 10.1042/bj2910479; Wong E, 1997, J BIOL CHEM, V272, P9280; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	54	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6801	6811		10.1074/jbc.273.12.6801	http://dx.doi.org/10.1074/jbc.273.12.6801			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506982	hybrid			2022-12-27	WOS:000072775900032
J	Hamada, K; Takuwa, N; Yokoyama, K; Takuwa, Y				Hamada, K; Takuwa, N; Yokoyama, K; Takuwa, Y			Stretch activates jun N-terminal kinase/stress-activated protein kinase in vascular smooth muscle cells through mechanisms involving autocrine ATP stimulation of purinoceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; C-JUN; ION CHANNELS; CARDIAC MYOCYTES; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; ANGIOTENSIN-II; STRESS; RECEPTOR; RELEASE	Mechanical strain has been implicated in phenotypic changes, including alteration of gene expression in vascular smooth muscle cells; however, the molecular basis for mechanotransduction leading to nuclear gene expression is largely unknown. We demonstrate in the present study that cyclic stretching of vascular smooth muscle cells dramatically activates Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) through an autocrine mechanism. Stretch causes time- and strength-dependent rise of the ATP concentration in media. The stretch-induced activation JNK/SAPK is attenuated by the addition of hexokinase or apyrase that scavenge ATP in media. Both the P-2 receptor antagonist and the A(1) subtype selective P-1 receptor antagonist partially inhibit stretch-induced activation of JNK/SAPK, The conditioned medium from stretched cells contains an activity to stimulate JNK/SAPK. The JNK-stimulating activity in the conditioned medium from stretched cells is attenuated by the addition of apyrase or P-1 and P-2 receptor antagonists. The addition of exog enous ATP or adenosine induces dose-dependent activation of JNK/SAPK. These results indicate that stretch activates JNK/SAPK in vascular smooth muscle cells through mechanisms involving autocrine stimulation of purinoceptors by ATP and its hydrolyzed product adenosine.	Univ Tokyo, Fac Med, Dept Physiol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Cardiovasc Biol, Bunkyo Ku, Tokyo 113, Japan; RIKEN Tsukuba Life Sci Ctr, Ibaraki, Osaka 305, Japan	University of Tokyo; University of Tokyo; RIKEN	Takuwa, Y (corresponding author), Univ Tokyo, Fac Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.			TAKUWA, Noriko/0000-0002-4278-2704				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; BRUNS RF, 1987, N-S ARCH PHARMACOL, V335, P59, DOI 10.1007/BF00165037; BURNSTOCK G, 1987, BRIT J PHARMACOL, V90, P383, DOI 10.1111/j.1476-5381.1987.tb08968.x; BURNSTOCK G, 1986, CIRC RES, V58, P319, DOI 10.1161/01.RES.58.3.319; BURNSTOCK G, 1985, METHOD PHARMACOL, V6, P193; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Charlton SJ, 1996, BRIT J PHARMACOL, V118, P704, DOI 10.1111/j.1476-5381.1996.tb15457.x; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ENOMOTO K, 1994, PFLUG ARCH EUR J PHY, V427, P533, DOI 10.1007/BF00374271; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NODA M, 1994, J BIOL CHEM, V269, P17911; Noda M, 1995, Curr Opin Nephrol Hypertens, V4, P383, DOI 10.1097/00041552-199509000-00001; Noda M, 1997, HYPERTENSION, V30, P1284, DOI 10.1161/01.HYP.30.5.1284; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SIGURDSON W, 1992, AM J PHYSIOL, V262, pH1110, DOI 10.1152/ajpheart.1992.262.4.H1110; UBL J, 1988, J MEMBRANE BIOL, V104, P223, DOI 10.1007/BF01872324; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAN MH, 1994, NATURE, V372, P798; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	54	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6334	6340		10.1074/jbc.273.11.6334	http://dx.doi.org/10.1074/jbc.273.11.6334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497362	hybrid			2022-12-27	WOS:000072488500054
J	Nikoshkov, A; Lajic, S; Vlamis-Gardikas, A; Tranebjaerg, L; Holst, M; Wedell, A; Luthman, H				Nikoshkov, A; Lajic, S; Vlamis-Gardikas, A; Tranebjaerg, L; Holst, M; Wedell, A; Luthman, H			Naturally occurring mutants of human steroid 21-hydroxylase (P450c21) pinpoint residues important for enzyme activity and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL ADRENAL-HYPERPLASIA; CRYSTAL-STRUCTURE; DEFICIENCY; GENE; MUTATIONS; GENOTYPE; DISEASE; PSEUDOGENE; COMPLEMENT; RESOLUTION	Three mutants (deletion of E196, G291S, and R483P) of steroid 21-hydroxylase (P450c21) from patients with inherited congenital adrenal hyperplasia had reduced activity toward progesterone and 17-hydroxyprogesterone after transient expression in cultured mammalian cells. In addition, both the E196 deletion and the R483P mutant had shorter half-lives than the wild-type enzyme, whereas the half-life of the G291S mutant was comparable with that of the normal protein. These results directly link the clinical situation with the three mutations and suggest that G291 is important for the catalytic activity of P450c21.	Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Woman & Child Hlth, S-17176 Stockholm, Sweden; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Tromso Hosp, Dept Med Genet, N-9038 Tromso, Norway	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; UiT The Arctic University of Tromso; University Hospital of North Norway	Wedell, A (corresponding author), Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden.		Vlamis, Alexios/AAF-5152-2020; Lajic, Svetlana/GYU-0526-2022	Vlamis, Alexios/0000-0001-5068-6459; Lajic, Svetlana/0000-0002-4398-0948				AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL MC, 1985, P NATL ACAD SCI USA, V82, P521, DOI 10.1073/pnas.82.2.521; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; IIDA T, 1994, HUM MOL GENET, V3, P1437; MILLER WL, 1987, J PEDIATR-US, V111, P1, DOI 10.1016/S0022-3476(87)80334-7; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; Nikoshkov A, 1997, J CLIN ENDOCR METAB, V82, P194, DOI 10.1210/jc.82.1.194; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; WEDELL A, 1994, J CLIN ENDOCR METAB, V78, P1145, DOI 10.1210/jc.78.5.1145; WEDELL A, 1993, HUM MOL GENET, V2, P499, DOI 10.1093/hmg/2.5.499; WEDELL A, 1992, P NATL ACAD SCI USA, V89, P7232, DOI 10.1073/pnas.89.15.7232; WEDELL A, 1993, HUM GENET, V91, P236; WHITE PC, 1985, P NATL ACAD SCI USA, V82, P1089, DOI 10.1073/pnas.82.4.1089; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2322, DOI 10.1210/jc.80.8.2322	24	42	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6163	6165		10.1074/jbc.273.11.6163	http://dx.doi.org/10.1074/jbc.273.11.6163			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497336	hybrid			2022-12-27	WOS:000072488500028
J	Schaertl, S; Konrad, M; Geeves, MA				Schaertl, S; Konrad, M; Geeves, MA			Substrate specificity of human nucleoside-diphosphate kinase revealed by transient kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; NM23 GENE; 2-ANGSTROM RESOLUTION; TUMOR-METASTASIS; ESCHERICHIA-COLI; PHOSPHORYLATION; PROTEINS; DICTYOSTELIUM; DROSOPHILA; EXPRESSION	Nucleoside diphosphate kinases (NDKs) catalyze the transfer of gamma-phosphoryl groups from NTPs via an active site histidine to NDPs using a ping-pong mechanism, We have used the change of intrinsic tryptophan fluorescence that occurs upon phosphorylation of NDK to measure the rates of phosphorylation and dephosphorylation with a range of nucleotides and nucleotide analogues, For natural nucleotides, the rates of phosphorylation and dephosphorylation were linearly dependent upon nucleotide concentration until they became tao fast to measure. The second order rate constants fori phosphorylation by natural NTPs varied between 0.7 and 13 x 10(6) M-1 s(-1). Dephosphorylation by NDPs was 2-3-fold faster than the corresponding phosphorylation reaction, and dephosphorylation by dNDPs was 3-4-fold slower than the equivalent NDPs. In all cases, second order rate constants were highest for guanine followed by adenine and lowest for cytosine nucleotides. NDK also catalyzes the transfer of thiophosphate from adenosine 5'-O-(thiotriphosphate) (ATP gamma S) and guanosine 5'O-(thiotriphosphate) (GTP gamma S) to NDP, but at 1/1000 of the equivalent phosphoryl transfer rates, hn this ease, the observed rate constants of phosphorylation and dephosphorylation were hyperbolically dependent on nucleotide concentration, Thiophosphorylation ATP gamma S and GTP gamma S occurred with k(max) of 2.8 and 1.35 s(-1) and K-d of 145 and 36 mu M respectively, For dethiophosphorylation by a range of NDPs, k(max) was in the range of 5-30 s(-1), whereas K-d varied between 0.16 and 3.3 mM. Guanine had the lowest K-d values, and cytosine had the highest. The data are consistent with fast reversible binding of the nucleotide followed by the rate-limiting phosphoryl transfer, Thiophosphates change only the rate of the phosphoryl transfer step, whereas both events are influenced by the base, Modification at the 2'-hydroxyl of ribose has only a small effect, while the overall rate of phosphoryl transfer is reduced 1000-fold by modification at the 3'-ribose.	Max Planck Inst Biophys Chem, Abt Mol Genet, D-37070 Gottingen, Germany; Max Planck Inst Mol Physiol, D-44026 Dortmund, Germany	Max Planck Society; Max Planck Society	Konrad, M (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Genet, D-37070 Gottingen, Germany.	mkonrad@gwdg.de	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898				BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHENG YC, 1971, BIOCHEMISTRY-US, V10, P2139; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; FREY PA, 1989, ADV ENZYMOL RAMB, V62, P119; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GUTFREUND H, 1995, KINETICS LIFE SCI, P261; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HAMBY CV, 1995, BIOCHEM BIOPH RES CO, V211, P578, DOI 10.1006/bbrc.1995.1852; KOWLURU A, 1994, BIOCHEMISTRY-US, V33, P12495, DOI 10.1021/bi00207a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCU I, 1983, EUR J BIOCHEM, V135, P497, DOI 10.1111/j.1432-1033.1983.tb07679.x; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; Lavie A, 1997, NAT MED, V3, P922, DOI 10.1038/nm0897-922; LECROISEY A, 1995, BIOCHEMISTRY-US, V34, P12445, DOI 10.1021/bi00038a043; LEONE A, 1993, ONCOGENE, V8, P855; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MOURAD N, 1966, J BIOL CHEM, V241, P271; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Schaertl S, 1996, FEBS LETT, V394, P316, DOI 10.1016/0014-5793(96)00978-7; STAHL JA, 1991, CANCER RES, V51, P445; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WALINDER O, 1969, J BIOL CHEM, V244, P1060; WEAVER RH, 1962, ENZYMES, V6, P151; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; WU YW, 1997, P NATL ACAD SCI USA, V94, P7162	42	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5662	5669		10.1074/jbc.273.10.5662	http://dx.doi.org/10.1074/jbc.273.10.5662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488696	hybrid			2022-12-27	WOS:000072345000039
J	Kleerekoper, Q; Liu, W; Choi, D; Putkey, JA				Kleerekoper, Q; Liu, W; Choi, D; Putkey, JA			Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SKELETAL-MUSCLE; CONFORMATIONAL-CHANGES; CALCIUM-BINDING; CA2+ AFFINITY; CALMODULIN; NMR; DOMAIN; SPIN; PHOSPHORYLATION	The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol. Chem. 272, 18216-18221) challenges existing structure/function models for this critical regulatory protein. For example, it is clear that the closed conformation of the regulatory N-terminal domain in Ca2+-bound cardiac troponin C (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought, We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-C-13]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+. There are 3-4 drug binding sites in the N- and C-terminal domains of intact cTnC that exhibit fast exchange on the NMR time scale, Use of a novel spin-labeled phenothiazine and detection of isotope-filtered nuclear Overhauser effects allowed identification of drug binding sites in the shallow hydrophobic cup in the C-terminal domain and on two hydrophobic surfaces on the N-terminal regulatory domain, The data presented here, coupled with our previous study using covalent blocking groups, support a model in which the Ca2+-sensitizing binding site includes Met-45 in helix B of site I, and Met-60 and -80 in helices B and C of the regulatory site II, This subregion in cTnC makes a likely target against which to design new and selective Ca2+-sensitizing compounds.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System	Putkey, JA (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	jputkey@utbmb.med.uth.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL45724] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; DALGARNO DC, 1984, BIOCHIM BIOPHYS ACTA, V791, P164, DOI 10.1016/0167-4838(84)90006-2; DOTSON DG, 1993, J BIOL CHEM, V268, P24067; DRABIKOWSKI W, 1985, EUR J BIOCHEM, V151, P17, DOI 10.1111/j.1432-1033.1985.tb09063.x; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GARIEPY J, 1983, BIOCHEMISTRY-US, V22, P1586, DOI 10.1021/bi00276a010; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HOWARTH JW, 1995, PROTEIN SCI, V4, P671; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; KOSEN PA, 1989, METHOD ENZYMOL, V177, P86; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; KUREBAYASHI N, 1988, J PHYSIOL-LONDON, V403, P407, DOI 10.1113/jphysiol.1988.sp017256; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LIN X, 1994, BIOCHEMISTRY-US, V33, P14434, DOI 10.1021/bi00252a009; Lin X, 1996, J BIOL CHEM, V271, P244, DOI 10.1074/jbc.271.1.244; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; MURPHY AM, 1996, PEDIATR RES, V28, P46; Ogawa Y, 1989, Prog Clin Biol Res, V315, P75; OTTING G, 1989, J MAGN RESON, V85, P586, DOI 10.1016/0022-2364(89)90249-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OVASKA M, 1991, PROTEINS, V11, P79, DOI 10.1002/prot.340110202; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SILVER PJ, 1986, BIOCHEM PHARMACOL, V35, P2545, DOI 10.1016/0006-2952(86)90052-3; SOLARO RJ, 1986, J PHARMACOL EXP THER, V238, P502; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	36	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8153	8160		10.1074/jbc.273.14.8153	http://dx.doi.org/10.1074/jbc.273.14.8153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525919	hybrid			2022-12-27	WOS:000072876300053
J	Balboa, MA; Balsinde, J; Dennis, EA				Balboa, MA; Balsinde, J; Dennis, EA			Involvement of phosphatidate phosphohydrolase in arachidonic acid mobilization in human amnionic WISH cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOSOLIC PHOSPHOLIPASE A(2); PROSTAGLANDIN H SYNTHASE-2; EPIDERMAL-GROWTH-FACTOR; SIGNAL-TRANSDUCTION; ANTISENSE INHIBITION; INDUCTION; INTERLEUKIN-1-BETA; DIACYLGLYCEROL; EXPRESSION	Prostaglandins are known to play a central role in the initiation of labor in humans, and amnionic cells constitute a major source of these compounds. Prostaglandin synthesis and release by amnion cells in response to hormones and ligands takes place after a characteristic 4-5 h lag. However, we report herein that free arachidonic acid (AA), the metabolic precursor of prostaglandins, can be induced at much shorter times (1 h) in human amnionic WISH cells by phorbol 12-myristate 13-acetate (PMA) through activation of protein kinase C alpha (PKC alpha). WISH cells were found to possess both cytosolic group IV phospholipase A(2) (cPLA(2)) and Group VI Ca2+-independent phospholipase A(2) (iPLA(2)). Of these, the cPLA, was found to be the likely mediator of AA mobilization in PMA-activated WISH cells. PMA also activates phospholipase D (PLD) in these cells and ethanol, a compound that inhibits PLD-mediated phosphatidic acid (PA) formation, blocked AA release. Moreover, prevention of PA dephosphorylation by the PA phosphohydrolase inhibitors propranolol and bromoenol lactone, resulted in inhibition of AA release by PMA-treated WISH cells. Collectively, these data suggest that activation of cPLA(2) and attendant AA release by phorbol esters in WISH cells requires prior generation of DAG by phosphatidate phosphohydrolase.	Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Revelle Coll, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Balboa, María A./V-9493-2018; Dennis, Edward A./M-5554-2019; Balsinde, Jesús/C-7833-2018	Balboa, María A./0000-0002-2130-5298; Dennis, Edward A./0000-0003-3738-3140; Balsinde, Jesús/0000-0002-4157-6714	NICHD NIH HHS [HD26171] Funding Source: Medline; NIGMS NIH HHS [GM20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERT TJ, 1994, PROSTAGLANDINS, V48, P401, DOI 10.1016/0090-6980(94)90006-X; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CALDER AA, 1979, PRACTICAL APPLICATIO, P301; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DAWSON RMC, 1984, BIOCHEM BIOPH RES CO, V125, P836, DOI 10.1016/0006-291X(84)90615-6; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dillon DA, 1997, J BIOL CHEM, V272, P10361; EMBREY M, 1971, ANN NY ACAD SCI, V180, P518, DOI 10.1111/j.1749-6632.1971.tb53219.x; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; FRENKEL RA, 1992, J BIOL CHEM, V267, P19186; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; HARRIS AN, 1988, AM J OBSTET GYNECOL, V159, P1385, DOI 10.1016/0002-9378(88)90561-3; HAYFLICK L, 1961, EXP CELL RES, V23, P14, DOI 10.1016/0014-4827(61)90059-3; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hulkower KI, 1997, J PHARMACOL EXP THER, V280, P1065; KNISS DA, 1990, AM J OBSTET GYNECOL, V163, P1883, DOI 10.1016/0002-9378(90)90768-3; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OKAZAKI T, 1981, AM J OBSTET GYNECOL, V139, P373, DOI 10.1016/0002-9378(81)90312-4; Perkins DJ, 1997, BIOCHEM J, V321, P677, DOI 10.1042/bj3210677; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PrigentTessier A, 1996, EUR J BIOCHEM, V241, P872, DOI 10.1111/j.1432-1033.1996.00872.x; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; XUE S, 1995, PROSTAG OTH LIPID M, V49, P351, DOI 10.1016/0090-6980(95)00069-M; Xue S, 1996, PROSTAGLANDINS, V51, P107, DOI 10.1016/0090-6980(95)00182-4	39	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7684	7690		10.1074/jbc.273.13.7684	http://dx.doi.org/10.1074/jbc.273.13.7684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516474	Green Published, hybrid			2022-12-27	WOS:000072738500070
J	Beckman, MTL; Kirkegaard, K				Beckman, MTL; Kirkegaard, K			Site size of cooperative single-stranded RNA binding by poliovirus RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE T4-GENE 32-PROTEIN; HIV-1 REVERSE-TRANSCRIPTASE; DNA MELTING PROTEINS; GENE 32 PROTEIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; ANGSTROM RESOLUTION; RECA PROTEIN; VIRAL CDNA	The poliovirus RNA-dependent RNA polymerase binds cooperatively to single stranded RNA. We have determined the minimal RNA-binding site size of the poliovirus polymerase using binding titration with oligonucleotides of increasing length. A dramatic increase in affinity was observed when the length of the oligo(U) increased from 8 to 10 nucleotides (nt), arguing that the minimal size of RNA for polymerase binding is 10 nt. Another increase in affinity seen as the oligo(U) reached 24 nt suggests that a 24-nucleotide RNA can be occupied by two polymerase molecules. Direct binding of wildtype polymerase to oligo(U)(12) and oligo(U)(24) RNAs showed differences in affinity and cooperativity consistent with this model. The increase in binding affinity seen for oligo(U)(10) suggests either that the RNA-binding determinants are widely spaced on the polymerase structure or that a substantial conformational change in the polymerase occurs upon the filling of its RNA binding site.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of Colorado System; University of Colorado Boulder; Stanford University	Kirkegaard, K (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.				NIAID NIH HHS [AI-25166] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025166, R29AI025166] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOTT S, 1973, J MOL BIOL, V81, P107, DOI 10.1016/0022-2836(73)90183-6; BLYN LB, 1995, J VIROL, V69, P4381, DOI 10.1128/JVI.69.7.4381-4389.1995; CASASFINET JR, 1993, BIOCHEMISTRY-US, V32, P9735, DOI 10.1021/bi00088a028; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; HILL TL, 1957, J POLYM SCI, V23, P549, DOI 10.1002/pol.1957.1202310403; HOPE DA, 1997, STRUCTURE, V71, P9490; ICHO T, 1989, J BIOL CHEM, V264, P6716; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KEYES RS, 1993, BIOPHYS CHEM, V45, P281, DOI 10.1016/0301-4622(93)80009-8; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KUMAR KA, 1993, J BIOL CHEM, V268, P26162; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MORROW CD, 1987, P NATL ACAD SCI USA, V84, P6050, DOI 10.1073/pnas.84.17.6050; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PATA JD, 1995, RNA, V1, P466; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; RICHARDS OC, 1987, VIROLOGY, V161, P348, DOI 10.1016/0042-6822(87)90127-9; Roehl HH, 1997, J VIROL, V71, P578, DOI 10.1128/JVI.71.1.578-585.1997; ROTHSTEIN MA, 1988, VIROLOGY, V164, P301, DOI 10.1016/0042-6822(88)90542-9; SANDHU DK, 1994, GENE, V144, P53, DOI 10.1016/0378-1119(94)90202-X; SARNOW P, 1989, J VIROL, V63, P467, DOI 10.1128/JVI.63.1.467-470.1989; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; STASSEN APM, 1995, MOL BIOL REP, V20, P109, DOI 10.1007/BF00990543; STOLE E, 1995, J BIOL CHEM, V270, P20322, DOI 10.1074/jbc.270.35.20322; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1994, ADV BIOPHYS, V30, P1, DOI 10.1016/0065-227X(94)90009-4; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276	41	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6724	6730		10.1074/jbc.273.12.6724	http://dx.doi.org/10.1074/jbc.273.12.6724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506971	hybrid, Green Submitted			2022-12-27	WOS:000072775900021
J	Gualberto, A; Marquez, G; Carballo, M; Youngblood, GL; Hunt, SW; Baldwin, AS; Sobrino, F				Gualberto, A; Marquez, G; Carballo, M; Youngblood, GL; Hunt, SW; Baldwin, AS; Sobrino, F			p53 transactivation of the HIV-1 long terminal repeat is blocked by PD 144795, a calcineurin-inhibitor with anti-HIV properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; T-CELL ACTIVATION; CYCLOSPORINE-A; INTERLEUKIN-2 PROMOTER; SUPPRESSOR PROTEIN; GENE-EXPRESSION; HTLV-III/LAV; TRANSCRIPTION	Previous reports have indicated that benzothiophenes exhibit broad anti-inflammatory properties and inhibit human immunodeficiency virus-type 1 (HIV-1) replication. We show that the immunosuppressant cyclosporin A (CsA) and benzothiophene-2-carboxamide, 5-methoxy-3-(1-methyl ethoxy)-1-oxide (PD 144795) block the induction of p53 and NF-kappa B binding to the HIV-1 long terminal repeat (LTR) by the T cell receptor activator phytohemagglutinin. CsA and PD 144795 also inhibit the induction by phytohemagglutinin of the transcription mediated by an HIV-1 LTR fragment containing the p53 and NF-kappa B sites. These effects of PD 144795 on HIV-1 transcription correlate with its ability to inhibit the phosphatase activity of calcineurin and are similar to those previously described for CsA. Moreover, a constitutive active form of calcineurin is able to induce expression from the HIV-1 LTR in a p53- and NF-kappa B-dependent manner and PD 144795 is able to block this induction. These results demonstrate that the DNA binding of p53 to the HIV-1 LTR can be modulated by calcineurin and provide a framework to understand the anti-HIV properties of benzothiophene derivatives.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Seville, Sch Med, Dept Biochem, E-41009 Seville, Spain; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Immunopathol, Ann Arbor, MI 48105 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Biol Mol, Ann Arbor, MI 48105 USA	Case Western Reserve University; Case Western Reserve University; University of Sevilla; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Pfizer; Pfizer	Gualberto, A (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	axg29@po.cwru.edu		Gualberto, Antonio/0000-0002-6590-839X; Sobrino, Francisco/0000-0002-4503-5739	NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098, R37AI035098] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778; BOSCHELLI DH, 1995, J MED CHEM, V38, P45597; Brini A T, 1990, Eur Cytokine Netw, V1, P131; BUTERA ST, 1995, MOL MED, V1, P758, DOI 10.1007/BF03401890; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FELDBUSH TL, 1991, J IMMUNOL, V147, P3690; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3689; GARCIA J, 1984, PROG NUCL ACIDS RES, V49, P157; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; HUBBARD MJ, 1989, MOL NEUROBIOL, P135; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, MOL CELL BIOL, V16, P3955; MCCAFFREY PG, 1994, NUCLEIC ACIDS RES, V22, P2134, DOI 10.1093/nar/22.11.2134; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PETERLIN BM, 1987, MOL CELL BIOL, V7, P1967, DOI 10.1128/MCB.7.5.1967; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502; ZHANG W, 1992, ONCOGENE, V7, P1645; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	48	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7088	7093		10.1074/jbc.273.12.7088	http://dx.doi.org/10.1074/jbc.273.12.7088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507019	Green Published, hybrid			2022-12-27	WOS:000072775900069
J	Walowitz, JL; Bradley, ME; Chen, SJ; Lee, TC				Walowitz, JL; Bradley, ME; Chen, SJ; Lee, TC			Proteolytic regulation of the zinc finger transcription factor YY1, a repressor of muscle-restricted gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; M-CALPAIN; IN-VIVO; MYOGENIC DIFFERENTIATION; EMBRYONIC MYOBLASTS; C-FOS; DEGRADATION; INHIBITORS; PROTEIN; FUSION	Regulated proteolysis has been postulated to be critical for proper control of cell functions, Muscle development, in particular, involves a great deal of structural adaptation and remodeling mediated by proteases. The transcription factor YY1 represses muscle-restricted expression of the sarcomeric alpha-actin genes, Consistent with this repressor function of YY1, the nuclear regulator is down-regulated at the protein level during skeletal as well as cardiac muscle cell differentiation. However, the YY1 message remains relatively unaltered throughout the myoblast-myotube transition, implicating a post-translational regulatory mechanism, We show that YY1 can be a substrate for cleavage by the calcium-activated neutral protease calpain II (m-calpain) and the 26 S proteasome. The calcium ionophore A23187 destabilized YY1 in cultured myoblasts, and the decrease in YY1 protein levels could be prevented by calpain inhibitor II and calpeptin. Treatment with the proteasome inhibitors MG132 and lactacystin resulted in the stabilization of YY1 protein, which is consistent with the finding that YY1 is readily polyubiquitinated in reticulocyte lysates. We further show that proteolytic targeting by calpain II and the proteasome involves different structural elements of YY1, This study thus illustrates two proteolytic pathways through which the transcriptional regulator can be differentially targeted under different cell growth conditions.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Lee, TC (corresponding author), SUNY Buffalo, Dept Biochem, 3435 Main St,140 Farber Hall, Buffalo, NY 14214 USA.							BRUSTIS JJ, 1994, EUR J CELL BIOL, V64, P320; BUROKERKILGORE M, 1993, ANAL BIOCHEM, V208, P387, DOI 10.1006/abio.1993.1066; CARILLO S, 1994, ONCOGENE, V9, P1679; CHEN SJ, 1998, IN PRESS MOL CELL BI; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DAVID JD, 1981, DEV BIOL, V82, P297, DOI 10.1016/0012-1606(81)90453-X; DAYTON WR, 1981, BIOCHIM BIOPHYS ACTA, V659, P48, DOI 10.1016/0005-2744(81)90270-9; DESHPANDE RV, 1995, J BIOL CHEM, V270, P2497, DOI 10.1074/jbc.270.6.2497; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GAULBERTO A, 1992, MOL CELL BIOL, V12, P4209; GOLL DE, 1992, BIOCHIMIE, V74, P225, DOI 10.1016/0300-9084(92)90121-T; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HUSTON RB, 1968, BIOCHEMISTRY-US, V7, P2116, DOI 10.1021/bi00846a014; JANE DT, 1994, BIOCHEM CELL BIOL, V72, P267, DOI 10.1139/o94-038; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kumar A, 1992, Cell Mol Biol (Noisy-le-grand), V38, P687; KWAK KB, 1993, FEBS LETT, V323, P151, DOI 10.1016/0014-5793(93)81468-F; KWAK KB, 1993, BIOCHIM BIOPHYS ACTA, V1175, P243, DOI 10.1016/0167-4889(93)90212-8; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE TC, 1994, ONCOGENE, V9, P1047; Maki CG, 1996, CANCER RES, V56, P2649; Mampuru LJ, 1996, EXP CELL RES, V226, P372, DOI 10.1006/excr.1996.0238; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PINSET C, 1991, EMBO J, V10, P2411, DOI 10.1002/j.1460-2075.1991.tb07780.x; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHOLLMEYER JE, 1986, EXP CELL RES, V163, P413, DOI 10.1016/0014-4827(86)90072-8; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHOSHANBARMATZ V, 1994, J MEMBRANE BIOL, V142, P281; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TUDELA J, 1986, INT J BIOCHEM, V18, P285, DOI 10.1016/0020-711X(86)90121-7; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	47	69	75	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6656	6661		10.1074/jbc.273.12.6656	http://dx.doi.org/10.1074/jbc.273.12.6656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506962	hybrid			2022-12-27	WOS:000072775900012
J	Garner, B; Waldeck, AR; Witting, PK; Rye, KA; Stocker, P				Garner, B; Waldeck, AR; Witting, PK; Rye, KA; Stocker, P			Oxidation of high density lipoproteins - II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER HYDROPEROXIDES; SULFOXIDE FORMATION; SELF-INACTIVATION; TRANSFER PROTEIN; SELECTIVE UPTAKE; HUMAN SERUM; PLASMA; CELLS; LECITHIN; EFFLUX	Human high density lipoproteins (HDL) can reduce cholesteryl ester hydroperoxides to the corresponding hydroxides (Sattler W,, Christison J, K,, and Stocker, R. (1995) Free Radical Biol, & Med. 18, 421-429), Here we demonstrate that this reducing activity extended to hydroperoxides of phosphatidylcholine, was similar in HDL2 and HDL3, was independent of arylesterase and lecithin:cholesteryl acyltransferase activity, was unaffected by sulfhydryl reagents, and was expressed by reconstituted particles containing apoAI, or apoAII only, as well as isolated human apoAI, Concomitant with the reduction of lipid hydroperoxides specific oxidized forms of apoAI and apoAII formed in blood-derived and reconstituted HDL, Similarly, specific oxidized forms of apoAI accumulated upon treatment of isolated apoAI with authentic cholesteryl linoleate hydroperoxide, These specific oxidized forms of apoAI and apoAII have been shown previously to contain Met sulfoxide (Met(O)) at Met residues and are also formed when HDL is exposed to Cu2+ Or soybean lipoxygenase, Lipid hydroperoxide reduction and the associated formation of specific oxidized forms of apoAI and apoAII were inhibited by solubilizing HDL with SDS or by pretreatment of HDL with chloramine T, The inhibitory effect of chloramine T was dose-dependent and accompanied by the conversion of specific Met residues of apoAI and apoAII into Met(O), Canine HDL, which contains apoAI as the predominant apolipoprotein and which lacks the oxidation-sensitive Met residues Met(112) and Met(148), showed much weaker lipid hydroperoxide reducing activity and lower extents of formation of oxidized forms of apoAI than human HDL, We conclude that the oxidation of specific Met residues of apoAI and apoAII to Met(O) plays a significant role in the 2-electron reduction of hydroperoxides of cholesteryl esters and phosphatidylcholine associated with human HDL.	Heart Res Inst, Biochem Grp, Sydney, NSW 2050, Australia; Royal Adelaide Hosp, Cardiovasc Invest Unit, Adelaide, SA 5000, Australia	University of Sydney; Heart Research Institute; Royal Adelaide Hospital	Stocker, P (corresponding author), Heart Res Inst, Biochem Grp, 145 Missenden Rd, Sydney, NSW 2050, Australia.	r.stocker@hri.edu.au	Witting, Paul/ABD-2053-2020; Witting, Paul/L-9786-2019	Witting, Paul/0000-0003-2237-7004; 				ALBERS JJ, 1981, J LIPID RES, V22, P1206; ANANTHARAMAIAH GM, 1988, J LIPID RES, V29, P309; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Christison J, 1996, BIOCHEM J, V314, P739, DOI 10.1042/bj3140739; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; CHUNG H, 1982, J BIOL CHEM, V257, P2961; CHUNGLIANG K, 1995, DRUG METAB DISPOS, V23, P935; EDELSTEIN C, 1973, J BIOL CHEM, V248, P7653; FLISS H, 1983, P NATL ACAD SCI-BIOL, V80, P7160, DOI 10.1073/pnas.80.23.7160; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; GAN QF, 1995, BIOCHEMISTRY-US, V34, P7069, DOI 10.1021/bi00021a019; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; GLASER CB, 1987, AM REV RESPIR DIS, V136, P857, DOI 10.1164/ajrccm/136.4.857; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; Keck RG, 1996, ANAL BIOCHEM, V236, P56, DOI 10.1006/abio.1996.0131; LUX SE, 1972, J BIOL CHEM, V247, P7519; MARCH J, 1977, ADV ORG CHEM, P1112; MILLER GJ, 1975, LANCET, V1, P16; MOREL DW, 1994, BIOCHEM BIOPH RES CO, V200, P408, DOI 10.1006/bbrc.1994.1464; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; RAPOPORT S, 1984, EUR J BIOCHEM, V139, P573, DOI 10.1111/j.1432-1033.1984.tb08043.x; RYE KA, 1994, J BIOL CHEM, V269, P10298; SALMON S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P230, DOI 10.1016/0005-2760(92)90050-6; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1995, FREE RADICAL BIO MED, V18, P421, DOI 10.1016/0891-5849(94)00170-O; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SEGREST JP, 1992, J LIPID RES, V33, P141; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; SMITH AB, 1995, P NATL ACAD SCI USA, V92, P10262, DOI 10.1073/pnas.92.22.10262; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; VONECKARDSTEIN A, 1991, J LIPID RES, V32, P1465; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	43	267	284	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6088	6095		10.1074/jbc.273.11.6088	http://dx.doi.org/10.1074/jbc.273.11.6088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497326	hybrid			2022-12-27	WOS:000072488500018
J	Guzder, SN; Sung, P; Prakash, L; Prakash, S				Guzder, SN; Sung, P; Prakash, L; Prakash, S			The DNA-dependent ATPase activity of yeast nucleotide excision repair factor 4 and its role in DNA damage recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; COCKAYNE-SYNDROME; CELL-EXTRACTS; FACTOR TFIIH; B GENE; RECONSTITUTION; HELICASE	Saccharomyces cerevisiae RAD7 and RAD16 genes function together in the nucleotide excision repair of transcriptionally inactive DNA. The RAD7- and RAD16-encoded proteins exist as a tight complex named nucleotide excision repair factor 4 or NEF4. Previously, we showed that NEF4 binds UV-damaged DNA with high specificity and with a dependence upon ATP and that inclusion of NEF4 to the reconstituted nucleotide excision repair system consisting of purified NEF1, NEF2, NEF3, and replication protein A results in marked stimulation of damage-specific DNA incision. Here we show that NEF4 possesses an ATPase activity that is entirely dependent on a DNA cofactor and that double-stranded DNA is twice as effective as single-stranded DNA in activating ATP hydrolysis. Even though DNA binding is promoted by the nonhydrolyzable ATP analogue adenosine 5'-O-(thiotriphosphate) (ATP gamma S), damage binding is more proficient with ATP than with ATP gamma S. Interestingly, UV irradiation of double-stranded DNA results in a pronounced attenuation of the ATPase activity. Taken together, our results suggest a model in which ATP hydrolysis by NEF4 fuels the translocation of NEF4 on DNA in search of UV lesions and damage binding by NEF4 leads to a down-regulation of the ATPase activity. Damage-bound NEF4 could then serve as a nucleation point for the assembly of other repair components.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NCI NIH HHS [CA41261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; Lauder S, 1996, MOL CELL BIOL, V16, P6783; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MUELLER JP, 1995, NUCLEIC ACIDS RES, V23, P3457, DOI 10.1093/nar/23.17.3457; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635	32	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6292	6296		10.1074/jbc.273.11.6292	http://dx.doi.org/10.1074/jbc.273.11.6292			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497356	hybrid			2022-12-27	WOS:000072488500048
J	Ellison, V; Stillman, B				Ellison, V; Stillman, B			Reconstitution of recombinant human replication factor C (RFC) and identification of an RFC subcomplex possessing DNA-dependent ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ONE HOLOENZYME PARTICLE; III ACCESSORY PROTEINS; BASE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; SACCHAROMYCES-CEREVISIAE; LARGE SUBUNIT; POLYMERASE-EPSILON; ESCHERICHIA-COLI; MAMMALIAN-CELLS	Replication factor C (RFC) is a five-subunit protein complex required for coordinate leading and lagging strand DNA synthesis during S phase and DNA repair in eukaryotic cells, It functions to load the proliferating cell nuclear antigen (PCNA), a processivity factor for polymerases delta and epsilon, onto primed DNA templates, This process, which is ATP-dependent, is carried out by 1) recognition of the primer terminus by RFC (2) binding to and disruption of the PCNA trimer, and then 3) topologically linking the PCNA to the DNA. In this report, we describe the purification and properties of recombinant human RFC expressed in Sf9 cells from baculovirus expression vectors, Like native RFC derived from 293 cells, recombinant RFC was found to support SV40 DNA synthesis and polymerase delta DNA synthesis in vitro and to possess an ATPase activity that was highly stimulated by DNA and further augmented by PCNA. Assembly of RFC was observed to involve distinct subunit interactions in which both the 36- and 38-kDa subunits interacted with the 37-kDa subunit, and the 40-kDa subunit interacted with the 36-kDa subunit-37-kDa subunit sub complex, The 140-kDa subunit was found to require interactions primarily with the 38- and 40-kDa subunits for incorporation into the complex, In addition, a stable subcomplex lacking the 140-kDa subunit, although defective for DNA replication, was found to possess DNA-dependent ATPase activity that was not responsive to the addition of PCNA.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAKER TA, 1992, ANNU REV GENET, V26, P447; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DEPAMPHILIS ML, 1996, COLD SPRING HARBOR M, V3, P639; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary SL, 1995, NUCLEIC ACIDS RES, V23, P4986, DOI 10.1093/nar/23.24.4986; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; LEE MYW, 1984, BIOCHEMISTRY-US, V2, P1906; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; McAlear MA, 1996, GENETICS, V142, P65; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Sambrok J., 1989, MOL CLONING LAB MANU; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11773; YODER BL, 1991, J BIOL CHEM, V266, P22689	46	51	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5979	5987		10.1074/jbc.273.10.5979	http://dx.doi.org/10.1074/jbc.273.10.5979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488738	hybrid, Green Accepted			2022-12-27	WOS:000072345000081
J	Terada, T; Saito, H; Inui, K				Terada, T; Saito, H; Inui, K			Interaction of beta-lactam antibiotics with histidine residue of rat H+/peptide cotransporters, PEPT1 and PEPT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; DIPEPTIDE TRANSPORT-SYSTEM; OLIGOPEPTIDE; INTESTINE; KIDNEY; RECOGNITION; VESICLES; AFFINITY; CARRIER; BINDING	Peptide transporters mediate the H+-coupled uphill transport of oligopeptides and peptide-like drugs such as beta-lactam antibiotics in the intestinal and renal brush-border membranes. Two H+/peptide cotransporters, PEPT1 and PEPT2, have been cloned and functionally characterized. In this study, we examined the interaction of the dipeptides and beta-lactam antibiotics with the histidine residue of rat PEPT1 and PEPT2 transfected into the renal epithelial cell line LLC-PK1. Diethylpyrocarbonate (DEPC), which is a histidine residue modifier, abolished the glycylsarcosine uptake by both transfectants. The DEPC-induced inhibition of glycylsarcosine uptake via PEPT1 or PEPT2 was attenuated by an excess of dipeptide or aminocephalosporin. In contrast, anionic cephalosporins without an alpha-amino group and bestatin, which is an antineoplastic drug with a beta-amino group, did not attenuate the DEPC-induced inactivation of PEPT1 and PEPT2. The DEPC inactivation of PEPT1 was almost prevented by various charged dipeptides, which suggests that the inability of the drugs without an alpha-amino group to prevent the DEPC inactivation was not due to their ionic charge. These findings suggest that the alpha-amino group of beta-lactam antibiotics interacts with the histidine residue of PEPT1 and PEPT2 and may he involved in the mechanism of substrate recognition by the peptide transporters.	Kyoto Univ Hosp, Fac Med, Dept Pharm, Sakyo Ku, Kyoto 60601, Japan	Kyoto University	Inui, K (corresponding author), Kyoto Univ Hosp, Fac Med, Dept Pharm, Sakyo Ku, Kyoto 60601, Japan.		Inui, Ken-ichi/AAH-8748-2020					Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DANIEL H, 1993, J CLIN INVEST, V92, P2215, DOI 10.1172/JCI116824; DANIEL H, 1997, AM J PHYSIOL, V273, pFU; Fei YJ, 1997, BIOCHEMISTRY-US, V36, P452, DOI 10.1021/bi962058p; GANAPATHY ME, 1995, J BIOL CHEM, V270, P25672, DOI 10.1074/jbc.270.43.25672; INUI KI, 1992, J PHARMACOL EXP THER, V260, P482; KATO M, 1989, J PHARMACOL EXP THER, V251, P745; Leibach FH, 1996, ANNU REV NUTR, V16, P99, DOI 10.1146/annurev.nu.16.070196.000531; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Miles E W, 1977, Methods Enzymol, V47, P431; MIYAMOTO Y, 1986, J BIOL CHEM, V261, P6133; MURANUSHI N, 1989, PHARMACEUT RES, V6, P308, DOI 10.1023/A:1015946407709; OKANO T, 1986, J BIOL CHEM, V261, P14130; SAITO H, 1993, AM J PHYSIOL, V265, pG289, DOI 10.1152/ajpgi.1993.265.2.G289; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; Steel A, 1997, J PHYSIOL-LONDON, V498, P563, DOI 10.1113/jphysiol.1997.sp021883; SWAAN PW, 1995, BBA-BIOMEMBRANES, V1236, P31, DOI 10.1016/0005-2736(95)00030-7; Terada T, 1996, FEBS LETT, V394, P196, DOI 10.1016/0014-5793(96)00952-0; Terada T, 1997, AM J PHYSIOL-RENAL, V273, pF706, DOI 10.1152/ajprenal.1997.273.5.F706; Terada T, 1997, J PHARMACOL EXP THER, V281, P1415; TSUJI A, 1987, J PHARMACOL EXP THER, V241, P594	23	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5582	5585		10.1074/jbc.273.10.5582	http://dx.doi.org/10.1074/jbc.273.10.5582			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488685	hybrid			2022-12-27	WOS:000072345000028
J	Benen, JAE; Sanchez-Torres, P; Wagemaker, MJM; Fraaije, MW; van Berkel, WJH; Visser, J				Benen, JAE; Sanchez-Torres, P; Wagemaker, MJM; Fraaije, MW; van Berkel, WJH; Visser, J			Molecular cloning, sequencing, and heterologous expression of the vaoA gene from Penicillium simplicissimum CBS 170.90 encoding vanillyl-alcohol oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-CRESOL METHYLHYDROXYLASE; PSEUDOMONAS-PUTIDA; LIPOAMIDE DEHYDROGENASE; ASPERGILLUS-NIDULANS; PROTEIN; FAD; PURIFICATION; CHRYSOGENUM; CYTOCHROME; PROMOTER	The cDNA encoding vanillyl-alcohol oxidase (EC 1.1.3.7) was selected from a cDNA library constructed from mRNA isolated from Penicillium simplicissimum CBS 170.90 grown on veratryl alcohol by immunochemical screening. The vaoA-cDNA nucleotide sequence revealed an open reading frame of 1680 base pairs encoding a 560-amino acid protein with a deduced mass of 62,915 Da excluding the covalently bound FAD. The deduced primary structure shares 31% sequence identity with the 8 alpha-(O-tyrosyl)-FAD containing subunit of the bacterial flavocytochrome p-cresol methyl hydroxylase. The vaoA gene was isolated from a P. simplicissimum genomic library constructed in lambda(EMBL3) using the vaoA-cDNA as a probe. Comparison of the nucleotide sequence of the vaoA gene with the cDNA nucleotide sequence demonstrated that the gene is interrupted by five short introns. Aspergillus niger NW156 prtF pyrA leuA cspA transformed with the pyrA containing plasmid and a plasmid harboring the complete vaoA gene including the promoter and terminator was able to produce vaoA mRNA and active vanillyl-alcohol oxidase when grown on veratryl alcohol and anisyl alcohol. A similar induction of the vaoA gene was found for P. simplicissimum, indicating that similar regulatory systems are involved in the induction of the vaoA gene in these fungi. Introduction of a consensus ribosome binding site, AGAAGGAG, in the vaoA-cDNA resulted in elevated expression levels of active vanillyl-alcohol oxidase from the lac promoter in Escherichia coli TG2. The catalytic and spectral properties of the purified recombinant enzyme were indistinguishable from the native enzyme.	Agr Univ Wageningen, Sect Mol Genet Ind Microorganisms, NL-6703 HA Wageningen, Netherlands; Agr Univ Wageningen, Dept Biochem, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Visser, J (corresponding author), Agr Univ Wageningen, Sect Mol Genet Ind Microorganisms, Dreyenlaan 2, NL-6703 HA Wageningen, Netherlands.	office@algemeen.mgim.wau.nl	Fraaije, Marco/E-8421-2014; Sánchez-Torres, Paloma/T-1306-2019; van Berkel, Willem J.H./O-2431-2014	Sánchez-Torres, Paloma/0000-0002-1691-4777; van Berkel, Willem J.H./0000-0002-6551-2782; Sanchez-Torres, Paloma/0000-0002-6300-9032; Fraaije, Marco/0000-0001-6346-5014				BENEN JAE, 1989, J GEN MICROBIOL, V135, P1787; BENSON TE, 1995, NAT STRUCT BIOL, V2, P644, DOI 10.1038/nsb0895-644; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; DEGRAAFF L, 1988, CURR GENET, V13, P315, DOI 10.1007/BF00424425; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRAAIJE MW, 1995, EUR J BIOCHEM, V234, P271, DOI 10.1111/j.1432-1033.1995.271_c.x; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Fraaije MW, 1996, EUR J BIOCHEM, V235, P192, DOI 10.1111/j.1432-1033.1996.00192.x; Fraaije MW, 1997, J BIOL CHEM, V272, P18111, DOI 10.1074/jbc.272.29.18111; FRAAIJE MW, 1997, FLAVINS FLAVOPROTEIN, V12, P261; GIBSON T, 1984, THESIS U CAMBRIDGE U; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HAAS H, 1995, CURR GENET, V28, P177, DOI 10.1007/BF00315785; HOPPER DJ, 1976, BIOCHEM BIOPH RES CO, V69, P462, DOI 10.1016/0006-291X(76)90544-1; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; KIM JH, 1994, J BACTERIOL, V176, P6349, DOI 10.1128/jb.176.20.6349-6361.1994; MACKENZIE DA, 1993, J GEN MICROBIOL, V139, P2295, DOI 10.1099/00221287-139-10-2295; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; Mernitz G, 1996, CURR GENET, V29, P490; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; MUSHEGIAN AR, 1995, PROTEIN SCI, V4, P1243, DOI 10.1002/pro.5560040623; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; Sambrook J, 1989, MOL CLONING LAB MANU, P1; Schaap PJ, 1996, MOL GEN GENET, V250, P339; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; Suarez T, 1996, MOL MICROBIOL, V20, P529, DOI 10.1046/j.1365-2958.1996.5421065.x; UNKLES SE, 1992, APPL MOL GENETICS FI, P28; VANBERKEL WJH, 1997, Patent No. 0710289; VANBERKEL WJH, 1994, FLAVINS FLAVOPROTEIN, V11, P709; VISHNIAC W, 1957, BACTERIOL REV, V21, P195, DOI 10.1128/MMBR.21.3.195-213.1957; WESTPHAL AH, 1988, EUR J BIOCHEM, V172, P299, DOI 10.1111/j.1432-1033.1988.tb13887.x; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	36	39	43	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7865	7872		10.1074/jbc.273.14.7865	http://dx.doi.org/10.1074/jbc.273.14.7865			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525880	hybrid, Green Published			2022-12-27	WOS:000072876300014
J	Brazill, DT; Lindsey, DF; Bishop, JD; Gomer, RH				Brazill, DT; Lindsey, DF; Bishop, JD; Gomer, RH			Cell density sensing mediated by a G protein-coupled receptor activating phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DICTYOSTELIUM-DISCOIDEUM; GENE-EXPRESSION; INOSITOL 1,4,5-TRISPHOSPHATE; GUANINE-NUCLEOTIDES; SURFACE-RECEPTOR; ADENYLATE-CYCLASE; CAMP RECEPTORS; BETA-GAMMA; CHEMOATTRACTANT	When the unicellular eukaryote Dictyostelium discoideum starves, it senses the local density of other starving cells by simultaneously secreting and sensing a glycoprotein called conditioned medium factor (CMF). When the density of starving cells is high, the corresponding high density of CMF permits signal transduction through cAR1, the chemoattractant cAMP receptor, cAR1 activates a heterotrimeric G protein whose alpha-subunit is G alpha 2, CMF regulates cAMP signal transduction in part by regulating the lifetime of the cAMP-stimulated G alpha 2-GTP configuration. We find here that guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) inhibits the binding of CMF to membranes, suggesting that the putative CMF receptor is coupled to a G protein, Cells lacking G alpha 1 (G alpha 1 null) do not exhibit GTP gamma S inhibition of CMF binding and do not exhibit CMF regulation of cAMP signal transduction, suggesting that the putative CMF receptor interacts with G alpha 1. Work by others has suggested that G alpha 1 inhibits phospholipase C (PLC), yet when cells lacking either G alpha 1 or PLC were starved at high cell densities (and thus in the presence of CMF), they developed normally and had normal cAMP signal transduction. We find that CMF activates PLC. G alpha 1 null cells starved in the absence or presence of CMF behave in a manner similar to control cells starved in the presence of CMF in that they extend pseudopods, have an activated PLC, have a low cAMP-stimulated GTPase, permit cAMP signal transduction, and aggregate, Cells lacking G beta have a low PLC activity that cannot be stimulated by CMF. Cells lacking PLC exhibit IP3 levels and cAMP-stimulated GTP hydrolysis rates intermediate to what is observed in wild-type cells starved in the absence or in the presence of an optimal amount of CMF. We hypothesize that CMF binds to its receptor, releasing G beta gamma from G alpha 1. This activates PLC, which causes the G alpha 2 GTPase to be inhibited, prolonging the lifetime of the cAMP-activated G alpha 2-GTP configuration. This, in turn, allows cAR1-mediated cAMP signal transduction to take place.	Rice Univ, Dept Biochem & Cell Biol, Howard Hughes Med Inst, Houston, TX 77005 USA	Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Dept Biochem & Cell Biol, Howard Hughes Med Inst, MS-140,6100 S Main st, Houston, TX 77005 USA.			Gomer, Richard/0000-0003-2361-4307				BLUSCH J, 1995, DIFFERENTIATION, V58, P253, DOI 10.1046/j.1432-0436.1995.5840253.x; BOMINAAR AA, 1994, BIOCHEM J, V297, P181, DOI 10.1042/bj2970181; BOMINAAR AA, 1994, BIOCHEM J, V297, P189, DOI 10.1042/bj2970189; Brazill DT, 1997, FEBS LETT, V404, P100, DOI 10.1016/S0014-5793(97)00104-X; Clarke M, 1995, EXPERIENTIA, V51, P1124, DOI 10.1007/BF01944730; CUBITT AB, 1993, J BIOL CHEM, V268, P17431; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DHARMAWARDHANE S, 1994, DEVELOPMENT, V120, P3549; DOTTIN RP, 1991, DEV GENET, V12, P2, DOI 10.1002/dvg.1020120103; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; DRAYER AL, 1994, EMBO J, V13, P1601, DOI 10.1002/j.1460-2075.1994.tb06423.x; EUROPEFINNER GN, 1987, J CELL SCI, V87, P221; EUROPEFINNER GN, 1987, J CELL SCI, V87, P513; EUROPEFINNER GN, 1987, J CELL SCI, V87, P518; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; GOMER RH, 1985, COLD SPRING HARB SYM, V50, P801, DOI 10.1101/SQB.1985.050.01.098; GOMER RH, 1994, CURR BIOL, V4, P734, DOI 10.1016/S0960-9822(00)00163-9; GOMER RH, 1991, DEVELOPMENT, V112, P269; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; JAIN R, 1994, J BIOL CHEM, V269, P9128; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOOMIS WF, 1993, CURR TOP DEV BIOL, V28, P1, DOI 10.1016/S0070-2153(08)60208-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; Rietdorf J, 1997, DEV BIOL, V181, P79, DOI 10.1006/dbio.1996.8447; SCHAAP P, 1991, INTERCELLULAR INTERA, P147; SCHNITZLER GR, 1995, CELL, V81, P737, DOI 10.1016/0092-8674(95)90535-9; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VanDijken P, 1997, EUR J BIOCHEM, V244, P113; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; VANHAASTERT PJM, 1989, ANAL BIOCHEM, V177, P115, DOI 10.1016/0003-2697(89)90024-9; VANHAASTERT PJM, 1984, J GEN MICROBIOL, V130, P2559; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VanHaastert PJM, 1996, J CELL BIOL, V134, P1543, DOI 10.1083/jcb.134.6.1543; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU L, 1995, DEV BIOL, V167, P1, DOI 10.1006/dbio.1995.1001; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251; YUEN IS, 1994, J THEOR BIOL, V167, P273, DOI 10.1006/jtbi.1994.1069; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8161	8168		10.1074/jbc.273.14.8161	http://dx.doi.org/10.1074/jbc.273.14.8161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525920	hybrid			2022-12-27	WOS:000072876300054
J	Falk, MM; Gilula, NB				Falk, MM; Gilula, NB			Connexin membrane protein biosynthesis is influenced by polypeptide positioning within the translocon and signal peptidase access	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GAP-JUNCTIONS; ACETYLCHOLINE-RECEPTOR; INTRACELLULAR-TRANSPORT; MICROSOMAL-MEMBRANES; TOPOLOGICAL ANALYSIS; INTERNAL SIGNAL; IN-VITRO; TRANSMEMBRANE; EXPRESSION; SEQUENCES	We reported previously (Falk, M.M., Kumar, N.M., and Gilula, N.B. (1994) J. Cell Biol. 127, 343-355) that the membrane integration of polytopic connexin polypeptides can be accompanied by an inappropriate cleavage that generates amino-terminal truncated connexins. While this cleavage was not detected in vivo, translation in standard cell-free translation/translocation systems resulted in the complete cleavage of all newly integrated connexins. Partial cleavage occurred in heterologous expression systems that correlated with the expression level. Here we report that the transmembrane topology of connexins generated in microsomal membranes was identical to the topology of functional connexins in plasma membranes. characterization of the cleavage site and reaction showed that the connexins were processed by signal peptidase immediately downstream of their first transmembrane domain in a reaction similar to the removal of signal peptides from pre-proteins. Increasing the length and hydrophobic character of the signal anchor sequence of connexins completely prevented the aberrant cleavage. This result indicates that their signal anchor sequence was falsely recognized and positioned as a cleavable signal peptide within the endoplasmic reticulum translocon, and that this mispositioning enabled signal peptidase to access the cleavage sites. The results provide direct evidence for the involvement of unknown cellular factors in the membrane integration process of connexins.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Falk, MM (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,MB6, La Jolla, CA 92037 USA.	MFalk@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037904, R01GM037904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; Bai LQ, 1996, J BIOL CHEM, V271, P5171; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Bruzzone R, 1996, BIOESSAYS, V18, P709, DOI 10.1002/bies.950180906; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; COWAN D, 1990, BRAIN RES, V509, P1, DOI 10.1016/0006-8993(90)90301-Q; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DERMIETZEL R, 1984, EMBO J, V3, P2261, DOI 10.1002/j.1460-2075.1984.tb02124.x; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; FALK MM, 1992, J VIROL, V66, P2251, DOI 10.1128/JVI.66.4.2251-2260.1992; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HART GW, 1979, J BIOL CHEM, V254, P9747; HEGNER M, 1992, J BIOL CHEM, V267, P16928; HERTZBERG EL, 1984, CELL, V39, P61, DOI 10.1016/0092-8674(84)90191-0; High S, 1997, TRENDS CELL BIOL, V7, P206; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LAIRD DW, 1995, J CELL BIOL, V131, P1198; LEUBE RE, 1995, J CELL SCI, V108, P883; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIVELY MO, 1983, J BIOL CHEM, V258, P9488; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NILSSON IM, 1991, J BIOL CHEM, V266, P3408; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; ROY P, 1993, J BIOL CHEM, V268, P2699; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SHEN NV, 1993, NEURON, V11, P67; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WALTER P, 1983, METHOD ENZYMOL, V96, P84; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	49	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7856	7864		10.1074/jbc.273.14.7856	http://dx.doi.org/10.1074/jbc.273.14.7856			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525879	hybrid			2022-12-27	WOS:000072876300013
J	Rothery, RA; Magalon, A; Giordano, G; Guigliarelli, B; Blasco, F; Weiner, JH				Rothery, RA; Magalon, A; Giordano, G; Guigliarelli, B; Blasco, F; Weiner, JH			The molybdenum cofactor of Escherichia coli nitrate reductase a (NarGHI) - Effect of a MobAB mutation and interactions with [Fe-S] clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; IRON-SULFUR CLUSTER; MOLYBDOPTERIN GUANINE DINUCLEOTIDE; SITE-DIRECTED MUTAGENESIS; BETA-SUBUNIT; EPR CHARACTERIZATION; DIMETHYLSULFOXIDE REDUCTASE; THIOSPHAERA-PANTOTROPHA; NUCLEOTIDE-SEQUENCE; ELECTRON-TRANSFER	We have studied the effect of a mobAB mutation and tungstate on molybdo-molybdopterin-guanine dinucleotide (Mo-MGD) insertion into Escherichia coli nitrate reductase (NarGHI). Preparation of fluorescent oxidized derivatives of MGD (Form A and Form B) indicates that in a mobAB mutant there is essentially no detectable cofactor present in either the membrane-bound (NarGHI) or purified soluble (NarGH) forms of the enzyme. Electron paramagnetic resonance characterization of membrane-bound cofactor-deficient NarGHI suggests that it has altered electrochemistry with respect to the dithionite reducibility of the [Fe-S] clusters of NarH. Potentiometric titrations of membrane-bound NarGHI indicate that the NarH [Fe-S] clusters have midpoint potentials at pH 8.0 (E-m,E- 8.0, values) of +180 mV ([3Fe-4S] cluster), +130, -55, and -420 mV ([4Fe-4S] clusters) in a wild-type background and +180, +80, -35, and -420 mV in a mobAB mutant background. These data support the following conclusions: (i) a model for Mo-MGD biosynthesis and assembly into NarGHI in which both metal chelation and nucleotide addition to molybdopterin precede cofactor insertion; and (ii) the absence of Mo-MGD significantly affects E-m,E- 8.0, of the highest potential [4Fe4S]cluster.	Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; CNRS, Chim Bacterienne Lab, F-13402 Marseille 9, France; CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille 9, France	University of Alberta; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, 474 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.			Magalon, Axel/0000-0002-3375-738X; Rothery, Richard/0000-0003-3265-1783				AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; AUGIER V, 1993, BIOCHEMISTRY-US, V32, P2013, DOI 10.1021/bi00059a018; AUGIER V, 1993, BIOCHEMISTRY-US, V32, P5099, DOI 10.1021/bi00070a018; BERG BL, 1991, J BIOL CHEM, V266, P22380; BERKS BC, 1995, BIOCHEM J, V309, P983, DOI 10.1042/bj3090983; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BLASCO F, 1992, MOL MICROBIOL, V6, P209, DOI 10.1111/j.1365-2958.1992.tb02002.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1992, MOL MICROBIOL, V6, P221, DOI 10.1111/j.1365-2958.1992.tb02003.x; BLASCO F, 1998, IN PRESS MOL MICROBI; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; BRETON J, 1994, FEBS LETT, V345, P76, DOI 10.1016/0014-5793(94)00445-5; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; GUIGLIARELLI B, 1992, EUR J BIOCHEM, V207, P61, DOI 10.1111/j.1432-1033.1992.tb17020.x; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; HINTON SM, 1990, CRIT REV MICROBIOL, V17, P169, DOI 10.3109/10408419009105724; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON MK, 1985, J BIOL CHEM, V260, P5456; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; KRAFFT T, 1992, EUR J BIOCHEM, V206, P5456; Liu XL, 1997, J BIOL CHEM, V272, P24266, DOI 10.1074/jbc.272.39.24266; Magalon A, 1997, J BIOL CHEM, V272, P25652, DOI 10.1074/jbc.272.41.25652; Magalon A, 1997, J BACTERIOL, V179, P5037, DOI 10.1128/jb.179.16.5037-5045.1997; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PASCAL MC, 1982, MOL GEN GENET, V188, P103, DOI 10.1007/BF00333001; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; RECH S, 1995, J BACTERIOL, V177, P1023, DOI 10.1128/jb.177.4.1023-1029.1995; Rech S, 1996, J BIOL CHEM, V271, P2557, DOI 10.1074/jbc.271.5.2557; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTINI CL, 1992, J BACTERIOL, V174, P7934, DOI 10.1128/JB.174.24.7934-7940.1992; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Trieber CA, 1996, J BIOL CHEM, V271, P4620; VINCENT SP, 1978, BIOCHEM J, V171, P639, DOI 10.1042/bj1710639; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WILLIAMSSMITH DL, 1977, BIOCHEM J, V167, P593, DOI 10.1042/bj1670593	43	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7462	7469		10.1074/jbc.273.13.7462	http://dx.doi.org/10.1074/jbc.273.13.7462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516445	hybrid			2022-12-27	WOS:000072738500041
J	Chan, BS; Satriano, JA; Pucci, M; Schuster, VL				Chan, BS; Satriano, JA; Pucci, M; Schuster, VL			Mechanism of prostaglandin E-2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter "PGT"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT LUNG; METABOLISM; INACTIVATION; REMOVAL; SYSTEM	We recently identified a novel prostaglandin transporter called PGT (Banal, N., Lu, R., Satriano, J.A., Bao, Y., Wolkoff, A. W, and Schuster, V. L. (1995) Science 268, 866-869). Eased on initial functional studies, we have hypothesized that PGT might mediate the release of newly synthesized prostaglandins (PG), epithelial transport of PGs, or metabolic clearance of PGs. Here we examined the mechanism of PGT transport as expressed in HeLa cells and Xenopus oocytes, using isotopic PG influx and efflux studies. In both native HeLa cells and oocytes, cell membranes were poorly permeable to PGs. In contrast, in oocytes injected with PGT mRNA, the PG influx permeability coefficient was 90-157 times that of oocytes injected with water. The rank order substrate profile was PGF(2 alpha) approximate to PGE(2) > TXB2 much greater than 6 keto-PGF(1 alpha). PG influx displayed an overshoot with rapid accumulation of tracer PGE(2), followed by a gradual return to baseline. Based on estimated oocyte volumes, the PGT-mediated accumulation of PGE(2) reached steady state at intra-oocyte concentrations 25-fold higher than the external media. The accumulation of PG was not due to intracellular binding or metabolism. PGT-mediated uptake was ATP-and temperature-dependent, but not sodium-dependent, and was inhibited by disulfonic stilbenes, niflumic acid, and the thiol reactive anion MTSES (Na(2-sulfonatoethyl)methanethiosulfonate). [H-3]PGE(2) efflux from PGT-transfected HeLa cells was stimulated by external (trans) PGE(2) in a dose-dependent fashion and was inhibited by bromcresol green and 4,4'-diisothiocyana tostilbene-2,2'-disulfonate. Membrane depolarization inhibited uptake of [H-3]PGE(2), consistent with a model of net outward movement of negative charge during the translocation event. These findings suggest that PGT mediates [H-3]PGE(2) accumulation via obligatory, electrogenic anion exchange.	Albert Einstein Coll Med, Dept Physiol & Med Biophys, Div Renal, Bronx, NY 10461 USA; Univ Calif San Diego, San Diego Vet Affairs Med Ctr, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92093 USA	Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Diego	Schuster, VL (corresponding author), Albert Einstein Coll Med, Dept Physiol & Med Biophys, Div Renal, Ulman 615,1300 Morris Pk Ave, Bronx, NY 10461 USA.	schuster@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002492, R01DK049688, T32DK007110] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK49688, DK07110, R01 DK049688, KO8-DK02492] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MW, 1976, PROSTAGLANDINS, V11, P645, DOI 10.1016/0090-6980(76)90067-8; BAROODY RA, 1981, PROSTAGLANDINS, V21, P133, DOI 10.1016/0090-6980(81)90203-3; BITO LZ, 1974, PROSTAGLANDINS, V8, P345, DOI 10.1016/S0090-6980(74)80100-0; BITO LZ, 1972, COMP BIOCHEM PHYSIOL, V43, P65, DOI 10.1016/0300-9629(72)90470-7; BITO LZ, 1977, AM J PHYSIOL, V232, pE382, DOI 10.1152/ajpendo.1977.232.4.E382; BITO LZ, 1975, NATURE, V256, P134, DOI 10.1038/256134a0; BITO LZ, 1975, AM J PHYSIOL, V229, P1580, DOI 10.1152/ajplegacy.1975.229.6.1580; BITO LZ, 1974, J PHYSIOL-LONDON, V236, pP39; BITO LZ, 1972, EXP EYE RES, V14, P233, DOI 10.1016/0014-4835(72)90008-5; BUCHER T, 1947, BIOCHIM BIOPHYS ACTA, V1, P292, DOI 10.1016/0006-3002(47)90143-1; ELING TE, 1977, PROSTAGLANDINS, V14, P51, DOI 10.1016/0090-6980(77)90156-3; ELING TE, 1976, AGENTS ACTIONS, V6, P543, DOI 10.1007/BF01973277; FEIGEN LP, 1977, AM J PHYSIOL, V233, pH573, DOI 10.1152/ajpheart.1977.233.5.H573; FERREIRA SH, 1967, NATURE, V216, P868, DOI 10.1038/216868a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAMBERG M, 1971, J BIOL CHEM, V246, P6713; HOOK R, 1975, PROSTAGLANDINS, V9, P193, DOI 10.1016/0090-6980(75)90024-6; HUMPHREYS BD, 1994, AM J PHYSIOL-CELL PH, V267, pC1295, DOI 10.1152/ajpcell.1994.267.5.C1295; Ip T K, 1988, ASAIO Trans, V34, P351; IRISH JM, 1979, AM J PHYSIOL, V237, pF268, DOI 10.1152/ajprenal.1979.237.4.F268; Itoh S, 1996, MOL PHARMACOL, V50, P736; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MOLLER JV, 1982, PHARMACOL REV, V34, P315; NAKANO J, 1972, BRAIN RES, V39, P545, DOI 10.1016/0006-8993(72)90462-3; NEAME KD, 1972, ELEMENTARY KINETICS, P56; PAPANICOLAOU N, 1972, REV CAN BIOL EXPTL, V31, P313; PIPER PJ, 1970, NATURE, V225, P600, DOI 10.1038/225600a0; PITT BR, 1983, J PHARMACOL EXP THER, V227, P531; Ren SJ, 1996, J DRUG TARGET, V4, P103, DOI 10.3109/10611869609046268; ROBINSON C, 1982, BIOCHEM PHARMACOL, V31, P633, DOI 10.1016/0006-2952(82)90442-7; SAMUELSSON B, 1972, FED PROC, V31, P1442; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; THELESTAM M, 1976, MED BIOL, V54, P39; Tokimasa T, 1996, J PHYSIOL-LONDON, V496, P677, DOI 10.1113/jphysiol.1996.sp021718; UEKAMA K, 1978, CHEM PHARM BULL, V26, pF58; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26	39	114	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6689	6697		10.1074/jbc.273.12.6689	http://dx.doi.org/10.1074/jbc.273.12.6689			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506966	hybrid			2022-12-27	WOS:000072775900016
J	Milev, P; Chiba, A; Haring, M; Rauvala, H; Schachner, M; Ranscht, B; Margolis, RK; Margolis, RU				Milev, P; Chiba, A; Haring, M; Rauvala, H; Schachner, M; Ranscht, B; Margolis, RK; Margolis, RU			High affinity binding and overlapping localization of neurocan and phosphacan protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-ADHESION MOLECULES; CENTRAL-NERVOUS-SYSTEM; NEURITE OUTGROWTH; IMMUNOCYTOCHEMICAL LOCALIZATION; EXTRACELLULAR VARIANT; DEVELOPING BRAIN; HB-GAM; N-CAM; RECEPTOR	We have studied the interactions of the nervous tissue-specific chondroitin sulfate proteoglycans neurocan and phosphacan with the extracellular matrix protein tenascin-a and two heparin-binding proteins, amphoterin and the heparin-binding growth-associated molecule (HB-GAM), using a radioligand binding assay, Both proteoglycans show saturable, high affinity binding to tenascin-R with apparent dissociation constants in the 2-7 nM range, Binding is reversible, inhibited in the presence of unlabeled proteoglycan, and increased by similar to 60% following chondroitinase treatment of the proteoglycans, indicating that the interactions are mediated via the core (glyco)proteins rather than by the glycosaminoglycan chains, which may in fact partially shield the binding sites, In contrast to their interactions with tenascin-C, in which binding was decreased by similar to 75% in the absence of calcium, binding of phosphacan to tenascin-R was not affected by the absence of divalent cations in the binding buffer, although there was a small but significant decrease in the binding of neurocan, Neurocan and phosphacan are also high affinity ligands of amphoterin and HB-GAM (K-d = 0.3-8 nM), two heparin-binding proteins that are developmentally regulated in brain and functionally involved in neurite outgrowth, The chondroitin sulfate chains on neurocan and phosphacan account for at least 80% of their binding to amphoterin and HB-GAM. The presence of amphoterin also produces a 5-fold increase in phosphacan binding to the neural cell adhesion molecule contactin, Immunocytochemical studies showed an overlapping localization of the proteoglycans and their ligands in the embryonic and postnatal brain, retina, and spinal cord, These studies have therefore revealed differences in the interactions of neurocan and phosphacan with the two major members of the tenascin family of extracellular matrix proteins, and also suggest that chondroitin sulfate proteoglycans play an important role in the binding and/or presentation of differentiation factors in the developing central nervous system.	NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Univ Helsinki, Dept Neurosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Mol Neurobiol Lab, FIN-00014 Helsinki, Finland; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; Burnham Inst, La Jolla, CA 92037 USA; SUNY Hlth Sci Ctr, Hlth Sci Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA	New York University; University of Helsinki; University of Helsinki; University of Hamburg; University Medical Center Hamburg-Eppendorf; Sanford Burnham Prebys Medical Discovery Institute; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Margolis, RU (corresponding author), NYU, Med Ctr, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.			Rauvala, Heikki/0000-0001-7809-9811				ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Engel M, 1996, J COMP NEUROL, V366, P34; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nair SM, 1997, J NEUROCHEM, V68, P1286; Norenberg U, 1996, INT J DEV NEUROSCI, V14, P217, DOI 10.1016/0736-5748(96)00009-3; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PESHEVA P, 1991, EUR J NEUROSCI, V3, P356, DOI 10.1111/j.1460-9568.1991.tb00823.x; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Rauvala H, 1997, PROG NEUROBIOL, V52, P127, DOI 10.1016/S0301-0082(97)00007-5; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SHITARA K, 1994, J BIOL CHEM, V269, P20189; SilosSantiago I, 1996, J NEUROBIOL, V31, P283, DOI 10.1002/(SICI)1097-4695(199611)31:3<283::AID-NEU2>3.0.CO;2-6; WEWETZER K, 1995, BRAIN RES, V693, P31, DOI 10.1016/0006-8993(95)00683-H; Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	40	167	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6998	7005		10.1074/jbc.273.12.6998	http://dx.doi.org/10.1074/jbc.273.12.6998			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507007	hybrid			2022-12-27	WOS:000072775900057
J	Shoukry, K; Schulz, H				Shoukry, K; Schulz, H			Significance of the reductase-dependent pathway for the beta-oxidation of unsaturated fatty acids with odd-numbered double bonds - Mitochondrial metabolism of 2-trans-5-cis-octadienoyl-CoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; REVISED PATHWAY; PURIFICATION; PEROXISOMES	The beta-oxidation of unsaturated fatty acids with odd-numbered double bonds proceeds by reduction of the double bond (reductase-dependent pathway) in addition to the well established isomerization of the double bond (isomerase-dependent pathway). The metabolic significance of the reductase-dependent pathway was assessed with 2-trans-5-cis-octadienoyl-CoA (2,5-octadienoyl-CoA) and its products, all of which are metabolites of alpha-linolenic acid, A kinetic evaluation of beta-oxidation enzymes revealed that the presence of a 5-cis double bond in the substrate most adversely affected the activity of 3-ketoacyl-CoA thiolase although not enough to become rate-limiting, Concentration dependent and time-dependent measurements indicated that most (80%) of 2,5-octadienoyl-CoA is metabolized via the isomerase-dependent pathway, The reason for the greater flux through the isomerase-dependent pathway is the higher activity of L-3-hydroxyacyl-CoA dehydrogenase as compared with Delta(3),Delta(2)-enoyl-CoA isomerase. These two enzymes catalyze the rate-limiting steps in the isomerase-dependent and reductase-dependent pathways, respectively, Once 2,5-octadienoyl-CoA is converted to 3,5-octadienoyl-CoA (perhaps fortuitously because of the presence of Delta(3),Delta(2)-enoyl-CoA isomerase), the only effective route for its degradation is via the reductase-dependent pathway, It is concluded that the reductase-dependent pathway assures the degradation of 3,5-dienoyl-CoA intermediates, thereby preventing the depletion of free coenzyme A and a likely impairment of mitochondrial oxidative function.	CUNY City Coll, Dept Chem, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave & 138th St, New York, NY 10031 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL30847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW RA, 1975, METHOD ENZYMOL, V35, P136; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LUO MJ, 1994, J BIOL CHEM, V269, P2384; NEDERGAARD J, 1979, METHOD ENZYMOL, V71, P390; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Schulz H, 1981, Methods Enzymol, V71 Pt C, P398; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STEINMAN H, 1965, METHOD ENZYMOL, V35, P136; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; TSERNG KY, 1995, BIOCHEM J, V307, P23, DOI 10.1042/bj3070023; TSERNG KY, 1995, BIOCHEM J, V308, P39, DOI 10.1042/bj3080039; Tserng KY, 1996, BIOCHEM J, V313, P581, DOI 10.1042/bj3130581	19	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6892	6899		10.1074/jbc.273.12.6892	http://dx.doi.org/10.1074/jbc.273.12.6892			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506993	hybrid			2022-12-27	WOS:000072775900043
J	Vatcher, GP; Thacker, CM; Kaletta, T; Schnabel, H; Schnabel, R; Baillie, DL				Vatcher, GP; Thacker, CM; Kaletta, T; Schnabel, H; Schnabel, R; Baillie, DL			Serine hydroxymethyltransferase is maternally essential in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; C-ELEGANS; ESCHERICHIA-COLI; GENE; EMBRYOS; MUTATIONS; CLONING; GLYCINE; ENCODES; BINDING	The mel-32 gene in the free living soil nematode Caenorhabditis elegans encodes a serine hydroxymethyltransferase (SHMT) isoform, Seventeen ethylmethanesulfonate (EMS)-induced mutant alleles of mel-32(SHMT) have been generated, each of which causes a recessive maternal effect lethal phenotype. Animals homozygous for the SHMT mutations have no observable mutant phenotype, but their offspring display an embryonic lethal phenotype, The Mel-32 phenotype has been rescued with a transgenic array containing only mel-32(SHMT) genomic DNA, Heteroduplex analysis of the 17 alleles allowed 14 of the mutations to be positioned to small regions, Subsequent sequence analysis has shown that 16 of the alleles alter highly conserved amino acids, while one allele introduces a stop codon that truncates two thirds of the predicted protein, mel-32(SHMT) has a 55-60% identity at the amino acid level with both isoforms of SHMT found in yeast and humans and a 50% identity with the Escherichia coli isoform, The C, elegans mel-32 mutation represents the first case where SHMT has been shown to be an essential gene.	Simon Fraser Univ, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Inst Genet, D-38023 Braunschweig, Germany	Simon Fraser University; University of British Columbia; Max Planck Society	Baillie, DL (corresponding author), Simon Fraser Univ, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	dbaillie@darwin.mbb.sfu.ca	Kaletta, Titus/F-5361-2012					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; Cai K, 1996, J BIOL CHEM, V271, P2987, DOI 10.1074/jbc.271.6.2987; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; DURBIN R, 1997, C ELEGANS, V2, P17; EICHLER HG, 1981, BIOSCIENCE REP, V1, P101, DOI 10.1007/BF01117006; FRATTE SD, 1994, EUR J BIOCHEM, V225, P395, DOI 10.1111/j.1432-1033.1994.00395.x; GARROW TA, 1993, J BIOL CHEM, V268, P11910; GAVILANES F, 1982, J BIOL CHEM, V257, P1431; GAVILANES F, 1983, J BIOL CHEM, V258, P3155; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HOPKINS S, 1986, J BIOL CHEM, V261, P3363; Janke DL, 1997, GENOME RES, V7, P974, DOI 10.1101/gr.7.10.974; KEEN J, 1991, TRENDS GENET, V7, P5; KEMPHUES KJ, 1988, GENETICS, V120, P977; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; MAINS PE, 1990, GENETICS, V125, P351; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Nakshatri H, 1996, GENE, V174, P79, DOI 10.1016/0378-1119(96)00391-5; Narkewicz MR, 1996, BIOCHEM J, V313, P991, DOI 10.1042/bj3130991; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; PASCARELLA S, 1993, FEBS LETT, V331, P145, DOI 10.1016/0014-5793(93)80314-K; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SCHIRCH D, 1993, J BIOL CHEM, V268, P23132; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1986, EUR J BIOCHEM, V161, P45, DOI 10.1111/j.1432-1033.1986.tb10122.x; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; STAUFFER GV, 1981, GENE, V14, P63, DOI 10.1016/0378-1119(81)90148-7; STOVER P, 1992, J BIOL CHEM, V267, P17679; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAKATELLIS A, 1994, POSTGRAD MED J, V70, pS89; USHA R, 1992, J BIOL CHEM, V267, P9289; USHA R, 1994, BBA-PROTEIN STRUCT M, V1204, P75, DOI 10.1016/0167-4838(94)90035-3; WILLIAMS BD, 1992, GENETICS, V131, P609; WOOD WB, 1988, NEMATODE CAENORHABDI, P217	50	16	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6066	6073		10.1074/jbc.273.11.6066	http://dx.doi.org/10.1074/jbc.273.11.6066			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497323	hybrid			2022-12-27	WOS:000072488500015
J	Watson, CE; Davies, PL				Watson, CE; Davies, PL			The high molecular weight chromatin proteins of winter flounder sperm are related to an extreme histone H1 variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIC-PROTEINS; NUCLEAR PROTEINS; GLOBULAR DOMAIN; H1-LIKE PROTEIN; GENE; MYTILUS; H-1; SPERMATOGENESIS; PROTAMINES; EXPRESSION	Unlike mammals, birds, and most other fishes, winter flounder completes spermatogenesis without replacing its germ cell histones with protamines. Instead, during spermiogenesis, these fish produce a family of high molecular weight (80,000-200,000) basic nuclear proteins (HM(r)BNPs) that bind to sperm chromatin containing the normal complement of histones. These large, basic proteins are built up of tandem iterations of oligopeptide repeats that contain phosphorylatable DNA-binding motifs. Although the HM(r)BNPs have no obvious homology to histones, protamines, or other sperm-specific chromatin proteins, we report here the isolation of a clone (2B) from a winter flounder genomic DNA library that establishes a link between the HM(r)BNPs and histone H1. The 2B sequence contains an open reading frame, which, when conceptually translated, encodes a 265-residue protein. At its N terminus the translation product contains numerous simple repeats that match the oligopeptides contained within the HM(r)BNPs. Unexpectedly, the C terminus of the putative protein shows 66% identity and 76% conservation to the histone H1 globular domain. This connection suggests that the HM(r)BNPs may have originated from the extended N-terminal tail region of a testis-specific, H1-like linker histone.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	DaviesP@post.queensu.ca						Ausio J, 1997, J MOL EVOL, V45, P91, DOI 10.1007/PL00006207; BLOCH DP, 1969, GENETICS, V61, P93; CARLOS S, 1993, J BIOL CHEM, V268, P185; CARLOS S, 1993, J BIOL CHEM, V268, P195; CERF C, 1993, BIOCHEMISTRY-US, V32, P11345, DOI 10.1021/bi00093a011; CHENG GH, 1989, P NATL ACAD SCI USA, V86, P7002, DOI 10.1073/pnas.86.18.7002; COLE KD, 1984, J BIOL CHEM, V259, P3695; COLES LS, 1987, J BIOL CHEM, V262, P9656; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DAISLEY S, 1982, BIOCHIM BIOPHYS ACTA, V698, P271, DOI 10.1016/0167-4781(82)90157-9; DRABENT B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P311, DOI 10.1016/0167-4781(93)90162-7; DRABENT B, 1991, GENE, V103, P263, DOI 10.1016/0378-1119(91)90284-I; GABRIELLI F, 1989, HISTONES OTHER BASIC, P3; GIANCOTTI V, 1992, BIOCHIM BIOPHYS ACTA, V1119, P296, DOI 10.1016/0167-4838(92)90217-2; JUTGLAR L, 1991, J BIOL CHEM, V266, P8184; KADURA SN, 1983, COMP BIOCHEM PHYS B, V74, P343, DOI 10.1016/0305-0491(83)90023-8; Kasinsky H. E., 1989, HISTONES OTHER BASIC, P73; KASINSKY HE, 1987, J EXP ZOOL, V243, P137, DOI 10.1002/jez.1402430116; KENNEDY BP, 1985, J BIOL CHEM, V260, P4338; KENNEDY BP, 1980, J BIOL CHEM, V255, P2533; KENNEDY BP, 1982, J BIOL CHEM, V257, P1160; KISTLER WS, 1989, HISTONES OTHER BASIC, P331; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MASSEY CB, 1992, J EXP ZOOL, V262, P9, DOI 10.1002/jez.1402620103; MEZQUITA J, 1984, Journal of Molecular Evolution, V21, P209; Oliva R., 1991, PROGR NUCL ACID RES, P26; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; ROCCHINI C, 1995, FEBS LETT, V363, P37, DOI 10.1016/0014-5793(95)00275-E; ROCCHINI C, 1995, BIOCHEMISTRY-US, V34, P15704, DOI 10.1021/bi00048a015; Rocchini C, 1996, J MOL EVOL, V42, P240, DOI 10.1007/BF02198850; ROMANO G, 1992, CELL BIOL INT REP, V16, P197, DOI 10.1016/S0309-1651(06)80121-9; SAPERAS N, 1994, J MOL EVOL, V39, P282, DOI 10.1007/BF00160152; SCHULZE E, 1993, P NATL ACAD SCI USA, V90, P2481, DOI 10.1073/pnas.90.6.2481; SCOTT GK, 1985, P NATL ACAD SCI USA, V82, P2613, DOI 10.1073/pnas.82.9.2613; SUBIRANA JA, 1973, BIOCHIM BIOPHYS ACTA, V317, P364, DOI 10.1016/0005-2795(73)90231-6; WATSON CE, 1995, THESIS QUEENS U KING; Wolffe A., 1995, CHROMATIN STRUCTURE; YOUNG DCR, 1987, BIOCHEM CELL BIOL, V65, P909, DOI 10.1139/o87-117; [No title captured]	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6157	6162		10.1074/jbc.273.11.6157	http://dx.doi.org/10.1074/jbc.273.11.6157			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497335	hybrid			2022-12-27	WOS:000072488500027
J	Zhen, L; Yu, LX; Dinauer, MC				Zhen, L; Yu, LX; Dinauer, MC			Probing the role of the carboxyl terminus of the gp91(phox) subunit of neutrophil flavocytochrome b(558) using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; PHAGOCYTE NADPH OXIDASE; LEUKEMIA CELL-LINE; CYTOCHROME-B; SUPEROXIDE PRODUCTION; CYTOSOLIC COMPONENT; PLASMA-MEMBRANE; BINDING-SITE; PERIPHERAL PHAGOCYTES	Site-directed mutagenesis was used to generate a series of substitutions and deletions in the carboxyl-terminal 11 residues of gp91(phox), the 91-kDa subunit of the phagocyte NADPH oxidase flavocytochrome b(558). This region encompasses (559)RGVHFIF(565), implicated as a contact point for the cytosolic oxidase subunit p47(phox) during oxidase activation, and a carboxyl-terminal phenylalanine (Phe(570)), which corresponds in position to a highly conserved aromatic residue that interacts with the flavin group in the ferredoxin-NADP(+) reductase flavoenzyme family, of which gp91(phox) is a member. Mutant proteins were expressed in human myeloid leukemia cells which lack expression of endogenous gp91(phox) due to targeted disruption of the X-linked gp91(phox) gene. Although specific residues within (559)RGVHFIF(565) had previously been identified by alanine scanning as essential for peptide inhibition of oxidase activity in a cell-free assay, comparable substitutions in the gp91(phox) polypeptide had either no or only a modest effect on oxidase activity in whole cells, Replacement of nonpolar with polar or charged residues had greater effects on oxidase activity, but were also associated with decreased gp91(phox) expression, suggesting that overall protein structure was perturbed. No stable gp91(phox) protein was detected upon deletion of the terminal 11 amino acids. Alanine substitution or deletion of the carboxyl-terminal Phe(570) in gp91(phox) resulted in a 2-fold reduction in superoxide production. This contrasts with a approximate to 300-800-fold reduction reported for comparable mutations in pea ferredoxin-NADP(+) reductase, which suggests that structural or functional differences exist between the carboxyl terminus of gp91(phox) and other ferredoxin-NADP(+) reductases.	Indiana Univ, James Whitcomb Riley Hosp Children, Med Ctr, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46702 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Med Ctr, Dept Pediat Hematol Oncol, Indianapolis, IN 46702 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Med Ctr, Dept Med & Mol Genet, Indianapolis, IN 46702 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Dinauer, MC (corresponding author), Indiana Univ, James Whitcomb Riley Hosp Children, Med Ctr, Herman B Wells Ctr Pediat Res, Rm 2600,702 Barnhill Dr, Indianapolis, IN 46702 USA.				NHLBI NIH HHS [R01HL45635] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Bjorgvinsdottir H, 1997, BLOOD, V89, P41, DOI 10.1182/blood.V89.1.41.41_41_48; BUGHANIM HN, 1995, BLOOD, V86, P3575, DOI 10.1182/blood.V86.9.3575.bloodjournal8693575; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CURNUTTE JT, 1994, MOL BASIS BLOOD DIS, P493; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; Ding CJ, 1996, BLOOD, V88, P1834; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; DOUSSIERE J, 1995, BIOCHEMISTRY-US, V34, P1760, DOI 10.1021/bi00005a033; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH P, 1991, J CLIN INVEST, V87, P321; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hui YF, 1996, BLOOD, V88, P4021, DOI 10.1182/blood.V88.10.4021.bloodjournal88104021; HURST JK, 1991, J BIOL CHEM, V266, P1627; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KLEINBERG ME, 1992, BIOCHEMISTRY-US, V31, P2686, DOI 10.1021/bi00125a008; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KUME A, 1994, BLOOD, V84, P3311; LETO T, 1995, P NATL ACAD SCI USA, V91, P10650; LEUSEN J, 1994, J EXP MED, V80, P2329; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; Maniatis T., 1982, MOL CLONING LAB MANU; NAKAMURA M, 1988, BLOOD, V72, P1550; NAKAMURA M, 1987, BLOOD, V69, P1404; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Smith RM, 1996, J CLIN INVEST, V98, P977, DOI 10.1172/JCI118882; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; TUCKER KA, 1987, BLOOD, V70, P372; UHLINGER DJ, 1995, BIOCHEMISTRY-US, V34, P524, DOI 10.1021/bi00002a017; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	63	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6575	6581		10.1074/jbc.273.11.6575	http://dx.doi.org/10.1074/jbc.273.11.6575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497394	hybrid			2022-12-27	WOS:000072488500086
J	Dam, TK; Bachhawat, K; Rani, PG; Surolia, A				Dam, TK; Bachhawat, K; Rani, PG; Surolia, A			Garlic (Allium sativum) lectins bind to high mannose oligosaccharide chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-CHROMATOGRAPHY; SPECIFICITY; BULBS; AMARYLLIDACEAE; GLYCOPEPTIDES; COMPLEX	Two mannose-binding lectins, Allium sativum agglutinin (ASA) I (25 kDa) and ASAIII (48 kDa), from garlic bulbs have been purified by affinity chromatography followed by gel filtration. The subunit structures of these lectins are different, but they display similar sugar specificities. Both ASI and ASAIII are made up of 12.5- and 11.5-kDa subunits. In addition, a complex (136 kDa) comprising a polypeptide chain of 54 +/- 4 kDa and the subunits of ASAI and ASAIII elutes earlier than these lectins on gel filtration. The 54-kDa subunit is proven to be alliinase, which is known, to form a complex with garlic lectins. Constituent subunits of ASAI and ASAIII exhibit the same sequence at their amino termini. ASAI and ASAIII recognize monosaccharides in mannosyl configuration. The potencies of the ligands for ASAs increase in the following order: mannobiose (Man alpha 1-3Man) < mannotriose (Man alpha 1-6Man alpha 1-3Man) approximate to mannopentaose much less than man(9)-oligosaccharide. The addition of two GIcNAc residues at the reducing end of manotriose or mannopentaose enhances their potencies significantly, whereas substitution of both alpha 1-3- and alpha 1-6-mannosyl residues of mannotriose with GlcNAc at the nonreducing end increases their activity only marginally. The best manno-oligosaccharide ligand is Man(9)GlcNAc(2)Asn, which bears several alpha 1-2-linked mannose residues. Interaction with glycoproteins suggests that these lectins recognize internal mannose as well as bind to the core pentasaccharide of N-linked glycans even when it is sialylated. The strongest inhibitors are the high mannose-containing glycoproteins, which carry larger glycan chains. Indeed, invertase, which contains 85% of its mannose residues in species larger than Man(20)GlcNAc, exhibited the highest binding affinity. No other mannose- or mannose/glucose-binding lectin has been shown to display such a specificity.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; Barre A, 1996, PLANT PHYSIOL, V112, P1531, DOI 10.1104/pp.112.4.1531; BHATTACHARYYA L, 1987, J BIOL CHEM, V262, P1294; CAMMUE BPA, 1986, PLANTA, V169, P583, DOI 10.1007/BF00392110; DAM TK, 1992, MOL CELL BIOCHEM, V117, P1; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; Gupta A, 1997, MOL CELL BIOCHEM, V166, P1, DOI 10.1023/A:1006827921151; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; KAKU H, 1992, CARBOHYD RES, V229, P347, DOI 10.1016/S0008-6215(00)90580-9; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; Nelson N, 1944, J BIOL CHEM, V153, P375; RABINKOV A, 1995, GLYCOCONJUGATE J, V12, P690, DOI 10.1007/BF00731266; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHIBUYA N, 1988, ARCH BIOCHEM BIOPHYS, V267, P676, DOI 10.1016/0003-9861(88)90076-8; Smeets K, 1997, GLYCOCONJUGATE J, V14, P331, DOI 10.1023/A:1018570628180; Smeets K, 1997, PLANT MOL BIOL, V33, P223, DOI 10.1023/A:1005717020021; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; Sureshkumar G, 1982, J BIOSCIENCE, V4, P257; SWAMY MJ, 1986, BIOCHEM J, V261, P14621; TAI T, 1977, J BIOL CHEM, V252, P6687; TAI T, 1975, J BIOL CHEM, V250, P8569; TRIMBLE RB, 1983, J BIOL CHEM, V258, P2562; VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52, DOI 10.1111/j.1399-3054.1988.tb09192.x; VANDAMME EJM, 1992, EUR J BIOCHEM, V206, P413, DOI 10.1111/j.1432-1033.1992.tb16941.x; VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1; VANDAMME EJM, 1991, PHYTOCHEMISTRY, V30, P509, DOI 10.1016/0031-9422(91)83716-X; WEBER K, 1969, J BIOL CHEM, V244, P4406; YASHIMATA K, 1978, J BIOL CHEM, V253, P3862	34	52	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5528	5535		10.1074/jbc.273.10.5528	http://dx.doi.org/10.1074/jbc.273.10.5528			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488677	hybrid			2022-12-27	WOS:000072345000020
J	Kimura, K; Fukata, Y; Matsuoka, Y; Bennett, V; Matsuura, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K				Kimura, K; Fukata, Y; Matsuoka, Y; Bennett, V; Matsuura, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K			Regulation of the association of adducin with actin filaments by Rho-associated kinase (Rho-kinase) and myosin phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; SERINE-THREONINE KINASE; SMOOTH-MUSCLE; ERYTHROCYTE ADDUCIN; PUTATIVE TARGET; MEMBRANE; PHOSPHORYLATION; FAMILY; INVOLVEMENT; ACTIVATION	The small GTPase Rho is believed to regulate the actin cytoskeleton and cell adhesion through its specific targets. We previously identified the Rho targets: protein kinase N, Rho-associated kinase (Rho-kinase), and the myosin-binding subunit (MBS) of myosin phosphatase. Here we purified MBS-interacting proteins, identified them as adducin, and found that MBS specifically interacted with adducin in vitro and in vivo. Adducin is a membrane-skeletal protein that promotes the binding of spectrin to actin filaments and is concentrated at the cell-cell contact sites in epithelial cells. We also found that Rho-kinase phosphorylated alpha-adducin in vitro and in vivo and that the phosphorylation of alpha-adducin by Rho-kinase enhanced the interaction of alpha-adducin with actin filaments in vitro. Myosin phosphatase composed of the catalytic subunit and MBS showed phosphatase activity toward alpha-adducin, which was phosphorylated by Rho-kinase. This phosphatase activity was inhibited by the phosphorylation of MBS by RHO-kinase. These results suggest that Rho-kinase and myosin phosphatase regulate the phosphorylation state of adducin downstream of Rho and that the increased phosphorylation of adducin by Rho-kinase causes the interaction of adducin with actin filaments.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 63001, Japan; Kyoto Univ, Grad Sch Med, Dept Anat & Neurobiol, Sakyo Ku, Kyoto 606, Japan; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Natl Inst Infect Dis, Dept Virol 2, Shinjyuku Ku, Tokyo 162, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan	Nara Institute of Science & Technology; Kyoto University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; National Institute of Infectious Diseases (NIID); Kirin Brewery Company Limited	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, 8916-5 Takayama, Ikoma 63001, Japan.		Kimura, Kazushi/ABB-4007-2020	Fukata, Yuko/0000-0001-7724-8643				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Harlow E., 1988, ANTIBODIES LAB MANUA; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; Inagaki N, 1997, BIOCHEM BIOPH RES CO, V230, P552, DOI 10.1006/bbrc.1996.5986; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LING E, 1986, J BIOL CHEM, V261, P13875; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; NAKA M, 1983, NATURE, V306, P490, DOI 10.1038/306490a0; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WEINMASTER G, 1991, DEVELOPMENT, V113, P199	52	175	185	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5542	5548		10.1074/jbc.273.10.5542	http://dx.doi.org/10.1074/jbc.273.10.5542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488679	Green Submitted, hybrid			2022-12-27	WOS:000072345000022
J	Wind, RD; Uitdehaag, JCM; Buitelaar, RM; Dijkstra, BW; Dijkhuizen, L				Wind, RD; Uitdehaag, JCM; Buitelaar, RM; Dijkstra, BW; Dijkhuizen, L			Engineering of cyclodextrin product specificity and pH optima of the thermostable cyclodextrin glycosyltransferase from Thermoanaerobacterium thermosulfurigenes EM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; BACILLUS-CIRCULANS STRAIN-251; ALPHA-AMYLASE; CYCLIZATION CHARACTERISTICS; NUCLEOTIDE-SEQUENCE; ANGSTROM RESOLUTION; CATALYTIC MECHANISM; ESCHERICHIA-COLI; PROTEIN MODELS; ACTIVE-CENTER	The product specificity and pH optimum of the thermostable cyclodextrin glycosyltransferase (CGTase) from Thermoanaerobacterium thermosulfurigenes EM1 was engineered using a combination of x-ray crystallography and site-directed mutagenesis. Previously, a crystal soaking experiment with the Bacillus circulans strain 251 beta-CGTase had revealed a maltohexaose inhibitor bound to the enzyme in an extended conformation. An identical experiment with the CGTase from T. thermosulfurigenes EM1 resulted in a 2.6-Angstrom resolution x-ray structure of a complex with a maltohexaose inhibitor, bound in a different conformation, We hypothesize that the new maltohexaose conformation is related to the enhanced alpha-cyclodextrin production of the CGTase. The detailed structural information subsequently allowed engineering of the cyclodextrin product specificity of the CGTase from T. thermosulfurigenes EM1 by site directed mutagenesis, Mutation D371R was aimed at hindering the maltohexaose conformation and resulted in enhanced production of larger size cyclodextrins (beta- and gamma-CD). Mutation D197H was aimed at stabilization of the new maltohexaose conformation and resulted in increased production of alpha-CD. Glu(258) is involved in catalysis in CGTases as well as alpha-amylases, and is the proton donor in the first step of the cyclization reaction. Amino acids close to Glu(258) in the CGTase from T. thermosulfurigenes EM1 were changed. Phe(284) was replaced by Lys and Asn(327) by Asp. The mutants showed changes in both the high and low pH slopes of the optimum curve for cyclization and hydrolysis when compared with the wild-type enzyme, This suggests that the pH optimum curve of CGTase is determined only by residue Glu(258).	DLO, ATO, Agrotechnol Res Inst, NL-6700 AA Wageningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol INst, BIOSON Res Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol INst, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen; University of Groningen	Wind, RD (corresponding author), DLO, ATO, Agrotechnol Res Inst, POB 17, NL-6700 AA Wageningen, Netherlands.		Dijkhuizen, Lubbert/E-9454-2014; Dijkstra, Bauke W./H-4308-2019; Dijkhuizen, Lubbert/K-3539-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Dijkhuizen, Lubbert/0000-0003-2312-7162				BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DIJKHUIZEN L, 1996, Patent No. 33267; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUJIWARA S, 1992, J BACTERIOL, V174, P7478, DOI 10.1128/jb.174.22.7478-7481.1992; HAECKEL K, 1989, FEMS MICROBIOL LETT, V60, P333, DOI 10.1016/0378-1097(89)90420-5; Harata K, 1996, ACTA CRYSTALLOGR D, V52, P1136, DOI 10.1107/S0907444996008438; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V30, P20; Knegtel RMA, 1996, J MOL BIOL, V256, P611, DOI 10.1006/jmbi.1996.0113; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON CL, 1994, J MOL BIOL, V236, P590, DOI 10.1006/jmbi.1994.1168; LAZZARONI JC, 1979, FEMS MICROBIOL LETT, V5, P411, DOI 10.1111/j.1574-6968.1979.tb03370.x; MONMA M, 1988, BIOTECHNOL BIOENG, V32, P404, DOI 10.1002/bit.260320323; NAKAMURA A, 1993, BIOCHEMISTRY-US, V32, P6624, DOI 10.1021/bi00077a015; NAKAMURA A, 1994, BIOCHEMISTRY-US, V33, P9929, DOI 10.1021/bi00199a015; Norman B. E., 1992, Denpun Kagaku = Journal for Starch and its Related Carbohydrates and Enzymes, V39, P101; PEDERSEN S, 1995, CHEMTECH, P19; PENNINGA D, 1995, BIOCHEMISTRY-US, V34, P3368, DOI 10.1021/bi00010a028; PENNINGA D, 1996, THESIS WAGENINGEN NE; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID G, 1989, TRENDS BIOTECHNOL, V7, P244, DOI 10.1016/0167-7799(89)90015-2; STARNES RL, 1990, CEREAL FOOD WORLD, V35, P1094; STARNES RL, 1991, Patent No. 9962; Strokopytov B, 1996, BIOCHEMISTRY-US, V35, P4241, DOI 10.1021/bi952339h; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; TAKASE K, 1993, EUR J BIOCHEM, V211, P899, DOI 10.1111/j.1432-1033.1993.tb17623.x; TAKUSAGAWA F, 1978, ACTA CRYSTALLOGR B, V34, P213, DOI 10.1107/S0567740878002630; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WIND RD, 1995, APPL ENVIRON MICROB, V61, P1257, DOI 10.1128/AEM.61.4.1257-1265.1995; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	106	116	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5771	5779		10.1074/jbc.273.10.5771	http://dx.doi.org/10.1074/jbc.273.10.5771			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488711	hybrid, Green Published			2022-12-27	WOS:000072345000054
J	Brzovic, PS; Meza, J; King, MC; Klevit, RE				Brzovic, PS; Meza, J; King, MC; Klevit, RE			The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; OVARIAN-CANCER; ZINC-FINGER; SEQUENCE; BREAST; FAMILIES; MOTIF; GENE	The breast and ovarian cancer tumor suppressor gene, BRCA1, encodes for a Zn2+-binding RING finger motif located near the protein NH2 terminus, The RING finger motif is characterized by eight conserved Cys and His residues which form two Zn2+-binding sites termed Site I and Site II, We used limited proteolysis in conjunction with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy to investigate the metal binding properties and to probe the solution structures of wild-type and mutant BRCA1 constructs that include the RING finger, Our results show that the RING finger motif is part of a larger proteolysis-resistant structural domain which encompasses the first 110 residues of BRCA1. Analytical gel-filtration chromatography and chemical cross-linking experiments demonstrate: that the BRCA1 NH2-terminal domain readily homodimerizes in solution. The cancer-predisposing C61G: mutation, which alters a conserved Zn2+-binding residue, abolishes metal binding to Site II of the RING finger motif, while Site I remains intact and functional. The C61G mutation also results in increased proteolytic susceptibility of the COOH-terminal portion of the NH2-terminal domain and perturbs the oligomerization properties of BRCA1.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Klevit, RE (corresponding author), Univ Washington, Dept Biochem, Box 357742, Seattle, WA 98195 USA.	klevit@u.washington.edu	Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X; King, Mary-Claire/0000-0001-9426-1743	NCI NIH HHS [R01 CA27632] Funding Source: Medline; NIGMS NIH HHS [R01 GM46701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Cohen SL, 1996, STRUCTURE, V4, P1013, DOI 10.1016/S0969-2126(96)00108-6; EVERETT RD, 1993, J MOL BIOL, V234, P1038, DOI 10.1006/jmbi.1993.1657; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kriwacki RW, 1996, J AM CHEM SOC, V118, P5320, DOI 10.1021/ja960752m; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Rodgers KK, 1996, J MOL BIOL, V260, P70, DOI 10.1006/jmbi.1996.0382; Roehm PC, 1997, BIOCHEMISTRY-US, V36, P10240, DOI 10.1021/bi970863d; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; STORM MC, 1985, BIOCHEMISTRY-US, V24, P1749, DOI 10.1021/bi00328a027; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	20	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7795	7799		10.1074/jbc.273.14.7795	http://dx.doi.org/10.1074/jbc.273.14.7795			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525870	hybrid			2022-12-27	WOS:000072876300004
J	Meijberg, W; Schuurman-Wolters, GK; Robillard, GT				Meijberg, W; Schuurman-Wolters, GK; Robillard, GT			Thermodynamic evidence for conformational coupling between the B and C domains of the mannitol transporter of Escherichia coli, enzyme IImtl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; PHOSPHOENOLPYRUVATE; BINDING; PROTEIN; PHOSPHORYLATION; PERMEASE; SITE; MEMBRANE; DIMER; PURIFICATION	The transport across the cytoplasmic membrane and concomitant phosphorylation of mannitol in Escherichia coli is catalyzed by the mannitol-specific transport protein from the phosphoenolpyruvate-dependent phosphotransferase system, enzyme IImtl. Interactions between the cytoplasmic B and the membrane embedded C domain play an important role in the catalytic cycle of this enzyme, but the nature of this interaction is largely unknown, We have studied the thermodynamics of binding of (i) mannitol to enzyme IImtl, (ii) the substrate analog perseitol to enzyme IImtl, (iii) perseitol to phosphorylated enzyme IImtl, and (iv) mannitol to enzyme IImtl treated with trypsin to eliminate the cytoplasmic domains. Analysis of the heat capacity increment of these reactions showed that approximately 50-60 residues are involved in the binding of mannitol and perseitol, but far less in the phosphorylated state or after removal of the B domain, A model is proposed in which binding of mannitol leads to the formation of a contact interface between the two domains, either by folding of unstructured parts or by docking of preexisting surfaces, thus positioning the incoming mannitol close to the phosphorylation site on the B domain to facilitate the transfer of the phosphoryl group.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.							Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1; BOER H, 1995, BIOCHEMISTRY-US, V34, P3239, DOI 10.1021/bi00010a013; BOER H, 1994, J BIOL CHEM, V269, P17863; BRANDTS JF, 1964, J AM CHEM SOC, V86, P4302, DOI 10.1021/ja01074a014; Christensen J.J., 1976, HDB PROTON IONIZATIO; DIJKSTRA DS, 1996, THESIS U GRONINGEN G; GRIKO YV, 1992, BIOCHEMISTRY-US, V31, P12701, DOI 10.1021/bi00165a022; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; GRUNWALD E, 1995, J AM CHEM SOC, V117, P5687, DOI 10.1021/ja00126a009; JACOBSON GR, 1983, J CELL BIOCHEM, V23, P231, DOI 10.1002/jcb.240230120; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6464; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10120, DOI 10.1021/bi00495a016; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P5848, DOI 10.1021/bi00073a018; LUNDBACK T, 1993, BIOCHEMISTRY-US, V32, P5074, DOI 10.1021/bi00070a015; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5520, DOI 10.1021/bi00415a020; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRIVALOV PL, 1990, J MOL BIOL, V213, P385, DOI 10.1016/S0022-2836(05)80198-6; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1979, BIOCHEMISTRY-US, V18, P2984, DOI 10.1021/bi00581a012; ROBILLARD GT, 1996, HDB BIOL PHYS, V2, P549; ROOSSIEN FF, 1986, FEBS LETT, V196, P284, DOI 10.1016/0014-5793(86)80264-2; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; SaraceniRichards CA, 1997, J BACTERIOL, V179, P1135, DOI 10.1128/jb.179.4.1135-1142.1997; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANWEEGHEL RP, 1990, P NATL ACAD SCI USA, V87, P2613, DOI 10.1073/pnas.87.7.2613; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	35	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7949	7956		10.1074/jbc.273.14.7949	http://dx.doi.org/10.1074/jbc.273.14.7949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525892	Green Published, hybrid			2022-12-27	WOS:000072876300026
J	Rodriguez-Zavala, JS; Moreno-Sanchez, R				Rodriguez-Zavala, JS; Moreno-Sanchez, R			Modulation of oxidative phosphorylation by Mg2+ in rat heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETOGLUTARATE DEHYDROGENASE COMPLEX; SUBLINGUAL MUCOUS ACINI; ADENINE-NUCLEOTIDES; 2-OXOGLUTARATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE; ALPHA-KETOGLUTARATE; LIVER-MITOCHONDRIA; FLUORESCENT-PROBES; ASCITES-CELLS; CALCIUM-ION	The effect of varying the Mg2+ concentration on the 2-oxoglutarate dehydrogenase (2-OGDH) activity and the rake of oxidative phosphorylation of rat heart mitochondria was studied, The ionophore A23187 was used to modify the mitochondrial free Mg2+ concentration. Half-maximal stimulation (K-0.5) of ATP synthesis by Mg2+ was obtained with 0.13 +/- 0.02 mM (n = 7) with succinate (+rotenone) and 0.48 +/- 0.13 mM (n = 6) with 2-oxoglutarate (2-OG) as substrates. Similar K-0.5 values were found for NAD(P)H formation, generation of membrane potential, and state 4 respiration with 2-OG. in the presence of ADP, an increase in P-i concentration promoted a decrease in the K-0.5 values of ATP synthesis, membrane potential formation and state 4 respiration for Mg2+ with 2-OG,, but blot with succinate, These results indicate that 2-OGDH is the main step of oxidative phosphorylation modulated by Mg2+ when 2-OG is the oxidizable substrate; with succinate, the ATP synthase is the Mg2+-sensitive step. Replacement of P-i by acetate, which promotes changes on intramitochondrial pH abolished Mg2+ activation of 2-OGDH. Thus, the modulation of the 2-OGDH activity by Mg2+ has an essential requirement for P-i (and ADP) in intact mitochondria which is mot associated to variations in matrix pH.	Inst Nacl Cardiol, Dept Bioquim, Mexico City 14080, DF, Mexico	National Institute of Cardiology - Mexico	Rodriguez-Zavala, JS (corresponding author), Inst Nacl Cardiol, Dept Bioquim, Juan Badiano 1,Col Secc XVI, Mexico City 14080, DF, Mexico.		Rodriguez-Zavala, Jose S/AAI-3604-2020; Moreno-Sanchez, Rafael/A-3158-2011	Rodriguez-Zavala, Jose S/0000-0002-7094-5523; Moreno-Sanchez, Rafael/0000-0002-9587-7184				AKERMAN KE, 1976, BIOCHIM BIOPHYS ACTA, V426, P624, DOI 10.1016/0005-2736(76)90126-7; ALTSCHULD RA, 1994, AM J PHYSIOL, V266, pH1103, DOI 10.1152/ajpheart.1994.266.3.H1103; DEBONO M, 1981, BIOCHEMISTRY-US, V20, P6865, DOI 10.1021/bi00527a019; Erdahl WL, 1996, BIOCHEMISTRY-US, V35, P13817, DOI 10.1021/bi961391q; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEADRICK JP, 1994, AM J PHYSIOL, V267, pH1074, DOI 10.1152/ajpheart.1994.267.3.H1074; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; Jung DW, 1996, ARCH BIOCHEM BIOPHYS, V332, P19, DOI 10.1006/abbi.1996.0311; KOVACEVIC Z, 1995, BIOCHEM J, V305, P837, DOI 10.1042/bj3050837; KOZLOV IA, 1977, BIOCHIM BIOPHYS ACTA, V463, P29, DOI 10.1016/0304-4173(77)90003-9; LAWLIS VB, 1981, BIOCHEMISTRY-US, V20, P2512, DOI 10.1021/bi00512a023; MORENOSANCHEZ R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P284, DOI 10.1016/S0005-2728(05)80318-4; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P2554; MORENOSANCHEZ R, 1991, INT J BIOCHEM, V23, P1163, DOI 10.1016/0020-711X(91)90212-6; MORENOSANCHEZ R, 1995, ARCH BIOCHEM BIOPHYS, V319, P432, DOI 10.1006/abbi.1995.1314; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; OKADA K, 1992, AM J PHYSIOL, V263, pC837; Panov A, 1996, BIOCHEMISTRY-US, V35, P427, DOI 10.1021/bi952101t; PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x; RODRIGUEZZAVALA JS, 1997, BIOCHEM MOL BIOL INT, V411, P179; ROMANI A, 1991, J BIOL CHEM, V266, P24376; ROMANI A, 1993, J BIOL CHEM, V268, P15489; ROMANI A, 1990, FEBS LETT, V269, P37, DOI 10.1016/0014-5793(90)81113-3; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1989, BIOCHEM J, V263, P445, DOI 10.1042/bj2630445; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; SINGH J, 1995, MOL CELL BIOCHEM, V149, P175, DOI 10.1007/BF01076575; SMITH BC, 1992, BIOCHEM J, V284, P819, DOI 10.1042/bj2840819; THOMAS AP, 1986, BIOCHEM J, V238, P83, DOI 10.1042/bj2380083; Wolf FI, 1996, ARCH BIOCHEM BIOPHYS, V331, P194, DOI 10.1006/abbi.1996.0298; WOLF FI, 1994, BIOCHEM BIOPH RES CO, V202, P1209, DOI 10.1006/bbrc.1994.2059; ZANOTTI A, 1980, ARCH BIOCHEM BIOPHYS, V201, P255, DOI 10.1016/0003-9861(80)90510-X; ZHANG GH, 1994, J BIOL CHEM, V269, P10352; ZHANG GH, 1992, J BIOL CHEM, V267, P20721	35	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7850	7855		10.1074/jbc.273.14.7850	http://dx.doi.org/10.1074/jbc.273.14.7850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525878	hybrid			2022-12-27	WOS:000072876300012
J	Trujillo, M; Alvarez, MN; Peluffo, G; Freeman, BA; Radi, R				Trujillo, M; Alvarez, MN; Peluffo, G; Freeman, BA; Radi, R			Xanthine oxidase-mediated decomposition of S-nitrosothiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; HUMAN NEUTROPHILS; SERUM-ALBUMIN; SUPEROXIDE; PEROXYNITRITE; GLUTATHIONE; KINETICS; MECHANISM; NITROSOGLUTATHIONE; INACTIVATION	S-Nitrosothiols (RSNO) occur in vivo and have been proposed as nitric oxide ((NO)-N-.) storage and transport biomolecules. Still, the biochemical mechanisms by which RSNO release (NO)-N-. in biological systems are not well defined, and in particular, the interactions between reactive oxygen species and RSNO have not been studied. In this work, we show that xanthine oxidase (XO), in the presence of purine (hypoxanthine, xanthine) or pteridine (lumazine) substrates, induces S-nitrosocysteine (CysNO) and S-nitrosoglutathione (GSNO) decomposition under aerobic conditions. The decomposition of RSNO by XO was inhibitable by copper-zinc superoxide dismutase, in agreement with the participation of superoxide anion (O-2 radical anion) in the process. However, while superoxide dismutase could totally inhibit aerobic decomposition of GSNO, it was only partially inhibitory for CysNO. Competition experiments indicated that O-2 radical anion reacted with GSNO with a rate constant of 1 x 10(4) M-1.S-1 at pH 7.4 and 25 degrees C. the decomposition of RSNO was accompanied by peroxynitrite formation as assessed by the oxidation of dihydrorhodamine and of cytochrome c(2+). The proposed mechanism involves the O-2 radical anion-dependent reduction of RSNO to yield (NO)-N-., which in turn reacts fast with a second O-2 radical anion molecule to yield peroxynitrite. Under anaerobic conditions, CysNO incubated with xanthine plus XO resulted in CysNO decomposition, (NO)-N-. detection, and cysteine and uric acid formation. We found that CysNO is an electron acceptor substrate for XO with a K-m of 0.7 mM. In agreement with this concept, the enzymatic reduction of CysNO by XO was inhibitable by oxypurinol and diphenyliodonium, inhibitors that interfere with the catalytic cycle at the molybdenum and flavin sites, respectively. In conclusion, XO decomposed RSNO by O-2 radical anion-dependent and -independent pathways, and in the presence of oxygen it leads to peroxynitrite formation.	Univ Republ, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA	Universidad de la Republica, Uruguay; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Radi, R (corresponding author), Univ Republ, Fac Med, Dept Bioquim, Ave Gen Flores 2125, Montevideo 11800, Uruguay.	rradi@fmed.edu.uy	Freeman, Bruce A/H-9342-2012	Trujillo, Madia/0000-0003-2087-017X	FIC NIH HHS [TW00489] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BARNETT DJ, 1994, J CHEM SOC PERK T 2, P1131, DOI 10.1039/p29940001131; BAZYLINSKI DA, 1985, INORG CHEM, V24, P4285, DOI 10.1021/ic00219a017; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; CANDEIAS LP, 1997, P 1 INT C PER ASC SW, P11; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASELLI A, 1994, J BIOL CHEM, V269, P24878; Castro L, 1996, ARCH BIOCHEM BIOPHYS, V333, P179, DOI 10.1006/abbi.1996.0379; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; DIXON M, 1979, ENZYMES, P62; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GUTFREUND H, 1959, BIOCHEM J, V73, P1; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KashibaIwatsuki M, 1996, FEBS LETT, V389, P149, DOI 10.1016/0014-5793(96)00560-1; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KOPPENOL WH, 1976, BIOCHIM BIOPHYS ACTA, V449, P157, DOI 10.1016/0005-2728(76)90130-4; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MCADAMS M, 1998, IN PRESS ARCH BIOCH; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; Miyamoto Y, 1996, P SOC EXP BIOL MED, V211, P366; Mohr S, 1996, J BIOL CHEM, V271, P4209; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NAGANO T, 1985, Journal of Free Radicals in Biology and Medicine, V1, P39, DOI 10.1016/0748-5514(85)90027-3; RADI R, 1991, J BIOL CHEM, V266, P4244; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; RUBHO H, 1994, J BIOL CHEM, V269, P26066; SEXTON DJ, 1994, PHOTOCHEM PHOTOBIOL, V59, P463, DOI 10.1111/j.1751-1097.1994.tb05065.x; SINGH RJ, 1995, FEBS LETT, V360, P47, DOI 10.1016/0014-5793(95)00065-H; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; WHITE CR, 1996, P NATL ACAD SCI USA, V93, P8749; WINK DA, 1996, METHODS NITRIC OXIDE, P408; WINTERBOURN CC, 1987, FREE RADICAL BIO MED, V3, P33, DOI 10.1016/0891-5849(87)90037-2; WOOD PM, 1974, FEBS LETT, V44, P21; [No title captured]	60	162	175	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7828	7834		10.1074/jbc.273.14.7828	http://dx.doi.org/10.1074/jbc.273.14.7828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525875	hybrid			2022-12-27	WOS:000072876300009
J	Yang, YL; Ramaswamy, SG; Jakoby, WB				Yang, YL; Ramaswamy, SG; Jakoby, WB			Enzymatic hydrolysis of organic cyclic carbonates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLISM	Ethylene carbonate, a cyclic organic carbonate widely used industrially, is toxic when metabolically converted to ethylene glyco. A rat liver enzyme active in catalyzing the ring opening has been purified to electrophoretic homogeneity and found to be active in the hydrolysis of ethylene, vinylene, and propylene carbonates to CO2 and the respective glycols. Neither thiocarbonates nor open chain carbonates served as substrate nor did a variety of esters, lactams, lactones, and related heterocycles. The enzyme was active, however, with imides and appears to be identical to rat liver imidase. The identification was confirmed by copurification of enzyme activities, by similarities in the pattern of inhibition, and by the reactivity with a polyclonal antibody directed against the enzyme purified here.	NIDDK, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Jakoby, WB (corresponding author), NIDDK, Biochem & Metab Lab, NIH, Bldg 10,9N119, Bethesda, MD 20892 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; Dafre AL, 1996, ARCH BIOCHEM BIOPHYS, V332, P288, DOI 10.1006/abbi.1996.0344; Darawshe S, 1997, BIOPHYS CHEM, V69, P53, DOI 10.1016/S0301-4622(97)00078-1; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GABRIEL O, 1992, GLYCOBIOLOGY, V2, P437, DOI 10.1093/glycob/2.5.437; GRIFFITH OW, 1986, ANNU REV BIOCHEM, V55, P855, DOI 10.1146/annurev.biochem.55.1.855; HANLEY TR, 1989, TOXICOL APPL PHARM, V100, P24, DOI 10.1016/0041-008X(89)90088-4; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KIM D-H, 1990, Protein Expression and Purification, V1, P19, DOI 10.1016/1046-5928(90)90040-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACFADYEN DA, 1945, J BIOL CHEM, V158, P107; Marshall AD, 1997, J BIOL CHEM, V272, P9153; Matsumoto K, 1996, B CHEM SOC JPN, V69, P2977, DOI 10.1246/bcsj.69.2977; SAMUNI A, 1991, FREE RADICAL BIO MED, V10, P305, DOI 10.1016/0891-5849(91)90037-4; YANG YS, 1993, J BIOL CHEM, V268, P10870	17	25	27	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7814	7817		10.1074/jbc.273.14.7814	http://dx.doi.org/10.1074/jbc.273.14.7814			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525873	hybrid			2022-12-27	WOS:000072876300007
J	Lecine, P; Blank, V; Shivdasani, R				Lecine, P; Blank, V; Shivdasani, R			Characterization of the hematopoietic transcription factor NF-E2 in primary murine megakaryocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; GLOBIN GENE-EXPRESSION; LOCUS-CONTROL REGION; SMALL MAF PROTEINS; CDNA CLONING; MICE LACKING; MPL LIGAND; C-MPL; BINDING; FAMILY	Biochemical analysis of megakaryocytes, the precursors of blood platelets, is limited by their rarity in vivo, and studies on lineage-specific gene expression have been conducted exclusively in cell lines with limited megakaryocytic potential. Mice lacking the transcription factor NF-E2 display arrested megakaryocyte differentiation and profound thrombocytopenia. To study the heterodimeric NF-E2 protein in primary cells, we cultured mouse fetal livers with the c-Mpl ligand, obtained highly enriched megakaryocyte populations, and readily detected NF-E2 activity in nuclear extracts. As in erythroid cells, p45 NF-E2 is the only large subunit in primary megakaryocytes that dimerizes with distinct small Maf proteins to constitute a heterogeneous NF-E2 complex. Whereas p18/MafK is the predominant small Maf protein in erythroid cells, the related polypeptides MafG and/or MafF predominate in megakaryocytes. Although this represents the first example of differential small Maf protein expression among closely related blood lineages, the DNA-binding specificity of NF-E2 is similar in both cell types. Although the megakaryocyte protein preferentially binds an asymmetric AP-1-related motif, it also recognizes cAMP-responsive element related sequences, albeit with lower affinity, and nucleotides outside the core sequence influence the DNA-protein interaction. These results demonstrate the feasibility of biochemical studies on primary murine megakaryocytes and provide a basis to dissect the critical functions of NF-E2 in megakaryocyte differentiation.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Shivdasani, R (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	ramesh_shivdasani@dfci.harvard.edu	Lecine, Patrick/H-9338-2016	Lecine, Patrick/0000-0002-8091-7286	NHLBI NIH HHS [HL03290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL003290, R37HL003290] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BLOCK KL, 1994, BLOOD, V84, P3385; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; CHOI ES, 1995, BLOOD, V85, P402; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kotkow KJ, 1996, P NATL ACAD SCI USA, V93, P3514, DOI 10.1073/pnas.93.8.3514; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SIVDASANI RA, 1997, EMBO J, V16, P3965; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Villeval JL, 1997, BLOOD, V90, P4369	40	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7572	7578		10.1074/jbc.273.13.7572	http://dx.doi.org/10.1074/jbc.273.13.7572			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516460	hybrid			2022-12-27	WOS:000072738500056
J	Martin, J				Martin, J			Role of the GroEL chaperonin intermediate domain in coupling ATP hydrolysis to polypeptide release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CAVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; BINDING; MECHANISM; CYCLE; COOPERATIVITY; SUBSTRATE	Modification of the Escherichia coli chaperonin GroEL with N-ethylmaleimide at residue Cys(138) affects the structural and functional integrity of the complex. Nucleotide affinity and ATPase activity of the modified chaperonin are increased, whereas cooperativity of ATP hydrolysis and affinity for GroES are reduced. As a consequence, release and folding of substrate proteins are strongly impaired and uncoupled from ATP hydrolysis in a temperature-dependent manner. Folding of dihydrofolate reductase at 25 degrees C becomes dependent on GroES, whereas folding of typically GroES-dependent proteins is blocked completely. At 37 degrees C, GroES binding is restored to normal levels, and the modified GroEL regains its chaperone activity to some extent. These results assign a central role to the intermediate GroEL domain for transmitting conformational changes between apical and central domains, and for coupling ATP hydrolysis to productive protein release.	Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	Brown University	Martin, J (corresponding author), Brown Univ, Dept Biochem Mol Biol & Cell Biol, Box G-J2, Providence, RI 02912 USA.	Jorg_Martin@Brown.edu			NIGMS NIH HHS [GM54534] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054534] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P44; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Churchich JE, 1997, J BIOL CHEM, V272, P19645, DOI 10.1074/jbc.272.32.19645; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Gross M, 1996, PROTEIN SCI, V5, P2506, DOI 10.1002/pro.5560051213; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LUO GX, 1994, J BIOL CHEM, V269, P32151; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MARTIN J, 1994, BIOL CHEM H-S, V375, P635; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Sambrook J., 1989, MOL CLONING MANUAL; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642	35	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7351	7357		10.1074/jbc.273.13.7351	http://dx.doi.org/10.1074/jbc.273.13.7351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516431	hybrid			2022-12-27	WOS:000072738500027
J	Perez, DG; Gomez, C; Lopez-Bayghen, E; Tannich, E; Orozco, E				Perez, DG; Gomez, C; Lopez-Bayghen, E; Tannich, E; Orozco, E			Transcriptional analysis of the EhPgpS5 promoter of Entamoeba histolytica multidrug-resistant mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC ENHANCER; P-GLYCOPROTEIN HOMOLOGS; REGULATORY ELEMENTS; BINDING-SITES; GENE PROMOTER; CELL-LINES; MDR1 GENE; EXPRESSION; DNA; SEQUENCES	We report here the cloning and transcriptional characterization of the EhPgp5 multidrug resistance gene promoter isolated from the drug-resistant clone C2 of Entamoeba histolytica. The EhPgp5 promoter has the TATA-like motif at -31 base pairs; transcription initiates three nucleotides upstream from the ATG in trophozoites grown in 225 mu M emetine (clone C2(225)), whereas in those grown without the drug (clone C2) a product with no open reading frame was detected, The promoter was active in transfected clone C2 trophozoites, its activity increased when trophozoites were cultured in 40 mu M emetine, while it was turned off in the drug-sensitive clone A. The first -235 base pair kept full promoter activity, suggesting that it has important drug responsive elements. Gel shift assays detected the complex Ib in clone C2, which was augmented in clone C2(225). Competition experiments suggested that complex Ib may be constituted by HOX and AP-1 like factors in clone C2, whereas in clone C2(225), complex Ib was only competed by the HOX sequence. Complexes Ie, detected in clones A and C2 but not in C2(225), and Ia, present in all clones, were competed by the TATA box oligonucleotide. Our results suggest that proteins forming complexes Ib and Ie may be participating in the regulation of the EhPgp5 gene expression.	Inst Politecn Nacl, CINVESTAV, Ctr Invest & Estudios Avanzados, Dept Patol Expt, Mexico City 07300, DF, Mexico; Inst Politecn Nacl, CINVESTAV, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Mexico City 07300, DF, Mexico; Ctr Invest Ciencia Aplicada & Tecnol Avanzada, Mexico City, DF, Mexico; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Bernhard Nocht Institut fur Tropenmedizin	Orozco, E (corresponding author), Inst Politecn Nacl, CINVESTAV, Ctr Invest & Estudios Avanzados, Dept Patol Expt, AP 14-740, Mexico City 07300, DF, Mexico.	eorozco@gwpat.pat.cinvestav.mx	Lopez-Bayghen, Esther/A-8006-2008	Lopez-Bayghen, Esther/0000-0002-2849-7587				AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AYALA P, 1990, EXP PARASITOL, V71, P169, DOI 10.1016/0014-4894(90)90019-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P923; BUSS H, 1995, MOL BIOCHEM PARASIT, V72, P1, DOI 10.1016/0166-6851(95)00060-E; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; COWMAN AF, 1991, PARASITOL TODAY, V7, P70, DOI 10.1016/0169-4758(91)90197-V; DESCOTEAUX S, 1995, GENE, V164, P179, DOI 10.1016/0378-1119(95)00533-C; DESCOTEAUX S, 1992, MOL BIOCHEM PARASIT, V54, P200; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; Gomez C, 1998, J BIOL CHEM, V273, P7277, DOI 10.1074/jbc.273.13.7277; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; Hernandez R, 1997, Arch Med Res, V28 Spec No, P43; Higgins CF, 1993, CURR OPIN CELL BIOL, V5, P684, DOI 10.1016/0955-0674(93)90140-L; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; KOHNO K, 1990, J BIOL CHEM, V265, P19690; LAVELLE D, 1991, P NATL ACAD SCI USA, V88, P7318, DOI 10.1073/pnas.88.16.7318; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; Maniatis T., 1982, MOL CLONING; NICKEL R, 1994, P NATL ACAD SCI USA, V91, P7095, DOI 10.1073/pnas.91.15.7095; OROZCO E, 1985, MOL BIOCHEM PARASIT, V15, P49, DOI 10.1016/0166-6851(85)90028-3; OROZCO E, 1995, PARASITOL TODAY, V11, P473, DOI 10.1016/0169-4758(95)80067-0; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POOLE SJ, 1984, J MOL BIOL, V172, P203, DOI 10.1016/S0022-2836(84)80038-8; Purdy JE, 1996, MOL BIOCHEM PARASIT, V78, P91, DOI 10.1016/S0166-6851(96)02614-X; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P459; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; YU LJ, 1993, J BIOL CHEM, V268, P7520	44	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7285	7292		10.1074/jbc.273.13.7285	http://dx.doi.org/10.1074/jbc.273.13.7285			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516422	hybrid			2022-12-27	WOS:000072738500018
J	Sahni, A; Odrljin, T; Francis, CW				Sahni, A; Odrljin, T; Francis, CW			Binding of basic fibroblast growth factor to fibrinogen and fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; AFFINITY RECEPTORS; GAMMA-CHAIN; FGF FAMILY; EXPRESSION; HEPARIN; PROTEIN; RELEASE; SITES	Fibrin is formed at sites of tissue injury and provides the temporary matrix needed to support the initial endothelial cell responses needed for vessel repair. Basic fibroblast growth factor (bFGF) also acts at sites of injury and stimulates similar vascular cell responses, We have, therefore, investigated whether there are specific interactions between bFGF and fibrinogen and fibrin that could play a role in coordinating these actions, Binding studies were performed using bFGF immobilized on Sepharose beads and soluble I-125-labeled fibrinogen and also using Sepharose-immobilized fibrinogen and soluble I-125-bFGF. Both systems demonstrated specific and saturable binding, Scatchard analysis indicated two classes of binding sites for each with K-d values of 1.3 and 260 nM using immobilized bFGF; and K-d values of 0.9 and 70 nM using immobilized fibrinogen, After conversion of Sepharose-immobilized fibrinogen to fibrin by treatment with thrombin, bFGF also demonstrated specific and saturable binding with two classes of binding sites having K-d values of 0.13 and 83 nM, Fibrin binding was also investigated by clotting a solution of bFGF and fibrinogen, and two classes of binding sites were demonstrated using this system with K-d values of 0.8 and 261 nM. The maximum molar binding ratios of bFGF to fibrinogen were between 2.0 and 4.0 with the four binding systems, We conclude that bFGF binds specifically and saturably to fibrinogen and fibrin with high affinity, and this may have implications regarding the localization of its effect at sites of tissue injury.	Univ Rochester, Sch Med & Dent, Dept Med, Vasc Med Unit, Rochester, NY 14642 USA	University of Rochester	Francis, CW (corresponding author), Univ Rochester, Med Ctr, Vasc Med Unit, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.				NHLBI NIH HHS [HL-30616, HL-07152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BHASKIN P, 1989, BIOCHEMISTRY-US, V28, P1737; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BINI A, 1994, THROMB RES, V75, P337, DOI 10.1016/0049-3848(94)90247-X; BINI A, 1995, ANN NY ACAD SCI, V748, P461; Brown KJ, 1996, LAB INVEST, V75, P539; BUNCE LA, 1992, J CLIN INVEST, V89, P842, DOI 10.1172/JCI115663; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; DEBLOIS C, 1994, BIOMATERIALS, V15, P665, DOI 10.1016/0142-9612(94)90164-3; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRANCIS CW, 1980, J BIOL CHEM, V255, P5599; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HANNA LS, 1984, BIOCHEMISTRY-US, V23, P4681, DOI 10.1021/bi00315a025; HANNEKEN A, 1994, P NATL ACAD SCI USA, V91, P9170, DOI 10.1073/pnas.91.19.9170; HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214; JINHO K, 1997, J GASTROENTEROL, V32, P119; KAPLAN KL, 1989, ARTERIOSCLEROSIS, V9, P43, DOI 10.1161/01.ATV.9.1.43; Klein S, 1997, EXS, V79, P159; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; Medalion B, 1997, CIRCULATION, V95, P1853; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MOHRI H, 1994, THROMB THROMBOLYSIS, V1, P49; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; ORDLJIN TM, 1996, BIOCHIM BIOPHYS ACTA, V1298, P69; ORDLJIN TM, 1996, BLOOD, V88, P2050; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RIBES JA, 1987, J CLIN INVEST, V79, P117, DOI 10.1172/JCI112771; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHEKHONIN BV, 1990, ATHEROSCLEROSIS, V82, P213, DOI 10.1016/0021-9150(90)90043-I; SPORN LA, 1995, BLOOD, V86, P1802, DOI 10.1182/blood.V86.5.1802.bloodjournal8651802; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Thompson RW, 1990, GROWTH FACTORS, V3, P221, DOI 10.3109/08977199009043906; VILLASCHI S, 1993, AM J PATHOL, V143, P181; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069	51	190	205	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7554	7559		10.1074/jbc.273.13.7554	http://dx.doi.org/10.1074/jbc.273.13.7554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516457	hybrid			2022-12-27	WOS:000072738500053
J	Gory, S; Dalmon, J; Prandini, MH; Kortulewski, T; de Launoit, Y; Huber, P				Gory, S; Dalmon, J; Prandini, MH; Kortulewski, T; de Launoit, Y; Huber, P			Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; MOLECULAR-CLONING; CELL-ADHESION; EXPRESSION; PROMOTER; PROTEINS; FAMILY; ALPHA; IDENTIFICATION; ACTIVATION	Vascular endothelial cadherin (VE cadherin) gene encodes a Ca2+-dependent cell adhesion molecule required for the organization of interendothelial junctions. This gene is exclusively and constitutively expressed in endothelial cells. Previous data with transgenic mice revealed that the transcriptional regulatory elements present within a -2486/+24 DNA fragment of mouse VE cadherin gene mimic the tissue-specific activity of the endogenous promoter. In this study, we analyzed elements implicated in the function of the proximal regulatory region. Electrophoretic mobility shift assay identified a GT-rich sequence (positions -49/-39) interacting with factors related to the Spl family. Point mutations abolished the binding of nuclear proteins in vitro and drastically diminished the activity of the promoter in transient transfection assay. Supershift assays with antibodies against proteins of the Spl family revealed that Spl and Sp3 interact with this region of the VE cadherin promoter. Furthermore, two GC;AA motifs, located at positions -93/-90 and -109/-106, were shown to interact with nuclear factors. Site-directed mutagenesis of these sequences demonstrated that these Ets binding sites are essential for promoter activity. In vitro binding assays in the presence of various antisera suggest that Erg is one of the proteins interacting with the -109/-106 site.	CEA, DBMS, TDC, Lab Transgenese & Differenciat Cellulaire, F-38054 Grenoble, France; Inst Pasteur Lille, UMR 319 CNRS, Inst Biol Lille, F-59021 Lille, France	CEA; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Huber, P (corresponding author), CEA, DBMS, TDC, Lab Transgenese & Differenciat Cellulaire, 17 Rue Martyrs, F-38054 Grenoble, France.	huber@carre.ceng.cea.fr	Huber, Philippe/C-7971-2019	Huber, Philippe/0000-0002-4153-7694; Gory, Sylvie/0000-0001-5743-8079				BALCONI G, 1986, MED BIOL, V64, P231; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Huber P, 1996, GENOMICS, V32, P21, DOI 10.1006/geno.1996.0072; HUBER P, 1990, J BIOL CHEM, V265, P5695; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Sambrook J., 2002, MOL CLONING LAB MANU; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WIGLER M, 1977, CELL, V11, P233; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	41	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6750	6755		10.1074/jbc.273.12.6750	http://dx.doi.org/10.1074/jbc.273.12.6750			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506975	hybrid			2022-12-27	WOS:000072775900025
J	Kitagawa, H; Tone, Y; Tamura, J; Neumann, KW; Ogawa, T; Oka, S; Kawasaki, T; Sugahara, K				Kitagawa, H; Tone, Y; Tamura, J; Neumann, KW; Ogawa, T; Oka, S; Kawasaki, T; Sugahara, K			Molecular cloning and expression of glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCURONOSYLTRANSFERASE	We isolated a cDNA encoding a novel glucuronyltransferase from human placenta cDNA with the use of the degenerate reverse transcriptase-polymerase chain reaction method, Degenerate primers were designed based upon the amino acid sequence alignment of rat glucuronyltransferase (GlcAT-P) involved in the biosynthesis of the carbohydrate epitope HNK-1 with putative proteins in Caenorhabditis elegans and Schistosoma mansoni, The new cDNA sequence revealed an open reading frame coding for a protein of 335 amino acids with a type II transmembrane protein topology. The amino acid sequence displayed 43% identity to the rat GlcAT-P, and the highest sequence identity was found in the COOH-terminal catalytic domain, The expression of a soluble recombinant form of the protein in COS-l cells produced an active glucuronyltransferase with marked specificity for a glycoserine Gal beta 1-3Gal beta 1-4Xy1 beta 1-O-Ser. In contrast, asialoorosomucoid, which contains the Gal beta 1-4GlcNAc sequence and is a good acceptor substrate for the GlcAT-P, did not serve as an acceptor. The reaction product was sensitive to beta-glucuronidase digestion and co-chromatographed with authentic GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser in high-performance liquid chromatography, suggesting that the enzyme is a beta 1,3-glucuronyltransferase. These results indicate that this new member of the glucuronyltransferase gene family is the enzyme previously described as glucuronyltransferase I that forms the glycosaminoglycan-protein linkage region, GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser, of proteoglycans.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 35101, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 113, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sakyo Ku, Kyoto 60601, Japan	Kobe Pharmaceutical University; RIKEN; University of Tokyo; Kyoto University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 658, Japan.		Ogawa, Tomoya/C-3655-2009; Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				BRANDT AE, 1969, P NATL ACAD SCI USA, V64, P374, DOI 10.1073/pnas.64.1.374; CHANG JY, 1981, BIOCHEM J, V199, P547, DOI 10.1042/bj1990547; CURENTON T, 1991, BIOCHEM BIOPH RES CO, V179, P416, DOI 10.1016/0006-291X(91)91386-Q; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HELTING T, 1969, J BIOL CHEM, V244, P2799; HELTING T, 1972, J BIOL CHEM, V247, P4327; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1996, J BIOL CHEM, V271, P6583, DOI 10.1074/jbc.271.12.6583; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; OKA S, 1992, J BIOL CHEM, V267, P22711; POOLE AR, 1986, BIOCHEM J, V236, P1; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugumaran G, 1997, J BIOL CHEM, V272, P14399, DOI 10.1074/jbc.272.22.14399; Tamura J, 1996, LIEBIGS ANN, P1239; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093	20	148	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6615	6618		10.1074/jbc.273.12.6615	http://dx.doi.org/10.1074/jbc.273.12.6615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506957	hybrid			2022-12-27	WOS:000072775900007
J	Numata, M; Petrecca, K; Lake, N; Orlowski, J				Numata, M; Petrecca, K; Lake, N; Orlowski, J			Identification of a mitochondrial Na+/H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GREEN FLUORESCENT PROTEIN; CATION-TRANSPORT SYSTEMS; RAT NA/H EXCHANGER; HEART-MITOCHONDRIA; K+/H+ ANTIPORT; OXIDATIVE-PHOSPHORYLATION; FUNCTIONAL-PROPERTIES; H+ EXCHANGE; CALCIUM	The electroneutral exchange of protons for Na+ and K+ across the mitochondrial inner membrane contributes to organellar volume and Ca2+ homeostasis. The molecular nature of these transporters remains unknown. In this report, we characterize a novel gene (YDR456w; renamed NHA2) in Saccharomyces cerevisiae whose deduced protein sequence is homologous to members of the mammalian Na+/H+ exchanger gene family. Fluorescence microscopy showed that a Nha2-green fluorescent protein chimera colocalizes with 4',6-diamidino-2-phenylindole staining of mitochondrial DNA. To assess the function of Nha2, we deleted the NHA2 gene by homologous disruption and found that benzamil-inhibitable, acid-activated Na-22(+) uptake into mitochondria was abolished in the mutant strain. It also showed retarded growth on nonfermentable carbon sources and severely reduced survival during the stationary phase of the cell cycle compared with the parental strain, consistent with a defect in aerobic metabolism. Sequence comparisons revealed that Nha2 has highest identity to a putative Na+/K+ exchanger homologue (KIAA0267; renamed NHE6) in humans, Northern blot analysis demonstrated that NHE6 is ubiquitously expressed but is most abundant in mitochondrion-rich tissues such as brain, skeletal muscle, and heart. Fluorescence microscopy showed that a NHE6-green fluorescent protein chimera also accumulates in mitochondria of transfected HeLa cells. These data indicate that NHA2 and NHE6 encode homologous Na+/M+ exchangers and suggest they may be important for mitochondrial function in lower and higher eukaryotes, respectively.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	orlowski@physio.mcgill.ca		Orlowski, John/0000-0001-7371-175X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BEAVIS AD, 1990, J BIOL CHEM, V265, P2538; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIRNSTIEL ML, 1985, CELL, V41, P359; BRIERLEY GP, 1984, J BIOL CHEM, V259, P4672; BRIERLEY GP, 1994, J BIOENERG BIOMEMBR, V26, P519, DOI 10.1007/BF00762736; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4337; CARAFOLI E, 1970, BIOCHIM BIOPHYS ACTA, V205, P18, DOI 10.1016/0005-2728(70)90057-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; CROMPTON M, 1978, EUR J BIOCHEM, V91, P599, DOI 10.1111/j.1432-1033.1978.tb12713.x; DAMUNI Z, 1988, ARCH BIOCHEM BIOPHYS, V262, P574, DOI 10.1016/0003-9861(88)90408-0; DIRESTA DJ, 1986, AM J PHYSIOL, V251, pR787, DOI 10.1152/ajpregu.1986.251.4.R787; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; GARLID KD, 1991, J BIOL CHEM, V266, P6518; GARLID KD, 1978, BIOCHEM BIOPH RES CO, V83, P1450, DOI 10.1016/0006-291X(78)91383-9; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; JUNG DW, 1992, AM J PHYSIOL, V262, pC1047, DOI 10.1152/ajpcell.1992.262.4.C1047; KAPUS A, 1988, BIOCHIM BIOPHYS ACTA, V944, P383, DOI 10.1016/0005-2736(88)90509-3; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MANON S, 1992, BIOCHIM BIOPHYS ACTA, V1108, P169, DOI 10.1016/0005-2736(92)90022-E; MARTIN WH, 1984, J BIOL CHEM, V259, P2062; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MITCHELL P, 1969, EUR J BIOCHEM, V9, P149, DOI 10.1111/j.1432-1033.1969.tb00588.x; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P4028; MORENOSANCHEZ R, 1983, BIOCHIM BIOPHYS ACTA, V724, P278, DOI 10.1016/0005-2728(83)90146-9; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nath S., 1988, INTEGRATION MITOCHON, P357; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SASTRASINH M, 1995, AM J PHYSIOL-CELL PH, V268, pC1227, DOI 10.1152/ajpcell.1995.268.5.C1227; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHWOCH G, 1990, BIOCHEM J, V270, P181, DOI 10.1042/bj2700181; SHERO JH, 1991, METHOD ENZYMOL, V194, P749; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSE CM, 1994, BIOCHEMISTRY-US, V33, P12954, DOI 10.1021/bi00248a003; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WELIHINDA AA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P367, DOI 10.1016/0005-2728(93)90122-V; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YAMADA EW, 1989, BIOCHEMISTRY-US, V28, P9714, DOI 10.1021/bi00451a026; YU FH, 1993, J BIOL CHEM, V268, P25536; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHU WH, 1995, BBA-MOL CELL RES, V1269, P122, DOI 10.1016/0167-4889(95)00102-X	69	226	243	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6951	6959		10.1074/jbc.273.12.6951	http://dx.doi.org/10.1074/jbc.273.12.6951			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507001	hybrid			2022-12-27	WOS:000072775900051
J	Tang, BL; Tan, AEH; Lim, LK; Lee, SS; Low, DYH; Hong, WJ				Tang, BL; Tan, AEH; Lim, LK; Lee, SS; Low, DYH; Hong, WJ			Syntaxin 12, a member of the syntaxin family localized to the endosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; INTEGRAL MEMBRANE-PROTEIN; BREFELDIN-A; PHOSPHATIDYLINOSITOL 3-KINASE; ORGANELLE STRUCTURE; SECRETORY PATHWAY; FUSION; VESICLES; CELLS; TGN	We have cloned a new member of the syntaxin family of proteins, The open reading frame encodes a polypeptide of 272 amino acids with potential coiled-coil domains and a C-terminal hydrophobic tail, Northern blot analysis showed that the transcript is fairly ubiquitous, A soluble recombinant form of the polypeptide without the hydrophobic region binds to alpha-SNAP (soluble N ethylmaleimide-sensitive factor attachment protein) and syndet/SNAP-23 in vitro, Polyclonal antibody raised against the recombinant protein recognized a 39-kDa protein in the membrane fraction of cell lysates, Indirect immunofluorescence studies using the polyclonal antibody showed that the protein is localized to intracellular membrane structures, Selective permeabilization studies with digitonin and saponin indicate that the epitope(s) recognized by the antibody is expose to the cytoplasm, consistent with the predicted orientation characteristic of SNAP receptor molecules, Morphological alterations of the staining pattern of the protein with brefeldin A and wortmannin treatment indicate that the protein is localize to the endosome, The cDNA we have cloned apparently corresponded to three previously described expressed sequence tags named as syntaxins 12, 13, and 14, respectively, We therefore propose to retain the name syntaxin 12 for this protein.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Tang, BL (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbhwj@leonis.nus.sg	HONG, Wanjin/E-9927-2010; Tang, Bor Luen/E-4548-2012	Tang, Bor Luen/0000-0002-1925-636X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LINK E, 1993, J BIOL CHEM, V268, P18423; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Reaves BJ, 1996, J CELL SCI, V109, P749; Robinson LJ, 1997, J CELL SCI, V110, P2079; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SWAROOP A, 1994, HUM MOL GENET, V3, P1281, DOI 10.1093/hmg/3.8.1281; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; TANG BL, 1995, EUR J CELL BIOL, V68, P199; Wang GY, 1997, J CELL SCI, V110, P505; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1995, CELL, V83, P703; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273	35	68	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6944	6950		10.1074/jbc.273.12.6944	http://dx.doi.org/10.1074/jbc.273.12.6944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507000	hybrid			2022-12-27	WOS:000072775900050
J	Chinenov, Y; Schmidt, T; Yang, XY; Martin, ME				Chinenov, Y; Schmidt, T; Yang, XY; Martin, ME			Identification of redox-sensitive cysteines in GA binding protein-alpha that regulate DNA binding and heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RESPIRATORY FACTORS; ETS ONCOGENE FAMILY; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; E4TF1 SUBUNITS; DOMAIN; GENE; ACTIVATION; COMPLEX	The transcription factor GA-binding protein (GABP) is composed of two subunits, GABP alpha and GABP beta. The DNA-binding subunit, GABP alpha, is a member of the Ets family of transcription factors, characterized by the conserved Ets-domain that mediates DNA binding and associates with GABP beta, which lacks a discernible DNA binding domain, through ankyrin repeats in the NH, terminus of GABP beta. We previously demonstrated that GABP is subject to redox regulation in vitro and in vivo through four COOH-terminal cysteines in GABP alpha. To determine the roles of individual cysteines in GABP redox regulation, we generated a series of serine substitution mutants by site-directed mutagenesis and identified three redox-sensitive cysteine residues in GABP alpha (Cys(388), Cys(401), and Cys(421)). Sulfhydryl modification of Cys(388) and Cys(401) inhibits DNA binding by GABP alpha whereas, modification of Cys(421) has no effect on GABP alpha DNA binding but inhibits dimerization with GABP beta. The positions of Cys(388) and Cys(401) within the known Ets-domain structure suggest two very different mechanisms for redox regulation of DNA binding. Sulfhydryl modification of Cys(388) could directly interfere with DNA binding or might alter the positioning of the DNA-binding helix 3. Modification of Cys(401) may inhibit DNA binding through stabilization of an inhibitory helix similar to that described in the Ets-1 protein. Thus, GABP is regulated through at least two redox-sensitive activities, DNA binding and heterodimerization.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Martin, ME (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65212 USA.							BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CLAKHOVEN F, 1996, BIOCHEM J, V317, P329; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HROMAS R, 1994, INT J HEMATOL, V59, P257; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Kornberg RD, 1996, TRENDS BIOCHEM SCI, V21, P325, DOI 10.1016/0968-0004(96)20021-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LAUDET V, 1992, BIOCHEM BIOPH RES CO, V190, P8; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MONTE D, 1994, ONCOGENE, V9, P1397; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REASON AJ, 1992, J BIOL CHEM, V267, P16911; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SEN CK, 1996, FASEB J, V10, P707; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHYAM E, 1990, CANCER RES, V50, P5013; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TORCHINSKII YM, 1974, SULFHYDRYL DISULFIDE, P23; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	49	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6203	6209		10.1074/jbc.273.11.6203	http://dx.doi.org/10.1074/jbc.273.11.6203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497343	hybrid			2022-12-27	WOS:000072488500035
J	Huang, HC; Wang, SC; Leu, YJ; Lu, SC; Liao, YD				Huang, HC; Wang, SC; Leu, YJ; Lu, SC; Liao, YD			The Rana catesbeiana rcr gene encoding a cytotoxic ribonuclease - Tissue distribution, cloning, purification, cytotoxicity, and active residues for RNase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; SEQUENCE-SPECIFIC RIBONUCLEASE; AMINO-ACID-SEQUENCE; PANCREATIC RIBONUCLEASE; XENOPUS-LAEVIS; SEMINAL RIBONUCLEASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; BULLFROG OOCYTES; YOLK GRANULES	Rana catesbeiana ribonuclease (RC-RNase) is a pyrimidine-guanine sequence-specific ribonuclease found in R. catesbeiana (bullfrog) oocytes. It possesses both ribonuclease activity and cytoxicity against tumor cells, We report here for the first time the cloning of RC-RNase cDNA from liver rather than from oocytes where RC-RNase is stored, An internal fragment of cDNA was obtained by reverse transcription-PCR using deduced oligonucleotides as primers. Full-length cDNA was obtained by 5'- and S'-RACE technique. The cDNA clone, named rcr gene, contained a 5'-untranslated region, a putative signal peptide (22 amino acids), a mature protein (111 amino acids), a 3'-untranslated region, and a polyadenylation site. The cDNA which encoded the mature protein was fused upstream with a modified pelB signal peptide DNA and inserted into pET11d for expression in Escherichia coli strain BL21(DE3). The secretory RC-RNase in the culture medium was enzymatically active and was purified to homogeneity. The recombinant RC-RNase had the same amino acid sequence, specific activity, substrate specificity, antigenicity, and cytotoxicity as that of native RC-RNase from frog oocytes. Amino acid residues His-10, Lys-35, and His-103 are involved in RC-RNase catalytic activity. Ribonucleolytic activity was involved in and may be essential for RC-RNase cytotoxicity. DNA sequence analysis showed that RC-RNase had approximately 45% identity to that of RNase superfamily genes. This indicates that RC-RNase is a distinct ribonuclease gene in the RNase superfamily.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei 10016, Taiwan; Natl Tsing Hua Univ, Inst Radiat Biol, Hsinchu 30043, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Tsing Hua University	Liao, YD (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.		Liao, You-Di/S-7018-2018	Liao, You-Di/0000-0001-5527-4736				ARDELT W, 1991, J BIOL CHEM, V266, P245; BARKER RL, 1989, J IMMUNOL, V143, P952; BARNARD EA, 1969, NATURE, V221, P340, DOI 10.1038/221340a0; Blackburn P, 1982, ENZYMES, VXV, P317; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; Chen CP, 1996, J BIOMOL NMR, V8, P331, DOI 10.1007/BF00410331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; KLENOVA EM, 1992, BIOCHEM BIOPH RES CO, V185, P231, DOI 10.1016/S0006-291X(05)80980-5; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5499; Larson KA, 1996, P NATL ACAD SCI USA, V93, P12370, DOI 10.1073/pnas.93.22.12370; LIAO YD, 1992, NUCLEIC ACIDS RES, V20, P1371, DOI 10.1093/nar/20.6.1371; Liao YD, 1996, PROTEIN EXPRES PURIF, V7, P194, DOI 10.1006/prep.1996.0027; LIAO YD, 1994, EUR J BIOCHEM, V222, P215, DOI 10.1111/j.1432-1033.1994.tb18859.x; LOW R, 1994, BIOTECHNIQUES, V17, P1026; MACDONALD RJ, 1982, J BIOL CHEM, V257, P4582; NEWTON DL, 1994, J NEUROSCI, V14, P538; NEWTON DL, 1997, PROTEIN ENG, V10, P462; NITTA K, 1987, CANCER RES, V47, P4877; Okabayashi K, 1996, BIOCHEM BIOPH RES CO, V224, P406, DOI 10.1006/bbrc.1996.1040; PREUSS KD, 1990, NUCLEIC ACIDS RES, V18, P1057, DOI 10.1093/nar/18.4.1057; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; SAKAKIBARA F, 1979, CANCER RES, V39, P1347; SASSO MP, 1991, NUCLEIC ACIDS RES, V19, P6469, DOI 10.1093/nar/19.23.6469; SCHULLER C, 1990, MOL BIOL EVOL, V7, P29; SENO M, 1994, BBA-GENE STRUCT EXPR, V1218, P466, DOI 10.1016/0167-4781(94)90208-9; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; STIFANI S, 1990, J BIOL CHEM, V265, P882; VESCIA S, 1980, CANCER RES, V40, P3740; WANG JJ, 1995, CELL TISSUE RES, V280, P259, DOI 10.1007/BF00307797; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	40	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6395	6401		10.1074/jbc.273.11.6395	http://dx.doi.org/10.1074/jbc.273.11.6395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497370	hybrid			2022-12-27	WOS:000072488500062
J	McQuibban, GA; Commisso-Cappelli, CN; Lewis, PN				McQuibban, GA; Commisso-Cappelli, CN; Lewis, PN			Assembly, remodeling, and histone binding capabilities of yeast nucleosome assembly protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DROSOPHILA EMBRYOS; CHROMATIN; DNA; INVITRO; CORE; OCTAMER; NUCLEI; ATP; NUCLEOPLASMIN	Recombinant yeast nucleosome assembly protein (yNAP-1) facilitates the formation of uniformly spaced nucleosomes from high molecular weight DNA and core histone octamers, No additional factors or metabolites are required, The repeat length of the chromatin produced is about 146 base pairs, To obtain the most distinct nucleosomal ladders, the core histones must preexist as an octamer complex, yNAP-1 forms complexes with core histones as judged by native gel electrophoresis, chemical cross-linking, limited histone proteolysis, and affinity blotting, A discrete complex was observed with a probable ratio of yNAP-1 to histone octamer of 4:1, Chromatin produced by salt dialysis does not contain uniformly spaced nucleosomes, but subsequent incubation with yNAP-1 creates uniform spacing, Trypsin treated core octamers that lack amino termini, although capable of forming core particles with core-length DNA by salt dialysis, are not assembled by yNAP-1 into uniformly spaced nucleosomes on high molecular weight DNA, Proteolytic removal of the amino termini of the core histones precludes complex fomation between a histone octamer and yNAP-1, Affinity blotting also demonstrates that yNAP-1 binds linker histones and high mobility group (HMG)-1/HMG-2 but not HMG-14. Competition experiments with poly-L-arginine, poly-L-lysine, and protamine reveal that yNAP-1 binds to core and linker histones more tightly despite the much higher positive charge densities of the former molecules, Naturally occurring acetylated histone H4 species show no evidence for differential yNAP-1 binding, yNAP-1 is not bound tightly to the resulting chromatin after deposition and thus could act catalytically.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Lewis, PN (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	peter.lewis@utoronto.ca						ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; BANERJEE S, 1991, NUCLEIC ACIDS RES, V19, P5999, DOI 10.1093/nar/19.21.5999; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; CHAN S, 1988, J BIOL CHEM, V263, P15643; CHANG L, 1995, BIOCHEMISTRY-US, V36, P469; CHUNG DG, 1986, BIOCHEMISTRY-US, V25, P5036, DOI 10.1021/bi00366a010; Dimitrov S, 1996, EMBO J, V15, P5897, DOI 10.1002/j.1460-2075.1996.tb00976.x; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; IOVCHEVA C, 1984, MOL BIOL REP, V10, P9, DOI 10.1007/BF00775147; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; Landsman D, 1996, TRENDS BIOCHEM SCI, V21, P287, DOI 10.1016/S0968-0004(96)30030-3; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; LEWIS PN, 1988, EUR J BIOCHEM, V172, P135, DOI 10.1111/j.1432-1033.1988.tb13865.x; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; NELSON T, 1979, P NATL ACAD SCI USA, V76, P5510, DOI 10.1073/pnas.76.11.5510; NELSON T, 1981, BIOCHEMISTRY-US, V20, P2594, DOI 10.1021/bi00512a035; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SOBOLEWSKI CHM, 1993, FEBS LETT, V318, P27, DOI 10.1016/0014-5793(93)81320-Y; SRIKANTHA T, 1988, J BIOL CHEM, V263, P13500; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STEIN A, 1977, P NATL ACAD SCI USA, V74, P2780, DOI 10.1073/pnas.74.7.2780; THOMAS JO, 1989, METHOD ENZYMOL, V170, P549; TREMETHICK DJ, 1993, J BIOL CHEM, V268, P11389; VANHOLDE KE, 1989, CHROMATIN, P241; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WOLFFE AP, 1995, CHROMATIN STRUCTURE, P100; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	48	57	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6582	6590		10.1074/jbc.273.11.6582	http://dx.doi.org/10.1074/jbc.273.11.6582			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497395	hybrid			2022-12-27	WOS:000072488500087
J	Larkin, RM; Guilfoyle, TJ				Larkin, RM; Guilfoyle, TJ			Two small subunits in Arabidopsis RNA polymerase II are related to yeast RPB4 and RPB7 and interact with one another	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 DISSOCIABLE SUBUNITS; STRESS SURVIVAL; EXPRESSION; PROTEINS; INVITRO; ENZYMES; PLANTS; GROWTH	An Arabidopsis cDNA (AtRPB15.9) that encoded a protein related to the RPB4 subunit in yeast RNA polymerase II was cloned. The predicted molecular mass of 15.9 kDa for the AtRPB15.9 protein was significantly smaller than 25 kDa for yeast RBP4. In SDS-PAGE, AtRPB15.9 migrated as the seventh or eighth largest subunit (i.e. apparent molecular mass of 14-15 kDa) in Arabidopsis RNA polymerase II, whereas RPB4 migrates as the fourth largest subunit (i.e. apparent molecular mass of 32 kDa) in yeast RNA polymerase II. Unlike yeast RPB4 and RPB7, which dissociate from RNA polymerase II under mildly denaturing conditions, plant subunits related to RPB4 and RPB7 are more stably associated with the enzyme. Recombinant AtRPB15.9 formed stable complexes with AtRPB19.5 (i.e. a subunit related to yeast RPB7) in vitro as did recombinant yeast RPB4 and RPB7 subunits. Stable heterodimers were also formed between AtRPB15.9 and yeast RPB7 and between yeast RPB4 and AtRPB19.5.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Guilfoyle, TJ (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.	bctguilf@muccmail.missouri.edu		, Robert/0000-0002-4665-3731				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; CHODER M, 1993, J BACTERIOL, V175, P6358, DOI 10.1128/JB.175.19.6358-6363.1993; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEZELEE S, 1976, EUR J BIOCHEM, V65, P543, DOI 10.1111/j.1432-1033.1976.tb10372.x; DOELLING JH, 1993, PLANT CELL REP, V12, P241, DOI 10.1007/BF00237127; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; GUILFOYLE TJ, 1978, BIOCHEMISTRY-US, V17, P1860, DOI 10.1021/bi00603a009; GUILFOYLE TJ, 1984, J BIOL CHEM, V259, P640; GUILFOYLE TJ, 1983, ENZYMES NUCLEIC ACID, V2, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; JENDRISAK J, 1978, BIOCHEMISTRY-US, V17, P1322, DOI 10.1021/bi00600a029; JENDRISAK JJ, 1977, BIOCHEMISTRY-US, V16, P1959, DOI 10.1021/bi00628a032; JENDRISAK JJ, 1975, BIOCHEMISTRY-US, V14, P4639, DOI 10.1021/bi00692a012; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larkin RM, 1997, J BIOL CHEM, V272, P12824, DOI 10.1074/jbc.272.19.12824; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; MCKUNE K, 1994, MOL CELL BIOL, V14, P4155, DOI 10.1128/MCB.14.6.4155; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; REGAD F, 1993, FEBS LETT, V316, P133, DOI 10.1016/0014-5793(93)81201-A; RUET A, 1980, J BIOL CHEM, V255, P6450; Sakurai H, 1996, GENE, V180, P63, DOI 10.1016/S0378-1119(96)00406-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P317; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; ULMASOV T, 1992, J BIOL CHEM, V267, P23165; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1994, TRANSCRIPTION MECH R, P227; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	37	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5631	5637		10.1074/jbc.273.10.5631	http://dx.doi.org/10.1074/jbc.273.10.5631			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488692	hybrid			2022-12-27	WOS:000072345000035
J	Tang, WL; Yang, L; Yang, YC; Leng, SX; Elias, JA				Tang, WL; Yang, L; Yang, YC; Leng, SX; Elias, JA			Transforming growth factor-beta stimulates interleukin-11 transcription via complex activating protein-1-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; DIFFERENTIAL REGULATION; HEMATOPOIETIC CYTOKINE; PHENOTYPIC SELECTION; OSTEOBLASTIC CELLS; GENE-EXPRESSION; IL-6 PRODUCTION; RETINOIC-ACID; MESSENGER-RNA; FACTOR AP-1	Studies were undertaken to characterize the mechanism by which transforming growth factor-beta(1) (TGF-beta(1)) stimulates epithelial cell interleukin (IL)-11 production, Nuclear run-on studies demonstrated that TGF-beta(1) is a potent stimulator of IL-11 gene transcription. TGF-beta(1) also stimulated the luciferase activity in cells transfected with reporter gene constructs containing nucleotides -728 to +58 of the IL-11 promoter. Studies with progressive 5' deletion constructs and site-specific mutations demonstrated that this stimulation was dependent on 2 AP-1 sites between nucleotides -100 and -82 in the IL-11 promoter. Mobility shift assays demonstrated that TGF-beta(1) stimulated AP-1 protein-DNA binding to both AP-1 sites. Supershift analysis demonstrated that JunD was the major moiety contributing to AP-1-DNA binding in unstimulated cells and that c-Jun-, Fra-1-, and Fra-2-DNA binding were increased whereas JunD-DNA binding was decreased in TGF-beta(1)-stimulated cells. The sequence in the IL-11 promoter that contains the AP-1 sites also conferred TGF-beta(1) responsiveness, in a position-independent fashion, on a heterologous minimal promoter. Thus, TGF-beta(1) stimulates IL-11 gene transcription via a complex AP-1-dependent pathway that is dependent on 2 AP-1 motifs between nucleotides -100 and -82 that function as am enhancer in the IL-11 promoter.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Med Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem Mol Biol, Indianapolis, IN 46202 USA	Yale University; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 333 Cedar St,105 LCI, New Haven, CT 06520 USA.	jack.elias@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054989, R01HL036708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034953] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36708, HL-54989] Funding Source: Medline; NIAID NIH HHS [AI-34953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Ding WQ, 1996, NEUROREPORT, V7, P2191, DOI 10.1097/00001756-199609020-00027; DU XX, 1994, BLOOD, V83, P33; DU XX, 1994, BLOOD, V83, P2023; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; ELIAS JA, 1991, J IMMUNOL, V146, P3437; ELIAS JA, 1994, J BIOL CHEM, V269, P22261; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; ELIAS JA, 1990, J IMMUNOL, V145, P161; ELIAS JA, 1994, J IMMUNOL, V152, P2421; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEITH JC, 1994, STEM CELLS, V12, P79; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBRUN CJ, 1995, NEUROSCIENCE, V65, P93, DOI 10.1016/0306-4522(94)00482-K; Leng SX, 1997, J IMMUNOL, V159, P2161; MAIER R, 1993, J BIOL CHEM, V268, P21527; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; POTTEN CS, 1995, INT J CANCER, V62, P356, DOI 10.1002/ijc.2910620321; QUESNIAUX VFJ, 1992, RES IMMUNOL, V143, P385, DOI 10.1016/S0923-2494(05)80071-9; QUESNIAUX VFJ, 1994, LEUKEMIA LYMPHOMA, V14, P241, DOI 10.3109/10428199409049674; QUESNIAUX VFJ, 1993, INT REV EXP PATHOL, V34, P205; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Redlich CA, 1996, J IMMUNOL, V157, P1705; Rochester CL, 1996, J IMMUNOL, V156, P4449; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TAKESHITA A, 1995, J IMMUNOL, V155, P419; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Wang HL, 1996, ONCOGENE, V13, P2639; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; YANG L, 1994, J BIOL CHEM, V269, P32732; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHENG T, 1994, J IMMUNOL, V153, P4742; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	48	60	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5506	5513		10.1074/jbc.273.10.5506	http://dx.doi.org/10.1074/jbc.273.10.5506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488674	hybrid			2022-12-27	WOS:000072345000017
J	Hautmann, MB; Madsen, CS; Mack, CP; Owens, GK				Hautmann, MB; Madsen, CS; Mack, CP; Owens, GK			Substitution of the degenerate smooth muscle (SM) alpha-actin CC(A/T-rich)(6)GG elements with c-fos serum response elements results in increased basal expression but relaxed SM cell specificity and reduced angiotensin II inducibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE ENHANCER; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSCRIPTION; PROMOTER ELEMENTS; TRANSGENIC MICE; HOMEODOMAIN PROTEINS; CARDIAC-MUSCLE; CHAIN GENE; GROWTH	We have previously demonstrated that both CC(A/T-rich)(6)GG (CArG) elements A and B of the smooth muscle (SM) alpha-actin promoter are required for smooth muscle cell (SMC)-specific expression and angiotensin If (AII)induced stimulation. Moreover, results provided evidence that AII responsiveness of SM alpha-actin was at least partially dependent on modulation of serum response factor (SRF) binding to the SIM alpha-actin CArGs by the homeodomain containing protein, MHox. The goal of the present study was to investigate whether the degeneracy of the SM alpha-actin CArGs (both contain a Gua or Cyt substitution in their A/T-rich center) and their reduced SRF binding activity as compared with c-fos serum response element (SRE) is important for conferring cell type-specific expression and AII responsiveness, Transient transfection assays using SM alpha-actin reporter gene constructs in which the endogenous SM alpha-actin CArGs were replaced by c-fos SREs demonstrated the following: 1) relaxation of cell-specific expression, 2) a 50% reduction in AII responsiveness, and 3) reduced ability to be transactivated by MHox, In addition, we also showed that the position of the SM alpha-actin CArGs was important in that interchanging them abolished both basal and AII-induced activities. Taken together these results suggest that the reduced SRF binding activities of the SM alpha-actin CArGs and CArG; positional context contribute to SMC-specific expression of SM alpha-actin as well as maximal AII responsiveness.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Bristol Myers Squibb, Cardiovasc Drug Discovery, Princeton, NJ 08543 USA	University of Virginia; Bristol-Myers Squibb	Owens, GK (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 449, Charlottesville, VA 22908 USA.	gko@virginia.edu			NHLBI NIH HHS [R01 HL 38854, P01 HL 19242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854, P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; Galvagni F, 1997, MOL CELL BIOL, V17, P1731, DOI 10.1128/MCB.17.3.1731; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hungerford JE, 1996, DEV BIOL, V178, P375, DOI 10.1006/dbio.1996.0225; JOHNSON AD, 1996, J VASC RES, V33, P43; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KIM JH, 1994, J BIOL CHEM, V269, P13740; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; Moessler H, 1996, DEVELOPMENT, V122, P2415; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MONICAL PL, 1993, AM J PHYSIOL, V264, pC1466, DOI 10.1152/ajpcell.1993.264.6.C1466; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; ZHU H, 1994, J BIOL CHEM, V269, P3489	68	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8398	8406		10.1074/jbc.273.14.8398	http://dx.doi.org/10.1074/jbc.273.14.8398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525950	hybrid			2022-12-27	WOS:000072876300084
J	Stoltz, C; Vachon, MH; Trottier, E; Dubois, S; Paquet, Y; Anderson, A				Stoltz, C; Vachon, MH; Trottier, E; Dubois, S; Paquet, Y; Anderson, A			The CYP2B2 phenobarbital response unit contains an accessory factor element and a putative glucocorticoid response element essential for conferring maximal phenobarbital responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; RAT-LIVER; INDUCIBLE CYTOCHROME-P-450; TRANSCRIPTIONAL REGULATION; 5'-FLANKING REGION; TRANSGENIC MICE; COUP-TF; INDUCTION; SEQUENCE; EXPRESSION	Hepatic cytochrome P450s play a critical role in the metabolism of hydrophobic xenobiotics. One of the major unsolved problems in xenobiotic metabolism is the molecular mechanism whereby phenobarbital induces hepatic enzymes, particularly CYP2B1 and CYP2B2 in rat liver, By using primary rat hepatocytes for transfection analyses, we previously identified in the CYP2B2 5'-flank a 163-base pair Sau3AI fragment that confers phenobarbital inducibility on a cat reporter gene and that has the properties of a transcriptional enhancer, Transfection experiments with sub-regions of the Sau3AI fragment now indicate that a central core together with an upstream or downstream accessory element within the fragment can confer phenobarbital responsiveness. One such accessory element, AF1, was identified and localized, DNase I footprinting analysis revealed the presence of a footprint overlapping this AF1 element. It also identified three other major protected regions, two of which are putative recognition sites for known transcription factors, Site-directed mutagenesis indicated that a putative glucocorticoid response element as well as a nuclear factor 1 site and an associated nuclear receptor hexamer half-site are essential for conferring maximal phenobarbital inducibility, Taken together, the results indicate that phenobarbital induction of CYP2B2 requires interactions among multiple regulatory proteins and cis-acting elements constituting a phenobarbital response unit.	Univ Laval, Ctr Rech Cancerol, Ctr Hosp Univ Quebec, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Dept Biol, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Anderson, A (corresponding author), Hotel Dieu, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.							ADESNIK M, 1981, J BIOL CHEM, V256, P340; ANDERSON A, 1997, FASEB J, V11, P777; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; CHRISTOU M, 1987, ARCH BIOCHEM BIOPHYS, V258, P519, DOI 10.1016/0003-9861(87)90374-2; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V1; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HE JS, 1991, J BIOL CHEM, V266, P7864; Hoffmann Marcel, 1992, Gene Expression, V2, P353; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JEAN A, 1988, DNA-J MOLEC CELL BIO, V7, P361, DOI 10.1089/dna.1.1988.7.361; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; LABBE D, 1988, DNA-J MOLEC CELL BIO, V7, P253, DOI 10.1089/dna.1988.7.253; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; Luc PV, 1996, BIOCHEM PHARMACOL, V51, P345, DOI 10.1016/0006-2952(95)02190-6; MIZUKAMI Y, 1983, P NATL ACAD SCI-BIOL, V80, P3958, DOI 10.1073/pnas.80.13.3958; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shaw PM, 1996, BBA-GENE STRUCT EXPR, V1305, P54, DOI 10.1016/0167-4781(95)00222-7; SINCLAIR PR, 1990, CANCER RES, V50, P5219; SUWA Y, 1985, J BIOL CHEM, V260, P7980; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; TROTTIER E, 1997, THESIS U LAVAL; TROTTIER E, 1996, 11 INT S MICR DRUG O; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; WILSON NM, 1987, ARCH BIOCHEM BIOPHYS, V256, P407, DOI 10.1016/0003-9861(87)90597-2; Woodward RN, 1997, MOL ENDOCRINOL, V11, P563, DOI 10.1210/me.11.5.563	49	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8528	8536		10.1074/jbc.273.14.8528	http://dx.doi.org/10.1074/jbc.273.14.8528			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525968	hybrid			2022-12-27	WOS:000072876300102
J	Tanaka, S; Nemoto, K; Yamamura, E; Ichikawa, A				Tanaka, S; Nemoto, K; Yamamura, E; Ichikawa, A			Intracellular localization of the 74- and 53-kDa forms of L-histidine decarboxylase in a rat basophilic mast cell line, RBL-2H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASTOCYTOMA P-815 CELLS; ENDOPLASMIC-RETICULUM; HISTAMINE SYNTHESIS; MOUSE STOMACH; PURIFICATION; EXPRESSION; HYPERGASTRINEMIA; PROLIFERATION; GROWTH; STRESS	To clarify the process of post-translational modification of L-histidine decarboxylase (HDC), we investigated the conversion of the 74-kDa form of HDC into the 53-kDa form in specialized organella of a rat basophilic/mast cell line (RBL-2H3). With treatment of streptolysin-O, RBL-2H3 cells released approximately 40% of HDC activity accompanied by over 90% of lactate dehydrogenase activity. Only the 74-kDa form of HDC was detected in the leaked fraction by SDS-polyacrylamide gel electrophoresis. The 74-kDa form in the homogenate of pulse-labeled cells was recovered in both the supernatant and particulate fractions, while the 53-kDa form was detected only in the particulate fraction containing marker proteins of microsomes, Golgi, and lysosomal granules, Confocal microscopic observation using double staining immunofluorescence with anti-GST fusion HDC antiserum showed that most of the HDC coexists with protein-disulfide isomerase, a typical marker of the luminal space of the ER. With treatment of distonin, RBL-2H3 cells released only 74-kDa HDC. Trypsin digestion of digitonin-permeabilized cells resulted in the disappearance of the 74-kDa form but not the 53-kDa form. From these results, it is assumed that the 74-kDa form of HDC, synthesized in the cytosol, is translocated into the lumen of the ER, where it is converted to the 53-kDa form.	Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan	Kyoto University	Ichikawa, A (corresponding author), Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan.		TANAKA, Satoshi/B-1624-2011; Tanaka, Satoshi/H-6800-2019	TANAKA, Satoshi/0000-0002-3468-7694; Tanaka, Satoshi/0000-0002-3468-7694				AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965; BARTHOLEYNS J, 1984, CANCER RES, V44, P639; BARTHOLEYNS J, 1985, TRENDS PHARMACOL SCI, V6, P123, DOI 10.1016/0165-6147(85)90055-0; BEAVEN MA, 1978, HISTAMINE ITS ROLE P; BRAUDRY M, 1973, AGENTS ACTIONS, V3, P175; CODE CF, 1965, FED PROC, V24, P1311; CORBEL S, 1995, BLOOD, V86, P531, DOI 10.1182/blood.V86.2.531.bloodjournal862531; CRICCO GP, 1994, AGENTS ACTIONS, V43, P17, DOI 10.1007/BF02005757; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; JOELSSON M, 1994, METHOD ENZYMOL, V228, P136; JOSEPH DR, 1990, P NATL ACAD SCI USA, V87, P733, DOI 10.1073/pnas.87.2.733; Kolby L, 1996, ENDOCRINOLOGY, V137, P4435, DOI 10.1210/en.137.10.4435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDFORD RE, 1987, VIRAL HEPATITIS LIVE, P372; Liao W, 1997, ENDOCRINOLOGY, V138, P1863, DOI 10.1210/en.138.5.1863; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; MARTIN SAM, 1986, BIOCHEM J, V234, P349, DOI 10.1042/bj2340349; MARTRES MP, 1975, BRAIN RES, V83, P261, DOI 10.1016/0006-8993(75)90935-X; Modlin IM, 1996, DIGESTION, V57, P310, DOI 10.1159/000201351; OHMORI E, 1990, J BIOCHEM, V107, P834, DOI 10.1093/oxfordjournals.jbchem.a123134; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; SAXENA SP, 1989, SCIENCE, V243, P1596, DOI 10.1126/science.2928797; SCHNEIDER E, 1990, J CELL PHYSIOL, V143, P337, DOI 10.1002/jcp.1041430218; SCHWARTZ JC, 1980, J NEUROCHEM, V35, P26, DOI 10.1111/j.1471-4159.1980.tb12485.x; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SNYDER SH, 1974, J NEUROCHEM, V23, P37, DOI 10.1111/j.1471-4159.1974.tb06913.x; TAGUCHI Y, 1984, J BIOL CHEM, V259, P5214; Tanaka S, 1997, FEBS LETT, V417, P203, DOI 10.1016/S0014-5793(97)01281-7; Tanaka S, 1995, METHOD FIND EXP CLIN, V17, P25; TANAKA S, 1995, BBA-PROTEIN STRUCT M, V1253, P9, DOI 10.1016/0167-4838(95)00185-W; TOLEDO A, 1988, J NEUROCHEM, V51, P1400, DOI 10.1111/j.1471-4159.1988.tb01104.x; TOLEDO A, 1991, J NEUROCHEM, V56, P380, DOI 10.1111/j.1471-4159.1991.tb08162.x; WATABE A, 1992, BIOCHEM PHARMACOL, V43, P587, DOI 10.1016/0006-2952(92)90582-4; YAMAMOTO J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P431, DOI 10.1016/0167-4781(93)90011-2; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891; Yatsunami K, 1995, J BIOL CHEM, V270, P30813, DOI 10.1074/jbc.270.51.30813	42	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8177	8182		10.1074/jbc.273.14.8177	http://dx.doi.org/10.1074/jbc.273.14.8177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525922	hybrid			2022-12-27	WOS:000072876300056
J	Yang, TT; Sinai, P; Green, G; Kitts, PA; Chen, YT; Lybarger, L; Chervenak, R; Patterson, GH; Piston, DW; Kain, SR				Yang, TT; Sinai, P; Green, G; Kitts, PA; Chen, YT; Lybarger, L; Chervenak, R; Patterson, GH; Piston, DW; Kain, SR			Improved fluorescence and dual color detection with enhanced blue and green variants of the green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODON USAGE; CELLS; EXPRESSION; MUTANTS; GFP; MUTATIONS; GENE	The green fluorescent protein (GFP) from the jellyfish Aequorea victor ia is a versatile reporter protein for monitoring gene expression and protein localization in a variety of systems, Applications using GFP reporters have expanded greatly due to the availability of mutants with altered spectral properties, including several blue emission variants, all of which contain the single point mutation Tyr-66 to His in the chromophore region of the protein. However, previously described "BFP" reporters have limited utility, primarily due to relatively dim fluorescence and low expression levels attained in higher eukaryotes with such variants. To improve upon these qualities, we have combined a blue emission mutant of GFP containing four point mutations (Phe-64 to Leu, Ser-65 to Thr, Tyr-66 to His, and Tyr-145 to Phe) with a synthetic gene sequence containing codons preferentially found in highly expressed human proteins. These mutations were chosen to optimize expression of properly folded fluorescent protein in mammalian cells cultured at 37 degrees C and to maximize signal intensity. The combination of improved fluorescence and higher expression levels yield an enhanced blue fluorescent protein that provides greater sensitivity and is suitable for dual color detection with green-emitting fluorophores.	Clontech Labs Inc, Cell Biol Grp, Palo Alto, CA 94303 USA; Stanford Univ, Dept Cellular & Mol Physiol, Sch Med, Stanford, CA 94305 USA; Louisiana State Univ, Med Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA	Stanford University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Vanderbilt University	Kain, SR (corresponding author), Clontech Labs Inc, Cell Biol Grp, 1020 E Meadow Circle, Palo Alto, CA 94303 USA.	srkain@clontech.com	Patterson, George/ABI-4751-2020					CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Levy JP, 1996, NAT BIOTECHNOL, V14, P610, DOI 10.1038/nbt0596-610; LINZHAO C, 1996, NAT BIOTECHNOL, V14, P606; Lybarger L, 1996, CYTOMETRY, V25, P211, DOI 10.1002/(SICI)1097-0320(19961101)25:3<211::AID-CYTO2>3.0.CO;2-I; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Muldoon RR, 1997, BIOTECHNIQUES, V22, P162, DOI 10.2144/97221rr03; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Yang TT, 1996, GENE, V173, P19, DOI 10.1016/0378-1119(95)00781-4; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592	25	115	128	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8212	8216		10.1074/jbc.273.14.8212	http://dx.doi.org/10.1074/jbc.273.14.8212			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525926	hybrid			2022-12-27	WOS:000072876300060
J	Kwon, H; Pelletier, N; DeLuca, C; Genin, P; Cisternas, S; Lin, BT; Wainberg, MA; Hiscott, J				Kwon, H; Pelletier, N; DeLuca, C; Genin, P; Cisternas, S; Lin, BT; Wainberg, MA; Hiscott, J			Inducible expression of I kappa B alpha repressor mutants interferes with NF-kappa B activity and HIV-1 replication in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SIGNAL-INDUCED PHOSPHORYLATION; B/REL TRANSCRIPTION FACTORS; TUMOR-NECROSIS-FACTOR; C-TERMINAL DOMAIN; DNA-BINDING; MYELOMONOBLASTIC CELLS; GENE-EXPRESSION; CYTOPLASMIC RETENTION; INDUCED APOPTOSIS	Human immunodeficiency virus (HIV-1) utilizes the NF-kappa B/Rel proteins to regulate transcription through NF-kappa B binding sites in the HIV-1 long terminal repeat (LTR). Normally, NF-kappa B is retained in the cytoplasm by inhibitory I kappa.B proteins; after stimulation by multiple activators including viruses, I kappa B alpha is phosphorylated and degraded, resulting in NF-kappa B release. In the present study, we examined the effect of tetracycline inducible expression of transdominant repressors of I kappa B alpha (TD-I kappa B alpha) on HIV-1 multiplication using stably selected Jurkat T cells, TD-I kappa B alpha was inducibly expressed as early as 3 h after doxycycline addition and dramatically reduced both NF-kappa B DNA binding activity and LTR directed gene activity. Interestingly, induced TD-I kappa B alpha expression also decreased endogenous I kappa B alpha expression to undetectable levels by 24 h after induction, demonstrating that TD-I kappa B alpha repressed endogenous NF-kappa B-dependent gene transcription. TD-I kappa B alpha expression also sensitized Jurkat cells to tumor necrosis factor-induced apoptosis. De novo HIV-1 infection of Jurbat cells was dramatically altered by TD-I kappa B alpha induction, resulting in inhibition of HIV-1 multiplication, as measured by p24 antigen, reverse transcriptase, and viral RNA. Given the multiple functions of the NF-kappa B/I kappa B pathway, TD-I kappa B alpha expression may interfere with HIV-1 multiplication at several levels: LTR-mediated transcription, Rev-mediated export of viral RNA, inhibition of HIV-1-induced pro-inflammatory cytokines, and increased sensitivity of HIV-1-infected cells to apoptosis.	McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mijh@musica.mcgill.ca	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503; Genin, Pierre/0000-0002-7502-3851				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; AMEISEN JC, 1995, TRENDS CELL BIOL, V5, P27, DOI 10.1016/S0962-8924(00)88933-3; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DADDARIO M, 1992, J IMMUNOL, V148, P1222; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DeLuca C, 1996, J VIROL, V70, P5183, DOI 10.1128/JVI.70.8.5183-5193.1996; DELUCA C, 1998, IN PRESS VIROLOGY; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KORNBLUTH RS, 1994, J LEUKOCYTE BIOL, V56, P247, DOI 10.1002/jlb.56.3.247; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE MH, 1987, J CLIN MICROBIOL, V25, P1717, DOI 10.1128/JCM.25.9.1717-1721.1987; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAUMANN M, 1993, ONCOGENE, V8, P2275; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROOKE R, 1990, VIROLOGY, V176, P205, DOI 10.1016/0042-6822(90)90245-M; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WU BY, 1995, P NATL ACAD SCI USA, V92, P1480, DOI 10.1073/pnas.92.5.1480; Wu BY, 1997, J VIROL, V71, P3161, DOI 10.1128/JVI.71.4.3161-3167.1997; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang LQ, 1997, J VIROL, V71, P1651, DOI 10.1128/JVI.71.2.1651-1656.1997	72	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7431	7440		10.1074/jbc.273.13.7431	http://dx.doi.org/10.1074/jbc.273.13.7431			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516441	hybrid			2022-12-27	WOS:000072738500037
J	Shaw, RJ; McClatchey, AI; Jacks, T				Shaw, RJ; McClatchey, AI; Jacks, T			Regulation of the neurofibromatosis type 2 tumor suppressor protein, Merlin, by adhesion and growth arrest stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL CONTACTS; ERM FAMILY MEMBERS; GENE-PRODUCT; PLASMA-MEMBRANE; MAMMALIAN-CELLS; EZRIN-LIKE; 3T3 CELLS; MOESIN; ACTIN; EXPRESSION	The neurofibromatosis type 2 tumor suppressor gene is inactivated in the development of familial and sporadic schwannomas and meningiomas. The encoded protein, Merlin, is closely related to the Ezrin, Radixin, and Moesin family of membrane/cytoskeletal linker proteins. Examination of Merlin in several cell lines revealed that the protein migrates as two distinct species near 70 kDa, Phosphatase treatment and orthophosphate labeling demonstrated that the species with decreased mobility is phosphorylated. Given Merlin's localization to cortical actin structures, we examined the effect of cell-cell contact or other forms of growth arrest on Merlin expression and post-translational modification, Under conditions of confluency or serum deprivation, the levels of phosphorylated and unphosphorylated Merlin species increased significantly. Cells arrested in G(1) by other methods or other phases of the cell cycle did not show changes in Merlin levels. Furthermore, loss of adhesion resulted in a nearly complete dephosphorylation of Merlin, which was reversed upon re-plating of cells, suggesting Merlin phosphorylation may be responsive to cell spreading or changes in cell shape. Thus, the tumor suppressor function of Merlin may involve the regulation of cellular responses to cues such as cell-cell contact, growth factor microenvironment, or changes in cell shape.	MIT, Howard Hughes Med Inst, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Howard Hughes Med Inst, Ctr Canc Res, Cambridge, MA 02139 USA.	tjacks@mit.edu						AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BOURN D, 1994, HUM MOL GENET, V3, P813, DOI 10.1093/hmg/3.5.813; BRANCOLINI C, 1994, J CELL BIOL, V124, P743, DOI 10.1083/jcb.124.5.743; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BUKANOVICH K, 1989, CELL, V58, P1097; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DENBAKKER MA, 1995, ONCOGENE, V10, P757; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; FRANCK Z, 1993, J CELL SCI, V105, P219; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; GUTMANN DH, 1995, HUM MOL GENET, V4, P471, DOI 10.1093/hmg/4.3.471; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huynh DP, 1996, ONCOGENE, V13, P73; Huynh DP, 1996, CELL GROWTH DIFFER, V7, P1551; Kaul SC, 1996, ONCOGENE, V13, P1231; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SATO N, 1992, J CELL SCI, V103, P131; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; SEFTON BM, 1995, CURRENT PROTOCOLS MO; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; UNGAR F, 1986, NATURE, V319, P787, DOI 10.1038/319787a0; WINCKLER B, 1994, J CELL SCI, V107, P2523; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	52	104	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7757	7764		10.1074/jbc.273.13.7757	http://dx.doi.org/10.1074/jbc.273.13.7757			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516485	hybrid			2022-12-27	WOS:000072738500081
J	Wu, GY; Benovic, JL; Hildebrandt, JD; Lanier, SM				Wu, GY; Benovic, JL; Hildebrandt, JD; Lanier, SM			Receptor docking sites for G-protein beta gamma subunits - Implications for signal regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; DEPENDENT PHOSPHORYLATION; ALPHA-SUBUNIT; KINASE; RHODOPSIN; ACTIVATION; BINDING; MECHANISM; ISOFORMS	We report the direct interaction of G beta gamma with the third intracellular (i3) loop of the M-2- and M-3-muscarinic receptors (MR) and the importance of this interaction relative to effective phosphorylation of the receptor subdomain. The i3 loop of the M-2- and the M-3-MR were expressed in bacteria and purified as glutathione S-transferase fusion proteins for utilization as an affinity matrix and to generate substrate for receptor subdomain phosphorylation, In its inactive heterotrimeric state stabilized by GDP, brain G-protein did not associate with the i3 peptide affinity matrix, However, stimulation of subunit dissociation by GTP gamma S/Mg2+ resulted in the retention of G beta gamma, but not the G alpha subunit, by the M-2- and M-3-MR i3 peptide resin, Purified G beta gamma bound to the M-3-MR i3 peptide with an apparent affinity similar to that observed for the G beta gamma binding domain of the receptor kinase GRK2 and Bruton tyrosine kinase, whereas transducin beta gamma was not recognized by the M-3-MR i3 peptide. Effective phosphorylation of the M-3-MR peptide by GRK2 required both G beta gamma and lipid as is the case for the intact receptor, Incubation of purified GRK2 with the i3 peptide in the presence of G beta gamma resulted in the formation of a functional ternary complex in which G beta gamma served as an adapter protein, Such a complex provides a mechanism for specific spatial translocation of GRK2 within the cell positioning the enzyme on its substrate, the activated receptor, The apparent ability of G beta gamma to act as a docking protein may also serve to provide an interface for this class of membrane-bound receptors to an expanded array of signaling pathways.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Medical University of South Carolina; Jefferson University	Lanier, SM (corresponding author), Med Univ S Carolina, Dept Pharmacol, 171 Ashley Ave, Charleston, SC 29425 USA.	laniersm@musc.edu		Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM047417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline; NIGMS NIH HHS [GM47417] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; HAGA K, 1992, J BIOL CHEM, V267, P2222; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KURSTJENS NP, 1991, EUR J BIOCHEM, V197, P167, DOI 10.1111/j.1432-1033.1991.tb15895.x; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; Makhlouf M, 1996, BBA-MOL CELL RES, V1312, P163, DOI 10.1016/0167-4889(96)00019-5; Nahorski SR, 1997, LIFE SCI, V60, P1039, DOI 10.1016/S0024-3205(97)00045-3; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; Stoffel RH, 1997, J MEMBRANE BIOL, V157, P1, DOI 10.1007/s002329900210; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a	31	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7197	7200		10.1074/jbc.273.13.7197	http://dx.doi.org/10.1074/jbc.273.13.7197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516410	hybrid			2022-12-27	WOS:000072738500006
J	Salvatore, P; Hanash, CR; Kido, Y; Imai, Y; Accili, D				Salvatore, P; Hanash, CR; Kido, Y; Imai, Y; Accili, D			Identification of sirm, a novel insulin-regulated SH3 binding protein that associates with Grb-2 and FYN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE; SH3-DOMAIN-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; SOS-GRB2 COMPLEX; C-SRC; SEQUENCE; DOMAINS; ABL; DISASSOCIATION; ELEGANS	We have previously developed a mouse model of insulin-resistant diabetes by targeted inactivation of the insulin receptor gene. During studies of gene expression in livers of insulin receptor-deficient mice, we identified a novel cDNA, which me have termed sirm (Son of Insulin Receptor Mutant mice), sirm is largely, albeit not exclusively, expressed in insulin-responsive tissues, Insulin is a potent modulator of sirm expression, and sirm mRNA levels correlate with tissue sensitivity to insulin. The product of the sirm gene is a serine/threonine-rich protein with several proline-rich motifs and an NPNY motif, conforming to the consensus sequence recognized by the phosphotyrosine binding domains of insulin receptor substrate and Shc proteins, However, Sirm bears no extended homologies with other known proteins. Based on the sequences of the proline-rich domains, we sought to determine whether Sirm binds to the SH3 domains of FYN and Grb-8, We demonstrate here that Sirm binds to FYN and Grb-8 in 3TS-L1 adipocytes and that insulin treatment results in the dissociation of the Sirm FYN and Sirm-Grb-2 complexes. We also show that Sirm is a substrate for the kinase activity of FYN in vitro, Based on the patterns of expression of sirm, its regulation by insulin, and the interactions with molecules in the insulin signaling pathway, we surmise that Sirm plays a role in modulating tissue sensitivity to insulin.	NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Sch Med, Div Endocrinol, Chapel Hill, NC 27514 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Accili, D (corresponding author), Bldg 10,Rm 10D18, Bethesda, MD 20892 USA.			SALVATORE, Paola/0000-0002-7294-9253; Imai, Yumi/0000-0001-5046-4223				ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Benian GM, 1996, J CELL BIOL, V132, P835, DOI 10.1083/jcb.132.5.835; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Masters JN, 1996, NEUROENDOCRINOLOGY, V63, P28, DOI 10.1159/000126932; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Parker F, 1996, MOL CELL BIOL, V16, P2561; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TAKEDA J, 1995, GENOMICS, V29, P276, DOI 10.1006/geno.1995.1245; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	30	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6989	6997		10.1074/jbc.273.12.6989	http://dx.doi.org/10.1074/jbc.273.12.6989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507006	Green Published, hybrid			2022-12-27	WOS:000072775900056
J	Sinha, KM; Gu, J; Chen, YH; Reddy, R				Sinha, KM; Gu, J; Chen, YH; Reddy, R			Adenylation of small RNAs in human cells - Development of a cell-free system for accurate adenylation on the 5 '-end of human signal recognition particle RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; SMALL NUCLEAR RNAS; NUCLEOTIDE-SEQUENCE; POLYMERASE-III; SECONDARY STRUCTURE; NOVIKOFF HEPATOMA; EUKARYOTIC GENES; 3' END; TRANSCRIPTION; DNA	The 3'-end sequences of several human small RNAs were determined, and the results show that a fraction of human cytoplasmic 7SL, ribosomal 5S, and nuclear U2, U6, and 7SK small RNAs contain a post-transcriptionally added adenylic acid residue on their 3'-ends. Incubation of HeLa cell extract in vitro in the presence of [alpha-P-32]ATP resulted in labeling of several small RNAs including ribosomal 5S and cytoplasmic 7SL as well as U2 and U6 small nuclear RNAs. Analysis of 7SL RNA labeled in this in vitro adenylation system showed that a single adenylic acid residue is added to the 3'-end. These results show that the adenylation observed in the in vitro system reflects the post-transcriptional adenylation occurring in vivo.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Reddy, R (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.		Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NIGMS NIH HHS [GM-52901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BAUSCH JN, 1983, J BIOL CHEM, V258, P1978; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BROWNLEE GG, 1968, J MOL BIOL, V34, P379; Chapon C, 1997, RNA, V3, P1337; CILIBERTO G, 1983, CURR TOP DEV BIOL, V18, P59; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DENIS H, 1973, BIOCHIMIE, V55, P1137, DOI 10.1016/S0300-9084(73)80453-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; England T E, 1980, Methods Enzymol, V65, P65; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; Gu J, 1997, J BIOL CHEM, V272, P21989, DOI 10.1074/jbc.272.35.21989; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KISS T, 1993, EMBO J, V12, P2913, DOI 10.1002/j.1460-2075.1993.tb05953.x; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KORN LJ, 1978, CELL, V15, P1145, DOI 10.1016/0092-8674(78)90042-9; KRAMEROV DA, 1985, NUCLEIC ACIDS RES, V13, P6423, DOI 10.1093/nar/13.18.6423; KRUEGER W, 1987, Journal of Molecular Biology, V195, P31; LABUDA D, 1994, J MOL EVOL, V39, P506; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LEVERETTE RD, 1992, CELL, V71, P1215, DOI 10.1016/S0092-8674(05)80069-8; LI WY, 1982, J BIOL CHEM, V257, P5136; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MURPHY S, 1986, NUCLEIC ACIDS RES, V14, P9243, DOI 10.1093/nar/14.23.9243; NAKAZATO H, 1975, NATURE, V256, P144, DOI 10.1038/256144a0; OBRIEN CA, 1994, GENE DEV, V8, P2891, DOI 10.1101/gad.8.23.2891; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; REDDY R, 1981, NUCLEIC ACIDS RES, V9, P5645, DOI 10.1093/nar/9.21.5645; REDDY R, 1981, J BIOL CHEM, V256, P8452; Reddy R., 1991, Progress in Molecular and Subcellular Biology, V12, P1; REDDY R, 1984, J BIOL CHEM, V259, P2265; REDDY R, 1987, J BIOL CHEM, V262, P75; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA H, 1975, J BIOL CHEM, V250, P3909; Silberklang M, 1979, Methods Enzymol, V59, P58; SORENSEN PD, 1990, NUCLEIC ACIDS RES, V18, P3060, DOI 10.1093/nar/18.10.3060; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; ULLU E, 1982, CELL, V29, P195, DOI 10.1016/0092-8674(82)90103-9; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WEINBERG RA, 1968, J MOL BIOL, V38, P289, DOI 10.1016/0022-2836(68)90387-2; WESTIN G, 1984, P NATL ACAD SCI-BIOL, V81, P3811, DOI 10.1073/pnas.81.12.3811; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; YANG H, 1992, MOL CELL BIOL, V12, P1553, DOI 10.1128/MCB.12.4.1553; Yue DX, 1996, RNA, V2, P895; YUO CY, 1985, CELL, V42, P193, DOI 10.1016/S0092-8674(85)80115-X	57	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6853	6859		10.1074/jbc.273.12.6853	http://dx.doi.org/10.1074/jbc.273.12.6853			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506988	hybrid			2022-12-27	WOS:000072775900038
J	Krobitsch, S; Brandau, S; Hoyer, C; Schmetz, C; Hubel, A; Clos, J				Krobitsch, S; Brandau, S; Hoyer, C; Schmetz, C; Hubel, A; Clos, J			Leishmania donovani heat shock protein 100 - Characterization and function in amastigote stage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; GENES; TRANSFECTION; TEMPERATURE; PARASITES; INVITRO; CLONING; REGION; CLPB; RNA	We report the cloning and molecular analysis of the Leishmania donovani clpB gene. The protein-coding region is highly conserved compared with its L. major homologue, while 5'-and 3'-flanking DNA sequences display considerable divergence, The encoded mRNA has an unusually long 5'-leader sequence typical for RNAs, which are translated preferentially under heat stress. The gene product, a 100-kDa heat shock protein, Hsp100, becomes abundant only during sustained heat stress, but not under common chemical stresses, Hsp100 associates into trimeric complexes and is found mostly in a cytoplasmic, possibly membrane-associated localization as deter mined by immune electron microscopy. Hsp100 shows immediate early expression kinetics during axenic amastigote development, In its absence, expression of at least one amastigote stage-specific protein family is impaired.	Bernhard Nocht Inst Trop Med, Leishmaniasis Unit, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Clos, J (corresponding author), Bernhard Nocht Inst Trop Med, Leishmaniasis Unit, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.			Brandau, Sven/0000-0002-2702-4163				ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; BATES PA, 1993, PARASITOL TODAY, V9, P143, DOI 10.1016/0169-4758(93)90181-E; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; BRANDAU S, 1996, THESIS U HAMBURG HAM; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DUNCAN RF, 1995, TRANSLATIONAL CONTRO, P271; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; Gupta N, 1996, TROP MED INT HEALTH, V1, P495, DOI 10.1046/j.1365-3156.1996.d01-90.x; Hubel A, 1997, MOL CELL BIOL, V17, P5987; HUBEL A, 1995, MOL BIOCHEM PARASIT, V70, P107, DOI 10.1016/0166-6851(95)00012-P; HUNTER KW, 1984, BIOCHEM BIOPH RES CO, V125, P755, DOI 10.1016/0006-291X(84)90603-X; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KELLY JM, 1994, MOL BIOCHEM PARASIT, V65, P51, DOI 10.1016/0166-6851(94)90114-7; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LINDQUIST S, 1987, TRANSLATIONAL REGULA, V2, P187; MILLER JS, 1988, MOL BIOCHEM PARASIT, V30, P175, DOI 10.1016/0166-6851(88)90110-7; PAN AA, 1993, J EUKARYOT MICROBIOL, V40, P213, DOI 10.1111/j.1550-7408.1993.tb04906.x; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Sambrook J., 2002, MOL CLONING LAB MANU; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; VANDERPLOEG LHT, 1985, SCIENCE, V228, P1443, DOI 10.1126/science.4012301; WOO KM, 1992, J BIOL CHEM, V267, P20429; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	32	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6488	6494		10.1074/jbc.273.11.6488	http://dx.doi.org/10.1074/jbc.273.11.6488			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497383	hybrid, Green Submitted			2022-12-27	WOS:000072488500075
J	Levy, M; Jing, J; Chikvashvili, D; Thornhill, WB; Lotan, I				Levy, M; Jing, J; Chikvashvili, D; Thornhill, WB; Lotan, I			Activation of a metabotropic glutamate receptor and protein kinase C reduce the extent of inactivation of the K+ channel Kv1.1/Kv beta 1.1 via dephosphorylation of Kv1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; XENOPUS-OOCYTES; ALPHA-SUBUNIT; CALYCULIN-A; RAT-BRAIN; PHOSPHORYLATION; PHOSPHATASE; INHIBITORS; CELLS; GLUTAMATE-RECEPTOR-1	Various brain K+ channels, which may normally exist as complexes of alpha (pore-farming) and beta (auxiliary) subunits, were subjected to regulation by metabotropic glutamate receptors, Kv1.1/Kv beta 1.1 is a voltage-dependent K+ channel composed of alpha and beta proteins that are widely expressed in the brain, Expression of this channel in Xenopus oocytes resulted in a current that had fast inactivating and noninactivating components, Previously we showed that basal and protein kinase A-induced phosphorylation of the alpha subunit at Ser-446 decreases the fraction of the noninactivating component. In this study we investigated the effect of protein kinase C (PKC) on the channel. We showed that a PHC-activating phorbol ester (phorbol 12-myristate 13-acetate (PMA)) increased the noninactivating fraction via activation of a PKC subtype that was inhibited by staurosporine and bisindolylmaleimide but not by calphostin C. However, it was not a PKC-induced phosphorylation but rather a dephosphorylation that mediated the effect. PMA reduced the basal phosphorylation of Ser-446 significantly in plasma membrane channels and failed to affect the inactivation of channels having an cu subunit that was mutated at Ser-446, Also, the activation of coexpressed mGluR1a known to activate phospholipase C mimicked the effect of PMA on the inactivation via induction of dephosphorylation at Ser-446, Thus, this study identified a potential neuronal pathway initiated by activation of metabotropic glutamate receptor fa coupled to a signaling cascade that possibly utilized PKC to induce dephosphorylation and thereby to decrease the extent of inactivation of a KC channel.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel; Mt Sinai Hosp, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Tel Aviv University; Sackler Faculty of Medicine; Icahn School of Medicine at Mount Sinai	Lotan, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel.	ilotan@post.tau.ac.il						ABE T, 1992, J BIOL CHEM, V267, P13361; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Breitwieser GE, 1996, J MEMBRANE BIOL, V152, P1, DOI 10.1007/s002329900080; Catarsi S, 1997, J NEUROSCI, V17, P5792; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; GERBER U, 1992, EUR J NEUROSCI, V4, P792, DOI 10.1111/j.1460-9568.1992.tb00189.x; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; GOODE N, 1992, J BIOL CHEM, V267, P16878; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jing J, 1997, J BIOL CHEM, V272, P14021, DOI 10.1074/jbc.272.22.14021; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; Kondratyuk T, 1997, J BIOL CHEM, V272, P16978, DOI 10.1074/jbc.272.27.16978; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; MARANTZ Y, 1995, MOL CELL ENDOCRINOL, V11, P7; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Peretz T, 1996, FEBS LETT, V381, P71, DOI 10.1016/0014-5793(96)00085-3; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prezeau L, 1996, MOL PHARMACOL, V49, P422; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; SHRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6495	6502		10.1074/jbc.273.11.6495	http://dx.doi.org/10.1074/jbc.273.11.6495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497384	hybrid			2022-12-27	WOS:000072488500076
J	Monney, L; Otter, I; Olivier, R; Ozer, HL; Haas, AL; Omura, S; Borner, C				Monney, L; Otter, I; Olivier, R; Ozer, HL; Haas, AL; Omura, S; Borner, C			Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NF-KAPPA-B; INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROTEASOME PATHWAY; POLY(ADP-RIBOSE) POLYMERASE; INTERSEGMENTAL MUSCLES; SYMPATHETIC NEURONS; ICE/CED-3 PROTEASE; MANDUCA-SEXTA; CYCLIN	Apoptosis requires the activation of caspases (formerly interleukin 1 beta-converting enzyme-like proteases), in particular those related to the caspase-3/7/6 subfamily. Recent data, however, revealed that, although caspase-specific inhibitors delay apoptosis, they are often incapable of preventing it. To obtain evidence for caspase-independent steps of apoptosis, we artificially created a high amount of short-lived or aberrant proteins by blocking the ubiquitin degradation pathway. A temperature-sensitive defect in the ubiquitin-activating enzyme E1 induced apoptosis independent of the activation of caspase-3 and -6 and the cleavage of their respective substrates poly(ADP-ribose) polymerase and Iamin A. In addition, neither the caspase 3/7-specific inhibitor N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone nor the general caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone were capable of blocking this type of cell death. By contrast, Bcl-2 overexpression effectively protected cells from apoptosis induced by a defect in the E1 enzyme at the nonpermissive temperature. Bcl-2 acted downstream of the accumulation of short-lived or aberrant proteins because it did not prevent the overexpression of the short-lived proteins p53, p27(kip1), and cyclins D1 and B1 under conditions of decreased ubiquitination. These results suggest the existence of short-lived proteins that may serve the role of caspase-independent effecters of apoptosis and attractive targets of the death-protective action of Bcl-2.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07107 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Kitasato Inst, Minato Ku, Tokyo 108, Japan	University of Fribourg; Rutgers State University New Brunswick; Rutgers State University Medical Center; Medical College of Wisconsin	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland.	christoph.borner@unifr.ch			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004821] Funding Source: NIH RePORTER; NIA NIH HHS [AG04821] Funding Source: Medline; NIGMS NIH HHS [GM34009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anel A, 1997, J IMMUNOL, V158, P1999; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Boulakia CA, 1996, ONCOGENE, V12, P529; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1982, J BIOL CHEM, V257, P13964; CIENCIARELLI C, 1992, SCIENCE, V257, P795; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; CORSI D, 1995, J BIOL CHEM, V270, P8928, DOI 10.1074/jbc.270.15.8928; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DARZYNKIEWICZ Z, 1996, TECHNIQUES APOPTOSIS, P90; DAWSON SP, 1995, J BIOL CHEM, V270, P1850, DOI 10.1074/jbc.270.4.1850; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DEWAR D, 1994, DEMENTIA, V5, P168, DOI 10.1159/000106716; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Duriez PJ, 1997, BBA-GEN SUBJECTS, V1334, P65, DOI 10.1016/S0304-4165(96)00077-3; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLOTZER M, 1995, CURR BIOL, V5, P970, DOI 10.1016/S0960-9822(95)00190-4; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HUNT LT, 1977, BIOCHEM BIOPH RES CO, V74, P650, DOI 10.1016/0006-291X(77)90352-7; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JONES MEE, 1995, DEV BIOL, V169, P436, DOI 10.1006/dbio.1995.1159; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi T, 1996, J BIOCHEM, V120, P699; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE J, 1995, J NEUROPATHOL EXP  S, pS6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; STRASSER A, 1995, CELL GROWTH DIFFER, V6, P799; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; White DW, 1996, ONCOGENE, V13, P891; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YONISHROUACH E, 1991, NATURE, V352, P35; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	90	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6121	6131		10.1074/jbc.273.11.6121	http://dx.doi.org/10.1074/jbc.273.11.6121			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497330	hybrid			2022-12-27	WOS:000072488500022
J	Ohashi, Y; Tachibana, K; Kamiguchi, K; Fujita, H; Morimoto, C				Ohashi, Y; Tachibana, K; Kamiguchi, K; Fujita, H; Morimoto, C			T cell receptor-mediated tyrosine phosphorylation of Cas-L, a 105-kDa Crk-associated substrate-related protein, and its association of Crk and C3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SH3 DOMAIN; SRC; COMPLEXES; BINDING; GROWTH; IDENTIFICATION; COSTIMULATION; LYMPHOCYTES; ACTIVATION	Cas-L (pp105), a Crk-associated substrate (p130(Cas))-related protein, was first identified as a 105-kDa protein that is tyrosine-phosphorylated following beta 1 integrin cross-linking in T cells. Cas-L contains possible multiple binding sites for the Src homology (SH) 2 domains of various signaling molecules, and appears to be involved in signal transduction through phosphorylated tyrosine-mediated protein-protein interaction, Since Cas-L is preferentially expressed in lymphocytes, it is conceivable that Cas-L plays an important role in lymphocyte-specific signals. Here, we show the involvement of Cas-L in the T cell receptor (TCR)/CD3 signaling pathway, Cas-L is transiently phosphorylated following CD3 cross-linking, and tyrosine-phosphorylated Cas-L binds to Crk and C3G. Furthermore, a Cas-L mutant that lacks the SH3 domain, the binding site for focal adhesion kinase (FAK), is also tyrosine-phosphorylated upon CD3 cross-linking, but not upon beta 1 integrin crosslinking, suggesting that FAK is not involved in CD3-dependent Cas-L phosphorylation. Taken together, the present study indicates a novel signaling pathway mediated by tyrosine-phosphorylated Cas-L upon the TCR/CD3 stimulation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Univ Tokyo, Inst Med Sci, Dept Clin Immunol, Minato Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Ctr AIDS Res, Minato Ku, Tokyo, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Tokyo; University of Tokyo	Tachibana, K (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29530] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BUNDAY L, 1996, J BIOL CHEM, V271, P6159; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishino M, 1995, ONCOGENE, V11, P2331; Kanda H, 1997, EUR J IMMUNOL, V27, P2113, DOI 10.1002/eji.1830270840; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Law SF, 1996, MOL CELL BIOL, V16, P3327; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATO T, 1995, J IMMUNOL, V155, P2938; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6446	6451		10.1074/jbc.273.11.6446	http://dx.doi.org/10.1074/jbc.273.11.6446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497377	hybrid			2022-12-27	WOS:000072488500069
J	Metz, RP; Ritter, JK				Metz, RP; Ritter, JK			Transcriptional activation of the UDP-glucuronosyltransferase 1A7 gene in rat liver by aryl hydrocarbon receptor ligands and oltipraz	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL; GLUCURONIDATION; EXPRESSION; BILIRUBIN; COMPLEX; CARCINOGENESIS; BENZO(A)PYRENE; DEFICIENCY; INDUCTION; ENZYMES	UDP-glucuronosyltransferase UGT1A7 catalyzes the glucuronidation of benzo(a)pyrene metabolites and other bulky aromatic compounds. Both UGT1A7 mRNA and an associated enzyme activity (benzo(a)pyrene-7,8-dihydrodioltransferase activity) are markedly increased in livers of rats treated with beta-naphthoflavone or 4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione (oltipraz), Nuclear runoff assays show that the effects of both inducers are primarily due to transcriptional activation. A 27-kilobase region that included the UGT1A7/UGT1A6 promoter regions was cloned. Primer extension and RNase protection studies indicated greater than or equal to 30 transcription start sites in five clusters between bases -85 and -40 respective to the translation start codon. There was no recognizable TATA box, but the promoter region is TA-rich. Sequence analysis revealed potential binding sites for CCAAT enhancer-binding protein, activator protein 1, and hepatic nuclear factors 1, 3, and 4, but no xenobiotic response elements or antioxidant response elements, implicated in the regulation of other genes by beta-naphthoflavone or oltipraz, were found. A UGT1A7 gene reporter plasmid directed strong constitutive expression in transient transfection assays using primary rat hepatocytes. Treatment with 3-methylcholanthrene or oltipraz had no effect compared with similarly treated pGL3-Basic-transfected cells. These results suggest that the regulatory elements controlling xenobiotic inducibility of UGT1A7 transcription are located either 5' or 3' of bases -1600 to +54. One possibility is that the polycyclic aromatic-mediated regulation of UGT1A7 occurs via the xenobiotic response element flanking the UGT1A6 locus 7 kilobase pairs downstream.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Ritter, JK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Box 980613, Richmond, VA 23298 USA.			Metz, Richard/0000-0002-9876-3385	NIEHS NIH HHS [1R29ES07762] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES007762] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOCK KW, 1993, BIOCHEM PHARMACOL, V45, P1809, DOI 10.1016/0006-2952(93)90437-2; Bruck M, 1997, ARCH BIOCHEM BIOPHYS, V344, P357, DOI 10.1006/abbi.1997.0214; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EGNER PA, 1994, CARCINOGENESIS, V15, P177, DOI 10.1093/carcin/15.2.177; EMI Y, 1995, J BIOCHEM, V117, P392, DOI 10.1093/jb/117.2.392; Emi Y, 1996, J BIOL CHEM, V271, P3952, DOI 10.1074/jbc.271.7.3952; FEI HH, 1993, BIOTECHNIQUES, V15, P838; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; Grove AD, 1997, J BIOL CHEM, V272, P1621, DOI 10.1074/jbc.272.3.1621; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HU ZH, 1992, J PHARMACOL EXP THER, V263, P334; HU ZH, 1994, TOXICOL APPL PHARM, V127, P306, DOI 10.1006/taap.1994.1166; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; Kessler FK, 1997, CARCINOGENESIS, V18, P107, DOI 10.1093/carcin/18.1.107; Kim W, 1997, CHEM RES TOXICOL, V10, P296, DOI 10.1021/tx9601667; LAMB JG, 1994, BIOCHEMISTRY-US, V33, P10513, DOI 10.1021/bi00200a037; Langouet S, 1997, CARCINOGENESIS, V18, P1343, DOI 10.1093/carcin/18.7.1343; LEE KL, 1986, ARCH BIOCHEM BIOPHYS, V248, P597, DOI 10.1016/0003-9861(86)90513-8; MACKENZIE PI, 1993, CANCER RES, V53, P1529; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; METZGER S, 1993, J BIOL CHEM, V268, P16831; MUNZEL PA, 1994, BIOCHEM PHARMACOL, V47, P1445, DOI 10.1016/0006-2952(94)90345-X; Munzel PA, 1996, ARCH BIOCHEM BIOPHYS, V335, P205, DOI 10.1006/abbi.1996.0499; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; TRONCHE F, 1994, LIVER GENE EXPRESSIO, P196; VIENNEAU DS, 1995, CANCER RES, V55, P1045	30	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5607	5614		10.1074/jbc.273.10.5607	http://dx.doi.org/10.1074/jbc.273.10.5607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488689	hybrid			2022-12-27	WOS:000072345000032
J	Iwabuchi, T; Harayama, S				Iwabuchi, T; Harayama, S			Biochemical and molecular characterization of 1-hydroxy-2-naphthoate dioxygenase from Nocardioides sp. KP7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENTISATE 1,2-DIOXYGENASE; PSEUDOMONAS; PHENANTHRENE; OXYGENASES; BACTERIA	1-Hydroxy-2-naphthoate dioxygenase, which cleaves the singly hydroxylated aromatic ring, tvas purified from phenanthrene-degrading Nocardioides sp. strain KP7, The purified enzyme had a molecular mass of 45 kDa by SDS-polyacrylamide gel electrophoresis and 270 kDa by gel filtration chromatography. The apparent K-m and k(cat) values of this enzyme for 1-hydroxy-2-naphthoate were 10 mu M and 114 s(-1), respectively. One mole of molecular oxygen was consumed when 1 mol of 1-hydroxy-2-naphthoate was oxidized, This enzyme contained 1 mol of Fe(II)/mol or the subunit and was inactivated by o-phenanthroline. The enzyme that had been inactivated by o-phenanthroline was reactivated by incubating with FeSO4 and ascorbic acid. Thus, Fe(lI) was required for the enzyme to exhibit activity. The structural gene for this enzyme was screened from a cosmid library and then sequenced, the length of the 1-hydroxy-2-naphthoate gene being 1161 base pairs, The deduced amino acid sequence of this enzyme was different from those of other ring-cleaving dioxygenases that cleave the doubly hydroxylated aromatic ring.	Marine Biotechnol Inst, Kamaishi Labs, Kamaishi, Iwate 026, Japan		Harayama, S (corresponding author), Marine Biotechnol Inst, Kamaishi Labs, 3-75-1 Heita, Kamaishi, Iwate 026, Japan.	sharayam@supernig.nig.ac.jp		Harayama, Shigeaki/0000-0003-2103-7796				BARNSLEY EA, 1983, J BACTERIOL, V154, P113, DOI 10.1128/JB.154.1.113-117.1983; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HARAYAMA S, 1992, MET IONS BIOL SYST, V28, P99; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.mi.46.100192.003025; Harayama S., 1989, Genetics of bacterial diversity., P151; HARPEL MR, 1990, J BIOL CHEM, V265, P6301; HARPEL MR, 1990, J BIOL CHEM, V265, P22187; Iwabuchi T, 1997, J BACTERIOL, V179, P6488, DOI 10.1128/jb.179.20.6488-6494.1997; IWABUCHI T, 1998, IN PRESS J MARINE BI; KIYOHARA H, 1977, AGR BIOL CHEM TOKYO, V41, P705, DOI 10.1080/00021369.1977.10862566; KIYOHARA H, 1976, AGR BIOL CHEM TOKYO, V40, P1075, DOI 10.1080/00021369.1976.10862190; MASSEY V, 1957, J BIOL CHEM, V229, P763; Nozaki M, 1979, Top Curr Chem, V78, P145, DOI 10.1007/BFb0048193; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987	16	66	77	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8332	8336		10.1074/jbc.273.14.8332	http://dx.doi.org/10.1074/jbc.273.14.8332			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525941	hybrid			2022-12-27	WOS:000072876300075
J	Runkel, L; Pfeffer, L; Lewerenz, M; Monneron, D; Yang, CH; Murti, A; Pellegrini, S; Goelz, S; Uze, G; Mogensen, K				Runkel, L; Pfeffer, L; Lewerenz, M; Monneron, D; Yang, CH; Murti, A; Pellegrini, S; Goelz, S; Uze, G; Mogensen, K			Differences in activity between alpha and beta type I interferons explored by mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MOLECULAR-CLONING; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; RECOMBINANT; CELLS; EXPRESSION; SUBUNIT; PHOSPHORYLATION	Type I interferon (IFN) subtypes alpha and beta share a common multicomponent, cell surface receptor and elicit a similar range of biological responses, including antiviral, antiproliferative, and immunomodulatory activities. However, alpha and beta IFNs exhibit key differences in several biological properties. For example, IFN-beta, but not IFN-alpha, induces the association of tyrosine-phosphorylated receptor components ifnar1 and ifnar2, and has activity in cells lacking the IFN receptor-associated, Janus kinase tyk2. To define the structural basis for these functional differences we produced human IFN-beta with point mutations and compared them to wild-type IFN-beta in assays that distinguish alpha and beta IFN subtypes. IFN-beta mutants with charged residues (N86K, N86E, or Y92D) introduced at two positions in the C helix lost the ability to induce the association of tyrosine-phosphorylated receptor chains and had reduced activity on tyk2-deficient cells. The combination of negatively charged residues N86E and Y92D (homologous with IFN-alpha 8) increased the cross-species activity of the mutant IFN-beta s on bovine cells to a level comparable to that of human IFN-alpha s. In contrast, point mutations in the AB loop and D helix had no significant effect on these subtype-specific activities. A subset of these latter mutations did, however, reduce activity in a manner analogous to IFN-alpha mutations, The effects of these mutations on IFN-beta activity are discussed in the context of a family of related ligands acting through a common receptor and signaling pathway.	CNRS, Inst Genet Mol, F-34293 Montpellier 5, France; Biogen Inc, Cambridge, MA 02142 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; Inst Pasteur, INSERM, U276, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Biogen; University of Tennessee System; University of Tennessee Health Science Center; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mogensen, K (corresponding author), CNRS, Inst Genet Mol, 1919 Route Mende, F-34293 Montpellier 5, France.		Uzé, Gilles/O-6383-2019; Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Uze, Gilles/0000-0002-4150-5772; Pfeffer, Lawrence/0000-0003-2809-1234				ABRAMOVITCH C, 1995, EMBO J, V13, P5871; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; CAMBLE R, 1986, BIOCHEM BIOPH RES CO, V134, P1404, DOI 10.1016/0006-291X(86)90405-5; CHEETHAM BF, 1991, ANTIVIR RES, V15, P27, DOI 10.1016/0166-3542(91)90038-S; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; EINHORN S, 1977, J GEN VIROL, V35, P573, DOI 10.1099/0022-1317-35-3-573; FLORES I, 1991, J BIOL CHEM, V266, P19875; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; HIMMLER A, 1986, DNA-J MOLEC CELL BIO, V5, P345, DOI 10.1089/dna.1986.5.345; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; KORN AP, 1994, J INTERFERON RES, V14, P1, DOI 10.1089/jir.1994.14.1; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Leung S, 1996, SCIENCE, V273, P750, DOI 10.1126/science.273.5276.750; LI JZ, 1994, J BIOL CHEM, V269, P13544; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MCINNES B, 1989, J INTERFERON RES, V9, P305, DOI 10.1089/jir.1989.9.305; MEISTER A, 1986, J GEN VIROL, V67, P1633, DOI 10.1099/0022-1317-67-8-1633; MITSUI Y, 1993, PHARMACOL THERAPEUT, V58, P93, DOI 10.1016/0163-7258(93)90068-O; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1997, INTERFERON THERAPY M; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; REHBERG E, 1982, J BIOL CHEM, V257, P1497; ROSENBLUM MG, 1990, J INTERFERON RES, V10, P141, DOI 10.1089/jir.1990.10.141; RUNKEL L, 1998, IN PRESS PHARM RES N; SENDA T, 1990, P JPN ACAD B-PHYS, V66, P77, DOI 10.2183/pjab.66.77; SENDA T, 1995, J MOL BIOL, V253, P187, DOI 10.1006/jmbi.1995.0544; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEWART WE, 1979, INTERFERON SYSTEM, P135; STREULI M, 1981, P NATL ACAD SCI-BIOL, V78, P2848, DOI 10.1073/pnas.78.5.2848; TYMMS MJ, 1989, ANTIVIR RES, V12, P37, DOI 10.1016/0166-3542(89)90066-1; Uddin S, 1997, J IMMUNOL, V158, P2390; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057	53	60	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8003	8008		10.1074/jbc.273.14.8003	http://dx.doi.org/10.1074/jbc.273.14.8003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525899	Green Published, hybrid			2022-12-27	WOS:000072876300033
J	Sullivan, FX; Kumar, R; Kriz, R; Stahl, M; Xu, GY; Rouse, J; Chang, XJ; Boodhoo, A; Potvin, B; Cumming, DA				Sullivan, FX; Kumar, R; Kriz, R; Stahl, M; Xu, GY; Rouse, J; Chang, XJ; Boodhoo, A; Potvin, B; Cumming, DA			Molecular cloning of human GDP-mannose 4,6-dehydratase and reconstitution of GDP-fucose biosynthesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; CONVERSION; PURIFICATION; SEQUENCE; LIGANDS; ACID	We have cloned the cDNA encoding human GDP-mannose 4,6-dehydratase, the first enzyme in the pathway converting GDP-mannose to GDP-fucose. The message is expressed in all tissues and cell lines examined, and the cDNA complements Lec13, a Chinese Hamster Ovary cell line deficient in GDP-mannose 4,6-dehydratase activity. The human GDP-mannose 4,6-dehydratase polypeptide shares 61% identity with the enzyme from Escherichia coli, suggesting broad evolutionary conservation. Purified recombinant enzyme utilizes NADP(+) as a cofactor and, like its E. coli counterpart, is inhibited by GDP-fucose, suggesting that this aspect of regulation is also conserved. We have isolated the product of the dehydratase reaction, GDP-4-keto-6-deoxymannose, and confirmed its structure by electrospray ionization-mass spectrometry and high field MMR. Using purified recombinant human GDP-mannose 4,6-dehydratase and FX protein (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase), we show that the two proteins alone are sufficient to convert GDP-mannose to CDP-fucose in vitro. This unequivocally demonstrates that the epimerase and reductase activities are on a single polypeptide. Finally, we show that the two homologous enzymes from E. coli are sufficient to carry out the same enzymatic pathway in bacteria.	Genet Inst, Small Mol Drug Discovery, Cambridge, MA 02140 USA; Onsite Biochromatog Inc, Edmonton, AB T6M 2H8, Canada; Yeshiva Univ, Dept Biol, New York, NY 10033 USA	Yeshiva University	Sullivan, FX (corresponding author), Genet Inst, Small Mol Drug Discovery, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.							Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; BROSCHAT KO, 1985, EUR J BIOCHEM, V153, P397, DOI 10.1111/j.1432-1033.1985.tb09315.x; BULET P, 1984, EUR J BIOCHEM, V144, P255, DOI 10.1111/j.1432-1033.1984.tb08458.x; CHANG S, 1988, J BIOL CHEM, V263, P1693; Chaplin M.F., 1986, MASS SPECTROM, P1; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FRYDMAN M, 1992, AM J MED GENET, V44, P297, DOI 10.1002/ajmg.1320440307; GINSBURG V, 1960, J BIOL CHEM, V235, P2196; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; GLASER L, 1971, ENZYMES, V5, P465; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KORNFELD RH, 1966, BIOCHIM BIOPHYS ACTA, V117, P79, DOI 10.1016/0304-4165(66)90154-1; KUMAR R, 1991, J BIOL CHEM, V266, P21777; MELO A, 1968, J BIOL CHEM, V243, P1475; Naundorf A, 1996, CARBOHYD RES, V285, P141, DOI 10.1016/S0008-6215(96)90180-9; OTHS PJ, 1990, CARBOHYD RES, V198, P91, DOI 10.1016/0008-6215(90)84279-4; OVERTON K, 1981, BIOCHIM BIOPHYS ACTA, V675, P281, DOI 10.1016/0304-4165(81)90238-5; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; RUGGIEROLOPEZ D, 1991, BIOCHEM J, V279, P801, DOI 10.1042/bj2790801; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; STEIN A, 1995, ANGEW CHEM INT EDIT, V34, P1748, DOI 10.1002/anie.199517481; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; Sturla L, 1997, FEBS LETT, V412, P126, DOI 10.1016/S0014-5793(97)00762-X; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAMAMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V300, P694, DOI 10.1006/abbi.1993.1096; YU Y, 1992, J BIOL CHEM, V267, P5868; YURCHENCO PD, 1977, BIOCHEMISTRY-US, V16, P944, DOI 10.1021/bi00624a021	33	126	140	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8193	8202		10.1074/jbc.273.14.8193	http://dx.doi.org/10.1074/jbc.273.14.8193			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525924	hybrid			2022-12-27	WOS:000072876300058
J	Leng, XH; Manolson, MF; Forgac, M				Leng, XH; Manolson, MF; Forgac, M			Function of the COOH-terminal domain of Vph1p in activity and assembly of the yeast V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; CDNA SEQUENCE; SACCHAROMYCES-CEREVISIAE; PROTEOLIPID SUBUNIT; STRUCTURAL-CHANGES; NEUROSPORA-CRASSA; SYNTHASE F1F0	We have previously shown that mutations in buried charged residues in the last two transmembrane helices of Vph1p (the 100-kDa subunit of the yeast V-ATPase) inhibit proton transport and ATPase activity (Leng, X. H,, Manolson, M,, Liu, Q., and Forgac, M, (1996) J, Biol, Chem. 271, 22487-22493), In this report we have further explored the function of this region of Vph1p (residues 721-840) using a combination of site-directed and random mutagenesis, Effects of mutations on stability of Vph1p, assembly of the V-ATPase complex, 9-amino-6-chloro-2-methoxyacridine quenching (as a measure of proton transport), and ATPase activity were assessed, Additional mutations were analyzed to test the importance of Glu-789 in TM7 and His-743 in TM6. Although substitution of Asp for Glu at position 789 led to a 50% decrease in 9-amino-6-chloro-2-methoxyacridine quenching, substitution of Ala at this position gave a mutant with 40% quenching relative to wild type, suggesting that a negative charge at this position is not absolutely essential for proton transport, Similarly a positive charge is not essential at position His-743, since the H743Y and H743A mutants retain 20 and 60% of wild-type quenching, respectively, Interestingly, H743A approaches wild-type ATPase activity at elevated pH while the E789D mutant shows a slightly lower pH optimum than wild type, suggesting that these residues are in a location to influence V-ATPase activity, The low pumping activity of the double mutant (E789H/H743E) suggests that these residues do not form a simple ion pair, Random mutagenesis identified a number of additional mutations both inside the membrane (L739S and L746S) as well as external to the membrane (H729R and V803D) which also significantly inhibited proton pumping and ATPase activity, By contrast, a cluster of five mutations were identified between residues 800 and 814 in the soluble segment just COOH-terminal to TM7 which affected either assembly or stability of the V-ATPase complex, Two mutations (F809L and G814D) may also affect targeting of the 100-kDa subunit, These results suggest that this segment of Vph1p plays a crucial role in organization of the V-ATPase complex.	Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA; Hosp Sick Children, Dept Cell Biol, Toronto, ON M5G 1X8, Canada	Tufts University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA.			Manolson, Morris/0000-0001-8755-5460	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FURGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P13; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HO MN, 1993, J BIOL CHEM, V268, P18286; HOPPE J, 1980, FEBS LETT, V109, P107, DOI 10.1016/0014-5793(80)81321-4; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MOSHER ME, 1983, J BACTERIOL, V156, P1078, DOI 10.1128/JB.156.3.1078-1092.1983; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SEBALD W, 1980, P NATL ACAD SCI-BIOL, V77, P785, DOI 10.1073/pnas.77.2.785; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	57	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6717	6723		10.1074/jbc.273.12.6717	http://dx.doi.org/10.1074/jbc.273.12.6717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506970	hybrid			2022-12-27	WOS:000072775900020
J	Trigon, S; Serizawa, H; Conaway, JW; Conaway, RC; Jackson, SP; Morange, M				Trigon, S; Serizawa, H; Conaway, JW; Conaway, RC; Jackson, SP; Morange, M			Characterization of the residues phosphorylated in vitro by different C-terminal domain kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR-DELTA; LARGEST SUBUNIT; SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; SUBSTRATE RECOGNITION; PRIMARY SEQUENCE; KU-AUTOANTIGEN; REPEAT DOMAIN	The C-terminal part of the largest subunit of eukaryotic RNA polymerase II is composed solely of the highly repeated consensus sequence Tyr(1)-Ser(2)-Pro(3)-Thr(4)-Ser(5)-Pro(6)-Ser(7). This domain, called the C-terminal domain (CTD), is phosphorylated mostly at serine residues during transcription initiation, but the precise role of this phosphorylation remains controversial, Several protein kinases are able to phosphorylate this sequence in vitro, The aim of this work was to define the positions of the amino acids phosphorylated by four of these CTD kinases (transcription factor (TF) IIH-kinase, DNA-dependent protein kinase, and the mitogen-activated protein kinases ERK1 and ERK2) and to compare the specificity of these different protein kinases, We show that TFIIH kinase and the mitogen-activated protein kinases phosphorylate only serine 5 of the CTD sequence, whereas DNA-dependent protein kinase phosphorylates serines 2 and 7, Among the different CTD kinases, only TFIIH kinase is appreciably more active on two repeats of the consensus sequence than on one motif, These in vitro results can provide some clues to the nature of the protein kinases responsible for the in vivo phosphorylation of the RNA polymerase CTD. In particular, the ratio of phosphorylated serine to threonine observed in vivo cannot be explained if TFIIH kinase is the only protein kinase involved in the phosphorylation of the CTD.	ENS, Unite Genet Mol, F-75230 Paris 05, France; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Wellcome Canc Res Campaign Inst, Cambridge CB2 1QR, England	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Massachusetts Institute of Technology (MIT); Whitehead Institute; Oklahoma Medical Research Foundation	Morange, M (corresponding author), ENS, Unite Genet Mol, 46 Rue Ulm, F-75230 Paris 05, France.	morange@biclogie.ens.fr	Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Conaway, Joan/0000-0002-2786-0663				Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BUHLER JM, 1976, FEBS LETT, V71, P37, DOI 10.1016/0014-5793(76)80893-9; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; KANG ME, 1993, J BIOL CHEM, V268, P25033; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STONE N, 1992, J BIOL CHEM, V267, P6353; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WEST ML, 1995, GENETICS, V140, P1223; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290	69	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6769	6775		10.1074/jbc.273.12.6769	http://dx.doi.org/10.1074/jbc.273.12.6769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506978	hybrid			2022-12-27	WOS:000072775900028
J	Lee, X; Thompson, A; Zhang, ZM; Ton-that, H; Biesterfeldt, J; Ogata, C; Xu, LL; Johnston, RAZ; Young, NM				Lee, X; Thompson, A; Zhang, ZM; Ton-that, H; Biesterfeldt, J; Ogata, C; Xu, LL; Johnston, RAZ; Young, NM			Structure of the complex of Maclura pomifera agglutinin and the T-antigen disaccharide, Gal beta 1,3GalNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THOMSEN-FRIEDENREICH-ANTIGEN; ADULT-RAT LUNG; RICIN-B-CHAIN; ARTOCARPUS-INTEGRIFOLIA; BINDING GLYCOPROTEIN; LECTIN; JACALIN; SPECIFICITY; SITE; FORMS	Maclura pomifera agglutinin is a tetrameric plant seed lectin with high affinity for the tumor-associated T-antigen disaccharide, Gal beta 1,3GalNAc alpha, and hence for many O-linked glycopeptide structures, Unlike members of most lectin families, it lacks both metal ions and Cys residues. The structure of its complex with Gal beta 1,3GalNAc was determined to 2.2 Angstrom by first using multiwavelength anomalous diffraction with a lead derivative of the native protein, and then using molecular replacement with the unrefined structure as a model to solve the structure of the complex. The subunits share the beta-prism architecture and three-fold pseudo-symmetry of the related lectin jacalin, with the 21-residue beta-chains in the center of the tetramer, Interactions with the GalNAc predominate in the binding of the disaccharide. It forms a network of H-bonds with only one side chain, from an Asp residue, the amino group of the N-terminal Gly of the alpha-chain, and peptide backbone atoms of two aromatic residues. The Gal moiety does not H-bond directly with residues in the same monomer, i.e. there is no true subsite for it, but there are interactions through two water molecules. In the crystal, it interacts with residues in the binding site of an adjacent tet tetramer. The minimum energy conformation expected for the disaccharide is retained, despite its mediating the tetramer tetramer interactions in the crystal packing. The resulting lattice is comparable to those seen for complexes of other lectins with branched glycopeptides.	Cleveland Clin Fdn, Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; European Synchrotron Radiat Facil, F-38042 Grenoble, France; Brookhaven Natl Lab, Howard Hughes Med Inst, Natl Synchrotron Light Source, Upton, NY 11973 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Cleveland Clinic Foundation; European Synchrotron Radiation Facility (ESRF); Howard Hughes Medical Institute; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory; National Research Council Canada	Lee, X (corresponding author), Cleveland Clin Fdn, Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.	lee@xtal.ri.ccf.org						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANERJEE R, 1991, J MOL BIOL, V221, P773, DOI 10.1016/0022-2836(91)80174-S; BREWER CF, 1996, CHEMTRACTS BIOCH MOL, V6, P165; BRUNGER A, 1993, XPLOR VERSION 3 1; BUSH CA, 1986, INT J PEPT PROT RES, V28, P386; CZAPLA TH, 1990, J ECON ENTOMOL, V83, P2480, DOI 10.1093/jee/83.6.2480; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Frankel A, 1996, PROTEIN ENG, V9, P371, DOI 10.1093/protein/9.4.371; Gupta D, 1996, GLYCOBIOLOGY, V6, P843, DOI 10.1093/glycob/6.8.843; HAMMERSLEY AP, 1994, FIT 2D MANUAL; HUI Y, 1993, J BIOL CHEM, V268, P5905; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRESCH MJ, 1991, LUNG, V169, P139, DOI 10.1007/BF02714150; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE X, 1989, J MOL BIOL, V210, P685, DOI 10.1016/0022-2836(89)90144-7; MAHANTA SK, 1990, BIOCHEM J, V265, P831, DOI 10.1042/bj2650831; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PirieShepherd SR, 1997, J BIOL CHEM, V272, P7408, DOI 10.1074/jbc.272.11.7408; Ravishankar R, 1997, CURR SCI INDIA, V72, P855; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; SARKAR M, 1981, ARCH BIOCHEM BIOPHYS, V209, P204, DOI 10.1016/0003-9861(81)90273-3; Sharma V, 1996, J BIOL CHEM, V271, P21209, DOI 10.1074/jbc.271.35.21209; SPRINGER GF, 1995, CRIT REV ONCOGENESIS, V6, P57, DOI 10.1615/CritRevOncog.v6.i1.50; Suresh S, 1997, ACTA CRYSTALLOGR D, V53, P469, DOI 10.1107/S0907444997000851; TRANSUE TR, 1995, GLYCOCONJ J, V12, P425; VanDamme EJM, 1996, FEBS LETT, V397, P352, DOI 10.1016/S0014-5793(96)01211-2; WARD GK, 1992, HISTOCHEM J, V24, P685, DOI 10.1007/BF01047590; WELLER NK, 1989, AM J PATHOL, V134, P277; Wright CS, 1996, STRUCTURE, V4, P1339, DOI 10.1016/S0969-2126(96)00141-4; YOUNG NM, 1991, FEBS LETT, V282, P382, DOI 10.1016/0014-5793(91)80518-8; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K; YOUNG NM, 1995, GLYCOCONJUGATE J, V12, P135, DOI 10.1007/BF00731357; YOUNG NM, 1989, ARCH BIOCHEM BIOPHYS, V270, P596, DOI 10.1016/0003-9861(89)90542-0	37	87	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6312	6318		10.1074/jbc.273.11.6312	http://dx.doi.org/10.1074/jbc.273.11.6312			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497359	hybrid			2022-12-27	WOS:000072488500051
J	Poulsen, LK; Jacobsen, N; Sorensen, BB; Bergenhem, NCH; Kelly, JD; Foster, DC; Thastrup, O; Ezban, M; Petersen, LC				Poulsen, LK; Jacobsen, N; Sorensen, BB; Bergenhem, NCH; Kelly, JD; Foster, DC; Thastrup, O; Ezban, M; Petersen, LC			Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; SMOOTH-MUSCLE CELLS; FACTOR-XA; RECEPTOR ACTIVATION; BLOOD-COAGULATION; EXTRINSIC PATHWAY; MOLECULAR-CLONING; PHOSPHORYLATION; ASSOCIATION; INHIBITOR	The putative role of tissue factor (TF) as a receptor involved in signal transduction is indicated by its sequence homology to cytokine receptors (Bazan, J. F. (1990) Proc. Natl. Acad. Sci. U.S.A. 87 6934-6938). Signal transduction induced by binding of FVIIa to cells expressing TF was studied with baby hamster kidney (BHK) cells stably transfected with TF and with a reporter gene construct encoding a luciferase gene under transcriptional control of tandem cassettes of signal transducer and activator of transcription (STAT) elements and one serum response element (SRE). FVIIa induced a significant luciferase response in cells expressing TF, BHK(+TF), but not in cells without TF. The BHK(+TF) cells responded to the addition of FVIIa in a dose-dependent manner, whereas no response was observed with active site-inhibited FVIIa, which also worked as an antagonist to FVIIa-induced signaling. Activation of the p44/42 MAPK pathway upon binding of FVIIa to TF was demonstrated by suppression of signaling with the specific kinase inhibitor PD98059 and demonstration of a transient p44/42 MAPK phosphorylation. No stimulation of p44/42 MAPK phosphorylation was observed with catalytically inactive FVIIa derivatives suggesting that the catalytic activity of FVIIa was obligatory for activation of the MAPK pathway. Signal transduction caused by a putative generation of FXa activity was excluded by experiments showing that FVIIa/TF-induced signaling was not quenched by tick anticoagulant protein, just as addition of FXa could not induce phosphorylation of p44/42 MAPK in BHK(+TF) cells. These results suggest a specific mechanism by which binding of FVIIa to cell surface TF independent of coagulation can modulate cellular functions and possibly play a role in angiogenesis and tumor metastasis as indicated by several recent observations.	Novo Nordisk AS, Hlth Care Discovery, Vessel Wall Biol, DK-2820 Gentofte, Denmark; Novo Nordisk AS, Bioimage, DK-2820 Gentofte, Denmark; Zymogenet Inc, Seattle, WA 98102 USA	Novo Nordisk; Novo Nordisk; Zymogenet Inc.	Petersen, LC (corresponding author), Novo Nordisk AS, Hlth Care Discovery, Vessel Wall Biol, Hagedornsvej 1, DK-2820 Gentofte, Denmark.	lcp@novo.dk						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; KARNITZ LM, 1995, CURR OPIN IMMUNOL, V7, P320, DOI 10.1016/0952-7915(95)80105-7; Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; Masuda M, 1996, EUR J IMMUNOL, V26, P2529, DOI 10.1002/eji.1830261037; Mody RS, 1997, BIOCHEMISTRY-US, V36, P7869, DOI 10.1021/bi9701235; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; MOTT HR, 1995, CURR OPIN STRUC BIOL, V5, P114, DOI 10.1016/0959-440X(95)80016-T; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MUELLER YA, 1994, BIOCHEMISTRY-US, V33, P10864; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; Nicholson AC, 1996, J BIOL CHEM, V271, P28407, DOI 10.1074/jbc.271.45.28407; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; PETERSEN LC, 1995, THROMB RES, V79, P1, DOI 10.1016/0049-3848(95)00069-4; Rao LVM, 1996, BLOOD, V87, P3738, DOI 10.1182/blood.V87.9.3738.bloodjournal8793738; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; RUF W, 1997, THROMB HAEMOSTASIS S, P594; Sato Y, 1997, THROMB HAEMOSTASIS, V78, P1138; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shoji M, 1997, TRENDS CARDIOVAS MED, V7, P52, DOI 10.1016/S1050-1738(96)00142-9; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; ZANG Y, 1994, J CLIN INVEST, V94, P1320; ZINOCHECK TF, 1992, J BIOL CHEM, V267, P3561	38	142	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6228	6232		10.1074/jbc.273.11.6228	http://dx.doi.org/10.1074/jbc.273.11.6228			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497347	hybrid			2022-12-27	WOS:000072488500039
J	Workman, RF; Low, PS				Workman, RF; Low, PS			Biochemical analysis of potential sites for protein 4.1-mediated anchoring of the spectrin-actin skeleton to the erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; GLYCOPHORIN-C; 4.1 BINDING; BETA-SPECTRIN; BAND 4.1; KINASE-C; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; VESICLES	Erythrocyte protein 4.1 has been hypothesized to link the spectrin-actin junctional complex directly to the cytoplasmic domain of glycophorin C, but this bridging function has never been directly demonstrated. Because an alternative protein-mediated bridge between the junctional complex and the cytoplasmic domain of band 3 is also plausible, me have undertaken to characterize the membrane sites to which protein 4.1 can anchor the spectrin and actin skeleton. me demonstrate that proteolytic removal of the cytoplasmic domain of band 3 has minimal effect on the ability of protein 4.1 to promote I-125-labeled spectrin and actin binding to KI-stripped erythrocyte membrane vesicles. We also show that quantitative blockade of all band 3 sites with either monoclonal or polyclonal antibodies to band 3 is equally ineffective in preventing protein 4.1-mediated association of spectrin and actin with the membrane. In contrast, obstruction of protein 4.1 binding to its docking site on the cytoplasmic pole of glycophorin C is demonstrated to reduce the same protein 4.1 bridging function by similar to 85%. We conclude from these data that (i) glycophorin C contributes the primary anchoring site of the protein 4.1-mediated bridge to the spectrin-actin skeleton; (ii) band 3 is incapable of serving the same function; and (iii) additional minor protein 4.1 bridging sites may exist on the human erythrocyte membrane.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	lowps@omni.cc.purdue.edu		Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; BECKER PS, 1990, EUR J BIOCHEM, V193, P827, DOI 10.1111/j.1432-1033.1990.tb19406.x; BECKER PS, 1986, J BIOL CHEM, V261, P4620; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BENNETT V, 1983, METHOD ENZYMOL, V96, P316; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; CHAO TS, 1991, BIOCHEMISTRY-US, V30, P10529, DOI 10.1021/bi00107a023; COHEN AM, 1988, BIOCHEMISTRY-US, V27, P614, DOI 10.1021/bi00402a018; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P6091, DOI 10.1021/bi00320a029; COHEN CM, 1980, BIOCHEM BIOPH RES CO, V97, P1429, DOI 10.1016/S0006-291X(80)80025-8; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P4488, DOI 10.1021/bi00314a039; COLEMAN TR, 1987, J CELL BIOL, V104, P519, DOI 10.1083/jcb.104.3.519; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DISCHER DE, 1994, SCIENCE, V266, P1032, DOI 10.1126/science.7973655; EDER PS, 1986, BIOCHEMISTRY-US, V25, P1764, DOI 10.1021/bi00355a047; FEO CJ, 1980, NOUV REV FR HEMATOL, V22, P315; GASCARD P, 1994, BLOOD, V83, P1102; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; LING E, 1988, J BIOL CHEM, V263, P2209; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LORENZO F, 1994, J CLIN INVEST, V94, P1651, DOI 10.1172/JCI117508; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MORIYAMA R, 1993, J BIOL CHEM, V268, P10990; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; MUELLER TJ, 1981, ERYTHROCYTE MEMBRANE, V2, P95; PALEK J, 1990, SEMIN HEMATOL, V27, P290; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PEKRUN A, 1989, EUR J BIOCHEM, V182, P713, DOI 10.1111/j.1432-1033.1989.tb14883.x; PINDER JC, 1995, BIOCHEM BIOPH RES CO, V210, P478, DOI 10.1006/bbrc.1995.1685; REID ME, 1990, BLOOD, V75, P2229; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; RYBICKI AC, 1988, J CLIN INVEST, V81, P255, DOI 10.1172/JCI113303; SATO SB, 1983, EUR J BIOCHEM, V130, P19; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SHIFFER KA, 1988, BIOCHIM BIOPHYS ACTA, V937, P269, DOI 10.1016/0005-2736(88)90249-0; SHIFFER KA, 1984, P NATL ACAD SCI-BIOL, V81, P4404, DOI 10.1073/pnas.81.14.4404; SMYTHE J, 1994, BLOOD, V83, P1668; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WORKMAN RF, 1998, IN PRESS PROTEIN EXP, V11	55	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6171	6176		10.1074/jbc.273.11.6171	http://dx.doi.org/10.1074/jbc.273.11.6171			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497338	hybrid			2022-12-27	WOS:000072488500030
J	Burgess, JW; Gould, DR; Marcel, YL				Burgess, JW; Gould, DR; Marcel, YL			The HepG2 extracellular matrix contains separate heparinase- and lipid-releasable pools of apoE - Implications for hepatic lipoprotein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; NORMAL RAT-LIVER; LOW-DENSITY-LIPOPROTEIN; HUMAN APOLIPOPROTEIN-E; CELL-SURFACE PROTEOGLYCANS; MONOCLONAL-ANTIBODIES; CHOLESTEROL EFFLUX; BINDING-ACTIVITY; A-I; LAMININ	We have examined the association of apoE with the extracellular matrix (ECM) of HepG2 cells. Comparison of ECM prepared by previously published methods demonstrated that cytochalasin B-prepared material yielded the highest endogenous apoE, representing 23.6% of that in cell monolayers. ECM prepared with EDTA or Triton X-100 exhibited decreased levels of apoE, 3 and 6%, respectively. ECM bound very law density lipoprotein poorly (5-6% of the monolayer capacity); however, these incubations dramatically increased the apoE content of the ECM. Heparinase or suramin decreased apoE of the ECM by 19.6 and 37.3%, respectively, suggesting association with heparin sulfate proteoglycans. EDTA or EGTA also displaced 35% of the apoE, suggesting a Ca2+-dependent association. Incubation with phosphatidylcholine vesicles (PCV) displaced 30% of the apoE, suggesting that lipid content affects association of apoE with the ECM, Data derived from sequential incubations with combinations of suramin, EGTA, and PCV were consistent with the presence of two distinct pools of apoE on the HepG2 ECM, one releasable with suramin and EGTA and the other releasable with lipids, Exogenously applied lipid-free apoE readily bound to the ECM; however, increasing the lipid content decreased its association. Lipid-free apoE could be equally displaced from the ECM with PCV or suramin, When lipid-free apoE adsorbed to microtiter wells was incubated with a triglyceride emulsion or palmitoyloleyl phosphatidylcholine micelles, the immunoreactivity of 3H1 (but not other antibodies), a monoclonal antibody against an epitope in the C-terminal domain of apoE, increased about 4-fold, In a similar manner, incubation of ECM with lipid dramatically increased the immunoreactivity of 3H1, indicating that apoE of the ECM exists in a lipid-poor form. Scatchard analysis demonstrated that the increased immunoreactivity was due to an increase in the number of antibody binding sites, In conclusion, the ECM contains two pools of lipid-poor apoE. One pool associates with the ECM through heparin sulfate proteoglycans-and Ca2+-dependent interactions, A second pool of apoE dissociates from the ECM upon lipidation. The lipid-sensitive pool of apoE may participate in secretion or efflux of lipids or in the capture of lipoproteins by providing the apoE needed for receptor-mediated uptake.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Dept Biochem, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Dept Biochem, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.							AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Alberts B., 1994, MOL BIOL CELL, P971; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; CHAJEKSHAUL T, 1990, BIOCHIM BIOPHYS ACTA, V1042, P168, DOI 10.1016/0005-2760(90)90003-G; CISAR LA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P196, DOI 10.1016/0005-2760(89)90268-3; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; Deng JT, 1997, J LIPID RES, V38, P217; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; FORTE TM, 1993, J LIPID RES, V34, P317; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; GEERTS A, 1986, HISTOCHEMISTRY, V84, P355, DOI 10.1007/BF00482963; GETZ GS, 1995, ATHEROSCLEROSIS, V10; GOSPODAROWICZ D, 1980, P NATL ACAD SCI-BIOL, V77, P4094, DOI 10.1073/pnas.77.7.4094; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; HUSSEIN MM, 1989, BIOCHIM BIOPHYS ACTA, V100, P90; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JOHNSON FL, 1986, J LIPID RES, V27, P537; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAHER JJ, 1988, GASTROENTEROLOGY, V94, P1053, DOI 10.1016/0016-5085(88)90566-5; MAI S, 1984, EXP CELL RES, V152, P500, DOI 10.1016/0014-4827(84)90652-9; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTINEZHERNANDEZ A, 1984, LAB INVEST, V51, P57; MARTINEZHERNANDEZ A, 1993, VIRCHOWS ARCH A, V423, P1, DOI 10.1007/BF01606425; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; MILNE RW, 1981, J CLIN INVEST, V68, P111, DOI 10.1172/JCI110225; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PEASE RJ, 1990, J BIOL CHEM, V265, P553; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RESCAN PY, 1991, HEPATOLOGY, V13, P289, DOI 10.1016/0270-9139(91)92442-B; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHGER L, 1996, DEV BIOL, V179, P264; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; SPARKS DL, 1995, J BIOL CHEM, V270, P5151, DOI 10.1074/jbc.270.10.5151; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; TAM SP, 1992, ATHEROSCLEROSIS, V95, P137, DOI 10.1016/0021-9150(92)90017-B; TIMPL R, 1993, MOL CELLULAR ASPECTS, P211; WEISGRABER KH, 1991, J BIOL CHEM, V266, P12029; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILLIAMS DL, 1995, J LIPID RES, V36, P745; WINKLER KE, 1989, J LIPID RES, V30, P979; ZANNIS VI, 1986, J BIOL CHEM, V261, P3415; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641	58	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5645	5654		10.1074/jbc.273.10.5645	http://dx.doi.org/10.1074/jbc.273.10.5645			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488694	hybrid			2022-12-27	WOS:000072345000037
J	Hebert, MC; Schwede, F; Jastorff, B; Cote, RH				Hebert, MC; Schwede, F; Jastorff, B; Cote, RH			Structural features of the noncatalytic cGMP binding sites of frog photoreceptor phosphodiesterase using cGMP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; BOVINE ADRENAL-TISSUE; STIMULATED PHOSPHODIESTERASE; CATALYTIC SITES; I-BETA; GMP; PURIFICATION; SPECIFICITY; DERIVATIVES	The cGMP-specific phosphodiesterase (PDE) of retinal photoreceptors is a central regulatory enzyme in the visual transduction pathway of vertebrate vision. Although the mechanism of activation of PDE by transducin is well understood, the role of the noncatalytic cGMP binding sites located on the catalytic subunits of PDE remains obscure. We report here for the first time the molecular basis of the noncovalent interactions between cGMP and the high affinity, noncatalytic cGMP binding sites of frog photoreceptor PDE. None of the tested cGMP analogs were able to bind with greater affinity than cGMP itself, and the noncatalytic sites were unable to bind cAMP. The major determinant for discrimination of cGMP over cAMP is in the N-1/C-6 region of the purine ring of cGMP where hydrogen bonding probably stabilizes the selective binding of cGMP. Substitutions at the C-2 position demonstrate that this region of the molecule plays a secondary but significant role in stabilizing cGMP binding to PDE through hydrogen bond interactions. The unaltered hydrogen at the C-8 position is also important for high affinity binding. A significant interaction between the binding pocket and the ribose ring of cGMP occurs at the 2'-hydroxyl position. Steric constraints were greatest in the C-8 and possibly the C-6/N-1 regions, whereas the C-2/N-3 and C-2' regions tolerated bulky substituents better, Several lines of evidence indicate that the noncatalytic site binds cGMP in the anti-conformation. The numerous noncovalent interactions between cGMP and the noncatalytic binding pocket of the photoreceptor PDE described in this study account for both the high affinity for cGMP and the high level of discrimination of cGMP from other cyclic nucleotides at the noncatalytic site.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Univ Bremen, Zentrum Umweltforsch & Umwelttechnol, Abt Bioorgan Chem 3, D-28359 Bremen, Germany	University System Of New Hampshire; University of New Hampshire; University of Bremen	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.	Rick.Cote@unh.edu	Cote, Rick/G-3363-2013	Cote, Rick/0000-0002-1573-6526	NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY005798, EY-05798] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BELTMAN J, 1995, MOL PHARMACOL, V47, P330; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BROWN RL, 1993, BIOCHEMISTRY-US, V32, P10089, DOI 10.1021/bi00089a026; BUTT E, 1995, MOL PHARMACOL, V47, P340; CHAE MY, 1994, J MED CHEM, V37, P342, DOI 10.1021/jm00029a005; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHO BP, 1991, BIOCHEM BIOPH RES CO, V180, P273, DOI 10.1016/S0006-291X(05)81288-4; CHWANG AK, 1974, ACTA CRYSTALLOGR B, V30, P1233, DOI 10.1107/S0567740874004602; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; ERNEUX C, 1985, J CYCLIC NUCL PROT, V10, P463; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; GENIESER HG, 1989, SYNTHESIS-STUTTGART, P53; GENIESER HG, 1988, TETRAHEDRON LETT, V29, P2803, DOI 10.1016/0040-4039(88)85214-6; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; JASTORFF B, 1972, CHEM BER-RECL, V105, P3192, DOI 10.1002/cber.19721051007; JASTORFF B, 1979, CYCLIC NUCLEOTIDES T, P85; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; KESBEKE F, 1985, EUR J BIOCHEM, V151, P179, DOI 10.1111/j.1432-1033.1985.tb09083.x; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; KUSMIEREK JT, 1987, J ORG CHEM, V52, P2374, DOI 10.1021/jo00388a007; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MEYER RB, 1975, J CYCLIC NUCL PROT, V1, P159; MICHAL G, 1974, PHARMACOL RES COMMUN, V6, P203, DOI 10.1016/S0031-6989(74)80043-3; MILLER JP, 1973, BIOCHEMISTRY-US, V12, P5310, DOI 10.1021/bi00750a014; MIOT F, 1985, EUR J BIOCHEM, V149, P59, DOI 10.1111/j.1432-1033.1985.tb08893.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NASS N, 1992, BIOCHEM J, V285, P129, DOI 10.1042/bj2850129; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SCHWEDE F, 1996, THESIS U BREMEN BREM; SCOTT SP, 1995, BIOCHEMISTRY-US, V34, P2338, DOI 10.1021/bi00007a030; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; STOLARSKI R, 1984, EUR J BIOCHEM, V138, P187, DOI 10.1111/j.1432-1033.1984.tb07898.x; TANAKA JC, 1989, BIOCHEMISTRY-US, V28, P2776, DOI 10.1021/bi00433a006; THOMAS MK, 1992, ADV SEC MESS PHOSPH, V25, P45; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; TOPIOL S, 1990, J AM CHEM SOC, V112, P1452, DOI 10.1021/ja00160a024; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	57	22	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5557	5565		10.1074/jbc.273.10.5557	http://dx.doi.org/10.1074/jbc.273.10.5557			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488681	hybrid, Green Published			2022-12-27	WOS:000072345000024
J	Pattanajitvilai, S; Kuroki, Y; Tsunezawa, W; McCormack, FX; Voelker, DR				Pattanajitvilai, S; Kuroki, Y; Tsunezawa, W; McCormack, FX; Voelker, DR			Mutational analysis of Arg(197) of rat surfactant protein A - His(197) creates specific lipid uptake defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; PULMONARY SURFACTANT; II CELLS; SP-A; PHOSPHOLIPID SECRETION; HIGH-AFFINITY; PHAGOCYTOSIS; RECEPTOR; PHOSPHATIDYLCHOLINE; MACROPHAGES	In previous studies, tandem mutagenesis of Glu(195) and Arg(197) of surfactant protein A (SP-A) has implicated both residues as critical participants in the interaction of the molecule with alveolar type II cells and phospholipids. We substituted Ala, Lys, His, Asp, and Asn mutations for Arg to evaluate the role of a basic amino acid at position 197 in SP-A action. Unexpectedly, Ala(197) retained complete activity in the SP-A functions of carbohydrate binding type HL cell binding inhibition of surfactant secretion, lipid binding, lipid aggregation, and lipid uptake by type II cells. The results unambiguously demonstrate that Arg(197) is not mechanistically essential for SP-A function, The Lys(197) mutation displayed all functions of the wild type protein but exhibited a 2-fold increase in lipid uptake activity. The His(197) mutation displayed all SP-B functions studied except for lipid uptake. The results obtained with the His(197) mutation clearly demonstrate that lipid aggregation alone by SP-A is insufficient to promote lipid uptake by type II cells, These findings indicate that specific interactions between type II cells send SP-A are involved in the phospholipid uptake processes.	Natl Jewish Med & Res Ctr, Lord & Taylor Lab Lung Biochem, Denver, CO 80206 USA; Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido, Japan; Univ Cincinnati, Sch Med, Div Pulm & Crit Care Med, Cincinnati, OH 45267 USA	National Jewish Health; Sapporo Medical University; University System of Ohio; University of Cincinnati	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Lord & Taylor Lab Lung Biochem, 1400 Jackson St, Denver, CO 80206 USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENSON BJ, 1984, BIOCHIM BIOPHYS ACTA, V793, P18, DOI 10.1016/0005-2760(84)90048-1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horowitz AD, 1996, AM J PHYSIOL-LUNG C, V270, pL69, DOI 10.1152/ajplung.1996.270.1.L69; Ikegami M, 1997, AM J PHYSIOL-LUNG C, V272, pL479, DOI 10.1152/ajplung.1997.272.3.L479; KAWADA H, 1989, AM REV RESPIR DIS, V140, P460, DOI 10.1164/ajrccm/140.2.460; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; O'Reilly D., 1992, BACULOVIRUS EXPRESSI, P109; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1986, J BIOL CHEM, V261, P14283; Ruano MLF, 1996, BIOCHEM J, V313, P683, DOI 10.1042/bj3130683; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; STEVENS PA, 1995, BIOCHEM J, V308, P77, DOI 10.1042/bj3080077; STRAYER DS, 1993, J BIOL CHEM, V268, P18679; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410	38	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5702	5707		10.1074/jbc.273.10.5702	http://dx.doi.org/10.1074/jbc.273.10.5702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488702	hybrid			2022-12-27	WOS:000072345000045
J	de Laat, WL; Appeldoorn, E; Jaspers, NGJ; Hoeijmakers, JHJ				de Laat, WL; Appeldoorn, E; Jaspers, NGJ; Hoeijmakers, JHJ			DNA structural elements required for ERCC1-XPF endonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; REPLICATION PROTEIN-A; GENE ERCC-1; NUCLEASE; RECOMBINATION; RAD1; XPG; XPF-ERCC1; INCISION; SUBUNITS	The heterodimeric complex ERCC1-XPF is a structure-specific endonuclease responsible for the 5' incision during mammalian nucleotide excision repair (NER). Additionally, ERCC1-XPF is thought to function in the repair of interstrand DNA cross-links and, by analogy to the homologous Rad1-Rad10 complex in Saccharomyces cerevisiae, in recombination between direct repeated DNA sequences. To gain insight into the role of ERCC1-XPF in such recombinational processes and in the NER reaction, we studied in detail the DNA structural elements required for ERCC1-XPF endonucleolytic activity, Recombinant ERCC1-XPF, purified from insect cells, was found to cleave stem-loop substrates at the DNA junction in the absence of other proteins like replication protein A, showing that the structure-specific endonuclease activity is intrinsic to the complex, Cleavage depended on the presence of divalent cations and was optimal in low Mn2+ concentrations (0.2 mM). A minimum of 4-8 unpaired nucleotides was required for incisions by ERCC1-XPF. Splayed arm and flap substrates were also cut by ERCC1-XPF, resulting in the removal of 3' protruding single-stranded arms, All incisions occurred in one strand of duplex DNA at the 5' side of a junction with single-stranded DNA, The exact cleavage position varied from 2 to 8 nucleotides away from the junction, One single-stranded arm, protruding either in the 3' or 5' direction, was necessary and sufficient for correct positioning of incisions by ERCC1-XPF, Our data specify the engagement of ERCC1-XPF in NER and allow a more direct search for its specific role in recombination.	Erasmus Univ, Dept Cell Biol & Genet, Ctr Med Genet, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Dept Cell Biol & Genet, Ctr Med Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Hoeijmakers, Jan/AAX-6972-2021	de Laat, Wouter/0000-0002-6393-595X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FRIEDBERG E, 1985, DNA REPAIR MUTAGENES; GUTZ H, 1985, CURR GENET, V9, P325, DOI 10.1007/BF00421601; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; VANDUIN M, 1988, NUCLEIC ACIDS RES, V16, P5305, DOI 10.1093/nar/16.12.5305; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022	38	180	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7835	7842		10.1074/jbc.273.14.7835	http://dx.doi.org/10.1074/jbc.273.14.7835			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525876	Green Published, hybrid			2022-12-27	WOS:000072876300010
J	Estienne, V; Duthoit, C; Vinet, L; Durand-Gorde, JM; Carayon, P; Ruf, J				Estienne, V; Duthoit, C; Vinet, L; Durand-Gorde, JM; Carayon, P; Ruf, J			A conformational B-cell epitope on the C-terminal end of the extracellular part of human thyroid peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; IMMUNODOMINANT REGION; MOLECULAR-CLONING; DISEASE; AUTOANTIBODIES; AUTOANTIGEN; ANTIBODY; THYROPEROXIDASE; FRAGMENTS; THYROGLOBULIN	To investigate the B-cell autoimmune epitopes on human thyroid peroxidase (TPO), we generated proteolytic peptides by enzymatic hydrolysis of TPO in nondenaturing and nonreducing conditions. The hydrolysate was chromatographed on a reverse phase column. We eluted a material immunoreactive with both a TPO monoclonal antibody recognizing a linear epitope (mAb47, amino acid 713-721) and TPO autoantibodies (aAb) from patients. The aAb immunoreactivity, but not that of mAb47, was lost after reduction. Western blots after electrophoresis without reduction showed that the aAb and mAb47 were immunoreactive with a 66-kDa band and that aAb identified a doublet at 20 kDa. For electrophoresis under reducing conditions, the 66-kDa band resolved into two peptides of 40 and 26 kDa, whereas the doublet at 20 kDa remained unchanged. None of these reduced peptides was immunoreactive with aAbm, whereas the 40-kDa paptide was immunoreactive with mAb47. The 40-kDa peptide extends from amino acids 549 to 933 of TPO, and its last 192 amino acids overlap the autoimmune 20-kDa peptide. After iodine labeling, the 20-kDa peptide lost its immunoreactivity. We conclude that the C-terminal end of the extracellular part of TPO, which includes all the tyrosine residues of the 20-kDa peptide, contains at least one conformational B-cell epitope involved in autoimmune thyroid diseases.	INSERM, U38, F-13385 Marseille 5, France; Fac Med Marseille, Lab Biochim Endocrinienne & Metab, F-13385 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Ruf, J (corresponding author), INSERM, U38, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.	Jean.Ruf@medecine.univ-mrs.fr	Ruf, Jean/E-3963-2016	Ruf, Jean/0000-0003-4300-8048				ALAMIHARCHALI A, 1994, CLIN CHEM, V40, P442; Arscott PL, 1996, J BIOL CHEM, V271, P4966; BANGA JP, 1991, AUTOIMMUNITY, V8, P335, DOI 10.3109/08916939109007642; BANGA JP, 1990, AUTOIMMUNITY, V6, P257, DOI 10.3109/08916939008998418; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CHAZENBALK GD, 1993, J CLIN ENDOCR METAB, V77, P1715, DOI 10.1210/jc.77.6.1715; CORDIEROCHSENBEIN F, 1995, BIO-TECHNOL, V13, P276, DOI 10.1038/nbt0395-276; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; DOBLE ND, 1988, IMMUNOLOGY, V64, P23; ELISEI R, 1990, AUTOIMMUNITY, V8, P65, DOI 10.3109/08916939008998434; FIUKE R, 1991, J CLIN ENDOCR METAB, V73, P919; FRORATH B, 1992, J BIOCHEM-TOKYO, V111, P633, DOI 10.1093/oxfordjournals.jbchem.a123810; KOHNO Y, 1986, CLIN EXP IMMUNOL, V65, P534; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LIBERT F, 1991, J CLIN ENDOCR METAB, V73, P857, DOI 10.1210/jcem-73-4-857; LUDGATE M, 1989, J CLIN ENDOCR METAB, V68, P1091, DOI 10.1210/jcem-68-6-1091; MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; Nishikawa T, 1996, ENDOCRINOLOGY, V137, P1000, DOI 10.1210/en.137.3.1000; NUNEZ J, 1980, THYROID GLAND, P39; OKAMOTO Y, 1989, J CLIN ENDOCR METAB, V68, P730, DOI 10.1210/jcem-68-4-730; PORTMANN L, 1985, J CLIN ENDOCR METAB, V61, P1001, DOI 10.1210/jcem-61-5-1001; PORTOLANO S, 1992, J CLIN INVEST, V90, P720, DOI 10.1172/JCI115943; Rapoport B., 1994, ENDOCRINE REVS, V3, P96; Rodien P, 1996, J CLIN ENDOCR METAB, V81, P2595, DOI 10.1210/jc.81.7.2595; RUF J, 1994, J CLIN ENDOCR METAB, V79, P1404, DOI 10.1210/jc.79.5.1404; RUF J, 1992, AUTOIMMUNITY, V11, P179, DOI 10.3109/08916939209035153; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; SALLER B, 1991, J CLIN ENDOCR METAB, V72, P188, DOI 10.1210/jcem-72-1-188; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAUROG A, 1990, ARCH BIOCHEM BIOPHYS, V278, P333, DOI 10.1016/0003-9861(90)90268-4; TAUROG A, 1986, WERNERS THYROID, P53; TONACCHERA M, 1995, EUR J ENDOCRINOL, V132, P53, DOI 10.1530/eje.0.1320053; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; YOKOYAMA N, 1989, J CLIN ENDOCR METAB, V68, P766, DOI 10.1210/jcem-68-4-766; ZANELLI E, 1992, CLIN EXP IMMUNOL, V87, P80	36	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8056	8062		10.1074/jbc.273.14.8056	http://dx.doi.org/10.1074/jbc.273.14.8056			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525906	hybrid			2022-12-27	WOS:000072876300040
J	Yamaguchi, M; Belogrudov, GI; Hatefi, Y				Yamaguchi, M; Belogrudov, GI; Hatefi, Y			Mitochondrial NADH-ubiquinone oxidoreductase (complex I) - Effects of substrates on the fragmentation of subunits by trypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; IRON-SULFUR CLUSTERS; ACYL-CARRIER PROTEIN; PARACOCCUS-DENITRIFICANS; QUINONE OXIDOREDUCTASE; PROTON TRANSLOCATION; NEUROSPORA-CRASSA; ELECTRON-TRANSPORT; DEHYDROGENASE; FLAVOPROTEIN	It has been shown that treatment of bovine mitochondrial complex I (NADH-ubiquinone oxidoreductase) with NADH or NADPH, but not with NAD or NADP, increases the susceptibility of a number of subunits to tryptic degradation. This increased susceptibility involved subunits that contain electron carriers, such as FMN and iron-sulfur clusters, as well as subunits that lack electron carriers. Results shown elsewhere on changes in the cross-linking pattern of complex I subunits when the enzyme was pretreated with NADH or NADPH (Belogrudov, G., and Hatefi, Y. (1994) Biochemistry 33, 4571-4576) also indicated that complex I undergoes extensive conformation changes when reduced by substrate. Furthermore, we had previously shown that in submitochondrial particles the affinity of complex I for NAD increases by greater than or equal to 20-fold in electron transfer from succinate to NAD when the particles are energized by ATP hydrolysis. Together, these results suggest that energy coupling in complex I may involve protein conformation changes as a key step. In addition, it has been shown here that treatment of complex I with trypsin in the presence of NADPH, but not NADH or NAD(P), produced from the 39-kDa subunit a 33-kDa degradation product that resisted further hydrolysis. Like the 39-kDa subunit, the 33-kDa product bound to a NADP-agarose affinity column, and could be eluted with a buffer containing NADPH. It is possible that together with the acyl carrier protein of complex I the NADP(H)-binding 39-kDa subunit is involved in intramitochondrial fatty acid synthesis.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92087 USA	Scripps Research Institute	Hatefi, Y (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92087 USA.				NIDDK NIH HHS [DK08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK008126, R37DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albracht SPJ, 1997, BBA-BIOENERGETICS, V1318, P92, DOI 10.1016/S0005-2728(96)00153-3; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Belogrudov GI, 1996, BIOCHEM BIOPH RES CO, V227, P135, DOI 10.1006/bbrc.1996.1479; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; DENG PSK, 1990, BIOCHEMISTRY-US, V29, P1094, DOI 10.1021/bi00456a036; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FECKE W, 1994, EUR J BIOCHEM, V220, P551, DOI 10.1111/j.1432-1033.1994.tb18655.x; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAN AL, 1988, ARCH BIOCHEM BIOPHYS, V267, P490, DOI 10.1016/0003-9861(88)90055-0; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HATEFI Y, 1967, BIOCHEM BIOPH RES CO, V26, P301, DOI 10.1016/0006-291X(67)90122-2; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; Hatefi Y, 1978, Methods Enzymol, V53, P11; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HATEFI Y, 1976, BIOCHEM BIOPH RES CO, V69, P1032, DOI 10.1016/0006-291X(76)90476-9; HATEFI Y, 1982, P NATL ACAD SCI-BIOL, V79, P1756, DOI 10.1073/pnas.79.6.1756; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HATEFI Y, 1973, BIOCHEMISTRY-US, V12, P3515, DOI 10.1021/bi00742a026; HATEFI Y, 1977, MOL BIOL MEMBRANES, P163; HATEFI Y, 1985, ENZYMES BIOL MEMBR, P1; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; KRISHNAMOORTHY G, 1988, J BIOL CHEM, V263, P17566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUI R, 1991, J BIOCHEM-TOKYO, V109, P534, DOI 10.1093/oxfordjournals.jbchem.a123416; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MatsunoYagi A, 1997, J BIOL CHEM, V272, P16928, DOI 10.1074/jbc.272.27.16928; MatsunoYagi A, 1996, J BIOL CHEM, V271, P6164, DOI 10.1074/jbc.271.11.6164; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOSBACH K, 1972, BIOCHEM J, V127, P625, DOI 10.1042/bj1270625; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PfenningerLi XD, 1996, BIOCHEMISTRY-US, V35, P6233, DOI 10.1021/bi953032l; Ragan C I, 1980, Subcell Biochem, V7, P267; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; RAGAN CI, 1976, BIOCHEM J, V156, P367, DOI 10.1042/bj1560367; RAGAN CI, 1982, BIOCHEMISTRY-US, V21, P2518, DOI 10.1021/bi00539a035; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; SCHULTE U, 1994, BBA-BIOENERGETICS, V1187, P121, DOI 10.1016/0005-2728(94)90096-5; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; SLED VD, 1993, BIOCHIM BIOPHYS ACTA, V1141, P262, DOI 10.1016/0005-2728(93)90051-G; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VINOGRADOV AD, 1993, J BIOENERG BIOMEMBR, V25, P367, DOI 10.1007/BF00762462; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEISS H, 1991, J BIOENERG BIOMEMBR, V23, P743, DOI 10.1007/BF00785999; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; YAMAGUCHI M, 1993, BIOCHEMISTRY-US, V32, P1935, DOI 10.1021/bi00059a008; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F	58	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8094	8098		10.1074/jbc.273.14.8094	http://dx.doi.org/10.1074/jbc.273.14.8094			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525911	hybrid			2022-12-27	WOS:000072876300045
J	Ariyoshi, N; Kim, YC; Artemenko, I; Bhattacharyya, KK; Jefcoate, CR				Ariyoshi, N; Kim, YC; Artemenko, I; Bhattacharyya, KK; Jefcoate, CR			Characterization of the rat Star gene that encodes the predominant 3.5-kilobase pair mRNA - ACTH stimulation of adrenal steroids in vivo precedes elevation of Star mRNA and protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; LEYDIG TUMOR-CELLS; URIDINE BINDING-FACTOR; ADRENOCORTICOTROPIC HORMONE; CORPUS-LUTEUM; CORTEX CELLS; EXPRESSION; STEROIDOGENESIS; IDENTIFICATION; CLONING	The steroidogenic acute regulatory protein (STAR) participates in steroidogenesis through the mitochondrial transfer of cholesterol to cytochrome P450scc. The rat adrenal Star gene is transcribed as a 3.5-kilobase pair (kb) and 1.6 kb mRNA with the larger mRNA predominating (similar to 85% of total) in. vivo, Hypophysectomy (HPX) produced a 3-5-fold decrease in Star mRNA along with a loss of adrenal steroids, whereas P450scc mRNA decreased by less than 2-fold, Adrenocorticotropic hormone (ACTH) treatment of HPX rats maximally stimulated steroidogenesis rates within 5 min with over 10-fold elevation of steady state blood levels occurring within 10 min. For intact rats there was a 5-10-fold larger increase, paralleling previously observed elevations of cholesterol-cytochrome P450scc association and metabolism in subsequently isolated adrenal mitochondria, ACTH did not increase either total STAR protein or a group of modified forms until at least 30 min after completion of acute stimulation, indicating that elevated translation of STAR protein cannot alone mediate this acute stimulation. Parallel slow changes in STAR protein and corticosterone formation after ACTH treatment are consistent with participation of STAR forms as co-regulators of these hormonal responses, ACTH stimulation of HPX rats increased Star mRNA by 2.5-fold within 20 min and by 4.5-fold after 1 h, thus preceding the rise in the STAR protein, A 3.5-kb Star cDNA clone isolated from a rat adrenal cDNA library exhibited a 0.9-kb open reading frame and a 2.5-kb 3'-untranslated region (3'-UTR). The open reading frame sequence differed at only 12 amino acids from that of the mouse Star. The rat Star gene seven exons with exon 7 encoding the entire 2.5 kb of 3'-UTR of the 3,5-kb mRNA. The 3'-UTR sequence suggests that 1.6- and 3,5-kb mRNA are formed by an alternative usage of different polyadenylation signals, Multiple UUAUUUA(U/A)(U/A) motifs also suggest additional regulation through this extended 3'-UTR, Although elevation of STAR protein by ACTH does not cause the acute increase in adrenal cholesterol metabolism, changes in the turnover or distribution of an active STAR subfraction cannot be excluded.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Jefcoate, CR (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	jefcoate@facstaff.wisc.edu						ALBERTA JA, 1989, J BIOL CHEM, V264, P2368; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; BOUJRAD N, 1994, ENDOCRINOLOGY, V135, P1576, DOI 10.1210/en.135.4.1576; BROWNIE AC, 1973, ANN NY ACAD SCI, V212, P344, DOI 10.1111/j.1749-6632.1973.tb47606.x; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; CHURCHILL PF, 1979, J BIOL CHEM, V254, P443; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; Clark BJ, 1995, MOL CELL ENDOCRINOL, V115, P215, DOI 10.1016/0303-7207(95)03683-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CRIVELLO JF, 1978, BIOCHIM BIOPHYS ACTA, V542, P315, DOI 10.1016/0304-4165(78)90027-2; ELLIOTT ME, 1993, ENDOCRINOLOGY, V133, P1669, DOI 10.1210/en.133.4.1669; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Fujieda K, 1997, J CLIN INVEST, V99, P1265, DOI 10.1172/JCI119284; Garren L D, 1971, Recent Prog Horm Res, V27, P433; HARTUNG S, 1995, BIOCHEM BIOPH RES CO, V215, P646, DOI 10.1006/bbrc.1995.2513; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; JEFCOATE CR, 1976, J BIOL CHEM, V251, P3706; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JUENGEL JL, 1995, ENDOCRINOLOGY, V136, P5423, DOI 10.1210/en.136.12.5423; Kim YC, 1997, STEROIDS, V62, P10, DOI 10.1016/S0039-128X(96)00153-5; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LANGADO CA, 1994, MOL CELL BIOL, V14, P7984; Lee HK, 1997, BIOCHEM BIOPH RES CO, V230, P528, DOI 10.1006/bbrc.1996.6001; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LIN T, 1996, 10 INT C END, P597; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Nakae J, 1997, HUM MOL GENET, V6, P571, DOI 10.1093/hmg/6.4.571; PAPADOPOULOS V, 1995, J STEROID BIOCHEM, V53, P103, DOI 10.1016/0960-0760(95)00027-W; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; PON LA, 1986, J BIOL CHEM, V261, P6594; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandhoff TW, 1996, ENDOCRINE, V4, P259, DOI 10.1007/BF02738692; SIMPSON ER, 1972, EUR J BIOCHEM, V28, P443; SIMPSON ER, 1979, J BIOL CHEM, V253, P3135; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STONE D, 1954, ARCH BIOCHEM BIOPHYS, V51, P457, DOI 10.1016/0003-9861(54)90501-9; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; SUGAWARA T, 1996, 10 INT C END, P95; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	58	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7610	7619		10.1074/jbc.273.13.7610	http://dx.doi.org/10.1074/jbc.273.13.7610			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516465	hybrid			2022-12-27	WOS:000072738500061
J	Pappolla, M; Bozner, P; Soto, C; Shao, HY; Robakis, NK; Zagorski, M; Frangione, B; Ghiso, J				Pappolla, M; Bozner, P; Soto, C; Shao, HY; Robakis, NK; Zagorski, M; Frangione, B; Ghiso, J			Inhibition of Alzheimer beta-fibrillogenesis by melatonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PEPTIDE; A-BETA; SECONDARY STRUCTURE; FIBRIL FORMATION; IN-VITRO; PROTEIN; DISEASE; AGGREGATION; DEMENTIA; CONFORMATIONS	It is generally postulated that the amyloid beta protein (A beta) plays a central role in the progressive neurodegeneration observed in Alzheimer's disease. Important pathologic properties of this protein, such as neurotoxicity and resistance to proteolytic degradation, depend on the ability of A beta to form beta-sheet structures or amyloid fibrils. We report that melatonin, a hormone recently found to protect neurons against A beta toxicity, interacts with A beta 1-40 and A beta 1-42 and inhibits the progressive formation of beta-sheets and amyloid fibrils. These interactions between melatonin and the amyloid peptides were demonstrated by circular dichroism and electron microscopy for A beta 1-40 and A beta 1-42 and by nuclear magnetic resonance spectroscopy for A beta 1-40. Inhibition of beta-sheets and fibrils could not be accomplished in control experiments when a free radical scavenger or a melatonin analog were substituted for melatonin under otherwise identical conditions. In sharp contrast with conventional anti-oxidants and available anti-amyloidogenic compounds, melatonin crosses the blood-brain barrier, is relatively devoid of toxicity, and constitutes a potential new therapeutic agent in Alzheimer's disease.	Univ S Alabama, Coll Med, Mobile, AL 36617 USA; NYU, New York, NY 10016 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA	University of South Alabama; New York University; Case Western Reserve University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pappolla, M (corresponding author), Univ S Alabama, Coll Med, Mobile, AL 36617 USA.		Robakis, Nikolaos/AAA-1838-2021; Pappolla, Miguel/ABE-4966-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR002594, R01AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011130, R01AG005891, R37AG005891] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02594] Funding Source: Medline; NIA NIH HHS [AG11130, AG05891] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Buchet R, 1996, BBA-MOL BASIS DIS, V1315, P40, DOI 10.1016/0925-4439(95)00102-6; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSH AI, 1994, J BIOL CHEM, V269, P12152; DORI D, 1994, CHRONOBIOLOGIA, V21, P121; DYRKS T, 1992, J BIOL CHEM, V267, P18210; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Huang THJ, 1997, J MOL BIOL, V269, P214; IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; MISHIMA K, 1994, ACTA PSYCHIAT SCAND, V89, P1, DOI 10.1111/j.1600-0447.1994.tb01477.x; Naiki H, 1997, BIOCHEMISTRY-US, V36, P6243, DOI 10.1021/bi9624705; Naiki H, 1996, LAB INVEST, V74, P374; NORDLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768, DOI 10.1210/jcem-45-4-768; PANG SF, 1974, GEN COMP ENDOCR, V22, P499, DOI 10.1016/0016-6480(74)90026-4; Pappolla MA, 1997, J NEUROSCI, V17, P1683; PAPPOLLA MA, 1990, EUR ARCH PSY CLIN N, V239, P314, DOI 10.1007/BF01735057; PAPPOLLA MA, 1995, CHRONIC DIS, P3; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERKINS SJ, 1982, BIOL MAGNETIC RESONA; PIERPAOLI W, 1991, ANN NY ACAD SCI, V621, P291; Pierpaoli W, 1991, Aging (Milano), V3, P99; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; Salomon AR, 1996, BIOCHEMISTRY-US, V35, P13568, DOI 10.1021/bi9617264; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; SOUETRE E, 1989, AM J PSYCHIAT, V146, P1037; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TOMLINSON BE, 1984, GREENFIELDS NEUROPAT, P951; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; WEMMER DE, 1994, METHOD ENZYMOL, V239, P739; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	59	294	314	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7185	7188		10.1074/jbc.273.13.7185	http://dx.doi.org/10.1074/jbc.273.13.7185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516407	hybrid			2022-12-27	WOS:000072738500003
J	Richieri, GV; Low, PJ; Ogata, RT; Kleinfeld, AM				Richieri, GV; Low, PJ; Ogata, RT; Kleinfeld, AM			Thermodynamics of fatty acid binding to engineered mutants of the adipocyte and intestinal fatty acid-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT-PROBE ADIFAB; TITRATION CALORIMETRY; TRANSPORT PROTEINS; BOUND PALMITATE; LIGAND-BINDING; RESOLUTION; REFINEMENT; APOPROTEIN; AFFINITY; FAMILY	We constructed 18 single amino acid mutants of the adipocyte fatty acid-binding protein (A-FABP) and 17 of the intestinal fatty acid-binding protein (I-FABP), at locations in the fatty acid (FA) binding sites, For each mutant protein, we measured thermodynamic parameters that characterize FA binding, Binding affinities ranged from about 200-fold smaller to 30-fold larger than the wild type (WT) proteins, Thermodynamic parameters revealed that binding affinities often inaccurately reported changes in protein-FA interactions because changes in the binding entropy and enthalpy were usually compensatory and larger than the binding free energy, FA-FABP interactions were quite different for I-FABP and A-FABP proteins, Binding affinities were larger and decreased to a greater degree with increasing FA solubility for most of the I-FABP as compared with the A-FABP proteins, consistent with a more hydrophobic binding site for the I-FABP proteins, In A-FABP, Ala substitutions for Arg(106) and Arg(126), which interact with the FA carboxylate, reduce affinities by about 100-fold, but in I-FABP, R106A increases affinities up to 30-fold, Moreover, in A-FABP, the thermodynamic parameters predict that the FA carboxylate location switches from the 126-position in R106A to the 106 position in R126A. Finally, the A-FABP proteins, in contrast to the I-FABP proteins, reveal significant heat capacity changes (Delta C-p) upon FA binding, and substitutions at residues Arg(106), and Arg(126) reduce the magnitude of Delta C-p.	Med Biol Inst, La Jolla, CA 92037 USA; Lidak Pharmaceut Inc, La Jolla, CA 92037 USA		Kleinfeld, AM (corresponding author), Med Biol Inst, 11077 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Cistola DP, 1996, BIOCHEMISTRY-US, V35, P7559, DOI 10.1021/bi952912x; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; EADS J, 1993, J BIOL CHEM, V268, P26375; Faergeman NJ, 1996, BIOCHEMISTRY-US, V35, P14118, DOI 10.1021/bi960545z; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HODSDON ME, 1995, J BIOMOL NMR, V6, P198, DOI 10.1007/BF00211784; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; Ory J, 1997, J BIOL CHEM, V272, P9793; Prinsen CFM, 1996, BIOCHEM J, V314, P253, DOI 10.1042/bj3140253; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Richieri GV, 1997, J BIOL CHEM, V272, P16737, DOI 10.1074/jbc.272.27.16737; Richieri GV, 1996, J BIOL CHEM, V271, P31068, DOI 10.1074/jbc.271.49.31068; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SANDBERG WS, 1993, P NATL ACAD SCI USA, V90, P8367, DOI 10.1073/pnas.90.18.8367; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SHA RS, 1993, J BIOL CHEM, V268, P7885; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6	33	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7397	7405		10.1074/jbc.273.13.7397	http://dx.doi.org/10.1074/jbc.273.13.7397			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516437	hybrid			2022-12-27	WOS:000072738500033
J	Kieselbach, T; Hagman, A; Andersson, B; Schroder, WP				Kieselbach, T; Hagman, A; Andersson, B; Schroder, WP			The thylakoid lumen of chloroplasts - Isolation and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; II REACTION-CENTER; PHOTOSYSTEM-II; SPINACH-CHLOROPLASTS; POLYPHENOL OXIDASE; HIGHER-PLANTS; ATP-SYNTHASE; PROTEINS; MEMBRANE; POLYPEPTIDE	The chloroplast compartment enclosed by the thylakoid membrane, the "lumen," is poorly characterized, The major aims of this work were to design a procedure for the isolation of the thylakoid lumen which could be generally used to characterize lumenal proteins, The preparation was a stepwise procedure in which thylakoid membranes were isolated from intact chloroplasts. Loosely associated thylakoid surface proteins were removed, and following Yeda press fragmentation the lumenal content was recovered in the supernatant following centrifugation, The purity and yield of lumenal proteins were determined using appropriate marker proteins specific for the different chloroplast compartments, Quantitative immunoblot analyses showed that the recovery of soluble lumenal proteins was 60-65% (as judged by the presence of plastocyanin), whereas contamination with stromal enzymes was less than 1% (ribulose-bisphosphate carboxylase) and negligible for thylakoid integral membrane proteins (D1 protein). Approximately 25 polypeptides were recovered in the lumenal fraction, of which several were identified for the first time, Enzymatic measurements and/or amino-terminal sequencing revealed the presence of proteolytic activities, violaxanthin de-epoxidase, polyphenol oxidase, peroxidase, as well as a novel prolyl cis/trans-isomerase.	Univ Stockholm, Arrhenius Lab Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden	Stockholm University	Schroder, WP (corresponding author), Univ Stockholm, Arrhenius Lab Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden.	Wolfgang@biokemi.su.se	Andersson, Bertil/C-9328-2009; Kieselbach, Thomas/O-6023-2015; Schröder, Wolfgang/A-8799-2008	Kieselbach, Thomas/0000-0001-5577-2938; Schroder, Wolfgang/0000-0001-9831-1533				AKERLUND HE, 1982, BIOCHIM BIOPHYS ACTA, V681, P1, DOI 10.1016/0005-2728(82)90271-7; AKERLUND HE, 1981, FEBS LETT, V124, P229, DOI 10.1016/0014-5793(81)80143-3; ANDERSSON B, 1978, BIOCHIM BIOPHYS ACTA, V503, P462, DOI 10.1016/0005-2728(78)90145-7; ANDERSSON B, 1994, ADV MOL CEL, V10, P1; ANDERSSON B, 1952, MOL BIOL PHOTOSYNTHE, P21; Andersson Bertil, 1992, P71; ARVIDSSON PO, 1996, PHOTOSYNTH RES, V46, P141; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER DP, 1980, ARCH BIOCHEM BIOPHYS, V2, P364; CLARK RD, 1983, J BIOL CHEM, V258, P348; EISENBERGDOMOVICH Y, 1995, J BIOL CHEM, V270, P30181; ERREDE E, 1978, METHOD ENZYMOL, V53, P45; ESPIN JC, 1995, ANAL BIOCHEM, V231, P237, DOI 10.1006/abio.1995.1526; ETTINGER WF, 1991, J CELL BIOL, V115, P321, DOI 10.1083/jcb.115.2.321; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; *GEN COMP GROUP, 1996, PROGR MAN WISC PACK; HAEHNEL W, 1981, BIOCHIM BIOPHYS ACTA, V637, P389, DOI 10.1016/0005-2728(81)90043-8; HAEHNEL W, 1984, ANNU REV PLANT PHYS, V35, P659, DOI 10.1146/annurev.pp.35.060184.003303; HAGER H, 1994, PLANTA, V192, P551; Hall D. O., 1994, PHOTOSYNTHESIS; Hashimoto A, 1996, FEBS LETT, V391, P29; HAYAKAWA T, 1984, PLANT CELL PHYSIOL, V25, P883; HE WZ, 1992, FEBS LETT, V308, P298, DOI 10.1016/0014-5793(92)81297-Y; HELDT HW, 1973, BIOCHIM BIOPHYS ACTA, V314, P224, DOI 10.1016/0005-2728(73)90137-0; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; INAGAKI N, 1995, PHOTOSYNTHESIS LIGHT, V3, P783; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KUWABARA T, 1990, PLANT CELL PHYSIOL, V31, P581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leegood R. C., 1986, Photosynthesis: energy transduction: a practical approach, P9; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; LUNDIN A, 1976, ANAL BIOCHEM, V75, P611, DOI 10.1016/0003-2697(76)90116-0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHL D, 1994, EMBO J, V13, P1370; MURATA N, 1985, TRENDS BIOCHEM SCI, V10, P122, DOI 10.1016/0968-0004(85)90272-5; Oelmuller R, 1996, J BIOL CHEM, V271, P21848, DOI 10.1074/jbc.271.36.21848; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; Pottosin II, 1996, J MEMBRANE BIOL, V152, P223, DOI 10.1007/s002329900100; POTTOSIN II, 1995, J MEMBRANE BIOL, V148, P143; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; ROBINSON C, 1996, MOL GENETICS PHOTOSY, P145; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlicher T, 1996, FEBS LETT, V379, P302, DOI 10.1016/0014-5793(95)01534-5; SCHRODER WP, 1986, BIOCHIM BIOPHYS ACTA, V848, P359, DOI 10.1016/0005-2728(86)90211-2; Shi LX, 1997, PHOTOSYNTH RES, V53, P45, DOI 10.1023/A:1005830405809; Sokolenko A, 1997, PLANT PHYSIOL, V115, P827, DOI 10.1104/pp.115.2.827; SOKOLENKO A, 1995, FEBS LETT, V371, P176, DOI 10.1016/0014-5793(95)00892-D; SOMMER A, 1994, PLANT PHYSIOL, V105, P1301, DOI 10.1104/pp.105.4.1301; VERMAAS WFJ, 1993, PHOTOSYNTH RES, V38, P249, DOI 10.1007/BF00046750; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WEIBULL C, 1988, J ULTRA MOL STRUCT R, V100, P55, DOI 10.1016/0889-1605(88)90058-4	58	116	127	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6710	6716		10.1074/jbc.273.12.6710	http://dx.doi.org/10.1074/jbc.273.12.6710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506969	hybrid			2022-12-27	WOS:000072775900019
J	Lee, HY; Walsh, GL; Dawson, MI; Hong, WK; Kurie, JM				Lee, HY; Walsh, GL; Dawson, MI; Hong, WK; Kurie, JM			All-trans-retinoic acid inhibits jun N-terminal kinase-dependent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; RECEPTOR-SPECIFIC RETINOIDS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; X-RECEPTOR; VITAMIN-A; RXR HETERODIMERS; TGF-ALPHA; C-JUN; DIFFERENTIATION	Retinoids, including retinol and retinoic acid derivatives, inhibit the growth of normal human bronchial epithelial (HBE) cells. The signaling pathways through which retinoids mediate this effect have not been defined. Normal HBE cell growth is stimulated by treatment with a variety of growth factors that increase mitogen activated protein (MAP) activity. In this study, we examined MAP kinase-dependent pathways as potential targets of retinoid signaling and the role of MAP kinases in retinoid-induced c-fos gene regulation. All-trans-retinoic acid (t-RA) inhibited Jun N-terminal kinase (JNK) and, to a lesser extent, extracellular signal-regulated kinase activity in normal HBE cells. t-RA reduced c-fos mRNA and protein levels by decreasing c-fos gene transcription. The c-fos promoter was activated by co-transfection with a constitutively active JNK kinase (SEK)-1 and suppressed by a dominant negative JNK kinase kinase (MEKK)-1. Furthermore, c-fos expression was inhibited by agonists of retinoic acid receptors (RARs) or retinoid X receptors (RXRs), and suppression of c-fos promoter activity by t-RA was abrogated by treatment with antagonists of RAR-alpha or of all the RXRs. These findings provide the first evidence that t-RA inhibits JNK activity and demonstrate a potential role of JNK-dependent pathways in the suppression of c-fos expression by t-RA. Furthermore, c-fos expression was inhibited through activation of RAR- and RXR-dependent signaling pathways. In light of the growth activation induced by JNK/SEK-dependent pathways in a variety of cells, these data support further investigation into the role of JNK-dependent signaling in the growth-suppressive effects of retinoids.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; SRI Int, Retinoid Program, Menlo Park, CA 94025 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; SRI International	Kurie, JM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Box 80, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312	NATIONAL CANCER INSTITUTE [R29CA067353, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA67353, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 1996, CELL GROWTH DIFFER, V7, P521; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BASELGA J, 1993, ONCOGENE, V8, P3257; CHEN LL, 1993, CELL GROWTH DIFFER, V4, P769; CHOPRA DP, 1982, J NATL CANCER I, V69, P895; DAWSON MI, 1995, J MED CHEM, V38, P3368, DOI 10.1021/jm00017a021; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; Hembree JR, 1996, CANCER RES, V56, P1794; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; JETTEN AM, 1986, BIOCHEM SOC T, V14, P930, DOI 10.1042/bst0140930; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM YH, 1995, CANCER RES, V55, P5603; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; Lee HY, 1996, CELL GROWTH DIFFER, V7, P997; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MILLER LA, 1993, CANCER RES, V53, P2527; Miller LA, 1996, J CLIN INVEST, V97, P1429, DOI 10.1172/JCI118564; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; Mills KJ, 1996, CELL GROWTH DIFFER, V7, P327; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGY L, 1995, MOL CELL BIOL, V15, P3540; NAGY L, 1995, MOL CELL BIOL, V15, P3450; PEREZ P, 1994, BIOCHEM BIOPH RES CO, V205, P135, DOI 10.1006/bbrc.1994.2640; ROULIER S, 1994, MOL CELL ENDOCRINOL, V105, P165, DOI 10.1016/0303-7207(94)90166-X; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; TALMAGE DA, 1994, ONCOGENE, V9, P3557; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; VuDac N, 1996, MOL CELL BIOL, V16, P3350; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLEY JC, 1984, CANCER RES, V44, P5124; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	46	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7066	7071		10.1074/jbc.273.12.7066	http://dx.doi.org/10.1074/jbc.273.12.7066			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507016	hybrid			2022-12-27	WOS:000072775900066
J	Liu, W; Ramachandran, V; Kang, J; Kishimoto, TK; Cummings, RD; McEver, RP				Liu, W; Ramachandran, V; Kang, J; Kishimoto, TK; Cummings, RD; McEver, RP			Identification of N-terminal residues on P-selectin glycoprotein ligand-1 required for binding to P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE SULFATION; MYELOID CELLS; CHROMOSOMAL LOCALIZATION; LINKED OLIGOSACCHARIDES; MOLECULAR-CLONING; HUMAN NEUTROPHILS; AMINO-TERMINUS; PSGL-1; RECEPTOR; FLOW	The major high affinity ligand for P-selectin on human leukocytes is P-selectin glycoprotein ligand-l (PSGL-1), To bind P-selectin, PSGL-1 must be modified with tyrosine sulfate and sialylated, fucosylated, core-a O-glycan(s). The required sites for these modifications on full-length PSGL-1 have not been defined, The N-terminal region of mature PSGL-1, which begins at residue 42, includes tyrosines at residues 46, 48, and 51, plus potential sites for Thr-linked O-glycans at residues 44 and 57, We expressed full-length PSGL-1 constructs with substitutions of these residues in transfected Chinese hamster ovary cells. The cells were co-transfected with cDNAs for the glycosyltransferases required to construct sialylated and fucosylated, core-2 O-glycans on PSGL-1. The transfected cells were assayed for their abilities to bind fluid-phase P-selectin and to support rolling adhesion of pre-B cells expressing P-selectin under hydrodynamic flow, In both assays, substitution of Thr-57 with alanine eliminated binding of PSGL-1 to P-selectin without affecting sulfation of PSGL-1, whereas substitution with serine, to which an O-glycan might also be attached, did not affect binding. Binding was not altered by substituting alanines for the two amino acids on either side of Thr-57, or by substituting alanine for Thr-44. Substitution of all three tyrosines with phenylalanines markedly reduced sulfation and prevented binding to P-selectin. However, all constructs in which one or two tyrosines were replaced with phenylalanines bound P-selectin, These results suggest that full-length PSGL-1 requires an O-glycan attached to Thr-57 plus sulfation of any one of its three clustered tyrosines to bind P-selectin.	Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Boehringer Ingelheim Pharmaceut Inc, Dept Immunol, Ridgefield, CT 06877 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Boehringer Ingelheim	McEver, RP (corresponding author), Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, 835 NW 13th St, Oklahoma City, OK 73104 USA.	rodger-mcever@ouhsc.edu			NHLBI NIH HHS [P01 HL 54304] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu WJ, 1997, AM J REPROD IMMUNOL, V37, P199; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIKKELSEN J, 1991, BIOCHEMISTRY-US, V30, P1533, DOI 10.1021/bi00220a013; Moore Kevin L., 1994, Journal of Tissue Culture Methods, V16, P255, DOI 10.1007/BF01540662; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Snapp KR, 1997, BLOOD, V89, P896, DOI 10.1182/blood.V89.3.896; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Tu LL, 1996, J IMMUNOL, V157, P3995; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VELDMAN GM, 1995, J BIOL CHEM, V270, P16470, DOI 10.1074/jbc.270.27.16470; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176	45	94	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7078	7087		10.1074/jbc.273.12.7078	http://dx.doi.org/10.1074/jbc.273.12.7078			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507018	hybrid			2022-12-27	WOS:000072775900068
J	Yoshimura, S; Banno, Y; Nakashima, S; Takenaka, K; Sakai, H; Nishimura, Y; Sakai, N; Shimizu, S; Eguchi, Y; Tsujimoto, Y; Nozawa, Y				Yoshimura, S; Banno, Y; Nakashima, S; Takenaka, K; Sakai, H; Nishimura, Y; Sakai, N; Shimizu, S; Eguchi, Y; Tsujimoto, Y; Nozawa, Y			Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death - Inhibitory effects of Bcl-2 on ceramide formation and caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FOLLICULAR LYMPHOMA; NECROSIS-FACTOR-ALPHA; INDUCED APOPTOSIS; ICE/CED-3 PROTEASE; CHROMOSOMAL BREAKPOINT; SPHINGOMYELIN TURNOVER; MAMMALIAN HOMOLOG; FREE SYSTEM; GENE CED-3; EXPRESSION	PC12 cells undergo apoptosis as well as necrosis following exposure to hypoxia. Following a 6-h hypoxic treatment, a time-dependent increase in intracellular ceramide level was observed with a concurrent decrease in sphingomyelin. It was also shown that the hypoxia-induced ceramide accumulation resulted from activation of neutral magnesium-dependent sphingomyelinase. Comparative kinetic analyses of the neutral sphingomyelinase in the cells under normoxia and hypoxia showed that hypoxia increased V-max but did not affect K-m of the enzyme. In PC12 cells overexpressing Bcl-2 which show strong resistance to hypoxia, sphingomyelin hydrolysis was decreased and activation of neutral sphingomyelinase was reduced. Addition of exogenous C-2-ceramide induced cell death and activated caspase-3 as markedly as the hypoxia treatment. On the other hand, in PC12 cells overexpressing Bcl-2, significant decreases in cell death and inhibition of caspase-3 activation were observed after exogenous addition of C, ceramide. The inhibitors of caspase-3 prevented cell death by either hypoxia or C-2-ceramide. These results suggest that ceramide generated by activation of neutral magnesium-dependent sphingomyelinase mediates hypoxic cell death and that Bcl-2 has inhibitory effects on ceramide formation and caspase activation.	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Suita, Osaka 565, Japan	Gifu University; Gifu University; Osaka University	Yoshimura, S (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, Tsukasamachi 40, Gifu 5008705, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BANERJEE P, 1992, BIOCHIM BIOPHYS ACTA, V1110, P65, DOI 10.1016/0005-2736(92)90295-W; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BONIECE IR, 1993, J NEUROSCI, V13, P4220; Brugg B, 1996, J NEUROCHEM, V66, P733; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JENNINGS RB, 1975, AM J PATHOL, V81, P179; JOZSA L, 1981, HEPATO-GASTROENTEROL, V28, P23; KIM MY, 1991, J BIOL CHEM, V266, P484; Kubota M, 1996, NEUROL RES, V18, P337; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NITATORI T, 1995, J NEUROSCI, V15, P1001; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohmori T, 1996, BRAIN RES, V743, P109, DOI 10.1016/S0006-8993(96)01034-7; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8597; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2251; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Yoshimura S, 1997, J NEUROCHEM, V69, P713; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	58	201	204	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6921	6927		10.1074/jbc.273.12.6921	http://dx.doi.org/10.1074/jbc.273.12.6921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506997	hybrid			2022-12-27	WOS:000072775900047
J	Zhang, D; Childs, G				Zhang, D; Childs, G			Human ZFM1 protein is a transcriptional repressor that interacts with the transcription activation domain of stage-specific activator protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; GENE-TRANSCRIPTION; MOLECULAR-CLONING; THYROID-HORMONE; FACTOR-TFIIB; ENHANCER; PROMOTER; COMPLEX; DNA	Stage specific activator protein (SSAP) is the transcription factor responsible for the activation of the sea urchin late H1 gene at the mid-blastula stage of embryogenesis. SSAP contains an extremely potent transcription activation domain that functions 4-5-fold better than VP16 in a variety of mammalian cell lines. We used the two-hybrid screening technique to identify human cDNAs from an HL60 cell-derived cDNA library that encode proteins that interact with the transcription activation domain of SSAP. One of these cDNAs encodes ZFM1, a protein previously identified at the locus linked to multiple endocrine neoplasia type 1 (MEN1) and as presplicing factor SF1. Functional assays establish the ZFM1 protein as a transcriptional repressor. ZFM1 protein represses Gal4-GQC-mediated transcription, and this activity requires both a repression domain found in the N-terminal 137 amino acids of the protein, as well as a GQC interaction region. The physiological significance of repression mediated by ZFM1 comes from the ability of its specific repression domain to function when fused to Gal4 and tethered to promoters containing Gal4 binding sites. The activity is unique in that activated but not basal transcription levels are affected.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Childs, G (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM30333] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030333] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Arning S, 1996, RNA, V2, P794; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COWELL IG, 1994, NUCLEIC ACIDS RES, V22, P59, DOI 10.1093/nar/22.1.59; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; DEANGELO DJ, 1993, MOL CELL BIOL, V13, P1746, DOI 10.1128/MCB.13.3.1746; DeFalco J, 1996, P NATL ACAD SCI USA, V93, P5802, DOI 10.1073/pnas.93.12.5802; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Fondell JD, 1996, MOL CELL BIOL, V16, P281; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; INOSTROZA JA, 1992, CELL, V70, P477; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; LAI ZC, 1989, MOL CELL BIOL, V9, P2315, DOI 10.1128/MCB.9.6.2315; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MERMOD N, 1989, CELL, V58, P711; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	45	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6868	6877		10.1074/jbc.273.12.6868	http://dx.doi.org/10.1074/jbc.273.12.6868			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506990	hybrid			2022-12-27	WOS:000072775900040
J	Arion, WJ; Canfield, WK; Callaway, ES; Burger, HJ; Hemmerle, H; Schubert, G; Herling, AW; Oekonomopulos, R				Arion, WJ; Canfield, WK; Callaway, ES; Burger, HJ; Hemmerle, H; Schubert, G; Herling, AW; Oekonomopulos, R			Direct evidence for the involvement of two glucose 6-phosphate-binding sites in the glucose-6-phosphatase activity of intact liver microsomes - Characterization of T1, the microsomal glucose 6-phosphate transport protein by a direct binding assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; COA ESTERS INHIBIT; RAT-LIVER; ENDOPLASMIC-RETICULUM; MANNOSE 6-PHOSPHATE; MEMBRANE INTEGRITY; RAPID KINETICS; SYSTEM; COMPONENT	S 5627 is a synthetic analogue of chlorogenic acid. S 5627 is a potent linear competitive inhibitor of glucose 6-phosphate (Glc-6-P) hydrolysis by intact microsomes (K-i = 41 nM) but is without effect on the enzyme in detergent- or NH4OH-disrupted microsomes. H-3-S 5627 was synthesized and used as a ligand in binding studies directed at characterizing T1, the Glc-6-P transporter. Binding was evaluated using Ca2+-aggregated microsomes, which can be sedimented at low g forces. Aside from a modest reduction in K values for both substrate and S 5627, Ca2+ aggregation had no effect on glucose-6-phosphatase (Glc-6-Pase). Scatchard plots of binding data are readily fit to a simple "two-site" model, with K-d = 21 nM for the high affinity site and K-d = 2 mu M for the low affinity site. Binding to the high affinity site was competitively blocked by Glc-B-P (K-i = 9 mM), whereas binding was unaffected by mannose-6-phosphate, P-i, and PPi and only modestly depressed by 2-deoxy-D-glucose 6-phosphate, a poor substrate for Glc-6-Pase in intact microsomes. Thus the high affinity H-3-S 5627 binding site fits the criteria for T1. Permeabilization of the membrane with 0.30% (3-[(chloramidopropyl)-dimethyl-ammonio]-1-propanesulfonate) activated Glc-6-Pase and broadened its substrate specificity, but it did not significantly alter the binding of SH-S 5627 to the high affinity sites or the ability of Glc-6-P to block binding. These data demonstrate unequivocally that two independent Glc-6-P binding sites are involved in the hydrolysis of Glc-6-P by intact microsomes. The present findings are the strongest and most direct evidence to date against the notion that the substrate specificity and the intrinsic activity of Glc-6-Pase in native membranes are determined by specific conformational constraints imposed on the enzyme protein. These data constitute compelling evidence for the role of T1 in Glc-6-Pase activity.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Hoechst Marion Roussel Deutschland GmbH, D-65926 Frankfurt, Germany	Cornell University; Sanofi-Aventis	Arion, WJ (corresponding author), Cornell Univ, Div Nutr Sci, 227 Savage Hall, Ithaca, NY 14853 USA.	WJA1@cornell.edu						Ajzannay A, 1996, ARCH BIOCHEM BIOPHYS, V326, P238, DOI 10.1006/abbi.1996.0071; ARION WJ, 1989, METHOD ENZYMOL, V174, P58; ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1972, J BIOL CHEM, V247, P2558; ARION WJ, 1993, EUR J PEDIATR, V152, pS7; ARION WJ, 1976, J BIOL CHEM, V251, P6784; ARION WJ, 1975, MOL CELL BIOCHEM, V6, P75, DOI 10.1007/BF01732001; ARION WJ, 1976, J BIOL CHEM, V251, P4901; ARION WJ, 1980, J BIOL CHEM, V255, P387; ARION WJ, 1972, J BIOL CHEM, V247, P2551; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; ARION WJ, 1998, IN PRESS ARCH BIOCH, V351; BALLAS LM, 1977, J BIOL CHEM, V252, P8512; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BERTELOOT A, 1995, J BIOL CHEM, V270, P21098, DOI 10.1074/jbc.270.36.21098; CHULZE HU, 1986, J BIOL CHEM, V261, P16571; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FULCERI R, 1995, BIOCHEM J, V307, P391, DOI 10.1042/bj3070391; Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360; HEMMERLE H, 1995, PREPARATION 3 CARBOX; HERS HG, 1951, B SOC CHIM BIOL, V33, P21; KAMATH SA, 1972, ANAL BIOCHEM, V48, P53, DOI 10.1016/0003-2697(72)90169-8; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; MITCHELL P, 1957, NATURE, V180, P134, DOI 10.1038/180134a0; Mithieux G, 1996, EUR J BIOCHEM, V235, P799, DOI 10.1111/j.1432-1033.1996.00799.x; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; NORDLIE RC, 1967, J BIOL CHEM, V242, P4144; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; STDENIS JF, 1994, J CLIN ENDOCR METAB, V79, P955, DOI 10.1210/jc.79.4.955; STETTEN MR, 1966, BIOCHIM BIOPHYS ACTA, V128, P344, DOI 10.1016/0926-6593(66)90181-0; STETTEN MR, 1967, BIOCHIM BIOPHYS ACTA, V139, P138, DOI 10.1016/0005-2744(67)90120-9; SUKALSKI KA, 1989, ADV ENZYMOL RAMB, V62, P93; WALLIN BK, 1972, BIOCHEM BIOPH RES CO, V48, P694, DOI 10.1016/0006-291X(72)90404-4; ZAKIM D, 1990, J BIOL CHEM, V265, P201	36	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6223	6227		10.1074/jbc.273.11.6223	http://dx.doi.org/10.1074/jbc.273.11.6223			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497346	hybrid			2022-12-27	WOS:000072488500038
J	Dong, F; Feldmesser, M; Casadevall, A; Rubin, CS				Dong, F; Feldmesser, M; Casadevall, A; Rubin, CS			Molecular characterization of a cDNA that encodes six isoforms of a novel murine A kinase anchor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT RII; A-KINASE; II-BETA; CAENORHABDITIS-ELEGANS; CATALYTIC SUBUNIT; EXPRESSION; CLONING; LOCALIZATION; CYTOSKELETON	We have cloned cDNA that encodes six novel A kinase anchor proteins (collectively named AKAP-KL). AKAP-KL diversity is generated by alternative mRNA splicing and utilization of two translation initiation codons, AKAP-KL polypeptides are evident in lung, kidney, and cerebellum, but are absent from many tissues. Different isoforms predominate in different tissues, Thus, AKAP-KL expression is differentially regulated in vivo. All AKAP-KL isoforms contain a 20-residue domain that avidly binds (K-d similar to 10 nM) regulatory subunits (RII) of protein kinase All and is highly homologous with the RII tethering site in neuronal AKAP75. The distribution of AKAP-KL is strikingly asymmetric (polarized) in situ, Anchor protein accumulates near the inner, apical surface of highly polarized epithelium in tubules of nephrons, Both RII and AKAP-KL are enriched at an intracellular site that lies just below the plasma membrane of alveolar epithelial cells in lung AKAP-KL interacts with and modulates the structure of the actin cytoskeleton in transfected cells, We also demonstrate that the tethering domain of AKAP-KL avidly ligates RII subunits in intact cells. AKAP-KL may be involved in (a) establishing polarity in signaling systems and (b) physically and functionally integrating PKAII isoforms with downstream effecters to capture, amplify, and precisely focus diffuse, trans-cellular signals carried by cAMP.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, F-229,1300 Morris Pk Ave, Bronx, NY 10461 USA.	rubin@aecom.yu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEEBE SJ, 1986, ENZYMES, V17, P14; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BREYER MD, 1994, ANNU REV PHYSIOL, V56, P711, DOI 10.1146/annurev.ph.56.030194.003431; CARR DW, 1992, J BIOL CHEM, V267, P16816; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; HU ED, 1990, J BIOL CHEM, V265, P5072; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAND M, 1994, J BIOL CHEM, V269, P9234; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; QU M, 1996, P NATL ACAD SCI USA, V93, P1571; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313	47	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6533	6541		10.1074/jbc.273.11.6533	http://dx.doi.org/10.1074/jbc.273.11.6533			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497389	hybrid			2022-12-27	WOS:000072488500081
J	Kim, CG; Yu, TW; Fryhle, CB; Handa, S; Floss, HG				Kim, CG; Yu, TW; Fryhle, CB; Handa, S; Floss, HG			3-amino-5-hydroxybenzoic acid synthase, the terminal enzyme in the formation of the precursor of mC(7)N units in rifamycin and related antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; YERSINIA-PSEUDOTUBERCULOSIS; ANSAMYCIN ANTIBIOTICS; MOLECULAR CHARACTERIZATION; SHIKIMATE PATHWAY; CLONING VECTORS; GENE-EXPRESSION; BIOSYNTHESIS; STREPTOMYCES; PROTEINS	The biosynthesis of ansamycin antibiotics, like rifamycin B, involves formation of 3-amino-5-hydroxybenzoic acid (AHBA) by a novel variant of the shikimate pathway. AHBA then serves as the starter unit for the assembly of a polyketide which eventually links back to the amino group of AHBA to form the macrolactam ring, The terminal enzyme of AHBA formation, which catalyzes the aromatization of 5-deoxy-5-amino-3-dehydroshikimic acid, has been purified to homogeneity from Amycolatopsis mediterranei, the encoding gene has been cloned, sequenced, and overexpressed in Escherichia coli, The recombinant enzyme, a (His)(6) fusion protein, as web as the native one, are dimers containing one molecule of pyridoxal phosphate per subunit. Mechanistic studies showed that the enzyme-bound pyridoxal phosphate forms a Schiffs base with the amino group of 5-deoxy-5-amino-3-dehydroshikimic acid and catalyzes both an cu,P-dehydration and a stereospecific 1,4-enolization of the substrate, Inactivation of the gene encoding AHBA synthase in the A. mediterranei genome results in loss of rifamycin formation; production of the antibiotic is restored when the mutant is supplemented with AHBA.	Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Floss, HG (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	floss@chem.washington.edu	Handa, Sandeep/AAV-2646-2021	Handa, Sandeep/0000-0002-7109-1523	NIAID NIH HHS [AI 20264] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020264] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahlert J, 1997, ARCH MICROBIOL, V168, P102, DOI 10.1007/s002030050475; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON MG, 1989, J CHEM SOC CHEM COMM, P311, DOI 10.1039/c39890000311; ANDERSON MG, 1980, J CHEM SOC CHEM COMM, P1277, DOI 10.1039/c39800001277; BASTIN DA, 1995, GENE, V164, P17, DOI 10.1016/0378-1119(95)00459-J; BIBB MJ, 1986, GENE, V41, pE357, DOI 10.1016/0378-1119(86)90122-8; BIBB MJ, 1982, MOL GEN GENET, V187, P265, DOI 10.1007/BF00331128; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; CHOLI T, 1989, J CHROMATOGR, V476, P59, DOI 10.1016/S0021-9673(01)93856-7; Davis L., 1972, ENZYMES, V7, P33; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; DOLPHIN D, 1986, VITAMIN B6 PYRIDOX B; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P765, DOI 10.1002/rcm.1290061211; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; FLOSS HG, 1989, ANGEW CHEM INT EDIT, V28, P146, DOI 10.1002/anie.198901461; FLOSS HG, 1982, STEREOCHEMISTRY, P161; FLOSS HG, 1989, ANGEW CHEM, V101, P147; GANEM B, 1978, TETRAHEDRON, V34, P3353, DOI 10.1016/0040-4020(78)80222-1; GERSHONI JM, 1982, ANAL BIOCHEM, V124, P396, DOI 10.1016/0003-2697(82)90056-2; GHISALBA O, 1985, CHIMIA, V39, P79; GHISALBA O, 1981, J ANTIBIOT, V34, P64, DOI 10.7164/antibiotics.34.64; GREWE R, 1956, CHEM BER-RECL, V89, P2080, DOI 10.1002/cber.19560890908; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; GYGAX D, 1982, FEMS MICROBIOL LETT, V15, P169, DOI 10.1111/j.1574-6968.1982.tb00061.x; HANDA S, 1997, J CHEM SOC CHEM COMM, P153; HATANO K, 1982, J ANTIBIOT, V35, P1415, DOI 10.7164/antibiotics.35.1415; HERMODSON M, 1983, METHOD ENZYMOL, V91, P352; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; KESSLER AC, 1993, J BACTERIOL, V175, P1412, DOI 10.1128/JB.175.5.1412-1422.1993; KIBBY JJ, 1980, J CHEM SOC CHEM COMM, P768, DOI 10.1039/c39800000768; KIM CG, 1992, J AM CHEM SOC, V114, P4941, DOI 10.1021/ja00038a090; Kim CG, 1996, J AM CHEM SOC, V118, P7486, DOI 10.1021/ja9601292; KIM CG, 1994, THESIS U WASHINGTON; Kirschning A, 1997, TOP CURR CHEM, V188, P1; KOBAYASHI K, 1976, TETRAHEDRON LETT, P537; LANCINI GC, 1986, BIOTECHNOLOGY, V4, P431; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MazyServais C, 1997, FEMS MICROBIOL LETT, V151, P135, DOI 10.1016/S0378-1097(97)00147-X; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MERSONDAVIES LA, 1994, MOL MICROBIOL, V13, P349, DOI 10.1111/j.1365-2958.1994.tb00428.x; PASCARELLA S, 1994, PROTEIN SCI, V3, P701; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PIEPERSBERG W, 1994, CRIT REV BIOTECHNOL, V14, P251, DOI 10.3109/07388554409079835; RINEHART KL, 1982, J AM CHEM SOC, V104, P2649, DOI 10.1021/ja00373a059; SCHARF KH, 1971, J CHEM SOC CHEM COMM, P765, DOI 10.1039/c29710000765; SCHIRCH L, 1962, J BIOL CHEM, V237, P2578; SIMPSON RJ, 1984, BIOCHEM INT, V8, P787; SOPER TS, 1985, TRANSAMINASES, P266; Stroeher UH, 1997, J BACTERIOL, V179, P2740, DOI 10.1128/jb.179.8.2740-2747.1997; STUTZMANENGWALL KJ, 1992, J BACTERIOL, V174, P144, DOI 10.1128/jb.174.1.144-154.1992; TAGAKI M, 1990, J BACTERIOL, V172, P411; Tercero JA, 1996, J BIOL CHEM, V271, P1579, DOI 10.1074/jbc.271.3.1579; THORSON JS, 1993, J AM CHEM SOC, V115, P12177, DOI 10.1021/ja00078a071; THORSON JS, 1993, J AM CHEM SOC, V115, P7539, DOI 10.1021/ja00069a078; THORSON JS, 1993, J AM CHEM SOC, V115, P6993, DOI 10.1021/ja00068a075; THORSON JS, 1994, J BACTERIOL, V176, P5483, DOI 10.1128/JB.176.17.5483-5493.1994; VEDERAS JC, 1980, ACCOUNTS CHEM RES, V13, P455, DOI 10.1021/ar50156a004; WEIGEL TM, 1992, BIOCHEMISTRY-US, V31, P2129, DOI 10.1021/bi00122a034; WEIGEL TM, 1992, BIOCHEMISTRY-US, V31, P2140, DOI 10.1021/bi00122a035	68	102	116	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6030	6040		10.1074/jbc.273.11.6030	http://dx.doi.org/10.1074/jbc.273.11.6030			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497318	hybrid			2022-12-27	WOS:000072488500010
J	Shen, QC; Wu, R; Leonard, JL; Newburger, PE				Shen, QC; Wu, R; Leonard, JL; Newburger, PE			Identification and molecular cloning of a human selenocysteine insertion sequence-binding protein - A bifunctional role for DNA-binding protein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOPROTEIN MESSENGER-RNAS; COLD-SHOCK DOMAIN; GLUTATHIONE-PEROXIDASE; Y-BOX; ACTIVE-SITE; ESCHERICHIA-COLI; STRUCTURAL MOTIF; RECOGNITION; DEHYDROGENASE; GENE	Prokaryotic and eukaryotic cells incorporate the unusual amino acid selenocysteine at a UGA codon, which conventionally serves as a termination signal, Translation of eukaryotic selenoprotein mRNA requires a nucleotide selenocysteine insertion sequence in the 3'-untranslated region, We report the molecular cloning of the binding protein that recognizes the selenocysteine insertion sequence element in human cellular glutathione peroxidase gene (GPX1) transcripts and its identification as DNA-binding protein B, a member of the EFIA/dbpB/YB-1 family. The predicted amino acid sequence contains four arginine-rich RNA-binding motifs, and one segment shows strong homology to the human immunodeficiency virus Tat domain. Recombinant DNA-binding protein B binds the selenocysteine insertion sequence elements from the GPX1 and type I iodothyronine 5'-deiodinase genes in RNA electrophoretic mobility shift assays and competes with endogenous GPX1 selenocysteine insertion sequence binding activity in COS-1 cytosol extracts. Addition of antibody to DNA-binding protein B to COS-1 electromobility shift assays produces a slowly migrating "supershift" band. The molecular cloning and identification of DNA-binding protein B as the first eukaryotic selenocysteine insertion sequence-binding protein opens the way to the elucidation of the entire complex necessary for the alternative reading of the genetic code that permits translation of selenoproteins.	Univ Massachusetts, Med Ctr, Dept Pediat, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Nucl Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Mol Genet Microbiol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Newburger, PE (corresponding author), Univ Massachusetts, Med Ctr, Dept Pediat, 373 Plantat St, Worcester, MA 01605 USA.			Newburger, Peter/0000-0002-8615-673X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038772, R01DK041625] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41625, DK38772] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Cohen H J, 1993, Prog Clin Biol Res, V380, P191; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; GELPI C, 1992, P NATL ACAD SCI USA, V89, P9739, DOI 10.1073/pnas.89.20.9739; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; Hubert N, 1996, NUCLEIC ACIDS RES, V24, P464, DOI 10.1093/nar/24.3.464; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUDO S, 1995, EUR J BIOCHEM, V231, P72; LADOMERY M, 1994, NUCLEIC ACIDS RES, V22, P5582, DOI 10.1093/nar/22.25.5582; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; MANIATIS T, 1990, MOL CLONING LAB MANU, P743; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; OZER J, 1990, J BIOL CHEM, V265, P22143; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PREISS T, 1995, FEBS LETT, V367, P291, DOI 10.1016/0014-5793(95)00569-U; RINGQUIST S, 1994, GENE DEV, V8, P376, DOI 10.1101/gad.8.3.376; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SAKURA H, 1988, GENE, V73, P499; Shen QC, 1995, J BIOL CHEM, V270, P30448, DOI 10.1074/jbc.270.51.30448; SHEN QC, 1995, RNA, V1, P519; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAKAHASHI K, 1986, BLOOD, V68, P640; Walczak R, 1996, RNA, V2, P367; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	44	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5443	5446		10.1074/jbc.273.10.5443	http://dx.doi.org/10.1074/jbc.273.10.5443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488664	hybrid			2022-12-27	WOS:000072345000007
J	Hagen, FK; Nehrke, K				Hagen, FK; Nehrke, K			cDNA cloning and expression of a family of UDP-N-acetyl-D-galactosamine : polypeptide N-acetylgalactosaminyltransferase sequence homologs from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; GALNAC; PURIFICATION	The initiation of mucin-type O-glycosylation is catalyzed by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (ppGaNTase) (EC 2.4.1.41), By screening two mixed-stage Caenorhabditis elegans cDNA libraries, a total of 11 distinct sequence homologs of the ppGaNTase gene family were cloned, sequenced, and expressed as truncated recombinant proteins (gly-3, gly-4, gly-5a, gly3-5b, gly-5c, gly-6a, gly-6b, gly-6c, gly-7, gly-8, and gly-9), All clones encoded type II membrane proteins that shaped 60-80% amino acid sequence similarity with the catalytic domain of mammalian ppGaNTase enzymes, Two sets of cDNA clones (gly-5 and gly-6) contained variants that appeared to be produced by alternative message processing. gly-6c contained a reading frameshift and premature termination codon in the C-terminal lectin-libe domain found in most other ppGaNTase proteins, and a second clone (gly-8) racked the typical C-terminal region completely, Homogenates of nematodes and immunopurified. preparations of the recombinant GLY proteins demonstrated that worms express functional ppGaNTase enzymes (GLY-3, GLY-4, GLY-SA, GLY-5B, and GLY-5C), which can O-glycosylate mammalian apomucin peptide sequences in vitro. In addition to demonstrating the existence of ppGaNTase enzymes in a nematode organism, the substantial diversity of these isoforms in C. elegans suggests that mucin O-glycosylation is catalyzed by a complex gene family, which is conserved among evolutionary-distinct organisms.	Univ Rochester, Sch Med & Dent, Ctr Oral Biol, Rochester, NY 14642 USA	University of Rochester	Hagen, FK (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Oral Biol, 601 Elmwood Ave,Box 611, Rochester, NY 14642 USA.	fred_hagen@urmc.rochester.edu		Nehrke, Keith/0000-0001-9697-726X	NIDCR NIH HHS [DE-08108] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008108, R37DE008108] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBONE EF, 1994, J BIOL CHEM, V269, P16845; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; HEMMER RM, 1991, J CELL BIOL, V115, P1237, DOI 10.1083/jcb.115.5.1237; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Wragg S, 1997, BIOCHEM J, V328, P193, DOI 10.1042/bj3280193; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	21	92	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8268	8277		10.1074/jbc.273.14.8268	http://dx.doi.org/10.1074/jbc.273.14.8268			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525933	hybrid			2022-12-27	WOS:000072876300067
J	Lu, Z; Cabiscol, E; Obradors, N; Tamarit, J; Ros, J; Aguilar, J; Lin, ECC				Lu, Z; Cabiscol, E; Obradors, N; Tamarit, J; Ros, J; Aguilar, J; Lin, ECC			Evolution of an Escherichia coli protein with increased resistance to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-CATALYZED OXIDATION; MIXED-FUNCTION OXIDATION; L-FUCOSE DISSIMILATION; GLUTAMINE-SYNTHETASE; PROPANEDIOL OXIDOREDUCTASE; ZYMOMONAS-MOBILIS; ALCOHOL-DEHYDROGENASE; L-RHAMNOSE; KLEBSIELLA-PNEUMONIAE; 4TH-DERIVATIVE SPECTROPHOTOMETRY	L-1,2-Propanediol:NAD(+) 1-oxidoreductase of Escherichia coli is encoded by the fucO gene, a member of the regulon specifying dissimilation of L-fucose, The enzyme normally fractions during fermentative growth to regenerate NAD from NADH by reducing the metabolic intermediate L-lactaldehyde to propanediol which is excreted. During aerobic growth L-lactaldehyde is converted to L-lactate and thence to the central metabolite pyruvate. The wasteful excretion of propanediol is minimized by oxidative inactivation of the oxidoreductase, an Fe(2+)-dependent enzyme which is subject to metal-catalyzed oxidation (MCO). Mutants acquiring the ability to grow aerobically on propanediol as sole carbon and energy source can be readily selected. These mutants express the fucO gene constitutively, as a result of an IS5 insertion in the promoter region. In this study we show that continued selection for aerobic growth on propanediol resulted in mutations in the oxidoreductase conferring increased resistance to MCO. In two independent mutants, the resistance of the protein was respectively conferred by all Ile(7) --> Leu and a Leu(8) --> Val substitution near the NAD-binding consensus amino acid sequence, A site-directed mutant protein with both substitutions showed an MCO resistance greater than either mutant protein with a single amino acid change.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain; Univ Barcelona, Fac Farm, Dept Bioquim, E-08028 Barcelona, Spain	Harvard University; Harvard Medical School; Universitat de Lleida; University of Barcelona	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	ELIN@WARREN.MED.HARVARD.EDU	Cabiscol, Elisa/A-4584-2009; Ros, Joaquim/A-7507-2010; ROS, Joaquim/ABG-7487-2020; Tamarit, Jordi/C-6316-2008; Obradors, Nuria/J-7680-2017	Cabiscol, Elisa/0000-0003-2795-7999; ROS, Joaquim/0000-0003-0901-8648; Tamarit, Jordi/0000-0003-3227-6928; Obradors, Nuria/0000-0002-4344-6681	NIGMS NIH HHS [GM40993, GM30693] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993, R01GM030693] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; BALDOMA L, 1987, J BIOL CHEM, V262, P13991; BALDOMA L, 1988, J BACTERIOL, V170, P416, DOI 10.1128/jb.170.1.416-421.1988; BARTKUS JM, 1986, J BACTERIOL, V165, P710, DOI 10.1128/jb.165.3.710-714.1986; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BORONAT A, 1981, BIOCHIM BIOPHYS ACTA, V672, P98, DOI 10.1016/0304-4165(81)90283-X; BORONAT A, 1981, J BACTERIOL, V147, P181, DOI 10.1128/JB.147.1.181-185.1981; BORONAT A, 1979, J BACTERIOL, V140, P320, DOI 10.1128/JB.140.2.320-326.1979; BORONAT A, 1983, J BACTERIOL, V153, P134, DOI 10.1128/JB.153.1.134-139.1983; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P134; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P145; Butler W L, 1979, Methods Enzymol, V56, P501; CABALLERO E, 1983, J BIOL CHEM, V258, P7788; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CABISCOL E, 1990, J BACTERIOL, V172, P5514, DOI 10.1128/jb.172.9.5514-5515.1990; CABISCOL E, 1992, BIOCHIM BIOPHYS ACTA, V1118, P155, DOI 10.1016/0167-4838(92)90144-3; CARR JG, 1974, BERGEYS MANUAL DETER, P533; CHEN YM, 1987, J BACTERIOL, V169, P3712, DOI 10.1128/jb.169.8.3712-3719.1987; CHEN YM, 1983, J GEN MICROBIOL, V129, P3355; CHEN YM, 1989, J BACTERIOL, V171, P6097, DOI 10.1128/jb.171.11.6097-6105.1989; CHEN YM, 1987, J BACTERIOL, V169, P3289, DOI 10.1128/jb.169.7.3289-3294.1987; CHEN YM, 1987, MOL GEN GENET, V210, P331, DOI 10.1007/BF00325702; CHEVALIER M, 1990, J BIOL CHEM, V265, P42; COCKS GT, 1974, J BACTERIOL, V118, P83, DOI 10.1128/JB.118.1.83-88.1974; CONWAY T, 1989, J BACTERIOL, V171, P3754, DOI 10.1128/jb.171.7.3754-3759.1989; CONWAY T, 1987, J BACTERIOL, V2591, P2597; Dean RT, 1997, BIOCHEM J, V324, P1; DEVRIES GE, 1992, J BACTERIOL, V174, P5346, DOI 10.1128/JB.174.16.5346-5353.1992; DONG JM, 1993, J BACTERIOL, V175, P6671, DOI 10.1128/jb.175.20.6671-6678.1993; DUNACH M, 1983, EUR J BIOCHEM, V134, P123, DOI 10.1111/j.1432-1033.1983.tb07540.x; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; Garvie E.I., 1974, BERGEYS MANUAL DETER, P510; HACKING AJ, 1976, J BACTERIOL, V126, P1166, DOI 10.1128/JB.126.3.1166-1172.1976; HACKING AJ, 1977, J BACTERIOL, V130, P832, DOI 10.1128/JB.130.2.832-838.1977; HACKING AJ, 1978, J BACTERIOL, V136, P522, DOI 10.1128/JB.136.2.522-530.1978; HEKTOR H, 1997, PHYSL BIOCH PRIMARY; HIDALGO E, 1991, J BACTERIOL, V175, P6671; JOHNSON EA, 1985, J BACTERIOL, V164, P479, DOI 10.1128/JB.164.1.479-483.1985; JOHNSON EA, 1987, J BACTERIOL, V169, P2050, DOI 10.1128/jb.169.5.2050-2054.1987; KESHAV KF, 1990, J BACTERIOL, V172, P2491, DOI 10.1128/jb.172.5.2491-2497.1990; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LEE YS, 1988, J BIOL CHEM, V263, P6643; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LIMON A, 1997, MICROBIOLOGY, V143, P285; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; LIN ECC, 1960, J BIOL CHEM, V235, P1824; LIN ECC, 1996, ESCHERICHIA COLI SAL, P307; LU Z, 1989, NUCLEIC ACIDS RES, V17, P4883, DOI 10.1093/nar/17.12.4883; MACKENZIE KF, 1989, J BACTERIOL, V171, P1063, DOI 10.1128/jb.171.2.1063-1067.1989; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; PADROS E, 1984, TRENDS BIOCHEM SCI, V9, P508, DOI 10.1016/0968-0004(84)90272-X; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; RUCH FE, 1980, J BACTERIOL, V141, P1077, DOI 10.1128/JB.141.3.1077-1085.1980; SKJOLD AC, 1982, J BACTERIOL, V152, P521; SRIDHARA S, 1969, J BIOL CHEM, V244, P5233; SRIDHARA S, 1969, J BACTERIOL, V93, P87; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stadtman ER, 1995, LIFE SCI R, V56, P129; SZWEDA LI, 1992, J BIOL CHEM, V267, P3096; Tamarit J, 1997, J BACTERIOL, V179, P1102, DOI 10.1128/jb.179.4.1102-1104.1997; WILLS C, 1981, ARCH BIOCHEM BIOPHYS, V210, P775, DOI 10.1016/0003-9861(81)90245-9; ZHU Y, 1988, J BACTERIOL, V170, P2352, DOI 10.1128/jb.170.5.2352-2358.1988; ZHU Y, 1989, J BACTERIOL, V171, P862, DOI 10.1128/jb.171.2.862-867.1989; ZHU Y, 1987, J BACTERIOL, V169, P785, DOI 10.1128/jb.169.2.785-789.1987	75	16	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8308	8316		10.1074/jbc.273.14.8308	http://dx.doi.org/10.1074/jbc.273.14.8308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525938	hybrid, Green Published			2022-12-27	WOS:000072876300072
J	Prince, RJ; Sine, SM				Prince, RJ; Sine, SM			Epibatidine binds with unique site and state selectivity to muscle nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DISSECTION; SUBUNIT INTERFACES; MYASTHENIC SYNDROME; MOUSE FIBROBLASTS; LIGAND-BINDING; AGONIST; IDENTIFICATION; ACTIVATION; AFFINITY; EXPRESSION	Ligand binding sites in fetal (alpha(2) beta gamma delta) and adult (alpha(2) beta delta epsilon) muscle acetylcholine receptors are formed by alpha delta, alpha gamma, or alpha epsilon subunit pairs. Each type of binding site shows unique ligand selectivity due to different contributions by the delta, gamma, or epsilon subunits. The present study compares epibatidine and carbamylcholine binding in terms of their site and state selectivities for muscle receptors expressed in human embryonic kidney 293 cells. Measurements of binding to alpha gamma, alpha delta, and alpha epsilon intracellular complexes reveal opposite site selectivities between epibatidine and carbamylcholine; for epibatidine the rank order of affinities is alpha epsilon > alpha gamma > alpha delta, whereas for carbamylcholine the rank order is alpha delta congruent to alpha epsilon > alpha gamma. Because the relative affinities of intracellular complexes resemble those of receptors in the closed activable state, the results suggest that epibatidine binds with unique site selectivity in activating the muscle receptor. Measurements of binding at equilibrium show that both enantiomers of epibatidine bind to adult and fetal receptors with shallow but monophasic binding curves. However, when receptors are fully desensitized, epibatidine binds in a biphasic manner, with dissociation constants of the two components differing by more than 170-fold. Studies of subunit-omitted receptors (alpha(2) beta delta(2), alpha(2) beta gamma(2) and alpha(2) beta epsilon(2)) reveal that in the desensitized state, the alpha delta interface forms the low affinity epibatidine site, whereas the alpha gamma and alpha epsilon interfaces form high affinity sites. In contrast to epibatidine, carbamylcholine shows little site selectivity for desensitized fetal or adult receptors. Thus epibatidine is a potentially valuable probe of acetylcholine receptor binding site structure and of elements that confer state-dependent selectivities of the binding sites.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	Mayo Clinic	Prince, RJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.	rprince@mayo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADIO B, 1994, MOL PHARMACOL, V45, P563; BLOUNT P, 1991, J BIOL CHEM, V266, P14692; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOUZAT C, 1994, NEURON, V13, P1395, DOI 10.1016/0896-6273(94)90424-3; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LINGLE CJ, 1992, J MEMBRANE BIOL, V126, P195; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONOD J, 1965, J MOL BIOL, V3, P318; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; Ohno K, 1996, NEURON, V17, P157, DOI 10.1016/S0896-6273(00)80289-5; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; PRINCE RJ, 1998, IN PRESS NICOTINIC R; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SINE SM, 1991, J BIOL CHEM, V266, P13679; SINE SM, 1988, J BIOL CHEM, V263, P18052; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SULLIVAN JP, 1994, J PHARMACOL EXP THER, V271, P624; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; ZHANG YN, 1995, J PHYSIOL-LONDON, V486, P189, DOI 10.1113/jphysiol.1995.sp020802	25	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7843	7849		10.1074/jbc.273.14.7843	http://dx.doi.org/10.1074/jbc.273.14.7843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525877	hybrid			2022-12-27	WOS:000072876300011
J	Reuter, M; Kupper, D; Meisel, A; Schroeder, C; Kruger, DH				Reuter, M; Kupper, D; Meisel, A; Schroeder, C; Kruger, DH			Cooperative binding properties of restriction endonuclease EcoRII with DNA recognition sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE; NAEI; DISTANCE; RECOMBINATION; TOPOISOMERASE; SEQUENCE; LEUCINE	EcoRII is a member of the expanding group of type IIe restriction endonucleases that share the distinguishing feature of requiring cooperativity between two recognition sites in their substrate DNA. To determine the stoichiometry of the active DNA-enzyme complex and the mode of cooperative interaction, we have investigated the dependence of EcoRII cleavage on the concentration of EcoRII dimers. Maximal restriction was observed at dimer/site ratios of 0.25 anti 0.5. The molecular weight of the DNA-enzyme complex eluted from a gel filtration column also corresponds to a dimeric enzyme structure bound to two substrate sites. We conclude that one EcoRII dimer is sufficient to interact cooperatively with two DNA recognition sites. A Lac repressor "barrier" bound between two normally reactive EcoRII sites did not inhibit restriction endonuclease activity, indicating that cooperativity between EcoRII sites is achieved by bending or looping of the intervening DNA stretch, Comparative cleavage of linear substrates with differently spaced interacting sites revealed an inverse correlation between cleavage rate and site distance, At the optimal distance of one helical turn, EcoRII cleavage is independent of the orientation of the recognition sequence in the DNA double strand.	Humboldt Univ, Med Sch Charite, Inst Med Virol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reuter, M (corresponding author), Humboldt Univ, Med Sch Charite, Inst Med Virol, Clara Zetkin Str 94, D-10098 Berlin, Germany.			Meisel, Andreas/0000-0001-7233-5342				BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P319, DOI 10.1016/S0065-3233(08)60022-4; BHAGWAT AS, 1990, J BIOL CHEM, V265, P767; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; BOYER HW, 1973, NATURE-NEW BIOL, V244, P40, DOI 10.1038/newbio244040a0; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; JELTSCH A, 1994, BIOCHEMISTRY-US, V33, P10215, DOI 10.1021/bi00200a001; Jeltsch A, 1996, EMBO J, V15, P5104, DOI 10.1002/j.1460-2075.1996.tb00891.x; Jo K, 1996, NUCLEIC ACIDS RES, V24, P4171, DOI 10.1093/nar/24.21.4171; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; Jo KW, 1996, BIOCHEMISTRY-US, V35, P10014, DOI 10.1021/bi9604542; KOLKHOF P, 1992, EMBO J, V11, P3031, DOI 10.1002/j.1460-2075.1992.tb05373.x; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; KOSYKH V G, 1982, Biokhimiya, V47, P619; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; KUPPER D, 1995, PROTEIN EXPRES PURIF, V6, P1, DOI 10.1006/prep.1995.1001; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MEISEL A, 1995, EMBO J, V14, P2958, DOI 10.1002/j.1460-2075.1995.tb07296.x; NOBBS TJ, 1995, J MOL BIOL, V252, P399, DOI 10.1006/jmbi.1995.0506; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PETRAUSKENE OV, 1994, BIOCHEM BIOPH RES CO, V198, P885, DOI 10.1006/bbrc.1994.1126; REUTER M, 1990, GENE, V95, P161, DOI 10.1016/0378-1119(90)90429-U; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; Szczelkun MD, 1996, EMBO J, V15, P1460, DOI 10.1002/j.1460-2075.1996.tb00488.x; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VINOGRADOVA M V, 1990, Molekulyarnaya Biologiya (Moscow), V24, P847; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; YANG CC, 1994, BIOCHEMISTRY-US, V33, P14918, DOI 10.1021/bi00253a031; YOLOV AA, 1984, FEBS LETT, V167, P147, DOI 10.1016/0014-5793(84)80850-9	37	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8294	8300		10.1074/jbc.273.14.8294	http://dx.doi.org/10.1074/jbc.273.14.8294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525936	hybrid			2022-12-27	WOS:000072876300070
J	Shaw, GC; Sung, CC; Liu, CH; Lin, CH				Shaw, GC; Sung, CC; Liu, CH; Lin, CH			Evidence against the Bm1P1 protein as a positive transcription factor for barbiturate-mediated induction of cytochrome P450(BM-1) in Bacillus megaterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL INDUCTION; MOLECULAR-CLONING; BM3R1 REPRESSOR; GLYCOPROTEIN GENE; ESCHERICHIA-COLI; PLASMID DNA; RAT-LIVER; SEQUENCE; EXPRESSION; OPERATOR	The Bm1P1 protein was previously proposed to act as a positive transcription factor involved in barbiturate-mediated induction of cytochrome P450(BM-1) in Bacillus megaterium. We now report that the bm1P1 gene encodes a protein of 217 amino acids, rather than the 98 amino acids as reported previously. In vitro gel shift assays indicate that the Bm1P1 protein did not interact with probes comprising the regulatory regions of the P450(BM-1) gene. Moreover, disruption of the bm1P1 gene did not markedly affect barbiturate induction of P450(BM-1) expression. A multicopy plasmid harboring only the P450(BM-1) promoter region could increase expression of the chromosome-encoded P450BM-1. The level of expression is comparable with that shown by a multicopy plasmid harboring the P450(BM-1) promoter region along with the bm1P1 gene. These results strongly suggest that the Bm1P1 protein is unlikely to act as a positive regulator for barbiturate induction of P450(BM-1) expression. Finally, deletion of the Barbie box did not markedly diminish the effect of pentobarbital on expression of a reporter gene transcriptionally fused to the P450(BM-1) promoter. This suggests that the Barbie box is unlikely to be a key element in barbiturate-mediated induction of P450(BM-1).	Natl Yang Ming Univ, Sch Life Sci, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Shaw, GC (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Biochem, Taipei 112, Taiwan.							BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHANG S, 1979, MOL GEN GENET, V168, P111, DOI 10.1007/BF00267940; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FERRARI FA, 1983, J BACTERIOL, V154, P1513, DOI 10.1128/JB.154.3.1513-1515.1983; FOURNIER T, 1994, J BIOL CHEM, V269, P27175; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; HE JS, 1995, J BIOL CHEM, V270, P18615, DOI 10.1074/jbc.270.31.18615; HE JS, 1991, J BIOL CHEM, V266, P7864; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; LIANG QW, 1995, J BIOL CHEM, V270, P18606, DOI 10.1074/jbc.270.31.18606; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Miura K., 1967, METHODS ENZYMOLOGY A, V12, P543; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; NARHI LO, 1982, J BIOL CHEM, V257, P2147; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PAN WB, 1994, MOL MICROBIOL, V11, P769, DOI 10.1111/j.1365-2958.1994.tb00354.x; Park Y, 1996, DNA CELL BIOL, V15, P693, DOI 10.1089/dna.1996.15.693; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RAY C, 1985, J BACTERIOL, V163, P610, DOI 10.1128/JB.163.2.610-614.1985; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLLMEIER K, 1984, J BACTERIOL, V160, P499, DOI 10.1128/JB.160.2.499-503.1984; SCHWALB H, 1985, BIOCHIM BIOPHYS ACTA, V838, P302, DOI 10.1016/0304-4165(85)90227-2; Shaw GC, 1997, J BACTERIOL, V179, P280, DOI 10.1128/jb.179.1.280-283.1997; SHAW GC, 1992, J BIOL CHEM, V267, P5515; Shaw GC, 1997, CURR MICROBIOL, V35, P28, DOI 10.1007/s002849900206; Shaw GC, 1995, BIOCHEM MOL BIOL INT, V37, P1197; SHAW GC, 1993, J BIOL CHEM, V268, P2997; Shaw W V, 1975, Methods Enzymol, V43, P737; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEN LP, 1989, J BIOL CHEM, V264, P10996; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7996	8002		10.1074/jbc.273.14.7996	http://dx.doi.org/10.1074/jbc.273.14.7996			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525898	hybrid			2022-12-27	WOS:000072876300032
J	Volchuk, A; Narine, S; Foster, LJ; Grabs, D; De Camilli, P; Klip, A				Volchuk, A; Narine, S; Foster, LJ; Grabs, D; De Camilli, P; Klip, A			Perturbation of dynamin II with an amphiphysin SH3 domain increases GLUT4 glucose transporters at the plasma membrane in 3T3-L1 adipocytes - Dynamin II participates in GLUT4 endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; RAT ADIPOSE-CELLS; GTP-GAMMA-S; NERVE-TERMINALS; INSULIN ACTION; SUBCELLULAR TRAFFICKING; INTERNALIZATION MOTIF; TRANSFERRIN RECEPTORS; SORTING SIGNALS; PROTEIN	The GLUT4 glucose transporter continuously recycles between the cell surface and an endosomal compartment in adipocytes, Insulin decreases the rate of GLUT4 endocytosis in addition to increasing its exocytosis. Endocytosis of the transporter is thought to occur at least in part via the clathrin-mediated endocytic system, The protein dynamin is involved in the final stages of clathrin-coated vesicle formation, Here we show that the dynamin II isoform is expressed in 3T3-L1 adipocytes and is present in isolated plasma membrane and low density microsomal fractions, Insulin reduced the levels of dynamin II associated with the plasma membrane by about half, raising the possibility that the hormone may reduce GLUT4 endocytosis by removing dynamin from the cell surface, A fusion protein containing the amphiphysin SH3 domain selectively bound dynamin II from 3T3-L1 adipocyte cell lysates, Microinjection of the fusion protein into these cells inhibited transferrin endocytosis and increased the levels of GLUT4 at the cell surface. Glutathione S-transferase alone, the SH3 domains of spectrin and Crk, and a mutated amphiphysin SH3 domain unable to bind dynamin II did not affect GLUT4 distribution. However, a peptide containing the dynamin II sequence that binds amphiphysin increased the surface presence of GLUT4, Moreover, in cells first treated with insulin to externalize GLUT4, the dynamin peptide, but not an unrelated control peptide, inhibited GLUT4 internalization upon insulin removal. These results suggest that interactions of dynamin II with amphiphysin may play an important role in GLUT4 endocytosis, We hypothesize that insulin may reduce GLUT4 endocytosis by regulating the function of dynamin II at the cell surface, as part of the mechanism to increase glucose uptake.	Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Yale University; Howard Hughes Medical Institute; Yale University	Klip, A (corresponding author), Hosp Sick Children, Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.				NCI NIH HHS [CA48128] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cook T, 1996, J NEUROCHEM, V67, P927; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; CORVERA S, 1985, P NATL ACAD SCI USA, V82, P7314, DOI 10.1073/pnas.82.21.7314; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MIKI H, 1994, J BIOL CHEM, V269, P5489; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NAKATA T, 1993, J CELL SCI, V105, P1; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Rice JE, 1996, BIOCHEM SOC T, V24, P540, DOI 10.1042/bst0240540; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	69	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8169	8176		10.1074/jbc.273.14.8169	http://dx.doi.org/10.1074/jbc.273.14.8169			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525921	hybrid			2022-12-27	WOS:000072876300055
J	Fullone, MR; Visconti, S; Marra, M; Fogliano, V; Aducci, P				Fullone, MR; Visconti, S; Marra, M; Fogliano, V; Aducci, P			Fusicoccin effect on the in vitro interaction between plant 14-3-3 proteins and plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED NITRATE REDUCTASE; INHIBITOR PROTEIN; BINDING; 14-3-3-PROTEIN; PURIFICATION; RECEPTOR; MAIZE; ACTIVATION; EXPRESSION; ISOFORM	A 17-amino acid peptide was selectively cleaved from the highly variant C terminus of the 33-kDa 14-3-3 isoform occurring in fusicoccin receptor preparations from maize and was sequenced, The determined C-terminal sequence was identical to that of the already known maize 14-3-3 homolog GF14-6, thus prompting the use of recombinant GF14-6 in an in vitro protein-protein inter action study. The cDNA of GF14-6 was expressed in Escherichia coli as a P-32-phosphorylatable glutathione S-transferase fusion protein and was used as a probe in overlay experiments with HC-ATPase partially purified from maize roots. The results demonstrated that the recombinant protein specifically bound to H+-ATPase. The binding was dependent on Mg2+ and was strongly increased by fusicoccin. Controlled trypsin digestion of H+-ATPase abolished the association with GF14-6, a finding that was suggestive of an interaction with the C terminus of the enzyme, To confirm this result, the C-terminal domain of H+-ATPase was expressed as a glutathione S-transferase fusion peptide and was used in overlay experiments, GF14-6 was also able to bind to the isolated C terminus, but only in the presence of fusicoccin.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Naples Federico II, Dipartimento Sci Alimenti, I-80055 Naples, Italy	University of Rome Tor Vergata; Sapienza University Rome; University of Naples Federico II	Aducci, P (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ricerca Sci, I-00133 Rome, Italy.	aducci@utovrm.it	fogliano, vincenzo/A-1419-2009; fogliano, vincenzo/W-6885-2019; Fogliano, Vincenzo/M-8166-2019	fogliano, vincenzo/0000-0001-8786-9355; fogliano, vincenzo/0000-0001-8786-9355; 				ADUCCI P, 1986, PLANT SCI, V45, P83, DOI 10.1016/0168-9452(86)90041-5; ADUCCI P, 1993, EUR J BIOCHEM, V214, P339, DOI 10.1111/j.1432-1033.1993.tb17929.x; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALLEN G, 1981, LABORATORY TECHNIQUE, P43; BACHMANN M, 1995, PLANT PHYSIOL, V108, P1083, DOI 10.1104/pp.108.3.1083; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; BALLIO A, 1968, Annali dell'Istituto Superiore di Sanita, V4, P317; BAUNSGAARD L, 1997, CELL MOL BIOL LETT, V2, P243; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Daugherty CJ, 1996, PLANT CELL, V8, P1239, DOI 10.1105/tpc.8.8.1239; DeMichelis MI, 1996, PLANT PHYSIOL, V110, P957, DOI 10.1104/pp.110.3.957; DEVETTEN NC, 1994, PLANT PHYSIOL, V106, P1593, DOI 10.1104/pp.106.4.1593; Ferl RJ, 1996, ANNU REV PLANT PHYS, V47, P49, DOI 10.1146/annurev.arplant.47.1.49; Frias I, 1996, PLANT CELL, V8, P1533; JAHN T, 1997, CELL MOL BIOL LETT, V2, P234; JOHANSSON F, 1993, PLANT CELL, V5, P321, DOI 10.2307/3869599; JOHANSSON F, 1994, PHYSIOL PLANTARUM, V92, P389; KORTHOUT HAAJ, 1994, PLANT CELL, V6, P1681, DOI 10.1105/tpc.6.11.1681; Marra M, 1996, FEBS LETT, V382, P293, DOI 10.1016/0014-5793(96)00187-1; MARRA M, 1994, PLANT PHYSIOL, V106, P1497, DOI 10.1104/pp.106.4.1497; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OECKING C, 1994, FEBS LETT, V352, P163, DOI 10.1016/0014-5793(94)00949-X; OECKING C, 1997, CELL MOL BIOL LETT, V2, P236; RASICALDOGNOV F, 1993, PLANT PHYSIOL, V103, P391, DOI 10.1104/pp.103.2.391; Sehnke PC, 1996, CURR BIOL, V6, P1403, DOI 10.1016/S0960-9822(96)00742-7; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43	29	89	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7698	7702		10.1074/jbc.273.13.7698	http://dx.doi.org/10.1074/jbc.273.13.7698			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516476	hybrid			2022-12-27	WOS:000072738500072
J	Habib, AA; Hognason, T; Ren, J; Stefansson, K; Ratan, RR				Habib, AA; Hognason, T; Ren, J; Stefansson, K; Ratan, RR			The epidermal growth factor receptor associates with and recruits phosphatidylinositol 3-kinase to the platelet-derived growth factor beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; KINASE-DEFICIENT NEU; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FAMILY MEMBERS; BREAST-CANCER; CELLS; HETERODIMERIZATION; BINDING	Receptor tyrosine kinases are classified into subfamilies, which are believed to function independently, with heterodimerization occurring only within the same subfamily, In this study, we present evidence suggesting a direct interaction between the epidermal growth factor (EGF) receptor (EGFR) and the platelet-derived growth factor beta (PDGF beta) receptor (PDGF beta R), members of different receptor tyrosine kinase subfamilies, We find that the addition of EGF to COS-7 cells and to human foreskin Hs27 fibroblasts results in a rapid tyrosine phosphorylation of the PDGF beta R and results in the recruitment of phosphatidylinositol 3-kinase to the PDGF beta R. In R1hER cells, which overexpress the EGFR, we find ligand-independent tyrosine phosphorylation of the PDGF beta R and the constitutive binding of a substantial amount of PI-3 kinase activity to it, mimicking the effect of Ligand in untransfected cells, In support of the possibility that this may be a direct interaction, we show that the two receptors can be coimmunoprecipitated from untransfected Hs27 fibroblasts and from COS-7 cells, This association can be reconstituted by introducing the two receptors into 293 EBNA cells, The EGFR/PDGF beta R association is ligand-independent in all cell lines tested, We also demonstrate that the fraction of PDGF beta R bound to the EGFR in R1hER cells undergoes an EGF-induced mobility shift on Western blots indicative of phosphorylation, Our findings indicate that direct interactions between receptor tyrosine kinases classified under different subfamilies may be more widespread than previously believed.	Beth Israel Med Ctr, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; DeCode Genet, Reykjavik, Iceland	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Habib, AA (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur,Room 807, Boston, MA 02115 USA.		Stefansson, Kari/AAE-7187-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032977] Funding Source: NIH RePORTER; NINDS NIH HHS [R0INS32977] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BOWENPOPE DF, 1983, J CELL BIOL, V96, P679, DOI 10.1083/jcb.96.3.679; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chan CL, 1996, J BIOL CHEM, V271, P22619, DOI 10.1074/jbc.271.37.22619; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P13642; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158	46	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6885	6891		10.1074/jbc.273.12.6885	http://dx.doi.org/10.1074/jbc.273.12.6885			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506992	hybrid			2022-12-27	WOS:000072775900042
J	Sankaran, B; Osterhout, J; Wu, DQ; Smrcka, AV				Sankaran, B; Osterhout, J; Wu, DQ; Smrcka, AV			Identification of a structural element in phospholipase C beta 2 that interacts with G protein beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; ACTIVATION; PURIFICATION; BINDING; ASSOCIATION; INHIBITION; FRAGMENTS	To delineate the specific regions of phospholipase C beta 2 (PLC beta 2) involved in binding and activation by G protein beta gamma subunits, we synthesized peptides corresponding to segments of PLC beta 2, Two overlapping peptides corresponding to Asn-564-Lys-583 (N20K) and Glu-574-Lys-593 (E20K) inhibited the activation of PLC beta 2 by beta gamma subunits (IC50 50 and 150 mu M, respectively), whereas two control peptides did not, N20K and E20K, but not the control peptides, inhibited beta gamma-dependent ADP-ribosylation of G alpha(i1) by pertussis toxin and beta gamma-dependent activation of phosphoinositide 3-kinase, To demonstrate direct binding of the peptides to beta gamma subunits, the peptides were chemically cross-linked to purified beta(1) gamma(2). N20K and E20K cross-linked to both beta(1) and gamma(2) subunits, whereas the control peptides did not, Cross-linking to beta and gamma was inhibited by incubation with excess PLC beta 2 or PLC beta 3, whereas cross-linking to gamma but not beta was inhibited by r-myr-alpha(i1). These data together demonstrate specificity of N20K and E20K for G beta gamma binding and inhibition of effector activation by beta gamma subunits, The results suggest that an overlapping region of the two active peptides, Glu-574-Lys-583, mimics a region of PLC beta 2 that is involved in binding to beta gamma subunits, Changing a tyrosine to a glutamine in this overlapping region of the peptides inhibited binding of the peptide to beta gamma subunits, Alignment of these peptides with the three-dimensional structure from PLC delta 1 identifies a putative alpha helical region on the surface of the catalytic domain of PLC beta 2 that could interact with beta gamma subunits.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	Smrcka@pharmacol.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053536, R29GM053162] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R01-GM53536-01, GM53162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE SB, 1993, J BIOL CHEM, V268, P25952; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; SCHACHT J, 1978, J LIPID RES, V19, P1063; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; UEDA N, 1994, J BIOL CHEM, V269, P4388; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; YANG K, 1997, J BIOL CHEM, V272, P2056	29	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7148	7154		10.1074/jbc.273.12.7148	http://dx.doi.org/10.1074/jbc.273.12.7148			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507029	hybrid			2022-12-27	WOS:000072775900079
J	Shibutani, M; Lazarovici, P; Johnson, AC; Katagiri, Y; Guroff, G				Shibutani, M; Lazarovici, P; Johnson, AC; Katagiri, Y; Guroff, G			Transcriptional down-regulation of epidermal growth factor receptors by nerve growth factor treatment of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; PROTEIN-BINDING; GENE PROMOTER; HUMAN P53; IDENTIFICATION; LINE; DIFFERENTIATION; ACTIVATION; RESPOND	Treatment of PC12 cells with nerve growth factor leads to a decrease in the number of epidermal growth factor receptors on the cell membrane, The mRNA for the epidermal growth factor receptor decreases in a comparable fashion. This decrease appears due to a decrease in the transcription of the epidermal growth factor receptor gene because first, there is no difference in the stability of the epidermal growth factor receptor mRNA, second, newly transcribed epidermal growth factor receptor mRNA is decreased in nerve growth factor-differentiated cells, and third, constructs containing the promoter region of the epidermal growth factor receptor gene are transcribed much less readily in nerve growth factor-differentiated cells than in untreated cells, The decreases in mRNA are not seen in the p140(trk)-deficient variant PC12nnr5 cells nor in cells containing either dominant-negative Ras or dominant-negative Src, Treatment with nerve growth factor also increases the cellular content of GCF2, a putative transcription factor inhibitory for the transcription of the epidermal growth factor receptor gene. The increase in GCF2, like the decrease in the epidermal growth factor receptor mRNA, is not seen in PC12nnr5 cells nor in cells expressing either dominant-negative Ras or dominant-negative Src, The results suggest that nerve growth factor-induced down-regulation of the epidermal growth factor receptor is under transcriptional control, is p140(trk), Ras-, and Src-dependent, and may involve transcriptional repression by GCF2.	NICHD, Growth Factors Sect, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Guroff, G (corresponding author), NICHD, Growth Factors Sect, NIH, Bldg 49,Rm 5A64, Bethesda, MD 20892 USA.	gordong@helix.nih.gov	Shibutani, Makoto/AGK-2801-2022; Shibutani, Makoto/C-2510-2013	Shibutani, Makoto/0000-0003-3417-9697; 				Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; BROWN AB, 1991, J NEUROCHEM, V57, P1740, DOI 10.1111/j.1471-4159.1991.tb06376.x; DEB SP, 1994, ONCOGENE, V9, P1341; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG M, 1995, CURRENT PROTOCOLS MO, V1; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HOU XY, 1994, J BIOL CHEM, V269, P4307; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JAMAL S, 1995, ONCOGENE, V10, P2095; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; Lazarovici P, 1997, J BIOL CHEM, V272, P11026, DOI 10.1074/jbc.272.17.11026; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; MOTHE I, 1993, MOL BIOL CELL, V4, P737, DOI 10.1091/mbc.4.7.737; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SHULDINER AR, 1993, CURRENT METHODS APPL, P169; Souaze F, 1996, BIOTECHNIQUES, V21, P280; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Tang KC, 1996, J BIOL CHEM, V271, P28382, DOI 10.1074/jbc.271.45.28382; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WANG SL, 1993, P NATL ACAD SCI USA, V90, P10385, DOI 10.1073/pnas.90.21.10385	33	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6878	6884		10.1074/jbc.273.12.6878	http://dx.doi.org/10.1074/jbc.273.12.6878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506991	hybrid			2022-12-27	WOS:000072775900041
J	Shimizu, K; Shirataki, H; Honda, T; Minami, S; Takai, Y				Shimizu, K; Shirataki, H; Honda, T; Minami, S; Takai, Y			Complex formation of SMAP/KAP3, a KIF3A/B ATPase motor-associated protein, with a human chromosome-associated polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE PROTEIN; CONDENSATION; CLONING; BINDING; KINASE	We have recently isolated SMAP (Smg GDS-associated protein; Smg GDS: small G protein GDP dissociation stimulator) as a novel Smg GDS-associated protein, which has Armadillo repeats and is phosphorylated by Src tyrosine kinase. SMAP is a human counterpart of mouse KAP3 (kinesin superfamily-associated protein) that is associated with mouse KIF3A/B (a kinesin superfamily protein), which functions as a microtubule-based ATPase motor for organelle transport, We isolated here a SMAP-interacting protein from a human brain cDNA library, identified it to be a human homolog of Xenopus XCAP-E (Xenopus chromosome-associated polypeptide), a subunit of condensins that regulate the assembly and structural maintenance of mitotic chromosomes, and named it HCAP (Human chromosome-associated polypeptide), Tissue and subcellular distribution analyses indicated that HCAP was ubiquitously expressed and highly concentrated in the nuclear fraction, where SMAP and KIF3B were also present, SMAP was extracted as a ternary complex with HCAP and KIF3B from the nuclear fraction in the presence of Mg-ATP. The results suggest that SMAP/KAP3 serves as a linker between HCAP and KIF3A/B in the nucleus, and that SMAP/KAP3 plays a role in the interaction of chromosomes with an ATPase motor protein.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HENSON JH, 1995, DEV BIOL, V171, P182, DOI 10.1006/dbio.1995.1270; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Holt CL, 1996, GENETICS, V142, P777; Hong CS, 1996, GENETICS, V142, P879; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STRUNNIKOV AV, 1995, GENE DEV, V9, P597; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435	26	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6591	6594		10.1074/jbc.273.12.6591	http://dx.doi.org/10.1074/jbc.273.12.6591			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506951	hybrid			2022-12-27	WOS:000072775900001
J	Stofega, MR; Wang, HY; Ullrich, A; Carter-Su, C				Stofega, MR; Wang, HY; Ullrich, A; Carter-Su, C			Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; CYTOKINE RECEPTORS; SH2 DOMAINS; GH RECEPTOR; PROTEIN; KINASE	SIRPs (signal-regulatory proteins) are a family of transmembrane glycoproteins that were identified by their association with the Src homology 2 domain-containing protein-tyrosine phosphatase SHP-2 in response to insulin. Here we examine whether SIRP alpha and SHP-2 are signaling molecules for the receptors for growth hormone (GH), leukemia inhibitory factor (LIF), or interferon-gamma (lFN gamma), cytokine receptor superfamily members that bind to and activate Janus kinase 2 (JAK2). In 3T3-F442A fibroblasts, GH rapidly stimulates tyrosyl phosphorylation of both SIRP alpha: and SHP-2 and enhances association of SHP-2 with SIRP alpha. Consistent with JAK2 binding and phosphorylating SIRP alpha in response to GH, co-expression of SIRP alpha and JAK2 in COS cells results in tyrosyl phosphorylation of SIRP alpha and JAK2 association with SIRP alpha. LIF does not stimulate tyrosyl phosphorylation of SIRP alpha but stimulates greater tyrosyl phosphorylation of SHP-2 than GH. Additionally, LIF enhances association of SHP-2 with the gp130 subunit of the LIF receptor signaling complex. IFN gamma, which stimulates JAK2 to a greater extent than LIF, is ineffective at stimulating tyrosyl phosphorylation of SIRP alpha or SHP-2. These results suggest that SIRP alpha is a signaling molecule for GH but not for LIF or IFN gamma. Differential phosphorylation of SIRP alpha and SHP-2 may contribute to the distinct physiological effects of these ligands.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Max Planck Society	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.	cartersu@umich.edu			NIDDK NIH HHS [DK 48283, R01 DK034171, DK 34171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048283, R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	77	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7112	7117		10.1074/jbc.273.12.7112	http://dx.doi.org/10.1074/jbc.273.12.7112			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507023	hybrid			2022-12-27	WOS:000072775900073
J	Dong, F; Cress, WD; Agrawal, D; Pledger, WJ				Dong, F; Cress, WD; Agrawal, D; Pledger, WJ			The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE FAMILY; TRANSCRIPTION FACTOR E2F; CELL-PROLIFERATION; PROTEIN P130; RB PROTEIN; G(1); P107; PRB; INHIBITION; EXPRESSION	We have observed that cyclin D3-dependent kinase activity is increased in the late G(1), phase in BALB/c 3T3 fibroblasts. The profile of cyclin D3-associated activity closely parallels that of cyclin D1, which is also induced after mitogenic stimulation of quiescent cells. These activities correlate with the appearance of hyperphosphorylated p130, an Rb family member important in regulating E2F-4 and E2F-5 activity in fibroblastic cells. We demonstrated, however, that only the cyclin D3 activity efficiently phosphorylated p130 in an in vitro kinase assay. This apparent specificity was further demonstrated by experiments which demonstrated that cyclin D3 was physically associated with p130 at the times when D3-dependent kinase activity and p130 hyperphosphorylation were observed. Examination of E2F by electrophoretic mobility shift assay revealed that E2F-4 DNA binding activity existed in a p130.E2F complex at times before D3-dependent kinase activity was apparent and in a free E2F 4 complex after D3 activity developed. Thus, our data suggest that cyclin D3 preferentially phosphorylates p130 and is thereby specifically targeted to overcoming growth-suppressive control mediated through p130 pathways.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA 67360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRAWAL D, 1995, CELL GROWTH DIFFER, V6, P1199; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPAN S, 1991, CELL, V65, P1052; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HERZINGER T, 1995, ONCOGENE, V10, P2079; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Levine K, 1996, MOL CELL BIOL, V16, P6794; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nagasawa M, 1997, J IMMUNOL, V158, P5146; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; NEVINS JR, 1992, SCIENCE, V258, P424; REED SI, 1991, COLD SH Q B, V56, P61; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	51	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6190	6195		10.1074/jbc.273.11.6190	http://dx.doi.org/10.1074/jbc.273.11.6190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497341	hybrid			2022-12-27	WOS:000072488500033
J	Levy, NS; Chung, SM; Furneaux, H; Levy, AP				Levy, NS; Chung, SM; Furneaux, H; Levy, AP			Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; AU-RICH ELEMENTS; GENE-PRODUCT; IN-VITRO; DEGRADATION; ELAV; SEQUENCE; AUUUA; CELLS; DIFFERENTIATION	Vascular endothelial growth factor (VEGF) is a potent angiogenic factor whose expression is dramatically induced by hypoxia due in large part to an increase in the stability of its mRNA. Here we show that HuR binds with high affinity and specificity to the element that regulates VEGF mRNA stability by hypoxia. Inhibition of HuR expression abrogates the hypoxia-mediated increase in VEGF mRNA stability. Overexpression of HuR increases the stability of VEGF mRNA. However, this only occurs efficiently in hypoxic cells. We further show that the stabilization of VEGF mRNA can be recapitulated in vitro. Using an S-100 extract, we show that the addition of recombinant HuR stabilizes VEGF mRNA markedly. These data support the critical role of HuR in mediating the hypoxic stabilization of VEGF mRNA by hypoxia.	Georgetown Univ, Med Ctr, Div Cardiol, Washington, DC 20007 USA; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA	Georgetown University; Memorial Sloan Kettering Cancer Center	Levy, AP (corresponding author), Technion Israel Inst Technol, Fac Med, POB 9649, IL-31096 Haifa, Israel.			furneaux, henry/0000-0003-2212-1017	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029682] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA08748] Funding Source: Medline; NHLBI NIH HHS [1K08HL03405-02] Funding Source: Medline; NINDS NIH HHS [NS29682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; DALMAU J, 1992, AM J PATHOL, V141, P1; Gao FB, 1996, J CELL SCI, V109, P579; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KING PH, 1994, J NEUROSCI, V14, P1943; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Levy NS, 1997, BBA-GENE STRUCT EXPR, V1352, P167, DOI 10.1016/S0167-4781(97)00052-3; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pugh CW, 1997, J BIOL CHEM, V272, P11205; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	540	557	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6417	6423		10.1074/jbc.273.11.6417	http://dx.doi.org/10.1074/jbc.273.11.6417			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497373	hybrid			2022-12-27	WOS:000072488500065
J	Panozzo, C; Cornillot, E; Felenbok, B				Panozzo, C; Cornillot, E; Felenbok, B			The CreA repressor is the sole DNA-binding protein responsible for carbon catabolite repression of the alcA gene in Aspergillus nidulans via its binding to a couple of specific sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHANOL UTILIZATION REGULON; POSITIVE REGULATORY GENE; GLUCOSE REPRESSION; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR ALCR; REGION; DEHYDROGENASE; PROMOTER; CLONING; FUNGI	Carbon catabolite repression is mediated in Aspergillus nidulans by the negative acting protein CreA. The CreA repressor plays a major role in the control of the expression of the ale regulon, encoding proteins required for the ethanol utilization pathway. It represses directly, at the transcriptional level, the specific transacting gene alcR, the two structural genes alcA and aldA, and other ale genes in all physiological growth conditions. Among the seven putative CreA sites identified in the alcA promoter region, we have determined the CreA functional targets in AlcR constitutive and derepressed genetic backgrounds. Two different divergent CreA sites, of which one overlaps a functional AlcR inverted repeat site, are largely responsible for alcA repression. Totally derepressed alcA expression is achieved when these two CreA sites are disrupted in addition to another single site, which overlaps the functional palindromic induction target. The fact that derepression is always associated with alcA overexpression is consistent with a competition model between AlcR and CreA for their cognate targets in the same region of the alcA promoter. Our results also indicate that the CreA repressor is necessary and sufficient for the total repression of the alcA gene.	Univ Paris Sud, Ctr Univ Orsay, Inst Genet & Microbiol, CNRS,URA D2225, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Felenbok, B (corresponding author), Univ Paris Sud, Ctr Univ Orsay, Inst Genet & Microbiol, CNRS,URA D2225, Batiment 409, F-91405 Orsay, France.		Cornillot, Emmanuel/P-9656-2017	Cornillot, Emmanuel/0000-0002-1202-1162				BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CREASER EH, 1985, BIOCHEM J, V225, P449, DOI 10.1042/bj2250449; CUBERO B, 1994, EMBO J, V13, P405; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; DRYSDALE MR, 1993, GENE, V130, P241, DOI 10.1016/0378-1119(93)90425-3; ESPESO EA, 1994, FEBS LETT, V342, P43, DOI 10.1016/0014-5793(94)80581-4; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FELENBOK B, 1996, MYCOTA, V3, P369; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FILLINGER S, 1995, FEBS LETT, V368, P547, DOI 10.1016/0014-5793(95)00736-S; Fillinger S, 1996, MOL MICROBIOL, V20, P475, DOI 10.1046/j.1365-2958.1996.5301061.x; FILLINGER S, 1996, THESIS U PARIS SUD F; Gonzalez R, 1997, EMBO J, V16, P2937, DOI 10.1093/emboj/16.10.2937; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; KULMBURG P, 1992, J BIOL CHEM, V267, P21146; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; KULMBURG P, 1993, MOL MICROBIOL, V7, P847, DOI 10.1111/j.1365-2958.1993.tb01175.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; LOCKINGTON R, 1987, MOL MICROBIOL, V1, P275, DOI 10.1111/j.1365-2958.1987.tb01933.x; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; Lutfiyya LL, 1996, MOL CELL BIOL, V16, P4790; MATHIEU M, 1994, EMBO J, V13, P4022, DOI 10.1002/j.1460-2075.1994.tb06718.x; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; Panozzo C, 1997, J BIOL CHEM, V272, P22859, DOI 10.1074/jbc.272.36.22859; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; SAMBROOK J, 1969, MOL CLONING LAB MANU; SEALYLEWIS HM, 1992, CURR GENET, V22, P293, DOI 10.1007/BF00317924; SEQUEVAL D, 1994, MOL GEN GENET, V242, P33, DOI 10.1007/BF00277345; STRAUSS J, 1995, FEBS LETT, V376, P103, DOI 10.1016/0014-5793(95)01255-5	35	62	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6367	6372		10.1074/jbc.273.11.6367	http://dx.doi.org/10.1074/jbc.273.11.6367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497366	hybrid			2022-12-27	WOS:000072488500058
J	Adachi, K; Saito, H; Tanaka, T; Oka, T				Adachi, K; Saito, H; Tanaka, T; Oka, T			Molecular cloning and characterization of the murine Staf cDNA encoding a transcription activating factor for the selenocysteine tRNA gene in mouse mammary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA(SER)SEC GENE; ZINC-FINGER PROTEIN; OPEN READING FRAME; TRANSFER-RNA GENE; MESSENGER-RNA; GLUTATHIONE-PEROXIDASE; EPITHELIAL-CELLS; ELEMENTS; TGA; TERMINATION	We have isolated and characterized a cDNA encoding a transcription activating factor for the mouse selenocysteine tRNA (tRNA(sec)) gene from mouse mammary gland. The full-length cDNA, designated m-Staf, has a 1878-base pair open reading frame encoding 626 amino acids. The predicted amino acid sequence of m-Staf is highly homologous to that of Staf, another selenocysteine tRNA gene transcription activating factor of Xenopus laevis. Like Staf, m-Staf contains seven tandemly repeated zinc fingers and four repeated motifs. Gel shift assays indicated that the recombinant m-Staf specifically bound to the activator element region in the mouse tRNA(sec) gene. Transient co-transfection experiments in Drosophila Schneider cells, which lack endogenous Staf-like binding activity, showed that m-Staf increased the mouse tRNA(sec) gene transcription about 15-fold, whereas it stimulated Pol II-dependent thymidine kinase promoter only 2-fold. Northern blot analysis detected the presence of a 3.4-kilobase pair m-Staf transcript, which was widely but differentially expressed in various murine tissues. The binding activity of m-Staf in mouse mammary gland was undetectable during virgin and postlactating periods but increased markedly in parallel with the increase of tRNA(sec) transcript during the periods of pregnancy and lactation, when the gland undergoes growth and development. These results indicate that m-Staf is a transcriptional activator of the mouse tRNA(sec) gene and that its binding activity in the mammary gland undergoes developmental alterations.	NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Oka, T (corresponding author), NIDDK, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 309, Bethesda, MD 20892 USA.							ACEVES C, 1989, ENDOCRINOLOGY, V124, P2818, DOI 10.1210/endo-124-6-2818; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; Baron Christian, 1995, P529; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BORELLINI F, 1989, ENVIRON HEALTH PERSP, V80, P85, DOI 10.2307/3430734; BOSL MR, 1995, MOL GEN GENET, V248, P247, DOI 10.1007/BF02191590; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P5463; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; JACK LJW, 1994, J ENDOCRINOL, V142, P205, DOI 10.1677/joe.0.1420205; LARSEN PR, 1995, ANNU REV NUTR, V15, P323, DOI 10.1146/annurev.nu.15.070195.001543; LEE BJ, 1989, J BIOL CHEM, V264, P9696; LEWIN B, 1994, GENES, V5, P887; MEISSNER W, 1994, NUCLEIC ACIDS RES, V22, P553; MYSLINSKI E, 1993, NUCLEIC ACIDS RES, V21, P5852, DOI 10.1093/nar/21.25.5852; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; RINGQUIST S, 1994, GENE DEV, V8, P376, DOI 10.1101/gad.8.3.376; Saito H, 1996, J BIOL CHEM, V271, P8911, DOI 10.1074/jbc.271.15.8911; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; TUCKER HA, 1981, J DAIRY SCI, V64, P1403, DOI 10.3168/jds.S0022-0302(81)82711-7; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	39	16	18	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8598	8606		10.1074/jbc.273.15.8598	http://dx.doi.org/10.1074/jbc.273.15.8598			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535833	hybrid			2022-12-27	WOS:000072990800010
J	Abe, A; Shayman, JA				Abe, A; Shayman, JA			Purification and characterization of 1-O-acylceramide synthase, a novel phospholipase A(2) with transacylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; BOVINE BRAIN; RAT; INHIBITION; CYCLE	A novel pathway for ceramide metabolism, 1-O-acylceramide formation, was previously reported (Abe, A, Shayman, J. A., and Radin, N. S. (1996) J. Biol. Chem. 271, 14383-14389), In this pathway a fatty acid in the sn-2 position of phosphatidylethanolamine or phosphatidylcholine is transferred to the 1-hydroxyl position of ceramide, An enzyme that catalyzes the esterification of N-acetylsphingosine was purified from the postmitochondrial supernatant of calf brain through consecutive steps, including ammonium sulfate fractionation, DEAE-Sephacel, phenyl-Sepharose, S-Sepharose, Sephadex G-75, concanavalin A-agarose, and heparin-Sepharose chromatography. The molecular mass of the enzyme was determined to be 40 kDa by gel filtration on Sephadex G-75, The enzyme bound to concanavalin A-agarose column was eluted with the buffer containing 500 mM alpha-methyl-D-mannopyranoside. Further purification by heparin-Sepharose chromatography resulted in separation of two peaks of enzyme activity, Coincidence between the transacylase activity and a stained protein of a molecular mass of 40 kDa was observed, as determined by SDS-polyacrylamide gel electrophoresis and recovery after separation over an acidic native gel, The second peak of activity from the heparin-Sepharose chromatography represented a purification of 193,000-fold, These results are consistent with the enzyme being a glycoprotein of a molecular mass of about 40 kDa with a single polypeptide chain. The purified enzyme had a pH optimum at pH 4.5, The divalent cations Ca2+ and Mg2+ enhanced but were not essential for the transacylase activity, Neither activation nor inactivation of the enzyme activity was observed in the presence of 2 mM ATP or 2 mM dithiothreitol, Preincubation of the enzyme with 1 mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride, or 3.1 mu M bromoenol lactone, a potent inhibitor of cytosolic Ca2+-independent phospholipase A(2), had no significant effect on the enzyme activity, The enzyme activity was completely abolished in the presence of greater than 773 mu M Triton X-100. Partial inhibition of the enzyme activity was observed in the presence of 10-100 mu g/ml heparin, In the absence of N-acetylsphingosine, the enzyme acted as a phospholipase A(2). These results strongly suggest that 1-O-acylceramide synthase is both a transacylase and a novel phospholipase A(2).	Univ Michigan, Dept Internal Med, Div Nephrol, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Dept Internal Med, Div Nephrol, Med Ctr, Box 0676,Rm 1560 MSRBII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	jshayman@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK41487] Funding Source: Medline; PHS HHS [R01139255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BARTOLF M, 1990, BIOCHIM BIOPHYS ACTA, V1042, P247, DOI 10.1016/0005-2760(90)90016-Q; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; CHEN J, 1994, J BIOL CHEM, V269, P23018; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; Kim TS, 1997, J BIOL CHEM, V272, P2542; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; Portilla D, 1996, J BIOL CHEM, V271, P15451, DOI 10.1074/jbc.271.26.15451; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SHARP JD, 1994, J BIOL CHEM, V269, P23250; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; WANG R, 1994, BIOCHEM J, V304, P131, DOI 10.1042/bj3040131; YANG HC, 1994, BIOCHEM J, V299, P91, DOI 10.1042/bj2990091; [No title captured]	28	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8467	8474		10.1074/jbc.273.14.8467	http://dx.doi.org/10.1074/jbc.273.14.8467			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525960	hybrid			2022-12-27	WOS:000072876300094
J	BouHamdan, M; Xue, YN; Baudat, Y; Hu, BC; Sire, J; Pomerantz, RJ; Duan, LX				BouHamdan, M; Xue, YN; Baudat, Y; Hu, BC; Sire, J; Pomerantz, RJ; Duan, LX			Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; URACIL-DNA-GLYCOSYLASE; GLUTATHIONE-S-TRANSFERASE; CHAIN VARIABLE FRAGMENTS; TYPE-1 VPR; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; FUSION PROTEINS; PRODUCTIVE INFECTION; RETROVIRAL VECTORS	Targeting protein or RNA moieties to specific cellular compartments may enhance their desired functions and specificities, Human immunodeficiency virus type I (HIV-1) encodes proteins in addition to Gag, Pol, and Env that are packaged into virus particles, One such retroviral-incorporated protein is Vpr, which is present in all primate lentiviruses, Vpr has been implicated in different roles within the HIV-1 life cycle, In testing a new hypothesis in which viral proteins are utilized as docking sites to incorporate protein moieties into virions, we used the peptide phage display approach to search for Vpr-specific binding peptides, In the present studies, we demonstrate that most of the peptides that bind to Vpr have a common motif, WXXF, More importantly, we demonstrate that the WXXF motif of uracil DNA glycosylase is implicated in the interaction of uracil DNA glycosylase with Vpr intracellularly. Finally, a dimer of the WXXF motif was fused to the chloramphenicol acetyl transferase (CAT) gene, and it was demonstrated that the WXXF dimer-CAT fusion protein construct produces CAT activity within virions in the presence of Vpr as a docking protein, This study provides a novel potential strategy in the targeting of antiviral agents to interfere with HIV-1 replication.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA; INSERM, U372, F-13276 Marseille 9, France	Jefferson University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Duan, LX (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038666] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36557, AI38666] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; BALLIET JW, 1994, VIROLOGY, V200, P623, DOI 10.1006/viro.1994.1225; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; CORNETTA K, 1993, HUM GENE THER, V4, P579, DOI 10.1089/hum.1993.4.5-579; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; Duan LX, 1995, HUM GENE THER, V6, P1561, DOI 10.1089/hum.1995.6.12-1561; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; LAVALLEE C, 1994, J VIROL, V68, P1926; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; Liu HM, 1997, J VIROL, V71, P7704, DOI 10.1128/JVI.71.10.7704-7710.1997; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller RH, 1996, AIDS RES HUM RETROV, V12, P859, DOI 10.1089/aid.1996.12.859; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; RICHMAN DD, 1995, CLIN INFECT DIS   S2, V21, P166; RIDKY T, 1995, J BIOL CHEM, V270, P29621, DOI 10.1074/jbc.270.50.29621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALMONS B, 1993, HUM GENE THER, V4, P129, DOI 10.1089/hum.1993.4.2-129; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Serio D, 1997, P NATL ACAD SCI USA, V94, P3346, DOI 10.1073/pnas.94.7.3346; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; TRISTEM M, 1992, EMBO J, V11, P3405, DOI 10.1002/j.1460-2075.1992.tb05419.x; Tung HYL, 1997, FEBS LETT, V401, P197, DOI 10.1016/S0014-5793(96)01470-6; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WANG CT, 1994, VIROLOGY, V200, P524, DOI 10.1006/viro.1994.1215; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; WELDON RA, 1990, J VIROL, V64, P4169, DOI 10.1128/JVI.64.9.4169-4179.1990; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988; Wu XY, 1996, VIROLOGY, V219, P307, DOI 10.1006/viro.1996.0253; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995	61	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8009	8016		10.1074/jbc.273.14.8009	http://dx.doi.org/10.1074/jbc.273.14.8009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525900	hybrid			2022-12-27	WOS:000072876300034
J	Hartson, SD; Ottinger, EA; Huang, WJ; Barany, G; Burn, P; Matts, RL				Hartson, SD; Ottinger, EA; Huang, WJ; Barany, G; Burn, P; Matts, RL			Modular folding and evidence for phosphorylation-induced stabilization of an hsp90-dependent kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSFORMING PROTEIN; CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; MOLECULAR CHAPERONES; ENDOPLASMIC-RETICULUM; IMMUNOGLOBULIN-CHAINS; HSP90; SRC; BINDING; GELDANAMYCIN	The de novo folding of the individual domains of the src family kinase p56(lck) was examined within the context of full-length p56(lck) molecules produced in rabbit reticulocyte lysate containing active chaperone machinery, The catalytic domain required geldanamycin-inhibitable heat shock protein 90 (hsp90) function to achieve its active protease-resistant conformation, but the src homology 2 (SH2) domain acquired phosphopeptide-binding competence independently of hsp90 function, The SH2 domain of hsp90-bound p56(lck) was folded and functional, In addition to the facilitation by hsp90 of kinase biogenesis, a conditional role in maintenance folding could be demonstrated; although wild type p56(lck) molecules with a negative-regulatory C-terminal tyrosine matured to a nearly hsp90-independent state, p56(lck) molecules with a mutated C-terminal tyrosine continued to require hsp90-mediated maintenance, De novo folding could be distinguished from maintenance folding on the basis of proteolytic fingerprints and the effects of different temperatures on folding behavior, Results indicate that during p56(lck) biogenesis, the SH2 domain rapidly folds independently of hsp90 function, followed by the slower hsp90-dependent folding of the catalytic domain and suggest the final stabilization of p56(lck) structure by phosphorylation-mediated interdomain interactions.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA	Oklahoma State University System; Oklahoma State University - Stillwater; University of Minnesota System; University of Minnesota Twin Cities; Roche Holding	Hartson, SD (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 246 NRC, Stillwater, OK 74078 USA.	shartson@bmb-fs1.biochem.okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042722, R01GM051608, R55GM051608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51608, GM42722] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; GARCIA P, 1994, J BIOL CHEM, V269, P30574; Garel Jean-Renaud, 1992, P405; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Makishima M, 1995, BBA-MOL BASIS DIS, V1272, P199, DOI 10.1016/0925-4439(95)00096-8; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NIELSEN CJ, 1977, J BIOL CHEM, V252, P7568; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; OTTINGER EA, 1995, INT J PEPT PROT RES, V46, P346; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Thanaraj TA, 1996, PROTEIN SCI, V5, P1594, DOI 10.1002/pro.5560050814; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; Uma S, 1997, J BIOL CHEM, V272, P11648; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu B, 1996, MOL CELL BIOCHEM, V158, P57; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8475	8482		10.1074/jbc.273.14.8475	http://dx.doi.org/10.1074/jbc.273.14.8475			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525961	hybrid			2022-12-27	WOS:000072876300095
J	Kundu, M; Sharma, S; De Luca, A; Giordano, A; Rappaport, J; Khalili, K; Amini, S				Kundu, M; Sharma, S; De Luca, A; Giordano, A; Rappaport, J; Khalili, K; Amini, S			HIV-1 Tat elongates the G(1) phase and indirectly promotes HIV-1 gene expression in cells of glial origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NECROSIS-FACTOR-ALPHA; PERIPHERAL-BLOOD MONOCYTES; TUMOR-SUPPRESSOR PROTEIN; E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; NERVOUS-SYSTEM; TRANSFORMING GROWTH-FACTOR-BETA-1; CYCLIN-E; LYMPHOCYTE-PROLIFERATION	Human immunodeficiency virus type-1 (HIV-1) infection of the central nervous system (CNS) gives rise to many of the neurological complications in patients with AIDS. Infection of microglial cells and astrocytes in the brain promotes the release of HIV-1 Tat and other candidate neurotoxins that may be associated with the widespread neuropathology. To examine the contribution of HIV-1 Tat to the interplay between virus and CNS cells, the human astrocytic cell line, U-87MG, was treated with recombinant Tat protein. Fluorescence-activated cell sorting analysis indicated that Tat induces a G(1) arrest in these cells. Consistent with this observation, lower levels of cyclin E-Cdk2 kinase activity and phosphorylated Rb were detected in the Tat-treated cells compared with the control cells. Interestingly, our observations indicate that the underphosphorylated form of Rb that is prevalent in Tat-treated cells promotes HIV-1 transcription by a mechanism involving the NF-kappa B enhancer region. Taken together, the data presented here provide the first evidence that the HIV-1 regulatory protein, Tat, may manipulate the host cell cycle to promote viral gene expression. The significance of these findings relates to the current hypothesis that indirect effects of HIV-1 infection of the CNS may contribute to the neurological complications associated with AIDS dementia complex.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, 245 N 15th St,Mailstop 406, Philadelphia, PA 19102 USA.		Giordano, Antonio/F-1927-2010; Kundu, Mondira/N-8139-2018; De Luca, Antonio/AAD-9562-2020	Giordano, Antonio/0000-0002-5959-016X; Kundu, Mondira/0000-0001-9946-2472; De Luca, Antonio/0000-0002-3905-6154	NINDS NIH HHS [NS30916, NS36466] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466, P01NS030916] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABMAYR SM, 1991, CURRENT PROTOCOLS MO, V2; AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BALASINGAM V, 1994, J NEUROSCI, V14, P846; BARNA BP, 1993, J NEUROIMMUNOL, V43, P185, DOI 10.1016/0165-5728(93)90090-L; BENJOUAD A, 1993, FEBS LETT, V319, P119, DOI 10.1016/0014-5793(93)80049-Z; BLUMBERG BM, 1994, VIRUS RES, V32, P253, DOI 10.1016/0168-1702(94)90044-2; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUDKA H, 1990, ACTA NEUROPATHOL, V79, P611, DOI 10.1007/BF00294238; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CHIRMULE N, 1995, J VIROL, V69, P492, DOI 10.1128/JVI.69.1.492-498.1995; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; CUPP C, 1993, ONCOGENE, V8, P2231; DACUNHA A, 1993, BRAIN RES, V631, P39, DOI 10.1016/0006-8993(93)91183-S; DACUNHA A, 1995, J NEUROIMMUNOL, V60, P125, DOI 10.1016/0165-5728(95)00062-7; Dewhurst S, 1996, MOL MED TODAY, V2, P16, DOI 10.1016/1357-4310(96)88754-5; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GIBELLINI D, 1995, BRIT J HAEMATOL, V89, P24, DOI 10.1111/j.1365-2141.1995.tb08915.x; GIBELLINI D, 1994, BRIT J HAEMATOL, V88, P261, DOI 10.1111/j.1365-2141.1994.tb05016.x; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; HOFMAN FM, 1993, BLOOD, V82, P2774; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KUNDU M, 1995, J VIROL, V69, P6940, DOI 10.1128/JVI.69.11.6940-6946.1995; Lachgar A, 1996, BIOMED PHARMACOTHER, V50, P13, DOI 10.1016/0753-3322(96)85092-X; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; NEVINS JR, 1992, SCIENCE, V258, P424; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; ODA S, 1995, ONCOGENE, V10, P1348; OLDSTONE MBA, 1982, SCIENCE, V218, P1125, DOI 10.1126/science.7146898; Patki AH, 1996, CELL IMMUNOL, V169, P40, DOI 10.1006/cimm.1996.0088; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PURI RK, 1995, AIDS RES HUM RETROV, V11, P31, DOI 10.1089/aid.1995.11.31; PURVIS SF, 1995, AIDS RES HUM RETROV, V11, P443, DOI 10.1089/aid.1995.11.443; Rasty S, 1996, P NATL ACAD SCI USA, V93, P6073, DOI 10.1073/pnas.93.12.6073; RAUTONEN J, 1994, AIDS RES HUM RETROV, V10, P781, DOI 10.1089/aid.1994.10.781; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; SATTERWHITE DJ, 1994, INVAS METAST, V14, P309; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SHARER LR, 1985, HUM PATHOL, V16, P760, DOI 10.1016/S0046-8177(85)80245-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIMPSON DM, 1995, ANN INTERN MED, V122, P317, DOI 10.7326/0003-4819-122-4-199502150-00023; SIMPSON DM, 1994, ANN INTERN MED, V121, P769, DOI 10.7326/0003-4819-121-10-199411150-00008; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STRIJBOS PJLM, 1995, NEUROSCI LETT, V197, P215, DOI 10.1016/0304-3940(95)11940-X; TANAKA S, 1994, J NEUROSURG, V81, P402, DOI 10.3171/jns.1994.81.3.0402; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; VAZEUX R, 1992, AM J PATHOL, V140, P137; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; ZAULI G, 1993, MICROBIOLOGICA, V16, P115; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306	86	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8130	8136		10.1074/jbc.273.14.8130	http://dx.doi.org/10.1074/jbc.273.14.8130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525916	hybrid			2022-12-27	WOS:000072876300050
J	Parra-Gessert, L; Koo, K; Fajardo, J; Weiss, RL				Parra-Gessert, L; Koo, K; Fajardo, J; Weiss, RL			Processing and function of a polyprotein precursor of two mitochondrial proteins in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE PEPTIDASE; TARGETING SEQUENCES; RECEPTOR COMPLEX; CLEAVAGE SITES; IDENTIFICATION; RECOGNITION; MEMBRANE; IMPORT; PURIFICATION; INSERTION	In Neurospora crassa, the mitochondrial arginine biosynthetic enzymes, N-acetylglutamate kinase (AGK) and N-acetyl-gamma-glutamyl-phosphate reductase (AGPR), are generated by processing of a 96-kDa cytosolic polyprotein precursor (pAGK-AGPR), The proximal kinase and distal reductase domains are separated by a short connector region, Substitutions of arginines at positions -2 and -3 upstream of the N terminus of the AGPR domain or replacement of threonine at position +3 in the nature AGPR domain revealed a second processing site at position -20, Substitution of arginine at position -22, in combination with changes at -2 and -3, prevented cleavage of the precursor and identified two proteolytic cleavage sites, Arg Gly down arrow Tyr-Leu-Thr at the N terminus of the AGPR domain and Arg-Gly-Tyr down arrow Ser-Thr located 20 residues upstream, Inhibitors of metal-dependent peptidases blocked proteolytic cleavage at both sites, Amino acid residues required for proteolytic cleavage in the connector were identified, and processing was abolished by mutations changing these residues, The unprocessed AGK-AGPR fusion had both catalytic activities, including feedback inhibition of AGK, and complemented AGK(-) AGPR(-) mutants. These results indicate that cleavage of pAGK-AGPR is not required for functioning of these enzymes in the mitochondria.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Weiss, RL (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM47631] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BIGELIS R, 1981, J BIOL CHEM, V256, P5144; BRAKCH N, 1993, BIOCHEMISTRY-US, V32, P4925, DOI 10.1021/bi00069a029; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; BRUNNER M, 1995, METHOD ENZYMOL, V248, P717; Creighton T. E., 1993, PROTEINS STRUCTURES; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DAVIS RH, 1983, MOL GEN GENET, V192, P46, DOI 10.1007/BF00327645; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GESSERT SF, 1994, J BIOL CHEM, V269, P8189; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Higuchi R., 1990, PCR PROTOCOLS GUIDE; HINDE RW, 1986, J BIOL CHEM, V261, P5848; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; ISAYA G, 1992, J BIOL CHEM, V267, P7904; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; OU WJ, 1994, J BIOL CHEM, V269, P24673; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER G, 1993, BIOCHEM BIOPH RES CO, V194, P951, DOI 10.1006/bbrc.1993.1913; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; Sjoling S, 1996, EUR J BIOCHEM, V242, P114, DOI 10.1111/j.1432-1033.1996.0114r.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; WANDINGERNESS AU, 1985, J BIOL CHEM, V260, P5974; WANDINGERNESS AU, 1987, J BIOL CHEM, V262, P5823; WEISS RL, 1976, J BACTERIOL, V126, P1173, DOI 10.1128/JB.126.3.1173-1179.1976; WEISS RL, 1980, J BACTERIOL, V141, P1305, DOI 10.1128/JB.141.3.1305-1311.1980; WOLF EC, 1980, J BIOL CHEM, V255, P9189	42	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7972	7980		10.1074/jbc.273.14.7972	http://dx.doi.org/10.1074/jbc.273.14.7972			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525895	hybrid			2022-12-27	WOS:000072876300029
J	Sarvazyan, NA; Remmers, AE; Neubig, RR				Sarvazyan, NA; Remmers, AE; Neubig, RR			Determinants of G(i1)alpha and beta gamma binding - Measuring high affinity interactions in a lipid environment using flow cytometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; GTP-BINDING; GUANINE-NUCLEOTIDES; BOVINE BRAIN; REGULATORY PROTEINS; MEMBRANE ATTACHMENT; ACTIVATING PROTEIN; PLASMA-MEMBRANE; MYRISTOYLATION; ASSOCIATION	G protein heterocomplex undergoes dissociation and association during its functional cycle, Quantitative measurements of alpha and beta gamma subunit binding have been difficult due to a very high affinity, We used fluorescence flow cytometry to quantitate binding of fluorescein-labeled G(il)alpha (F-alpha) to picomolar concentrations of biotinylated G beta gamma. Association in Lubrol solution was rapid (k(on) = 0.7 x 10(6) M-1 s(-1)), and equilibrium binding revealed a K-d of 2.9 +/- 0.8 nM. The binding showed a complex dependence on magnesium concentration, but activation of F-alpha with either GDP/aluminum fluoride or guanosine 5'-O-(3-thiotriphosphate) completely prevented formation of the heterocomplex (K-d > 100 nM). The binding was also influenced by the detergent or lipid environment, Unlabeled By reconstituted in biotinylated phospholipid vesicles (pure phosphatidylcholine or mixed brain lipids) bound F-alpha similar to 2-3-fold less tightly (K-d = 6-9 nM) than in Lubrol. In contrast, beta gamma in ionic detergents such as cholate and 3-[(cholamidopropyl)diethylammonio]-1-propanesulfonate exhibited substantially lower affinities for F-alpha. Dissociation of F-alpha from beta gamma reconstituted in lipid vesicles was observed upon addition of aluminum fluoride or excess unlabeled alpha subunit, indicating that myristoylated alpha subunit has only a weak interaction with lipids without the beta gamma subunit, The kinetics of aluminum fluoride-stimulated dissociation were slower than those of the alpha subunit conformational change detected by intrinsic fluorescence. These results quantitatively demonstrate G protein subunit dissociation upon activation ante provide a simple but powerful new approach for studying high affinity protein/protein interactions ire solution or in a lipid environment.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med Hypertens, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Neubig, RR (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	BNeubig@umich.edu		Neubig, Richard/0000-0003-0501-0008; Remmers, Ann/0000-0002-2465-7651	NCRR NIH HHS [RR01315] Funding Source: Medline; NIGMS NIH HHS [GM 39561] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Basi NS, 1996, CELL SIGNAL, V8, P209, DOI 10.1016/0898-6568(95)02056-X; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CODINA J, 1984, J BIOL CHEM, V259, P1408; DIGNUS J, 1994, METHOD ENZYMOL, V237, P457; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; HEITHIER H, 1992, EUR J BIOCHEM, V204, P1169, DOI 10.1111/j.1432-1033.1992.tb16744.x; HELLER C, 1991, J PROTEIN CHEM, V10, P325, DOI 10.1007/BF01025631; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HUFF RM, 1985, J BIOL CHEM, V260, P864; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1984, J BIOL CHEM, V259, P3568; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MCARDLE H, 1988, BIOCHEM BIOPH RES CO, V152, P243, DOI 10.1016/S0006-291X(88)80706-X; MILLIGAN G, 1988, BIOCHEM J, V254, P391, DOI 10.1042/bj2540391; MITTAL R, 1994, BIOCHEMISTRY-US, V33, P10178, DOI 10.1021/bi00199a046; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEUBIG RR, 1994, FEBS LETT, V355, P251, DOI 10.1016/0014-5793(94)01212-1; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; NOLAN JP, 1995, CYTOMETRY, V21, P223, DOI 10.1002/cyto.990210302; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; REMMERS AE, 1993, BIOCHEMISTRY-US, V32, P2409, DOI 10.1021/bi00060a036; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; UEDA N, 1994, J BIOL CHEM, V269, P4388; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001	39	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7934	7940		10.1074/jbc.273.14.7934	http://dx.doi.org/10.1074/jbc.273.14.7934			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525890	hybrid			2022-12-27	WOS:000072876300024
J	Wonerow, P; Schoneberg, T; Schultz, G; Gudermann, T; Paschke, R				Wonerow, P; Schoneberg, T; Schultz, G; Gudermann, T; Paschke, R			Deletions in the third intracellular loop of the thyrotropin receptor - A new mechanism for constitutive activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD CYTOPLASMIC LOOP; HYPERFUNCTIONING THYROID ADENOMAS; TSH-RECEPTOR; GERMLINE MUTATIONS; SOMATIC MUTATIONS; SIGNAL-TRANSDUCTION; BINDING-SITES; CYCLIC-AMP; GENE; PHOSPHATIDYLINOSITOL	Gain-of-function mutations of the thyrotropin receptor (TSHR) gene have been invoked as one of the major causes of toxic thyroid adenomas. In a toxic thyroid nodule, we recently identified a 9-amino acid deletion (amino acid positions 613-621) within the third intracellular (i3) loop of the TSHR resulting in constitutive receptor activity. This finding exemplifies a new mechanism of TSHR activation and raises new questions concerning the function of the i3 loop. Because the i3 loop is thought to be critical for receptor/G protein coupling. Thus, various deletion mutants were generated and functionally characterized. We identified an optimal deletion length responsible for constitutive activity. If the number of deleted amino acids was reduced, elevated basal cAMP accumulation was found to be concomitantly diminished. Expansion of the deletion dramatically impaired cell surface expression of the receptor. Shifting the deletion toward the N terminus of the i3 loop resulted in unaltered strong constitutive receptor activity. In contrast, translocation of the deletion toward the C terminus led to significantly reduced basal cAMP formation, most probably due to destruction of a conserved cluster of amino acids. In this study, we show for the first time that amino acid deletions within the i3 loop of a G protein-coupled receptor result in constitutive receptor activity. In the TSHR, 75% of the i3 loop generally assumed to play an essential role in G protein coupling can be deleted without rendering the mutant receptor unresponsive to thyrotropin. These findings support a novel model explaining the molecular events accompanying receptor activation by agonist.	Univ Leipzig, Med Klin & Poliklin 3, D-04103 Leipzig, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Leipzig University; Free University of Berlin	Paschke, R (corresponding author), Univ Leipzig, Med Klin & Poliklin 3, Philipp Rosenthal Str 27, D-04103 Leipzig, Germany.							Abell AN, 1997, J BIOL CHEM, V272, P14586, DOI 10.1074/jbc.272.23.14586; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; Chicchi GG, 1997, J BIOL CHEM, V272, P7765, DOI 10.1074/jbc.272.12.7765; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DROUX N, 1996, J CLIN ENDOCR METAB, V81, P2023; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; GRASSO P, 1995, MOL CELL ENDOCRINOL, V110, P35, DOI 10.1016/0303-7207(95)91392-T; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Higuchi R., 1989, PCR TECHNOLOGY, P61; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; KOSUGI S, 1994, FEBS LETT, V356, P291, DOI 10.1016/0014-5793(94)01286-5; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Perlman JH, 1997, J BIOL CHEM, V272, P11937, DOI 10.1074/jbc.272.18.11937; PORCELLINI A, 1995, ONCOGENE, V11, P1089; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SHAPIRO RA, 1993, J BIOL CHEM, V268, P21734; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; TAKESHITA A, 1995, J CLIN ENDOCR METAB, V80, P2607, DOI 10.1210/jc.80.9.2607; Takhar S, 1996, ENDOCRINOLOGY, V137, P2175, DOI 10.1210/en.137.5.2175; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596	45	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7900	7905		10.1074/jbc.273.14.7900	http://dx.doi.org/10.1074/jbc.273.14.7900			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525885	hybrid			2022-12-27	WOS:000072876300019
J	Cabello-Hurtado, F; Batard, Y; Salaun, JP; Durst, F; Pinot, F; Werck-Reichhart, D				Cabello-Hurtado, F; Batard, Y; Salaun, JP; Durst, F; Pinot, F; Werck-Reichhart, D			Cloning, expression in yeast, and functional characterization of CYP81B1, a plant cytochrome P450 that catalyzes in-chain hydroxylation of fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAURIC-ACID; UNSATURATED ANALOGS; MICROSOMAL CYTOCHROME-P-450; SUBSTRATE-SPECIFICITY; CATHARANTHUS-ROSEUS; ESCHERICHIA-COLI; INDUCTION; METABOLISM; WHEAT; MONOOXYGENASE	Several omega and in-chain fatty acid hydroxylases have been characterized in higher plants, In microsomes from Helianthus tuberosus tuber the omega-2, omega-3, and omega-4 hydroxylation of lauric acid is catalyzed by one or a few closely related aminopyrine and MnCl2-inducible cytochrome P450(s). To isolate the cDNA and determine the sequences of the(se) enzyme(s), we used antibodies directed against a P450-enriched fraction purified from Mn2+-induced tissues, Screening of a cDNA expression library from aminopyrine-treated tubers led to the identification of a cDNA (CYP81B1) corresponding to a transcript induced by aminopyrine, CYP81B1 was expressed in yeast, A systematic exploration of its function revealed that it specifically catalyzes the hydroxylation of medium chain saturated fatty acids, capric (C10:0), lauric (C12:0), and myristic (C14:0) acids, The same metabolites were obtained with transgenic yeast and plant microsomes, a mixture of omega-1 to omega-5 monohydroxylated products, The three fatty acids were metabolized with high and similar efficiencies, the major position of attack depending on chain length, When lauric acid was the substrate, turnover was 30.7 +/- 1.4 min(-1) and K-m(app) 788 +/- 400 nM, No metabolism of long chain fatty acids, aromatic molecules, or herbicides was detected, This new fatty acid hydroxylase is typical from higher plants and differs from those already isolated from other living organisms.	Inst Biol Mol Plantes, Dept Enzymol Cellulaire & Mol, CNRS, UPR 406, F-67000 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Werck-Reichhart, D (corresponding author), Inst Biol Mol Plantes, Dept Enzymol Cellulaire & Mol, CNRS, UPR 406, 28 Rue Goethe, F-67000 Strasbourg, France.	daniele.werck@ibmp-ulp.u-strasbg.fr	WERCK-REICHHART, Danièle/U-3713-2019	WERCK-REICHHART, Danièle/0000-0003-2869-4262				BATARD Y, 1995, PLANT CELL ENVIRON, V18, P523, DOI 10.1111/j.1365-3040.1995.tb00552.x; BATARD Y, 1998, IN PRESS PLANT J; BENVENISTE I, 1982, PLANT PHYSIOL, V70, P122, DOI 10.1104/pp.70.1.122; BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; Budziszewski GJ, 1996, LIPIDS, V31, P557, DOI 10.1007/BF02523826; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CHASAN R, 1995, PLANT CELL, V7, P235; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Durst Francis, 1995, Drug Metabolism and Drug Interactions, V12, P189; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; FONNEPFISTER R, 1988, PLANT SCI, V55, P9, DOI 10.1016/0168-9452(88)90036-2; GABRIAC B, 1991, ARCH BIOCHEM BIOPHYS, V288, P302, DOI 10.1016/0003-9861(91)90199-S; GILLARD DF, 1976, PLANT PHYSIOL, V58, P790, DOI 10.1104/pp.58.6.790; HOLTON TA, 1993, NATURE, V366, P276, DOI 10.1038/366276a0; KATO T, 1983, TETRAHEDRON LETT, V24, P4715, DOI 10.1016/S0040-4039(00)86236-X; KLATTUKUDY PE, 1981, ANNU REV PLANT PHYS, V32, P127; LESOT A, 1990, PLANT CELL PHYSIOL, V31, P1177; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MASUI H, 1989, PHYTOCHEMISTRY, V28, P2613, DOI 10.1016/S0031-9422(00)98051-8; MCFADDEN JJ, 1990, BIOCHEM BIOPH RES CO, V168, P206, DOI 10.1016/0006-291X(90)91695-O; MEIJER AH, 1993, PLANT MOL BIOL, V22, P379, DOI 10.1007/BF00014944; Nakayama N, 1996, J BIOCHEM-TOKYO, V119, P435; NAMAI T, 1993, BIOSCI BIOTECH BIOCH, V57, P611, DOI 10.1271/bbb.57.611; OHLROGGE JB, 1994, PLANT PHYSIOL, V104, P821, DOI 10.1104/pp.104.3.821; OHTA H, 1990, PLANT CELL PHYSIOL, V31, P1117; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PERDUE RE, 1989, AGR ENG, V70, P11; PIERREL MA, 1994, EUR J BIOCHEM, V224, P835, DOI 10.1111/j.1432-1033.1994.00835.x; PINOT F, 1994, BIOCHEM BIOPH RES CO, V198, P795, DOI 10.1006/bbrc.1994.1114; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Potter Sharon, 1995, Drug Metabolism and Drug Interactions, V12, P317; REICHHART D, 1980, PLANT PHYSIOL, V66, P600, DOI 10.1104/pp.66.4.600; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; SAGARA Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P272, DOI 10.1006/abbi.1993.1349; Salaun Jean-Pierre, 1995, Drug Metabolism and Drug Interactions, V12, P261; SALAUN JP, 1978, EUR J BIOCHEM, V90, P155, DOI 10.1111/j.1432-1033.1978.tb12586.x; SALAUN JP, 1989, FEBS LETT, V246, P120, DOI 10.1016/0014-5793(89)80266-2; SALAUN JP, 1982, PHYSIOL VEG, V20, P613; SALAUN JP, 1986, LIPIDS, V21, P776, DOI 10.1007/BF02535411; SALAUN JP, 1981, EUR J BIOCHEM, V119, P651, DOI 10.1111/j.1432-1033.1981.tb05657.x; SALAUN JP, 1993, PLANT PHYSIOL BIOCH, V31, P285; SALAUN JP, 1992, FEBS LETT, V303, P109, DOI 10.1016/0014-5793(92)80499-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schweizer P, 1996, PLANT J, V10, P331, DOI 10.1046/j.1365-313X.1996.10020331.x; SUEYOSHI T, 1995, ARCH BIOCHEM BIOPHYS, V322, P265, DOI 10.1006/abbi.1995.1461; TEUTSCH HG, 1993, P NATL ACAD SCI USA, V90, P4102, DOI 10.1073/pnas.90.9.4102; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOPFER R, 1995, SCIENCE, V268, P681, DOI 10.1126/science.268.5211.681; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176; Van De Loo Frank J., 1993, P91; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; VANDERLEIJ FR, 1995, CAN J MICROBIOL, V41, P222, DOI 10.1139/m95-191; VETTER HP, 1992, PLANT PHYSIOL, V100, P998, DOI 10.1104/pp.100.2.998; VOELKER TA, 1992, SCIENCE, V257, P72, DOI 10.1126/science.1621095; Voelker TA, 1996, PLANT J, V9, P229, DOI 10.1046/j.1365-313X.1996.09020229.x; WERCKREICHHART D, 1990, BIOCHEM J, V270, P729, DOI 10.1042/bj2700729; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; ZIMMERLIN A, 1992, PLANT PHYSIOL, V100, P874, DOI 10.1104/pp.100.2.874; ZIMMERLIN A, 1992, PLANT PHYSIOL, V100, P868, DOI 10.1104/pp.100.2.868	59	75	83	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7260	7267		10.1074/jbc.273.13.7260	http://dx.doi.org/10.1074/jbc.273.13.7260			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516419	hybrid			2022-12-27	WOS:000072738500015
J	Calera, MR; Martinez, C; Liu, HZ; El Jack, AK; Birnbaum, MJ; Pilch, PF				Calera, MR; Martinez, C; Liu, HZ; El Jack, AK; Birnbaum, MJ; Pilch, PF			Insulin increases the association of akt-2 with Glut4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-KINASE-B; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; RESPONSIVE GLUCOSE-TRANSPORTER; STIMULATED GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; MOLECULAR-CLONING; C-AKT; PLASMA-MEMBRANE; SKELETAL-MUSCLE	Expression of a constitutively active, membrane-associated Akt-1 (PKB alpha) construct in 3T3L1 adipocytes was shown to induce glucose uptake in the absence of insulin by stimulating Glut4 translocation to the plasma membrane (Kohn, A.D., Summers, S.A., Birnbaum, M.J., and Roth, R.A. (1996) J. Biol. Chem. 271, 31372-31378). However, in rat fat cell the vast majority of Akt-1 is cytosolic and shows no re-distribution to the plasma membrane in response to insulin. On the other hand, little work has been done with other Akt family members such as Akt-2 (PKB beta) or Akt-3 (PKB gamma). In this report, an analysis of the subcellular distribution of Akt-2 in rat adipocytes shows that Akt-2 is present in significant amounts in various membrane compartments, as well as in the cytosol, and the former include the light microsomes where Glut4 is present in the basal state. The distribution of Akt-2 in resting adipocytes was found to substantially overlap with that of Glut4 when light microsomes were subfractionated by a sucrose velocity gradient indicating possible co-localization. We confirmed co-localization of Akt-2 and Glut4 in the basal state by immunopurification of Glut4 vesicles, which exhibited a 5.5-fold increase in Akt-2 in response to insulin relative to the amount of Glut4. These results are consistent with the possibility that Akt-2 may be involved in Glut4 vesicle translocation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Boston University; Howard Hughes Medical Institute; University of Pennsylvania	Pilch, PF (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	pilch@med-biochem.bu.edu	Martinez, Carmen/P-6661-2017	Martinez, Carmen/0000-0001-7226-9154; Birnbaum, Morris/0000-0001-9972-8680; El Jack, Amr/0000-0002-5892-5538; Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK 36424] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FRANKE TF, 1994, ONCOGENE, V9, P141; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FREVERT H, 1997, MOL CELL BIOL, V17, P190; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; OKADA T, 1994, J BIOL CHEM, V269, P3568; RODBELL M, 1964, J BIOL CHEM, V239, P375; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TANTI JF, 1996, J BIOL CHEM, V271, P2527; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	47	188	191	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7201	7204		10.1074/jbc.273.13.7201	http://dx.doi.org/10.1074/jbc.273.13.7201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516411	hybrid			2022-12-27	WOS:000072738500007
J	Fiddes, RJ; Campbell, DH; Janes, PW; Sivertsen, SP; Sasaki, H; Wallasch, C; Daly, RJ				Fiddes, RJ; Campbell, DH; Janes, PW; Sivertsen, SP; Sasaki, H; Wallasch, C; Daly, RJ			Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; BREAST-CANCER CELLS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; GENE-PRODUCT; SIGNAL-TRANSDUCTION; PROTEIN; FAMILY; EXPRESSION	Heregulin-mediated activation of particular erbB receptor combinations was used as a model system to investigate the interaction of erbB3 and erbB4 with the adaptor protein growth factor receptor-bound (Grb)7. In human breast cancer cell lines, co-immunoprecipitation of Grb7 with both receptors was detected upon heregulin stimulation. This association was direct and mediated by the Grb7 Src homology (SH)2 domain. Coexpression of erbB2 with erbB3 point mutants was used to map Grb7 binding sites. This demonstrated that tyrosine 1180 and 1243 represent the major and minor sites of Grb7 interaction, respectively. Although these recognition sequences possess an Asn residue at +2 relative to the phosphotyrosine and therefore represent potential Grb2 binding sites, phosphopeptide competition and "pull-down" experiments demonstrated that they interact preferentially with the Grb7 versus the Grb2 SH2 domain. Substitution analysis indicated that an Arg residue at +3 could act as a selectivity determinant, but the effect was context-dependent. Consequently, the Grb2 and Grb7 SH2 domains possess overlapping, but distinct, specificities. These studies therefore identify Grb7 as an in vivo target of erbB3 and erbB4 and provide an underlying mechanism for the ability of erbB3 to recruit Grb7 and not Grb2, a property unique among erbB receptors.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Cooperat Res Ctr Biopharmaceut Res, Sydney, NSW 2010, Australia; Natl Inst Canc Res, Chuo Ku, Tokyo, Japan; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; National Cancer Center - Japan; Max Planck Society	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.	r.daly@garvan.unsw.edu.au	Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027; Campbell, Douglas/0000-0001-9699-1854; Janes, Peter/0000-0002-9039-1097				ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bacus SS, 1996, AM J PATHOL, V148, P549; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Cohen BM, 1996, J BIOL CHEM, V271, P4813; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; JANES PW, 1994, ONCOGENE, V9, P3601; Keegan K, 1996, ONCOGENE, V12, P1537; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Levkowitz G, 1996, ONCOGENE, V12, P1117; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRIGENT SA, 1992, ONCOGENE, V7, P1273; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; RICCI A, 1995, ONCOGENE, V11, P1519; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	63	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7717	7724		10.1074/jbc.273.13.7717	http://dx.doi.org/10.1074/jbc.273.13.7717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516479	hybrid			2022-12-27	WOS:000072738500075
J	Ghosh, JK; Shai, Y				Ghosh, JK; Shai, Y			A peptide derived from a conserved domain of sendai virus fusion protein inhibits virus-cell fusion - A plausible mode of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENTLY LABELED ANALOGS; INFLUENZA-VIRUS; PHOSPHOLIPID-MEMBRANES; LEUCINE ZIPPER; PARAMYXOVIRUS FUSION; HEPTAD REPEAT; TRANSMEMBRANE GLYCOPROTEIN; POTENT INHIBITORS; HEMAGGLUTININ; GP41	SV-201, a peptide derived from a conserved and potentially amphipathic region (amino acids 201-229) in the Sendai virus ectodomain, specifically inhibited virus-mediated hemolysis only when added to virions prior to their attachment to red blood cells. Sendai virus-mediated hemagglutinin assay in the presence of SV-201 demonstrated that the peptide does not disturb the binding of virions to the target red blood cells. A mutated peptide with 2 amino acids substitution, rendering the peptide neutral, was biologically inactive. A second mutant with 7 amino acids randomized at the N terminus keeping the hydrophobicity of the peptide unaltered was only slightly active. A hydrophobic peptide corresponding to the fusion peptide domain was also inactive. SV-201, the two mutants, and the fusion peptide bind similarly with high affinity to both negatively charged phosphatidylserine/phosphatidylcholine and zwitterionic phosphatidylcholine lipid vesicles, suggesting that the inhibitory effect is not due merely to membrane modulation. Fluorescence studies with rhodamine-labeled peptides and SV-201-induced inhibition assays, demonstrated that the SV-201 binding site is most probably located in the region corresponding to amino acids 201-229 of the Sendai virus fusion protein. The data presented here suggest that SV-201 disturbs a functional domain in the Sendai virus fusion protein, which is most probably associated with the assembly of the fusion protein and/or membrane apposition. The existence of homologous SV-201 regions in other viruses suggests that these regions may have a similar role, and their synthetic counterparts may act as inhibitors for the corresponding viruses.	Weizmann Inst Sci, Dept Membrane Res & Biophys, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Membrane Res & Biophys, IL-76100 Rehovot, Israel.	bmshai@weizmann.weizmann.ac.il						ASANO K, 1988, BIOCHEMISTRY-US, V27, P1321, DOI 10.1021/bi00404a035; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLUMBERG BM, 1985, J GEN VIROL, V66, P317, DOI 10.1099/0022-1317-66-2-317; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BUCKLAND R, 1992, J GEN VIROL, V73, P1703, DOI 10.1099/0022-1317-73-7-1703; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GHOSH JK, 1996, 10 INT C VIR JER ISR, P166; HAYWOOD AM, 1974, J MOL BIOL, V83, P427, DOI 10.1016/0022-2836(74)90504-X; HOEKSTRA D, 1989, BIOSCIENCE REP, V9, P273, DOI 10.1007/BF01114682; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; HORVATH CM, 1992, J VIROL, V66, P2443, DOI 10.1128/JVI.66.4.2443-2455.1992; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; KELSEY DR, 1990, J BIOL CHEM, V265, P12178; KELSEY DR, 1991, VIROLOGY, V182, P690, DOI 10.1016/0042-6822(91)90610-N; KENNEDY DW, 1983, J CELL PHYSIOL, V114, P257, DOI 10.1002/jcp.1041140302; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LOYTER A, 1982, CELL SURF REV, V8, P215; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MIURA N, 1982, EXP CELL RES, V141, P409, DOI 10.1016/0014-4827(82)90229-4; MURATA M, 1987, J BIOCHEM-TOKYO, V102, P957, DOI 10.1093/oxfordjournals.jbchem.a122137; NUSSBAUM O, 1984, VIROLOGY, V138, P185, DOI 10.1016/0042-6822(84)90344-1; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; Rott R., 1977, CELL SURF REV, V2, P47; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; SERGELGERMANO T, 1994, J VIROL, V68, P7654, DOI 10.1128/JVI.68.11.7654-7658.1994; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SHIMIZU YK, 1976, VIROLOGY, V27, P48; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; SLEPUSHKIN VA, 1990, BIOCHEM BIOPH RES CO, V172, P952, DOI 10.1016/0006-291X(90)90768-I; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P75; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; YAMADA KM, 1975, P NATL ACAD SCI USA, V72, P3158, DOI 10.1073/pnas.72.8.3158; YEAGLE PL, 1993, FUSION SENDAI VIRUS; YU YG, 1994, SCIENCE, V266, P274, DOI 10.1126/science.7939662	66	29	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7252	7259		10.1074/jbc.273.13.7252	http://dx.doi.org/10.1074/jbc.273.13.7252			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516418	hybrid			2022-12-27	WOS:000072738500014
J	Scheller, T; Kraev, A; Skinner, S; Carafoli, E				Scheller, T; Kraev, A; Skinner, S; Carafoli, E			Cloning of the multipartite promoter of the sodium-calcium exchanger gene NCX1 and characterization of its activity in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NA+-CA2+ EXCHANGER; DROSOPHILA-MELANOGASTER; ALTERNATIVE PROMOTERS; MULTIPLE PROMOTERS; RECEPTOR GENE; TRANSCRIPTION; ORGANIZATION; ISOFORMS; IDENTIFICATION	The sodium-calcium exchange activity is mediated by proteins encoded in a small gene family, of which the gene NCX1 is ubiquitously expressed in mammalian tissues. In this study, the multipartite promoter of this gene was analyzed in the human and rat genomes by means of DNA cloning, reverse transcriptase-polymerase chain reaction, and transient transfection of fusion constructs with the firefly luciferase gene into cultured rat aortic smooth muscle cells. The gene-proximal promoter, located 30 kilobase pairs (kb) away from the first coding exon 2, has features of a GC rich housekeeping promoter and is apparently always active; in specific tissues, however, it is augmented by one or two additional promoters, located either within 1.5 kb upstream of it, or 35 kb upstream. The gene proximal promoter shows the highest activity in aortic smooth muscle cells. In mammalian species transcripts from all three promoters undergo splicing via an intermediate, containing two noncoding exons, of which the downstream one is normally not present in the terminal splicing product.	Swiss Fed Inst Technol, Biochem Lab 3, Inst Biochem, CH-8092 Zurich, Switzerland; Univ Padua, Dept Biochem, I-35121 Padua, Italy	ETH Zurich; University of Padua	Carafoli, E (corresponding author), Swiss Fed Inst Technol, Biochem Lab 3, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	carafoli@bc.biol.ethz.ch	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094	NIGMS NIH HHS [GM 31208] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; Biben C, 1996, DEV BIOL, V173, P200, DOI 10.1006/dbio.1996.0017; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dumas S, 1996, J NEUROCHEM, V67, P19; Furukawa K, 1996, J BIOL CHEM, V271, P20836, DOI 10.1074/jbc.271.34.20836; HILFIKER H, 1993, J BIOL CHEM, V268, P19717; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; JUHASZOVA M, 1994, AM J PHYSIOL, V266, pC234, DOI 10.1152/ajpcell.1994.266.1.C234; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; Menick DR, 1996, ANN NY ACAD SCI, V779, P489, DOI 10.1111/j.1749-6632.1996.tb44823.x; Min N, 1996, J NEUROCHEM, V67, P11; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Philipson K D, 1993, Int Rev Cytol, V137C, P199; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Ross RS, 1996, DEVELOPMENT, V122, P1799; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH L, 1994, J BIOL CHEM, V269, P27527; STROEHER VL, 1986, MOL CELL BIOL, V6, P4667, DOI 10.1128/MCB.6.12.4667; VIGNE P, 1988, J BIOL CHEM, V263, P8078; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835; Ye K, 1996, CYTOKINE, V8, P421, DOI 10.1006/cyto.1996.0058	37	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7643	7649		10.1074/jbc.273.13.7643	http://dx.doi.org/10.1074/jbc.273.13.7643			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516469	hybrid			2022-12-27	WOS:000072738500065
J	Chiarugi, P; Cirri, P; Marra, F; Raugei, G; Fiaschi, T; Camici, G; Manao, G; Romanelli, RG; Ramponi, G				Chiarugi, P; Cirri, P; Marra, F; Raugei, G; Fiaschi, T; Camici, G; Manao, G; Romanelli, RG; Ramponi, G			The Src and signal transducers and activators of transcription pathways as specific targets for low molecular weight phosphotyrosine-protein phosphatase in platelet-derived growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; PDGF RECEPTOR; KINASE; PHOSPHORYLATION; OVEREXPRESSION; MITOGENESIS; INHIBITION; YERSINIA	The low molecular weight phosphotyrosine protein phosphatase (LMW-PTP) is a cytosolic phosphotyrosine-protein phosphatase specifically interacting with the activated platelet-derived growth factor (PDGF) receptor through its active site, Overexpression of the LMW-PTP results in modulation of PDGF-dependent mitogenesis. In this study we investigated the effects of this tyrosine phosphatase on the signaling pathways relevant for PDGF-dependent DNA synthesis, MH 3T3 cells were stably transfected with active or dominant negative LMW-PTP, The effects of LMW-PTP were essentially restricted to the G(1) phase of the cell cycle, Upon stimulation with PDGF, cells transfected with the dominant negative LMW-PTP showed an increased activation of Src, whereas the active LMW-PTP induced a reduced activation of this proto-oncogene. We observe that c-Src binding to PDGF receptor upon stimulation is prevented by overexpression of LMW-PTP. These effects were associated with parallel changes in myc expression, Moreover, wild-type and dominant negative LMW-PTP differentially regulated STAT1 and STAT3 activation and tyrosine phosphorylation, whereas they did not modify extracellular signal-regulated kinase activity, However, these modifications were associated with changes in fos expression despite the lack of any effect on extracellular signal-regulated kinase activation. Other independent pathways involved in PDGF-induced mitogenesis, such as phosphatidylinositol 3-kinase and phospholipase C-gamma 1, were not affected by LMW-PTP, These data indicate that this phosphatase selectively interferes with the Src and the STATs pathways in PDGF downstream signaling. The resulting changes in myc and fos proto-oncogene expression are likely to mediate the modifications observed in the G(1) phase of the cell cycle.	Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Ist Med Interna, I-50134 Florence, Italy	University of Florence	Raugei, G (corresponding author), Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.		Chiarugi, Paola/CDD-7988-2022; Marra, Fabio/K-7263-2016; ROMANELLI, Roberto Giulio/K-4406-2018; Camici, Giovanni/H-1631-2018	Marra, Fabio/0000-0001-8629-0878; ROMANELLI, Roberto Giulio/0000-0001-9219-8189; raugei, giovanni/0000-0003-1294-786X; Chiarugi, Paola/0000-0001-7655-2969; Camici, Giovanni/0000-0002-0523-0695				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; BONFINI L, 1996, TRENDS BIOCHEM SCI, V21, P258; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; CHIARUGI P, 1992, FEBS LETT, V310, P9, DOI 10.1016/0014-5793(92)81134-8; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1996, BIOCHEM BIOPH RES CO, V219, P21, DOI 10.1006/bbrc.1996.0174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; CIRRI P, 1993, BIOCHIM BIOPHYS ACTA, V1161, P216, DOI 10.1016/0167-4838(93)90216-E; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; STONE RL, 1994, J BIOL CHEM, V269, P31323; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	41	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6776	6785		10.1074/jbc.273.12.6776	http://dx.doi.org/10.1074/jbc.273.12.6776			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506979	hybrid			2022-12-27	WOS:000072775900029
J	Demolombe, S; Baro, I; Pereon, Y; Bliek, J; Mohammad-Panah, R; Pollard, H; Morid, S; Mannens, M; Wilde, A; Barhanin, J; Charpentier, F; Escande, D				Demolombe, S; Baro, I; Pereon, Y; Bliek, J; Mohammad-Panah, R; Pollard, H; Morid, S; Mannens, M; Wilde, A; Barhanin, J; Charpentier, F; Escande, D			A dominant negative isoform of the long QT syndrome 1 gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; K(V)LQT1; PROTEINS; FORM	Mutations in the KvLQT1 gene are the cause of the long QT syndrome I, KvLQT1 gene product is associated with the regulator protein IsK to produce a component of the delayed rectifier K+ current in cardiac myocytes, We identified an N-terminal truncated isoform of the KvLQT1 gene product, referred to as isoform 2, In RNase protection assays, isoform 2 represented 28.1 +/- 0.6% of the total KvLQT1 expression in the human adult ventricle, COS-7 cells injected intranuclearly with KvLQT1 isoform 1 cDNA exhibited a fast-activating K+ current, whereas those injected with a KvLQT1 isoform 1 plus IsK cDNA showed a slow-activating K+ current, Cells injected with KvLQT1 isoform 2 plasmid showed no detectable K+ current, Those injected with a 1/1 isoform 2/isoform 1 ratio showed no detectable H+ current, Those injected with 1/5 and 2/5 ratios showed a K+ current with markedly reduced amplitude, Coexpression of the IsK regulator consistently reduced the dominant negative effects of isoform 2, Our results indicate that KvLQT1 isoform 2 exerts a pronounced negative dominance on isoform 1 channels and that the cardiac KvLQT1 K+ channel complex is composed of at least three different proteins as follows: isoform 1, isoform 2, and IsK.	Hop Hotel Dieu, INSERM CJF 96 01, Lab Physiopathol & Pharmacol Cellulaires & Mol, F-44093 Nantes, France; UPR CNRS 411, Inst Pharmacol Mol & Cellulaire, Sophia Antipolis, France; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; UDICE-French Research Universities; Universite Cote d'Azur; University of Amsterdam; Academic Medical Center Amsterdam	Escande, D (corresponding author), Hop Hotel Dieu, INSERM CJF 96 01, Lab Physiopathol & Pharmacol Cellulaires & Mol, Bat HBN,BP 1005, F-44093 Nantes, France.	denis.escande@sante.univ-nantes.fr	Charpentier, Flavien/D-3586-2015; Baró, Isabelle/ABH-5667-2020; Baró, Isabelle/D-3604-2015	Charpentier, Flavien/0000-0002-5057-0998; Baró, Isabelle/0000-0003-4850-4171; Baró, Isabelle/0000-0003-4850-4171				Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BUSCH AE, 1993, FEBS LETT, V334, P221, DOI 10.1016/0014-5793(93)81715-C; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Jiang M, 1997, J BIOL CHEM, V272, P24109, DOI 10.1074/jbc.272.39.24109; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MOHAMMADPANAH R, 1998, IN PRESS AM J PHYSL; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Pereon Y, 1997, PFLUG ARCH EUR J PHY, V433, P221; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	23	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6837	6843		10.1074/jbc.273.12.6837	http://dx.doi.org/10.1074/jbc.273.12.6837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506986	hybrid			2022-12-27	WOS:000072775900036
J	Park, ST; Sun, XH				Park, ST; Sun, XH			The Tal1 oncoprotein inhibits E47-mediated transcription - Mechanism of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; TRANSGENIC MICE; MAMMALIAN-CELLS; GENE; TRANSLOCATION; ACTIVATION; E2A	The Tall oncogene is a class II basic helix-loop-helix (bHLH) transcription factor, overexpressed in as much as 60% of T cell acute lymphoblastic leukemia cases. Like other class II bHLH proteins, Tall can heterodimerize with the class I bHLH proteins, such as E47, and bind to a DNA recognition sequence termed E box. Therefore, it is believed that the oncogenic capacity of Tall lies in its ability, as a heterodimer with E47, to activate aberrantly a set of "leukemogenic" genes in T cells. However, compared with E47 homodimers, Tal1/E47 heterodimers are very poor transactivators. Thus the effect of Tall is actually to inhibit E47 homodimer activity. Here we propose that the transforming properties of Tall are the result of its ability to inhibit E47 activity. We address the mechanism of Tall inhibition and demonstrate that Tal1/E47 heterodimers cannot activate transcription because their respective activation domains are incompatible. Furthermore, we present data showing that Tall can inhibit E47-mediated activation of the CIP1 gene. Finally, we demonstrate that Tall inhibits E47 activity in leukemic T cells.	NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA	New York University	Sun, XH (corresponding author), NYU, Med Ctr, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033597, R01AI033597] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33597] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; AUSUBAL FM, 1994, CURRENT PROTOCOLS MO; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; Condorelli GL, 1996, CANCER RES, V56, P5113; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCH P, 1992, ONCOGENE, V7, P2389; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HARPER JW, 1993, CELL, V75, P805; Hofmann TJ, 1996, ONCOGENE, V13, P617; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KIM JK, 1996, EMBO J, V15, P5014; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Mahajan MA, 1996, ONCOGENE, V12, P2343; Massari ME, 1996, MOL CELL BIOL, V16, P121; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAISANIT S, 1995, MOL CELL BIOL, V15, P1513; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Vitola SJ, 1996, NUCLEIC ACIDS RES, V24, P1921, DOI 10.1093/nar/24.10.1921; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7030	7037		10.1074/jbc.273.12.7030	http://dx.doi.org/10.1074/jbc.273.12.7030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507011	hybrid			2022-12-27	WOS:000072775900061
J	Namsaraev, EA; Berg, P				Namsaraev, EA; Berg, P			Binding of Rad51p to DNA - Interaction of Rad5lp with single- and double-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; ATP HYDROLYSIS; EXCHANGE; GENE; RECOMBINATION; TOPOISOMERASE; SEQUENCE	Like RecA, Saccharomyces cerevisiae Rad51p promotes strand exchange between circular single-stranded DNA (ssDNA) and linear double-stranded DNA (dsDNA). We have investigated several parameters characteristic of the interaction of Rad51p with ssDNA and dsDNA, particularly the effects of the nucleotide cofactors ATP and ADP and the analogs adenosine 5'-O-(thio-triphosphate) (ATP gamma S) and adenylyl-imidodiphosphate (AMP-PNP). Rad51p binding to both 1-N-6-ethenoadenosine and 3-N-4-ethenocytidine ssDNA (epsilon DNA) and dsDNA requires the presence of Mg2+ and ATP; no binding occurs in the presence of ADP, AMP-PNP, or ATP gamma S. Binding of Rad51p to dsDNA also requires ATP; ADP is ineffective, whereas ATP gamma S and AMP-PNP are considerably less able to promote binding and only at elevated concentrations of Rad51p, ATP binding, not ATP hydrolysis, is required for Rad51p binding to DNA. The K-d. values for ATP for promoting binding of Rad51p to ssDNA and dsDNA are 1 and 3 mu M, respectively. Rad51p binding occurs with a stoichiometry of one monomer of Rad51p per similar to 6.3 nucleotides of epsilon DNA and similar to 3.3 base pairs of dsDNA. Once formed. Rad51p ssDNA complexes are stable so long as sufficient ATP levels are maintained. ATP hydrolysis causes dissociation of Rad51p from DNA. Moreover, the preformed complex is stable in the presence of a 10-fold excess of ADP or AMP-PNP over ATP. ATP gamma S, however, in the same-fold excess over ATP causes dissociation of the Rad51p ssDNA complex.	Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Berg, P (corresponding author), Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Biochem, B062, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM13235] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013235, R37GM013235] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; COX MM, 1983, J BIOL CHEM, V258, P2577; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; CUNNINGHAM RP, 1981, CELL, V24, P213, DOI 10.1016/0092-8674(81)90517-1; DASGUPTA C, 1980, CELL, V22, P437, DOI 10.1016/0092-8674(80)90354-2; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1989, J MOL BIOL, V207, P719, DOI 10.1016/0022-2836(89)90239-8; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1987, J BIOL CHEM, V262, P2085; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PUGH BF, 1987, J BIOL CHEM, V262, P1326; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8845; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; ZLOTNICK A, 1993, J BIOL CHEM, V268, P22525	26	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6177	6182		10.1074/jbc.273.11.6177	http://dx.doi.org/10.1074/jbc.273.11.6177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497339	hybrid			2022-12-27	WOS:000072488500031
J	Shibatohge, M; Kariya, K; Liao, YH; Hu, CD; Watari, Y; Goshima, M; Shima, F; Kataoka, T				Shibatohge, M; Kariya, K; Liao, YH; Hu, CD; Watari, Y; Goshima, M; Shima, F; Kataoka, T			Identification of PLC210, a Caenorhabditis elegans phospholipase C, as a putative effector of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VULVAR INDUCTION; SIGNALING PATHWAY; PROTEIN; TRANSFORMATION; KINASE; GENE; ACTIVATION; ENCODES; BINDING; CYCLASE	Mammalian Ras proteins regulate multiple effecters including Raf, Ral guanine nucleotide dissociation stimulator (RalGDS), and phosphoinositide 3-kinase. In the nematode Caenorhabditis elegans, LIN-45 Raf has been identified by genetic analyses as an effector of LET-60 Ras. To search for other effecters in C. elegans, we performed a yeast two-hybrid screening for LET-60-binding proteins. The screening identified two cDNA clones encoding a phosphoinositide-specific phospholipase C (PI-PLC) with a predicted molecular mass of 210 kDa, designated PLC210, PLC210 possesses two additional functional domains unseen in any known PI-PLCs. One is the C-terminal Ras-associating domain bearing a structural homology with those of RalGDS and AF-6. This domain, which could be narrowed down to 100 amino acid residues, associated in vitro with human Ha-Ras in a GTP-dependent manner and competed with yeast adenylyl cyclase for binding Ha-Ras. The binding was abolished by specific mutations within the effector region of Ha-Ras. The other functional domain is the N-terminal CDC25-like domain, which possesses a structural homology to guanine nucleotide exchange proteins for Ras. These results strongly suggest that PLC210 belongs to a novel class of PI-PLC, which is a putative effector of Ras.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 650, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki Chol, Kobe, Hyogo 650, Japan.							Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HOMMA Y, 1997, SIGNALING INOSITIDES, P99; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; KRAUSE M, 1995, CAENORHABDITIS ELEGA, P513; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MASUDA T, 1995, J BIOL CHEM, V270, P1979, DOI 10.1074/jbc.270.5.1979; MINATO T, 1994, J BIOL CHEM, V269, P20845; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Okada T, 1996, J BIOL CHEM, V271, P4671; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; Sundaram M, 1996, DEVELOPMENT, V122, P2823; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	35	90	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6218	6222		10.1074/jbc.273.11.6218	http://dx.doi.org/10.1074/jbc.273.11.6218			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497345	hybrid			2022-12-27	WOS:000072488500037
J	Kennedy, BN; Goldflam, S; Chang, MA; Campochiaro, P; Davis, AA; Zack, DJ; Crabb, JW				Kennedy, BN; Goldflam, S; Chang, MA; Campochiaro, P; Davis, AA; Zack, DJ; Crabb, JW			Transcriptional regulation of cellular retinaldehyde-binding protein in the retinal pigment epithelium - A role for the photoreceptor consensus element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENT; RAT OPSIN GENE; UPSTREAM REGION; MOLECULAR-CLONING; EXPRESSION; PROMOTER; SITE; MOUSE; CELLS; BOVINE	Cellular retinaldehyde-binding protein (CRALBP) is abundantly expressed in the retinal pigment epithelium (RPE) and Muller cells of the retina, where it is thought to function in retinoid metabolism and visual pigment regeneration, Mutations in human CRALBP that destroy retinoid binding have been linked to autosomal recessive retinitis pigmentosa. To identify the DNA elements that regulate expression of the human CRALBP gene in the RPE, transient transfection studies were carried out with three CRALBP-expressing human RPE cell culture systems. The regions from -2089 to -1539 base pairs and from -243 to +80 base pairs demonstrated positive regulatory activity, Similar activity was not observed with cultured human breast, liver, or skin cells, Since sequence analysis of the -243 to +80 region identified the presence of two photoreceptor consensus element-1 (PCE-1) sites, elements that have been implicated in photoreceptor gene regulation, the role of these sequences in RPE expression was examined. Mutation of either PCE-1 site significantly reduced reporter activity, and mutation or deletion of both sites dramatically reduced activity. Electrophoretic mobility shift analysis with RPE nuclear extracts revealed two complexes that required intact PCE-1 sites. These studies also identified two identical sequences (GCAGGA) flanking PCE-1, termed the binding CRALBP element (BCE), that are also important for complex formation. Southwestern analysis with PCE-1/BCEcontaining probes identified species with apparent masses near 90-100 and 31 kDa. These results bean to identify the regulatory regions required for RPE expression of CRALBP and suggest that PCE-1-binding factor(s) may play a role in regulating RPE as well as photoreceptor gene expression.	Adirondack Biomed Res Inst, Prot Chem Facil, Lake Placid, NY 12946 USA; Univ Texas, SW Med Ctr, Dept Anat & Cell Biol, Dallas, TX 75235 USA; Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21287 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University; Johns Hopkins Medicine	Crabb, JW (corresponding author), Adirondack Biomed Res Inst, Prot Chem Facil, 10 Old Barn Rd, Lake Placid, NY 12946 USA.	jcrabb@cell-science.org	kennedy, Breandan/H-5643-2019	kennedy, Breandan/0000-0001-7991-4689; Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY009769, P30EY001765] Funding Source: NIH RePORTER; NEI NIH HHS [EY06603, EY01765, EY09769] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1994, J NEUROCHEM, V62, P396; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; BOK D, 1993, J CELL SCI S, V17, P89; CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158; Crabb JW, 1998, METH MOL B, V89, P91; CRABB JW, 1988, J BIOL CHEM, V263, P18688; CRABB JW, 1991, J BIOL CHEM, V266, P16674; CRABB JW, 1998, IN PRESS PROTEIN SCI; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; DELEEUW AM, 1990, J NEUROCYTOL, V19, P253, DOI 10.1007/BF01217303; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; INTRES R, 1994, J BIOL CHEM, V269, P25411; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KIKUCHI T, 1995, INVEST OPHTH VIS SCI, V36, pS772; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; MARTINALONSO JM, 1993, EXP EYE RES, V56, P659, DOI 10.1006/exer.1993.1083; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; Saari JC, 1997, GLIA, V21, P259; Saari John C., 1994, P351; Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212; Sidman RL, 1996, INVEST OPHTH VIS SCI, V37, P1097; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPARKES RS, 1992, GENOMICS, V12, P58, DOI 10.1016/0888-7543(92)90406-I; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P596, DOI 10.1073/pnas.93.2.596; YU X, 1994, J MOL NEUROSCI, V5, P259, DOI 10.1007/BF02736726; Yu X, 1996, J NEUROCHEM, V67, P2494; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5591	5598		10.1074/jbc.273.10.5591	http://dx.doi.org/10.1074/jbc.273.10.5591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488687	hybrid			2022-12-27	WOS:000072345000030
J	Lazure, C; Gauthier, D; Jean, F; Boudreault, A; Seidah, NG; Bennett, HPJ; Hendy, GN				Lazure, C; Gauthier, D; Jean, F; Boudreault, A; Seidah, NG; Bennett, HPJ; Hendy, GN			In vitro cleavage of internally quenched fluorogenic human proparathyroid hormone and proparathyroid-related peptide substrates by furin - Generation of a potent inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASE PC2; CONSTITUTIVE SECRETORY PATHWAY; NEUROENDOCRINE POLYPEPTIDE 7B2; PARATHYROID-HORMONE; PRECURSOR PROTEINS; ENZYMATIC CHARACTERIZATION; PROCESSING ENDOPROTEASES; PROPROTEIN CONVERTASES; AMINO-ACID; IN-VITRO	The cleavage of parathyroid hormone (PTH) from its precursor proparathyroid hormone (pro-PTH) is accomplished efficiently by the proprotein convertase furin (Hendy, G. N., Bennett, H. P. J., Gibbs, B. F., Lazure, C., Day, R., and Seidah, N. G. (1995) J. Biol. Chem. 270, 9517-9525). We also showed that a synthetic peptide comprising the -6 to +7 sequence of human pro-PTH is appropriately cleaved by purified furin in vitro. The human pro-PTH processing site Lys-Ser-Val-Lys-Lys-Arg differs from the consensus furin site Arg-Xaa-(Lys/Arg)-Arg that is represented by Arg-Arg-Leu-Lys-Arg in the cleavage site of pro-PTH-related peptide (pro-PTHrP). An earlier study demonstrated that an internally quenched fluorogenic substrate bearing an O-aminobenzoyl fluorescent donor at the NH2 terminus and an acceptor 3-nitrotyrosine near the COOH terminus was appropriately cleaved by the convertases furin and PC1 (Jean, F., Basak, A., DiMaio, J., Seidah, N. G., and Lazure, C. (1995) Biochem. J. 307, 689-695). Here, we have synthesized a series of internally quenched fluorogenic substrates based upon the pro-PTH and pro-PTHrP sequences to determine which residues are important for furin cleavage. Purified recombinant furin and PC1 cleaved the human pro-PTH internally quenched substrate at the appropriate site in an identical manner to that observed with the nonfluorescent peptide. Several substitutions in the P-6-P-3 sequence were well tolerated; however, replacement of the Lys at the P-6 position with Gly and replacement of the P-3 Lys by an acidic residue led to markedly compromised cleavage by furin. Furin activity was very sensitive to substitution in P' positions. Replacement of Ser at P-1' with Gly and Val at P-2' with Ala generated substrates that were less well cleaved. Substitution at the P-1' position of Val for Ser in conjunction with Ala for Val at P-2', as well as a single substitution of Lys for Val at P-2', generated specific inhibitors of furin cleavage. The findings of this study open the way to the rational design of inhibitors of furin with therapeutic potential.	Royal Victoria Hosp, Endocrine Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada; Univ Montreal, Inst Rech Clin Montreal, Lab Neuropeptide Struct & Metab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Inst Rech Clin Montreal, JA DeSeve Lab Biochem Neuroendocrinol, Montreal, PQ H2W 1R7, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Bennett, HPJ (corresponding author), Royal Victoria Hosp, Endocrine Lab, Rm L2-05,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASAK A, 1995, INT J PEPT PROT RES, V46, P228; BASAK A, 1994, INT J PEPT PROT RES, V44, P253; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BRESNAHAN PA, 1993, MECHANISMS INTRACELL, P225; CAMPAN M, 1996, BIOCHEMISTRY-US, V35, P3793; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; HABENER JF, 1979, J CELL BIOL, V80, P715, DOI 10.1083/jcb.80.3.715; HALLORAN BP, 1992, PARATHYROID HORMONE; HAMILTON JW, 1974, P NATL ACAD SCI USA, V71, P653, DOI 10.1073/pnas.71.3.653; Hendy Geoffrey N., 1997, P307; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; LIU B, 1995, INT J CANCER, V63, P276, DOI 10.1002/ijc.2910630222; LIU B, 1995, AM J PHYSIOL-ENDOC M, V268, pE832, DOI 10.1152/ajpendo.1995.268.5.E832; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moseley J. M., 1996, P363; Nachtigal MW, 1996, P NATL ACAD SCI USA, V93, P7711, DOI 10.1073/pnas.93.15.7711; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; ROEBROEK AJM, 1994, BIOCHIMIE, V76, P210, DOI 10.1016/0300-9084(94)90148-1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOPSI L, 1995, J CLIN ENDOCR METAB, V80, P294, DOI 10.1210/jc.80.1.294; Segel IH, 1993, ENZYME KINETICS BEHA, P161; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; STEINER DF, 1992, J BIOL CHEM, V267, P23435; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WULFF BS, 1993, J BIOL CHEM, V268, P13327; Zhu XR, 1996, J BIOL CHEM, V271, P23582, DOI 10.1074/jbc.271.38.23582	47	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8572	8580		10.1074/jbc.273.15.8572	http://dx.doi.org/10.1074/jbc.273.15.8572			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535830	hybrid			2022-12-27	WOS:000072990800007
J	Rhee, S; Miles, EW; Davies, DR				Rhee, S; Miles, EW; Davies, DR			Cryo-crystallography of a true substrate, indole-3-glycerol phosphate, bound to a mutant (alpha D60N) tryptophan synthase alpha(2)beta(2) complex reveals the correct orientation of active site alpha Glu49	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SALMONELLA-TYPHIMURIUM; CATALYTIC RESIDUE; SUBUNIT	The reversible cleavage of indole-3-glycerol by the cy-subunit of tryptophan synthase has been proposed to be catalyzed by alpha Glu49 and alpha Asp60. Although previous x-ray crystallographic structures of the tryptophan synthase alpha(2) beta(2) complex showed an interaction between the carboxylate of alpha Asp60 and the bound inhibitor indole-3-propanol phosphate, the carboxylate of alpha Glu49 was too distant to play its proposed role, To clarify the structural and functional roles of alpha Glu49, we have determined crystal structures of a mutant (alpha D60N) alpha(2) beta(2) complex in the presence and absence of the true substrate, indole-3-glycerol phosphate. The enzyme in the crystal cleaves indole-3-glycerol phosphate very slowly at room temperature but not under cryo-conditions of 95 K. The structure of the complex with the true substrate obtained by cryo-crystallography reveals that indole-3-glycerol phosphate and indole-3-propanol phosphate have similar binding modes but different torsion angles. Most importantly, the side chain of alpha Glu49 interacts with S-hydroxyl group of indole-3-glycerol phosphate as proposed, The movement of the side chain of alpha Glu49 into an extended conformation upon binding the true substrate provides evidence for an induced fit mechanism. Our results demonstrate how cryo-crystallography and mutagenesis can provide insight into enzyme mechanism.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Davies, DR (corresponding author), NIDDK, Mol Biol Lab, NIH, Bldg 5,Rm 338, Bethesda, MD 20892 USA.							AHMED SA, 1985, J BIOL CHEM, V260, P3716; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; HELINSKI DR, 1963, J BIOL CHEM, V238, P1043; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; NAGATA S, 1989, J BIOL CHEM, V264, P6288; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; YUTANI K, 1987, J BIOL CHEM, V262, P13429	15	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8553	8555		10.1074/jbc.273.15.8553	http://dx.doi.org/10.1074/jbc.273.15.8553			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535826	hybrid			2022-12-27	WOS:000072990800003
J	Sano, H; Higashi, T; Matsumoto, K; Melkko, J; Jinnouchi, Y; Ikeda, K; Ebina, Y; Makino, H; Smedsrod, B; Horiuchi, S				Sano, H; Higashi, T; Matsumoto, K; Melkko, J; Jinnouchi, Y; Ikeda, K; Ebina, Y; Makino, H; Smedsrod, B; Horiuchi, S			Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ADVANCED GLYCOSYLATION; MAILLARD REACTION; PHOSPHOINOSITIDE 3-KINASE; MONOCLONAL-ANTIBODY; GLUCOSE-TRANSPORTER; DIABETES-MELLITUS	Hyperglycemia accelerates the formation and accu???? mulation of advanced glycation end products (AGE) in plasma and tissue, which may cause diabetic vascular complications. We recently reported that scavenger receptors expressed by liver endothelial cells (LECs) dominantly mediate the endocytic uptake of AGE proteins from plasma, suggesting its potential role as an eliminating system for AGE proteins in vivo (Smedsrod, B., Melkko, J., Araki, N., Sane, H., and Horiuchi, S. (1997) Biochem. J. 322, 567-573). In the present study we examined the effects of insulin on macrophage scavenger receptor (MSR)-mediated endocytic uptake of AGE proteins. LECs expressing MSR showed an insulin-sensitive increase of endocytic uptake of AGE-bovine serum albumin (AGE-BSA). Next, RAW 264.7 cells expressing a high amount of MSR were overexpressed with human insulin receptor (HIR). Insulin caused a 3.7-fold increase in endocytic uptake of I-125-AGE-BSA by these cells. The effect of insulin was inhibited by wortmannin, a phosphatidylinositol-3-OH kinase (PI3 kinase) inhibitor. To examine at a molecular level the relationship between insulin signal and MSR function, Chinese hamster ovary (CHO) cells expressing a negligible level of MSR were cotransfected with both MSR and HIR. Insulin caused a 1.7-fold increase in the endocytic degradation of I-125-AGE-BSA by these cells, the effect of which was also inhibited by wortmannin and LY294002, another PI3 kinase inhibitor. Transfection of CHO cells overexpressing MSR with two HTR mutants, a kinase deficient mutant, and another lacking the binding site for insulin receptor substrates (IRS) resulted in disappearance of the stimulatory effect of insulin on endocytic uptake of AGE proteins. The present results indicate that insulin may accelerate MSR-mediated endocytic uptake of AGE proteins through an IRS/PI3 kinase pathway.	Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; Univ Tromso, Dept Expt Pathol, N-9037 Tromso, Norway; Univ Tokushima, Inst Enzyme Res, Dept Enzyme Genet, Tokushima 770, Japan; Ehime Univ, Sch Med, Dept Lab Med, Matsuyama, Ehime 791, Japan	Kumamoto University; UiT The Arctic University of Tromso; Tokushima University; Ehime University	Horiuchi, S (corresponding author), Kumamoto Univ, Sch Med, Dept Biochem, Honjo 2-2-1, Kumamoto 8600811, Japan.	horiuchi@gpo.kumamoto-u.ac.jp						ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; BAYNES JW, 1981, ARCH BIOCHEM BIOPHYS, V206, P372, DOI 10.1016/0003-9861(81)90104-1; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; *DCCT, 1993, NEW ENGL J MED, V329, P976; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; Higashi T, 1997, DIABETES, V46, P463, DOI 10.2337/diabetes.46.3.463; HORIUCHI S, 1996, TRENDS CARDIOVAS MED, V6, P21; INABA T, 1992, J BIOL CHEM, V267, P13107; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KANAI F, 1993, J BIOL CHEM, V268, P14523; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUME S, 1995, AM J PATHOL, V147, P654; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Ling WH, 1997, J CLIN INVEST, V100, P244, DOI 10.1172/JCI119528; MAKINO H, 1995, KIDNEY INT, V48, P517, DOI 10.1038/ki.1995.322; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Meng J, 1996, DIABETES, V45, P1037, DOI 10.2337/diabetes.45.8.1037; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MIYAZAKI A, 1994, J BIOL CHEM, V269, P5264; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; NEEPER M, 1992, J BIOL CHEM, V267, P14998; PERTOFT H, 1987, CELL SEPARATION METH, V4, P1; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TAKATA K, 1988, J BIOL CHEM, V263, P14819; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1994, LAB INVEST, V70, P138; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; YANO H, 1993, J BIOL CHEM, V268, P25846; YUI S, 1994, J IMMUNOL, V152, P1943	58	49	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8630	8637		10.1074/jbc.273.15.8630	http://dx.doi.org/10.1074/jbc.273.15.8630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535837	hybrid			2022-12-27	WOS:000072990800014
J	Assaraf, YG; Babani, S; Goldman, ID				Assaraf, YG; Babani, S; Goldman, ID			Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; L1210 LEUKEMIA-CELLS; CARRIER-MEDIATED TRANSPORT; MAMMALIAN-CELLS; FOLIC-ACID; METHOTREXATE; INTESTINE; RECEPTOR; BINDING; KIDNEY	Previous studies described a Chinese hamster ovary cell line, Pyr(R100), resistant to lipid-soluble antifolates due to the loss of an energy-coupled folate exporter resulting in a marked increase in intracellular folate cofactor accumulation. There was, in addition, an unexplained increase in folic acid influx in Pyr(R100) cells which is shown in this paper to be mediated by a transporter with a low pH optimum. The pH profile for folic acid influx in parental Chinese hamster ovary AA8 cells indicated peak activity at pH 6; this was increased >3-fold in Pyr(R100) cells. In contrast, methotrexate (MTX) influx in AA8 cells showed two peaks of comparable activities at pH 6 and 7.5; in Pyr(R100) cells, the component at pH 6 was increased 2-fold. Folic acid was a potent inhibitor of [H-3]MTX or [H-3]folic acid influx (1 mu M) via the low pH route with IC50 values of similar to 1 mu M. Prostaglandin A(1) was a potent inhibitor of [H-3]MTXia the reduced folate carrier 1 at pH 7.5 with only a small inhibitory effect on the low pH 7.5 with only a small inhibitory effect on the low pH route. The addition of 10 mu M folic acid to Pyr(R100) cells resulted in a MTX influx pH profile identical to that of AA8 cells, consistent with suppression of the low pH route. In contrast, addition of 25 mu M prostaglandin A(1) to Pyr(R100) cells resulted in a MTX influx pH profile comparable to that of folic acid, consistent with the loss of the reduced folate carrier-mediated component. Inhibition (similar to 70%) of [H-3]follux by similar to 10 mu M unlabeled folic acid at pH 7.5 indicated that the low pH transporter accounts for the majority of folic acid transport at physiological pH. This study demonstrates the functional importance of a low pH folate transporter that is increased when enhanced folic acid entry into cells is required as an adaptive response to antifolate selective pressure. This may represent a mechanism of resistance to new antifolate inhibitors of folate cofactor-dependent enzymes in which cytotoxic activity is limited by expanded cellular folate pools.	Yeshiva Univ Albert Einstein Coll Med, Ctr Comprehens Canc, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Comprehens Canc, Dept Mol Pharmacol, Bronx, NY 10461 USA; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Technion Israel Institute of Technology	Goldman, ID (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Ctr Comprehens Canc, Dept Med, 1300 Morris Pk Ave,Channin 2, Bronx, NY 10461 USA.			Assaraf, Yehuda G./0000-0001-6692-8221	NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; ASSARAF YG, 1993, J BIOL CHEM, V268, P4556; BHANDARI SD, 1991, P SOC EXP BIOL MED, V196, P451; BHANDARI SD, 1988, BIOCHIM BIOPHYS ACTA, V937, P211, DOI 10.1016/0005-2736(88)90243-X; Fei YJ, 1997, BIOCHEMISTRY-US, V36, P452, DOI 10.1021/bi962058p; FRY DW, 1982, J MEMBRANE BIOL, V66, P87, DOI 10.1007/BF01868485; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1986, CANCER RES, V46, P1639; HENDERSON GB, 1986, FOLATES PTERINS NUTR, V3, P207; JANSEN G, 1997, PTERIDINES, V8, P116; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; Leibach FH, 1996, ANNU REV NUTR, V16, P99, DOI 10.1146/annurev.nu.16.070196.000531; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; MAURITZ R, 1997, PTERIDINES, V8, P92; POE M, 1977, J BIOL CHEM, V252, P3724; SCHRON CM, 1985, J CLIN INVEST, V76, P2030, DOI 10.1172/JCI112205; SCHRON CM, 1990, J MEMBRANE BIOL, V120, P192; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SELHUB J, 1981, J BIOL CHEM, V256, P4489; SHARMA RC, 1991, CANCER RES, V51, P2949; SIERRA EE, 1995, BIOCHEM PHARMACOL, V50, P1287, DOI 10.1016/0006-2952(95)94097-Y; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1986, MEMBRANE TRANSPORT A, P241; SMITH ME, 1970, BIOCHIM BIOPHYS ACTA, V219, P37, DOI 10.1016/0005-2736(70)90059-3; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; SPRECHER H, 1995, J BIOL CHEM, V270, P20668, DOI 10.1074/jbc.270.35.20668; TEMPLE C, 1984, CHEM BIOCH FOLATES, P61; Tse A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P162; YANG CH, 1983, J MEMBRANE BIOL, V75, P11, DOI 10.1007/BF01870795; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207; ZIMMERMAN J, 1990, GASTROENTEROLOGY, V99, P964, DOI 10.1016/0016-5085(90)90614-7	35	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8106	8111		10.1074/jbc.273.14.8106	http://dx.doi.org/10.1074/jbc.273.14.8106			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525913	hybrid			2022-12-27	WOS:000072876300047
J	Chaudhary, A; Gu, QM; Thum, O; Profit, AA; Qi, Y; Jeyakumar, L; Fleischer, S; Prestwich, GD				Chaudhary, A; Gu, QM; Thum, O; Profit, AA; Qi, Y; Jeyakumar, L; Fleischer, S; Prestwich, GD			Specific interaction of Golgi coatomer protein alpha-COP with phosphatidylinositol 3,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; CLATHRIN-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; INOSITOL POLYPHOSPHATES; GUANINE-NUCLEOTIDE; SECRETORY PATHWAY; BREFELDIN-A; BETA-COP; IN-VITRO; SUBUNIT	The phosphoinositide binding selectivity of Golgi coatomer COPI polypeptides mas examined using photoaffinity analogs of the soluble inositol polyphosphates Ins(1,4,5)P-3, Ins(1,3,4,5)P-4, and InsP(6), and of the polyphosphoinositides PtdIns(3,4,5)P-3, Pt-dIns(4,5)P-2, and PtdIns(3,4)P-2. Highly selective Ins(1,5,4,5)P-4-displaceable photocovalent modification of the alpha-COP subunit was observed with ap-benzoyldihydrocinnamide (BZDC)-containing probe, [3(H)]BZDC-Ins(1,3,4,5)P-4. A more highly phosphorylated probe, [H-3]BZDC-InsP(6) probe labeled six of the seven subunits, with only beta, beta', delta and epsilon-COP showing competitive displacement by excess InsP(6). Importantly, [H-3]BZDC-triester-PtdIns(3,4,5)P-3, the lipid with the same phosphorylation pattern as Ins(1,3,4,5)P-4, showed specific, PtdIns(3,4,5)P-3-displaceable labeling of only a alpha-COP. Labeling by the PtdIns(4,5)P-2 and PtdIns(3,4)P-2 photoaffinity probes was less intense and showed no discrimination based on PtdInsP(n) ligand. Thus, both the D-3 and D-5 phosphates are critical for the alpha-COP-PtdIns(3,4,5)P-3 interaction, suggesting an important role for this polyphosphoinositide in vesicular trafficking.	Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	Utah System of Higher Education; University of Utah; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vanderbilt University	Prestwich, GD (corresponding author), Univ Utah, Dept Med Chem, 30 South,2000 East,Rm 201, Salt Lake City, UT 84112 USA.	gprestwich@deans.pharm.utah.edu	Thum, Oliver/F-2201-2010	Thum, Oliver/0000-0002-2568-1450	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32711] Funding Source: Medline; NINDS NIH HHS [NS 29632] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Beron W, 1996, BIOCELL, V20, P307; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chaudhary A, 1997, BIOTECHNIQUES, V23, P427, DOI 10.2144/97233bm17; Chow VTK, 1996, GENE, V169, P223, DOI 10.1016/0378-1119(95)00738-5; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ESTEVEZ VA, 1991, J AM CHEM SOC, V113, P9885, DOI 10.1021/ja00026a043; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GERICH B, 1995, P NATL ACAD SCI USA, V92, P3229, DOI 10.1073/pnas.92.8.3229; Gu QM, 1996, J ORG CHEM, V61, P8642, DOI 10.1021/jo961226g; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KIJIMA Y, 1993, J BIOL CHEM, V268, P16253; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LETOURNEUR F, 1994, CELL, V79, P1198; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; Nickel W, 1997, FEBS LETT, V413, P395, DOI 10.1016/S0014-5793(97)00939-3; OLSZEWSKI JD, 1995, BIOCONJUGATE CHEM, V6, P395, DOI 10.1021/bc00034a009; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; Quek HH, 1997, DNA CELL BIOL, V16, P275, DOI 10.1089/dna.1997.16.275; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sabatini DD, 1996, BIOCELL, V20, P287; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schimmoller F, 1997, CURR BIOL, V7, pR235, DOI 10.1016/S0960-9822(06)00109-6; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Thum O, 1996, TETRAHEDRON LETT, V37, P9017, DOI 10.1016/S0040-4039(96)02117-X; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	57	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8344	8350		10.1074/jbc.273.14.8344	http://dx.doi.org/10.1074/jbc.273.14.8344			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525943	hybrid			2022-12-27	WOS:000072876300077
J	Sato, S; Ward, CL; Kopito, RR				Sato, S; Ward, CL; Kopito, RR			Cotranslational ubiquitination of cystic fibrosis transmembrane conductance regulator in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; DEGRADATION; PROTEIN; PROTEASOME; PATHWAY; MEMBRANE; CFTR	Ubiquitination is a covalent protein modification that can target proteins in eukaryotic cells for degradation by the 26 S proteasome. Substrates for this degradation pathway include abnormal proteins that arise from mis-folding and/or mutation, How and when the ubiquitination machinery recognizes misfolded proteins and targets them for degradation remains largely unknown, We have previously shown that cystic fibrosis transmembrane conductance regulator (CFTR), is rapidly degraded in a ubiquitin-dependent fashion, without any detectable lag following its synthesis (Ward, C. L., and Kopito, R. R. (1994) J. Biol. Chem. 269, 25710-25718), suggesting that ubiquitination and protein synthesis may be temporally linked, In the present study, we have investigated the timing of CFTR ubiquitination relative to its translation in reticulocyte lysates containing I-125-ubiquitin, In synchronized, proteasome-inhibited lysates, translation of full-length CFTR chains was completed in approximately 30 min, whereas modification of CFTR with [I-125]ubiquitin was evident by 20 min, indicating that ubiquitination precedes the completion of full-length polypeptide chains, Moreover, ubiquitin was also found to be transferred to nascent CFTR chains while attached to ribosomes, Together, these data establish that ubiquitination, which is widely assumed to be a post-translational event, can occur cotranslationally and suggest a role for ubiquitination early in protein biosynthesis.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Kopito, RR (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	kopito@stanford.edu			NIDDK NIH HHS [DK43994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; PIND S, 1994, J BIOL CHEM, V269, P12784; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	21	112	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7189	7192		10.1074/jbc.273.13.7189	http://dx.doi.org/10.1074/jbc.273.13.7189			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516408	hybrid			2022-12-27	WOS:000072738500004
J	Giang, DG; Cravatt, BF				Giang, DG; Cravatt, BF			A second mammalian N-myristoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYRISTOYL-COA; SACCHAROMYCES-CEREVISIAE; BOVINE BRAIN; PROTEIN; TRANSFERASE; PURIFICATION; ACYLATION; IDENTIFICATION; RESIDUES; CANCER	N-terminal myristoylation is a cotranslational lipid modification common to many signaling proteins that often serves an integral role in the targeting and/or function of these proteins. Myristoylation is catalyzed by an enzyme activity, N-myristoyltransferase (NMT), which transfers myristic acid from myristoyl coenzyme A to the amino group of a protein's N-terminal glycine residue. While a single human NMT cDNA has been isolated and characterized (hNMT-1), biochemical evidence has indicated the presence of several distinct NMTs in vivo, often varying in either apparent molecular weight and/or subcellular distribution. We now report the cloning and characterization of a second, genetically distinct human NMT (hNMT-2), as well as the isolation of the respective mouse NMT homologue for each human enzyme. The mouse and human versions of each NMT are highly homologous, displaying greater than 95% amino acid sequence identity. Comparisons between the NMT-1 and NMT-2 proteins revealed reduced levels of sequence identity (76-77%), indicating that NMT-1 and NMT-2 comprise two distinct families of N-myristoyltransferases. Transient transfection of either the hNMT-1 or hNMT-2 cDNA into COS-7 cells resulted in the expression of high levels of NMT enzyme activity. Both hNMT-1 and hNMT-2 were found to myristoylate several commonly studied peptide substrates with similar, hut distinguishable, relative selectivities. Western analysis revealed that while hNMT-2 appeared as a single 65-kDa protein in transfected COS-7 cells, hNMT-1 was processed to provide four distinct protein isoforms ranging from 49 to 68 kDa in size. Collectively, these studies demonstrate a heretofore unappreciated level of genetic complexity underlying the enzymology of N-terminal myristoylation and suggest that the specific inhibition or regulation of either NMT in vivo may in turn allow for the selective control of particular myristoylation-dependent cellular functions.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; BOUTIN JA, 1997, CELL SIGNAL, V9, P5; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; Devadas B, 1997, J MED CHEM, V40, P2609, DOI 10.1021/jm970094w; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; FELSTED RL, 1995, J NATL CANCER I, V87, P1571, DOI 10.1093/jnci/87.21.1571; Furuishi K, 1997, BIOCHEM BIOPH RES CO, V237, P504, DOI 10.1006/bbrc.1997.7178; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GLOVER CJ, 1995, J BIOL CHEM, V270, P23226, DOI 10.1074/jbc.270.39.23226; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; GORDON JI, 1991, J BIOL CHEM, V266, P8647; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; KING MJ, 1993, BIOCHIM BIOPHYS ACTA, V1165, P259, DOI 10.1016/0005-2760(93)90134-U; KING MJ, 1993, BIOCHEM J, V291, P635, DOI 10.1042/bj2910635; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; MAGNUSON BA, 1995, J NATL CANCER I, V87, P1630, DOI 10.1093/jnci/87.21.1630; McIlhinney RAJ, 1996, EXP CELL RES, V223, P348, DOI 10.1006/excr.1996.0090; PESECKIS SM, 1994, J BIOL CHEM, V269, P30888; Raju RVS, 1997, EXP CELL RES, V235, P145, DOI 10.1006/excr.1997.3679; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; STEVENSON FT, 1992, J EXP MED, V176, P1053, DOI 10.1084/jem.176.4.1053; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	33	126	138	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6595	6598		10.1074/jbc.273.12.6595	http://dx.doi.org/10.1074/jbc.273.12.6595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506952	hybrid			2022-12-27	WOS:000072775900002
J	Zeller, Y; Lohr, J; Sammar, M; Butcher, EC; Altevogt, P				Zeller, Y; Lohr, J; Sammar, M; Butcher, EC; Altevogt, P			Asp-698 and Asp-811 of the integrin alpha(4)-subunit are critical for the formation of a functional heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; III CONNECTING SEGMENT; BINDING-SITE; ALPHA-4-BETA-1 INTEGRIN; MONOCLONAL-ANTIBODY; HUMAN-LYMPHOCYTES; CRYSTAL-STRUCTURE; LIGAND-BINDING; FIBRONECTIN; RECEPTOR	The amino acid motif LDV is the principal binding site for alpha(4) integrins in fibronectin, and homologous motifs are recognized in vascular cell adhesion molecule-1 and MAdCAM-1. Three conserved LDV motifs (LDV-1 to 3) occur in the ectodomain of the human and mouse alpha(4)-subunit, the functions of which are unknown. We demonstrate here that alpha(4)-transfected fibroblasts with mutation in LDV-1 (D489N) behaved like alpha(4)-wild type but that LDV-2 (D698N) and LDV-3 (D811N) mutants were impaired in binding and spreading on alpha(4)-specific substrates. On the ROD-containing fibronectin fragment FN-120 there was an inverse behavior; now the alpha(4)-wild type and the LDV-1 mutant could not adhere whereas the two other mutants could, The beta(1) chain was critical for the differential integrin response. Biochemical analysis demonstrated that the LDV-2 and -3 mutations reduced the strength of the alpha(4) beta(1) association, favored the formation of alpha(5) beta(1), and prevented the expression of alpha(4) beta(7) on the cell surface. Our results indicate that LDV-2 and LDV-3 are critical for the formation of a functional heterodimer. The presence of similar amino acid motifs in ligands and the alpha(4)-subunit suggest that metal coordination plays an important role in integrin-ligand binding as well as for heterodimer formation.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; Stanford Univ, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Ctr Digest Dis, Stanford, CA 94305 USA; Vet Adm Med Ctr, Ctr Mol Biol Med, Palo Alto, CA 94304 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, 0710,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.altevogt@dkfz-heidelberg.de	Sammar, Marei/Q-1410-2019					Abe Y, 1996, J IMMUNOL, V157, P5061; Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; ALTEVOGT P, 1995, J EXP MED, V182, P345, DOI 10.1084/jem.182.2.345; ANDREW DP, 1994, J IMMUNOL, V153, P3847; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Briskin MJ, 1996, J IMMUNOL, V156, P719; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; Gosslar U, 1996, P NATL ACAD SCI USA, V93, P4821, DOI 10.1073/pnas.93.10.4821; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAMANN A, 1994, J IMMUNOL, V152, P3283; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; LANG E, 1987, EXP CELL RES, V173, P232, DOI 10.1016/0014-4827(87)90348-X; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MA L, 1995, J BIOL CHEM, V270, P18401, DOI 10.1074/jbc.270.31.18401; Mannion BA, 1996, J IMMUNOL, V157, P2039; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NEEDHAM LA, 1994, CELL ADHES COMMUN, V2, P87, DOI 10.3109/15419069409004429; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PULIDO R, 1991, J BIOL CHEM, V266, P10241; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; SanchezMateos P, 1996, SEMIN CANCER BIOL, V7, P99, DOI 10.1006/scbi.1996.0015; SMYTH SS, 1993, BLOOD, V81, P2827; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKAHASHI K, 1990, J IMMUNOL, V145, P4371; Tidswell M, 1997, J IMMUNOL, V159, P1497; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; Webb DL, 1996, J CELL BIOCHEM, V61, P127, DOI 10.1002/(SICI)1097-4644(19960401)61:1<127::AID-JCB14>3.0.CO;2-L; Yang JT, 1996, J CELL BIOL, V135, P829, DOI 10.1083/jcb.135.3.829; YANG JT, 1995, DEVELOPMENT, V121, P549; YASUDA M, 1995, INT IMMUNOL, V7, P251, DOI 10.1093/intimm/7.2.251	55	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6786	6795		10.1074/jbc.273.12.6786	http://dx.doi.org/10.1074/jbc.273.12.6786			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506980	hybrid			2022-12-27	WOS:000072775900030
J	Chen, SJ; Wang, JC				Chen, SJ; Wang, JC			Identification of active site residues in Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PHOSPHORYL-TRANSFER; TERMINAL FRAGMENT; PROTEIN-OMEGA; CLEAVAGE; MUTAGENESIS; CATALYSIS; TYROSINE; COMPLEX; ENZYME	Alanine substitution mutagenesis of Escherichia coli DNA topoisomerase I, a member of the type IA subfamily of DNA topoisomerases, was carried out to identify amino acid side chains that are involved in transesterification between DNA and the active site tyrosine Tyr-319 of the enzyme, Twelve polar residues that are highly conserved among the type IA enzymes, Glu-9, His-33, Asp-111, Glu-115, Gln-309, Glu-313, Thr-318, Arg-321, Thr-322, Asp-323, His-365, and Thr-496, were selected for alanine substitution, Each of the mutant enzymes was overexpressed, purified, and characterized. Surprisingly, only substitution at Glu-9 and Arg-321 was found to reduce the DNA relaxation activity of the enzyme to an insignificant level, The R321A mutant enzyme, but not the E9A mutant enzyme, was found to retain a reduced level of DNA cleavage activity, Two additional mutant enzymes R321K and E9Q were also constructed and purified, Replacing Arg-321 by lysine has little effect on enzymatic activities; replacing Glu-9 by glutamine greatly reduces the supercoil removal activity but not the DNA cleavage and rejoining activities, From these results and the locations of the amino acids in the crystal structure of the enzyme, it appears that Glu-9 has a critical role in DNA breakage and rejoining, probably through its interaction with the 3' deoxyribosyl oxygen, The positively charged Arg-321 may also participate in these reactions by interacting with the scissile DNA phosphate as a monodentate. Because of the strict conservation of these residues, the findings for the E, coli enzyme are likely to apply to all type IA DNA topoisomerases.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.				NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; Caron P R, 1994, Adv Pharmacol, V29B, P271; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1979, J BIOL CHEM, V254, P1082; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; TSE YC, 1980, J BIOL CHEM, V255, P5560; Tse-Dinh Y C, 1994, Adv Pharmacol, V29A, P21; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; TSEDINH YC, 1991, J BIOL CHEM, V261, P10931; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LK, 1997, BIOCHEMISTRY-US, V36, P7944, DOI 10.1021/bi970498q; WILKINSON AJ, 1990, STRUCTURE AND FUNCTION OF NUCLEIC ACIDS AND PROTEINS, P61; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; YU LP, 1995, BIOCHEMISTRY-US, V34, P7622, DOI 10.1021/bi00023a008; Zhu CX, 1997, J BIOL CHEM, V272, P16206, DOI 10.1074/jbc.272.26.16206; ZHU CX, 1995, J MOL BIOL, V250, P609, DOI 10.1006/jmbi.1995.0402; ZHU CX, 1995, BIOCHEM MOL BIOL INT, V35, P375; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	33	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6050	6056		10.1074/jbc.273.11.6050	http://dx.doi.org/10.1074/jbc.273.11.6050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497321	hybrid			2022-12-27	WOS:000072488500013
J	Jarolim, P; Shayakul, C; Prabakaran, D; Jiang, LW; Stuart-Tilley, A; Rubin, HL; Simova, S; Zavadil, J; Herrin, JT; Brouillette, J; Somers, MJG; Seemanova, E; Brugnara, C; Guay-Woodford, LM; Alper, SL				Jarolim, P; Shayakul, C; Prabakaran, D; Jiang, LW; Stuart-Tilley, A; Rubin, HL; Simova, S; Zavadil, J; Herrin, JT; Brouillette, J; Somers, MJG; Seemanova, E; Brugnara, C; Guay-Woodford, LM; Alper, SL			Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	39th Annual Meeting of the American-Society-of-Hematology	DEC 05-09, 1997	SAN DIEGO, CALIFORNIA	Amer Soc Hematol			DEFECTIVE ANION TRANSPORT; VACUOLAR H+-ATPASE; HEREDITARY SPHEROCYTOSIS; INTERCALATED CELLS; ERYTHROID BAND-3; GENE; DEFICIENCY; KIDNEY; POLYMORPHISM; EPB3	Distal renal tubular acidosis (dRTA) is characterized by defective urinary acidification by the distal nephron. Cl-/HCO3- exchange mediated by the AE1 anion exchanger in the basolateral membrane of type A intercalated cells is thought to be an essential component of lumenal H+ secretion by collecting duct intercalated cells. We evaluated the AE1 gene as a possible candidate gene for familial dRTA. We found in three unrelated families with autosomal dominant dRTA that all clinically affected individuals were heterozygous for a single missense mutation encoding the mutant AE1 polypeptide R589H, Patient red cells showed similar to 20% reduction in sulfate influx of normal 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid sensitivity and pH dependence. Recombinant kidney AE1 R589H expressed in Xenopus oocytes showed 20-50% reduction in Cl-/Cl- and Cl-/HCO3- exchange, but did not display a dominant negative phenotype for anion transport when coexpressed with wild-type AE1, One apparently unaffected individual for whom acid-loading data were unavailable also was heterozygous for the mutation. Thus, in contrast to previously described heterozygous loss-of-function mutations in AE1 associated with red cell abnormalities and apparently normal renal acidification, the heterozygous hypomorphic AE1 mutation R589H is associated with dominant dRTA and normal red cells.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Lab Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Nephrol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Div Nephrol, Birmingham, AL 35294 USA; Charles Univ, Sch Med, Prague 12820, Czech Republic; Charles Univ, Inst Hematol, Prague 12820, Czech Republic	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Charles University Prague; Charles University Prague; Institute of Hematology Prague	Alper, SL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Mol Med Unit, 330 Brookline Ave, Boston, MA 02215 USA.	salper@bidmc.harvard.edu	Simova, Sarka/F-8625-2014; Zavadil, Jiri/ABG-1780-2020; Brugnara, Carlo/A-8041-2010	Zavadil, Jiri/0000-0003-0640-5562; Brugnara, Carlo/0000-0001-8192-8713	NHLBI NIH HHS [HL15157] Funding Source: Medline; NIDDK NIH HHS [DK43495, DK34854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043495, R01DK043495, P30DK034854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BRAHM J, 1977, J GEN PHYSIOL, V70, P283, DOI 10.1085/jgp.70.3.283; Breton S, 1995, AM J PHYSIOL-RENAL, V269, pF761, DOI 10.1152/ajprenal.1995.269.6.F761; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; CHERNOVA MN, 1995, J MEMBRANE BIOL, V148, P203; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; COHEN EP, 1992, J AM SOC NEPHROL, V3, P264; Dubose TDJ, 1995, METABOLIC MOL BASES, P3655; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; HUMPHREYS BD, 1995, AM J PHYSIOL-CELL PH, V268, pC201, DOI 10.1152/ajpcell.1995.268.1.C201; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; Jarolim P, 1996, BLOOD, V88, P4366; JAROLIM P, 1995, BLOOD, V85, P634, DOI 10.1182/blood.V85.3.634.bloodjournal853634; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENKINS PB, 1993, BRIT J HAEMATOL, V85, P816, DOI 10.1111/j.1365-2141.1993.tb03232.x; Jiang LW, 1997, AM J PHYSIOL-CELL PH, V272, pC191, DOI 10.1152/ajpcell.1997.272.1.C191; Karolyi L, 1997, HUM MOL GENET, V6, P17; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; Kraut JA, 1997, AM J PHYSIOL-RENAL, V272, pF744, DOI 10.1152/ajprenal.1997.272.6.F744; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEWIS SE, 1988, P NATL ACAD SCI USA, V85, P1962, DOI 10.1073/pnas.85.6.1962; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; Malek AM, 1997, BIOTECHNIQUES, V22, P1150; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; RODRIGUEZSORIAN.J, 1992, PEDIAT KIDNEY DIS, P1737; Rysava R, 1997, NEPHROL DIAL TRANSPL, V12, P1869, DOI 10.1093/ndt/12.9.1869; SAHR KE, 1994, GENOMICS, V24, P491, DOI 10.1006/geno.1994.1658; Sahr KE, 1996, BLOOD, V88, P4500, DOI 10.1182/blood.V88.12.4500.bloodjournal88124500; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SCHOFIELD AE, 1994, BLOOD, V84, P2000; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; STEWART EA, 1989, GENOMICS, V5, P633, DOI 10.1016/0888-7543(89)90034-7; WINGO CS, 1995, AM J PHYSIOL-RENAL, V269, pF1, DOI 10.1152/ajprenal.1995.269.1.F1; YANNOUKAKOS D, 1991, BLOOD, V78, P1117; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741	42	153	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6380	6388		10.1074/jbc.273.11.6380	http://dx.doi.org/10.1074/jbc.273.11.6380			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497368	hybrid, Green Published			2022-12-27	WOS:000072488500060
J	Long, FX; Sonenshein, GE; Linsenmayer, TF				Long, FX; Sonenshein, GE; Linsenmayer, TF			Multiple transcriptional elements in the avian type X collagen gene - Identification of Sp1 family proteins as regulators for high level expression in hypertrophic chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR WEIGHT COLLAGEN; CARTILAGE MATRIX; FIBRIL ASSOCIATION; CHICK-EMBRYO; PROMOTER; GROWTH; DIFFERENTIATION; PHOSPHORYLATION; PROTEOGLYCAN; TIBIOTARSUS	During the cartilage-to-bone transition, participating chondrocytes eventually undergo hypertrophy and are replaced by bone and marrow. Type X collagen is sythesized by chondrocytes specifically when they become hypertrophic, and this specificity is primarily regulated at the level of transcription, Previously, we demonstrated that a proximal promoter region from nucleotide -562 to +86 contained cis-acting elements that directed high level expression of a reporter gene in a cell specific manner (Long, F., and Linsenmayer, T. F. (1995) J. Biol. Chem. 270, 31310-31314). In the present study, we have further dissected this region by generating a series of constructs and examining their expression in hypertrophic versus nonhypertrophic chondrocytes, Several positive and negative elements have been delineated within the proximal promoter region to mediate the regulation of transcription in hypertrophic chondrocytes. Most notably, a sequence from nucleotide -139 to +5 was sufficient to direct high level expression in this cell type, Electrophoresis mobility shift assay and supershift experiments identified within this sequence two 10-base pair noncanonical binding sites for Sp1 proteins, Mutations within the Sp1 binding sites either diminished or abolished the expression driven by the sequence from -139 to +5. These results indicate that the Spl proteins mediate the cell-specific expression of type X collagen.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Tufts University; Boston University	Linsenmayer, TF (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 13262] Funding Source: Medline; NICHD NIH HHS [HD 23681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABMAYR SM, 1995, CURRENT PROTOCOLS MO; CAPASSO O, 1984, EMBO J, V3, P823, DOI 10.1002/j.1460-2075.1984.tb01891.x; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; CHEN Q, 1992, BONE MINER, V17, P223, DOI 10.1016/0169-6009(92)90741-U; CHEN Q, 1990, P NATL ACAD SCI USA, V87, P8046, DOI 10.1073/pnas.87.20.8046; CHEN Q, 1993, DEV DYNAM, V196, P47, DOI 10.1002/aja.1001960106; CHEN Q, 1992, J CELL BIOL, V117, P687, DOI 10.1083/jcb.117.3.687; CHODOSH LA, 1995, CURRENT PROTOCOLS MO; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LINSENMAYER TF, 1991, DEVELOPMENT, V111, P191; Long FX, 1995, J BIOL CHEM, V270, P31310, DOI 10.1074/jbc.270.52.31310; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; LUVALLE P, 1989, DEV BIOL, V133, P613, DOI 10.1016/0012-1606(89)90065-1; MUELLER PR, 1994, CURRENT PROTOCOLS MO; POOLE AR, 1989, J CELL BIOL, V109, P2547, DOI 10.1083/jcb.109.5.2547; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; SCHMID TM, 1982, J BIOL CHEM, V257, P2444; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; SHINOMURA T, 1984, DEV BIOL, V103, P211, DOI 10.1016/0012-1606(84)90022-8; STOCUM DL, 1979, J EMBRYOL EXP MORPH, V54, P155; THOMAS JT, 1995, GENE, V160, P291, DOI 10.1016/0378-1119(95)00189-D; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	37	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6542	6549		10.1074/jbc.273.11.6542	http://dx.doi.org/10.1074/jbc.273.11.6542			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497390	hybrid			2022-12-27	WOS:000072488500082
J	Talis, AL; Huibregtse, JM; Howley, PM				Talis, AL; Huibregtse, JM; Howley, PM			The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; INVITRO MUTAGENESIS; CARRIER PROTEIN; DEGRADATION; LIGASE; E6-AP; IDENTIFICATION; ASSOCIATION; ONCOPROTEIN; TYPE-16	The E6 protein encoded by the oncogenic human papillomaviruses (HPVs) targets p53 for ubiquitin-dependent proteolysis. E6-mediated p53 degradation requires the 100-kDa cellular protein E6-associated protein (E6AP). E6AP and E6 together provide the E3-ubiquitin protein ligase activity in the transfer of ubiquitin to p53, In vitro studies have shown that E6AP can form a high energy thiolester bond with ubiquitin and, in the presence of E6, transfer ubiquitin to p53. In this study we have addressed the role of E6AP in vivo in the degradation of p53. Overexpression of mild-type E6AP in HeLa cells, which are HPV18-positive and express E6, resulted in a decreased steady state level of p53 and a decrease in the half-life of p53. Mutant forms of E6AP proteins were identified that were catalytically incapable of participating in E6-dependent ubiquitination of p53 and functioned in a dominant-negative manner in that they inhibited the E6-mediated ubiquitination of p53 by the wild-type E6AP in vitro. Transient transfection of one of these dominant negative (dn) mutants resulted in an increase in both the steady state level and half-life of p53 in vivo in HeLa cells. Consistent with this observation, overexpression of the dn E6AP resulted in a marked G(1) shift in the cell cycle profile. In contrast, dn E6AP had no effect on p53 levels in U2OS cells, an HPV-negative cell line that contains wild-type p53. These studies provide evidence for the involvement of E6AP in E6-mediated p53 degradation in vivo and also indicate that E6AP may not be involved in the regulation of p53 ubiquitination in the absence of E6.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA	Harvard University; Harvard Medical School; Rutgers State University New Brunswick	Howley, PM (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	phowley@warren.med.harvard.edu		Howley, Peter/0000-0002-8668-9579	NATIONAL CANCER INSTITUTE [R01CA064888, P01CA050661, T32CA009031] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09031-19, R01-CA 64888-2, P01-CA050661-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Maki CG, 1996, CANCER RES, V56, P2649; MATSUKURA T, 1997, NAT GENET, V15, P1; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; REISS Y, 1989, J BIOL CHEM, V264, P10378; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	37	198	204	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6439	6445		10.1074/jbc.273.11.6439	http://dx.doi.org/10.1074/jbc.273.11.6439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497376	hybrid			2022-12-27	WOS:000072488500068
J	Eisenthal, R; Cornish-Bowden, A				Eisenthal, R; Cornish-Bowden, A			Prospects for antiparasitic drugs - The case of Trypanosoma brucei, the causative agent of African sleeping sickness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROL ANALYSIS PROGRAM; COMBINATORIAL CHEMISTRY; INHIBITION; METABOLISM; SIMULATOR; SCAMP	Glycolysis in the bloodstream form of Trypanosoma brucei provides a convenient context for studying the prospects for using enzyme inhibitors as antiparasitic drugs, As the recently developed model of this system (Bakker, B. M., Michels, P. A. M., Opperdoes, F. R., and Westerhoff, H. V. (1997) J. Biol. Chem. 272, 3207-3215) contains 20 enzyme-catalyzed reactions or transport steps, there are apparently numerous potential targets for drugs, However, as mast flux control resides in the glucose-transport step, this is the only step for which inhibition can be expected to produce large effects on flux, and in the computer model such effects prove to be surprisingly small (although larger than those obtained by inhibiting any other step). It follows that there is little prospect of killing trypanosomes by depressing their glycolysis to a level incapable of sustaining life. The alternative is to use inhibition to increase the concentration of a metabolite sufficiently to interfere with the viability of the organism, For this purpose, only uncompetitive inhibition of pyruvate export proves effective in the model; in all ether eases studied, the effects on metabolite concentrations are little more than trivial, This observation can be explained by the fact that nearly all of the metabolite concentrations in the system are held within relatively narrow ranges by stoichiometric constraints.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Inst Federat Biol Struct & Microbiol, Chim Bacterienne Lab, CNRS, F-13402 Marseille 20, France	University of Bath; Centre National de la Recherche Scientifique (CNRS)	Eisenthal, R (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.		Cornish-Bowden, Athel J/E-3474-2010; Cornish-Bowden, Athel/G-7362-2019	Cornish-Bowden, Athel/0000-0001-6670-3006				Bakker BM, 1995, J BIOENERG BIOMEMBR, V27, P513, DOI 10.1007/BF02110191; Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; Bakker BM, 1996, BIOTHERMOKINETICS LI, P136; Blundell TL, 1996, NATURE, V384, P23; BOOCOCK MR, 1983, FEBS LETT, V154, P127, DOI 10.1016/0014-5793(83)80888-6; Broach JR, 1996, NATURE, V384, P14; CLARKSON AB, 1976, SCIENCE, V194, P204, DOI 10.1126/science.986688; Cornish-Bowden A, 1995, FUNDAMENTALS ENZYME, P247; CORNISHBOWDEN A, 1986, FEBS LETT, V203, P3, DOI 10.1016/0014-5793(86)81424-7; CORNISHBOWDEN A, 1991, COMPUT APPL BIOSCI, V7, P89; EISENTHAL R, 1985, FEBS LETT, V181, P23, DOI 10.1016/0014-5793(85)81106-6; EISENTHAL R, 1985, FEBS LETT, V190, P185; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FAIRLAMB AH, 1980, EXP PARASITOL, V49, P366, DOI 10.1016/0014-4894(80)90072-7; FAIRLAMB AH, 1977, NATURE, V265, P270, DOI 10.1038/265270a0; GRANT PT, 1957, BIOCHEM J, V66, P242, DOI 10.1042/bj0660242; HANNAERT V, 1994, J BIOENERG BIOMEMBR, V26, P205, DOI 10.1007/BF00763069; Hofmeyr JHS, 1997, COMPUT APPL BIOSCI, V13, P377; Hogan JC, 1996, NATURE, V384, P17; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P431; Matteucci MD, 1996, NATURE, V384, P20; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Petsko GA, 1996, NATURE, V384, P7; REDER C, 1988, J THEOR BIOL, V135, P175, DOI 10.1016/S0022-5193(88)80073-0; RYLEY JF, 1962, BIOCHEM J, V85, P211, DOI 10.1042/bj0850211; RYLEY JF, 1956, BIOCHEM J, V62, P215, DOI 10.1042/bj0620215; SAURO HM, 1993, COMPUT APPL BIOSCI, V9, P441; SAURO HM, 1991, MATH COMPUT MODEL, V15, P15, DOI 10.1016/0895-7177(91)90038-9; Verdine GL, 1996, NATURE, V384, P11	30	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5500	5505		10.1074/jbc.273.10.5500	http://dx.doi.org/10.1074/jbc.273.10.5500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488673	hybrid			2022-12-27	WOS:000072345000016
J	Krych, M; Hauhart, R; Atkinson, JP				Krych, M; Hauhart, R; Atkinson, JP			Structure-function analysis of the active sites of complement receptor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C3B C4B RECEPTOR; C3B/C4B RECEPTOR; LIGAND-BINDING; DELETION MUTAGENESIS; REPEATING DOMAINS; CR-1; IDENTIFICATION; PROTEIN; CD35; SUBSTITUTION	Two functionally distinct but homologous sites in complement receptor type 1 (CR1) (CD35) were further characterized by homologous substitution mutagenesis of two CR1 derivatives, each containing one site. In both sites, reducing negative and/or increasing positive charge augmented interaction with iC3/C3b and C4b, supporting a role of ionic forces in the binding reaction. In one case, substitution of Asp at the end of complement control protein repeat (CCP) 2 with an Asn transformed the protein, with negligible cofactor activity and iC3 binding, into a mutant with activities similar to native CR1. Consequently, this protein, one-fourth the size of CRI, is a therapeutic candidate for a complement inhibitor. Another important observation is that the residues between two CCPs contribute to activity, probably because they influence positioning of one CCP relative to the next. The initial characterization of the third CCP of an active site led to identification of three peptides necessary for binding. In line with earlier findings for the first two CCPs, interactions with iC3/C3b are similar but not identical to those with C4b, implying overlapping but distinct binding domains. Moreover, changes in cofactor activity usually, but not always, parallel alterations in binding, indicating that these two activities are separable. We also mapped epitopes for a blocking and a function enhancing monoclonal antibody. Their effects can be explained by epitope location. The first antibody binds near functionally important residues. The second may shield inhibitory (negatively charged) residues. These results represent a comprehensive analysis of the active sites of CR1, which is built of modules found in more than 50 mammalian proteins.	Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA	Washington University (WUSTL)	Atkinson, JP (corresponding author), Washington Univ, Sch Med, Dept Med, Div Rheumatol, 660 S Euclid Ave, Box 8045, St Louis, MO 63110 USA.			Atkinson, John/0000-0002-2514-3441	NIAID NIH HHS [R01 AI41592] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS EM, 1991, J IMMUNOL, V147, P3005; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; Birmingham DJ, 1996, J IMMUNOL, V157, P2586; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; COLE JL, 1985, P NATL ACAD SCI USA, V82, P859, DOI 10.1073/pnas.82.3.859; COYNE KE, 1992, J IMMUNOL, V149, P2906; DYKMAN TR, 1983, P NATL ACAD SCI-BIOL, V80, P1698, DOI 10.1073/pnas.80.6.1698; DYKMAN TR, 1983, J EXP MED, V157, P2160, DOI 10.1084/jem.157.6.2160; HOGG N, 1984, EUR J IMMUNOL, V14, P236, DOI 10.1002/eji.1830140307; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; KRYCH M, 1994, J BIOL CHEM, V269, P13273; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; Nickells M, 1998, CLIN EXP IMMUNOL, V112, P27; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; REILLY BD, 1994, J BIOL CHEM, V269, P7696; SEYA T, 1990, J BIOCHEM, V107, P310, DOI 10.1093/oxfordjournals.jbchem.a123044; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Subramanian VB, 1996, J IMMUNOL, V157, P1242; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; WONG WW, 1989, J EXP MED, V169, P847, DOI 10.1084/jem.169.3.847	26	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8623	8629		10.1074/jbc.273.15.8623	http://dx.doi.org/10.1074/jbc.273.15.8623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535836	hybrid			2022-12-27	WOS:000072990800013
J	Deed, RW; Jasiok, M; Norton, JD				Deed, RW; Jasiok, M; Norton, JD			Lymphoid-specific expression of the Id3 gene in hematopoietic cells - Selective antagonism of E2A basic helix-loop-helix protein associated with Id3-induced differentiation of erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTUALLY EXCLUSIVE EXPRESSION; DNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; IN-VIVO; ERYTHROID-DIFFERENTIATION; MYELOID DIFFERENTIATION; LEUKEMIA; TAL1; ONCOPROTEIN; INHIBITION	Accumulating evidence implicates functions of the Id family of helix-loop-helix proteins in the regulation of cell growth and differentiation in metazoa, Within the mammalian hematopoietic organ, expression of the Id3 gene is restricted to the lymphoid cell compartment. We show here that in non-lymphoid hematopoietic cells, repression of transcription is correlated with hypermethylation of sequences in the vicinity of the upstream regulatory region of the Id3 gene, suggestive of a strict developmental control of expression of this gene in lymphoid versus non-lymphoid hematopoietic cells, Enforced ectopic expression of Id3 in KF562 erythroid progenitor cells promotes erythroid differentiation and is correlated with a quantitative/qualitative shift in the profile of interacting TAL1 and E protein heterodimers that bind to a consensus E box sequence in in vitro band shift assays, consistent with selective targeting of E2A E protein(s) by Id3 and suggesting a possible mechanism involving TAL1-mediatod differentiation, By using a Gal 4-VP16 two-hybrid competition assay and an E box-dependent reporter assay, we demonstrate directly that the E2A protein E47 preferentially associates with Id3 in vivo, These observations provide a paradigm for understanding how overlapping but distinct specificities of individual Id proteins may constitute a developmentally regulated program underlying cell determination in diverse lineages.	Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Dept Gene Regulat, Manchester M20 9BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Norton, JD (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Dept Gene Regulat, Wilmslow Rd, Manchester M20 9BX, Lancs, England.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; ATHERTON GT, 1996, CELL GROWTH DIFFER, V7, P1353; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P2512; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEED RW, 1994, BBA-GENE STRUCT EXPR, V1219, P160, DOI 10.1016/0167-4781(94)90261-5; DEED RW, 1993, ONCOGENE, V8, P599; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; DEED RW, 1996, BIOCHEM SOC T, V24, P5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; ELLMEIER W, 1995, DEV DYNAM, V203, P163, DOI 10.1002/aja.1002030205; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; GOLDFARB AN, 1995, BLOOD, V85, P465; HARA E, 1994, J BIOL CHEM, V269, P2139; HARLOW A, 1988, ANTIBODIES LAB MANUA; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hoang T, 1996, BLOOD, V87, P102; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishiguro A, 1995, LEUKEMIA RES, V19, P989, DOI 10.1016/0145-2126(95)00084-4; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JONES AP, 1990, ADV CANCER RES, V54, P1; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; Loveys DA, 1996, NUCLEIC ACIDS RES, V24, P2813, DOI 10.1093/nar/24.14.2813; MEYER KB, 1995, EUR J IMMUNOL, V25, P1770, DOI 10.1002/eji.1830250643; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; PEVERALI FA, 1994, EMBO J, V13, P3291; PHILLIPS SEV, 1994, STRUCTURE, V2, P1, DOI 10.1016/S0969-2126(00)00002-2; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; RIECHMANN V, 1995, CELL GROWTH DIFFER, V6, P837; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wibley J, 1996, BBA-PROTEIN STRUCT M, V1294, P138, DOI 10.1016/0167-4838(96)00008-8	64	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8278	8286		10.1074/jbc.273.14.8278	http://dx.doi.org/10.1074/jbc.273.14.8278			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525934	hybrid			2022-12-27	WOS:000072876300068
J	Hammache, D; Pieroni, G; Yahi, N; Delezay, O; Koch, N; Lafont, H; Tamalet, C; Fantini, J				Hammache, D; Pieroni, G; Yahi, N; Delezay, O; Koch, N; Lafont, H; Tamalet, C; Fantini, J			Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-LYMPHOTROPIC RETROVIRUS; CELL-LINES; V3 LOOP; MEMBRANE-FUSION; CD4-INDEPENDENT INFECTION; GP120 BINDING; SOLUBLE CD4; TYPE-1; RECEPTOR	Cellular glycosphingolipids mediate the fusion between some viruses and the plasma membrane of target cells, In the present study, we have analyzed the interaction of human immunodeficiency virus (HIV)-1 and HIV-2 surface envelope glycoproteins from distinct viral isolates with monolayers of various glycosphingolipids at the air-water interface, The penetration of the viral glycoproteins into glycosphingolipid monolayers was detected as an increase in the surface pressure, We found that HIV-1 recombinant gp120 (IIIB isolate) could penetrate into a monomolecular film of alpha-hydroxylated galactosylceramide (GalCer-HFA), while ceramides, GluCer, and nonhydroxylated GalCer were totally inactive, The glycoproteins isolated from HIV-1 isolates LAI and NDK and from HIV-2(ROD) could also interact with a GalCer-HFA monolayer, whereas gp120 from HIV-1(SEN) and HIV-1(89.6) did not react, These data correlated with the ability of the corresponding viruses to gain entry into the CD4(-)/GalCer(+) cell line HT-29, demonstrating the determinant role of GalCer-HFA in this CD4-independent pathway of HIV-1 and HIV-2 infection. In contrast, all HIV-1 and HIV-2 glycoproteins tested were found to interact with a monolayer of GM3, a ganglioside abundantly expressed in the plasma membrane of CD4(+) lymphocytes and macrophages. A V3 loop-derived synthetic peptide inhibitor of HIV-1 and HIV-2 infection in both CD4(-) and CD4(+) cells could penetrate into various glycosphingolipid monolayers, including GalCer-HFA and GM3, Taken together, these data suggest that the adsorption of human immunodeficiency viruses to the surface of target cells involves an interaction between the V3 domain of the surface envelope glycoprotein and specific glycosphingolipids, i.e. GalCer-HFA for CD4(-) cells and GM3 for CD4(+) cells.	Fac Sci & Tech St Jerome, Lab Biochim & Biol Nutr, CNRS, UPRESA 6033, F-13397 Marseille 20, France; INSERM, U130, F-13009 Marseille, France; Hop Enfants La Timone, UF SIDA, Virol Lab, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Fantini, J (corresponding author), Fac Sci & Tech St Jerome, Lab Biochim & Biol Nutr, CNRS, UPRESA 6033, F-13397 Marseille 20, France.			Fantini, Jacques/0000-0001-8653-5521				BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; COOK DG, 1994, VIROLOGY, V201, P206, DOI 10.1006/viro.1994.1287; Delezay O, 1997, AIDS, V11, P1311, DOI 10.1097/00002030-199711000-00004; Delezay O, 1996, PERSPECT DRUG DISCOV, V5, P192, DOI 10.1007/BF02174014; Delezay O, 1996, BIOCHEMISTRY-US, V35, P15663, DOI 10.1021/bi961205g; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; ELLRODT A, 1984, LANCET, V1, P1383; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; Fantini J, 1997, J BIOL CHEM, V272, P7245, DOI 10.1074/jbc.272.11.7245; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GILLJAM G, 1993, AIDS RES HUM RETROV, V9, P431, DOI 10.1089/aid.1993.9.431; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, 1995, J VIROL, V69, P7383, DOI 10.1128/JVI.69.12.7383-7390.1995; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HUANG RTC, 1983, LIPIDS, V18, P489, DOI 10.1007/BF02535790; JOHNSTON DS, 1988, BIOCHIM BIOPHYS ACTA, V937, P10, DOI 10.1016/0005-2736(88)90222-2; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LEAR JD, 1993, VIRAL FUSION MECH, P55; LONG D, 1994, J VIROL, V68, P5890, DOI 10.1128/JVI.68.9.5890-5898.1994; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAGGIO B, 1994, PROG BIOPHYS MOL BIO, V62, P55, DOI 10.1016/0079-6107(94)90006-X; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; MOORE JP, 1990, AIDS, V4, P297, DOI 10.1097/00002030-199004000-00003; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Sorice M, 1997, J LIPID RES, V38, P969; SYMINGTON FW, 1985, LYMPHOKINES, V12, P201; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; THOMPSON TE, 1985, ANN REV BIOPHYS CHEM, V14, P387; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; YAHI N, 1995, J VIROL, V69, P320, DOI 10.1128/JVI.69.1.320-325.1995; YAHI N, 1995, P NATL ACAD SCI USA, V92, P4867, DOI 10.1073/pnas.92.11.4867; YAHI N, 1994, VIROLOGY, V204, P550, DOI 10.1006/viro.1994.1568	45	121	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7967	7971		10.1074/jbc.273.14.7967	http://dx.doi.org/10.1074/jbc.273.14.7967			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525894	hybrid			2022-12-27	WOS:000072876300028
J	Hann, C; Evans, DL; Fertala, J; Benedetti, P; Bjornsti, MA; Hall, DJ				Hann, C; Evans, DL; Fertala, J; Benedetti, P; Bjornsti, MA; Hall, DJ			Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG CAMPTOTHECIN; C-MYC PROMOTER; REPLICATION FORKS; YEAST; TRANSCRIPTION; POISONS; FIBROBLASTS; MECHANISMS; INHIBITORS; RESISTANCE	The yeast Saccharomyces cerevisiae has been useful in establishing the phenotypic effects of specific mutations on the enzymatic activity and camptothecin sensitivity of yeast and human DNA topoisomerase I. To determine whether these phenotypes were faithfully reiterated in higher eukaryotic cells, wild-type and mutant yeast Top1 proteins were epitope-tagged at the amino terminus and transiently overexpressed in mammalian COS cells, Camptothecin preferentially induced apoptosis in cells expressing wild-type eScTop1p yet did not appreciably increase the cytotoxic response of cells expressing a catalytically inactive (eSctop1Y727F) or a catalytically active, camptothecin-resistant eSctop1vac mutant, Using an epitope-specific antibody, immobilized precipitates of eScTop1p were active in DNA relaxation assays, whereas immunoprecipitates of eScTop1Y727Fp were not, Thus, the enzyme retained catalytic activity while tethered to a support, Interestingly, the mutant eSctop1T722A, which mimics camptothecin-induced cytotoxicity in yeast through stabilization of the covalent enzyme-DNA intermediate, induced apoptosis in COS cells in the absence of camptothecin. This correlated with increased DNA cleavage in immunoprecipitates of eScTop1T722Ap, in the absence of the drug, The observation that the phenotypic consequences of expressing wild-type and mutant yeast enzymes were reiterated in mammalian cells suggests that the mechanisms underlying cellular responses to DNA topoisomerase I-mediated DNA damage are conserved between yeast and mammalian cells.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; CNR, Ist Biol Cellulare, I-00137 Rome, Italy	Jefferson University; Consiglio Nazionale delle Ricerche (CNR)	Hall, DJ (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, 233 S 10th St, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA070406, R01CA067032] Funding Source: NIH RePORTER; NCI NIH HHS [CA67032, CA70406] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; BAKER SD, 1995, CYTOMETRY, V19, P134, DOI 10.1002/cyto.990190208; BENEDETTI P, 1993, CANCER RES, V53, P4343; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BJORNSTI MA, 1994, CANCER CHEMOTH PHARM, V34, pS1, DOI 10.1007/BF00684856; Bjornsti MA, 1991, CURR OPIN STRUC BIOL, V1, P99, DOI 10.1016/0959-440X(91)90017-N; Buckwalter CA, 1996, CANCER RES, V56, P1674; CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Danks MK, 1996, CANCER RES, V56, P1664; DARPA P, 1990, CANCER RES, V50, P6919; ENG WK, 1988, MOL PHARMACOL, V34, P755; FOX MH, 1991, J CELL SCI, V99, P247; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GONG JP, 1993, J CELL PHYSIOL, V157, P263; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMANN SH, 1995, CANCER RES, V55, P1255; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; LEVIN NA, 1993, GENETICS, V133, P799; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1992, CANCER RES, V52, P525; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MOBERG KH, 1992, ONCOGENE, V7, P411; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PYRC J, 1994, INT J ONCOL, V5, P1085; SADOFF BU, 1995, GENETICS, V141, P465; Shykind BM, 1997, GENE DEV, V11, P397, DOI 10.1101/gad.11.3.397; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	38	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8425	8433		10.1074/jbc.273.14.8425	http://dx.doi.org/10.1074/jbc.273.14.8425			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525954	hybrid			2022-12-27	WOS:000072876300088
J	Inaba, K; Ishimori, K; Imai, K; Morishima, I				Inaba, K; Ishimori, K; Imai, K; Morishima, I			Structural and functional effects of pseudo-module substitution in hemoglobin subunits - New structural and functional units in globin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; SEQUENCE-SPECIFIC PROTEOLYSIS; ESCHERICHIA-COLI; ALPHA-1-BETA-2 INTERFACE; QUATERNARY STRUCTURES; ABNORMAL-HEMOGLOBINS; PROTON RESONANCES; ADULT HEMOGLOBIN; HYDROGEN-BONDS	Functional and structural significance of the "module" in proteins has been investigated for globin proteins. Our previous studies have revealed that some modules in globins are responsible for regulating the subunit association and heme environmental structures, whereas the module substitution often induces fatal structural destabilization, resulting in failure of functional regulation. In this paper, to gain further insight into functional and structural significance of the modular structure in globins, we focused upon the "pseudo-module" in globin structure where boundaries are located at the center of modules. Although the pseudo-module has been supposed not to retain a compactness, the beta alpha(PM3)-subunit, in which one of the pseudo-modules, the F1-H6 regoin, of the alpha-subunit is implanted into the beta-subunit, conserved stable globin structure, and its association property was converted into that of the alpha-subunit, as the case for the module substituted globin, the beta alpha(M4)-subunit. These results suggest that modules are not unique structural and functional units for globins. Interestingly, however, the recent reconsideration of the module boundary indicates that the modules in globins can be further divided into two small modules, and one of the boundaries for the new small modules coincides with that of the pseudo-module we substituted in this study. Although it would be premature to conclude the significance of the modular structure in globins, it can be safely said that we have found new structural units in globin structure, probably new modules.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Osaka Univ, Sch Med, Dept Physicochem Physiol, Osaka 5650871, Japan	Kyoto University; Osaka University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Inaba, Kenji/0000-0001-8229-0467				ASAKURA T, 1976, J MOL BIOL, V104, P185, DOI 10.1016/0022-2836(76)90008-5; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BEYCHOK S, 1967, J BIOL CHEM, V242, P2460; BLAKE CCF, 1979, NATURE, V277, P598, DOI 10.1038/277598a0; CRAESCU CT, 1988, EUR J BIOCHEM, V176, P171, DOI 10.1111/j.1432-1033.1988.tb14265.x; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; EATON WA, 1980, NATURE, V284, P183, DOI 10.1038/284183a0; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; Go M, 1995, TRACING BIOLOGICAL EVOLUTION IN PROTEIN AND GENE STRUCTURES, P229; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HASHIMOTO M, 1993, BIOCHEMISTRY-US, V32, P13688, DOI 10.1021/bi00212a038; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; IMAI K, 1994, METHOD ENZYMOL, V232, P559; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1991, J MOL BIOL, V218, P769, DOI 10.1016/0022-2836(91)90265-8; Imai K, 1981, Methods Enzymol, V76, P438; Imai K., 1982, ALLOSTERIC EFFECT HA; Inaba K, 1997, J BIOL CHEM, V272, P30054, DOI 10.1074/jbc.272.48.30054; ISHIMORI K, 1994, BIOCHEMISTRY-US, V33, P2546, DOI 10.1021/bi00175a025; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JOHNSON ME, 1977, J AM CHEM SOC, V99, P1245, DOI 10.1021/ja00446a041; KINCAID J, 1979, P NATL ACAD SCI USA, V76, P549, DOI 10.1073/pnas.76.2.549; KONNO T, 1993, BIOCHIM BIOPHYS ACTA, V1162, P93, DOI 10.1016/0167-4838(93)90133-C; LAMAR GN, 1984, J MOL BIOL, V178, P929, DOI 10.1016/0022-2836(84)90320-6; LINDSTROM TR, 1972, BIOCHEMISTRY-US, V11, P1677, DOI 10.1021/bi00759a023; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; MIURA S, 1984, BIOCHEMISTRY-US, V23, P2492, DOI 10.1021/bi00306a027; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; NAGAI K, 1982, BIOCHEMISTRY-US, V21, P842, DOI 10.1021/bi00534a005; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAGAI M, 1975, J BIOL CHEM, V250, P3169; NOGUTI T, 1993, PROTEINS, V16, P357, DOI 10.1002/prot.340160405; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; ROCHETTE J, 1984, FEBS LETT, V166, P8, DOI 10.1016/0014-5793(84)80034-4; RUSSU IM, 1987, BIOCHIM BIOPHYS ACTA, V914, P40, DOI 10.1016/0167-4838(87)90159-2; SCHAEFFER C, 1988, EUR J BIOCHEM, V173, P317, DOI 10.1111/j.1432-1033.1988.tb14001.x; SHULMAN RG, 1970, J MOL BIOL, V53, P143, DOI 10.1016/0022-2836(70)90050-1; TAKAHASHI S, 1980, BIOCHEMISTRY-US, V19, P5196, DOI 10.1021/bi00564a007; TAKAHASHI S, 1982, BIOPHYS J, V39, P33, DOI 10.1016/S0006-3495(82)84487-1; THILLET J, 1981, BIOCHIM BIOPHYS ACTA, V670, P260, DOI 10.1016/0005-2795(81)90018-0; VALDES R, 1977, J BIOL CHEM, V252, P74; WADA Y, 1989, BIOMED ENVIRON MASS, V18, P563, DOI 10.1002/bms.1200180809; Wakasugi K, 1997, BIOPHYS CHEM, V68, P265, DOI 10.1016/S0301-4622(97)80556-X; WAKASUGI K, 1994, J BIOL CHEM, V269, P18750; WEATHERALL DJ, 1977, BRIT J HAEMATOL, V35, P177, DOI 10.1111/j.1365-2141.1977.tb00575.x; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; Yura K, 1995, TRACING BIOLOGICAL EVOLUTION IN PROTEIN AND GENE STRUCTURES, P187	54	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8080	8087		10.1074/jbc.273.14.8080	http://dx.doi.org/10.1074/jbc.273.14.8080			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525909	hybrid			2022-12-27	WOS:000072876300043
J	Taylor, JM; Hildebrand, JD; Mack, CP; Cox, ME; Parsons, JT				Taylor, JM; Hildebrand, JD; Mack, CP; Cox, ME; Parsons, JT			Characterization of Graf, the GTPase-activating protein for Rho associated with focal adhesion kinase - Phosphorylation and possible regulation by mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIN STRESS FIBERS; MAP KINASE; SURFACE-MORPHOLOGY; BINDING PROTEINS; EXCHANGE FACTOR; N-CHIMAERIN; PC12 CELLS; RAS; PATHWAYS	Graf is a GTPase-activating protein for Rho that interacts with focal adhesion kinase and co-localizes with the actin cytoskeleton (Hildebrand, J. D., Taylor, J. M. and Parsons, J. T. (1996) Mol. Cell. Biol. 16, 3169-3178), We examined the expression and regulation of Graf as a prelude to understanding the role of Graf in mediating signal transduction in vivo. We demonstrated that Graf is a ubiquitously expressed 95-kDa protein with high levels observed in heart and brain and cells derived from these tissues. Stimulation of PC12 cells with epidermal growth factor or nerve growth factor induced a phosphatase-reversible mobility shift upon gel electrophoresis, indicative of phosphorylation. In vitro, purified mitogen-activated protein (MAP) kinase catalyzed the phosphorylation of Graf on serine 510, suggesting that Graf phosphorylation may be mediated through MAP kinase signaling, In addition, the mutation of serine 510 to alanine inhibited the epidermal growth factor-induced mobility shift of mutant Graf protein in vivo, consistent with serine 510 being the site of in vivo phosphorylation. Based on these data we suggest that phosphorylation of Graf by MAP kinase or related kinases may be a mechanism by which growth factor signaling modulates Rho-mediated cytoskeletal changes in PC12 and perhaps other cells.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.			Taylor, Joan/0000-0002-8794-5167	NCI NIH HHS [CA40042, CA29243] Funding Source: Medline; NIGMS NIH HHS [H1-F32-GM18297-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA029243, R01CA029243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD R, 1990, ANAL BIOCHEM, V187, P56, DOI 10.1016/0003-2697(90)90417-8; AHMED S, 1993, J BIOL CHEM, V268, P10709; BAUMANN WK, 1997, FEBS LETT, V8, P257; BEEZIN IV, 1997, FEBS LETT, V8, P261; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CONNOLLY JL, 1979, J CELL BIOL, V82, P820, DOI 10.1083/jcb.82.3.820; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HALL A, 1992, AM J RESP CELL MOL, V6, P245, DOI 10.1165/ajrcmb/6.3.245; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SHLAFER M, 1982, J THORAC CARDIOV SUR, V83, P830; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	48	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8063	8070		10.1074/jbc.273.14.8063	http://dx.doi.org/10.1074/jbc.273.14.8063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525907	hybrid			2022-12-27	WOS:000072876300041
J	Vallejo, AN; Nestel, AR; Schirmer, M; Weyand, CM; Goronzy, JJ				Vallejo, AN; Nestel, AR; Schirmer, M; Weyand, CM; Goronzy, JJ			Aging-related deficiency of CD28 expression in CD4+ T cells is associated with the loss of gene-specific nuclear factor binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS-RELATED PROTEIN; RHEUMATOID-ARTHRITIS; ENHANCER ACTIVITY; LYMPHOKINE PRODUCTION; TRANSCRIPTION FACTORS; RESPONSIVE ELEMENT; C-FOS; AGE; ACTIVATION; SUBSETS	Changes in T cell populations and concomitant perturbation of T cell effector functions have been postulated to account for many aging-related immune dysfunctions, Here, we report that high frequencies of CD28(null) CD4+ T cells were found in elderly individuals. Because deviations in the function of these unusual CD4+ T cells might be directly related to CD28 deficiency, we examined the molecular basis for the loss of CD28 expression in CD4+ T cells. In reporter gene bioassays, the minimal promoter of the CD28 gene was mapped to the proximal 400 base pairs (bp) of the 5' untranslated region, CD28 deficiency was associated with the loss of two noncompeting binding activities within a 67-bp segment of the minimal promoter, These binding activities were not competed by consensus Ets, Elk, or AP3 motifs that were found within the sequence stretch. The DNA-protein complexes were also not recognized by antibodies to Ets-related transcription factors, Furthermore, introduction of mutations into the 67-bp segment at positions corresponding to the two DNA-protein interaction sites, i.e. nucleotides spanning -206 to -179 and -171 to -148, resulted in the loss of specific nuclear factor binding activities and the abrogation of promoter activity. These observations implicate at least two regulatory motifs in the constitutive expression of CD28. The loss of binding activity of transacting factors specific for these sequences may contribute to the accumulation CD4+CD28(null) T cells during aging.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Div Rheumatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Goronzy, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.		Schirmer, Michael/B-1893-2012; Weyand, Cornelia/AAH-3343-2021	Schirmer, Michael/0000-0001-9208-7809; Goronzy, Jorg/0000-0001-7670-1856	NIAMS NIH HHS [R01 AR42527, R01-AR41974] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041974, R01AR042527] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADLER V, 1995, J CELL PHYSIOL, V164, P26, DOI 10.1002/jcp.1041640105; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; CORRY DB, 1994, J IMMUNOL, V153, P4142; Degelau John J., 1994, Aging Immunology and Infectious Disease, V5, P27; DOBBER R, 1994, INT IMMUNOL, V6, P1227, DOI 10.1093/intimm/6.8.1227; ERNST DN, 1993, STEM CELLS, V11, P487, DOI 10.1002/stem.5530110618; ERNST DN, 1993, J IMMUNOL, V151, P575; FAGIOLO U, 1993, AGING-CLIN EXP RES, V5, P451, DOI 10.1007/BF03324202; GABRIEL H, 1993, EUR J IMMUNOL, V23, P2704, DOI 10.1002/eji.1830231049; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hathcock KS, 1996, ADV IMMUNOL, V62, P131, DOI 10.1016/S0065-2776(08)60429-0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOBBS MV, 1993, J IMMUNOL, V150, P3602; JARMIN DI, 1994, J IMMUNOL, V153, P5720; LEE KP, 1990, J IMMUNOL, V145, P344; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEUNG S, 1993, ONCOGENE, V8, P989; LINSLEY PS, 1993, J IMMUNOL, V150, P3161; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; NAGELKERKEN L, 1991, EUR J IMMUNOL, V21, P273, DOI 10.1002/eji.1830210206; Park W, 1997, EUR J IMMUNOL, V27, P1082, DOI 10.1002/eji.1830270507; RAO VN, 1992, ONCOGENE, V7, P65; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Schmidt D, 1996, MOL MED, V2, P608, DOI 10.1007/BF03401644; Schmidt D, 1996, J CLIN INVEST, V97, P2027, DOI 10.1172/JCI118638; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHANINIAN A, 1993, SCIENCE, V261, P609; SHI J, 1993, J IMMUNOL, V151, P730; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SONG LJ, 1993, EXP GERONTOL, V28, P313, DOI 10.1016/0531-5565(93)90058-L; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TU KY, 1995, MECH AGEING DEV, V82, P105, DOI 10.1016/0047-6374(95)01596-R; TURKA LA, 1990, J IMMUNOL, V144, P1646; UTSUYAMA M, 1993, INT IMMUNOL, V5, P1177, DOI 10.1093/intimm/5.9.1177; Vallejo AN, 1996, J BIOL CHEM, V271, P29813, DOI 10.1074/jbc.271.47.29813; VALLEJO AN, 1995, INT IMMUNOL, V7, P853, DOI 10.1093/intimm/7.5.853; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; Waase I, 1996, ARTHRITIS RHEUM, V39, P904, DOI 10.1002/art.1780390606; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WEYAND CM, 1998, IN PRESS MECH AGEING; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; Yang XH, 1996, J EXP MED, V183, P959, DOI 10.1084/jem.183.3.959; ZAMEL L, 1995, ANNU REV BIOCHEM, V64, P533	54	109	122	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8119	8129		10.1074/jbc.273.14.8119	http://dx.doi.org/10.1074/jbc.273.14.8119			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525915	hybrid			2022-12-27	WOS:000072876300049
J	Zechner, D; Craig, R; Hanford, DS; McDonough, PM; Sabbadini, RA; Glembotski, CC				Zechner, D; Craig, R; Hanford, DS; McDonough, PM; Sabbadini, RA; Glembotski, CC			MKK6 activates myocardial cell NF-kappa B and inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MAPKAP KINASE-2; DNA FRAGMENTATION; GENE-EXPRESSION; JNK ACTIVATION; RAT-HEART; DEATH; STRESS; PHOSPHORYLATION; PATHWAY	In cardiac myocytes the stimulation of p38 mitogen-activated protein kinase activates a hypertrophic growth program and the induction of the cardiac-spe cific genes associated with this program, This study focused on determining whether these novel growth-promoting effects are accompanied by the p35-mediated inhibition of apoptosis, and if so, what signaling pathways might be responsible. Primary neonatal rat ventricular myocytes were driven into apoptosis by treatments known to induce apoptosis in other cell types, e.g, incubation with anisomycin or overexpression constitutively active MEKK-1 (MEKK-1(COOH)), a protein that strongly activates extracellular signal-regulated kinase and N-terminal c-Jun kinase, but not p38. Overexpression of constitutively active MKK6, MKK6 (Glu), which selectively activates p38 in cardiac myocytes, protected cells from either anisomycin- or MEKK-1(COOH)-induced apoptosis. This protection was blocked by SB 203580, a selective p38 inhibitor. MMK6 (Glu) also activated transcription mediated by NF-kappa B, a factor which protects other cell types from apoptosis. The activation of NF-kappa B and the protection from apoptosis mediated by MKK6 (Glu) were both blocked by SE 203580. interestingly, overexpression of a mutant form of I-kappa B alpha, which inhibits nuclear translocation of NF-kappa B, completely blocked MKK6 (Glu)-activated NF-kappa B but had little effect on MKK6s anti-apoptotic effects. These findings suggest that, in part, the overexpression of MKK6 (Glu) may foster growth and survival of cardiac myocytes by protecting them from apoptosis in a p38-dependent manner, Additionally, while NF-kappa B is activated in myocardial cells by p38, this does not appear to be the major mechanism by which MKK6 (Glu) exerts its anti-apoptotic effects in this cell type, suggesting a novel pathway for p38-mediated protection from apoptosis.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	cglembotski@sunstroke.sdsu.edu			NHLBI NIH HHS [HL-56861, HL-46345] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056861, P01HL046345] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLERS A, 1994, MOL PHARMACOL, V46, P1077; Barunwald E, 1996, HEART DIS TXB CARDIO, P1626; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Chin JH, 1996, J CLIN INVEST, V97, P2316, DOI 10.1172/JCI118674; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CLARKE PGH, 1995, NATURE, V378, P230, DOI 10.1038/378230c0; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GLEMBOTSKI CC, 1987, ENDOCRINOLOGY, V121, P843, DOI 10.1210/endo-121-3-843; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JAMES TN, 1994, CIRCULATION, V90, P556, DOI 10.1161/01.CIR.90.1.556; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KAJSTURA J, 1995, EXP CELL RES, V219, P110, DOI 10.1006/excr.1995.1211; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; KRSTIC R, 1973, Z ANAT ENTWICKLUNGS, V140, P337, DOI 10.1007/BF00525060; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; Maulik N, 1996, FEBS LETT, V396, P233, DOI 10.1016/0014-5793(96)01109-X; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Meng XZ, 1996, CARDIOVASC RES, V32, P374, DOI 10.1016/0008-6363(96)00078-8; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; Murray DR, 1996, J NEUROIMMUNOL, V71, P107, DOI 10.1016/S0165-5728(96)00138-5; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Sharma HS, 1996, MOL CELL BIOCHEM, V161, P217, DOI 10.1007/BF00240052; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Takeda K, 1996, J MOL CELL CARDIOL, V28, P209, DOI 10.1006/jmcc.1996.0020; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WALKER PR, 1994, BIOCHEM CELL BIOL, V72, P615, DOI 10.1139/o94-081; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAZAKI T, 1995, J MOL CELL CARDIOL, V27, P133, DOI 10.1016/S0022-2828(08)80013-2; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	76	198	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8232	8239		10.1074/jbc.273.14.8232	http://dx.doi.org/10.1074/jbc.273.14.8232			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525929	hybrid			2022-12-27	WOS:000072876300063
J	Butt, AJ; Harvey, NL; Parasivam, G; Kumar, S				Butt, AJ; Harvey, NL; Parasivam, G; Kumar, S			Dimerization and autoprocessing of the Nedd2 (caspase-2) precursor requires both the prodomain and the carboxyl-terminal regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE PROTEASES; DEATH GENE CED-3; CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; APOPTOSIS; EXPRESSION; ENCODES; SELECTION	Nedd2 (caspase-2) is a cysteine protease of the caspase family that has been demonstrated to play a role in the apoptotic pathway. The 51-kDa precursor of Nedd2 undergoes cleavage into two subunits following various apoptotic stimuli. In this study, we have investigated the dimerization of the Nedd2 precursor (pro-Nedd2) in Saccharomyces cerevisiae and its self-processing activity in vivo. We demonstrate that the expression of pro-Nedd2 in yeast cells results in processing of the precursor. A catalytically inactive pro-Nedd2 mutant dimerized in yeast, and the dimerization required both the prodomain and the carboxyl-terminal residues. Aspartate mutants that block the removal of the p14/p12 subunits, but not the wild-type Nedd2, were shown to dimerize in yeast cells, suggesting that dimerization occurs prior to processing. In vitro processing of pro-Nedd2 by recombinant active Nedd2 defined the aspartate residues that are crucial for processing to occur. Both the in vivo and in vitro processing of pro-Nedd2 directly correlated with its ability to induce cell death in transient overexpression experiments.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Frome Rd,POB 14,Rundle Mall, Adelaide, SA 5000, Australia.		Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Harvey, Natasha/0000-0001-9839-8966; Butt, Alison/0000-0002-6216-5105				ALLET B, 1996, J CELL BIOL, V135, P480; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Asahi M, 1997, J CEREBR BLOOD F MET, V17, P11, DOI 10.1097/00004647-199701000-00003; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; FLAWS JA, 1995, ENDOCRINOLOGY, V136, P5042, DOI 10.1210/en.136.11.5042; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Kinoshita M, 1997, J CEREBR BLOOD F MET, V17, P507, DOI 10.1097/00004647-199705000-00004; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Troy CM, 1997, J NEUROSCI, V17, P1911; VanCriekinge W, 1996, J BIOL CHEM, V271, P27245, DOI 10.1074/jbc.271.44.27245; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6763	6768		10.1074/jbc.273.12.6763	http://dx.doi.org/10.1074/jbc.273.12.6763			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506977	hybrid			2022-12-27	WOS:000072775900027
J	Calkins, CC; Platt, K; Potempa, J; Travis, J				Calkins, CC; Platt, K; Potempa, J; Travis, J			Inactivation of tumor necrosis factor-alpha by proteinases (gingipains) from the periodontal pathogen, Porphyromonas gingivalis - Implications of immune evasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY ENHANCEMENT; BACTEROIDES-GINGIVALIS; CYSTEINE PROTEINASE; CREVICULAR FLUID; DISEASE; CELLS; PURIFICATION; ACTIVATION; GENERATION; CYTOKINES	Porphyromonas gingivalis is one of the major pathogens associated with adult periodontitis, a major chronic inflammatory disease. Potent proteinases elaborated by these bacteria aid directly and indirectly in both the development of the pathophysiology of the disease and in host defense evasion. For these reasons they are considered key virulence factors. To investigate whether possible immune evasion mechanisms involve the dysregulation of the host cytokine network, we examined the ability of P. gingivalis cysteine proteinases, including Arg-specific gingipains HRGP and RGP2 and Lys-specific KGP, to degrade the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). All three gingipains rapidly degraded TNF-alpha as exhibited by immunoblot analysis. Moreover, all biological activity was significantly reduced over extended incubation periods with the proteinases tested, whereas the host neutrophil proteinases were ineffective. These results indicate that the gingipain proteinases elaborated by P. gingivalis are capable of disrupting the cytokine network at the site of infection through the degradation of the proinflammatory cytokine TNF-alpha, suggesting the removal of one of several mediators important to the function of polymorphonuclear leukocytes. Such a mechanism is likely to be utilized by other infective organisms not only for survival but also for growth and proliferation.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Inst Mol Biol, Dept Microbiol & Immunol, PL-31120 Krakow, Poland	University System of Georgia; University of Georgia; Jagiellonian University	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BICKEL M, 1985, J PERIODONTAL RES, V20, P35, DOI 10.1111/j.1600-0765.1985.tb00408.x; BRANDT E, 1992, J IMMUNOL, V149, P1356; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; Discipio RG, 1996, IMMUNOLOGY, V87, P660, DOI 10.1046/j.1365-2567.1996.478594.x; GOH CR, 1991, PROTEIN ENG, V4, P385, DOI 10.1093/protein/4.4.385; GRANT DA, 1988, PERIODONTICS, P348; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; HINODE D, 1992, ARCH ORAL BIOL, V37, P859, DOI 10.1016/0003-9969(92)90120-W; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; IMAMURA T, 1995, INFECT IMMUN, V63, P1999, DOI 10.1128/IAI.63.5.1999-2003.1995; IMAMURA T, 1995, INFECT IMMUN, V63, P4677; Jagels MA, 1996, INFECT IMMUN, V64, P1984, DOI 10.1128/IAI.64.6.1984-1991.1996; KLEINBERG I, 1964, ARCH ORAL BIOL, V9, P493, DOI 10.1016/0003-9969(64)90015-9; KLEINBURG I, 1969, Journal of Periodontal Research, V4, P109, DOI 10.1111/j.1600-0765.1969.tb01955.x; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; MATSUKI Y, 1992, IMMUNOLOGY, V76, P42; MATTHEWS N, 1987, LYMPHOKINES INTERFER, P221; MCPHAILLC, 1993, NATURAL IMMUNE SYSTE, P63; PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x; PIKE R, 1994, J BIOL CHEM, V269, P406; ROSSOMANDO EF, 1990, ARCH ORAL BIOL, V35, P431, DOI 10.1016/0003-9969(90)90205-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SHAW JH, 1987, NEW ENGL J MED, V317, P996, DOI 10.1056/NEJM198710153171605; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STASHENKO P, 1991, J PERIODONTOL, V62, P504, DOI 10.1902/jop.1991.62.8.504; STEPHEN KW, 1980, BRIT J CLIN PHARMACO, V9, P51, DOI 10.1111/j.1365-2125.1980.tb04796.x; Tokoro Y, 1997, CLIN EXP IMMUNOL, V107, P166, DOI 10.1046/j.1365-2249.1997.d01-880.x; Van Damme J, 1994, CYTOKINE HDB, P185; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x; WILLIAMS RC, 1990, NEW ENGL J MED, V322, P373, DOI 10.1056/NEJM199002083220606; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; YAMAZAKI K, 1994, J ORAL PATHOL MED, V23, P347, DOI 10.1111/j.1600-0714.1994.tb00074.x	37	114	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6611	6614		10.1074/jbc.273.12.6611	http://dx.doi.org/10.1074/jbc.273.12.6611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506956	hybrid			2022-12-27	WOS:000072775900006
J	Kim, KH; Voelker, DR; Flocco, MT; Carman, GM				Kim, KH; Voelker, DR; Flocco, MT; Carman, GM			Expression, purification, and characterization of choline kinase, product of the CKI gene from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; PHOSPHATIDYLSERINE DECARBOXYLASE ACTIVITY; PHOSPHATIDATE PHOSPHATASE-ACTIVITY; PHOSPHOLIPID BIOSYNTHESIS; COORDINATE REGULATION; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ETHANOLAMINE KINASE; CDP-DIACYLGLYCEROL; INOSITOL SYNTHESIS; SYNTHASE ACTIVITY	In the yeast Saccharomyces cerevisiae, choline kinase (ATP:choline phosphotransferase, EC 2.7.1.32) is the product of the CKI gene, Choline kinase catalyzes the committed step in the synthesis of phosphatidylcholine by the CDP-choline pathway, The yeast enzyme was overexpressed 106-fold in Sf-9 insect cells and purified 71.2-fold to homogeneity from the cytosolic fraction by chromatography with concanavalin A, Affi-Gel Blue, and Mono Q, The N-terminal amino acid sequence of purified choline kinase matched perfectly with the deduced sequence of the CKI gene, The minimum subunit molecular mass (73 kDa) of purified choline kinase was in good agreement with the predicted size (66.3 kDa) of the CRI gene product, Native choline kinase existed in oligomeric structures of dimers, tetramers, and octomers, The amounts of the tetrameric and octomeric forms increased in the presence of the substrate ATP, Antibodies were raised against the purified enzyme and were used to identify choline kinase in insect cells and in S. cerevisiae, Maximum choline kinase activity was dependent on Mg2+ ions (10 mM) at pH 9.5 and at 30 degrees C, The equilibrium constant (0.2) for the reaction indicated that the reverse reaction was favored in vitro, The activation energy for the reaction was 6.26 kcal/mol, and the enzyme was labile above 30 degrees C. Choline kinase exhibited saturation kinetics with respect to choline and positive cooperative kinetics with respect to ATP (n = 1.4-2.3), Results of the kinetic experiments indicated that the enzyme catalyzes a sequential Bi Bi reaction, The V-max for the reaction was 138.7 mu mol/min/mg, and the K-m values for choline and ATP were 0.27 mM and 90 mu M, respectively, The turnover number per choline kinase subunit was 153 s(-1), Ethanolamine was a poor substrate for the purified choline kinase, and it was also poor inhibitor of choline kinase activity, ADP inhibited choline kinase activity (IC50 = 0.32 mM) in a positive cooperative manner (n = 1.5), and the mechanism of inhibition with respect to ATP and choline was complex. The regulation of choline kinase activity by ATP and ADP may be physiologically relevant.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08903 USA; Natl Jewish Ctr Immunol & Resp Med, Taylor Lab Lung Biochem, Denver, CO 80206 USA; Natl Jewish Ctr Immunol & Resp Med, Anna Perahia Adatto Clin Res Ctr, Denver, CO 80206 USA; Beckman Instruments, N Amer Operat Biores, Somerset, NJ 08875 USA	Rutgers State University New Brunswick; National Jewish Health; National Jewish Health	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08903 USA.				NIGMS NIH HHS [GM-32453, GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679, R37GM032453, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROSTROM MA, 1973, J BIOL CHEM, V248, P2364; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CARMAN GM, 1996, ADV LIPOBIOLOGY, P367; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CARSON MA, 1982, J BIOL CHEM, V257, P8115; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1975, GENETICS, V80, P23; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HENRY SA, 1998, IN PRESS PROG NUCL A; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; ISHIDATE K, 1984, J BIOL CHEM, V259, P4706; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MORASH SC, 1994, J BIOL CHEM, V269, P28769; O'Reilly D., 1992, BACULOVIRUS EXPRESSI, P109; OVERMEYER JH, 1991, ARCH BIOCHEM BIOPHYS, V290, P511, DOI 10.1016/0003-9861(91)90574-3; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; PORTER TJ, 1990, J BIOL CHEM, V265, P414; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; Segel IH, 1975, ENZYME KINETICS BEHA; STORER AC, 1976, BIOCHEM J, V159, P1; SUMMERS EF, 1988, GENETICS, V120, P909; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; WU WI, 1994, J BIOL CHEM, V269, P29495; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589; YAMASHITA S, 1997, BIOCHIM BIOPHYS ACTA, P63	76	43	53	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6844	6852		10.1074/jbc.273.12.6844	http://dx.doi.org/10.1074/jbc.273.12.6844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506987	hybrid			2022-12-27	WOS:000072775900037
J	Zimmermann, G; Zhou, DM; Taussig, R				Zimmermann, G; Zhou, DM; Taussig, R			Genetic selection of mammalian adenylyl cyclases insensitive to stimulation by G(s alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CALMODULIN-BINDING DOMAIN; GS-ALPHA; ESCHERICHIA-COLI; EXPRESSION; PROTEIN; PURIFICATION; INHIBITION; CLONING; CEREVISIAE	We describe the development of a genetic system allowing for the isolation of mutant mammalian adenylyl cyclases defective in their responses to G protein subunits, thus allowing for the identification of structural elements within the cyclase that are responsible for the recognition of these regulators. Expression of mammalian type V adenylyl cyclase in a cyclase-deleted yeast strain can conditionally complement the lethal phenotype of this strain. Type V adenylyl cyclase-expressing yeast grow only when the cyclase is activated by coexpression of G(s alpha) or addition of forskolin to the medium; however, growth arrest is observed in the presence of both activators or under basal conditions. Utilizing this genetic system, we have isolated 25 adenylyl cyclase mutants defective in their response to G(s alpha). Sequence analysis and biochemical characterization of these mutants have identified residues in both cytoplasmic domains of the cyclase that are involved in the specific binding of and regulation by G(s alpha).	Univ Michigan, Med Ctr, Dept Sci Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Taussig, R (corresponding author), Univ Michigan, Med Ctr, Dept Sci Biol, 1500 E Med Ctr Dr,3301E MSRB 3, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, P60DK020572, P30DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053645] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34933, DK20572] Funding Source: Medline; NIGMS NIH HHS [GM53645] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASPERSON GF, 1985, P NATL ACAD SCI USA, V82, P5060, DOI 10.1073/pnas.82.15.5060; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; ISHIKAWA T, 1988, METHOD ENZYMOL, V159, P27; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; ITOH H, 1991, J BIOL CHEM, V266, P16226; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; LEE E, 1994, METHOD ENZYMOL, V237, P146; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; UNO I, 1981, J GEN APPL MICROBIOL, V27, P219, DOI 10.2323/jgam.27.219; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	41	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6968	6975		10.1074/jbc.273.12.6968	http://dx.doi.org/10.1074/jbc.273.12.6968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507003	hybrid			2022-12-27	WOS:000072775900053
J	Sweeney, HL; Rosenfeld, SS; Brown, F; Faust, L; Smith, J; Xing, J; Stein, LA; Sellers, JR				Sweeney, HL; Rosenfeld, SS; Brown, F; Faust, L; Smith, J; Xing, J; Stein, LA; Sellers, JR			Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; ENZYMATIC-ACTIVITIES; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; CARDIAC MYOSIN; ACTIN; SUBFRAGMENT-1; SITE; PROTEINS	A surface loop (25/50-kDa loop) near the nucleotide pocket of myosin has been proposed to be an important element in determining the rate of ADP release from myosin, and as a consequence, the rate of actin-myosin filament sliding (Spudich, J. A. (1991) Nature 372, 515-518). To test this hypothesis, loops derived from different myosin II isoforms that display a range of actin filament sliding velocities were inserted into a smooth muscle myosin backbone. Chimeric myosins were produced by baculovirus/Sf9 cell expression. Although the nature of this loop affected the rate of ADP release (up to 9-fold), in vitro motility (2.7-fold), and the V-max of actin-activated ATPase activity (up to a-fold), the properties of each chimera did not correlate with the relative speed of the myosin from which the loop was derived. Rather, the rate of ADP release was a function of loop size/flexibility with the larger loops giving faster rates of ADP release. The rate of actin filament translocation was altered by the rate of ADP release, but was not solely determined by it. Through a combination of solute quenching and transient fluorescence measurements, it is concluded that, as the loop gets smaller, access to the nucleotide pocket is more restricted. ATP binding becomes less favored, and ADP binding becomes more favored, In addition, the rate of ATP hydrolysis is slowed.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.	lsweeney@mail.med.upenn.edu	Sweeney, H Lee/F-1862-2010		NIAMS NIH HHS [AR-35661] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGUIRRE R, 1989, BIOCHEMISTRY-US, V28, P799, DOI 10.1021/bi00428a058; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; Coleman DE, 1996, TRENDS BIOCHEM SCI, V21, P41, DOI 10.1016/S0968-0004(96)80176-9; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; Dong WJ, 1996, J BIOL CHEM, V271, P688, DOI 10.1074/jbc.271.2.688; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GREENE LE, 1987, J BIOL CHEM, V262, P4177; HOMSHER E, 1992, AM J PHYSIOL, V262, pC724; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PerreaultMicale CL, 1996, J MUSCLE RES CELL M, V17, P543, DOI 10.1007/BF00124354; PERRIE WT, 1973, BIOCHEM J, V135, P151, DOI 10.1042/bj1350151; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; SATA M, 1993, CIRC RES, V73, P696, DOI 10.1161/01.RES.73.4.696; SELLERS JR, 1973, MOTILITY ASSAYS MOTO, P23; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SLEEP JA, 1980, BIOCHEMISTRY-US, V19, P1276, DOI 10.1021/bi00548a002; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stern O, 1919, PHYS Z, V20, P183; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WINKELMANN DA, 1995, BIOPHYS J, V68, P2444, DOI 10.1016/S0006-3495(95)80426-1	45	201	202	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6262	6270		10.1074/jbc.273.11.6262	http://dx.doi.org/10.1074/jbc.273.11.6262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497352	hybrid			2022-12-27	WOS:000072488500044
J	delCardayre, SB; Davies, JE				delCardayre, SB; Davies, JE			Staphylococcus aureus coenzyme A disulfide reductase, a new subfamily of pyridine nucleotide-disulfide oxidoreductase - Sequence, expression, and analysis of cdr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCOCCAL NADH PEROXIDASE; STREPTOCOCCUS-FAECALIS 10C1; RNA-POLYMERASE; CLONED GENES; SITE; GLUTATHIONE; RESOLUTION; CATALYSIS; CLONING	The cdr gene encoding coenzyme A disulfide reductase (CoADR) from Staphylococcus aureus 8325-4 was cloned, sequenced, and overexpressed. The gene encodes a 438-amino acid polypeptide that has a calculated molecular weight of 49,200 and sequence similarity to the pyridine nucleotide-disulfide oxidoreductase family of flavoenzymes. The deduced primary structure contains consensus sequences for flavin adenine dinucleotide and NADPH-binding regions but lacks the catalytic disulfide signature sequence typical of the glutathione reductase family of disulfide reductases. The active site region of CoADR has only a single cysteine residue that is similar to that in the conserved SFXXC active site motif of NADH oxidase and NADH peroxidase from Enterococcus faecalis. CoADR is the first disulfide reductase reported having this active site region, and sequence comparisons of CoADR to representative members of the pyridine nucleotide-disulfide reductase superfamily placed CoADR in a distinct subfamily. CoADR was overexpressed in Escherichia coli using the pET expression system, and 5-10 mg of fully active recombinant enzyme were recovered per liter of E. coli cells.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	delCardayre, SB (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.		Zhang, Ning/F-1387-2014					Ausubel FM, 1988, MOL REPROD DEV; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CLAIBORNE A, 1992, TRENDS BIOCHEM SCI, V17, P183, DOI 10.1016/0968-0004(92)90263-9; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Crane EJ, 1996, BIOCHEMISTRY-US, V35, P2380, DOI 10.1021/bi952347y; delCardayre SB, 1998, J BIOL CHEM, V273, P5744, DOI 10.1074/jbc.273.10.5744; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; MANDE SS, 1995, BIOCHEMISTRY-US, V34, P6985, DOI 10.1021/bi00021a010; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; ROSS RP, 1991, J MOL BIOL, V221, P857, DOI 10.1016/0022-2836(91)80180-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; STEHLE T, 1993, EUR J BIOCHEM, V211, P221, DOI 10.1111/j.1432-1033.1993.tb19889.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	22	50	53	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5752	5757		10.1074/jbc.273.10.5752	http://dx.doi.org/10.1074/jbc.273.10.5752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488708	hybrid			2022-12-27	WOS:000072345000051
J	Ferrington, DA; Krainev, AG; Bigelow, DJ				Ferrington, DA; Krainev, AG; Bigelow, DJ			Altered turnover of calcium regulatory proteins of the sarcoplasmic reticulum in aged skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; FAST-TWITCH; 53,000-DALTON GLYCOPROTEIN; MOLECULAR-CLONING; EXPRESSION; DEGRADATION; CALMODULIN; ATPASE; PHOSPHORYLATION; CA-2+-ATPASE	We have measured the in vivo protein turnover for the major calcium regulatory proteins of the sarcoplasmic reticulum from the skeletal muscle of young adult (7 months) and aged (28 months) Fischer 344 rats. From the time course of the incorporation and decay of protein-associated radioactivity after a pulse injection of [C-14]leucine and correcting for leucine reutilization, in young rats, the apparent half-lives for calsequestrin, the 53-kDa glycoprotein, and ryanodine receptor are 5.4 +/- 0.4, 6.3 +/- 1.3, and 8.3 +/- 1.3 days, respectively. A half-life of 14.5 +/- 2.5 days was estimated for the Ca-ATPase isolated from young muscle. Differences in protein turnover associated with aging were determined using sequential injection of two different isotopic labels ([C-14]leucine and [H-3]leucine) to provide an estimate of protein synthesis and degradation within the same animal. The Ca-ATPase and ryanodine receptor isolated from aged muscle exhibits 27 +/- 5% and 25 +/- 3% slower protein turnover, respectively, relative to that from young muscle. In contrast, the 53-kDa glycoprotein exhibits a 25 +/- 5% more rapid turnover in aged SR, while calsequestrin exhibits no age-dependent alteration in turnover. Statistical analysis comparing the sensitivity of various methods for discriminating different rates of protein turnover validates the approach used in this study and demonstrates that the use of two isotopic labels provides at least a 6-fold more sensitive means to detect age-related differences in protein turnover relative to other methods.	Univ Kansas, Dept Biochem, Lawrence, KS 66045 USA	University of Kansas	Bigelow, DJ (corresponding author), Univ Kansas, Dept Biochem, Haworth Hall, Lawrence, KS 66045 USA.			Ferrington, Deborah/0000-0003-2561-7464	NATIONAL INSTITUTE ON AGING [R01AG012275, P01AG012993] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG12275, P01 AG12993A] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; ARIAS IM, 1969, J BIOL CHEM, V244, P3303; Bevington PR., 2002, DATA REDUCTION ERROR; BOCK KW, 1971, J BIOL CHEM, V246, P188; BRANDT NR, 1993, J MEMBRANE BIOL, V131, P219, DOI 10.1007/BF02260110; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CHIESI M, 1982, J BIOL CHEM, V257, P984; CIARANELLO RD, 1973, J BIOL CHEM, V248, P5616; Damiani E, 1996, CELL CALCIUM, V19, P15, DOI 10.1016/S0143-4160(96)90010-X; DAMONTEIL E, 1995, AM J PHYSIOL, V269, pC955; DOYLE D, 1969, J BIOL CHEM, V244, P5449; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; Ferrington DA, 1997, BBA-BIOMEMBRANES, V1330, P233, DOI 10.1016/S0005-2736(97)00158-2; Ferrington DA, 1996, BBA-BIOMEMBRANES, V1279, P203, DOI 10.1016/0005-2736(95)00235-9; Ferrington DA, 1997, BIOCHEM BIOPH RES CO, V237, P163, DOI 10.1006/bbrc.1997.7105; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; GAFNI A, 1989, MECH AGEING DEV, V49, P105, DOI 10.1016/0047-6374(89)90094-8; GAFNI A, 1990, REV BIOL RES AGING, V4, P315; GANSCHOW RE, 1969, J BIOL CHEM, V244, P4649; GLASS RD, 1972, J BIOL CHEM, V247, P5234; GRACY RW, 1985, MODIFICATION PROTEIN, P1; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LARSSON L, 1989, J PHYSIOL-LONDON, V419, P253, DOI 10.1113/jphysiol.1989.sp017872; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LI X, 1996, J PHYSIOL, V494, P555; LO CS, 1980, J BIOL CHEM, V255, P2131; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN AF, 1977, J BIOL CHEM, V252, P3422; MARTONOSI A, 1972, ARCH BIOCHEM BIOPHYS, V152, P440, DOI 10.1016/0003-9861(72)90237-8; MATSUI H, 1995, AM J PHYSIOL-CELL PH, V268, pC252, DOI 10.1152/ajpcell.1995.268.1.C252; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; Negash S, 1996, BIOCHEMISTRY-US, V35, P11247, DOI 10.1021/bi960864q; *NIH, 1985, 8623 NIH; POOLE B, 1971, J BIOL CHEM, V246, P6587; SAMAREL AM, 1991, FASEB J, V5, P2020, DOI 10.1096/fasebj.5.7.2010055; Sokol R. R., 1981, BIOMETRY, P797; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Remmen Holly, 1995, P171; Viner RI, 1997, BBA-BIOMEMBRANES, V1329, P321, DOI 10.1016/S0005-2736(97)00125-9; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; ZILVERSMIT DB, 1960, AM J MED, V29, P832, DOI 10.1016/0002-9343(60)90117-0	47	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5885	5891		10.1074/jbc.273.10.5885	http://dx.doi.org/10.1074/jbc.273.10.5885			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488726	hybrid			2022-12-27	WOS:000072345000069
J	Ostergaard, HL; Lou, O; Arendt, CW; Berg, NN				Ostergaard, HL; Lou, O; Arendt, CW; Berg, NN			Paxillin phosphorylation and association with Lck and Pyk2 in anti-CD3- or anti-CD45-stimulated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; HOMOTYPIC ADHESION; LYMPHOCYTES-T; SH2 DOMAIN; CD45; ACTIVATION; ENGAGEMENT; LFA-1	Antibodies to either CD3 or CD45 have been shown to induce dramatic changes in cell morphology, increased tyrosine phosphorylation of cellular proteins, and the association of a subset of these proteins with the tyrosine kinase I;ck, The current study was initiated to determine the identity of the tyrosine-phosphorylated 70-80 kDa protein that becomes Lck-associated after stimulation with anti-CD45 or anti-CD3. We demonstrate that the cytoskeletal protein paxillin becomes tyrosine-phosphorylated when cells are plated on immobilized antibodies specific for CD45 or CD3. Only tyrosine-phosphorylated paxillin is associated with Lck, suggesting that the association is through. the SH2 domain of Lck, Consistent with this eve demonstrate that the SH2 domain of Lck hinds tyrosine-phosphorylated paxillin. In contrast, the association of paxillin with the FAK-related kinase Pyk2 was found to be constitutive and not altered by the phosphorylation of either protein, Finally, we establish that the phosphorylation of paxillin is dependent on the expression of Lck. Taken together, these results demonstrate that paxillin is physically associated with kinases from two different families in T cells and suggest that paxillin may function as an adaptor protein linking cellular signals with cytoskeletal changes during T cell activation.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Ostergaard, HL (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 141 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.							ARENDT CW, 1995, J IMMUNOL, V155, P5095; Berg NN, 1997, J IMMUNOL, V159, P1753; BERNARD G, 1994, J IMMUNOL, V152, P5161; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; KANE KP, 1989, J IMMUNOL, V142, P4153; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lewis LA, 1997, J IMMUNOL, V159, P2292; LORENZ HM, 1993, CELL IMMUNOL, V147, P110, DOI 10.1006/cimm.1993.1052; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; OROURKE AM, 1991, J EXP MED, V173, P241, DOI 10.1084/jem.173.1.241; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PERI KG, 1993, ONCOGENE, V8, P2765; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SPERTINI F, 1994, J IMMUNOL, V153, P1593; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	28	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5692	5696		10.1074/jbc.273.10.5692	http://dx.doi.org/10.1074/jbc.273.10.5692			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488700	hybrid			2022-12-27	WOS:000072345000043
J	Rogakou, EP; Pilch, DR; Orr, AH; Ivanova, VS; Bonner, WM				Rogakou, EP; Pilch, DR; Orr, AH; Ivanova, VS; Bonner, WM			DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; TREATED HELA-CELLS; ACETYLATION; GENE; CHROMATIN; SEQUENCE; NUCLEI; DAMAGE; MOUSE	When mammalian cell cultures or mice are exposed to ionizing radiation in survivable or lethal amounts, novel mass components are found in the histone H2A region of two-dimensional gels, Collectively referred to as gamma, these components are formed in vivo by several procedures that introduce double-stranded breaks into DNA. gamma-Components, which appeared to be the only major novel components detected by mass or (PO4)-P-32 incorporation on acetic acid-urea-Triton X-100-acetic acid-urea-cetyltrimethylammonium bromide or SDS-acetic. acidurea-cetyltrimethylammonium bromide gels after exposure of cells to ionizing radiation, are shown to be histone H2AX species that have been phosphorylated specifically at serine 139. gamma-H2AX appears rapidly after exposure of cell, cultures to ionizing radiation; half-maximal amounts are reached by I min and maximal amounts by 10 min, At the maximum, approximately 1% of the H2AX becomes gamma-phosphorylated per gray of ionizing radiation, a finding that indicates that 35 DNA double-stranded breaks, the number introduced by each gray into the 6 x 10(9) base pairs of a mammalian G(1) genome, leads to the gamma-phosphorylation of H2AX distributed over 1% of the chromatin, Thus, about 0.03% of the chromatin appears to be involved per DNA double-stranded break, This value, which corresponds to about 2 x 10(6) base pairs of DNA per double-stranded break, indicates that large amounts of chromatin are involved with each DNA double-stranded break, Thus, gamma-H2AX formation is a rapid and sensitive cellular response to the presence of DNA double-stranded breaks, a response that may provide insight into higher order chromatid structures.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bonner, WM (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D17, Bethesda, MD 20892 USA.							ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Baxevanis AD, 1996, NUCLEIC ACIDS RES, V24, P245, DOI 10.1093/nar/24.1.245; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CANO E, 1992, NATURE, V360, P116, DOI 10.1038/360116a0; Casarett AP, 1968, RAD BIOL; CHABNER B, 1996, CANC CHEMOTHERAPY BI, P379; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; GOLDKNOPF IL, 1979, BIOCHEM BIOPH RES CO, V90, P269, DOI 10.1016/0006-291X(79)91620-6; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HORNSEY S, 1957, ADV RADIOBIOL, P248; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; NAGATA T, 1991, NUCLEIC ACIDS RES, V19, P2441, DOI 10.1093/nar/19.9.2441; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; ORCUTT RP, 1993, 31 ANN M NASH TN NOV; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SESTILI P, 1995, BIOCHIM BIOPHYS ACTA, V31, P130; SIMPSON RT, 1978, NUCLEIC ACIDS RES, V5, P1109, DOI 10.1093/nar/5.4.1109; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P174, DOI 10.1093/nar/22.2.174; THOMPSON LH, 1980, SOMAT CELL GENET, V6, P391, DOI 10.1007/BF01542791; THOMPSON LH, 1996, MUTAT RES, V337, P131; THOMSON JF, 1962, RAD PROTECTION ANIMA; Ueda T, 1996, INT J RADIAT BIOL, V69, P199, DOI 10.1080/095530096146039; van Holde KE., 1989, SPRINGER SERIES MOL; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; WARD JF, 1991, DNA DAMAGE REPAIR PH; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WEST MHP, 1981, NUCLEIC ACIDS RES, V20, P4671; WHITLOCK JP, 1980, NATURE, V287, P74, DOI 10.1038/287074a0; WHITLOCK JP, 1983, J BIOL CHEM, V258, P1299; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239; YUNIS JJ, 1981, HUM GENET, V56, P293, DOI 10.1007/BF00274682; ZDZIENICKA MZ, 1995, MUTAT RES-DNA REPAIR, V336, P203, DOI 10.1016/0921-8777(95)00003-3; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	44	4014	4150	8	227	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5858	5868		10.1074/jbc.273.10.5858	http://dx.doi.org/10.1074/jbc.273.10.5858			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488723	hybrid			2022-12-27	WOS:000072345000066
J	Shou, YP; Baron, S; Poncz, M				Shou, YP; Baron, S; Poncz, M			An Sp1-binding silencer element is a critical negative regulator of the megakaryocyte-specific alpha(IIb) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; ZINC-FINGER PROTEIN; DNA-BINDING PROTEINS; TATA-LESS PROMOTER; TRANSCRIPTION FACTOR; RECEPTOR GENE; GPIIB GENE; 5'-FLANKING REGION; SP1 BINDING; C-MYC	The Sp1 family of transcription factors are often involved in the regulated expression of TATA-less genes, frequently enhancing gene transcription, In this paper, we demonstrate that an Sp1-binding element inhibits the expression of the megakaryocyte-specific alpha(IIb) gene in all cell lines tested and that this inhibition is actively overcome only in megakaryocyte-like cell lines, We had noted previously in primary megakaryocytes that a 50-base pair (bp) deletion from -1.50 to -101 bp in the rat alpha(IIb) promoter region resulted in increased expression. We now show that deletion of this region markedly increased expression in both megakaryocytic and nonmegakaryocytic cell lines, eliminating the tissue specificity of the alpha(IIb) promoter, Electrophoretic mobility shift assays (EMSA) defined a single complex, which bound, to a -145 to -125 bp subregion, Point mutations within this region, localized the critical point of binding around bases -136/-135, and expression studies showed that introduction of the -136/-135 mutation into the rat alpha(IIb) promoter had a comparable result to that seen with the 50-bp deletion, EMSA studies with the homologous human alpha(IIb) promoter region gave are identical migrating band, Southwestern blots or HeLa nuclear proteins with both the rat -145 to -125 DNA and its human homologue bound to a single similar to 110-kDa protein, the known molecular weight of Sp1. Confirmation that this region of the alpha(IIb) gene promoter bound Sp1 was accomplished using EMSA studies with are Sp1 consensus probe, anti-Sp1 and -Sp3 antibodies, and recombinant Sp1 protein, Further support for the role of Sp1 in the silencing of the alpha(IIb) promoter was obtained using a GaI4 binding site substitution for the silencer region of alpha(IIb) and co-expression of near full-length Sp1/Ga14 fusion protein expression vectors, Ectopic reinsertion of the -150 to -101 bp region, back into the -150 to -101 bp deleted promoter, enhanced Father than decreased expression, suggesting that Sp1's inhibitory role at -136/-135 depends on its local interactions, In summary, we believe that we have identified a cross-species, non-consensus Spl-binding site that binds Sp1 and that acts as a silencer of alpha(IIb) expression in many cell lines, A model is presented as to how this Sp1-binding silencer dement contributes to the megakaryocyte-specific expression of alpha(IIb) gene.	Allegheny Univ Hlth Sci, Program Mol & Cellular Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Drexel University; University of Pennsylvania	Poncz, M (corresponding author), Childrens Hosp, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	poncz@email.chop.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; BATES RC, 1991, J BIOL CHEM, V266, P18593; Bennett JS, 1996, TRENDS CARDIOVAS MED, V6, P31, DOI 10.1016/1050-1738(95)00126-3; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; BLOCK KL, 1994, BLOOD, V84, P3385; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DENARIER E, 1993, BIOCHEM BIOPH RES CO, V195, P1360, DOI 10.1006/bbrc.1993.2193; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FONG AM, 1994, J BIOL CHEM, V269, P18441; FUGMAN DA, 1990, BLOOD, V75, P1252; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAGEN G, 1982, NUCLEIC ACIDS RES, V20, P5519; HANDY DE, 1995, BIOCHEM J, V311, P541, DOI 10.1042/bj3110541; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMAN R, 1989, BLOOD, V74, P1196; Husmann M, 1996, EUR J IMMUNOL, V26, P3008, DOI 10.1002/eji.1830261228; JOEL P, 1993, NUCLEIC ACIDS RES, V21, P5786, DOI 10.1093/nar/21.24.5786; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MINOWA T, 1994, J BIOL CHEM, V269, P11656; Parks CL, 1996, J BIOL CHEM, V271, P4417; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; Rauch J, 1990, Transfus Med Rev, V4, P110, DOI 10.1016/S0887-7963(90)70255-6; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SOSNOSKI DM, 1988, J CLIN INVEST, V81, P1993, DOI 10.1172/JCI113548; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UZAN G, 1991, J BIOL CHEM, V266, P8932; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; ZUTTER MM, 1995, BLOOD, V86, P3006	66	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5716	5726		10.1074/jbc.273.10.5716	http://dx.doi.org/10.1074/jbc.273.10.5716			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488704	hybrid			2022-12-27	WOS:000072345000047
J	Badia, J; Ibanez, E; Sabate, M; Baldoma, L; Aguilar, J				Badia, J; Ibanez, E; Sabate, M; Baldoma, L; Aguilar, J			A rare 920-kilobase chromosomal inversion mediated by IS1 transposition causes constitutive expression of the yiaK-S operon for carbohydrate utilization in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; BACTERIAL CHROMOSOME; SEQUENCE; GENOME; RECOMBINATION; DUPLICATIONS; MUTAGENESIS; ACTIVATION; DELETIONS; INSERTION	The regulator of the yiaK-S operon, currently assigned a carbohydrate utilization function in Escherichia coli, is inactivated by a genome rearrangement that: leads to the constitutive expression of the operon, The yiaK-S constitutive cells acquire the ability to utilize the rare pentose L-lyxose. Restriction analysis and sequencing of the regulator gene indicate that it is disrupted by foreign DNA. The insert consists of a larger, inverted fragment of DNA of 920 kilobases flanked by two ISI elements with opposite polarity. One corresponds to that found naturally at min 0.4 of the bacterial chromosome and the other to a new copy transposed into the regulator gene located at min 80.6. This insertion-inversion could be the result of the intramolecular transposition mechanism itself, a gene rearrangement rarely originated by IS1, Alternatively, it could be attributed to the homologous recombination between the IS1 at min 0.4 and the IS1 transposed intermolecularly into the yiaK-S regulator gene. The participation of a rare IS1-mediated inversion in the evolution of a stable phenotype is thus identified.	Univ Barcelona, Sch Pharm, Dept Biochem, E-08028 Barcelona, Spain	University of Barcelona	Aguilar, J (corresponding author), Univ Barcelona, Sch Pharm, Dept Biochem, Diagonal 643, E-08028 Barcelona, Spain.		Badia, Josefa/G-7292-2015; Baldomà, Laura/G-7301-2015	Badia, Josefa/0000-0003-0768-5033; Baldomà, Laura/0000-0002-7678-269X				ANDERSON RP, 1978, J MOL BIOL, V119, P147, DOI 10.1016/0022-2836(78)90274-7; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boot HJ, 1996, MOL MICROBIOL, V21, P799, DOI 10.1046/j.1365-2958.1996.401406.x; BORONAT A, 1979, J BACTERIOL, V140, P320, DOI 10.1128/JB.140.2.320-326.1979; CORNELIS G, 1980, MOL GEN GENET, V178, P367, DOI 10.1007/BF00270486; ELEUTERIO M, 1972, J BACTERIOL, V111, P383, DOI 10.1128/JB.111.2.383-391.1972; FONSTEIN M, 1994, J BACTERIOL, V176, P2265, DOI 10.1128/JB.176.8.2265-2271.1994; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUQUA WC, 1992, BIOTECHNIQUES, V12, P223; GALAS DJ, 1989, MOBILE DNA, P109; Gibbs CP, 1996, FEMS MICROBIOL LETT, V145, P173, DOI 10.1016/S0378-1097(96)00404-1; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; HILL CW, 1988, GENETICS, V119, P771; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; KLECKNER N, 1990, ANNU REV CELL BIOL, V6, P297, DOI 10.1146/annurev.cb.06.110190.001501; KOONIN EV, 1995, P NATL ACAD SCI USA, V92, P11921, DOI 10.1073/pnas.92.25.11921; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; MAHAN MJ, 1991, GENETICS, V129, P1021; MAKINO K, 1991, J BACTERIOL, V173, P2665, DOI 10.1128/jb.173.8.2665-2672.1991; MIYADA GC, 1983, J BACTERIOL, V156, P765; MORALEJO P, 1993, J BACTERIOL, V175, P5585, DOI 10.1128/JB.175.17.5585-5594.1993; PARKER LL, 1990, GENETICS, V124, P473; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REVERCHON S, 1991, MOL MICROBIOL, V5, P2203, DOI 10.1111/j.1365-2958.1991.tb02150.x; ROTH JR, 1996, ESCHERICHIA COLI SAL, P2256; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ JC, 1994, J BIOL CHEM, V269, P29665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALL A, 1988, SCIENCE, V241, P1314, DOI 10.1126/science.3045970; SHYAMALA V, 1990, EMBO J, V9, P939, DOI 10.1002/j.1460-2075.1990.tb08192.x; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; TURLAN C, 1995, EMBO J, V14, P5410, DOI 10.1002/j.1460-2075.1995.tb00225.x; WACKERNAGEL W, 1973, BIOCHEM BIOPH RES CO, V51, P306, DOI 10.1016/0006-291X(73)91257-6; WEINERT TA, 1983, SCIENCE, V222, P755, DOI 10.1126/science.6314502; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; XIA XM, 1986, MOL GEN GENET, V205, P376, DOI 10.1007/BF00430454; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	38	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8376	8381		10.1074/jbc.273.14.8376	http://dx.doi.org/10.1074/jbc.273.14.8376			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525947	hybrid			2022-12-27	WOS:000072876300081
J	Codina, J; Delmas-Mata, JT; DuBose, TD				Codina, J; Delmas-Mata, JT; DuBose, TD			The alpha-subunit of the colonic H+,K+-ATPase assembles with beta(1)-Na+,K+-ATPase in kidney and distal colon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; RAT; NA+,K+-ATPASE; PROTEIN; BRAIN; H,K-ATPASE; ISOFORM	Previous experiments from our laboratory (Codina, J., Kone, B. C., Delmas-Mata, J. T., and DuBose, T. D., Jr. (1996) J. Biol chem. 271, 29759-29763) demonstrated that the alpha-subunit of the colonic H+, K+-ATPase (HK alpha(2)) requires coexpression with a beta-subunit to support H+/K+ transport in a heterologous expression system (Xenopus laevis oocytes). In these studies, HK alpha(2) formed stable and functional alpha.beta complexes when coexpressed with either the rat beta(1)-subunit of the Na+, K+-ATPase or the beta-subunit of the gastric H+, K+-ATPase, suggesting that different beta-subunits may interact with HK alpha(2). The present studies tested this hypothesis by development and application of a specific antibody against HK alpha(2). peptide. Subsequently, immunoprecipitation experiments were preformed to determine if HK alpha(2) co-precipitates with the same beta-subunit in organs known to express HK alpha(2) protein. The data demonstrate that HK alpha(2) assembles with beta(1)-Na+, K+-ATPase in the renal medulla and in distal colon.	Univ Texas, Sch Med, Div Renal Dis & Hypertens, Dept Internal Med, Houston, TX 77030 USA	University of Texas System	DuBose, TD (corresponding author), Univ Texas, Sch Med, Div Renal Dis & Hypertens, Dept Internal Med, 6431 Fannin St,Room 4-148, Houston, TX 77030 USA.	tdubose@heart.med.uth.tmc.edu			PHS HHS [DO-30603-16] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; CODINA J, 1997, J AM SOC NEPHROL, V8, P31; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DUBOSE TD, 1995, AM J PHYSIOL-RENAL, V269, pF500, DOI 10.1152/ajprenal.1995.269.4.F500; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; HSU WH, 1990, J BIOL CHEM, V265, P11220; Kone BC, 1996, MINER ELECTROL METAB, V22, P349; KRAUT J, 1995, 10 INT C NEPHR JUL 2, P43; Kraut JA, 1997, AM J PHYSIOL-RENAL, V272, pF744, DOI 10.1152/ajprenal.1997.272.6.F744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; SANFORD J, 1991, J BIOL CHEM, V266, P9570; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; TARENTINO A, 1970, J BIOL CHEM, V245, P4150; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	29	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7894	7899		10.1074/jbc.273.14.7894	http://dx.doi.org/10.1074/jbc.273.14.7894			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525884	hybrid			2022-12-27	WOS:000072876300018
J	Feshchenko, EA; Langdon, WY; Tsygankov, AY				Feshchenko, EA; Langdon, WY; Tsygankov, AY			Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; SH3 DOMAIN; EGF STIMULATION; SRC-FAMILY; IN-VIVO	Protooncogenic protein c-Cbl undergoes tyrosine phosphorylation in response to stimulation through the receptors for antigens, immunoglobulins, cytokines, and growth factors as well as through the integrins. Tyrosine phosphorylation of c-Cbl may play a functional role in signal transduction, since c-Cbl interacts with many crucial signaling molecules including protein tyrosine kinases, adaptor proteins, and phosphatidylinositol 3'-kinase. Therefore, it is essential for our understanding of the functions of c-Cbl in signal transduction to identify its tyrosine phosphorylation sites, to determine the protein-tyrosine kinases that phosphorylate these sites, and to elucidate the role of these sites in the interactions of c-Cbl with other signaling proteins. In this report, we demonstrate that tyrosines 700, 731, and 774 are the major tyrosine phosphorylation sites of c-Cbl in T cells in response to pervanadate treatment, as well as in response to TcR/CD3 ligation. Coexpression experiments in COS cells demonstrate that among T cell-expressed Src-and Syk-related protein-tyrosine kinases, Fyn, Yes, and Syk appear to play a major role in phosphorylation of c-Cbl, whereas Lck and Zap phosphorylate c-Cbl ineffectively. Fyn, Yes, and Syk phosphorylate the same sites of c-Cbl that become phosphorylated in stimulated T cells. Among these kinases, Fyn and Yes demonstrate strong binding to c-Cbl, which involves both phosphotyrosine-dependent and phosphotyrosine-independent mechanisms.	Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA; Univ Western Australia, Dept Pathol, Nedlands, WA 6009, Australia	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Western Australia	Tsygankov, AY (corresponding author), Temple Univ, Dept Microbiol & Immunol, Sch Med, Room 506,3400 Broad St, Philadelphia, PA 19140 USA.	tsygan@astro.ocis.temple.edu	Tsygankov, Alexander Y/K-6205-2017					Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BARNES DM, 1995, J CELL PHYSIOL, V164, P304, DOI 10.1002/jcp.1041640211; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brizzi MF, 1996, ONCOGENE, V13, P2067; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Collins TL, 1997, IMMUNOL TODAY, V18, P221; CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Khwaja A, 1996, ONCOGENE, V12, P2491; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Manie SN, 1997, EXP HEMATOL, V25, P45; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Marengere LEM, 1997, J IMMUNOL, V159, P70; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROWLEY RB, 1995, J BIOL CHEM, V270, P12659, DOI 10.1074/jbc.270.21.12659; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Smit L, 1996, ONCOGENE, V13, P381; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TESHIMA R, 1994, BIOCHEM J, V302, P867, DOI 10.1042/bj3020867; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1994, J LEUKOCYTE BIOL, V55, P289, DOI 10.1002/jlb.55.3.289; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TSYGANKOV AY, 1993, STEM CELLS, V11, P371, DOI 10.1002/stem.5530110504; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; YAMAGUCHI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P382, DOI 10.1006/abbi.1995.0058; ZENNER G, 1995, BIOESSAYS, V17, P967, DOI 10.1002/bies.950171110; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; Zhou Songyang, 1995, Nature (London), V373, P536	77	145	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8323	8331		10.1074/jbc.273.14.8323	http://dx.doi.org/10.1074/jbc.273.14.8323			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525940	hybrid			2022-12-27	WOS:000072876300074
J	Ristimaki, A; Narko, K; Enholm, B; Joukov, V; Alitalo, K				Ristimaki, A; Narko, K; Enholm, B; Joukov, V; Alitalo, K			Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; FACTOR GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; POSTTRANSCRIPTIONAL REGULATION; PERMEABILITY FACTOR; DOWN-REGULATION; MESSENGER-RNA; FACTOR-B; IN-VIVO; HYPOXIA	Vascular endothelial growth factor (VEGF) is a prime regulator of normal and pathological angiogenesis. Three related endothelial cell growth factors, VEGF-B, VEGF-C, and VEGF-D were recently cloned. We have here studied the regulation of VEGF-C, a lymphatic endothelial growth factor, by angiogenic proinflammatory cytokines, Interleukin (IL)-1 beta induced a concentration- and a time-dependent increase in VEGF-C, but not in VEGF-B, mRNA steady-state levels in human lung fibroblasts, The increase in VEGF-C mRNA levels was mainly due to increased transcription rather than elevated mRNA stability as detected by the nuclear run-on method and by following mRNA decay in the presence of an inhibitor of transcription, respectively, In contrast, angiopoietin-1 mRNA, encoding the ligand for the endothelial-specific Tek/Tie-2 receptor, was down-regulated by IL-1 beta. Tumor necrosis factor-alpha and IL-1 alpha also elevated VEGF-C mRNA steady-state levels, whereas the IL-1 receptor antagonist and dexamethasone inhibited the effect of IL-1 beta. Experiments with cycloheximide indicated that the effect of IL-1 beta was independent of protein synthesis. Hypoxia, which is an important inducer of VEGF expression, had no effect on VEGF-B or VEGF-C mRNA levels, IL-1 beta and tumor necrosis factor-alpha also stimulated the production of VEGF-C protein by the fibroblasts. Cytokines and growth factors have previously been shown to down-regulate VEGF receptors in vascular endothelial cells. We found that the mRNA for the VEGF- and VEGF-C-binding VEGFR-2 (KDR/Flk-1) was stimulated by IL-1 beta in human umbilical vein endothelial cells, whereas the mRNA levels of VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4) were not altered, Our data suggest that in addition to VEGF, VEGF-C may also serve as an endothelial stimulus at sites of cytokine activation, In particular, these results raise the possibility that certain proinflammatory cytokines regulate the lymphatic vessels indirectly via VEGF-C.	Univ Helsinki, Res Lab, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland; Univ Helsinki, Dept Bacteriol & Immunol, FIN-00290 Helsinki, Finland; Univ Helsinki, Haartman Inst, FIN-00290 Helsinki, Finland; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Ristimaki, A (corresponding author), Univ Helsinki, Res Lab, Dept Obstet & Gynecol, Haartmaninkatu 2, FIN-00290 Helsinki, Finland.		Joukov, Vladimir/K-3525-2019; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CELANO P, 1989, BIOTECHNIQUES, V7, P942; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, ENDOCR REV, V18, P497; Fitz LJ, 1997, ONCOGENE, V15, P613, DOI 10.1038/sj.onc.1201191; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRENCH LA, 1962, CLIN NEUROSURG, V10, P212; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Heiss JD, 1996, J CLIN INVEST, V98, P1400, DOI 10.1172/JCI118927; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; Hu JS, 1997, FASEB J, V11, P498, DOI 10.1096/fasebj.11.6.9194531; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Isner JM, 1996, CLIN IMMUNOL IMMUNOP, V80, pS82, DOI 10.1006/clin.1996.0145; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lagercrantz J, 1996, BIOCHEM BIOPH RES CO, V220, P147, DOI 10.1006/bbrc.1996.0372; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Townson S, 1996, BIOCHEM BIOPH RES CO, V220, P922, DOI 10.1006/bbrc.1996.0507; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Ware JA, 1997, NAT MED, V3, P158, DOI 10.1038/nm0297-158; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	68	317	344	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8413	8418		10.1074/jbc.273.14.8413	http://dx.doi.org/10.1074/jbc.273.14.8413			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525952	hybrid			2022-12-27	WOS:000072876300086
J	Venema, RC; Ju, H; Venema, VJ; Schieffer, B; Harp, JB; Ling, BN; Eaton, DC; Marrero, MB				Venema, RC; Ju, H; Venema, VJ; Schieffer, B; Harp, JB; Ling, BN; Eaton, DC; Marrero, MB			Angiotensin II-induced association of phospholipase C gamma 1 with the G-protein-coupled AT(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; SRC-FAMILY; C-GAMMA; KINASES; ACTIVATION; STIMULATION; MECHANISM	An early event in signaling by the G-protein-coupled angiotensin II (Ang II) AT(1) receptor in vascular smooth muscle cells is the tyrosine phosphorylation and activation of phospholipase C gamma 1 (PLC gamma 1). In the present study, we show that stimulation of this event by Ang II in vascular smooth muscle cells is accompanied by binding of PLC gamma 1 to the AT(1) receptor in an Ang II- and tyrosine phosphorylation-dependent manner. The PLC gamma 1-AT(1), receptor interaction appears to depend on phosphorylation of tyrosine 319 in a YIPP motif in the C-terminal intracellular domain of the AT(1) receptor and binding of the phosphorylated receptor by the most C-terminal of two Src homology 2 domains in PLC gamma 1. PLC gamma 1 thus binds to the same site in the receptor previously identified for binding by the SHP-2 phosphotyrosine phosphatase-JAK2 tyrosine kinase complex. A single site in the C-terminal tail of the AT(1) receptor can, therefore, be bound in a ligand-independent manner by two different downstream effector proteins. These data demonstrate that G-protein-coupled receptors can physically associate with intracellular proteins other than G proteins, creating membrane-delimited signal transduction complexes similar to those observed for classic growth factor receptors.	Med Coll Georgia, Vasc Biol Ctr, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Hannover Med Sch, Div Cardiol, Hannover, Germany; Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Emory Univ, Sch Med, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Hannover Medical School; University of North Carolina; University of North Carolina Chapel Hill; Emory University	Marrero, MB (corresponding author), Emory Univ, Sch Med, Ctr Cell & Mol Signaling, Physiol Bldg,1648 Pierce Dr NE, Atlanta, GA 30322 USA.	mmarrero@ccms-renal.physio.emory.edu		Eaton, Douglas/0000-0002-2686-6692	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057201, R29HL057201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002111, P01DK050268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57201] Funding Source: Medline; NIDDK NIH HHS [DK-02111, P01-DK50268] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; DHAR A, 1994, J BIOL CHEM, V269, P9123; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; PAXTON WG, 1994, BIOCHEM BIOPH RES CO, V200, P260, DOI 10.1006/bbrc.1994.1443; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133	18	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7703	7708		10.1074/jbc.273.13.7703	http://dx.doi.org/10.1074/jbc.273.13.7703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516477	hybrid			2022-12-27	WOS:000072738500073
J	Zhang, XP; Kamata, T; Yokoyama, K; Puzon-McLaughlin, W; Takada, Y				Zhang, XP; Kamata, T; Yokoyama, K; Puzon-McLaughlin, W; Takada, Y			Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alpha v beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN IIB/IIA COMPLEX; INDUCED PLATELET-AGGREGATION; LIGAND-BINDING SITES; SPERM-EGG FUSION; INTERCELLULAR-ADHESION; IIB-IIIA; PROTEIN; RECEPTOR; CELL; IDENTIFICATION	MDC-15 (ADAM-15, metargidin), a membrane-anchored metalloprotease/disintegrin/cysteine-rich protein, is expressed on the surface of a wide range of cells and has an RGD tripeptide in its disintegrin-like domain, MDC-15 is potentially involved in cell-cell interactions through its interaction with integrins, We expressed a recombinant MDC-15 disintegrin-like domain as a fusion protein with glutathione S-transferase (designated D-15) in bacteria and examined its binding function to integrins using mammalian cells expressing different recombinant integrins, We found that D-15 specifically interacts with alpha v beta 3 but not with the other integrins tested (alpha 2 beta 1, alpha 3 beta 1, alpha 4 beta 1, alpha 5 beta 1, alpha 6 beta 1, alpha 6 beta 4, alpha v beta 1, alpha IIb beta 3, and alpha L beta 2). Mutation of the tripeptide RGD to SGA totally blocked binding of D-15 to alpha v beta 3, suggesting that D-15-alpha v beta 3 interaction is RGD-dependent. When the sequence <(RPT)under bar>RGD is mutated to <(NWK)under bar>RGD, D-15 is recognized by both alpha IIb beta 3 and alpha v beta 3, suggesting that the receptor binding specificity is mediated by the sequence flanking the RGD tripeptide, as in snake venom disintegrins, These results indicate that the disintegrin-like domain of MDC-15 functions as an adhesion molecule and may be involved n alpha v beta 3-mediated cell cell interactions.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, XP (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-1,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takada@scripps.edu		takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRACIALE TJ, 1986, J IMMUNOL, V137, P995; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; Kamiguti AS, 1996, BIOCHEM J, V320, P635, DOI 10.1042/bj3200635; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; Lu XJ, 1996, J BIOL CHEM, V271, P289, DOI 10.1074/jbc.271.1.289; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; USAMI Y, 1994, BIOCHEM BIOPH RES CO, V201, P331, DOI 10.1006/bbrc.1994.1706; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOODS VL, 1984, BLOOD, V63, P368; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YLANNE J, 1988, BLOOD, V72, P1478	47	193	212	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7345	7350		10.1074/jbc.273.13.7345	http://dx.doi.org/10.1074/jbc.273.13.7345			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516430	hybrid			2022-12-27	WOS:000072738500026
J	Boehm, JE; Chaika, OV; Lewis, RE				Boehm, JE; Chaika, OV; Lewis, RE			Anti-apoptotic signaling by a colony-stimulating factor-1 receptor insulin receptor chimera with a juxtamembrane deletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; PHOSPHOTYROSINE-DEPENDENT INTERACTION; SHC PHOSPHORYLATION; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; NON-SH2 DOMAINS; KINASE-ACTIVITY; DNA-SYNTHESIS; CELL-DEATH	The intracellular mechanisms used by insulin and insulin-like growth factors to block programmed cell death are unknown, To identify receptor structures and signaling pathways essential for anti-apoptotic effects on cells, we have created a chimeric receptor (colony-stimulating factor-1 receptor/insulin receptor chimera (CSF1R/IR)) connecting the extracellular, ligand-binding domain of the colony-stimulating factor-1 (CSF-1) receptor to the transmembrane and cytoplasmic domains of the insulin receptor, Upon activation with CSF-1, the CSF1R/IR phosphorylates itself and intracellular substrates in a manner characteristic of normal insulin receptors, CSF-1 treatment protected cells expressing the CSF1R/IR from staurosporine-induced apoptosis, A chimeric receptor (CSF1R/IR Delta 960) with a deletion of 12 amino acids from its juxtamembrane domain was constructed and expressed, CSF-1-treated cells expressing the CSF1R/IR Delta 960 are unable to phosphorylate IRS-1 and Shc (Chaika, O. V., Chaika, N., Volle, D. J., Wilden, P. A. Pirrucello, S. J., and Lewis, R. E. (1997) J. Biol. Chem. 272, 11968-11974), CSF-1 stimulated glucose uptake, mitogen-activated protein kinases, and IRS-1-associated phosphatidylinositol 3' kinase in cells expressing the CSF1R/IR but not in cells expressing the CSF1R/IR Delta 960. Surprisingly, the CSF1R/IR Delta 960 was as effective as the CSF1R/IR in mediating CSF-1 protection of cells from staurosporine-induced apoptosis, These observations indicate that the anti-apoptotic effects of the insulin receptor cytoplasmic domain can be mediated by signaling pathways distinct from those requiring IRS-1 and Shc.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lewis, RE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42Nd St, Omaha, NE 68198 USA.		Lewis, Robert E./H-3404-2019		NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052809] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727, CA09476] Funding Source: Medline; NIDDK NIH HHS [DK52809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FROST SC, 1985, J BIOL CHEM, V260, P2646; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OKADA T, 1994, J BIOL CHEM, V269, P3568; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; Parrizas M, 1997, J BIOL CHEM, V272, P154; RESNICOFF M, 1994, CANCER RES, V54, P4848; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tagami M, 1997, LAB INVEST, V76, P603; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; THEIS RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	61	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7169	7176		10.1074/jbc.273.12.7169	http://dx.doi.org/10.1074/jbc.273.12.7169			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507032	hybrid			2022-12-27	WOS:000072775900082
J	LeRoy, G; Drapkin, R; Weis, L; Reinberg, D				LeRoy, G; Drapkin, R; Weis, L; Reinberg, D			Immunoaffinity purification of the human multisubunit transcription factor IIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; CDK-ACTIVATING KINASE; DNA-REPAIR; FACTOR TFIIH; XERODERMA-PIGMENTOSUM; TERMINAL-DOMAIN; COMPLEX; PROTEIN; COMPONENT	A procedure to immunoaffinity purify the human transcription factor IIH (TFIIH) was developed using a monoclonal antibody that recognizes an epitope in ERCC3 (XPB), the largest subunit of TFIIH. The epitope recognized by the monoclonal antibody was mapped to 20 amino acids. A peptide containing the epitope was capable of displacing TFIIH from an immunoaffinity column containing the monoclonal antibody. The immunoaffinity purification procedure described allows a simple and efficient method to purify both the "core" and "holo" TFIIH complexes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Div Nucl Acid Enzymol,Dept Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Div Nucl Acid Enzymol,Dept Biochem, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu	Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008360, R01GM037120, R37GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37120, GM08360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Harlow E, 1988, ANTIBODIES LABORATOR, P521; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAINA CV, 1988, GENE, V40, P183; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MATSUI P, 1995, NUCLEIC ACIDS RES, V23, P767, DOI 10.1093/nar/23.5.767; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PETERSON MG, 1991, NATURE, V354, P369; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rickert P, 1996, ONCOGENE, V12, P2631; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	55	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7134	7140		10.1074/jbc.273.12.7134	http://dx.doi.org/10.1074/jbc.273.12.7134			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507027	hybrid			2022-12-27	WOS:000072775900077
J	Sukhodolets, MV; Jin, DJ				Sukhodolets, MV; Jin, DJ			RapA, a novel RNA polymerase-associated protein, is a bacterial homolog of SWI2/SNF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT CLEAVAGE FACTORS; YEAST SWI/SNF COMPLEX; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PUTATIVE HELICASES; GLOBAL ACTIVATOR; DNA; BINDING; GENE; FAMILY	We have identified a novel Escherichia coli RNA polymerase (RNAP)-associated protein, an ATPase named RapA. Almost all of this 110-kDa protein in the cell copurifies with RNAP holoenzyme as a 1:1 complex. Purified to homogeneity, RapA also forms a stable complex with RNAP, as if it were a subunit of RNAP. The ATPase activity of RapA is stimulated by binding to RNAP, and thus, RapA and RNAP interact physically as well as functionally. Interestingly, RapA is a homolog of the SWI/SNF family of eukaryotic proteins whose members are involved in transcription activation, nucleosome remodeling, and DNA repair.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jin, DJ (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 2E14,9000 Rockville Pike, Bethesda, MD 20892 USA.							AHNE F, 1992, CURR GENET, V22, P277, DOI 10.1007/BF00317921; ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; EMERY HS, 1991, GENE DEV, V5, P1786; FENG GH, 1994, J BIOL CHEM, V269, P22282; Friedman DI., 1983, LAMBDA 2, P21; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1987, PROTEINS, V2, P42, DOI 10.1002/prot.340020106; Jin DJ, 1996, J BIOL CHEM, V271, P11659; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOLSTO AB, 1993, J MOL BIOL, V230, P684, DOI 10.1006/jmbi.1993.1185; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1987, GENETICS, V115, P247; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; SCHILD D, 1992, YEAST, V8, P385, DOI 10.1002/yea.320080506; SPARKOWSKI J, 1991, J BACTERIOL, V173, P5256, DOI 10.1128/jb.173.17.5256-5257.1991; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STETTER KO, 1974, EUR J BIOCHEM, V48, P527, DOI 10.1111/j.1432-1033.1974.tb03794.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	49	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7018	7023		10.1074/jbc.273.12.7018	http://dx.doi.org/10.1074/jbc.273.12.7018			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507009	hybrid			2022-12-27	WOS:000072775900059
J	Cooke, DW; Lane, MD				Cooke, DW; Lane, MD			A sequence element in the GLUT4 gene that mediates repression by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; ENHANCER-BINDING-PROTEIN; TRANSGENIC MICE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; REGULATED EXPRESSION; ADIPOSE-TISSUE; PROLACTIN GENE; AMYLASE GENE; PEPCK GENE; TRANSCRIPTION	Prolonged treatment of 3T3-L1 adipocytes decreases expression of GLUT4, the insulin-responsive glucose transporter. Expression of promoter-reporter gene constructs that contained 2900 or 785 base pairs of 5'-flanking region of the murine GLUT4 gene was down-regulated by insulin (p < 0.0005), whereas expression of constructs that contained 641, 469, or 78 base pairs of 5'-flanking region was not. Nuclear extract from 3T3-L1 adipocytes protected the region from -707 to -681 in the GLUT4 5'-flanking region from DNase I digestion. Using an oligonucleotide probe that corresponded to this footprinted region, two major protein-DNA complexes were identified by a gel mobility shift assay. Southwestern analysis identified four protein bands with molecular masses from 38 to 46 kDa that bound to the insulin-responsive region probe. A reporter gene construct in which bases -706 to -676 were deleted was not repressed by insulin treatment, confirming that this sequence is necessary for the repression of the GLUT4 promoter by insulin in 3T3-L1 adipocytes. This sequence does not show homology to previously described insulin response elements and thus represents a distinct mechanism of gene regulation by insulin.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Cooke, DW (corresponding author), CMSC 3-110,600 N Wolfe St, Baltimore, MD 21287 USA.	dcooke@welchlink.welch.jhu.edu						ALEXANDERBRIDGES M, 1992, MOL CELL BIOCHEM, V109, P99; BODEN G, 1996, DIABETES, V46, P3; BRENOWITZ M, 1997, CURRENT PROTOCOLS MO; BUSE JB, 1992, DIABETES, V41, P1436, DOI 10.2337/diabetes.41.11.1436; EZAKI O, 1993, P NATL ACAD SCI USA, V90, P3348, DOI 10.1073/pnas.90.8.3348; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FLORESRIVEROS JR, 1993, BIOCHEM BIOPH RES CO, V194, P1148, DOI 10.1006/bbrc.1993.1942; Fukuda H, 1997, FEBS LETT, V406, P243, DOI 10.1016/S0014-5793(97)00219-6; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGOWAN KM, 1995, PHARMACOL THERAPEUT, V66, P465, DOI 10.1016/0163-7258(95)00007-4; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OLSON AL, 1995, J BIOL CHEM, V270, P23491, DOI 10.1074/jbc.270.40.23491; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PEDERSEN O, 1992, J CLIN INVEST, V89, P1964, DOI 10.1172/JCI115804; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PRAGER D, 1990, J CLIN INVEST, V85, P1680, DOI 10.1172/JCI114620; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsunoda N, 1997, BIOCHEM BIOPH RES CO, V239, P503, DOI 10.1006/bbrc.1997.7516; Villafuerte BC, 1997, J BIOL CHEM, V272, P5024, DOI 10.1074/jbc.272.8.5024; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367	45	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6210	6217		10.1074/jbc.273.11.6210	http://dx.doi.org/10.1074/jbc.273.11.6210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497344	hybrid			2022-12-27	WOS:000072488500036
J	Ohga, T; Uchiumi, T; Makino, Y; Koike, K; Wada, M; Kuwano, M; Kohno, K				Ohga, T; Uchiumi, T; Makino, Y; Koike, K; Wada, M; Kuwano, M; Kohno, K			Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDR1 GENE; CHEMOTHERAPEUTIC DRUGS; CELL-LINES; EXPRESSION; PROMOTER; AGENTS; KINASE; LIGHT	The human multidrug resistance 1 (MDR1) gene encoding P-glycoprotein is often overexpressed in various human tumors after chemotherapy. During treatment with various chemotherapeutic agents, the MDR1 gene is activated at the transcriptional level and/or amplified, resulting in overexpression. Our previous studies demonstrated that an inverted CCAAT box (Y-box) might be a critical cis-regulatory element regulating UV or drug-induced MDR1 gene expression. We have now established various cell lines from human head and neck cancer KB cells which were stably transfected with the chloramphenicol acetyltransferase (CAT) reporter gene driven by various MDR1 promoter deletion constructs. Transient transfection of antisense YB-1 expression constructs resulted in a decrease of both YB-1 protein levels and DNA binding activity to the inverted CCAAT box, as determined by Western blot and gel mobility shift assays. The limited expression and binding activity due to expression of antisense YB-1 constructs were also observed when cells were treated with UV. CAT activity of constructs containing the Y-box was enhanced after treatment with UV irradiation as well as genotoxic agents such as cisplatin and etoposide. Moreover, this activation was reduced by 50-80% by transfection of antisense YB-1 expression constructs. In contrast, transfection of antisense YB-1 expression constructs had no effect on CAT activity driven by MDR1 promoter constructs not containing the Y-box. These data indicate that YB-1 is directly involved in MDR1 gene activation in response to genotoxic stress.	Kyushu Univ, Sch Med, Dept Biochem, Higashi Ku, Fukuoka 81282, Japan; Univ Occupat & Environm Hlth, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan	Kyushu University; University of Occupational & Environmental Health - Japan	Ohga, T (corresponding author), Kyushu Univ, Sch Med, Dept Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 81282, Japan.	ohga@biochem1.med.kyushu-u.ac.jp						ALVAREZ M, 1995, J CLIN INVEST, V95, P2205, DOI 10.1172/JCI117910; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Beck WT, 1996, CANCER RES, V56, P3010; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Combates NJ, 1997, CELL GROWTH DIFFER, V8, P213; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; KOHNO K, 1992, INT J ONCOL, V1, P73; KOHNO K, 1994, J BIOL CHEM, V269, P20503; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KUSABA H, 1995, GENOME RES, V5, P245, DOI 10.1101/gr.5.3.245; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Makino Y, 1996, NUCLEIC ACIDS RES, V24, P1873, DOI 10.1093/nar/24.10.1873; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; Nakagawa M, 1997, J UROLOGY, V157, P1260, DOI 10.1016/S0022-5347(01)64944-9; Ohga T, 1996, CANCER RES, V56, P4224; Okimoto T, 1996, ONCOGENE, V12, P1625; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Sato S., 1995, Cellular Pharmacology, V2, P153; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; Toh S, 1998, GENE, V206, P93, DOI 10.1016/S0378-1119(97)00570-2; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; WOLFFE AP, 1992, NEW BIOL, V4, P290; YOKOMIZO A, 1995, J BIOL CHEM, V270, P19451, DOI 10.1074/jbc.270.33.19451	30	211	229	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					5997	6000		10.1074/jbc.273.11.5997	http://dx.doi.org/10.1074/jbc.273.11.5997			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497311	hybrid			2022-12-27	WOS:000072488500003
J	Ozawa, M; Kemler, R				Ozawa, M; Kemler, R			Altered cell adhesion activity by pervanadate due to the dissociation of alpha-catenin from the E-cadherin catenin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; AMINO-ACID SUBSTITUTIONS; EPIDERMAL GROWTH-FACTOR; BETA-CATENIN; N-CADHERIN; CYTOPLASMIC DOMAIN; KINASE SUBSTRATE; APC PROTEIN; C-ABL; BINDING	Leukemia cells (K562) that grow as non-adhesive single cells and have no endogenous cadherin were transfected with an E-cadherin expression vector, and cell clones stably expressing E-cadherin on their surface were established. The expression of E-cadherin induced the up-regulation of catenins, and E-cadherin became associated with catenins. The transfected cells grew as floating aggregates. Cell aggregation was Ca2+-dependent and was inhibited by E-cadherin antibodies. The aggregates dissociated into single cells on the addition of pervanadate. Pervanadate caused a dramatic augmentation of the phosphorylation of E-cadherin, beta-catenin, and gamma-catenin (plakoglobin), but alpha-catenin was not detectably phosphorylated. After pervanadate treat ment, beta-catenin and gamma-catenin migrated more slowly on gel electrophoresis, suggesting changes in their conformations due to eventual changes in their phosphorylation levels. In the treated cells, a significant amount of alpha-catenin was dissociated from the E-cadherin catenin complex, Aggregates of cells expressing an E-cadherin chimeric molecule covalently linked with alpha-catenin were not dissociated on pervanadate treatment, supporting the idea that the dissociation of alpha-catenin from the complex underlies the observed E-cadherin dysfunction.	Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan; Max Planck Inst Immunbiol, Abt Mol Embryol, D-79108 Freiburg, Germany	Kagoshima University; Max Planck Society	Ozawa, M (corresponding author), Kagoshima Univ, Fac Med, Dept Biochem, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	mozawa@med2.kufm.kagoshima-u.ac.jp						Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; Ayalon O, 1997, J CELL SCI, V110, P547; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nieset JE, 1997, J CELL SCI, V110, P1013; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Obama H, 1997, J BIOL CHEM, V272, P11017; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1995, J BIOCHEM-TOKYO, V118, P1077, DOI 10.1093/jb/118.5.1077; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Troyanovsky RB, 1996, J CELL SCI, V109, P3069; Tsutsui J, 1996, J BIOCHEM-TOKYO, V120, P1034; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Wahl JK, 1996, J CELL SCI, V109, P1143; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904	54	179	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6166	6170		10.1074/jbc.273.11.6166	http://dx.doi.org/10.1074/jbc.273.11.6166			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497337	hybrid			2022-12-27	WOS:000072488500029
J	Sakakibara, Y; Takami, Y; Nakayama, T; Suiko, M; Liu, MC				Sakakibara, Y; Takami, Y; Nakayama, T; Suiko, M; Liu, MC			Localization and functional analysis of the substrate specificity catalytic domains of human M-form and P-form phenol sulfotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER; SULFATING FORM; KINETIC CHARACTERIZATION; BINDING; IDENTIFICATION; EXPRESSION; SEQUENCE; CDNA; INHIBITOR; PROTEINS	Human monoamine (M)-form and simple phenol (P)-form phenol sulfotransferases (PSTs), which are greater than 93% identical in their primary sequences, were used as models for investigating the structural determinants responsible for their distinct substrate specificity and other enzymatic properties. A series of chimeric PSTs were constructed by reciprocal exchanges of DNA segments between cDNAs encoding M-form and P form PSTs. Functional characterization of the recombinant wild-type M-form, P-form, and chimeric PSTs expressed in Escherichia coli and purified to homogeneity revealed that internal domain spanning amino acid residues 84-148 contain the structural determinants for the substrate specificity of either M form or P-form PST. Data on the kinetic constants (K-m, V-max, and V-max/K-m) further showed the differential roles of the two highly variable regions (Region I spanning amino acid residues 84-89 and Region II spanning amino acid residues 143-148) in substrate binding, catalysis, and sensitivity to the inhibition by 2,6-dichloro-4-nitrophenol. In contrast to the differential sulfotransferase activities of M-form and P-form PSTs toward dopamine and p-nitrophenol, the Dopa/tyrosine sulfotransferase activities were found to be restricted to M-form, but not P-form, PST. Furthermore, the variable Region II of M-form PST appeared to play a predominant role in determining the Dopa/tyrosine sulfotransferase activities of chimeric PSTs. Kinetic studies indicated the role of manganese ions in dramatically enhancing the binding of D-p-tyrosine to wild-type M-form PST. Taken together, these results pinpoint unequivocally the sequence encompassing amino acid residues 84-148 to be the substrate specificity/catalytic domain of both M form and P-form PSTs and indicate the importance of the variable Regions I and II in determining their distinct enzymatic properties.	Univ Texas, Ctr Hlth, Dept Biochem, Tyler, TX 75710 USA; Miyazaki Univ, Dept Biol Resource Sci, Miyazaki 88921, Japan; Miyazaki Med Coll, Dept Biochem, Miyazaki 88916, Japan	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of Miyazaki; University of Miyazaki	Liu, MC (corresponding author), Univ Texas, Ctr Hlth, Dept Biochem, POB 2003, Tyler, TX 75710 USA.	liu@uthct.edu						BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Falany C., 1993, HUMAN DRUG METABOLIS, P101; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FERNANDO PHP, 1993, BIOSCI BIOTECH BIOCH, V5, P1974; FORBESBAMFORTH KJ, 1994, BIOCHEM BIOPH RES CO, V198, P707, DOI 10.1006/bbrc.1994.1102; GANGULY TC, 1995, DRUG METAB DISPOS, V23, P945; JEVONS FR, 1963, BIOCHEM J, V89, P621, DOI 10.1042/bj0890621; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; LIU MC, 1984, P NATL ACAD SCI-BIOL, V81, P3695, DOI 10.1073/pnas.81.12.3695; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; MENA I, 1977, HDB CLIN NEUROLOGY, P217; Molinoff Perry B., 1994, P85; MSTSUI M, 1994, INT J BIOCHEM, V26, P1237; Mulder G.J., 1990, CONJUGATION REACTION, P107; MULDER GJ, 1977, BIOCHEM J, V165, P553, DOI 10.1042/bj1650553; MYTILINEOU C, 1984, SCIENCE, V225, P529, DOI 10.1126/science.6610939; OZAWA S, 1995, PHARMACOGENETICS, V5, pS135, DOI 10.1097/00008571-199512001-00015; REIN G, 1982, BIOCHEM PHARMACOL, V31, P1893, DOI 10.1016/0006-2952(82)90493-2; REITER C, 1982, J PHARMACOL EXP THER, V221, P43; Sakakibara Y, 1997, BBA-MOL CELL RES, V1355, P102, DOI 10.1016/S0167-4889(96)00166-8; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; Suiko M, 1996, BIOCHEM J, V314, P151, DOI 10.1042/bj3140151; Tamura H, 1997, ARCH BIOCHEM BIOPHYS, V341, P309, DOI 10.1006/abbi.1997.9979; VARIN L, 1995, J BIOL CHEM, V270, P12498, DOI 10.1074/jbc.270.21.12498; VERONESE ME, 1994, BIOCHEM J, V302, P497, DOI 10.1042/bj3020497; WEINSHILBOUM R, 1994, CONJUGATION DECONJUG, P45, DOI DOI 10.1007/978-3-642-78429-3; WHITTEMORE RM, 1985, BIOCHEMISTRY-US, V24, P2477, DOI 10.1021/bi00331a013; WILBORN TW, 1993, MOL PHARMACOL, V43, P70; WOOD TC, 1994, BIOCHEM BIOPH RES CO, V198, P1119, DOI 10.1006/bbrc.1994.1159; YAMAZOE Y, 1994, CHEM-BIOL INTERACT, V92, P107, DOI 10.1016/0009-2797(94)90057-4; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313; Zhu XY, 1996, INT J BIOCHEM CELL B, V28, P565, DOI 10.1016/1357-2725(95)00164-6; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V192, P671, DOI 10.1006/bbrc.1993.1467	38	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6242	6247		10.1074/jbc.273.11.6242	http://dx.doi.org/10.1074/jbc.273.11.6242			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497349	hybrid			2022-12-27	WOS:000072488500041
J	Li, H; Chen, JD				Li, H; Chen, JD			The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-RECEPTOR; RETINOIC ACID RECEPTOR; NUCLEAR RECEPTORS; CO-REPRESSOR; ORPHAN RECEPTORS; RESPONSE ELEMENT; X RECEPTOR; SUPERFAMILY; MEDIATE; COMPLEX	Transcriptional coactivators are involved in gene activation by nuclear hormone receptors. The receptor-associated coactivator 3 (RAC3) was recently identified to be highly related to the steroid receptor coactivator-1 and transcriptional intermediate factor 2, thereby establishing a novel family of nuclear receptor coactivators. in this study, we identified a RAC3 fragment containing three LXXLL motifs conserved among this family, which is sufficient to mediate nuclear receptor interaction in viva and in vitro. Point mutations that disrupt ligand-dependent activation function of the receptors inhibited the interaction, We found that a 162-amino acid fragment of RAC3 conferred transcriptional activation and recruited the CREB-binding protein and that three distinct LXXLL motifs mediated the transcriptional activation. A trimeric far Western analysis demonstrated the formation of a ternary complex containing CREB-binding protein, RAC3, and the receptor, in addition, we showed that RAC3, transcriptional intermediate factor 2, and steroid receptor coactivator-1 are expressed in specific tissues and cancer cells and that RAC3 transcript is directly up-regulated by retinoid treatment. These results suggest that RAC3 may contribute to amplified transcriptional responses through both recruitment of additional coactivators and autoregulation by the receptor-coactivator complex.	Univ Massachusetts, Med Ctr, Dept Mol Pharmacol & Toxicol, Sch Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Chen, JD (corresponding author), Univ Massachusetts, Med Ctr, Dept Mol Pharmacol & Toxicol, Sch Med, 55 Lake Ave N, Worcester, MA 01655 USA.	J.Chen@ummed.edu						Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JD, 1997, IN PRESS CRIT REV EU; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lee HY, 1997, CELL GROWTH DIFFER, V8, P283; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZELZER E, 1997, GENE DEV, V11, P2065; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	61	68	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5948	5954		10.1074/jbc.273.10.5948	http://dx.doi.org/10.1074/jbc.273.10.5948			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488734	Green Published, hybrid			2022-12-27	WOS:000072345000077
J	Vavvas, D; Li, X; Avruch, J; Zhang, XF				Vavvas, D; Li, X; Avruch, J; Zhang, XF			Identification of Nore1 as a potential Ras effector	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; KINASE; RECEPTOR; P21(RAS); BINDING; CELLS; TRANSFORMATION; SUFFICIENT; PATHWAY; FAMILY	The small GTP-binding protein Ras is pivotal in transmitting growth and differentiation signals downstream of cell surface receptors. Many observations have indicated that Ras transmits signals from cell surface receptors into multiple pathways via direct interaction with different effecters in mammalian cells. We have identified a novel potential Ras effector or target named Nore1. Nore1 has no significant sequence similarity to known mammalian proteins and lacks an identifiable catalytic domain, but contains sequence motifs that predict DAG_PE binding and SH3 domain binding. We show that Nore1 directly interacts with Ras in vitro in a GTP-dependent manner, and the interaction requires an intact Ras effector domain. Nore1 becomes associated with Ras in situ following activation of epidermal growth factor receptor in COS-7 and in KB cells.	Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Diabet Unit & Med Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Med, Charlestown, MA 02129 USA	Harvard University; Harvard University	Zhang, XF (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Diabet Unit & Med Serv, Charlestown, MA 02129 USA.			Vavvas, Demetrios/0000-0002-8622-6478	NIGMS NIH HHS [GM51281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051281] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; WOODROW MA, 1993, J IMMUNOL, V150, P3853; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	16	165	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5439	5442		10.1074/jbc.273.10.5439	http://dx.doi.org/10.1074/jbc.273.10.5439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488663	hybrid			2022-12-27	WOS:000072345000006
J	Yan, SZ; Rodrigues, RG; Cahn-Hidalgo, D; Walsh, TJ; Roberts, DD				Yan, SZ; Rodrigues, RG; Cahn-Hidalgo, D; Walsh, TJ; Roberts, DD			Hemoglobin induces binding of several extracellular matrix proteins to Candida albicans - Identification of a common receptor for fibronectin, fibrinogen, and laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; STAPHYLOCOCCUS-AUREUS; THROMBOSPONDIN; ADHERENCE; ADHESION; PATHOGENESIS; SPECIFICITY; SEQUENCES; SYSTEMS; LIGAND	Host infection by the pathogenic fungus Candida albicans is initiated by adhesion and mediated by binding to several host extracellular matrix proteins. Previously, we demonstrated that hemoglobin supplemented into a chemically defined medium significantly and specifically induced fibronectin binding to C. albicans. We now report that hemoglobin also induces binding of laminin, fibrinogen, and type IV collagen but not of thrombospondin-1 or type I collagen. The binding of each protein was inhibited by the respective unlabelled ligand in a concentration-dependent manner. Fibrinogen inhibited the binding of radiolabeled fibronectin,, laminin, and fibrinogen with similar IC50 values, suggesting that a single promiscuous, receptor recognizes these three proteins, Competitive binding studies indicated that a second class of receptor binds specifically to laminin. Growth of C. albicans in the presence of hemoglobin also increased cell adhesion to immobilized fibronectin, laminin, fibrinogen, and type IV collagen but not to thrombospondin-1 or type I collagen. Exposure to hemoglobin induced increased or de novo expression of several surface proteins on C. albicans. One of these proteins with a molecular weight of 55,000 recognized fibronectin, based an ligand protection and affinity chromatography an immobilized fibronectin. Thus, hemoglobin induces both promiscuous and specific receptors for extracellular matrix proteins and, therefore, may regulate matrix adhesion during dissemination of C. albicans infections.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Pediat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.		Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BACONBAGULEY T, 1990, J BIOL CHEM, V265, P2317; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BOUCHARA J, 1945, INFECT IMMUN, V48, P90; CALDERONE R, 1994, J MED VET MYCOL, V32, P151; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CASANOVA M, 1992, INFECT IMMUN, V60, P4221, DOI 10.1128/IAI.60.10.4221-4229.1992; DARDIK R, 1989, EUR J BIOCHEM, V185, P581, DOI 10.1111/j.1432-1033.1989.tb15153.x; ESTERLY NB, 1967, J INVEST DERMATOL, V49, P437, DOI 10.1038/jid.1967.66; Hostetter MK, 1996, PEDIATR RES, V39, P569, DOI 10.1203/00006450-199604000-00001; JAKAB E, 1993, APMIS, V101, P187, DOI 10.1111/j.1699-0463.1993.tb00100.x; KLOTZ SA, 1993, MICROB PATHOGENESIS, V14, P133, DOI 10.1006/mpat.1993.1014; KLOTZ SA, 1992, FEMS MICROBIOL LETT, V99, P205, DOI 10.1111/j.1574-6968.1992.tb05567.x; KLOTZ SA, 1991, J INFECT DIS, V163, P604, DOI 10.1093/infdis/163.3.604; KLOTZ SA, 1994, INFECT IMMUN, V62, P4679, DOI 10.1128/IAI.62.10.4679-4681.1994; KLOTZ SA, 1995, MICROBIOL-UK, V141, P2681, DOI 10.1099/13500872-141-10-2681; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LIMPER AH, 1994, IMMUNOL LETT, V42, P139, DOI 10.1016/0165-2478(94)90077-9; LOPEZRIBOT JL, 1994, INFECT IMMUN, V62, P742; LOPEZRIBOT JL, 1994, INFECT IMMUN, V62, P4564; LOPEZRIBOT JL, 1995, INFECT IMMUN, V63, P2126; MANNS JM, 1994, INFECT IMMUN, V62, P5154, DOI 10.1128/IAI.62.11.5154-5156.1994; MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479, DOI 10.1128/IAI.61.6.2479-2485.1993; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEGRE E, 1994, J BIOL CHEM, V269, P22039; Odds F. C., 1994, ASM News (Washington), V60, P313; ODDS FC, 1994, J AM ACAD DERMATOL, V31, pS2, DOI 10.1016/S0190-9622(08)81257-1; PARK PW, 1991, J BIOL CHEM, V266, P23399; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; ROBERTS DD, 1990, AM J RESP CELL MOL, V3, P181, DOI 10.1165/ajrcmb/3.3.181; SEGAL E, 1987, MICROBIOL SCI, V4, P344; Tanaka WTH, 1997, BIOCHEM BIOPH RES CO, V232, P350, DOI 10.1006/bbrc.1997.6247; TANDON NN, 1989, J BIOL CHEM, V264, P7576; THAKUR AK, 1980, ANAL BIOCHEM, V103, P240, DOI 10.1016/0003-2697(80)90263-8; Thornton BP, 1996, J IMMUNOL, V156, P1235; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yan SH, 1996, INFECT IMMUN, V64, P2930, DOI 10.1128/IAI.64.8.2930-2935.1996	40	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5638	5644		10.1074/jbc.273.10.5638	http://dx.doi.org/10.1074/jbc.273.10.5638			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488693	hybrid			2022-12-27	WOS:000072345000036
J	Zhao, Y; Wu, L; Noh, SJ; Guan, KL; Zhang, ZY				Zhao, Y; Wu, L; Noh, SJ; Guan, KL; Zhang, ZY			Altering the nucleophile specificity of a protein-tyrosine phosphatase-catalyzed reaction - Probing the function of the invariant glutamine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-STEADY-STATE; CRYSTAL-STRUCTURE; TRANSITION-STATE; VIRULENCE DETERMINANT; BOVINE HEART; YERSINIA; INTERMEDIATE; PURIFICATION; DEPHOSPHORYLATION; HYDROLYSIS	Protein-tyrosine phosphatases (PTPases) catalysis involves a cysteinyl phosphate intermediate, in which the phosphoryl group cannot be transferred to nucleophiles other than water. The dual specificity phosphatases and the low molecular weight phosphatases utilize the same chemical mechanism far catalysis and contain the same (H/V)C(X)(5)R(S/T) signature motif present in PTPases, Interestingly, the latter two groups of phosphatases do catalyze phosphoryl transfers to alcohols in addition to water, Unique to the PTPase family are two invariant Gin residues which are located at the active site, Mutations at Gln-446 (and to a much smaller extent Gln-450) to Ala, Asn, or Met (but not Glu) residues disrupt a bifurcated hydrogen bond between the side chain of Gln-446 and the nucleophilic water and confer phosphotransferase activity to the Yersinia PTPase, Thus, the conserved Gln-446 residue is responsible for maintaining PTPases' strict hydrolytic activity and for preventing the PTPases from acting as kinases to phosphorylate undesirable substrates, This explains why phosphoryl transfer from the phosphoenzyme intermediate in PTPases can only occur to mater and not to other nucleophilic accepters. Detailed kinetic analyses also suggest roles for Gln-446 and Gln-450 in PTPase catalysis. Although Gln-446 is not essential for the phosphoenzyme formation step, it plays an important role during the hydrolysis of the intermediate by sequestering and positioning the nucleophilic water in the active site for an in-line attack on the phosphorus atom of the cysteinyl phosphate intermediate. Gln-450 interacts through a bound water molecule with the phosphoryl moiety and may play a role for the precise alignment of active site residues, which are important for substrate binding and transition state stabilization for both of the chemical steps.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Yeshiva University; Albert Einstein College of Medicine; University of Michigan System; University of Michigan	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P206; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P7928, DOI 10.1021/bi970364c; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang J, 1997, BIOCHEMISTRY-US, V36, P2993, DOI 10.1021/bi9611873; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1995, BIOCHEMISTRY-US, V34, P10560, DOI 10.1021/bi00033a031; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1996, BIOCHEMISTRY-US, V35, P11797, DOI 10.1021/bi960471r	36	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5484	5492		10.1074/jbc.273.10.5484	http://dx.doi.org/10.1074/jbc.273.10.5484			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488671	hybrid			2022-12-27	WOS:000072345000014
J	Alberts, AS; Bouquin, N; Johnston, LH; Treisman, R				Alberts, AS; Bouquin, N; Johnston, LH; Treisman, R			Analysis of RhoA-binding proteins reveals an interaction domain conserved in heterotrimeric G protein beta subunits and the yeast response regulator protein Skn7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE KINASE; PUTATIVE TARGET; ACTIN POLYMERIZATION; COILED-COIL; FAMILY; GTPASE; RAC; IDENTIFICATION	To identify potential RhoA effector proteins, we conducted a two-hybrid screen for cDNAs encoding proteins that interact with a Gal4-RhoA.V14 fusion protein. In addition to the RhoA effector ROCK-I we identified cDNAs encoding Kinectin, mDia2 (a p140 mDia-related protein), and the guanine nucleotide exchange factor, mNET1. ROCK-I, Kinectin, and mDia2 can bind the wild type forms of both RhoA and Cdc42 in a GTP-dependent manner in vitro. Comparison of the ROCK-I and Kinectin sequences revealed a short region of sequence homology that is both required for interaction in the two-hybrid assay and sufficient for weak interaction in vitro. Sequences related to the ROCK-I/Kinectin sequence homology are present in heterotrimeric G protein beta subunits and in the Saccharomyces cerevisiae Skn7 protein. We show that beta 2 and Skn7 can interact with mammalian RhoA and Cdc42 and yeast Rho1, both in vivo and in vitro. Functional assays in yeast suggest that the Skn7 ROCK-I/Kinectin homology region is required for its function in vivo.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	Cancer Research UK; MRC National Institute for Medical Research	Alberts, AS (corresponding author), Univ Calif San Francisco, Ctr Canc, Box 0128, San Francisco, CA 94143 USA.	alberts@cc.ucsf.edu		Treisman, Richard/0000-0002-9658-0067	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	51	163	172	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 10	1998	273	15					8616	8622		10.1074/jbc.273.15.8616	http://dx.doi.org/10.1074/jbc.273.15.8616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZG331	9535835	hybrid			2022-12-27	WOS:000072990800012
J	DeAngelis, PL; Jing, W; Drake, RR; Achyuthan, AM				DeAngelis, PL; Jing, W; Drake, RR; Achyuthan, AM			Identification and molecular cloning of a unique hyaluronan synthase from Pasteurella multocida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; SYNTHESIZE HYALURONAN; ESCHERICHIA-COLI; GENE; SEQUENCE; RESISTANCE; ALIGNMENT; PYOGENES; CAPSULE; STRAINS	Type A Pasteurella multocida, a prevalent animal pathogen, employs a hyaluronan [HA] polysaccharide capsule to avoid host defenses, We utilized transposon insertional mutagenesis to identify the P. multocida HA synthase, the enzyme that polymerizes HA. A DNA fragment from a wild-type genomic library could direct HA production in vivo in Escherichia coli, a bacterium that normally does not produce HA. Analysis of truncated plasmids derived from the original clone indicated that an open reading frame encoding a 972-residue protein was responsible for HA polymerization, This identification was confirmed by expression cloning in E. coli; we observed HA capsule formation in vivo and detected activity in membrane preparations in vitro, The polypeptide size was verified by photoaffinity labeling of the native P. multocida HA synthase with azido-UDP sugar analogs, Overall, the P. multocida sequence is not very similar to the other known HA synthases from streptococci, PBCV-1 virus, or vertebrates. Instead, a portion of the central region of the new enzyme is more homologous to the amino termini of other bacterial glycosyltransferases that produce different capsular polysaccharides or lipopolysaccharides. In summary, rye have discovered a unique HA synthase that differs in sequence and predicted topology from the other known enzymes.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Arkansas System; University of Arkansas Medical Sciences	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@OUHSC.edu			NIGMS NIH HHS [R01-GM56497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; CARTER GR, 1953, AM J VET RES, V14, P475; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DEANGELIS PL, 1994, DIAGN MICR INFEC DIS, V20, P77, DOI 10.1016/0732-8893(94)90095-7; DEANGELIS PL, 1998, IN PRESS MICROB PATH, V24; HANSEN LM, 1989, VET MICROBIOL, V21, P177, DOI 10.1016/0378-1135(89)90030-8; HARMON BG, 1991, AM J VET RES, V52, P1507; HELDERMON CD, 1997, GLYCOBIOLOGY, V7, P1032; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KROLL JS, 1990, MOL MICROBIOL, V4, P1853, DOI 10.1111/j.1365-2958.1990.tb02034.x; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; QUINN RW, 1957, BIOCHEM J, V95, P290; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; ROBERTS IS, 1988, J BACTERIOL, V170, P1305, DOI 10.1128/jb.170.3.1305-1310.1988; SNIPES KP, 1987, AVIAN DIS, V31, P254, DOI 10.2307/1590869; SUNTHANKAR P, 1998, IN PRESS ANAL BIOCH; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; [No title captured]	31	105	127	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8454	8458		10.1074/jbc.273.14.8454	http://dx.doi.org/10.1074/jbc.273.14.8454			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525958	hybrid			2022-12-27	WOS:000072876300092
J	Eng, FJ; Novikova, EG; Kuroki, K; Ganem, D; Fricker, LD				Eng, FJ; Novikova, EG; Kuroki, K; Ganem, D; Fricker, LD			gp180, a protein that binds duck hepatitis B virus particles, has metallocarboxypeptidase D-like enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND CARBOXYPEPTIDASE; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; AMINOPEPTIDASE-N; CDNA CLONING; HUMAN-PLASMA; PURIFICATION; GLYCOPROTEIN; RECEPTOR; BOVINE	Duck gp180 was previously identified by its ability to bind to the preS envelope. protein of duck hepatitis B virus particles (Kuroki, K. Cheung R., Marion, P. L., and Ganem, D. (1994) J. Virol, 68, 2091-2096). Cloning and sequencing of gp180 cDNA revealed that it is a polyprotein with three carboxypeptidase-like domains (Kuroki, K., Eng, F., Ishikawa, T., Turck, C., Harada, F., and Ganem, D. (1995) J. Biol. Chem, 270, 15022-15028), To evaluate enzymatic properties of this protein, a soluble 1.70-kDa form of the protein (gp170) lacking the C-terminal transmembrane domain and cytoplasmic tail was expressed in a baculovirus system, The purified 170-kDa protein cleaved 5-dimethylaminonaphthalene-1-sulfonyl (dansyl)-Phe-Ala-Arg with a pH optimum of 5.5-6.5, With this substrate at pH 5.5, the 170-kDa protein displayed a K-m of 12 mu M and a K-cat of 57 s(-1). Dansyl-Pro-Ala-Arg and dansyl-Phe-Phe-Arg were cleaved with K-m values of 17 and 21 mu M, and a K-cat of 57 and 17 s(-1), respectively. Constructs containing only the first or second carboxypeptidase domains also showed enzymatic activity. The effects of inhibitors and ions on enzyme activity of gp170 were generally similar to the effects of these compounds on purified bovine carboxypeptidase D. To evaluate the regions within gp180 necessary for binding preS, a series of deletion mutants mere expressed in the 293T human kidney cell fine, Deletions of the first and second domains, leaving the third domain intact, eliminated carboxypeptidase activity but retained preS binding, Deletion of the third domain eliminated preS binding but not carboxypeptidase activity. These results indicate that the third domain is responsible for preS binding, and this binding does not require carboxypeptidase activity.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Calif San Francisco, Dept Microbiol, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Kanazawa Univ, Canc Res Inst, Dept Biophys, Kanazawa, Ishikawa 920, Japan	Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Kanazawa University	Eng, FJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [5T32CA09043] Funding Source: Medline; NIAID NIH HHS [AI-31973] Funding Source: Medline; NIDDK NIH HHS [DK-51271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1995, METH NEUROSCI; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; BUNNETT NW, 1992, GASTROENTEROLOGY, V102, P76, DOI 10.1016/0016-5085(92)91786-4; DAVIES RC, 1968, BIOCHEMISTRY-US, V7, P1090, DOI 10.1021/bi00843a029; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; EATON DL, 1991, J BIOL CHEM, V266, P21833; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FIGUEIREDO E, 1994, BIOCHEM J, V300, P15, DOI 10.1042/bj3000015; Folk J. E., 1971, ENZYMES, P57; FOLK JE, 1960, J BIOL CHEM, V235, P2272; FRICKER LD, 1982, LIFE SCI, V31, P1841, DOI 10.1016/0024-3205(82)90224-7; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1988, BRAIN RES, V453, P281, DOI 10.1016/0006-8993(88)90168-0; FRICKER LD, 1901, PEPTIDE BIOSYNTHESIS, P199; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; GREENE D, 1992, BIOCHEM J, V285, P613, DOI 10.1042/bj2850613; ISHIKAWA T, 1994, VIROLOGY, V202, P1061, DOI 10.1006/viro.1994.1440; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NARAHASHI Y, 1979, J BIOCHEM-TOKYO, V86, P683, DOI 10.1093/oxfordjournals.jbchem.a132572; OSTERMAN A L, 1984, Biokhimiya, V49, P292; PLUMMER TH, 1981, METHOD ENZYMOL, V80, P442; Sambrook J., 2002, MOL CLONING LAB MANU; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; Song LX, 1997, J BIOL CHEM, V272, P10543; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; TAN FL, 1989, J BIOL CHEM, V264, P13165; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0	37	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					8382	8388		10.1074/jbc.273.14.8382	http://dx.doi.org/10.1074/jbc.273.14.8382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525948	hybrid			2022-12-27	WOS:000072876300082
J	Matsumoto, K; Yamamoto, T; Kurachi, H; Nishio, Y; Takeda, T; Homma, H; Morishige, K; Miyake, A; Murata, Y				Matsumoto, K; Yamamoto, T; Kurachi, H; Nishio, Y; Takeda, T; Homma, H; Morishige, K; Miyake, A; Murata, Y			Human chorionic gonadotropin-alpha gene is transcriptionally activated by epidermal growth factor through cAMP response element in trophoblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIOCARCINOMA CELLS; BINDING PROTEIN CREB; CYCLIC-AMP; SUBUNIT GENE; SIGNAL-TRANSDUCTION; DIRECT PHOSPHORYLATION; PLACENTAL-LACTOGEN; SOMATOSTATIN GENE; CYP11A1 PROMOTER; EGF RECEPTOR	The purpose of this study was to analyze the mechanism of transcriptional activation of human chorionic gonadotropin-alpha (hCG alpha) gene by epidermal growth factor (EGF) in trophoblast cells. We stably transfected hCG alpha promotor-chloramphenicol acetyltransferase constructs into Rcho-1 trophoblast cells and monitored the promoter activities. -290-base pair hCG alpha promoter containing a tandem repeat of cAMP response element (CRE) was activated by EGF in a dose- and time-dependent manner. Deletion analysis of hCG alpha promoter suggested an involvement of CRE in EGF-induced hCG alpha transcriptional activation. Moreover, the hCG alpha promoter, of which both CREs were mutated, did not respond to EGF. These results indicate that EGF activates the hCG alpha gene transcription through CRE. Although EGF did not alter the amount of CRE-binding protein (CREB), EGF induced CREB phosphorylation. We next examined the mechanism of CREB phosphorylation by EGF. Protein kinase C inhibitors (H7, staurosporin, and chelerythrine) inhibited EGF-induced CREB phosphorylation, whereas either mitogen-activated protein kinase kinase-1 inhibitor (PD98059) or protein kinase A inhibitor (H8) showed no effect. Furthermore, H7 and staurosporin but not H8 inhibited hCG alpha promoter activation by EGF. In conclusion,. EGF promotes hCG alpha gene transcription via the CRE region probably by phosphorylating CREB mainly through the protein kinase C pathway in trophoblast cells.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 565, Japan	Osaka University	Yamamoto, T (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	yamamato@gyne.med.osaka-u.ac.jp						ADAMSON ED, 1984, DEV BIOL, V103, P62, DOI 10.1016/0012-1606(84)90007-1; AMEMIYA K, 1994, J ENDOCRINOL, V143, P291, DOI 10.1677/joe.0.1430291; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; BARNEA ER, 1990, J CLIN ENDOCR METAB, V71, P923, DOI 10.1210/jcem-71-4-923; BENVENISTE R, 1978, J CLIN ENDOCR METAB, V46, P169, DOI 10.1210/jcem-46-1-169; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CAO H, 1994, ENDOCRINOLOGY, V135, P962, DOI 10.1210/en.135.3.962; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEGINI N, 1985, J CLIN ENDOCR METAB, V61, P529, DOI 10.1210/jcem-61-3-529; CHEN CF, 1988, J CLIN ENDOCR METAB, V67, P1171, DOI 10.1210/jcem-67-6-1171; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895, DOI 10.1210/endo-129-6-2895; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; FUJITA Y, 1991, J CLIN ENDOCR METAB, V72, P1340, DOI 10.1210/jcem-72-6-1340; FUTAMURA K, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P1641; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; JAMESON JL, 1988, MOL CELL BIOL, V8, P5100, DOI 10.1128/MCB.8.12.5100; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KURACHI H, 1985, J ENDOCRINOL, V106, P197, DOI 10.1677/joe.0.1060197; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; MARUO T, 1992, J CLIN ENDOCR METAB, V75, P1362, DOI 10.1210/jcem.75.5.1430098; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; MEDCALF RL, 1991, MOL ENDOCRINOL, V5, P1773, DOI 10.1210/mend-5-12-1773; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MORRISH DW, 1987, J CLIN ENDOCR METAB, V65, P1282, DOI 10.1210/jcem-65-6-1282; Pestell RG, 1996, MOL ENDOCRINOL, V10, P1084, DOI 10.1210/me.10.9.1084; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; RAO CV, 1984, J CLIN ENDOCR METAB, V58, P1034, DOI 10.1210/jcem-58-6-1034; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; RITVOS O, 1988, ENDOCRINOLOGY, V123, P859, DOI 10.1210/endo-123-2-859; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHI HP, 1994, J BIOL CHEM, V269, P12973; SHIDA MM, 1993, MOL ENDOCRINOL, V7, P181, DOI 10.1210/me.7.2.181; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TESHIMA S, 1983, JPN J CANCER RES, V74, P205; TSUTSUMI O, 1987, AM J OBSTET GYNECOL, V156, P241, DOI 10.1016/0002-9378(87)90245-6; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; XIE HJ, 1995, J IMMUNOL, V154, P1717; Yamamoto T, 1997, J REPROD FERTIL, V111, P15, DOI 10.1530/jrf.0.1110015; YAMAMOTO T, 1994, J BIOL CHEM, V269, P6517	62	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7800	7806		10.1074/jbc.273.14.7800	http://dx.doi.org/10.1074/jbc.273.14.7800			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525871	hybrid			2022-12-27	WOS:000072876300005
J	Clement, S; Velasco, PT; Murthy, SNP; Wilson, JH; Lukas, TJ; Goldman, RD; Lorand, L				Clement, S; Velasco, PT; Murthy, SNP; Wilson, JH; Lukas, TJ; Goldman, RD; Lorand, L			The intermediate filament protein, vimentin, in the lens is a target for cross-linking by transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; BINDING PROTEIN; FACTOR-XIIIA; AMINE-DONOR; ALPHA-1-ADRENERGIC RECEPTOR; TISSUE TRANSGLUTAMINASE; BETA-CRYSTALLIN; OCULAR LENS; HEAD DOMAIN; KINASE-A	Mere addition of Ca2+ to a lens cortical homogenate (bovine) generates a series of products composed of a variety of high molecular weight vimentin species. The Ca2+-induced cross-linking of this cytoskeletal element seems to be mediated by the intrinsic transglutaminase of lens, because the reaction could be blocked at the monomeric state of vimentin by the inclusion of small synthetic substrates of the enzyme dansylcadaverine or dansyl-epsilon-aminocaproyl-Gln-Gln-Ile-Val. These compounds are known to compete against the Gin or Lys functionalities of proteins that would participate in forming the N-epsilon(gamma-glutamyl)lysine protein-to-protein cross-links. The cytosolic transglutaminase-catalyzed reactions could be reproduced with purified bovine lens vimentin and also with recombinant human vimentin preparations. Employing the latter system, we have titrated the transglutaminase-reactive sites of vimentin and, by sequencing the dansyl-tracer-labeled segments of the protein, we have shown that residues Gln(453) and Gln(460) served as acceptor functionalities and Lys(97), Lys(104), Lys(294), and Lys(439) as electron donor functionalities in vimentin. The transglutaminase-dependent reaction of this intermediate filament protein might influence the shape and plasticity of the fiber cells, and the enzyme catalyzed crosslinking of vimentin, in conjunction with other lens constituents, may contribute to the process of cataract formation.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Lorand, L (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NEI NIH HHS [EY-03942] Funding Source: Medline; NIGMS NIH HHS [NIGMS-30861, NIGMS-36806] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036806, R01GM036806, R01GM030861] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; BAGCHI M, 1985, EXP EYE RES, V40, P385, DOI 10.1016/0014-4835(85)90151-4; BERBERS GAM, 1983, EUR J BIOCHEM, V135, P315, DOI 10.1111/j.1432-1033.1983.tb07655.x; BJERRUM OJ, 1981, J SUPRAMOL STR CELL, V16, P289, DOI 10.1002/jsscb.1981.380160309; CARY RB, 1994, J CELL SCI, V107, P1609; Chan YM, 1996, J INVEST DERMATOL, V106, P327, DOI 10.1111/1523-1747.ep12342985; CHEN H, 1995, J INVEST DERMATOL, V105, P629, DOI 10.1111/1523-1747.ep12323846; Chou YH, 1996, J CELL SCI, V109, P817; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Clement S, 1997, J INVEST DERMATOL, V109, P778, DOI 10.1111/1523-1747.ep12340949; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CROALL DE, 1986, CELL CALCIUM, V7, P29, DOI 10.1016/0143-4160(86)90028-X; ECKELT A, 1992, EUR J CELL BIOL, V58, P319; EVANS RM, 1989, J CELL BIOL, V108, P67, DOI 10.1083/jcb.108.1.67; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; Fuchs E, 1997, MOL BIOL CELL, V8, P189, DOI 10.1091/mbc.8.2.189; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GROENEN PJTA, 1993, BIOCHEM J, V295, P399, DOI 10.1042/bj2950399; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; HOVNANIAN A, 1993, NAT GENET, V3, P327, DOI 10.1038/ng0493-327; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; KOUKLIS PD, 1993, J CELL SCI, V106, P919; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LEHTO VP, 1983, J CELL BIOL, V96, P703, DOI 10.1083/jcb.96.3.703; LIESKA N, 1980, BIOCHIM BIOPHYS ACTA, V626, P136, DOI 10.1016/0005-2795(80)90205-6; LISMA SE, 1997, BIOCHEMISTRY-US, V36, P11655; LORAND L, 1985, BIOCHEMISTRY-US, V24, P1525, DOI 10.1021/bi00327a035; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; Lorand L, 1998, P NATL ACAD SCI USA, V95, P537, DOI 10.1073/pnas.95.2.537; LORAND L, 1992, BIOCONJUGATE CHEM, V3, P37, DOI 10.1021/bc00013a006; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; MANN KG, 1993, METHOD ENZYMOL, V222, P1; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; MOCKROS LF, 1974, BIOPHYS CHEM, V2, P164, DOI 10.1016/0301-4622(74)80037-2; MURTHY SNP, 1994, J BIOL CHEM, V269, P22907; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NELSON WJ, 1983, MOL CELL BIOL, V3, P1146, DOI 10.1128/MCB.3.6.1146; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; SAMOKHIN GP, 1995, J BIOL CHEM, V270, P21827, DOI 10.1074/jbc.270.37.21827; SAX CM, 1993, GENE, V130, P277, DOI 10.1016/0378-1119(93)90431-2; SAX CM, 1990, DEV BIOL, V139, P56, DOI 10.1016/0012-1606(90)90278-Q; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SIMON M, 1988, J BIOL CHEM, V263, P18093; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; SYBERT VP, 1994, J INVEST DERMATOL, V102, P822, DOI 10.1111/1523-1747.ep12381585; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREJOSKALLI AV, 1995, P NATL ACAD SCI USA, V92, P8940, DOI 10.1073/pnas.92.19.8940; VELASCO PT, 1988, BIOCHEM BIOPH RES CO, V152, P505, DOI 10.1016/S0006-291X(88)80066-4; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121; YANG HY, 1985, J CELL BIOL, V100, P620, DOI 10.1083/jcb.100.2.620	65	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7604	7609		10.1074/jbc.273.13.7604	http://dx.doi.org/10.1074/jbc.273.13.7604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516464	hybrid			2022-12-27	WOS:000072738500060
J	Bittel, D; Dalton, T; Samson, SLA; Gedamu, L; Andrews, GK				Bittel, D; Dalton, T; Samson, SLA; Gedamu, L; Andrews, GK			The DNA binding activity of metal response element-binding transcription factor-1 is activated in vivo and in vitro by zinc, but not by other transition metals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN-II GENES; FACTOR MTF-1; CONFERS RESISTANCE; PROMOTER ELEMENTS; OXIDATIVE STRESS; TRANSGENIC MICE; HEAVY-METALS; CADMIUM; PROTEIN; MOUSE	We examined the DNA binding activity of mouse and human MTF-1 in whole cell extracts from cells cultured in medium containing zinc or cadmium and from untreated cells after the in vitro addition of zinc or cadmium, as well as using recombinant MTF-1 transcribed and translated in vitro and treated with various transition metals, Incubation of human (HeLa) or mouse (Hepa) cells in medium containing cadmium (5-15 mu M) did not lead to a significant increase (<2-fold) in the amount of MTF-I DNA binding activity, whereas zinc (100 mu M) led to a 6-15-fold increase within 1 h, MTF-1 binding activity was low, but detectable, in control whole cell extracts and was increased (>10 fold) after the in vitro addition of zinc (30 mu M) and incubation at 37 degrees C for 15 min, In contrast, addition of cadmium (6 or 60 mu M) did not activate MTF-1 binding activity, Recombinant mouse and human MTF-1 were also dependent on exogenous zinc for DNA binding activity, Cadmium did not facilitate activation of recombinant MTF-1, but instead inhibited the activation of the recombinant protein by zinc, Interestingly, glutathione (1 mM) protected recombinant MIF-1 from inactivation by cadmium, and allowed for activation by zinc, It was also noted that zinc-activated recombinant MTF-1 was protected from cadmium only when bound to DNA These results suggest that cadmium interacts with the zinc fingers of MTF-1 and forms an inactive complex, Of the several transition metals (zinc, cadmium, nickel, silver, copper, and cobalt) examined, only zinc facilitated activation of the DNA binding activity of recombinant MTF-1, These data suggest that transition metals, other than zinc, that activate MT gene expression may do so by mechanisms independent of an increase in the DNA binding activity of MTF-1.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Kansas; University of Kansas Medical Center; University of Calgary	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	gandrews@kumc.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005753, R01ES005704] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05753, ES05704] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSEN RD, 1990, NUCLEIC ACIDS RES, V18, P6049, DOI 10.1093/nar/18.20.6049; ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; Ballatori N, 1994, Adv Pharmacol, V27, P271, DOI 10.1016/S1054-3589(08)61036-4; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CHABEREK S, 1959, ORGANIC SEQUESTERING; CHAO SH, 1995, ARCH TOXICOL, V69, P197, DOI 10.1007/s002040050158; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; FERREIRA AMD, 1993, BIOCHEM J, V292, P673, DOI 10.1042/bj2920673; FOSTER R, 1991, J BIOL CHEM, V266, P9866; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; SAMSON SLA, 1995, J BIOL CHEM, V270, P6864, DOI 10.1074/jbc.270.12.6864; SHI YG, 1993, BIOPHYS J, V64, P749, DOI 10.1016/S0006-3495(93)81435-8; SMITH JB, 1989, J BIOL CHEM, V264, P7115; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TANG N, 1993, TOXICOLOGY, V81, P155, DOI 10.1016/0300-483X(93)90007-F; VIG PJS, 1991, BIOCHEM INT, V23, P927; WAN M, 1993, BIOCHEM J, V292, P609, DOI 10.1042/bj2920609; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	43	160	167	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7127	7133		10.1074/jbc.273.12.7127	http://dx.doi.org/10.1074/jbc.273.12.7127			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507026	hybrid			2022-12-27	WOS:000072775900076
J	Kang, SW; Baines, IC; Rhee, SG				Kang, SW; Baines, IC; Rhee, SG			Characterization of a mammalian peroxiredoxin that contains one conserved cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; THIOL-SPECIFIC ANTIOXIDANT; SALMONELLA-TYPHIMURIUM; THIOREDOXIN REDUCTASE; ESCHERICHIA-COLI; NADH PEROXIDASE; SULFENIC ACID; REDOX CENTER; PURIFICATION; CLONING	A new type of peroxidase enzyme, named thioredoxin peroxidase (TPx), that reduces H2O2 with the use of electrons from thioredoxin and contains two essential cysteines was recently identified. TPx homologs, termed peroxiredoxin (Prx), have also been identified and include several proteins, designated 1-Cys Prx, that contain only one conserved cysteine, Recombinant human 1-Cys Prx expressed in and purified from Escherichia coli has now been shown to reduce H2O2 with electrons provided by dithiothreitol. Furthermore, human 1-Cys Prx transiently expressed in NIH 3T3 cells was able to remove intracellular H2O2 generated in response either to the addition of exogenous H2O2 or to treatment with platelet-derived growth factor. The conserved Cys(47)-SH group was shown to be the site of oxidation by H2O2. Thus, mutation of Cys(47) to serine abolished peroxidase activity. Moreover, the oxidized intermediate appears to be Cys-SOH. In contrast to TPx, in which one of the two conserved cysteines is oxidized to Cys-SOH and then immediately reacts with the second conserved cysteine of the second subunit of the enzyme homodimer to form an intermolecular disulfide, the Cys-SOH of 1-Cys Prx does not form a disulfide. Neither thioredoxin, which reduces the disulfide of TPx, nor glutathione, which reduces the Cys-SeOH of oxidized glutathione peroxidase, was able to reduce the Cys-SOH of 1-Cys Prx and consequently could not support peroxidase activity. Human 1-Cys Prx was previously shown to exhibit a low level of phospholipase A(2) activity at an acidic pH; the enzyme was thus proposed to be lysosomal, and Ser(32) was proposed to be critical for lipase function. However, the mutation of Ser(32) or Cys(47) has now been shown to have no effect on the lipase activity of 1-Cys Prx, which was also shown to be a cytosolic protein. Thus, the primary cellular function of 1-Cys Prx appears to be to reduce peroxides with the use of electrons provided by an as yet unidentified source; the enzyme therefore represents a new type of peroxidase.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Room 122, Bethesda, MD 20892 USA.							ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAE HZ, 1994, BIOFACTORS, V4, P177; DAVIS FA, 1981, J AM CHEM SOC, V103, P7016, DOI 10.1021/ja00413a064; DEBOER E, 1988, J BIOL CHEM, V263, P12326; DREWENDA ZS, 1993, TENDS BIOCH SCI, V18, P20; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; Halliwell B, 1989, FREE RADICAL BIOL ME; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim TS, 1997, J BIOL CHEM, V272, P2542; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; POOLE LB, 1989, J BIOL CHEM, V264, P12330; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; RHEE SG, 1994, MOL CELLS, V4, P137; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tappel A L, 1978, Methods Enzymol, V52, P506; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	33	396	411	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6303	6311		10.1074/jbc.273.11.6303	http://dx.doi.org/10.1074/jbc.273.11.6303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497358	hybrid			2022-12-27	WOS:000072488500050
J	Chen, P; Tian, J; Kovesdi, I; Bruder, JT				Chen, P; Tian, J; Kovesdi, I; Bruder, JT			Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF-INDUCED RELEASE; ARACHIDONIC-ACID; MOLECULAR MECHANISMS; E3 REGION; DEATH; CYTOLYSIS; RECEPTOR; COMPLEX; PATHWAY	Adenovirus type 5 encodes a 14.7-kDa protein that protects infected cells from tumor necrosis factor-induced cytolysis by an unknown mechanism, In this report, we demonstrate that infection of cells with an adenovirus vector expressing Fas ligand induced rapid apoptosis that was blocked by coinfection with a virus expressing 14.7K. Moreover, AdFasL/G infection resulted in the rapid activation of DEVD-specific caspases, and caspase activation was blocked by coinfection with Ad14.7/G. Cell death induced by the overexpression of Fas ligand, Fas-associated death domain-containing protein (FADD)/MORT1, or FADD-like interleukin-1 beta-converting enzyme (FLICE)/caspase-8 in a virus-free system was efficiently blocked by 14.7K expression. Moreover, we demonstrate that 14.7K interacts with FLICE. These results support the idea that FLICE is a cellular target for the 14.7-kDa protein.	GenVec Inc, Rockville, MD 20852 USA		Bruder, JT (corresponding author), GenVec Inc, 12111 Parklawn Dr, Rockville, MD 20852 USA.			Kovesdi, Imre/0000-0002-0322-3969				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bruder JT, 1997, J VIROL, V71, P7623, DOI 10.1128/JVI.71.10.7623-7628.1997; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; GOODING LR, 1990, CRIT REV IMMUNOL, V10, P53; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; Kovesdi I, 1997, CURR OPIN BIOTECH, V8, P583, DOI 10.1016/S0958-1669(97)80033-X; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; RANHEIM TS, 1993, J VIROL, V67, P2159, DOI 10.1128/JVI.67.4.2159-2167.1993; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; ZILLI D, 1992, BIOCHEM BIOPH RES CO, V188, P177, DOI 10.1016/0006-291X(92)92366-6	28	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5815	5820		10.1074/jbc.273.10.5815	http://dx.doi.org/10.1074/jbc.273.10.5815			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488717	hybrid			2022-12-27	WOS:000072345000060
J	Tortorella, MD; Pratta, MA; Fox, JW; Arner, EC				Tortorella, MD; Pratta, MA; Fox, JW; Arner, EC			The interglobular domain of cartilage aggrecan is cleaved by hemorrhagic metalloproteinase HT-d (Atrolysin C) at the matrix metalloproteinase and aggrecanase sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTICULAR-CARTILAGE; DISINTEGRIN PROTEIN; STROMELYSIN; PROTEOLYSIS; CATABOLISM; CLONING; VENOM	Two primary cleavage sites have been identified within the interglobular domain of the cartilage aggrecan core protein: one is between amino acid residues Asn(341) and Phe(342), where many matrix metalloproteinases (MMP) have been shown to cleave; and the other is between amino acid residues Glu(373) and Ala(374). Although cleavage ma, the Glu(373)-Ala(374) site is believed to play a critical role in cartilage aggrecan degradation in arthritic diseases, the enzyme responsible for cleavage at this site, "aggrecanase," has not been identified, Members of the ADAM (a disintegrin and metalloproteinase) family of proteins, which shows structural homology to the snake venom hemorrhagic metalloproteinases (reprolysins), have recently been demonstrated to be expressed in articular chondrocytes. Because many ADAM family members have a putative proteinase function, this raises the possibility that aggrecanase may be a member of this family of proteases. Tea examine whether reprolysins have the ability to cleave aggrecan at either the aggrecanase site or the MMP site, the snake venom hemorrhagic toxin metalloproteinase HT-d (atrolysin C) was tested for its ability to cleave bovine aggrecan monomer. Cleavage was monitored using the BC-3 antibody, which recognizes aggrecan fragments with the neu NH2 terminus ARGSV generated by cleavage at the aggrecanase site, and with the AF-28 antibody, which recognizes aggrecan fragments with the new NH2 terminus FFGVG generated lay cleavage at the MMP site, Cleavage at both the aggrecanase and MMP sites occurred in a concentration-dependent manner with 100 net atrolysin C or greater, AF-28-reactive fragments were generated by 30 min of incubation, and levels were maximal by 8 h; BC-3-reactive fragments were detected at 2 h and continued to increase through 48 h, thus suggesting that atrolysin C can cleave at the MMP and aggrecanase sites, NH2-terminal aggrecan fragments generated by cleavage at the aggrecanase site were also detected using antisera recognizing the new COOH terminus, NITEGE, formed by cleavage at the Glu(373)-Ala(374) bond, indicating that cleavage at this site does not require prior cleavage at the MMP site, These data provide the first demonstration that a reprolysin can cleave the core protein of aggrecan and the first example of a specific protease that can cleave at the first example site independent of cleavage at the MMP cleavage site.	Dupont Merck Pharmaceut Co, Expt Stn E400 4243, Inflammatory Dis Res, Wilmington, DE 19880 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	DuPont; University of Virginia	Tortorella, MD (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn E400 4243, Inflammatory Dis Res, POB 400, Wilmington, DE 19880 USA.							ANDREWS HJ, 1992, AGENTS ACTIONS, V37, P147, DOI 10.1007/BF01987904; Arner EC, 1997, J BIOL CHEM, V272, P9294; BJARNASON JB, 1978, BIOCHEMISTRY-US, V17, P3395, DOI 10.1021/bi00609a033; DALAS DJ, 1996, J BONE MINER RES, V11, P326; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FOX JW, 1996, ZINC METALLOPROTEINA, P47; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HOWARD L, 1995, METHOD ENZYMOL, V248, P388; HUANG JJ, 1987, MOL BIOL MED, V4, P169; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Kopper L, 1990, In Vivo, V4, P149; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOEHMANDER SL, 1993, ARTHRITIS RHEUM, V36, P181; McKie N, 1997, BIOCHEM BIOPH RES CO, V230, P335, DOI 10.1006/bbrc.1996.5957; McKie N, 1996, BIOCHEM J, V318, P459, DOI 10.1042/bj3180459; Melrose J, 1996, ELECTROPHORESIS, V17, P205, DOI 10.1002/elps.1150170134; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585; ZHANG DC, 1994, P NATL ACAD SCI USA, V91, P8447, DOI 10.1073/pnas.91.18.8447	30	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5846	5850		10.1074/jbc.273.10.5846	http://dx.doi.org/10.1074/jbc.273.10.5846			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488721	hybrid			2022-12-27	WOS:000072345000064
J	Liu, YT; Yin, HL				Liu, YT; Yin, HL			Identification of the binding partners for flightless I, a novel protein bridging the Leucine-rich repeat and the gelsolin superfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; ACTIN; GENE; EXPRESSION; DOMAINS; DIFFERENTIATION; TRANSFORMATION; GCAP39; MOTIF; CELLS	Flightless-I (fliI) is a novel member of the gelsolin family that is important for actin organization during Drosophila embryogenesis and myogenesis. Drosophila fliI and the human homolog FLI both contain the classic gelsolin 6-fold segmental repeats and an amino-terminal extension of 16 tandem leucine-rich repeats (LRR). LRR repeats form amphipathic beta-alpha structural units that mediate protein-protein interactions. Although there are close to 100 known LRR domain-containing proteins, only a few binding pairs have been identified. In this paper, we used biochemical and genetic approaches to identity proteins that interact with human FLI. In vitro synthesized FLI bound to actin-Sepharose and binding was reduced by competition with excess soluble actin. Actin binding was mediated though the gelsolin-like domain and not the LRR domain. Although the FLI LRR module is most closely related to the LRR domains of Ras-interactive proteins, FLI does not associate with Ras, selected Ras effectors, or other Ras-related small GTPases. Two-hybrid screens using FLI LRR as bait identified a novel LRR binding partner. The 0.65-kilobase pair (kb) clone from the screen survived additional rounds of stringent two-hybrid pairwise assays, establishing a specific interaction. Binding FLI LRR was corroborated by co-immunoprecipitation with FLI LRR. The translated sequence of the FLI LRR associated protein (FLAP) encodes a novel protein not represented in the data base. Northern blot analyses revealed four FLAP messages of approximately 2.7, 2.9, 3.3, and 5.1 kb, which are differentially expressed in the tissues tested. Skeletal and cardiac muscles are particularly rich in the 3.3-kb FLAP message, and the FLI message aas well. Full-length FLAP clones were isolated from a mouse skeletal muscle cDNA library. They have an open reading frame which encodes for a protein containing 626 amino acids. Sequence analyses predict that the FLAP protein is rich in alpha-helices and contains stretches of dimeric coiled coil in its middle region and COOH terminus. The identification of actin and FLAP as a binding ligands for the gelsolin-like domain and the LRR domain, respectively, suggests that FLI may link the actin cytoskeleton to other modules implicated in intermolecular recognition and structural organization.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Cell Regulat Grad Program, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA.	yin0l@utsw.swmed.edu			NIGMS NIH HHS [R01 GM51112] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051112] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; Campbell HD, 1997, GENOMICS, V42, P46, DOI 10.1006/geno.1997.4709; CHEN KS, 1995, AM J HUM GENET, V56, P175; CLAUDIANOS C, 1995, MOL BIOL EVOL, V12, P405; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECOUET HG, 1995, GENETICS, V141, P1049; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; LIU YT, 1997, IN PRESS G PROTEINS; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; MARKUS MA, 1994, PROTEIN SCI, V3, P70; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MIKLOS GLG, 1990, J NEUROGENET, V6, P133, DOI 10.3109/01677069009107106; MINATO T, 1994, J BIOL CHEM, V269, P20845; ONODA K, 1993, CELL MOTIL CYTOSKEL, V26, P227, DOI 10.1002/cm.970260306; PRINGAULT E, 1986, EMBO J, V5, P3119, DOI 10.1002/j.1460-2075.1986.tb04618.x; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHNUCHEL A, 1995, J MOL BIOL, V247, P21, DOI 10.1006/jmbi.1994.0118; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; Straub KL, 1996, J CELL SCI, V109, P263; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TAYAR EN, 1996, MOL CELL ENDOCRINOL, V125, P65; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	52	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 3	1998	273	14					7920	7927		10.1074/jbc.273.14.7920	http://dx.doi.org/10.1074/jbc.273.14.7920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZF226	9525888	hybrid			2022-12-27	WOS:000072876300022
J	Kleeff, J; Korc, M				Kleeff, J; Korc, M			Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta 1 in COLO-357 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITORS; HUMAN PANCREATIC-CANCER; TGF-BETA; CYCLE ARREST; II RECEPTOR; CARCINOMA CELLS; DPC4 GENE; IGF-I; EXPRESSION; BINDING	In the present study we investigated the actions of transforming growth factor (TGF)-beta 1 on gene induction and cyclin-dependent kinase inhibitors in relation to TGF-beta receptor modulation in COLO-357 pancreatic cancer cells. TGF-beta 1 inhibited the growth of COLO-357 cells in a time- and dose dependent manner and caused a rapid but transient increase in plasminogen activator inhibitor-I and insulin-like growth factor binding protein-3 mRNA levels. TGF-beta 1 caused a delayed but sustained increase in the protein levels of the cyclin-dependent kinase inhibitors p15(Ink4B), p21(Cip1), and p27(Kip1) and a sustained increase in type I and II TGF-beta receptors (T beta RI and T beta RII) mRNA and protein levels. The protein synthesis inhibitor cycloheximide (10 mu g/ml) completely blocked the TGF-beta 1-mediated increase in T beta RI and T beta RII expression. Furthermore, a nuclear runoff transcription assay revealed that the increase in receptor mRNA levels was due to newly transcribed RNA. There was a significant increase in T beta RI and T beta RII mRNA levels in confluent cells in comparison to subconfluent (less than or equal to 80% confluent) controls, as well as in serum-starved cells when compared with cells incubated in medium containing 10% fetal bovine serum. COLO-357 cells expressed a normal SMAD4 gene as determined by Northern blot analysis and sequencing. These results indicate that TGF-beta 1 modulates a variety of functions in COLO-357 cells and up-regulates TGF-beta receptor expression via a transcriptional mechanism, which has the potential to maximize TGF-beta 1-dependent antiproliferative responses.	Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Korc, M (corresponding author), Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Med, C240, Irvine, CA 92697 USA.		Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669	NATIONAL CANCER INSTITUTE [R01CA075059, R37CA075059] Funding Source: NIH RePORTER; NCI NIH HHS [CA-75059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Bertherat J, 1996, EUR J ENDOCRINOL, V134, P426, DOI 10.1530/eje.0.1340426; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Bouchard C, 1997, J IMMUNOL, V159, P4155; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Erondu NE, 1996, GROWTH REGULAT, V6, P1; FINE A, 1995, BBA-GENE STRUCT EXPR, V1261, P19, DOI 10.1016/0167-4781(94)00210-T; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GrondahlHansen J, 1997, BREAST CANCER RES TR, V43, P153, DOI 10.1023/A:1005744914124; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hembree JR, 1996, J ANIM SCI, V74, P1530; IIMURA T, 1994, BIOCHEM BIOPH RES CO, V204, P918, DOI 10.1006/bbrc.1994.2547; Ito H, 1996, VIRCHOWS ARCH, V427, P487; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Koura AN, 1996, CANCER RES, V56, P3891; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIZUNO K, 1993, J BIOCHEM-TOKYO, V114, P96, DOI 10.1093/oxfordjournals.jbchem.a124147; MORELAND RB, 1995, J UROLOGY, V153, P826, DOI 10.1016/S0022-5347(01)67730-9; MOSES HL, 1985, CANCER CELL, V3, P65; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; Oh Youngman, 1995, Progress in Growth Factor Research, V6, P503, DOI 10.1016/0955-2235(95)00025-9; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P19; Schutte M, 1996, CANCER RES, V56, P2527; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SPRENGERS ED, 1987, BLOOD, V69, P381; SUAREZQUIAN CA, 1993, TISSUE CELL, V25, P1, DOI 10.1016/0040-8166(93)90061-O; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takenoshita S, 1996, GENOMICS, V36, P341, DOI 10.1006/geno.1996.0471; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521	45	73	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7495	7500		10.1074/jbc.273.13.7495	http://dx.doi.org/10.1074/jbc.273.13.7495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516449	hybrid			2022-12-27	WOS:000072738500045
J	Pastorino, JG; Chen, ST; Tafani, M; Snyder, JW; Farber, JL				Pastorino, JG; Chen, ST; Tafani, M; Snyder, JW; Farber, JL			The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; LETHAL INJURY; PORE; APOPTOSIS; HEPATOCYTES; INHIBITION; PHOSPHOLIPASE-A2; IDENTIFICATION; MEMBRANE	Stably transfected Jurkat T cells were produced in which Bax expression is inducible by muristerone A. The cell death resulting from induction of the overexpression of Bax was prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A(2) inhibitor aristolochic acid (ArA). The caspase-3 inhibitor Z-Asp-Glu-Val aspartic acid fluoromethylketone (Z-DEVD-FMK) had no effect on the loss of viability. The MPT was measured as the CyA plus ArA-preventable loss of the mitochondrial membrane potential (Delta Psi(m)). The MPT was accompanied by the release of cytochrome c from the mitochondria, caspase-3 activation in the cytosol, cleavage of the nuclear enzyme poly(ADP-ribose)polymerase (PARP), and DNA fragmentation, all of which were inhibited by CyA plus ArA, Z-DEVD-FMK had no effect on the loss of Delta Psi(m) and the redistribution of cytochrome c but did prevent caspase-3 activation, PARP cleavage, and DNA fragmentation. It is concluded that Bax induces the MPT, a critical event in the loss of cell viability. In addition to the cell death, the MPT mediates other typical manifestations of apoptosis in this model, namely release of cytochrome c, caspase activation with PARP cleavage, and DNA fragmentation.	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, Rm 251,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	farber1@jeflfin.tju.edu	Tafani, Marco/C-3275-2017; Tafani, Marco/U-7230-2019	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X	NIDDK NIH HHS [DK-38305] Funding Source: Medline; NIGMS NIH HHS [GM 51430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; CROMPTON M, 1988, BIOCHEM J, V255, P357; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Hassouna I, 1996, NEUROSCI LETT, V204, P85, DOI 10.1016/0304-3940(96)12323-5; IGBAVBOA U, 1989, BIOCHEM BIOPH RES CO, V161, P619, DOI 10.1016/0006-291X(89)92644-2; IMBERTI R, 1992, RES COMMUN CHEM PATH, V78, P27; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orrenius S, 1997, CELL DEATH DIFFER, V4, P427, DOI 10.1038/sj.cdd.4400272; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SCHALKWIJK CG, 1991, J LIPID MEDIATOR, V4, P83; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	38	516	532	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7770	7775		10.1074/jbc.273.13.7770	http://dx.doi.org/10.1074/jbc.273.13.7770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516487	hybrid			2022-12-27	WOS:000072738500083
J	Prasad, PD; Wang, HP; Kekuda, R; Fujita, T; Fei, YJ; Devoe, LD; Leibach, FH; Ganapathy, V				Prasad, PD; Wang, HP; Kekuda, R; Fujita, T; Fei, YJ; Devoe, LD; Leibach, FH; Ganapathy, V			Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PLACENTA; SYSTEM; COTRANSPORT; SEQUENCE	Previous studies have shown that a Na+-dependent transport system is responsible for the transplacental transfer of the vitamins pantothenate and biotin and the essential metabolite lipoate, We now report the isolation of a rat placental cDNA encoding a transport protein responsible for this function, The cloned cDNA, when expressed in HeLa cells, induces Na+-dependent pantothenate and biotin transport activities, The transporter is specific for pantothenate, biotin, and lipoate, The Michaelis-Menten constant (K-t) for the transport of pantothenate and biotin in cDNA-transfected cells is 4.9 +/- 1.1 and 15.1 +/- 1.2 mu M, respectively, The transport of both vitamins in cDNA-transfected cells is inhibited by lipoate with an inhibition constant (K-i) of approximately 5 mu M. The nucleotide sequence of the cDNA (sodium-dependent multivitamin transporter (SMVT)) predicts a protein of 68.6 kDa with 634 amino acids and 12 potential transmembrane domains, Protein data base search indicates significant sequence similarity between SMVT and known members of the Na+-dependent glucose transporter family, Northern blot analysis shows that SMVT transcripts are present in all of the tissues that were tested, The size of the principal transcript is 3.2 kilobases, SMVT represents the first Na+-dependent vitamin transporter to be cloned from a mammalian tissue.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Prasad, PD (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	pprasad@mail.mcg.edu	Fujita, Takuya/AAC-3442-2022	Fujita, Takuya/0000-0002-7724-6522	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347, R01HD024451] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24451, HD 33347] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benson DA, 1996, NUCLEIC ACIDS RES, V24, P1, DOI 10.1093/nar/24.1.1; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; CHENG YC, 1993, BIOCHEM PHARMACOL, V22, P3099; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; GRASSL SM, 1992, J BIOL CHEM, V267, P22902; GRASSL SM, 1992, J BIOL CHEM, V267, P17760; HALE G, 1992, P ROY SOC LOND B BIO, V249, P247; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; KARNITZ LM, 1984, BIOCHIM BIOPHYS ACTA, V769, P486, DOI 10.1016/0005-2736(84)90334-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Prasad PD, 1997, PLACENTA, V18, P527, DOI 10.1016/0143-4004(77)90006-6; PRASAD PD, 1992, J BIOL CHEM, V267, P23632; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SAID HM, 1987, AM J PHYSIOL, V252, pG52, DOI 10.1152/ajpgi.1987.252.1.G52; SMITH CH, 1992, ANNU REV NUTR, V12, P183, DOI 10.1146/annurev.nu.12.070192.001151; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VOGELI G, 1987, METHOD ENZYMOL, V152, P407	22	170	178	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	1998	273	13					7501	7506		10.1074/jbc.273.13.7501	http://dx.doi.org/10.1074/jbc.273.13.7501			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZD917	9516450	hybrid			2022-12-27	WOS:000072738500046
J	Bousquet, C; Delesque, N; Lopez, F; Saint-Laurent, N; Esteve, JP; Bedecs, K; Buscail, L; Vaysse, N; Susini, C				Bousquet, C; Delesque, N; Lopez, F; Saint-Laurent, N; Esteve, JP; Bedecs, K; Buscail, L; Vaysse, N; Susini, C			sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-CELLS; SH2 DOMAIN; MOLECULAR-CLONING; FACTOR-I; PROTEIN; PHOSPHORYLATION; PROLIFERATION; ACTIVATION; ANALOGS; PTP1C	We have previously reported in Chinese hamster ovary (CHO) cells expressing sst2 that activation of the sst2 somatostatin receptor inhibits insulin-induced cell proliferation by a mechanism involving stimulation of a tyrosine phosphatase activity, Here we show that the tyrosine phosphatase SHP-1 was associated with the insulin receptor (HC) at the basal level, Activation of IR by insulin resulted in a rapid and transient increase of tyrosine phosphorylation of IR, its substrates IRS-1 and Shc, and also of SHP-1, This was then followed by a rapid dephosphorylation of these molecules, which was related to the insulin-induced increase of SHP-1 association to IR and of SHP-1 activity, On the other hand, addition to insulin of the somatostatin analogue, RC160, resulted in a higher and faster increase of SHP-1 association to IR directly correlated with an inhibition of phosphorylation of IR and its substrates, IRS-1 and She. RC160 also induced a higher and more sustained increase in SHP-1 activity, Furthermore, RC160 completely suppressed the effect of insulin on SHP-1 phosphorylation. Finally, in CHO cells coexpressing sst2 and a catalytically inactive mutant SHP-1, insulin as well as RC160 could no longer stimulate SHP-1 activity, Over-expression of the SHP-1 mutant prevented the insulin-induced signaling to be terminated by dephosphorylation of IR, suppressed the inhibitory effect of RC160 on insulin-induced IR phosphorylation, and abolished the cell proliferation modulation by insulin and RC160, Our results suggest that SHP-1 plays a role in negatively modulating insulin signaling by association with IR. Furthermore, somatostatin inhibits the insulin-induced mitogenic signal by accelerating and amplifying the effect of SHP-1 on the termination of the insulin signaling pathway.	CHU Rangueil, Inst Louis Bugnard, INSERM, U151,IFR 31, F-31403 Toulouse 04, France; Inst Cochin Genet Mol, F-75014 Paris, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Susini, C (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U151,IFR 31, F-31403 Toulouse 04, France.	susinich@rangueil.inserm.fr	Bousquet, Corinne/P-2917-2014; Nathalie, Saint-Laurent/G-5487-2017	Bousquet, Corinne/0000-0002-2501-0593; 				Ahmad F, 1997, J BIOL CHEM, V272, P448; AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; GAITS F, 1996, J BIOL CHEM, V271, P20145; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LEWIN MJM, 1992, ANNU REV PHYSIOL, V54, P455, DOI 10.1146/annurev.physiol.54.1.455; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHALLY AV, 1988, CANCER RES, V48, P6977; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamada T, 1989, HDB PHYSL 6, P431; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZEGGARI M, 1994, BIOCHEM J, V303, P441, DOI 10.1042/bj3030441	48	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7099	7106		10.1074/jbc.273.12.7099	http://dx.doi.org/10.1074/jbc.273.12.7099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507021	hybrid			2022-12-27	WOS:000072775900071
J	Li, JX; Rosen, BP				Li, JX; Rosen, BP			Steric limitations in the interaction of the ATP binding domains of the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; ARSENICAL RESISTANCE OPERON; CATALYTIC SUBUNIT; BETA-SUBUNIT; PROTEIN; PUMP; MUTAGENESIS; SYNTHASE; METALLOACTIVATION; RESOLUTION	ArsA, the catalytic subunit of an anion-translocating ATPase, has two consensus nucleotide binding sites, one N-terminal and one C-terminal. A mutation producing a G15C substitution in the N-terminal domain resulted in substantial reductions in arsenite resistance, transport, and ATPase activity. A second site revertant (A344V) adjacent to the C-terminal nucleotide binding site was previously shown to restore arsenite resistance, suggesting the interaction of the nucleotide binding sites in ArsA (Li, J., Liu, S., and Rosen, B. P. (1996) J. Biol. Chem. 271, 25247-25252). In this study, it is shown that alteration of Ala-344 to bulkier residues, including Cys, Thr, Pro, Asp, Leu, Phe, Tyr, or Arg, also suppressed the G15C substitution. However, A344G or A344S substitutions only marginally suppressed the primary mutation. Alteration of Gly-15 to Ala, Cys, Asp, Tyr, or Arg each resulted in decreased arsenite resistance. The larger the residue volume of the substitution, the lower the resistance, with a G15R substitution producing the least resistance. Resistance in a strain expressing an arsA gene encoding the G15R substitution could be rescued by A344S, A344T, A344D, A344R, or A344V second site suppressors. The larger the residue is then the greater the suppression is. The in vitro ArsA ATPase activities from purified wild type, G15A, G15C, and G15R exhibits an inverse relationship between activity and residue volume. Purified G15A and G15C exhibited both an increase in the K-m for ATP and a decrease in V-max. The results are consistent with a physical interaction of the two nucleotide binding domains and indicate that the geometry at the interface between the N- and C-terminal nucleotide binding sites places spatial constraints on allowable residues in that interface.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM55425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055425, R01GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Bruhn DF, 1996, FEMS MICROBIOL LETT, V139, P149, DOI 10.1016/0378-1097(96)00134-6; CHEN CM, 1986, J BIOL CHEM, V261, P5030; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; HSU CM, 1989, J BIOL CHEM, V264, P17349; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1994, J BIOL CHEM, V269, P9698; KAUR P, 1992, J BIOL CHEM, V267, P19272; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Miller J.H., 1972, EXPT MOL GENETICS; OMOTE H, 1994, J BIOL CHEM, V269, P10265; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN HG, 1994, J BIOL CHEM, V269, P9424; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Tsai KJ, 1997, ZOOL STUD, V36, P1; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WilkeMounts S, 1995, ARCH BIOCHEM BIOPHYS, V324, P153, DOI 10.1006/abbi.1995.9915; WU JH, 1992, J BIOL CHEM, V267, P12570; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	34	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6796	6800		10.1074/jbc.273.12.6796	http://dx.doi.org/10.1074/jbc.273.12.6796			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506981	hybrid			2022-12-27	WOS:000072775900031
J	O'Connell, DP; Nanavaty, T; McDevitt, D; Gurusiddappa, S; Hook, M; Foster, TJ				O'Connell, DP; Nanavaty, T; McDevitt, D; Gurusiddappa, S; Hook, M; Foster, TJ			The fibrinogen-binding MSCRAMM (clumping factor) of Staphylococcus aureus has a Ca2+-dependent inhibitory site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; GAMMA-CHAIN; CATION-BINDING; ESCHERICHIA-COLI; ALPHA-CHAIN; GPIIB-IIIA; INTEGRIN; CALCIUM; RECEPTOR; PROTEINS	The clumping factor (ClfA) is a cell surface-associated protein of Staphylococcus aureus that promotes binding of fibrinogen or fibrin to the bacterial cell, Previous studies have shown that ClfA and the platelet integrin alpha(IIb)beta(3) recognize the same domain at the extreme C terminus of the fibrinogen gamma-chain. alpha(IIb)beta(3) interaction with this domain is known to occur in close proximity to a Ca2+-binding EF-hand structure in the cr-subunit. Analysis of the primary structure of ClfA indicated the presence of a potential Ca2+-binding EF-hand-like motif at residues 310-321 within the fibrinogen-binding domain. Deletion mutagenesis and site-directed mutagenesis of this EF-hand in recombinant truncated ClfA proteins (Clf40, residues 40-559; and Clf41, residues 221-559) resulted in a significant reduction of affinity for native fibrinogen and a fibrinogen gamma-chain peptide. Furthermore, Ca2+ (or Mn2+) could inhibit the binding of the fibrinogen gamma-chain peptide to Clf40-(40-559) and the adhesion of S. aureus cells to immobilized fibrinogen with an IC50 of 2-3 mns. In contrast, Mg2+ (or Na+) at similar concentrations had no effect on the ClfA-fibrinogen interaction. Far-UV CD analysis of Clf40-(40-559) and Clf41-(221-559) in the presence of metal ions indicated Ca2+- and Mn2+-induced differences in secondary structure, These data suggest that Ca2+ binds to an inhibitory site(s) within ClfA and induces a conformational change that is incompatible with binding to the C terminus of the gamma-chain of fibrinogen. Mutagenesis studies indicate that the Ca2+-dependent inhibitory site is located within the EF-hand motif at residues 310-321.	Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Texas A&M Univ, Inst Biosci & Technol, Dept Biochem & Biophys, Houston, TX 77030 USA; Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	Trinity College Dublin; Texas A&M University System; Texas A&M University System	Foster, TJ (corresponding author), Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.				NIAID NIH HHS [AI20624] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI020624, R01AI020624] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BOLLET C, 1991, NUCLEIC ACIDS RES, V19, P1955, DOI 10.1093/nar/19.8.1955; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; Gale C, 1996, P NATL ACAD SCI USA, V93, P357, DOI 10.1073/pnas.93.1.357; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULINO D, 1992, J BIOL CHEM, V267, P1001; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HETTASCH JM, 1992, THROMB HAEMOSTASIS, V68, P701; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Jackson DE, 1996, EUR J BIOCHEM, V240, P280, DOI 10.1111/j.1432-1033.1996.0280h.x; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MARGUERIE G, 1977, BIOCHIM BIOPHYS ACTA, V490, P94, DOI 10.1016/0005-2795(77)90109-X; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; ROBERTSON WG, 1981, CRC CR REV CL LAB SC, V15, P85, DOI 10.3109/10408368109105869; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Sambrook J., 2002, MOL CLONING LAB MANU; SAVAGE B, 1995, J BIOL CHEM, V270, P28812, DOI 10.1074/jbc.270.48.28812; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STRONG DD, 1982, BIOCHEMISTRY-US, V21, P1414, DOI 10.1021/bi00535a048; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865; VAUDAUX PE, 1995, INFECT IMMUN, V63, P585, DOI 10.1128/IAI.63.2.585-590.1995	40	92	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					6821	6829		10.1074/jbc.273.12.6821	http://dx.doi.org/10.1074/jbc.273.12.6821			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9506984	hybrid			2022-12-27	WOS:000072775900034
J	Yoshida, R; Nagira, M; Kitaura, M; Imagawa, N; Imai, T; Yoshie, O				Yoshida, R; Nagira, M; Kitaura, M; Imagawa, N; Imai, T; Yoshie, O			Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-3; HUMAN INTERLEUKIN-8 RECEPTOR; EOSINOPHIL EOTAXIN RECEPTOR; MOLECULAR-CLONING; EXPRESSION; SIGNALS; RANTES; GENES; LYMPHOCYTES; LESTR/FUSIN	Secondary Lymphoid-tissue Chemokine (SLC) is a recently identified CC chemokine that is constitutively expressed in various lymphoid tissues and is a potent and specific chemoattractant for lymphocytes. The SLC gene and the gene encoding another lymphocyte-specific CC chemokine, EBI1-ligand chemokine (ELC), form a mini-cluster at human chromosome 9p13. Here, we show that SLC is a high affinity functional ligand for chemokine receptor 7 (CCR7) that is expressed on T and B lymphocytes and a known receptor for ELC. SLC induced a vigorous calcium mobilization in murine L1.2 cells stably expressing human CCR7. SLC tagged with the secreted form of alkaline phosphatase (SLC-SEAP) showed specific binding to CCR7 that was fully competed by SLC with an IC50 of 0.5 nM. SLC also induced a vigorous chemotactic response in CCR7-expressing L1.2 cells with a typical bell-shaped dose-response curve and a maximal migration at 10 nM. When assessed using CCR7-transfected L1.2 cells, SLC and ELC were essentially equivalent in terms of cross desensitization in calcium mobilization via CCR7, cross-competition in binding to CCR7, and induction of chemotaxis via CCR7. SLC and ELC were also shown to fully share receptors expressed on cultured normal T cells known to express CCR7. Notably, however, SLC was somehow less efficient in cross-desensitization against ELC in calcium mobilization and in cross-competition with ELC for binding when assessed using cultured normal T cells. Thus, SLC and ELC, even though sharing only 32% amino acid identity, constitute a genetically and functionally highly related subgroup of CC chemokines.	Shionogi Inst Med Sci, Osaka 566, Japan	Shionogi & Company Limited	Yoshie, O (corresponding author), Shionogi Inst Med Sci, 2-5-1 Mishima, Osaka 566, Japan.	osamu.yoshie@shionogi.co.jp		Yoshie, Osamu/0000-0003-4353-5809				Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; FRANCI C, 1995, J IMMUNOL, V154, P6511; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GEISER T, 1993, J BIOL CHEM, V268, P15419; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; HASEGAWA H, 1994, J VIROL, V68, P5326, DOI 10.1128/JVI.68.8.5326-5329.1994; Hedrick JA, 1997, J IMMUNOL, V159, P1589; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Hromas R, 1997, J IMMUNOL, V159, P2554; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LEE J, 1992, J BIOL CHEM, V267, P16288; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMIYAMA H, 1998, IN PRESS CYTOGENET C; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; TUNNACLIFFE A, 1992, BLOOD, V79, P2896; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634	55	257	277	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 20	1998	273	12					7118	7122		10.1074/jbc.273.12.7118	http://dx.doi.org/10.1074/jbc.273.12.7118			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZE277	9507024	hybrid			2022-12-27	WOS:000072775900074
J	Ringdahl, U; Svensson, M; Wistedt, AC; Renne, T; Kellner, R; Muller-Esterl, W; Sjobring, U				Ringdahl, U; Svensson, M; Wistedt, AC; Renne, T; Kellner, R; Muller-Esterl, W; Sjobring, U			Molecular co-operation between protein PAM and streptokinase for plasmin acquisition by Streptococcus pyogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; SURFACE PROTEIN; BINDING-PROTEIN; RECEPTOR; GENE; IDENTIFICATION; EXPRESSION; ALPHA-2-ANTIPLASMIN	Bacterial surface-associated plasmin formation is believed to contribute to invasion, although the underlying molecular mechanisms are poorly understood. To define the components necessary for plasmin generation on group A streptococci we used strain AP53 which exposes an M-like protein ("PAM") that contains a plasminogen-binding sequence with two 13-amino acid residues long tandem repeats (a1 and a2). Utilizing an Escherichia coli-streptococcal shuttle vector, we replaced a 29-residue long sequence segment of Arp4, an M-like protein that does not bind plasminogen, with a single (a1) or the combined a1a2 repeats of PAM. When expressed in E. coli, the purified chimeric Arp/PAM proteins both bound plasminogen, as well as plasmin, and when used to transform group A streptococcal strains lacking the plasminogen-binding ability, transformants with the Arp/PAM constructs efficiently bound plasminogen. Moreover, when grown in the presence of plasminogen, both Arp/PAM- and PAM-expressing streptococci acquired surface-bound plasmin. In contrast, plasminogen activation failed to occur on PAM- and Arp/PAM-expressing streptococci carrying an inactivated streptokinase gene: this block was overcome by exogenous streptokinase. Together, these results provide evidence for an unusual co operation between a surface-bound protein, PAM, and a secreted protein, streptokinase, resulting in bacterial acquisition of a host protease that is likely to spur parasite invasion of host tissues.	Univ Lund, Dept Med Microbiol, S-22362 Lund, Sweden; Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany	Lund University; Johannes Gutenberg University of Mainz	Sjobring, U (corresponding author), Univ Lund, Dept Med Microbiol, Solvegatan 23, S-22362 Lund, Sweden.			Renne, Thomas/0000-0003-4594-5975				BERGE A, 1993, J BIOL CHEM, V268, P25417; Bessen DE, 1996, J INFECT DIS, V173, P896, DOI 10.1093/infdis/173.4.896; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BRODER CC, 1991, J BIOL CHEM, V266, P4922; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; CASTELLINO FJ, 1984, SEMIN THROMB HEMOST, V10, P18, DOI 10.1055/s-2007-1004404; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; Christner R, 1997, J INFECT DIS, V175, P1115, DOI 10.1086/516450; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; COLMAN G, 1993, J MED MICROBIOL, V39, P165, DOI 10.1099/00222615-39-3-165; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HUANG TT, 1989, MOL MICROBIOL, V3, P197, DOI 10.1111/j.1365-2958.1989.tb01808.x; HUSMANN LK, 1995, INFECT IMMUN, V63, P345, DOI 10.1128/IAI.63.1.345-348.1995; JOHNSSON E, 1994, J IMMUNOL, V153, P3557; Johnsson E, 1996, J IMMUNOL, V157, P3021; LEYTUS SP, 1981, P NATL ACAD SCI USA, V78, P1458; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; MARTIN DR, 1994, PEDIATR INFECT DIS J, V13, P264, DOI 10.1097/00006454-199404000-00004; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NILSON BHK, 1995, BIOCHEMISTRY-US, V34, P13688, DOI 10.1021/bi00041a051; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PANCHOLI V, 1996, 13 LANC INT S STREPT, P87; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; POONKING R, 1993, J EXP MED, V178, P759, DOI 10.1084/jem.178.2.759; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROE B, 1997, STREPTOCOCCAL GENOME; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WANG H, 1995, MICROB PATHOGENESIS, V18, P153, DOI 10.1016/S0882-4010(95)90013-6; WIMAN B, 1979, BIOCHIM BIOPHYS ACTA, V579, P142, DOI 10.1016/0005-2795(79)90094-1; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x	46	60	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6424	6430		10.1074/jbc.273.11.6424	http://dx.doi.org/10.1074/jbc.273.11.6424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497374	hybrid			2022-12-27	WOS:000072488500066
J	Tomita, S; Kirino, Y; Suzuki, T				Tomita, S; Kirino, Y; Suzuki, T			Cleavage of Alzheimer's amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway - Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BETA-PROTEIN; EXTRACELLULAR DOMAIN; GOLGI-APPARATUS; DISEASE; CELLS; PHOSPHORYLATION; PEPTIDE; LOCALIZATION; CDNA	beta-Amyloid peptide (A beta) is a principal component of parenchymal amyloid deposits in Alzheimer's disease, A beta is derived from amyloid precursor protein (APP) by proteolytic cleavage. APP is subject to N- and O-glycosylation and potential tyrosine sulfation, following protein synthesis, and is then thought to be cleaved in an intracellular secretory pathway after or during these post-translational modifications. Studies utilizing agents that affect a series of steps in the protein secretory pathway have identified the possible intracellular sites of APP cleavage and A beta generation within the protein secretory pathway. In the present study, using cells with normal protein metabolism, but expressing mutant APP with defective O-glycosylation, we demonstrated that the majority of APP cleavage by alpha-, beta-, and gamma-secretases occurs after O-glycosylation. Cells expressing the mutant APP noticeably decreased the generation of the intracellular APP carboxyl-terminal fragment (alpha APP-(COOH)), a product of alpha-secretase, and both A beta 40 and A beta 42 in medium, a product of beta- and gamma-secretases. Furthermore, we found that the cells accumulate the mutant APP in intracellular reticular compartments such as the endoplasmic reticulum. Agents that could ambiguously affect the function of specific intracellular organelles and that may be toxic mere not used. The present results indicate that APP is cleaved by alpha-, beta-, and gamma-secretases in step(s) during the transport of APP through Golgi complex, where O-glycosylation occurs, or in compartments subsequent to trans-Golgi of the APP secretory pathway.	Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	t-suzuki@mayqueen.f.u-tokyo.ac.jp	Suzuki, Toshiharu/B-5342-2013					ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CODELL B, 1994, ANN REV PHARM TOXICO, V34, P69; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DANPHY WG, 1985, CELL, V42, P13; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DeStrooper B, 1995, J BIOL CHEM, V270, P30310, DOI 10.1074/jbc.270.51.30310; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GRAEBERT KS, 1995, EUR J CELL BIOL, V66, P39; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNOPS J, 1993, BIOCHEM BIOPH RES CO, V197, P380, DOI 10.1006/bbrc.1993.2490; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Muramatsu T, 1978, Methods Enzymol, V50, P555; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PAHLSSON P, 1992, BIOCHEM BIOPH RES CO, V189, P1667, DOI 10.1016/0006-291X(92)90269-Q; Pahlsson P, 1996, ARCH BIOCHEM BIOPHYS, V331, P177, DOI 10.1006/abbi.1996.0296; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085	50	158	159	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6277	6284		10.1074/jbc.273.11.6277	http://dx.doi.org/10.1074/jbc.273.11.6277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497354	hybrid			2022-12-27	WOS:000072488500046
J	Zufferey, R; Arslan, E; Thony-Meyer, L; Hennecke, H				Zufferey, R; Arslan, E; Thony-Meyer, L; Hennecke, H			How replacements of the 12 conserved histidines of subunit I affect assembly, cofactor binding, and enzymatic activity of the Bradyrhizobium japonicum cbb(3)-type oxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SITE-DIRECTED MUTAGENESIS; PARACOCCUS-DENITRIFICANS; RHODOBACTER-SPHAEROIDES; RHIZOBIUM-JAPONICUM; MAGNETOSPIRILLUM-MAGNETOTACTICUM; TERMINAL OXIDASES; ESCHERICHIA-COLI; 2.8 ANGSTROM; GENES	Alignments of the amino acid sequences of subunit I (FixN or CcoN) of the cbb(3)-type oxidases show 12 conserved histidines. Six of them are diagnostic of heme-copper oxidases and are thought to bind the following cofactors: the low spin heme B and the binuclear high spin heme B Cu-B center. The other six are FixN(CcoN)-specific and their function is unknown. To analyze the contribution of these 12 invariant histidines of FixN in cofactor binding and function of the Bradyrhizobium japonicum cbb(3)-type oxidase, they were substituted by valine or alanine by site-directed mutagenesis. The H131A mutant enzyme had already been reported previously to be defective in oxidase assembly and function (Zufferey, R., Thony-Meyer, L., and Hennecke, H. (1996) FEBS Lett. 394, 349-352). Four of the remaining histidines were not essential for activity or assembly (positions 226, 246, 333, and 457); by contrast, histidines 331, 410, and 418 were required both for activity and stability of the enzyme. The last group of mutant enzymes, H420A, H280A, H330A, and H316V, were assembled but not functional. To purify the latter mutant proteins and the wild-type enzyme, a six-histidine tag was added to the C terminus of subunit I. The His(6)-tagged cbb(3)-oxidase complexes were purified 20-fold by a three-step purification protocol. With the exception of the H420A mutant oxidase, the mutant enzymes H280A, H316V, and H331A contained normal amounts of copper and heme B, and they displayed similar visible light spectroscopic characteristics like the wild-type His(6)-tagged enzyme. The His(6)-tagged H420A mutant oxidase differed from the His(6)-tagged wild-type protein by showing altered visible light spectroscopic characteristics. No stable mutant oxidase lacking copper or heme B was obtained. This strongly suggests that copper and heme B incorporations in subunit I are prerequisites for assembly of the enzyme.	Swiss Fed Inst Technol, Inst Microbiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Hennecke, H (corresponding author), Swiss Fed Inst Technol, Inst Microbiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	hennecke@micro.biol.ethz.ch						BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BOTT M, 1992, ARCH MICROBIOL, V158, P335, DOI 10.1007/BF00245362; DANIEL RM, 1972, BIOCHIM BIOPHYS ACTA, V275, P347, DOI 10.1016/0005-2728(72)90215-0; deGier JWL, 1996, MOL MICROBIOL, V20, P1247; ESPE MP, 1995, BIOCHEMISTRY-US, V34, P7593, DOI 10.1021/bi00023a005; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; Fujiwara T, 1996, J BACTERIOL, V178, P1866, DOI 10.1128/jb.178.7.1866-1871.1996; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; HAHN M, 1984, MOL GEN GENET, V193, P46, DOI 10.1007/BF00327412; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jones C. W., 1985, METHOD MICROBIOL, V18, P285; KAHN D, 1993, NEW HORIZONS NITROGE, P474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MANDON K, 1994, J BACTERIOL, V174, P6444; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Preisig O, 1996, J BACTERIOL, V178, P1532, DOI 10.1128/JB.178.6.1532-1538.1996; Preisig O, 1996, ARCH MICROBIOL, V165, P297, DOI 10.1007/s002030050330; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; REGENSBURGER B, 1983, ARCH MICROBIOL, V135, P103, DOI 10.1007/BF00408017; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1991, DIRECTED MUTAGENESIS, P49; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schluter A, 1997, MOL PLANT MICROBE IN, V10, P605, DOI 10.1094/MPMI.1997.10.5.605; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; TAMEGAI H, 1994, FEBS LETT, V347, P22, DOI 10.1016/0014-5793(94)00500-1; THONYMEYER L, 1994, MOL MICROBIOL, V14, P705, DOI 10.1111/j.1365-2958.1994.tb01308.x; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Witt H, 1997, J BIOL CHEM, V272, P5514, DOI 10.1074/jbc.272.9.5514; YAMAZAKI T, 1995, EUR J BIOCHEM, V233, P665, DOI 10.1111/j.1432-1033.1995.665_2.x; Zufferey R, 1997, FEBS LETT, V412, P75, DOI 10.1016/S0014-5793(97)00746-1; Zufferey R, 1996, FEBS LETT, V394, P349, DOI 10.1016/0014-5793(96)00982-9; Zufferey R, 1996, J BIOL CHEM, V271, P9114, DOI 10.1074/jbc.271.15.9114	44	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	1998	273	11					6452	6459		10.1074/jbc.273.11.6452	http://dx.doi.org/10.1074/jbc.273.11.6452			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZB597	9497378	hybrid			2022-12-27	WOS:000072488500070
J	Bandyopadhyay, PK; Colledge, CJ; Walker, CS; Zhou, LM; Hillyard, DR; Olivera, BM				Bandyopadhyay, PK; Colledge, CJ; Walker, CS; Zhou, LM; Hillyard, DR; Olivera, BM			Conantokin-G precursor and its role in gamma-carboxylation by a vitamin K-dependent carboxylase from a Conus snail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; PROPEPTIDE REGION; ENZYME-ACTIVITY; FACTOR-X; SUBSTRATE; PEPTIDE; CDNA; CARBOXYGLUTAMATE; IDENTIFICATION; PURIFICATION	Conantokin-G isolated from the marine snail Conus geographus is a 17-amino acid gamma-carboxyglutamate (Gla)-containing peptide that inhibits the N-methyl-D-aspartate receptor, We describe the cloning and sequence of conantokin-G cDNA and the possible role of the propeptide sequence, The cDNA encodes a 100-amino acid peptide, The N-terminal 80 amino acids constitute the prepro-sequence, and the mature peptide is derived from the remaining C-terminal residues after proteolysis, C-terminal amidation, and a unique posttranslational modification, gamma-carboxylation of glutamate residues to Gla, Mature conantokin-G peptide containing Glu residues (E.Con-G) in place of Gla is a poor substrate for the vitamin K-dependent gamma-glutamyl carboxylase (apparent K-m = 3.4 mM). Using peptides corresponding to different segments of the propeptide we investigated a potential role for the propeptide sequences in gamma-carboxylation. Propeptide segment -20 to -1 covalently linked to E.Con-G or the synthetic pentapeptide FLEEL increased their apparent affinities 2 orders of magnitude. These substrates are not efficiently carboxylated by the bovine microsomal gamma-glutamyl carboxylase, suggesting differences in specificities between the Conus and the mammalian enzyme. However, the role of propeptide in enhancing the efficiency of carboxylation is maintained.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Cognetix Inc, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bandyopadhyay, PK (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	bandyop@biology.utah.edu			NIGMS NIH HHS [GM 48677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKNER KL, 1992, P NATL ACAD SCI USA, V89, P6242, DOI 10.1073/pnas.89.14.6242; BUITENHUIS HC, 1990, BIOCHIM BIOPHYS ACTA, V1034, P170, DOI 10.1016/0304-4165(90)90072-5; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; COLLEDGE CJ, 1992, TOXICON, V30, P111; DEGAN SJF, 1983, BIOCHEMISTRY-US, V22, P2087; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; HAACK JA, 1990, J BIOL CHEM, V265, P6025; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P9436, DOI 10.1021/bi00154a016; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1985, J BIOL CHEM, V260, P4971; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; White H. S., 1997, Society for Neuroscience Abstracts, V23, P2164; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236	26	80	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5447	5450		10.1074/jbc.273.10.5447	http://dx.doi.org/10.1074/jbc.273.10.5447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488665	hybrid			2022-12-27	WOS:000072345000008
J	Tang, ZH; Yanagida, M; Lin, RJ				Tang, ZH; Yanagida, M; Lin, RJ			Fission yeast mitotic regulator Dsk1 is an SR protein-specific kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SPLICING FACTORS; SISTER-CHROMATID SEPARATION; XENOPUS CDC2 PROTEIN; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE DEPHOSPHORYLATION; CONSERVED FAMILY; SERINE-RICH; MUTANTS; PHOSPHORYLATION	Intricate interplay may exist between pre-mRNA splicing and the cell division cycle, and fission yeast Dsk1 appears to play a role in such a connection, Previous genetic analyses have implicated Dsk1 in the regulation of chromosome segregation at the metaphase/anaphase transition, Yet, its protein sequence suggests that Dsk1 may function as a kinase specific for SR proteins, a family of pre-mRNA splicing factors containing arginine-serine repeats, Using an in vitro system with purified components, we showed that Dsk1 phosphorylated human and yeast SR proteins with high specificity, The Dsk1-phosphorylated SF2/ASF protein was recognized strongly by a monoclonal antibody (mAb104) known to bind the in vivo phosphoepitope shared by SR proteins, indicating that the phosphorylation sites resided in the RS domain, Moreover, the fission yeast U2AF65 homolog, Prp2/Mis11 protein, was phosphorylated more efficiently by Dsk1 than by a human SR protein-specific kinase, SRPK1, Thus, these in vitro results suggest that Dsk1 is a fission yeast SR protein-specific kinase, and Prp2/Mis11 is likely an in vivo target for Dsk1, Together with previous genetic data, the studies support the notion that Dsk1 may play a role in coordinating pre-mRNA splicing and the cell division cycle.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol Mol, Duarte, CA 91010 USA; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 606, Japan	City of Hope; Beckman Research Institute of City of Hope; Kyoto University	Lin, RJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol Mol, 1450 E Duarte Rd, Duarte, CA 91010 USA.		Lin, Ren-Jang/G-2052-2014	Lin, Ren-Jang/0000-0002-2738-2438				ALAHARI SK, 1993, NUCLEIC ACIDS RES, V21, P4079, DOI 10.1093/nar/21.17.4079; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Gross T, 1997, NUCLEIC ACIDS RES, V25, P1028, DOI 10.1093/nar/25.5.1028; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E., 1988, ANTIBODIES LAB MANUA; Hunt T, 1993, CURR OPIN CELL BIOL, V5, P163, DOI 10.1016/0955-0674(93)90098-B; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KAUFER NF, 1985, NATURE, V318, P78, DOI 10.1038/318078a0; KIRSCHNER M, 1992, TRENDS BIOCHEM SCI, V17, P281, DOI 10.1016/0968-0004(92)90435-C; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Lundgren K, 1996, MOL BIOL CELL, V7, P1083, DOI 10.1091/mbc.7.7.1083; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; POTASHKIN J, 1993, SCIENCE, V262, P573, DOI 10.1126/science.8211184; POTASHKIN J, 1989, EMBO J, V8, P551, DOI 10.1002/j.1460-2075.1989.tb03409.x; PRABHALA G, 1992, YEAST, V8, P171, DOI 10.1002/yea.320080303; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Sambrook J., 2002, MOL CLONING LAB MANU; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; TAKEUCHI M, 1994, MOL BIOL CELL, V5, P1145; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; Urushiyama S, 1996, MOL GEN GENET, V253, P118, DOI 10.1007/s004380050304; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	50	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5963	5969		10.1074/jbc.273.10.5963	http://dx.doi.org/10.1074/jbc.273.10.5963			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488736	hybrid, Green Published			2022-12-27	WOS:000072345000079
